DDI-MedLine.d141.s0	Toxicity	0	7	O	Toxicity	ity	city	NN	False
DDI-MedLine.d141.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d141.s0	cadmium	12	18	O	cadmium	ium	mium	NN	drug
DDI-MedLine.d141.s0	and	20	22	O	and	and	and	CC	False
DDI-MedLine.d141.s0	zinc	24	27	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d141.s0	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d141.s0	encystment	32	41	O	encystment	ent	ment	NN	False
DDI-MedLine.d141.s0	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d141.s0	in	47	48	O	in	in	in	IN	False
DDI-MedLine.d141.s0	vitro	50	54	O	vitro	tro	itro	NN	False
DDI-MedLine.d141.s0	excystment	56	65	O	excystment	ent	ment	NN	False
DDI-MedLine.d141.s0	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d141.s0	Parorchis	70	78	O	Parorchis	his	chis	NN	False
DDI-MedLine.d141.s0	acanthus	80	87	O	acanthus	hus	thus	RB	False
DDI-MedLine.d141.s0	(	89	89	O	(	(	(	(	False
DDI-MedLine.d141.s0	Digenea	90	96	O	Digenea	nea	enea	NN	False
DDI-MedLine.d141.s0	:	97	97	O	:	:	:	:	False
DDI-MedLine.d141.s0	Philophthalmidae	99	114	O	Philophthalmidae	dae	idae	NN	False
DDI-MedLine.d141.s0	)	115	115	O	)	)	)	)	False
DDI-MedLine.d141.s0	.	116	116	O	.	.	.	.	False

DDI-MedLine.d141.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d141.s1	toxicity	4	11	O	toxicity	ity	city	NN	False
DDI-MedLine.d141.s1	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d141.s1	cadmium	16	22	O	cadmium	ium	mium	NN	drug
DDI-MedLine.d141.s1	,	23	23	O	,	,	,	,	False
DDI-MedLine.d141.s1	zinc	25	28	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d141.s1	and	30	32	O	and	and	and	CC	False
DDI-MedLine.d141.s1	cadmium/zinc	34	45	O	cadmium/zinc	inc	zinc	NN	False
DDI-MedLine.d141.s1	mixtures	47	54	O	mixtures	res	ures	NNS	False
DDI-MedLine.d141.s1	at	56	57	O	at	at	at	IN	False
DDI-MedLine.d141.s1	concentrations	59	72	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d141.s1	ranging	74	80	O	ranging	ing	ging	VBG	False
DDI-MedLine.d141.s1	from	82	85	O	from	rom	from	IN	False
DDI-MedLine.d141.s1	1000	87	90	O	1000	000	1000	CD	False
DDI-MedLine.d141.s1	to	92	93	O	to	to	to	TO	False
DDI-MedLine.d141.s1	50000	95	99	O	50000	000	0000	CD	False
DDI-MedLine.d141.s1	microg/l	101	108	O	microg/l	g/l	og/l	NN	False
DDI-MedLine.d141.s1	were	110	113	O	were	ere	were	VBD	False
DDI-MedLine.d141.s1	investigated	115	126	O	investigated	ted	ated	VBN	False
DDI-MedLine.d141.s1	against	128	134	O	against	nst	inst	IN	False
DDI-MedLine.d141.s1	cercariae	136	144	O	cercariae	iae	riae	NN	False
DDI-MedLine.d141.s1	and	146	148	O	and	and	and	CC	False
DDI-MedLine.d141.s1	metacercariae	150	162	O	metacercariae	iae	riae	NN	False
DDI-MedLine.d141.s1	of	164	165	O	of	of	of	IN	False
DDI-MedLine.d141.s1	Parorchis	167	175	O	Parorchis	his	chis	NN	False
DDI-MedLine.d141.s1	acanthus	177	184	O	acanthus	hus	thus	RB	False
DDI-MedLine.d141.s1	obtained	186	193	O	obtained	ned	ined	VBN	False
DDI-MedLine.d141.s1	from	195	198	O	from	rom	from	IN	False
DDI-MedLine.d141.s1	the	200	202	O	the	the	the	DT	False
DDI-MedLine.d141.s1	dog	204	206	O	dog	dog	dog	NN	False
DDI-MedLine.d141.s1	whelk	208	212	O	whelk	elk	helk	NN	False
DDI-MedLine.d141.s1	Nucella	214	220	O	Nucella	lla	ella	NN	False
DDI-MedLine.d141.s1	lapillus	222	229	O	lapillus	lus	llus	NN	False
DDI-MedLine.d141.s1	.	230	230	O	.	.	.	.	False

DDI-MedLine.d141.s2	Cercarial	0	8	O	Cercarial	ial	rial	JJ	False
DDI-MedLine.d141.s2	encystment	10	19	O	encystment	ent	ment	NN	False
DDI-MedLine.d141.s2	at	21	22	O	at	at	at	IN	False
DDI-MedLine.d141.s2	concentrations	24	37	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d141.s2	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d141.s2	25000	42	46	O	25000	000	5000	CD	False
DDI-MedLine.d141.s2	microg/l	48	55	O	microg/l	g/l	og/l	NN	False
DDI-MedLine.d141.s2	or	57	58	O	or	or	or	CC	False
DDI-MedLine.d141.s2	higher	60	65	O	higher	her	gher	JJR	False
DDI-MedLine.d141.s2	was	67	69	O	was	was	was	VBD	False
DDI-MedLine.d141.s2	significantly	71	83	O	significantly	tly	ntly	RB	False
DDI-MedLine.d141.s2	impaired	85	92	O	impaired	red	ired	JJ	False
DDI-MedLine.d141.s2	by	94	95	O	by	by	by	IN	False
DDI-MedLine.d141.s2	all	97	99	O	all	all	all	DT	False
DDI-MedLine.d141.s2	test	101	104	O	test	est	test	NN	False
DDI-MedLine.d141.s2	metals	106	111	O	metals	als	tals	NNS	False
DDI-MedLine.d141.s2	;	112	112	O	;	;	;	:	False

DDI-MedLine.d141.s3	however	0	6	O	however	ver	ever	RB	False
DDI-MedLine.d141.s3	,	7	7	O	,	,	,	,	False
DDI-MedLine.d141.s3	at	9	10	O	at	at	at	IN	False
DDI-MedLine.d141.s3	lower	12	16	O	lower	wer	ower	JJR	False
DDI-MedLine.d141.s3	concentrations	18	31	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d141.s3	only	33	36	O	only	nly	only	RB	False
DDI-MedLine.d141.s3	zinc	38	41	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d141.s3	demonstrated	43	54	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d141.s3	toxicity	56	63	O	toxicity	ity	city	NN	False
DDI-MedLine.d141.s3	.	64	64	O	.	.	.	.	False

DDI-MedLine.d141.s4	Mixtures	0	7	O	Mixtures	res	ures	NNS	False
DDI-MedLine.d141.s4	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d141.s4	cadmium	12	18	O	cadmium	ium	mium	NN	drug
DDI-MedLine.d141.s4	and	20	22	O	and	and	and	CC	False
DDI-MedLine.d141.s4	zinc	24	27	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d141.s4	had	29	31	O	had	had	had	VBD	False
DDI-MedLine.d141.s4	a	33	33	O	a	a	a	DT	False
DDI-MedLine.d141.s4	synergistic	35	45	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d141.s4	effect	47	52	O	effect	ect	fect	NN	False
DDI-MedLine.d141.s4	compared	54	61	O	compared	red	ared	VBN	False
DDI-MedLine.d141.s4	with	63	66	O	with	ith	with	IN	False
DDI-MedLine.d141.s4	single	68	73	O	single	gle	ngle	JJ	False
DDI-MedLine.d141.s4	metal	75	79	O	metal	tal	etal	NN	False
DDI-MedLine.d141.s4	toxicity	81	88	O	toxicity	ity	city	NN	False
DDI-MedLine.d141.s4	but	90	92	O	but	but	but	CC	False
DDI-MedLine.d141.s4	only	94	97	O	only	nly	only	RB	False
DDI-MedLine.d141.s4	at	99	100	O	at	at	at	IN	False
DDI-MedLine.d141.s4	50000	102	106	O	50000	000	0000	CD	False
DDI-MedLine.d141.s4	microg/l	108	115	O	microg/l	g/l	og/l	NN	False
DDI-MedLine.d141.s4	.	116	116	O	.	.	.	.	False

DDI-MedLine.d141.s5	Excystment	0	9	O	Excystment	ent	ment	NN	False
DDI-MedLine.d141.s5	in	11	12	O	in	in	in	IN	False
DDI-MedLine.d141.s5	vitro	14	18	O	vitro	tro	itro	NN	False
DDI-MedLine.d141.s5	was	20	22	O	was	was	was	VBD	False
DDI-MedLine.d141.s5	only	24	27	O	only	nly	only	RB	False
DDI-MedLine.d141.s5	significantly	29	41	O	significantly	tly	ntly	RB	False
DDI-MedLine.d141.s5	affected	43	50	O	affected	ted	cted	JJ	False
DDI-MedLine.d141.s5	by	52	53	O	by	by	by	IN	False
DDI-MedLine.d141.s5	cercariae	55	63	O	cercariae	iae	riae	NN	False
DDI-MedLine.d141.s5	exposed	65	71	O	exposed	sed	osed	VBN	False
DDI-MedLine.d141.s5	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d141.s5	cadmium/zinc	76	87	O	cadmium/zinc	inc	zinc	NN	False
DDI-MedLine.d141.s5	mixtures	89	96	O	mixtures	res	ures	NNS	False
DDI-MedLine.d141.s5	whilst	98	103	O	whilst	lst	ilst	NN	False
DDI-MedLine.d141.s5	encysting	105	113	O	encysting	ing	ting	VBG	False
DDI-MedLine.d141.s5	.	114	114	O	.	.	.	.	False

DDI-MedLine.d141.s6	Twenty-four	0	10	O	Twenty-four	our	four	NN	False
DDI-MedLine.d141.s6	h	12	12	O	h	h	h	NN	False
DDI-MedLine.d141.s6	exposures	14	22	O	exposures	res	ures	NNS	False
DDI-MedLine.d141.s6	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d141.s6	fully	27	31	O	fully	lly	ully	RB	False
DDI-MedLine.d141.s6	formed	33	38	O	formed	med	rmed	VBN	False
DDI-MedLine.d141.s6	cysts	40	44	O	cysts	sts	ysts	NNS	False
DDI-MedLine.d141.s6	had	46	48	O	had	had	had	VBD	False
DDI-MedLine.d141.s6	no	50	51	O	no	no	no	DT	False
DDI-MedLine.d141.s6	effect	53	58	O	effect	ect	fect	NN	False
DDI-MedLine.d141.s6	on	60	61	O	on	on	on	IN	False
DDI-MedLine.d141.s6	excystment	63	72	O	excystment	ent	ment	NN	False
DDI-MedLine.d141.s6	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d141.s6	vitro	77	81	O	vitro	tro	itro	NN	False
DDI-MedLine.d141.s6	.	82	82	O	.	.	.	.	False

DDI-MedLine.d141.s7	Effects	0	6	O	Effects	cts	ects	NNS	False
DDI-MedLine.d141.s7	on	8	9	O	on	on	on	IN	False
DDI-MedLine.d141.s7	in	11	12	O	in	in	in	IN	False
DDI-MedLine.d141.s7	vitro	14	18	O	vitro	tro	itro	NN	False
DDI-MedLine.d141.s7	excystment	20	29	O	excystment	ent	ment	NN	False
DDI-MedLine.d141.s7	rates	31	35	O	rates	tes	ates	NNS	False
DDI-MedLine.d141.s7	over	37	40	O	over	ver	over	IN	False
DDI-MedLine.d141.s7	a	42	42	O	a	a	a	DT	False
DDI-MedLine.d141.s7	2	44	44	O	2	2	2	CD	False
DDI-MedLine.d141.s7	h	46	46	O	h	h	h	NN	False
DDI-MedLine.d141.s7	period	48	53	O	period	iod	riod	NN	False
DDI-MedLine.d141.s7	demonstrated	55	66	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d141.s7	widespread	68	77	O	widespread	ead	read	JJ	False
DDI-MedLine.d141.s7	effects	79	85	O	effects	cts	ects	NNS	False
DDI-MedLine.d141.s7	for	87	89	O	for	for	for	IN	False
DDI-MedLine.d141.s7	cercariae-exposed	91	107	O	cercariae-exposed	sed	osed	JJ	False
DDI-MedLine.d141.s7	P	109	109	O	P	P	P	NN	brand
DDI-MedLine.d141.s7	.	110	110	O	.	.	.	.	False

DDI-MedLine.d141.s8	acanthus	0	7	O	acanthus	hus	thus	RB	False
DDI-MedLine.d141.s8	.	8	8	O	.	.	.	.	False

DDI-MedLine.d141.s9	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d141.s9	effects	3	9	O	effects	cts	ects	NNS	False
DDI-MedLine.d141.s9	were	11	14	O	were	ere	were	VBD	False
DDI-MedLine.d141.s9	evident	16	22	O	evident	ent	dent	NN	False
DDI-MedLine.d141.s9	on	24	25	O	on	on	on	IN	False
DDI-MedLine.d141.s9	excystment	27	36	O	excystment	ent	ment	NN	False
DDI-MedLine.d141.s9	rates	38	42	O	rates	tes	ates	NNS	False
DDI-MedLine.d141.s9	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d141.s9	cyst-exposed	47	58	O	cyst-exposed	sed	osed	JJ	False
DDI-MedLine.d141.s9	parasites	60	68	O	parasites	tes	ites	NNS	False
DDI-MedLine.d141.s9	.	69	69	O	.	.	.	.	False

DDI-MedLine.d103.s0	Magnesium	0	8	B-drug	Magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s0	and	10	12	O	and	and	and	CC	False
DDI-MedLine.d103.s0	therapeutics	14	25	O	therapeutics	ics	tics	NNS	False
DDI-MedLine.d103.s0	.	26	26	O	.	.	.	.	False

DDI-MedLine.d103.s1	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d103.s1	different	4	12	O	different	ent	rent	JJ	False
DDI-MedLine.d103.s1	types	14	18	O	types	pes	ypes	NNS	False
DDI-MedLine.d103.s1	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d103.s1	therapy	23	29	O	therapy	apy	rapy	NN	False
DDI-MedLine.d103.s1	with	31	34	O	with	ith	with	IN	False
DDI-MedLine.d103.s1	magnesium	36	44	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s1	are	46	48	O	are	are	are	VBP	False
DDI-MedLine.d103.s1	used	50	53	O	used	sed	used	VBN	False
DDI-MedLine.d103.s1	:	54	54	O	:	:	:	:	False
DDI-MedLine.d103.s1	physiological	56	68	O	physiological	cal	ical	JJ	False
DDI-MedLine.d103.s1	oral	70	73	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s1	magnesium	75	83	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s1	supplementation	85	99	O	supplementation	ion	tion	NN	False
DDI-MedLine.d103.s1	which	101	105	O	which	ich	hich	WDT	False
DDI-MedLine.d103.s1	is	107	108	O	is	is	is	VBZ	False
DDI-MedLine.d103.s1	totally	110	116	O	totally	lly	ally	RB	False
DDI-MedLine.d103.s1	atoxic	118	123	O	atoxic	xic	oxic	NN	False
DDI-MedLine.d103.s1	since	125	129	O	since	nce	ince	IN	False
DDI-MedLine.d103.s1	it	131	132	O	it	it	it	PRP	False
DDI-MedLine.d103.s1	palliates	134	142	O	palliates	tes	ates	NNS	False
DDI-MedLine.d103.s1	magnesium	144	152	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s1	deficiencies	154	165	O	deficiencies	ies	cies	NNS	False
DDI-MedLine.d103.s1	by	167	168	O	by	by	by	IN	False
DDI-MedLine.d103.s1	simply	170	175	O	simply	ply	mply	RB	False
DDI-MedLine.d103.s1	normalizing	177	187	O	normalizing	ing	zing	VBG	False
DDI-MedLine.d103.s1	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d103.s1	magnesium	193	201	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s1	intake	203	208	O	intake	ake	take	NN	False
DDI-MedLine.d103.s1	and	210	212	O	and	and	and	CC	False
DDI-MedLine.d103.s1	pharmacological	214	228	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s1	magnesium	230	238	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s1	therapy	240	246	O	therapy	apy	rapy	NN	False
DDI-MedLine.d103.s1	which	248	252	O	which	ich	hich	WDT	False
DDI-MedLine.d103.s1	may	254	256	O	may	may	may	MD	False
DDI-MedLine.d103.s1	induce	258	263	O	induce	uce	duce	NN	False
DDI-MedLine.d103.s1	toxicity	265	272	O	toxicity	ity	city	NN	False
DDI-MedLine.d103.s1	since	274	278	O	since	nce	ince	IN	False
DDI-MedLine.d103.s1	it	280	281	O	it	it	it	PRP	False
DDI-MedLine.d103.s1	creates	283	289	O	creates	tes	ates	NNS	False
DDI-MedLine.d103.s1	iatrogenic	291	300	O	iatrogenic	nic	enic	NN	False
DDI-MedLine.d103.s1	magnesium	302	310	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s1	overload	312	319	O	overload	oad	load	NN	False
DDI-MedLine.d103.s1	.	320	320	O	.	.	.	.	False

DDI-MedLine.d103.s2	Primary	0	6	O	Primary	ary	mary	JJ	False
DDI-MedLine.d103.s2	and	8	10	O	and	and	and	CC	False
DDI-MedLine.d103.s2	secondary	12	20	O	secondary	ary	dary	JJ	False
DDI-MedLine.d103.s2	magnesium	22	30	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s2	deficiencies	32	43	O	deficiencies	ies	cies	NNS	False
DDI-MedLine.d103.s2	constitute	45	54	O	constitute	ute	tute	NN	False
DDI-MedLine.d103.s2	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d103.s2	sole	60	63	O	sole	ole	sole	NN	False
DDI-MedLine.d103.s2	indication	65	74	O	indication	ion	tion	NN	False
DDI-MedLine.d103.s2	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d103.s2	physiological	79	91	O	physiological	cal	ical	JJ	False
DDI-MedLine.d103.s2	oral	93	96	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s2	magnesium	98	106	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s2	therapy	108	114	O	therapy	apy	rapy	NN	False
DDI-MedLine.d103.s2	.	115	115	O	.	.	.	.	False

DDI-MedLine.d103.s3	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d103.s3	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d103.s3	therefore	6	14	O	therefore	ore	fore	RB	False
DDI-MedLine.d103.s3	necessary	16	24	O	necessary	ary	sary	JJ	False
DDI-MedLine.d103.s3	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d103.s3	be	29	30	O	be	be	be	VB	False
DDI-MedLine.d103.s3	well	32	35	O	well	ell	well	RB	False
DDI-MedLine.d103.s3	acquainted	37	46	O	acquainted	ted	nted	VBN	False
DDI-MedLine.d103.s3	with	48	51	O	with	ith	with	IN	False
DDI-MedLine.d103.s3	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d103.s3	clinical	57	64	O	clinical	cal	ical	JJ	False
DDI-MedLine.d103.s3	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d103.s3	paraclinical	70	81	O	paraclinical	cal	ical	JJ	False
DDI-MedLine.d103.s3	pattern	83	89	O	pattern	ern	tern	NN	False
DDI-MedLine.d103.s3	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d103.s3	magnesium	94	102	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s3	deficit	104	110	O	deficit	cit	icit	NN	False
DDI-MedLine.d103.s3	and	112	114	O	and	and	and	CC	False
DDI-MedLine.d103.s3	to	116	117	O	to	to	to	TO	False
DDI-MedLine.d103.s3	discriminate	119	130	O	discriminate	ate	nate	NN	False
DDI-MedLine.d103.s3	between	132	138	O	between	een	ween	IN	False
DDI-MedLine.d103.s3	magnesium	140	148	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s3	deficiency	150	159	O	deficiency	ncy	ency	NN	False
DDI-MedLine.d103.s3	due	161	163	O	due	due	due	JJ	False
DDI-MedLine.d103.s3	to	165	166	O	to	to	to	TO	False
DDI-MedLine.d103.s3	an	168	169	O	an	an	an	DT	False
DDI-MedLine.d103.s3	insufficient	171	182	O	insufficient	ent	ient	NN	False
DDI-MedLine.d103.s3	magnesium	184	192	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s3	intake	194	199	O	intake	ake	take	NN	False
DDI-MedLine.d103.s3	which	201	205	O	which	ich	hich	WDT	False
DDI-MedLine.d103.s3	only	207	210	O	only	nly	only	RB	False
DDI-MedLine.d103.s3	requires	212	219	O	requires	res	ires	VBZ	False
DDI-MedLine.d103.s3	oral	221	224	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s3	physiological	226	238	O	physiological	cal	ical	JJ	False
DDI-MedLine.d103.s3	supplementation	240	254	O	supplementation	ion	tion	NN	False
DDI-MedLine.d103.s3	and	256	258	O	and	and	and	CC	False
DDI-MedLine.d103.s3	magnesium	260	268	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s3	depletion	270	278	O	depletion	ion	tion	NN	False
DDI-MedLine.d103.s3	related	280	286	O	related	ted	ated	JJ	False
DDI-MedLine.d103.s3	to	288	289	O	to	to	to	TO	False
DDI-MedLine.d103.s3	a	291	291	O	a	a	a	DT	False
DDI-MedLine.d103.s3	dysregulation	293	305	O	dysregulation	ion	tion	NN	False
DDI-MedLine.d103.s3	of	307	308	O	of	of	of	IN	False
DDI-MedLine.d103.s3	the	310	312	O	the	the	the	DT	False
DDI-MedLine.d103.s3	control	314	320	O	control	rol	trol	NN	False
DDI-MedLine.d103.s3	mechanisms	322	331	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d103.s3	of	333	334	O	of	of	of	IN	False
DDI-MedLine.d103.s3	magnesium	336	344	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s3	status	346	351	O	status	tus	atus	NN	False
DDI-MedLine.d103.s3	which	353	357	O	which	ich	hich	WDT	False
DDI-MedLine.d103.s3	requires	359	366	O	requires	res	ires	VBZ	False
DDI-MedLine.d103.s3	more	368	371	O	more	ore	more	RBR	False
DDI-MedLine.d103.s3	or	373	374	O	or	or	or	CC	False
DDI-MedLine.d103.s3	less	376	379	O	less	ess	less	RBR	False
DDI-MedLine.d103.s3	specific	381	388	O	specific	fic	ific	JJ	False
DDI-MedLine.d103.s3	regulation	390	399	O	regulation	ion	tion	NN	False
DDI-MedLine.d103.s3	of	401	402	O	of	of	of	IN	False
DDI-MedLine.d103.s3	its	404	406	O	its	its	its	PRP$	False
DDI-MedLine.d103.s3	causal	408	413	O	causal	sal	usal	NN	False
DDI-MedLine.d103.s3	dysregulation	415	427	O	dysregulation	ion	tion	NN	False
DDI-MedLine.d103.s3	.	428	428	O	.	.	.	.	False

DDI-MedLine.d103.s4	Physiological	0	12	O	Physiological	cal	ical	JJ	False
DDI-MedLine.d103.s4	oral	14	17	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s4	magnesium	19	27	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s4	load	29	32	O	load	oad	load	NN	False
DDI-MedLine.d103.s4	constitutes	34	44	O	constitutes	tes	utes	NNS	False
DDI-MedLine.d103.s4	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d103.s4	best	50	53	O	best	est	best	JJS	False
DDI-MedLine.d103.s4	tool	55	58	O	tool	ool	tool	NN	False
DDI-MedLine.d103.s4	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d103.s4	diagnosis	64	72	O	diagnosis	sis	osis	NN	False
DDI-MedLine.d103.s4	of	74	75	O	of	of	of	IN	False
DDI-MedLine.d103.s4	magnesium	77	85	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s4	deficiency	87	96	O	deficiency	ncy	ency	NN	False
DDI-MedLine.d103.s4	and	98	100	O	and	and	and	CC	False
DDI-MedLine.d103.s4	the	102	104	O	the	the	the	DT	False
DDI-MedLine.d103.s4	first	106	110	O	first	rst	irst	RB	False
DDI-MedLine.d103.s4	step	112	115	O	step	tep	step	NN	False
DDI-MedLine.d103.s4	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d103.s4	its	120	122	O	its	its	its	PRP$	False
DDI-MedLine.d103.s4	treatment	124	132	O	treatment	ent	ment	NN	False
DDI-MedLine.d103.s4	.	133	133	O	.	.	.	.	False

DDI-MedLine.d103.s5	Physiological	0	12	O	Physiological	cal	ical	JJ	False
DDI-MedLine.d103.s5	oral	14	17	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s5	magnesium	19	27	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s5	supplementation	29	43	O	supplementation	ion	tion	NN	False
DDI-MedLine.d103.s5	(	45	45	O	(	(	(	(	False
DDI-MedLine.d103.s5	5	46	46	O	5	5	5	CD	False
DDI-MedLine.d103.s5	mg/kg/day	48	56	O	mg/kg/day	day	/day	NN	False
DDI-MedLine.d103.s5	)	57	57	O	)	)	)	)	False
DDI-MedLine.d103.s5	is	59	60	O	is	is	is	VBZ	False
DDI-MedLine.d103.s5	easy	62	65	O	easy	asy	easy	JJ	False
DDI-MedLine.d103.s5	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d103.s5	can	71	73	O	can	can	can	MD	False
DDI-MedLine.d103.s5	be	75	76	O	be	be	be	VB	False
DDI-MedLine.d103.s5	carried	78	84	O	carried	ied	ried	VBN	False
DDI-MedLine.d103.s5	out	86	88	O	out	out	out	IN	False
DDI-MedLine.d103.s5	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d103.s5	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d103.s5	diet	97	100	O	diet	iet	diet	NN	False
DDI-MedLine.d103.s5	or	102	103	O	or	or	or	CC	False
DDI-MedLine.d103.s5	with	105	108	O	with	ith	with	IN	False
DDI-MedLine.d103.s5	magnesium	110	118	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s5	salts	120	124	O	salts	lts	alts	NNS	False
DDI-MedLine.d103.s5	,	125	125	O	,	,	,	,	False
DDI-MedLine.d103.s5	with	127	130	O	with	ith	with	IN	False
DDI-MedLine.d103.s5	practically	132	142	O	practically	lly	ally	RB	False
DDI-MedLine.d103.s5	only	144	147	O	only	nly	only	RB	False
DDI-MedLine.d103.s5	one	149	151	O	one	one	one	CD	False
DDI-MedLine.d103.s5	contra-indication	153	169	O	contra-indication	ion	tion	NN	False
DDI-MedLine.d103.s5	:	170	170	O	:	:	:	:	False
DDI-MedLine.d103.s5	overt	172	176	O	overt	ert	vert	NN	False
DDI-MedLine.d103.s5	renal	178	182	O	renal	nal	enal	NN	False
DDI-MedLine.d103.s5	failure	184	190	O	failure	ure	lure	NN	False
DDI-MedLine.d103.s5	.	191	191	O	.	.	.	.	False

DDI-MedLine.d103.s6	Specific	0	7	O	Specific	fic	ific	JJ	False
DDI-MedLine.d103.s6	and	9	11	O	and	and	and	CC	False
DDI-MedLine.d103.s6	aspecific	13	21	O	aspecific	fic	ific	NN	False
DDI-MedLine.d103.s6	treatments	23	32	O	treatments	nts	ents	NNS	False
DDI-MedLine.d103.s6	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d103.s6	magnesium	37	45	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s6	depletion	47	55	O	depletion	ion	tion	NN	False
DDI-MedLine.d103.s6	are	57	59	O	are	are	are	VBP	False
DDI-MedLine.d103.s6	tricky	61	66	O	tricky	cky	icky	NN	False
DDI-MedLine.d103.s6	using	68	72	O	using	ing	sing	VBG	False
DDI-MedLine.d103.s6	for	74	76	O	for	for	for	IN	False
DDI-MedLine.d103.s6	example	78	84	O	example	ple	mple	NN	False
DDI-MedLine.d103.s6	magnesium	86	94	B-group	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s6	sparing	96	102	I-group	sparing	ing	ring	VBG	False
DDI-MedLine.d103.s6	diuretics	104	112	I-group	diuretics	ics	tics	NNS	False
DDI-MedLine.d103.s6	,	113	113	O	,	,	,	,	False
DDI-MedLine.d103.s6	pharmacological	115	129	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s6	doses	131	135	O	doses	ses	oses	NNS	False
DDI-MedLine.d103.s6	of	137	138	O	of	of	of	IN	False
DDI-MedLine.d103.s6	vitamin	140	146	B-drug	vitamin	min	amin	NN	False
DDI-MedLine.d103.s6	B6	148	149	I-drug	B6	B6	B6	NN	brand
DDI-MedLine.d103.s6	,	150	150	O	,	,	,	,	False
DDI-MedLine.d103.s6	physiological	152	164	O	physiological	cal	ical	JJ	False
DDI-MedLine.d103.s6	doses	166	170	O	doses	ses	oses	NNS	False
DDI-MedLine.d103.s6	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d103.s6	vitamin	175	181	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d103.s6	D	183	183	I-group	D	D	D	NN	brand
DDI-MedLine.d103.s6	and	185	187	O	and	and	and	CC	False
DDI-MedLine.d103.s6	of	189	190	O	of	of	of	IN	False
DDI-MedLine.d103.s6	selenium	192	199	B-drug	selenium	ium	nium	NN	drug
DDI-MedLine.d103.s6	.	200	200	O	.	.	.	.	False

DDI-MedLine.d103.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d103.s7	order	3	7	O	order	der	rder	NN	False
DDI-MedLine.d103.s7	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d103.s7	use	12	14	O	use	use	use	NN	False
DDI-MedLine.d103.s7	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d103.s7	pharmacological	20	34	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s7	properties	36	45	O	properties	ies	ties	NNS	False
DDI-MedLine.d103.s7	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d103.s7	induced	50	56	O	induced	ced	uced	JJ	False
DDI-MedLine.d103.s7	therapeutic	58	68	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d103.s7	hypermagnesaemia	70	85	O	hypermagnesaemia	mia	emia	NN	False
DDI-MedLine.d103.s7	,	86	86	O	,	,	,	,	False
DDI-MedLine.d103.s7	high	88	91	O	high	igh	high	JJ	False
DDI-MedLine.d103.s7	oral	93	96	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s7	doses	98	102	O	doses	ses	oses	NNS	False
DDI-MedLine.d103.s7	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d103.s7	magnesium	107	115	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s7	(	117	117	O	(	(	(	(	False
DDI-MedLine.d103.s7	>	118	118	O	>	>	>	NN	False
DDI-MedLine.d103.s7	10	120	121	O	10	10	10	CD	False
DDI-MedLine.d103.s7	mg/kg/day	123	131	O	mg/kg/day	day	/day	NN	False
DDI-MedLine.d103.s7	)	132	132	O	)	)	)	)	False
DDI-MedLine.d103.s7	are	134	136	O	are	are	are	VBP	False
DDI-MedLine.d103.s7	advisable	138	146	O	advisable	ble	able	JJ	False
DDI-MedLine.d103.s7	for	148	150	O	for	for	for	IN	False
DDI-MedLine.d103.s7	chronic	152	158	O	chronic	nic	onic	NN	False
DDI-MedLine.d103.s7	indications	160	170	O	indications	ons	ions	NNS	False
DDI-MedLine.d103.s7	and	172	174	O	and	and	and	CC	False
DDI-MedLine.d103.s7	the	176	178	O	the	the	the	DT	False
DDI-MedLine.d103.s7	parenteral	180	189	O	parenteral	ral	eral	JJ	False
DDI-MedLine.d103.s7	route	191	195	O	route	ute	oute	NN	False
DDI-MedLine.d103.s7	is	197	198	O	is	is	is	VBZ	False
DDI-MedLine.d103.s7	suitable	200	207	O	suitable	ble	able	JJ	False
DDI-MedLine.d103.s7	for	209	211	O	for	for	for	IN	False
DDI-MedLine.d103.s7	acute	213	217	O	acute	ute	cute	NN	False
DDI-MedLine.d103.s7	indications	219	229	O	indications	ons	ions	NNS	False
DDI-MedLine.d103.s7	.	230	230	O	.	.	.	.	False

DDI-MedLine.d103.s8	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d103.s8	are	6	8	O	are	are	are	VBP	False
DDI-MedLine.d103.s8	3	10	10	O	3	3	3	CD	False
DDI-MedLine.d103.s8	types	12	16	O	types	pes	ypes	NNS	False
DDI-MedLine.d103.s8	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d103.s8	indications	21	31	O	indications	ons	ions	NNS	False
DDI-MedLine.d103.s8	:	32	32	O	:	:	:	:	False
DDI-MedLine.d103.s8	specific	34	41	O	specific	fic	ific	JJ	False
DDI-MedLine.d103.s8	(	43	43	O	(	(	(	(	False
DDI-MedLine.d103.s8	for	44	46	O	for	for	for	IN	False
DDI-MedLine.d103.s8	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d103.s8	treatment	52	60	O	treatment	ent	ment	NN	False
DDI-MedLine.d103.s8	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d103.s8	some	65	68	O	some	ome	some	DT	False
DDI-MedLine.d103.s8	forms	70	74	O	forms	rms	orms	NNS	False
DDI-MedLine.d103.s8	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d103.s8	magnesium	79	87	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s8	deficit	89	95	O	deficit	cit	icit	NN	False
DDI-MedLine.d103.s8	i.e	97	99	O	i.e	i.e	i.e	NN	False
DDI-MedLine.d103.s8	.	100	100	O	.	.	.	.	False
DDI-MedLine.d103.s8	acute	102	106	O	acute	ute	cute	NN	False
DDI-MedLine.d103.s8	)	107	107	O	)	)	)	)	False
DDI-MedLine.d103.s8	,	108	108	O	,	,	,	,	False
DDI-MedLine.d103.s8	pharmacological	110	124	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s8	(	126	126	O	(	(	(	(	False
DDI-MedLine.d103.s8	i.e	127	129	O	i.e	i.e	i.e	NN	False
DDI-MedLine.d103.s8	.	130	130	O	.	.	.	.	False
DDI-MedLine.d103.s8	without	132	138	O	without	out	hout	IN	False
DDI-MedLine.d103.s8	alterations	140	150	O	alterations	ons	ions	NNS	False
DDI-MedLine.d103.s8	of	152	153	O	of	of	of	IN	False
DDI-MedLine.d103.s8	magnesium	155	163	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s8	status	165	170	O	status	tus	atus	NN	False
DDI-MedLine.d103.s8	)	171	171	O	)	)	)	)	False
DDI-MedLine.d103.s8	and	173	175	O	and	and	and	CC	False
DDI-MedLine.d103.s8	mixed	177	181	O	mixed	xed	ixed	JJ	False
DDI-MedLine.d103.s8	--	182	183	O	--	--	--	:	False
DDI-MedLine.d103.s8	pharmacological	184	198	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s8	and	200	202	O	and	and	and	CC	False
DDI-MedLine.d103.s8	aetiopathogenic	204	218	O	aetiopathogenic	nic	enic	NN	False
DDI-MedLine.d103.s8	--	219	220	O	--	--	--	:	False
DDI-MedLine.d103.s8	(	221	221	O	(	(	(	(	False
DDI-MedLine.d103.s8	for	222	224	O	for	for	for	IN	False
DDI-MedLine.d103.s8	example	226	232	O	example	ple	mple	NN	False
DDI-MedLine.d103.s8	complications	234	246	O	complications	ons	ions	NNS	False
DDI-MedLine.d103.s8	of	248	249	O	of	of	of	IN	False
DDI-MedLine.d103.s8	chronic	251	257	O	chronic	nic	onic	NN	False
DDI-MedLine.d103.s8	alcoholism	259	268	O	alcoholism	ism	lism	NN	False
DDI-MedLine.d103.s8	)	269	269	O	)	)	)	)	False
DDI-MedLine.d103.s8	.	270	270	O	.	.	.	.	False

DDI-MedLine.d103.s9	Today	0	4	O	Today	day	oday	NN	False
DDI-MedLine.d103.s9	pharmacological	6	20	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s9	magnesium	22	30	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s9	therapy	32	38	O	therapy	apy	rapy	NN	False
DDI-MedLine.d103.s9	mainly	40	45	O	mainly	nly	inly	RB	False
DDI-MedLine.d103.s9	concerns	47	54	O	concerns	rns	erns	NNS	False
DDI-MedLine.d103.s9	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d103.s9	obstetrical	60	70	O	obstetrical	cal	ical	JJ	False
DDI-MedLine.d103.s9	,	71	71	O	,	,	,	,	False
DDI-MedLine.d103.s9	cardiological	73	85	O	cardiological	cal	ical	JJ	False
DDI-MedLine.d103.s9	and	87	89	O	and	and	and	CC	False
DDI-MedLine.d103.s9	anaesthesiological	91	108	O	anaesthesiological	cal	ical	JJ	False
DDI-MedLine.d103.s9	fields	110	115	O	fields	lds	elds	NNS	False
DDI-MedLine.d103.s9	.	116	116	O	.	.	.	.	False

DDI-MedLine.d103.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d103.s10	main	4	7	O	main	ain	main	JJ	False
DDI-MedLine.d103.s10	indications	9	19	O	indications	ons	ions	NNS	False
DDI-MedLine.d103.s10	are	21	23	O	are	are	are	VBP	False
DDI-MedLine.d103.s10	eclampsia	25	33	O	eclampsia	sia	psia	NN	False
DDI-MedLine.d103.s10	,	34	34	O	,	,	,	,	False
DDI-MedLine.d103.s10	some	36	39	O	some	ome	some	DT	False
DDI-MedLine.d103.s10	dysrhythmias	41	52	O	dysrhythmias	ias	mias	NN	False
DDI-MedLine.d103.s10	(	54	54	O	(	(	(	(	False
DDI-MedLine.d103.s10	torsades	55	62	O	torsades	des	ades	NNS	False
DDI-MedLine.d103.s10	de	64	65	O	de	de	de	NNS	False
DDI-MedLine.d103.s10	pointe	67	72	O	pointe	nte	inte	NN	False
DDI-MedLine.d103.s10	particularly	74	85	O	particularly	rly	arly	RB	False
DDI-MedLine.d103.s10	)	86	86	O	)	)	)	)	False
DDI-MedLine.d103.s10	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d103.s10	myocardial	92	101	O	myocardial	ial	dial	NN	False
DDI-MedLine.d103.s10	ischaemias	103	112	O	ischaemias	ias	mias	NN	False
DDI-MedLine.d103.s10	.	113	113	O	.	.	.	.	False

DDI-MedLine.d103.s11	But	0	2	O	But	But	But	CC	False
DDI-MedLine.d103.s11	it	4	5	O	it	it	it	PRP	False
DDI-MedLine.d103.s11	is	7	8	O	is	is	is	VBZ	False
DDI-MedLine.d103.s11	now	10	12	O	now	now	now	RB	False
DDI-MedLine.d103.s11	difficult	14	22	O	difficult	ult	cult	JJ	False
DDI-MedLine.d103.s11	to	24	25	O	to	to	to	TO	False
DDI-MedLine.d103.s11	situate	27	33	O	situate	ate	uate	NN	False
DDI-MedLine.d103.s11	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d103.s11	exact	39	43	O	exact	act	xact	NN	False
DDI-MedLine.d103.s11	place	45	49	O	place	ace	lace	NN	False
DDI-MedLine.d103.s11	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d103.s11	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d103.s11	pharmacological	58	72	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d103.s11	indications	74	84	O	indications	ons	ions	NNS	False
DDI-MedLine.d103.s11	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d103.s11	magnesium	89	97	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s11	.	98	98	O	.	.	.	.	False

DDI-MedLine.d103.s12	Magnesium	0	8	B-drug	Magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s12	infusions	10	18	O	infusions	ons	ions	NNS	False
DDI-MedLine.d103.s12	can	20	22	O	can	can	can	MD	False
DDI-MedLine.d103.s12	only	24	27	O	only	nly	only	RB	False
DDI-MedLine.d103.s12	be	29	30	O	be	be	be	VB	False
DDI-MedLine.d103.s12	envisaged	32	40	O	envisaged	ged	aged	VBN	False
DDI-MedLine.d103.s12	in	42	43	O	in	in	in	IN	False
DDI-MedLine.d103.s12	intensive	45	53	O	intensive	ive	sive	JJ	False
DDI-MedLine.d103.s12	care	55	58	O	care	are	care	NN	False
DDI-MedLine.d103.s12	units	60	64	O	units	its	nits	NNS	False
DDI-MedLine.d103.s12	with	66	69	O	with	ith	with	IN	False
DDI-MedLine.d103.s12	careful	71	77	O	careful	ful	eful	NN	False
DDI-MedLine.d103.s12	monitoring	79	88	O	monitoring	ing	ring	NN	False
DDI-MedLine.d103.s12	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d103.s12	pulse	93	97	O	pulse	lse	ulse	NN	False
DDI-MedLine.d103.s12	,	98	98	O	,	,	,	,	False
DDI-MedLine.d103.s12	arterial	100	107	O	arterial	ial	rial	JJ	False
DDI-MedLine.d103.s12	pressure	109	116	O	pressure	ure	sure	NN	False
DDI-MedLine.d103.s12	,	117	117	O	,	,	,	,	False
DDI-MedLine.d103.s12	deep	119	122	O	deep	eep	deep	NN	False
DDI-MedLine.d103.s12	tendon	124	129	O	tendon	don	ndon	NN	False
DDI-MedLine.d103.s12	reflexes	131	138	O	reflexes	xes	exes	NNS	False
DDI-MedLine.d103.s12	,	139	139	O	,	,	,	,	False
DDI-MedLine.d103.s12	hourly	141	146	O	hourly	rly	urly	RB	False
DDI-MedLine.d103.s12	diuresis	148	155	O	diuresis	sis	esis	NN	False
DDI-MedLine.d103.s12	,	156	156	O	,	,	,	,	False
DDI-MedLine.d103.s12	electrocardiogram	158	174	O	electrocardiogram	ram	gram	NN	False
DDI-MedLine.d103.s12	and	176	178	O	and	and	and	CC	False
DDI-MedLine.d103.s12	respiratory	180	190	O	respiratory	ory	tory	NN	False
DDI-MedLine.d103.s12	recordings	192	201	O	recordings	ngs	ings	NNS	False
DDI-MedLine.d103.s12	.	202	202	O	.	.	.	.	False

DDI-MedLine.d103.s13	High	0	3	O	High	igh	High	JJ	False
DDI-MedLine.d103.s13	oral	5	8	O	oral	ral	oral	JJ	False
DDI-MedLine.d103.s13	magnesium	10	18	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s13	doses	20	24	O	doses	ses	oses	NNS	False
DDI-MedLine.d103.s13	besides	26	32	O	besides	des	ides	IN	group
DDI-MedLine.d103.s13	their	34	38	O	their	eir	heir	PRP$	False
DDI-MedLine.d103.s13	laxative	40	47	O	laxative	ive	tive	NN	False
DDI-MedLine.d103.s13	action	49	54	O	action	ion	tion	NN	False
DDI-MedLine.d103.s13	may	56	58	O	may	may	may	MD	False
DDI-MedLine.d103.s13	bring	60	64	O	bring	ing	ring	NN	False
DDI-MedLine.d103.s13	latent	66	71	O	latent	ent	tent	NN	False
DDI-MedLine.d103.s13	complications	73	85	O	complications	ons	ions	NNS	False
DDI-MedLine.d103.s13	which	87	91	O	which	ich	hich	WDT	False
DDI-MedLine.d103.s13	may	93	95	O	may	may	may	MD	False
DDI-MedLine.d103.s13	reduce	97	102	O	reduce	uce	duce	VB	False
DDI-MedLine.d103.s13	lifespan	104	111	O	lifespan	pan	span	NN	False
DDI-MedLine.d103.s13	.	112	112	O	.	.	.	.	False

DDI-MedLine.d103.s14	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d103.s14	may	6	8	O	may	may	may	MD	False
DDI-MedLine.d103.s14	remain	10	15	O	remain	ain	main	NN	False
DDI-MedLine.d103.s14	some	17	20	O	some	ome	some	DT	False
DDI-MedLine.d103.s14	indications	22	32	O	indications	ons	ions	NNS	False
DDI-MedLine.d103.s14	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d103.s14	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d103.s14	laxative	41	48	O	laxative	ive	tive	NN	False
DDI-MedLine.d103.s14	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d103.s14	antacid	54	60	O	antacid	cid	acid	NN	False
DDI-MedLine.d103.s14	properties	62	71	O	properties	ies	ties	NNS	False
DDI-MedLine.d103.s14	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d103.s14	non	76	78	O	non	non	non	NN	False
DDI-MedLine.d103.s14	soluble	80	86	O	soluble	ble	uble	JJ	False
DDI-MedLine.d103.s14	magnesium	88	96	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s14	,	97	97	O	,	,	,	,	False
DDI-MedLine.d103.s14	particularly	99	110	O	particularly	rly	arly	RB	False
DDI-MedLine.d103.s14	during	112	117	O	during	ing	ring	IN	False
DDI-MedLine.d103.s14	intermittent	119	130	O	intermittent	ent	tent	NN	False
DDI-MedLine.d103.s14	haemodialysis	132	144	O	haemodialysis	sis	ysis	NN	False
DDI-MedLine.d103.s14	.	145	145	O	.	.	.	.	False

DDI-MedLine.d103.s15	Lastly	0	5	O	Lastly	tly	stly	RB	False
DDI-MedLine.d103.s15	local	7	11	O	local	cal	ocal	JJ	False
DDI-MedLine.d103.s15	use	13	15	O	use	use	use	NN	False
DDI-MedLine.d103.s15	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d103.s15	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d103.s15	mucocutaneous	24	36	O	mucocutaneous	ous	eous	JJ	False
DDI-MedLine.d103.s15	and	38	40	O	and	and	and	CC	False
DDI-MedLine.d103.s15	cytoprotective	42	55	O	cytoprotective	ive	tive	NN	False
DDI-MedLine.d103.s15	properties	57	66	O	properties	ies	ties	NNS	False
DDI-MedLine.d103.s15	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d103.s15	magnesium	71	79	B-drug	magnesium	ium	sium	NN	drug
DDI-MedLine.d103.s15	is	81	82	O	is	is	is	VBZ	False
DDI-MedLine.d103.s15	still	84	88	O	still	ill	till	RB	False
DDI-MedLine.d103.s15	valid	90	94	O	valid	lid	alid	JJ	False
DDI-MedLine.d103.s15	,	95	95	O	,	,	,	,	False
DDI-MedLine.d103.s15	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d103.s15	cardioplegic	100	111	B-drug	cardioplegic	gic	egic	NN	False
DDI-MedLine.d103.s15	solutions	113	121	I-drug	solutions	ons	ions	NNS	False
DDI-MedLine.d103.s15	and	123	125	O	and	and	and	CC	False
DDI-MedLine.d103.s15	for	127	129	O	for	for	for	IN	False
DDI-MedLine.d103.s15	preservation	131	142	O	preservation	ion	tion	NN	False
DDI-MedLine.d103.s15	of	144	145	O	of	of	of	IN	False
DDI-MedLine.d103.s15	transplants	147	157	O	transplants	nts	ants	NNS	False
DDI-MedLine.d103.s15	particularly	159	170	O	particularly	rly	arly	RB	False
DDI-MedLine.d103.s15	.	171	171	O	.	.	.	.	False

DDI-MedLine.d60.s0	Phenytoin	0	8	O	Phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s0	intoxication	10	21	O	intoxication	ion	tion	NN	False
DDI-MedLine.d60.s0	induced	23	29	O	induced	ced	uced	JJ	False
DDI-MedLine.d60.s0	by	31	32	O	by	by	by	IN	False
DDI-MedLine.d60.s0	fluvoxamine	34	44	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d60.s0	.	45	45	O	.	.	.	.	False

DDI-MedLine.d60.s1	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d60.s1	patient	2	8	O	patient	ent	ient	NN	False
DDI-MedLine.d60.s1	had	10	12	O	had	had	had	VBD	False
DDI-MedLine.d60.s1	phenytoin	14	22	O	phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s1	intoxication	24	35	O	intoxication	ion	tion	NN	False
DDI-MedLine.d60.s1	after	37	41	O	after	ter	fter	IN	False
DDI-MedLine.d60.s1	administration	43	56	O	administration	ion	tion	NN	False
DDI-MedLine.d60.s1	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d60.s1	fluvoxamine	61	71	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d60.s1	,	72	72	O	,	,	,	,	False
DDI-MedLine.d60.s1	a	74	74	O	a	a	a	DT	False
DDI-MedLine.d60.s1	selective	76	84	O	selective	ive	tive	NN	False
DDI-MedLine.d60.s1	serotonin	86	94	O	serotonin	nin	onin	NN	False
DDI-MedLine.d60.s1	reuptake	96	103	O	reuptake	ake	take	NN	False
DDI-MedLine.d60.s1	inhibitor	105	113	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d60.s1	.	114	114	O	.	.	.	.	False

DDI-MedLine.d60.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d60.s2	serum	4	8	O	serum	rum	erum	NN	False
DDI-MedLine.d60.s2	concentration	10	22	O	concentration	ion	tion	NN	False
DDI-MedLine.d60.s2	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d60.s2	phenytoin	27	35	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s2	increased	37	45	O	increased	sed	ased	VBN	False
DDI-MedLine.d60.s2	dramatically	47	58	O	dramatically	lly	ally	RB	False
DDI-MedLine.d60.s2	from	60	63	O	from	rom	from	IN	False
DDI-MedLine.d60.s2	16.6	65	68	O	16.6	6.6	16.6	CD	False
DDI-MedLine.d60.s2	to	70	71	O	to	to	to	TO	False
DDI-MedLine.d60.s2	49.1	73	76	O	49.1	9.1	49.1	CD	False
DDI-MedLine.d60.s2	microg/mL	78	86	O	microg/mL	/mL	g/mL	NN	False
DDI-MedLine.d60.s2	when	88	91	O	when	hen	when	WRB	False
DDI-MedLine.d60.s2	fluvoxamine	93	103	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d60.s2	was	105	107	O	was	was	was	VBD	False
DDI-MedLine.d60.s2	coadministered	109	122	O	coadministered	red	ered	VBN	False
DDI-MedLine.d60.s2	,	123	123	O	,	,	,	,	False
DDI-MedLine.d60.s2	although	125	132	O	although	ugh	ough	IN	False
DDI-MedLine.d60.s2	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d60.s2	daily	138	142	O	daily	ily	aily	JJ	False
DDI-MedLine.d60.s2	dosage	144	149	O	dosage	age	sage	NN	False
DDI-MedLine.d60.s2	of	151	152	O	of	of	of	IN	False
DDI-MedLine.d60.s2	phenytoin	154	162	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s2	and	164	166	O	and	and	and	CC	False
DDI-MedLine.d60.s2	other	168	172	O	other	her	ther	JJ	False
DDI-MedLine.d60.s2	drugs	174	178	B-drug	drugs	ugs	rugs	NNS	False
DDI-MedLine.d60.s2	had	180	182	O	had	had	had	VBD	False
DDI-MedLine.d60.s2	not	184	186	O	not	not	not	RB	False
DDI-MedLine.d60.s2	changed	188	194	O	changed	ged	nged	VBN	False
DDI-MedLine.d60.s2	.	195	195	O	.	.	.	.	False

DDI-MedLine.d60.s3	During	0	5	O	During	ing	ring	IN	False
DDI-MedLine.d60.s3	phenytoin	7	15	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s3	and	17	19	O	and	and	and	CC	False
DDI-MedLine.d60.s3	fluvoxamine	21	31	O	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d60.s3	treatment	33	41	O	treatment	ent	ment	NN	False
DDI-MedLine.d60.s3	,	42	42	O	,	,	,	,	False
DDI-MedLine.d60.s3	ataxia	44	49	O	ataxia	xia	axia	NN	False
DDI-MedLine.d60.s3	,	50	50	O	,	,	,	,	False
DDI-MedLine.d60.s3	a	52	52	O	a	a	a	DT	False
DDI-MedLine.d60.s3	typical	54	60	O	typical	cal	ical	JJ	False
DDI-MedLine.d60.s3	side	62	65	O	side	ide	side	NN	False
DDI-MedLine.d60.s3	effect	67	72	O	effect	ect	fect	NN	False
DDI-MedLine.d60.s3	of	74	75	O	of	of	of	IN	False
DDI-MedLine.d60.s3	phenytoin	77	85	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s3	,	86	86	O	,	,	,	,	False
DDI-MedLine.d60.s3	was	88	90	O	was	was	was	VBD	False
DDI-MedLine.d60.s3	observed	92	99	O	observed	ved	rved	VBN	False
DDI-MedLine.d60.s3	.	100	100	O	.	.	.	.	False

DDI-MedLine.d60.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d60.s4	genotypes	4	12	O	genotypes	pes	ypes	NNS	False
DDI-MedLine.d60.s4	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d60.s4	CYP2C9	17	22	B-drug	CYP2C9	2C9	P2C9	NN	brand
DDI-MedLine.d60.s4	and	24	26	O	and	and	and	CC	False
DDI-MedLine.d60.s4	2C19	28	31	O	2C19	C19	2C19	CD	brand
DDI-MedLine.d60.s4	,	32	32	O	,	,	,	,	False
DDI-MedLine.d60.s4	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d60.s4	enzymes	38	44	O	enzymes	mes	ymes	NNS	False
DDI-MedLine.d60.s4	responsible	46	56	O	responsible	ble	ible	JJ	False
DDI-MedLine.d60.s4	for	58	60	O	for	for	for	IN	False
DDI-MedLine.d60.s4	phenytoin	62	70	O	phenytoin	oin	toin	NN	False
DDI-MedLine.d60.s4	metabolism	72	81	O	metabolism	ism	lism	NN	False
DDI-MedLine.d60.s4	,	82	82	O	,	,	,	,	False
DDI-MedLine.d60.s4	were	84	87	O	were	ere	were	VBD	False
DDI-MedLine.d60.s4	homozygous	89	98	O	homozygous	ous	gous	JJ	False
DDI-MedLine.d60.s4	for	100	102	O	for	for	for	IN	False
DDI-MedLine.d60.s4	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d60.s4	wild-type	108	116	O	wild-type	ype	type	NN	False
DDI-MedLine.d60.s4	alleles	118	124	O	alleles	les	eles	NNS	False
DDI-MedLine.d60.s4	(	126	126	O	(	(	(	(	False
DDI-MedLine.d60.s4	CYP2C9*1/*1	127	137	O	CYP2C9*1/*1	/*1	1/*1	NN	brand
DDI-MedLine.d60.s4	and	139	141	O	and	and	and	CC	False
DDI-MedLine.d60.s4	2C19*1/	143	149	O	2C19*1/	*1/	9*1/	CD	brand
DDI-MedLine.d60.s4	*1	151	152	O	*1	*1	*1	NN	False
DDI-MedLine.d60.s4	)	153	153	O	)	)	)	)	False
DDI-MedLine.d60.s4	.	154	154	O	.	.	.	.	False

DDI-MedLine.d60.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d60.s5	interaction	4	14	O	interaction	ion	tion	NN	False
DDI-MedLine.d60.s5	may	16	18	O	may	may	may	MD	False
DDI-MedLine.d60.s5	be	20	21	O	be	be	be	VB	False
DDI-MedLine.d60.s5	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d60.s5	result	25	30	O	result	ult	sult	NN	False
DDI-MedLine.d60.s5	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d60.s5	inhibition	35	44	O	inhibition	ion	tion	NN	False
DDI-MedLine.d60.s5	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d60.s5	both	49	52	O	both	oth	both	DT	False
DDI-MedLine.d60.s5	CYP2C9	54	59	B-drug	CYP2C9	2C9	P2C9	NN	brand
DDI-MedLine.d60.s5	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d60.s5	2C19	65	68	O	2C19	C19	2C19	CD	brand
DDI-MedLine.d60.s5	by	70	71	O	by	by	by	IN	False
DDI-MedLine.d60.s5	fluvoxamine	73	83	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d60.s5	.	84	84	O	.	.	.	.	False

DDI-MedLine.d80.s0	Progestin-only	0	13	O	Progestin-only	nly	only	RB	False
DDI-MedLine.d80.s0	oral	15	18	O	oral	ral	oral	JJ	False
DDI-MedLine.d80.s0	contraception	20	32	O	contraception	ion	tion	NN	False
DDI-MedLine.d80.s0	:	33	33	O	:	:	:	:	False
DDI-MedLine.d80.s0	a	35	35	O	a	a	a	DT	False
DDI-MedLine.d80.s0	comprehensive	37	49	O	comprehensive	ive	sive	NN	False
DDI-MedLine.d80.s0	review	51	56	O	review	iew	view	NN	False
DDI-MedLine.d80.s0	.	57	57	O	.	.	.	.	False

DDI-MedLine.d80.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d80.s1	order	3	7	O	order	der	rder	NN	False
DDI-MedLine.d80.s1	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d80.s1	provide	12	18	O	provide	ide	vide	NN	False
DDI-MedLine.d80.s1	information	20	30	O	information	ion	tion	NN	False
DDI-MedLine.d80.s1	for	32	34	O	for	for	for	IN	False
DDI-MedLine.d80.s1	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d80.s1	appropriate	40	50	O	appropriate	ate	iate	NN	False
DDI-MedLine.d80.s1	package	52	58	O	package	age	kage	NN	False
DDI-MedLine.d80.s1	insert	60	65	O	insert	ert	sert	NN	False
DDI-MedLine.d80.s1	labeling	67	74	O	labeling	ing	ling	VBG	False
DDI-MedLine.d80.s1	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d80.s1	progestin-only	79	92	B-group	progestin-only	nly	only	RB	False
DDI-MedLine.d80.s1	oral	94	97	I-group	oral	ral	oral	JJ	False
DDI-MedLine.d80.s1	contraceptives	99	112	I-group	contraceptives	ves	ives	NNS	False
DDI-MedLine.d80.s1	(	114	114	O	(	(	(	(	False
DDI-MedLine.d80.s1	POC	115	117	B-group	POC	POC	POC	NN	brand
DDI-MedLine.d80.s1	)	118	118	O	)	)	)	)	False
DDI-MedLine.d80.s1	in	120	121	O	in	in	in	IN	False
DDI-MedLine.d80.s1	the	123	125	O	the	the	the	DT	False
DDI-MedLine.d80.s1	US	127	128	O	US	US	US	NN	brand
DDI-MedLine.d80.s1	,	129	129	O	,	,	,	,	False
DDI-MedLine.d80.s1	a	131	131	O	a	a	a	DT	False
DDI-MedLine.d80.s1	comprehensive	133	145	O	comprehensive	ive	sive	NN	False
DDI-MedLine.d80.s1	review	147	152	O	review	iew	view	NN	False
DDI-MedLine.d80.s1	was	154	156	O	was	was	was	VBD	False
DDI-MedLine.d80.s1	made	158	161	O	made	ade	made	VBN	False
DDI-MedLine.d80.s1	of	163	164	O	of	of	of	IN	False
DDI-MedLine.d80.s1	norgestrel	166	175	B-drug	norgestrel	rel	trel	NN	False
DDI-MedLine.d80.s1	(	177	177	O	(	(	(	(	False
DDI-MedLine.d80.s1	0.075	178	182	O	0.075	075	.075	CD	False
DDI-MedLine.d80.s1	mg	184	185	O	mg	mg	mg	NN	False
DDI-MedLine.d80.s1	)	186	186	O	)	)	)	)	False
DDI-MedLine.d80.s1	and	188	190	O	and	and	and	CC	False
DDI-MedLine.d80.s1	norethindrone	192	204	B-drug	norethindrone	one	rone	NN	False
DDI-MedLine.d80.s1	(	206	206	O	(	(	(	(	False
DDI-MedLine.d80.s1	0.35	207	210	O	0.35	.35	0.35	CD	False
DDI-MedLine.d80.s1	mg	212	213	O	mg	mg	mg	NN	False
DDI-MedLine.d80.s1	)	214	214	O	)	)	)	)	False
DDI-MedLine.d80.s1	,	215	215	O	,	,	,	,	False
DDI-MedLine.d80.s1	with	217	220	O	with	ith	with	IN	False
DDI-MedLine.d80.s1	the	222	224	O	the	the	the	DT	False
DDI-MedLine.d80.s1	clinical	226	233	O	clinical	cal	ical	JJ	False
DDI-MedLine.d80.s1	differences	235	245	O	differences	ces	nces	NNS	False
DDI-MedLine.d80.s1	indicated	247	255	O	indicated	ted	ated	VBN	False
DDI-MedLine.d80.s1	where	257	261	O	where	ere	here	WRB	False
DDI-MedLine.d80.s1	applicable	263	272	O	applicable	ble	able	JJ	False
DDI-MedLine.d80.s1	.	273	273	O	.	.	.	.	False

DDI-MedLine.d80.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d80.s2	goal	4	7	O	goal	oal	goal	NN	False
DDI-MedLine.d80.s2	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d80.s2	this	12	15	O	this	his	this	DT	False
DDI-MedLine.d80.s2	review	17	22	O	review	iew	view	NN	False
DDI-MedLine.d80.s2	was	24	26	O	was	was	was	VBD	False
DDI-MedLine.d80.s2	to	28	29	O	to	to	to	TO	False
DDI-MedLine.d80.s2	cite	31	34	O	cite	ite	cite	NN	False
DDI-MedLine.d80.s2	primary	36	42	O	primary	ary	mary	NN	False
DDI-MedLine.d80.s2	sources	44	50	O	sources	ces	rces	NNS	False
DDI-MedLine.d80.s2	for	52	54	O	for	for	for	IN	False
DDI-MedLine.d80.s2	virtually	56	64	O	virtually	lly	ally	RB	False
DDI-MedLine.d80.s2	all	66	68	O	all	all	all	DT	False
DDI-MedLine.d80.s2	research	70	77	O	research	rch	arch	NN	False
DDI-MedLine.d80.s2	specific	79	86	O	specific	fic	ific	JJ	False
DDI-MedLine.d80.s2	to	88	89	O	to	to	to	TO	False
DDI-MedLine.d80.s2	POPs	91	94	O	POPs	OPs	POPs	NN	False
DDI-MedLine.d80.s2	since	96	100	O	since	nce	ince	IN	False
DDI-MedLine.d80.s2	1975	102	105	O	1975	975	1975	CD	False
DDI-MedLine.d80.s2	.	106	106	O	.	.	.	.	False

DDI-MedLine.d80.s3	Conclusions	0	10	O	Conclusions	ons	ions	NNS	False
DDI-MedLine.d80.s3	and	12	14	O	and	and	and	CC	False
DDI-MedLine.d80.s3	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d80.s3	types	20	24	O	types	pes	ypes	NNS	False
DDI-MedLine.d80.s3	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d80.s3	studies	29	35	O	studies	ies	dies	NNS	False
DDI-MedLine.d80.s3	which	37	41	O	which	ich	hich	WDT	False
DDI-MedLine.d80.s3	support	43	49	O	support	ort	port	NN	False
DDI-MedLine.d80.s3	these	51	55	O	these	ese	hese	DT	False
DDI-MedLine.d80.s3	conclusions	57	67	O	conclusions	ons	ions	NNS	False
DDI-MedLine.d80.s3	are	69	71	O	are	are	are	VBP	False
DDI-MedLine.d80.s3	given	73	77	O	given	ven	iven	VBN	False
DDI-MedLine.d80.s3	for	79	81	O	for	for	for	IN	False
DDI-MedLine.d80.s3	each	83	86	O	each	ach	each	DT	False
DDI-MedLine.d80.s3	major	88	92	O	major	jor	ajor	JJ	False
DDI-MedLine.d80.s3	section	94	100	O	section	ion	tion	NN	False
DDI-MedLine.d80.s3	.	101	101	O	.	.	.	.	False

DDI-MedLine.d80.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d80.s4	introductory	4	15	O	introductory	ory	tory	NN	False
DDI-MedLine.d80.s4	chapter	17	23	O	chapter	ter	pter	NN	False
DDI-MedLine.d80.s4	discusses	25	33	O	discusses	ses	sses	NNS	False
DDI-MedLine.d80.s4	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d80.s4	advantages	39	48	O	advantages	ges	ages	NNS	False
DDI-MedLine.d80.s4	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d80.s4	disadvantages	54	66	O	disadvantages	ges	ages	NNS	False
DDI-MedLine.d80.s4	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d80.s4	POCs	71	74	B-group	POCs	OCs	POCs	NN	False
DDI-MedLine.d80.s4	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d80.s4	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d80.s4	magnitude	84	92	O	magnitude	ude	tude	NN	False
DDI-MedLine.d80.s4	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d80.s4	prevalence	98	107	O	prevalence	nce	ence	NN	False
DDI-MedLine.d80.s4	of	109	110	O	of	of	of	IN	False
DDI-MedLine.d80.s4	their	112	116	O	their	eir	heir	PRP$	False
DDI-MedLine.d80.s4	use	118	120	O	use	use	use	NN	False
DDI-MedLine.d80.s4	.	121	121	O	.	.	.	.	False

DDI-MedLine.d80.s5	Future	0	5	O	Future	ure	ture	NN	False
DDI-MedLine.d80.s5	trends	7	12	O	trends	nds	ends	NNS	False
DDI-MedLine.d80.s5	are	14	16	O	are	are	are	VBP	False
DDI-MedLine.d80.s5	also	18	21	O	also	lso	also	RB	False
DDI-MedLine.d80.s5	predicted	23	31	O	predicted	ted	cted	VBN	False
DDI-MedLine.d80.s5	.	32	32	O	.	.	.	.	False

DDI-MedLine.d80.s6	Chapter	0	6	O	Chapter	ter	pter	NN	False
DDI-MedLine.d80.s6	2	8	8	O	2	2	2	CD	False
DDI-MedLine.d80.s6	considers	10	18	O	considers	ers	ders	NNS	False
DDI-MedLine.d80.s6	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d80.s6	mode	24	27	O	mode	ode	mode	NN	False
DDI-MedLine.d80.s6	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d80.s6	action	32	37	O	action	ion	tion	NN	False
DDI-MedLine.d80.s6	,	38	38	O	,	,	,	,	False
DDI-MedLine.d80.s6	including	40	48	O	including	ing	ding	VBG	False
DDI-MedLine.d80.s6	ovulation	50	58	O	ovulation	ion	tion	NN	False
DDI-MedLine.d80.s6	prevention	60	69	O	prevention	ion	tion	NN	False
DDI-MedLine.d80.s6	;	70	70	O	;	;	;	:	False

DDI-MedLine.d80.s7	suppression	0	10	O	suppression	ion	sion	NN	False
DDI-MedLine.d80.s7	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d80.s7	midcycle	15	22	O	midcycle	cle	ycle	NN	False
DDI-MedLine.d80.s7	gonadotropin	24	35	O	gonadotropin	pin	opin	NN	False
DDI-MedLine.d80.s7	peaks	37	41	O	peaks	aks	eaks	NNS	False
DDI-MedLine.d80.s7	;	42	42	O	;	;	;	:	False

DDI-MedLine.d80.s8	changes	0	6	O	changes	ges	nges	NNS	False
DDI-MedLine.d80.s8	in	8	9	O	in	in	in	IN	False
DDI-MedLine.d80.s8	cervical	11	18	O	cervical	cal	ical	JJ	False
DDI-MedLine.d80.s8	mucus	20	24	O	mucus	cus	ucus	NN	False
DDI-MedLine.d80.s8	,	25	25	O	,	,	,	,	False
DDI-MedLine.d80.s8	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d80.s8	endometrium	31	41	O	endometrium	ium	rium	NN	drug
DDI-MedLine.d80.s8	,	42	42	O	,	,	,	,	False
DDI-MedLine.d80.s8	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d80.s8	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d80.s8	fallopian	52	60	O	fallopian	ian	pian	JJ	False
DDI-MedLine.d80.s8	tubes	62	66	O	tubes	bes	ubes	NNS	False
DDI-MedLine.d80.s8	;	67	67	O	;	;	;	:	False

DDI-MedLine.d80.s9	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d80.s9	clinical	4	11	O	clinical	cal	ical	JJ	False
DDI-MedLine.d80.s9	implications	13	24	O	implications	ons	ions	NNS	False
DDI-MedLine.d80.s9	.	25	25	O	.	.	.	.	False

DDI-MedLine.d80.s10	Chapter	0	6	O	Chapter	ter	pter	NN	False
DDI-MedLine.d80.s10	3	8	8	O	3	3	3	CD	False
DDI-MedLine.d80.s10	covers	10	15	O	covers	ers	vers	NNS	False
DDI-MedLine.d80.s10	pharmacology	17	28	O	pharmacology	ogy	logy	NN	False
DDI-MedLine.d80.s10	(	30	30	O	(	(	(	(	False
DDI-MedLine.d80.s10	pharmacokinetics	31	46	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d80.s10	,	47	47	O	,	,	,	,	False
DDI-MedLine.d80.s10	pharmacodynamics	49	64	O	pharmacodynamics	ics	mics	NNS	False
DDI-MedLine.d80.s10	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d80.s10	potency	70	76	O	potency	ncy	ency	NN	False
DDI-MedLine.d80.s10	,	77	77	O	,	,	,	,	False
DDI-MedLine.d80.s10	and	79	81	O	and	and	and	CC	False
DDI-MedLine.d80.s10	clinical	83	90	O	clinical	cal	ical	JJ	False
DDI-MedLine.d80.s10	implications	92	103	O	implications	ons	ions	NNS	False
DDI-MedLine.d80.s10	)	104	104	O	)	)	)	)	False
DDI-MedLine.d80.s10	.	105	105	O	.	.	.	.	False

DDI-MedLine.d80.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d80.s11	next	4	7	O	next	ext	next	JJ	False
DDI-MedLine.d80.s11	chapter	9	15	O	chapter	ter	pter	NN	False
DDI-MedLine.d80.s11	presents	17	24	O	presents	nts	ents	NNS	False
DDI-MedLine.d80.s11	information	26	36	O	information	ion	tion	NN	False
DDI-MedLine.d80.s11	on	38	39	O	on	on	on	IN	False
DDI-MedLine.d80.s11	efficacy	41	48	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d80.s11	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d80.s11	pregnancy	54	62	O	pregnancy	ncy	ancy	NN	False
DDI-MedLine.d80.s11	outcomes	64	71	O	outcomes	mes	omes	NNS	False
DDI-MedLine.d80.s11	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d80.s11	terms	76	80	O	terms	rms	erms	NNS	False
DDI-MedLine.d80.s11	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d80.s11	pregnancy	85	93	O	pregnancy	ncy	ancy	NN	False
DDI-MedLine.d80.s11	rates	95	99	O	rates	tes	ates	NNS	False
DDI-MedLine.d80.s11	,	100	100	O	,	,	,	,	False
DDI-MedLine.d80.s11	compliance	102	111	O	compliance	nce	ance	NN	False
DDI-MedLine.d80.s11	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d80.s11	efficacy	117	124	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d80.s11	,	125	125	O	,	,	,	,	False
DDI-MedLine.d80.s11	ectopic	127	133	O	ectopic	pic	opic	NN	False
DDI-MedLine.d80.s11	pregnancies	135	145	O	pregnancies	ies	cies	NNS	False
DDI-MedLine.d80.s11	,	146	146	O	,	,	,	,	False
DDI-MedLine.d80.s11	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d80.s11	outcome	152	158	O	outcome	ome	come	NN	False
DDI-MedLine.d80.s11	of	160	161	O	of	of	of	IN	False
DDI-MedLine.d80.s11	pregnancies	163	173	O	pregnancies	ies	cies	NNS	False
DDI-MedLine.d80.s11	conceived	175	183	O	conceived	ved	ived	VBN	False
DDI-MedLine.d80.s11	while	185	189	O	while	ile	hile	IN	False
DDI-MedLine.d80.s11	using	191	195	O	using	ing	sing	VBG	False
DDI-MedLine.d80.s11	POCs	197	200	B-group	POCs	OCs	POCs	NN	False
DDI-MedLine.d80.s11	,	201	201	O	,	,	,	,	False
DDI-MedLine.d80.s11	and	203	205	O	and	and	and	CC	False
DDI-MedLine.d80.s11	fertility	207	215	O	fertility	ity	lity	NN	False
DDI-MedLine.d80.s11	following	217	225	O	following	ing	wing	VBG	False
DDI-MedLine.d80.s11	discontinuation	227	241	O	discontinuation	ion	tion	NN	False
DDI-MedLine.d80.s11	.	242	242	O	.	.	.	.	False

DDI-MedLine.d80.s12	Chapter	0	6	O	Chapter	ter	pter	NN	False
DDI-MedLine.d80.s12	5	8	8	O	5	5	5	CD	False
DDI-MedLine.d80.s12	focuses	10	16	O	focuses	ses	uses	NNS	False
DDI-MedLine.d80.s12	on	18	19	O	on	on	on	IN	False
DDI-MedLine.d80.s12	metabolic	21	29	O	metabolic	lic	olic	NN	False
DDI-MedLine.d80.s12	effects	31	37	O	effects	cts	ects	NNS	False
DDI-MedLine.d80.s12	,	38	38	O	,	,	,	,	False
DDI-MedLine.d80.s12	specifically	40	51	O	specifically	lly	ally	RB	False
DDI-MedLine.d80.s12	lipid	53	57	O	lipid	pid	ipid	NN	False
DDI-MedLine.d80.s12	metabolism	59	68	O	metabolism	ism	lism	NN	False
DDI-MedLine.d80.s12	,	69	69	O	,	,	,	,	False
DDI-MedLine.d80.s12	carbohydrate	71	82	O	carbohydrate	ate	rate	NN	False
DDI-MedLine.d80.s12	metabolism	84	93	O	metabolism	ism	lism	NN	False
DDI-MedLine.d80.s12	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d80.s12	diabetes	99	106	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d80.s12	,	107	107	O	,	,	,	,	False
DDI-MedLine.d80.s12	coagulation	109	119	O	coagulation	ion	tion	NN	False
DDI-MedLine.d80.s12	factors	121	127	O	factors	ors	tors	NNS	False
DDI-MedLine.d80.s12	,	128	128	O	,	,	,	,	False
DDI-MedLine.d80.s12	and	130	132	O	and	and	and	CC	False
DDI-MedLine.d80.s12	blood	134	138	O	blood	ood	lood	NN	False
DDI-MedLine.d80.s12	pressure	140	147	O	pressure	ure	sure	NN	False
DDI-MedLine.d80.s12	.	148	148	O	.	.	.	.	False

DDI-MedLine.d80.s13	Cardiovascular	0	13	O	Cardiovascular	lar	ular	JJ	False
DDI-MedLine.d80.s13	disease	15	21	O	disease	ase	ease	NN	False
DDI-MedLine.d80.s13	is	23	24	O	is	is	is	VBZ	False
DDI-MedLine.d80.s13	considered	26	35	O	considered	red	ered	VBN	False
DDI-MedLine.d80.s13	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d80.s13	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d80.s13	next	44	47	O	next	ext	next	JJ	False
DDI-MedLine.d80.s13	chapter	49	55	O	chapter	ter	pter	NN	False
DDI-MedLine.d80.s13	,	56	56	O	,	,	,	,	False
DDI-MedLine.d80.s13	and	58	60	O	and	and	and	CC	False
DDI-MedLine.d80.s13	chapter	62	68	O	chapter	ter	pter	NN	False
DDI-MedLine.d80.s13	7	70	70	O	7	7	7	CD	False
DDI-MedLine.d80.s13	presents	72	79	O	presents	nts	ents	NNS	False
DDI-MedLine.d80.s13	findings	81	88	O	findings	ngs	ings	NNS	False
DDI-MedLine.d80.s13	on	90	91	O	on	on	on	IN	False
DDI-MedLine.d80.s13	endometrial	93	103	O	endometrial	ial	rial	JJ	False
DDI-MedLine.d80.s13	,	104	104	O	,	,	,	,	False
DDI-MedLine.d80.s13	ovarian	106	112	O	ovarian	ian	rian	JJ	False
DDI-MedLine.d80.s13	,	113	113	O	,	,	,	,	False
DDI-MedLine.d80.s13	cervical	115	122	O	cervical	cal	ical	JJ	False
DDI-MedLine.d80.s13	,	123	123	O	,	,	,	,	False
DDI-MedLine.d80.s13	breast	125	130	O	breast	ast	east	NN	False
DDI-MedLine.d80.s13	,	131	131	O	,	,	,	,	False
DDI-MedLine.d80.s13	and	133	135	O	and	and	and	CC	False
DDI-MedLine.d80.s13	other	137	141	O	other	her	ther	JJ	False
DDI-MedLine.d80.s13	cancers	143	149	O	cancers	ers	cers	NNS	False
DDI-MedLine.d80.s13	.	150	150	O	.	.	.	.	False

DDI-MedLine.d80.s14	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d80.s14	host	2	5	O	host	ost	host	NN	False
DDI-MedLine.d80.s14	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d80.s14	other	10	14	O	other	her	ther	JJ	False
DDI-MedLine.d80.s14	medical	16	22	O	medical	cal	ical	JJ	False
DDI-MedLine.d80.s14	considerations	24	37	O	considerations	ons	ions	NNS	False
DDI-MedLine.d80.s14	are	39	41	O	are	are	are	VBP	False
DDI-MedLine.d80.s14	discussed	43	51	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d80.s14	in	53	54	O	in	in	in	IN	False
DDI-MedLine.d80.s14	chapter	56	62	O	chapter	ter	pter	NN	False
DDI-MedLine.d80.s14	8	64	64	O	8	8	8	CD	False
DDI-MedLine.d80.s14	,	65	65	O	,	,	,	,	False
DDI-MedLine.d80.s14	including	67	75	O	including	ing	ding	VBG	False
DDI-MedLine.d80.s14	persistent	77	86	O	persistent	ent	tent	NN	False
DDI-MedLine.d80.s14	ovarian	88	94	O	ovarian	ian	rian	JJ	False
DDI-MedLine.d80.s14	follicles	96	104	O	follicles	les	cles	NNS	False
DDI-MedLine.d80.s14	;	105	105	O	;	;	;	:	False

DDI-MedLine.d80.s15	reproductive	0	11	O	reproductive	ive	tive	NN	False
DDI-MedLine.d80.s15	tract	13	17	O	tract	act	ract	NN	False
DDI-MedLine.d80.s15	infections	19	28	O	infections	ons	ions	NNS	False
DDI-MedLine.d80.s15	;	29	29	O	;	;	;	:	False

DDI-MedLine.d80.s16	abnormal	0	7	O	abnormal	mal	rmal	JJ	False
DDI-MedLine.d80.s16	vaginal	9	15	O	vaginal	nal	inal	JJ	False
DDI-MedLine.d80.s16	bleeding	17	24	O	bleeding	ing	ding	NN	False
DDI-MedLine.d80.s16	;	25	25	O	;	;	;	:	False

DDI-MedLine.d80.s17	uterine	0	6	O	uterine	ine	rine	NN	drug
DDI-MedLine.d80.s17	fibroids	8	15	O	fibroids	ids	oids	NNS	False
DDI-MedLine.d80.s17	;	16	16	O	;	;	;	:	False

DDI-MedLine.d80.s18	gestational	0	10	O	gestational	nal	onal	NN	False
DDI-MedLine.d80.s18	trophoblastic	12	24	O	trophoblastic	tic	stic	JJ	False
DDI-MedLine.d80.s18	disease	26	32	O	disease	ase	ease	NN	False
DDI-MedLine.d80.s18	;	33	33	O	;	;	;	:	False

DDI-MedLine.d80.s19	benign	0	5	O	benign	ign	nign	NN	False
DDI-MedLine.d80.s19	breast	7	12	O	breast	ast	east	NN	False
DDI-MedLine.d80.s19	disease	14	20	O	disease	ase	ease	NN	False
DDI-MedLine.d80.s19	;	21	21	O	;	;	;	:	False

DDI-MedLine.d80.s20	diseases	0	7	O	diseases	ses	ases	NNS	False
DDI-MedLine.d80.s20	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d80.s20	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d80.s20	liver	16	20	O	liver	ver	iver	NN	False
DDI-MedLine.d80.s20	,	21	21	O	,	,	,	,	False
DDI-MedLine.d80.s20	gallbladder	23	33	O	gallbladder	der	dder	NN	False
DDI-MedLine.d80.s20	,	34	34	O	,	,	,	,	False
DDI-MedLine.d80.s20	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d80.s20	bowel	40	44	O	bowel	wel	owel	NN	False
DDI-MedLine.d80.s20	;	45	45	O	;	;	;	:	False

DDI-MedLine.d80.s21	endocrine	0	8	O	endocrine	ine	rine	NN	drug
DDI-MedLine.d80.s21	dysfunction	10	20	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d80.s21	;	21	21	O	;	;	;	:	False

DDI-MedLine.d80.s22	epilepsy	0	7	O	epilepsy	psy	epsy	NN	False
DDI-MedLine.d80.s22	;	8	8	O	;	;	;	:	False

DDI-MedLine.d80.s23	bone	0	3	O	bone	one	bone	NN	False
DDI-MedLine.d80.s23	density	5	11	O	density	ity	sity	NN	False
DDI-MedLine.d80.s23	;	12	12	O	;	;	;	:	False

DDI-MedLine.d80.s24	sickle	0	5	O	sickle	kle	ckle	NN	False
DDI-MedLine.d80.s24	cell	7	10	O	cell	ell	cell	NN	False
DDI-MedLine.d80.s24	disease	12	18	O	disease	ase	ease	NN	False
DDI-MedLine.d80.s24	;	19	19	O	;	;	;	:	False

DDI-MedLine.d80.s25	ocular	0	5	O	ocular	lar	ular	NN	False
DDI-MedLine.d80.s25	effects	7	13	O	effects	cts	ects	NNS	False
DDI-MedLine.d80.s25	;	14	14	O	;	;	;	:	False

DDI-MedLine.d80.s26	surgery	0	6	O	surgery	ery	gery	NN	False
DDI-MedLine.d80.s26	;	7	7	O	;	;	;	:	False

DDI-MedLine.d80.s27	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d80.s27	overdose	4	11	O	overdose	ose	dose	NN	False
DDI-MedLine.d80.s27	.	12	12	O	.	.	.	.	False

DDI-MedLine.d80.s28	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d80.s28	last	4	7	O	last	ast	last	JJ	False
DDI-MedLine.d80.s28	4	9	9	O	4	4	4	CD	False
DDI-MedLine.d80.s28	chapters	11	18	O	chapters	ers	ters	NNS	False
DDI-MedLine.d80.s28	cover	20	24	O	cover	ver	over	NN	False
DDI-MedLine.d80.s28	interactions	26	37	O	interactions	ons	ions	NNS	False
DDI-MedLine.d80.s28	with	39	42	O	with	ith	with	IN	False
DDI-MedLine.d80.s28	drugs	44	48	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d80.s28	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d80.s28	laboratory	54	63	O	laboratory	ory	tory	NN	False
DDI-MedLine.d80.s28	tests	65	69	O	tests	sts	ests	NNS	False
DDI-MedLine.d80.s28	,	70	70	O	,	,	,	,	False
DDI-MedLine.d80.s28	common	72	77	O	common	mon	mmon	JJ	False
DDI-MedLine.d80.s28	side	79	82	O	side	ide	side	NN	False
DDI-MedLine.d80.s28	effects	84	90	O	effects	cts	ects	NNS	False
DDI-MedLine.d80.s28	,	91	91	O	,	,	,	,	False
DDI-MedLine.d80.s28	breast	93	98	O	breast	ast	east	NN	False
DDI-MedLine.d80.s28	feeding	100	106	O	feeding	ing	ding	VBG	False
DDI-MedLine.d80.s28	,	107	107	O	,	,	,	,	False
DDI-MedLine.d80.s28	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d80.s28	effective	113	121	O	effective	ive	tive	JJ	False
DDI-MedLine.d80.s28	use	123	125	O	use	use	use	NN	False
DDI-MedLine.d80.s28	of	127	128	O	of	of	of	IN	False
DDI-MedLine.d80.s28	POCs	130	133	B-group	POCs	OCs	POCs	NN	False
DDI-MedLine.d80.s28	.	134	134	O	.	.	.	.	False

DDI-MedLine.d80.s29	Information	0	10	O	Information	ion	tion	NN	False
DDI-MedLine.d80.s29	on	12	13	O	on	on	on	IN	False
DDI-MedLine.d80.s29	precautions	15	25	O	precautions	ons	ions	NNS	False
DDI-MedLine.d80.s29	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d80.s29	contraindications	31	47	O	contraindications	ons	ions	NNS	False
DDI-MedLine.d80.s29	,	48	48	O	,	,	,	,	False
DDI-MedLine.d80.s29	indications	50	60	O	indications	ons	ions	NNS	False
DDI-MedLine.d80.s29	,	61	61	O	,	,	,	,	False
DDI-MedLine.d80.s29	use	63	65	O	use	use	use	NN	False
DDI-MedLine.d80.s29	instructions	67	78	O	instructions	ons	ions	NNS	False
DDI-MedLine.d80.s29	,	79	79	O	,	,	,	,	False
DDI-MedLine.d80.s29	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d80.s29	instructions	85	96	O	instructions	ons	ions	NNS	False
DDI-MedLine.d80.s29	for	98	100	O	for	for	for	IN	False
DDI-MedLine.d80.s29	appropriate	102	112	O	appropriate	ate	iate	NN	False
DDI-MedLine.d80.s29	actions	114	120	O	actions	ons	ions	NNS	False
DDI-MedLine.d80.s29	after	122	126	O	after	ter	fter	IN	False
DDI-MedLine.d80.s29	missing	128	134	O	missing	ing	sing	VBG	False
DDI-MedLine.d80.s29	a	136	136	O	a	a	a	DT	False
DDI-MedLine.d80.s29	pill	138	141	O	pill	ill	pill	NN	False
DDI-MedLine.d80.s29	is	143	144	O	is	is	is	VBZ	False
DDI-MedLine.d80.s29	appended	146	153	O	appended	ded	nded	VBD	False
DDI-MedLine.d80.s29	.	154	154	O	.	.	.	.	False

DDI-MedLine.d73.s0	Neurochemical	0	12	O	Neurochemical	cal	ical	JJ	False
DDI-MedLine.d73.s0	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d73.s0	functional	18	27	O	functional	nal	onal	JJ	False
DDI-MedLine.d73.s0	consequences	29	40	O	consequences	ces	nces	NNS	False
DDI-MedLine.d73.s0	following	42	50	O	following	ing	wing	VBG	False
DDI-MedLine.d73.s0	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	52	95	B-drug_n	1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine	ine	dine	JJ	drug
DDI-MedLine.d73.s0	(	97	97	O	(	(	(	(	False
DDI-MedLine.d73.s0	MPTP	98	101	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d73.s0	)	102	102	O	)	)	)	)	False
DDI-MedLine.d73.s0	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d73.s0	methamphetamine	108	122	B-drug	methamphetamine	ine	mine	NN	drug
DDI-MedLine.d73.s0	.	123	123	O	.	.	.	.	False

DDI-MedLine.d73.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d73.s1	neurochemical	4	16	O	neurochemical	cal	ical	JJ	False
DDI-MedLine.d73.s1	and	18	20	O	and	and	and	CC	False
DDI-MedLine.d73.s1	functional	22	31	O	functional	nal	onal	JJ	False
DDI-MedLine.d73.s1	consequences	33	44	O	consequences	ces	nces	NNS	False
DDI-MedLine.d73.s1	following	46	54	O	following	ing	wing	VBG	False
DDI-MedLine.d73.s1	MPTP	56	59	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d73.s1	administration	61	74	O	administration	ion	tion	NN	False
DDI-MedLine.d73.s1	to	76	77	O	to	to	to	TO	False
DDI-MedLine.d73.s1	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d73.s1	rat	83	85	O	rat	rat	rat	NN	False
DDI-MedLine.d73.s1	were	87	90	O	were	ere	were	VBD	False
DDI-MedLine.d73.s1	evaluated	92	100	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d73.s1	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d73.s1	compared	106	113	O	compared	red	ared	VBN	False
DDI-MedLine.d73.s1	to	115	116	O	to	to	to	TO	False
DDI-MedLine.d73.s1	similar	118	124	O	similar	lar	ilar	JJ	False
DDI-MedLine.d73.s1	effects	126	132	O	effects	cts	ects	NNS	False
DDI-MedLine.d73.s1	following	134	142	O	following	ing	wing	VBG	False
DDI-MedLine.d73.s1	methamphetamine	144	158	B-drug	methamphetamine	ine	mine	NN	drug
DDI-MedLine.d73.s1	administration	160	173	O	administration	ion	tion	NN	False
DDI-MedLine.d73.s1	.	174	174	O	.	.	.	.	False

DDI-MedLine.d73.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d73.s2	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d73.s2	observed	7	14	O	observed	ved	rved	VBN	False
DDI-MedLine.d73.s2	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d73.s2	MPTP	21	24	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d73.s2	induced	26	32	O	induced	ced	uced	JJ	False
DDI-MedLine.d73.s2	long	34	37	O	long	ong	long	RB	False
DDI-MedLine.d73.s2	lasting	39	45	O	lasting	ing	ting	VBG	False
DDI-MedLine.d73.s2	depletions	47	56	O	depletions	ons	ions	NNS	False
DDI-MedLine.d73.s2	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d73.s2	striatal	61	68	O	striatal	tal	atal	NN	False
DDI-MedLine.d73.s2	dopamine	70	77	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d73.s2	concentrations	79	92	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d73.s2	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d73.s2	this	98	101	O	this	his	this	DT	False
DDI-MedLine.d73.s2	neurotoxic	103	112	O	neurotoxic	xic	oxic	NN	False
DDI-MedLine.d73.s2	effect	114	119	O	effect	ect	fect	NN	False
DDI-MedLine.d73.s2	could	121	125	O	could	uld	ould	MD	False
DDI-MedLine.d73.s2	be	127	128	O	be	be	be	VB	False
DDI-MedLine.d73.s2	prevented	130	138	O	prevented	ted	nted	VBN	False
DDI-MedLine.d73.s2	by	140	141	O	by	by	by	IN	False
DDI-MedLine.d73.s2	pargyline	143	151	B-drug	pargyline	ine	line	NN	drug
DDI-MedLine.d73.s2	pretreatment	153	164	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d73.s2	.	165	165	O	.	.	.	.	False

DDI-MedLine.d73.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d73.s3	MPTP-induced	4	15	O	MPTP-induced	ced	uced	JJ	False
DDI-MedLine.d73.s3	neuronal	17	24	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d73.s3	damage	26	31	O	damage	age	mage	NN	False
DDI-MedLine.d73.s3	produced	33	40	O	produced	ced	uced	VBN	False
DDI-MedLine.d73.s3	a	42	42	O	a	a	a	DT	False
DDI-MedLine.d73.s3	tolerance	44	52	O	tolerance	nce	ance	NN	False
DDI-MedLine.d73.s3	to	54	55	O	to	to	to	TO	False
DDI-MedLine.d73.s3	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d73.s3	disruptive	61	70	O	disruptive	ive	tive	NN	False
DDI-MedLine.d73.s3	effects	72	78	O	effects	cts	ects	NNS	False
DDI-MedLine.d73.s3	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d73.s3	amphetamine	83	93	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d73.s3	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d73.s3	a	99	99	O	a	a	a	DT	False
DDI-MedLine.d73.s3	supersensitivity	101	116	O	supersensitivity	ity	vity	NN	False
DDI-MedLine.d73.s3	to	118	119	O	to	to	to	TO	False
DDI-MedLine.d73.s3	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d73.s3	disruptive	125	134	O	disruptive	ive	tive	NN	False
DDI-MedLine.d73.s3	effects	136	142	O	effects	cts	ects	NNS	False
DDI-MedLine.d73.s3	of	144	145	O	of	of	of	IN	False
DDI-MedLine.d73.s3	apomorphine	147	157	B-drug	apomorphine	ine	hine	NN	drug
DDI-MedLine.d73.s3	in	159	160	O	in	in	in	IN	False
DDI-MedLine.d73.s3	rats	162	165	O	rats	ats	rats	NNS	False
DDI-MedLine.d73.s3	responding	167	176	O	responding	ing	ding	VBG	False
DDI-MedLine.d73.s3	in	178	179	O	in	in	in	IN	False
DDI-MedLine.d73.s3	a	181	181	O	a	a	a	DT	False
DDI-MedLine.d73.s3	schedule	183	190	O	schedule	ule	dule	NN	False
DDI-MedLine.d73.s3	controlled	192	201	O	controlled	led	lled	VBN	False
DDI-MedLine.d73.s3	paradigm	203	210	O	paradigm	igm	digm	NN	False
DDI-MedLine.d73.s3	.	211	211	O	.	.	.	.	False

DDI-MedLine.d73.s4	Methamphetamine	0	14	B-drug	Methamphetamine	ine	mine	NN	drug
DDI-MedLine.d73.s4	,	15	15	O	,	,	,	,	False
DDI-MedLine.d73.s4	like	17	20	O	like	ike	like	IN	False
DDI-MedLine.d73.s4	MPTP	22	25	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d73.s4	,	26	26	O	,	,	,	,	False
DDI-MedLine.d73.s4	produced	28	35	O	produced	ced	uced	VBN	False
DDI-MedLine.d73.s4	depletions	37	46	O	depletions	ons	ions	NNS	False
DDI-MedLine.d73.s4	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d73.s4	striatal	51	58	O	striatal	tal	atal	NN	False
DDI-MedLine.d73.s4	dopamine	60	67	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d73.s4	but	69	71	O	but	but	but	CC	False
DDI-MedLine.d73.s4	these	73	77	O	these	ese	hese	DT	False
DDI-MedLine.d73.s4	actions	79	85	O	actions	ons	ions	NNS	False
DDI-MedLine.d73.s4	were	87	90	O	were	ere	were	VBD	False
DDI-MedLine.d73.s4	potentiated	92	102	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d73.s4	by	104	105	O	by	by	by	IN	False
DDI-MedLine.d73.s4	pargyline	107	115	B-drug	pargyline	ine	line	NN	drug
DDI-MedLine.d73.s4	pretreatment	117	128	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d73.s4	.	129	129	O	.	.	.	.	False

DDI-MedLine.d73.s5	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d73.s5	observations	6	17	O	observations	ons	ions	NNS	False
DDI-MedLine.d73.s5	are	19	21	O	are	are	are	VBP	False
DDI-MedLine.d73.s5	discussed	23	31	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d73.s5	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d73.s5	reference	36	44	O	reference	nce	ence	NN	False
DDI-MedLine.d73.s5	to	46	47	O	to	to	to	TO	False
DDI-MedLine.d73.s5	possible	49	56	O	possible	ble	ible	JJ	False
DDI-MedLine.d73.s5	deleterious	58	68	O	deleterious	ous	ious	JJ	False
DDI-MedLine.d73.s5	effects	70	76	O	effects	cts	ects	NNS	False
DDI-MedLine.d73.s5	following	78	86	O	following	ing	wing	VBG	False
DDI-MedLine.d73.s5	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d73.s5	administration	92	105	O	administration	ion	tion	NN	False
DDI-MedLine.d73.s5	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d73.s5	pargyline	110	118	B-drug	pargyline	ine	line	NN	drug
DDI-MedLine.d73.s5	to	120	121	O	to	to	to	TO	False
DDI-MedLine.d73.s5	patients	123	130	O	patients	nts	ents	NNS	False
DDI-MedLine.d73.s5	with	132	135	O	with	ith	with	IN	False
DDI-MedLine.d73.s5	Parkinson	137	145	O	Parkinson	son	nson	NN	False
DDI-MedLine.d73.s5	's	146	147	O	's	's	's	POS	False
DDI-MedLine.d73.s5	Disease	149	155	O	Disease	ase	ease	NN	False
DDI-MedLine.d73.s5	.	156	156	O	.	.	.	.	False

DDI-MedLine.d19.s0	Anaesthesia	0	10	O	Anaesthesia	sia	esia	NN	False
DDI-MedLine.d19.s0	and	12	14	O	and	and	and	CC	False
DDI-MedLine.d19.s0	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d19.s0	epileptic	20	28	O	epileptic	tic	ptic	JJ	False
DDI-MedLine.d19.s0	pateint	30	36	O	pateint	int	eint	NN	False
DDI-MedLine.d19.s0	.	37	37	O	.	.	.	.	False

DDI-MedLine.d19.s1	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d19.s1	review	2	7	O	review	iew	view	NN	False
DDI-MedLine.d19.s1	.	8	8	O	.	.	.	.	False

DDI-MedLine.d19.s2	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d19.s2	review	2	7	O	review	iew	view	NN	False
DDI-MedLine.d19.s2	is	9	10	O	is	is	is	VBZ	False
DDI-MedLine.d19.s2	presented	12	20	O	presented	ted	nted	VBN	False
DDI-MedLine.d19.s2	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d19.s2	some	25	28	O	some	ome	some	DT	False
DDI-MedLine.d19.s2	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d19.s2	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d19.s2	problems	37	44	O	problems	ems	lems	NNS	False
DDI-MedLine.d19.s2	that	46	49	O	that	hat	that	IN	False
DDI-MedLine.d19.s2	may	51	53	O	may	may	may	MD	False
DDI-MedLine.d19.s2	arise	55	59	O	arise	ise	rise	NN	False
DDI-MedLine.d19.s2	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d19.s2	association	64	74	O	association	ion	tion	NN	False
DDI-MedLine.d19.s2	with	76	79	O	with	ith	with	IN	False
DDI-MedLine.d19.s2	anaesthesia	81	91	O	anaesthesia	sia	esia	NN	False
DDI-MedLine.d19.s2	for	93	95	O	for	for	for	IN	False
DDI-MedLine.d19.s2	epileptic	97	105	O	epileptic	tic	ptic	JJ	False
DDI-MedLine.d19.s2	patients	107	114	O	patients	nts	ents	NNS	False
DDI-MedLine.d19.s2	.	115	115	O	.	.	.	.	False

DDI-MedLine.d19.s3	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d19.s3	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d19.s3	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d19.s3	possibility	13	23	O	possibility	ity	lity	NN	False
DDI-MedLine.d19.s3	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d19.s3	precipitating	28	40	O	precipitating	ing	ting	VBG	False
DDI-MedLine.d19.s3	anticonvulsant	42	55	O	anticonvulsant	ant	sant	NN	False
DDI-MedLine.d19.s3	drug	57	60	O	drug	rug	drug	NN	False
DDI-MedLine.d19.s3	toxicity	62	69	O	toxicity	ity	city	NN	False
DDI-MedLine.d19.s3	.	70	70	O	.	.	.	.	False

DDI-MedLine.d19.s4	Numerous	0	7	O	Numerous	ous	rous	JJ	False
DDI-MedLine.d19.s4	drug	9	12	O	drug	rug	drug	NN	False
DDI-MedLine.d19.s4	interactions	14	25	O	interactions	ons	ions	NNS	False
DDI-MedLine.d19.s4	are	27	29	O	are	are	are	VBP	False
DDI-MedLine.d19.s4	possible	31	38	O	possible	ble	ible	JJ	False
DDI-MedLine.d19.s4	with	40	43	O	with	ith	with	IN	False
DDI-MedLine.d19.s4	some	45	48	O	some	ome	some	DT	False
DDI-MedLine.d19.s4	anticonvulsant	50	63	B-group	anticonvulsant	ant	sant	NN	False
DDI-MedLine.d19.s4	agents	65	70	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d19.s4	,	71	71	O	,	,	,	,	False
DDI-MedLine.d19.s4	such	73	76	O	such	uch	such	JJ	False
DDI-MedLine.d19.s4	as	78	79	O	as	as	as	IN	False
DDI-MedLine.d19.s4	phenobarbitone	81	94	B-drug	phenobarbitone	one	tone	NN	False
DDI-MedLine.d19.s4	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d19.s4	phenytoin	100	108	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d19.s4	,	109	109	O	,	,	,	,	False
DDI-MedLine.d19.s4	which	111	115	O	which	ich	hich	WDT	False
DDI-MedLine.d19.s4	affect	117	122	O	affect	ect	fect	NN	False
DDI-MedLine.d19.s4	hepatic	124	130	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d19.s4	microsomal	132	141	O	microsomal	mal	omal	NN	False
DDI-MedLine.d19.s4	enzyme	143	148	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d19.s4	systems	150	156	O	systems	ems	tems	NNS	False
DDI-MedLine.d19.s4	.	157	157	O	.	.	.	.	False

DDI-MedLine.d19.s5	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d19.s5	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d19.s5	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d19.s5	risk	13	16	O	risk	isk	risk	NN	False
DDI-MedLine.d19.s5	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d19.s5	convulsions	21	31	O	convulsions	ons	ions	NNS	False
DDI-MedLine.d19.s5	occurring	33	41	O	occurring	ing	ring	VBG	False
DDI-MedLine.d19.s5	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d19.s5	susceptible	46	56	O	susceptible	ble	ible	JJ	False
DDI-MedLine.d19.s5	patients	58	65	O	patients	nts	ents	NNS	False
DDI-MedLine.d19.s5	following	67	75	O	following	ing	wing	VBG	False
DDI-MedLine.d19.s5	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d19.s5	use	81	83	O	use	use	use	NN	False
DDI-MedLine.d19.s5	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d19.s5	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d19.s5	new	92	94	O	new	new	new	JJ	False
DDI-MedLine.d19.s5	anaesthetic	96	106	B-group	anaesthetic	tic	etic	JJ	False
DDI-MedLine.d19.s5	agents	108	113	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d19.s5	which	115	119	O	which	ich	hich	WDT	False
DDI-MedLine.d19.s5	are	121	123	O	are	are	are	VBP	False
DDI-MedLine.d19.s5	capable	125	131	O	capable	ble	able	JJ	False
DDI-MedLine.d19.s5	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d19.s5	inducing	136	143	O	inducing	ing	cing	VBG	False
DDI-MedLine.d19.s5	CNS	145	147	O	CNS	CNS	CNS	NN	brand
DDI-MedLine.d19.s5	excitability	149	160	O	excitability	ity	lity	NN	False
DDI-MedLine.d19.s5	.	161	161	O	.	.	.	.	False

DDI-MedLine.d0.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d0.s0	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d0.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d0.s0	concomitant	15	25	O	concomitant	ant	tant	NN	False
DDI-MedLine.d0.s0	phenytoin	27	35	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d0.s0	administration	37	50	O	administration	ion	tion	NN	False
DDI-MedLine.d0.s0	on	52	53	O	on	on	on	IN	False
DDI-MedLine.d0.s0	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d0.s0	steady-state	59	70	O	steady-state	ate	tate	NN	False
DDI-MedLine.d0.s0	pharmacokinetics	72	87	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d0.s0	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d0.s0	quetiapine	92	101	B-drug	quetiapine	ine	pine	NN	drug
DDI-MedLine.d0.s0	.	102	102	O	.	.	.	.	False

DDI-MedLine.d0.s1	Quetiapine	0	9	B-drug	Quetiapine	ine	pine	NN	drug
DDI-MedLine.d0.s1	fumarate	11	18	I-drug	fumarate	ate	rate	NN	False
DDI-MedLine.d0.s1	(	20	20	O	(	(	(	(	False
DDI-MedLine.d0.s1	'Seroquel	21	29	O	'Seroquel	uel	quel	NN	False
DDI-MedLine.d0.s1	'	30	30	O	'	'	'	''	False
DDI-MedLine.d0.s1	)	31	31	O	)	)	)	)	False
DDI-MedLine.d0.s1	is	33	34	O	is	is	is	VBZ	False
DDI-MedLine.d0.s1	a	36	36	O	a	a	a	DT	False
DDI-MedLine.d0.s1	newly	38	42	O	newly	wly	ewly	RB	False
DDI-MedLine.d0.s1	introduced	44	53	O	introduced	ced	uced	VBN	False
DDI-MedLine.d0.s1	atypical	55	62	B-group	atypical	cal	ical	JJ	False
DDI-MedLine.d0.s1	antipsychotic	64	76	I-group	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d0.s1	with	78	81	O	with	ith	with	IN	False
DDI-MedLine.d0.s1	demonstrated	83	94	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d0.s1	efficacy	96	103	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d0.s1	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d0.s1	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d0.s1	treatment	112	120	O	treatment	ent	ment	NN	False
DDI-MedLine.d0.s1	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d0.s1	positive	125	132	O	positive	ive	tive	JJ	False
DDI-MedLine.d0.s1	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d0.s1	negative	138	145	O	negative	ive	tive	JJ	False
DDI-MedLine.d0.s1	symptoms	147	154	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d0.s1	of	156	157	O	of	of	of	IN	False
DDI-MedLine.d0.s1	schizophrenia	159	171	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d0.s1	.	172	172	O	.	.	.	.	False

DDI-MedLine.d0.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d0.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d0.s2	extensively	6	16	O	extensively	ely	vely	RB	False
DDI-MedLine.d0.s2	metabolized	18	28	O	metabolized	zed	ized	VBN	False
DDI-MedLine.d0.s2	,	29	29	O	,	,	,	,	False
DDI-MedLine.d0.s2	predominantly	31	43	O	predominantly	tly	ntly	RB	False
DDI-MedLine.d0.s2	by	45	46	O	by	by	by	IN	False
DDI-MedLine.d0.s2	cytochrome	48	57	O	cytochrome	ome	rome	NN	False
DDI-MedLine.d0.s2	P450	59	62	O	P450	450	P450	NN	brand
DDI-MedLine.d0.s2	3A4	64	66	O	3A4	3A4	3A4	CD	brand
DDI-MedLine.d0.s2	.	67	67	O	.	.	.	.	False

DDI-MedLine.d0.s3	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d0.s3	,	9	9	O	,	,	,	,	False
DDI-MedLine.d0.s3	concurrent	11	20	O	concurrent	ent	rent	NN	False
DDI-MedLine.d0.s3	administration	22	35	O	administration	ion	tion	NN	False
DDI-MedLine.d0.s3	of	37	38	O	of	of	of	IN	False
DDI-MedLine.d0.s3	drugs	40	44	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d0.s3	that	46	49	O	that	hat	that	IN	False
DDI-MedLine.d0.s3	induce	51	56	O	induce	uce	duce	NN	False
DDI-MedLine.d0.s3	or	58	59	O	or	or	or	CC	False
DDI-MedLine.d0.s3	inhibit	61	67	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d0.s3	this	69	72	O	this	his	this	DT	False
DDI-MedLine.d0.s3	enzyme	74	79	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d0.s3	may	81	83	O	may	may	may	MD	False
DDI-MedLine.d0.s3	affect	85	90	O	affect	ect	fect	NN	False
DDI-MedLine.d0.s3	quetiapine	92	101	B-drug	quetiapine	ine	pine	NN	drug
DDI-MedLine.d0.s3	pharmacokinetics	103	118	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d0.s3	.	119	119	O	.	.	.	.	False

DDI-MedLine.d0.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d0.s4	study	5	9	O	study	udy	tudy	NN	False
DDI-MedLine.d0.s4	demonstrated	11	22	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d0.s4	that	24	27	O	that	hat	that	IN	False
DDI-MedLine.d0.s4	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d0.s4	potent	33	38	O	potent	ent	tent	NN	False
DDI-MedLine.d0.s4	cytochrome	40	49	O	cytochrome	ome	rome	NN	False
DDI-MedLine.d0.s4	P450	51	54	O	P450	450	P450	NN	brand
DDI-MedLine.d0.s4	enzyme-inducer	56	69	O	enzyme-inducer	cer	ucer	NN	False
DDI-MedLine.d0.s4	phenytoin	71	79	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d0.s4	did	81	83	O	did	did	did	VBD	False
DDI-MedLine.d0.s4	indeed	85	90	O	indeed	eed	deed	RB	False
DDI-MedLine.d0.s4	have	92	95	O	have	ave	have	VB	False
DDI-MedLine.d0.s4	a	97	97	O	a	a	a	DT	False
DDI-MedLine.d0.s4	marked	99	104	O	marked	ked	rked	NNS	False
DDI-MedLine.d0.s4	effect	106	111	O	effect	ect	fect	NN	False
DDI-MedLine.d0.s4	on	113	114	O	on	on	on	IN	False
DDI-MedLine.d0.s4	the	116	118	O	the	the	the	DT	False
DDI-MedLine.d0.s4	metabolism	120	129	O	metabolism	ism	lism	NN	False
DDI-MedLine.d0.s4	of	131	132	O	of	of	of	IN	False
DDI-MedLine.d0.s4	quetiapine	134	143	B-drug	quetiapine	ine	pine	NN	drug
DDI-MedLine.d0.s4	,	144	144	O	,	,	,	,	False
DDI-MedLine.d0.s4	resulting	146	154	O	resulting	ing	ting	VBG	False
DDI-MedLine.d0.s4	in	156	157	O	in	in	in	IN	False
DDI-MedLine.d0.s4	a	159	159	O	a	a	a	DT	False
DDI-MedLine.d0.s4	5-fold	161	166	O	5-fold	old	fold	JJ	False
DDI-MedLine.d0.s4	increase	168	175	O	increase	ase	ease	NN	False
DDI-MedLine.d0.s4	in	177	178	O	in	in	in	IN	False
DDI-MedLine.d0.s4	clearance	180	188	O	clearance	nce	ance	NN	False
DDI-MedLine.d0.s4	when	190	193	O	when	hen	when	WRB	False
DDI-MedLine.d0.s4	administered	195	206	O	administered	red	ered	VBN	False
DDI-MedLine.d0.s4	concomitantly	208	220	O	concomitantly	tly	ntly	RB	False
DDI-MedLine.d0.s4	to	222	223	O	to	to	to	TO	False
DDI-MedLine.d0.s4	patients	225	232	O	patients	nts	ents	NNS	False
DDI-MedLine.d0.s4	with	234	237	O	with	ith	with	IN	False
DDI-MedLine.d0.s4	DSM-IV-diagnosed	239	254	O	DSM-IV-diagnosed	sed	osed	JJ	False
DDI-MedLine.d0.s4	schizophrenia	256	268	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d0.s4	,	269	269	O	,	,	,	,	False
DDI-MedLine.d0.s4	schizoaffective	271	285	O	schizoaffective	ive	tive	NN	False
DDI-MedLine.d0.s4	disorder	287	294	O	disorder	der	rder	NN	False
DDI-MedLine.d0.s4	,	295	295	O	,	,	,	,	False
DDI-MedLine.d0.s4	or	297	298	O	or	or	or	CC	False
DDI-MedLine.d0.s4	bipolar	300	306	O	bipolar	lar	olar	NN	False
DDI-MedLine.d0.s4	disorder	308	315	O	disorder	der	rder	NN	False
DDI-MedLine.d0.s4	.	316	316	O	.	.	.	.	False

DDI-MedLine.d0.s5	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d0.s5	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d0.s5	indicate	14	21	O	indicate	ate	cate	NN	False
DDI-MedLine.d0.s5	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d0.s5	dosage	28	33	O	dosage	age	sage	NN	False
DDI-MedLine.d0.s5	adjustment	35	44	O	adjustment	ent	ment	NN	False
DDI-MedLine.d0.s5	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d0.s5	quetiapine	49	58	B-drug	quetiapine	ine	pine	NN	drug
DDI-MedLine.d0.s5	may	60	62	O	may	may	may	MD	False
DDI-MedLine.d0.s5	be	64	65	O	be	be	be	VB	False
DDI-MedLine.d0.s5	necessary	67	75	O	necessary	ary	sary	JJ	False
DDI-MedLine.d0.s5	when	77	80	O	when	hen	when	WRB	False
DDI-MedLine.d0.s5	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d0.s5	two	86	88	O	two	two	two	CD	False
DDI-MedLine.d0.s5	drugs	90	94	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d0.s5	are	96	98	O	are	are	are	VBP	False
DDI-MedLine.d0.s5	given	100	104	O	given	ven	iven	VBN	False
DDI-MedLine.d0.s5	concurrently	106	117	O	concurrently	tly	ntly	RB	False
DDI-MedLine.d0.s5	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d0.s5	that	123	126	O	that	hat	that	IN	False
DDI-MedLine.d0.s5	caution	128	134	O	caution	ion	tion	NN	False
DDI-MedLine.d0.s5	may	136	138	O	may	may	may	MD	False
DDI-MedLine.d0.s5	be	140	141	O	be	be	be	VB	False
DDI-MedLine.d0.s5	required	143	150	O	required	red	ired	VBN	False
DDI-MedLine.d0.s5	when	152	155	O	when	hen	when	WRB	False
DDI-MedLine.d0.s5	administering	157	169	O	administering	ing	ring	VBG	False
DDI-MedLine.d0.s5	other	171	175	O	other	her	ther	JJ	False
DDI-MedLine.d0.s5	drugs	177	181	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d0.s5	that	183	186	O	that	hat	that	IN	False
DDI-MedLine.d0.s5	inhibit	188	194	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d0.s5	or	196	197	O	or	or	or	CC	False
DDI-MedLine.d0.s5	induce	199	204	O	induce	uce	duce	NN	False
DDI-MedLine.d0.s5	cytochromes	206	216	O	cytochromes	mes	omes	NNS	False
DDI-MedLine.d0.s5	,	217	217	O	,	,	,	,	False
DDI-MedLine.d0.s5	particularly	219	230	O	particularly	rly	arly	RB	False
DDI-MedLine.d0.s5	P450	232	235	O	P450	450	P450	NN	brand
DDI-MedLine.d0.s5	3A4	237	239	O	3A4	3A4	3A4	CD	brand
DDI-MedLine.d0.s5	.	240	240	O	.	.	.	.	False

DDI-MedLine.d91.s0	Diagnostic	0	9	O	Diagnostic	tic	stic	JJ	False
DDI-MedLine.d91.s0	,	10	10	O	,	,	,	,	False
DDI-MedLine.d91.s0	treatment	12	20	O	treatment	ent	ment	NN	False
DDI-MedLine.d91.s0	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d91.s0	aftercare	26	34	O	aftercare	are	care	NN	False
DDI-MedLine.d91.s0	approaches	36	45	O	approaches	hes	ches	NNS	False
DDI-MedLine.d91.s0	to	47	48	O	to	to	to	TO	False
DDI-MedLine.d91.s0	cocaine	50	56	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s0	abuse	58	62	O	abuse	use	buse	NN	False
DDI-MedLine.d91.s0	.	63	63	O	.	.	.	.	False

DDI-MedLine.d91.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d91.s1	general	4	10	O	general	ral	eral	JJ	False
DDI-MedLine.d91.s1	public	12	17	O	public	lic	blic	NN	False
DDI-MedLine.d91.s1	feels	19	23	O	feels	els	eels	NNS	False
DDI-MedLine.d91.s1	that	25	28	O	that	hat	that	IN	False
DDI-MedLine.d91.s1	cocaine	30	36	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s1	is	38	39	O	is	is	is	VBZ	False
DDI-MedLine.d91.s1	not	41	43	O	not	not	not	RB	False
DDI-MedLine.d91.s1	particularly	45	56	O	particularly	rly	arly	RB	False
DDI-MedLine.d91.s1	dangerous	58	66	O	dangerous	ous	rous	JJ	False
DDI-MedLine.d91.s1	because	68	74	O	because	use	ause	IN	False
DDI-MedLine.d91.s1	it	76	77	O	it	it	it	PRP	False
DDI-MedLine.d91.s1	does	79	82	O	does	oes	does	VBZ	False
DDI-MedLine.d91.s1	not	84	86	O	not	not	not	RB	False
DDI-MedLine.d91.s1	produce	88	94	O	produce	uce	duce	NN	False
DDI-MedLine.d91.s1	a	96	96	O	a	a	a	DT	False
DDI-MedLine.d91.s1	well	98	101	O	well	ell	well	RB	False
DDI-MedLine.d91.s1	defined	103	109	O	defined	ned	ined	VBN	False
DDI-MedLine.d91.s1	physical	111	118	O	physical	cal	ical	JJ	False
DDI-MedLine.d91.s1	dependency	120	129	O	dependency	ncy	ency	NN	False
DDI-MedLine.d91.s1	and	131	133	O	and	and	and	CC	False
DDI-MedLine.d91.s1	abstinence	135	144	O	abstinence	nce	ence	NN	False
DDI-MedLine.d91.s1	syndrome	146	153	O	syndrome	ome	rome	NN	False
DDI-MedLine.d91.s1	.	154	154	O	.	.	.	.	False

DDI-MedLine.d91.s2	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d91.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d91.s2	when	9	12	O	when	hen	when	WRB	False
DDI-MedLine.d91.s2	addiction	14	22	O	addiction	ion	tion	NN	False
DDI-MedLine.d91.s2	is	24	25	O	is	is	is	VBZ	False
DDI-MedLine.d91.s2	defined	27	33	O	defined	ned	ined	VBN	False
DDI-MedLine.d91.s2	as	35	36	O	as	as	as	IN	False
DDI-MedLine.d91.s2	compulsion	38	47	O	compulsion	ion	sion	NN	False
DDI-MedLine.d91.s2	,	48	48	O	,	,	,	,	False
DDI-MedLine.d91.s2	loss	50	53	O	loss	oss	loss	NN	False
DDI-MedLine.d91.s2	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d91.s2	control	58	64	O	control	rol	trol	NN	False
DDI-MedLine.d91.s2	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d91.s2	continued	70	78	O	continued	ued	nued	JJ	False
DDI-MedLine.d91.s2	use	80	82	O	use	use	use	NN	False
DDI-MedLine.d91.s2	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d91.s2	spite	87	91	O	spite	ite	pite	NN	False
DDI-MedLine.d91.s2	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d91.s2	adverse	96	102	O	adverse	rse	erse	NN	False
DDI-MedLine.d91.s2	consequences	104	115	O	consequences	ces	nces	NNS	False
DDI-MedLine.d91.s2	,	116	116	O	,	,	,	,	False
DDI-MedLine.d91.s2	cocaine	118	124	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s2	drug	126	129	O	drug	rug	drug	NN	False
DDI-MedLine.d91.s2	hunger	131	136	O	hunger	ger	nger	NN	False
DDI-MedLine.d91.s2	can	138	140	O	can	can	can	MD	False
DDI-MedLine.d91.s2	be	142	143	O	be	be	be	VB	False
DDI-MedLine.d91.s2	seen	145	148	O	seen	een	seen	VBN	False
DDI-MedLine.d91.s2	as	150	151	O	as	as	as	IN	False
DDI-MedLine.d91.s2	an	153	154	O	an	an	an	DT	False
DDI-MedLine.d91.s2	agent	156	160	O	agent	ent	gent	NN	False
DDI-MedLine.d91.s2	of	162	163	O	of	of	of	IN	False
DDI-MedLine.d91.s2	addictive	165	173	O	addictive	ive	tive	JJ	False
DDI-MedLine.d91.s2	disease	175	181	O	disease	ase	ease	NN	False
DDI-MedLine.d91.s2	.	182	182	O	.	.	.	.	False

DDI-MedLine.d91.s3	Withdrawal	0	9	O	Withdrawal	wal	awal	NN	False
DDI-MedLine.d91.s3	from	11	14	O	from	rom	from	IN	False
DDI-MedLine.d91.s3	cocaine	16	22	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s3	dependence	24	33	O	dependence	nce	ence	NN	False
DDI-MedLine.d91.s3	usually	35	41	O	usually	lly	ally	RB	False
DDI-MedLine.d91.s3	involves	43	50	O	involves	ves	lves	NNS	False
DDI-MedLine.d91.s3	depression	52	61	O	depression	ion	sion	NN	False
DDI-MedLine.d91.s3	,	62	62	O	,	,	,	,	False
DDI-MedLine.d91.s3	anxiety	64	70	O	anxiety	ety	iety	NN	False
DDI-MedLine.d91.s3	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d91.s3	lethargy	76	83	O	lethargy	rgy	argy	NN	False
DDI-MedLine.d91.s3	.	84	84	O	.	.	.	.	False

DDI-MedLine.d91.s4	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d91.s4	usually	6	12	O	usually	lly	ally	RB	False
DDI-MedLine.d91.s4	clear	14	18	O	clear	ear	lear	JJ	False
DDI-MedLine.d91.s4	within	20	25	O	within	hin	thin	IN	False
DDI-MedLine.d91.s4	a	27	27	O	a	a	a	DT	False
DDI-MedLine.d91.s4	week	29	32	O	week	eek	week	NN	False
DDI-MedLine.d91.s4	,	33	33	O	,	,	,	,	False
DDI-MedLine.d91.s4	leaving	35	41	O	leaving	ing	ving	VBG	False
DDI-MedLine.d91.s4	only	43	46	O	only	nly	only	RB	False
DDI-MedLine.d91.s4	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d91.s4	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d91.s4	drug	53	56	O	drug	rug	drug	NN	False
DDI-MedLine.d91.s4	hunger	58	63	O	hunger	ger	nger	NN	False
DDI-MedLine.d91.s4	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d91.s5	to	0	1	O	to	to	to	TO	False
DDI-MedLine.d91.s5	contend	3	9	O	contend	end	tend	NN	False
DDI-MedLine.d91.s5	with	11	14	O	with	ith	with	IN	False
DDI-MedLine.d91.s5	.	15	15	O	.	.	.	.	False

DDI-MedLine.d91.s6	Medication	0	9	O	Medication	ion	tion	NN	False
DDI-MedLine.d91.s6	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d91.s6	rarely	14	19	O	rarely	ely	rely	RB	False
DDI-MedLine.d91.s6	needed	21	26	O	needed	ded	eded	VBN	False
DDI-MedLine.d91.s6	.	27	27	O	.	.	.	.	False

DDI-MedLine.d91.s7	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d91.s7	cocaine	5	11	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s7	is	13	14	O	is	is	is	VBZ	False
DDI-MedLine.d91.s7	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d91.s7	primary	20	26	O	primary	ary	mary	NN	False
DDI-MedLine.d91.s7	addiction	28	36	O	addiction	ion	tion	NN	False
DDI-MedLine.d91.s7	,	37	37	O	,	,	,	,	False
DDI-MedLine.d91.s7	after	39	43	O	after	ter	fter	IN	False
DDI-MedLine.d91.s7	withdrawal	45	54	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d91.s7	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d91.s7	most	60	63	O	most	ost	most	JJS	False
DDI-MedLine.d91.s7	effective	65	73	O	effective	ive	tive	JJ	False
DDI-MedLine.d91.s7	treatment	75	83	O	treatment	ent	ment	NN	False
DDI-MedLine.d91.s7	is	85	86	O	is	is	is	VBZ	False
DDI-MedLine.d91.s7	group	88	92	O	group	oup	roup	NN	False
DDI-MedLine.d91.s7	therapy	94	100	O	therapy	apy	rapy	NN	False
DDI-MedLine.d91.s7	with	102	105	O	with	ith	with	IN	False
DDI-MedLine.d91.s7	other	107	111	O	other	her	ther	JJ	False
DDI-MedLine.d91.s7	recovering	113	122	O	recovering	ing	ring	VBG	False
DDI-MedLine.d91.s7	cocaine	124	130	O	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s7	abusers	132	138	O	abusers	ers	sers	NNS	False
DDI-MedLine.d91.s7	.	139	139	O	.	.	.	.	False

DDI-MedLine.d91.s8	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d91.s8	incorporate	3	13	O	incorporate	ate	rate	NN	False
DDI-MedLine.d91.s8	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d91.s8	principles	19	28	O	principles	les	ples	NNS	False
DDI-MedLine.d91.s8	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d91.s8	recovery	33	40	O	recovery	ery	very	NN	False
DDI-MedLine.d91.s8	and	42	44	O	and	and	and	CC	False
DDI-MedLine.d91.s8	define	46	51	O	define	ine	fine	NN	drug
DDI-MedLine.d91.s8	positive	53	60	O	positive	ive	tive	JJ	False
DDI-MedLine.d91.s8	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d91.s8	constructive	66	77	O	constructive	ive	tive	NN	False
DDI-MedLine.d91.s8	alternatives	79	90	O	alternatives	ves	ives	NNS	False
DDI-MedLine.d91.s8	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d91.s8	dealing	95	101	O	dealing	ing	ling	VBG	False
DDI-MedLine.d91.s8	with	103	106	O	with	ith	with	IN	False
DDI-MedLine.d91.s8	cocaine	108	114	O	cocaine	ine	aine	NN	drug
DDI-MedLine.d91.s8	hunger	116	121	O	hunger	ger	nger	NN	False
DDI-MedLine.d91.s8	.	122	122	O	.	.	.	.	False

DDI-MedLine.d91.s9	Recovery	0	7	O	Recovery	ery	very	NN	False
DDI-MedLine.d91.s9	programs	9	16	O	programs	ams	rams	NNS	False
DDI-MedLine.d91.s9	should	18	23	O	should	uld	ould	MD	False
DDI-MedLine.d91.s9	be	25	26	O	be	be	be	VB	False
DDI-MedLine.d91.s9	flexible	28	35	O	flexible	ble	ible	JJ	False
DDI-MedLine.d91.s9	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d91.s9	involve	41	47	O	involve	lve	olve	NN	False
DDI-MedLine.d91.s9	individual	49	58	O	individual	ual	dual	JJ	False
DDI-MedLine.d91.s9	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d91.s9	family	64	69	O	family	ily	mily	NN	False
DDI-MedLine.d91.s9	education	71	79	O	education	ion	tion	NN	False
DDI-MedLine.d91.s9	on	81	82	O	on	on	on	IN	False
DDI-MedLine.d91.s9	recovery	84	91	O	recovery	ery	very	NN	False
DDI-MedLine.d91.s9	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d91.s9	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d91.s9	nature	101	106	O	nature	ure	ture	NN	False
DDI-MedLine.d91.s9	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d91.s9	addictive	111	119	O	addictive	ive	tive	JJ	False
DDI-MedLine.d91.s9	disease	121	127	O	disease	ase	ease	NN	False
DDI-MedLine.d91.s9	.	128	128	O	.	.	.	.	False

DDI-MedLine.d91.s10	Exercise	0	7	O	Exercise	ise	cise	NN	False
DDI-MedLine.d91.s10	that	9	12	O	that	hat	that	IN	False
DDI-MedLine.d91.s10	produces	14	21	O	produces	ces	uces	NNS	False
DDI-MedLine.d91.s10	cardiopulmonary	23	37	O	cardiopulmonary	ary	nary	NN	False
DDI-MedLine.d91.s10	stimulation	39	49	O	stimulation	ion	tion	NN	False
DDI-MedLine.d91.s10	is	51	52	O	is	is	is	VBZ	False
DDI-MedLine.d91.s10	a	54	54	O	a	a	a	DT	False
DDI-MedLine.d91.s10	helpful	56	62	O	helpful	ful	pful	NN	False
DDI-MedLine.d91.s10	means	64	68	O	means	ans	eans	NNS	False
DDI-MedLine.d91.s10	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d91.s10	reducing	73	80	O	reducing	ing	cing	VBG	False
DDI-MedLine.d91.s10	drug	82	85	O	drug	rug	drug	NN	False
DDI-MedLine.d91.s10	hunger	87	92	O	hunger	ger	nger	NN	False
DDI-MedLine.d91.s10	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d91.s10	anxiety	98	104	O	anxiety	ety	iety	NN	False
DDI-MedLine.d91.s10	during	106	111	O	during	ing	ring	IN	False
DDI-MedLine.d91.s10	recovery	113	120	O	recovery	ery	very	NN	False
DDI-MedLine.d91.s10	therapy	122	128	O	therapy	apy	rapy	NN	False
DDI-MedLine.d91.s10	.	129	129	O	.	.	.	.	False

DDI-MedLine.d14.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d14.s0	A	1	1	O	A	A	A	DT	brand
DDI-MedLine.d14.s0	pharmacological	3	17	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d14.s0	analysis	19	26	O	analysis	sis	ysis	NN	False
DDI-MedLine.d14.s0	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d14.s0	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d14.s0	effect	35	40	O	effect	ect	fect	NN	False
DDI-MedLine.d14.s0	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d14.s0	angiotensin	45	55	B-drug_n	angiotensin	sin	nsin	NN	False
DDI-MedLine.d14.s0	on	57	58	O	on	on	on	IN	False
DDI-MedLine.d14.s0	stimulated	60	69	O	stimulated	ted	ated	VBN	False
DDI-MedLine.d14.s0	gastric	71	77	O	gastric	ric	tric	NN	False
DDI-MedLine.d14.s0	secretion	79	87	O	secretion	ion	tion	NN	False
DDI-MedLine.d14.s0	]	88	88	O	]	]	]	NN	False
DDI-MedLine.d14.s0	Chronic	91	97	O	Chronic	nic	onic	JJ	False
DDI-MedLine.d14.s0	experiments	99	109	O	experiments	nts	ents	NNS	False
DDI-MedLine.d14.s0	on	111	112	O	on	on	on	IN	False
DDI-MedLine.d14.s0	dogs	114	117	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d14.s0	with	119	122	O	with	ith	with	IN	False
DDI-MedLine.d14.s0	gastric	124	130	O	gastric	ric	tric	NN	False
DDI-MedLine.d14.s0	fistulas	132	139	O	fistulas	las	ulas	NNS	False
DDI-MedLine.d14.s0	were	141	144	O	were	ere	were	VBD	False
DDI-MedLine.d14.s0	carried	146	152	O	carried	ied	ried	VBN	False
DDI-MedLine.d14.s0	out	154	156	O	out	out	out	IN	False
DDI-MedLine.d14.s0	to	158	159	O	to	to	to	TO	False
DDI-MedLine.d14.s0	study	161	165	O	study	udy	tudy	NN	False
DDI-MedLine.d14.s0	the	167	169	O	the	the	the	DT	False
DDI-MedLine.d14.s0	influence	171	179	O	influence	nce	ence	NN	False
DDI-MedLine.d14.s0	of	181	182	O	of	of	of	IN	False
DDI-MedLine.d14.s0	angiotensin	184	194	B-drug_n	angiotensin	sin	nsin	NN	False
DDI-MedLine.d14.s0	1	196	196	I-drug_n	1	1	1	CD	False
DDI-MedLine.d14.s0	and	198	200	O	and	and	and	CC	False
DDI-MedLine.d14.s0	angiotensin	202	212	B-drug_n	angiotensin	sin	nsin	NN	False
DDI-MedLine.d14.s0	2	214	214	I-drug_n	2	2	2	CD	False
DDI-MedLine.d14.s0	on	216	217	O	on	on	on	IN	False
DDI-MedLine.d14.s0	pentagastrin-	219	231	O	pentagastrin-	in-	rin-	NN	False
DDI-MedLine.d14.s0	and	233	235	O	and	and	and	CC	False
DDI-MedLine.d14.s0	histamine-induced	237	253	O	histamine-induced	ced	uced	JJ	False
DDI-MedLine.d14.s0	gastric	255	261	O	gastric	ric	tric	NN	False
DDI-MedLine.d14.s0	acid	263	266	O	acid	cid	acid	NN	False
DDI-MedLine.d14.s0	secretion	268	276	O	secretion	ion	tion	NN	False
DDI-MedLine.d14.s0	.	277	277	O	.	.	.	.	False

DDI-MedLine.d14.s1	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d14.s1	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d14.s1	established	7	17	O	established	hed	shed	VBN	False
DDI-MedLine.d14.s1	that	19	22	O	that	hat	that	IN	False
DDI-MedLine.d14.s1	both	24	27	O	both	oth	both	DT	False
DDI-MedLine.d14.s1	angiotensins	29	40	O	angiotensins	ins	sins	NNS	False
DDI-MedLine.d14.s1	inhibited	42	50	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d14.s1	gastric	52	58	O	gastric	ric	tric	NN	False
DDI-MedLine.d14.s1	acid	60	63	O	acid	cid	acid	NN	False
DDI-MedLine.d14.s1	secretion	65	73	O	secretion	ion	tion	NN	False
DDI-MedLine.d14.s1	stimulated	75	84	O	stimulated	ted	ated	VBN	False
DDI-MedLine.d14.s1	by	86	87	O	by	by	by	IN	False
DDI-MedLine.d14.s1	pentagastrin	89	100	B-drug	pentagastrin	rin	trin	NN	False
DDI-MedLine.d14.s1	but	102	104	O	but	but	but	CC	False
DDI-MedLine.d14.s1	not	106	108	O	not	not	not	RB	False
DDI-MedLine.d14.s1	by	110	111	O	by	by	by	IN	False
DDI-MedLine.d14.s1	histamine	113	121	B-drug	histamine	ine	mine	NN	drug
DDI-MedLine.d14.s1	.	122	122	O	.	.	.	.	False

DDI-MedLine.d14.s2	Comparative	0	10	O	Comparative	ive	tive	JJ	False
DDI-MedLine.d14.s2	analysis	12	19	O	analysis	sis	ysis	NN	False
DDI-MedLine.d14.s2	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d14.s2	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d14.s2	effects	28	34	O	effects	cts	ects	NNS	False
DDI-MedLine.d14.s2	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d14.s2	stimulation	39	49	O	stimulation	ion	tion	NN	False
DDI-MedLine.d14.s2	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d14.s2	inhibition	55	64	O	inhibition	ion	tion	NN	False
DDI-MedLine.d14.s2	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d14.s2	cholino-	69	76	O	cholino-	no-	ino-	NN	False
DDI-MedLine.d14.s2	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d14.s2	adrenoreceptors	82	96	O	adrenoreceptors	ors	tors	NNS	False
DDI-MedLine.d14.s2	on	98	99	O	on	on	on	IN	False
DDI-MedLine.d14.s2	this	101	104	O	this	his	this	DT	False
DDI-MedLine.d14.s2	inhibitory	106	115	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d14.s2	action	117	122	O	action	ion	tion	NN	False
DDI-MedLine.d14.s2	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d14.s2	angiotensins	127	138	B-drug_n	angiotensins	ins	sins	NNS	False
DDI-MedLine.d14.s2	suggested	140	148	O	suggested	ted	sted	VBN	False
DDI-MedLine.d14.s2	the	150	152	O	the	the	the	DT	False
DDI-MedLine.d14.s2	mediation	154	162	O	mediation	ion	tion	NN	False
DDI-MedLine.d14.s2	of	164	165	O	of	of	of	IN	False
DDI-MedLine.d14.s2	angiotensin	167	177	B-drug_n	angiotensin	sin	nsin	NN	False
DDI-MedLine.d14.s2	influence	179	187	O	influence	nce	ence	NN	False
DDI-MedLine.d14.s2	through	189	195	O	through	ugh	ough	IN	False
DDI-MedLine.d14.s2	the	197	199	O	the	the	the	DT	False
DDI-MedLine.d14.s2	modulation	201	210	O	modulation	ion	tion	NN	False
DDI-MedLine.d14.s2	of	212	213	O	of	of	of	IN	False
DDI-MedLine.d14.s2	cholinergic	215	225	O	cholinergic	gic	rgic	NN	False
DDI-MedLine.d14.s2	reactions	227	235	O	reactions	ons	ions	NNS	False
DDI-MedLine.d14.s2	of	237	238	O	of	of	of	IN	False
DDI-MedLine.d14.s2	parietal	240	247	O	parietal	tal	etal	NN	False
DDI-MedLine.d14.s2	cells	249	253	O	cells	lls	ells	NNS	False
DDI-MedLine.d14.s2	in	255	256	O	in	in	in	IN	False
DDI-MedLine.d14.s2	the	258	260	O	the	the	the	DT	False
DDI-MedLine.d14.s2	stomach	262	268	O	stomach	ach	mach	NN	False
DDI-MedLine.d14.s2	.	269	269	O	.	.	.	.	False

DDI-MedLine.d67.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d67.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d67.s0	diazepam	10	17	B-drug	diazepam	pam	epam	NN	False
DDI-MedLine.d67.s0	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d67.s0	midazolam	23	31	B-drug	midazolam	lam	olam	NN	False
DDI-MedLine.d67.s0	on	33	34	O	on	on	on	IN	False
DDI-MedLine.d67.s0	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d67.s0	antinociceptive	40	54	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d67.s0	effect	56	61	O	effect	ect	fect	NN	False
DDI-MedLine.d67.s0	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d67.s0	morphine	66	73	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d67.s0	,	74	74	O	,	,	,	,	False
DDI-MedLine.d67.s0	metamizol	76	84	B-drug	metamizol	zol	izol	NN	False
DDI-MedLine.d67.s0	and	86	88	O	and	and	and	CC	False
DDI-MedLine.d67.s0	indomethacin	90	101	B-drug	indomethacin	cin	acin	NN	drug
DDI-MedLine.d67.s0	in	103	104	O	in	in	in	IN	False
DDI-MedLine.d67.s0	mice	106	109	O	mice	ice	mice	NN	False
DDI-MedLine.d67.s0	.	110	110	O	.	.	.	.	False

DDI-MedLine.d67.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d67.s1	influence	4	12	O	influence	nce	ence	NN	False
DDI-MedLine.d67.s1	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d67.s1	midazolam	17	25	B-drug	midazolam	lam	olam	NN	False
DDI-MedLine.d67.s1	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d67.s1	diazepam	31	38	B-drug	diazepam	pam	epam	NN	False
DDI-MedLine.d67.s1	on	40	41	O	on	on	on	IN	False
DDI-MedLine.d67.s1	antinociceptive	43	57	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d67.s1	effect	59	64	O	effect	ect	fect	NN	False
DDI-MedLine.d67.s1	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d67.s1	morphine	69	76	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d67.s1	(	78	78	O	(	(	(	(	False
DDI-MedLine.d67.s1	10	79	80	O	10	10	10	CD	False
DDI-MedLine.d67.s1	mg/kg	82	86	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s1	)	87	87	O	)	)	)	)	False
DDI-MedLine.d67.s1	,	88	88	O	,	,	,	,	False
DDI-MedLine.d67.s1	metamizol	90	98	B-drug	metamizol	zol	izol	NN	False
DDI-MedLine.d67.s1	(	100	100	O	(	(	(	(	False
DDI-MedLine.d67.s1	500	101	103	O	500	500	500	CD	False
DDI-MedLine.d67.s1	mg/kg	105	109	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s1	)	110	110	O	)	)	)	)	False
DDI-MedLine.d67.s1	and	112	114	O	and	and	and	CC	False
DDI-MedLine.d67.s1	indomethacin	116	127	B-drug	indomethacin	cin	acin	NN	drug
DDI-MedLine.d67.s1	(	129	129	O	(	(	(	(	False
DDI-MedLine.d67.s1	10	130	131	O	10	10	10	CD	False
DDI-MedLine.d67.s1	mg/kg	133	137	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s1	)	138	138	O	)	)	)	)	False
DDI-MedLine.d67.s1	was	140	142	O	was	was	was	VBD	False
DDI-MedLine.d67.s1	investigated	144	155	O	investigated	ted	ated	VBN	False
DDI-MedLine.d67.s1	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d67.s1	a	160	160	O	a	a	a	DT	False
DDI-MedLine.d67.s1	mouse	162	166	O	mouse	use	ouse	NN	False
DDI-MedLine.d67.s1	model	168	172	O	model	del	odel	NN	False
DDI-MedLine.d67.s1	using	174	178	O	using	ing	sing	VBG	False
DDI-MedLine.d67.s1	the	180	182	O	the	the	the	DT	False
DDI-MedLine.d67.s1	tail-flick	184	193	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d67.s1	and	195	197	O	and	and	and	CC	False
DDI-MedLine.d67.s1	hot-plate	199	207	O	hot-plate	ate	late	NN	False
DDI-MedLine.d67.s1	tests	209	213	O	tests	sts	ests	NNS	False
DDI-MedLine.d67.s1	.	214	214	O	.	.	.	.	False

DDI-MedLine.d67.s2	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d67.s2	drugs	4	8	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d67.s2	were	10	13	O	were	ere	were	VBD	False
DDI-MedLine.d67.s2	injected	15	22	O	injected	ted	cted	VBN	False
DDI-MedLine.d67.s2	intraperitoneally	24	40	O	intraperitoneally	lly	ally	RB	False
DDI-MedLine.d67.s2	.	41	41	O	.	.	.	.	False

DDI-MedLine.d67.s3	Benzodiazepines	0	14	B-group	Benzodiazepines	nes	ines	NNS	group
DDI-MedLine.d67.s3	were	16	19	O	were	ere	were	VBD	False
DDI-MedLine.d67.s3	administered	21	32	O	administered	red	ered	VBN	False
DDI-MedLine.d67.s3	to	34	35	O	to	to	to	TO	False
DDI-MedLine.d67.s3	mice	37	40	O	mice	ice	mice	NN	False
DDI-MedLine.d67.s3	30	42	43	O	30	30	30	CD	False
DDI-MedLine.d67.s3	min	45	47	O	min	min	min	NN	False
DDI-MedLine.d67.s3	before	49	54	O	before	ore	fore	IN	False
DDI-MedLine.d67.s3	applying	56	63	O	applying	ing	ying	VBG	False
DDI-MedLine.d67.s3	the	65	67	O	the	the	the	DT	False
DDI-MedLine.d67.s3	analgesic	69	77	B-group	analgesic	sic	esic	JJ	False
DDI-MedLine.d67.s3	drugs	79	83	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d67.s3	.	84	84	O	.	.	.	.	False

DDI-MedLine.d67.s4	Measurement	0	10	O	Measurement	ent	ment	NN	False
DDI-MedLine.d67.s4	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d67.s4	nociception	15	25	O	nociception	ion	tion	NN	False
DDI-MedLine.d67.s4	was	27	29	O	was	was	was	VBD	False
DDI-MedLine.d67.s4	performed	31	39	O	performed	med	rmed	VBN	False
DDI-MedLine.d67.s4	within	41	46	O	within	hin	thin	IN	False
DDI-MedLine.d67.s4	2	48	48	O	2	2	2	CD	False
DDI-MedLine.d67.s4	h	50	50	O	h	h	h	NN	False
DDI-MedLine.d67.s4	after	52	56	O	after	ter	fter	IN	False
DDI-MedLine.d67.s4	benzodiazepine	58	71	B-group	benzodiazepine	ine	pine	NN	drug
DDI-MedLine.d67.s4	administration	73	86	O	administration	ion	tion	NN	False
DDI-MedLine.d67.s4	.	87	87	O	.	.	.	.	False

DDI-MedLine.d67.s5	Diazepam	0	7	B-drug	Diazepam	pam	epam	NN	False
DDI-MedLine.d67.s5	at	9	10	O	at	at	at	IN	False
DDI-MedLine.d67.s5	doses	12	16	O	doses	ses	oses	NNS	False
DDI-MedLine.d67.s5	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d67.s5	0.25	21	24	O	0.25	.25	0.25	CD	False
DDI-MedLine.d67.s5	mg/kg	26	30	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s5	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d67.s5	2.5	36	38	O	2.5	2.5	2.5	CD	False
DDI-MedLine.d67.s5	mg/kg	40	44	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s5	injected	46	53	O	injected	ted	cted	VBN	False
DDI-MedLine.d67.s5	with	55	58	O	with	ith	with	IN	False
DDI-MedLine.d67.s5	morphine	60	67	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d67.s5	was	69	71	O	was	was	was	VBD	False
DDI-MedLine.d67.s5	found	73	77	O	found	und	ound	NN	False
DDI-MedLine.d67.s5	to	79	80	O	to	to	to	TO	False
DDI-MedLine.d67.s5	decrease	82	89	O	decrease	ase	ease	NN	False
DDI-MedLine.d67.s5	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d67.s5	antinociceptive	95	109	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d67.s5	effect	111	116	O	effect	ect	fect	NN	False
DDI-MedLine.d67.s5	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d67.s5	morphine	121	128	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d67.s5	.	129	129	O	.	.	.	.	False

DDI-MedLine.d67.s6	Similarly	0	8	O	Similarly	rly	arly	RB	False
DDI-MedLine.d67.s6	,	9	9	O	,	,	,	,	False
DDI-MedLine.d67.s6	diazepam	11	18	B-drug	diazepam	pam	epam	NN	False
DDI-MedLine.d67.s6	decreased	20	28	O	decreased	sed	ased	VBN	False
DDI-MedLine.d67.s6	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d67.s6	antinociceptive	34	48	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d67.s6	effect	50	55	O	effect	ect	fect	NN	False
DDI-MedLine.d67.s6	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d67.s6	metamizol	60	68	B-drug	metamizol	zol	izol	NN	False
DDI-MedLine.d67.s6	(	70	70	O	(	(	(	(	False
DDI-MedLine.d67.s6	only	71	74	O	only	nly	only	RB	False
DDI-MedLine.d67.s6	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d67.s6	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d67.s6	tail-flick	83	92	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d67.s6	test	94	97	O	test	est	test	NN	False
DDI-MedLine.d67.s6	)	98	98	O	)	)	)	)	False
DDI-MedLine.d67.s6	and	100	102	O	and	and	and	CC	False
DDI-MedLine.d67.s6	indomethacin	104	115	B-drug	indomethacin	cin	acin	NN	drug
DDI-MedLine.d67.s6	.	116	116	O	.	.	.	.	False

DDI-MedLine.d67.s7	Midazolam	0	8	B-drug	Midazolam	lam	olam	NN	False
DDI-MedLine.d67.s7	used	10	13	O	used	sed	used	VBN	False
DDI-MedLine.d67.s7	at	15	16	O	at	at	at	IN	False
DDI-MedLine.d67.s7	doses	18	22	O	doses	ses	oses	NNS	False
DDI-MedLine.d67.s7	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d67.s7	1.25	27	30	O	1.25	.25	1.25	CD	False
DDI-MedLine.d67.s7	mg/kg	32	36	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s7	and	38	40	O	and	and	and	CC	False
DDI-MedLine.d67.s7	2.5	42	44	O	2.5	2.5	2.5	CD	False
DDI-MedLine.d67.s7	mg/kg	46	50	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d67.s7	decreased	52	60	O	decreased	sed	ased	VBN	False
DDI-MedLine.d67.s7	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d67.s7	antinociceptive	66	80	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d67.s7	effect	82	87	O	effect	ect	fect	NN	False
DDI-MedLine.d67.s7	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d67.s7	morphine	92	99	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d67.s7	,	100	100	O	,	,	,	,	False
DDI-MedLine.d67.s7	metamizol	102	110	B-drug	metamizol	zol	izol	NN	False
DDI-MedLine.d67.s7	(	112	112	O	(	(	(	(	False
DDI-MedLine.d67.s7	only	113	116	O	only	nly	only	RB	False
DDI-MedLine.d67.s7	in	118	119	O	in	in	in	IN	False
DDI-MedLine.d67.s7	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d67.s7	tail-flick	125	134	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d67.s7	test	136	139	O	test	est	test	NN	False
DDI-MedLine.d67.s7	)	140	140	O	)	)	)	)	False
DDI-MedLine.d67.s7	and	142	144	O	and	and	and	CC	False
DDI-MedLine.d67.s7	indomethacin	146	157	B-drug	indomethacin	cin	acin	NN	drug
DDI-MedLine.d67.s7	.	158	158	O	.	.	.	.	False

DDI-MedLine.d32.s0	Prescribing	0	10	O	Prescribing	ing	bing	VBG	False
DDI-MedLine.d32.s0	.	11	11	O	.	.	.	.	False

DDI-MedLine.d32.s1	Keys	0	3	O	Keys	eys	Keys	NNS	False
DDI-MedLine.d32.s1	to	5	6	O	to	to	to	TO	False
DDI-MedLine.d32.s1	maximizing	8	17	O	maximizing	ing	zing	VBG	False
DDI-MedLine.d32.s1	benefit	19	25	O	benefit	fit	efit	NN	False
DDI-MedLine.d32.s1	while	27	31	O	while	ile	hile	IN	False
DDI-MedLine.d32.s1	avoiding	33	40	O	avoiding	ing	ding	VBG	False
DDI-MedLine.d32.s1	adverse	42	48	O	adverse	rse	erse	NN	False
DDI-MedLine.d32.s1	drug	50	53	O	drug	rug	drug	NN	False
DDI-MedLine.d32.s1	effects	55	61	O	effects	cts	ects	NNS	False
DDI-MedLine.d32.s1	.	62	62	O	.	.	.	.	False

DDI-MedLine.d32.s2	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d32.s2	prescribing	5	15	O	prescribing	ing	bing	VBG	False
DDI-MedLine.d32.s2	for	17	19	O	for	for	for	IN	False
DDI-MedLine.d32.s2	older	21	25	O	older	der	lder	JJR	False
DDI-MedLine.d32.s2	patients	27	34	O	patients	nts	ents	NNS	False
DDI-MedLine.d32.s2	,	35	35	O	,	,	,	,	False
DDI-MedLine.d32.s2	some	37	40	O	some	ome	some	DT	False
DDI-MedLine.d32.s2	physicians	42	51	O	physicians	ans	ians	NNS	False
DDI-MedLine.d32.s2	are	53	55	O	are	are	are	VBP	False
DDI-MedLine.d32.s2	overly	57	62	O	overly	rly	erly	RB	False
DDI-MedLine.d32.s2	cautious	64	71	O	cautious	ous	ious	JJ	False
DDI-MedLine.d32.s2	,	72	72	O	,	,	,	,	False
DDI-MedLine.d32.s2	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d32.s2	this	78	81	O	this	his	this	DT	False
DDI-MedLine.d32.s2	strategy	83	90	O	strategy	egy	tegy	NN	False
DDI-MedLine.d32.s2	can	92	94	O	can	can	can	MD	False
DDI-MedLine.d32.s2	result	96	101	O	result	ult	sult	NN	False
DDI-MedLine.d32.s2	in	103	104	O	in	in	in	IN	False
DDI-MedLine.d32.s2	a	106	106	O	a	a	a	DT	False
DDI-MedLine.d32.s2	less	108	111	O	less	ess	less	RBR	False
DDI-MedLine.d32.s2	than	113	116	O	than	han	than	IN	False
DDI-MedLine.d32.s2	optimal	118	124	O	optimal	mal	imal	JJ	False
DDI-MedLine.d32.s2	treatment	126	134	O	treatment	ent	ment	NN	False
DDI-MedLine.d32.s2	outcome	136	142	O	outcome	ome	come	NN	False
DDI-MedLine.d32.s2	.	143	143	O	.	.	.	.	False

DDI-MedLine.d32.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d32.s3	reluctance	4	13	O	reluctance	nce	ance	NN	False
DDI-MedLine.d32.s3	to	15	16	O	to	to	to	TO	False
DDI-MedLine.d32.s3	treat	18	22	O	treat	eat	reat	NN	False
DDI-MedLine.d32.s3	aggressively	24	35	O	aggressively	ely	vely	RB	False
DDI-MedLine.d32.s3	is	37	38	O	is	is	is	VBZ	False
DDI-MedLine.d32.s3	understandable	40	53	O	understandable	ble	able	JJ	False
DDI-MedLine.d32.s3	because	55	61	O	because	use	ause	IN	False
DDI-MedLine.d32.s3	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d32.s3	geriatric	67	75	O	geriatric	ric	tric	NN	False
DDI-MedLine.d32.s3	population	77	86	O	population	ion	tion	NN	False
DDI-MedLine.d32.s3	is	88	89	O	is	is	is	VBZ	False
DDI-MedLine.d32.s3	susceptible	91	101	O	susceptible	ble	ible	JJ	False
DDI-MedLine.d32.s3	to	103	104	O	to	to	to	TO	False
DDI-MedLine.d32.s3	adverse	106	112	O	adverse	rse	erse	NN	False
DDI-MedLine.d32.s3	drug	114	117	O	drug	rug	drug	NN	False
DDI-MedLine.d32.s3	reactions	119	127	O	reactions	ons	ions	NNS	False
DDI-MedLine.d32.s3	.	128	128	O	.	.	.	.	False

DDI-MedLine.d32.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d32.s4	key	4	6	O	key	key	key	NN	False
DDI-MedLine.d32.s4	to	8	9	O	to	to	to	TO	False
DDI-MedLine.d32.s4	maximizing	11	20	O	maximizing	ing	zing	VBG	False
DDI-MedLine.d32.s4	therapy	22	28	O	therapy	apy	rapy	NN	False
DDI-MedLine.d32.s4	lies	30	33	O	lies	ies	lies	NNS	False
DDI-MedLine.d32.s4	in	35	36	O	in	in	in	IN	False
DDI-MedLine.d32.s4	individualizing	38	52	O	individualizing	ing	zing	VBG	False
DDI-MedLine.d32.s4	it	54	55	O	it	it	it	PRP	False
DDI-MedLine.d32.s4	as	57	58	O	as	as	as	IN	False
DDI-MedLine.d32.s4	much	60	63	O	much	uch	much	JJ	False
DDI-MedLine.d32.s4	as	65	66	O	as	as	as	IN	False
DDI-MedLine.d32.s4	possible	68	75	O	possible	ble	ible	JJ	False
DDI-MedLine.d32.s4	.	76	76	O	.	.	.	.	False

DDI-MedLine.d32.s5	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d32.s5	are	6	8	O	are	are	are	VBP	False
DDI-MedLine.d32.s5	a	10	10	O	a	a	a	DT	False
DDI-MedLine.d32.s5	number	12	17	O	number	ber	mber	NN	False
DDI-MedLine.d32.s5	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d32.s5	steps	22	26	O	steps	eps	teps	NNS	False
DDI-MedLine.d32.s5	physicians	28	37	O	physicians	ans	ians	NNS	False
DDI-MedLine.d32.s5	can	39	41	O	can	can	can	MD	False
DDI-MedLine.d32.s5	take	43	46	O	take	ake	take	VB	False
DDI-MedLine.d32.s5	to	48	49	O	to	to	to	TO	False
DDI-MedLine.d32.s5	ensure	51	56	O	ensure	ure	sure	VB	False
DDI-MedLine.d32.s5	that	58	61	O	that	hat	that	IN	False
DDI-MedLine.d32.s5	their	63	67	O	their	eir	heir	PRP$	False
DDI-MedLine.d32.s5	patients	69	76	O	patients	nts	ents	NNS	False
DDI-MedLine.d32.s5	are	78	80	O	are	are	are	VBP	False
DDI-MedLine.d32.s5	not	82	84	O	not	not	not	RB	False
DDI-MedLine.d32.s5	being	86	90	O	being	ing	eing	VBG	False
DDI-MedLine.d32.s5	undertreated	92	103	O	undertreated	ted	ated	JJ	False
DDI-MedLine.d32.s5	.	104	104	O	.	.	.	.	False

DDI-MedLine.d32.s6	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d32.s6	steps	6	10	O	steps	eps	teps	NNS	False
DDI-MedLine.d32.s6	include	12	18	O	include	ude	lude	NN	False
DDI-MedLine.d32.s6	regular	20	26	O	regular	lar	ular	JJ	False
DDI-MedLine.d32.s6	reevaluations	28	40	O	reevaluations	ons	ions	NNS	False
DDI-MedLine.d32.s6	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d32.s6	dosages	45	51	O	dosages	ges	ages	NNS	False
DDI-MedLine.d32.s6	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d32.s6	plasma	57	62	O	plasma	sma	asma	NN	False
DDI-MedLine.d32.s6	drug	64	67	O	drug	rug	drug	NN	False
DDI-MedLine.d32.s6	concentrations	69	82	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d32.s6	,	83	83	O	,	,	,	,	False
DDI-MedLine.d32.s6	recognition	85	95	O	recognition	ion	tion	NN	False
DDI-MedLine.d32.s6	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d32.s6	understanding	101	113	O	understanding	ing	ding	VBG	False
DDI-MedLine.d32.s6	of	115	116	O	of	of	of	IN	False
DDI-MedLine.d32.s6	drug	118	121	O	drug	rug	drug	NN	False
DDI-MedLine.d32.s6	side	123	126	O	side	ide	side	NN	False
DDI-MedLine.d32.s6	effects	128	134	O	effects	cts	ects	NNS	False
DDI-MedLine.d32.s6	,	135	135	O	,	,	,	,	False
DDI-MedLine.d32.s6	and	137	139	O	and	and	and	CC	False
DDI-MedLine.d32.s6	avoidance	141	149	O	avoidance	nce	ance	NN	False
DDI-MedLine.d32.s6	of	151	152	O	of	of	of	IN	False
DDI-MedLine.d32.s6	certain	154	160	O	certain	ain	tain	JJ	False
DDI-MedLine.d32.s6	agents	162	167	O	agents	nts	ents	NNS	False
DDI-MedLine.d32.s6	.	168	168	O	.	.	.	.	False

DDI-MedLine.d32.s7	Close	0	4	O	Close	ose	lose	RB	False
DDI-MedLine.d32.s7	monitoring	6	15	O	monitoring	ing	ring	NN	False
DDI-MedLine.d32.s7	allows	17	22	O	allows	ows	lows	NNS	False
DDI-MedLine.d32.s7	physicians	24	33	O	physicians	ans	ians	NNS	False
DDI-MedLine.d32.s7	to	35	36	O	to	to	to	TO	False
DDI-MedLine.d32.s7	minimize	38	45	O	minimize	ize	mize	VB	False
DDI-MedLine.d32.s7	risks	47	51	O	risks	sks	isks	NNS	False
DDI-MedLine.d32.s7	,	52	52	O	,	,	,	,	False
DDI-MedLine.d32.s7	maximize	54	61	O	maximize	ize	mize	VB	False
DDI-MedLine.d32.s7	benefits	63	70	O	benefits	its	fits	NNS	False
DDI-MedLine.d32.s7	,	71	71	O	,	,	,	,	False
DDI-MedLine.d32.s7	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d32.s7	get	77	79	O	get	get	get	VB	False
DDI-MedLine.d32.s7	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d32.s7	most	85	88	O	most	ost	most	JJS	False
DDI-MedLine.d32.s7	out	90	92	O	out	out	out	IN	False
DDI-MedLine.d32.s7	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d32.s7	what	97	100	O	what	hat	what	WP	False
DDI-MedLine.d32.s7	modern	102	107	O	modern	ern	dern	JJ	False
DDI-MedLine.d32.s7	medications	109	119	O	medications	ons	ions	NNS	False
DDI-MedLine.d32.s7	can	121	123	O	can	can	can	MD	False
DDI-MedLine.d32.s7	do	125	126	O	do	do	do	VB	False
DDI-MedLine.d32.s7	to	128	129	O	to	to	to	TO	False
DDI-MedLine.d32.s7	help	131	134	O	help	elp	help	NN	False
DDI-MedLine.d32.s7	older	136	140	O	older	der	lder	JJR	False
DDI-MedLine.d32.s7	patients	142	149	O	patients	nts	ents	NNS	False
DDI-MedLine.d32.s7	.	150	150	O	.	.	.	.	False

DDI-MedLine.d9.s0	Pharmacokinetics	0	15	O	Pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d9.s0	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d9.s0	calcium-entry	20	32	B-group	calcium-entry	try	ntry	NN	False
DDI-MedLine.d9.s0	blockers	34	41	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d9.s0	.	42	42	O	.	.	.	.	False

DDI-MedLine.d9.s1	Effective	0	8	O	Effective	ive	tive	JJ	False
DDI-MedLine.d9.s1	use	10	12	O	use	use	use	NN	False
DDI-MedLine.d9.s1	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d9.s1	drugs	17	21	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d9.s1	in	23	24	O	in	in	in	IN	False
DDI-MedLine.d9.s1	therapy	26	32	O	therapy	apy	rapy	NN	False
DDI-MedLine.d9.s1	depends	34	40	O	depends	nds	ends	NNS	False
DDI-MedLine.d9.s1	not	42	44	O	not	not	not	RB	False
DDI-MedLine.d9.s1	only	46	49	O	only	nly	only	RB	False
DDI-MedLine.d9.s1	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d9.s1	clinical	54	61	O	clinical	cal	ical	JJ	False
DDI-MedLine.d9.s1	acumen	63	68	O	acumen	men	umen	NNS	False
DDI-MedLine.d9.s1	but	70	72	O	but	but	but	CC	False
DDI-MedLine.d9.s1	also	74	77	O	also	lso	also	RB	False
DDI-MedLine.d9.s1	on	79	80	O	on	on	on	IN	False
DDI-MedLine.d9.s1	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d9.s1	availability	86	97	O	availability	ity	lity	NN	False
DDI-MedLine.d9.s1	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d9.s1	relevant	102	109	O	relevant	ant	vant	NN	False
DDI-MedLine.d9.s1	pharmacokinetic	111	125	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d9.s1	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d9.s1	pharmacodynamic	131	145	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d9.s1	data	147	150	O	data	ata	data	NNS	False
DDI-MedLine.d9.s1	.	151	151	O	.	.	.	.	False

DDI-MedLine.d9.s2	Such	0	3	O	Such	uch	Such	JJ	False
DDI-MedLine.d9.s2	information	5	15	O	information	ion	tion	NN	False
DDI-MedLine.d9.s2	assists	17	23	O	assists	sts	ists	NNS	False
DDI-MedLine.d9.s2	in	25	26	O	in	in	in	IN	False
DDI-MedLine.d9.s2	development	28	38	O	development	ent	ment	NN	False
DDI-MedLine.d9.s2	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d9.s2	safe	43	46	O	safe	afe	safe	JJ	False
DDI-MedLine.d9.s2	dosing	48	53	O	dosing	ing	sing	VBG	False
DDI-MedLine.d9.s2	regimens	55	62	O	regimens	ens	mens	NNS	False
DDI-MedLine.d9.s2	,	63	63	O	,	,	,	,	False
DDI-MedLine.d9.s2	prediction	65	74	O	prediction	ion	tion	NN	False
DDI-MedLine.d9.s2	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d9.s2	abnormal	79	86	O	abnormal	mal	rmal	JJ	False
DDI-MedLine.d9.s2	handling	88	95	O	handling	ing	ling	VBG	False
DDI-MedLine.d9.s2	of	97	98	O	of	of	of	IN	False
DDI-MedLine.d9.s2	drugs	100	104	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d9.s2	in	106	107	O	in	in	in	IN	False
DDI-MedLine.d9.s2	states	109	114	O	states	tes	ates	NNS	False
DDI-MedLine.d9.s2	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d9.s2	disease	119	125	O	disease	ase	ease	NN	False
DDI-MedLine.d9.s2	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d9.s2	disorder	131	138	O	disorder	der	rder	NN	False
DDI-MedLine.d9.s2	and	140	142	O	and	and	and	CC	False
DDI-MedLine.d9.s2	anticipation	144	155	O	anticipation	ion	tion	NN	False
DDI-MedLine.d9.s2	of	157	158	O	of	of	of	IN	False
DDI-MedLine.d9.s2	drug	160	163	O	drug	rug	drug	NN	False
DDI-MedLine.d9.s2	interactions	165	176	O	interactions	ons	ions	NNS	False
DDI-MedLine.d9.s2	.	177	177	O	.	.	.	.	False

DDI-MedLine.d9.s3	For	0	2	O	For	For	For	IN	False
DDI-MedLine.d9.s3	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d9.s3	calcium-entry	8	20	B-group	calcium-entry	try	ntry	NN	False
DDI-MedLine.d9.s3	blocking	22	29	I-group	blocking	ing	king	VBG	False
DDI-MedLine.d9.s3	agents	31	36	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d9.s3	now	38	40	O	now	now	now	RB	False
DDI-MedLine.d9.s3	available	42	50	O	available	ble	able	JJ	False
DDI-MedLine.d9.s3	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d9.s3	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d9.s3	United	59	64	O	United	ted	ited	NNP	False
DDI-MedLine.d9.s3	States	66	71	O	States	tes	ates	NNS	False
DDI-MedLine.d9.s3	(	73	73	O	(	(	(	(	False
DDI-MedLine.d9.s3	verapamil	74	82	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d9.s3	,	83	83	O	,	,	,	,	False
DDI-MedLine.d9.s3	nifedipine	85	94	B-drug	nifedipine	ine	pine	NN	drug
DDI-MedLine.d9.s3	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d9.s3	diltiazem	100	108	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d9.s3	)	109	109	O	)	)	)	)	False
DDI-MedLine.d9.s3	,	110	110	O	,	,	,	,	False
DDI-MedLine.d9.s3	these	112	116	O	these	ese	hese	DT	False
DDI-MedLine.d9.s3	data	118	121	O	data	ata	data	NNS	False
DDI-MedLine.d9.s3	appeared	123	130	O	appeared	red	ared	VBD	False
DDI-MedLine.d9.s3	well	132	135	O	well	ell	well	RB	False
DDI-MedLine.d9.s3	after	137	141	O	after	ter	fter	IN	False
DDI-MedLine.d9.s3	clinical	143	150	O	clinical	cal	ical	JJ	False
DDI-MedLine.d9.s3	patterns	152	159	O	patterns	rns	erns	NNS	False
DDI-MedLine.d9.s3	of	161	162	O	of	of	of	IN	False
DDI-MedLine.d9.s3	use	164	166	O	use	use	use	NN	False
DDI-MedLine.d9.s3	evolved	168	174	O	evolved	ved	lved	VBN	False
DDI-MedLine.d9.s3	.	175	175	O	.	.	.	.	False

DDI-MedLine.d9.s4	Nonetheless	0	10	O	Nonetheless	ess	less	RB	False
DDI-MedLine.d9.s4	,	11	11	O	,	,	,	,	False
DDI-MedLine.d9.s4	their	13	17	O	their	eir	heir	PRP$	False
DDI-MedLine.d9.s4	relevance	19	27	O	relevance	nce	ance	NN	False
DDI-MedLine.d9.s4	continues	29	37	O	continues	ues	nues	VBZ	False
DDI-MedLine.d9.s4	to	39	40	O	to	to	to	TO	False
DDI-MedLine.d9.s4	be	42	43	O	be	be	be	VB	False
DDI-MedLine.d9.s4	demonstrated	45	56	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d9.s4	by	58	59	O	by	by	by	IN	False
DDI-MedLine.d9.s4	the	61	63	O	the	the	the	DT	False
DDI-MedLine.d9.s4	dependence	65	74	O	dependence	nce	ence	NN	False
DDI-MedLine.d9.s4	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d9.s4	each	79	82	O	each	ach	each	DT	False
DDI-MedLine.d9.s4	agent	84	88	O	agent	ent	gent	NN	False
DDI-MedLine.d9.s4	on	90	91	O	on	on	on	IN	False
DDI-MedLine.d9.s4	intact	93	98	O	intact	act	tact	JJ	False
DDI-MedLine.d9.s4	liver	100	104	O	liver	ver	iver	NN	False
DDI-MedLine.d9.s4	blood	106	110	O	blood	ood	lood	NN	False
DDI-MedLine.d9.s4	flow	112	115	O	flow	low	flow	NN	False
DDI-MedLine.d9.s4	and	117	119	O	and	and	and	CC	False
DDI-MedLine.d9.s4	function	121	128	O	function	ion	tion	NN	False
DDI-MedLine.d9.s4	for	130	132	O	for	for	for	IN	False
DDI-MedLine.d9.s4	normal	134	139	O	normal	mal	rmal	JJ	False
DDI-MedLine.d9.s4	rates	141	145	O	rates	tes	ates	NNS	False
DDI-MedLine.d9.s4	of	147	148	O	of	of	of	IN	False
DDI-MedLine.d9.s4	elimination	150	160	O	elimination	ion	tion	NN	False
DDI-MedLine.d9.s4	;	161	161	O	;	;	;	:	False

DDI-MedLine.d9.s5	by	0	1	O	by	by	by	IN	False
DDI-MedLine.d9.s5	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d9.s5	nonlinear	7	15	O	nonlinear	ear	near	JJ	False
DDI-MedLine.d9.s5	kinetic	17	23	O	kinetic	tic	etic	JJ	False
DDI-MedLine.d9.s5	characteristics	25	39	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d9.s5	for	41	43	O	for	for	for	IN	False
DDI-MedLine.d9.s5	verapamil	45	53	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d9.s5	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d9.s5	diltiazem	59	67	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d9.s5	(	69	69	O	(	(	(	(	False
DDI-MedLine.d9.s5	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d9.s5	probably	74	81	O	probably	bly	ably	RB	False
DDI-MedLine.d9.s5	for	83	85	O	for	for	for	IN	False
DDI-MedLine.d9.s5	nifedipine	87	96	B-drug	nifedipine	ine	pine	NN	drug
DDI-MedLine.d9.s5	,	97	97	O	,	,	,	,	False
DDI-MedLine.d9.s5	as	99	100	O	as	as	as	IN	False
DDI-MedLine.d9.s5	well	102	105	O	well	ell	well	RB	False
DDI-MedLine.d9.s5	)	106	106	O	)	)	)	)	False
DDI-MedLine.d9.s5	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d9.s5	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d9.s5	derivative	116	125	O	derivative	ive	tive	JJ	False
DDI-MedLine.d9.s5	implications	127	138	O	implications	ons	ions	NNS	False
DDI-MedLine.d9.s5	for	140	142	O	for	for	for	IN	False
DDI-MedLine.d9.s5	decreased	144	152	O	decreased	sed	ased	VBN	False
DDI-MedLine.d9.s5	dosing	154	159	O	dosing	ing	sing	VBG	False
DDI-MedLine.d9.s5	frequency	161	169	O	frequency	ncy	ency	NN	False
DDI-MedLine.d9.s5	requirements	171	182	O	requirements	nts	ents	NNS	False
DDI-MedLine.d9.s5	;	183	183	O	;	;	;	:	False

DDI-MedLine.d9.s6	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d9.s6	by	4	5	O	by	by	by	IN	False
DDI-MedLine.d9.s6	observations	7	18	O	observations	ons	ions	NNS	False
DDI-MedLine.d9.s6	now	20	22	O	now	now	now	RB	False
DDI-MedLine.d9.s6	appearing	24	32	O	appearing	ing	ring	VBG	False
DDI-MedLine.d9.s6	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d9.s6	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d9.s6	relation	41	48	O	relation	ion	tion	NN	False
DDI-MedLine.d9.s6	between	50	56	O	between	een	ween	IN	False
DDI-MedLine.d9.s6	plasma	58	63	O	plasma	sma	asma	NN	False
DDI-MedLine.d9.s6	drug	65	68	O	drug	rug	drug	NN	False
DDI-MedLine.d9.s6	levels	70	75	O	levels	els	vels	NNS	False
DDI-MedLine.d9.s6	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d9.s6	drug	81	84	O	drug	rug	drug	NN	False
DDI-MedLine.d9.s6	effects	86	92	O	effects	cts	ects	NNS	False
DDI-MedLine.d9.s6	,	93	93	O	,	,	,	,	False
DDI-MedLine.d9.s6	both	95	98	O	both	oth	both	DT	False
DDI-MedLine.d9.s6	therapeutic	100	110	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d9.s6	and	112	114	O	and	and	and	CC	False
DDI-MedLine.d9.s6	toxic	116	120	O	toxic	xic	oxic	NN	False
DDI-MedLine.d9.s6	.	121	121	O	.	.	.	.	False

DDI-MedLine.d9.s7	Such	0	3	O	Such	uch	Such	JJ	False
DDI-MedLine.d9.s7	data	5	8	O	data	ata	data	NNS	False
DDI-MedLine.d9.s7	are	10	12	O	are	are	are	VBP	False
DDI-MedLine.d9.s7	discussed	14	22	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d9.s7	herein	24	29	O	herein	ein	rein	NN	False
DDI-MedLine.d9.s7	,	30	30	O	,	,	,	,	False
DDI-MedLine.d9.s7	with	32	35	O	with	ith	with	IN	False
DDI-MedLine.d9.s7	emphasis	37	44	O	emphasis	sis	asis	NN	False
DDI-MedLine.d9.s7	on	46	47	O	on	on	on	IN	False
DDI-MedLine.d9.s7	those	49	53	O	those	ose	hose	DT	False
DDI-MedLine.d9.s7	aspects	55	61	O	aspects	cts	ects	NNS	False
DDI-MedLine.d9.s7	that	63	66	O	that	hat	that	IN	False
DDI-MedLine.d9.s7	impact	68	73	O	impact	act	pact	NN	False
DDI-MedLine.d9.s7	on	75	76	O	on	on	on	IN	False
DDI-MedLine.d9.s7	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d9.s7	clinical	82	89	O	clinical	cal	ical	JJ	False
DDI-MedLine.d9.s7	use	91	93	O	use	use	use	NN	False
DDI-MedLine.d9.s7	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d9.s7	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d9.s7	calcium-entry	102	114	B-group	calcium-entry	try	ntry	NN	False
DDI-MedLine.d9.s7	antagonists	116	126	I-group	antagonists	sts	ists	NNS	False
DDI-MedLine.d9.s7	.	127	127	O	.	.	.	.	False

DDI-MedLine.d26.s0	Optimal	0	6	O	Optimal	mal	imal	NN	False
DDI-MedLine.d26.s0	designs	8	14	O	designs	gns	igns	NNS	False
DDI-MedLine.d26.s0	for	16	18	O	for	for	for	IN	False
DDI-MedLine.d26.s0	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d26.s0	individual	24	33	O	individual	ual	dual	JJ	False
DDI-MedLine.d26.s0	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d26.s0	joint	39	43	O	joint	int	oint	NN	False
DDI-MedLine.d26.s0	exposure	45	52	O	exposure	ure	sure	NN	False
DDI-MedLine.d26.s0	general	54	60	O	general	ral	eral	JJ	False
DDI-MedLine.d26.s0	logistic	62	69	O	logistic	tic	stic	JJ	False
DDI-MedLine.d26.s0	regression	71	80	O	regression	ion	sion	NN	False
DDI-MedLine.d26.s0	models	82	87	O	models	els	dels	NNS	False
DDI-MedLine.d26.s0	.	88	88	O	.	.	.	.	False

DDI-MedLine.d26.s1	Interest	0	7	O	Interest	est	rest	NN	False
DDI-MedLine.d26.s1	in	9	10	O	in	in	in	IN	False
DDI-MedLine.d26.s1	administering	12	24	O	administering	ing	ring	VBG	False
DDI-MedLine.d26.s1	compounds	26	34	O	compounds	nds	unds	NNS	False
DDI-MedLine.d26.s1	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d26.s1	combination	39	49	O	combination	ion	tion	NN	False
DDI-MedLine.d26.s1	lies	51	54	O	lies	ies	lies	NNS	False
DDI-MedLine.d26.s1	both	56	59	O	both	oth	both	DT	False
DDI-MedLine.d26.s1	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d26.s1	enhancing	64	72	O	enhancing	ing	cing	VBG	False
DDI-MedLine.d26.s1	efficacious	74	84	O	efficacious	ous	ious	JJ	False
DDI-MedLine.d26.s1	effects	86	92	O	effects	cts	ects	NNS	False
DDI-MedLine.d26.s1	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d26.s1	in	98	99	O	in	in	in	IN	False
DDI-MedLine.d26.s1	limiting	101	108	O	limiting	ing	ting	VBG	False
DDI-MedLine.d26.s1	adverse	110	116	O	adverse	rse	erse	NN	False
DDI-MedLine.d26.s1	effects	118	124	O	effects	cts	ects	NNS	False
DDI-MedLine.d26.s1	.	125	125	O	.	.	.	.	False

DDI-MedLine.d26.s2	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d26.s2	much	9	12	O	much	uch	much	JJ	False
DDI-MedLine.d26.s2	statistical	14	24	O	statistical	cal	ical	JJ	False
DDI-MedLine.d26.s2	work	26	29	O	work	ork	work	NN	False
DDI-MedLine.d26.s2	has	31	33	O	has	has	has	VBZ	False
DDI-MedLine.d26.s2	focused	35	41	O	focused	sed	used	VBN	False
DDI-MedLine.d26.s2	on	43	44	O	on	on	on	IN	False
DDI-MedLine.d26.s2	developing	46	55	O	developing	ing	ping	VBG	False
DDI-MedLine.d26.s2	mathematical	57	68	O	mathematical	cal	ical	JJ	False
DDI-MedLine.d26.s2	functions	70	78	O	functions	ons	ions	NNS	False
DDI-MedLine.d26.s2	to	80	81	O	to	to	to	TO	False
DDI-MedLine.d26.s2	model	83	87	O	model	del	odel	NN	False
DDI-MedLine.d26.s2	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d26.s2	joint	93	97	O	joint	int	oint	NN	False
DDI-MedLine.d26.s2	dose-response	99	111	O	dose-response	nse	onse	NN	False
DDI-MedLine.d26.s2	curves	113	118	O	curves	ves	rves	NNS	False
DDI-MedLine.d26.s2	,	119	119	O	,	,	,	,	False
DDI-MedLine.d26.s2	relatively	121	130	O	relatively	ely	vely	RB	False
DDI-MedLine.d26.s2	little	132	137	O	little	tle	ttle	JJ	False
DDI-MedLine.d26.s2	work	139	142	O	work	ork	work	NN	False
DDI-MedLine.d26.s2	exists	144	149	O	exists	sts	ists	NNS	False
DDI-MedLine.d26.s2	in	151	152	O	in	in	in	IN	False
DDI-MedLine.d26.s2	regard	154	159	O	regard	ard	gard	NN	False
DDI-MedLine.d26.s2	to	161	162	O	to	to	to	TO	False
DDI-MedLine.d26.s2	designing	164	172	O	designing	ing	ning	VBG	False
DDI-MedLine.d26.s2	experiments	174	184	O	experiments	nts	ents	NNS	False
DDI-MedLine.d26.s2	for	186	188	O	for	for	for	IN	False
DDI-MedLine.d26.s2	assessing	190	198	O	assessing	ing	sing	VBG	False
DDI-MedLine.d26.s2	joint	200	204	O	joint	int	oint	NN	False
DDI-MedLine.d26.s2	action	206	211	O	action	ion	tion	NN	False
DDI-MedLine.d26.s2	.	212	212	O	.	.	.	.	False

DDI-MedLine.d26.s3	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d26.s3	variety	2	8	O	variety	ety	iety	NN	False
DDI-MedLine.d26.s3	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d26.s3	parametric	13	22	O	parametric	ric	tric	NN	False
DDI-MedLine.d26.s3	dose-response	24	36	O	dose-response	nse	onse	NN	False
DDI-MedLine.d26.s3	models	38	43	O	models	els	dels	NNS	False
DDI-MedLine.d26.s3	based	45	49	O	based	sed	ased	VBN	False
DDI-MedLine.d26.s3	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d26.s3	either	54	59	O	either	her	ther	DT	False
DDI-MedLine.d26.s3	the	61	63	O	the	the	the	DT	False
DDI-MedLine.d26.s3	normal	65	70	O	normal	mal	rmal	JJ	False
DDI-MedLine.d26.s3	or	72	73	O	or	or	or	CC	False
DDI-MedLine.d26.s3	logistic	75	82	O	logistic	tic	stic	JJ	False
DDI-MedLine.d26.s3	probability	84	94	O	probability	ity	lity	NN	False
DDI-MedLine.d26.s3	distribution	96	107	O	distribution	ion	tion	NN	False
DDI-MedLine.d26.s3	have	109	112	O	have	ave	have	VB	False
DDI-MedLine.d26.s3	been	114	117	O	been	een	been	VBN	False
DDI-MedLine.d26.s3	proposed	119	126	O	proposed	sed	osed	VBN	False
DDI-MedLine.d26.s3	in	128	129	O	in	in	in	IN	False
DDI-MedLine.d26.s3	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d26.s3	literature	135	144	O	literature	ure	ture	NN	False
DDI-MedLine.d26.s3	.	145	145	O	.	.	.	.	False

DDI-MedLine.d26.s4	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d26.s4	models	6	11	O	models	els	dels	NNS	False
DDI-MedLine.d26.s4	are	13	15	O	are	are	are	VBP	False
DDI-MedLine.d26.s4	typically	17	25	O	typically	lly	ally	RB	False
DDI-MedLine.d26.s4	nonlinear	27	35	O	nonlinear	ear	near	JJ	False
DDI-MedLine.d26.s4	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d26.s4	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d26.s4	parameters	44	53	O	parameters	ers	ters	NNS	False
DDI-MedLine.d26.s4	,	54	54	O	,	,	,	,	False
DDI-MedLine.d26.s4	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d26.s4	as	60	61	O	as	as	as	IN	False
DDI-MedLine.d26.s4	such	63	66	O	such	uch	such	JJ	False
DDI-MedLine.d26.s4	,	67	67	O	,	,	,	,	False
DDI-MedLine.d26.s4	a	69	69	O	a	a	a	DT	False
DDI-MedLine.d26.s4	nonlinear	71	79	O	nonlinear	ear	near	JJ	False
DDI-MedLine.d26.s4	weighted	81	88	O	weighted	ted	hted	VBN	False
DDI-MedLine.d26.s4	least	90	94	O	least	ast	east	JJS	False
DDI-MedLine.d26.s4	squares	96	102	O	squares	res	ares	NNS	False
DDI-MedLine.d26.s4	approach	104	111	O	approach	ach	oach	NN	False
DDI-MedLine.d26.s4	can	113	115	O	can	can	can	MD	False
DDI-MedLine.d26.s4	be	117	118	O	be	be	be	VB	False
DDI-MedLine.d26.s4	employed	120	127	O	employed	yed	oyed	VBN	False
DDI-MedLine.d26.s4	for	129	131	O	for	for	for	IN	False
DDI-MedLine.d26.s4	the	133	135	O	the	the	the	DT	False
DDI-MedLine.d26.s4	purpose	137	143	O	purpose	ose	pose	NN	False
DDI-MedLine.d26.s4	of	145	146	O	of	of	of	IN	False
DDI-MedLine.d26.s4	designing	148	156	O	designing	ing	ning	VBG	False
DDI-MedLine.d26.s4	experiments	158	168	O	experiments	nts	ents	NNS	False
DDI-MedLine.d26.s4	.	169	169	O	.	.	.	.	False

DDI-MedLine.d26.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d26.s5	approach	4	11	O	approach	ach	oach	NN	False
DDI-MedLine.d26.s5	is	13	14	O	is	is	is	VBZ	False
DDI-MedLine.d26.s5	applicable	16	25	O	applicable	ble	able	JJ	False
DDI-MedLine.d26.s5	across	27	32	O	across	oss	ross	IN	False
DDI-MedLine.d26.s5	a	34	34	O	a	a	a	DT	False
DDI-MedLine.d26.s5	wide	36	39	O	wide	ide	wide	JJ	False
DDI-MedLine.d26.s5	variety	41	47	O	variety	ety	iety	NN	False
DDI-MedLine.d26.s5	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d26.s5	settings	52	59	O	settings	ngs	ings	NNS	False
DDI-MedLine.d26.s5	commonly	61	68	O	commonly	nly	only	RB	False
DDI-MedLine.d26.s5	associated	70	79	O	associated	ted	ated	VBN	False
DDI-MedLine.d26.s5	with	81	84	O	with	ith	with	IN	False
DDI-MedLine.d26.s5	joint	86	90	O	joint	int	oint	NN	False
DDI-MedLine.d26.s5	action	92	97	O	action	ion	tion	NN	False
DDI-MedLine.d26.s5	data	99	102	O	data	ata	data	NNS	False
DDI-MedLine.d26.s5	,	103	103	O	,	,	,	,	False
DDI-MedLine.d26.s5	including	105	113	O	including	ing	ding	VBG	False
DDI-MedLine.d26.s5	continuous	115	124	O	continuous	ous	uous	JJ	False
DDI-MedLine.d26.s5	and	126	128	O	and	and	and	CC	False
DDI-MedLine.d26.s5	discrete	130	137	O	discrete	ete	rete	NN	False
DDI-MedLine.d26.s5	responses	139	147	O	responses	ses	nses	NNS	False
DDI-MedLine.d26.s5	,	148	148	O	,	,	,	,	False
DDI-MedLine.d26.s5	alternative	150	160	O	alternative	ive	tive	NN	False
DDI-MedLine.d26.s5	error	162	166	O	error	ror	rror	NN	False
DDI-MedLine.d26.s5	structures	168	177	O	structures	res	ures	NNS	False
DDI-MedLine.d26.s5	,	178	178	O	,	,	,	,	False
DDI-MedLine.d26.s5	and	180	182	O	and	and	and	CC	False
DDI-MedLine.d26.s5	nonzero	184	190	O	nonzero	ero	zero	NN	False
DDI-MedLine.d26.s5	background	192	201	O	background	und	ound	NN	False
DDI-MedLine.d26.s5	response	203	210	O	response	nse	onse	NN	False
DDI-MedLine.d26.s5	.	211	211	O	.	.	.	.	False

DDI-MedLine.d26.s6	Further	0	6	O	Further	her	ther	RB	False
DDI-MedLine.d26.s6	,	7	7	O	,	,	,	,	False
DDI-MedLine.d26.s6	designs	9	15	O	designs	gns	igns	NNS	False
DDI-MedLine.d26.s6	can	17	19	O	can	can	can	MD	False
DDI-MedLine.d26.s6	be	21	22	O	be	be	be	VB	False
DDI-MedLine.d26.s6	expressed	24	32	O	expressed	sed	ssed	VBN	False
DDI-MedLine.d26.s6	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d26.s6	terms	37	41	O	terms	rms	erms	NNS	False
DDI-MedLine.d26.s6	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d26.s6	proportionate	46	58	O	proportionate	ate	nate	NN	False
DDI-MedLine.d26.s6	responses	60	68	O	responses	ses	nses	NNS	False
DDI-MedLine.d26.s6	associated	70	79	O	associated	ted	ated	VBN	False
DDI-MedLine.d26.s6	with	81	84	O	with	ith	with	IN	False
DDI-MedLine.d26.s6	the	86	88	O	the	the	the	DT	False
DDI-MedLine.d26.s6	individual	90	99	O	individual	ual	dual	JJ	False
DDI-MedLine.d26.s6	compounds	101	109	O	compounds	nds	unds	NNS	False
DDI-MedLine.d26.s6	rather	111	116	O	rather	her	ther	RB	False
DDI-MedLine.d26.s6	than	118	121	O	than	han	than	IN	False
DDI-MedLine.d26.s6	dose	123	126	O	dose	ose	dose	NN	False
DDI-MedLine.d26.s6	levels	128	133	O	levels	els	vels	NNS	False
DDI-MedLine.d26.s6	,	134	134	O	,	,	,	,	False
DDI-MedLine.d26.s6	thereby	136	142	O	thereby	eby	reby	RB	False
DDI-MedLine.d26.s6	providing	144	152	O	providing	ing	ding	VBG	False
DDI-MedLine.d26.s6	for	154	156	O	for	for	for	IN	False
DDI-MedLine.d26.s6	results	158	164	O	results	lts	ults	NNS	False
DDI-MedLine.d26.s6	that	166	169	O	that	hat	that	IN	False
DDI-MedLine.d26.s6	are	171	173	O	are	are	are	VBP	False
DDI-MedLine.d26.s6	applicable	175	184	O	applicable	ble	able	JJ	False
DDI-MedLine.d26.s6	across	186	191	O	across	oss	ross	IN	False
DDI-MedLine.d26.s6	compounds	193	201	O	compounds	nds	unds	NNS	False
DDI-MedLine.d26.s6	.	202	202	O	.	.	.	.	False

DDI-MedLine.d26.s7	As	0	1	O	As	As	As	IN	False
DDI-MedLine.d26.s7	a	3	3	O	a	a	a	DT	False
DDI-MedLine.d26.s7	precursor	5	13	O	precursor	sor	rsor	NN	False
DDI-MedLine.d26.s7	to	15	16	O	to	to	to	TO	False
DDI-MedLine.d26.s7	this	18	21	O	this	his	this	DT	False
DDI-MedLine.d26.s7	effort	23	28	O	effort	ort	fort	NN	False
DDI-MedLine.d26.s7	,	29	29	O	,	,	,	,	False
DDI-MedLine.d26.s7	optimal	31	37	O	optimal	mal	imal	JJ	False
DDI-MedLine.d26.s7	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d26.s7	minimal	43	49	O	minimal	mal	imal	NN	False
DDI-MedLine.d26.s7	experimental	51	62	O	experimental	tal	ntal	NN	False
DDI-MedLine.d26.s7	designs	64	70	O	designs	gns	igns	NNS	False
DDI-MedLine.d26.s7	for	72	74	O	for	for	for	IN	False
DDI-MedLine.d26.s7	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d26.s7	case	80	83	O	case	ase	case	NN	False
DDI-MedLine.d26.s7	in	85	86	O	in	in	in	IN	False
DDI-MedLine.d26.s7	which	88	92	O	which	ich	hich	WDT	False
DDI-MedLine.d26.s7	a	94	94	O	a	a	a	DT	False
DDI-MedLine.d26.s7	single	96	101	O	single	gle	ngle	JJ	False
DDI-MedLine.d26.s7	compound	103	110	O	compound	und	ound	NN	False
DDI-MedLine.d26.s7	is	112	113	O	is	is	is	VBZ	False
DDI-MedLine.d26.s7	administered	115	126	O	administered	red	ered	VBN	False
DDI-MedLine.d26.s7	have	128	131	O	have	ave	have	VB	False
DDI-MedLine.d26.s7	also	133	136	O	also	lso	also	RB	False
DDI-MedLine.d26.s7	been	138	141	O	been	een	been	VBN	False
DDI-MedLine.d26.s7	developed	143	151	O	developed	ped	oped	NN	False
DDI-MedLine.d26.s7	.	152	152	O	.	.	.	.	False

DDI-MedLine.d26.s8	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d26.s8	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d26.s8	proposed	13	20	O	proposed	sed	osed	VBN	False
DDI-MedLine.d26.s8	methodology	22	32	O	methodology	ogy	logy	NN	False
DDI-MedLine.d26.s8	for	34	36	O	for	for	for	IN	False
DDI-MedLine.d26.s8	deriving	38	45	O	deriving	ing	ving	VBG	False
DDI-MedLine.d26.s8	experimental	47	58	O	experimental	tal	ntal	NN	False
DDI-MedLine.d26.s8	designs	60	66	O	designs	gns	igns	NNS	False
DDI-MedLine.d26.s8	can	68	70	O	can	can	can	MD	False
DDI-MedLine.d26.s8	be	72	73	O	be	be	be	VB	False
DDI-MedLine.d26.s8	applied	75	81	O	applied	ied	lied	VBN	False
DDI-MedLine.d26.s8	to	83	84	O	to	to	to	TO	False
DDI-MedLine.d26.s8	any	86	88	O	any	any	any	DT	False
DDI-MedLine.d26.s8	nonlinear	90	98	O	nonlinear	ear	near	JJ	False
DDI-MedLine.d26.s8	regression	100	109	O	regression	ion	sion	NN	False
DDI-MedLine.d26.s8	model	111	115	O	model	del	odel	NN	False
DDI-MedLine.d26.s8	,	116	116	O	,	,	,	,	False
DDI-MedLine.d26.s8	primary	118	124	O	primary	ary	mary	NN	False
DDI-MedLine.d26.s8	focus	126	130	O	focus	cus	ocus	NN	False
DDI-MedLine.d26.s8	is	132	133	O	is	is	is	VBZ	False
DDI-MedLine.d26.s8	given	135	139	O	given	ven	iven	VBN	False
DDI-MedLine.d26.s8	to	141	142	O	to	to	to	TO	False
DDI-MedLine.d26.s8	the	144	146	O	the	the	the	DT	False
DDI-MedLine.d26.s8	additive	148	155	O	additive	ive	tive	JJ	False
DDI-MedLine.d26.s8	and	157	159	O	and	and	and	CC	False
DDI-MedLine.d26.s8	nonadditive	161	171	O	nonadditive	ive	tive	JJ	False
DDI-MedLine.d26.s8	independent	173	183	O	independent	ent	dent	JJ	False
DDI-MedLine.d26.s8	joint	185	189	O	joint	int	oint	NN	False
DDI-MedLine.d26.s8	action	191	196	O	action	ion	tion	NN	False
DDI-MedLine.d26.s8	(	198	198	O	(	(	(	(	False
DDI-MedLine.d26.s8	IJA	199	201	O	IJA	IJA	IJA	NN	brand
DDI-MedLine.d26.s8	)	202	202	O	)	)	)	)	False
DDI-MedLine.d26.s8	models	204	209	O	models	els	dels	NNS	False
DDI-MedLine.d26.s8	for	211	213	O	for	for	for	IN	False
DDI-MedLine.d26.s8	individual	215	224	O	individual	ual	dual	JJ	False
DDI-MedLine.d26.s8	and	226	228	O	and	and	and	CC	False
DDI-MedLine.d26.s8	combined	230	237	O	combined	ned	ined	VBN	False
DDI-MedLine.d26.s8	exposures	239	247	O	exposures	res	ures	NNS	False
DDI-MedLine.d26.s8	proposed	249	256	O	proposed	sed	osed	VBN	False
DDI-MedLine.d26.s8	by	258	259	O	by	by	by	IN	False
DDI-MedLine.d26.s8	Barton	261	266	O	Barton	ton	rton	NNP	False
DDI-MedLine.d26.s8	,	267	267	O	,	,	,	,	False
DDI-MedLine.d26.s8	Braunberg	269	277	O	Braunberg	erg	berg	NNP	False
DDI-MedLine.d26.s8	,	278	278	O	,	,	,	,	False
DDI-MedLine.d26.s8	and	280	282	O	and	and	and	CC	False
DDI-MedLine.d26.s8	Friedman	284	291	O	Friedman	man	dman	NN	False
DDI-MedLine.d26.s8	(	293	293	O	(	(	(	(	False
DDI-MedLine.d26.s8	1	294	294	O	1	1	1	CD	False
DDI-MedLine.d26.s8	)	295	295	O	)	)	)	)	False
DDI-MedLine.d26.s8	.	296	296	O	.	.	.	.	False

DDI-MedLine.d129.s0	Green	0	4	B-drug	Green	een	reen	JJ	False
DDI-MedLine.d129.s0	tea	6	8	I-drug	tea	tea	tea	NN	False
DDI-MedLine.d129.s0	polyphenols	10	20	I-drug	polyphenols	ols	nols	NNS	False
DDI-MedLine.d129.s0	as	22	23	O	as	as	as	IN	False
DDI-MedLine.d129.s0	potent	25	30	O	potent	ent	tent	NN	False
DDI-MedLine.d129.s0	enhancers	32	40	B-drug	enhancers	ers	cers	NNS	False
DDI-MedLine.d129.s0	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d129.s0	glucocorticoid-induced	45	66	O	glucocorticoid-induced	ced	uced	JJ	False
DDI-MedLine.d129.s0	mouse	68	72	O	mouse	use	ouse	NN	False
DDI-MedLine.d129.s0	mammary	74	80	O	mammary	ary	mary	NN	False
DDI-MedLine.d129.s0	tumor	82	86	O	tumor	mor	umor	NN	False
DDI-MedLine.d129.s0	virus	88	92	O	virus	rus	irus	NN	False
DDI-MedLine.d129.s0	gene	94	97	O	gene	ene	gene	NN	False
DDI-MedLine.d129.s0	expression	99	108	O	expression	ion	sion	NN	False
DDI-MedLine.d129.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d129.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d129.s1	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d129.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d129.s1	natural	14	20	O	natural	ral	ural	JJ	False
DDI-MedLine.d129.s1	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d129.s1	synthetic	26	34	O	synthetic	tic	etic	JJ	False
DDI-MedLine.d129.s1	galloyl	36	42	O	galloyl	oyl	loyl	NN	False
DDI-MedLine.d129.s1	esters	44	49	O	esters	ers	ters	NNS	False
DDI-MedLine.d129.s1	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d129.s1	glucocorticoid-induced	54	75	O	glucocorticoid-induced	ced	uced	JJ	False
DDI-MedLine.d129.s1	gene	77	80	O	gene	ene	gene	NN	False
DDI-MedLine.d129.s1	expression	82	91	O	expression	ion	sion	NN	False
DDI-MedLine.d129.s1	was	93	95	O	was	was	was	VBD	False
DDI-MedLine.d129.s1	evaluated	97	105	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d129.s1	by	107	108	O	by	by	by	IN	False
DDI-MedLine.d129.s1	using	110	114	O	using	ing	sing	VBG	False
DDI-MedLine.d129.s1	rat	116	118	O	rat	rat	rat	NN	False
DDI-MedLine.d129.s1	fibroblast	120	129	O	fibroblast	ast	last	NN	False
DDI-MedLine.d129.s1	3Y1	131	133	O	3Y1	3Y1	3Y1	CD	brand
DDI-MedLine.d129.s1	cells	135	139	O	cells	lls	ells	NNS	False
DDI-MedLine.d129.s1	stably	141	146	O	stably	bly	ably	RB	False
DDI-MedLine.d129.s1	transfected	148	158	O	transfected	ted	cted	VBN	False
DDI-MedLine.d129.s1	with	160	163	O	with	ith	with	IN	False
DDI-MedLine.d129.s1	a	165	165	O	a	a	a	DT	False
DDI-MedLine.d129.s1	luciferase	167	176	O	luciferase	ase	rase	NN	False
DDI-MedLine.d129.s1	reporter	178	185	O	reporter	ter	rter	NN	False
DDI-MedLine.d129.s1	gene	187	190	O	gene	ene	gene	NN	False
DDI-MedLine.d129.s1	under	192	196	O	under	der	nder	IN	False
DDI-MedLine.d129.s1	the	198	200	O	the	the	the	DT	False
DDI-MedLine.d129.s1	transcriptional	202	216	O	transcriptional	nal	onal	JJ	False
DDI-MedLine.d129.s1	regulation	218	227	O	regulation	ion	tion	NN	False
DDI-MedLine.d129.s1	of	229	230	O	of	of	of	IN	False
DDI-MedLine.d129.s1	the	232	234	O	the	the	the	DT	False
DDI-MedLine.d129.s1	mouse	236	240	O	mouse	use	ouse	NN	False
DDI-MedLine.d129.s1	mammary	242	248	O	mammary	ary	mary	NN	False
DDI-MedLine.d129.s1	tumor	250	254	O	tumor	mor	umor	NN	False
DDI-MedLine.d129.s1	virus	256	260	O	virus	rus	irus	NN	False
DDI-MedLine.d129.s1	promoter	262	269	B-drug	promoter	ter	oter	NN	False
DDI-MedLine.d129.s1	.	270	270	O	.	.	.	.	False

DDI-MedLine.d129.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d129.s2	glucocorticoid-induced	4	25	O	glucocorticoid-induced	ced	uced	JJ	False
DDI-MedLine.d129.s2	gene	27	30	O	gene	ene	gene	NN	False
DDI-MedLine.d129.s2	transcription	32	44	O	transcription	ion	tion	NN	False
DDI-MedLine.d129.s2	was	46	48	O	was	was	was	VBD	False
DDI-MedLine.d129.s2	strongly	50	57	O	strongly	gly	ngly	RB	False
DDI-MedLine.d129.s2	suppressed	59	68	O	suppressed	sed	ssed	VBN	False
DDI-MedLine.d129.s2	by	70	71	O	by	by	by	IN	False
DDI-MedLine.d129.s2	synthetic	73	81	O	synthetic	tic	etic	JJ	False
DDI-MedLine.d129.s2	alkyl	83	87	O	alkyl	kyl	lkyl	NN	False
DDI-MedLine.d129.s2	esters	89	94	O	esters	ers	ters	NNS	False
DDI-MedLine.d129.s2	;	95	95	O	;	;	;	:	False

DDI-MedLine.d129.s3	n-dodecyl	0	8	B-drug	n-dodecyl	cyl	ecyl	JJ	False
DDI-MedLine.d129.s3	gallate	10	16	I-drug	gallate	ate	late	NN	False
DDI-MedLine.d129.s3	showed	18	23	O	showed	wed	owed	VBD	False
DDI-MedLine.d129.s3	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d129.s3	most	29	32	O	most	ost	most	JJS	False
DDI-MedLine.d129.s3	potent	34	39	O	potent	ent	tent	NN	False
DDI-MedLine.d129.s3	inhibition	41	50	O	inhibition	ion	tion	NN	False
DDI-MedLine.d129.s3	(	52	52	O	(	(	(	(	False
DDI-MedLine.d129.s3	66	53	54	O	66	66	66	CD	False
DDI-MedLine.d129.s3	%	55	55	O	%	%	%	NN	False
DDI-MedLine.d129.s3	inhibition	57	66	O	inhibition	ion	tion	NN	False
DDI-MedLine.d129.s3	at	68	69	O	at	at	at	IN	False
DDI-MedLine.d129.s3	10	71	72	O	10	10	10	CD	False
DDI-MedLine.d129.s3	microM	74	79	O	microM	roM	croM	NN	False
DDI-MedLine.d129.s3	)	80	80	O	)	)	)	)	False
DDI-MedLine.d129.s3	,	81	81	O	,	,	,	,	False
DDI-MedLine.d129.s3	which	83	87	O	which	ich	hich	WDT	False
DDI-MedLine.d129.s3	was	89	91	O	was	was	was	VBD	False
DDI-MedLine.d129.s3	far	93	95	O	far	far	far	RB	False
DDI-MedLine.d129.s3	more	97	100	O	more	ore	more	RBR	False
DDI-MedLine.d129.s3	potent	102	107	O	potent	ent	tent	NN	False
DDI-MedLine.d129.s3	than	109	112	O	than	han	than	IN	False
DDI-MedLine.d129.s3	that	114	117	O	that	hat	that	IN	False
DDI-MedLine.d129.s3	of	119	120	O	of	of	of	IN	False
DDI-MedLine.d129.s3	crude	122	126	O	crude	ude	rude	NN	False
DDI-MedLine.d129.s3	tannic	128	133	B-drug	tannic	nic	nnic	NN	False
DDI-MedLine.d129.s3	acid	135	138	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d129.s3	.	139	139	O	.	.	.	.	False

DDI-MedLine.d129.s4	n-Octyl	0	6	O	n-Octyl	tyl	ctyl	JJ	False
DDI-MedLine.d129.s4	and	8	10	O	and	and	and	CC	False
DDI-MedLine.d129.s4	n-cetyl	12	18	O	n-cetyl	tyl	etyl	JJ	False
DDI-MedLine.d129.s4	gallate	20	26	O	gallate	ate	late	NN	False
DDI-MedLine.d129.s4	also	28	31	O	also	lso	also	RB	False
DDI-MedLine.d129.s4	showed	33	38	O	showed	wed	owed	VBD	False
DDI-MedLine.d129.s4	good	40	43	O	good	ood	good	JJ	False
DDI-MedLine.d129.s4	inhibition	45	54	O	inhibition	ion	tion	NN	False
DDI-MedLine.d129.s4	,	55	55	O	,	,	,	,	False
DDI-MedLine.d129.s4	while	57	61	O	while	ile	hile	IN	False
DDI-MedLine.d129.s4	gallic	63	68	O	gallic	lic	llic	NN	False
DDI-MedLine.d129.s4	acid	70	73	O	acid	cid	acid	NN	False
DDI-MedLine.d129.s4	itself	75	80	O	itself	elf	self	PRP	False
DDI-MedLine.d129.s4	was	82	84	O	was	was	was	VBD	False
DDI-MedLine.d129.s4	not	86	88	O	not	not	not	RB	False
DDI-MedLine.d129.s4	so	90	91	O	so	so	so	RB	False
DDI-MedLine.d129.s4	active	93	98	O	active	ive	tive	JJ	False
DDI-MedLine.d129.s4	,	99	99	O	,	,	,	,	False
DDI-MedLine.d129.s4	suggesting	101	110	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d129.s4	that	112	115	O	that	hat	that	IN	False
DDI-MedLine.d129.s4	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d129.s4	presence	121	128	O	presence	nce	ence	NN	False
DDI-MedLine.d129.s4	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d129.s4	hydrophobic	133	143	O	hydrophobic	bic	obic	NN	False
DDI-MedLine.d129.s4	side	145	148	O	side	ide	side	NN	False
DDI-MedLine.d129.s4	chain	150	154	O	chain	ain	hain	NN	False
DDI-MedLine.d129.s4	is	156	157	O	is	is	is	VBZ	False
DDI-MedLine.d129.s4	important	159	167	O	important	ant	tant	JJ	False
DDI-MedLine.d129.s4	for	169	171	O	for	for	for	IN	False
DDI-MedLine.d129.s4	the	173	175	O	the	the	the	DT	False
DDI-MedLine.d129.s4	suppressive	177	187	O	suppressive	ive	sive	NN	False
DDI-MedLine.d129.s4	effect	189	194	O	effect	ect	fect	NN	False
DDI-MedLine.d129.s4	.	195	195	O	.	.	.	.	False

DDI-MedLine.d129.s5	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d129.s5	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d129.s5	other	7	11	O	other	her	ther	JJ	False
DDI-MedLine.d129.s5	hand	13	16	O	hand	and	hand	NN	False
DDI-MedLine.d129.s5	,	17	17	O	,	,	,	,	False
DDI-MedLine.d129.s5	surprisingly	19	30	O	surprisingly	gly	ngly	RB	False
DDI-MedLine.d129.s5	,	31	31	O	,	,	,	,	False
DDI-MedLine.d129.s5	green	33	37	B-drug	green	een	reen	JJ	False
DDI-MedLine.d129.s5	tea	39	41	I-drug	tea	tea	tea	NN	False
DDI-MedLine.d129.s5	gallocatechins	43	56	I-drug	gallocatechins	ins	hins	NNS	False
DDI-MedLine.d129.s5	,	57	57	O	,	,	,	,	False
DDI-MedLine.d129.s5	(	59	59	O	(	(	(	(	False
DDI-MedLine.d129.s5	-	60	60	O	-	-	-	:	False
DDI-MedLine.d129.s5	)	61	61	O	)	)	)	)	False
DDI-MedLine.d129.s5	-epigallocatechin-3-O-gallate	62	90	O	-epigallocatechin-3-O-gallate	ate	late	NN	False
DDI-MedLine.d129.s5	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d129.s5	theasinensin	96	107	O	theasinensin	sin	nsin	NN	False
DDI-MedLine.d129.s5	A	109	109	O	A	A	A	DT	brand
DDI-MedLine.d129.s5	,	110	110	O	,	,	,	,	False
DDI-MedLine.d129.s5	potently	112	119	O	potently	tly	ntly	RB	False
DDI-MedLine.d129.s5	enhanced	121	128	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d129.s5	the	130	132	O	the	the	the	DT	False
DDI-MedLine.d129.s5	promoter	134	141	O	promoter	ter	oter	NN	False
DDI-MedLine.d129.s5	activity	143	150	O	activity	ity	vity	NN	False
DDI-MedLine.d129.s5	(	152	152	O	(	(	(	(	False
DDI-MedLine.d129.s5	182	153	155	O	182	182	182	CD	False
DDI-MedLine.d129.s5	and	157	159	O	and	and	and	CC	False
DDI-MedLine.d129.s5	247	161	163	O	247	247	247	CD	False
DDI-MedLine.d129.s5	%	164	164	O	%	%	%	NN	False
DDI-MedLine.d129.s5	activity	166	173	O	activity	ity	vity	NN	False
DDI-MedLine.d129.s5	at	175	176	O	at	at	at	IN	False
DDI-MedLine.d129.s5	1	178	178	O	1	1	1	CD	False
DDI-MedLine.d129.s5	microM	180	185	O	microM	roM	croM	NN	False
DDI-MedLine.d129.s5	,	186	186	O	,	,	,	,	False
DDI-MedLine.d129.s5	respectively	188	199	O	respectively	ely	vely	RB	False
DDI-MedLine.d129.s5	)	200	200	O	)	)	)	)	False
DDI-MedLine.d129.s5	.	201	201	O	.	.	.	.	False

DDI-MedLine.d129.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d129.s6	regulation	4	13	O	regulation	ion	tion	NN	False
DDI-MedLine.d129.s6	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d129.s6	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d129.s6	level	22	26	O	level	vel	evel	NN	False
DDI-MedLine.d129.s6	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d129.s6	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d129.s6	glucocorticoid-induced	35	56	O	glucocorticoid-induced	ced	uced	JJ	False
DDI-MedLine.d129.s6	gene	58	61	O	gene	ene	gene	NN	False
DDI-MedLine.d129.s6	expression	63	72	O	expression	ion	sion	NN	False
DDI-MedLine.d129.s6	by	74	75	O	by	by	by	IN	False
DDI-MedLine.d129.s6	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d129.s6	antioxidative	81	93	O	antioxidative	ive	tive	JJ	False
DDI-MedLine.d129.s6	gallates	95	102	O	gallates	tes	ates	NNS	False
DDI-MedLine.d129.s6	is	104	105	O	is	is	is	VBZ	False
DDI-MedLine.d129.s6	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d129.s6	great	110	114	O	great	eat	reat	JJ	False
DDI-MedLine.d129.s6	interest	116	123	O	interest	est	rest	NN	False
DDI-MedLine.d129.s6	from	125	128	O	from	rom	from	IN	False
DDI-MedLine.d129.s6	a	130	130	O	a	a	a	DT	False
DDI-MedLine.d129.s6	therapeutic	132	142	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d129.s6	point	144	148	O	point	int	oint	NN	False
DDI-MedLine.d129.s6	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d129.s6	view	153	156	O	view	iew	view	NN	False
DDI-MedLine.d129.s6	.	157	157	O	.	.	.	.	False

DDI-MedLine.d137.s0	Glucose	0	6	B-drug	Glucose	ose	cose	VB	False
DDI-MedLine.d137.s0	and	8	10	O	and	and	and	CC	False
DDI-MedLine.d137.s0	insulin	12	18	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s0	exert	20	24	O	exert	ert	xert	NN	False
DDI-MedLine.d137.s0	additive	26	33	O	additive	ive	tive	JJ	False
DDI-MedLine.d137.s0	ocular	35	40	O	ocular	lar	ular	NN	False
DDI-MedLine.d137.s0	and	42	44	O	and	and	and	CC	False
DDI-MedLine.d137.s0	renal	46	50	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s0	vasodilator	52	62	O	vasodilator	tor	ator	NN	False
DDI-MedLine.d137.s0	effects	64	70	O	effects	cts	ects	NNS	False
DDI-MedLine.d137.s0	on	72	73	O	on	on	on	IN	False
DDI-MedLine.d137.s0	healthy	75	81	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d137.s0	humans	83	88	O	humans	ans	mans	NNS	False
DDI-MedLine.d137.s0	.	89	89	O	.	.	.	.	False

DDI-MedLine.d137.s1	AIMS/HYPOTHESIS	0	14	O	AIMS/HYPOTHESIS	SIS	ESIS	NN	brand
DDI-MedLine.d137.s1	:	15	15	O	:	:	:	:	False
DDI-MedLine.d137.s1	There	17	21	O	There	ere	here	EX	False
DDI-MedLine.d137.s1	is	23	24	O	is	is	is	VBZ	False
DDI-MedLine.d137.s1	evidence	26	33	O	evidence	nce	ence	NN	False
DDI-MedLine.d137.s1	that	35	38	O	that	hat	that	IN	False
DDI-MedLine.d137.s1	insulin	40	46	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s1	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d137.s1	glucose	52	58	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d137.s1	cause	60	64	O	cause	use	ause	NN	False
DDI-MedLine.d137.s1	renal	66	70	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s1	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d137.s1	ocular	76	81	O	ocular	lar	ular	NN	False
DDI-MedLine.d137.s1	vasodilation	83	94	O	vasodilation	ion	tion	NN	False
DDI-MedLine.d137.s1	.	95	95	O	.	.	.	.	False

DDI-MedLine.d137.s2	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d137.s2	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d137.s2	,	8	8	O	,	,	,	,	False
DDI-MedLine.d137.s2	however	10	16	O	however	ver	ever	RB	False
DDI-MedLine.d137.s2	,	17	17	O	,	,	,	,	False
DDI-MedLine.d137.s2	currently	19	27	O	currently	tly	ntly	RB	False
DDI-MedLine.d137.s2	no	29	30	O	no	no	no	DT	False
DDI-MedLine.d137.s2	data	32	35	O	data	ata	data	NNS	False
DDI-MedLine.d137.s2	on	37	38	O	on	on	on	IN	False
DDI-MedLine.d137.s2	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d137.s2	effect	44	49	O	effect	ect	fect	NN	False
DDI-MedLine.d137.s2	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d137.s2	combined	54	61	O	combined	ned	ined	VBN	False
DDI-MedLine.d137.s2	hyperglycaemia	63	76	O	hyperglycaemia	mia	emia	NN	False
DDI-MedLine.d137.s2	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d137.s2	hyperinsulinaemia	82	98	O	hyperinsulinaemia	mia	emia	NN	False
DDI-MedLine.d137.s2	on	100	101	O	on	on	on	IN	False
DDI-MedLine.d137.s2	the	103	105	O	the	the	the	DT	False
DDI-MedLine.d137.s2	renal	107	111	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s2	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d137.s2	ocular	117	122	O	ocular	lar	ular	NN	False
DDI-MedLine.d137.s2	blood	124	128	O	blood	ood	lood	NN	False
DDI-MedLine.d137.s2	flow	130	133	O	flow	low	flow	NN	False
DDI-MedLine.d137.s2	seen	135	138	O	seen	een	seen	VBN	False
DDI-MedLine.d137.s2	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d137.s2	diabetic	143	150	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d137.s2	patients	152	159	O	patients	nts	ents	NNS	False
DDI-MedLine.d137.s2	on	161	162	O	on	on	on	IN	False
DDI-MedLine.d137.s2	insulin	164	170	O	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s2	therapy	172	178	O	therapy	apy	rapy	NN	False
DDI-MedLine.d137.s2	.	179	179	O	.	.	.	.	False

DDI-MedLine.d137.s3	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d137.s3	:	7	7	O	:	:	:	:	False
DDI-MedLine.d137.s3	We	9	10	O	We	We	We	PRP	False
DDI-MedLine.d137.s3	carried	12	18	O	carried	ied	ried	VBN	False
DDI-MedLine.d137.s3	out	20	22	O	out	out	out	IN	False
DDI-MedLine.d137.s3	two	24	26	O	two	two	two	CD	False
DDI-MedLine.d137.s3	different	28	36	O	different	ent	rent	JJ	False
DDI-MedLine.d137.s3	3-way	38	42	O	3-way	way	-way	JJ	False
DDI-MedLine.d137.s3	crossover	44	52	O	crossover	ver	over	NN	False
DDI-MedLine.d137.s3	studies	54	60	O	studies	ies	dies	NNS	False
DDI-MedLine.d137.s3	in	62	63	O	in	in	in	IN	False
DDI-MedLine.d137.s3	healthy	65	71	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d137.s3	subjects	73	80	O	subjects	cts	ects	NNS	False
DDI-MedLine.d137.s3	(	82	82	O	(	(	(	(	False
DDI-MedLine.d137.s3	each	83	86	O	each	ach	each	DT	False
DDI-MedLine.d137.s3	,	87	87	O	,	,	,	,	False
DDI-MedLine.d137.s3	n	89	89	O	n	n	n	NN	False
DDI-MedLine.d137.s3	=	91	91	O	=	=	=	NN	False
DDI-MedLine.d137.s3	9	93	93	O	9	9	9	CD	False
DDI-MedLine.d137.s3	)	94	94	O	)	)	)	)	False
DDI-MedLine.d137.s3	.	95	95	O	.	.	.	.	False

DDI-MedLine.d137.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d137.s4	study	3	7	O	study	udy	tudy	NN	False
DDI-MedLine.d137.s4	one	9	11	O	one	one	one	CD	False
DDI-MedLine.d137.s4	,	12	12	O	,	,	,	,	False
DDI-MedLine.d137.s4	hyperglycaemic	14	27	O	hyperglycaemic	mic	emic	NN	False
DDI-MedLine.d137.s4	clamps	29	34	O	clamps	mps	amps	NNS	False
DDI-MedLine.d137.s4	(	36	36	O	(	(	(	(	False
DDI-MedLine.d137.s4	5.6	37	39	O	5.6	5.6	5.6	CD	False
DDI-MedLine.d137.s4	mmol/l	41	46	O	mmol/l	l/l	ol/l	NN	False
DDI-MedLine.d137.s4	,	47	47	O	,	,	,	,	False
DDI-MedLine.d137.s4	11.1	49	52	O	11.1	1.1	11.1	CD	False
DDI-MedLine.d137.s4	mmol/	54	58	O	mmol/	ol/	mol/	NN	False
DDI-MedLine.d137.s4	1	60	60	O	1	1	1	CD	False
DDI-MedLine.d137.s4	,	61	61	O	,	,	,	,	False
DDI-MedLine.d137.s4	16.7	63	66	O	16.7	6.7	16.7	CD	False
DDI-MedLine.d137.s4	mmol/l	68	73	O	mmol/l	l/l	ol/l	NN	False
DDI-MedLine.d137.s4	)	74	74	O	)	)	)	)	False
DDI-MedLine.d137.s4	were	76	79	O	were	ere	were	VBD	False
DDI-MedLine.d137.s4	carried	81	87	O	carried	ied	ried	VBN	False
DDI-MedLine.d137.s4	out	89	91	O	out	out	out	IN	False
DDI-MedLine.d137.s4	during	93	98	O	during	ing	ring	IN	False
DDI-MedLine.d137.s4	placebo	100	106	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d137.s4	or	108	109	O	or	or	or	CC	False
DDI-MedLine.d137.s4	insulin	111	117	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s4	(	119	119	O	(	(	(	(	False
DDI-MedLine.d137.s4	dose	120	123	O	dose	ose	dose	NN	False
DDI-MedLine.d137.s4	1	125	125	O	1	1	1	CD	False
DDI-MedLine.d137.s4	:	126	126	O	:	:	:	:	False
DDI-MedLine.d137.s4	1	128	128	O	1	1	1	CD	False
DDI-MedLine.d137.s4	mU/kg/min	130	138	O	mU/kg/min	min	/min	NN	False
DDI-MedLine.d137.s4	;	139	139	O	;	;	;	:	False
DDI-MedLine.d137.s4	dose	141	144	O	dose	ose	dose	NN	False
DDI-MedLine.d137.s4	2	146	146	O	2	2	2	CD	False
DDI-MedLine.d137.s4	:	147	147	O	:	:	:	:	False
DDI-MedLine.d137.s4	2	149	149	O	2	2	2	CD	False
DDI-MedLine.d137.s4	mU/kg/min	151	159	O	mU/kg/min	min	/min	NN	False
DDI-MedLine.d137.s4	)	160	160	O	)	)	)	)	False
DDI-MedLine.d137.s4	infusion	162	169	O	infusion	ion	sion	NN	False
DDI-MedLine.d137.s4	.	170	170	O	.	.	.	.	False

DDI-MedLine.d137.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d137.s5	second	4	9	O	second	ond	cond	JJ	False
DDI-MedLine.d137.s5	study	11	15	O	study	udy	tudy	NN	False
DDI-MedLine.d137.s5	was	17	19	O	was	was	was	VBD	False
DDI-MedLine.d137.s5	identical	21	29	O	identical	cal	ical	JJ	False
DDI-MedLine.d137.s5	but	31	33	O	but	but	but	CC	False
DDI-MedLine.d137.s5	endogenous	35	44	O	endogenous	ous	nous	JJ	False
DDI-MedLine.d137.s5	insulin	46	52	O	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s5	secretion	54	62	O	secretion	ion	tion	NN	False
DDI-MedLine.d137.s5	was	64	66	O	was	was	was	VBD	False
DDI-MedLine.d137.s5	blocked	68	74	O	blocked	ked	cked	VBN	False
DDI-MedLine.d137.s5	with	76	79	O	with	ith	with	IN	False
DDI-MedLine.d137.s5	somatostatin	81	92	B-drug	somatostatin	tin	atin	NN	False
DDI-MedLine.d137.s5	.	93	93	O	.	.	.	.	False

DDI-MedLine.d137.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d137.s6	renal	4	8	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s6	plasma	10	15	O	plasma	sma	asma	NN	False
DDI-MedLine.d137.s6	flow	17	20	O	flow	low	flow	NN	False
DDI-MedLine.d137.s6	,	21	21	O	,	,	,	,	False
DDI-MedLine.d137.s6	glomerular	23	32	O	glomerular	lar	ular	NN	False
DDI-MedLine.d137.s6	filtration	34	43	O	filtration	ion	tion	NN	False
DDI-MedLine.d137.s6	rate	45	48	O	rate	ate	rate	NN	False
DDI-MedLine.d137.s6	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d137.s6	pulsatile	54	62	O	pulsatile	ile	tile	NN	False
DDI-MedLine.d137.s6	choroidal	64	72	O	choroidal	dal	idal	NN	False
DDI-MedLine.d137.s6	blood	74	78	O	blood	ood	lood	NN	False
DDI-MedLine.d137.s6	flow	80	83	O	flow	low	flow	NN	False
DDI-MedLine.d137.s6	were	85	88	O	were	ere	were	VBD	False
DDI-MedLine.d137.s6	measured	90	97	O	measured	red	ured	VBN	False
DDI-MedLine.d137.s6	using	99	103	O	using	ing	sing	VBG	False
DDI-MedLine.d137.s6	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d137.s6	paraaminohippurate	109	126	O	paraaminohippurate	ate	rate	NN	False
DDI-MedLine.d137.s6	method	128	133	O	method	hod	thod	NN	False
DDI-MedLine.d137.s6	,	134	134	O	,	,	,	,	False
DDI-MedLine.d137.s6	the	136	138	O	the	the	the	DT	False
DDI-MedLine.d137.s6	inulin	140	145	O	inulin	lin	ulin	NN	False
DDI-MedLine.d137.s6	method	147	152	O	method	hod	thod	NN	False
DDI-MedLine.d137.s6	and	154	156	O	and	and	and	CC	False
DDI-MedLine.d137.s6	a	158	158	O	a	a	a	DT	False
DDI-MedLine.d137.s6	laser	160	164	O	laser	ser	aser	NN	False
DDI-MedLine.d137.s6	interferometric	166	180	O	interferometric	ric	tric	NN	False
DDI-MedLine.d137.s6	measurement	182	192	O	measurement	ent	ment	NN	False
DDI-MedLine.d137.s6	of	194	195	O	of	of	of	IN	False
DDI-MedLine.d137.s6	fundus	197	202	O	fundus	dus	ndus	NN	False
DDI-MedLine.d137.s6	pulsation	204	212	O	pulsation	ion	tion	NN	False
DDI-MedLine.d137.s6	amplitude	214	222	O	amplitude	ude	tude	NN	False
DDI-MedLine.d137.s6	,	223	223	O	,	,	,	,	False
DDI-MedLine.d137.s6	respectively	225	236	O	respectively	ely	vely	RB	False
DDI-MedLine.d137.s6	.	237	237	O	.	.	.	.	False

DDI-MedLine.d137.s7	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d137.s7	:	7	7	O	:	:	:	:	False
DDI-MedLine.d137.s7	Insulin	9	15	B-drug	Insulin	lin	ulin	NN	False
DDI-MedLine.d137.s7	increased	17	25	O	increased	sed	ased	VBN	False
DDI-MedLine.d137.s7	renal	27	31	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s7	plasma	33	38	O	plasma	sma	asma	NN	False
DDI-MedLine.d137.s7	flow	40	43	O	flow	low	flow	NN	False
DDI-MedLine.d137.s7	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d137.s7	fundus	49	54	O	fundus	dus	ndus	NN	False
DDI-MedLine.d137.s7	pulsation	56	64	O	pulsation	ion	tion	NN	False
DDI-MedLine.d137.s7	amplitude	66	74	O	amplitude	ude	tude	NN	False
DDI-MedLine.d137.s7	but	76	78	O	but	but	but	CC	False
DDI-MedLine.d137.s7	not	80	82	O	not	not	not	RB	False
DDI-MedLine.d137.s7	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d137.s7	glomerular	88	97	O	glomerular	lar	ular	NN	False
DDI-MedLine.d137.s7	filtration	99	108	O	filtration	ion	tion	NN	False
DDI-MedLine.d137.s7	rate	110	113	O	rate	ate	rate	NN	False
DDI-MedLine.d137.s7	.	114	114	O	.	.	.	.	False

DDI-MedLine.d137.s8	Hyperglycaemia	0	13	O	Hyperglycaemia	mia	emia	NN	False
DDI-MedLine.d137.s8	increased	15	23	O	increased	sed	ased	VBN	False
DDI-MedLine.d137.s8	all	25	27	O	all	all	all	DT	False
DDI-MedLine.d137.s8	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d137.s8	renal	33	37	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s8	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d137.s8	ocular	43	48	O	ocular	lar	ular	NN	False
DDI-MedLine.d137.s8	parameters	50	59	O	parameters	ers	ters	NNS	False
DDI-MedLine.d137.s8	studied	61	67	O	studied	ied	died	VBN	False
DDI-MedLine.d137.s8	.	68	68	O	.	.	.	.	False

DDI-MedLine.d137.s9	Haemodynamic	0	11	O	Haemodynamic	mic	amic	NNP	False
DDI-MedLine.d137.s9	effects	13	19	O	effects	cts	ects	NNS	False
DDI-MedLine.d137.s9	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d137.s9	glucose	24	30	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d137.s9	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d137.s9	insulin	36	42	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s9	were	44	47	O	were	ere	were	VBD	False
DDI-MedLine.d137.s9	additive	49	56	O	additive	ive	tive	JJ	False
DDI-MedLine.d137.s9	when	58	61	O	when	hen	when	WRB	False
DDI-MedLine.d137.s9	somatostatin	63	74	B-drug	somatostatin	tin	atin	NN	False
DDI-MedLine.d137.s9	was	76	78	O	was	was	was	VBD	False
DDI-MedLine.d137.s9	co-administered	80	94	O	co-administered	red	ered	JJ	False
DDI-MedLine.d137.s9	but	96	98	O	but	but	but	CC	False
DDI-MedLine.d137.s9	not	100	102	O	not	not	not	RB	False
DDI-MedLine.d137.s9	under	104	108	O	under	der	nder	IN	False
DDI-MedLine.d137.s9	basal	110	114	O	basal	sal	asal	NN	False
DDI-MedLine.d137.s9	conditions	116	125	O	conditions	ons	ions	NNS	False
DDI-MedLine.d137.s9	.	126	126	O	.	.	.	.	False

DDI-MedLine.d137.s10	CONCLUSIONS/INTERPRETATION	0	25	O	CONCLUSIONS/INTERPRETATION	ION	TION	NN	brand
DDI-MedLine.d137.s10	:	26	26	O	:	:	:	:	False
DDI-MedLine.d137.s10	Glucose	28	34	B-drug	Glucose	ose	cose	VB	False
DDI-MedLine.d137.s10	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d137.s10	insulin	40	46	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d137.s10	can	48	50	O	can	can	can	MD	False
DDI-MedLine.d137.s10	exert	52	56	O	exert	ert	xert	NN	False
DDI-MedLine.d137.s10	additive	58	65	O	additive	ive	tive	JJ	False
DDI-MedLine.d137.s10	vasodilator	67	77	O	vasodilator	tor	ator	NN	False
DDI-MedLine.d137.s10	properties	79	88	O	properties	ies	ties	NNS	False
DDI-MedLine.d137.s10	on	90	91	O	on	on	on	IN	False
DDI-MedLine.d137.s10	renal	93	97	O	renal	nal	enal	NN	False
DDI-MedLine.d137.s10	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d137.s10	ocular	103	108	O	ocular	lar	ular	NN	False
DDI-MedLine.d137.s10	circulation	110	120	O	circulation	ion	tion	NN	False
DDI-MedLine.d137.s10	.	121	121	O	.	.	.	.	False

DDI-MedLine.d137.s11	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d137.s11	find	3	6	O	find	ind	find	VB	False
DDI-MedLine.d137.s11	out	8	10	O	out	out	out	IN	False
DDI-MedLine.d137.s11	whether	12	18	O	whether	her	ther	IN	False
DDI-MedLine.d137.s11	this	20	23	O	this	his	this	DT	False
DDI-MedLine.d137.s11	observation	25	35	O	observation	ion	tion	NN	False
DDI-MedLine.d137.s11	is	37	38	O	is	is	is	VBZ	False
DDI-MedLine.d137.s11	related	40	46	O	related	ted	ated	JJ	False
DDI-MedLine.d137.s11	to	48	49	O	to	to	to	TO	False
DDI-MedLine.d137.s11	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d137.s11	increased	55	63	O	increased	sed	ased	VBN	False
DDI-MedLine.d137.s11	regional	65	72	O	regional	nal	onal	JJ	False
DDI-MedLine.d137.s11	perfusion	74	82	O	perfusion	ion	sion	NN	False
DDI-MedLine.d137.s11	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d137.s11	diabetes	87	94	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d137.s11	longitudinal	96	107	O	longitudinal	nal	inal	JJ	False
DDI-MedLine.d137.s11	studies	109	115	O	studies	ies	dies	NNS	False
DDI-MedLine.d137.s11	on	117	118	O	on	on	on	IN	False
DDI-MedLine.d137.s11	patients	120	127	O	patients	nts	ents	NNS	False
DDI-MedLine.d137.s11	with	129	132	O	with	ith	with	IN	False
DDI-MedLine.d137.s11	Type	134	137	O	Type	ype	Type	NN	False
DDI-MedLine.d137.s11	I	139	139	O	I	I	I	PRP	brand
DDI-MedLine.d137.s11	(	141	141	O	(	(	(	(	False
DDI-MedLine.d137.s11	insulin-dependent	142	158	O	insulin-dependent	ent	dent	NN	False
DDI-MedLine.d137.s11	)	159	159	O	)	)	)	)	False
DDI-MedLine.d137.s11	diabetes	161	168	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d137.s11	mellitus	170	177	O	mellitus	tus	itus	NN	False
DDI-MedLine.d137.s11	are	179	181	O	are	are	are	VBP	False
DDI-MedLine.d137.s11	needed	183	188	O	needed	ded	eded	VBN	False
DDI-MedLine.d137.s11	.	189	189	O	.	.	.	.	False

DDI-MedLine.d55.s0	Increased	0	8	O	Increased	sed	ased	VBN	False
DDI-MedLine.d55.s0	hepatotoxicity	10	23	O	hepatotoxicity	ity	city	NN	False
DDI-MedLine.d55.s0	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d55.s0	acetaminophen	28	40	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d55.s0	by	42	43	O	by	by	by	IN	False
DDI-MedLine.d55.s0	concomitant	45	55	O	concomitant	ant	tant	NN	False
DDI-MedLine.d55.s0	administration	57	70	O	administration	ion	tion	NN	False
DDI-MedLine.d55.s0	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d55.s0	caffeine	75	82	B-drug	caffeine	ine	eine	NN	drug
DDI-MedLine.d55.s0	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d55.s0	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d55.s0	rat	91	93	O	rat	rat	rat	NN	False
DDI-MedLine.d55.s0	.	94	94	O	.	.	.	.	False

DDI-MedLine.d55.s1	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d55.s1	caffeine	6	13	B-drug	caffeine	ine	eine	NN	drug
DDI-MedLine.d55.s1	is	15	16	O	is	is	is	VBZ	False
DDI-MedLine.d55.s1	frequently	18	27	O	frequently	tly	ntly	RB	False
DDI-MedLine.d55.s1	co-administered	29	43	O	co-administered	red	ered	JJ	False
DDI-MedLine.d55.s1	with	45	48	O	with	ith	with	IN	False
DDI-MedLine.d55.s1	acetaminophen	50	62	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d55.s1	,	63	63	O	,	,	,	,	False
DDI-MedLine.d55.s1	it	65	66	O	it	it	it	PRP	False
DDI-MedLine.d55.s1	is	68	69	O	is	is	is	VBZ	False
DDI-MedLine.d55.s1	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d55.s1	clinical	74	81	O	clinical	cal	ical	JJ	False
DDI-MedLine.d55.s1	interest	83	90	O	interest	est	rest	NN	False
DDI-MedLine.d55.s1	to	92	93	O	to	to	to	TO	False
DDI-MedLine.d55.s1	study	95	99	O	study	udy	tudy	NN	False
DDI-MedLine.d55.s1	the	101	103	O	the	the	the	DT	False
DDI-MedLine.d55.s1	effect	105	110	O	effect	ect	fect	NN	False
DDI-MedLine.d55.s1	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d55.s1	caffeine	115	122	B-drug	caffeine	ine	eine	NN	drug
DDI-MedLine.d55.s1	on	124	125	O	on	on	on	IN	False
DDI-MedLine.d55.s1	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d55.s1	hepatotoxicity	131	144	O	hepatotoxicity	ity	city	NN	False
DDI-MedLine.d55.s1	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d55.s1	acetaminophen	149	161	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d55.s1	.	162	162	O	.	.	.	.	False

DDI-MedLine.d55.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d55.s2	male	3	6	O	male	ale	male	NN	False
DDI-MedLine.d55.s2	Sprague-Dawley	8	21	O	Sprague-Dawley	ley	wley	NN	False
DDI-MedLine.d55.s2	rats	23	26	O	rats	ats	rats	NNS	False
DDI-MedLine.d55.s2	fasted	28	33	O	fasted	ted	sted	VBN	False
DDI-MedLine.d55.s2	for	35	37	O	for	for	for	IN	False
DDI-MedLine.d55.s2	18	39	40	O	18	18	18	CD	False
DDI-MedLine.d55.s2	h	42	42	O	h	h	h	NN	False
DDI-MedLine.d55.s2	,	43	43	O	,	,	,	,	False
DDI-MedLine.d55.s2	concomitant	45	55	O	concomitant	ant	tant	NN	False
DDI-MedLine.d55.s2	administration	57	70	O	administration	ion	tion	NN	False
DDI-MedLine.d55.s2	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d55.s2	caffeine	75	82	B-drug	caffeine	ine	eine	NN	drug
DDI-MedLine.d55.s2	(	84	84	O	(	(	(	(	False
DDI-MedLine.d55.s2	0.1	85	87	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d55.s2	g/kg	89	92	O	g/kg	/kg	g/kg	NN	False
DDI-MedLine.d55.s2	,	93	93	O	,	,	,	,	False
DDI-MedLine.d55.s2	i.p	95	97	O	i.p	i.p	i.p	NN	False
DDI-MedLine.d55.s2	.	98	98	O	.	.	.	.	False
DDI-MedLine.d55.s2	)	99	99	O	)	)	)	)	False

DDI-MedLine.d55.s3	as	0	1	O	as	as	as	IN	False
DDI-MedLine.d55.s3	judged	3	8	O	judged	ged	dged	NN	False
DDI-MedLine.d55.s3	by	10	11	O	by	by	by	IN	False
DDI-MedLine.d55.s3	increased	13	21	O	increased	sed	ased	VBN	False
DDI-MedLine.d55.s3	serum	23	27	O	serum	rum	erum	NN	False
DDI-MedLine.d55.s3	enzyme	29	34	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d55.s3	activities	36	45	O	activities	ies	ties	NNS	False
DDI-MedLine.d55.s3	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d55.s3	increased	51	59	O	increased	sed	ased	VBN	False
DDI-MedLine.d55.s3	incidence	61	69	O	incidence	nce	ence	NN	False
DDI-MedLine.d55.s3	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d55.s3	hepatic	74	80	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d55.s3	necrosis	82	89	O	necrosis	sis	osis	NN	False
DDI-MedLine.d55.s3	.	90	90	O	.	.	.	.	False

DDI-MedLine.d55.s4	Careful	0	6	O	Careful	ful	eful	JJ	False
DDI-MedLine.d55.s4	observations	8	19	O	observations	ons	ions	NNS	False
DDI-MedLine.d55.s4	on	21	22	O	on	on	on	IN	False
DDI-MedLine.d55.s4	hepatotoxicity	24	37	O	hepatotoxicity	ity	city	NN	False
DDI-MedLine.d55.s4	are	39	41	O	are	are	are	VBP	False
DDI-MedLine.d55.s4	suggested	43	51	O	suggested	ted	sted	VBN	False
DDI-MedLine.d55.s4	when	53	56	O	when	hen	when	WRB	False
DDI-MedLine.d55.s4	acetaminophen	58	70	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d55.s4	is	72	73	O	is	is	is	VBZ	False
DDI-MedLine.d55.s4	prescribed	75	84	O	prescribed	bed	ibed	NNS	False
DDI-MedLine.d55.s4	with	86	89	O	with	ith	with	IN	False
DDI-MedLine.d55.s4	caffeine	91	98	B-drug	caffeine	ine	eine	NN	drug
DDI-MedLine.d55.s4	.	99	99	O	.	.	.	.	False

DDI-MedLine.d120.s0	Molecular	0	8	O	Molecular	lar	ular	JJ	False
DDI-MedLine.d120.s0	basis	10	14	O	basis	sis	asis	NN	False
DDI-MedLine.d120.s0	for	16	18	O	for	for	for	IN	False
DDI-MedLine.d120.s0	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d120.s0	selective	24	32	O	selective	ive	tive	NN	False
DDI-MedLine.d120.s0	toxicity	34	41	O	toxicity	ity	city	NN	False
DDI-MedLine.d120.s0	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d120.s0	amphotericin	46	57	B-drug	amphotericin	cin	icin	NN	drug
DDI-MedLine.d120.s0	B	59	59	I-drug	B	B	B	NN	brand
DDI-MedLine.d120.s0	for	61	63	O	for	for	for	IN	False
DDI-MedLine.d120.s0	yeast	65	69	O	yeast	ast	east	NN	False
DDI-MedLine.d120.s0	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d120.s0	filipin	75	81	B-drug_n	filipin	pin	ipin	NN	False
DDI-MedLine.d120.s0	for	83	85	O	for	for	for	IN	False
DDI-MedLine.d120.s0	animal	87	92	O	animal	mal	imal	NN	False
DDI-MedLine.d120.s0	cells	94	98	O	cells	lls	ells	NNS	False
DDI-MedLine.d120.s0	.	99	99	O	.	.	.	.	False

DDI-MedLine.d120.s1	Among	0	4	O	Among	ong	mong	IN	False
DDI-MedLine.d120.s1	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d120.s1	polyene	10	16	B-group	polyene	ene	yene	NN	False
DDI-MedLine.d120.s1	antibiotics	18	28	I-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d120.s1	,	29	29	O	,	,	,	,	False
DDI-MedLine.d120.s1	many	31	34	O	many	any	many	JJ	False
DDI-MedLine.d120.s1	,	35	35	O	,	,	,	,	False
DDI-MedLine.d120.s1	like	37	40	O	like	ike	like	IN	False
DDI-MedLine.d120.s1	filipin	42	48	B-drug_n	filipin	pin	ipin	NN	False
DDI-MedLine.d120.s1	,	49	49	O	,	,	,	,	False
DDI-MedLine.d120.s1	can	51	53	O	can	can	can	MD	False
DDI-MedLine.d120.s1	not	54	56	O	not	not	not	RB	False
DDI-MedLine.d120.s1	be	58	59	O	be	be	be	VB	False
DDI-MedLine.d120.s1	used	61	64	O	used	sed	used	VBN	False
DDI-MedLine.d120.s1	clinically	66	75	O	clinically	lly	ally	RB	False
DDI-MedLine.d120.s1	because	77	83	O	because	use	ause	IN	False
DDI-MedLine.d120.s1	they	85	88	O	they	hey	they	PRP	False
DDI-MedLine.d120.s1	are	90	92	O	are	are	are	VBP	False
DDI-MedLine.d120.s1	toxic	94	98	O	toxic	xic	oxic	NN	False
DDI-MedLine.d120.s1	;	99	99	O	;	;	;	:	False

DDI-MedLine.d120.s2	amphotericin	0	11	B-drug	amphotericin	cin	icin	NN	drug
DDI-MedLine.d120.s2	B	13	13	I-drug	B	B	B	NN	brand
DDI-MedLine.d120.s2	,	14	14	O	,	,	,	,	False
DDI-MedLine.d120.s2	however	16	22	O	however	ver	ever	RB	False
DDI-MedLine.d120.s2	,	23	23	O	,	,	,	,	False
DDI-MedLine.d120.s2	is	25	26	O	is	is	is	VBZ	False
DDI-MedLine.d120.s2	useful	28	33	O	useful	ful	eful	JJ	False
DDI-MedLine.d120.s2	in	35	36	O	in	in	in	IN	False
DDI-MedLine.d120.s2	therapy	38	44	O	therapy	apy	rapy	NN	False
DDI-MedLine.d120.s2	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d120.s2	human	49	53	O	human	man	uman	NN	False
DDI-MedLine.d120.s2	fungal	55	60	O	fungal	gal	ngal	NN	False
DDI-MedLine.d120.s2	infections	62	71	O	infections	ons	ions	NNS	False
DDI-MedLine.d120.s2	because	73	79	O	because	use	ause	IN	False
DDI-MedLine.d120.s2	it	81	82	O	it	it	it	PRP	False
DDI-MedLine.d120.s2	is	84	85	O	is	is	is	VBZ	False
DDI-MedLine.d120.s2	less	87	90	O	less	ess	less	RBR	False
DDI-MedLine.d120.s2	toxic	92	96	O	toxic	xic	oxic	NN	False
DDI-MedLine.d120.s2	.	97	97	O	.	.	.	.	False

DDI-MedLine.d120.s3	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d120.s3	the	5	7	O	the	the	the	DT	False
DDI-MedLine.d120.s3	toxicity	9	16	O	toxicity	ity	city	NN	False
DDI-MedLine.d120.s3	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d120.s3	filipin	21	27	B-drug_n	filipin	pin	ipin	NN	False
DDI-MedLine.d120.s3	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d120.s3	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d120.s3	therapeutic	37	47	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d120.s3	value	49	53	O	value	lue	alue	NN	False
DDI-MedLine.d120.s3	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d120.s3	amphotericin	58	69	B-drug	amphotericin	cin	icin	NN	drug
DDI-MedLine.d120.s3	B	71	71	I-drug	B	B	B	NN	brand
DDI-MedLine.d120.s3	can	73	75	O	can	can	can	MD	False
DDI-MedLine.d120.s3	be	77	78	O	be	be	be	VB	False
DDI-MedLine.d120.s3	rationalized	80	91	O	rationalized	zed	ized	VBN	False
DDI-MedLine.d120.s3	at	93	94	O	at	at	at	IN	False
DDI-MedLine.d120.s3	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d120.s3	cellular	100	107	O	cellular	lar	ular	JJ	False
DDI-MedLine.d120.s3	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d120.s3	molecular	113	121	O	molecular	lar	ular	NN	False
DDI-MedLine.d120.s3	level	123	127	O	level	vel	evel	NN	False
DDI-MedLine.d120.s3	by	129	130	O	by	by	by	IN	False
DDI-MedLine.d120.s3	the	132	134	O	the	the	the	DT	False
DDI-MedLine.d120.s3	following	136	144	O	following	ing	wing	VBG	False
DDI-MedLine.d120.s3	observations	146	157	O	observations	ons	ions	NNS	False
DDI-MedLine.d120.s3	:	158	158	O	:	:	:	:	False
DDI-MedLine.d120.s3	(	160	160	O	(	(	(	(	False
DDI-MedLine.d120.s3	i	161	161	O	i	i	i	NN	False
DDI-MedLine.d120.s3	)	162	162	O	)	)	)	)	False
DDI-MedLine.d120.s3	these	164	168	O	these	ese	hese	DT	False
DDI-MedLine.d120.s3	polyene	170	176	B-group	polyene	ene	yene	NN	False
DDI-MedLine.d120.s3	antibiotics	178	188	I-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d120.s3	showed	190	195	O	showed	wed	owed	VBD	False
DDI-MedLine.d120.s3	differential	197	208	O	differential	ial	tial	NN	False
DDI-MedLine.d120.s3	effects	210	216	O	effects	cts	ects	NNS	False
DDI-MedLine.d120.s3	on	218	219	O	on	on	on	IN	False
DDI-MedLine.d120.s3	cells	221	225	O	cells	lls	ells	NNS	False
DDI-MedLine.d120.s3	;	226	226	O	;	;	;	:	False

DDI-MedLine.d120.s4	filipin	0	6	B-drug_n	filipin	pin	ipin	NN	False
DDI-MedLine.d120.s4	was	8	10	O	was	was	was	VBD	False
DDI-MedLine.d120.s4	more	12	15	O	more	ore	more	RBR	False
DDI-MedLine.d120.s4	potent	17	22	O	potent	ent	tent	NN	False
DDI-MedLine.d120.s4	in	24	25	O	in	in	in	IN	False
DDI-MedLine.d120.s4	lysing	27	32	O	lysing	ing	sing	VBG	False
DDI-MedLine.d120.s4	human	34	38	O	human	man	uman	NN	False
DDI-MedLine.d120.s4	red	40	42	O	red	red	red	JJ	False
DDI-MedLine.d120.s4	blood	44	48	O	blood	ood	lood	NN	False
DDI-MedLine.d120.s4	cells	50	54	O	cells	lls	ells	NNS	False
DDI-MedLine.d120.s4	,	55	55	O	,	,	,	,	False
DDI-MedLine.d120.s4	whereas	57	63	O	whereas	eas	reas	NNS	False
DDI-MedLine.d120.s4	amphotericin	65	76	B-drug	amphotericin	cin	icin	NN	drug
DDI-MedLine.d120.s4	B	78	78	I-drug	B	B	B	NN	brand
DDI-MedLine.d120.s4	was	80	82	O	was	was	was	VBD	False
DDI-MedLine.d120.s4	more	84	87	O	more	ore	more	RBR	False
DDI-MedLine.d120.s4	potent	89	94	O	potent	ent	tent	NN	False
DDI-MedLine.d120.s4	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d120.s4	inhibiting	99	108	O	inhibiting	ing	ting	VBG	False
DDI-MedLine.d120.s4	yeast	110	114	O	yeast	ast	east	NN	False
DDI-MedLine.d120.s4	cell	116	119	O	cell	ell	cell	NN	False
DDI-MedLine.d120.s4	growth	121	126	O	growth	wth	owth	NN	False
DDI-MedLine.d120.s4	;	127	127	O	;	;	;	:	False

DDI-MedLine.d120.s5	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d120.s5	(	4	4	O	(	(	(	(	False
DDI-MedLine.d120.s5	ii	5	6	O	ii	ii	ii	NN	False
DDI-MedLine.d120.s5	)	7	7	O	)	)	)	)	False
DDI-MedLine.d120.s5	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d120.s5	effects	13	19	O	effects	cts	ects	NNS	False
DDI-MedLine.d120.s5	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d120.s5	filipin	24	30	B-drug_n	filipin	pin	ipin	NN	False
DDI-MedLine.d120.s5	were	32	35	O	were	ere	were	VBD	False
DDI-MedLine.d120.s5	more	37	40	O	more	ore	more	RBR	False
DDI-MedLine.d120.s5	efficiently	42	52	O	efficiently	tly	ntly	RB	False
DDI-MedLine.d120.s5	inhibited	54	62	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d120.s5	by	64	65	O	by	by	by	IN	False
DDI-MedLine.d120.s5	added	67	71	O	added	ded	dded	VBD	False
DDI-MedLine.d120.s5	cholesterol	73	83	O	cholesterol	rol	erol	NN	False
DDI-MedLine.d120.s5	,	84	84	O	,	,	,	,	False
DDI-MedLine.d120.s5	the	86	88	O	the	the	the	DT	False
DDI-MedLine.d120.s5	major	90	94	O	major	jor	ajor	JJ	False
DDI-MedLine.d120.s5	membrane	96	103	O	membrane	ane	rane	NN	False
DDI-MedLine.d120.s5	sterol	105	110	O	sterol	rol	erol	NN	False
DDI-MedLine.d120.s5	in	112	113	O	in	in	in	IN	False
DDI-MedLine.d120.s5	human	115	119	O	human	man	uman	NN	False
DDI-MedLine.d120.s5	cells	121	125	O	cells	lls	ells	NNS	False
DDI-MedLine.d120.s5	,	126	126	O	,	,	,	,	False
DDI-MedLine.d120.s5	whereas	128	134	O	whereas	eas	reas	NNS	False
DDI-MedLine.d120.s5	the	136	138	O	the	the	the	DT	False
DDI-MedLine.d120.s5	effects	140	146	O	effects	cts	ects	NNS	False
DDI-MedLine.d120.s5	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d120.s5	amphotericin	151	162	B-drug	amphotericin	cin	icin	NN	drug
DDI-MedLine.d120.s5	B	164	164	I-drug	B	B	B	NN	brand
DDI-MedLine.d120.s5	were	166	169	O	were	ere	were	VBD	False
DDI-MedLine.d120.s5	more	171	174	O	more	ore	more	RBR	False
DDI-MedLine.d120.s5	efficiently	176	186	O	efficiently	tly	ntly	RB	False
DDI-MedLine.d120.s5	inhibited	188	196	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d120.s5	by	198	199	O	by	by	by	IN	False
DDI-MedLine.d120.s5	ergosterol	201	210	O	ergosterol	rol	erol	NN	False
DDI-MedLine.d120.s5	,	211	211	O	,	,	,	,	False
DDI-MedLine.d120.s5	the	213	215	O	the	the	the	DT	False
DDI-MedLine.d120.s5	major	217	221	O	major	jor	ajor	JJ	False
DDI-MedLine.d120.s5	membrane	223	230	O	membrane	ane	rane	NN	False
DDI-MedLine.d120.s5	sterol	232	237	O	sterol	rol	erol	NN	False
DDI-MedLine.d120.s5	in	239	240	O	in	in	in	IN	False
DDI-MedLine.d120.s5	yeast	242	246	O	yeast	ast	east	NN	False
DDI-MedLine.d120.s5	.	247	247	O	.	.	.	.	False

DDI-MedLine.d120.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d120.s6	simplest	4	11	O	simplest	est	lest	NN	False
DDI-MedLine.d120.s6	inference	13	21	O	inference	nce	ence	NN	False
DDI-MedLine.d120.s6	is	23	24	O	is	is	is	VBZ	False
DDI-MedLine.d120.s6	that	26	29	O	that	hat	that	IN	False
DDI-MedLine.d120.s6	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d120.s6	toxicity	35	42	O	toxicity	ity	city	NN	False
DDI-MedLine.d120.s6	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d120.s6	effectiveness	48	60	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d120.s6	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d120.s6	polyenes	65	72	O	polyenes	nes	enes	NNS	False
DDI-MedLine.d120.s6	are	74	76	O	are	are	are	VBP	False
DDI-MedLine.d120.s6	determined	78	87	O	determined	ned	ined	VBN	False
DDI-MedLine.d120.s6	by	89	90	O	by	by	by	IN	False
DDI-MedLine.d120.s6	their	92	96	O	their	eir	heir	PRP$	False
DDI-MedLine.d120.s6	relative	98	105	O	relative	ive	tive	NN	False
DDI-MedLine.d120.s6	avidities	107	115	O	avidities	ies	ties	NNS	False
DDI-MedLine.d120.s6	for	117	119	O	for	for	for	IN	False
DDI-MedLine.d120.s6	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d120.s6	predominant	125	135	O	predominant	ant	nant	NN	False
DDI-MedLine.d120.s6	sterol	137	142	O	sterol	rol	erol	NN	False
DDI-MedLine.d120.s6	in	144	145	O	in	in	in	IN	False
DDI-MedLine.d120.s6	cell	147	150	O	cell	ell	cell	NN	False
DDI-MedLine.d120.s6	membranes	152	160	O	membranes	nes	anes	NNS	False
DDI-MedLine.d120.s6	.	161	161	O	.	.	.	.	False

DDI-MedLine.d2.s0	Failure	0	6	O	Failure	ure	lure	NN	False
DDI-MedLine.d2.s0	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d2.s0	neomycin	11	18	B-drug	neomycin	cin	ycin	NN	drug
DDI-MedLine.d2.s0	to	20	21	O	to	to	to	TO	False
DDI-MedLine.d2.s0	modify	23	28	O	modify	ify	dify	NN	False
DDI-MedLine.d2.s0	ACTH	30	33	B-group	ACTH	CTH	ACTH	NN	brand
DDI-MedLine.d2.s0	induced	35	41	O	induced	ced	uced	JJ	False
DDI-MedLine.d2.s0	hypertension	43	54	O	hypertension	ion	sion	NN	False
DDI-MedLine.d2.s0	in	56	57	O	in	in	in	IN	False
DDI-MedLine.d2.s0	sheep	59	63	O	sheep	eep	heep	NN	False
DDI-MedLine.d2.s0	.	64	64	O	.	.	.	.	False

DDI-MedLine.d2.s1	Studies	0	6	O	Studies	ies	dies	NNS	False
DDI-MedLine.d2.s1	in	8	9	O	in	in	in	IN	False
DDI-MedLine.d2.s1	rats	11	14	O	rats	ats	rats	NNS	False
DDI-MedLine.d2.s1	have	16	19	O	have	ave	have	VB	False
DDI-MedLine.d2.s1	shown	21	25	O	shown	own	hown	VBN	False
DDI-MedLine.d2.s1	that	27	30	O	that	hat	that	IN	False
DDI-MedLine.d2.s1	neomycin	32	39	B-drug	neomycin	cin	ycin	NN	drug
DDI-MedLine.d2.s1	administration	41	54	O	administration	ion	tion	NN	False
DDI-MedLine.d2.s1	attenuates	56	65	O	attenuates	tes	ates	NNS	False
DDI-MedLine.d2.s1	certain	67	73	O	certain	ain	tain	JJ	False
DDI-MedLine.d2.s1	types	75	79	O	types	pes	ypes	NNS	False
DDI-MedLine.d2.s1	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d2.s1	adrenocortical	84	97	B-group	adrenocortical	cal	ical	JJ	False
DDI-MedLine.d2.s1	steroid	99	105	I-group	steroid	oid	roid	NN	False
DDI-MedLine.d2.s1	dependent	107	115	O	dependent	ent	dent	NN	False
DDI-MedLine.d2.s1	hypertension	117	128	O	hypertension	ion	sion	NN	False
DDI-MedLine.d2.s1	,	129	129	O	,	,	,	,	False
DDI-MedLine.d2.s1	including	131	139	O	including	ing	ding	VBG	False
DDI-MedLine.d2.s1	ACTH	141	144	B-drug	ACTH	CTH	ACTH	NN	brand
DDI-MedLine.d2.s1	hypertension	146	157	O	hypertension	ion	sion	NN	False
DDI-MedLine.d2.s1	.	158	158	O	.	.	.	.	False

DDI-MedLine.d2.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d2.s2	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d2.s2	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d2.s2	oral	15	18	O	oral	ral	oral	JJ	False
DDI-MedLine.d2.s2	neomycin	20	27	B-drug	neomycin	cin	ycin	NN	drug
DDI-MedLine.d2.s2	on	29	30	O	on	on	on	IN	False
DDI-MedLine.d2.s2	ACTH	32	35	B-group	ACTH	CTH	ACTH	NN	brand
DDI-MedLine.d2.s2	induced	37	43	O	induced	ced	uced	JJ	False
DDI-MedLine.d2.s2	hypertension	45	56	O	hypertension	ion	sion	NN	False
DDI-MedLine.d2.s2	were	58	61	O	were	ere	were	VBD	False
DDI-MedLine.d2.s2	examined	63	70	O	examined	ned	ined	VBN	False
DDI-MedLine.d2.s2	in	72	73	O	in	in	in	IN	False
DDI-MedLine.d2.s2	conscious	75	83	O	conscious	ous	ious	JJ	False
DDI-MedLine.d2.s2	sheep	85	89	O	sheep	eep	heep	NN	False
DDI-MedLine.d2.s2	.	90	90	O	.	.	.	.	False

DDI-MedLine.d2.s3	Neomycin	0	7	B-drug	Neomycin	cin	ycin	NN	drug
DDI-MedLine.d2.s3	has	9	11	O	has	has	has	VBZ	False
DDI-MedLine.d2.s3	no	13	14	O	no	no	no	DT	False
DDI-MedLine.d2.s3	effect	16	21	O	effect	ect	fect	NN	False
DDI-MedLine.d2.s3	on	23	24	O	on	on	on	IN	False
DDI-MedLine.d2.s3	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d2.s3	blood	30	34	O	blood	ood	lood	NN	False
DDI-MedLine.d2.s3	pressure	36	43	O	pressure	ure	sure	NN	False
DDI-MedLine.d2.s3	or	45	46	O	or	or	or	CC	False
DDI-MedLine.d2.s3	metabolic	48	56	O	metabolic	lic	olic	NN	False
DDI-MedLine.d2.s3	responses	58	66	O	responses	ses	nses	NNS	False
DDI-MedLine.d2.s3	to	68	69	O	to	to	to	TO	False
DDI-MedLine.d2.s3	ACTH	71	74	B-group	ACTH	CTH	ACTH	NN	brand
DDI-MedLine.d2.s3	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d2.s3	sheep	79	83	O	sheep	eep	heep	NN	False
DDI-MedLine.d2.s3	.	84	84	O	.	.	.	.	False

DDI-MedLine.d20.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d20.s0	between	12	18	O	between	een	ween	IN	False
DDI-MedLine.d20.s0	glycine	20	26	B-drug	glycine	ine	cine	NN	drug
DDI-MedLine.d20.s0	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d20.s0	glutamate	32	40	B-drug	glutamate	ate	mate	NN	False
DDI-MedLine.d20.s0	in	42	43	O	in	in	in	IN	False
DDI-MedLine.d20.s0	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d20.s0	development	49	59	O	development	ent	ment	NN	False
DDI-MedLine.d20.s0	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d20.s0	spontaneous	64	74	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d20.s0	motility	76	83	O	motility	ity	lity	NN	False
DDI-MedLine.d20.s0	in	85	86	O	in	in	in	IN	False
DDI-MedLine.d20.s0	chick	88	92	O	chick	ick	hick	NN	False
DDI-MedLine.d20.s0	embryos	94	100	O	embryos	yos	ryos	NN	False
DDI-MedLine.d20.s0	.	101	101	O	.	.	.	.	False

DDI-MedLine.d20.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d20.s1	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d20.s1	study	8	12	O	study	udy	tudy	NN	False
DDI-MedLine.d20.s1	we	14	15	O	we	we	we	PRP	False
DDI-MedLine.d20.s1	investigated	17	28	O	investigated	ted	ated	VBN	False
DDI-MedLine.d20.s1	whether	30	36	O	whether	her	ther	IN	False
DDI-MedLine.d20.s1	also	38	41	O	also	lso	also	RB	False
DDI-MedLine.d20.s1	glycine	43	49	B-drug	glycine	ine	cine	NN	drug
DDI-MedLine.d20.s1	fulfils	51	57	O	fulfils	ils	fils	NNS	False
DDI-MedLine.d20.s1	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d20.s1	function	63	70	O	function	ion	tion	NN	False
DDI-MedLine.d20.s1	as	72	73	O	as	as	as	IN	False
DDI-MedLine.d20.s1	co-activator	75	86	O	co-activator	tor	ator	NN	False
DDI-MedLine.d20.s1	in	88	89	O	in	in	in	IN	False
DDI-MedLine.d20.s1	glutamatergic	91	103	O	glutamatergic	gic	rgic	NN	False
DDI-MedLine.d20.s1	activation	105	114	O	activation	ion	tion	NN	False
DDI-MedLine.d20.s1	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d20.s1	NMDA	119	122	O	NMDA	MDA	NMDA	NN	brand
DDI-MedLine.d20.s1	receptors	124	132	O	receptors	ors	tors	NNS	False
DDI-MedLine.d20.s1	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d20.s1	the	137	139	O	the	the	the	DT	False
DDI-MedLine.d20.s1	neuronal	141	148	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d20.s1	apparatus	150	158	O	apparatus	tus	atus	NN	False
DDI-MedLine.d20.s1	of	160	161	O	of	of	of	IN	False
DDI-MedLine.d20.s1	spontaneous	163	173	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d20.s1	motility	175	182	O	motility	ity	lity	NN	False
DDI-MedLine.d20.s1	in	184	185	O	in	in	in	IN	False
DDI-MedLine.d20.s1	chick	187	191	O	chick	ick	hick	NN	False
DDI-MedLine.d20.s1	embryos	193	199	O	embryos	yos	ryos	NN	False
DDI-MedLine.d20.s1	.	200	200	O	.	.	.	.	False

DDI-MedLine.d20.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d20.s2	successive	4	13	O	successive	ive	sive	NN	False
DDI-MedLine.d20.s2	application	15	25	O	application	ion	tion	NN	False
DDI-MedLine.d20.s2	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d20.s2	glycine	30	36	B-drug	glycine	ine	cine	NN	drug
DDI-MedLine.d20.s2	(	38	38	O	(	(	(	(	False
DDI-MedLine.d20.s2	5	39	39	O	5	5	5	CD	False
DDI-MedLine.d20.s2	or	41	42	O	or	or	or	CC	False
DDI-MedLine.d20.s2	10	44	45	O	10	10	10	CD	False
DDI-MedLine.d20.s2	mg/kg	47	51	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d20.s2	egg	53	55	O	egg	egg	egg	NN	False
DDI-MedLine.d20.s2	weight	57	62	O	weight	ght	ight	NN	False
DDI-MedLine.d20.s2	(	64	64	O	(	(	(	(	False
DDI-MedLine.d20.s2	e.w	65	67	O	e.w	e.w	e.w	NN	False
DDI-MedLine.d20.s2	.	68	68	O	.	.	.	.	False
DDI-MedLine.d20.s2	)	69	69	O	)	)	)	)	False

DDI-MedLine.d20.s3	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d20.s3	glutamate	4	12	B-drug	glutamate	ate	mate	NN	False
DDI-MedLine.d20.s3	(	14	14	O	(	(	(	(	False
DDI-MedLine.d20.s3	15	15	16	O	15	15	15	CD	False
DDI-MedLine.d20.s3	mg/kg	18	22	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d20.s3	e.w	24	26	O	e.w	e.w	e.w	NN	False
DDI-MedLine.d20.s3	.	27	27	O	.	.	.	.	False
DDI-MedLine.d20.s3	)	28	28	O	)	)	)	)	False

DDI-MedLine.d20.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d20.s4	successive	4	13	O	successive	ive	sive	NN	False
DDI-MedLine.d20.s4	application	15	25	O	application	ion	tion	NN	False
DDI-MedLine.d20.s4	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d20.s4	glycine	30	36	B-drug	glycine	ine	cine	NN	drug
DDI-MedLine.d20.s4	(	38	38	O	(	(	(	(	False
DDI-MedLine.d20.s4	5	39	39	O	5	5	5	CD	False
DDI-MedLine.d20.s4	or	41	42	O	or	or	or	CC	False
DDI-MedLine.d20.s4	10	44	45	O	10	10	10	CD	False
DDI-MedLine.d20.s4	mg/kg	47	51	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d20.s4	egg	53	55	O	egg	egg	egg	NN	False
DDI-MedLine.d20.s4	weight	57	62	O	weight	ght	ight	NN	False
DDI-MedLine.d20.s4	(	64	64	O	(	(	(	(	False
DDI-MedLine.d20.s4	e.w	65	67	O	e.w	e.w	e.w	NN	False
DDI-MedLine.d20.s4	.	68	68	O	.	.	.	.	False
DDI-MedLine.d20.s4	)	69	69	O	)	)	)	)	False
DDI-MedLine.d20.s4	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d20.s4	glutamate	75	83	B-drug	glutamate	ate	mate	NN	False
DDI-MedLine.d20.s4	(	85	85	O	(	(	(	(	False
DDI-MedLine.d20.s4	15	86	87	O	15	15	15	CD	False
DDI-MedLine.d20.s4	mg/kg	89	93	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d20.s4	e.w	95	97	O	e.w	e.w	e.w	NN	False
DDI-MedLine.d20.s4	.	98	98	O	.	.	.	.	False
DDI-MedLine.d20.s4	)	99	99	O	)	)	)	)	False
DDI-MedLine.d20.s4	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d20.s4	a	104	104	O	a	a	a	DT	False
DDI-MedLine.d20.s4	10	106	107	O	10	10	10	CD	False
DDI-MedLine.d20.s4	min	109	111	O	min	min	min	NN	False
DDI-MedLine.d20.s4	interval	113	120	O	interval	val	rval	NN	False
DDI-MedLine.d20.s4	significantly	122	134	O	significantly	tly	ntly	RB	False
DDI-MedLine.d20.s4	increased	136	144	O	increased	sed	ased	VBN	False
DDI-MedLine.d20.s4	the	146	148	O	the	the	the	DT	False
DDI-MedLine.d20.s4	activation	150	159	O	activation	ion	tion	NN	False
DDI-MedLine.d20.s4	of	161	162	O	of	of	of	IN	False
DDI-MedLine.d20.s4	spontaneous	164	174	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d20.s4	motility	176	183	O	motility	ity	lity	NN	False
DDI-MedLine.d20.s4	of	185	186	O	of	of	of	IN	False
DDI-MedLine.d20.s4	17-day-old	188	197	O	17-day-old	old	-old	JJ	False
DDI-MedLine.d20.s4	chick	199	203	O	chick	ick	hick	NN	False
DDI-MedLine.d20.s4	embryos	205	211	O	embryos	yos	ryos	NN	False
DDI-MedLine.d20.s4	in	213	214	O	in	in	in	IN	False
DDI-MedLine.d20.s4	comparison	216	225	O	comparison	son	ison	NN	False
DDI-MedLine.d20.s4	with	227	230	O	with	ith	with	IN	False
DDI-MedLine.d20.s4	the	232	234	O	the	the	the	DT	False
DDI-MedLine.d20.s4	effect	236	241	O	effect	ect	fect	NN	False
DDI-MedLine.d20.s4	of	243	244	O	of	of	of	IN	False
DDI-MedLine.d20.s4	glutamate	246	254	B-drug	glutamate	ate	mate	NN	False
DDI-MedLine.d20.s4	alone	256	260	O	alone	one	lone	RB	False
DDI-MedLine.d20.s4	.	261	261	O	.	.	.	.	False

DDI-MedLine.d20.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d20.s5	effect	5	10	O	effect	ect	fect	NN	False
DDI-MedLine.d20.s5	did	12	14	O	did	did	did	VBD	False
DDI-MedLine.d20.s5	not	16	18	O	not	not	not	RB	False
DDI-MedLine.d20.s5	depend	20	25	O	depend	end	pend	NN	False
DDI-MedLine.d20.s5	on	27	28	O	on	on	on	IN	False
DDI-MedLine.d20.s5	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d20.s5	order	34	38	O	order	der	rder	NN	False
DDI-MedLine.d20.s5	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d20.s5	application	43	53	O	application	ion	tion	NN	False
DDI-MedLine.d20.s5	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d20.s5	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d20.s5	drugs	62	66	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d20.s5	.	67	67	O	.	.	.	.	False

DDI-MedLine.d20.s6	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d20.s6	13-day-old	3	12	O	13-day-old	old	-old	JJ	False
DDI-MedLine.d20.s6	embryos	14	20	O	embryos	yos	ryos	NN	False
DDI-MedLine.d20.s6	,	21	21	O	,	,	,	,	False
DDI-MedLine.d20.s6	glycine	23	29	B-drug	glycine	ine	cine	NN	drug
DDI-MedLine.d20.s6	was	31	33	O	was	was	was	VBD	False
DDI-MedLine.d20.s6	ineffective	35	45	O	ineffective	ive	tive	JJ	False
DDI-MedLine.d20.s6	in	47	48	O	in	in	in	IN	False
DDI-MedLine.d20.s6	both	50	53	O	both	oth	both	DT	False
DDI-MedLine.d20.s6	doses	55	59	O	doses	ses	oses	NNS	False
DDI-MedLine.d20.s6	.	60	60	O	.	.	.	.	False

DDI-MedLine.d20.s7	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d20.s7	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d20.s7	concluded	6	14	O	concluded	ded	uded	VBD	False
DDI-MedLine.d20.s7	from	16	19	O	from	rom	from	IN	False
DDI-MedLine.d20.s7	these	21	25	O	these	ese	hese	DT	False
DDI-MedLine.d20.s7	results	27	33	O	results	lts	ults	NNS	False
DDI-MedLine.d20.s7	that	35	38	O	that	hat	that	IN	False
DDI-MedLine.d20.s7	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d20.s7	modulatory	44	53	O	modulatory	ory	tory	NN	False
DDI-MedLine.d20.s7	effect	55	60	O	effect	ect	fect	NN	False
DDI-MedLine.d20.s7	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d20.s7	glycine	65	71	B-drug	glycine	ine	cine	NN	drug
DDI-MedLine.d20.s7	is	73	74	O	is	is	is	VBZ	False
DDI-MedLine.d20.s7	evidently	76	84	O	evidently	tly	ntly	RB	False
DDI-MedLine.d20.s7	a	86	86	O	a	a	a	DT	False
DDI-MedLine.d20.s7	later	88	92	O	later	ter	ater	RB	False
DDI-MedLine.d20.s7	developmental	94	106	O	developmental	tal	ntal	NN	False
DDI-MedLine.d20.s7	acquisition	108	118	O	acquisition	ion	tion	NN	False
DDI-MedLine.d20.s7	(	120	120	O	(	(	(	(	False
DDI-MedLine.d20.s7	after	121	125	O	after	ter	fter	IN	False
DDI-MedLine.d20.s7	day	127	129	O	day	day	day	NN	False
DDI-MedLine.d20.s7	15	131	132	O	15	15	15	CD	False
DDI-MedLine.d20.s7	of	134	135	O	of	of	of	IN	False
DDI-MedLine.d20.s7	incubation	137	146	O	incubation	ion	tion	NN	False
DDI-MedLine.d20.s7	)	147	147	O	)	)	)	)	False
DDI-MedLine.d20.s7	in	149	150	O	in	in	in	IN	False
DDI-MedLine.d20.s7	the	152	154	O	the	the	the	DT	False
DDI-MedLine.d20.s7	embryogenesis	156	168	O	embryogenesis	sis	esis	NN	False
DDI-MedLine.d20.s7	of	170	171	O	of	of	of	IN	False
DDI-MedLine.d20.s7	NMDA-ergic	173	182	O	NMDA-ergic	gic	rgic	JJ	False
DDI-MedLine.d20.s7	activation	184	193	O	activation	ion	tion	NN	False
DDI-MedLine.d20.s7	of	195	196	O	of	of	of	IN	False
DDI-MedLine.d20.s7	spontaneous	198	208	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d20.s7	motility	210	217	O	motility	ity	lity	NN	False
DDI-MedLine.d20.s7	in	219	220	O	in	in	in	IN	False
DDI-MedLine.d20.s7	chick	222	226	O	chick	ick	hick	NN	False
DDI-MedLine.d20.s7	embryos	228	234	O	embryos	yos	ryos	NN	False
DDI-MedLine.d20.s7	similarly	236	244	O	similarly	rly	arly	RB	False
DDI-MedLine.d20.s7	as	246	247	O	as	as	as	IN	False
DDI-MedLine.d20.s7	glycinergic	249	259	O	glycinergic	gic	rgic	NN	False
DDI-MedLine.d20.s7	inhibition	261	270	O	inhibition	ion	tion	NN	False
DDI-MedLine.d20.s7	.	271	271	O	.	.	.	.	False

DDI-MedLine.d44.s0	Effects	0	6	O	Effects	cts	ects	NNS	False
DDI-MedLine.d44.s0	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d44.s0	etofibrate	11	20	B-drug	etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s0	upon	22	25	O	upon	pon	upon	IN	False
DDI-MedLine.d44.s0	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d44.s0	metabolism	31	40	O	metabolism	ism	lism	NN	False
DDI-MedLine.d44.s0	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d44.s0	chylomicron-like	45	60	O	chylomicron-like	ike	like	NN	False
DDI-MedLine.d44.s0	emulsions	62	70	O	emulsions	ons	ions	NNS	False
DDI-MedLine.d44.s0	in	72	73	O	in	in	in	IN	False
DDI-MedLine.d44.s0	patients	75	82	O	patients	nts	ents	NNS	False
DDI-MedLine.d44.s0	with	84	87	O	with	ith	with	IN	False
DDI-MedLine.d44.s0	coronary	89	96	O	coronary	ary	nary	NN	False
DDI-MedLine.d44.s0	artery	98	103	O	artery	ery	tery	NN	False
DDI-MedLine.d44.s0	disease	105	111	O	disease	ase	ease	NN	False
DDI-MedLine.d44.s0	.	112	112	O	.	.	.	.	False

DDI-MedLine.d44.s1	Slow	0	3	O	Slow	low	Slow	VB	False
DDI-MedLine.d44.s1	chylomicron	5	15	O	chylomicron	ron	cron	NN	False
DDI-MedLine.d44.s1	intravascular	17	29	O	intravascular	lar	ular	NN	False
DDI-MedLine.d44.s1	catabolism	31	40	O	catabolism	ism	lism	NN	False
DDI-MedLine.d44.s1	has	42	44	O	has	has	has	VBZ	False
DDI-MedLine.d44.s1	been	46	49	O	been	een	been	VBN	False
DDI-MedLine.d44.s1	associated	51	60	O	associated	ted	ated	VBN	False
DDI-MedLine.d44.s1	with	62	65	O	with	ith	with	IN	False
DDI-MedLine.d44.s1	coronary	67	74	O	coronary	ary	nary	NN	False
DDI-MedLine.d44.s1	artery	76	81	O	artery	ery	tery	NN	False
DDI-MedLine.d44.s1	disease	83	89	O	disease	ase	ease	NN	False
DDI-MedLine.d44.s1	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d44.s1	screening	95	103	O	screening	ing	ning	VBG	False
DDI-MedLine.d44.s1	for	105	107	O	for	for	for	IN	False
DDI-MedLine.d44.s1	drugs	109	113	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d44.s1	that	115	118	O	that	hat	that	IN	False
DDI-MedLine.d44.s1	can	120	122	O	can	can	can	MD	False
DDI-MedLine.d44.s1	speed-up	124	131	O	speed-up	-up	d-up	NN	False
DDI-MedLine.d44.s1	this	133	136	O	this	his	this	DT	False
DDI-MedLine.d44.s1	process	138	144	O	process	ess	cess	NN	False
DDI-MedLine.d44.s1	can	146	148	O	can	can	can	MD	False
DDI-MedLine.d44.s1	be	150	151	O	be	be	be	VB	False
DDI-MedLine.d44.s1	important	153	161	O	important	ant	tant	JJ	False
DDI-MedLine.d44.s1	.	162	162	O	.	.	.	.	False

DDI-MedLine.d44.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d44.s2	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d44.s2	study	8	12	O	study	udy	tudy	NN	False
DDI-MedLine.d44.s2	,	13	13	O	,	,	,	,	False
DDI-MedLine.d44.s2	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d44.s2	effects	19	25	O	effects	cts	ects	NNS	False
DDI-MedLine.d44.s2	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d44.s2	etofibrate	30	39	B-drug	etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s2	upon	41	44	O	upon	pon	upon	IN	False
DDI-MedLine.d44.s2	chylomicron	46	56	O	chylomicron	ron	cron	NN	False
DDI-MedLine.d44.s2	metabolism	58	67	O	metabolism	ism	lism	NN	False
DDI-MedLine.d44.s2	was	69	71	O	was	was	was	VBD	False
DDI-MedLine.d44.s2	tested	73	78	O	tested	ted	sted	VBN	False
DDI-MedLine.d44.s2	by	80	81	O	by	by	by	IN	False
DDI-MedLine.d44.s2	determination	83	95	O	determination	ion	tion	NN	False
DDI-MedLine.d44.s2	of	97	98	O	of	of	of	IN	False
DDI-MedLine.d44.s2	the	100	102	O	the	the	the	DT	False
DDI-MedLine.d44.s2	plasma	104	109	O	plasma	sma	asma	NN	False
DDI-MedLine.d44.s2	kinetics	111	118	O	kinetics	ics	tics	NNS	False
DDI-MedLine.d44.s2	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d44.s2	a	123	123	O	a	a	a	DT	False
DDI-MedLine.d44.s2	chylomicron-like	125	140	O	chylomicron-like	ike	like	NN	False
DDI-MedLine.d44.s2	emulsion	142	149	O	emulsion	ion	sion	NN	False
DDI-MedLine.d44.s2	model	151	155	O	model	del	odel	NN	False
DDI-MedLine.d44.s2	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d44.s2	12	160	161	O	12	12	12	CD	False
DDI-MedLine.d44.s2	patients	163	170	O	patients	nts	ents	NNS	False
DDI-MedLine.d44.s2	with	172	175	O	with	ith	with	IN	False
DDI-MedLine.d44.s2	coronary	177	184	O	coronary	ary	nary	NN	False
DDI-MedLine.d44.s2	artery	186	191	O	artery	ery	tery	NN	False
DDI-MedLine.d44.s2	disease	193	199	O	disease	ase	ease	NN	False
DDI-MedLine.d44.s2	,	200	200	O	,	,	,	,	False
DDI-MedLine.d44.s2	aged	202	205	O	aged	ged	aged	VBN	False
DDI-MedLine.d44.s2	59+/-11	207	213	O	59+/-11	-11	/-11	JJ	False
DDI-MedLine.d44.s2	years	215	219	O	years	ars	ears	NNS	False
DDI-MedLine.d44.s2	,	220	220	O	,	,	,	,	False
DDI-MedLine.d44.s2	(	222	222	O	(	(	(	(	False
DDI-MedLine.d44.s2	total	223	227	O	total	tal	otal	JJ	False
DDI-MedLine.d44.s2	cholesterol	229	239	O	cholesterol	rol	erol	NN	False
DDI-MedLine.d44.s2	:	240	240	O	:	:	:	:	False
DDI-MedLine.d44.s2	240+/-41	242	249	O	240+/-41	-41	/-41	JJ	False
DDI-MedLine.d44.s2	mg/dl	251	255	O	mg/dl	/dl	g/dl	NN	False
DDI-MedLine.d44.s2	;	256	256	O	;	;	;	:	False
DDI-MedLine.d44.s2	triglycerides	258	270	O	triglycerides	des	ides	NNS	group
DDI-MedLine.d44.s2	:	271	271	O	:	:	:	:	False
DDI-MedLine.d44.s2	188+/-42	273	280	O	188+/-42	-42	/-42	JJ	False
DDI-MedLine.d44.s2	mg/dl	282	286	O	mg/dl	/dl	g/dl	NN	False
DDI-MedLine.d44.s2	)	287	287	O	)	)	)	)	False
DDI-MedLine.d44.s2	submitted	289	297	O	submitted	ted	tted	VBN	False
DDI-MedLine.d44.s2	to	299	300	O	to	to	to	TO	False
DDI-MedLine.d44.s2	a	302	302	O	a	a	a	DT	False
DDI-MedLine.d44.s2	randomized	304	313	O	randomized	zed	ized	VBN	False
DDI-MedLine.d44.s2	,	314	314	O	,	,	,	,	False
DDI-MedLine.d44.s2	crossover	316	324	O	crossover	ver	over	NN	False
DDI-MedLine.d44.s2	,	325	325	O	,	,	,	,	False
DDI-MedLine.d44.s2	double-blind	327	338	O	double-blind	ind	lind	NN	False
DDI-MedLine.d44.s2	,	339	339	O	,	,	,	,	False
DDI-MedLine.d44.s2	placebo-controlled	341	358	O	placebo-controlled	led	lled	JJ	False
DDI-MedLine.d44.s2	study	360	364	O	study	udy	tudy	NN	False
DDI-MedLine.d44.s2	with	366	369	O	with	ith	with	IN	False
DDI-MedLine.d44.s2	administration	371	384	O	administration	ion	tion	NN	False
DDI-MedLine.d44.s2	of	386	387	O	of	of	of	IN	False
DDI-MedLine.d44.s2	1	389	389	O	1	1	1	CD	False
DDI-MedLine.d44.s2	g	391	391	O	g	g	g	NN	False
DDI-MedLine.d44.s2	per	393	395	O	per	per	per	IN	False
DDI-MedLine.d44.s2	day	397	399	O	day	day	day	NN	False
DDI-MedLine.d44.s2	etofibrate	401	410	B-drug	etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s2	or	412	413	O	or	or	or	CC	False
DDI-MedLine.d44.s2	placebo	415	421	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d44.s2	for	423	425	O	for	for	for	IN	False
DDI-MedLine.d44.s2	1-month	427	433	O	1-month	nth	onth	JJ	False
DDI-MedLine.d44.s2	.	434	434	O	.	.	.	.	False

DDI-MedLine.d44.s3	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d44.s3	1-month	2	8	O	1-month	nth	onth	JJ	False
DDI-MedLine.d44.s3	washout	10	16	O	washout	out	hout	NN	False
DDI-MedLine.d44.s3	period	18	23	O	period	iod	riod	NN	False
DDI-MedLine.d44.s3	was	25	27	O	was	was	was	VBD	False
DDI-MedLine.d44.s3	inserted	29	36	O	inserted	ted	rted	VBN	False
DDI-MedLine.d44.s3	between	38	44	O	between	een	ween	IN	False
DDI-MedLine.d44.s3	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d44.s3	treatment	50	58	O	treatment	ent	ment	NN	False
DDI-MedLine.d44.s3	periods	60	66	O	periods	ods	iods	NNS	False
DDI-MedLine.d44.s3	.	67	67	O	.	.	.	.	False

DDI-MedLine.d44.s4	Patients	0	7	O	Patients	nts	ents	NNS	False
DDI-MedLine.d44.s4	were	9	12	O	were	ere	were	VBD	False
DDI-MedLine.d44.s4	intravenously	14	26	O	intravenously	sly	usly	RB	False
DDI-MedLine.d44.s4	injected	28	35	O	injected	ted	cted	VBN	False
DDI-MedLine.d44.s4	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d44.s4	chylomicron-like	39	54	O	chylomicron-like	ike	like	NN	False
DDI-MedLine.d44.s4	emulsion	56	63	O	emulsion	ion	sion	NN	False
DDI-MedLine.d44.s4	doubly	65	70	O	doubly	bly	ubly	RB	False
DDI-MedLine.d44.s4	labeled	72	78	O	labeled	led	eled	VBN	False
DDI-MedLine.d44.s4	with	80	83	O	with	ith	with	IN	False
DDI-MedLine.d44.s4	14C-cholesteryl	85	99	O	14C-cholesteryl	ryl	eryl	JJ	False
DDI-MedLine.d44.s4	oleate	101	106	O	oleate	ate	eate	NN	False
DDI-MedLine.d44.s4	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d44.s4	3H-triolein	112	122	O	3H-triolein	ein	lein	JJ	False
DDI-MedLine.d44.s4	at	124	125	O	at	at	at	IN	False
DDI-MedLine.d44.s4	baseline	127	134	O	baseline	ine	line	NN	drug
DDI-MedLine.d44.s4	and	136	138	O	and	and	and	CC	False
DDI-MedLine.d44.s4	after	140	144	O	after	ter	fter	IN	False
DDI-MedLine.d44.s4	treatments	146	155	O	treatments	nts	ents	NNS	False
DDI-MedLine.d44.s4	.	156	156	O	.	.	.	.	False

DDI-MedLine.d44.s5	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d44.s5	etofibrate	6	15	B-drug	etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s5	treatment	17	25	O	treatment	ent	ment	NN	False
DDI-MedLine.d44.s5	,	26	26	O	,	,	,	,	False
DDI-MedLine.d44.s5	there	28	32	O	there	ere	here	RB	False
DDI-MedLine.d44.s5	was	34	36	O	was	was	was	VBD	False
DDI-MedLine.d44.s5	decrease	38	45	O	decrease	ase	ease	NN	False
DDI-MedLine.d44.s5	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d44.s5	total	50	54	O	total	tal	otal	JJ	False
DDI-MedLine.d44.s5	cholesterol	56	66	O	cholesterol	rol	erol	NN	False
DDI-MedLine.d44.s5	and	68	70	O	and	and	and	CC	False
DDI-MedLine.d44.s5	triglyceride	72	83	O	triglyceride	ide	ride	NN	False
DDI-MedLine.d44.s5	plasma	85	90	O	plasma	sma	asma	NN	False
DDI-MedLine.d44.s5	levels	92	97	O	levels	els	vels	NNS	False
DDI-MedLine.d44.s5	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d44.s5	a	103	103	O	a	a	a	DT	False
DDI-MedLine.d44.s5	trend	105	109	O	trend	end	rend	NN	False
DDI-MedLine.d44.s5	to	111	112	O	to	to	to	TO	False
DDI-MedLine.d44.s5	increase	114	121	O	increase	ase	ease	NN	False
DDI-MedLine.d44.s5	high-density	123	134	O	high-density	ity	sity	NN	False
DDI-MedLine.d44.s5	lipoprotein	136	146	O	lipoprotein	ein	tein	NN	False
DDI-MedLine.d44.s5	cholesterol	148	158	O	cholesterol	rol	erol	NN	False
DDI-MedLine.d44.s5	plasma	160	165	O	plasma	sma	asma	NN	False
DDI-MedLine.d44.s5	levels	167	172	O	levels	els	vels	NNS	False
DDI-MedLine.d44.s5	.	173	173	O	.	.	.	.	False

DDI-MedLine.d44.s6	Etofibrate	0	9	B-drug	Etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s6	elicited	11	18	O	elicited	ted	ited	VBN	False
DDI-MedLine.d44.s6	62	20	21	O	62	62	62	CD	False
DDI-MedLine.d44.s6	%	22	22	O	%	%	%	NN	False
DDI-MedLine.d44.s6	enhancement	24	34	O	enhancement	ent	ment	NN	False
DDI-MedLine.d44.s6	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d44.s6	post-heparin	39	50	O	post-heparin	rin	arin	NN	False
DDI-MedLine.d44.s6	lipolytic	52	60	O	lipolytic	tic	ytic	JJ	False
DDI-MedLine.d44.s6	activity	62	69	O	activity	ity	vity	NN	False
DDI-MedLine.d44.s6	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d44.s6	100	75	77	O	100	100	100	CD	False
DDI-MedLine.d44.s6	%	78	78	O	%	%	%	NN	False
DDI-MedLine.d44.s6	increase	80	87	O	increase	ase	ease	NN	False
DDI-MedLine.d44.s6	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d44.s6	3H-triglyceride	92	106	O	3H-triglyceride	ide	ride	JJ	False
DDI-MedLine.d44.s6	fractional	108	117	O	fractional	nal	onal	JJ	False
DDI-MedLine.d44.s6	clearance	119	127	O	clearance	nce	ance	NN	False
DDI-MedLine.d44.s6	rate	129	132	O	rate	ate	rate	NN	False
DDI-MedLine.d44.s6	compared	134	141	O	compared	red	ared	VBN	False
DDI-MedLine.d44.s6	with	143	146	O	with	ith	with	IN	False
DDI-MedLine.d44.s6	placebo	148	154	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d44.s6	treatment	156	164	O	treatment	ent	ment	NN	False
DDI-MedLine.d44.s6	.	165	165	O	.	.	.	.	False

DDI-MedLine.d44.s7	14C-cholesterol	0	14	O	14C-cholesterol	rol	erol	JJ	False
DDI-MedLine.d44.s7	ester	16	20	O	ester	ter	ster	NN	False
DDI-MedLine.d44.s7	fractional	22	31	O	fractional	nal	onal	JJ	False
DDI-MedLine.d44.s7	clearance	33	41	O	clearance	nce	ance	NN	False
DDI-MedLine.d44.s7	rate	43	46	O	rate	ate	rate	NN	False
DDI-MedLine.d44.s7	was	48	50	O	was	was	was	VBD	False
DDI-MedLine.d44.s7	260	52	54	O	260	260	260	CD	False
DDI-MedLine.d44.s7	%	55	55	O	%	%	%	NN	False
DDI-MedLine.d44.s7	greater	57	63	O	greater	ter	ater	JJR	False
DDI-MedLine.d44.s7	after	65	69	O	after	ter	fter	IN	False
DDI-MedLine.d44.s7	etofibrate	71	80	B-drug	etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s7	than	82	85	O	than	han	than	IN	False
DDI-MedLine.d44.s7	after	87	91	O	after	ter	fter	IN	False
DDI-MedLine.d44.s7	placebo	93	99	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d44.s7	.	100	100	O	.	.	.	.	False

DDI-MedLine.d44.s8	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d44.s8	,	9	9	O	,	,	,	,	False
DDI-MedLine.d44.s8	a	11	11	O	a	a	a	DT	False
DDI-MedLine.d44.s8	potent	13	18	O	potent	ent	tent	NN	False
DDI-MedLine.d44.s8	effect	20	25	O	effect	ect	fect	NN	False
DDI-MedLine.d44.s8	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d44.s8	etofibrate	30	39	B-drug	etofibrate	ate	rate	NN	False
DDI-MedLine.d44.s8	on	41	42	O	on	on	on	IN	False
DDI-MedLine.d44.s8	both	44	47	O	both	oth	both	DT	False
DDI-MedLine.d44.s8	chylomicron	49	59	O	chylomicron	ron	cron	NN	False
DDI-MedLine.d44.s8	lipolysis	61	69	O	lipolysis	sis	ysis	NN	False
DDI-MedLine.d44.s8	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d44.s8	remnant	75	81	O	remnant	ant	nant	NN	False
DDI-MedLine.d44.s8	removal	83	89	O	removal	val	oval	NN	False
DDI-MedLine.d44.s8	was	91	93	O	was	was	was	VBD	False
DDI-MedLine.d44.s8	achieved	95	102	O	achieved	ved	eved	VBN	False
DDI-MedLine.d44.s8	,	103	103	O	,	,	,	,	False
DDI-MedLine.d44.s8	indicating	105	114	O	indicating	ing	ting	VBG	False
DDI-MedLine.d44.s8	that	116	119	O	that	hat	that	IN	False
DDI-MedLine.d44.s8	this	121	124	O	this	his	this	DT	False
DDI-MedLine.d44.s8	drug	126	129	O	drug	rug	drug	NN	False
DDI-MedLine.d44.s8	can	131	133	O	can	can	can	MD	False
DDI-MedLine.d44.s8	be	135	136	O	be	be	be	VB	False
DDI-MedLine.d44.s8	used	138	141	O	used	sed	used	VBN	False
DDI-MedLine.d44.s8	to	143	144	O	to	to	to	TO	False
DDI-MedLine.d44.s8	improve	146	152	O	improve	ove	rove	VB	False
DDI-MedLine.d44.s8	this	154	157	O	this	his	this	DT	False
DDI-MedLine.d44.s8	metabolism	159	168	O	metabolism	ism	lism	NN	False
DDI-MedLine.d44.s8	in	170	171	O	in	in	in	IN	False
DDI-MedLine.d44.s8	future	173	178	O	future	ure	ture	NN	False
DDI-MedLine.d44.s8	prospective	180	190	O	prospective	ive	tive	JJ	False
DDI-MedLine.d44.s8	studies	192	198	O	studies	ies	dies	NNS	False
DDI-MedLine.d44.s8	.	199	199	O	.	.	.	.	False

DDI-MedLine.d92.s0	Systemic	0	7	O	Systemic	mic	emic	JJ	False
DDI-MedLine.d92.s0	antibiotic	9	18	B-group	antibiotic	tic	otic	JJ	False
DDI-MedLine.d92.s0	agents	20	25	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d92.s0	.	26	26	O	.	.	.	.	False

DDI-MedLine.d92.s1	Understanding	0	12	O	Understanding	ing	ding	VBG	False
DDI-MedLine.d92.s1	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d92.s1	breadth	18	24	O	breadth	dth	adth	NN	False
DDI-MedLine.d92.s1	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d92.s1	systemic	29	36	O	systemic	mic	emic	JJ	False
DDI-MedLine.d92.s1	antimicrobial	38	50	B-group	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d92.s1	agents	52	57	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d92.s1	available	59	67	O	available	ble	able	JJ	False
DDI-MedLine.d92.s1	for	69	71	O	for	for	for	IN	False
DDI-MedLine.d92.s1	use	73	75	O	use	use	use	NN	False
DDI-MedLine.d92.s1	by	77	78	O	by	by	by	IN	False
DDI-MedLine.d92.s1	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d92.s1	dermatologist	84	96	O	dermatologist	ist	gist	NN	False
DDI-MedLine.d92.s1	and	98	100	O	and	and	and	CC	False
DDI-MedLine.d92.s1	their	102	106	O	their	eir	heir	PRP$	False
DDI-MedLine.d92.s1	associated	108	117	O	associated	ted	ated	VBN	False
DDI-MedLine.d92.s1	side-effect	119	129	O	side-effect	ect	fect	JJ	False
DDI-MedLine.d92.s1	profiles	131	138	O	profiles	les	iles	NNS	False
DDI-MedLine.d92.s1	and	140	142	O	and	and	and	CC	False
DDI-MedLine.d92.s1	drug	144	147	O	drug	rug	drug	NN	False
DDI-MedLine.d92.s1	interactions	149	160	O	interactions	ons	ions	NNS	False
DDI-MedLine.d92.s1	allows	162	167	O	allows	ows	lows	NNS	False
DDI-MedLine.d92.s1	the	169	171	O	the	the	the	DT	False
DDI-MedLine.d92.s1	clinician	173	181	O	clinician	ian	cian	NN	False
DDI-MedLine.d92.s1	to	183	184	O	to	to	to	TO	False
DDI-MedLine.d92.s1	offer	186	190	O	offer	fer	ffer	NN	False
DDI-MedLine.d92.s1	patients	192	199	O	patients	nts	ents	NNS	False
DDI-MedLine.d92.s1	optimal	201	207	O	optimal	mal	imal	JJ	False
DDI-MedLine.d92.s1	care	209	212	O	care	are	care	NN	False
DDI-MedLine.d92.s1	in	214	215	O	in	in	in	IN	False
DDI-MedLine.d92.s1	the	217	219	O	the	the	the	DT	False
DDI-MedLine.d92.s1	management	221	230	O	management	ent	ment	NN	False
DDI-MedLine.d92.s1	of	232	233	O	of	of	of	IN	False
DDI-MedLine.d92.s1	cutaneous	235	243	O	cutaneous	ous	eous	JJ	False
DDI-MedLine.d92.s1	infectious	245	254	O	infectious	ous	ious	JJ	False
DDI-MedLine.d92.s1	disease	256	262	O	disease	ase	ease	NN	False
DDI-MedLine.d92.s1	.	263	263	O	.	.	.	.	False

DDI-MedLine.d5.s0	Repeated	0	7	O	Repeated	ted	ated	VBN	False
DDI-MedLine.d5.s0	oral	9	12	O	oral	ral	oral	JJ	False
DDI-MedLine.d5.s0	administration	14	27	O	administration	ion	tion	NN	False
DDI-MedLine.d5.s0	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d5.s0	coumaphos	32	40	B-drug_n	coumaphos	hos	phos	NN	False
DDI-MedLine.d5.s0	in	42	43	O	in	in	in	IN	False
DDI-MedLine.d5.s0	sheep	45	49	O	sheep	eep	heep	NN	False
DDI-MedLine.d5.s0	:	50	50	O	:	:	:	:	False
DDI-MedLine.d5.s0	interactions	52	63	O	interactions	ons	ions	NNS	False
DDI-MedLine.d5.s0	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d5.s0	coumaphos	68	76	B-drug_n	coumaphos	hos	phos	NN	False
DDI-MedLine.d5.s0	with	78	81	O	with	ith	with	IN	False
DDI-MedLine.d5.s0	bishydroxycoumarin	83	100	B-drug	bishydroxycoumarin	rin	arin	NN	False
DDI-MedLine.d5.s0	,	101	101	O	,	,	,	,	False
DDI-MedLine.d5.s0	trichlorfon	103	113	B-drug_n	trichlorfon	fon	rfon	NN	False
DDI-MedLine.d5.s0	,	114	114	O	,	,	,	,	False
DDI-MedLine.d5.s0	and	116	118	O	and	and	and	CC	False
DDI-MedLine.d5.s0	phenobarbital	120	132	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d5.s0	sodium	134	139	I-drug	sodium	ium	dium	NN	drug
DDI-MedLine.d5.s0	.	140	140	O	.	.	.	.	False

DDI-MedLine.d5.s1	Interactions	0	11	O	Interactions	ons	ions	NNS	False
DDI-MedLine.d5.s1	between	13	19	O	between	een	ween	IN	False
DDI-MedLine.d5.s1	treatments	21	30	O	treatments	nts	ents	NNS	False
DDI-MedLine.d5.s1	with	32	35	O	with	ith	with	IN	False
DDI-MedLine.d5.s1	coumaphos	37	45	B-drug_n	coumaphos	hos	phos	NN	False
DDI-MedLine.d5.s1	,	46	46	O	,	,	,	,	False
DDI-MedLine.d5.s1	bishydroxycoumarin	48	65	B-drug	bishydroxycoumarin	rin	arin	NN	False
DDI-MedLine.d5.s1	(	67	67	O	(	(	(	(	False
DDI-MedLine.d5.s1	an	68	69	O	an	an	an	DT	False
DDI-MedLine.d5.s1	anticoagulant	71	83	B-group	anticoagulant	ant	lant	NN	False
DDI-MedLine.d5.s1	)	84	84	O	)	)	)	)	False
DDI-MedLine.d5.s1	,	85	85	O	,	,	,	,	False
DDI-MedLine.d5.s1	trichlorfon	87	97	B-drug_n	trichlorfon	fon	rfon	NN	False
DDI-MedLine.d5.s1	(	99	99	O	(	(	(	(	False
DDI-MedLine.d5.s1	an	100	101	O	an	an	an	DT	False
DDI-MedLine.d5.s1	organophosphorous	103	119	B-group	organophosphorous	ous	rous	JJ	False
DDI-MedLine.d5.s1	compound	121	128	I-group	compound	und	ound	NN	False
DDI-MedLine.d5.s1	)	129	129	O	)	)	)	)	False
DDI-MedLine.d5.s1	,	130	130	O	,	,	,	,	False
DDI-MedLine.d5.s1	and	132	134	O	and	and	and	CC	False
DDI-MedLine.d5.s1	phenobarbital	136	148	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d5.s1	sodium	150	155	I-drug	sodium	ium	dium	NN	drug
DDI-MedLine.d5.s1	(	157	157	O	(	(	(	(	False
DDI-MedLine.d5.s1	an	158	159	O	an	an	an	DT	False
DDI-MedLine.d5.s1	inducer	161	167	O	inducer	cer	ucer	NN	False
DDI-MedLine.d5.s1	of	169	170	O	of	of	of	IN	False
DDI-MedLine.d5.s1	microsomal	172	181	O	microsomal	mal	omal	NN	False
DDI-MedLine.d5.s1	enzymes	183	189	O	enzymes	mes	ymes	NNS	False
DDI-MedLine.d5.s1	)	190	190	O	)	)	)	)	False
DDI-MedLine.d5.s1	were	192	195	O	were	ere	were	VBD	False
DDI-MedLine.d5.s1	investigated	197	208	O	investigated	ted	ated	VBN	False
DDI-MedLine.d5.s1	in	210	211	O	in	in	in	IN	False
DDI-MedLine.d5.s1	sheep	213	217	O	sheep	eep	heep	NN	False
DDI-MedLine.d5.s1	.	218	218	O	.	.	.	.	False

DDI-MedLine.d5.s2	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d5.s2	daily	2	6	O	daily	ily	aily	JJ	False
DDI-MedLine.d5.s2	dose	8	11	O	dose	ose	dose	NN	False
DDI-MedLine.d5.s2	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d5.s2	2	16	16	O	2	2	2	CD	False
DDI-MedLine.d5.s2	mg	18	19	O	mg	mg	mg	NN	False
DDI-MedLine.d5.s2	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d5.s2	coumaphos/kg	24	35	O	coumaphos/kg	/kg	s/kg	NN	False
DDI-MedLine.d5.s2	of	37	38	O	of	of	of	IN	False
DDI-MedLine.d5.s2	body	40	43	O	body	ody	body	NN	False
DDI-MedLine.d5.s2	weight	45	50	O	weight	ght	ight	NN	False
DDI-MedLine.d5.s2	for	52	54	O	for	for	for	IN	False
DDI-MedLine.d5.s2	6	56	56	O	6	6	6	CD	False
DDI-MedLine.d5.s2	days	58	61	O	days	ays	days	NNS	False
DDI-MedLine.d5.s2	did	63	65	O	did	did	did	VBD	False
DDI-MedLine.d5.s2	not	67	69	O	not	not	not	RB	False
DDI-MedLine.d5.s2	affect	71	76	O	affect	ect	fect	NN	False
DDI-MedLine.d5.s2	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d5.s2	plasma	82	87	O	plasma	sma	asma	NN	False
DDI-MedLine.d5.s2	enzymes	89	95	O	enzymes	mes	ymes	NNS	False
DDI-MedLine.d5.s2	or	97	98	O	or	or	or	CC	False
DDI-MedLine.d5.s2	the	100	102	O	the	the	the	DT	False
DDI-MedLine.d5.s2	antiprothrombinemic	104	122	O	antiprothrombinemic	mic	emic	JJ	False
DDI-MedLine.d5.s2	effect	124	129	O	effect	ect	fect	NN	False
DDI-MedLine.d5.s2	of	131	132	O	of	of	of	IN	False
DDI-MedLine.d5.s2	bishydroxy-coumarin	134	152	B-drug	bishydroxy-coumarin	rin	arin	NN	False
DDI-MedLine.d5.s2	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d5.s2	wethers	157	163	O	wethers	ers	hers	NNS	False
DDI-MedLine.d5.s2	.	164	164	O	.	.	.	.	False

DDI-MedLine.d5.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d5.s3	treatment	4	12	O	treatment	ent	ment	NN	False
DDI-MedLine.d5.s3	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d5.s3	ewes	17	20	O	ewes	wes	ewes	NN	False
DDI-MedLine.d5.s3	with	22	25	O	with	ith	with	IN	False
DDI-MedLine.d5.s3	an	27	28	O	an	an	an	DT	False
DDI-MedLine.d5.s3	intravenous	30	40	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d5.s3	(	42	42	O	(	(	(	(	False
DDI-MedLine.d5.s3	IV	43	44	O	IV	IV	IV	NN	brand
DDI-MedLine.d5.s3	)	45	45	O	)	)	)	)	False
DDI-MedLine.d5.s3	injection	47	55	O	injection	ion	tion	NN	False
DDI-MedLine.d5.s3	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d5.s3	trichlorfon	60	70	B-drug_n	trichlorfon	fon	rfon	NN	False
DDI-MedLine.d5.s3	,	71	71	O	,	,	,	,	False
DDI-MedLine.d5.s3	insufficient	73	84	O	insufficient	ent	ient	NN	False
DDI-MedLine.d5.s3	to	86	87	O	to	to	to	TO	False
DDI-MedLine.d5.s3	produce	89	95	O	produce	uce	duce	NN	False
DDI-MedLine.d5.s3	significant	97	107	O	significant	ant	cant	JJ	False
DDI-MedLine.d5.s3	inhibition	109	118	O	inhibition	ion	tion	NN	False
DDI-MedLine.d5.s3	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d5.s3	erythrocyte	123	133	O	erythrocyte	yte	cyte	NN	False
DDI-MedLine.d5.s3	acetylcholinesterase	135	154	O	acetylcholinesterase	ase	rase	NN	False
DDI-MedLine.d5.s3	(	156	156	O	(	(	(	(	False
DDI-MedLine.d5.s3	AChE	157	160	O	AChE	ChE	AChE	NN	False
DDI-MedLine.d5.s3	)	161	161	O	)	)	)	)	False
DDI-MedLine.d5.s3	activity	163	170	O	activity	ity	vity	NN	False
DDI-MedLine.d5.s3	,	171	171	O	,	,	,	,	False
DDI-MedLine.d5.s3	appeared	173	180	O	appeared	red	ared	VBD	False
DDI-MedLine.d5.s3	to	182	183	O	to	to	to	TO	False
DDI-MedLine.d5.s3	produce	185	191	O	produce	uce	duce	NN	False
DDI-MedLine.d5.s3	additive	193	200	O	additive	ive	tive	JJ	False
DDI-MedLine.d5.s3	effects	202	208	O	effects	cts	ects	NNS	False
DDI-MedLine.d5.s3	with	210	213	O	with	ith	with	IN	False
DDI-MedLine.d5.s3	those	215	219	O	those	ose	hose	DT	False
DDI-MedLine.d5.s3	produced	221	228	O	produced	ced	uced	VBN	False
DDI-MedLine.d5.s3	by	230	231	O	by	by	by	IN	False
DDI-MedLine.d5.s3	subsequent	233	242	O	subsequent	ent	uent	NN	False
DDI-MedLine.d5.s3	treatment	244	252	O	treatment	ent	ment	NN	False
DDI-MedLine.d5.s3	with	254	257	O	with	ith	with	IN	False
DDI-MedLine.d5.s3	4	259	259	O	4	4	4	CD	False
DDI-MedLine.d5.s3	mg	261	262	O	mg	mg	mg	NN	False
DDI-MedLine.d5.s3	of	264	265	O	of	of	of	IN	False
DDI-MedLine.d5.s3	coumaphos/kg/day	267	282	O	coumaphos/kg/day	day	/day	NN	False
DDI-MedLine.d5.s3	.	283	283	O	.	.	.	.	False

DDI-MedLine.d5.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d5.s4	ewes	3	6	O	ewes	wes	ewes	NN	False
DDI-MedLine.d5.s4	given	8	12	O	given	ven	iven	VBN	False
DDI-MedLine.d5.s4	40	14	15	O	40	40	40	CD	False
DDI-MedLine.d5.s4	mg	17	18	O	mg	mg	mg	NN	False
DDI-MedLine.d5.s4	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d5.s4	phenobarbital	23	35	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d5.s4	sodium/kg	37	45	O	sodium/kg	/kg	m/kg	NN	False
DDI-MedLine.d5.s4	for	47	49	O	for	for	for	IN	False
DDI-MedLine.d5.s4	5	51	51	O	5	5	5	CD	False
DDI-MedLine.d5.s4	days	53	56	O	days	ays	days	NNS	False
DDI-MedLine.d5.s4	intraperitoneally	58	74	O	intraperitoneally	lly	ally	RB	False
DDI-MedLine.d5.s4	(	76	76	O	(	(	(	(	False
DDI-MedLine.d5.s4	IP	77	78	O	IP	IP	IP	NN	brand
DDI-MedLine.d5.s4	)	79	79	O	)	)	)	)	False
DDI-MedLine.d5.s4	,	80	80	O	,	,	,	,	False
DDI-MedLine.d5.s4	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d5.s4	anticholinesterase	86	103	O	anticholinesterase	ase	rase	NN	False
DDI-MedLine.d5.s4	effect	105	110	O	effect	ect	fect	NN	False
DDI-MedLine.d5.s4	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d5.s4	4	115	115	O	4	4	4	CD	False
DDI-MedLine.d5.s4	mg	117	118	O	mg	mg	mg	NN	False
DDI-MedLine.d5.s4	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d5.s4	coumaphos/kg	123	134	O	coumaphos/kg	/kg	s/kg	NN	False
DDI-MedLine.d5.s4	was	136	138	O	was	was	was	VBD	False
DDI-MedLine.d5.s4	significantly	140	152	O	significantly	tly	ntly	RB	False
DDI-MedLine.d5.s4	reduced	154	160	O	reduced	ced	uced	VBN	False
DDI-MedLine.d5.s4	and	162	164	O	and	and	and	CC	False
DDI-MedLine.d5.s4	signs	166	170	O	signs	gns	igns	NNS	False
DDI-MedLine.d5.s4	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d5.s4	toxicity	175	182	O	toxicity	ity	city	NN	False
DDI-MedLine.d5.s4	were	184	187	O	were	ere	were	VBD	False
DDI-MedLine.d5.s4	not	189	191	O	not	not	not	RB	False
DDI-MedLine.d5.s4	present	193	199	O	present	ent	sent	NN	False
DDI-MedLine.d5.s4	.	200	200	O	.	.	.	.	False

DDI-MedLine.d5.s5	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d5.s5	with	10	13	O	with	ith	with	IN	False
DDI-MedLine.d5.s5	daily	15	19	O	daily	ily	aily	JJ	False
DDI-MedLine.d5.s5	doses	21	25	O	doses	ses	oses	NNS	False
DDI-MedLine.d5.s5	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d5.s5	2	30	30	O	2	2	2	CD	False
DDI-MedLine.d5.s5	mg	32	33	O	mg	mg	mg	NN	False
DDI-MedLine.d5.s5	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d5.s5	coumaphos/kg	38	49	O	coumaphos/kg	/kg	s/kg	NN	False
DDI-MedLine.d5.s5	for	51	53	O	for	for	for	IN	False
DDI-MedLine.d5.s5	6	55	55	O	6	6	6	CD	False
DDI-MedLine.d5.s5	days	57	60	O	days	ays	days	NNS	False
DDI-MedLine.d5.s5	did	62	64	O	did	did	did	VBD	False
DDI-MedLine.d5.s5	not	66	68	O	not	not	not	RB	False
DDI-MedLine.d5.s5	modify	70	75	O	modify	ify	dify	NN	False
DDI-MedLine.d5.s5	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d5.s5	anticholinesterase	81	98	O	anticholinesterase	ase	rase	NN	False
DDI-MedLine.d5.s5	effect	100	105	O	effect	ect	fect	NN	False
DDI-MedLine.d5.s5	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d5.s5	a	110	110	O	a	a	a	DT	False
DDI-MedLine.d5.s5	2nd	112	114	O	2nd	2nd	2nd	CD	False
DDI-MedLine.d5.s5	series	116	121	O	series	ies	ries	NN	False
DDI-MedLine.d5.s5	of	123	124	O	of	of	of	IN	False
DDI-MedLine.d5.s5	treatments	126	135	O	treatments	nts	ents	NNS	False
DDI-MedLine.d5.s5	given	137	141	O	given	ven	iven	VBN	False
DDI-MedLine.d5.s5	6	143	143	O	6	6	6	CD	False
DDI-MedLine.d5.s5	weeks	145	149	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d5.s5	later	151	155	O	later	ter	ater	RB	False
DDI-MedLine.d5.s5	.	156	156	O	.	.	.	.	False

DDI-MedLine.d102.s0	Influence	0	8	O	Influence	nce	ence	NN	False
DDI-MedLine.d102.s0	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d102.s0	estradiol	13	21	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d102.s0	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d102.s0	progesterone	27	38	B-drug	progesterone	one	rone	NN	False
DDI-MedLine.d102.s0	on	40	41	O	on	on	on	IN	False
DDI-MedLine.d102.s0	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d102.s0	sensitivity	47	57	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d102.s0	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d102.s0	rat	62	64	O	rat	rat	rat	NN	False
DDI-MedLine.d102.s0	thoracic	66	73	O	thoracic	cic	acic	NN	False
DDI-MedLine.d102.s0	aorta	75	79	O	aorta	rta	orta	NN	False
DDI-MedLine.d102.s0	to	81	82	O	to	to	to	TO	False
DDI-MedLine.d102.s0	noradrenaline	84	96	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d102.s0	.	97	97	O	.	.	.	.	False

DDI-MedLine.d102.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d102.s1	aim	4	6	O	aim	aim	aim	NN	False
DDI-MedLine.d102.s1	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d102.s1	this	11	14	O	this	his	this	DT	False
DDI-MedLine.d102.s1	study	16	20	O	study	udy	tudy	NN	False
DDI-MedLine.d102.s1	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d102.s1	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d102.s1	investigate	29	39	O	investigate	ate	gate	NN	False
DDI-MedLine.d102.s1	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d102.s1	effects	45	51	O	effects	cts	ects	NNS	False
DDI-MedLine.d102.s1	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d102.s1	low	56	58	O	low	low	low	JJ	False
DDI-MedLine.d102.s1	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d102.s1	high	64	67	O	high	igh	high	JJ	False
DDI-MedLine.d102.s1	doses	69	73	O	doses	ses	oses	NNS	False
DDI-MedLine.d102.s1	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d102.s1	estradiol	78	86	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d102.s1	,	87	87	O	,	,	,	,	False
DDI-MedLine.d102.s1	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d102.s1	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d102.s1	progesterone	96	107	B-drug	progesterone	one	rone	NN	False
DDI-MedLine.d102.s1	on	109	110	O	on	on	on	IN	False
DDI-MedLine.d102.s1	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d102.s1	response	116	123	O	response	nse	onse	NN	False
DDI-MedLine.d102.s1	to	125	126	O	to	to	to	TO	False
DDI-MedLine.d102.s1	noradrenaline	128	140	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d102.s1	in	142	143	O	in	in	in	IN	False
DDI-MedLine.d102.s1	rat	145	147	O	rat	rat	rat	NN	False
DDI-MedLine.d102.s1	thoracic	149	156	O	thoracic	cic	acic	NN	False
DDI-MedLine.d102.s1	aorta	158	162	O	aorta	rta	orta	NN	False
DDI-MedLine.d102.s1	.	163	163	O	.	.	.	.	False

DDI-MedLine.d102.s2	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d102.s2	weeks	4	8	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d102.s2	after	10	14	O	after	ter	fter	IN	False
DDI-MedLine.d102.s2	bilateral	16	24	O	bilateral	ral	eral	JJ	False
DDI-MedLine.d102.s2	ovariectomy	26	36	O	ovariectomy	omy	tomy	NN	False
DDI-MedLine.d102.s2	,	37	37	O	,	,	,	,	False
DDI-MedLine.d102.s2	female	39	44	O	female	ale	male	NN	False
DDI-MedLine.d102.s2	rats	46	49	O	rats	ats	rats	NNS	False
DDI-MedLine.d102.s2	received	51	58	O	received	ved	ived	VBN	False
DDI-MedLine.d102.s2	a	60	60	O	a	a	a	DT	False
DDI-MedLine.d102.s2	s.c	62	64	O	s.c	s.c	s.c	NN	False
DDI-MedLine.d102.s2	.	65	65	O	.	.	.	.	False

DDI-MedLine.d102.s3	injection	0	8	O	injection	ion	tion	NN	False
DDI-MedLine.d102.s3	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d102.s3	vehicle	13	19	O	vehicle	cle	icle	NN	False
DDI-MedLine.d102.s3	(	21	21	O	(	(	(	(	False
DDI-MedLine.d102.s3	corn	22	25	O	corn	orn	corn	NN	False
DDI-MedLine.d102.s3	oil	27	29	O	oil	oil	oil	NN	False
DDI-MedLine.d102.s3	,	30	30	O	,	,	,	,	False
DDI-MedLine.d102.s3	0.1	32	34	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d102.s3	mL/day	36	41	O	mL/day	day	/day	NN	False
DDI-MedLine.d102.s3	)	42	42	O	)	)	)	)	False
DDI-MedLine.d102.s3	,	43	43	O	,	,	,	,	False
DDI-MedLine.d102.s3	estradiol	45	53	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d102.s3	(	55	55	O	(	(	(	(	False
DDI-MedLine.d102.s3	10	56	57	O	10	10	10	CD	False
DDI-MedLine.d102.s3	microg/kg/day	59	71	O	microg/kg/day	day	/day	NN	False
DDI-MedLine.d102.s3	or	73	74	O	or	or	or	CC	False
DDI-MedLine.d102.s3	4	76	76	O	4	4	4	CD	False
DDI-MedLine.d102.s3	mg/kg/day	78	86	O	mg/kg/day	day	/day	NN	False
DDI-MedLine.d102.s3	)	87	87	O	)	)	)	)	False
DDI-MedLine.d102.s3	and/or	89	94	O	and/or	/or	d/or	NN	False
DDI-MedLine.d102.s3	progesterone	96	107	B-drug	progesterone	one	rone	NN	False
DDI-MedLine.d102.s3	(	109	109	O	(	(	(	(	False
DDI-MedLine.d102.s3	20	110	111	O	20	20	20	CD	False
DDI-MedLine.d102.s3	mg/kg/day	113	121	O	mg/kg/day	day	/day	NN	False
DDI-MedLine.d102.s3	)	122	122	O	)	)	)	)	False
DDI-MedLine.d102.s3	,	123	123	O	,	,	,	,	False
DDI-MedLine.d102.s3	for	125	127	O	for	for	for	IN	False
DDI-MedLine.d102.s3	eight	129	133	O	eight	ght	ight	CD	False
DDI-MedLine.d102.s3	days	135	138	O	days	ays	days	NNS	False
DDI-MedLine.d102.s3	.	139	139	O	.	.	.	.	False

DDI-MedLine.d102.s4	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d102.s4	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d102.s4	ninth	7	11	O	ninth	nth	inth	JJ	False
DDI-MedLine.d102.s4	day	13	15	O	day	day	day	NN	False
DDI-MedLine.d102.s4	,	16	16	O	,	,	,	,	False
DDI-MedLine.d102.s4	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d102.s4	rats	22	25	O	rats	ats	rats	NNS	False
DDI-MedLine.d102.s4	were	27	30	O	were	ere	were	VBD	False
DDI-MedLine.d102.s4	sacrificed	32	41	O	sacrificed	ced	iced	VBN	False
DDI-MedLine.d102.s4	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d102.s4	aortic	47	52	O	aortic	tic	rtic	JJ	False
DDI-MedLine.d102.s4	rings	54	58	O	rings	ngs	ings	NNS	False
DDI-MedLine.d102.s4	,	59	59	O	,	,	,	,	False
DDI-MedLine.d102.s4	with	61	64	O	with	ith	with	IN	False
DDI-MedLine.d102.s4	or	66	67	O	or	or	or	CC	False
DDI-MedLine.d102.s4	without	69	75	O	without	out	hout	IN	False
DDI-MedLine.d102.s4	endothelium	77	87	O	endothelium	ium	lium	NN	drug
DDI-MedLine.d102.s4	,	88	88	O	,	,	,	,	False
DDI-MedLine.d102.s4	were	90	93	O	were	ere	were	VBD	False
DDI-MedLine.d102.s4	used	95	98	O	used	sed	used	VBN	False
DDI-MedLine.d102.s4	to	100	101	O	to	to	to	TO	False
DDI-MedLine.d102.s4	generate	103	110	O	generate	ate	rate	NN	False
DDI-MedLine.d102.s4	concentration-response	112	133	O	concentration-response	nse	onse	NN	False
DDI-MedLine.d102.s4	curves	135	140	O	curves	ves	rves	NNS	False
DDI-MedLine.d102.s4	to	142	143	O	to	to	to	TO	False
DDI-MedLine.d102.s4	noradrenaline	145	157	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d102.s4	.	158	158	O	.	.	.	.	False

DDI-MedLine.d102.s5	Aortic	0	5	O	Aortic	tic	rtic	JJ	False
DDI-MedLine.d102.s5	rings	7	11	O	rings	ngs	ings	NNS	False
DDI-MedLine.d102.s5	with	13	16	O	with	ith	with	IN	False
DDI-MedLine.d102.s5	intact	18	23	O	intact	act	tact	JJ	False
DDI-MedLine.d102.s5	endothelium	25	35	O	endothelium	ium	lium	NN	drug
DDI-MedLine.d102.s5	from	37	40	O	from	rom	from	IN	False
DDI-MedLine.d102.s5	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d102.s5	high-dose	46	54	O	high-dose	ose	dose	JJ	False
DDI-MedLine.d102.s5	(	56	56	O	(	(	(	(	False
DDI-MedLine.d102.s5	4	57	57	O	4	4	4	CD	False
DDI-MedLine.d102.s5	mg/kg/day	59	67	O	mg/kg/day	day	/day	NN	False
DDI-MedLine.d102.s5	)	68	68	O	)	)	)	)	False
DDI-MedLine.d102.s5	estradiol	70	78	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d102.s5	group	80	84	O	group	oup	roup	NN	False
DDI-MedLine.d102.s5	were	86	89	O	were	ere	were	VBD	False
DDI-MedLine.d102.s5	supersensitive	91	104	O	supersensitive	ive	tive	NN	False
DDI-MedLine.d102.s5	to	106	107	O	to	to	to	TO	False
DDI-MedLine.d102.s5	noradrenaline	109	121	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d102.s5	compared	123	130	O	compared	red	ared	VBN	False
DDI-MedLine.d102.s5	to	132	133	O	to	to	to	TO	False
DDI-MedLine.d102.s5	the	135	137	O	the	the	the	DT	False
DDI-MedLine.d102.s5	vehicle	139	145	O	vehicle	cle	icle	NN	False
DDI-MedLine.d102.s5	or	147	148	O	or	or	or	CC	False
DDI-MedLine.d102.s5	low-dose	150	157	O	low-dose	ose	dose	JJ	False
DDI-MedLine.d102.s5	(	159	159	O	(	(	(	(	False
DDI-MedLine.d102.s5	10	160	161	O	10	10	10	CD	False
DDI-MedLine.d102.s5	microg/kg/day	163	175	O	microg/kg/day	day	/day	NN	False
DDI-MedLine.d102.s5	)	176	176	O	)	)	)	)	False
DDI-MedLine.d102.s5	estradiol	178	186	O	estradiol	iol	diol	NN	drug
DDI-MedLine.d102.s5	groups	188	193	O	groups	ups	oups	NNS	False
DDI-MedLine.d102.s5	(	195	195	O	(	(	(	(	False
DDI-MedLine.d102.s5	pD2	196	198	O	pD2	pD2	pD2	NN	False
DDI-MedLine.d102.s5	values	200	205	O	values	ues	lues	NNS	False
DDI-MedLine.d102.s5	=	207	207	O	=	=	=	NN	False
DDI-MedLine.d102.s5	7.86+/-0.09	209	219	O	7.86+/-0.09	.09	0.09	JJ	False
DDI-MedLine.d102.s5	,	220	220	O	,	,	,	,	False
DDI-MedLine.d102.s5	7.30+/-0.11	222	232	O	7.30+/-0.11	.11	0.11	JJ	False
DDI-MedLine.d102.s5	and	234	236	O	and	and	and	CC	False
DDI-MedLine.d102.s5	7.35+/-0.04	238	248	O	7.35+/-0.04	.04	0.04	JJ	False
DDI-MedLine.d102.s5	,	249	249	O	,	,	,	,	False
DDI-MedLine.d102.s5	respectively	251	262	O	respectively	ely	vely	RB	False
DDI-MedLine.d102.s5	)	263	263	O	)	)	)	)	False
DDI-MedLine.d102.s5	.	264	264	O	.	.	.	.	False

DDI-MedLine.d102.s6	Endothelium-intact	0	17	O	Endothelium-intact	act	tact	JJ	False
DDI-MedLine.d102.s6	aortic	19	24	O	aortic	tic	rtic	JJ	False
DDI-MedLine.d102.s6	rings	26	30	O	rings	ngs	ings	NNS	False
DDI-MedLine.d102.s6	from	32	35	O	from	rom	from	IN	False
DDI-MedLine.d102.s6	high-estradiol	37	50	O	high-estradiol	iol	diol	NN	drug
DDI-MedLine.d102.s6	rats	52	55	O	rats	ats	rats	NNS	False
DDI-MedLine.d102.s6	were	57	60	O	were	ere	were	VBD	False
DDI-MedLine.d102.s6	supersensitive	62	75	O	supersensitive	ive	tive	NN	False
DDI-MedLine.d102.s6	to	77	78	O	to	to	to	TO	False
DDI-MedLine.d102.s6	noradrenaline	80	92	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d102.s6	when	94	97	O	when	hen	when	WRB	False
DDI-MedLine.d102.s6	compared	99	106	O	compared	red	ared	VBN	False
DDI-MedLine.d102.s6	to	108	109	O	to	to	to	TO	False
DDI-MedLine.d102.s6	vehicle-	111	118	O	vehicle-	le-	cle-	NN	False
DDI-MedLine.d102.s6	,	119	119	O	,	,	,	,	False
DDI-MedLine.d102.s6	progesterone-	121	133	O	progesterone-	ne-	one-	NN	False
DDI-MedLine.d102.s6	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d102.s6	progesterone	139	150	B-drug	progesterone	one	rone	NN	False
DDI-MedLine.d102.s6	+	152	152	O	+	+	+	NN	False
DDI-MedLine.d102.s6	high-estradiol-treated	154	175	O	high-estradiol-treated	ted	ated	JJ	False
DDI-MedLine.d102.s6	rats	177	180	O	rats	ats	rats	NNS	False
DDI-MedLine.d102.s6	(	182	182	O	(	(	(	(	False
DDI-MedLine.d102.s6	pD2	183	185	O	pD2	pD2	pD2	NN	False
DDI-MedLine.d102.s6	values	187	192	O	values	ues	lues	NNS	False
DDI-MedLine.d102.s6	=	194	194	O	=	=	=	NN	False
DDI-MedLine.d102.s6	7.77+/-0.12	196	206	O	7.77+/-0.12	.12	0.12	JJ	False
DDI-MedLine.d102.s6	,	207	207	O	,	,	,	,	False
DDI-MedLine.d102.s6	7.21+/-0.13	209	219	O	7.21+/-0.13	.13	0.13	JJ	False
DDI-MedLine.d102.s6	,	220	220	O	,	,	,	,	False
DDI-MedLine.d102.s6	6.93+/-0.04	222	232	O	6.93+/-0.04	.04	0.04	JJ	False
DDI-MedLine.d102.s6	and	234	236	O	and	and	and	CC	False
DDI-MedLine.d102.s6	7.22+/-0.18	238	248	O	7.22+/-0.18	.18	0.18	JJ	False
DDI-MedLine.d102.s6	,	249	249	O	,	,	,	,	False
DDI-MedLine.d102.s6	respectively	251	262	O	respectively	ely	vely	RB	False
DDI-MedLine.d102.s6	)	263	263	O	)	)	)	)	False
DDI-MedLine.d102.s6	.	264	264	O	.	.	.	.	False

DDI-MedLine.d102.s7	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d102.s7	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d102.s7	no	11	12	O	no	no	no	DT	False
DDI-MedLine.d102.s7	significant	14	24	O	significant	ant	cant	JJ	False
DDI-MedLine.d102.s7	differences	26	36	O	differences	ces	nces	NNS	False
DDI-MedLine.d102.s7	among	38	42	O	among	ong	mong	IN	False
DDI-MedLine.d102.s7	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d102.s7	pD2	48	50	O	pD2	pD2	pD2	NN	False
DDI-MedLine.d102.s7	values	52	57	O	values	ues	lues	NNS	False
DDI-MedLine.d102.s7	for	59	61	O	for	for	for	IN	False
DDI-MedLine.d102.s7	noradrenaline	63	75	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d102.s7	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d102.s7	aortic	80	85	O	aortic	tic	rtic	JJ	False
DDI-MedLine.d102.s7	rings	87	91	O	rings	ngs	ings	NNS	False
DDI-MedLine.d102.s7	without	93	99	O	without	out	hout	IN	False
DDI-MedLine.d102.s7	endothelium	101	111	O	endothelium	ium	lium	NN	drug
DDI-MedLine.d102.s7	.	112	112	O	.	.	.	.	False

DDI-MedLine.d102.s8	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d102.s8	of	5	6	O	of	of	of	IN	False
DDI-MedLine.d102.s8	these	8	12	O	these	ese	hese	DT	False
DDI-MedLine.d102.s8	effects	14	20	O	effects	cts	ects	NNS	False
DDI-MedLine.d102.s8	were	22	25	O	were	ere	were	VBD	False
DDI-MedLine.d102.s8	endothelium-dependent	27	47	O	endothelium-dependent	ent	dent	NN	False
DDI-MedLine.d102.s8	.	48	48	O	.	.	.	.	False

DDI-MedLine.d121.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d121.s0	Hippocampus	1	11	O	Hippocampus	pus	mpus	NN	False
DDI-MedLine.d121.s0	as	13	14	O	as	as	as	IN	False
DDI-MedLine.d121.s0	interaction	16	26	O	interaction	ion	tion	NN	False
DDI-MedLine.d121.s0	sites	28	32	O	sites	tes	ites	NNS	False
DDI-MedLine.d121.s0	between	34	40	O	between	een	ween	IN	False
DDI-MedLine.d121.s0	cerebral	42	49	O	cerebral	ral	bral	JJ	False
DDI-MedLine.d121.s0	memory	51	56	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s0	systems	58	64	O	systems	ems	tems	NNS	False
DDI-MedLine.d121.s0	]	65	65	O	]	]	]	NN	False
DDI-MedLine.d121.s0	Most	67	70	O	Most	ost	Most	JJS	False
DDI-MedLine.d121.s0	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d121.s0	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d121.s0	current	79	85	O	current	ent	rent	JJ	False
DDI-MedLine.d121.s0	theories	87	94	O	theories	ies	ries	NNS	False
DDI-MedLine.d121.s0	assume	96	101	O	assume	ume	sume	VB	False
DDI-MedLine.d121.s0	that	103	106	O	that	hat	that	IN	False
DDI-MedLine.d121.s0	there	108	112	O	there	ere	here	RB	False
DDI-MedLine.d121.s0	are	114	116	O	are	are	are	VBP	False
DDI-MedLine.d121.s0	multiple	118	125	O	multiple	ple	iple	NN	False
DDI-MedLine.d121.s0	forms	127	131	O	forms	rms	orms	NNS	False
DDI-MedLine.d121.s0	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d121.s0	memory	136	141	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s0	that	143	146	O	that	hat	that	IN	False
DDI-MedLine.d121.s0	are	148	150	O	are	are	are	VBP	False
DDI-MedLine.d121.s0	supported	152	160	O	supported	ted	rted	VBN	False
DDI-MedLine.d121.s0	by	162	163	O	by	by	by	IN	False
DDI-MedLine.d121.s0	separate	165	172	O	separate	ate	rate	JJ	False
DDI-MedLine.d121.s0	brain	174	178	O	brain	ain	rain	NN	False
DDI-MedLine.d121.s0	systems	180	186	O	systems	ems	tems	NNS	False
DDI-MedLine.d121.s0	and	188	190	O	and	and	and	CC	False
DDI-MedLine.d121.s0	have	192	195	O	have	ave	have	VB	False
DDI-MedLine.d121.s0	different	197	205	O	different	ent	rent	JJ	False
DDI-MedLine.d121.s0	characteristics	207	221	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d121.s0	.	222	222	O	.	.	.	.	False

DDI-MedLine.d121.s1	Animals	0	6	O	Animals	als	mals	NNS	False
DDI-MedLine.d121.s1	studies	8	14	O	studies	ies	dies	NNS	False
DDI-MedLine.d121.s1	on	16	17	O	on	on	on	IN	False
DDI-MedLine.d121.s1	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d121.s1	various	23	29	O	various	ous	ious	JJ	False
DDI-MedLine.d121.s1	dual-memory	31	41	O	dual-memory	ory	mory	NN	False
DDI-MedLine.d121.s1	theories	43	50	O	theories	ies	ries	NNS	False
DDI-MedLine.d121.s1	have	52	55	O	have	ave	have	VB	False
DDI-MedLine.d121.s1	been	57	60	O	been	een	been	VBN	False
DDI-MedLine.d121.s1	carried	62	68	O	carried	ied	ried	VBN	False
DDI-MedLine.d121.s1	out	70	72	O	out	out	out	IN	False
DDI-MedLine.d121.s1	mainly	74	79	O	mainly	nly	inly	RB	False
DDI-MedLine.d121.s1	on	81	82	O	on	on	on	IN	False
DDI-MedLine.d121.s1	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d121.s1	basis	88	92	O	basis	sis	asis	NN	False
DDI-MedLine.d121.s1	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d121.s1	hippocampal	97	107	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d121.s1	system	109	114	O	system	tem	stem	NN	False
DDI-MedLine.d121.s1	function	116	123	O	function	ion	tion	NN	False
DDI-MedLine.d121.s1	.	124	124	O	.	.	.	.	False

DDI-MedLine.d121.s2	Specifically	0	11	O	Specifically	lly	ally	RB	False
DDI-MedLine.d121.s2	,	12	12	O	,	,	,	,	False
DDI-MedLine.d121.s2	they	14	17	O	they	hey	they	PRP	False
DDI-MedLine.d121.s2	have	19	22	O	have	ave	have	VB	False
DDI-MedLine.d121.s2	focused	24	30	O	focused	sed	used	VBN	False
DDI-MedLine.d121.s2	on	32	33	O	on	on	on	IN	False
DDI-MedLine.d121.s2	aspects	35	41	O	aspects	cts	ects	NNS	False
DDI-MedLine.d121.s2	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d121.s2	learning	46	53	O	learning	ing	ning	VBG	False
DDI-MedLine.d121.s2	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d121.s2	memory	59	64	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s2	that	66	69	O	that	hat	that	IN	False
DDI-MedLine.d121.s2	are	71	73	O	are	are	are	VBP	False
DDI-MedLine.d121.s2	impaired	75	82	O	impaired	red	ired	JJ	False
DDI-MedLine.d121.s2	(	84	84	O	(	(	(	(	False
DDI-MedLine.d121.s2	vs.	85	87	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d121.s2	spared	89	94	O	spared	red	ared	VBN	False
DDI-MedLine.d121.s2	)	95	95	O	)	)	)	)	False
DDI-MedLine.d121.s2	by	97	98	O	by	by	by	IN	False
DDI-MedLine.d121.s2	lesions	100	106	O	lesions	ons	ions	NNS	False
DDI-MedLine.d121.s2	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d121.s2	the	111	113	O	the	the	the	DT	False
DDI-MedLine.d121.s2	hippocampal	115	125	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d121.s2	formation	127	135	O	formation	ion	tion	NN	False
DDI-MedLine.d121.s2	.	136	136	O	.	.	.	.	False

DDI-MedLine.d121.s3	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d121.s3	,	7	7	O	,	,	,	,	False
DDI-MedLine.d121.s3	there	9	13	O	there	ere	here	RB	False
DDI-MedLine.d121.s3	are	15	17	O	are	are	are	VBP	False
DDI-MedLine.d121.s3	several	19	25	O	several	ral	eral	JJ	False
DDI-MedLine.d121.s3	instances	27	35	O	instances	ces	nces	NNS	False
DDI-MedLine.d121.s3	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d121.s3	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d121.s3	animal	44	49	O	animal	mal	imal	NN	False
DDI-MedLine.d121.s3	literature	51	60	O	literature	ure	ture	NN	False
DDI-MedLine.d121.s3	showing	62	68	O	showing	ing	wing	VBG	False
DDI-MedLine.d121.s3	that	70	73	O	that	hat	that	IN	False
DDI-MedLine.d121.s3	hippocampal	75	85	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d121.s3	lesions	87	93	O	lesions	ons	ions	NNS	False
DDI-MedLine.d121.s3	actually	95	102	O	actually	lly	ally	RB	False
DDI-MedLine.d121.s3	produced	104	111	O	produced	ced	uced	VBN	False
DDI-MedLine.d121.s3	enhanced	113	120	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d121.s3	learning	122	129	O	learning	ing	ning	VBG	False
DDI-MedLine.d121.s3	and	131	133	O	and	and	and	CC	False
DDI-MedLine.d121.s3	memory	135	140	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s3	function	142	149	O	function	ion	tion	NN	False
DDI-MedLine.d121.s3	.	150	150	O	.	.	.	.	False

DDI-MedLine.d121.s4	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d121.s4	,	8	8	O	,	,	,	,	False
DDI-MedLine.d121.s4	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d121.s4	acquisition	14	24	O	acquisition	ion	tion	NN	False
DDI-MedLine.d121.s4	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d121.s4	tasks	29	33	O	tasks	sks	asks	NNS	False
DDI-MedLine.d121.s4	that	35	38	O	that	hat	that	IN	False
DDI-MedLine.d121.s4	are	40	42	O	are	are	are	VBP	False
DDI-MedLine.d121.s4	facilitated	44	54	O	facilitated	ted	ated	VBN	False
DDI-MedLine.d121.s4	by	56	57	O	by	by	by	IN	False
DDI-MedLine.d121.s4	hippocampal	59	69	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d121.s4	lesions	71	77	O	lesions	ons	ions	NNS	False
DDI-MedLine.d121.s4	(	79	79	O	(	(	(	(	False
DDI-MedLine.d121.s4	or	80	81	O	or	or	or	CC	False
DDI-MedLine.d121.s4	dysfunction	83	93	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d121.s4	)	94	94	O	)	)	)	)	False
DDI-MedLine.d121.s4	is	96	97	O	is	is	is	VBZ	False
DDI-MedLine.d121.s4	nevertheless	99	110	O	nevertheless	ess	less	RB	False
DDI-MedLine.d121.s4	associated	112	121	O	associated	ted	ated	VBN	False
DDI-MedLine.d121.s4	,	122	122	O	,	,	,	,	False
DDI-MedLine.d121.s4	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d121.s4	intact	127	132	O	intact	act	tact	JJ	False
DDI-MedLine.d121.s4	subjects	134	141	O	subjects	cts	ects	NNS	False
DDI-MedLine.d121.s4	,	142	142	O	,	,	,	,	False
DDI-MedLine.d121.s4	with	144	147	O	with	ith	with	IN	False
DDI-MedLine.d121.s4	specific	149	156	O	specific	fic	ific	JJ	False
DDI-MedLine.d121.s4	neurobiological	158	172	O	neurobiological	cal	ical	JJ	False
DDI-MedLine.d121.s4	alterations	174	184	O	alterations	ons	ions	NNS	False
DDI-MedLine.d121.s4	in	186	187	O	in	in	in	IN	False
DDI-MedLine.d121.s4	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d121.s4	hippocampus	193	203	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d121.s4	.	204	204	O	.	.	.	.	False

DDI-MedLine.d121.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d121.s5	problem	5	11	O	problem	lem	blem	NN	False
DDI-MedLine.d121.s5	has	13	15	O	has	has	has	VBZ	False
DDI-MedLine.d121.s5	been	17	20	O	been	een	been	VBN	False
DDI-MedLine.d121.s5	analysed	22	29	O	analysed	sed	ysed	VBN	False
DDI-MedLine.d121.s5	using	31	35	O	using	ing	sing	VBG	False
DDI-MedLine.d121.s5	two	37	39	O	two	two	two	CD	False
DDI-MedLine.d121.s5	different	41	49	O	different	ent	rent	JJ	False
DDI-MedLine.d121.s5	tasks	51	55	O	tasks	sks	asks	NNS	False
DDI-MedLine.d121.s5	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d121.s5	mice	60	63	O	mice	ice	mice	NN	False
DDI-MedLine.d121.s5	:	64	64	O	:	:	:	:	False
DDI-MedLine.d121.s5	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d121.s5	bar-press	68	76	O	bar-press	ess	ress	NN	False
DDI-MedLine.d121.s5	conditioning	78	89	O	conditioning	ing	ning	NN	False
DDI-MedLine.d121.s5	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d121.s5	a	95	95	O	a	a	a	DT	False
DDI-MedLine.d121.s5	spatial	97	103	O	spatial	ial	tial	JJ	False
DDI-MedLine.d121.s5	discrimination	105	118	O	discrimination	ion	tion	NN	False
DDI-MedLine.d121.s5	task	120	123	O	task	ask	task	NN	False
DDI-MedLine.d121.s5	.	124	124	O	.	.	.	.	False

DDI-MedLine.d121.s6	Results	0	6	O	Results	lts	ults	NNS	False
DDI-MedLine.d121.s6	showed	8	13	O	showed	wed	owed	VBD	False
DDI-MedLine.d121.s6	that	15	18	O	that	hat	that	IN	False
DDI-MedLine.d121.s6	,	19	19	O	,	,	,	,	False
DDI-MedLine.d121.s6	depending	21	29	O	depending	ing	ding	VBG	False
DDI-MedLine.d121.s6	on	31	32	O	on	on	on	IN	False
DDI-MedLine.d121.s6	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d121.s6	task	38	41	O	task	ask	task	NN	False
DDI-MedLine.d121.s6	considered	43	52	O	considered	red	ered	VBN	False
DDI-MedLine.d121.s6	,	53	53	O	,	,	,	,	False
DDI-MedLine.d121.s6	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d121.s6	same	59	62	O	same	ame	same	JJ	False
DDI-MedLine.d121.s6	pharmacological	64	78	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d121.s6	treatment	80	88	O	treatment	ent	ment	NN	False
DDI-MedLine.d121.s6	produced	90	97	O	produced	ced	uced	VBN	False
DDI-MedLine.d121.s6	either	99	104	O	either	her	ther	DT	False
DDI-MedLine.d121.s6	a	106	106	O	a	a	a	DT	False
DDI-MedLine.d121.s6	facilitation	108	119	O	facilitation	ion	tion	NN	False
DDI-MedLine.d121.s6	or	121	122	O	or	or	or	CC	False
DDI-MedLine.d121.s6	an	124	125	O	an	an	an	DT	False
DDI-MedLine.d121.s6	impairment	127	136	O	impairment	ent	ment	NN	False
DDI-MedLine.d121.s6	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d121.s6	acquisition	141	151	O	acquisition	ion	tion	NN	False
DDI-MedLine.d121.s6	.	152	152	O	.	.	.	.	False

DDI-MedLine.d121.s7	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d121.s7	,	8	8	O	,	,	,	,	False
DDI-MedLine.d121.s7	each	10	13	O	each	ach	each	DT	False
DDI-MedLine.d121.s7	task	15	18	O	task	ask	task	NN	False
DDI-MedLine.d121.s7	induced	20	26	O	induced	ced	uced	JJ	False
DDI-MedLine.d121.s7	significant	28	38	O	significant	ant	cant	JJ	False
DDI-MedLine.d121.s7	alterations	40	50	O	alterations	ons	ions	NNS	False
DDI-MedLine.d121.s7	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d121.s7	hippocampal	55	65	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d121.s7	adenylate	67	75	O	adenylate	ate	late	NN	False
DDI-MedLine.d121.s7	cyclase	77	83	O	cyclase	ase	lase	NN	False
DDI-MedLine.d121.s7	activity	85	92	O	activity	ity	vity	NN	False
DDI-MedLine.d121.s7	but	94	96	O	but	but	but	CC	False
DDI-MedLine.d121.s7	in	98	99	O	in	in	in	IN	False
DDI-MedLine.d121.s7	opposite	101	108	O	opposite	ite	site	NN	False
DDI-MedLine.d121.s7	directions	110	119	O	directions	ons	ions	NNS	False
DDI-MedLine.d121.s7	.	120	120	O	.	.	.	.	False

DDI-MedLine.d121.s8	Together	0	7	O	Together	her	ther	RB	False
DDI-MedLine.d121.s8	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d121.s8	previous	14	21	O	previous	ous	ious	JJ	False
DDI-MedLine.d121.s8	findings	23	30	O	findings	ngs	ings	NNS	False
DDI-MedLine.d121.s8	,	31	31	O	,	,	,	,	False
DDI-MedLine.d121.s8	these	33	37	O	these	ese	hese	DT	False
DDI-MedLine.d121.s8	results	39	45	O	results	lts	ults	NNS	False
DDI-MedLine.d121.s8	suggest	47	53	O	suggest	est	gest	NN	False
DDI-MedLine.d121.s8	that	55	58	O	that	hat	that	IN	False
DDI-MedLine.d121.s8	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d121.s8	hippocampus	64	74	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d121.s8	is	76	77	O	is	is	is	VBZ	False
DDI-MedLine.d121.s8	involved	79	86	O	involved	ved	lved	VBN	False
DDI-MedLine.d121.s8	in	88	89	O	in	in	in	IN	False
DDI-MedLine.d121.s8	both	91	94	O	both	oth	both	DT	False
DDI-MedLine.d121.s8	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d121.s8	so-called	100	108	O	so-called	led	lled	JJ	False
DDI-MedLine.d121.s8	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d121.s8	hippocampal-dependent	111	131	O	hippocampal-dependent	ent	dent	NN	False
DDI-MedLine.d121.s8	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d121.s9	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d121.s9	hippocampal-independent	1	23	O	hippocampal-independent	ent	dent	NN	False
DDI-MedLine.d121.s9	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d121.s10	forms	0	4	O	forms	rms	orms	NNS	False
DDI-MedLine.d121.s10	of	6	7	O	of	of	of	IN	False
DDI-MedLine.d121.s10	memory	9	14	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s10	.	15	15	O	.	.	.	.	False

DDI-MedLine.d121.s11	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d121.s11	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d121.s11	postulated	6	15	O	postulated	ted	ated	VBN	False
DDI-MedLine.d121.s11	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d121.s11	some	22	25	O	some	ome	some	DT	False
DDI-MedLine.d121.s11	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d121.s11	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d121.s11	observed	34	41	O	observed	ved	rved	VBN	False
DDI-MedLine.d121.s11	training-induced	43	58	O	training-induced	ced	uced	JJ	False
DDI-MedLine.d121.s11	neurobiological	60	74	O	neurobiological	cal	ical	JJ	False
DDI-MedLine.d121.s11	alterations	76	86	O	alterations	ons	ions	NNS	False
DDI-MedLine.d121.s11	might	88	92	O	might	ght	ight	MD	False
DDI-MedLine.d121.s11	reflect	94	100	O	reflect	ect	lect	NN	False
DDI-MedLine.d121.s11	the	102	104	O	the	the	the	DT	False
DDI-MedLine.d121.s11	interaction	106	116	O	interaction	ion	tion	NN	False
DDI-MedLine.d121.s11	between	118	124	O	between	een	ween	IN	False
DDI-MedLine.d121.s11	two	126	128	O	two	two	two	CD	False
DDI-MedLine.d121.s11	(	130	130	O	(	(	(	(	False
DDI-MedLine.d121.s11	or	131	132	O	or	or	or	CC	False
DDI-MedLine.d121.s11	more	134	137	O	more	ore	more	RBR	False
DDI-MedLine.d121.s11	)	138	138	O	)	)	)	)	False
DDI-MedLine.d121.s11	competing	140	148	O	competing	ing	ting	VBG	False
DDI-MedLine.d121.s11	memory	150	155	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s11	systems	157	163	O	systems	ems	tems	NNS	False
DDI-MedLine.d121.s11	at	165	166	O	at	at	at	IN	False
DDI-MedLine.d121.s11	the	168	170	O	the	the	the	DT	False
DDI-MedLine.d121.s11	hippocampal	172	182	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d121.s11	level	184	188	O	level	vel	evel	NN	False
DDI-MedLine.d121.s11	.	189	189	O	.	.	.	.	False

DDI-MedLine.d121.s12	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d121.s12	,	4	4	O	,	,	,	,	False
DDI-MedLine.d121.s12	in	6	7	O	in	in	in	IN	False
DDI-MedLine.d121.s12	addition	9	16	O	addition	ion	tion	NN	False
DDI-MedLine.d121.s12	to	18	19	O	to	to	to	TO	False
DDI-MedLine.d121.s12	its	21	23	O	its	its	its	PRP$	False
DDI-MedLine.d121.s12	proposed	25	32	O	proposed	sed	osed	VBN	False
DDI-MedLine.d121.s12	specific	34	41	O	specific	fic	ific	JJ	False
DDI-MedLine.d121.s12	information	43	53	O	information	ion	tion	NN	False
DDI-MedLine.d121.s12	processing	55	64	O	processing	ing	sing	NN	False
DDI-MedLine.d121.s12	functions	66	74	O	functions	ons	ions	NNS	False
DDI-MedLine.d121.s12	(	76	76	O	(	(	(	(	False
DDI-MedLine.d121.s12	i.e.	77	80	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d121.s12	,	81	81	O	,	,	,	,	False
DDI-MedLine.d121.s12	relational	83	92	O	relational	nal	onal	NN	False
DDI-MedLine.d121.s12	)	93	93	O	)	)	)	)	False
DDI-MedLine.d121.s12	,	94	94	O	,	,	,	,	False
DDI-MedLine.d121.s12	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d121.s12	hippocampus	100	110	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d121.s12	would	112	116	O	would	uld	ould	MD	False
DDI-MedLine.d121.s12	play	118	121	O	play	lay	play	NN	False
DDI-MedLine.d121.s12	a	123	123	O	a	a	a	DT	False
DDI-MedLine.d121.s12	role	125	128	O	role	ole	role	NN	False
DDI-MedLine.d121.s12	in	130	131	O	in	in	in	IN	False
DDI-MedLine.d121.s12	addressing	133	142	O	addressing	ing	sing	VBG	False
DDI-MedLine.d121.s12	information	144	154	O	information	ion	tion	NN	False
DDI-MedLine.d121.s12	to	156	157	O	to	to	to	TO	False
DDI-MedLine.d121.s12	the	159	161	O	the	the	the	DT	False
DDI-MedLine.d121.s12	brain	163	167	O	brain	ain	rain	NN	False
DDI-MedLine.d121.s12	memory	169	174	O	memory	ory	mory	NN	False
DDI-MedLine.d121.s12	system	176	181	O	system	tem	stem	NN	False
DDI-MedLine.d121.s12	that	183	186	O	that	hat	that	IN	False
DDI-MedLine.d121.s12	,	187	187	O	,	,	,	,	False
DDI-MedLine.d121.s12	in	189	190	O	in	in	in	IN	False
DDI-MedLine.d121.s12	a	192	192	O	a	a	a	DT	False
DDI-MedLine.d121.s12	given	194	198	O	given	ven	iven	VBN	False
DDI-MedLine.d121.s12	situation	200	208	O	situation	ion	tion	NN	False
DDI-MedLine.d121.s12	,	209	209	O	,	,	,	,	False
DDI-MedLine.d121.s12	has	211	213	O	has	has	has	VBZ	False
DDI-MedLine.d121.s12	the	215	217	O	the	the	the	DT	False
DDI-MedLine.d121.s12	best	219	222	O	best	est	best	JJS	False
DDI-MedLine.d121.s12	adaptive	224	231	O	adaptive	ive	tive	JJ	False
DDI-MedLine.d121.s12	value	233	237	O	value	lue	alue	NN	False
DDI-MedLine.d121.s12	.	238	238	O	.	.	.	.	False
DDI-MedLine.d121.s12	(	239	239	O	(	(	(	(	False
DDI-MedLine.d121.s12	ABSTRACT	240	247	O	ABSTRACT	ACT	RACT	NN	brand
DDI-MedLine.d121.s12	TRUNCATED	249	257	O	TRUNCATED	TED	ATED	NN	brand
DDI-MedLine.d121.s12	AT	259	260	O	AT	AT	AT	NN	brand
DDI-MedLine.d121.s12	250	262	264	O	250	250	250	CD	False
DDI-MedLine.d121.s12	WORDS	266	270	O	WORDS	RDS	ORDS	NN	brand
DDI-MedLine.d121.s12	)	271	271	O	)	)	)	)	False

DDI-MedLine.d125.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d125.s0	mode	4	7	O	mode	ode	mode	NN	False
DDI-MedLine.d125.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d125.s0	toxic	12	16	O	toxic	xic	oxic	NN	False
DDI-MedLine.d125.s0	action	18	23	O	action	ion	tion	NN	False
DDI-MedLine.d125.s0	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d125.s0	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d125.s0	pesticide	32	40	O	pesticide	ide	cide	NN	False
DDI-MedLine.d125.s0	gliftor	42	48	B-drug_n	gliftor	tor	ftor	NN	False
DDI-MedLine.d125.s0	:	49	49	O	:	:	:	:	False
DDI-MedLine.d125.s0	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d125.s0	metabolism	55	64	O	metabolism	ism	lism	NN	False
DDI-MedLine.d125.s0	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d125.s0	1,3-difluoroacetone	69	87	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s0	to	89	90	O	to	to	to	TO	False
DDI-MedLine.d125.s0	(	92	92	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s0	-	93	93	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s0	)	94	94	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s0	-erythro-fluorocitrate	95	116	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s0	.	117	117	O	.	.	.	.	False

DDI-MedLine.d125.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d125.s1	biochemical	4	14	O	biochemical	cal	ical	JJ	False
DDI-MedLine.d125.s1	toxicology	16	25	O	toxicology	ogy	logy	NN	False
DDI-MedLine.d125.s1	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d125.s1	1,3-difluoroacetone	30	48	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s1	,	49	49	O	,	,	,	,	False
DDI-MedLine.d125.s1	a	51	51	O	a	a	a	DT	False
DDI-MedLine.d125.s1	known	53	57	O	known	own	nown	VBN	False
DDI-MedLine.d125.s1	metabolite	59	68	O	metabolite	ite	lite	NN	False
DDI-MedLine.d125.s1	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d125.s1	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d125.s1	major	77	81	O	major	jor	ajor	JJ	False
DDI-MedLine.d125.s1	ingredient	83	92	O	ingredient	ent	ient	NN	False
DDI-MedLine.d125.s1	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d125.s1	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d125.s1	pesticide	101	109	O	pesticide	ide	cide	NN	False
DDI-MedLine.d125.s1	Gliftor	111	117	B-drug_n	Gliftor	tor	ftor	NN	False
DDI-MedLine.d125.s1	(	119	119	O	(	(	(	(	False
DDI-MedLine.d125.s1	1,3-difluoro-2-propanol	120	142	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s1	)	143	143	O	)	)	)	)	False
DDI-MedLine.d125.s1	,	144	144	O	,	,	,	,	False
DDI-MedLine.d125.s1	was	146	148	O	was	was	was	VBD	False
DDI-MedLine.d125.s1	investigated	150	161	O	investigated	ted	ated	VBN	False
DDI-MedLine.d125.s1	in	163	164	O	in	in	in	IN	False
DDI-MedLine.d125.s1	vivo	166	169	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d125.s1	and	171	173	O	and	and	and	CC	False
DDI-MedLine.d125.s1	in	175	176	O	in	in	in	IN	False
DDI-MedLine.d125.s1	vitro	178	182	O	vitro	tro	itro	NN	False
DDI-MedLine.d125.s1	.	183	183	O	.	.	.	.	False

DDI-MedLine.d125.s2	Rat	0	2	O	Rat	Rat	Rat	NN	False
DDI-MedLine.d125.s2	kidney	4	9	O	kidney	ney	dney	NN	False
DDI-MedLine.d125.s2	homogenates	11	21	O	homogenates	tes	ates	NNS	False
DDI-MedLine.d125.s2	supplemented	23	34	O	supplemented	ted	nted	VBN	False
DDI-MedLine.d125.s2	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d125.s2	coenzyme	41	48	O	coenzyme	yme	zyme	NN	False
DDI-MedLine.d125.s2	A	50	50	O	A	A	A	DT	brand
DDI-MedLine.d125.s2	,	51	51	O	,	,	,	,	False
DDI-MedLine.d125.s2	ATP	53	55	O	ATP	ATP	ATP	NN	brand
DDI-MedLine.d125.s2	,	56	56	O	,	,	,	,	False
DDI-MedLine.d125.s2	oxaloacetate	58	69	O	oxaloacetate	ate	tate	NN	False
DDI-MedLine.d125.s2	,	70	70	O	,	,	,	,	False
DDI-MedLine.d125.s2	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d125.s2	Mg2+	76	79	O	Mg2+	g2+	Mg2+	NN	False
DDI-MedLine.d125.s2	converted	81	89	O	converted	ted	rted	VBN	False
DDI-MedLine.d125.s2	1,3-difluoroacetone	91	109	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s2	to	111	112	O	to	to	to	TO	False
DDI-MedLine.d125.s2	(	114	114	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s2	-	115	115	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s2	)	116	116	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s2	-erythro-fluorocitrate	117	138	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s2	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d125.s2	vitro	143	147	O	vitro	tro	itro	NN	False
DDI-MedLine.d125.s2	.	148	148	O	.	.	.	.	False

DDI-MedLine.d125.s3	Administration	0	13	O	Administration	ion	tion	NN	False
DDI-MedLine.d125.s3	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d125.s3	1,3-difluoroacetone	18	36	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s3	(	38	38	O	(	(	(	(	False
DDI-MedLine.d125.s3	100	39	41	O	100	100	100	CD	False
DDI-MedLine.d125.s3	mg	43	44	O	mg	mg	mg	NN	False
DDI-MedLine.d125.s3	kg	46	47	O	kg	kg	kg	NN	False
DDI-MedLine.d125.s3	(	48	48	O	(	(	(	(	False
DDI-MedLine.d125.s3	-1	49	50	O	-1	-1	-1	NN	False
DDI-MedLine.d125.s3	)	51	51	O	)	)	)	)	False
DDI-MedLine.d125.s3	body	53	56	O	body	ody	body	NN	False
DDI-MedLine.d125.s3	weight	58	63	O	weight	ght	ight	NN	False
DDI-MedLine.d125.s3	)	64	64	O	)	)	)	)	False
DDI-MedLine.d125.s3	to	66	67	O	to	to	to	TO	False
DDI-MedLine.d125.s3	rats	69	72	O	rats	ats	rats	NNS	False
DDI-MedLine.d125.s3	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d125.s3	vivo	77	80	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d125.s3	resulted	82	89	O	resulted	ted	lted	VBD	False
DDI-MedLine.d125.s3	in	91	92	O	in	in	in	IN	False
DDI-MedLine.d125.s3	(	94	94	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s3	-	95	95	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s3	)	96	96	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s3	-erythro-fluorocitrate	97	118	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s3	synthesis	120	128	O	synthesis	sis	esis	NN	False
DDI-MedLine.d125.s3	in	130	131	O	in	in	in	IN	False
DDI-MedLine.d125.s3	the	133	135	O	the	the	the	DT	False
DDI-MedLine.d125.s3	kidney	137	142	O	kidney	ney	dney	NN	False
DDI-MedLine.d125.s3	,	143	143	O	,	,	,	,	False
DDI-MedLine.d125.s3	which	145	149	O	which	ich	hich	WDT	False
DDI-MedLine.d125.s3	was	151	153	O	was	was	was	VBD	False
DDI-MedLine.d125.s3	preceded	155	162	O	preceded	ded	eded	VBN	False
DDI-MedLine.d125.s3	by	164	165	O	by	by	by	IN	False
DDI-MedLine.d125.s3	an	167	168	O	an	an	an	DT	False
DDI-MedLine.d125.s3	elevation	170	178	O	elevation	ion	tion	NN	False
DDI-MedLine.d125.s3	in	180	181	O	in	in	in	IN	False
DDI-MedLine.d125.s3	fluoride	183	190	O	fluoride	ide	ride	NN	False
DDI-MedLine.d125.s3	levels	192	197	O	levels	els	vels	NNS	False
DDI-MedLine.d125.s3	and	199	201	O	and	and	and	CC	False
DDI-MedLine.d125.s3	followed	203	210	O	followed	wed	owed	VBD	False
DDI-MedLine.d125.s3	by	212	213	O	by	by	by	IN	False
DDI-MedLine.d125.s3	citrate	215	221	O	citrate	ate	rate	NN	False
DDI-MedLine.d125.s3	accumulation	223	234	O	accumulation	ion	tion	NN	False
DDI-MedLine.d125.s3	.	235	235	O	.	.	.	.	False

DDI-MedLine.d125.s4	Animals	0	6	O	Animals	als	mals	NNS	False
DDI-MedLine.d125.s4	dosed	8	12	O	dosed	sed	osed	VBN	False
DDI-MedLine.d125.s4	with	14	17	O	with	ith	with	IN	False
DDI-MedLine.d125.s4	1,3-difluoroacetone	19	37	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s4	did	39	41	O	did	did	did	VBD	False
DDI-MedLine.d125.s4	not	43	45	O	not	not	not	RB	False
DDI-MedLine.d125.s4	display	47	53	O	display	lay	play	NN	False
DDI-MedLine.d125.s4	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d125.s4	2-3	59	61	O	2-3	2-3	2-3	JJ	False
DDI-MedLine.d125.s4	hour	63	66	O	hour	our	hour	NN	False
DDI-MedLine.d125.s4	lag	68	70	O	lag	lag	lag	NN	False
DDI-MedLine.d125.s4	phase	72	76	O	phase	ase	hase	NN	False
DDI-MedLine.d125.s4	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d125.s4	either	81	86	O	either	her	ther	DT	False
DDI-MedLine.d125.s4	(	88	88	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s4	-	89	89	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s4	)	90	90	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s4	-erythro-fluorocitrate	91	112	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s4	synthesis	114	122	O	synthesis	sis	esis	NN	False
DDI-MedLine.d125.s4	or	124	125	O	or	or	or	CC	False
DDI-MedLine.d125.s4	in	127	128	O	in	in	in	IN	False
DDI-MedLine.d125.s4	citrate	130	136	O	citrate	ate	rate	NN	False
DDI-MedLine.d125.s4	and	138	140	O	and	and	and	CC	False
DDI-MedLine.d125.s4	fluoride	142	149	O	fluoride	ide	ride	NN	False
DDI-MedLine.d125.s4	accumulation	151	162	O	accumulation	ion	tion	NN	False
DDI-MedLine.d125.s4	characteristic	164	177	O	characteristic	tic	stic	JJ	False
DDI-MedLine.d125.s4	of	179	180	O	of	of	of	IN	False
DDI-MedLine.d125.s4	animals	182	188	O	animals	als	mals	NNS	False
DDI-MedLine.d125.s4	dosed	190	194	O	dosed	sed	osed	VBN	False
DDI-MedLine.d125.s4	with	196	199	O	with	ith	with	IN	False
DDI-MedLine.d125.s4	1,3-difluoro-2-propanol	201	223	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s4	.	224	224	O	.	.	.	.	False

DDI-MedLine.d125.s5	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d125.s5	demonstrate	3	13	O	demonstrate	ate	rate	NN	False
DDI-MedLine.d125.s5	that	15	18	O	that	hat	that	IN	False
DDI-MedLine.d125.s5	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d125.s5	conversion	24	33	O	conversion	ion	sion	NN	False
DDI-MedLine.d125.s5	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d125.s5	1,3-difluoro-2-propanol	38	60	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s5	to	62	63	O	to	to	to	TO	False
DDI-MedLine.d125.s5	1,3-difluoroacetone	65	83	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s5	by	85	86	O	by	by	by	IN	False
DDI-MedLine.d125.s5	an	88	89	O	an	an	an	DT	False
DDI-MedLine.d125.s5	NAD+-dependent	91	104	O	NAD+-dependent	ent	dent	NN	False
DDI-MedLine.d125.s5	oxidation	106	114	O	oxidation	ion	tion	NN	False
DDI-MedLine.d125.s5	is	116	117	O	is	is	is	VBZ	False
DDI-MedLine.d125.s5	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d125.s5	rate-limiting	123	135	O	rate-limiting	ing	ting	NN	False
DDI-MedLine.d125.s5	step	137	140	O	step	tep	step	NN	False
DDI-MedLine.d125.s5	in	142	143	O	in	in	in	IN	False
DDI-MedLine.d125.s5	the	145	147	O	the	the	the	DT	False
DDI-MedLine.d125.s5	synthesis	149	157	O	synthesis	sis	esis	NN	False
DDI-MedLine.d125.s5	of	159	160	O	of	of	of	IN	False
DDI-MedLine.d125.s5	the	162	164	O	the	the	the	DT	False
DDI-MedLine.d125.s5	toxic	166	170	O	toxic	xic	oxic	NN	False
DDI-MedLine.d125.s5	product	172	178	O	product	uct	duct	NN	False
DDI-MedLine.d125.s5	,	179	179	O	,	,	,	,	False
DDI-MedLine.d125.s5	(	181	181	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s5	-	182	182	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s5	)	183	183	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s5	-erythro-fluorocitrate	184	205	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s5	from	207	210	O	from	rom	from	IN	False
DDI-MedLine.d125.s5	1,3-difluoro-2-propanol	212	234	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s5	.	235	235	O	.	.	.	.	False

DDI-MedLine.d125.s6	Prior	0	4	O	Prior	ior	rior	RB	False
DDI-MedLine.d125.s6	administration	6	19	O	administration	ion	tion	NN	False
DDI-MedLine.d125.s6	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d125.s6	4-methylpyrazole	24	39	B-drug	4-methylpyrazole	ole	zole	JJ	drug
DDI-MedLine.d125.s6	(	41	41	O	(	(	(	(	False
DDI-MedLine.d125.s6	90	42	43	O	90	90	90	CD	False
DDI-MedLine.d125.s6	mg	45	46	O	mg	mg	mg	NN	False
DDI-MedLine.d125.s6	kg	48	49	O	kg	kg	kg	NN	False
DDI-MedLine.d125.s6	(	50	50	O	(	(	(	(	False
DDI-MedLine.d125.s6	-1	51	52	O	-1	-1	-1	NN	False
DDI-MedLine.d125.s6	)	53	53	O	)	)	)	)	False
DDI-MedLine.d125.s6	body	55	58	O	body	ody	body	NN	False
DDI-MedLine.d125.s6	weight	60	65	O	weight	ght	ight	NN	False
DDI-MedLine.d125.s6	)	66	66	O	)	)	)	)	False
DDI-MedLine.d125.s6	was	68	70	O	was	was	was	VBD	False
DDI-MedLine.d125.s6	shown	72	76	O	shown	own	hown	VBN	False
DDI-MedLine.d125.s6	to	78	79	O	to	to	to	TO	False
DDI-MedLine.d125.s6	prevent	81	87	O	prevent	ent	vent	NN	False
DDI-MedLine.d125.s6	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d125.s6	conversion	93	102	O	conversion	ion	sion	NN	False
DDI-MedLine.d125.s6	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d125.s6	1,3-difluoro-2-propanol	107	129	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s6	(	131	131	O	(	(	(	(	False
DDI-MedLine.d125.s6	100	132	134	O	100	100	100	CD	False
DDI-MedLine.d125.s6	mg	136	137	O	mg	mg	mg	NN	False
DDI-MedLine.d125.s6	kg	139	140	O	kg	kg	kg	NN	False
DDI-MedLine.d125.s6	(	141	141	O	(	(	(	(	False
DDI-MedLine.d125.s6	-1	142	143	O	-1	-1	-1	NN	False
DDI-MedLine.d125.s6	)	144	144	O	)	)	)	)	False
DDI-MedLine.d125.s6	body	146	149	O	body	ody	body	NN	False
DDI-MedLine.d125.s6	weight	151	156	O	weight	ght	ight	NN	False
DDI-MedLine.d125.s6	)	157	157	O	)	)	)	)	False
DDI-MedLine.d125.s6	to	159	160	O	to	to	to	TO	False
DDI-MedLine.d125.s6	(	162	162	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s6	-	163	163	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s6	)	164	164	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s6	-erythro-fluorocitrate	165	186	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s6	in	188	189	O	in	in	in	IN	False
DDI-MedLine.d125.s6	vivo	191	194	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d125.s6	and	196	198	O	and	and	and	CC	False
DDI-MedLine.d125.s6	to	200	201	O	to	to	to	TO	False
DDI-MedLine.d125.s6	eliminate	203	211	O	eliminate	ate	nate	NN	False
DDI-MedLine.d125.s6	the	213	215	O	the	the	the	DT	False
DDI-MedLine.d125.s6	fluoride	217	224	O	fluoride	ide	ride	NN	False
DDI-MedLine.d125.s6	and	226	228	O	and	and	and	CC	False
DDI-MedLine.d125.s6	citrate	230	236	O	citrate	ate	rate	NN	False
DDI-MedLine.d125.s6	elevations	238	247	O	elevations	ons	ions	NNS	False
DDI-MedLine.d125.s6	seen	249	252	O	seen	een	seen	VBN	False
DDI-MedLine.d125.s6	in	254	255	O	in	in	in	IN	False
DDI-MedLine.d125.s6	1,3-difluoro-2-propanol-intoxicated	257	291	O	1,3-difluoro-2-propanol-intoxicated	ted	ated	JJ	False
DDI-MedLine.d125.s6	animals	293	299	O	animals	als	mals	NNS	False
DDI-MedLine.d125.s6	.	300	300	O	.	.	.	.	False

DDI-MedLine.d125.s7	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d125.s7	,	7	7	O	,	,	,	,	False
DDI-MedLine.d125.s7	administration	9	22	O	administration	ion	tion	NN	False
DDI-MedLine.d125.s7	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d125.s7	4-methylpyrazole	27	42	B-drug	4-methylpyrazole	ole	zole	JJ	drug
DDI-MedLine.d125.s7	(	44	44	O	(	(	(	(	False
DDI-MedLine.d125.s7	90	45	46	O	90	90	90	CD	False
DDI-MedLine.d125.s7	mg	48	49	O	mg	mg	mg	NN	False
DDI-MedLine.d125.s7	kg	51	52	O	kg	kg	kg	NN	False
DDI-MedLine.d125.s7	(	53	53	O	(	(	(	(	False
DDI-MedLine.d125.s7	-1	54	55	O	-1	-1	-1	NN	False
DDI-MedLine.d125.s7	)	56	56	O	)	)	)	)	False
DDI-MedLine.d125.s7	body	58	61	O	body	ody	body	NN	False
DDI-MedLine.d125.s7	weight	63	68	O	weight	ght	ight	NN	False
DDI-MedLine.d125.s7	)	69	69	O	)	)	)	)	False
DDI-MedLine.d125.s7	to	71	72	O	to	to	to	TO	False
DDI-MedLine.d125.s7	rats	74	77	O	rats	ats	rats	NNS	False
DDI-MedLine.d125.s7	2	79	79	O	2	2	2	CD	False
DDI-MedLine.d125.s7	hours	81	85	O	hours	urs	ours	NNS	False
DDI-MedLine.d125.s7	prior	87	91	O	prior	ior	rior	RB	False
DDI-MedLine.d125.s7	to	93	94	O	to	to	to	TO	False
DDI-MedLine.d125.s7	1,3-difluoroacetone	96	114	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s7	(	116	116	O	(	(	(	(	False
DDI-MedLine.d125.s7	100	117	119	O	100	100	100	CD	False
DDI-MedLine.d125.s7	mg	121	122	O	mg	mg	mg	NN	False
DDI-MedLine.d125.s7	kg	124	125	O	kg	kg	kg	NN	False
DDI-MedLine.d125.s7	(	126	126	O	(	(	(	(	False
DDI-MedLine.d125.s7	-1	127	128	O	-1	-1	-1	NN	False
DDI-MedLine.d125.s7	)	129	129	O	)	)	)	)	False
DDI-MedLine.d125.s7	body	131	134	O	body	ody	body	NN	False
DDI-MedLine.d125.s7	weight	136	141	O	weight	ght	ight	NN	False
DDI-MedLine.d125.s7	)	142	142	O	)	)	)	)	False
DDI-MedLine.d125.s7	was	144	146	O	was	was	was	VBD	False
DDI-MedLine.d125.s7	ineffective	148	158	O	ineffective	ive	tive	JJ	False
DDI-MedLine.d125.s7	in	160	161	O	in	in	in	IN	False
DDI-MedLine.d125.s7	preventing	163	172	O	preventing	ing	ting	VBG	False
DDI-MedLine.d125.s7	(	174	174	B-drug_n	(	(	(	(	False
DDI-MedLine.d125.s7	-	175	175	I-drug_n	-	-	-	:	False
DDI-MedLine.d125.s7	)	176	176	I-drug_n	)	)	)	)	False
DDI-MedLine.d125.s7	-erythro-fluorocitrate	177	198	I-drug_n	-erythro-fluorocitrate	ate	rate	NN	False
DDI-MedLine.d125.s7	synthesis	200	208	O	synthesis	sis	esis	NN	False
DDI-MedLine.d125.s7	and	210	212	O	and	and	and	CC	False
DDI-MedLine.d125.s7	did	214	216	O	did	did	did	VBD	False
DDI-MedLine.d125.s7	not	218	220	O	not	not	not	RB	False
DDI-MedLine.d125.s7	diminish	222	229	O	diminish	ish	nish	NN	False
DDI-MedLine.d125.s7	fluoride	231	238	O	fluoride	ide	ride	NN	False
DDI-MedLine.d125.s7	or	240	241	O	or	or	or	CC	False
DDI-MedLine.d125.s7	citrate	243	249	O	citrate	ate	rate	NN	False
DDI-MedLine.d125.s7	accumulation	251	262	O	accumulation	ion	tion	NN	False
DDI-MedLine.d125.s7	in	264	265	O	in	in	in	IN	False
DDI-MedLine.d125.s7	vivo	267	270	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d125.s7	.	271	271	O	.	.	.	.	False

DDI-MedLine.d125.s8	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d125.s8	conclude	3	10	O	conclude	ude	lude	NN	False
DDI-MedLine.d125.s8	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d125.s8	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d125.s8	prophylactic	21	32	O	prophylactic	tic	ctic	JJ	False
DDI-MedLine.d125.s8	and	34	36	O	and	and	and	CC	False
DDI-MedLine.d125.s8	antidotal	38	46	O	antidotal	tal	otal	NN	False
DDI-MedLine.d125.s8	properties	48	57	O	properties	ies	ties	NNS	False
DDI-MedLine.d125.s8	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d125.s8	4-methylpyrazole	62	77	B-drug	4-methylpyrazole	ole	zole	JJ	drug
DDI-MedLine.d125.s8	seen	79	82	O	seen	een	seen	VBN	False
DDI-MedLine.d125.s8	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d125.s8	animals	87	93	O	animals	als	mals	NNS	False
DDI-MedLine.d125.s8	treated	95	101	O	treated	ted	ated	VBN	False
DDI-MedLine.d125.s8	with	103	106	O	with	ith	with	IN	False
DDI-MedLine.d125.s8	1,3-difluoro-2-propanol	108	130	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s8	derive	132	137	O	derive	ive	rive	NN	False
DDI-MedLine.d125.s8	from	139	142	O	from	rom	from	IN	False
DDI-MedLine.d125.s8	its	144	146	O	its	its	its	PRP$	False
DDI-MedLine.d125.s8	capacity	148	155	O	capacity	ity	city	NN	False
DDI-MedLine.d125.s8	to	157	158	O	to	to	to	TO	False
DDI-MedLine.d125.s8	inhibit	160	166	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d125.s8	the	168	170	O	the	the	the	DT	False
DDI-MedLine.d125.s8	NAD+-dependent	172	185	O	NAD+-dependent	ent	dent	NN	False
DDI-MedLine.d125.s8	oxidation	187	195	O	oxidation	ion	tion	NN	False
DDI-MedLine.d125.s8	responsible	197	207	O	responsible	ble	ible	JJ	False
DDI-MedLine.d125.s8	for	209	211	O	for	for	for	IN	False
DDI-MedLine.d125.s8	converting	213	222	O	converting	ing	ting	VBG	False
DDI-MedLine.d125.s8	1,3-difluoro-2-propanol	224	246	B-drug_n	1,3-difluoro-2-propanol	nol	anol	JJ	False
DDI-MedLine.d125.s8	to	248	249	O	to	to	to	TO	False
DDI-MedLine.d125.s8	1,3-difluoroacetone	251	269	B-drug_n	1,3-difluoroacetone	one	tone	CD	False
DDI-MedLine.d125.s8	in	271	272	O	in	in	in	IN	False
DDI-MedLine.d125.s8	the	274	276	O	the	the	the	DT	False
DDI-MedLine.d125.s8	committed	278	286	O	committed	ted	tted	VBN	False
DDI-MedLine.d125.s8	step	288	291	O	step	tep	step	NN	False
DDI-MedLine.d125.s8	of	293	294	O	of	of	of	IN	False
DDI-MedLine.d125.s8	the	296	298	O	the	the	the	DT	False
DDI-MedLine.d125.s8	toxic	300	304	O	toxic	xic	oxic	NN	False
DDI-MedLine.d125.s8	pathway	306	312	O	pathway	way	hway	NN	False
DDI-MedLine.d125.s8	.	313	313	O	.	.	.	.	False

DDI-MedLine.d15.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d15.s0	Stimulation	1	11	O	Stimulation	ion	tion	NN	False
DDI-MedLine.d15.s0	by	13	14	O	by	by	by	IN	False
DDI-MedLine.d15.s0	cerulein	16	23	B-drug_n	cerulein	ein	lein	NN	False
DDI-MedLine.d15.s0	--	24	25	O	--	--	--	:	False
DDI-MedLine.d15.s0	an	26	27	O	an	an	an	DT	False
DDI-MedLine.d15.s0	analog	29	34	O	analog	log	alog	NN	False
DDI-MedLine.d15.s0	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d15.s0	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d15.s0	octapeptide	43	53	O	octapeptide	ide	tide	NN	False
DDI-MedLine.d15.s0	cholecystokinin	55	69	O	cholecystokinin	nin	inin	NN	False
DDI-MedLine.d15.s0	--	70	71	O	--	--	--	:	False
DDI-MedLine.d15.s0	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d15.s0	3H-spiroperidol	75	89	B-drug_n	3H-spiroperidol	dol	idol	JJ	False
DDI-MedLine.d15.s0	binding	91	97	O	binding	ing	ding	NN	False
DDI-MedLine.d15.s0	after	99	103	O	after	ter	fter	IN	False
DDI-MedLine.d15.s0	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d15.s0	long-term	109	117	O	long-term	erm	term	JJ	False
DDI-MedLine.d15.s0	administration	119	132	O	administration	ion	tion	NN	False
DDI-MedLine.d15.s0	of	134	135	O	of	of	of	IN	False
DDI-MedLine.d15.s0	neuroleptics	137	148	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d15.s0	]	149	149	O	]	]	]	NN	False
DDI-MedLine.d15.s0	It	152	153	O	It	It	It	PRP	False
DDI-MedLine.d15.s0	has	155	157	O	has	has	has	VBZ	False
DDI-MedLine.d15.s0	been	159	162	O	been	een	been	VBN	False
DDI-MedLine.d15.s0	established	164	174	O	established	hed	shed	VBN	False
DDI-MedLine.d15.s0	in	176	177	O	in	in	in	IN	False
DDI-MedLine.d15.s0	experiments	179	189	O	experiments	nts	ents	NNS	False
DDI-MedLine.d15.s0	on	191	192	O	on	on	on	IN	False
DDI-MedLine.d15.s0	white	194	198	O	white	ite	hite	JJ	False
DDI-MedLine.d15.s0	male	200	203	O	male	ale	male	NN	False
DDI-MedLine.d15.s0	rats	205	208	O	rats	ats	rats	NNS	False
DDI-MedLine.d15.s0	that	210	213	O	that	hat	that	IN	False
DDI-MedLine.d15.s0	prolonged	215	223	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d15.s0	administration	225	238	O	administration	ion	tion	NN	False
DDI-MedLine.d15.s0	(	240	240	O	(	(	(	(	False
DDI-MedLine.d15.s0	twice	241	245	O	twice	ice	wice	RB	False
DDI-MedLine.d15.s0	a	247	247	O	a	a	a	DT	False
DDI-MedLine.d15.s0	day	249	251	O	day	day	day	NN	False
DDI-MedLine.d15.s0	for	253	255	O	for	for	for	IN	False
DDI-MedLine.d15.s0	14	257	258	O	14	14	14	CD	False
DDI-MedLine.d15.s0	days	260	263	O	days	ays	days	NNS	False
DDI-MedLine.d15.s0	)	264	264	O	)	)	)	)	False
DDI-MedLine.d15.s0	of	266	267	O	of	of	of	IN	False
DDI-MedLine.d15.s0	haloperidol	269	279	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d15.s0	(	281	281	O	(	(	(	(	False
DDI-MedLine.d15.s0	0.25	282	285	O	0.25	.25	0.25	CD	False
DDI-MedLine.d15.s0	mg/kg	287	291	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d15.s0	)	292	292	O	)	)	)	)	False
DDI-MedLine.d15.s0	and	294	296	O	and	and	and	CC	False
DDI-MedLine.d15.s0	pyreneperone	298	309	B-drug_n	pyreneperone	one	rone	NN	False
DDI-MedLine.d15.s0	(	311	311	O	(	(	(	(	False
DDI-MedLine.d15.s0	0.25	312	315	O	0.25	.25	0.25	CD	False
DDI-MedLine.d15.s0	mg/kg	317	321	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d15.s0	)	322	322	O	)	)	)	)	False
DDI-MedLine.d15.s0	resulted	324	331	O	resulted	ted	lted	VBD	False
DDI-MedLine.d15.s0	in	333	334	O	in	in	in	IN	False
DDI-MedLine.d15.s0	the	336	338	O	the	the	the	DT	False
DDI-MedLine.d15.s0	reduced	340	346	O	reduced	ced	uced	VBN	False
DDI-MedLine.d15.s0	interaction	348	358	O	interaction	ion	tion	NN	False
DDI-MedLine.d15.s0	between	360	366	O	between	een	ween	IN	False
DDI-MedLine.d15.s0	3H-spiroperidol	368	382	B-drug_n	3H-spiroperidol	dol	idol	JJ	False
DDI-MedLine.d15.s0	and	384	386	O	and	and	and	CC	False
DDI-MedLine.d15.s0	low	388	390	O	low	low	low	JJ	False
DDI-MedLine.d15.s0	affinity	392	399	O	affinity	ity	nity	NN	False
DDI-MedLine.d15.s0	binding	401	407	O	binding	ing	ding	NN	False
DDI-MedLine.d15.s0	sites	409	413	O	sites	tes	ites	NNS	False
DDI-MedLine.d15.s0	for	415	417	O	for	for	for	IN	False
DDI-MedLine.d15.s0	apomorphine	419	429	B-drug	apomorphine	ine	hine	NN	drug
DDI-MedLine.d15.s0	in	431	432	O	in	in	in	IN	False
DDI-MedLine.d15.s0	subcortical	434	444	O	subcortical	cal	ical	JJ	False
DDI-MedLine.d15.s0	structures	446	455	O	structures	res	ures	NNS	False
DDI-MedLine.d15.s0	,	456	456	O	,	,	,	,	False
DDI-MedLine.d15.s0	whereas	458	464	O	whereas	eas	reas	NNS	False
DDI-MedLine.d15.s0	3H-spiroperidol	466	480	B-drug_n	3H-spiroperidol	dol	idol	JJ	False
DDI-MedLine.d15.s0	binding	482	488	O	binding	ing	ding	NN	False
DDI-MedLine.d15.s0	with	490	493	O	with	ith	with	IN	False
DDI-MedLine.d15.s0	high	495	498	O	high	igh	high	JJ	False
DDI-MedLine.d15.s0	affinity	500	507	O	affinity	ity	nity	NN	False
DDI-MedLine.d15.s0	binding	509	515	O	binding	ing	ding	NN	False
DDI-MedLine.d15.s0	sites	517	521	O	sites	tes	ites	NNS	False
DDI-MedLine.d15.s0	for	523	525	O	for	for	for	IN	False
DDI-MedLine.d15.s0	apomorphine	527	537	B-drug	apomorphine	ine	hine	NN	drug
DDI-MedLine.d15.s0	increased	539	547	O	increased	sed	ased	VBN	False
DDI-MedLine.d15.s0	both	549	552	O	both	oth	both	DT	False
DDI-MedLine.d15.s0	in	554	555	O	in	in	in	IN	False
DDI-MedLine.d15.s0	the	557	559	O	the	the	the	DT	False
DDI-MedLine.d15.s0	frontal	561	567	O	frontal	tal	ntal	NN	False
DDI-MedLine.d15.s0	cortex	569	574	O	cortex	tex	rtex	NN	False
DDI-MedLine.d15.s0	and	576	578	O	and	and	and	CC	False
DDI-MedLine.d15.s0	subcortical	580	590	O	subcortical	cal	ical	JJ	False
DDI-MedLine.d15.s0	structures	592	601	O	structures	res	ures	NNS	False
DDI-MedLine.d15.s0	of	603	604	O	of	of	of	IN	False
DDI-MedLine.d15.s0	the	606	608	O	the	the	the	DT	False
DDI-MedLine.d15.s0	forebrain	610	618	O	forebrain	ain	rain	NN	False
DDI-MedLine.d15.s0	.	619	619	O	.	.	.	.	False

DDI-MedLine.d15.s1	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d15.s1	prolonged	6	14	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d15.s1	administration	16	29	O	administration	ion	tion	NN	False
DDI-MedLine.d15.s1	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d15.s1	neuroleptics	34	45	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d15.s1	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d15.s1	displacing	51	60	O	displacing	ing	cing	VBG	False
DDI-MedLine.d15.s1	effect	62	67	O	effect	ect	fect	NN	False
DDI-MedLine.d15.s1	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d15.s1	cerulein	72	79	B-drug_n	cerulein	ein	lein	NN	False
DDI-MedLine.d15.s1	,	80	80	O	,	,	,	,	False
DDI-MedLine.d15.s1	an	82	83	O	an	an	an	DT	False
DDI-MedLine.d15.s1	analog	85	90	O	analog	log	alog	NN	False
DDI-MedLine.d15.s1	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d15.s1	cholecystokinin	95	109	O	cholecystokinin	nin	inin	NN	False
DDI-MedLine.d15.s1	octapeptide	111	121	O	octapeptide	ide	tide	NN	False
DDI-MedLine.d15.s1	,	122	122	O	,	,	,	,	False
DDI-MedLine.d15.s1	was	124	126	O	was	was	was	VBD	False
DDI-MedLine.d15.s1	replaced	128	135	O	replaced	ced	aced	VBN	False
DDI-MedLine.d15.s1	by	137	138	O	by	by	by	IN	False
DDI-MedLine.d15.s1	the	140	142	O	the	the	the	DT	False
DDI-MedLine.d15.s1	stimulant	144	152	O	stimulant	ant	lant	NN	False
DDI-MedLine.d15.s1	action	154	159	O	action	ion	tion	NN	False
DDI-MedLine.d15.s1	on	161	162	O	on	on	on	IN	False
DDI-MedLine.d15.s1	3H-spiroperidol	164	178	B-drug_n	3H-spiroperidol	dol	idol	JJ	False
DDI-MedLine.d15.s1	binding	180	186	O	binding	ing	ding	NN	False
DDI-MedLine.d15.s1	.	187	187	O	.	.	.	.	False

DDI-MedLine.d15.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d15.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d15.s2	assumed	6	12	O	assumed	med	umed	VBN	False
DDI-MedLine.d15.s2	that	14	17	O	that	hat	that	IN	False
DDI-MedLine.d15.s2	increased	19	27	O	increased	sed	ased	VBN	False
DDI-MedLine.d15.s2	interaction	29	39	O	interaction	ion	tion	NN	False
DDI-MedLine.d15.s2	between	41	47	O	between	een	ween	IN	False
DDI-MedLine.d15.s2	3H-spiroperidol	49	63	B-drug_n	3H-spiroperidol	dol	idol	JJ	False
DDI-MedLine.d15.s2	and	65	67	O	and	and	and	CC	False
DDI-MedLine.d15.s2	high	69	72	O	high	igh	high	JJ	False
DDI-MedLine.d15.s2	affinity	74	81	O	affinity	ity	nity	NN	False
DDI-MedLine.d15.s2	binding	83	89	O	binding	ing	ding	NN	False
DDI-MedLine.d15.s2	sites	91	95	O	sites	tes	ites	NNS	False
DDI-MedLine.d15.s2	for	97	99	O	for	for	for	IN	False
DDI-MedLine.d15.s2	apomorphine	101	111	B-drug	apomorphine	ine	hine	NN	drug
DDI-MedLine.d15.s2	on	113	114	O	on	on	on	IN	False
DDI-MedLine.d15.s2	dopamine2-	116	125	O	dopamine2-	e2-	ne2-	NN	False
DDI-MedLine.d15.s2	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d15.s2	serotonin2-receptors	131	150	O	serotonin2-receptors	ors	tors	NNS	False
DDI-MedLine.d15.s2	underlies	152	160	O	underlies	ies	lies	NNS	False
DDI-MedLine.d15.s2	the	162	164	O	the	the	the	DT	False
DDI-MedLine.d15.s2	antipsychotic	166	178	O	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d15.s2	action	180	185	O	action	ion	tion	NN	False
DDI-MedLine.d15.s2	of	187	188	O	of	of	of	IN	False
DDI-MedLine.d15.s2	neuroleptics	190	201	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d15.s2	after	203	207	O	after	ter	fter	IN	False
DDI-MedLine.d15.s2	their	209	213	O	their	eir	heir	PRP$	False
DDI-MedLine.d15.s2	prolonged	215	223	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d15.s2	administration	225	238	O	administration	ion	tion	NN	False
DDI-MedLine.d15.s2	.	239	239	O	.	.	.	.	False

DDI-MedLine.d15.s3	Cholecystokinin	0	14	O	Cholecystokinin	nin	inin	NN	False
DDI-MedLine.d15.s3	octapeptide	16	26	O	octapeptide	ide	tide	NN	False
DDI-MedLine.d15.s3	is	28	29	O	is	is	is	VBZ	False
DDI-MedLine.d15.s3	a	31	31	O	a	a	a	DT	False
DDI-MedLine.d15.s3	necessary	33	41	O	necessary	ary	sary	JJ	False
DDI-MedLine.d15.s3	factor	43	48	O	factor	tor	ctor	NN	False
DDI-MedLine.d15.s3	for	50	52	O	for	for	for	IN	False
DDI-MedLine.d15.s3	realization	54	64	O	realization	ion	tion	NN	False
DDI-MedLine.d15.s3	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d15.s3	this	69	72	O	this	his	this	DT	False
DDI-MedLine.d15.s3	action	74	79	O	action	ion	tion	NN	False
DDI-MedLine.d15.s3	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d15.s3	neuroleptics	84	95	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d15.s3	.	96	96	O	.	.	.	.	False

DDI-MedLine.d29.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d29.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d29.s0	probenecid	10	19	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s0	on	21	22	O	on	on	on	IN	False
DDI-MedLine.d29.s0	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d29.s0	apparent	28	35	O	apparent	ent	rent	NN	False
DDI-MedLine.d29.s0	volume	37	42	O	volume	ume	lume	NN	False
DDI-MedLine.d29.s0	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d29.s0	distribution	47	58	O	distribution	ion	tion	NN	False
DDI-MedLine.d29.s0	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d29.s0	elimination	64	74	O	elimination	ion	tion	NN	False
DDI-MedLine.d29.s0	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d29.s0	cloxacillin	79	89	B-drug	cloxacillin	lin	llin	NN	False
DDI-MedLine.d29.s0	.	90	90	O	.	.	.	.	False

DDI-MedLine.d29.s1	According	0	8	O	According	ing	ding	VBG	False
DDI-MedLine.d29.s1	to	10	11	O	to	to	to	TO	False
DDI-MedLine.d29.s1	Gibaldi	13	19	O	Gibaldi	ldi	aldi	NN	False
DDI-MedLine.d29.s1	et	21	22	O	et	et	et	NN	False
DDI-MedLine.d29.s1	al	24	25	O	al	al	al	NN	False
DDI-MedLine.d29.s1	.	26	26	O	.	.	.	.	False

DDI-MedLine.d29.s2	(	0	0	O	(	(	(	(	False
DDI-MedLine.d29.s2	1968	1	4	O	1968	968	1968	CD	False
DDI-MedLine.d29.s2	,	5	5	O	,	,	,	,	False
DDI-MedLine.d29.s2	1970	7	10	O	1970	970	1970	CD	False
DDI-MedLine.d29.s2	)	11	11	O	)	)	)	)	False
DDI-MedLine.d29.s2	,	12	12	O	,	,	,	,	False
DDI-MedLine.d29.s2	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d29.s2	higher	18	23	O	higher	her	gher	JJR	False
DDI-MedLine.d29.s2	serum	25	29	O	serum	rum	erum	NN	False
DDI-MedLine.d29.s2	concentrations	31	44	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d29.s2	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d29.s2	penicillins	49	59	B-group	penicillins	ins	lins	NNS	False
DDI-MedLine.d29.s2	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d29.s2	cephaloridine	65	77	B-drug	cephaloridine	ine	dine	NN	drug
DDI-MedLine.d29.s2	reached	79	85	O	reached	hed	ched	VBN	False
DDI-MedLine.d29.s2	after	87	91	O	after	ter	fter	IN	False
DDI-MedLine.d29.s2	administration	93	106	O	administration	ion	tion	NN	False
DDI-MedLine.d29.s2	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d29.s2	probenecid	111	120	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s2	are	122	124	O	are	are	are	VBP	False
DDI-MedLine.d29.s2	due	126	128	O	due	due	due	JJ	False
DDI-MedLine.d29.s2	not	130	132	O	not	not	not	RB	False
DDI-MedLine.d29.s2	only	134	137	O	only	nly	only	RB	False
DDI-MedLine.d29.s2	to	139	140	O	to	to	to	TO	False
DDI-MedLine.d29.s2	slower	142	147	O	slower	wer	ower	JJR	False
DDI-MedLine.d29.s2	renal	149	153	O	renal	nal	enal	NN	False
DDI-MedLine.d29.s2	elimination	155	165	O	elimination	ion	tion	NN	False
DDI-MedLine.d29.s2	but	167	169	O	but	but	but	CC	False
DDI-MedLine.d29.s2	also	171	174	O	also	lso	also	RB	False
DDI-MedLine.d29.s2	to	176	177	O	to	to	to	TO	False
DDI-MedLine.d29.s2	an	179	180	O	an	an	an	DT	False
DDI-MedLine.d29.s2	altered	182	188	O	altered	red	ered	VBN	False
DDI-MedLine.d29.s2	distribution	190	201	O	distribution	ion	tion	NN	False
DDI-MedLine.d29.s2	in	203	204	O	in	in	in	IN	False
DDI-MedLine.d29.s2	the	206	208	O	the	the	the	DT	False
DDI-MedLine.d29.s2	body	210	213	O	body	ody	body	NN	False
DDI-MedLine.d29.s2	.	214	214	O	.	.	.	.	False

DDI-MedLine.d29.s3	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d29.s3	determine	3	11	O	determine	ine	mine	NN	drug
DDI-MedLine.d29.s3	whether	13	19	O	whether	her	ther	IN	False
DDI-MedLine.d29.s3	probenecid	21	30	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s3	has	32	34	O	has	has	has	VBZ	False
DDI-MedLine.d29.s3	a	36	36	O	a	a	a	DT	False
DDI-MedLine.d29.s3	direct	38	43	O	direct	ect	rect	JJ	False
DDI-MedLine.d29.s3	effect	45	50	O	effect	ect	fect	NN	False
DDI-MedLine.d29.s3	on	52	53	O	on	on	on	IN	False
DDI-MedLine.d29.s3	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d29.s3	distribution	59	70	O	distribution	ion	tion	NN	False
DDI-MedLine.d29.s3	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d29.s3	cloxacillin	75	85	B-drug	cloxacillin	lin	llin	NN	False
DDI-MedLine.d29.s3	,	86	86	O	,	,	,	,	False
DDI-MedLine.d29.s3	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d29.s3	elimination	92	102	O	elimination	ion	tion	NN	False
DDI-MedLine.d29.s3	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d29.s3	distribution	108	119	O	distribution	ion	tion	NN	False
DDI-MedLine.d29.s3	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d29.s3	cloxacillin	124	134	B-drug	cloxacillin	lin	llin	NN	False
DDI-MedLine.d29.s3	was	136	138	O	was	was	was	VBD	False
DDI-MedLine.d29.s3	studied	140	146	O	studied	ied	died	VBN	False
DDI-MedLine.d29.s3	in	148	149	O	in	in	in	IN	False
DDI-MedLine.d29.s3	six	151	153	O	six	six	six	CD	False
DDI-MedLine.d29.s3	patients	155	162	O	patients	nts	ents	NNS	False
DDI-MedLine.d29.s3	,	163	163	O	,	,	,	,	False
DDI-MedLine.d29.s3	five	165	168	O	five	ive	five	CD	False
DDI-MedLine.d29.s3	lacking	170	176	O	lacking	ing	king	VBG	False
DDI-MedLine.d29.s3	kidney	178	183	O	kidney	ney	dney	NN	False
DDI-MedLine.d29.s3	function	185	192	O	function	ion	tion	NN	False
DDI-MedLine.d29.s3	and	194	196	O	and	and	and	CC	False
DDI-MedLine.d29.s3	one	198	200	O	one	one	one	CD	False
DDI-MedLine.d29.s3	with	202	205	O	with	ith	with	IN	False
DDI-MedLine.d29.s3	a	207	207	O	a	a	a	DT	False
DDI-MedLine.d29.s3	partially	209	217	O	partially	lly	ally	RB	False
DDI-MedLine.d29.s3	impaired	219	226	O	impaired	red	ired	JJ	False
DDI-MedLine.d29.s3	renal	228	232	O	renal	nal	enal	NN	False
DDI-MedLine.d29.s3	function	234	241	O	function	ion	tion	NN	False
DDI-MedLine.d29.s3	,	242	242	O	,	,	,	,	False
DDI-MedLine.d29.s3	in	244	245	O	in	in	in	IN	False
DDI-MedLine.d29.s3	the	247	249	O	the	the	the	DT	False
DDI-MedLine.d29.s3	presence	251	258	O	presence	nce	ence	NN	False
DDI-MedLine.d29.s3	or	260	261	O	or	or	or	CC	False
DDI-MedLine.d29.s3	absence	263	269	O	absence	nce	ence	NN	False
DDI-MedLine.d29.s3	of	271	272	O	of	of	of	IN	False
DDI-MedLine.d29.s3	probenecid	274	283	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s3	.	284	284	O	.	.	.	.	False

DDI-MedLine.d29.s4	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d29.s4	significant	3	13	O	significant	ant	cant	JJ	False
DDI-MedLine.d29.s4	difference	15	24	O	difference	nce	ence	NN	False
DDI-MedLine.d29.s4	was	26	28	O	was	was	was	VBD	False
DDI-MedLine.d29.s4	found	30	34	O	found	und	ound	NN	False
DDI-MedLine.d29.s4	between	36	42	O	between	een	ween	IN	False
DDI-MedLine.d29.s4	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d29.s4	mean	48	51	O	mean	ean	mean	NN	False
DDI-MedLine.d29.s4	values	53	58	O	values	ues	lues	NNS	False
DDI-MedLine.d29.s4	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d29.s4	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d29.s4	volume	67	72	O	volume	ume	lume	NN	False
DDI-MedLine.d29.s4	of	74	75	O	of	of	of	IN	False
DDI-MedLine.d29.s4	distribution	77	88	O	distribution	ion	tion	NN	False
DDI-MedLine.d29.s4	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d29.s4	cloxacillin	93	103	B-drug	cloxacillin	lin	llin	NN	False
DDI-MedLine.d29.s4	with	105	108	O	with	ith	with	IN	False
DDI-MedLine.d29.s4	and	110	112	O	and	and	and	CC	False
DDI-MedLine.d29.s4	without	114	120	O	without	out	hout	IN	False
DDI-MedLine.d29.s4	probenecid	122	131	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s4	(	133	133	O	(	(	(	(	False
DDI-MedLine.d29.s4	13.0	134	137	O	13.0	3.0	13.0	CD	False
DDI-MedLine.d29.s4	and	139	141	O	and	and	and	CC	False
DDI-MedLine.d29.s4	12.6	143	146	O	12.6	2.6	12.6	CD	False
DDI-MedLine.d29.s4	liters	148	153	O	liters	ers	ters	NNS	False
DDI-MedLine.d29.s4	,	154	154	O	,	,	,	,	False
DDI-MedLine.d29.s4	respectively	156	167	O	respectively	ely	vely	RB	False
DDI-MedLine.d29.s4	)	168	168	O	)	)	)	)	False
DDI-MedLine.d29.s4	.	169	169	O	.	.	.	.	False

DDI-MedLine.d29.s5	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d29.s5	,	4	4	O	,	,	,	,	False
DDI-MedLine.d29.s5	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d29.s5	hypothesis	10	19	O	hypothesis	sis	esis	NN	False
DDI-MedLine.d29.s5	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d29.s5	Gibaldi	24	30	O	Gibaldi	ldi	aldi	NN	False
DDI-MedLine.d29.s5	et	32	33	O	et	et	et	NN	False
DDI-MedLine.d29.s5	al	35	36	O	al	al	al	NN	False
DDI-MedLine.d29.s5	.	37	37	O	.	.	.	.	False

DDI-MedLine.d29.s6	could	0	4	O	could	uld	ould	MD	False
DDI-MedLine.d29.s6	not	6	8	O	not	not	not	RB	False
DDI-MedLine.d29.s6	be	10	11	O	be	be	be	VB	False
DDI-MedLine.d29.s6	confirmed	13	21	O	confirmed	med	rmed	VBN	False
DDI-MedLine.d29.s6	for	23	25	O	for	for	for	IN	False
DDI-MedLine.d29.s6	cloxacillin	27	37	B-drug	cloxacillin	lin	llin	NN	False
DDI-MedLine.d29.s6	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d29.s6	patients	42	49	O	patients	nts	ents	NNS	False
DDI-MedLine.d29.s6	lacking	51	57	O	lacking	ing	king	VBG	False
DDI-MedLine.d29.s6	kidney	59	64	O	kidney	ney	dney	NN	False
DDI-MedLine.d29.s6	function	66	73	O	function	ion	tion	NN	False
DDI-MedLine.d29.s6	.	74	74	O	.	.	.	.	False

DDI-MedLine.d29.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d29.s7	spite	3	7	O	spite	ite	pite	NN	False
DDI-MedLine.d29.s7	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d29.s7	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d29.s7	absence	16	22	O	absence	nce	ence	NN	False
DDI-MedLine.d29.s7	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d29.s7	kidney	27	32	O	kidney	ney	dney	NN	False
DDI-MedLine.d29.s7	function	34	41	O	function	ion	tion	NN	False
DDI-MedLine.d29.s7	,	42	42	O	,	,	,	,	False
DDI-MedLine.d29.s7	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d29.s7	value	48	52	O	value	lue	alue	NN	False
DDI-MedLine.d29.s7	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d29.s7	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d29.s7	elimination	61	71	O	elimination	ion	tion	NN	False
DDI-MedLine.d29.s7	rate	73	76	O	rate	ate	rate	NN	False
DDI-MedLine.d29.s7	constant	78	85	O	constant	ant	tant	JJ	False
DDI-MedLine.d29.s7	was	87	89	O	was	was	was	VBD	False
DDI-MedLine.d29.s7	significantly	91	103	O	significantly	tly	ntly	RB	False
DDI-MedLine.d29.s7	decreased	105	113	O	decreased	sed	ased	VBN	False
DDI-MedLine.d29.s7	in	115	116	O	in	in	in	IN	False
DDI-MedLine.d29.s7	the	118	120	O	the	the	the	DT	False
DDI-MedLine.d29.s7	presence	122	129	O	presence	nce	ence	NN	False
DDI-MedLine.d29.s7	of	131	132	O	of	of	of	IN	False
DDI-MedLine.d29.s7	probenecid	134	143	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s7	(	145	145	O	(	(	(	(	False
DDI-MedLine.d29.s7	from	146	149	O	from	rom	from	IN	False
DDI-MedLine.d29.s7	0.326	151	155	O	0.326	326	.326	CD	False
DDI-MedLine.d29.s7	to	157	158	O	to	to	to	TO	False
DDI-MedLine.d29.s7	0.263/h	160	166	O	0.263/h	3/h	63/h	CD	False
DDI-MedLine.d29.s7	)	167	167	O	)	)	)	)	False
DDI-MedLine.d29.s7	.	168	168	O	.	.	.	.	False

DDI-MedLine.d29.s8	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d29.s8	might	5	9	O	might	ght	ight	MD	False
DDI-MedLine.d29.s8	be	11	12	O	be	be	be	VB	False
DDI-MedLine.d29.s8	explained	14	22	O	explained	ned	ined	VBD	False
DDI-MedLine.d29.s8	by	24	25	O	by	by	by	IN	False
DDI-MedLine.d29.s8	a	27	27	O	a	a	a	DT	False
DDI-MedLine.d29.s8	blockade	29	36	O	blockade	ade	kade	NN	False
DDI-MedLine.d29.s8	by	38	39	O	by	by	by	IN	False
DDI-MedLine.d29.s8	probenecid	41	50	B-drug	probenecid	cid	ecid	NN	False
DDI-MedLine.d29.s8	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d29.s8	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d29.s8	elimination	59	69	O	elimination	ion	tion	NN	False
DDI-MedLine.d29.s8	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d29.s8	cloxacillin	74	84	B-drug	cloxacillin	lin	llin	NN	False
DDI-MedLine.d29.s8	by	86	87	O	by	by	by	IN	False
DDI-MedLine.d29.s8	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d29.s8	liver	93	97	O	liver	ver	iver	NN	False
DDI-MedLine.d29.s8	.	98	98	O	.	.	.	.	False

DDI-MedLine.d101.s0	Pharmacology	0	11	O	Pharmacology	ogy	logy	NN	False
DDI-MedLine.d101.s0	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d101.s0	pharmacotherapy	17	31	O	pharmacotherapy	apy	rapy	NN	False
DDI-MedLine.d101.s0	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d101.s0	cardiovascular	36	49	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d101.s0	drugs	51	55	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d101.s0	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d101.s0	patients	60	67	O	patients	nts	ents	NNS	False
DDI-MedLine.d101.s0	with	69	72	O	with	ith	with	IN	False
DDI-MedLine.d101.s0	chronic	74	80	O	chronic	nic	onic	NN	False
DDI-MedLine.d101.s0	renal	82	86	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s0	disease	88	94	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s0	.	95	95	O	.	.	.	.	False

DDI-MedLine.d101.s1	Cardiovascular	0	13	O	Cardiovascular	lar	ular	JJ	False
DDI-MedLine.d101.s1	disease	15	21	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s1	is	23	24	O	is	is	is	VBZ	False
DDI-MedLine.d101.s1	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d101.s1	common	28	33	O	common	mon	mmon	JJ	False
DDI-MedLine.d101.s1	comorbidity	35	45	O	comorbidity	ity	dity	NN	False
DDI-MedLine.d101.s1	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d101.s1	a	51	51	O	a	a	a	DT	False
DDI-MedLine.d101.s1	major	53	57	O	major	jor	ajor	JJ	False
DDI-MedLine.d101.s1	cause	59	63	O	cause	use	ause	NN	False
DDI-MedLine.d101.s1	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d101.s1	mortality	68	76	O	mortality	ity	lity	NN	False
DDI-MedLine.d101.s1	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d101.s1	patients	81	88	O	patients	nts	ents	NNS	False
DDI-MedLine.d101.s1	with	90	93	O	with	ith	with	IN	False
DDI-MedLine.d101.s1	chronic	95	101	O	chronic	nic	onic	NN	False
DDI-MedLine.d101.s1	renal	103	107	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s1	disease	109	115	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s1	.	116	116	O	.	.	.	.	False

DDI-MedLine.d101.s2	Drug	0	3	O	Drug	rug	Drug	NN	False
DDI-MedLine.d101.s2	regimens	5	12	O	regimens	ens	mens	NNS	False
DDI-MedLine.d101.s2	in	14	15	O	in	in	in	IN	False
DDI-MedLine.d101.s2	patients	17	24	O	patients	nts	ents	NNS	False
DDI-MedLine.d101.s2	with	26	29	O	with	ith	with	IN	False
DDI-MedLine.d101.s2	cardiovascular	31	44	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d101.s2	disease	46	52	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s2	are	54	56	O	are	are	are	VBP	False
DDI-MedLine.d101.s2	frequently	58	67	O	frequently	tly	ntly	RB	False
DDI-MedLine.d101.s2	complex	69	75	O	complex	lex	plex	JJ	False
DDI-MedLine.d101.s2	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d101.s2	can	81	83	O	can	can	can	MD	False
DDI-MedLine.d101.s2	be	85	86	O	be	be	be	VB	False
DDI-MedLine.d101.s2	significantly	88	100	O	significantly	tly	ntly	RB	False
DDI-MedLine.d101.s2	affected	102	109	O	affected	ted	cted	JJ	False
DDI-MedLine.d101.s2	by	111	112	O	by	by	by	IN	False
DDI-MedLine.d101.s2	alterations	114	124	O	alterations	ons	ions	NNS	False
DDI-MedLine.d101.s2	in	126	127	O	in	in	in	IN	False
DDI-MedLine.d101.s2	renal	129	133	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s2	function	135	142	O	function	ion	tion	NN	False
DDI-MedLine.d101.s2	.	143	143	O	.	.	.	.	False

DDI-MedLine.d101.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d101.s3	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d101.s3	,	11	11	O	,	,	,	,	False
DDI-MedLine.d101.s3	several	13	19	O	several	ral	eral	JJ	False
DDI-MedLine.d101.s3	cardiovascular	21	34	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d101.s3	drugs	36	40	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d101.s3	directly	42	49	O	directly	tly	ctly	RB	False
DDI-MedLine.d101.s3	affect	51	56	O	affect	ect	fect	NN	False
DDI-MedLine.d101.s3	renal	58	62	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s3	function	64	71	O	function	ion	tion	NN	False
DDI-MedLine.d101.s3	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d101.s3	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d101.s3	management	81	90	O	management	ent	ment	NN	False
DDI-MedLine.d101.s3	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d101.s3	patients	95	102	O	patients	nts	ents	NNS	False
DDI-MedLine.d101.s3	with	104	107	O	with	ith	with	IN	False
DDI-MedLine.d101.s3	renal	109	113	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s3	disease	115	121	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s3	.	122	122	O	.	.	.	.	False

DDI-MedLine.d101.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d101.s4	article	5	11	O	article	cle	icle	NN	False
DDI-MedLine.d101.s4	reviews	13	19	O	reviews	ews	iews	NNS	False
DDI-MedLine.d101.s4	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d101.s4	impact	25	30	O	impact	act	pact	NN	False
DDI-MedLine.d101.s4	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d101.s4	renal	35	39	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s4	disease	41	47	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s4	on	49	50	O	on	on	on	IN	False
DDI-MedLine.d101.s4	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d101.s4	pharmacokinetics	56	71	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d101.s4	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d101.s4	cardiovascular	76	89	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d101.s4	drugs	91	95	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d101.s4	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d101.s4	identifies	101	110	O	identifies	ies	fies	NNS	False
DDI-MedLine.d101.s4	clinically	112	121	O	clinically	lly	ally	RB	False
DDI-MedLine.d101.s4	important	123	131	O	important	ant	tant	JJ	False
DDI-MedLine.d101.s4	interactions	133	144	O	interactions	ons	ions	NNS	False
DDI-MedLine.d101.s4	between	146	152	O	between	een	ween	IN	False
DDI-MedLine.d101.s4	these	154	158	O	these	ese	hese	DT	False
DDI-MedLine.d101.s4	and	160	162	O	and	and	and	CC	False
DDI-MedLine.d101.s4	other	164	168	O	other	her	ther	JJ	False
DDI-MedLine.d101.s4	drugs	170	174	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d101.s4	commonly	176	183	O	commonly	nly	only	RB	False
DDI-MedLine.d101.s4	used	185	188	O	used	sed	used	VBN	False
DDI-MedLine.d101.s4	in	190	191	O	in	in	in	IN	False
DDI-MedLine.d101.s4	the	193	195	O	the	the	the	DT	False
DDI-MedLine.d101.s4	management	197	206	O	management	ent	ment	NN	False
DDI-MedLine.d101.s4	of	208	209	O	of	of	of	IN	False
DDI-MedLine.d101.s4	chronic	211	217	O	chronic	nic	onic	NN	False
DDI-MedLine.d101.s4	renal	219	223	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s4	disease	225	231	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s4	.	232	232	O	.	.	.	.	False

DDI-MedLine.d101.s5	Several	0	6	O	Several	ral	eral	JJ	False
DDI-MedLine.d101.s5	classes	8	14	O	classes	ses	sses	NNS	False
DDI-MedLine.d101.s5	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d101.s5	cardiovascular	19	32	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d101.s5	drugs	34	38	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d101.s5	are	40	42	O	are	are	are	VBP	False
DDI-MedLine.d101.s5	also	44	47	O	also	lso	also	RB	False
DDI-MedLine.d101.s5	discussed	49	57	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d101.s5	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d101.s5	relationship	62	73	O	relationship	hip	ship	NN	False
DDI-MedLine.d101.s5	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d101.s5	their	78	82	O	their	eir	heir	PRP$	False
DDI-MedLine.d101.s5	differential	84	95	O	differential	ial	tial	NN	False
DDI-MedLine.d101.s5	effects	97	103	O	effects	cts	ects	NNS	False
DDI-MedLine.d101.s5	on	105	106	O	on	on	on	IN	False
DDI-MedLine.d101.s5	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d101.s5	management	112	121	O	management	ent	ment	NN	False
DDI-MedLine.d101.s5	and	123	125	O	and	and	and	CC	False
DDI-MedLine.d101.s5	progression	127	137	O	progression	ion	sion	NN	False
DDI-MedLine.d101.s5	of	139	140	O	of	of	of	IN	False
DDI-MedLine.d101.s5	renal	142	146	O	renal	nal	enal	NN	False
DDI-MedLine.d101.s5	disease	148	154	O	disease	ase	ease	NN	False
DDI-MedLine.d101.s5	.	155	155	O	.	.	.	.	False

DDI-MedLine.d57.s0	Analgesic	0	8	O	Analgesic	sic	esic	JJ	False
DDI-MedLine.d57.s0	effects	10	16	O	effects	cts	ects	NNS	False
DDI-MedLine.d57.s0	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d57.s0	antihistaminics	21	35	B-group	antihistaminics	ics	nics	NNS	False
DDI-MedLine.d57.s0	.	36	36	O	.	.	.	.	False

DDI-MedLine.d57.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d57.s1	literature	4	13	O	literature	ure	ture	NN	False
DDI-MedLine.d57.s1	provides	15	22	O	provides	des	ides	VBZ	group
DDI-MedLine.d57.s1	considerable	24	35	O	considerable	ble	able	JJ	False
DDI-MedLine.d57.s1	evidence	37	44	O	evidence	nce	ence	NN	False
DDI-MedLine.d57.s1	indicating	46	55	O	indicating	ing	ting	VBG	False
DDI-MedLine.d57.s1	that	57	60	O	that	hat	that	IN	False
DDI-MedLine.d57.s1	several	62	68	O	several	ral	eral	JJ	False
DDI-MedLine.d57.s1	,	69	69	O	,	,	,	,	False
DDI-MedLine.d57.s1	but	71	73	O	but	but	but	CC	False
DDI-MedLine.d57.s1	not	75	77	O	not	not	not	RB	False
DDI-MedLine.d57.s1	all	79	81	O	all	all	all	DT	False
DDI-MedLine.d57.s1	antihistaminics	83	97	B-group	antihistaminics	ics	nics	NNS	False
DDI-MedLine.d57.s1	,	98	98	O	,	,	,	,	False
DDI-MedLine.d57.s1	are	100	102	O	are	are	are	VBP	False
DDI-MedLine.d57.s1	indeed	104	109	O	indeed	eed	deed	RB	False
DDI-MedLine.d57.s1	analgesic	111	119	B-group	analgesic	sic	esic	JJ	False
DDI-MedLine.d57.s1	agents	121	126	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d57.s1	and	128	130	O	and	and	and	CC	False
DDI-MedLine.d57.s1	some	132	135	O	some	ome	some	DT	False
DDI-MedLine.d57.s1	are	137	139	O	are	are	are	VBP	False
DDI-MedLine.d57.s1	analgesic	141	149	B-group	analgesic	sic	esic	JJ	False
DDI-MedLine.d57.s1	adjuvants	151	159	I-group	adjuvants	nts	ants	NNS	False
DDI-MedLine.d57.s1	as	161	162	O	as	as	as	IN	False
DDI-MedLine.d57.s1	well	164	167	O	well	ell	well	RB	False
DDI-MedLine.d57.s1	.	168	168	O	.	.	.	.	False

DDI-MedLine.d57.s2	Those	0	4	O	Those	ose	hose	DT	False
DDI-MedLine.d57.s2	for	6	8	O	for	for	for	IN	False
DDI-MedLine.d57.s2	which	10	14	O	which	ich	hich	WDT	False
DDI-MedLine.d57.s2	effectiveness	16	28	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d57.s2	is	30	31	O	is	is	is	VBZ	False
DDI-MedLine.d57.s2	reported	33	40	O	reported	ted	rted	VBD	False
DDI-MedLine.d57.s2	includes	42	49	O	includes	des	udes	VBZ	False
DDI-MedLine.d57.s2	diphenhydramine	51	65	B-drug	diphenhydramine	ine	mine	NN	drug
DDI-MedLine.d57.s2	,	66	66	O	,	,	,	,	False
DDI-MedLine.d57.s2	hydroxyzine	68	78	B-drug	hydroxyzine	ine	zine	NN	drug
DDI-MedLine.d57.s2	,	79	79	O	,	,	,	,	False
DDI-MedLine.d57.s2	orphenadrine	81	92	B-drug	orphenadrine	ine	rine	NN	drug
DDI-MedLine.d57.s2	,	93	93	O	,	,	,	,	False
DDI-MedLine.d57.s2	pyrilamine	95	104	B-drug	pyrilamine	ine	mine	NN	drug
DDI-MedLine.d57.s2	,	105	105	O	,	,	,	,	False
DDI-MedLine.d57.s2	phenyltoloxamine	107	122	B-drug_n	phenyltoloxamine	ine	mine	NN	drug
DDI-MedLine.d57.s2	,	123	123	O	,	,	,	,	False
DDI-MedLine.d57.s2	promethazine	125	136	B-drug	promethazine	ine	zine	NN	drug
DDI-MedLine.d57.s2	,	137	137	O	,	,	,	,	False
DDI-MedLine.d57.s2	methdilazine	139	150	B-drug	methdilazine	ine	zine	NN	drug
DDI-MedLine.d57.s2	,	151	151	O	,	,	,	,	False
DDI-MedLine.d57.s2	and	153	155	O	and	and	and	CC	False
DDI-MedLine.d57.s2	tripelennamine	157	170	B-drug	tripelennamine	ine	mine	NN	drug
DDI-MedLine.d57.s2	.	171	171	O	.	.	.	.	False

DDI-MedLine.d57.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d57.s3	proposed	4	11	O	proposed	sed	osed	VBN	False
DDI-MedLine.d57.s3	mechanisms	13	22	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d57.s3	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d57.s3	analgesic	27	35	O	analgesic	sic	esic	JJ	False
DDI-MedLine.d57.s3	action	37	42	O	action	ion	tion	NN	False
DDI-MedLine.d57.s3	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d57.s3	antihistaminics	47	61	B-group	antihistaminics	ics	nics	NNS	False
DDI-MedLine.d57.s3	are	63	65	O	are	are	are	VBP	False
DDI-MedLine.d57.s3	reviewed	67	74	O	reviewed	wed	ewed	VBN	False
DDI-MedLine.d57.s3	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d57.s3	discussed	80	88	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d57.s3	.	89	89	O	.	.	.	.	False

DDI-MedLine.d57.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d57.s4	literature	4	13	O	literature	ure	ture	NN	False
DDI-MedLine.d57.s4	suggests	15	22	O	suggests	sts	ests	NNS	False
DDI-MedLine.d57.s4	that	24	27	O	that	hat	that	IN	False
DDI-MedLine.d57.s4	more	29	32	O	more	ore	more	RBR	False
DDI-MedLine.d57.s4	than	34	37	O	than	han	than	IN	False
DDI-MedLine.d57.s4	one	39	41	O	one	one	one	CD	False
DDI-MedLine.d57.s4	mechanism	43	51	O	mechanism	ism	nism	NN	False
DDI-MedLine.d57.s4	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d57.s4	action	56	61	O	action	ion	tion	NN	False
DDI-MedLine.d57.s4	exists	63	68	O	exists	sts	ists	NNS	False
DDI-MedLine.d57.s4	for	70	72	O	for	for	for	IN	False
DDI-MedLine.d57.s4	them	74	77	O	them	hem	them	PRP	False
DDI-MedLine.d57.s4	.	78	78	O	.	.	.	.	False

DDI-MedLine.d57.s5	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d57.s5	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d57.s5	considerable	9	20	O	considerable	ble	able	JJ	False
DDI-MedLine.d57.s5	evidence	22	29	O	evidence	nce	ence	NN	False
DDI-MedLine.d57.s5	suggesting	31	40	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d57.s5	that	42	45	O	that	hat	that	IN	False
DDI-MedLine.d57.s5	histaminergic	47	59	O	histaminergic	gic	rgic	NN	False
DDI-MedLine.d57.s5	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d57.s5	serotoninergic	65	78	O	serotoninergic	gic	rgic	NN	False
DDI-MedLine.d57.s5	central	80	86	O	central	ral	tral	JJ	False
DDI-MedLine.d57.s5	pathways	88	95	O	pathways	ays	ways	NNS	False
DDI-MedLine.d57.s5	are	97	99	O	are	are	are	VBP	False
DDI-MedLine.d57.s5	involved	101	108	O	involved	ved	lved	VBN	False
DDI-MedLine.d57.s5	in	110	111	O	in	in	in	IN	False
DDI-MedLine.d57.s5	nociception	113	123	O	nociception	ion	tion	NN	False
DDI-MedLine.d57.s5	and	125	127	O	and	and	and	CC	False
DDI-MedLine.d57.s5	that	129	132	O	that	hat	that	IN	False
DDI-MedLine.d57.s5	antihistaminic	134	147	B-group	antihistaminic	nic	inic	NN	False
DDI-MedLine.d57.s5	drugs	149	153	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d57.s5	can	155	157	O	can	can	can	MD	False
DDI-MedLine.d57.s5	modulate	159	166	O	modulate	ate	late	NN	False
DDI-MedLine.d57.s5	their	168	172	O	their	eir	heir	PRP$	False
DDI-MedLine.d57.s5	responses	174	182	O	responses	ses	nses	NNS	False
DDI-MedLine.d57.s5	(	184	184	O	(	(	(	(	False
DDI-MedLine.d57.s5	1	185	185	O	1	1	1	CD	False
DDI-MedLine.d57.s5	)	186	186	O	)	)	)	)	False
DDI-MedLine.d57.s5	.	187	187	O	.	.	.	.	False

DDI-MedLine.d57.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d57.s6	evidence	4	11	O	evidence	nce	ence	NN	False
DDI-MedLine.d57.s6	for	13	15	O	for	for	for	IN	False
DDI-MedLine.d57.s6	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d57.s6	role	19	22	O	role	ole	role	NN	False
DDI-MedLine.d57.s6	for	24	26	O	for	for	for	IN	False
DDI-MedLine.d57.s6	norepinephrine	28	41	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d57.s6	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d57.s6	dopamine	47	54	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d57.s6	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d57.s6	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d57.s6	effects	64	70	O	effects	cts	ects	NNS	False
DDI-MedLine.d57.s6	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d57.s6	antihistaminics	75	89	B-group	antihistaminics	ics	nics	NNS	False
DDI-MedLine.d57.s6	on	91	92	O	on	on	on	IN	False
DDI-MedLine.d57.s6	them	94	97	O	them	hem	them	PRP	False
DDI-MedLine.d57.s6	are	99	101	O	are	are	are	VBP	False
DDI-MedLine.d57.s6	less	103	106	O	less	ess	less	RBR	False
DDI-MedLine.d57.s6	well	108	111	O	well	ell	well	RB	False
DDI-MedLine.d57.s6	established	113	123	O	established	hed	shed	VBN	False
DDI-MedLine.d57.s6	.	124	124	O	.	.	.	.	False

DDI-MedLine.d57.s7	Still	0	4	O	Still	ill	till	RB	False
DDI-MedLine.d57.s7	other	6	10	O	other	her	ther	JJ	False
DDI-MedLine.d57.s7	pathways	12	19	O	pathways	ays	ways	NNS	False
DDI-MedLine.d57.s7	have	21	24	O	have	ave	have	VB	False
DDI-MedLine.d57.s7	been	26	29	O	been	een	been	VBN	False
DDI-MedLine.d57.s7	proposed	31	38	O	proposed	sed	osed	VBN	False
DDI-MedLine.d57.s7	.	39	39	O	.	.	.	.	False

DDI-MedLine.d57.s8	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d57.s8	greater	2	8	O	greater	ter	ater	JJR	False
DDI-MedLine.d57.s8	understanding	10	22	O	understanding	ing	ding	VBG	False
DDI-MedLine.d57.s8	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d57.s8	pain	27	30	O	pain	ain	pain	NN	False
DDI-MedLine.d57.s8	mechanisms	32	41	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d57.s8	will	43	46	O	will	ill	will	MD	False
DDI-MedLine.d57.s8	aid	48	50	O	aid	aid	aid	NN	False
DDI-MedLine.d57.s8	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d57.s8	elucidating	55	65	O	elucidating	ing	ting	VBG	False
DDI-MedLine.d57.s8	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d57.s8	role	71	74	O	role	ole	role	NN	False
DDI-MedLine.d57.s8	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d57.s8	antihistaminics	79	93	B-group	antihistaminics	ics	nics	NNS	False
DDI-MedLine.d57.s8	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d57.s8	analgesia	98	106	O	analgesia	sia	esia	NN	False
DDI-MedLine.d57.s8	.	107	107	O	.	.	.	.	False

DDI-MedLine.d118.s0	Sirolimus	0	8	B-drug	Sirolimus	mus	imus	NN	False
DDI-MedLine.d118.s0	:	9	9	O	:	:	:	:	False
DDI-MedLine.d118.s0	mammalian	11	19	O	mammalian	ian	lian	JJ	False
DDI-MedLine.d118.s0	target	21	26	O	target	get	rget	NN	False
DDI-MedLine.d118.s0	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d118.s0	rapamycin	31	39	B-drug	rapamycin	cin	ycin	NN	drug
DDI-MedLine.d118.s0	inhibitor	41	49	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d118.s0	to	51	52	O	to	to	to	TO	False
DDI-MedLine.d118.s0	prevent	54	60	O	prevent	ent	vent	NN	False
DDI-MedLine.d118.s0	kidney	62	67	O	kidney	ney	dney	NN	False
DDI-MedLine.d118.s0	rejection	69	77	O	rejection	ion	tion	NN	False
DDI-MedLine.d118.s0	.	78	78	O	.	.	.	.	False

DDI-MedLine.d118.s1	Current	0	6	O	Current	ent	rent	NN	False
DDI-MedLine.d118.s1	immunosuppressive	8	24	O	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d118.s1	therapies	26	34	O	therapies	ies	pies	NNS	False
DDI-MedLine.d118.s1	are	36	38	O	are	are	are	VBP	False
DDI-MedLine.d118.s1	effective	40	48	O	effective	ive	tive	JJ	False
DDI-MedLine.d118.s1	but	50	52	O	but	but	but	CC	False
DDI-MedLine.d118.s1	can	54	56	O	can	can	can	MD	False
DDI-MedLine.d118.s1	be	58	59	O	be	be	be	VB	False
DDI-MedLine.d118.s1	associated	61	70	O	associated	ted	ated	VBN	False
DDI-MedLine.d118.s1	with	72	75	O	with	ith	with	IN	False
DDI-MedLine.d118.s1	significant	77	87	O	significant	ant	cant	JJ	False
DDI-MedLine.d118.s1	adverse	89	95	O	adverse	rse	erse	NN	False
DDI-MedLine.d118.s1	reactions	97	105	O	reactions	ons	ions	NNS	False
DDI-MedLine.d118.s1	.	106	106	O	.	.	.	.	False

DDI-MedLine.d118.s2	Sirolimus	0	8	B-drug	Sirolimus	mus	imus	NN	False
DDI-MedLine.d118.s2	works	10	14	O	works	rks	orks	NNS	False
DDI-MedLine.d118.s2	differently	16	26	O	differently	tly	ntly	RB	False
DDI-MedLine.d118.s2	from	28	31	O	from	rom	from	IN	False
DDI-MedLine.d118.s2	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d118.s2	immunosuppressants	37	54	B-group	immunosuppressants	nts	ants	NNS	False
DDI-MedLine.d118.s2	currently	56	64	O	currently	tly	ntly	RB	False
DDI-MedLine.d118.s2	available	66	74	O	available	ble	able	JJ	False
DDI-MedLine.d118.s2	,	75	75	O	,	,	,	,	False
DDI-MedLine.d118.s2	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d118.s2	except	81	86	O	except	ept	cept	IN	False
DDI-MedLine.d118.s2	for	88	90	O	for	for	for	IN	False
DDI-MedLine.d118.s2	increased	92	100	O	increased	sed	ased	VBN	False
DDI-MedLine.d118.s2	lipid	102	106	O	lipid	pid	ipid	NN	False
DDI-MedLine.d118.s2	levels	108	113	O	levels	els	vels	NNS	False
DDI-MedLine.d118.s2	,	114	114	O	,	,	,	,	False
DDI-MedLine.d118.s2	the	116	118	O	the	the	the	DT	False
DDI-MedLine.d118.s2	adverse	120	126	O	adverse	rse	erse	NN	False
DDI-MedLine.d118.s2	reaction	128	135	O	reaction	ion	tion	NN	False
DDI-MedLine.d118.s2	profile	137	143	O	profile	ile	file	NN	False
DDI-MedLine.d118.s2	of	145	146	O	of	of	of	IN	False
DDI-MedLine.d118.s2	sirolimus	148	156	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d118.s2	does	158	161	O	does	oes	does	VBZ	False
DDI-MedLine.d118.s2	not	163	165	O	not	not	not	RB	False
DDI-MedLine.d118.s2	appear	167	172	O	appear	ear	pear	VB	False
DDI-MedLine.d118.s2	to	174	175	O	to	to	to	TO	False
DDI-MedLine.d118.s2	overlap	177	183	O	overlap	lap	rlap	NN	False
DDI-MedLine.d118.s2	to	185	186	O	to	to	to	TO	False
DDI-MedLine.d118.s2	any	188	190	O	any	any	any	DT	False
DDI-MedLine.d118.s2	great	192	196	O	great	eat	reat	JJ	False
DDI-MedLine.d118.s2	extent	198	203	O	extent	ent	tent	NN	False
DDI-MedLine.d118.s2	with	205	208	O	with	ith	with	IN	False
DDI-MedLine.d118.s2	that	210	213	O	that	hat	that	IN	False
DDI-MedLine.d118.s2	associated	215	224	O	associated	ted	ated	VBN	False
DDI-MedLine.d118.s2	with	226	229	O	with	ith	with	IN	False
DDI-MedLine.d118.s2	cyclosporine	231	242	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d118.s2	or	244	245	O	or	or	or	CC	False
DDI-MedLine.d118.s2	tacrolimus	247	256	B-drug	tacrolimus	mus	imus	NN	False
DDI-MedLine.d118.s2	.	257	257	O	.	.	.	.	False

DDI-MedLine.d118.s3	While	0	4	O	While	ile	hile	IN	False
DDI-MedLine.d118.s3	additional	6	15	O	additional	nal	onal	JJ	False
DDI-MedLine.d118.s3	research	17	24	O	research	rch	arch	NN	False
DDI-MedLine.d118.s3	is	26	27	O	is	is	is	VBZ	False
DDI-MedLine.d118.s3	needed	29	34	O	needed	ded	eded	VBN	False
DDI-MedLine.d118.s3	,	35	35	O	,	,	,	,	False
DDI-MedLine.d118.s3	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d118.s3	initial	41	47	O	initial	ial	tial	JJ	False
DDI-MedLine.d118.s3	clinical	49	56	O	clinical	cal	ical	JJ	False
DDI-MedLine.d118.s3	data	58	61	O	data	ata	data	NNS	False
DDI-MedLine.d118.s3	in	63	64	O	in	in	in	IN	False
DDI-MedLine.d118.s3	kidney	66	71	O	kidney	ney	dney	NN	False
DDI-MedLine.d118.s3	recipients	73	82	O	recipients	nts	ents	NNS	False
DDI-MedLine.d118.s3	suggest	84	90	O	suggest	est	gest	NN	False
DDI-MedLine.d118.s3	that	92	95	O	that	hat	that	IN	False
DDI-MedLine.d118.s3	sirolimus	97	105	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d118.s3	,	106	106	O	,	,	,	,	False
DDI-MedLine.d118.s3	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d118.s3	combination	111	121	O	combination	ion	tion	NN	False
DDI-MedLine.d118.s3	with	123	126	O	with	ith	with	IN	False
DDI-MedLine.d118.s3	cyclosporine	128	139	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d118.s3	or	141	142	O	or	or	or	CC	False
DDI-MedLine.d118.s3	tacrolimus	144	153	B-drug	tacrolimus	mus	imus	NN	False
DDI-MedLine.d118.s3	,	154	154	O	,	,	,	,	False
DDI-MedLine.d118.s3	might	156	160	O	might	ght	ight	MD	False
DDI-MedLine.d118.s3	have	162	165	O	have	ave	have	VB	False
DDI-MedLine.d118.s3	the	167	169	O	the	the	the	DT	False
DDI-MedLine.d118.s3	potential	171	179	O	potential	ial	tial	JJ	False
DDI-MedLine.d118.s3	to	181	182	O	to	to	to	TO	False
DDI-MedLine.d118.s3	reduce	184	189	O	reduce	uce	duce	VB	False
DDI-MedLine.d118.s3	the	191	193	O	the	the	the	DT	False
DDI-MedLine.d118.s3	frequency	195	203	O	frequency	ncy	ency	NN	False
DDI-MedLine.d118.s3	of	205	206	O	of	of	of	IN	False
DDI-MedLine.d118.s3	rejection	208	216	O	rejection	ion	tion	NN	False
DDI-MedLine.d118.s3	episodes	218	225	O	episodes	des	odes	NNS	False
DDI-MedLine.d118.s3	,	226	226	O	,	,	,	,	False
DDI-MedLine.d118.s3	permit	228	233	O	permit	mit	rmit	NN	False
DDI-MedLine.d118.s3	reductions	235	244	O	reductions	ons	ions	NNS	False
DDI-MedLine.d118.s3	in	246	247	O	in	in	in	IN	False
DDI-MedLine.d118.s3	cyclosporine	249	260	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d118.s3	or	262	263	O	or	or	or	CC	False
DDI-MedLine.d118.s3	tacrolimus	265	274	B-drug	tacrolimus	mus	imus	NN	False
DDI-MedLine.d118.s3	dosage	276	281	O	dosage	age	sage	NN	False
DDI-MedLine.d118.s3	,	282	282	O	,	,	,	,	False
DDI-MedLine.d118.s3	and	284	286	O	and	and	and	CC	False
DDI-MedLine.d118.s3	permit	288	293	O	permit	mit	rmit	NN	False
DDI-MedLine.d118.s3	steroid	295	301	O	steroid	oid	roid	NN	False
DDI-MedLine.d118.s3	withdrawal	303	312	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d118.s3	(	314	314	O	(	(	(	(	False
DDI-MedLine.d118.s3	Kelly	315	319	O	Kelly	lly	elly	RB	False
DDI-MedLine.d118.s3	,	320	320	O	,	,	,	,	False
DDI-MedLine.d118.s3	1999	322	325	O	1999	999	1999	CD	False
DDI-MedLine.d118.s3	)	326	326	O	)	)	)	)	False
DDI-MedLine.d118.s3	.	327	327	O	.	.	.	.	False

DDI-MedLine.d105.s0	Lack	0	3	O	Lack	ack	Lack	NN	False
DDI-MedLine.d105.s0	of	5	6	O	of	of	of	IN	False
DDI-MedLine.d105.s0	an	8	9	O	an	an	an	DT	False
DDI-MedLine.d105.s0	effect	11	16	O	effect	ect	fect	NN	False
DDI-MedLine.d105.s0	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d105.s0	azithromycin	21	32	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s0	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d105.s0	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d105.s0	disposition	41	51	O	disposition	ion	tion	NN	False
DDI-MedLine.d105.s0	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d105.s0	zidovudine	56	65	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s0	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d105.s0	dideoxyinosine	71	84	B-drug	dideoxyinosine	ine	sine	NN	drug
DDI-MedLine.d105.s0	in	86	87	O	in	in	in	IN	False
DDI-MedLine.d105.s0	HIV-infected	89	100	O	HIV-infected	ted	cted	JJ	False
DDI-MedLine.d105.s0	patients	102	109	O	patients	nts	ents	NNS	False
DDI-MedLine.d105.s0	.	110	110	O	.	.	.	.	False

DDI-MedLine.d105.s1	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d105.s1	studies	4	10	O	studies	ies	dies	NNS	False
DDI-MedLine.d105.s1	were	12	15	O	were	ere	were	VBD	False
DDI-MedLine.d105.s1	conducted	17	25	O	conducted	ted	cted	VBN	False
DDI-MedLine.d105.s1	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d105.s1	HIV-infected	30	41	O	HIV-infected	ted	cted	JJ	False
DDI-MedLine.d105.s1	subjects	43	50	O	subjects	cts	ects	NNS	False
DDI-MedLine.d105.s1	to	52	53	O	to	to	to	TO	False
DDI-MedLine.d105.s1	assess	55	60	O	assess	ess	sess	NN	False
DDI-MedLine.d105.s1	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d105.s1	potential	66	74	O	potential	ial	tial	JJ	False
DDI-MedLine.d105.s1	for	76	78	O	for	for	for	IN	False
DDI-MedLine.d105.s1	azithromycin	80	91	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s1	to	93	94	O	to	to	to	TO	False
DDI-MedLine.d105.s1	interact	96	103	O	interact	act	ract	NN	False
DDI-MedLine.d105.s1	with	105	108	O	with	ith	with	IN	False
DDI-MedLine.d105.s1	zidovudine	110	119	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s1	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d105.s1	dideoxyinosine	125	138	B-drug	dideoxyinosine	ine	sine	NN	drug
DDI-MedLine.d105.s1	.	139	139	O	.	.	.	.	False

DDI-MedLine.d105.s2	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d105.s2	studies	5	11	O	studies	ies	dies	NNS	False
DDI-MedLine.d105.s2	used	13	16	O	used	sed	used	VBN	False
DDI-MedLine.d105.s2	12	18	19	O	12	12	12	CD	False
DDI-MedLine.d105.s2	subjects	21	28	O	subjects	cts	ects	NNS	False
DDI-MedLine.d105.s2	.	29	29	O	.	.	.	.	False

DDI-MedLine.d105.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d105.s3	zidovudine	4	13	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s3	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d105.s3	dosed	21	25	O	dosed	sed	osed	VBN	False
DDI-MedLine.d105.s3	subjects	27	34	O	subjects	cts	ects	NNS	False
DDI-MedLine.d105.s3	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d105.s3	1200	41	44	O	1200	200	1200	CD	False
DDI-MedLine.d105.s3	mg/day	46	51	O	mg/day	day	/day	NN	False
DDI-MedLine.d105.s3	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d105.s3	azithromycin	56	67	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s3	(	69	69	O	(	(	(	(	False
DDI-MedLine.d105.s3	n	70	70	O	n	n	n	NN	False
DDI-MedLine.d105.s3	=	72	72	O	=	=	=	NN	False
DDI-MedLine.d105.s3	7	74	74	O	7	7	7	CD	False
DDI-MedLine.d105.s3	)	75	75	O	)	)	)	)	False
DDI-MedLine.d105.s3	(	77	77	O	(	(	(	(	False
DDI-MedLine.d105.s3	later	78	82	O	later	ter	ater	RB	False
DDI-MedLine.d105.s3	changed	84	90	O	changed	ged	nged	VBN	False
DDI-MedLine.d105.s3	to	92	93	O	to	to	to	TO	False
DDI-MedLine.d105.s3	600	95	97	O	600	600	600	CD	False
DDI-MedLine.d105.s3	mg/day	99	104	O	mg/day	day	/day	NN	False
DDI-MedLine.d105.s3	[	106	106	O	[	[	[	NN	False
DDI-MedLine.d105.s3	n	107	107	O	n	n	n	NN	False
DDI-MedLine.d105.s3	=	109	109	O	=	=	=	NN	False
DDI-MedLine.d105.s3	5	111	111	O	5	5	5	CD	False
DDI-MedLine.d105.s3	]	112	112	O	]	]	]	NN	False
DDI-MedLine.d105.s3	)	113	113	O	)	)	)	)	False
DDI-MedLine.d105.s3	for	115	117	O	for	for	for	IN	False
DDI-MedLine.d105.s3	Days	119	122	O	Days	ays	Days	NNS	False
DDI-MedLine.d105.s3	8	124	124	O	8	8	8	CD	False
DDI-MedLine.d105.s3	to	126	127	O	to	to	to	TO	False
DDI-MedLine.d105.s3	21	129	130	O	21	21	21	CD	False
DDI-MedLine.d105.s3	of	132	133	O	of	of	of	IN	False
DDI-MedLine.d105.s3	a	135	135	O	a	a	a	DT	False
DDI-MedLine.d105.s3	21-day	137	142	O	21-day	day	-day	JJ	False
DDI-MedLine.d105.s3	course	144	149	O	course	rse	urse	NN	False
DDI-MedLine.d105.s3	of	151	152	O	of	of	of	IN	False
DDI-MedLine.d105.s3	100	154	156	O	100	100	100	CD	False
DDI-MedLine.d105.s3	mg	158	159	O	mg	mg	mg	NN	False
DDI-MedLine.d105.s3	,	160	160	O	,	,	,	,	False
DDI-MedLine.d105.s3	five	162	165	O	five	ive	five	CD	False
DDI-MedLine.d105.s3	times/day	167	175	O	times/day	day	/day	NN	False
DDI-MedLine.d105.s3	of	177	178	O	of	of	of	IN	False
DDI-MedLine.d105.s3	zidovudine	180	189	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s3	.	190	190	O	.	.	.	.	False

DDI-MedLine.d105.s4	Subjects	0	7	O	Subjects	cts	ects	NNS	False
DDI-MedLine.d105.s4	treated	9	15	O	treated	ted	ated	VBN	False
DDI-MedLine.d105.s4	with	17	20	O	with	ith	with	IN	False
DDI-MedLine.d105.s4	200	22	24	O	200	200	200	CD	False
DDI-MedLine.d105.s4	mg	26	27	O	mg	mg	mg	NN	False
DDI-MedLine.d105.s4	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d105.s4	dideoxyinosine	32	45	B-drug	dideoxyinosine	ine	sine	NN	drug
DDI-MedLine.d105.s4	twice	47	51	O	twice	ice	wice	RB	False
DDI-MedLine.d105.s4	daily	53	57	O	daily	ily	aily	JJ	False
DDI-MedLine.d105.s4	for	59	61	O	for	for	for	IN	False
DDI-MedLine.d105.s4	21	63	64	O	21	21	21	CD	False
DDI-MedLine.d105.s4	days	66	69	O	days	ays	days	NNS	False
DDI-MedLine.d105.s4	received	71	78	O	received	ved	ived	VBN	False
DDI-MedLine.d105.s4	1200	80	83	O	1200	200	1200	CD	False
DDI-MedLine.d105.s4	mg	85	86	O	mg	mg	mg	NN	False
DDI-MedLine.d105.s4	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d105.s4	azithromycin	91	102	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s4	or	104	105	O	or	or	or	CC	False
DDI-MedLine.d105.s4	an	107	108	O	an	an	an	DT	False
DDI-MedLine.d105.s4	equivalent	110	119	O	equivalent	ent	lent	NN	False
DDI-MedLine.d105.s4	amount	121	126	O	amount	unt	ount	NN	False
DDI-MedLine.d105.s4	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d105.s4	placebo/day	131	141	O	placebo/day	day	/day	NN	False
DDI-MedLine.d105.s4	for	143	145	O	for	for	for	IN	False
DDI-MedLine.d105.s4	Days	147	150	O	Days	ays	Days	NNS	False
DDI-MedLine.d105.s4	8	152	152	O	8	8	8	CD	False
DDI-MedLine.d105.s4	to	154	155	O	to	to	to	TO	False
DDI-MedLine.d105.s4	21	157	158	O	21	21	21	CD	False
DDI-MedLine.d105.s4	.	159	159	O	.	.	.	.	False

DDI-MedLine.d105.s5	Antiretroviral	0	13	B-group	Antiretroviral	ral	iral	JJ	False
DDI-MedLine.d105.s5	plasma	15	20	O	plasma	sma	asma	NN	False
DDI-MedLine.d105.s5	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d105.s5	urine	26	30	O	urine	ine	rine	NN	drug
DDI-MedLine.d105.s5	sampling	32	39	O	sampling	ing	ling	VBG	False
DDI-MedLine.d105.s5	were	41	44	O	were	ere	were	VBD	False
DDI-MedLine.d105.s5	conducted	46	54	O	conducted	ted	cted	VBN	False
DDI-MedLine.d105.s5	on	56	57	O	on	on	on	IN	False
DDI-MedLine.d105.s5	Days	59	62	O	Days	ays	Days	NNS	False
DDI-MedLine.d105.s5	1	64	64	O	1	1	1	CD	False
DDI-MedLine.d105.s5	,	65	65	O	,	,	,	,	False
DDI-MedLine.d105.s5	7	67	67	O	7	7	7	CD	False
DDI-MedLine.d105.s5	,	68	68	O	,	,	,	,	False
DDI-MedLine.d105.s5	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d105.s5	21	74	75	O	21	21	21	CD	False
DDI-MedLine.d105.s5	for	77	79	O	for	for	for	IN	False
DDI-MedLine.d105.s5	zidovudine	81	90	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s5	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d105.s5	on	96	97	O	on	on	on	IN	False
DDI-MedLine.d105.s5	Days	99	102	O	Days	ays	Days	NNS	False
DDI-MedLine.d105.s5	7	104	104	O	7	7	7	CD	False
DDI-MedLine.d105.s5	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d105.s5	21	110	111	O	21	21	21	CD	False
DDI-MedLine.d105.s5	for	113	115	O	for	for	for	IN	False
DDI-MedLine.d105.s5	dideoxyinosine	117	130	B-drug	dideoxyinosine	ine	sine	NN	drug
DDI-MedLine.d105.s5	.	131	131	O	.	.	.	.	False

DDI-MedLine.d105.s6	Peripheral	0	9	O	Peripheral	ral	eral	JJ	False
DDI-MedLine.d105.s6	mononuclear	11	21	O	mononuclear	ear	lear	NN	False
DDI-MedLine.d105.s6	cells	23	27	O	cells	lls	ells	NNS	False
DDI-MedLine.d105.s6	were	29	32	O	were	ere	were	VBD	False
DDI-MedLine.d105.s6	also	34	37	O	also	lso	also	RB	False
DDI-MedLine.d105.s6	collected	39	47	O	collected	ted	cted	VBN	False
DDI-MedLine.d105.s6	for	49	51	O	for	for	for	IN	False
DDI-MedLine.d105.s6	quantitation	53	64	O	quantitation	ion	tion	NN	False
DDI-MedLine.d105.s6	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d105.s6	phosphorylated	69	82	O	phosphorylated	ted	ated	VBN	False
DDI-MedLine.d105.s6	zidovudine	84	93	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s6	.	94	94	O	.	.	.	.	False

DDI-MedLine.d105.s7	Azithromycin	0	11	B-drug	Azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s7	had	13	15	O	had	had	had	VBD	False
DDI-MedLine.d105.s7	no	17	18	O	no	no	no	DT	False
DDI-MedLine.d105.s7	significant	20	30	O	significant	ant	cant	JJ	False
DDI-MedLine.d105.s7	impact	32	37	O	impact	act	pact	NN	False
DDI-MedLine.d105.s7	on	39	40	O	on	on	on	IN	False
DDI-MedLine.d105.s7	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d105.s7	Cmax	46	49	O	Cmax	max	Cmax	NN	False
DDI-MedLine.d105.s7	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d105.s7	AUC	55	57	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d105.s7	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d105.s7	zidovudine	62	71	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s7	,	72	72	O	,	,	,	,	False
DDI-MedLine.d105.s7	although	74	81	O	although	ugh	ough	IN	False
DDI-MedLine.d105.s7	it	83	84	O	it	it	it	PRP	False
DDI-MedLine.d105.s7	significantly	86	98	O	significantly	tly	ntly	RB	False
DDI-MedLine.d105.s7	decreased	100	108	O	decreased	sed	ased	VBN	False
DDI-MedLine.d105.s7	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d105.s7	zidovudine	114	123	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s7	tmax	125	128	O	tmax	max	tmax	NN	False
DDI-MedLine.d105.s7	by	130	131	O	by	by	by	IN	False
DDI-MedLine.d105.s7	44	133	134	O	44	44	44	CD	False
DDI-MedLine.d105.s7	%	135	135	O	%	%	%	NN	False
DDI-MedLine.d105.s7	and	137	139	O	and	and	and	CC	False
DDI-MedLine.d105.s7	increased	141	149	O	increased	sed	ased	VBN	False
DDI-MedLine.d105.s7	the	151	153	O	the	the	the	DT	False
DDI-MedLine.d105.s7	intracellular	155	167	O	intracellular	lar	ular	NN	False
DDI-MedLine.d105.s7	exposure	169	176	O	exposure	ure	sure	NN	False
DDI-MedLine.d105.s7	to	178	179	O	to	to	to	TO	False
DDI-MedLine.d105.s7	phosphorylated	181	194	O	phosphorylated	ted	ated	VBN	False
DDI-MedLine.d105.s7	zidovudine	196	205	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s7	by	207	208	O	by	by	by	IN	False
DDI-MedLine.d105.s7	110	210	212	O	110	110	110	CD	False
DDI-MedLine.d105.s7	%	213	213	O	%	%	%	NN	False
DDI-MedLine.d105.s7	.	214	214	O	.	.	.	.	False

DDI-MedLine.d105.s8	Azithromycin	0	11	B-drug	Azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s8	had	13	15	O	had	had	had	VBD	False
DDI-MedLine.d105.s8	no	17	18	O	no	no	no	DT	False
DDI-MedLine.d105.s8	significant	20	30	O	significant	ant	cant	JJ	False
DDI-MedLine.d105.s8	effect	32	37	O	effect	ect	fect	NN	False
DDI-MedLine.d105.s8	on	39	40	O	on	on	on	IN	False
DDI-MedLine.d105.s8	dideoxyinosine	42	55	B-drug	dideoxyinosine	ine	sine	NN	drug
DDI-MedLine.d105.s8	pharmacokinetics	57	72	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d105.s8	.	73	73	O	.	.	.	.	False

DDI-MedLine.d105.s9	Based	0	4	O	Based	sed	ased	VBN	False
DDI-MedLine.d105.s9	on	6	7	O	on	on	on	IN	False
DDI-MedLine.d105.s9	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d105.s9	results	13	19	O	results	lts	ults	NNS	False
DDI-MedLine.d105.s9	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d105.s9	these	24	28	O	these	ese	hese	DT	False
DDI-MedLine.d105.s9	studies	30	36	O	studies	ies	dies	NNS	False
DDI-MedLine.d105.s9	,	37	37	O	,	,	,	,	False
DDI-MedLine.d105.s9	it	39	40	O	it	it	it	PRP	False
DDI-MedLine.d105.s9	is	42	43	O	is	is	is	VBZ	False
DDI-MedLine.d105.s9	concluded	45	53	O	concluded	ded	uded	VBD	False
DDI-MedLine.d105.s9	that	55	58	O	that	hat	that	IN	False
DDI-MedLine.d105.s9	azithromycin	60	71	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d105.s9	may	73	75	O	may	may	may	MD	False
DDI-MedLine.d105.s9	be	77	78	O	be	be	be	VB	False
DDI-MedLine.d105.s9	safely	80	85	O	safely	ely	fely	RB	False
DDI-MedLine.d105.s9	coadministered	87	100	O	coadministered	red	ered	VBN	False
DDI-MedLine.d105.s9	with	102	105	O	with	ith	with	IN	False
DDI-MedLine.d105.s9	both	107	110	O	both	oth	both	DT	False
DDI-MedLine.d105.s9	zidovudine	112	121	B-drug	zidovudine	ine	dine	NN	drug
DDI-MedLine.d105.s9	and	123	125	O	and	and	and	CC	False
DDI-MedLine.d105.s9	dideoxyinosine	127	140	B-drug	dideoxyinosine	ine	sine	NN	drug
DDI-MedLine.d105.s9	.	141	141	O	.	.	.	.	False

DDI-MedLine.d126.s0	Cypermethrin-induced	0	19	O	Cypermethrin-induced	ced	uced	JJ	False
DDI-MedLine.d126.s0	oxidative	21	29	O	oxidative	ive	tive	JJ	False
DDI-MedLine.d126.s0	stress	31	36	O	stress	ess	ress	NN	False
DDI-MedLine.d126.s0	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d126.s0	rat	41	43	O	rat	rat	rat	NN	False
DDI-MedLine.d126.s0	brain	45	49	O	brain	ain	rain	NN	False
DDI-MedLine.d126.s0	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d126.s0	liver	55	59	O	liver	ver	iver	NN	False
DDI-MedLine.d126.s0	is	61	62	O	is	is	is	VBZ	False
DDI-MedLine.d126.s0	prevented	64	72	O	prevented	ted	nted	VBN	False
DDI-MedLine.d126.s0	by	74	75	O	by	by	by	IN	False
DDI-MedLine.d126.s0	vitamin	77	83	B-drug	vitamin	min	amin	NN	False
DDI-MedLine.d126.s0	E	85	85	I-drug	E	E	E	NN	brand
DDI-MedLine.d126.s0	or	87	88	O	or	or	or	CC	False
DDI-MedLine.d126.s0	allopurinol	90	100	B-drug	allopurinol	nol	inol	NN	False
DDI-MedLine.d126.s0	.	101	101	O	.	.	.	.	False

DDI-MedLine.d126.s1	Considering	0	10	O	Considering	ing	ring	VBG	False
DDI-MedLine.d126.s1	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d126.s1	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d126.s1	involvement	21	31	O	involvement	ent	ment	NN	False
DDI-MedLine.d126.s1	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d126.s1	reactive	36	43	O	reactive	ive	tive	NN	False
DDI-MedLine.d126.s1	oxygen	45	50	O	oxygen	gen	ygen	NN	brand
DDI-MedLine.d126.s1	species	52	58	O	species	ies	cies	NNS	False
DDI-MedLine.d126.s1	(	60	60	O	(	(	(	(	False
DDI-MedLine.d126.s1	ROS	61	63	O	ROS	ROS	ROS	NN	brand
DDI-MedLine.d126.s1	)	64	64	O	)	)	)	)	False
DDI-MedLine.d126.s1	has	66	68	O	has	has	has	VBZ	False
DDI-MedLine.d126.s1	been	70	73	O	been	een	been	VBN	False
DDI-MedLine.d126.s1	implicated	75	84	O	implicated	ted	ated	VBN	False
DDI-MedLine.d126.s1	in	86	87	O	in	in	in	IN	False
DDI-MedLine.d126.s1	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d126.s1	toxicity	93	100	O	toxicity	ity	city	NN	False
DDI-MedLine.d126.s1	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d126.s1	various	105	111	O	various	ous	ious	JJ	False
DDI-MedLine.d126.s1	pesticides	113	122	O	pesticides	des	ides	NNS	group
DDI-MedLine.d126.s1	,	123	123	O	,	,	,	,	False
DDI-MedLine.d126.s1	this	125	128	O	this	his	this	DT	False
DDI-MedLine.d126.s1	study	130	134	O	study	udy	tudy	NN	False
DDI-MedLine.d126.s1	was	136	138	O	was	was	was	VBD	False
DDI-MedLine.d126.s1	designed	140	147	O	designed	ned	gned	VBN	False
DDI-MedLine.d126.s1	to	149	150	O	to	to	to	TO	False
DDI-MedLine.d126.s1	investigate	152	162	O	investigate	ate	gate	NN	False
DDI-MedLine.d126.s1	the	164	166	O	the	the	the	DT	False
DDI-MedLine.d126.s1	possibility	168	178	O	possibility	ity	lity	NN	False
DDI-MedLine.d126.s1	of	180	181	O	of	of	of	IN	False
DDI-MedLine.d126.s1	oxidative	183	191	O	oxidative	ive	tive	JJ	False
DDI-MedLine.d126.s1	stress	193	198	O	stress	ess	ress	NN	False
DDI-MedLine.d126.s1	induction	200	208	O	induction	ion	tion	NN	False
DDI-MedLine.d126.s1	by	210	211	O	by	by	by	IN	False
DDI-MedLine.d126.s1	cypermethrin	213	224	B-drug	cypermethrin	rin	hrin	NN	False
DDI-MedLine.d126.s1	,	225	225	O	,	,	,	,	False
DDI-MedLine.d126.s1	a	227	227	O	a	a	a	DT	False
DDI-MedLine.d126.s1	Type	229	232	B-drug_n	Type	ype	Type	NN	False
DDI-MedLine.d126.s1	II	234	235	I-drug_n	II	II	II	NN	brand
DDI-MedLine.d126.s1	pyrethroid	237	246	I-drug_n	pyrethroid	oid	roid	NN	False
DDI-MedLine.d126.s1	.	247	247	O	.	.	.	.	False

DDI-MedLine.d126.s2	Either	0	5	O	Either	her	ther	DT	False
DDI-MedLine.d126.s2	single	7	12	O	single	gle	ngle	JJ	False
DDI-MedLine.d126.s2	(	14	14	O	(	(	(	(	False
DDI-MedLine.d126.s2	170	15	17	O	170	170	170	CD	False
DDI-MedLine.d126.s2	mg/kg	19	23	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d126.s2	)	24	24	O	)	)	)	)	False
DDI-MedLine.d126.s2	or	26	27	O	or	or	or	CC	False
DDI-MedLine.d126.s2	repeated	29	36	O	repeated	ted	ated	VBN	False
DDI-MedLine.d126.s2	(	38	38	O	(	(	(	(	False
DDI-MedLine.d126.s2	75	39	40	O	75	75	75	CD	False
DDI-MedLine.d126.s2	mg/kg	42	46	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d126.s2	per	48	50	O	per	per	per	IN	False
DDI-MedLine.d126.s2	day	52	54	O	day	day	day	NN	False
DDI-MedLine.d126.s2	for	56	58	O	for	for	for	IN	False
DDI-MedLine.d126.s2	5	60	60	O	5	5	5	CD	False
DDI-MedLine.d126.s2	days	62	65	O	days	ays	days	NNS	False
DDI-MedLine.d126.s2	)	66	66	O	)	)	)	)	False
DDI-MedLine.d126.s2	oral	68	71	O	oral	ral	oral	JJ	False
DDI-MedLine.d126.s2	administration	73	86	O	administration	ion	tion	NN	False
DDI-MedLine.d126.s2	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d126.s2	cypermethrin	91	102	B-drug	cypermethrin	rin	hrin	NN	False
DDI-MedLine.d126.s2	was	104	106	O	was	was	was	VBD	False
DDI-MedLine.d126.s2	found	108	112	O	found	und	ound	NN	False
DDI-MedLine.d126.s2	to	114	115	O	to	to	to	TO	False
DDI-MedLine.d126.s2	produce	117	123	O	produce	uce	duce	NN	False
DDI-MedLine.d126.s2	significant	125	135	O	significant	ant	cant	JJ	False
DDI-MedLine.d126.s2	oxidative	137	145	O	oxidative	ive	tive	JJ	False
DDI-MedLine.d126.s2	stress	147	152	O	stress	ess	ress	NN	False
DDI-MedLine.d126.s2	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d126.s2	cerebral	157	164	O	cerebral	ral	bral	JJ	False
DDI-MedLine.d126.s2	and	166	168	O	and	and	and	CC	False
DDI-MedLine.d126.s2	hepatic	170	176	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d126.s2	tissues	178	184	O	tissues	ues	sues	NNS	False
DDI-MedLine.d126.s2	of	186	187	O	of	of	of	IN	False
DDI-MedLine.d126.s2	rats	189	192	O	rats	ats	rats	NNS	False
DDI-MedLine.d126.s2	,	193	193	O	,	,	,	,	False
DDI-MedLine.d126.s2	as	195	196	O	as	as	as	IN	False
DDI-MedLine.d126.s2	was	198	200	O	was	was	was	VBD	False
DDI-MedLine.d126.s2	evident	202	208	O	evident	ent	dent	NN	False
DDI-MedLine.d126.s2	by	210	211	O	by	by	by	IN	False
DDI-MedLine.d126.s2	the	213	215	O	the	the	the	DT	False
DDI-MedLine.d126.s2	elevation	217	225	O	elevation	ion	tion	NN	False
DDI-MedLine.d126.s2	of	227	228	O	of	of	of	IN	False
DDI-MedLine.d126.s2	the	230	232	O	the	the	the	DT	False
DDI-MedLine.d126.s2	level	234	238	O	level	vel	evel	NN	False
DDI-MedLine.d126.s2	of	240	241	O	of	of	of	IN	False
DDI-MedLine.d126.s2	thiobarbituric	243	256	O	thiobarbituric	ric	uric	NN	False
DDI-MedLine.d126.s2	acid	258	261	O	acid	cid	acid	NN	False
DDI-MedLine.d126.s2	reactive	263	270	O	reactive	ive	tive	NN	False
DDI-MedLine.d126.s2	substances	272	281	O	substances	ces	nces	NNS	False
DDI-MedLine.d126.s2	(	283	283	O	(	(	(	(	False
DDI-MedLine.d126.s2	TBARS	284	288	O	TBARS	ARS	BARS	NNS	brand
DDI-MedLine.d126.s2	)	289	289	O	)	)	)	)	False
DDI-MedLine.d126.s2	in	291	292	O	in	in	in	IN	False
DDI-MedLine.d126.s2	both	294	297	O	both	oth	both	DT	False
DDI-MedLine.d126.s2	tissues	299	305	O	tissues	ues	sues	NNS	False
DDI-MedLine.d126.s2	,	306	306	O	,	,	,	,	False
DDI-MedLine.d126.s2	either	308	313	O	either	her	ther	DT	False
DDI-MedLine.d126.s2	4	315	315	O	4	4	4	CD	False
DDI-MedLine.d126.s2	or	317	318	O	or	or	or	CC	False
DDI-MedLine.d126.s2	24	320	321	O	24	24	24	CD	False
DDI-MedLine.d126.s2	h	323	323	O	h	h	h	NN	False
DDI-MedLine.d126.s2	after	325	329	O	after	ter	fter	IN	False
DDI-MedLine.d126.s2	treatment	331	339	O	treatment	ent	ment	NN	False
DDI-MedLine.d126.s2	.	340	340	O	.	.	.	.	False

DDI-MedLine.d126.s3	Much	0	3	O	Much	uch	Much	JJ	False
DDI-MedLine.d126.s3	higher	5	10	O	higher	her	gher	JJR	False
DDI-MedLine.d126.s3	changes	12	18	O	changes	ges	nges	NNS	False
DDI-MedLine.d126.s3	were	20	23	O	were	ere	were	VBD	False
DDI-MedLine.d126.s3	observed	25	32	O	observed	ved	rved	VBN	False
DDI-MedLine.d126.s3	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d126.s3	liver	37	41	O	liver	ver	iver	NN	False
DDI-MedLine.d126.s3	,	42	42	O	,	,	,	,	False
DDI-MedLine.d126.s3	increasing	44	53	O	increasing	ing	sing	VBG	False
DDI-MedLine.d126.s3	from	55	58	O	from	rom	from	IN	False
DDI-MedLine.d126.s3	a	60	60	O	a	a	a	DT	False
DDI-MedLine.d126.s3	level	62	66	O	level	vel	evel	NN	False
DDI-MedLine.d126.s3	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d126.s3	60	71	72	O	60	60	60	CD	False
DDI-MedLine.d126.s3	%	73	73	O	%	%	%	NN	False
DDI-MedLine.d126.s3	at	75	76	O	at	at	at	IN	False
DDI-MedLine.d126.s3	4	78	78	O	4	4	4	CD	False
DDI-MedLine.d126.s3	h	80	80	O	h	h	h	NN	False
DDI-MedLine.d126.s3	up	82	83	O	up	up	up	RB	False
DDI-MedLine.d126.s3	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d126.s3	nearly	88	93	O	nearly	rly	arly	RB	False
DDI-MedLine.d126.s3	4	95	95	O	4	4	4	CD	False
DDI-MedLine.d126.s3	times	97	101	O	times	mes	imes	NNS	False
DDI-MedLine.d126.s3	the	103	105	O	the	the	the	DT	False
DDI-MedLine.d126.s3	control	107	113	O	control	rol	trol	NN	False
DDI-MedLine.d126.s3	at	115	116	O	at	at	at	IN	False
DDI-MedLine.d126.s3	24	118	119	O	24	24	24	CD	False
DDI-MedLine.d126.s3	h	121	121	O	h	h	h	NN	False
DDI-MedLine.d126.s3	for	123	125	O	for	for	for	IN	False
DDI-MedLine.d126.s3	single	127	132	O	single	gle	ngle	JJ	False
DDI-MedLine.d126.s3	dose	134	137	O	dose	ose	dose	NN	False
DDI-MedLine.d126.s3	.	138	138	O	.	.	.	.	False

DDI-MedLine.d126.s4	Reduced	0	6	O	Reduced	ced	uced	VBN	False
DDI-MedLine.d126.s4	levels	8	13	O	levels	els	vels	NNS	False
DDI-MedLine.d126.s4	(	15	15	O	(	(	(	(	False
DDI-MedLine.d126.s4	up	16	17	O	up	up	up	RB	False
DDI-MedLine.d126.s4	to	19	20	O	to	to	to	TO	False
DDI-MedLine.d126.s4	20	22	23	O	20	20	20	CD	False
DDI-MedLine.d126.s4	%	24	24	O	%	%	%	NN	False
DDI-MedLine.d126.s4	)	25	25	O	)	)	)	)	False
DDI-MedLine.d126.s4	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d126.s4	total	30	34	O	total	tal	otal	JJ	False
DDI-MedLine.d126.s4	glutathione	36	46	O	glutathione	one	ione	NN	False
DDI-MedLine.d126.s4	(	48	48	O	(	(	(	(	False
DDI-MedLine.d126.s4	total	49	53	O	total	tal	otal	JJ	False
DDI-MedLine.d126.s4	GSH	55	57	O	GSH	GSH	GSH	NN	brand
DDI-MedLine.d126.s4	)	58	58	O	)	)	)	)	False
DDI-MedLine.d126.s4	,	59	59	O	,	,	,	,	False
DDI-MedLine.d126.s4	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d126.s4	elevation	65	73	O	elevation	ion	tion	NN	False
DDI-MedLine.d126.s4	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d126.s4	conjugated	78	87	O	conjugated	ted	ated	VBN	False
DDI-MedLine.d126.s4	dienes	89	94	O	dienes	nes	enes	NNS	False
DDI-MedLine.d126.s4	(	96	96	O	(	(	(	(	False
DDI-MedLine.d126.s4	approximately	98	110	O	approximately	ely	tely	RB	False
DDI-MedLine.d126.s4	60	112	113	O	60	60	60	CD	False
DDI-MedLine.d126.s4	%	114	114	O	%	%	%	NN	False
DDI-MedLine.d126.s4	in	116	117	O	in	in	in	IN	False
DDI-MedLine.d126.s4	liver	119	123	O	liver	ver	iver	NN	False
DDI-MedLine.d126.s4	by	125	126	O	by	by	by	IN	False
DDI-MedLine.d126.s4	single	128	133	O	single	gle	ngle	JJ	False
DDI-MedLine.d126.s4	dose	135	138	O	dose	ose	dose	NN	False
DDI-MedLine.d126.s4	at	140	141	O	at	at	at	IN	False
DDI-MedLine.d126.s4	4	143	143	O	4	4	4	CD	False
DDI-MedLine.d126.s4	h	145	145	O	h	h	h	NN	False
DDI-MedLine.d126.s4	)	146	146	O	)	)	)	)	False
DDI-MedLine.d126.s4	also	148	151	O	also	lso	also	RB	False
DDI-MedLine.d126.s4	indicated	153	161	O	indicated	ted	ated	VBN	False
DDI-MedLine.d126.s4	the	163	165	O	the	the	the	DT	False
DDI-MedLine.d126.s4	presence	167	174	O	presence	nce	ence	NN	False
DDI-MedLine.d126.s4	of	176	177	O	of	of	of	IN	False
DDI-MedLine.d126.s4	an	179	180	O	an	an	an	DT	False
DDI-MedLine.d126.s4	oxidative	182	190	O	oxidative	ive	tive	JJ	False
DDI-MedLine.d126.s4	insult	192	197	O	insult	ult	sult	NN	False
DDI-MedLine.d126.s4	.	198	198	O	.	.	.	.	False

DDI-MedLine.d126.s5	Glutathione-S-transferase	0	24	O	Glutathione-S-transferase	ase	rase	NN	False
DDI-MedLine.d126.s5	(	26	26	O	(	(	(	(	False
DDI-MedLine.d126.s5	GST	27	29	O	GST	GST	GST	NN	brand
DDI-MedLine.d126.s5	)	30	30	O	)	)	)	)	False
DDI-MedLine.d126.s5	activity	32	39	O	activity	ity	vity	NN	False
DDI-MedLine.d126.s5	,	40	40	O	,	,	,	,	False
DDI-MedLine.d126.s5	however	42	48	O	however	ver	ever	RB	False
DDI-MedLine.d126.s5	,	49	49	O	,	,	,	,	False
DDI-MedLine.d126.s5	did	51	53	O	did	did	did	VBD	False
DDI-MedLine.d126.s5	not	55	57	O	not	not	not	RB	False
DDI-MedLine.d126.s5	differ	59	64	O	differ	fer	ffer	NN	False
DDI-MedLine.d126.s5	from	66	69	O	from	rom	from	IN	False
DDI-MedLine.d126.s5	control	71	77	O	control	rol	trol	NN	False
DDI-MedLine.d126.s5	values	79	84	O	values	ues	lues	NNS	False
DDI-MedLine.d126.s5	for	86	88	O	for	for	for	IN	False
DDI-MedLine.d126.s5	any	90	92	O	any	any	any	DT	False
DDI-MedLine.d126.s5	dose	94	97	O	dose	ose	dose	NN	False
DDI-MedLine.d126.s5	or	99	100	O	or	or	or	CC	False
DDI-MedLine.d126.s5	at	102	103	O	at	at	at	IN	False
DDI-MedLine.d126.s5	any	105	107	O	any	any	any	DT	False
DDI-MedLine.d126.s5	time	109	112	O	time	ime	time	NN	False
DDI-MedLine.d126.s5	point	114	118	O	point	int	oint	NN	False
DDI-MedLine.d126.s5	in	120	121	O	in	in	in	IN	False
DDI-MedLine.d126.s5	cerebral	123	130	O	cerebral	ral	bral	JJ	False
DDI-MedLine.d126.s5	and	132	134	O	and	and	and	CC	False
DDI-MedLine.d126.s5	hepatic	136	142	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d126.s5	tissues	144	150	O	tissues	ues	sues	NNS	False
DDI-MedLine.d126.s5	.	151	151	O	.	.	.	.	False

DDI-MedLine.d126.s6	Pretreatment	0	11	O	Pretreatment	ent	ment	NN	False
DDI-MedLine.d126.s6	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d126.s6	rats	16	19	O	rats	ats	rats	NNS	False
DDI-MedLine.d126.s6	with	21	24	O	with	ith	with	IN	False
DDI-MedLine.d126.s6	allopurinol	26	36	B-drug	allopurinol	nol	inol	NN	False
DDI-MedLine.d126.s6	(	38	38	O	(	(	(	(	False
DDI-MedLine.d126.s6	100	39	41	O	100	100	100	CD	False
DDI-MedLine.d126.s6	mg/kg	43	47	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d126.s6	,	48	48	O	,	,	,	,	False
DDI-MedLine.d126.s6	ip	50	51	O	ip	ip	ip	NN	False
DDI-MedLine.d126.s6	)	52	52	O	)	)	)	)	False
DDI-MedLine.d126.s6	or	54	55	O	or	or	or	CC	False
DDI-MedLine.d126.s6	Vitamin	57	63	B-drug	Vitamin	min	amin	NN	False
DDI-MedLine.d126.s6	E	65	65	I-drug	E	E	E	NN	brand
DDI-MedLine.d126.s6	(	67	67	O	(	(	(	(	False
DDI-MedLine.d126.s6	100	68	70	O	100	100	100	CD	False
DDI-MedLine.d126.s6	mg/kg	72	76	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d126.s6	per	78	80	O	per	per	per	IN	False
DDI-MedLine.d126.s6	day	82	84	O	day	day	day	NN	False
DDI-MedLine.d126.s6	,	85	85	O	,	,	,	,	False
DDI-MedLine.d126.s6	ig	87	88	O	ig	ig	ig	NN	False
DDI-MedLine.d126.s6	,	89	89	O	,	,	,	,	False
DDI-MedLine.d126.s6	for	91	93	O	for	for	for	IN	False
DDI-MedLine.d126.s6	3	95	95	O	3	3	3	CD	False
DDI-MedLine.d126.s6	days	97	100	O	days	ays	days	NNS	False
DDI-MedLine.d126.s6	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d126.s6	a	106	106	O	a	a	a	DT	False
DDI-MedLine.d126.s6	dose	108	111	O	dose	ose	dose	NN	False
DDI-MedLine.d126.s6	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d126.s6	40	116	117	O	40	40	40	CD	False
DDI-MedLine.d126.s6	mg/kg	119	123	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d126.s6	on	125	126	O	on	on	on	IN	False
DDI-MedLine.d126.s6	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d126.s6	4th	132	134	O	4th	4th	4th	CD	False
DDI-MedLine.d126.s6	day	136	138	O	day	day	day	NN	False
DDI-MedLine.d126.s6	)	139	139	O	)	)	)	)	False
DDI-MedLine.d126.s6	provided	141	148	O	provided	ded	ided	VBN	False
DDI-MedLine.d126.s6	significant	150	160	O	significant	ant	cant	JJ	False
DDI-MedLine.d126.s6	protection	162	171	O	protection	ion	tion	NN	False
DDI-MedLine.d126.s6	against	173	179	O	against	nst	inst	IN	False
DDI-MedLine.d126.s6	the	181	183	O	the	the	the	DT	False
DDI-MedLine.d126.s6	elevation	185	193	O	elevation	ion	tion	NN	False
DDI-MedLine.d126.s6	of	195	196	O	of	of	of	IN	False
DDI-MedLine.d126.s6	TBARS	198	202	O	TBARS	ARS	BARS	NNS	brand
DDI-MedLine.d126.s6	levels	204	209	O	levels	els	vels	NNS	False
DDI-MedLine.d126.s6	in	211	212	O	in	in	in	IN	False
DDI-MedLine.d126.s6	cerebral	214	221	O	cerebral	ral	bral	JJ	False
DDI-MedLine.d126.s6	and	223	225	O	and	and	and	CC	False
DDI-MedLine.d126.s6	hepatic	227	233	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d126.s6	tissues	235	241	O	tissues	ues	sues	NNS	False
DDI-MedLine.d126.s6	,	242	242	O	,	,	,	,	False
DDI-MedLine.d126.s6	induced	244	250	O	induced	ced	uced	JJ	False
DDI-MedLine.d126.s6	by	252	253	O	by	by	by	IN	False
DDI-MedLine.d126.s6	single	255	260	O	single	gle	ngle	JJ	False
DDI-MedLine.d126.s6	high	262	265	O	high	igh	high	JJ	False
DDI-MedLine.d126.s6	dose	267	270	O	dose	ose	dose	NN	False
DDI-MedLine.d126.s6	of	272	273	O	of	of	of	IN	False
DDI-MedLine.d126.s6	oral	275	278	O	oral	ral	oral	JJ	False
DDI-MedLine.d126.s6	cypermethrin	280	291	B-drug	cypermethrin	rin	hrin	NN	False
DDI-MedLine.d126.s6	administration	293	306	O	administration	ion	tion	NN	False
DDI-MedLine.d126.s6	within	308	313	O	within	hin	thin	IN	False
DDI-MedLine.d126.s6	4	315	315	O	4	4	4	CD	False
DDI-MedLine.d126.s6	h	317	317	O	h	h	h	NN	False
DDI-MedLine.d126.s6	.	318	318	O	.	.	.	.	False

DDI-MedLine.d126.s7	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d126.s7	,	4	4	O	,	,	,	,	False
DDI-MedLine.d126.s7	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d126.s7	results	10	16	O	results	lts	ults	NNS	False
DDI-MedLine.d126.s7	suggest	18	24	O	suggest	est	gest	NN	False
DDI-MedLine.d126.s7	that	26	29	O	that	hat	that	IN	False
DDI-MedLine.d126.s7	cypermethrin	31	42	B-drug	cypermethrin	rin	hrin	NN	False
DDI-MedLine.d126.s7	exposure	44	51	O	exposure	ure	sure	NN	False
DDI-MedLine.d126.s7	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d126.s7	rats	56	59	O	rats	ats	rats	NNS	False
DDI-MedLine.d126.s7	results	61	67	O	results	lts	ults	NNS	False
DDI-MedLine.d126.s7	in	69	70	O	in	in	in	IN	False
DDI-MedLine.d126.s7	free	72	75	O	free	ree	free	JJ	False
DDI-MedLine.d126.s7	radical-mediated	77	92	O	radical-mediated	ted	ated	JJ	False
DDI-MedLine.d126.s7	tissue	94	99	O	tissue	sue	ssue	NN	False
DDI-MedLine.d126.s7	damage	101	106	O	damage	age	mage	NN	False
DDI-MedLine.d126.s7	,	107	107	O	,	,	,	,	False
DDI-MedLine.d126.s7	as	109	110	O	as	as	as	IN	False
DDI-MedLine.d126.s7	indicated	112	120	O	indicated	ted	ated	VBN	False
DDI-MedLine.d126.s7	by	122	123	O	by	by	by	IN	False
DDI-MedLine.d126.s7	elevated	125	132	O	elevated	ted	ated	VBN	False
DDI-MedLine.d126.s7	cerebral	134	141	O	cerebral	ral	bral	JJ	False
DDI-MedLine.d126.s7	and	143	145	O	and	and	and	CC	False
DDI-MedLine.d126.s7	hepatic	147	153	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d126.s7	lipid	155	159	O	lipid	pid	ipid	NN	False
DDI-MedLine.d126.s7	peroxidation	161	172	O	peroxidation	ion	tion	NN	False
DDI-MedLine.d126.s7	,	173	173	O	,	,	,	,	False
DDI-MedLine.d126.s7	which	175	179	O	which	ich	hich	WDT	False
DDI-MedLine.d126.s7	was	181	183	O	was	was	was	VBD	False
DDI-MedLine.d126.s7	prevented	185	193	O	prevented	ted	nted	VBN	False
DDI-MedLine.d126.s7	by	195	196	O	by	by	by	IN	False
DDI-MedLine.d126.s7	allopurinol	198	208	B-drug	allopurinol	nol	inol	NN	False
DDI-MedLine.d126.s7	and	210	212	O	and	and	and	CC	False
DDI-MedLine.d126.s7	Vitamin	214	220	B-drug	Vitamin	min	amin	NN	False
DDI-MedLine.d126.s7	E	222	222	I-drug	E	E	E	NN	brand
DDI-MedLine.d126.s7	.	223	223	O	.	.	.	.	False

DDI-MedLine.d25.s0	Rhabdomyolysis	0	13	O	Rhabdomyolysis	sis	ysis	NN	False
DDI-MedLine.d25.s0	secondary	15	23	O	secondary	ary	dary	JJ	False
DDI-MedLine.d25.s0	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d25.s0	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d25.s0	drug	30	33	O	drug	rug	drug	NN	False
DDI-MedLine.d25.s0	interaction	35	45	O	interaction	ion	tion	NN	False
DDI-MedLine.d25.s0	between	47	53	O	between	een	ween	IN	False
DDI-MedLine.d25.s0	simvastatin	55	65	B-drug	simvastatin	tin	atin	NN	False
DDI-MedLine.d25.s0	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d25.s0	clarithromycin	71	84	B-drug	clarithromycin	cin	ycin	NN	drug
DDI-MedLine.d25.s0	.	85	85	O	.	.	.	.	False

DDI-MedLine.d25.s1	OBJECTIVE	0	8	O	OBJECTIVE	IVE	TIVE	NN	brand
DDI-MedLine.d25.s1	:	9	9	O	:	:	:	:	False
DDI-MedLine.d25.s1	To	11	12	O	To	To	To	TO	False
DDI-MedLine.d25.s1	report	14	19	O	report	ort	port	NN	False
DDI-MedLine.d25.s1	a	21	21	O	a	a	a	DT	False
DDI-MedLine.d25.s1	case	23	26	O	case	ase	case	NN	False
DDI-MedLine.d25.s1	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d25.s1	rhabdomyolysis	31	44	O	rhabdomyolysis	sis	ysis	NN	False
DDI-MedLine.d25.s1	resulting	46	54	O	resulting	ing	ting	VBG	False
DDI-MedLine.d25.s1	from	56	59	O	from	rom	from	IN	False
DDI-MedLine.d25.s1	concomitant	61	71	O	concomitant	ant	tant	NN	False
DDI-MedLine.d25.s1	use	73	75	O	use	use	use	NN	False
DDI-MedLine.d25.s1	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d25.s1	clarithromycin	80	93	B-drug	clarithromycin	cin	ycin	NN	drug
DDI-MedLine.d25.s1	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d25.s1	simvastatin	99	109	B-drug	simvastatin	tin	atin	NN	False
DDI-MedLine.d25.s1	.	110	110	O	.	.	.	.	False

DDI-MedLine.d25.s2	CASE	0	3	O	CASE	ASE	CASE	NN	brand
DDI-MedLine.d25.s2	SUMMARY	5	11	O	SUMMARY	ARY	MARY	NN	brand
DDI-MedLine.d25.s2	:	12	12	O	:	:	:	:	False
DDI-MedLine.d25.s2	A	14	14	O	A	A	A	DT	brand
DDI-MedLine.d25.s2	64-year-old	16	26	O	64-year-old	old	-old	JJ	False
DDI-MedLine.d25.s2	African-American	28	43	O	African-American	can	ican	JJ	False
DDI-MedLine.d25.s2	man	45	47	O	man	man	man	NN	False
DDI-MedLine.d25.s2	was	49	51	O	was	was	was	VBD	False
DDI-MedLine.d25.s2	admitted	53	60	O	admitted	ted	tted	VBN	False
DDI-MedLine.d25.s2	to	62	63	O	to	to	to	TO	False
DDI-MedLine.d25.s2	the	65	67	O	the	the	the	DT	False
DDI-MedLine.d25.s2	hospital	69	76	O	hospital	tal	ital	NN	False
DDI-MedLine.d25.s2	for	78	80	O	for	for	for	IN	False
DDI-MedLine.d25.s2	worsening	82	90	O	worsening	ing	ning	VBG	False
DDI-MedLine.d25.s2	renal	92	96	O	renal	nal	enal	NN	False
DDI-MedLine.d25.s2	failure	98	104	O	failure	ure	lure	NN	False
DDI-MedLine.d25.s2	,	105	105	O	,	,	,	,	False
DDI-MedLine.d25.s2	elevated	107	114	O	elevated	ted	ated	VBN	False
DDI-MedLine.d25.s2	creatine	116	123	O	creatine	ine	tine	NN	drug
DDI-MedLine.d25.s2	phosphokinase	125	137	O	phosphokinase	ase	nase	NN	False
DDI-MedLine.d25.s2	,	138	138	O	,	,	,	,	False
DDI-MedLine.d25.s2	diffuse	140	146	O	diffuse	use	fuse	NN	False
DDI-MedLine.d25.s2	muscle	148	153	O	muscle	cle	scle	NN	False
DDI-MedLine.d25.s2	pain	155	158	O	pain	ain	pain	NN	False
DDI-MedLine.d25.s2	,	159	159	O	,	,	,	,	False
DDI-MedLine.d25.s2	and	161	163	O	and	and	and	CC	False
DDI-MedLine.d25.s2	severe	165	170	O	severe	ere	vere	JJ	False
DDI-MedLine.d25.s2	muscle	172	177	O	muscle	cle	scle	NN	False
DDI-MedLine.d25.s2	weakness	179	186	O	weakness	ess	ness	NN	False
DDI-MedLine.d25.s2	.	187	187	O	.	.	.	.	False

DDI-MedLine.d25.s3	About	0	4	O	About	out	bout	IN	False
DDI-MedLine.d25.s3	three	6	10	O	three	ree	hree	CD	False
DDI-MedLine.d25.s3	weeks	12	16	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d25.s3	prior	18	22	O	prior	ior	rior	RB	False
DDI-MedLine.d25.s3	to	24	25	O	to	to	to	TO	False
DDI-MedLine.d25.s3	admission	27	35	O	admission	ion	sion	NN	False
DDI-MedLine.d25.s3	,	36	36	O	,	,	,	,	False
DDI-MedLine.d25.s3	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d25.s3	patient	42	48	O	patient	ent	ient	NN	False
DDI-MedLine.d25.s3	was	50	52	O	was	was	was	VBD	False
DDI-MedLine.d25.s3	started	54	60	O	started	ted	rted	VBN	False
DDI-MedLine.d25.s3	on	62	63	O	on	on	on	IN	False
DDI-MedLine.d25.s3	clarithromycin	65	78	B-drug	clarithromycin	cin	ycin	NN	drug
DDI-MedLine.d25.s3	for	80	82	O	for	for	for	IN	False
DDI-MedLine.d25.s3	sinusitis	84	92	O	sinusitis	tis	itis	NN	False
DDI-MedLine.d25.s3	.	93	93	O	.	.	.	.	False

DDI-MedLine.d25.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d25.s4	patient	4	10	O	patient	ent	ient	NN	False
DDI-MedLine.d25.s4	had	12	14	O	had	had	had	VBD	False
DDI-MedLine.d25.s4	been	16	19	O	been	een	been	VBN	False
DDI-MedLine.d25.s4	receiving	21	29	O	receiving	ing	ving	VBG	False
DDI-MedLine.d25.s4	simvastatin	31	41	B-drug	simvastatin	tin	atin	NN	False
DDI-MedLine.d25.s4	for	43	45	O	for	for	for	IN	False
DDI-MedLine.d25.s4	approximately	47	59	O	approximately	ely	tely	RB	False
DDI-MedLine.d25.s4	six	61	63	O	six	six	six	CD	False
DDI-MedLine.d25.s4	months	65	70	O	months	ths	nths	NNS	False
DDI-MedLine.d25.s4	.	71	71	O	.	.	.	.	False

DDI-MedLine.d25.s5	He	0	1	O	He	He	He	PRP	False
DDI-MedLine.d25.s5	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d25.s5	treated	7	13	O	treated	ted	ated	VBN	False
DDI-MedLine.d25.s5	aggressively	15	26	O	aggressively	ely	vely	RB	False
DDI-MedLine.d25.s5	with	28	31	O	with	ith	with	IN	False
DDI-MedLine.d25.s5	intravenous	33	43	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d25.s5	hydration	45	53	O	hydration	ion	tion	NN	False
DDI-MedLine.d25.s5	,	54	54	O	,	,	,	,	False
DDI-MedLine.d25.s5	sodium	56	61	B-drug	sodium	ium	dium	NN	drug
DDI-MedLine.d25.s5	bicarbonate	63	73	I-drug	bicarbonate	ate	nate	NN	False
DDI-MedLine.d25.s5	,	74	74	O	,	,	,	,	False
DDI-MedLine.d25.s5	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d25.s5	hemodialysis	80	91	O	hemodialysis	sis	ysis	NN	False
DDI-MedLine.d25.s5	.	92	92	O	.	.	.	.	False

DDI-MedLine.d25.s6	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d25.s6	muscle	2	7	O	muscle	cle	scle	NN	False
DDI-MedLine.d25.s6	biopsy	9	14	O	biopsy	psy	opsy	NN	False
DDI-MedLine.d25.s6	revealed	16	23	O	revealed	led	aled	VBD	False
DDI-MedLine.d25.s6	necrotizing	25	35	O	necrotizing	ing	zing	VBG	False
DDI-MedLine.d25.s6	myopathy	37	44	O	myopathy	thy	athy	NN	False
DDI-MedLine.d25.s6	secondary	46	54	O	secondary	ary	dary	JJ	False
DDI-MedLine.d25.s6	to	56	57	O	to	to	to	TO	False
DDI-MedLine.d25.s6	a	59	59	O	a	a	a	DT	False
DDI-MedLine.d25.s6	toxin	61	65	O	toxin	xin	oxin	NN	False
DDI-MedLine.d25.s6	.	66	66	O	.	.	.	.	False

DDI-MedLine.d25.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d25.s7	patient	4	10	O	patient	ent	ient	NN	False
DDI-MedLine.d25.s7	continued	12	20	O	continued	ued	nued	JJ	False
DDI-MedLine.d25.s7	to	22	23	O	to	to	to	TO	False
DDI-MedLine.d25.s7	receive	25	31	O	receive	ive	eive	NN	False
DDI-MedLine.d25.s7	intermittent	33	44	O	intermittent	ent	tent	NN	False
DDI-MedLine.d25.s7	hemodialysis	46	57	O	hemodialysis	sis	ysis	NN	False
DDI-MedLine.d25.s7	until	59	63	O	until	til	ntil	IN	False
DDI-MedLine.d25.s7	his	65	67	O	his	his	his	PRP$	False
DDI-MedLine.d25.s7	death	69	73	O	death	ath	eath	NN	False
DDI-MedLine.d25.s7	from	75	78	O	from	rom	from	IN	False
DDI-MedLine.d25.s7	infectious	80	89	O	infectious	ous	ious	JJ	False
DDI-MedLine.d25.s7	complications	91	103	O	complications	ons	ions	NNS	False
DDI-MedLine.d25.s7	that	105	108	O	that	hat	that	IN	False
DDI-MedLine.d25.s7	occurred	110	117	O	occurred	red	rred	VBD	False
DDI-MedLine.d25.s7	three	119	123	O	three	ree	hree	CD	False
DDI-MedLine.d25.s7	months	125	130	O	months	ths	nths	NNS	False
DDI-MedLine.d25.s7	after	132	136	O	after	ter	fter	IN	False
DDI-MedLine.d25.s7	admission	138	146	O	admission	ion	sion	NN	False
DDI-MedLine.d25.s7	.	147	147	O	.	.	.	.	False

DDI-MedLine.d25.s8	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d25.s8	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d25.s8	several	11	17	O	several	ral	eral	JJ	False
DDI-MedLine.d25.s8	factors	19	25	O	factors	ors	tors	NNS	False
DDI-MedLine.d25.s8	that	27	30	O	that	hat	that	IN	False
DDI-MedLine.d25.s8	could	32	36	O	could	uld	ould	MD	False
DDI-MedLine.d25.s8	have	38	41	O	have	ave	have	VB	False
DDI-MedLine.d25.s8	increased	43	51	O	increased	sed	ased	VBN	False
DDI-MedLine.d25.s8	his	53	55	O	his	his	his	PRP$	False
DDI-MedLine.d25.s8	risk	57	60	O	risk	isk	risk	NN	False
DDI-MedLine.d25.s8	for	62	64	O	for	for	for	IN	False
DDI-MedLine.d25.s8	developing	66	75	O	developing	ing	ping	VBG	False
DDI-MedLine.d25.s8	rhabdomyolysis	77	90	O	rhabdomyolysis	sis	ysis	NN	False
DDI-MedLine.d25.s8	,	91	91	O	,	,	,	,	False
DDI-MedLine.d25.s8	including	93	101	O	including	ing	ding	VBG	False
DDI-MedLine.d25.s8	chronic	103	109	O	chronic	nic	onic	NN	False
DDI-MedLine.d25.s8	renal	111	115	O	renal	nal	enal	NN	False
DDI-MedLine.d25.s8	failure	117	123	O	failure	ure	lure	NN	False
DDI-MedLine.d25.s8	.	124	124	O	.	.	.	.	False

DDI-MedLine.d25.s9	DISCUSSION	0	9	O	DISCUSSION	ION	SION	NN	brand
DDI-MedLine.d25.s9	:	10	10	O	:	:	:	:	False
DDI-MedLine.d25.s9	Clarithromycin	12	25	B-drug	Clarithromycin	cin	ycin	NN	drug
DDI-MedLine.d25.s9	is	27	28	O	is	is	is	VBZ	False
DDI-MedLine.d25.s9	a	30	30	O	a	a	a	DT	False
DDI-MedLine.d25.s9	potent	32	37	O	potent	ent	tent	NN	False
DDI-MedLine.d25.s9	inhibitor	39	47	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d25.s9	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d25.s9	CYP3A4	52	57	O	CYP3A4	3A4	P3A4	NN	brand
DDI-MedLine.d25.s9	,	58	58	O	,	,	,	,	False
DDI-MedLine.d25.s9	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d25.s9	major	64	68	O	major	jor	ajor	JJ	False
DDI-MedLine.d25.s9	enzyme	70	75	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d25.s9	responsible	77	87	O	responsible	ble	ible	JJ	False
DDI-MedLine.d25.s9	for	89	91	O	for	for	for	IN	False
DDI-MedLine.d25.s9	simvastatin	93	103	B-drug	simvastatin	tin	atin	NN	False
DDI-MedLine.d25.s9	metabolism	105	114	O	metabolism	ism	lism	NN	False
DDI-MedLine.d25.s9	.	115	115	O	.	.	.	.	False

DDI-MedLine.d25.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d25.s10	concomitant	4	14	O	concomitant	ant	tant	NN	False
DDI-MedLine.d25.s10	administration	16	29	O	administration	ion	tion	NN	False
DDI-MedLine.d25.s10	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d25.s10	macrolide	34	42	B-group	macrolide	ide	lide	NN	False
DDI-MedLine.d25.s10	antibiotics	44	54	I-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d25.s10	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d25.s10	other	60	64	O	other	her	ther	JJ	False
DDI-MedLine.d25.s10	hydroxymethylglutaryl	66	86	B-group	hydroxymethylglutaryl	ryl	aryl	NN	False
DDI-MedLine.d25.s10	coenzyme	88	95	I-group	coenzyme	yme	zyme	NN	False
DDI-MedLine.d25.s10	A	97	97	I-group	A	A	A	DT	brand
DDI-MedLine.d25.s10	(	99	99	I-group	(	(	(	(	False
DDI-MedLine.d25.s10	HMG-CoA	100	106	I-group	HMG-CoA	CoA	-CoA	NN	False
DDI-MedLine.d25.s10	)	107	107	I-group	)	)	)	)	False
DDI-MedLine.d25.s10	reductase	109	117	I-group	reductase	ase	tase	NN	False
DDI-MedLine.d25.s10	inhibitors	119	128	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d25.s10	have	130	133	O	have	ave	have	VB	False
DDI-MedLine.d25.s10	resulted	135	142	O	resulted	ted	lted	VBD	False
DDI-MedLine.d25.s10	in	144	145	O	in	in	in	IN	False
DDI-MedLine.d25.s10	previous	147	154	O	previous	ous	ious	JJ	False
DDI-MedLine.d25.s10	reports	156	162	O	reports	rts	orts	NNS	False
DDI-MedLine.d25.s10	of	164	165	O	of	of	of	IN	False
DDI-MedLine.d25.s10	rhabdomyolysis	167	180	O	rhabdomyolysis	sis	ysis	NN	False
DDI-MedLine.d25.s10	.	181	181	O	.	.	.	.	False

DDI-MedLine.d25.s11	Other	0	4	O	Other	her	ther	JJ	False
DDI-MedLine.d25.s11	factors	6	12	O	factors	ors	tors	NNS	False
DDI-MedLine.d25.s11	may	14	16	O	may	may	may	MD	False
DDI-MedLine.d25.s11	increase	18	25	O	increase	ase	ease	NN	False
DDI-MedLine.d25.s11	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d25.s11	risk	31	34	O	risk	isk	risk	NN	False
DDI-MedLine.d25.s11	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d25.s11	this	39	42	O	this	his	this	DT	False
DDI-MedLine.d25.s11	drug	44	47	O	drug	rug	drug	NN	False
DDI-MedLine.d25.s11	interaction	49	59	O	interaction	ion	tion	NN	False
DDI-MedLine.d25.s11	,	60	60	O	,	,	,	,	False
DDI-MedLine.d25.s11	including	62	70	O	including	ing	ding	VBG	False
DDI-MedLine.d25.s11	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d25.s11	administration	76	89	O	administration	ion	tion	NN	False
DDI-MedLine.d25.s11	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d25.s11	other	94	98	O	other	her	ther	JJ	False
DDI-MedLine.d25.s11	medications	100	110	O	medications	ons	ions	NNS	False
DDI-MedLine.d25.s11	that	112	115	O	that	hat	that	IN	False
DDI-MedLine.d25.s11	are	117	119	O	are	are	are	VBP	False
DDI-MedLine.d25.s11	associated	121	130	O	associated	ted	ated	VBN	False
DDI-MedLine.d25.s11	with	132	135	O	with	ith	with	IN	False
DDI-MedLine.d25.s11	myopathy	137	144	O	myopathy	thy	athy	NN	False
DDI-MedLine.d25.s11	,	145	145	O	,	,	,	,	False
DDI-MedLine.d25.s11	underlying	147	156	O	underlying	ing	ying	VBG	False
DDI-MedLine.d25.s11	renal	158	162	O	renal	nal	enal	NN	False
DDI-MedLine.d25.s11	insufficiency	164	176	O	insufficiency	ncy	ency	NN	False
DDI-MedLine.d25.s11	,	177	177	O	,	,	,	,	False
DDI-MedLine.d25.s11	and	179	181	O	and	and	and	CC	False
DDI-MedLine.d25.s11	administration	183	196	O	administration	ion	tion	NN	False
DDI-MedLine.d25.s11	of	198	199	O	of	of	of	IN	False
DDI-MedLine.d25.s11	high	201	204	O	high	igh	high	JJ	False
DDI-MedLine.d25.s11	doses	206	210	O	doses	ses	oses	NNS	False
DDI-MedLine.d25.s11	of	212	213	O	of	of	of	IN	False
DDI-MedLine.d25.s11	HMG-CoA	215	221	B-group	HMG-CoA	CoA	-CoA	NN	False
DDI-MedLine.d25.s11	reductase	223	231	I-group	reductase	ase	tase	NN	False
DDI-MedLine.d25.s11	inhibitors	233	242	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d25.s11	.	243	243	O	.	.	.	.	False

DDI-MedLine.d25.s12	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d25.s12	:	11	11	O	:	:	:	:	False
DDI-MedLine.d25.s12	Macrolide	13	21	B-group	Macrolide	ide	lide	NN	False
DDI-MedLine.d25.s12	antibiotics	23	33	I-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d25.s12	inhibit	35	41	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d25.s12	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d25.s12	metabolism	47	56	O	metabolism	ism	lism	NN	False
DDI-MedLine.d25.s12	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d25.s12	HMG-CoA	61	67	B-group	HMG-CoA	CoA	-CoA	NN	False
DDI-MedLine.d25.s12	reductase	69	77	I-group	reductase	ase	tase	NN	False
DDI-MedLine.d25.s12	inhibitors	79	88	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d25.s12	that	90	93	O	that	hat	that	IN	False
DDI-MedLine.d25.s12	are	95	97	O	are	are	are	VBP	False
DDI-MedLine.d25.s12	metabolized	99	109	O	metabolized	zed	ized	VBN	False
DDI-MedLine.d25.s12	by	111	112	O	by	by	by	IN	False
DDI-MedLine.d25.s12	CYP3A4	114	119	O	CYP3A4	3A4	P3A4	NN	brand
DDI-MedLine.d25.s12	(	121	121	O	(	(	(	(	False
DDI-MedLine.d25.s12	i.e.	122	125	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d25.s12	,	126	126	O	,	,	,	,	False
DDI-MedLine.d25.s12	atorvastatin	128	139	B-drug	atorvastatin	tin	atin	NN	False
DDI-MedLine.d25.s12	,	140	140	O	,	,	,	,	False
DDI-MedLine.d25.s12	cerivastatin	142	153	B-drug	cerivastatin	tin	atin	NN	False
DDI-MedLine.d25.s12	,	154	154	O	,	,	,	,	False
DDI-MedLine.d25.s12	lovastatin	156	165	B-drug	lovastatin	tin	atin	NN	False
DDI-MedLine.d25.s12	,	166	166	O	,	,	,	,	False
DDI-MedLine.d25.s12	simvastatin	168	178	B-drug	simvastatin	tin	atin	NN	False
DDI-MedLine.d25.s12	)	179	179	O	)	)	)	)	False
DDI-MedLine.d25.s12	.	180	180	O	.	.	.	.	False

DDI-MedLine.d25.s13	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d25.s13	interaction	5	15	O	interaction	ion	tion	NN	False
DDI-MedLine.d25.s13	may	17	19	O	may	may	may	MD	False
DDI-MedLine.d25.s13	result	21	26	O	result	ult	sult	NN	False
DDI-MedLine.d25.s13	in	28	29	O	in	in	in	IN	False
DDI-MedLine.d25.s13	myopathy	31	38	O	myopathy	thy	athy	NN	False
DDI-MedLine.d25.s13	and	40	42	O	and	and	and	CC	False
DDI-MedLine.d25.s13	rhabdomyolysis	44	57	O	rhabdomyolysis	sis	ysis	NN	False
DDI-MedLine.d25.s13	,	58	58	O	,	,	,	,	False
DDI-MedLine.d25.s13	particularly	60	71	O	particularly	rly	arly	RB	False
DDI-MedLine.d25.s13	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d25.s13	patients	76	83	O	patients	nts	ents	NNS	False
DDI-MedLine.d25.s13	with	85	88	O	with	ith	with	IN	False
DDI-MedLine.d25.s13	renal	90	94	O	renal	nal	enal	NN	False
DDI-MedLine.d25.s13	insufficiency	96	108	O	insufficiency	ncy	ency	NN	False
DDI-MedLine.d25.s13	or	110	111	O	or	or	or	CC	False
DDI-MedLine.d25.s13	those	113	117	O	those	ose	hose	DT	False
DDI-MedLine.d25.s13	who	119	121	O	who	who	who	WP	False
DDI-MedLine.d25.s13	are	123	125	O	are	are	are	VBP	False
DDI-MedLine.d25.s13	concurrently	127	138	O	concurrently	tly	ntly	RB	False
DDI-MedLine.d25.s13	taking	140	145	O	taking	ing	king	VBG	False
DDI-MedLine.d25.s13	medications	147	157	O	medications	ons	ions	NNS	False
DDI-MedLine.d25.s13	associated	159	168	O	associated	ted	ated	VBN	False
DDI-MedLine.d25.s13	with	170	173	O	with	ith	with	IN	False
DDI-MedLine.d25.s13	myopathy	175	182	O	myopathy	thy	athy	NN	False
DDI-MedLine.d25.s13	.	183	183	O	.	.	.	.	False

DDI-MedLine.d133.s0	Suppression	0	10	O	Suppression	ion	sion	NN	False
DDI-MedLine.d133.s0	by	12	13	O	by	by	by	IN	False
DDI-MedLine.d133.s0	verapamil	15	23	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d133.s0	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d133.s0	bombesin-enhanced	28	44	O	bombesin-enhanced	ced	nced	JJ	False
DDI-MedLine.d133.s0	peritoneal	46	55	O	peritoneal	eal	neal	NN	False
DDI-MedLine.d133.s0	metastasis	57	66	O	metastasis	sis	asis	NN	False
DDI-MedLine.d133.s0	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d133.s0	intestinal	71	80	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s0	adenocarcinomas	82	96	O	adenocarcinomas	mas	omas	NN	False
DDI-MedLine.d133.s0	induced	98	104	O	induced	ced	uced	JJ	False
DDI-MedLine.d133.s0	by	106	107	O	by	by	by	IN	False
DDI-MedLine.d133.s0	azoxymethane	109	120	B-drug_n	azoxymethane	ane	hane	NN	False
DDI-MedLine.d133.s0	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d133.s0	wistar	125	130	O	wistar	tar	star	NN	False
DDI-MedLine.d133.s0	rats	132	135	O	rats	ats	rats	NNS	False
DDI-MedLine.d133.s0	.	136	136	O	.	.	.	.	False

DDI-MedLine.d133.s1	BACKGROUND	0	9	O	BACKGROUND	UND	OUND	NN	brand
DDI-MedLine.d133.s1	:	10	10	O	:	:	:	:	False
DDI-MedLine.d133.s1	The	12	14	O	The	The	The	DT	False
DDI-MedLine.d133.s1	effects	16	22	O	effects	cts	ects	NNS	False
DDI-MedLine.d133.s1	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d133.s1	combined	27	34	O	combined	ned	ined	VBN	False
DDI-MedLine.d133.s1	administration	36	49	O	administration	ion	tion	NN	False
DDI-MedLine.d133.s1	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d133.s1	bombesin	54	61	B-drug_n	bombesin	sin	esin	NN	False
DDI-MedLine.d133.s1	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d133.s1	verapamil	67	75	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d133.s1	hydrochloride	77	89	I-drug	hydrochloride	ide	ride	NN	False
DDI-MedLine.d133.s1	(	91	91	O	(	(	(	(	False
DDI-MedLine.d133.s1	verapamil	92	100	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d133.s1	)	101	101	O	)	)	)	)	False
DDI-MedLine.d133.s1	,	102	102	O	,	,	,	,	False
DDI-MedLine.d133.s1	a	104	104	O	a	a	a	DT	False
DDI-MedLine.d133.s1	calcium	106	112	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d133.s1	channel	114	120	I-group	channel	nel	nnel	NNS	False
DDI-MedLine.d133.s1	blocker	122	128	I-group	blocker	ker	cker	NN	False
DDI-MedLine.d133.s1	,	129	129	O	,	,	,	,	False
DDI-MedLine.d133.s1	on	131	132	O	on	on	on	IN	False
DDI-MedLine.d133.s1	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d133.s1	incidence	138	146	O	incidence	nce	ence	NN	False
DDI-MedLine.d133.s1	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d133.s1	peritoneal	151	160	O	peritoneal	eal	neal	NN	False
DDI-MedLine.d133.s1	metastasis	162	171	O	metastasis	sis	asis	NN	False
DDI-MedLine.d133.s1	of	173	174	O	of	of	of	IN	False
DDI-MedLine.d133.s1	intestinal	176	185	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s1	adenocarcinomas	187	201	O	adenocarcinomas	mas	omas	NN	False
DDI-MedLine.d133.s1	induced	203	209	O	induced	ced	uced	JJ	False
DDI-MedLine.d133.s1	by	211	212	O	by	by	by	IN	False
DDI-MedLine.d133.s1	azoxymethane	214	225	B-drug_n	azoxymethane	ane	hane	NN	False
DDI-MedLine.d133.s1	(	227	227	O	(	(	(	(	False
DDI-MedLine.d133.s1	AOM	228	230	B-drug_n	AOM	AOM	AOM	NN	brand
DDI-MedLine.d133.s1	)	231	231	O	)	)	)	)	False
DDI-MedLine.d133.s1	and	233	235	O	and	and	and	CC	False
DDI-MedLine.d133.s1	the	237	239	O	the	the	the	DT	False
DDI-MedLine.d133.s1	labeling	241	248	O	labeling	ing	ling	VBG	False
DDI-MedLine.d133.s1	index	250	254	O	index	dex	ndex	NN	False
DDI-MedLine.d133.s1	of	256	257	O	of	of	of	IN	False
DDI-MedLine.d133.s1	intestinal	259	268	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s1	cancers	270	276	O	cancers	ers	cers	NNS	False
DDI-MedLine.d133.s1	were	278	281	O	were	ere	were	VBD	False
DDI-MedLine.d133.s1	investigated	283	294	O	investigated	ted	ated	VBN	False
DDI-MedLine.d133.s1	in	296	297	O	in	in	in	IN	False
DDI-MedLine.d133.s1	male	299	302	O	male	ale	male	NN	False
DDI-MedLine.d133.s1	Wistar	304	309	O	Wistar	tar	star	NN	False
DDI-MedLine.d133.s1	rats	311	314	O	rats	ats	rats	NNS	False
DDI-MedLine.d133.s1	.	315	315	O	.	.	.	.	False

DDI-MedLine.d133.s2	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d133.s2	:	7	7	O	:	:	:	:	False
DDI-MedLine.d133.s2	From	9	12	O	From	rom	From	IN	False
DDI-MedLine.d133.s2	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d133.s2	beginning	18	26	O	beginning	ing	ning	VBG	False
DDI-MedLine.d133.s2	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d133.s2	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d133.s2	experiment	35	44	O	experiment	ent	ment	NN	False
DDI-MedLine.d133.s2	,	45	45	O	,	,	,	,	False
DDI-MedLine.d133.s2	rats	47	50	O	rats	ats	rats	NNS	False
DDI-MedLine.d133.s2	were	52	55	O	were	ere	were	VBD	False
DDI-MedLine.d133.s2	given	57	61	O	given	ven	iven	VBN	False
DDI-MedLine.d133.s2	10	63	64	O	10	10	10	CD	False
DDI-MedLine.d133.s2	weekly	66	71	O	weekly	kly	ekly	JJ	False
DDI-MedLine.d133.s2	subcutaneous	73	84	O	subcutaneous	ous	eous	JJ	False
DDI-MedLine.d133.s2	injections	86	95	O	injections	ons	ions	NNS	False
DDI-MedLine.d133.s2	of	97	98	O	of	of	of	IN	False
DDI-MedLine.d133.s2	AOM	100	102	B-drug_n	AOM	AOM	AOM	NN	brand
DDI-MedLine.d133.s2	(	104	104	O	(	(	(	(	False
DDI-MedLine.d133.s2	7.4	105	107	O	7.4	7.4	7.4	CD	False
DDI-MedLine.d133.s2	mg/kg	109	113	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d133.s2	body	115	118	O	body	ody	body	NN	False
DDI-MedLine.d133.s2	weight	120	125	O	weight	ght	ight	NN	False
DDI-MedLine.d133.s2	)	126	126	O	)	)	)	)	False
DDI-MedLine.d133.s2	and	128	130	O	and	and	and	CC	False
DDI-MedLine.d133.s2	subcutaneous	132	143	O	subcutaneous	ous	eous	JJ	False
DDI-MedLine.d133.s2	injections	145	154	O	injections	ons	ions	NNS	False
DDI-MedLine.d133.s2	of	156	157	O	of	of	of	IN	False
DDI-MedLine.d133.s2	bombesin	159	166	B-drug_n	bombesin	sin	esin	NN	False
DDI-MedLine.d133.s2	(	168	168	O	(	(	(	(	False
DDI-MedLine.d133.s2	40	169	170	O	40	40	40	CD	False
DDI-MedLine.d133.s2	microg/kg	172	180	O	microg/kg	/kg	g/kg	NN	False
DDI-MedLine.d133.s2	body	182	185	O	body	ody	body	NN	False
DDI-MedLine.d133.s2	weight	187	192	O	weight	ght	ight	NN	False
DDI-MedLine.d133.s2	)	193	193	O	)	)	)	)	False
DDI-MedLine.d133.s2	every	195	199	O	every	ery	very	DT	False
DDI-MedLine.d133.s2	other	201	205	O	other	her	ther	JJ	False
DDI-MedLine.d133.s2	day	207	209	O	day	day	day	NN	False
DDI-MedLine.d133.s2	,	210	210	O	,	,	,	,	False
DDI-MedLine.d133.s2	and	212	214	O	and	and	and	CC	False
DDI-MedLine.d133.s2	from	216	219	O	from	rom	from	IN	False
DDI-MedLine.d133.s2	week	221	224	O	week	eek	week	NN	False
DDI-MedLine.d133.s2	16	226	227	O	16	16	16	CD	False
DDI-MedLine.d133.s2	,	228	228	O	,	,	,	,	False
DDI-MedLine.d133.s2	intraperitoneal	230	244	O	intraperitoneal	eal	neal	NN	False
DDI-MedLine.d133.s2	injections	246	255	O	injections	ons	ions	NNS	False
DDI-MedLine.d133.s2	of	257	258	O	of	of	of	IN	False
DDI-MedLine.d133.s2	verapamil	260	268	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d133.s2	(	270	270	O	(	(	(	(	False
DDI-MedLine.d133.s2	10	271	272	O	10	10	10	CD	False
DDI-MedLine.d133.s2	or	274	275	O	or	or	or	CC	False
DDI-MedLine.d133.s2	20	277	278	O	20	20	20	CD	False
DDI-MedLine.d133.s2	mg/kg	280	284	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d133.s2	body	286	289	O	body	ody	body	NN	False
DDI-MedLine.d133.s2	weight	291	296	O	weight	ght	ight	NN	False
DDI-MedLine.d133.s2	)	297	297	O	)	)	)	)	False
DDI-MedLine.d133.s2	every	299	303	O	every	ery	very	DT	False
DDI-MedLine.d133.s2	other	305	309	O	other	her	ther	JJ	False
DDI-MedLine.d133.s2	day	311	313	O	day	day	day	NN	False
DDI-MedLine.d133.s2	until	315	319	O	until	til	ntil	IN	False
DDI-MedLine.d133.s2	the	321	323	O	the	the	the	DT	False
DDI-MedLine.d133.s2	end	325	327	O	end	end	end	NN	False
DDI-MedLine.d133.s2	fo	329	330	O	fo	fo	fo	NN	False
DDI-MedLine.d133.s2	the	332	334	O	the	the	the	DT	False
DDI-MedLine.d133.s2	experiment	336	345	O	experiment	ent	ment	NN	False
DDI-MedLine.d133.s2	in	347	348	O	in	in	in	IN	False
DDI-MedLine.d133.s2	week	350	353	O	week	eek	week	NN	False
DDI-MedLine.d133.s2	45	355	356	O	45	45	45	CD	False
DDI-MedLine.d133.s2	.	357	357	O	.	.	.	.	False

DDI-MedLine.d133.s3	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d133.s3	:	7	7	O	:	:	:	:	False
DDI-MedLine.d133.s3	Bombesin	9	16	B-drug_n	Bombesin	sin	esin	NN	False
DDI-MedLine.d133.s3	significantly	18	30	O	significantly	tly	ntly	RB	False
DDI-MedLine.d133.s3	increased	32	40	O	increased	sed	ased	VBN	False
DDI-MedLine.d133.s3	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d133.s3	incidence	46	54	O	incidence	nce	ence	NN	False
DDI-MedLine.d133.s3	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d133.s3	intestinal	59	68	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s3	tumors	70	75	O	tumors	ors	mors	NNS	False
DDI-MedLine.d133.s3	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d133.s3	cancer	81	86	O	cancer	cer	ncer	NN	False
DDI-MedLine.d133.s3	metastasis	88	97	O	metastasis	sis	asis	NN	False
DDI-MedLine.d133.s3	to	99	100	O	to	to	to	TO	False
DDI-MedLine.d133.s3	the	102	104	O	the	the	the	DT	False
DDI-MedLine.d133.s3	peritoneum	106	115	O	peritoneum	eum	neum	NN	False
DDI-MedLine.d133.s3	.	116	116	O	.	.	.	.	False

DDI-MedLine.d133.s4	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d133.s4	verapamil	9	17	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d133.s4	administered	19	30	O	administered	red	ered	VBN	False
DDI-MedLine.d133.s4	at	32	33	O	at	at	at	IN	False
DDI-MedLine.d133.s4	either	35	40	O	either	her	ther	DT	False
DDI-MedLine.d133.s4	dose	42	45	O	dose	ose	dose	NN	False
DDI-MedLine.d133.s4	had	47	49	O	had	had	had	VBD	False
DDI-MedLine.d133.s4	little	51	56	O	little	tle	ttle	JJ	False
DDI-MedLine.d133.s4	or	58	59	O	or	or	or	CC	False
DDI-MedLine.d133.s4	no	61	62	O	no	no	no	DT	False
DDI-MedLine.d133.s4	effect	64	69	O	effect	ect	fect	NN	False
DDI-MedLine.d133.s4	on	71	72	O	on	on	on	IN	False
DDI-MedLine.d133.s4	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d133.s4	enhancement	78	88	O	enhancement	ent	ment	NN	False
DDI-MedLine.d133.s4	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d133.s4	intestinal	93	102	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s4	carcinogenesis	104	117	O	carcinogenesis	sis	esis	NN	False
DDI-MedLine.d133.s4	by	119	120	O	by	by	by	IN	False
DDI-MedLine.d133.s4	bombesin	122	129	B-drug_n	bombesin	sin	esin	NN	False
DDI-MedLine.d133.s4	or	131	132	O	or	or	or	CC	False
DDI-MedLine.d133.s4	on	134	135	O	on	on	on	IN	False
DDI-MedLine.d133.s4	the	137	139	O	the	the	the	DT	False
DDI-MedLine.d133.s4	location	141	148	O	location	ion	tion	NN	False
DDI-MedLine.d133.s4	,	149	149	O	,	,	,	,	False
DDI-MedLine.d133.s4	histologic	151	160	O	histologic	gic	ogic	NN	False
DDI-MedLine.d133.s4	type	162	165	O	type	ype	type	NN	False
DDI-MedLine.d133.s4	,	166	166	O	,	,	,	,	False
DDI-MedLine.d133.s4	depth	168	172	O	depth	pth	epth	NN	False
DDI-MedLine.d133.s4	of	174	175	O	of	of	of	IN	False
DDI-MedLine.d133.s4	involvement	177	187	O	involvement	ent	ment	NN	False
DDI-MedLine.d133.s4	,	188	188	O	,	,	,	,	False
DDI-MedLine.d133.s4	labeling	190	197	O	labeling	ing	ling	VBG	False
DDI-MedLine.d133.s4	index	199	203	O	index	dex	ndex	NN	False
DDI-MedLine.d133.s4	,	204	204	O	,	,	,	,	False
DDI-MedLine.d133.s4	apoptotic	206	214	O	apoptotic	tic	otic	JJ	False
DDI-MedLine.d133.s4	index	216	220	O	index	dex	ndex	NN	False
DDI-MedLine.d133.s4	or	222	223	O	or	or	or	CC	False
DDI-MedLine.d133.s4	tumor	225	229	O	tumor	mor	umor	NN	False
DDI-MedLine.d133.s4	vascularity	231	241	O	vascularity	ity	rity	NN	False
DDI-MedLine.d133.s4	of	243	244	O	of	of	of	IN	False
DDI-MedLine.d133.s4	intestinal	246	255	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s4	cancers	257	263	O	cancers	ers	cers	NNS	False
DDI-MedLine.d133.s4	,	264	264	O	,	,	,	,	False
DDI-MedLine.d133.s4	it	266	267	O	it	it	it	PRP	False
DDI-MedLine.d133.s4	significantly	269	281	O	significantly	tly	ntly	RB	False
DDI-MedLine.d133.s4	decreased	283	291	O	decreased	sed	ased	VBN	False
DDI-MedLine.d133.s4	the	293	295	O	the	the	the	DT	False
DDI-MedLine.d133.s4	incidence	297	305	O	incidence	nce	ence	NN	False
DDI-MedLine.d133.s4	of	307	308	O	of	of	of	IN	False
DDI-MedLine.d133.s4	cancer	310	315	O	cancer	cer	ncer	NN	False
DDI-MedLine.d133.s4	metastasis	317	326	O	metastasis	sis	asis	NN	False
DDI-MedLine.d133.s4	.	327	327	O	.	.	.	.	False

DDI-MedLine.d133.s5	Verapamil	0	8	B-drug	Verapamil	mil	amil	NN	False
DDI-MedLine.d133.s5	also	10	13	O	also	lso	also	RB	False
DDI-MedLine.d133.s5	significantly	15	27	O	significantly	tly	ntly	RB	False
DDI-MedLine.d133.s5	decreased	29	37	O	decreased	sed	ased	VBN	False
DDI-MedLine.d133.s5	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d133.s5	incidence	43	51	O	incidence	nce	ence	NN	False
DDI-MedLine.d133.s5	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d133.s5	lymphatic	56	64	O	lymphatic	tic	atic	JJ	False
DDI-MedLine.d133.s5	invasion	66	73	O	invasion	ion	sion	NN	False
DDI-MedLine.d133.s5	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d133.s5	adenocarcinomas	78	92	O	adenocarcinomas	mas	omas	NN	False
DDI-MedLine.d133.s5	,	93	93	O	,	,	,	,	False
DDI-MedLine.d133.s5	which	95	99	O	which	ich	hich	WDT	False
DDI-MedLine.d133.s5	was	101	103	O	was	was	was	VBD	False
DDI-MedLine.d133.s5	enhanced	105	112	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d133.s5	by	114	115	O	by	by	by	IN	False
DDI-MedLine.d133.s5	bombesin	117	124	B-drug_n	bombesin	sin	esin	NN	False
DDI-MedLine.d133.s5	.	125	125	O	.	.	.	.	False

DDI-MedLine.d133.s6	CONCLUSION	0	9	O	CONCLUSION	ION	SION	NN	brand
DDI-MedLine.d133.s6	:	10	10	O	:	:	:	:	False
DDI-MedLine.d133.s6	These	12	16	O	These	ese	hese	DT	False
DDI-MedLine.d133.s6	findings	18	25	O	findings	ngs	ings	NNS	False
DDI-MedLine.d133.s6	indicate	27	34	O	indicate	ate	cate	NN	False
DDI-MedLine.d133.s6	that	36	39	O	that	hat	that	IN	False
DDI-MedLine.d133.s6	verapamil	41	49	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d133.s6	inhibits	51	58	O	inhibits	its	bits	NNS	False
DDI-MedLine.d133.s6	cancer	60	65	O	cancer	cer	ncer	NN	False
DDI-MedLine.d133.s6	metastasis	67	76	O	metastasis	sis	asis	NN	False
DDI-MedLine.d133.s6	through	78	84	O	through	ugh	ough	IN	False
DDI-MedLine.d133.s6	actions	86	92	O	actions	ons	ions	NNS	False
DDI-MedLine.d133.s6	that	94	97	O	that	hat	that	IN	False
DDI-MedLine.d133.s6	do	99	100	O	do	do	do	VB	False
DDI-MedLine.d133.s6	not	102	104	O	not	not	not	RB	False
DDI-MedLine.d133.s6	affect	106	111	O	affect	ect	fect	NN	False
DDI-MedLine.d133.s6	the	113	115	O	the	the	the	DT	False
DDI-MedLine.d133.s6	growth	117	122	O	growth	wth	owth	NN	False
DDI-MedLine.d133.s6	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d133.s6	intestinal	127	136	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d133.s6	cancers	138	144	O	cancers	ers	cers	NNS	False
DDI-MedLine.d133.s6	.	145	145	O	.	.	.	.	False

DDI-MedLine.d30.s0	Stereoselective	0	14	O	Stereoselective	ive	tive	JJ	False
DDI-MedLine.d30.s0	behavioral	16	25	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d30.s0	effects	27	33	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s0	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d30.s0	N-allylnormetazocine	38	57	B-drug_n	N-allylnormetazocine	ine	cine	NN	drug
DDI-MedLine.d30.s0	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d30.s0	pigeons	62	68	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s0	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d30.s0	squirrel	74	81	O	squirrel	rel	rrel	NN	False
DDI-MedLine.d30.s0	monkeys	83	89	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d30.s0	.	90	90	O	.	.	.	.	False

DDI-MedLine.d30.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d30.s1	behavioral	4	13	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d30.s1	effects	15	21	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s1	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d30.s1	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d30.s1	stereoisomers	30	42	O	stereoisomers	ers	mers	NNS	False
DDI-MedLine.d30.s1	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d30.s1	N-allylnormetazocine	47	66	B-drug_n	N-allylnormetazocine	ine	cine	NN	drug
DDI-MedLine.d30.s1	(	68	68	O	(	(	(	(	False
DDI-MedLine.d30.s1	NANM	69	72	B-drug_n	NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s1	)	73	73	O	)	)	)	)	False
DDI-MedLine.d30.s1	were	75	78	O	were	ere	were	VBD	False
DDI-MedLine.d30.s1	compared	80	87	O	compared	red	ared	VBN	False
DDI-MedLine.d30.s1	with	89	92	O	with	ith	with	IN	False
DDI-MedLine.d30.s1	those	94	98	O	those	ose	hose	DT	False
DDI-MedLine.d30.s1	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d30.s1	phencyclidine	103	115	B-drug_n	phencyclidine	ine	dine	NN	drug
DDI-MedLine.d30.s1	(	117	117	O	(	(	(	(	False
DDI-MedLine.d30.s1	PCP	118	120	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s1	)	121	121	O	)	)	)	)	False
DDI-MedLine.d30.s1	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d30.s1	pigeons	126	132	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s1	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d30.s1	squirrel	138	145	O	squirrel	rel	rrel	NN	False
DDI-MedLine.d30.s1	monkeys	147	153	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d30.s1	responding	155	164	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s1	under	166	170	O	under	der	nder	IN	False
DDI-MedLine.d30.s1	a	172	172	O	a	a	a	DT	False
DDI-MedLine.d30.s1	multiple	174	181	O	multiple	ple	iple	NN	False
DDI-MedLine.d30.s1	fixed-interval	183	196	O	fixed-interval	val	rval	NN	False
DDI-MedLine.d30.s1	fixed-ratio	198	208	O	fixed-ratio	tio	atio	NN	False
DDI-MedLine.d30.s1	(	210	210	O	(	(	(	(	False
DDI-MedLine.d30.s1	FI	211	212	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s1	FR	214	215	O	FR	FR	FR	NN	brand
DDI-MedLine.d30.s1	)	216	216	O	)	)	)	)	False
DDI-MedLine.d30.s1	schedule	218	225	O	schedule	ule	dule	NN	False
DDI-MedLine.d30.s1	of	227	228	O	of	of	of	IN	False
DDI-MedLine.d30.s1	food	230	233	O	food	ood	food	NN	False
DDI-MedLine.d30.s1	presentation	235	246	O	presentation	ion	tion	NN	False
DDI-MedLine.d30.s1	.	247	247	O	.	.	.	.	False

DDI-MedLine.d30.s2	Intermediate	0	11	O	Intermediate	ate	iate	NN	False
DDI-MedLine.d30.s2	doses	13	17	O	doses	ses	oses	NNS	False
DDI-MedLine.d30.s2	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d30.s2	(	22	22	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s2	+	23	23	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s2	)	24	24	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s2	-NANM	25	29	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s2	or	31	32	O	or	or	or	CC	False
DDI-MedLine.d30.s2	PCP	34	36	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s2	produced	38	45	O	produced	ced	uced	VBN	False
DDI-MedLine.d30.s2	transient	47	55	O	transient	ent	ient	NN	False
DDI-MedLine.d30.s2	increases	57	65	O	increases	ses	ases	NNS	False
DDI-MedLine.d30.s2	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d30.s2	FI	70	71	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s2	responding	73	82	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s2	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d30.s2	monkeys	87	93	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d30.s2	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d30.s2	sustained	99	107	O	sustained	ned	ined	VBN	False
DDI-MedLine.d30.s2	increases	109	117	O	increases	ses	ases	NNS	False
DDI-MedLine.d30.s2	in	119	120	O	in	in	in	IN	False
DDI-MedLine.d30.s2	FI	122	123	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s2	responding	125	134	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s2	in	136	137	O	in	in	in	IN	False
DDI-MedLine.d30.s2	pigeons	139	145	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s2	;	146	146	O	;	;	;	:	False

DDI-MedLine.d30.s3	higher	0	5	O	higher	her	gher	JJR	False
DDI-MedLine.d30.s3	doses	7	11	O	doses	ses	oses	NNS	False
DDI-MedLine.d30.s3	decreased	13	21	O	decreased	sed	ased	VBN	False
DDI-MedLine.d30.s3	FI	23	24	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s3	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d30.s3	FR	30	31	O	FR	FR	FR	NN	brand
DDI-MedLine.d30.s3	responding	33	42	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s3	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d30.s3	both	47	50	O	both	oth	both	DT	False
DDI-MedLine.d30.s3	species	52	58	O	species	ies	cies	NNS	False
DDI-MedLine.d30.s3	.	59	59	O	.	.	.	.	False

DDI-MedLine.d30.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d30.s4	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d30.s4	to	12	13	O	to	to	to	TO	False
DDI-MedLine.d30.s4	its	15	17	O	its	its	its	PRP$	False
DDI-MedLine.d30.s4	enantiomer	19	28	O	enantiomer	mer	omer	NN	False
DDI-MedLine.d30.s4	,	29	29	O	,	,	,	,	False
DDI-MedLine.d30.s4	(	31	31	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s4	-	32	32	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s4	)	33	33	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s4	-NANM	34	38	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s4	failed	40	45	O	failed	led	iled	VBD	False
DDI-MedLine.d30.s4	to	47	48	O	to	to	to	TO	False
DDI-MedLine.d30.s4	increase	50	57	O	increase	ase	ease	NN	False
DDI-MedLine.d30.s4	FI	59	60	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s4	responding	62	71	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s4	significantly	73	85	O	significantly	tly	ntly	RB	False
DDI-MedLine.d30.s4	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d30.s4	either	90	95	O	either	her	ther	DT	False
DDI-MedLine.d30.s4	species	97	103	O	species	ies	cies	NNS	False
DDI-MedLine.d30.s4	;	104	104	O	;	;	;	:	False

DDI-MedLine.d30.s5	at	0	1	O	at	at	at	IN	False
DDI-MedLine.d30.s5	high	3	6	O	high	igh	high	JJ	False
DDI-MedLine.d30.s5	doses	8	12	O	doses	ses	oses	NNS	False
DDI-MedLine.d30.s5	,	13	13	O	,	,	,	,	False
DDI-MedLine.d30.s5	(	15	15	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s5	-	16	16	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s5	)	17	17	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s5	-NANM	18	22	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s5	decreased	24	32	O	decreased	sed	ased	VBN	False
DDI-MedLine.d30.s5	FI	34	35	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s5	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d30.s5	FR	41	42	O	FR	FR	FR	NN	brand
DDI-MedLine.d30.s5	responding	44	53	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s5	.	54	54	O	.	.	.	.	False

DDI-MedLine.d30.s6	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d30.s6	monkeys	3	9	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d30.s6	,	10	10	O	,	,	,	,	False
DDI-MedLine.d30.s6	(	12	12	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s6	-	13	13	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s6	)	14	14	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s6	-NANM	15	19	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s6	was	21	23	O	was	was	was	VBD	False
DDI-MedLine.d30.s6	about	25	29	O	about	out	bout	IN	False
DDI-MedLine.d30.s6	10	31	32	O	10	10	10	CD	False
DDI-MedLine.d30.s6	times	34	38	O	times	mes	imes	NNS	False
DDI-MedLine.d30.s6	more	40	43	O	more	ore	more	RBR	False
DDI-MedLine.d30.s6	potent	45	50	O	potent	ent	tent	NN	False
DDI-MedLine.d30.s6	than	52	55	O	than	han	than	IN	False
DDI-MedLine.d30.s6	(	57	57	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s6	+	58	58	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s6	)	59	59	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s6	-NANM	60	64	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s6	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d30.s6	decreasing	69	78	O	decreasing	ing	sing	VBG	False
DDI-MedLine.d30.s6	responding	80	89	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s6	,	90	90	O	,	,	,	,	False
DDI-MedLine.d30.s6	whereas	92	98	O	whereas	eas	reas	NNS	False
DDI-MedLine.d30.s6	in	100	101	O	in	in	in	IN	False
DDI-MedLine.d30.s6	pigeons	103	109	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s6	(	111	111	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s6	-	112	112	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s6	)	113	113	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s6	-NANM	114	118	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s6	was	120	122	O	was	was	was	VBD	False
DDI-MedLine.d30.s6	about	124	128	O	about	out	bout	IN	False
DDI-MedLine.d30.s6	equipotent	130	139	O	equipotent	ent	tent	NN	False
DDI-MedLine.d30.s6	with	141	144	O	with	ith	with	IN	False
DDI-MedLine.d30.s6	(	146	146	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s6	+	147	147	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s6	)	148	148	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s6	-NANM	149	153	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s6	.	154	154	O	.	.	.	.	False

DDI-MedLine.d30.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d30.s7	both	3	6	O	both	oth	both	DT	False
DDI-MedLine.d30.s7	species	8	14	O	species	ies	cies	NNS	False
DDI-MedLine.d30.s7	,	15	15	O	,	,	,	,	False
DDI-MedLine.d30.s7	(	17	17	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s7	-	18	18	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s7	)	19	19	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s7	-NANM	20	24	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s7	,	25	25	O	,	,	,	,	False
DDI-MedLine.d30.s7	but	27	29	O	but	but	but	CC	False
DDI-MedLine.d30.s7	not	31	33	O	not	not	not	RB	False
DDI-MedLine.d30.s7	(	35	35	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s7	+	36	36	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s7	)	37	37	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s7	-NANM	38	42	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s7	,	43	43	O	,	,	,	,	False
DDI-MedLine.d30.s7	antagonized	45	55	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d30.s7	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d30.s7	rate-decreasing	61	75	O	rate-decreasing	ing	sing	NN	False
DDI-MedLine.d30.s7	effects	77	83	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s7	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d30.s7	morphine	88	95	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d30.s7	on	97	98	O	on	on	on	IN	False
DDI-MedLine.d30.s7	FI	100	101	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s7	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d30.s7	FR	107	108	O	FR	FR	FR	NN	brand
DDI-MedLine.d30.s7	responding	110	119	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s7	.	120	120	O	.	.	.	.	False

DDI-MedLine.d30.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d30.s8	monkeys	3	9	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d30.s8	,	10	10	O	,	,	,	,	False
DDI-MedLine.d30.s8	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d30.s8	effects	16	22	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s8	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d30.s8	(	27	27	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s8	-	28	28	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s8	)	29	29	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s8	-NANM	30	34	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s8	,	35	35	O	,	,	,	,	False
DDI-MedLine.d30.s8	but	37	39	O	but	but	but	CC	False
DDI-MedLine.d30.s8	not	41	43	O	not	not	not	RB	False
DDI-MedLine.d30.s8	(	45	45	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s8	+	46	46	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s8	)	47	47	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s8	-NANM	48	52	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s8	or	54	55	O	or	or	or	CC	False
DDI-MedLine.d30.s8	PCP	57	59	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s8	,	60	60	O	,	,	,	,	False
DDI-MedLine.d30.s8	were	62	65	O	were	ere	were	VBD	False
DDI-MedLine.d30.s8	antagonized	67	77	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d30.s8	by	79	80	O	by	by	by	IN	False
DDI-MedLine.d30.s8	naloxone	82	89	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d30.s8	;	90	90	O	;	;	;	:	False

DDI-MedLine.d30.s9	the	0	2	O	the	the	the	DT	False
DDI-MedLine.d30.s9	doses	4	8	O	doses	ses	oses	NNS	False
DDI-MedLine.d30.s9	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d30.s9	naloxone	13	20	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d30.s9	required	22	29	O	required	red	ired	VBN	False
DDI-MedLine.d30.s9	to	31	32	O	to	to	to	TO	False
DDI-MedLine.d30.s9	antagonize	34	43	O	antagonize	ize	nize	VB	False
DDI-MedLine.d30.s9	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d30.s9	effects	49	55	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s9	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d30.s9	(	60	60	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s9	-	61	61	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s9	)	62	62	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s9	-NANM	63	67	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s9	were	69	72	O	were	ere	were	VBD	False
DDI-MedLine.d30.s9	more	74	77	O	more	ore	more	RBR	False
DDI-MedLine.d30.s9	than	79	82	O	than	han	than	IN	False
DDI-MedLine.d30.s9	100	84	86	O	100	100	100	CD	False
DDI-MedLine.d30.s9	times	88	92	O	times	mes	imes	NNS	False
DDI-MedLine.d30.s9	higher	94	99	O	higher	her	gher	JJR	False
DDI-MedLine.d30.s9	than	101	104	O	than	han	than	IN	False
DDI-MedLine.d30.s9	those	106	110	O	those	ose	hose	DT	False
DDI-MedLine.d30.s9	required	112	119	O	required	red	ired	VBN	False
DDI-MedLine.d30.s9	to	121	122	O	to	to	to	TO	False
DDI-MedLine.d30.s9	antagonize	124	133	O	antagonize	ize	nize	VB	False
DDI-MedLine.d30.s9	the	135	137	O	the	the	the	DT	False
DDI-MedLine.d30.s9	effects	139	145	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s9	of	147	148	O	of	of	of	IN	False
DDI-MedLine.d30.s9	morphine	150	157	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d30.s9	.	158	158	O	.	.	.	.	False

DDI-MedLine.d30.s10	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d30.s10	pigeons	3	9	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s10	,	10	10	O	,	,	,	,	False
DDI-MedLine.d30.s10	naloxone	12	19	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d30.s10	did	21	23	O	did	did	did	VBD	False
DDI-MedLine.d30.s10	not	25	27	O	not	not	not	RB	False
DDI-MedLine.d30.s10	systematically	29	42	O	systematically	lly	ally	RB	False
DDI-MedLine.d30.s10	alter	44	48	O	alter	ter	lter	NN	False
DDI-MedLine.d30.s10	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d30.s10	effects	54	60	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s10	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d30.s10	(	65	65	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s10	-	66	66	I-drug_n	-	-	-	:	False
DDI-MedLine.d30.s10	)	67	67	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s10	-NANM	68	72	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s10	,	73	73	O	,	,	,	,	False
DDI-MedLine.d30.s10	(	75	75	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s10	+	76	76	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s10	)	77	77	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s10	-NANM	78	82	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s10	or	84	85	O	or	or	or	CC	False
DDI-MedLine.d30.s10	PCP	87	89	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s10	.	90	90	O	.	.	.	.	False

DDI-MedLine.d30.s11	Haloperidol	0	10	B-drug	Haloperidol	dol	idol	NN	False
DDI-MedLine.d30.s11	reduced	12	18	O	reduced	ced	uced	VBN	False
DDI-MedLine.d30.s11	or	20	21	O	or	or	or	CC	False
DDI-MedLine.d30.s11	eliminated	23	32	O	eliminated	ted	ated	VBN	False
DDI-MedLine.d30.s11	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d30.s11	increases	38	46	O	increases	ses	ases	NNS	False
DDI-MedLine.d30.s11	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d30.s11	FI	51	52	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s11	responding	54	63	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s11	produced	65	72	O	produced	ced	uced	VBN	False
DDI-MedLine.d30.s11	by	74	75	O	by	by	by	IN	False
DDI-MedLine.d30.s11	intermediate	77	88	O	intermediate	ate	iate	NN	False
DDI-MedLine.d30.s11	doses	90	94	O	doses	ses	oses	NNS	False
DDI-MedLine.d30.s11	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d30.s11	either	99	104	O	either	her	ther	DT	False
DDI-MedLine.d30.s11	(	106	106	B-drug_n	(	(	(	(	False
DDI-MedLine.d30.s11	+	107	107	I-drug_n	+	+	+	NN	False
DDI-MedLine.d30.s11	)	108	108	I-drug_n	)	)	)	)	False
DDI-MedLine.d30.s11	-NANM	109	113	I-drug_n	-NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s11	or	115	116	O	or	or	or	CC	False
DDI-MedLine.d30.s11	PCP	118	120	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s11	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d30.s11	pigeons	125	131	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s11	,	132	132	O	,	,	,	,	False
DDI-MedLine.d30.s11	but	134	136	O	but	but	but	CC	False
DDI-MedLine.d30.s11	did	138	140	O	did	did	did	VBD	False
DDI-MedLine.d30.s11	not	142	144	O	not	not	not	RB	False
DDI-MedLine.d30.s11	antagonize	146	155	O	antagonize	ize	nize	VB	False
DDI-MedLine.d30.s11	the	157	159	O	the	the	the	DT	False
DDI-MedLine.d30.s11	decreases	161	169	O	decreases	ses	ases	NNS	False
DDI-MedLine.d30.s11	in	171	172	O	in	in	in	IN	False
DDI-MedLine.d30.s11	FI	174	175	O	FI	FI	FI	NN	brand
DDI-MedLine.d30.s11	or	177	178	O	or	or	or	CC	False
DDI-MedLine.d30.s11	FR	180	181	O	FR	FR	FR	NN	brand
DDI-MedLine.d30.s11	responding	183	192	O	responding	ing	ding	VBG	False
DDI-MedLine.d30.s11	produced	194	201	O	produced	ced	uced	VBN	False
DDI-MedLine.d30.s11	by	203	204	O	by	by	by	IN	False
DDI-MedLine.d30.s11	high	206	209	O	high	igh	high	JJ	False
DDI-MedLine.d30.s11	doses	211	215	O	doses	ses	oses	NNS	False
DDI-MedLine.d30.s11	of	217	218	O	of	of	of	IN	False
DDI-MedLine.d30.s11	PCP	220	222	O	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s11	or	224	225	O	or	or	or	CC	False
DDI-MedLine.d30.s11	either	227	232	O	either	her	ther	DT	False
DDI-MedLine.d30.s11	stereoisomer	234	245	O	stereoisomer	mer	omer	NN	False
DDI-MedLine.d30.s11	of	247	248	O	of	of	of	IN	False
DDI-MedLine.d30.s11	NANM	250	253	B-drug_n	NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s11	.	254	254	O	.	.	.	.	False

DDI-MedLine.d30.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d30.s12	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d30.s12	demonstrate	12	22	O	demonstrate	ate	rate	NN	False
DDI-MedLine.d30.s12	a	24	24	O	a	a	a	DT	False
DDI-MedLine.d30.s12	high	26	29	O	high	igh	high	JJ	False
DDI-MedLine.d30.s12	degree	31	36	O	degree	ree	gree	NN	False
DDI-MedLine.d30.s12	of	38	39	O	of	of	of	IN	False
DDI-MedLine.d30.s12	stereoselectivity	41	57	O	stereoselectivity	ity	vity	NN	False
DDI-MedLine.d30.s12	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d30.s12	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d30.s12	behavioral	66	75	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d30.s12	effects	77	83	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s12	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d30.s12	NANM	88	91	B-drug_n	NANM	ANM	NANM	NN	brand
DDI-MedLine.d30.s12	.	92	92	O	.	.	.	.	False

DDI-MedLine.d30.s13	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d30.s13	levorotatory	4	15	O	levorotatory	ory	tory	NN	False
DDI-MedLine.d30.s13	isomer	17	22	O	isomer	mer	omer	NN	False
DDI-MedLine.d30.s13	had	24	26	O	had	had	had	VBD	False
DDI-MedLine.d30.s13	opioid-antagonist	28	44	O	opioid-antagonist	ist	nist	NN	False
DDI-MedLine.d30.s13	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d30.s13	non-opioid	50	59	O	non-opioid	oid	ioid	JJ	False
DDI-MedLine.d30.s13	agonist	61	67	O	agonist	ist	nist	NN	False
DDI-MedLine.d30.s13	effects	69	75	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s13	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d30.s13	pigeons	80	86	O	pigeons	ons	eons	NNS	False
DDI-MedLine.d30.s13	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d30.s13	mixed	92	96	O	mixed	xed	ixed	JJ	False
DDI-MedLine.d30.s13	opioid	98	103	O	opioid	oid	ioid	NN	False
DDI-MedLine.d30.s13	agonist-antagonist	105	122	O	agonist-antagonist	ist	nist	NN	False
DDI-MedLine.d30.s13	effects	124	130	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s13	in	132	133	O	in	in	in	IN	False
DDI-MedLine.d30.s13	monkeys	135	141	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d30.s13	.	142	142	O	.	.	.	.	False

DDI-MedLine.d30.s14	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d30.s14	dextrorotatory	4	17	O	dextrorotatory	ory	tory	NN	False
DDI-MedLine.d30.s14	isomer	19	24	O	isomer	mer	omer	NN	False
DDI-MedLine.d30.s14	,	25	25	O	,	,	,	,	False
DDI-MedLine.d30.s14	on	27	28	O	on	on	on	IN	False
DDI-MedLine.d30.s14	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d30.s14	other	34	38	O	other	her	ther	JJ	False
DDI-MedLine.d30.s14	hand	40	43	O	hand	and	hand	NN	False
DDI-MedLine.d30.s14	,	44	44	O	,	,	,	,	False
DDI-MedLine.d30.s14	had	46	48	O	had	had	had	VBD	False
DDI-MedLine.d30.s14	effects	50	56	O	effects	cts	ects	NNS	False
DDI-MedLine.d30.s14	similar	58	64	O	similar	lar	ilar	JJ	False
DDI-MedLine.d30.s14	to	66	67	O	to	to	to	TO	False
DDI-MedLine.d30.s14	those	69	73	O	those	ose	hose	DT	False
DDI-MedLine.d30.s14	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d30.s14	PCP	78	80	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d30.s14	in	82	83	O	in	in	in	IN	False
DDI-MedLine.d30.s14	both	85	88	O	both	oth	both	DT	False
DDI-MedLine.d30.s14	species	90	96	O	species	ies	cies	NNS	False
DDI-MedLine.d30.s14	.	97	97	O	.	.	.	.	False

DDI-MedLine.d96.s0	Jacalin	0	6	B-drug_n	Jacalin	lin	alin	NN	False
DDI-MedLine.d96.s0	:	7	7	O	:	:	:	:	False
DDI-MedLine.d96.s0	an	9	10	O	an	an	an	DT	False
DDI-MedLine.d96.s0	IgA-binding	12	22	O	IgA-binding	ing	ding	NN	False
DDI-MedLine.d96.s0	lectin	24	29	O	lectin	tin	ctin	NN	False
DDI-MedLine.d96.s0	.	30	30	O	.	.	.	.	False

DDI-MedLine.d96.s1	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d96.s1	previously	3	12	O	previously	sly	usly	RB	False
DDI-MedLine.d96.s1	reported	14	21	O	reported	ted	rted	VBD	False
DDI-MedLine.d96.s1	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d96.s1	seeds	28	32	O	seeds	eds	eeds	NNS	False
DDI-MedLine.d96.s1	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d96.s1	Artocarpus	37	46	O	Artocarpus	pus	rpus	NN	False
DDI-MedLine.d96.s1	integrifolia	48	59	O	integrifolia	lia	olia	NN	False
DDI-MedLine.d96.s1	(	61	61	O	(	(	(	(	False
DDI-MedLine.d96.s1	jackfruit	62	70	O	jackfruit	uit	ruit	NN	False
DDI-MedLine.d96.s1	)	71	71	O	)	)	)	)	False
DDI-MedLine.d96.s1	contain	73	79	O	contain	ain	tain	NN	False
DDI-MedLine.d96.s1	a	81	81	O	a	a	a	DT	False
DDI-MedLine.d96.s1	lectin	83	88	O	lectin	tin	ctin	NN	False
DDI-MedLine.d96.s1	,	89	89	O	,	,	,	,	False
DDI-MedLine.d96.s1	which	91	95	O	which	ich	hich	WDT	False
DDI-MedLine.d96.s1	we	97	98	O	we	we	we	PRP	False
DDI-MedLine.d96.s1	call	100	103	O	call	all	call	NN	False
DDI-MedLine.d96.s1	jacalin	105	111	B-drug_n	jacalin	lin	alin	NN	False
DDI-MedLine.d96.s1	,	112	112	O	,	,	,	,	False
DDI-MedLine.d96.s1	that	114	117	O	that	hat	that	IN	False
DDI-MedLine.d96.s1	is	119	120	O	is	is	is	VBZ	False
DDI-MedLine.d96.s1	both	122	125	O	both	oth	both	DT	False
DDI-MedLine.d96.s1	a	127	127	O	a	a	a	DT	False
DDI-MedLine.d96.s1	potent	129	134	O	potent	ent	tent	NN	False
DDI-MedLine.d96.s1	T	136	136	O	T	T	T	NN	brand
DDI-MedLine.d96.s1	cell	138	141	O	cell	ell	cell	NN	False
DDI-MedLine.d96.s1	mitogen	143	149	O	mitogen	gen	ogen	NN	brand
DDI-MedLine.d96.s1	and	151	153	O	and	and	and	CC	False
DDI-MedLine.d96.s1	an	155	156	O	an	an	an	DT	False
DDI-MedLine.d96.s1	apparently	158	167	O	apparently	tly	ntly	RB	False
DDI-MedLine.d96.s1	T	169	169	O	T	T	T	NN	brand
DDI-MedLine.d96.s1	cell-independent	171	186	O	cell-independent	ent	dent	NN	False
DDI-MedLine.d96.s1	activator	188	196	O	activator	tor	ator	NN	False
DDI-MedLine.d96.s1	of	198	199	O	of	of	of	IN	False
DDI-MedLine.d96.s1	human	201	205	O	human	man	uman	NN	False
DDI-MedLine.d96.s1	B	207	207	O	B	B	B	NN	brand
DDI-MedLine.d96.s1	cells	209	213	O	cells	lls	ells	NNS	False
DDI-MedLine.d96.s1	for	215	217	O	for	for	for	IN	False
DDI-MedLine.d96.s1	the	219	221	O	the	the	the	DT	False
DDI-MedLine.d96.s1	secretion	223	231	O	secretion	ion	tion	NN	False
DDI-MedLine.d96.s1	of	233	234	O	of	of	of	IN	False
DDI-MedLine.d96.s1	immunoglobulins	236	250	O	immunoglobulins	ins	lins	NNS	False
DDI-MedLine.d96.s1	.	251	251	O	.	.	.	.	False

DDI-MedLine.d96.s2	During	0	5	O	During	ing	ring	IN	False
DDI-MedLine.d96.s2	the	7	9	O	the	the	the	DT	False
DDI-MedLine.d96.s2	above	11	15	O	above	ove	bove	IN	False
DDI-MedLine.d96.s2	experiments	17	27	O	experiments	nts	ents	NNS	False
DDI-MedLine.d96.s2	we	29	30	O	we	we	we	PRP	False
DDI-MedLine.d96.s2	noted	32	36	O	noted	ted	oted	VBN	False
DDI-MedLine.d96.s2	a	38	38	O	a	a	a	DT	False
DDI-MedLine.d96.s2	massive	40	46	O	massive	ive	sive	JJ	False
DDI-MedLine.d96.s2	precipitation	48	60	O	precipitation	ion	tion	NN	False
DDI-MedLine.d96.s2	in	62	63	O	in	in	in	IN	False
DDI-MedLine.d96.s2	cell	65	68	O	cell	ell	cell	NN	False
DDI-MedLine.d96.s2	cultures	70	77	O	cultures	res	ures	NNS	False
DDI-MedLine.d96.s2	stimulated	79	88	O	stimulated	ted	ated	VBN	False
DDI-MedLine.d96.s2	with	90	93	O	with	ith	with	IN	False
DDI-MedLine.d96.s2	greater	95	101	O	greater	ter	ater	JJR	False
DDI-MedLine.d96.s2	than	103	106	O	than	han	than	IN	False
DDI-MedLine.d96.s2	or	108	109	O	or	or	or	CC	False
DDI-MedLine.d96.s2	equal	111	115	O	equal	ual	qual	JJ	False
DDI-MedLine.d96.s2	to	117	118	O	to	to	to	TO	False
DDI-MedLine.d96.s2	100	120	122	O	100	100	100	CD	False
DDI-MedLine.d96.s2	micrograms	124	133	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d96.s2	of	135	136	O	of	of	of	IN	False
DDI-MedLine.d96.s2	lectin	138	143	O	lectin	tin	ctin	NN	False
DDI-MedLine.d96.s2	.	144	144	O	.	.	.	.	False

DDI-MedLine.d96.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d96.s3	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d96.s3	paper	8	12	O	paper	per	aper	NN	False
DDI-MedLine.d96.s3	,	13	13	O	,	,	,	,	False
DDI-MedLine.d96.s3	we	15	16	O	we	we	we	PRP	False
DDI-MedLine.d96.s3	show	18	21	O	show	how	show	NN	False
DDI-MedLine.d96.s3	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d96.s3	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d96.s3	precipitate	32	42	O	precipitate	ate	tate	NN	False
DDI-MedLine.d96.s3	is	44	45	O	is	is	is	VBZ	False
DDI-MedLine.d96.s3	formed	47	52	O	formed	med	rmed	VBN	False
DDI-MedLine.d96.s3	after	54	58	O	after	ter	fter	IN	False
DDI-MedLine.d96.s3	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d96.s3	interaction	64	74	O	interaction	ion	tion	NN	False
DDI-MedLine.d96.s3	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d96.s3	jacalin	79	85	B-drug_n	jacalin	lin	alin	NN	False
DDI-MedLine.d96.s3	and	87	89	O	and	and	and	CC	False
DDI-MedLine.d96.s3	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d96.s3	serum	95	99	O	serum	rum	erum	NN	False
DDI-MedLine.d96.s3	protein	101	107	O	protein	ein	tein	NN	False
DDI-MedLine.d96.s3	added	109	113	O	added	ded	dded	VBD	False
DDI-MedLine.d96.s3	to	115	116	O	to	to	to	TO	False
DDI-MedLine.d96.s3	the	118	120	O	the	the	the	DT	False
DDI-MedLine.d96.s3	culture	122	128	O	culture	ure	ture	NN	False
DDI-MedLine.d96.s3	medium	130	135	O	medium	ium	dium	NN	drug
DDI-MedLine.d96.s3	.	136	136	O	.	.	.	.	False

DDI-MedLine.d96.s4	More	0	3	O	More	ore	More	RBR	False
DDI-MedLine.d96.s4	importantly	5	15	O	importantly	tly	ntly	RB	False
DDI-MedLine.d96.s4	,	16	16	O	,	,	,	,	False
DDI-MedLine.d96.s4	we	18	19	O	we	we	we	PRP	False
DDI-MedLine.d96.s4	demonstrate	21	31	O	demonstrate	ate	rate	NN	False
DDI-MedLine.d96.s4	that	33	36	O	that	hat	that	IN	False
DDI-MedLine.d96.s4	IgA	38	40	O	IgA	IgA	IgA	NN	False
DDI-MedLine.d96.s4	is	42	43	O	is	is	is	VBZ	False
DDI-MedLine.d96.s4	probably	45	52	O	probably	bly	ably	RB	False
DDI-MedLine.d96.s4	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d96.s4	major	58	62	O	major	jor	ajor	JJ	False
DDI-MedLine.d96.s4	serum	64	68	O	serum	rum	erum	NN	False
DDI-MedLine.d96.s4	constituent	70	80	O	constituent	ent	uent	NN	False
DDI-MedLine.d96.s4	precipitated	82	93	O	precipitated	ted	ated	VBN	False
DDI-MedLine.d96.s4	by	95	96	O	by	by	by	IN	False
DDI-MedLine.d96.s4	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d96.s4	lectin	102	107	O	lectin	tin	ctin	NN	False
DDI-MedLine.d96.s4	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d96.s4	that	113	116	O	that	hat	that	IN	False
DDI-MedLine.d96.s4	no	118	119	O	no	no	no	DT	False
DDI-MedLine.d96.s4	IgG	121	123	O	IgG	IgG	IgG	NN	False
DDI-MedLine.d96.s4	or	125	126	O	or	or	or	CC	False
DDI-MedLine.d96.s4	IgM	128	130	O	IgM	IgM	IgM	NN	False
DDI-MedLine.d96.s4	can	132	134	O	can	can	can	MD	False
DDI-MedLine.d96.s4	be	136	137	O	be	be	be	VB	False
DDI-MedLine.d96.s4	detected	139	146	O	detected	ted	cted	VBN	False
DDI-MedLine.d96.s4	in	148	149	O	in	in	in	IN	False
DDI-MedLine.d96.s4	the	151	153	O	the	the	the	DT	False
DDI-MedLine.d96.s4	precipitates	155	166	O	precipitates	tes	ates	NNS	False
DDI-MedLine.d96.s4	.	167	167	O	.	.	.	.	False

DDI-MedLine.d96.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d96.s5	secretions	3	12	O	secretions	ons	ions	NNS	False
DDI-MedLine.d96.s5	such	14	17	O	such	uch	such	JJ	False
DDI-MedLine.d96.s5	as	19	20	O	as	as	as	IN	False
DDI-MedLine.d96.s5	colostrum	22	30	O	colostrum	rum	trum	NN	False
DDI-MedLine.d96.s5	,	31	31	O	,	,	,	,	False
DDI-MedLine.d96.s5	IgA	33	35	O	IgA	IgA	IgA	NN	False
DDI-MedLine.d96.s5	is	37	38	O	is	is	is	VBZ	False
DDI-MedLine.d96.s5	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d96.s5	only	44	47	O	only	nly	only	RB	False
DDI-MedLine.d96.s5	protein	49	55	O	protein	ein	tein	NN	False
DDI-MedLine.d96.s5	precipitated	57	68	O	precipitated	ted	ated	VBN	False
DDI-MedLine.d96.s5	by	70	71	O	by	by	by	IN	False
DDI-MedLine.d96.s5	jacalin	73	79	B-drug_n	jacalin	lin	alin	NN	False
DDI-MedLine.d96.s5	.	80	80	O	.	.	.	.	False

DDI-MedLine.d96.s6	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d96.s6	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d96.s6	basis	7	11	O	basis	sis	asis	NN	False
DDI-MedLine.d96.s6	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d96.s6	this	16	19	O	this	his	this	DT	False
DDI-MedLine.d96.s6	specificity	21	31	O	specificity	ity	city	NN	False
DDI-MedLine.d96.s6	we	33	34	O	we	we	we	PRP	False
DDI-MedLine.d96.s6	describe	36	43	O	describe	ibe	ribe	NN	False
DDI-MedLine.d96.s6	a	45	45	O	a	a	a	DT	False
DDI-MedLine.d96.s6	simple	47	52	O	simple	ple	mple	NN	False
DDI-MedLine.d96.s6	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d96.s6	reliable	58	65	O	reliable	ble	able	JJ	False
DDI-MedLine.d96.s6	affinity	67	74	O	affinity	ity	nity	NN	False
DDI-MedLine.d96.s6	chromatography	76	89	O	chromatography	phy	aphy	NN	False
DDI-MedLine.d96.s6	procedure	91	99	O	procedure	ure	dure	NN	False
DDI-MedLine.d96.s6	for	101	103	O	for	for	for	IN	False
DDI-MedLine.d96.s6	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d96.s6	purification	109	120	O	purification	ion	tion	NN	False
DDI-MedLine.d96.s6	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d96.s6	both	125	128	O	both	oth	both	DT	False
DDI-MedLine.d96.s6	human	130	134	O	human	man	uman	NN	False
DDI-MedLine.d96.s6	serum	136	140	O	serum	rum	erum	NN	False
DDI-MedLine.d96.s6	and	142	144	O	and	and	and	CC	False
DDI-MedLine.d96.s6	colostrum	146	154	O	colostrum	rum	trum	NN	False
DDI-MedLine.d96.s6	IgA	156	158	O	IgA	IgA	IgA	NN	False
DDI-MedLine.d96.s6	.	159	159	O	.	.	.	.	False

DDI-MedLine.d96.s7	Jacalin	0	6	B-drug_n	Jacalin	lin	alin	NN	False
DDI-MedLine.d96.s7	is	8	9	O	is	is	is	VBZ	False
DDI-MedLine.d96.s7	a	11	11	O	a	a	a	DT	False
DDI-MedLine.d96.s7	D-Gal	13	17	O	D-Gal	Gal	-Gal	NN	False
DDI-MedLine.d96.s7	binding	19	25	O	binding	ing	ding	NN	False
DDI-MedLine.d96.s7	lectin	27	32	O	lectin	tin	ctin	NN	False
DDI-MedLine.d96.s7	and	34	36	O	and	and	and	CC	False
DDI-MedLine.d96.s7	should	38	43	O	should	uld	ould	MD	False
DDI-MedLine.d96.s7	be	45	46	O	be	be	be	VB	False
DDI-MedLine.d96.s7	a	48	48	O	a	a	a	DT	False
DDI-MedLine.d96.s7	useful	50	55	O	useful	ful	eful	JJ	False
DDI-MedLine.d96.s7	tool	57	60	O	tool	ool	tool	NN	False
DDI-MedLine.d96.s7	for	62	64	O	for	for	for	IN	False
DDI-MedLine.d96.s7	studying	66	73	O	studying	ing	ying	VBG	False
DDI-MedLine.d96.s7	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d96.s7	serum	78	82	O	serum	rum	erum	NN	False
DDI-MedLine.d96.s7	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d96.s7	secretory	88	96	O	secretory	ory	tory	NN	False
DDI-MedLine.d96.s7	IgA	98	100	O	IgA	IgA	IgA	NN	False
DDI-MedLine.d96.s7	.	101	101	O	.	.	.	.	False

DDI-MedLine.d75.s0	Interference	0	11	O	Interference	nce	ence	NN	False
DDI-MedLine.d75.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d75.s0	biocytin	16	23	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s0	with	25	28	O	with	ith	with	IN	False
DDI-MedLine.d75.s0	opioid-evoked	30	42	O	opioid-evoked	ked	oked	JJ	False
DDI-MedLine.d75.s0	hyperpolarization	44	60	O	hyperpolarization	ion	tion	NN	False
DDI-MedLine.d75.s0	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d75.s0	membrane	66	73	O	membrane	ane	rane	NN	False
DDI-MedLine.d75.s0	properties	75	84	O	properties	ies	ties	NNS	False
DDI-MedLine.d75.s0	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d75.s0	rat	89	91	O	rat	rat	rat	NN	False
DDI-MedLine.d75.s0	spinal	93	98	O	spinal	nal	inal	NN	False
DDI-MedLine.d75.s0	substantia	100	109	O	substantia	tia	ntia	NN	False
DDI-MedLine.d75.s0	gelatinosa	111	120	O	gelatinosa	osa	nosa	NN	False
DDI-MedLine.d75.s0	neurons	122	128	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s0	.	129	129	O	.	.	.	.	False

DDI-MedLine.d75.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d75.s1	our	3	5	O	our	our	our	PRP$	False
DDI-MedLine.d75.s1	laboratory	7	16	O	laboratory	ory	tory	NN	False
DDI-MedLine.d75.s1	,	17	17	O	,	,	,	,	False
DDI-MedLine.d75.s1	preliminary	19	29	O	preliminary	ary	nary	JJ	False
DDI-MedLine.d75.s1	whole-cell	31	40	O	whole-cell	ell	cell	NN	False
DDI-MedLine.d75.s1	,	41	41	O	,	,	,	,	False
DDI-MedLine.d75.s1	tight	43	47	O	tight	ght	ight	NN	False
DDI-MedLine.d75.s1	seal	49	52	O	seal	eal	seal	NN	False
DDI-MedLine.d75.s1	recordings	54	63	O	recordings	ngs	ings	NNS	False
DDI-MedLine.d75.s1	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d75.s1	rat	68	70	O	rat	rat	rat	NN	False
DDI-MedLine.d75.s1	spinal	72	77	O	spinal	nal	inal	NN	False
DDI-MedLine.d75.s1	substantia	79	88	O	substantia	tia	ntia	NN	False
DDI-MedLine.d75.s1	gelatinosa	90	99	O	gelatinosa	osa	nosa	NN	False
DDI-MedLine.d75.s1	neurons	101	107	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s1	including	109	117	O	including	ing	ding	VBG	False
DDI-MedLine.d75.s1	biocytin	119	126	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s1	in	128	129	O	in	in	in	IN	False
DDI-MedLine.d75.s1	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d75.s1	patch	135	139	O	patch	tch	atch	NN	False
DDI-MedLine.d75.s1	pipette	141	147	O	pipette	tte	ette	NN	False
DDI-MedLine.d75.s1	yielded	149	155	O	yielded	ded	lded	VBN	False
DDI-MedLine.d75.s1	a	157	157	O	a	a	a	DT	False
DDI-MedLine.d75.s1	significantly	159	171	O	significantly	tly	ntly	RB	False
DDI-MedLine.d75.s1	smaller	173	179	O	smaller	ler	ller	JJR	False
DDI-MedLine.d75.s1	proportion	181	190	O	proportion	ion	tion	NN	False
DDI-MedLine.d75.s1	of	192	193	O	of	of	of	IN	False
DDI-MedLine.d75.s1	neurons	195	201	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s1	hyperpolarized	203	216	O	hyperpolarized	zed	ized	VBN	False
DDI-MedLine.d75.s1	by	218	219	O	by	by	by	IN	False
DDI-MedLine.d75.s1	selective	221	229	B-group	selective	ive	tive	NN	False
DDI-MedLine.d75.s1	opioid	231	236	I-group	opioid	oid	ioid	NN	False
DDI-MedLine.d75.s1	agonists	238	245	I-group	agonists	sts	ists	NNS	False
DDI-MedLine.d75.s1	compared	247	254	O	compared	red	ared	VBN	False
DDI-MedLine.d75.s1	with	256	259	O	with	ith	with	IN	False
DDI-MedLine.d75.s1	recordings	261	270	O	recordings	ngs	ings	NNS	False
DDI-MedLine.d75.s1	without	272	278	O	without	out	hout	IN	False
DDI-MedLine.d75.s1	biocytin	280	287	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s1	.	288	288	O	.	.	.	.	False

DDI-MedLine.d75.s2	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d75.s2	,	9	9	O	,	,	,	,	False
DDI-MedLine.d75.s2	we	11	12	O	we	we	we	PRP	False
DDI-MedLine.d75.s2	investigated	14	25	O	investigated	ted	ated	VBN	False
DDI-MedLine.d75.s2	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d75.s2	effects	31	37	O	effects	cts	ects	NNS	False
DDI-MedLine.d75.s2	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d75.s2	biocytin	42	49	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s2	inclusion	51	59	O	inclusion	ion	sion	NN	False
DDI-MedLine.d75.s2	on	61	62	O	on	on	on	IN	False
DDI-MedLine.d75.s2	opioid	64	69	B-group	opioid	oid	ioid	NN	False
DDI-MedLine.d75.s2	responses	71	79	O	responses	ses	nses	NNS	False
DDI-MedLine.d75.s2	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d75.s2	other	85	89	O	other	her	ther	JJ	False
DDI-MedLine.d75.s2	membrane	91	98	O	membrane	ane	rane	NN	False
DDI-MedLine.d75.s2	properties	100	109	O	properties	ies	ties	NNS	False
DDI-MedLine.d75.s2	during	111	116	O	during	ing	ring	IN	False
DDI-MedLine.d75.s2	whole-cell	118	127	O	whole-cell	ell	cell	NN	False
DDI-MedLine.d75.s2	,	128	128	O	,	,	,	,	False
DDI-MedLine.d75.s2	tight	130	134	O	tight	ght	ight	NN	False
DDI-MedLine.d75.s2	seal	136	139	O	seal	eal	seal	NN	False
DDI-MedLine.d75.s2	recordings	141	150	O	recordings	ngs	ings	NNS	False
DDI-MedLine.d75.s2	of	152	153	O	of	of	of	IN	False
DDI-MedLine.d75.s2	these	155	159	O	these	ese	hese	DT	False
DDI-MedLine.d75.s2	neurons	161	167	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s2	.	168	168	O	.	.	.	.	False

DDI-MedLine.d75.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d75.s3	percentage	4	13	O	percentage	age	tage	NN	False
DDI-MedLine.d75.s3	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d75.s3	neurons	18	24	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s3	hyperpolarized	26	39	O	hyperpolarized	zed	ized	VBN	False
DDI-MedLine.d75.s3	by	41	42	O	by	by	by	IN	False
DDI-MedLine.d75.s3	mu-	44	46	B-group	mu-	mu-	mu-	NN	False
DDI-MedLine.d75.s3	,	47	47	O	,	,	,	,	False
DDI-MedLine.d75.s3	delta	49	53	B-group	delta	lta	elta	NN	False
DDI-MedLine.d75.s3	(	54	54	I-group	(	(	(	(	False
DDI-MedLine.d75.s3	1	55	55	I-group	1	1	1	CD	False
DDI-MedLine.d75.s3	)	56	56	I-group	)	)	)	)	False
DDI-MedLine.d75.s3	-	57	57	I-group	-	-	-	:	False
DDI-MedLine.d75.s3	,	58	58	O	,	,	,	,	False
DDI-MedLine.d75.s3	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d75.s3	kappa-selective	64	78	B-group	kappa-selective	ive	tive	JJ	False
DDI-MedLine.d75.s3	opioids	80	86	I-group	opioids	ids	oids	NNS	False
DDI-MedLine.d75.s3	was	88	90	O	was	was	was	VBD	False
DDI-MedLine.d75.s3	significantly	92	104	O	significantly	tly	ntly	RB	False
DDI-MedLine.d75.s3	reduced	106	112	O	reduced	ced	uced	VBN	False
DDI-MedLine.d75.s3	when	114	117	O	when	hen	when	WRB	False
DDI-MedLine.d75.s3	1	119	119	O	1	1	1	CD	False
DDI-MedLine.d75.s3	%	120	120	O	%	%	%	NN	False
DDI-MedLine.d75.s3	but	122	124	O	but	but	but	CC	False
DDI-MedLine.d75.s3	not	126	128	O	not	not	not	RB	False
DDI-MedLine.d75.s3	<	130	130	O	<	<	<	NN	False

DDI-MedLine.d75.s4	or	0	1	O	or	or	or	CC	False
DDI-MedLine.d75.s4	=0.2	3	6	O	=0.2	0.2	=0.2	NN	False
DDI-MedLine.d75.s4	%	7	7	O	%	%	%	NN	False
DDI-MedLine.d75.s4	biocytin	9	16	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s4	was	18	20	O	was	was	was	VBD	False
DDI-MedLine.d75.s4	included	22	29	O	included	ded	uded	VBD	False
DDI-MedLine.d75.s4	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d75.s4	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d75.s4	recording	38	46	O	recording	ing	ding	VBG	False
DDI-MedLine.d75.s4	pipette	48	54	O	pipette	tte	ette	NN	False
DDI-MedLine.d75.s4	,	55	55	O	,	,	,	,	False
DDI-MedLine.d75.s4	compared	57	64	O	compared	red	ared	VBN	False
DDI-MedLine.d75.s4	with	66	69	O	with	ith	with	IN	False
DDI-MedLine.d75.s4	neurons	71	77	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s4	recorded	79	86	O	recorded	ded	rded	VBN	False
DDI-MedLine.d75.s4	without	88	94	O	without	out	hout	IN	False
DDI-MedLine.d75.s4	biocytin	96	103	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s4	.	104	104	O	.	.	.	.	False

DDI-MedLine.d75.s5	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d75.s5	,	7	7	O	,	,	,	,	False
DDI-MedLine.d75.s5	a	9	9	O	a	a	a	DT	False
DDI-MedLine.d75.s5	significantly	11	23	O	significantly	tly	ntly	RB	False
DDI-MedLine.d75.s5	higher	25	30	O	higher	her	gher	JJR	False
DDI-MedLine.d75.s5	proportion	32	41	O	proportion	ion	tion	NN	False
DDI-MedLine.d75.s5	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d75.s5	neurons	46	52	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s5	fired	54	58	O	fired	red	ired	VBN	False
DDI-MedLine.d75.s5	spontaneous	60	70	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d75.s5	action	72	77	O	action	ion	tion	NN	False
DDI-MedLine.d75.s5	potentials	79	88	O	potentials	als	ials	NNS	False
DDI-MedLine.d75.s5	with	90	93	O	with	ith	with	IN	False
DDI-MedLine.d75.s5	either	95	100	O	either	her	ther	DT	False
DDI-MedLine.d75.s5	0.05-0.2	102	109	O	0.05-0.2	0.2	-0.2	NN	False
DDI-MedLine.d75.s5	or	111	112	O	or	or	or	CC	False
DDI-MedLine.d75.s5	1	114	114	O	1	1	1	CD	False
DDI-MedLine.d75.s5	%	115	115	O	%	%	%	NN	False
DDI-MedLine.d75.s5	biocytin	117	124	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s5	compared	126	133	O	compared	red	ared	VBN	False
DDI-MedLine.d75.s5	to	135	136	O	to	to	to	TO	False
DDI-MedLine.d75.s5	no	138	139	O	no	no	no	DT	False
DDI-MedLine.d75.s5	biocytin	141	148	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s5	.	149	149	O	.	.	.	.	False

DDI-MedLine.d75.s6	Resting	0	6	O	Resting	ing	ting	VBG	False
DDI-MedLine.d75.s6	membrane	8	15	O	membrane	ane	rane	NN	False
DDI-MedLine.d75.s6	potential	17	25	O	potential	ial	tial	JJ	False
DDI-MedLine.d75.s6	,	26	26	O	,	,	,	,	False
DDI-MedLine.d75.s6	input	28	32	O	input	put	nput	NN	False
DDI-MedLine.d75.s6	impedance	34	42	O	impedance	nce	ance	NN	False
DDI-MedLine.d75.s6	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d75.s6	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d75.s6	proportion	52	61	O	proportion	ion	tion	NN	False
DDI-MedLine.d75.s6	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d75.s6	neurons	66	72	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s6	displaying	74	83	O	displaying	ing	ying	VBG	False
DDI-MedLine.d75.s6	transient	85	93	O	transient	ent	ient	NN	False
DDI-MedLine.d75.s6	outward	95	101	O	outward	ard	ward	NN	False
DDI-MedLine.d75.s6	rectification	103	115	O	rectification	ion	tion	NN	False
DDI-MedLine.d75.s6	were	117	120	O	were	ere	were	VBD	False
DDI-MedLine.d75.s6	each	122	125	O	each	ach	each	DT	False
DDI-MedLine.d75.s6	significantly	127	139	O	significantly	tly	ntly	RB	False
DDI-MedLine.d75.s6	altered	141	147	O	altered	red	ered	VBN	False
DDI-MedLine.d75.s6	for	149	151	O	for	for	for	IN	False
DDI-MedLine.d75.s6	neurons	153	159	O	neurons	ons	rons	NNS	False
DDI-MedLine.d75.s6	recorded	161	168	O	recorded	ded	rded	VBN	False
DDI-MedLine.d75.s6	with	170	173	O	with	ith	with	IN	False
DDI-MedLine.d75.s6	1	175	175	O	1	1	1	CD	False
DDI-MedLine.d75.s6	%	176	176	O	%	%	%	NN	False
DDI-MedLine.d75.s6	but	178	180	O	but	but	but	CC	False
DDI-MedLine.d75.s6	not	182	184	O	not	not	not	RB	False
DDI-MedLine.d75.s6	0.05-0.2	186	193	O	0.05-0.2	0.2	-0.2	NN	False
DDI-MedLine.d75.s6	%	194	194	O	%	%	%	NN	False
DDI-MedLine.d75.s6	biocytin	196	203	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s6	.	204	204	O	.	.	.	.	False

DDI-MedLine.d75.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d75.s7	effects	6	12	O	effects	cts	ects	NNS	False
DDI-MedLine.d75.s7	may	14	16	O	may	may	may	MD	False
DDI-MedLine.d75.s7	be	18	19	O	be	be	be	VB	False
DDI-MedLine.d75.s7	due	21	23	O	due	due	due	JJ	False
DDI-MedLine.d75.s7	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d75.s7	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d75.s7	relatively	30	39	O	relatively	ely	vely	RB	False
DDI-MedLine.d75.s7	specific	41	48	O	specific	fic	ific	JJ	False
DDI-MedLine.d75.s7	blockade	50	57	O	blockade	ade	kade	NN	False
DDI-MedLine.d75.s7	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d75.s7	diverse	62	68	O	diverse	rse	erse	NN	False
DDI-MedLine.d75.s7	potassium	70	78	O	potassium	ium	sium	NN	drug
DDI-MedLine.d75.s7	channel	80	86	O	channel	nel	nnel	NNS	False
DDI-MedLine.d75.s7	types	88	92	O	types	pes	ypes	NNS	False
DDI-MedLine.d75.s7	.	93	93	O	.	.	.	.	False

DDI-MedLine.d75.s8	Because	0	6	O	Because	use	ause	IN	False
DDI-MedLine.d75.s8	efficient	8	16	O	efficient	ent	ient	NN	False
DDI-MedLine.d75.s8	labeling	18	25	O	labeling	ing	ling	VBG	False
DDI-MedLine.d75.s8	can	27	29	O	can	can	can	MD	False
DDI-MedLine.d75.s8	be	31	32	O	be	be	be	VB	False
DDI-MedLine.d75.s8	achieved	34	41	O	achieved	ved	eved	VBN	False
DDI-MedLine.d75.s8	with	43	46	O	with	ith	with	IN	False
DDI-MedLine.d75.s8	0.1	48	50	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d75.s8	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d75.s8	biocytin	53	60	O	biocytin	tin	ytin	NN	False
DDI-MedLine.d75.s8	with	62	65	O	with	ith	with	IN	False
DDI-MedLine.d75.s8	whole-cell	67	76	O	whole-cell	ell	cell	NN	False
DDI-MedLine.d75.s8	recording	78	86	O	recording	ing	ding	VBG	False
DDI-MedLine.d75.s8	,	87	87	O	,	,	,	,	False
DDI-MedLine.d75.s8	higher	89	94	O	higher	her	gher	JJR	False
DDI-MedLine.d75.s8	concentrations	96	109	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d75.s8	are	111	113	O	are	are	are	VBP	False
DDI-MedLine.d75.s8	contraindicated	115	129	O	contraindicated	ted	ated	VBN	False
DDI-MedLine.d75.s8	.	130	130	O	.	.	.	.	False

DDI-MedLine.d131.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d131.s0	on	12	13	O	on	on	on	IN	False
DDI-MedLine.d131.s0	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d131.s0	antinociceptive	19	33	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d131.s0	effect	35	40	O	effect	ect	fect	NN	False
DDI-MedLine.d131.s0	between	42	48	O	between	een	ween	IN	False
DDI-MedLine.d131.s0	neurotensin	50	60	B-drug_n	neurotensin	sin	nsin	NN	False
DDI-MedLine.d131.s0	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d131.s0	enkephalins	66	76	B-drug_n	enkephalins	ins	lins	NNS	False
DDI-MedLine.d131.s0	or	78	79	O	or	or	or	CC	False
DDI-MedLine.d131.s0	tuftsin	81	87	B-drug_n	tuftsin	sin	tsin	NN	False
DDI-MedLine.d131.s0	.	88	88	O	.	.	.	.	False

DDI-MedLine.d131.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d131.s1	aim	4	6	O	aim	aim	aim	NN	False
DDI-MedLine.d131.s1	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d131.s1	this	11	14	O	this	his	this	DT	False
DDI-MedLine.d131.s1	paper	16	20	O	paper	per	aper	NN	False
DDI-MedLine.d131.s1	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d131.s1	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d131.s1	study	29	33	O	study	udy	tudy	NN	False
DDI-MedLine.d131.s1	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d131.s1	interaction	39	49	O	interaction	ion	tion	NN	False
DDI-MedLine.d131.s1	between	51	57	O	between	een	ween	IN	False
DDI-MedLine.d131.s1	neurotensin	59	69	B-drug_n	neurotensin	sin	nsin	NN	False
DDI-MedLine.d131.s1	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d131.s1	both	75	78	O	both	oth	both	DT	False
DDI-MedLine.d131.s1	enkephalins	80	90	B-drug_n	enkephalins	ins	lins	NNS	False
DDI-MedLine.d131.s1	or	92	93	O	or	or	or	CC	False
DDI-MedLine.d131.s1	its	95	97	O	its	its	its	PRP$	False
DDI-MedLine.d131.s1	synthetic	99	107	O	synthetic	tic	etic	JJ	False
DDI-MedLine.d131.s1	analogue	109	116	O	analogue	gue	ogue	NN	False
DDI-MedLine.d131.s1	D-Ala2-metenkephalinamide	118	142	B-drug_n	D-Ala2-metenkephalinamide	ide	mide	NN	False
DDI-MedLine.d131.s1	,	143	143	O	,	,	,	,	False
DDI-MedLine.d131.s1	or	145	146	O	or	or	or	CC	False
DDI-MedLine.d131.s1	tuftsin	148	154	B-drug_n	tuftsin	sin	tsin	NN	False
DDI-MedLine.d131.s1	,	155	155	O	,	,	,	,	False
DDI-MedLine.d131.s1	on	157	158	O	on	on	on	IN	False
DDI-MedLine.d131.s1	the	160	162	O	the	the	the	DT	False
DDI-MedLine.d131.s1	antinonciceptive	164	179	O	antinonciceptive	ive	tive	JJ	False
DDI-MedLine.d131.s1	effect	181	186	O	effect	ect	fect	NN	False
DDI-MedLine.d131.s1	of	188	189	O	of	of	of	IN	False
DDI-MedLine.d131.s1	these	191	195	O	these	ese	hese	DT	False
DDI-MedLine.d131.s1	peptides	197	204	O	peptides	des	ides	NNS	group
DDI-MedLine.d131.s1	in	206	207	O	in	in	in	IN	False
DDI-MedLine.d131.s1	mice	209	212	O	mice	ice	mice	NN	False
DDI-MedLine.d131.s1	after	214	218	O	after	ter	fter	IN	False
DDI-MedLine.d131.s1	intracisternal	220	233	O	intracisternal	nal	rnal	JJ	False
DDI-MedLine.d131.s1	injection	235	243	O	injection	ion	tion	NN	False
DDI-MedLine.d131.s1	.	244	244	O	.	.	.	.	False

DDI-MedLine.d131.s2	Antinociception	0	14	O	Antinociception	ion	tion	NN	False
DDI-MedLine.d131.s2	was	16	18	O	was	was	was	VBD	False
DDI-MedLine.d131.s2	measured	20	27	O	measured	red	ured	VBN	False
DDI-MedLine.d131.s2	by	29	30	O	by	by	by	IN	False
DDI-MedLine.d131.s2	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d131.s2	hot-plate	36	44	O	hot-plate	ate	late	NN	False
DDI-MedLine.d131.s2	method	46	51	O	method	hod	thod	NN	False
DDI-MedLine.d131.s2	.	52	52	O	.	.	.	.	False

DDI-MedLine.d131.s3	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d131.s3	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d131.s3	shown	7	11	O	shown	own	hown	VBN	False
DDI-MedLine.d131.s3	that	13	16	O	that	hat	that	IN	False
DDI-MedLine.d131.s3	neurotensin	18	28	B-drug_n	neurotensin	sin	nsin	NN	False
DDI-MedLine.d131.s3	antagonized	30	40	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d131.s3	evidently	42	50	O	evidently	tly	ntly	RB	False
DDI-MedLine.d131.s3	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d131.s3	antinociceptive	56	70	O	antinociceptive	ive	tive	JJ	False
DDI-MedLine.d131.s3	effect	72	77	O	effect	ect	fect	NN	False
DDI-MedLine.d131.s3	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d131.s3	enkephalins	82	92	B-drug_n	enkephalins	ins	lins	NNS	False
DDI-MedLine.d131.s3	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d131.s3	their	98	102	O	their	eir	heir	PRP$	False
DDI-MedLine.d131.s3	analogue	104	111	O	analogue	gue	ogue	NN	False
DDI-MedLine.d131.s3	.	112	112	O	.	.	.	.	False

DDI-MedLine.d131.s4	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d131.s4	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d131.s4	contrary	7	14	O	contrary	ary	rary	JJ	False
DDI-MedLine.d131.s4	,	15	15	O	,	,	,	,	False
DDI-MedLine.d131.s4	neurotensin	17	27	B-drug_n	neurotensin	sin	nsin	NN	False
DDI-MedLine.d131.s4	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d131.s4	tuftsin	33	39	B-drug_n	tuftsin	sin	tsin	NN	False
DDI-MedLine.d131.s4	were	41	44	O	were	ere	were	VBD	False
DDI-MedLine.d131.s4	agonists	46	53	O	agonists	sts	ists	NNS	False
DDI-MedLine.d131.s4	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d131.s4	induction	58	66	O	induction	ion	tion	NN	False
DDI-MedLine.d131.s4	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d131.s4	analgesia	71	79	O	analgesia	sia	esia	NN	False
DDI-MedLine.d131.s4	.	80	80	O	.	.	.	.	False

DDI-MedLine.d131.s5	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d131.s5	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d131.s5	concluded	6	14	O	concluded	ded	uded	VBD	False
DDI-MedLine.d131.s5	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d131.s5	neurotensin	21	31	B-drug_n	neurotensin	sin	nsin	NN	False
DDI-MedLine.d131.s5	modulates	33	41	O	modulates	tes	ates	NNS	False
DDI-MedLine.d131.s5	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d131.s5	an	46	47	O	an	an	an	DT	False
DDI-MedLine.d131.s5	opposite	49	56	O	opposite	ite	site	NN	False
DDI-MedLine.d131.s5	way	58	60	O	way	way	way	NN	False
DDI-MedLine.d131.s5	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d131.s5	function	66	73	O	function	ion	tion	NN	False
DDI-MedLine.d131.s5	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d131.s5	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d131.s5	enkephalinergic	82	96	O	enkephalinergic	gic	rgic	NN	False
DDI-MedLine.d131.s5	neurons	98	104	O	neurons	ons	rons	NNS	False
DDI-MedLine.d131.s5	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d131.s5	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d131.s5	central	114	120	O	central	ral	tral	JJ	False
DDI-MedLine.d131.s5	action	122	127	O	action	ion	tion	NN	False
DDI-MedLine.d131.s5	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d131.s5	tuftsin	132	138	B-drug_n	tuftsin	sin	tsin	NN	False
DDI-MedLine.d131.s5	.	139	139	O	.	.	.	.	False

DDI-MedLine.d84.s0	Antimicrobial	0	12	O	Antimicrobial	ial	bial	JJ	False
DDI-MedLine.d84.s0	activity	14	21	O	activity	ity	vity	NN	False
DDI-MedLine.d84.s0	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d84.s0	Ganoderma	26	34	B-drug_n	Ganoderma	rma	erma	NN	False
DDI-MedLine.d84.s0	lucidum	36	42	I-drug_n	lucidum	dum	idum	NN	False
DDI-MedLine.d84.s0	extract	44	50	I-drug_n	extract	act	ract	NN	False
DDI-MedLine.d84.s0	alone	52	56	O	alone	one	lone	RB	False
DDI-MedLine.d84.s0	and	58	60	O	and	and	and	CC	False
DDI-MedLine.d84.s0	in	62	63	O	in	in	in	IN	False
DDI-MedLine.d84.s0	combination	65	75	O	combination	ion	tion	NN	False
DDI-MedLine.d84.s0	with	77	80	O	with	ith	with	IN	False
DDI-MedLine.d84.s0	some	82	85	O	some	ome	some	DT	False
DDI-MedLine.d84.s0	antibiotics	87	97	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d84.s0	.	98	98	O	.	.	.	.	False

DDI-MedLine.d84.s1	Antimicrobial	0	12	O	Antimicrobial	ial	bial	JJ	False
DDI-MedLine.d84.s1	activity	14	21	O	activity	ity	vity	NN	False
DDI-MedLine.d84.s1	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d84.s1	GL	26	27	B-drug_n	GL	GL	GL	NN	brand
DDI-MedLine.d84.s1	(	29	29	O	(	(	(	(	False
DDI-MedLine.d84.s1	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d84.s1	aqueous	34	40	O	aqueous	ous	eous	JJ	False
DDI-MedLine.d84.s1	extract	42	48	O	extract	act	ract	NN	False
DDI-MedLine.d84.s1	from	50	53	O	from	rom	from	IN	False
DDI-MedLine.d84.s1	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d84.s1	carpophores	59	69	O	carpophores	res	ores	NNS	False
DDI-MedLine.d84.s1	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d84.s1	Ganoderma	74	82	O	Ganoderma	rma	erma	NN	False
DDI-MedLine.d84.s1	lucidum	84	90	O	lucidum	dum	idum	NN	False
DDI-MedLine.d84.s1	(	92	92	O	(	(	(	(	False
DDI-MedLine.d84.s1	FR	93	94	O	FR	FR	FR	NN	brand
DDI-MedLine.d84.s1	)	95	95	O	)	)	)	)	False
DDI-MedLine.d84.s1	KARST	96	100	O	KARST	RST	ARST	NNP	brand
DDI-MedLine.d84.s1	)	101	101	O	)	)	)	)	False
DDI-MedLine.d84.s1	was	103	105	O	was	was	was	VBD	False
DDI-MedLine.d84.s1	tested	107	112	O	tested	ted	sted	VBN	False
DDI-MedLine.d84.s1	in	114	115	O	in	in	in	IN	False
DDI-MedLine.d84.s1	vitro	117	121	O	vitro	tro	itro	NN	False
DDI-MedLine.d84.s1	against	123	129	O	against	nst	inst	IN	False
DDI-MedLine.d84.s1	Gram	131	134	O	Gram	ram	Gram	NN	False
DDI-MedLine.d84.s1	positive	136	143	O	positive	ive	tive	JJ	False
DDI-MedLine.d84.s1	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d84.s1	Gram	149	152	O	Gram	ram	Gram	NN	False
DDI-MedLine.d84.s1	negative	154	161	O	negative	ive	tive	JJ	False
DDI-MedLine.d84.s1	bacteria	163	170	O	bacteria	ria	eria	NNS	False
DDI-MedLine.d84.s1	by	172	173	O	by	by	by	IN	False
DDI-MedLine.d84.s1	serial	175	180	O	serial	ial	rial	JJ	False
DDI-MedLine.d84.s1	broth	182	186	O	broth	oth	roth	NN	False
DDI-MedLine.d84.s1	dilution	188	195	O	dilution	ion	tion	NN	False
DDI-MedLine.d84.s1	method	197	202	O	method	hod	thod	NN	False
DDI-MedLine.d84.s1	,	203	203	O	,	,	,	,	False
DDI-MedLine.d84.s1	and	205	207	O	and	and	and	CC	False
DDI-MedLine.d84.s1	the	209	211	O	the	the	the	DT	False
DDI-MedLine.d84.s1	antimicrobial	213	225	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d84.s1	activity	227	234	O	activity	ity	vity	NN	False
DDI-MedLine.d84.s1	was	236	238	O	was	was	was	VBD	False
DDI-MedLine.d84.s1	expressed	240	248	O	expressed	sed	ssed	VBN	False
DDI-MedLine.d84.s1	by	250	251	O	by	by	by	IN	False
DDI-MedLine.d84.s1	minimal	253	259	O	minimal	mal	imal	NN	False
DDI-MedLine.d84.s1	inhibitory	261	270	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d84.s1	concentration	272	284	O	concentration	ion	tion	NN	False
DDI-MedLine.d84.s1	(	286	286	O	(	(	(	(	False
DDI-MedLine.d84.s1	MIC	287	289	O	MIC	MIC	MIC	NN	brand
DDI-MedLine.d84.s1	)	290	290	O	)	)	)	)	False
DDI-MedLine.d84.s1	.	291	291	O	.	.	.	.	False

DDI-MedLine.d84.s2	Among	0	4	O	Among	ong	mong	IN	False
DDI-MedLine.d84.s2	fifteen	6	12	O	fifteen	een	teen	NN	False
DDI-MedLine.d84.s2	species	14	20	O	species	ies	cies	NNS	False
DDI-MedLine.d84.s2	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d84.s2	bacteria	25	32	O	bacteria	ria	eria	NNS	False
DDI-MedLine.d84.s2	tested	34	39	O	tested	ted	sted	VBN	False
DDI-MedLine.d84.s2	,	40	40	O	,	,	,	,	False
DDI-MedLine.d84.s2	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d84.s2	antimicrobial	46	58	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d84.s2	activity	60	67	O	activity	ity	vity	NN	False
DDI-MedLine.d84.s2	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d84.s2	GL	72	73	B-drug_n	GL	GL	GL	NN	brand
DDI-MedLine.d84.s2	was	75	77	O	was	was	was	VBD	False
DDI-MedLine.d84.s2	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d84.s2	most	83	86	O	most	ost	most	JJS	False
DDI-MedLine.d84.s2	potent	88	93	O	potent	ent	tent	NN	False
DDI-MedLine.d84.s2	against	95	101	O	against	nst	inst	IN	False
DDI-MedLine.d84.s2	Micrococcus	103	113	O	Micrococcus	cus	ccus	NN	False
DDI-MedLine.d84.s2	luteus	115	120	O	luteus	eus	teus	NN	False
DDI-MedLine.d84.s2	(	122	122	O	(	(	(	(	False
DDI-MedLine.d84.s2	MIC	123	125	O	MIC	MIC	MIC	NN	brand
DDI-MedLine.d84.s2	,	126	126	O	,	,	,	,	False
DDI-MedLine.d84.s2	0.75	128	131	O	0.75	.75	0.75	CD	False
DDI-MedLine.d84.s2	mg/ml	133	137	O	mg/ml	/ml	g/ml	NN	False
DDI-MedLine.d84.s2	)	138	138	O	)	)	)	)	False
DDI-MedLine.d84.s2	.	139	139	O	.	.	.	.	False

DDI-MedLine.d84.s3	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d84.s3	investigate	3	13	O	investigate	ate	gate	NN	False
DDI-MedLine.d84.s3	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d84.s3	effects	19	25	O	effects	cts	ects	NNS	False
DDI-MedLine.d84.s3	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d84.s3	antimicrobial	30	42	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d84.s3	combinations	44	55	O	combinations	ons	ions	NNS	False
DDI-MedLine.d84.s3	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d84.s3	GL	60	61	B-drug_n	GL	GL	GL	NN	brand
DDI-MedLine.d84.s3	with	63	66	O	with	ith	with	IN	False
DDI-MedLine.d84.s3	four	68	71	O	four	our	four	CD	False
DDI-MedLine.d84.s3	kinds	73	77	O	kinds	nds	inds	NNS	False
DDI-MedLine.d84.s3	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d84.s3	antibiotics	82	92	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d84.s3	(	94	94	O	(	(	(	(	False
DDI-MedLine.d84.s3	ampicillin	95	104	B-drug	ampicillin	lin	llin	NN	False
DDI-MedLine.d84.s3	,	105	105	O	,	,	,	,	False
DDI-MedLine.d84.s3	cefazolin	107	115	B-drug	cefazolin	lin	olin	NN	False
DDI-MedLine.d84.s3	,	116	116	O	,	,	,	,	False
DDI-MedLine.d84.s3	oxytetracycline	118	132	B-drug	oxytetracycline	ine	line	NN	drug
DDI-MedLine.d84.s3	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d84.s3	chloramphenicol	138	152	B-drug	chloramphenicol	col	icol	NN	False
DDI-MedLine.d84.s3	)	153	153	O	)	)	)	)	False
DDI-MedLine.d84.s3	,	154	154	O	,	,	,	,	False
DDI-MedLine.d84.s3	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d84.s3	fractional	160	169	O	fractional	nal	onal	JJ	False
DDI-MedLine.d84.s3	inhibitory	171	180	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d84.s3	concentration	182	194	O	concentration	ion	tion	NN	False
DDI-MedLine.d84.s3	index	196	200	O	index	dex	ndex	NN	False
DDI-MedLine.d84.s3	(	202	202	O	(	(	(	(	False
DDI-MedLine.d84.s3	FICI	203	206	O	FICI	ICI	FICI	NN	brand
DDI-MedLine.d84.s3	)	207	207	O	)	)	)	)	False
DDI-MedLine.d84.s3	was	209	211	O	was	was	was	VBD	False
DDI-MedLine.d84.s3	determined	213	222	O	determined	ned	ined	VBN	False
DDI-MedLine.d84.s3	by	224	225	O	by	by	by	IN	False
DDI-MedLine.d84.s3	checkerboard	227	238	O	checkerboard	ard	oard	NN	False
DDI-MedLine.d84.s3	assay	240	244	O	assay	say	ssay	NN	False
DDI-MedLine.d84.s3	for	246	248	O	for	for	for	IN	False
DDI-MedLine.d84.s3	each	250	253	O	each	ach	each	DT	False
DDI-MedLine.d84.s3	strain	255	260	O	strain	ain	rain	NN	False
DDI-MedLine.d84.s3	.	261	261	O	.	.	.	.	False

DDI-MedLine.d84.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d84.s4	antimicrobial	4	16	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d84.s4	combinations	18	29	O	combinations	ons	ions	NNS	False
DDI-MedLine.d84.s4	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d84.s4	GL	34	35	B-drug_n	GL	GL	GL	NN	brand
DDI-MedLine.d84.s4	with	37	40	O	with	ith	with	IN	False
DDI-MedLine.d84.s4	four	42	45	O	four	our	four	CD	False
DDI-MedLine.d84.s4	antibiotics	47	57	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d84.s4	resulted	59	66	O	resulted	ted	lted	VBD	False
DDI-MedLine.d84.s4	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d84.s4	additive	71	78	O	additive	ive	tive	JJ	False
DDI-MedLine.d84.s4	effect	80	85	O	effect	ect	fect	NN	False
DDI-MedLine.d84.s4	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d84.s4	most	90	93	O	most	ost	most	JJS	False
DDI-MedLine.d84.s4	instances	95	103	O	instances	ces	nces	NNS	False
DDI-MedLine.d84.s4	,	104	104	O	,	,	,	,	False
DDI-MedLine.d84.s4	synergism	106	114	O	synergism	ism	gism	NN	False
DDI-MedLine.d84.s4	in	116	117	O	in	in	in	IN	False
DDI-MedLine.d84.s4	two	119	121	O	two	two	two	CD	False
DDI-MedLine.d84.s4	instances	123	131	O	instances	ces	nces	NNS	False
DDI-MedLine.d84.s4	,	132	132	O	,	,	,	,	False
DDI-MedLine.d84.s4	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d84.s4	antagonism	138	147	O	antagonism	ism	nism	NN	False
DDI-MedLine.d84.s4	in	149	150	O	in	in	in	IN	False
DDI-MedLine.d84.s4	two	152	154	O	two	two	two	CD	False
DDI-MedLine.d84.s4	instances	156	164	O	instances	ces	nces	NNS	False
DDI-MedLine.d84.s4	.	165	165	O	.	.	.	.	False

DDI-MedLine.d84.s5	Synergism	0	8	O	Synergism	ism	gism	NN	False
DDI-MedLine.d84.s5	was	10	12	O	was	was	was	VBD	False
DDI-MedLine.d84.s5	observed	14	21	O	observed	ved	rved	VBN	False
DDI-MedLine.d84.s5	when	23	26	O	when	hen	when	WRB	False
DDI-MedLine.d84.s5	GL	28	29	B-drug_n	GL	GL	GL	NN	brand
DDI-MedLine.d84.s5	was	31	33	O	was	was	was	VBD	False
DDI-MedLine.d84.s5	combined	35	42	O	combined	ned	ined	VBN	False
DDI-MedLine.d84.s5	with	44	47	O	with	ith	with	IN	False
DDI-MedLine.d84.s5	cefazolin	49	57	B-drug	cefazolin	lin	olin	NN	False
DDI-MedLine.d84.s5	against	59	65	O	against	nst	inst	IN	False
DDI-MedLine.d84.s5	Bacillus	67	74	O	Bacillus	lus	llus	NN	False
DDI-MedLine.d84.s5	subtilis	76	83	O	subtilis	lis	ilis	NNS	False
DDI-MedLine.d84.s5	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d84.s5	Klebsiella	89	98	O	Klebsiella	lla	ella	NN	False
DDI-MedLine.d84.s5	oxytoca	100	106	O	oxytoca	oca	toca	NN	False
DDI-MedLine.d84.s5	.	107	107	O	.	.	.	.	False

DDI-MedLine.d16.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d16.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d16.s0	ketamine	15	22	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s0	and	24	26	O	and	and	and	CC	False
DDI-MedLine.d16.s0	halothane	28	36	B-drug	halothane	ane	hane	NN	False
DDI-MedLine.d16.s0	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d16.s0	rats	41	44	O	rats	ats	rats	NNS	False
DDI-MedLine.d16.s0	.	45	45	O	.	.	.	.	False

DDI-MedLine.d16.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d16.s1	interaction	4	14	O	interaction	ion	tion	NN	False
DDI-MedLine.d16.s1	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d16.s1	intramuscularly	19	33	O	intramuscularly	rly	arly	RB	False
DDI-MedLine.d16.s1	injected	35	42	O	injected	ted	cted	VBN	False
DDI-MedLine.d16.s1	ketamine	44	51	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s1	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d16.s1	its	57	59	O	its	its	its	PRP$	False
DDI-MedLine.d16.s1	N-demethylated	61	74	O	N-demethylated	ted	ated	JJ	False
DDI-MedLine.d16.s1	metabolite	76	85	O	metabolite	ite	lite	NN	False
DDI-MedLine.d16.s1	(	87	87	O	(	(	(	(	False
DDI-MedLine.d16.s1	metabolite	88	97	O	metabolite	ite	lite	NN	False
DDI-MedLine.d16.s1	I	99	99	O	I	I	I	PRP	brand
DDI-MedLine.d16.s1	)	100	100	O	)	)	)	)	False
DDI-MedLine.d16.s1	with	102	105	O	with	ith	with	IN	False
DDI-MedLine.d16.s1	halothane	107	115	B-drug	halothane	ane	hane	NN	False
DDI-MedLine.d16.s1	was	117	119	O	was	was	was	VBD	False
DDI-MedLine.d16.s1	evaluated	121	129	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d16.s1	in	131	132	O	in	in	in	IN	False
DDI-MedLine.d16.s1	rats	134	137	O	rats	ats	rats	NNS	False
DDI-MedLine.d16.s1	.	138	138	O	.	.	.	.	False

DDI-MedLine.d16.s2	Five	0	3	O	Five	ive	Five	CD	False
DDI-MedLine.d16.s2	,	4	4	O	,	,	,	,	False
DDI-MedLine.d16.s2	10	6	7	O	10	10	10	CD	False
DDI-MedLine.d16.s2	,	8	8	O	,	,	,	,	False
DDI-MedLine.d16.s2	20	10	11	O	20	20	20	CD	False
DDI-MedLine.d16.s2	,	12	12	O	,	,	,	,	False
DDI-MedLine.d16.s2	or	14	15	O	or	or	or	CC	False
DDI-MedLine.d16.s2	50	17	18	O	50	50	50	CD	False
DDI-MedLine.d16.s2	mg/kg	20	24	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d16.s2	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d16.s2	ketamine	29	36	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s2	alone	38	42	O	alone	one	lone	RB	False
DDI-MedLine.d16.s2	or	44	45	O	or	or	or	CC	False
DDI-MedLine.d16.s2	20	47	48	O	20	20	20	CD	False
DDI-MedLine.d16.s2	,	49	49	O	,	,	,	,	False
DDI-MedLine.d16.s2	50	51	52	O	50	50	50	CD	False
DDI-MedLine.d16.s2	,	53	53	O	,	,	,	,	False
DDI-MedLine.d16.s2	or	55	56	O	or	or	or	CC	False
DDI-MedLine.d16.s2	100	58	60	O	100	100	100	CD	False
DDI-MedLine.d16.s2	mg/kg	62	66	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d16.s2	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d16.s2	metabolite	71	80	O	metabolite	ite	lite	NN	False
DDI-MedLine.d16.s2	I	82	82	O	I	I	I	PRP	brand
DDI-MedLine.d16.s2	alone	84	88	O	alone	one	lone	RB	False
DDI-MedLine.d16.s2	produced	90	97	O	produced	ced	uced	VBN	False
DDI-MedLine.d16.s2	less	99	102	O	less	ess	less	RBR	False
DDI-MedLine.d16.s2	than	104	107	O	than	han	than	IN	False
DDI-MedLine.d16.s2	10	109	110	O	10	10	10	CD	False
DDI-MedLine.d16.s2	minutes	112	118	O	minutes	tes	utes	NNS	False
DDI-MedLine.d16.s2	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d16.s2	hypnosis	123	130	O	hypnosis	sis	osis	NN	False
DDI-MedLine.d16.s2	.	131	131	O	.	.	.	.	False

DDI-MedLine.d16.s3	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d16.s3	,	7	7	O	,	,	,	,	False
DDI-MedLine.d16.s3	halothane	9	17	B-drug	halothane	ane	hane	NN	False
DDI-MedLine.d16.s3	anesthetic	19	28	O	anesthetic	tic	etic	JJ	False
DDI-MedLine.d16.s3	requirement	30	40	O	requirement	ent	ment	NN	False
DDI-MedLine.d16.s3	(	42	42	O	(	(	(	(	False
DDI-MedLine.d16.s3	i.e.	43	46	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d16.s3	,	47	47	O	,	,	,	,	False
DDI-MedLine.d16.s3	MAC	49	51	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d16.s3	)	52	52	O	)	)	)	)	False
DDI-MedLine.d16.s3	was	54	56	O	was	was	was	VBD	False
DDI-MedLine.d16.s3	depressed	58	66	O	depressed	sed	ssed	JJ	False
DDI-MedLine.d16.s3	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d16.s3	a	71	71	O	a	a	a	DT	False
DDI-MedLine.d16.s3	dose-dependent	73	86	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d16.s3	fashion	88	94	O	fashion	ion	hion	NN	False
DDI-MedLine.d16.s3	as	96	97	O	as	as	as	IN	False
DDI-MedLine.d16.s3	much	99	102	O	much	uch	much	JJ	False
DDI-MedLine.d16.s3	as	104	105	O	as	as	as	IN	False
DDI-MedLine.d16.s3	56	107	108	O	56	56	56	CD	False
DDI-MedLine.d16.s3	%	109	109	O	%	%	%	NN	False
DDI-MedLine.d16.s3	1-2	111	113	O	1-2	1-2	1-2	JJ	False
DDI-MedLine.d16.s3	hours	115	119	O	hours	urs	ours	NNS	False
DDI-MedLine.d16.s3	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d16.s3	as	125	126	O	as	as	as	IN	False
DDI-MedLine.d16.s3	much	128	131	O	much	uch	much	JJ	False
DDI-MedLine.d16.s3	as	133	134	O	as	as	as	IN	False
DDI-MedLine.d16.s3	14	136	137	O	14	14	14	CD	False
DDI-MedLine.d16.s3	%	138	138	O	%	%	%	NN	False
DDI-MedLine.d16.s3	5-6	140	142	O	5-6	5-6	5-6	JJ	False
DDI-MedLine.d16.s3	hours	144	148	O	hours	urs	ours	NNS	False
DDI-MedLine.d16.s3	after	150	154	O	after	ter	fter	IN	False
DDI-MedLine.d16.s3	injection	156	164	O	injection	ion	tion	NN	False
DDI-MedLine.d16.s3	of	166	167	O	of	of	of	IN	False
DDI-MedLine.d16.s3	ketamine	169	176	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s3	,	177	177	O	,	,	,	,	False
DDI-MedLine.d16.s3	50	179	180	O	50	50	50	CD	False
DDI-MedLine.d16.s3	mg/kg	182	186	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d16.s3	,	187	187	O	,	,	,	,	False
DDI-MedLine.d16.s3	im	189	190	O	im	im	im	NN	False
DDI-MedLine.d16.s3	.	191	191	O	.	.	.	.	False

DDI-MedLine.d16.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d16.s4	reduction	4	12	O	reduction	ion	tion	NN	False
DDI-MedLine.d16.s4	in	14	15	O	in	in	in	IN	False
DDI-MedLine.d16.s4	MAC	17	19	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d16.s4	was	21	23	O	was	was	was	VBD	False
DDI-MedLine.d16.s4	correlated	25	34	O	correlated	ted	ated	VBN	False
DDI-MedLine.d16.s4	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d16.s4	brain	41	45	O	brain	ain	rain	NN	False
DDI-MedLine.d16.s4	levels	47	52	O	levels	els	vels	NNS	False
DDI-MedLine.d16.s4	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d16.s4	ketamine	57	64	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s4	or	66	67	O	or	or	or	CC	False
DDI-MedLine.d16.s4	metabolite	69	78	O	metabolite	ite	lite	NN	False
DDI-MedLine.d16.s4	I	80	80	O	I	I	I	PRP	brand
DDI-MedLine.d16.s4	,	81	81	O	,	,	,	,	False
DDI-MedLine.d16.s4	suggesting	83	92	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d16.s4	a	94	94	O	a	a	a	DT	False
DDI-MedLine.d16.s4	ketamine	96	103	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s4	:	104	104	O	:	:	:	:	False
DDI-MedLine.d16.s4	metabolite	105	114	O	metabolite	ite	lite	NN	False
DDI-MedLine.d16.s4	I	116	116	O	I	I	I	PRP	brand
DDI-MedLine.d16.s4	potency	118	124	O	potency	ncy	ency	NN	False
DDI-MedLine.d16.s4	ration	126	131	O	ration	ion	tion	NN	False
DDI-MedLine.d16.s4	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d16.s4	3:1	136	138	O	3:1	3:1	3:1	CD	False
DDI-MedLine.d16.s4	.	139	139	O	.	.	.	.	False

DDI-MedLine.d16.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d16.s5	half-life	4	12	O	half-life	ife	life	NN	False
DDI-MedLine.d16.s5	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d16.s5	ketamine	17	24	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s5	in	26	27	O	in	in	in	IN	False
DDI-MedLine.d16.s5	plasma	29	34	O	plasma	sma	asma	NN	False
DDI-MedLine.d16.s5	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d16.s5	brain	40	44	O	brain	ain	rain	NN	False
DDI-MedLine.d16.s5	was	46	48	O	was	was	was	VBD	False
DDI-MedLine.d16.s5	longer	50	55	O	longer	ger	nger	NN	False
DDI-MedLine.d16.s5	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d16.s5	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d16.s5	presence	64	71	O	presence	nce	ence	NN	False
DDI-MedLine.d16.s5	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d16.s5	halothane	76	84	B-drug	halothane	ane	hane	NN	False
DDI-MedLine.d16.s5	than	86	89	O	than	han	than	IN	False
DDI-MedLine.d16.s5	when	91	94	O	when	hen	when	WRB	False
DDI-MedLine.d16.s5	ketamine	96	103	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s5	was	105	107	O	was	was	was	VBD	False
DDI-MedLine.d16.s5	given	109	113	O	given	ven	iven	VBN	False
DDI-MedLine.d16.s5	alone	115	119	O	alone	one	lone	RB	False
DDI-MedLine.d16.s5	.	120	120	O	.	.	.	.	False

DDI-MedLine.d16.s6	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d16.s6	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d16.s6	concluded	6	14	O	concluded	ded	uded	VBD	False
DDI-MedLine.d16.s6	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d16.s6	ketamine	21	28	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d16.s6	is	30	31	O	is	is	is	VBZ	False
DDI-MedLine.d16.s6	not	33	35	O	not	not	not	RB	False
DDI-MedLine.d16.s6	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d16.s6	short-acting	39	50	O	short-acting	ing	ting	NN	False
DDI-MedLine.d16.s6	drug	52	55	O	drug	rug	drug	NN	False
DDI-MedLine.d16.s6	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d16.s6	that	61	64	O	that	hat	that	IN	False
DDI-MedLine.d16.s6	concomitant	66	76	O	concomitant	ant	tant	NN	False
DDI-MedLine.d16.s6	use	78	80	O	use	use	use	NN	False
DDI-MedLine.d16.s6	with	82	85	O	with	ith	with	IN	False
DDI-MedLine.d16.s6	halothane	87	95	B-drug	halothane	ane	hane	NN	False
DDI-MedLine.d16.s6	would	97	101	O	would	uld	ould	MD	False
DDI-MedLine.d16.s6	be	103	104	O	be	be	be	VB	False
DDI-MedLine.d16.s6	expected	106	113	O	expected	ted	cted	VBN	False
DDI-MedLine.d16.s6	to	115	116	O	to	to	to	TO	False
DDI-MedLine.d16.s6	prolong	118	124	O	prolong	ong	long	NN	False
DDI-MedLine.d16.s6	further	126	132	O	further	her	ther	RB	False
DDI-MedLine.d16.s6	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d16.s6	duration	138	145	O	duration	ion	tion	NN	False
DDI-MedLine.d16.s6	of	147	148	O	of	of	of	IN	False
DDI-MedLine.d16.s6	its	150	152	O	its	its	its	PRP$	False
DDI-MedLine.d16.s6	action	154	159	O	action	ion	tion	NN	False
DDI-MedLine.d16.s6	on	161	162	O	on	on	on	IN	False
DDI-MedLine.d16.s6	the	164	166	O	the	the	the	DT	False
DDI-MedLine.d16.s6	central	168	174	O	central	ral	tral	JJ	False
DDI-MedLine.d16.s6	nervous	176	182	O	nervous	ous	vous	JJ	False
DDI-MedLine.d16.s6	system	184	189	O	system	tem	stem	NN	False
DDI-MedLine.d16.s6	.	190	190	O	.	.	.	.	False

DDI-MedLine.d4.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d4.s0	The	1	3	O	The	The	The	DT	False
DDI-MedLine.d4.s0	effect	5	10	O	effect	ect	fect	NN	False
DDI-MedLine.d4.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d4.s0	sandimmune	15	24	B-brand	sandimmune	une	mune	NN	False
DDI-MedLine.d4.s0	on	26	27	O	on	on	on	IN	False
DDI-MedLine.d4.s0	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d4.s0	activity	33	40	O	activity	ity	vity	NN	False
DDI-MedLine.d4.s0	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d4.s0	mixed-function	45	58	O	mixed-function	ion	tion	NN	False
DDI-MedLine.d4.s0	mono-oxidases	60	72	O	mono-oxidases	ses	ases	NNS	False
DDI-MedLine.d4.s0	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d4.s0	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d4.s0	liver	81	85	O	liver	ver	iver	NN	False
DDI-MedLine.d4.s0	microsomes	87	96	O	microsomes	mes	omes	NNS	False
DDI-MedLine.d4.s0	]	97	97	O	]	]	]	NN	False
DDI-MedLine.d4.s0	The	100	102	O	The	The	The	DT	False
DDI-MedLine.d4.s0	effects	104	110	O	effects	cts	ects	NNS	False
DDI-MedLine.d4.s0	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d4.s0	the	115	117	O	the	the	the	DT	False
DDI-MedLine.d4.s0	immunodepressant	119	134	B-group	immunodepressant	ant	sant	NN	False
DDI-MedLine.d4.s0	--	135	136	O	--	--	--	:	False
DDI-MedLine.d4.s0	the	137	139	O	the	the	the	DT	False
DDI-MedLine.d4.s0	drug	141	144	O	drug	rug	drug	NN	False
DDI-MedLine.d4.s0	sandimmune	146	155	B-brand	sandimmune	une	mune	NN	False
DDI-MedLine.d4.s0	--	156	157	O	--	--	--	:	False
DDI-MedLine.d4.s0	on	158	159	O	on	on	on	IN	False
DDI-MedLine.d4.s0	hepatic	161	167	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d4.s0	microsomal	169	178	O	microsomal	mal	omal	NN	False
DDI-MedLine.d4.s0	monooxygenase	180	192	O	monooxygenase	ase	nase	NN	False
DDI-MedLine.d4.s0	activities	194	203	O	activities	ies	ties	NNS	False
DDI-MedLine.d4.s0	were	205	208	O	were	ere	were	VBD	False
DDI-MedLine.d4.s0	studied	210	216	O	studied	ied	died	VBN	False
DDI-MedLine.d4.s0	.	217	217	O	.	.	.	.	False

DDI-MedLine.d4.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d4.s1	agent	4	8	O	agent	ent	gent	NN	False
DDI-MedLine.d4.s1	was	10	12	O	was	was	was	VBD	False
DDI-MedLine.d4.s1	found	14	18	O	found	und	ound	NN	False
DDI-MedLine.d4.s1	to	20	21	O	to	to	to	TO	False
DDI-MedLine.d4.s1	produce	23	29	O	produce	uce	duce	NN	False
DDI-MedLine.d4.s1	some	31	34	O	some	ome	some	DT	False
DDI-MedLine.d4.s1	inhibiting	36	45	O	inhibiting	ing	ting	VBG	False
DDI-MedLine.d4.s1	activity	47	54	O	activity	ity	vity	NN	False
DDI-MedLine.d4.s1	against	56	62	O	against	nst	inst	IN	False
DDI-MedLine.d4.s1	hepatic	64	70	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d4.s1	microsomal	72	81	O	microsomal	mal	omal	NN	False
DDI-MedLine.d4.s1	7-ethoxycoumarine	83	99	O	7-ethoxycoumarine	ine	rine	JJ	drug
DDI-MedLine.d4.s1	deethylase	101	110	O	deethylase	ase	lase	NN	False
DDI-MedLine.d4.s1	in	112	113	O	in	in	in	IN	False
DDI-MedLine.d4.s1	male	115	118	O	male	ale	male	NN	False
DDI-MedLine.d4.s1	Wistar	120	125	O	Wistar	tar	star	NN	False
DDI-MedLine.d4.s1	rats	127	130	O	rats	ats	rats	NNS	False
DDI-MedLine.d4.s1	in	132	133	O	in	in	in	IN	False
DDI-MedLine.d4.s1	vitro	135	139	O	vitro	tro	itro	NN	False
DDI-MedLine.d4.s1	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d4.s1	in	145	146	O	in	in	in	IN	False
DDI-MedLine.d4.s1	vivo	148	151	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d4.s1	experiments	153	163	O	experiments	nts	ents	NNS	False
DDI-MedLine.d4.s1	.	164	164	O	.	.	.	.	False

DDI-MedLine.d4.s2	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d4.s2	given	5	9	O	given	ven	iven	VBN	False
DDI-MedLine.d4.s2	in	11	12	O	in	in	in	IN	False
DDI-MedLine.d4.s2	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d4.s2	dose	16	19	O	dose	ose	dose	NN	False
DDI-MedLine.d4.s2	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d4.s2	50	24	25	O	50	50	50	CD	False
DDI-MedLine.d4.s2	mg/kg	27	31	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d4.s2	,	32	32	O	,	,	,	,	False
DDI-MedLine.d4.s2	sandimmune	34	43	B-brand	sandimmune	une	mune	NN	False
DDI-MedLine.d4.s2	produced	45	52	O	produced	ced	uced	VBN	False
DDI-MedLine.d4.s2	no	54	55	O	no	no	no	DT	False
DDI-MedLine.d4.s2	statistically	57	69	O	statistically	lly	ally	RB	False
DDI-MedLine.d4.s2	significant	71	81	O	significant	ant	cant	JJ	False
DDI-MedLine.d4.s2	effect	83	88	O	effect	ect	fect	NN	False
DDI-MedLine.d4.s2	on	90	91	O	on	on	on	IN	False
DDI-MedLine.d4.s2	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d4.s2	duration	97	104	O	duration	ion	tion	NN	False
DDI-MedLine.d4.s2	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d4.s2	hexanal-induced	109	123	O	hexanal-induced	ced	uced	JJ	False
DDI-MedLine.d4.s2	sleep	125	129	O	sleep	eep	leep	NN	False
DDI-MedLine.d4.s2	in	131	132	O	in	in	in	IN	False
DDI-MedLine.d4.s2	mice	134	137	O	mice	ice	mice	NN	False
DDI-MedLine.d4.s2	.	138	138	O	.	.	.	.	False

DDI-MedLine.d4.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d4.s3	findings	4	11	O	findings	ngs	ings	NNS	False
DDI-MedLine.d4.s3	suggest	13	19	O	suggest	est	gest	NN	False
DDI-MedLine.d4.s3	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d4.s3	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d4.s3	agent	30	34	O	agent	ent	gent	NN	False
DDI-MedLine.d4.s3	has	36	38	O	has	has	has	VBZ	False
DDI-MedLine.d4.s3	slight	40	45	O	slight	ght	ight	NN	False
DDI-MedLine.d4.s3	effects	47	53	O	effects	cts	ects	NNS	False
DDI-MedLine.d4.s3	on	55	56	O	on	on	on	IN	False
DDI-MedLine.d4.s3	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d4.s3	tested	62	67	O	tested	ted	sted	VBN	False
DDI-MedLine.d4.s3	activities	69	78	O	activities	ies	ties	NNS	False
DDI-MedLine.d4.s3	.	79	79	O	.	.	.	.	False

DDI-MedLine.d128.s0	Analysis	0	7	O	Analysis	sis	ysis	NN	False
DDI-MedLine.d128.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d128.s0	16,16-dimethylprostaglandin	12	38	B-drug_n	16,16-dimethylprostaglandin	din	ndin	JJ	False
DDI-MedLine.d128.s0	E2-induced	40	49	O	E2-induced	ced	uced	JJ	False
DDI-MedLine.d128.s0	diarrhea	51	58	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d128.s0	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d128.s0	cecectomized	63	74	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s0	rats	76	79	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s0	.	80	80	O	.	.	.	.	False

DDI-MedLine.d128.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d128.s1	16,16-dimethylprostaglandin	4	30	B-drug_n	16,16-dimethylprostaglandin	din	ndin	JJ	False
DDI-MedLine.d128.s1	E2	32	33	I-drug_n	E2	E2	E2	NN	brand
DDI-MedLine.d128.s1	(	35	35	O	(	(	(	(	False
DDI-MedLine.d128.s1	dmPGE2	36	41	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s1	)	42	42	O	)	)	)	)	False
DDI-MedLine.d128.s1	-induced	43	50	O	-induced	ced	uced	VBN	False
DDI-MedLine.d128.s1	diarrhea	52	59	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d128.s1	was	61	63	O	was	was	was	VBD	False
DDI-MedLine.d128.s1	analyzed	65	72	O	analyzed	zed	yzed	VBN	False
DDI-MedLine.d128.s1	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d128.s1	cecectomized	77	88	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s1	rats	90	93	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s1	prepared	95	102	O	prepared	red	ared	JJ	False
DDI-MedLine.d128.s1	by	104	105	O	by	by	by	IN	False
DDI-MedLine.d128.s1	resecting	107	115	O	resecting	ing	ting	VBG	False
DDI-MedLine.d128.s1	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d128.s1	cecum	121	125	O	cecum	cum	ecum	NN	False
DDI-MedLine.d128.s1	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d128.s1	its	131	133	O	its	its	its	PRP$	False
DDI-MedLine.d128.s1	vasculature	135	145	O	vasculature	ure	ture	NN	False
DDI-MedLine.d128.s1	without	147	153	O	without	out	hout	IN	False
DDI-MedLine.d128.s1	disturbing	155	164	O	disturbing	ing	bing	VBG	False
DDI-MedLine.d128.s1	the	166	168	O	the	the	the	DT	False
DDI-MedLine.d128.s1	ileocecal	170	178	O	ileocecal	cal	ecal	JJ	False
DDI-MedLine.d128.s1	junction	180	187	O	junction	ion	tion	NN	False
DDI-MedLine.d128.s1	.	188	188	O	.	.	.	.	False

DDI-MedLine.d128.s2	dmPGE2	0	5	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s2	(	7	7	O	(	(	(	(	False
DDI-MedLine.d128.s2	0.1-1.0	8	14	O	0.1-1.0	1.0	-1.0	NN	False
DDI-MedLine.d128.s2	mg/kg	16	20	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s2	,	21	21	O	,	,	,	,	False
DDI-MedLine.d128.s2	p.o	23	25	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d128.s2	.	26	26	O	.	.	.	.	False
DDI-MedLine.d128.s2	)	27	27	O	)	)	)	)	False

DDI-MedLine.d128.s3	dose-dependently	0	15	O	dose-dependently	tly	ntly	RB	False
DDI-MedLine.d128.s3	increased	17	25	O	increased	sed	ased	VBN	False
DDI-MedLine.d128.s3	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d128.s3	number	31	36	O	number	ber	mber	NN	False
DDI-MedLine.d128.s3	of	38	39	O	of	of	of	IN	False
DDI-MedLine.d128.s3	defecation	41	50	O	defecation	ion	tion	NN	False
DDI-MedLine.d128.s3	episodes	52	59	O	episodes	des	odes	NNS	False
DDI-MedLine.d128.s3	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d128.s3	induced	65	71	O	induced	ced	uced	JJ	False
DDI-MedLine.d128.s3	a	73	73	O	a	a	a	DT	False
DDI-MedLine.d128.s3	soft	75	78	O	soft	oft	soft	JJ	False
DDI-MedLine.d128.s3	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d128.s3	watery	84	89	O	watery	ery	tery	NN	False
DDI-MedLine.d128.s3	stool	91	95	O	stool	ool	tool	NN	False
DDI-MedLine.d128.s3	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d128.s3	cecectomized	100	111	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s3	rats	113	116	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s3	.	117	117	O	.	.	.	.	False

DDI-MedLine.d128.s4	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d128.s4	0.3	3	5	O	0.3	0.3	0.3	CD	False
DDI-MedLine.d128.s4	mg/kg	7	11	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s4	,	12	12	O	,	,	,	,	False
DDI-MedLine.d128.s4	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d128.s4	diarrhea-inducing	18	34	O	diarrhea-inducing	ing	cing	NN	False
DDI-MedLine.d128.s4	effects	36	42	O	effects	cts	ects	NNS	False
DDI-MedLine.d128.s4	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d128.s4	dmPGE2	47	52	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s4	were	54	57	O	were	ere	were	VBD	False
DDI-MedLine.d128.s4	more	59	62	O	more	ore	more	RBR	False
DDI-MedLine.d128.s4	pronounced	64	73	O	pronounced	ced	nced	VBN	False
DDI-MedLine.d128.s4	in	75	76	O	in	in	in	IN	False
DDI-MedLine.d128.s4	cecectomized	78	89	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s4	than	91	94	O	than	han	than	IN	False
DDI-MedLine.d128.s4	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d128.s4	control	99	105	O	control	rol	trol	NN	False
DDI-MedLine.d128.s4	rats	107	110	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s4	.	111	111	O	.	.	.	.	False

DDI-MedLine.d128.s5	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d128.s5	given	5	9	O	given	ven	iven	VBN	False
DDI-MedLine.d128.s5	i.p.	11	14	O	i.p.	.p.	i.p.	NN	False
DDI-MedLine.d128.s5	,	15	15	O	,	,	,	,	False
DDI-MedLine.d128.s5	dmPGE2	17	22	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s5	(	24	24	O	(	(	(	(	False
DDI-MedLine.d128.s5	0.3	25	27	O	0.3	0.3	0.3	CD	False
DDI-MedLine.d128.s5	mg/kg	29	33	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s5	)	34	34	O	)	)	)	)	False
DDI-MedLine.d128.s5	induced	36	42	O	induced	ced	uced	JJ	False
DDI-MedLine.d128.s5	a	44	44	O	a	a	a	DT	False
DDI-MedLine.d128.s5	watery	46	51	O	watery	ery	tery	NN	False
DDI-MedLine.d128.s5	stool	53	57	O	stool	ool	tool	NN	False
DDI-MedLine.d128.s5	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d128.s5	cecectomized	62	73	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s5	and	75	77	O	and	and	and	CC	False
DDI-MedLine.d128.s5	control	79	85	O	control	rol	trol	NN	False
DDI-MedLine.d128.s5	rats	87	90	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s5	with	92	95	O	with	ith	with	IN	False
DDI-MedLine.d128.s5	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d128.s5	same	101	104	O	same	ame	same	JJ	False
DDI-MedLine.d128.s5	efficacy	106	113	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d128.s5	,	114	114	O	,	,	,	,	False
DDI-MedLine.d128.s5	although	116	123	O	although	ugh	ough	IN	False
DDI-MedLine.d128.s5	these	125	129	O	these	ese	hese	DT	False
DDI-MedLine.d128.s5	effects	131	137	O	effects	cts	ects	NNS	False
DDI-MedLine.d128.s5	were	139	142	O	were	ere	were	VBD	False
DDI-MedLine.d128.s5	short-lasting	144	156	O	short-lasting	ing	ting	NN	False
DDI-MedLine.d128.s5	as	158	159	O	as	as	as	IN	False
DDI-MedLine.d128.s5	compared	161	168	O	compared	red	ared	VBN	False
DDI-MedLine.d128.s5	to	170	171	O	to	to	to	TO	False
DDI-MedLine.d128.s5	oral	173	176	O	oral	ral	oral	JJ	False
DDI-MedLine.d128.s5	administration	178	191	O	administration	ion	tion	NN	False
DDI-MedLine.d128.s5	.	192	192	O	.	.	.	.	False

DDI-MedLine.d128.s6	Castor	0	5	B-drug	Castor	tor	stor	NN	False
DDI-MedLine.d128.s6	oil	7	9	I-drug	oil	oil	oil	NN	False
DDI-MedLine.d128.s6	(	11	11	O	(	(	(	(	False
DDI-MedLine.d128.s6	4	12	12	O	4	4	4	CD	False
DDI-MedLine.d128.s6	ml/kg	14	18	O	ml/kg	/kg	l/kg	NN	False
DDI-MedLine.d128.s6	,	19	19	O	,	,	,	,	False
DDI-MedLine.d128.s6	p.o	21	23	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d128.s6	.	24	24	O	.	.	.	.	False
DDI-MedLine.d128.s6	)	25	25	O	)	)	)	)	False

DDI-MedLine.d128.s7	also	0	3	O	also	lso	also	RB	False
DDI-MedLine.d128.s7	induced	5	11	O	induced	ced	uced	JJ	False
DDI-MedLine.d128.s7	diarrhea	13	20	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d128.s7	,	21	21	O	,	,	,	,	False
DDI-MedLine.d128.s7	but	23	25	O	but	but	but	CC	False
DDI-MedLine.d128.s7	did	27	29	O	did	did	did	VBD	False
DDI-MedLine.d128.s7	not	31	33	O	not	not	not	RB	False
DDI-MedLine.d128.s7	produce	35	41	O	produce	uce	duce	NN	False
DDI-MedLine.d128.s7	a	43	43	O	a	a	a	DT	False
DDI-MedLine.d128.s7	watery	45	50	O	watery	ery	tery	NN	False
DDI-MedLine.d128.s7	stool	52	56	O	stool	ool	tool	NN	False
DDI-MedLine.d128.s7	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d128.s7	cecectomized	61	72	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s7	rats	74	77	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s7	.	78	78	O	.	.	.	.	False

DDI-MedLine.d128.s8	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d128.s8	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d128.s8	no	11	12	O	no	no	no	DT	False
DDI-MedLine.d128.s8	differences	14	24	O	differences	ces	nces	NNS	False
DDI-MedLine.d128.s8	between	26	32	O	between	een	ween	IN	False
DDI-MedLine.d128.s8	cecectomized	34	45	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s8	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d128.s8	control	51	57	O	control	rol	trol	NN	False
DDI-MedLine.d128.s8	rats	59	62	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s8	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d128.s8	basal	67	71	O	basal	sal	asal	NN	False
DDI-MedLine.d128.s8	small	73	77	O	small	all	mall	JJ	False
DDI-MedLine.d128.s8	intestinal	79	88	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d128.s8	transits	90	97	O	transits	its	sits	NNS	False
DDI-MedLine.d128.s8	or	99	100	O	or	or	or	CC	False
DDI-MedLine.d128.s8	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d128.s8	dmPGE2	105	110	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s8	(	112	112	O	(	(	(	(	False
DDI-MedLine.d128.s8	0.3	113	115	O	0.3	0.3	0.3	CD	False
DDI-MedLine.d128.s8	mg/kg	117	121	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s8	,	122	122	O	,	,	,	,	False
DDI-MedLine.d128.s8	p.o	124	126	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d128.s8	.	127	127	O	.	.	.	.	False
DDI-MedLine.d128.s8	)	128	128	O	)	)	)	)	False
DDI-MedLine.d128.s8	-induced	129	136	O	-induced	ced	uced	VBN	False
DDI-MedLine.d128.s8	enhancements	138	149	O	enhancements	nts	ents	NNS	False
DDI-MedLine.d128.s8	.	150	150	O	.	.	.	.	False

DDI-MedLine.d128.s9	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d128.s9	,	8	8	O	,	,	,	,	False
DDI-MedLine.d128.s9	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d128.s9	basal	14	18	O	basal	sal	asal	NN	False
DDI-MedLine.d128.s9	and	20	22	O	and	and	and	CC	False
DDI-MedLine.d128.s9	dmPGE2-induced	24	37	O	dmPGE2-induced	ced	uced	JJ	False
DDI-MedLine.d128.s9	jejunal	39	45	O	jejunal	nal	unal	NN	False
DDI-MedLine.d128.s9	net	47	49	O	net	net	net	NN	False
DDI-MedLine.d128.s9	fluid	51	55	O	fluid	uid	luid	NN	False
DDI-MedLine.d128.s9	transfers	57	65	O	transfers	ers	fers	NNS	False
DDI-MedLine.d128.s9	were	67	70	O	were	ere	were	VBD	False
DDI-MedLine.d128.s9	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d128.s9	same	76	79	O	same	ame	same	JJ	False
DDI-MedLine.d128.s9	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d128.s9	cecectomized	84	95	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s9	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d128.s9	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d128.s9	control	104	110	O	control	rol	trol	NN	False
DDI-MedLine.d128.s9	rats	112	115	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s9	.	116	116	O	.	.	.	.	False

DDI-MedLine.d128.s10	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d128.s10	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d128.s10	other	7	11	O	other	her	ther	JJ	False
DDI-MedLine.d128.s10	hand	13	16	O	hand	and	hand	NN	False
DDI-MedLine.d128.s10	,	17	17	O	,	,	,	,	False
DDI-MedLine.d128.s10	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d128.s10	enhanced	23	30	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d128.s10	secretion	32	40	O	secretion	ion	tion	NN	False
DDI-MedLine.d128.s10	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d128.s10	colonic	45	51	O	colonic	nic	onic	NN	False
DDI-MedLine.d128.s10	fluid	53	57	O	fluid	uid	luid	NN	False
DDI-MedLine.d128.s10	by	59	60	O	by	by	by	IN	False
DDI-MedLine.d128.s10	dmPGE2	62	67	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s10	,	68	68	O	,	,	,	,	False
DDI-MedLine.d128.s10	given	70	74	O	given	ven	iven	VBN	False
DDI-MedLine.d128.s10	intraluminally	76	89	O	intraluminally	lly	ally	RB	False
DDI-MedLine.d128.s10	,	90	90	O	,	,	,	,	False
DDI-MedLine.d128.s10	was	92	94	O	was	was	was	VBD	False
DDI-MedLine.d128.s10	only	96	99	O	only	nly	only	RB	False
DDI-MedLine.d128.s10	half	101	104	O	half	alf	half	NN	False
DDI-MedLine.d128.s10	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d128.s10	that	109	112	O	that	hat	that	IN	False
DDI-MedLine.d128.s10	in	114	115	O	in	in	in	IN	False
DDI-MedLine.d128.s10	control	117	123	O	control	rol	trol	NN	False
DDI-MedLine.d128.s10	rats	125	128	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s10	,	129	129	O	,	,	,	,	False
DDI-MedLine.d128.s10	whereas	131	137	O	whereas	eas	reas	NNS	False
DDI-MedLine.d128.s10	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d128.s10	colonic	143	149	O	colonic	nic	onic	NN	False
DDI-MedLine.d128.s10	transit-enhancing	151	167	O	transit-enhancing	ing	cing	NN	False
DDI-MedLine.d128.s10	effect	169	174	O	effect	ect	fect	NN	False
DDI-MedLine.d128.s10	of	176	177	O	of	of	of	IN	False
DDI-MedLine.d128.s10	dmPGE2	179	184	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s10	in	186	187	O	in	in	in	IN	False
DDI-MedLine.d128.s10	cecectomized	189	200	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s10	rats	202	205	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s10	was	207	209	O	was	was	was	VBD	False
DDI-MedLine.d128.s10	more	211	214	O	more	ore	more	RBR	False
DDI-MedLine.d128.s10	pronounced	216	225	O	pronounced	ced	nced	VBN	False
DDI-MedLine.d128.s10	than	227	230	O	than	han	than	IN	False
DDI-MedLine.d128.s10	in	232	233	O	in	in	in	IN	False
DDI-MedLine.d128.s10	control	235	241	O	control	rol	trol	NN	False
DDI-MedLine.d128.s10	rats	243	246	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s10	at	248	249	O	at	at	at	IN	False
DDI-MedLine.d128.s10	15	251	252	O	15	15	15	CD	False
DDI-MedLine.d128.s10	but	254	256	O	but	but	but	CC	False
DDI-MedLine.d128.s10	not	258	260	O	not	not	not	RB	False
DDI-MedLine.d128.s10	at	262	263	O	at	at	at	IN	False
DDI-MedLine.d128.s10	30	265	266	O	30	30	30	CD	False
DDI-MedLine.d128.s10	min	268	270	O	min	min	min	NN	False
DDI-MedLine.d128.s10	after	272	276	O	after	ter	fter	IN	False
DDI-MedLine.d128.s10	its	278	280	O	its	its	its	PRP$	False
DDI-MedLine.d128.s10	administration	282	295	O	administration	ion	tion	NN	False
DDI-MedLine.d128.s10	.	296	296	O	.	.	.	.	False

DDI-MedLine.d128.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d128.s11	basal	4	8	O	basal	sal	asal	NN	False
DDI-MedLine.d128.s11	colonic	10	16	O	colonic	nic	onic	NN	False
DDI-MedLine.d128.s11	fluid	18	22	O	fluid	uid	luid	NN	False
DDI-MedLine.d128.s11	contents	24	31	O	contents	nts	ents	NNS	False
DDI-MedLine.d128.s11	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d128.s11	transits	37	44	O	transits	its	sits	NNS	False
DDI-MedLine.d128.s11	were	46	49	O	were	ere	were	VBD	False
DDI-MedLine.d128.s11	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d128.s11	same	55	58	O	same	ame	same	JJ	False
DDI-MedLine.d128.s11	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d128.s11	cecectomized	63	74	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s11	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d128.s11	in	80	81	O	in	in	in	IN	False
DDI-MedLine.d128.s11	control	83	89	O	control	rol	trol	NN	False
DDI-MedLine.d128.s11	rats	91	94	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s11	.	95	95	O	.	.	.	.	False

DDI-MedLine.d128.s12	Loperamide	0	9	B-drug	Loperamide	ide	mide	NN	False
DDI-MedLine.d128.s12	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d128.s12	morphine	15	22	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d128.s12	(	24	24	O	(	(	(	(	False
DDI-MedLine.d128.s12	0.1	25	27	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d128.s12	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d128.s12	1.0	33	35	O	1.0	1.0	1.0	CD	False
DDI-MedLine.d128.s12	mg/kg	37	41	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s12	,	42	42	O	,	,	,	,	False
DDI-MedLine.d128.s12	s.c	44	46	O	s.c	s.c	s.c	NN	False
DDI-MedLine.d128.s12	.	47	47	O	.	.	.	.	False
DDI-MedLine.d128.s12	)	48	48	O	)	)	)	)	False

DDI-MedLine.d128.s13	Loperamide	0	9	B-drug	Loperamide	ide	mide	NN	False
DDI-MedLine.d128.s13	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d128.s13	morphine	15	22	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d128.s13	(	24	24	O	(	(	(	(	False
DDI-MedLine.d128.s13	0.1	25	27	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d128.s13	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d128.s13	1.0	33	35	O	1.0	1.0	1.0	CD	False
DDI-MedLine.d128.s13	mg/kg	37	41	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s13	,	42	42	O	,	,	,	,	False
DDI-MedLine.d128.s13	s.c.	44	47	O	s.c.	.c.	s.c.	NN	False
DDI-MedLine.d128.s13	)	48	48	O	)	)	)	)	False
DDI-MedLine.d128.s13	inhibited	50	58	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d128.s13	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d128.s13	dmPGE2	64	69	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s13	(	71	71	O	(	(	(	(	False
DDI-MedLine.d128.s13	0.3	72	74	O	0.3	0.3	0.3	CD	False
DDI-MedLine.d128.s13	mg/kg	76	80	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s13	,	81	81	O	,	,	,	,	False
DDI-MedLine.d128.s13	p.o	83	85	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d128.s13	.	86	86	O	.	.	.	.	False
DDI-MedLine.d128.s13	)	87	87	O	)	)	)	)	False
DDI-MedLine.d128.s13	-induced	88	95	O	-induced	ced	uced	VBN	False
DDI-MedLine.d128.s13	diarrhea	97	104	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d128.s13	in	106	107	O	in	in	in	IN	False
DDI-MedLine.d128.s13	cecectomized	109	120	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s13	rats	122	125	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s13	.	126	126	O	.	.	.	.	False

DDI-MedLine.d128.s14	N-methyllevallorphan	0	19	B-drug_n	N-methyllevallorphan	han	phan	NN	False
DDI-MedLine.d128.s14	(	21	21	O	(	(	(	(	False
DDI-MedLine.d128.s14	5	22	22	O	5	5	5	CD	False
DDI-MedLine.d128.s14	mg/kg	24	28	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s14	,	29	29	O	,	,	,	,	False
DDI-MedLine.d128.s14	s.c	31	33	O	s.c	s.c	s.c	NN	False
DDI-MedLine.d128.s14	.	34	34	O	.	.	.	.	False
DDI-MedLine.d128.s14	)	35	35	O	)	)	)	)	False

DDI-MedLine.d128.s15	N-methyllevallorphan	0	19	B-drug_n	N-methyllevallorphan	han	phan	NN	False
DDI-MedLine.d128.s15	(	21	21	O	(	(	(	(	False
DDI-MedLine.d128.s15	5	22	22	O	5	5	5	CD	False
DDI-MedLine.d128.s15	mg/kg	24	28	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d128.s15	,	29	29	O	,	,	,	,	False
DDI-MedLine.d128.s15	s.c.	31	34	O	s.c.	.c.	s.c.	NN	False
DDI-MedLine.d128.s15	)	35	35	O	)	)	)	)	False
DDI-MedLine.d128.s15	completely	37	46	O	completely	ely	tely	RB	False
DDI-MedLine.d128.s15	antagonized	48	58	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d128.s15	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d128.s15	inhibitory	64	73	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d128.s15	effect	75	80	O	effect	ect	fect	NN	False
DDI-MedLine.d128.s15	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d128.s15	loperamide	85	94	B-drug	loperamide	ide	mide	NN	False
DDI-MedLine.d128.s15	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d128.s15	partly	100	105	O	partly	tly	rtly	RB	False
DDI-MedLine.d128.s15	antagonized	107	117	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d128.s15	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d128.s15	effect	123	128	O	effect	ect	fect	NN	False
DDI-MedLine.d128.s15	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d128.s15	morphine	133	140	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d128.s15	.	141	141	O	.	.	.	.	False

DDI-MedLine.d128.s16	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d128.s16	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d128.s16	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d128.s16	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d128.s16	oral	27	30	O	oral	ral	oral	JJ	False
DDI-MedLine.d128.s16	administration	32	45	O	administration	ion	tion	NN	False
DDI-MedLine.d128.s16	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d128.s16	dmPGE2	50	55	B-drug_n	dmPGE2	GE2	PGE2	NN	False
DDI-MedLine.d128.s16	induces	57	63	O	induces	ces	uces	NNS	False
DDI-MedLine.d128.s16	a	65	65	O	a	a	a	DT	False
DDI-MedLine.d128.s16	more	67	70	O	more	ore	more	RBR	False
DDI-MedLine.d128.s16	pronounced	72	81	O	pronounced	ced	nced	VBN	False
DDI-MedLine.d128.s16	secretory	83	91	O	secretory	ory	tory	NN	False
DDI-MedLine.d128.s16	diarrhea	93	100	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d128.s16	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d128.s16	cecectomized	105	116	O	cecectomized	zed	ized	VBN	False
DDI-MedLine.d128.s16	than	118	121	O	than	han	than	IN	False
DDI-MedLine.d128.s16	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d128.s16	control	126	132	O	control	rol	trol	NN	False
DDI-MedLine.d128.s16	rats	134	137	O	rats	ats	rats	NNS	False
DDI-MedLine.d128.s16	,	138	138	O	,	,	,	,	False
DDI-MedLine.d128.s16	probably	140	147	O	probably	bly	ably	RB	False
DDI-MedLine.d128.s16	due	149	151	O	due	due	due	JJ	False
DDI-MedLine.d128.s16	to	153	154	O	to	to	to	TO	False
DDI-MedLine.d128.s16	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d128.s16	lack	160	163	O	lack	ack	lack	NN	False
DDI-MedLine.d128.s16	of	165	166	O	of	of	of	IN	False
DDI-MedLine.d128.s16	the	168	170	O	the	the	the	DT	False
DDI-MedLine.d128.s16	reservoir	172	180	O	reservoir	oir	voir	NN	False
DDI-MedLine.d128.s16	function	182	189	O	function	ion	tion	NN	False
DDI-MedLine.d128.s16	of	191	192	O	of	of	of	IN	False
DDI-MedLine.d128.s16	the	194	196	O	the	the	the	DT	False
DDI-MedLine.d128.s16	cecum	198	202	O	cecum	cum	ecum	NN	False
DDI-MedLine.d128.s16	in	204	205	O	in	in	in	IN	False
DDI-MedLine.d128.s16	the	207	209	O	the	the	the	DT	False
DDI-MedLine.d128.s16	operated	211	218	O	operated	ted	ated	VBN	False
DDI-MedLine.d128.s16	animals	220	226	O	animals	als	mals	NNS	False
DDI-MedLine.d128.s16	.	227	227	O	.	.	.	.	False

DDI-MedLine.d128.s17	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d128.s17	secretory	5	13	O	secretory	ory	tory	NN	False
DDI-MedLine.d128.s17	diarrhea	15	22	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d128.s17	model	24	28	O	model	del	odel	NN	False
DDI-MedLine.d128.s17	is	30	31	O	is	is	is	VBZ	False
DDI-MedLine.d128.s17	suitable	33	40	O	suitable	ble	able	JJ	False
DDI-MedLine.d128.s17	for	42	44	O	for	for	for	IN	False
DDI-MedLine.d128.s17	evaluating	46	55	O	evaluating	ing	ting	VBG	False
DDI-MedLine.d128.s17	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d128.s17	antidiarrheal	61	73	O	antidiarrheal	eal	heal	NN	False
DDI-MedLine.d128.s17	activity	75	82	O	activity	ity	vity	NN	False
DDI-MedLine.d128.s17	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d128.s17	drugs	87	91	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d128.s17	.	92	92	O	.	.	.	.	False

DDI-MedLine.d52.s0	Restoration	0	10	O	Restoration	ion	tion	NN	False
DDI-MedLine.d52.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d52.s0	vancomycin	15	24	B-drug	vancomycin	cin	ycin	NN	drug
DDI-MedLine.d52.s0	susceptibility	26	39	O	susceptibility	ity	lity	NN	False
DDI-MedLine.d52.s0	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d52.s0	Enterococcus	44	55	O	Enterococcus	cus	ccus	NN	False
DDI-MedLine.d52.s0	faecalis	57	64	O	faecalis	lis	alis	NN	False
DDI-MedLine.d52.s0	by	66	67	O	by	by	by	IN	False
DDI-MedLine.d52.s0	antiresistance	69	82	O	antiresistance	nce	ance	NN	False
DDI-MedLine.d52.s0	determinant	84	94	O	determinant	ant	nant	NN	False
DDI-MedLine.d52.s0	gene	96	99	O	gene	ene	gene	NN	False
DDI-MedLine.d52.s0	transfer	101	108	O	transfer	fer	sfer	NN	False
DDI-MedLine.d52.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d52.s1	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d52.s1	assessed	3	10	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d52.s1	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d52.s1	ability	16	22	O	ability	ity	lity	NN	False
DDI-MedLine.d52.s1	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d52.s1	gene	27	30	O	gene	ene	gene	NN	False
DDI-MedLine.d52.s1	transfer	32	39	O	transfer	fer	sfer	NN	False
DDI-MedLine.d52.s1	to	41	42	O	to	to	to	TO	False
DDI-MedLine.d52.s1	reverse	44	50	O	reverse	rse	erse	NN	False
DDI-MedLine.d52.s1	vancomycin	52	61	B-drug	vancomycin	cin	ycin	NN	drug
DDI-MedLine.d52.s1	resistance	63	72	O	resistance	nce	ance	NN	False
DDI-MedLine.d52.s1	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d52.s1	class	77	81	O	class	ass	lass	NN	False
DDI-MedLine.d52.s1	A	83	83	O	A	A	A	DT	brand
DDI-MedLine.d52.s1	(	85	85	O	(	(	(	(	False
DDI-MedLine.d52.s1	VanA	86	89	O	VanA	anA	VanA	NN	False
DDI-MedLine.d52.s1	)	90	90	O	)	)	)	)	False
DDI-MedLine.d52.s1	glycopeptide-resistant	92	113	O	glycopeptide-resistant	ant	tant	JJ	False
DDI-MedLine.d52.s1	Enterococcus	115	126	O	Enterococcus	cus	ccus	NN	False
DDI-MedLine.d52.s1	faecalis	128	135	O	faecalis	lis	alis	NN	False
DDI-MedLine.d52.s1	.	136	136	O	.	.	.	.	False

DDI-MedLine.d52.s2	Recombinant	0	10	O	Recombinant	ant	nant	NN	False
DDI-MedLine.d52.s2	shuttle	12	18	O	shuttle	tle	ttle	NN	False
DDI-MedLine.d52.s2	vectors	20	26	O	vectors	ors	tors	NNS	False
DDI-MedLine.d52.s2	containing	28	37	O	containing	ing	ning	VBG	False
DDI-MedLine.d52.s2	a	39	39	O	a	a	a	DT	False
DDI-MedLine.d52.s2	vanH	41	44	O	vanH	anH	vanH	NN	False
DDI-MedLine.d52.s2	promoter-vanA	46	58	O	promoter-vanA	anA	vanA	NN	False
DDI-MedLine.d52.s2	antisense	60	68	O	antisense	nse	ense	NN	False
DDI-MedLine.d52.s2	gene	70	73	O	gene	ene	gene	NN	False
DDI-MedLine.d52.s2	cassette	75	82	O	cassette	tte	ette	NN	False
DDI-MedLine.d52.s2	fully	84	88	O	fully	lly	ully	RB	False
DDI-MedLine.d52.s2	restored	90	97	O	restored	red	ored	VBN	False
DDI-MedLine.d52.s2	vancomycin	99	108	B-drug	vancomycin	cin	ycin	NN	drug
DDI-MedLine.d52.s2	susceptibility	110	123	O	susceptibility	ity	lity	NN	False
DDI-MedLine.d52.s2	through	125	131	O	through	ugh	ough	IN	False
DDI-MedLine.d52.s2	a	133	133	O	a	a	a	DT	False
DDI-MedLine.d52.s2	combined	135	142	O	combined	ned	ined	VBN	False
DDI-MedLine.d52.s2	transcriptional	144	158	O	transcriptional	nal	onal	JJ	False
DDI-MedLine.d52.s2	activator	160	168	O	activator	tor	ator	NN	False
DDI-MedLine.d52.s2	binding	170	176	O	binding	ing	ding	NN	False
DDI-MedLine.d52.s2	domain	178	183	O	domain	ain	main	NN	False
DDI-MedLine.d52.s2	decoy	185	189	O	decoy	coy	ecoy	NN	False
DDI-MedLine.d52.s2	and	191	193	O	and	and	and	CC	False
DDI-MedLine.d52.s2	inducible	195	203	O	inducible	ble	ible	JJ	False
DDI-MedLine.d52.s2	vanA	205	208	O	vanA	anA	vanA	NN	False
DDI-MedLine.d52.s2	antisense	210	218	O	antisense	nse	ense	NN	False
DDI-MedLine.d52.s2	RNA	220	222	O	RNA	RNA	RNA	NN	brand
DDI-MedLine.d52.s2	effect	224	229	O	effect	ect	fect	NN	False
DDI-MedLine.d52.s2	.	230	230	O	.	.	.	.	False

DDI-MedLine.d89.s0	Therapeutic	0	10	O	Therapeutic	tic	utic	JJ	False
DDI-MedLine.d89.s0	drug	12	15	O	drug	rug	drug	NN	False
DDI-MedLine.d89.s0	monitoring	17	26	O	monitoring	ing	ring	NN	False
DDI-MedLine.d89.s0	can	28	30	O	can	can	can	MD	False
DDI-MedLine.d89.s0	avoid	32	36	O	avoid	oid	void	NN	False
DDI-MedLine.d89.s0	iatrogenic	38	47	O	iatrogenic	nic	enic	NN	False
DDI-MedLine.d89.s0	alterations	49	59	O	alterations	ons	ions	NNS	False
DDI-MedLine.d89.s0	caused	61	66	O	caused	sed	used	VBN	False
DDI-MedLine.d89.s0	by	68	69	O	by	by	by	IN	False
DDI-MedLine.d89.s0	99mTc-methylene	71	85	B-drug	99mTc-methylene	ene	lene	JJ	False
DDI-MedLine.d89.s0	diphosphonate	87	99	I-drug	diphosphonate	ate	nate	NN	False
DDI-MedLine.d89.s0	(	101	101	O	(	(	(	(	False
DDI-MedLine.d89.s0	MDP	102	104	O	MDP	MDP	MDP	NN	brand
DDI-MedLine.d89.s0	)	105	105	O	)	)	)	)	False
DDI-MedLine.d89.s0	-gentamicin	106	116	O	-gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s0	interaction	118	128	O	interaction	ion	tion	NN	False
DDI-MedLine.d89.s0	.	129	129	O	.	.	.	.	False

DDI-MedLine.d89.s1	Gentamicin	0	9	B-drug	Gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s1	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d89.s1	an	14	15	O	an	an	an	DT	False
DDI-MedLine.d89.s1	aminoglycoside	17	30	B-group	aminoglycoside	ide	side	NN	False
DDI-MedLine.d89.s1	antibiotic	32	41	I-group	antibiotic	tic	otic	JJ	False
DDI-MedLine.d89.s1	used	43	46	O	used	sed	used	VBN	False
DDI-MedLine.d89.s1	to	48	49	O	to	to	to	TO	False
DDI-MedLine.d89.s1	treat	51	55	O	treat	eat	reat	NN	False
DDI-MedLine.d89.s1	a	57	57	O	a	a	a	DT	False
DDI-MedLine.d89.s1	wide	59	62	O	wide	ide	wide	JJ	False
DDI-MedLine.d89.s1	variety	64	70	O	variety	ety	iety	NN	False
DDI-MedLine.d89.s1	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d89.s1	infections	75	84	O	infections	ons	ions	NNS	False
DDI-MedLine.d89.s1	caused	86	91	O	caused	sed	used	VBN	False
DDI-MedLine.d89.s1	by	93	94	O	by	by	by	IN	False
DDI-MedLine.d89.s1	gram-negative	96	108	O	gram-negative	ive	tive	JJ	False
DDI-MedLine.d89.s1	organisms	110	118	O	organisms	sms	isms	NNS	False
DDI-MedLine.d89.s1	,	119	119	O	,	,	,	,	False
DDI-MedLine.d89.s1	but	121	123	O	but	but	but	CC	False
DDI-MedLine.d89.s1	it	125	126	O	it	it	it	PRP	False
DDI-MedLine.d89.s1	is	128	129	O	is	is	is	VBZ	False
DDI-MedLine.d89.s1	potentially	131	141	O	potentially	lly	ally	RB	False
DDI-MedLine.d89.s1	toxic	143	147	O	toxic	xic	oxic	NN	False
DDI-MedLine.d89.s1	to	149	150	O	to	to	to	TO	False
DDI-MedLine.d89.s1	the	152	154	O	the	the	the	DT	False
DDI-MedLine.d89.s1	kidneys	156	162	O	kidneys	eys	neys	NNS	False
DDI-MedLine.d89.s1	.	163	163	O	.	.	.	.	False

DDI-MedLine.d89.s2	Due	0	2	O	Due	Due	Due	JJ	False
DDI-MedLine.d89.s2	to	4	5	O	to	to	to	TO	False
DDI-MedLine.d89.s2	its	7	9	O	its	its	its	PRP$	False
DDI-MedLine.d89.s2	nephrotoxicity	11	24	O	nephrotoxicity	ity	city	NN	False
DDI-MedLine.d89.s2	,	25	25	O	,	,	,	,	False
DDI-MedLine.d89.s2	gentamicin	27	36	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s2	may	38	40	O	may	may	may	MD	False
DDI-MedLine.d89.s2	cause	42	46	O	cause	use	ause	NN	False
DDI-MedLine.d89.s2	abnormal	48	55	O	abnormal	mal	rmal	JJ	False
DDI-MedLine.d89.s2	renal	57	61	O	renal	nal	enal	NN	False
DDI-MedLine.d89.s2	uptake	63	68	O	uptake	ake	take	NN	False
DDI-MedLine.d89.s2	to	70	71	O	to	to	to	TO	False
DDI-MedLine.d89.s2	be	73	74	O	be	be	be	VB	False
DDI-MedLine.d89.s2	seen	76	79	O	seen	een	seen	VBN	False
DDI-MedLine.d89.s2	on	81	82	O	on	on	on	IN	False
DDI-MedLine.d89.s2	99mTc-MDP	84	92	B-drug	99mTc-MDP	MDP	-MDP	CD	False
DDI-MedLine.d89.s2	bone	94	97	O	bone	one	bone	NN	False
DDI-MedLine.d89.s2	scintigraphy	99	110	O	scintigraphy	phy	aphy	NN	False
DDI-MedLine.d89.s2	.	111	111	O	.	.	.	.	False

DDI-MedLine.d89.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d89.s3	presence	4	11	O	presence	nce	ence	NN	False
DDI-MedLine.d89.s3	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d89.s3	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d89.s3	radiopharmaceutical	20	38	B-group	radiopharmaceutical	cal	ical	JJ	False
DDI-MedLine.d89.s3	in	40	41	O	in	in	in	IN	False
DDI-MedLine.d89.s3	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d89.s3	kidneys	47	53	O	kidneys	eys	neys	NNS	False
DDI-MedLine.d89.s3	,	54	54	O	,	,	,	,	False
DDI-MedLine.d89.s3	along	56	60	O	along	ong	long	IN	False
DDI-MedLine.d89.s3	with	62	65	O	with	ith	with	IN	False
DDI-MedLine.d89.s3	an	67	68	O	an	an	an	DT	False
DDI-MedLine.d89.s3	increase	70	77	O	increase	ase	ease	NN	False
DDI-MedLine.d89.s3	in	79	80	O	in	in	in	IN	False
DDI-MedLine.d89.s3	renal	82	86	O	renal	nal	enal	NN	False
DDI-MedLine.d89.s3	retention	88	96	O	retention	ion	tion	NN	False
DDI-MedLine.d89.s3	,	97	97	O	,	,	,	,	False
DDI-MedLine.d89.s3	tend	99	102	O	tend	end	tend	NN	False
DDI-MedLine.d89.s3	to	104	105	O	to	to	to	TO	False
DDI-MedLine.d89.s3	produce	107	113	O	produce	uce	duce	NN	False
DDI-MedLine.d89.s3	scintigraphic	115	127	O	scintigraphic	hic	phic	JJ	False
DDI-MedLine.d89.s3	results	129	135	O	results	lts	ults	NNS	False
DDI-MedLine.d89.s3	that	137	140	O	that	hat	that	IN	False
DDI-MedLine.d89.s3	falsely	142	148	O	falsely	ely	sely	RB	False
DDI-MedLine.d89.s3	identify	150	157	O	identify	ify	tify	VB	False
DDI-MedLine.d89.s3	characteristics	159	173	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d89.s3	related	175	181	O	related	ted	ated	JJ	False
DDI-MedLine.d89.s3	to	183	184	O	to	to	to	TO	False
DDI-MedLine.d89.s3	diseases	186	193	O	diseases	ses	ases	NNS	False
DDI-MedLine.d89.s3	such	195	198	O	such	uch	such	JJ	False
DDI-MedLine.d89.s3	as	200	201	O	as	as	as	IN	False
DDI-MedLine.d89.s3	renal	203	207	O	renal	nal	enal	NN	False
DDI-MedLine.d89.s3	vascular	209	216	O	vascular	lar	ular	NN	False
DDI-MedLine.d89.s3	,	217	217	O	,	,	,	,	False
DDI-MedLine.d89.s3	or	219	220	O	or	or	or	CC	False
DDI-MedLine.d89.s3	urinary	222	228	O	urinary	ary	nary	JJ	False
DDI-MedLine.d89.s3	tract	230	234	O	tract	act	ract	NN	False
DDI-MedLine.d89.s3	obstruction	236	246	O	obstruction	ion	tion	NN	False
DDI-MedLine.d89.s3	,	247	247	O	,	,	,	,	False
DDI-MedLine.d89.s3	and	249	251	O	and	and	and	CC	False
DDI-MedLine.d89.s3	even	253	256	O	even	ven	even	RB	False
DDI-MedLine.d89.s3	renal	258	262	O	renal	nal	enal	NN	False
DDI-MedLine.d89.s3	cancer	264	269	O	cancer	cer	ncer	NN	False
DDI-MedLine.d89.s3	.	270	270	O	.	.	.	.	False

DDI-MedLine.d89.s4	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d89.s4	altered	3	9	O	altered	red	ered	VBN	False
DDI-MedLine.d89.s4	biodistribution	11	25	O	biodistribution	ion	tion	NN	False
DDI-MedLine.d89.s4	may	27	29	O	may	may	may	MD	False
DDI-MedLine.d89.s4	provide	31	37	O	provide	ide	vide	NN	False
DDI-MedLine.d89.s4	misleading	39	48	O	misleading	ing	ding	VBG	False
DDI-MedLine.d89.s4	information	50	60	O	information	ion	tion	NN	False
DDI-MedLine.d89.s4	that	62	65	O	that	hat	that	IN	False
DDI-MedLine.d89.s4	can	67	69	O	can	can	can	MD	False
DDI-MedLine.d89.s4	either	71	76	O	either	her	ther	DT	False
DDI-MedLine.d89.s4	mask	78	81	O	mask	ask	mask	NN	False
DDI-MedLine.d89.s4	or	83	84	O	or	or	or	CC	False
DDI-MedLine.d89.s4	mimic	86	90	O	mimic	mic	imic	NN	False
DDI-MedLine.d89.s4	certain	92	98	O	certain	ain	tain	JJ	False
DDI-MedLine.d89.s4	disease	100	106	O	disease	ase	ease	NN	False
DDI-MedLine.d89.s4	symptoms	108	115	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d89.s4	.	116	116	O	.	.	.	.	False

DDI-MedLine.d89.s5	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d89.s5	method	2	7	O	method	hod	thod	NN	False
DDI-MedLine.d89.s5	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d89.s5	maximize	12	19	O	maximize	ize	mize	VB	False
DDI-MedLine.d89.s5	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d89.s5	therapeutic	25	35	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d89.s5	benefit	37	43	O	benefit	fit	efit	NN	False
DDI-MedLine.d89.s5	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d89.s5	gentamicin	48	57	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s5	while	59	63	O	while	ile	hile	IN	False
DDI-MedLine.d89.s5	minimizing	65	74	O	minimizing	ing	zing	VBG	False
DDI-MedLine.d89.s5	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d89.s5	risk	80	83	O	risk	isk	risk	NN	False
DDI-MedLine.d89.s5	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d89.s5	nephrotoxicity	88	101	O	nephrotoxicity	ity	city	NN	False
DDI-MedLine.d89.s5	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d89.s5	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d89.s5	appearance	111	120	O	appearance	nce	ance	NN	False
DDI-MedLine.d89.s5	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d89.s5	a	125	125	O	a	a	a	DT	False
DDI-MedLine.d89.s5	hot	127	129	O	hot	hot	hot	JJ	False
DDI-MedLine.d89.s5	kidney	131	136	O	kidney	ney	dney	NN	False
DDI-MedLine.d89.s5	on	138	139	O	on	on	on	IN	False
DDI-MedLine.d89.s5	scintigraphy	141	152	O	scintigraphy	phy	aphy	NN	False
DDI-MedLine.d89.s5	is	154	155	O	is	is	is	VBZ	False
DDI-MedLine.d89.s5	desirable	157	165	O	desirable	ble	able	JJ	False
DDI-MedLine.d89.s5	.	166	166	O	.	.	.	.	False

DDI-MedLine.d89.s6	Serial	0	5	O	Serial	ial	rial	JJ	False
DDI-MedLine.d89.s6	pharmacokinetic	7	21	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d89.s6	dosing	23	28	O	dosing	ing	sing	VBG	False
DDI-MedLine.d89.s6	has	30	32	O	has	has	has	VBZ	False
DDI-MedLine.d89.s6	been	34	37	O	been	een	been	VBN	False
DDI-MedLine.d89.s6	proposed	39	46	O	proposed	sed	osed	VBN	False
DDI-MedLine.d89.s6	as	48	49	O	as	as	as	IN	False
DDI-MedLine.d89.s6	a	51	51	O	a	a	a	DT	False
DDI-MedLine.d89.s6	method	53	58	O	method	hod	thod	NN	False
DDI-MedLine.d89.s6	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d89.s6	accomplish	63	72	O	accomplish	ish	lish	NN	False
DDI-MedLine.d89.s6	this	74	77	O	this	his	this	DT	False
DDI-MedLine.d89.s6	goal	79	82	O	goal	oal	goal	NN	False
DDI-MedLine.d89.s6	.	83	83	O	.	.	.	.	False

DDI-MedLine.d89.s7	Therapeutic	0	10	O	Therapeutic	tic	utic	JJ	False
DDI-MedLine.d89.s7	drug	12	15	O	drug	rug	drug	NN	False
DDI-MedLine.d89.s7	monitoring	17	26	O	monitoring	ing	ring	NN	False
DDI-MedLine.d89.s7	(	28	28	O	(	(	(	(	False
DDI-MedLine.d89.s7	TDM	29	31	O	TDM	TDM	TDM	NN	brand
DDI-MedLine.d89.s7	)	32	32	O	)	)	)	)	False
DDI-MedLine.d89.s7	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d89.s7	gentamicin	37	46	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s7	therapy	48	54	O	therapy	apy	rapy	NN	False
DDI-MedLine.d89.s7	,	55	55	O	,	,	,	,	False
DDI-MedLine.d89.s7	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d89.s7	bone	61	64	O	bone	one	bone	NN	False
DDI-MedLine.d89.s7	scintigraphy	66	77	O	scintigraphy	phy	aphy	NN	False
DDI-MedLine.d89.s7	employing	79	87	O	employing	ing	ying	VBG	False
DDI-MedLine.d89.s7	99mTc-MDP	89	97	B-drug	99mTc-MDP	MDP	-MDP	CD	False
DDI-MedLine.d89.s7	as	99	100	O	as	as	as	IN	False
DDI-MedLine.d89.s7	the	102	104	O	the	the	the	DT	False
DDI-MedLine.d89.s7	radiopharmaceutical	106	124	B-group	radiopharmaceutical	cal	ical	JJ	False
DDI-MedLine.d89.s7	was	126	128	O	was	was	was	VBD	False
DDI-MedLine.d89.s7	carried	130	136	O	carried	ied	ried	VBN	False
DDI-MedLine.d89.s7	out	138	140	O	out	out	out	IN	False
DDI-MedLine.d89.s7	in	142	143	O	in	in	in	IN	False
DDI-MedLine.d89.s7	22	145	146	O	22	22	22	CD	False
DDI-MedLine.d89.s7	patients	148	155	O	patients	nts	ents	NNS	False
DDI-MedLine.d89.s7	.	156	156	O	.	.	.	.	False

DDI-MedLine.d89.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d89.s8	data	4	7	O	data	ata	data	NNS	False
DDI-MedLine.d89.s8	presented	9	17	O	presented	ted	nted	VBN	False
DDI-MedLine.d89.s8	here	19	22	O	here	ere	here	RB	False
DDI-MedLine.d89.s8	demonstrate	24	34	O	demonstrate	ate	rate	NN	False
DDI-MedLine.d89.s8	that	36	39	O	that	hat	that	IN	False
DDI-MedLine.d89.s8	with	41	44	O	with	ith	with	IN	False
DDI-MedLine.d89.s8	serial	46	51	O	serial	ial	rial	JJ	False
DDI-MedLine.d89.s8	pharmacokinetic	53	67	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d89.s8	dosing	69	74	O	dosing	ing	sing	VBG	False
DDI-MedLine.d89.s8	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d89.s8	gentamicin	79	88	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s8	,	89	89	O	,	,	,	,	False
DDI-MedLine.d89.s8	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d89.s8	iatrogenic	95	104	O	iatrogenic	nic	enic	NN	False
DDI-MedLine.d89.s8	alteration	106	115	O	alteration	ion	tion	NN	False
DDI-MedLine.d89.s8	caused	117	122	O	caused	sed	used	VBN	False
DDI-MedLine.d89.s8	by	124	125	O	by	by	by	IN	False
DDI-MedLine.d89.s8	gentamicin	127	136	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d89.s8	therapy	138	144	O	therapy	apy	rapy	NN	False
DDI-MedLine.d89.s8	can	146	148	O	can	can	can	MD	False
DDI-MedLine.d89.s8	be	150	151	O	be	be	be	VB	False
DDI-MedLine.d89.s8	avoided	153	159	O	avoided	ded	ided	VBD	False
DDI-MedLine.d89.s8	.	160	160	O	.	.	.	.	False

DDI-MedLine.d8.s0	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d8.s0	vitro	3	7	O	vitro	tro	itro	NN	False
DDI-MedLine.d8.s0	activity	9	16	O	activity	ity	vity	NN	False
DDI-MedLine.d8.s0	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d8.s0	KRM-1648	21	28	B-drug_n	KRM-1648	648	1648	NNP	brand
DDI-MedLine.d8.s0	,	29	29	O	,	,	,	,	False
DDI-MedLine.d8.s0	either	31	36	O	either	her	ther	DT	False
DDI-MedLine.d8.s0	singly	38	43	O	singly	gly	ngly	RB	False
DDI-MedLine.d8.s0	or	45	46	O	or	or	or	CC	False
DDI-MedLine.d8.s0	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d8.s0	combination	51	61	O	combination	ion	tion	NN	False
DDI-MedLine.d8.s0	with	63	66	O	with	ith	with	IN	False
DDI-MedLine.d8.s0	ofloxacin	68	76	B-drug	ofloxacin	cin	acin	NN	drug
DDI-MedLine.d8.s0	,	77	77	O	,	,	,	,	False
DDI-MedLine.d8.s0	against	79	85	O	against	nst	inst	IN	False
DDI-MedLine.d8.s0	Mycobacterium	87	99	O	Mycobacterium	ium	rium	NN	drug
DDI-MedLine.d8.s0	ulcerans	101	108	O	ulcerans	ans	rans	NNS	False
DDI-MedLine.d8.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d8.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d8.s1	antimicrobial	4	16	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d8.s1	effect	18	23	O	effect	ect	fect	NN	False
DDI-MedLine.d8.s1	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d8.s1	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d8.s1	benzoxazinorifamycin	30	49	B-drug_n	benzoxazinorifamycin	cin	ycin	NN	drug
DDI-MedLine.d8.s1	,	50	50	O	,	,	,	,	False
DDI-MedLine.d8.s1	KRM-1648	52	59	B-drug_n	KRM-1648	648	1648	NNP	brand
DDI-MedLine.d8.s1	,	60	60	O	,	,	,	,	False
DDI-MedLine.d8.s1	either	62	67	O	either	her	ther	DT	False
DDI-MedLine.d8.s1	alone	69	73	O	alone	one	lone	RB	False
DDI-MedLine.d8.s1	or	75	76	O	or	or	or	CC	False
DDI-MedLine.d8.s1	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d8.s1	combination	81	91	O	combination	ion	tion	NN	False
DDI-MedLine.d8.s1	with	93	96	O	with	ith	with	IN	False
DDI-MedLine.d8.s1	ofloxacin	98	106	B-drug	ofloxacin	cin	acin	NN	drug
DDI-MedLine.d8.s1	,	107	107	O	,	,	,	,	False
DDI-MedLine.d8.s1	was	109	111	O	was	was	was	VBD	False
DDI-MedLine.d8.s1	evaluated	113	121	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d8.s1	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d8.s1	vitro	126	130	O	vitro	tro	itro	NN	False
DDI-MedLine.d8.s1	against	132	138	O	against	nst	inst	IN	False
DDI-MedLine.d8.s1	two	140	142	O	two	two	two	CD	False
DDI-MedLine.d8.s1	type	144	147	O	type	ype	type	NN	False
DDI-MedLine.d8.s1	strains	149	155	O	strains	ins	ains	NNS	False
DDI-MedLine.d8.s1	and	157	159	O	and	and	and	CC	False
DDI-MedLine.d8.s1	six	161	163	O	six	six	six	CD	False
DDI-MedLine.d8.s1	clinical	165	172	O	clinical	cal	ical	JJ	False
DDI-MedLine.d8.s1	isolates	174	181	O	isolates	tes	ates	NNS	False
DDI-MedLine.d8.s1	of	183	184	O	of	of	of	IN	False
DDI-MedLine.d8.s1	Mycobacterium	186	198	O	Mycobacterium	ium	rium	NN	drug
DDI-MedLine.d8.s1	ulcerans	200	207	O	ulcerans	ans	rans	NNS	False
DDI-MedLine.d8.s1	.	208	208	O	.	.	.	.	False

DDI-MedLine.d8.s2	Growth	0	5	O	Growth	wth	owth	NN	False
DDI-MedLine.d8.s2	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d8.s2	M	10	10	O	M	M	M	NN	brand
DDI-MedLine.d8.s2	.	11	11	O	.	.	.	.	False

DDI-MedLine.d8.s3	ulcerans	0	7	O	ulcerans	ans	rans	NNS	False
DDI-MedLine.d8.s3	was	9	11	O	was	was	was	VBD	False
DDI-MedLine.d8.s3	measured	13	20	O	measured	red	ured	VBN	False
DDI-MedLine.d8.s3	by	22	23	O	by	by	by	IN	False
DDI-MedLine.d8.s3	plate	25	29	O	plate	ate	late	NN	False
DDI-MedLine.d8.s3	counts	31	36	O	counts	nts	unts	NNS	False
DDI-MedLine.d8.s3	and	38	40	O	and	and	and	CC	False
DDI-MedLine.d8.s3	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d8.s3	BACTEC	46	51	O	BACTEC	TEC	CTEC	NN	brand
DDI-MedLine.d8.s3	radiometric	53	63	O	radiometric	ric	tric	NN	False
DDI-MedLine.d8.s3	method	65	70	O	method	hod	thod	NN	False
DDI-MedLine.d8.s3	.	71	71	O	.	.	.	.	False

DDI-MedLine.d8.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d8.s4	minimal	4	10	O	minimal	mal	imal	NN	False
DDI-MedLine.d8.s4	inhibitory	12	21	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d8.s4	concentration	23	35	O	concentration	ion	tion	NN	False
DDI-MedLine.d8.s4	as	37	38	O	as	as	as	IN	False
DDI-MedLine.d8.s4	well	40	43	O	well	ell	well	RB	False
DDI-MedLine.d8.s4	as	45	46	O	as	as	as	IN	False
DDI-MedLine.d8.s4	minimal	48	54	O	minimal	mal	imal	NN	False
DDI-MedLine.d8.s4	bactericidal	56	67	O	bactericidal	dal	idal	NN	False
DDI-MedLine.d8.s4	concentration	69	81	O	concentration	ion	tion	NN	False
DDI-MedLine.d8.s4	of	83	84	O	of	of	of	IN	False
DDI-MedLine.d8.s4	KRM-1648	86	93	B-drug_n	KRM-1648	648	1648	NNP	brand
DDI-MedLine.d8.s4	against	95	101	O	against	nst	inst	IN	False
DDI-MedLine.d8.s4	M	103	103	O	M	M	M	NN	brand
DDI-MedLine.d8.s4	.	104	104	O	.	.	.	.	False

DDI-MedLine.d8.s5	ulcerans	0	7	O	ulcerans	ans	rans	NNS	False
DDI-MedLine.d8.s5	was	9	11	O	was	was	was	VBD	False
DDI-MedLine.d8.s5	between	13	19	O	between	een	ween	IN	False
DDI-MedLine.d8.s5	0.012	21	25	O	0.012	012	.012	CD	False
DDI-MedLine.d8.s5	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d8.s5	0.025	31	35	O	0.025	025	.025	CD	False
DDI-MedLine.d8.s5	mg/l	37	40	O	mg/l	g/l	mg/l	NN	False
DDI-MedLine.d8.s5	,	41	41	O	,	,	,	,	False
DDI-MedLine.d8.s5	while	43	47	O	while	ile	hile	IN	False
DDI-MedLine.d8.s5	corresponding	49	61	O	corresponding	ing	ding	VBG	False
DDI-MedLine.d8.s5	values	63	68	O	values	ues	lues	NNS	False
DDI-MedLine.d8.s5	for	70	72	O	for	for	for	IN	False
DDI-MedLine.d8.s5	rifampicin	74	83	B-drug	rifampicin	cin	icin	NN	drug
DDI-MedLine.d8.s5	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d8.s5	rifabutin	89	97	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d8.s5	were	99	102	O	were	ere	were	VBD	False
DDI-MedLine.d8.s5	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d8.s5	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d8.s5	range	111	115	O	range	nge	ange	NN	False
DDI-MedLine.d8.s5	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d8.s5	0.1-0.8	120	126	O	0.1-0.8	0.8	-0.8	NN	False
DDI-MedLine.d8.s5	mg/l	128	131	O	mg/l	g/l	mg/l	NN	False
DDI-MedLine.d8.s5	and	133	135	O	and	and	and	CC	False
DDI-MedLine.d8.s5	0.1-0.4	137	143	O	0.1-0.4	0.4	-0.4	NN	False
DDI-MedLine.d8.s5	mg/l	145	148	O	mg/l	g/l	mg/l	NN	False
DDI-MedLine.d8.s5	respectively	150	161	O	respectively	ely	vely	RB	False
DDI-MedLine.d8.s5	.	162	162	O	.	.	.	.	False

DDI-MedLine.d8.s6	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d8.s6	combined	5	12	O	combined	ned	ined	VBN	False
DDI-MedLine.d8.s6	with	14	17	O	with	ith	with	IN	False
DDI-MedLine.d8.s6	ofloxacin	19	27	B-drug	ofloxacin	cin	acin	NN	drug
DDI-MedLine.d8.s6	,	28	28	O	,	,	,	,	False
DDI-MedLine.d8.s6	KRM-1648	30	37	B-drug_n	KRM-1648	648	1648	NNP	brand
DDI-MedLine.d8.s6	exhibited	39	47	O	exhibited	ted	ited	VBN	False
DDI-MedLine.d8.s6	strong	49	54	O	strong	ong	rong	JJ	False
DDI-MedLine.d8.s6	synergistic	56	66	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d8.s6	activity	68	75	O	activity	ity	vity	NN	False
DDI-MedLine.d8.s6	while	77	81	O	while	ile	hile	IN	False
DDI-MedLine.d8.s6	only	83	86	O	only	nly	only	RB	False
DDI-MedLine.d8.s6	additive	88	95	O	additive	ive	tive	JJ	False
DDI-MedLine.d8.s6	effects	97	103	O	effects	cts	ects	NNS	False
DDI-MedLine.d8.s6	were	105	108	O	were	ere	were	VBD	False
DDI-MedLine.d8.s6	observed	110	117	O	observed	ved	rved	VBN	False
DDI-MedLine.d8.s6	with	119	122	O	with	ith	with	IN	False
DDI-MedLine.d8.s6	the	124	126	O	the	the	the	DT	False
DDI-MedLine.d8.s6	combination	128	138	O	combination	ion	tion	NN	False
DDI-MedLine.d8.s6	of	140	141	O	of	of	of	IN	False
DDI-MedLine.d8.s6	rifampicin	143	152	B-drug	rifampicin	cin	icin	NN	drug
DDI-MedLine.d8.s6	(	154	154	O	(	(	(	(	False
DDI-MedLine.d8.s6	or	155	156	O	or	or	or	CC	False
DDI-MedLine.d8.s6	rifabutin	158	166	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d8.s6	)	167	167	O	)	)	)	)	False
DDI-MedLine.d8.s6	and	169	171	O	and	and	and	CC	False
DDI-MedLine.d8.s6	ofloxacin	173	181	B-drug	ofloxacin	cin	acin	NN	drug
DDI-MedLine.d8.s6	.	182	182	O	.	.	.	.	False

DDI-MedLine.d8.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d8.s7	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d8.s7	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d8.s7	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d8.s7	KRM-1648	27	34	B-drug_n	KRM-1648	648	1648	NNP	brand
DDI-MedLine.d8.s7	has	36	38	O	has	has	has	VBZ	False
DDI-MedLine.d8.s7	a	40	40	O	a	a	a	DT	False
DDI-MedLine.d8.s7	great	42	46	O	great	eat	reat	JJ	False
DDI-MedLine.d8.s7	potential	48	56	O	potential	ial	tial	JJ	False
DDI-MedLine.d8.s7	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d8.s7	the	61	63	O	the	the	the	DT	False
DDI-MedLine.d8.s7	treatment	65	73	O	treatment	ent	ment	NN	False
DDI-MedLine.d8.s7	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d8.s7	M	78	78	O	M	M	M	NN	brand
DDI-MedLine.d8.s7	.	79	79	O	.	.	.	.	False

DDI-MedLine.d8.s8	ulcerans	0	7	O	ulcerans	ans	rans	NNS	False
DDI-MedLine.d8.s8	infection	9	17	O	infection	ion	tion	NN	False
DDI-MedLine.d8.s8	.	18	18	O	.	.	.	.	False

DDI-MedLine.d94.s0	Evidence	0	7	O	Evidence	nce	ence	NN	False
DDI-MedLine.d94.s0	for	9	11	O	for	for	for	IN	False
DDI-MedLine.d94.s0	reduction	13	21	O	reduction	ion	tion	NN	False
DDI-MedLine.d94.s0	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d94.s0	norepinephrine	26	39	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s0	uptake	41	46	O	uptake	ake	take	NN	False
DDI-MedLine.d94.s0	sites	48	52	O	sites	tes	ites	NNS	False
DDI-MedLine.d94.s0	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d94.s0	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d94.s0	failing	61	67	O	failing	ing	ling	VBG	False
DDI-MedLine.d94.s0	human	69	73	O	human	man	uman	NN	False
DDI-MedLine.d94.s0	heart	75	79	O	heart	art	eart	NN	False
DDI-MedLine.d94.s0	.	80	80	O	.	.	.	.	False

DDI-MedLine.d94.s1	OBJECTIVES	0	9	O	OBJECTIVES	VES	IVES	NN	brand
DDI-MedLine.d94.s1	.	10	10	O	.	.	.	.	False

DDI-MedLine.d94.s2	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d94.s2	study	5	9	O	study	udy	tudy	NN	False
DDI-MedLine.d94.s2	investigated	11	22	O	investigated	ted	ated	VBN	False
DDI-MedLine.d94.s2	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d94.s2	role	28	31	O	role	ole	role	NN	False
DDI-MedLine.d94.s2	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d94.s2	neuronal	36	43	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d94.s2	uptake	45	50	O	uptake	ake	take	NN	False
DDI-MedLine.d94.s2	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d94.s2	norepinephrine	55	68	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s2	(	70	70	O	(	(	(	(	False
DDI-MedLine.d94.s2	uptake-1	71	78	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s2	)	79	79	O	)	)	)	)	False
DDI-MedLine.d94.s2	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d94.s2	human	84	88	O	human	man	uman	NN	False
DDI-MedLine.d94.s2	heart	90	94	O	heart	art	eart	NN	False
DDI-MedLine.d94.s2	failure	96	102	O	failure	ure	lure	NN	False
DDI-MedLine.d94.s2	as	104	105	O	as	as	as	IN	False
DDI-MedLine.d94.s2	a	107	107	O	a	a	a	DT	False
DDI-MedLine.d94.s2	local	109	113	O	local	cal	ocal	JJ	False
DDI-MedLine.d94.s2	factor	115	120	O	factor	tor	ctor	NN	False
DDI-MedLine.d94.s2	for	122	124	O	for	for	for	IN	False
DDI-MedLine.d94.s2	altering	126	133	O	altering	ing	ring	VBG	False
DDI-MedLine.d94.s2	concentrations	135	148	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d94.s2	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d94.s2	norepinephrine	153	166	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s2	at	168	169	O	at	at	at	IN	False
DDI-MedLine.d94.s2	the	171	173	O	the	the	the	DT	False
DDI-MedLine.d94.s2	cardiac	175	181	O	cardiac	iac	diac	NN	False
DDI-MedLine.d94.s2	myocyte	183	189	O	myocyte	yte	cyte	NN	False
DDI-MedLine.d94.s2	membranes	191	199	O	membranes	nes	anes	NNS	False
DDI-MedLine.d94.s2	.	200	200	O	.	.	.	.	False

DDI-MedLine.d94.s3	BACKGROUND	0	9	O	BACKGROUND	UND	OUND	NN	brand
DDI-MedLine.d94.s3	.	10	10	O	.	.	.	.	False

DDI-MedLine.d94.s4	Several	0	6	O	Several	ral	eral	JJ	False
DDI-MedLine.d94.s4	beta-adrenergic	8	22	O	beta-adrenergic	gic	rgic	NN	False
DDI-MedLine.d94.s4	neuroeffector	24	36	O	neuroeffector	tor	ctor	NN	False
DDI-MedLine.d94.s4	defects	38	44	O	defects	cts	ects	NNS	False
DDI-MedLine.d94.s4	occur	46	50	O	occur	cur	ccur	NN	False
DDI-MedLine.d94.s4	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d94.s4	heart	55	59	O	heart	art	eart	NN	False
DDI-MedLine.d94.s4	failure	61	67	O	failure	ure	lure	NN	False
DDI-MedLine.d94.s4	.	68	68	O	.	.	.	.	False

DDI-MedLine.d94.s5	Whether	0	6	O	Whether	her	ther	IN	False
DDI-MedLine.d94.s5	an	8	9	O	an	an	an	DT	False
DDI-MedLine.d94.s5	alteration	11	20	O	alteration	ion	tion	NN	False
DDI-MedLine.d94.s5	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d94.s5	norepinephrine	25	38	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s5	uptake-1	40	47	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s5	occurs	49	54	O	occurs	urs	curs	NNS	False
DDI-MedLine.d94.s5	is	56	57	O	is	is	is	VBZ	False
DDI-MedLine.d94.s5	still	59	63	O	still	ill	till	RB	False
DDI-MedLine.d94.s5	unresolved	65	74	O	unresolved	ved	lved	JJ	False
DDI-MedLine.d94.s5	.	75	75	O	.	.	.	.	False

DDI-MedLine.d94.s6	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d94.s6	.	7	7	O	.	.	.	.	False

DDI-MedLine.d94.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d94.s7	role	4	7	O	role	ole	role	NN	False
DDI-MedLine.d94.s7	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d94.s7	norepinephrine	12	25	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s7	uptake-1	27	34	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s7	was	36	38	O	was	was	was	VBD	False
DDI-MedLine.d94.s7	studied	40	46	O	studied	ied	died	VBN	False
DDI-MedLine.d94.s7	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d94.s7	electrically	51	62	O	electrically	lly	ally	RB	False
DDI-MedLine.d94.s7	stimulated	64	73	O	stimulated	ted	ated	VBN	False
DDI-MedLine.d94.s7	(	75	75	O	(	(	(	(	False
DDI-MedLine.d94.s7	1	76	76	O	1	1	1	CD	False
DDI-MedLine.d94.s7	Hz	78	79	O	Hz	Hz	Hz	NN	False
DDI-MedLine.d94.s7	,	80	80	O	,	,	,	,	False
DDI-MedLine.d94.s7	37	82	83	O	37	37	37	CD	False
DDI-MedLine.d94.s7	degrees	85	91	O	degrees	ees	rees	NNS	False
DDI-MedLine.d94.s7	C	93	93	O	C	C	C	SYM	brand
DDI-MedLine.d94.s7	)	94	94	O	)	)	)	)	False
DDI-MedLine.d94.s7	human	96	100	O	human	man	uman	NN	False
DDI-MedLine.d94.s7	ventricular	102	112	O	ventricular	lar	ular	NN	False
DDI-MedLine.d94.s7	cardiac	114	120	O	cardiac	iac	diac	NN	False
DDI-MedLine.d94.s7	preparations	122	133	O	preparations	ons	ions	NNS	False
DDI-MedLine.d94.s7	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d94.s7	isolated	139	146	O	isolated	ted	ated	JJ	False
DDI-MedLine.d94.s7	myocardial	148	157	O	myocardial	ial	dial	NN	False
DDI-MedLine.d94.s7	membranes	159	167	O	membranes	nes	anes	NNS	False
DDI-MedLine.d94.s7	.	168	168	O	.	.	.	.	False

DDI-MedLine.d94.s8	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d94.s8	.	7	7	O	.	.	.	.	False

DDI-MedLine.d94.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d94.s9	effectiveness	4	16	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d94.s9	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d94.s9	norepinephrine	21	34	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s9	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d94.s9	increasing	39	48	O	increasing	ing	sing	VBG	False
DDI-MedLine.d94.s9	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d94.s9	force	54	58	O	force	rce	orce	NN	False
DDI-MedLine.d94.s9	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d94.s9	contraction	63	73	O	contraction	ion	tion	NN	False
DDI-MedLine.d94.s9	was	75	77	O	was	was	was	VBD	False
DDI-MedLine.d94.s9	decreased	79	87	O	decreased	sed	ased	VBN	False
DDI-MedLine.d94.s9	in	89	90	O	in	in	in	IN	False
DDI-MedLine.d94.s9	relation	92	99	O	relation	ion	tion	NN	False
DDI-MedLine.d94.s9	to	101	102	O	to	to	to	TO	False
DDI-MedLine.d94.s9	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d94.s9	degree	108	113	O	degree	ree	gree	NN	False
DDI-MedLine.d94.s9	of	115	116	O	of	of	of	IN	False
DDI-MedLine.d94.s9	heart	118	122	O	heart	art	eart	NN	False
DDI-MedLine.d94.s9	failure	124	130	O	failure	ure	lure	NN	False
DDI-MedLine.d94.s9	.	131	131	O	.	.	.	.	False

DDI-MedLine.d94.s10	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d94.s10	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d94.s10	,	11	11	O	,	,	,	,	False
DDI-MedLine.d94.s10	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d94.s10	potency	17	23	O	potency	ncy	ency	NN	False
DDI-MedLine.d94.s10	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d94.s10	norepinephrine	28	41	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s10	was	43	45	O	was	was	was	VBD	False
DDI-MedLine.d94.s10	increased	47	55	O	increased	sed	ased	VBN	False
DDI-MedLine.d94.s10	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d94.s10	failing	60	66	O	failing	ing	ling	VBG	False
DDI-MedLine.d94.s10	hearts	68	73	O	hearts	rts	arts	NNS	False
DDI-MedLine.d94.s10	(	75	75	O	(	(	(	(	False
DDI-MedLine.d94.s10	New	76	78	O	New	New	New	NNP	False
DDI-MedLine.d94.s10	York	80	83	O	York	ork	York	NNP	False
DDI-MedLine.d94.s10	Heart	85	89	O	Heart	art	eart	NN	False
DDI-MedLine.d94.s10	Association	91	101	O	Association	ion	tion	NNP	False
DDI-MedLine.d94.s10	functional	103	112	O	functional	nal	onal	JJ	False
DDI-MedLine.d94.s10	class	114	118	O	class	ass	lass	NN	False
DDI-MedLine.d94.s10	IV	120	121	O	IV	IV	IV	NN	brand
DDI-MedLine.d94.s10	)	122	122	O	)	)	)	)	False
DDI-MedLine.d94.s10	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d94.s10	relation	127	134	O	relation	ion	tion	NN	False
DDI-MedLine.d94.s10	to	136	137	O	to	to	to	TO	False
DDI-MedLine.d94.s10	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d94.s10	concentrations	143	156	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d94.s10	producing	158	166	O	producing	ing	cing	VBG	False
DDI-MedLine.d94.s10	50	168	169	O	50	50	50	CD	False
DDI-MedLine.d94.s10	%	170	170	O	%	%	%	NN	False
DDI-MedLine.d94.s10	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d94.s10	the	175	177	O	the	the	the	DT	False
DDI-MedLine.d94.s10	maximal	179	185	O	maximal	mal	imal	NN	False
DDI-MedLine.d94.s10	effect	187	192	O	effect	ect	fect	NN	False
DDI-MedLine.d94.s10	(	194	194	O	(	(	(	(	False
DDI-MedLine.d94.s10	EC50	195	198	O	EC50	C50	EC50	NN	brand
DDI-MedLine.d94.s10	)	199	199	O	)	)	)	)	False
DDI-MedLine.d94.s10	.	200	200	O	.	.	.	.	False

DDI-MedLine.d94.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d94.s11	EC50	4	7	O	EC50	C50	EC50	NN	brand
DDI-MedLine.d94.s11	values	9	14	O	values	ues	lues	NNS	False
DDI-MedLine.d94.s11	for	16	18	O	for	for	for	IN	False
DDI-MedLine.d94.s11	isoproterenol	20	32	B-drug	isoproterenol	nol	enol	NN	False
DDI-MedLine.d94.s11	,	33	33	O	,	,	,	,	False
DDI-MedLine.d94.s11	which	35	39	O	which	ich	hich	WDT	False
DDI-MedLine.d94.s11	is	41	42	O	is	is	is	VBZ	False
DDI-MedLine.d94.s11	not	44	46	O	not	not	not	RB	False
DDI-MedLine.d94.s11	a	48	48	O	a	a	a	DT	False
DDI-MedLine.d94.s11	substrate	50	58	O	substrate	ate	rate	NN	False
DDI-MedLine.d94.s11	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d94.s11	norepinephrine	64	77	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s11	uptake-1	79	86	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s11	,	87	87	O	,	,	,	,	False
DDI-MedLine.d94.s11	were	89	92	O	were	ere	were	VBD	False
DDI-MedLine.d94.s11	reduced	94	100	O	reduced	ced	uced	VBN	False
DDI-MedLine.d94.s11	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d94.s11	myocardium	105	114	O	myocardium	ium	dium	NN	drug
DDI-MedLine.d94.s11	in	116	117	O	in	in	in	IN	False
DDI-MedLine.d94.s11	functional	119	128	O	functional	nal	onal	JJ	False
DDI-MedLine.d94.s11	classes	130	136	O	classes	ses	sses	NNS	False
DDI-MedLine.d94.s11	II	138	139	O	II	II	II	NN	brand
DDI-MedLine.d94.s11	to	141	142	O	to	to	to	TO	False
DDI-MedLine.d94.s11	III	144	146	O	III	III	III	NN	brand
DDI-MedLine.d94.s11	and	148	150	O	and	and	and	CC	False
DDI-MedLine.d94.s11	IV	152	153	O	IV	IV	IV	NN	brand
DDI-MedLine.d94.s11	compared	155	162	O	compared	red	ared	VBN	False
DDI-MedLine.d94.s11	with	164	167	O	with	ith	with	IN	False
DDI-MedLine.d94.s11	those	169	173	O	those	ose	hose	DT	False
DDI-MedLine.d94.s11	in	175	176	O	in	in	in	IN	False
DDI-MedLine.d94.s11	nonfailing	178	187	O	nonfailing	ing	ling	VBG	False
DDI-MedLine.d94.s11	myocardium	189	198	O	myocardium	ium	dium	NN	drug
DDI-MedLine.d94.s11	.	199	199	O	.	.	.	.	False

DDI-MedLine.d94.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d94.s12	uptake	4	9	O	uptake	ake	take	NN	False
DDI-MedLine.d94.s12	inhibitors	11	20	O	inhibitors	ors	tors	NNS	False
DDI-MedLine.d94.s12	cocaine	22	28	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d94.s12	and	30	32	O	and	and	and	CC	False
DDI-MedLine.d94.s12	desipramine	34	44	B-drug	desipramine	ine	mine	NN	drug
DDI-MedLine.d94.s12	(	46	46	O	(	(	(	(	False
DDI-MedLine.d94.s12	3	47	47	O	3	3	3	CD	False
DDI-MedLine.d94.s12	mumol/liter	49	59	O	mumol/liter	ter	iter	NN	False
DDI-MedLine.d94.s12	)	60	60	O	)	)	)	)	False
DDI-MedLine.d94.s12	potentiated	62	72	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d94.s12	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d94.s12	positive	78	85	O	positive	ive	tive	JJ	False
DDI-MedLine.d94.s12	inotropic	87	95	O	inotropic	pic	opic	NN	False
DDI-MedLine.d94.s12	effects	97	103	O	effects	cts	ects	NNS	False
DDI-MedLine.d94.s12	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d94.s12	norepinephrine	108	121	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s12	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d94.s12	nonfailing	126	135	O	nonfailing	ing	ling	VBG	False
DDI-MedLine.d94.s12	myocardium	137	146	O	myocardium	ium	dium	NN	drug
DDI-MedLine.d94.s12	(	148	148	O	(	(	(	(	False
DDI-MedLine.d94.s12	p	149	149	O	p	p	p	NN	False
DDI-MedLine.d94.s12	<	151	151	O	<	<	<	NN	False
DDI-MedLine.d94.s12	0.05	153	156	O	0.05	.05	0.05	CD	False
DDI-MedLine.d94.s12	)	157	157	O	)	)	)	)	False
DDI-MedLine.d94.s12	but	159	161	O	but	but	but	CC	False
DDI-MedLine.d94.s12	not	163	165	O	not	not	not	RB	False
DDI-MedLine.d94.s12	in	167	168	O	in	in	in	IN	False
DDI-MedLine.d94.s12	functional	170	179	O	functional	nal	onal	JJ	False
DDI-MedLine.d94.s12	class	181	185	O	class	ass	lass	NN	False
DDI-MedLine.d94.s12	IV	187	188	O	IV	IV	IV	NN	brand
DDI-MedLine.d94.s12	myocardium	190	199	O	myocardium	ium	dium	NN	drug
DDI-MedLine.d94.s12	.	200	200	O	.	.	.	.	False

DDI-MedLine.d94.s13	Radioligand	0	10	O	Radioligand	and	gand	NN	False
DDI-MedLine.d94.s13	binding	12	18	O	binding	ing	ding	NN	False
DDI-MedLine.d94.s13	experiments	20	30	O	experiments	nts	ents	NNS	False
DDI-MedLine.d94.s13	using	32	36	O	using	ing	sing	VBG	False
DDI-MedLine.d94.s13	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d94.s13	uptake	42	47	O	uptake	ake	take	NN	False
DDI-MedLine.d94.s13	inhibitor	49	57	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d94.s13	hydrogen-3	59	68	O	hydrogen-3	n-3	en-3	NN	False
DDI-MedLine.d94.s13	mazindol	70	77	B-drug	mazindol	dol	ndol	NN	False
DDI-MedLine.d94.s13	revealed	79	86	O	revealed	led	aled	VBD	False
DDI-MedLine.d94.s13	a	88	88	O	a	a	a	DT	False
DDI-MedLine.d94.s13	significant	90	100	O	significant	ant	cant	JJ	False
DDI-MedLine.d94.s13	decrease	102	109	O	decrease	ase	ease	NN	False
DDI-MedLine.d94.s13	by	111	112	O	by	by	by	IN	False
DDI-MedLine.d94.s13	approximately	114	126	O	approximately	ely	tely	RB	False
DDI-MedLine.d94.s13	30	128	129	O	30	30	30	CD	False
DDI-MedLine.d94.s13	%	130	130	O	%	%	%	NN	False
DDI-MedLine.d94.s13	in	132	133	O	in	in	in	IN	False
DDI-MedLine.d94.s13	norepinephrine	135	148	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s13	uptake-1	150	157	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s13	carrier	159	165	O	carrier	ier	rier	NN	False
DDI-MedLine.d94.s13	density	167	173	O	density	ity	sity	NN	False
DDI-MedLine.d94.s13	in	175	176	O	in	in	in	IN	False
DDI-MedLine.d94.s13	functional	178	187	O	functional	nal	onal	JJ	False
DDI-MedLine.d94.s13	classes	189	195	O	classes	ses	sses	NNS	False
DDI-MedLine.d94.s13	II	197	198	O	II	II	II	NN	brand
DDI-MedLine.d94.s13	to	200	201	O	to	to	to	TO	False
DDI-MedLine.d94.s13	III	203	205	O	III	III	III	NN	brand
DDI-MedLine.d94.s13	and	207	209	O	and	and	and	CC	False
DDI-MedLine.d94.s13	IV	211	212	O	IV	IV	IV	NN	brand
DDI-MedLine.d94.s13	myocardium	214	223	O	myocardium	ium	dium	NN	drug
DDI-MedLine.d94.s13	versus	225	230	O	versus	sus	rsus	NN	False
DDI-MedLine.d94.s13	nonfailing	232	241	O	nonfailing	ing	ling	VBG	False
DDI-MedLine.d94.s13	myocardium	243	252	O	myocardium	ium	dium	NN	drug
DDI-MedLine.d94.s13	(	254	254	O	(	(	(	(	False
DDI-MedLine.d94.s13	p	255	255	O	p	p	p	NN	False
DDI-MedLine.d94.s13	<	257	257	O	<	<	<	NN	False
DDI-MedLine.d94.s13	0.05	259	262	O	0.05	.05	0.05	CD	False
DDI-MedLine.d94.s13	)	263	263	O	)	)	)	)	False
DDI-MedLine.d94.s13	.	264	264	O	.	.	.	.	False

DDI-MedLine.d94.s14	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d94.s14	.	11	11	O	.	.	.	.	False

DDI-MedLine.d94.s15	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d94.s15	human	3	7	O	human	man	uman	NN	False
DDI-MedLine.d94.s15	heart	9	13	O	heart	art	eart	NN	False
DDI-MedLine.d94.s15	failure	15	21	O	failure	ure	lure	NN	False
DDI-MedLine.d94.s15	,	22	22	O	,	,	,	,	False
DDI-MedLine.d94.s15	there	24	28	O	there	ere	here	RB	False
DDI-MedLine.d94.s15	is	30	31	O	is	is	is	VBZ	False
DDI-MedLine.d94.s15	a	33	33	O	a	a	a	DT	False
DDI-MedLine.d94.s15	presynaptic	35	45	O	presynaptic	tic	ptic	JJ	False
DDI-MedLine.d94.s15	defect	47	52	O	defect	ect	fect	NN	False
DDI-MedLine.d94.s15	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d94.s15	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d94.s15	sympathetic	61	71	O	sympathetic	tic	etic	JJ	False
DDI-MedLine.d94.s15	nervous	73	79	O	nervous	ous	vous	JJ	False
DDI-MedLine.d94.s15	system	81	86	O	system	tem	stem	NN	False
DDI-MedLine.d94.s15	,	87	87	O	,	,	,	,	False
DDI-MedLine.d94.s15	leading	89	95	O	leading	ing	ding	VBG	False
DDI-MedLine.d94.s15	to	97	98	O	to	to	to	TO	False
DDI-MedLine.d94.s15	reduced	100	106	O	reduced	ced	uced	VBN	False
DDI-MedLine.d94.s15	uptake-1	108	115	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s15	activity	117	124	O	activity	ity	vity	NN	False
DDI-MedLine.d94.s15	.	125	125	O	.	.	.	.	False

DDI-MedLine.d94.s16	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d94.s16	defect	5	10	O	defect	ect	fect	NN	False
DDI-MedLine.d94.s16	in	12	13	O	in	in	in	IN	False
DDI-MedLine.d94.s16	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d94.s16	failing	19	25	O	failing	ing	ling	VBG	False
DDI-MedLine.d94.s16	heart	27	31	O	heart	art	eart	NN	False
DDI-MedLine.d94.s16	can	33	35	O	can	can	can	MD	False
DDI-MedLine.d94.s16	be	37	38	O	be	be	be	VB	False
DDI-MedLine.d94.s16	mimicked	40	47	O	mimicked	ked	cked	NNS	False
DDI-MedLine.d94.s16	by	49	50	O	by	by	by	IN	False
DDI-MedLine.d94.s16	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d94.s16	effects	56	62	O	effects	cts	ects	NNS	False
DDI-MedLine.d94.s16	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d94.s16	uptake	67	72	O	uptake	ake	take	NN	False
DDI-MedLine.d94.s16	blocking	74	81	O	blocking	ing	king	VBG	False
DDI-MedLine.d94.s16	agents	83	88	O	agents	nts	ents	NNS	False
DDI-MedLine.d94.s16	,	89	89	O	,	,	,	,	False
DDI-MedLine.d94.s16	such	91	94	O	such	uch	such	JJ	False
DDI-MedLine.d94.s16	as	96	97	O	as	as	as	IN	False
DDI-MedLine.d94.s16	cocaine	99	105	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d94.s16	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d94.s16	desipramine	111	121	B-drug	desipramine	ine	mine	NN	drug
DDI-MedLine.d94.s16	,	122	122	O	,	,	,	,	False
DDI-MedLine.d94.s16	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d94.s16	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d94.s16	nonfailing	131	140	O	nonfailing	ing	ling	VBG	False
DDI-MedLine.d94.s16	heart	142	146	O	heart	art	eart	NN	False
DDI-MedLine.d94.s16	only	148	151	O	only	nly	only	RB	False
DDI-MedLine.d94.s16	.	152	152	O	.	.	.	.	False

DDI-MedLine.d94.s17	Compromised	0	10	O	Compromised	sed	ised	VBN	False
DDI-MedLine.d94.s17	norepinephrine	12	25	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s17	uptake-1	27	34	O	uptake-1	e-1	ke-1	JJ	False
DDI-MedLine.d94.s17	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d94.s17	functional	39	48	O	functional	nal	onal	JJ	False
DDI-MedLine.d94.s17	class	50	54	O	class	ass	lass	NN	False
DDI-MedLine.d94.s17	IV	56	57	O	IV	IV	IV	NN	brand
DDI-MedLine.d94.s17	can	59	61	O	can	can	can	MD	False
DDI-MedLine.d94.s17	not	62	64	O	not	not	not	RB	False
DDI-MedLine.d94.s17	be	66	67	O	be	be	be	VB	False
DDI-MedLine.d94.s17	further	69	75	O	further	her	ther	RB	False
DDI-MedLine.d94.s17	increased	77	85	O	increased	sed	ased	VBN	False
DDI-MedLine.d94.s17	by	87	88	O	by	by	by	IN	False
DDI-MedLine.d94.s17	cocaine	90	96	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d94.s17	and	98	100	O	and	and	and	CC	False
DDI-MedLine.d94.s17	desipramine	102	112	B-drug	desipramine	ine	mine	NN	drug
DDI-MedLine.d94.s17	.	113	113	O	.	.	.	.	False

DDI-MedLine.d94.s18	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d94.s18	pathophysiologic	4	19	O	pathophysiologic	gic	ogic	NN	False
DDI-MedLine.d94.s18	consequences	21	32	O	consequences	ces	nces	NNS	False
DDI-MedLine.d94.s18	could	34	38	O	could	uld	ould	MD	False
DDI-MedLine.d94.s18	be	40	41	O	be	be	be	VB	False
DDI-MedLine.d94.s18	an	43	44	O	an	an	an	DT	False
DDI-MedLine.d94.s18	increased	46	54	O	increased	sed	ased	VBN	False
DDI-MedLine.d94.s18	synaptic	56	63	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d94.s18	concentration	65	77	O	concentration	ion	tion	NN	False
DDI-MedLine.d94.s18	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d94.s18	norepinephrine	82	95	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d94.s18	predisposing	97	108	O	predisposing	ing	sing	VBG	False
DDI-MedLine.d94.s18	to	110	111	O	to	to	to	TO	False
DDI-MedLine.d94.s18	adenylyl	113	120	O	adenylyl	lyl	ylyl	NN	False
DDI-MedLine.d94.s18	cyclase	122	128	O	cyclase	ase	lase	NN	False
DDI-MedLine.d94.s18	desensitization	130	144	O	desensitization	ion	tion	NN	False
DDI-MedLine.d94.s18	.	145	145	O	.	.	.	.	False

DDI-MedLine.d3.s0	Pharmacokinetic	0	14	O	Pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d3.s0	Interaction	16	26	O	Interaction	ion	tion	NN	False
DDI-MedLine.d3.s0	between	28	34	O	between	een	ween	IN	False
DDI-MedLine.d3.s0	amprenavir	36	45	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s0	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d3.s0	rifabutin	51	59	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s0	or	61	62	O	or	or	or	CC	False
DDI-MedLine.d3.s0	rifampin	64	71	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s0	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d3.s0	healthy	76	82	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d3.s0	males	84	88	O	males	les	ales	NNS	False
DDI-MedLine.d3.s0	.	89	89	O	.	.	.	.	False

DDI-MedLine.d3.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d3.s1	objective	4	12	O	objective	ive	tive	NN	False
DDI-MedLine.d3.s1	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d3.s1	this	17	20	O	this	his	this	DT	False
DDI-MedLine.d3.s1	study	22	26	O	study	udy	tudy	NN	False
DDI-MedLine.d3.s1	was	28	30	O	was	was	was	VBD	False
DDI-MedLine.d3.s1	to	32	33	O	to	to	to	TO	False
DDI-MedLine.d3.s1	determine	35	43	O	determine	ine	mine	NN	drug
DDI-MedLine.d3.s1	if	45	46	O	if	if	if	IN	False
DDI-MedLine.d3.s1	there	48	52	O	there	ere	here	RB	False
DDI-MedLine.d3.s1	is	54	55	O	is	is	is	VBZ	False
DDI-MedLine.d3.s1	a	57	57	O	a	a	a	DT	False
DDI-MedLine.d3.s1	pharmacokinetic	59	73	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d3.s1	interaction	75	85	O	interaction	ion	tion	NN	False
DDI-MedLine.d3.s1	when	87	90	O	when	hen	when	WRB	False
DDI-MedLine.d3.s1	amprenavir	92	101	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s1	is	103	104	O	is	is	is	VBZ	False
DDI-MedLine.d3.s1	given	106	110	O	given	ven	iven	VBN	False
DDI-MedLine.d3.s1	with	112	115	O	with	ith	with	IN	False
DDI-MedLine.d3.s1	rifabutin	117	125	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s1	or	127	128	O	or	or	or	CC	False
DDI-MedLine.d3.s1	rifampin	130	137	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s1	and	139	141	O	and	and	and	CC	False
DDI-MedLine.d3.s1	to	143	144	O	to	to	to	TO	False
DDI-MedLine.d3.s1	determine	146	154	O	determine	ine	mine	NN	drug
DDI-MedLine.d3.s1	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d3.s1	effects	160	166	O	effects	cts	ects	NNS	False
DDI-MedLine.d3.s1	of	168	169	O	of	of	of	IN	False
DDI-MedLine.d3.s1	these	171	175	O	these	ese	hese	DT	False
DDI-MedLine.d3.s1	drugs	177	181	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d3.s1	on	183	184	O	on	on	on	IN	False
DDI-MedLine.d3.s1	the	186	188	O	the	the	the	DT	False
DDI-MedLine.d3.s1	erythromycin	190	201	O	erythromycin	cin	ycin	NN	drug
DDI-MedLine.d3.s1	breath	203	208	O	breath	ath	eath	NN	False
DDI-MedLine.d3.s1	test	210	213	O	test	est	test	NN	False
DDI-MedLine.d3.s1	(	215	215	O	(	(	(	(	False
DDI-MedLine.d3.s1	ERMBT	216	220	O	ERMBT	MBT	RMBT	NN	brand
DDI-MedLine.d3.s1	)	221	221	O	)	)	)	)	False
DDI-MedLine.d3.s1	.	222	222	O	.	.	.	.	False

DDI-MedLine.d3.s2	Twenty-four	0	10	O	Twenty-four	our	four	NN	False
DDI-MedLine.d3.s2	healthy	12	18	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d3.s2	male	20	23	O	male	ale	male	NN	False
DDI-MedLine.d3.s2	subjects	25	32	O	subjects	cts	ects	NNS	False
DDI-MedLine.d3.s2	were	34	37	O	were	ere	were	VBD	False
DDI-MedLine.d3.s2	randomized	39	48	O	randomized	zed	ized	VBN	False
DDI-MedLine.d3.s2	to	50	51	O	to	to	to	TO	False
DDI-MedLine.d3.s2	one	53	55	O	one	one	one	CD	False
DDI-MedLine.d3.s2	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d3.s2	two	60	62	O	two	two	two	CD	False
DDI-MedLine.d3.s2	cohorts	64	70	O	cohorts	rts	orts	NNS	False
DDI-MedLine.d3.s2	.	71	71	O	.	.	.	.	False

DDI-MedLine.d3.s3	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d3.s3	subjects	4	11	O	subjects	cts	ects	NNS	False
DDI-MedLine.d3.s3	received	13	20	O	received	ved	ived	VBN	False
DDI-MedLine.d3.s3	amprenavir	22	31	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s3	(	33	33	O	(	(	(	(	False
DDI-MedLine.d3.s3	1,200	34	38	O	1,200	200	,200	CD	False
DDI-MedLine.d3.s3	mg	40	41	O	mg	mg	mg	NN	False
DDI-MedLine.d3.s3	twice	43	47	O	twice	ice	wice	RB	False
DDI-MedLine.d3.s3	a	49	49	O	a	a	a	DT	False
DDI-MedLine.d3.s3	day	51	53	O	day	day	day	NN	False
DDI-MedLine.d3.s3	)	54	54	O	)	)	)	)	False
DDI-MedLine.d3.s3	for	56	58	O	for	for	for	IN	False
DDI-MedLine.d3.s3	4	60	60	O	4	4	4	CD	False
DDI-MedLine.d3.s3	days	62	65	O	days	ays	days	NNS	False
DDI-MedLine.d3.s3	,	66	66	O	,	,	,	,	False
DDI-MedLine.d3.s3	followed	68	75	O	followed	wed	owed	VBD	False
DDI-MedLine.d3.s3	by	77	78	O	by	by	by	IN	False
DDI-MedLine.d3.s3	a	80	80	O	a	a	a	DT	False
DDI-MedLine.d3.s3	7-day	82	86	O	7-day	day	-day	JJ	False
DDI-MedLine.d3.s3	washout	88	94	O	washout	out	hout	NN	False
DDI-MedLine.d3.s3	period	96	101	O	period	iod	riod	NN	False
DDI-MedLine.d3.s3	,	102	102	O	,	,	,	,	False
DDI-MedLine.d3.s3	followed	104	111	O	followed	wed	owed	VBD	False
DDI-MedLine.d3.s3	by	113	114	O	by	by	by	IN	False
DDI-MedLine.d3.s3	either	116	121	O	either	her	ther	DT	False
DDI-MedLine.d3.s3	rifabutin	123	131	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s3	(	133	133	O	(	(	(	(	False
DDI-MedLine.d3.s3	300	134	136	O	300	300	300	CD	False
DDI-MedLine.d3.s3	mg	138	139	O	mg	mg	mg	NN	False
DDI-MedLine.d3.s3	once	141	144	O	once	nce	once	RB	False
DDI-MedLine.d3.s3	a	146	146	O	a	a	a	DT	False
DDI-MedLine.d3.s3	day	148	150	O	day	day	day	NN	False
DDI-MedLine.d3.s3	[	152	152	O	[	[	[	NN	False
DDI-MedLine.d3.s3	QD	153	154	O	QD	QD	QD	NN	brand
DDI-MedLine.d3.s3	]	155	155	O	]	]	]	NN	False
DDI-MedLine.d3.s3	)	156	156	O	)	)	)	)	False
DDI-MedLine.d3.s3	(	158	158	O	(	(	(	(	False
DDI-MedLine.d3.s3	cohort	159	164	O	cohort	ort	hort	NN	False
DDI-MedLine.d3.s3	1	166	166	O	1	1	1	CD	False
DDI-MedLine.d3.s3	)	167	167	O	)	)	)	)	False
DDI-MedLine.d3.s3	or	169	170	O	or	or	or	CC	False
DDI-MedLine.d3.s3	rifampin	172	179	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s3	(	181	181	O	(	(	(	(	False
DDI-MedLine.d3.s3	600	182	184	O	600	600	600	CD	False
DDI-MedLine.d3.s3	mg	186	187	O	mg	mg	mg	NN	False
DDI-MedLine.d3.s3	QD	189	190	O	QD	QD	QD	NN	brand
DDI-MedLine.d3.s3	)	191	191	O	)	)	)	)	False
DDI-MedLine.d3.s3	(	193	193	O	(	(	(	(	False
DDI-MedLine.d3.s3	cohort	194	199	O	cohort	ort	hort	NN	False
DDI-MedLine.d3.s3	2	201	201	O	2	2	2	CD	False
DDI-MedLine.d3.s3	)	202	202	O	)	)	)	)	False
DDI-MedLine.d3.s3	for	204	206	O	for	for	for	IN	False
DDI-MedLine.d3.s3	14	208	209	O	14	14	14	CD	False
DDI-MedLine.d3.s3	days	211	214	O	days	ays	days	NNS	False
DDI-MedLine.d3.s3	.	215	215	O	.	.	.	.	False

DDI-MedLine.d3.s4	Cohort	0	5	O	Cohort	ort	hort	NN	False
DDI-MedLine.d3.s4	1	7	7	O	1	1	1	CD	False
DDI-MedLine.d3.s4	then	9	12	O	then	hen	then	RB	False
DDI-MedLine.d3.s4	received	14	21	O	received	ved	ived	VBN	False
DDI-MedLine.d3.s4	amprenavir	23	32	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s4	plus	34	37	O	plus	lus	plus	CC	False
DDI-MedLine.d3.s4	rifabutin	39	47	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s4	for	49	51	O	for	for	for	IN	False
DDI-MedLine.d3.s4	10	53	54	O	10	10	10	CD	False
DDI-MedLine.d3.s4	days	56	59	O	days	ays	days	NNS	False
DDI-MedLine.d3.s4	,	60	60	O	,	,	,	,	False
DDI-MedLine.d3.s4	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d3.s4	cohort	66	71	O	cohort	ort	hort	NN	False
DDI-MedLine.d3.s4	2	73	73	O	2	2	2	CD	False
DDI-MedLine.d3.s4	received	75	82	O	received	ved	ived	VBN	False
DDI-MedLine.d3.s4	amprenavir	84	93	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s4	plus	95	98	O	plus	lus	plus	CC	False
DDI-MedLine.d3.s4	rifampin	100	107	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s4	for	109	111	O	for	for	for	IN	False
DDI-MedLine.d3.s4	4	113	113	O	4	4	4	CD	False
DDI-MedLine.d3.s4	days	115	118	O	days	ays	days	NNS	False
DDI-MedLine.d3.s4	.	119	119	O	.	.	.	.	False

DDI-MedLine.d3.s5	Serial	0	5	O	Serial	ial	rial	JJ	False
DDI-MedLine.d3.s5	plasma	7	12	O	plasma	sma	asma	NN	False
DDI-MedLine.d3.s5	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d3.s5	urine	18	22	O	urine	ine	rine	NN	drug
DDI-MedLine.d3.s5	samples	24	30	O	samples	les	ples	NNS	False
DDI-MedLine.d3.s5	for	32	34	O	for	for	for	IN	False
DDI-MedLine.d3.s5	measurement	36	46	O	measurement	ent	ment	NN	False
DDI-MedLine.d3.s5	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d3.s5	amprenavir	51	60	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s5	,	61	61	O	,	,	,	,	False
DDI-MedLine.d3.s5	rifabutin	63	71	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s5	,	72	72	O	,	,	,	,	False
DDI-MedLine.d3.s5	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d3.s5	rifampin	78	85	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s5	and	87	89	O	and	and	and	CC	False
DDI-MedLine.d3.s5	their	91	95	O	their	eir	heir	PRP$	False
DDI-MedLine.d3.s5	25-O-desacetyl	97	110	B-drug_n	25-O-desacetyl	tyl	etyl	JJ	False
DDI-MedLine.d3.s5	metabolites	112	122	I-drug_n	metabolites	tes	ites	NNS	False
DDI-MedLine.d3.s5	,	123	123	O	,	,	,	,	False
DDI-MedLine.d3.s5	were	125	128	O	were	ere	were	VBD	False
DDI-MedLine.d3.s5	measured	130	137	O	measured	red	ured	VBN	False
DDI-MedLine.d3.s5	by	139	140	O	by	by	by	IN	False
DDI-MedLine.d3.s5	high-performance	142	157	O	high-performance	nce	ance	NN	False
DDI-MedLine.d3.s5	liquid	159	164	O	liquid	uid	quid	NN	False
DDI-MedLine.d3.s5	chromatography	166	179	O	chromatography	phy	aphy	NN	False
DDI-MedLine.d3.s5	.	180	180	O	.	.	.	.	False

DDI-MedLine.d3.s6	Rifabutin	0	8	B-drug	Rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s6	did	10	12	O	did	did	did	VBD	False
DDI-MedLine.d3.s6	not	14	16	O	not	not	not	RB	False
DDI-MedLine.d3.s6	significantly	18	30	O	significantly	tly	ntly	RB	False
DDI-MedLine.d3.s6	affect	32	37	O	affect	ect	fect	NN	False
DDI-MedLine.d3.s6	amprenavir	39	48	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s6	's	49	50	O	's	's	's	POS	False
DDI-MedLine.d3.s6	pharmacokinetics	52	67	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d3.s6	.	68	68	O	.	.	.	.	False

DDI-MedLine.d3.s7	Amprenavir	0	9	B-drug	Amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s7	significantly	11	23	O	significantly	tly	ntly	RB	False
DDI-MedLine.d3.s7	increased	25	33	O	increased	sed	ased	VBN	False
DDI-MedLine.d3.s7	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d3.s7	area	39	42	O	area	rea	area	NN	False
DDI-MedLine.d3.s7	under	44	48	O	under	der	nder	IN	False
DDI-MedLine.d3.s7	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d3.s7	curve	54	58	O	curve	rve	urve	NN	False
DDI-MedLine.d3.s7	at	60	61	O	at	at	at	IN	False
DDI-MedLine.d3.s7	steady	63	68	O	steady	ady	eady	JJ	False
DDI-MedLine.d3.s7	state	70	74	O	state	ate	tate	NN	False
DDI-MedLine.d3.s7	(	76	76	O	(	(	(	(	False
DDI-MedLine.d3.s7	AUC	77	79	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d3.s7	(	80	80	O	(	(	(	(	False
DDI-MedLine.d3.s7	ss	81	82	O	ss	ss	ss	NN	False
DDI-MedLine.d3.s7	)	83	83	O	)	)	)	)	False
DDI-MedLine.d3.s7	)	84	84	O	)	)	)	)	False
DDI-MedLine.d3.s7	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d3.s7	rifabutin	89	97	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s7	by	99	100	O	by	by	by	IN	False
DDI-MedLine.d3.s7	2.93-fold	102	110	O	2.93-fold	old	fold	JJ	False
DDI-MedLine.d3.s7	and	112	114	O	and	and	and	CC	False
DDI-MedLine.d3.s7	the	116	118	O	the	the	the	DT	False
DDI-MedLine.d3.s7	AUC	120	122	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d3.s7	(	123	123	O	(	(	(	(	False
DDI-MedLine.d3.s7	ss	124	125	O	ss	ss	ss	NN	False
DDI-MedLine.d3.s7	)	126	126	O	)	)	)	)	False
DDI-MedLine.d3.s7	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d3.s7	25-O-desacetylrifabutin	131	153	B-drug_n	25-O-desacetylrifabutin	tin	utin	JJ	False
DDI-MedLine.d3.s7	by	155	156	O	by	by	by	IN	False
DDI-MedLine.d3.s7	13.3-fold	158	166	O	13.3-fold	old	fold	JJ	False
DDI-MedLine.d3.s7	.	167	167	O	.	.	.	.	False

DDI-MedLine.d3.s8	Rifampin	0	7	B-drug	Rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s8	significantly	9	21	O	significantly	tly	ntly	RB	False
DDI-MedLine.d3.s8	decreased	23	31	O	decreased	sed	ased	VBN	False
DDI-MedLine.d3.s8	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d3.s8	AUC	37	39	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d3.s8	(	40	40	O	(	(	(	(	False
DDI-MedLine.d3.s8	ss	41	42	O	ss	ss	ss	NN	False
DDI-MedLine.d3.s8	)	43	43	O	)	)	)	)	False
DDI-MedLine.d3.s8	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d3.s8	amprenavir	48	57	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s8	by	59	60	O	by	by	by	IN	False
DDI-MedLine.d3.s8	82	62	63	O	82	82	82	CD	False
DDI-MedLine.d3.s8	%	64	64	O	%	%	%	NN	False
DDI-MedLine.d3.s8	,	65	65	O	,	,	,	,	False
DDI-MedLine.d3.s8	but	67	69	O	but	but	but	CC	False
DDI-MedLine.d3.s8	amprenavir	71	80	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s8	had	82	84	O	had	had	had	VBD	False
DDI-MedLine.d3.s8	no	86	87	O	no	no	no	DT	False
DDI-MedLine.d3.s8	effect	89	94	O	effect	ect	fect	NN	False
DDI-MedLine.d3.s8	on	96	97	O	on	on	on	IN	False
DDI-MedLine.d3.s8	rifampin	99	106	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s8	pharmacokinetics	108	123	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d3.s8	.	124	124	O	.	.	.	.	False

DDI-MedLine.d3.s9	Amprenavir	0	9	B-drug	Amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s9	decreased	11	19	O	decreased	sed	ased	VBN	False
DDI-MedLine.d3.s9	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d3.s9	results	25	31	O	results	lts	ults	NNS	False
DDI-MedLine.d3.s9	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d3.s9	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d3.s9	ERMBT	40	44	O	ERMBT	MBT	RMBT	NN	brand
DDI-MedLine.d3.s9	by	46	47	O	by	by	by	IN	False
DDI-MedLine.d3.s9	83	49	50	O	83	83	83	CD	False
DDI-MedLine.d3.s9	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d3.s9	.	52	52	O	.	.	.	.	False

DDI-MedLine.d3.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d3.s10	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d3.s10	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d3.s10	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d3.s10	ERMBT	19	23	O	ERMBT	MBT	RMBT	NN	brand
DDI-MedLine.d3.s10	after	25	29	O	after	ter	fter	IN	False
DDI-MedLine.d3.s10	2	31	31	O	2	2	2	CD	False
DDI-MedLine.d3.s10	weeks	33	37	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d3.s10	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d3.s10	rifabutin	42	50	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s10	and	52	54	O	and	and	and	CC	False
DDI-MedLine.d3.s10	rifampin	56	63	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s10	therapy	65	71	O	therapy	apy	rapy	NN	False
DDI-MedLine.d3.s10	were	73	76	O	were	ere	were	VBD	False
DDI-MedLine.d3.s10	increased	78	86	O	increased	sed	ased	VBN	False
DDI-MedLine.d3.s10	187	88	90	O	187	187	187	CD	False
DDI-MedLine.d3.s10	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d3.s10	156	96	98	O	156	156	156	CD	False
DDI-MedLine.d3.s10	%	99	99	O	%	%	%	NN	False
DDI-MedLine.d3.s10	,	100	100	O	,	,	,	,	False
DDI-MedLine.d3.s10	respectively	102	113	O	respectively	ely	vely	RB	False
DDI-MedLine.d3.s10	.	114	114	O	.	.	.	.	False

DDI-MedLine.d3.s11	Amprenavir	0	9	B-drug	Amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s11	plus	11	14	O	plus	lus	plus	CC	False
DDI-MedLine.d3.s11	rifampin	16	23	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s11	was	25	27	O	was	was	was	VBD	False
DDI-MedLine.d3.s11	well	29	32	O	well	ell	well	RB	False
DDI-MedLine.d3.s11	tolerated	34	42	O	tolerated	ted	ated	VBN	False
DDI-MedLine.d3.s11	.	43	43	O	.	.	.	.	False

DDI-MedLine.d3.s12	Amprenavir	0	9	B-drug	Amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s12	plus	11	14	O	plus	lus	plus	CC	False
DDI-MedLine.d3.s12	rifabutin	16	24	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s12	was	26	28	O	was	was	was	VBD	False
DDI-MedLine.d3.s12	poorly	30	35	O	poorly	rly	orly	RB	False
DDI-MedLine.d3.s12	tolerated	37	45	O	tolerated	ted	ated	VBN	False
DDI-MedLine.d3.s12	,	46	46	O	,	,	,	,	False
DDI-MedLine.d3.s12	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d3.s12	5	52	52	O	5	5	5	CD	False
DDI-MedLine.d3.s12	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d3.s12	11	57	58	O	11	11	11	CD	False
DDI-MedLine.d3.s12	subjects	60	67	O	subjects	cts	ects	NNS	False
DDI-MedLine.d3.s12	discontinued	69	80	O	discontinued	ued	nued	VBN	False
DDI-MedLine.d3.s12	therapy	82	88	O	therapy	apy	rapy	NN	False
DDI-MedLine.d3.s12	.	89	89	O	.	.	.	.	False

DDI-MedLine.d3.s13	Rifampin	0	7	B-drug	Rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s13	markedly	9	16	O	markedly	dly	edly	RB	False
DDI-MedLine.d3.s13	increases	18	26	O	increases	ses	ases	NNS	False
DDI-MedLine.d3.s13	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d3.s13	metabolic	32	40	O	metabolic	lic	olic	NN	False
DDI-MedLine.d3.s13	clearance	42	50	O	clearance	nce	ance	NN	False
DDI-MedLine.d3.s13	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d3.s13	amprenavir	55	64	B-drug	amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s13	,	65	65	O	,	,	,	,	False
DDI-MedLine.d3.s13	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d3.s13	coadministration	71	86	O	coadministration	ion	tion	NN	False
DDI-MedLine.d3.s13	is	88	89	O	is	is	is	VBZ	False
DDI-MedLine.d3.s13	contraindicated	91	105	O	contraindicated	ted	ated	VBN	False
DDI-MedLine.d3.s13	.	106	106	O	.	.	.	.	False

DDI-MedLine.d3.s14	Amprenavir	0	9	B-drug	Amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s14	significantly	11	23	O	significantly	tly	ntly	RB	False
DDI-MedLine.d3.s14	decreases	25	33	O	decreases	ses	ases	NNS	False
DDI-MedLine.d3.s14	clearance	35	43	O	clearance	nce	ance	NN	False
DDI-MedLine.d3.s14	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d3.s14	rifabutin	48	56	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s14	and	58	60	O	and	and	and	CC	False
DDI-MedLine.d3.s14	25-O-desacetylrifabutin	62	84	B-drug_n	25-O-desacetylrifabutin	tin	utin	JJ	False
DDI-MedLine.d3.s14	,	85	85	O	,	,	,	,	False
DDI-MedLine.d3.s14	and	87	89	O	and	and	and	CC	False
DDI-MedLine.d3.s14	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d3.s14	combination	95	105	O	combination	ion	tion	NN	False
DDI-MedLine.d3.s14	is	107	108	O	is	is	is	VBZ	False
DDI-MedLine.d3.s14	poorly	110	115	O	poorly	rly	orly	RB	False
DDI-MedLine.d3.s14	tolerated	117	125	O	tolerated	ted	ated	VBN	False
DDI-MedLine.d3.s14	.	126	126	O	.	.	.	.	False

DDI-MedLine.d3.s15	Amprenavir	0	9	B-drug	Amprenavir	vir	avir	NN	False
DDI-MedLine.d3.s15	inhibits	11	18	O	inhibits	its	bits	NNS	False
DDI-MedLine.d3.s15	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d3.s15	ERMBT	24	28	O	ERMBT	MBT	RMBT	NN	brand
DDI-MedLine.d3.s15	,	29	29	O	,	,	,	,	False
DDI-MedLine.d3.s15	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d3.s15	rifampin	35	42	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d3.s15	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d3.s15	rifabutin	48	56	B-drug	rifabutin	tin	utin	NN	False
DDI-MedLine.d3.s15	are	58	60	O	are	are	are	VBP	False
DDI-MedLine.d3.s15	equipotent	62	71	O	equipotent	ent	tent	NN	False
DDI-MedLine.d3.s15	inducers	73	80	O	inducers	ers	cers	NNS	False
DDI-MedLine.d3.s15	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d3.s15	the	85	87	O	the	the	the	DT	False
DDI-MedLine.d3.s15	ERMBT	89	93	O	ERMBT	MBT	RMBT	NN	brand
DDI-MedLine.d3.s15	.	94	94	O	.	.	.	.	False

DDI-MedLine.d56.s0	Dual	0	3	O	Dual	ual	Dual	JJ	False
DDI-MedLine.d56.s0	effect	5	10	O	effect	ect	fect	NN	False
DDI-MedLine.d56.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d56.s0	ouabain	15	21	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d56.s0	on	23	24	O	on	on	on	IN	False
DDI-MedLine.d56.s0	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d56.s0	palytoxin-induced	30	46	O	palytoxin-induced	ced	uced	JJ	False
DDI-MedLine.d56.s0	contraction	48	58	O	contraction	ion	tion	NN	False
DDI-MedLine.d56.s0	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d56.s0	norepinephrine	64	77	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d56.s0	release	79	85	O	release	ase	ease	NN	False
DDI-MedLine.d56.s0	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d56.s0	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d56.s0	guinea-pig	94	103	O	guinea-pig	pig	-pig	NN	False
DDI-MedLine.d56.s0	vas	105	107	O	vas	vas	vas	NN	False
DDI-MedLine.d56.s0	deferens	109	116	O	deferens	ens	rens	NNS	False
DDI-MedLine.d56.s0	.	117	117	O	.	.	.	.	False

DDI-MedLine.d56.s1	Palytoxin	0	8	B-drug_n	Palytoxin	xin	oxin	NN	False
DDI-MedLine.d56.s1	(	10	10	O	(	(	(	(	False
DDI-MedLine.d56.s1	PTX	11	13	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s1	)	14	14	O	)	)	)	)	False
DDI-MedLine.d56.s1	,	15	15	O	,	,	,	,	False
DDI-MedLine.d56.s1	C129H223N3O54	17	29	O	C129H223N3O54	O54	3O54	NN	brand
DDI-MedLine.d56.s1	,	30	30	O	,	,	,	,	False
DDI-MedLine.d56.s1	isolated	32	39	O	isolated	ted	ated	JJ	False
DDI-MedLine.d56.s1	from	41	44	O	from	rom	from	IN	False
DDI-MedLine.d56.s1	marine	46	51	O	marine	ine	rine	NN	drug
DDI-MedLine.d56.s1	coelenterates	53	65	O	coelenterates	tes	ates	NNS	False
DDI-MedLine.d56.s1	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d56.s1	Palythoa	70	77	O	Palythoa	hoa	thoa	NN	False
DDI-MedLine.d56.s1	tuberculosa	79	89	O	tuberculosa	osa	losa	NN	False
DDI-MedLine.d56.s1	,	90	90	O	,	,	,	,	False
DDI-MedLine.d56.s1	caused	92	97	O	caused	sed	used	VBN	False
DDI-MedLine.d56.s1	a	99	99	O	a	a	a	DT	False
DDI-MedLine.d56.s1	first	101	105	O	first	rst	irst	RB	False
DDI-MedLine.d56.s1	rapid	107	111	O	rapid	pid	apid	JJ	False
DDI-MedLine.d56.s1	contraction	113	123	O	contraction	ion	tion	NN	False
DDI-MedLine.d56.s1	followed	125	132	O	followed	wed	owed	VBD	False
DDI-MedLine.d56.s1	by	134	135	O	by	by	by	IN	False
DDI-MedLine.d56.s1	the	137	139	O	the	the	the	DT	False
DDI-MedLine.d56.s1	slow	141	144	O	slow	low	slow	VB	False
DDI-MedLine.d56.s1	phasic	146	151	O	phasic	sic	asic	NN	False
DDI-MedLine.d56.s1	contraction	153	163	O	contraction	ion	tion	NN	False
DDI-MedLine.d56.s1	of	165	166	O	of	of	of	IN	False
DDI-MedLine.d56.s1	guinea-pig	168	177	O	guinea-pig	pig	-pig	NN	False
DDI-MedLine.d56.s1	vas	179	181	O	vas	vas	vas	NN	False
DDI-MedLine.d56.s1	deferens	183	190	O	deferens	ens	rens	NNS	False
DDI-MedLine.d56.s1	.	191	191	O	.	.	.	.	False

DDI-MedLine.d56.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d56.s2	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d56.s2	presence	7	14	O	presence	nce	ence	NN	False
DDI-MedLine.d56.s2	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d56.s2	ouabain	19	25	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d56.s2	(	27	27	O	(	(	(	(	False
DDI-MedLine.d56.s2	10	28	29	O	10	10	10	CD	False
DDI-MedLine.d56.s2	(	30	30	O	(	(	(	(	False
DDI-MedLine.d56.s2	-5	31	32	O	-5	-5	-5	NN	False
DDI-MedLine.d56.s2	)	33	33	O	)	)	)	)	False
DDI-MedLine.d56.s2	M	35	35	O	M	M	M	NN	brand
DDI-MedLine.d56.s2	)	36	36	O	)	)	)	)	False
DDI-MedLine.d56.s2	,	37	37	O	,	,	,	,	False
DDI-MedLine.d56.s2	PTX	39	41	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s2	(	43	43	O	(	(	(	(	False
DDI-MedLine.d56.s2	10	44	45	O	10	10	10	CD	False
DDI-MedLine.d56.s2	(	46	46	O	(	(	(	(	False
DDI-MedLine.d56.s2	-8	47	48	O	-8	-8	-8	NN	False
DDI-MedLine.d56.s2	)	49	49	O	)	)	)	)	False
DDI-MedLine.d56.s2	M	51	51	O	M	M	M	NN	brand
DDI-MedLine.d56.s2	)	52	52	O	)	)	)	)	False
DDI-MedLine.d56.s2	failed	54	59	O	failed	led	iled	VBD	False
DDI-MedLine.d56.s2	to	61	62	O	to	to	to	TO	False
DDI-MedLine.d56.s2	cause	64	68	O	cause	use	ause	NN	False
DDI-MedLine.d56.s2	the	70	72	O	the	the	the	DT	False
DDI-MedLine.d56.s2	first	74	78	O	first	rst	irst	RB	False
DDI-MedLine.d56.s2	contraction	80	90	O	contraction	ion	tion	NN	False
DDI-MedLine.d56.s2	;	91	91	O	;	;	;	:	False

DDI-MedLine.d56.s3	however	0	6	O	however	ver	ever	RB	False
DDI-MedLine.d56.s3	,	7	7	O	,	,	,	,	False
DDI-MedLine.d56.s3	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d56.s3	second	13	18	O	second	ond	cond	JJ	False
DDI-MedLine.d56.s3	contraction	20	30	O	contraction	ion	tion	NN	False
DDI-MedLine.d56.s3	was	32	34	O	was	was	was	VBD	False
DDI-MedLine.d56.s3	potentiated	36	46	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d56.s3	.	47	47	O	.	.	.	.	False

DDI-MedLine.d56.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d56.s4	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d56.s4	presence	7	14	O	presence	nce	ence	NN	False
DDI-MedLine.d56.s4	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d56.s4	phentolamine	19	30	B-drug	phentolamine	ine	mine	NN	drug
DDI-MedLine.d56.s4	(	32	32	O	(	(	(	(	False
DDI-MedLine.d56.s4	10	33	34	O	10	10	10	CD	False
DDI-MedLine.d56.s4	(	35	35	O	(	(	(	(	False
DDI-MedLine.d56.s4	-6	36	37	O	-6	-6	-6	NN	False
DDI-MedLine.d56.s4	)	38	38	O	)	)	)	)	False
DDI-MedLine.d56.s4	M	40	40	O	M	M	M	NN	brand
DDI-MedLine.d56.s4	)	41	41	O	)	)	)	)	False
DDI-MedLine.d56.s4	,	42	42	O	,	,	,	,	False
DDI-MedLine.d56.s4	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d56.s4	second	48	53	O	second	ond	cond	JJ	False
DDI-MedLine.d56.s4	contraction	55	65	O	contraction	ion	tion	NN	False
DDI-MedLine.d56.s4	was	67	69	O	was	was	was	VBD	False
DDI-MedLine.d56.s4	inhibited	71	79	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d56.s4	selectively	81	91	O	selectively	ely	vely	RB	False
DDI-MedLine.d56.s4	.	92	92	O	.	.	.	.	False

DDI-MedLine.d56.s5	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d56.s5	ouabain	5	11	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d56.s5	was	13	15	O	was	was	was	VBD	False
DDI-MedLine.d56.s5	applied	17	23	O	applied	ied	lied	VBN	False
DDI-MedLine.d56.s5	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d56.s5	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d56.s5	muscle	32	37	O	muscle	cle	scle	NN	False
DDI-MedLine.d56.s5	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d56.s5	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d56.s5	presence	46	53	O	presence	nce	ence	NN	False
DDI-MedLine.d56.s5	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d56.s5	phentolamine	58	69	B-drug	phentolamine	ine	mine	NN	drug
DDI-MedLine.d56.s5	,	70	70	O	,	,	,	,	False
DDI-MedLine.d56.s5	both	72	75	O	both	oth	both	DT	False
DDI-MedLine.d56.s5	first	77	81	O	first	rst	irst	RB	False
DDI-MedLine.d56.s5	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d56.s5	second	87	92	O	second	ond	cond	JJ	False
DDI-MedLine.d56.s5	contractile	94	104	O	contractile	ile	tile	NN	False
DDI-MedLine.d56.s5	responses	106	114	O	responses	ses	nses	NNS	False
DDI-MedLine.d56.s5	to	116	117	O	to	to	to	TO	False
DDI-MedLine.d56.s5	PTX	119	121	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s5	were	123	126	O	were	ere	were	VBD	False
DDI-MedLine.d56.s5	abolished	128	136	O	abolished	hed	shed	VBN	False
DDI-MedLine.d56.s5	.	137	137	O	.	.	.	.	False

DDI-MedLine.d56.s6	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d56.s6	the	5	7	O	the	the	the	DT	False
DDI-MedLine.d56.s6	muscle	9	14	O	muscle	cle	scle	NN	False
DDI-MedLine.d56.s6	was	16	18	O	was	was	was	VBD	False
DDI-MedLine.d56.s6	exposed	20	26	O	exposed	sed	osed	VBN	False
DDI-MedLine.d56.s6	to	28	29	O	to	to	to	TO	False
DDI-MedLine.d56.s6	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d56.s6	potassium-depleted	35	52	O	potassium-depleted	ted	eted	JJ	False
DDI-MedLine.d56.s6	solution	54	61	O	solution	ion	tion	NN	False
DDI-MedLine.d56.s6	,	62	62	O	,	,	,	,	False
DDI-MedLine.d56.s6	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d56.s6	first	68	72	O	first	rst	irst	RB	False
DDI-MedLine.d56.s6	contractile	74	84	O	contractile	ile	tile	NN	False
DDI-MedLine.d56.s6	response	86	93	O	response	nse	onse	NN	False
DDI-MedLine.d56.s6	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d56.s6	PTX	98	100	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s6	was	102	104	O	was	was	was	VBD	False
DDI-MedLine.d56.s6	rather	106	111	O	rather	her	ther	RB	False
DDI-MedLine.d56.s6	potentiated	113	123	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d56.s6	.	124	124	O	.	.	.	.	False

DDI-MedLine.d56.s7	PTX	0	2	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s7	caused	4	9	O	caused	sed	used	VBN	False
DDI-MedLine.d56.s7	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d56.s7	release	15	21	O	release	ase	ease	NN	False
DDI-MedLine.d56.s7	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d56.s7	norepinephrine	26	39	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d56.s7	from	41	44	O	from	rom	from	IN	False
DDI-MedLine.d56.s7	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d56.s7	muscle	50	55	O	muscle	cle	scle	NN	False
DDI-MedLine.d56.s7	.	56	56	O	.	.	.	.	False

DDI-MedLine.d56.s8	Exposure	0	7	O	Exposure	ure	sure	NN	False
DDI-MedLine.d56.s8	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d56.s8	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d56.s8	muscle	16	21	O	muscle	cle	scle	NN	False
DDI-MedLine.d56.s8	to	23	24	O	to	to	to	TO	False
DDI-MedLine.d56.s8	ouabain	26	32	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d56.s8	(	34	34	O	(	(	(	(	False
DDI-MedLine.d56.s8	10	35	36	O	10	10	10	CD	False
DDI-MedLine.d56.s8	(	37	37	O	(	(	(	(	False
DDI-MedLine.d56.s8	-5	38	39	O	-5	-5	-5	NN	False
DDI-MedLine.d56.s8	)	40	40	O	)	)	)	)	False
DDI-MedLine.d56.s8	M	42	42	O	M	M	M	NN	brand
DDI-MedLine.d56.s8	)	43	43	O	)	)	)	)	False
DDI-MedLine.d56.s8	markedly	45	52	O	markedly	dly	edly	RB	False
DDI-MedLine.d56.s8	increased	54	62	O	increased	sed	ased	VBN	False
DDI-MedLine.d56.s8	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d56.s8	PTX-induced	68	78	O	PTX-induced	ced	uced	JJ	False
DDI-MedLine.d56.s8	release	80	86	O	release	ase	ease	NN	False
DDI-MedLine.d56.s8	.	87	87	O	.	.	.	.	False

DDI-MedLine.d56.s9	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d56.s9	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d56.s9	indicated	6	14	O	indicated	ted	ated	VBN	False
DDI-MedLine.d56.s9	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d56.s9	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d56.s9	first	25	29	O	first	rst	irst	RB	False
DDI-MedLine.d56.s9	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d56.s9	second	35	40	O	second	ond	cond	JJ	False
DDI-MedLine.d56.s9	contractile	42	52	O	contractile	ile	tile	NN	False
DDI-MedLine.d56.s9	responses	54	62	O	responses	ses	nses	NNS	False
DDI-MedLine.d56.s9	to	64	65	O	to	to	to	TO	False
DDI-MedLine.d56.s9	PTX	67	69	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s9	have	71	74	O	have	ave	have	VB	False
DDI-MedLine.d56.s9	entirely	76	83	O	entirely	ely	rely	RB	False
DDI-MedLine.d56.s9	different	85	93	O	different	ent	rent	JJ	False
DDI-MedLine.d56.s9	properties	95	104	O	properties	ies	ties	NNS	False
DDI-MedLine.d56.s9	.	105	105	O	.	.	.	.	False

DDI-MedLine.d56.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d56.s10	second	4	9	O	second	ond	cond	JJ	False
DDI-MedLine.d56.s10	response	11	18	O	response	nse	onse	NN	False
DDI-MedLine.d56.s10	is	20	21	O	is	is	is	VBZ	False
DDI-MedLine.d56.s10	due	23	25	O	due	due	due	JJ	False
DDI-MedLine.d56.s10	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d56.s10	a	30	30	O	a	a	a	DT	False
DDI-MedLine.d56.s10	release	32	38	O	release	ase	ease	NN	False
DDI-MedLine.d56.s10	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d56.s10	norepinephrine	43	56	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d56.s10	from	58	61	O	from	rom	from	IN	False
DDI-MedLine.d56.s10	nerves	63	68	O	nerves	ves	rves	NNS	False
DDI-MedLine.d56.s10	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d56.s10	was	74	76	O	was	was	was	VBD	False
DDI-MedLine.d56.s10	potentiated	78	88	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d56.s10	by	90	91	O	by	by	by	IN	False
DDI-MedLine.d56.s10	ouabain	93	99	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d56.s10	through	101	107	O	through	ugh	ough	IN	False
DDI-MedLine.d56.s10	the	109	111	O	the	the	the	DT	False
DDI-MedLine.d56.s10	increase	113	120	O	increase	ase	ease	NN	False
DDI-MedLine.d56.s10	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d56.s10	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d56.s10	norepinephrine	129	142	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d56.s10	release	144	150	O	release	ase	ease	NN	False
DDI-MedLine.d56.s10	,	151	151	O	,	,	,	,	False
DDI-MedLine.d56.s10	whereas	153	159	O	whereas	eas	reas	NNS	False
DDI-MedLine.d56.s10	the	161	163	O	the	the	the	DT	False
DDI-MedLine.d56.s10	first	165	169	O	first	rst	irst	RB	False
DDI-MedLine.d56.s10	response	171	178	O	response	nse	onse	NN	False
DDI-MedLine.d56.s10	was	180	182	O	was	was	was	VBD	False
DDI-MedLine.d56.s10	not	184	186	O	not	not	not	RB	False
DDI-MedLine.d56.s10	due	188	190	O	due	due	due	JJ	False
DDI-MedLine.d56.s10	to	192	193	O	to	to	to	TO	False
DDI-MedLine.d56.s10	the	195	197	O	the	the	the	DT	False
DDI-MedLine.d56.s10	norepinephrine	199	212	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d56.s10	release	214	220	O	release	ase	ease	NN	False
DDI-MedLine.d56.s10	but	222	224	O	but	but	but	CC	False
DDI-MedLine.d56.s10	presumably	226	235	O	presumably	bly	ably	RB	False
DDI-MedLine.d56.s10	to	237	238	O	to	to	to	TO	False
DDI-MedLine.d56.s10	a	240	240	O	a	a	a	DT	False
DDI-MedLine.d56.s10	direct	242	247	O	direct	ect	rect	JJ	False
DDI-MedLine.d56.s10	action	249	254	O	action	ion	tion	NN	False
DDI-MedLine.d56.s10	on	256	257	O	on	on	on	IN	False
DDI-MedLine.d56.s10	smooth	259	264	O	smooth	oth	ooth	NN	False
DDI-MedLine.d56.s10	muscle	266	271	O	muscle	cle	scle	NN	False
DDI-MedLine.d56.s10	cell	273	276	O	cell	ell	cell	NN	False
DDI-MedLine.d56.s10	and	278	280	O	and	and	and	CC	False
DDI-MedLine.d56.s10	was	282	284	O	was	was	was	VBD	False
DDI-MedLine.d56.s10	inhibited	286	294	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d56.s10	by	296	297	O	by	by	by	IN	False
DDI-MedLine.d56.s10	ouabain	299	305	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d56.s10	.	306	306	O	.	.	.	.	False

DDI-MedLine.d56.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d56.s11	mechanism	4	12	O	mechanism	ism	nism	NN	False
DDI-MedLine.d56.s11	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d56.s11	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d56.s11	action	21	26	O	action	ion	tion	NN	False
DDI-MedLine.d56.s11	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d56.s11	PTX	31	33	B-drug_n	PTX	PTX	PTX	NN	brand
DDI-MedLine.d56.s11	was	35	37	O	was	was	was	VBD	False
DDI-MedLine.d56.s11	discussed	39	47	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d56.s11	in	49	50	O	in	in	in	IN	False
DDI-MedLine.d56.s11	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d56.s11	relation	56	63	O	relation	ion	tion	NN	False
DDI-MedLine.d56.s11	with	65	68	O	with	ith	with	IN	False
DDI-MedLine.d56.s11	Na	70	71	O	Na	Na	Na	NN	False
DDI-MedLine.d56.s11	,	72	72	O	,	,	,	,	False
DDI-MedLine.d56.s11	K-ATPase	73	80	O	K-ATPase	ase	Pase	NN	False
DDI-MedLine.d56.s11	.	81	81	O	.	.	.	.	False

DDI-MedLine.d64.s0	Pharmacological	0	14	O	Pharmacological	cal	ical	JJ	False
DDI-MedLine.d64.s0	treatment	16	24	O	treatment	ent	ment	NN	False
DDI-MedLine.d64.s0	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d64.s0	depression	29	38	O	depression	ion	sion	NN	False
DDI-MedLine.d64.s0	:	39	39	O	:	:	:	:	False
DDI-MedLine.d64.s0	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d64.s0	role	45	48	O	role	ole	role	NN	False
DDI-MedLine.d64.s0	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d64.s0	paroxetine	53	62	B-drug	paroxetine	ine	tine	NN	drug
DDI-MedLine.d64.s0	.	63	63	O	.	.	.	.	False

DDI-MedLine.d64.s1	Depression	0	9	O	Depression	ion	sion	NN	False
DDI-MedLine.d64.s1	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d64.s1	reaching	14	21	O	reaching	ing	hing	VBG	False
DDI-MedLine.d64.s1	epidemic	23	30	O	epidemic	mic	emic	JJ	False
DDI-MedLine.d64.s1	proportions	32	42	O	proportions	ons	ions	NNS	False
DDI-MedLine.d64.s1	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d64.s1	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d64.s1	western	51	57	O	western	ern	tern	JJ	False
DDI-MedLine.d64.s1	world	59	63	O	world	rld	orld	NN	False
DDI-MedLine.d64.s1	.	64	64	O	.	.	.	.	False

DDI-MedLine.d64.s2	With	0	3	O	With	ith	With	IN	False
DDI-MedLine.d64.s2	each	5	8	O	each	ach	each	DT	False
DDI-MedLine.d64.s2	successive	10	19	O	successive	ive	sive	NN	False
DDI-MedLine.d64.s2	generation	21	30	O	generation	ion	tion	NN	False
DDI-MedLine.d64.s2	more	32	35	O	more	ore	more	RBR	False
DDI-MedLine.d64.s2	people	37	42	O	people	ple	ople	NNS	False
DDI-MedLine.d64.s2	are	44	46	O	are	are	are	VBP	False
DDI-MedLine.d64.s2	becoming	48	55	O	becoming	ing	ming	VBG	False
DDI-MedLine.d64.s2	more	57	60	O	more	ore	more	RBR	False
DDI-MedLine.d64.s2	severely	62	69	O	severely	ely	rely	RB	False
DDI-MedLine.d64.s2	depressed	71	79	O	depressed	sed	ssed	JJ	False
DDI-MedLine.d64.s2	at	81	82	O	at	at	at	IN	False
DDI-MedLine.d64.s2	a	84	84	O	a	a	a	DT	False
DDI-MedLine.d64.s2	younger	86	92	O	younger	ger	nger	JJR	False
DDI-MedLine.d64.s2	age	94	96	O	age	age	age	NN	False
DDI-MedLine.d64.s2	.	97	97	O	.	.	.	.	False

DDI-MedLine.d23.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d23.s0	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d23.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d23.s0	ketamine	15	22	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d23.s0	and	24	26	O	and	and	and	CC	False
DDI-MedLine.d23.s0	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d23.s0	Innovar	31	37	B-brand	Innovar	var	ovar	NN	False
DDI-MedLine.d23.s0	anesthesia	39	48	O	anesthesia	sia	esia	NN	False
DDI-MedLine.d23.s0	on	50	51	O	on	on	on	IN	False
DDI-MedLine.d23.s0	digitalis	53	61	B-group	digitalis	lis	alis	NN	False
DDI-MedLine.d23.s0	tolerance	63	71	O	tolerance	nce	ance	NN	False
DDI-MedLine.d23.s0	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d23.s0	dogs	76	79	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d23.s0	.	80	80	O	.	.	.	.	False

DDI-MedLine.d23.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d23.s1	a	3	3	O	a	a	a	DT	False
DDI-MedLine.d23.s1	comparison	5	14	O	comparison	son	ison	NN	False
DDI-MedLine.d23.s1	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d23.s1	digitalis	19	27	B-group	digitalis	lis	alis	NN	False
DDI-MedLine.d23.s1	tolerance	29	37	O	tolerance	nce	ance	NN	False
DDI-MedLine.d23.s1	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d23.s1	dogs	42	45	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d23.s1	anesthetized	47	58	O	anesthetized	zed	ized	VBN	False
DDI-MedLine.d23.s1	with	60	63	O	with	ith	with	IN	False
DDI-MedLine.d23.s1	ketamine	65	72	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d23.s1	,	73	73	O	,	,	,	,	False
DDI-MedLine.d23.s1	Innovar	75	81	B-brand	Innovar	var	ovar	NN	False
DDI-MedLine.d23.s1	Vet	83	85	I-brand	Vet	Vet	Vet	NN	False
DDI-MedLine.d23.s1	,	86	86	O	,	,	,	,	False
DDI-MedLine.d23.s1	or	88	89	O	or	or	or	CC	False
DDI-MedLine.d23.s1	pentobarbital	91	103	B-drug	pentobarbital	tal	ital	NN	False
DDI-MedLine.d23.s1	,	104	104	O	,	,	,	,	False
DDI-MedLine.d23.s1	the	106	108	O	the	the	the	DT	False
DDI-MedLine.d23.s1	dosage	110	115	O	dosage	age	sage	NN	False
DDI-MedLine.d23.s1	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d23.s1	ouabain	120	126	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d23.s1	needed	128	133	O	needed	ded	eded	VBN	False
DDI-MedLine.d23.s1	to	135	136	O	to	to	to	TO	False
DDI-MedLine.d23.s1	cause	138	142	O	cause	use	ause	NN	False
DDI-MedLine.d23.s1	ventricular	144	154	O	ventricular	lar	ular	NN	False
DDI-MedLine.d23.s1	tachycardia	156	166	O	tachycardia	dia	rdia	NN	False
DDI-MedLine.d23.s1	was	168	170	O	was	was	was	VBD	False
DDI-MedLine.d23.s1	significantly	172	184	O	significantly	tly	ntly	RB	False
DDI-MedLine.d23.s1	higher	186	191	O	higher	her	gher	JJR	False
DDI-MedLine.d23.s1	,	192	192	O	,	,	,	,	False
DDI-MedLine.d23.s1	as	194	195	O	as	as	as	IN	False
DDI-MedLine.d23.s1	was	197	199	O	was	was	was	VBD	False
DDI-MedLine.d23.s1	the	201	203	O	the	the	the	DT	False
DDI-MedLine.d23.s1	LD50	205	208	O	LD50	D50	LD50	NN	brand
DDI-MedLine.d23.s1	of	210	211	O	of	of	of	IN	False
DDI-MedLine.d23.s1	ouabain	213	219	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d23.s1	,	220	220	O	,	,	,	,	False
DDI-MedLine.d23.s1	with	222	225	O	with	ith	with	IN	False
DDI-MedLine.d23.s1	ketamine	227	234	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d23.s1	or	236	237	O	or	or	or	CC	False
DDI-MedLine.d23.s1	Innovar	239	245	B-brand	Innovar	var	ovar	NN	False
DDI-MedLine.d23.s1	than	247	250	O	than	han	than	IN	False
DDI-MedLine.d23.s1	with	252	255	O	with	ith	with	IN	False
DDI-MedLine.d23.s1	pentobarbital	257	269	B-drug	pentobarbital	tal	ital	NN	False
DDI-MedLine.d23.s1	.	270	270	O	.	.	.	.	False

DDI-MedLine.d23.s2	Ventricular	0	10	O	Ventricular	lar	ular	JJ	False
DDI-MedLine.d23.s2	tachycardia	12	22	O	tachycardia	dia	rdia	NN	False
DDI-MedLine.d23.s2	induced	24	30	O	induced	ced	uced	JJ	False
DDI-MedLine.d23.s2	by	32	33	O	by	by	by	IN	False
DDI-MedLine.d23.s2	ouabain	35	41	B-drug	ouabain	ain	bain	NN	False
DDI-MedLine.d23.s2	was	43	45	O	was	was	was	VBD	False
DDI-MedLine.d23.s2	generally	47	55	O	generally	lly	ally	RB	False
DDI-MedLine.d23.s2	converted	57	65	O	converted	ted	rted	VBN	False
DDI-MedLine.d23.s2	to	67	68	O	to	to	to	TO	False
DDI-MedLine.d23.s2	sinus	70	74	O	sinus	nus	inus	NN	False
DDI-MedLine.d23.s2	rhythm	76	81	O	rhythm	thm	ythm	NN	False
DDI-MedLine.d23.s2	following	83	91	O	following	ing	wing	VBG	False
DDI-MedLine.d23.s2	administration	93	106	O	administration	ion	tion	NN	False
DDI-MedLine.d23.s2	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d23.s2	Innovar	111	117	B-brand	Innovar	var	ovar	NN	False
DDI-MedLine.d23.s2	,	118	118	O	,	,	,	,	False
DDI-MedLine.d23.s2	ketamine	120	127	B-drug	ketamine	ine	mine	NN	drug
DDI-MedLine.d23.s2	,	128	128	O	,	,	,	,	False
DDI-MedLine.d23.s2	or	130	131	O	or	or	or	CC	False
DDI-MedLine.d23.s2	droperidol	133	142	B-drug	droperidol	dol	idol	NN	False
DDI-MedLine.d23.s2	but	144	146	O	but	but	but	CC	False
DDI-MedLine.d23.s2	not	148	150	O	not	not	not	RB	False
DDI-MedLine.d23.s2	after	152	156	O	after	ter	fter	IN	False
DDI-MedLine.d23.s2	administration	158	171	O	administration	ion	tion	NN	False
DDI-MedLine.d23.s2	of	173	174	O	of	of	of	IN	False
DDI-MedLine.d23.s2	fentayl	176	182	B-drug	fentayl	ayl	tayl	NN	False
DDI-MedLine.d23.s2	alone	184	188	O	alone	one	lone	RB	False
DDI-MedLine.d23.s2	or	190	191	O	or	or	or	CC	False
DDI-MedLine.d23.s2	after	193	197	O	after	ter	fter	IN	False
DDI-MedLine.d23.s2	pentobarbital	199	211	B-drug	pentobarbital	tal	ital	NN	False
DDI-MedLine.d23.s2	.	212	212	O	.	.	.	.	False

DDI-MedLine.d21.s0	Acute	0	4	O	Acute	ute	cute	NN	False
DDI-MedLine.d21.s0	effect	6	11	O	effect	ect	fect	NN	False
DDI-MedLine.d21.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d21.s0	different	16	24	O	different	ent	rent	JJ	False
DDI-MedLine.d21.s0	antidepressants	26	40	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d21.s0	on	42	43	O	on	on	on	IN	False
DDI-MedLine.d21.s0	glycemia	45	52	O	glycemia	mia	emia	NN	False
DDI-MedLine.d21.s0	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d21.s0	diabetic	57	64	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s0	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d21.s0	non-diabetic	70	81	O	non-diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s0	rats	83	86	O	rats	ats	rats	NNS	False
DDI-MedLine.d21.s0	.	87	87	O	.	.	.	.	False

DDI-MedLine.d21.s1	Diabetic	0	7	O	Diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s1	patients	9	16	O	patients	nts	ents	NNS	False
DDI-MedLine.d21.s1	have	18	21	O	have	ave	have	VB	False
DDI-MedLine.d21.s1	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d21.s1	20	25	26	O	20	20	20	CD	False
DDI-MedLine.d21.s1	%	27	27	O	%	%	%	NN	False
DDI-MedLine.d21.s1	higher	29	34	O	higher	her	gher	JJR	False
DDI-MedLine.d21.s1	risk	36	39	O	risk	isk	risk	NN	False
DDI-MedLine.d21.s1	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d21.s1	depression	44	53	O	depression	ion	sion	NN	False
DDI-MedLine.d21.s1	than	55	58	O	than	han	than	IN	False
DDI-MedLine.d21.s1	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d21.s1	general	64	70	O	general	ral	eral	JJ	False
DDI-MedLine.d21.s1	population	72	81	O	population	ion	tion	NN	False
DDI-MedLine.d21.s1	.	82	82	O	.	.	.	.	False

DDI-MedLine.d21.s2	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d21.s2	with	10	13	O	with	ith	with	IN	False
DDI-MedLine.d21.s2	antidepressant	15	28	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d21.s2	drugs	30	34	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d21.s2	can	36	38	O	can	can	can	MD	False
DDI-MedLine.d21.s2	directly	40	47	O	directly	tly	ctly	RB	False
DDI-MedLine.d21.s2	interfere	49	57	O	interfere	ere	fere	RB	False
DDI-MedLine.d21.s2	with	59	62	O	with	ith	with	IN	False
DDI-MedLine.d21.s2	blood	64	68	O	blood	ood	lood	NN	False
DDI-MedLine.d21.s2	glucose	70	76	O	glucose	ose	cose	NN	False
DDI-MedLine.d21.s2	levels	78	83	O	levels	els	vels	NNS	False
DDI-MedLine.d21.s2	or	85	86	O	or	or	or	CC	False
DDI-MedLine.d21.s2	may	88	90	O	may	may	may	MD	False
DDI-MedLine.d21.s2	interact	92	99	O	interact	act	ract	NN	False
DDI-MedLine.d21.s2	with	101	104	O	with	ith	with	IN	False
DDI-MedLine.d21.s2	hypoglycemic	106	117	B-group	hypoglycemic	mic	emic	NN	False
DDI-MedLine.d21.s2	agents	119	124	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d21.s2	.	125	125	O	.	.	.	.	False

DDI-MedLine.d21.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d21.s3	treatment	4	12	O	treatment	ent	ment	NN	False
DDI-MedLine.d21.s3	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d21.s3	depression	17	26	O	depression	ion	sion	NN	False
DDI-MedLine.d21.s3	in	28	29	O	in	in	in	IN	False
DDI-MedLine.d21.s3	diabetic	31	38	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s3	patients	40	47	O	patients	nts	ents	NNS	False
DDI-MedLine.d21.s3	must	49	52	O	must	ust	must	MD	False
DDI-MedLine.d21.s3	take	54	57	O	take	ake	take	VB	False
DDI-MedLine.d21.s3	into	59	62	O	into	nto	into	IN	False
DDI-MedLine.d21.s3	account	64	70	O	account	unt	ount	NN	False
DDI-MedLine.d21.s3	variations	72	81	O	variations	ons	ions	NNS	False
DDI-MedLine.d21.s3	of	83	84	O	of	of	of	IN	False
DDI-MedLine.d21.s3	glycemic	86	93	O	glycemic	mic	emic	NN	False
DDI-MedLine.d21.s3	levels	95	100	O	levels	els	vels	NNS	False
DDI-MedLine.d21.s3	at	102	103	O	at	at	at	IN	False
DDI-MedLine.d21.s3	different	105	113	O	different	ent	rent	JJ	False
DDI-MedLine.d21.s3	times	115	119	O	times	mes	imes	NNS	False
DDI-MedLine.d21.s3	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d21.s3	a	125	125	O	a	a	a	DT	False
DDI-MedLine.d21.s3	comparison	127	136	O	comparison	son	ison	NN	False
DDI-MedLine.d21.s3	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d21.s3	the	141	143	O	the	the	the	DT	False
DDI-MedLine.d21.s3	available	145	153	O	available	ble	able	JJ	False
DDI-MedLine.d21.s3	antidepressant	155	168	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d21.s3	agents	170	175	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d21.s3	is	177	178	O	is	is	is	VBZ	False
DDI-MedLine.d21.s3	important	180	188	O	important	ant	tant	JJ	False
DDI-MedLine.d21.s3	.	189	189	O	.	.	.	.	False

DDI-MedLine.d21.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d21.s4	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d21.s4	present	7	13	O	present	ent	sent	NN	False
DDI-MedLine.d21.s4	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d21.s4	we	21	22	O	we	we	we	PRP	False
DDI-MedLine.d21.s4	evaluated	24	32	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d21.s4	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d21.s4	interference	38	49	O	interference	nce	ence	NN	False
DDI-MedLine.d21.s4	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d21.s4	antidepressants	54	68	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d21.s4	with	70	73	O	with	ith	with	IN	False
DDI-MedLine.d21.s4	blood	75	79	O	blood	ood	lood	NN	False
DDI-MedLine.d21.s4	glucose	81	87	O	glucose	ose	cose	NN	False
DDI-MedLine.d21.s4	levels	89	94	O	levels	els	vels	NNS	False
DDI-MedLine.d21.s4	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d21.s4	diabetic	99	106	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s4	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d21.s4	non-diabetic	112	123	O	non-diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s4	rats	125	128	O	rats	ats	rats	NNS	False
DDI-MedLine.d21.s4	.	129	129	O	.	.	.	.	False

DDI-MedLine.d21.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d21.s5	a	3	3	O	a	a	a	DT	False
DDI-MedLine.d21.s5	first	5	9	O	first	rst	irst	RB	False
DDI-MedLine.d21.s5	experiment	11	20	O	experiment	ent	ment	NN	False
DDI-MedLine.d21.s5	,	21	21	O	,	,	,	,	False
DDI-MedLine.d21.s5	male	23	26	O	male	ale	male	NN	False
DDI-MedLine.d21.s5	adult	28	32	O	adult	ult	dult	NN	False
DDI-MedLine.d21.s5	Wistar	34	39	O	Wistar	tar	star	NN	False
DDI-MedLine.d21.s5	rats	41	44	O	rats	ats	rats	NNS	False
DDI-MedLine.d21.s5	were	46	49	O	were	ere	were	VBD	False
DDI-MedLine.d21.s5	fasted	51	56	O	fasted	ted	sted	VBN	False
DDI-MedLine.d21.s5	for	58	60	O	for	for	for	IN	False
DDI-MedLine.d21.s5	12	62	63	O	12	12	12	CD	False
DDI-MedLine.d21.s5	h	65	65	O	h	h	h	NN	False
DDI-MedLine.d21.s5	.	66	66	O	.	.	.	.	False

DDI-MedLine.d21.s6	Imipramine	0	9	B-drug	Imipramine	ine	mine	NN	drug
DDI-MedLine.d21.s6	(	11	11	O	(	(	(	(	False
DDI-MedLine.d21.s6	5	12	12	O	5	5	5	CD	False
DDI-MedLine.d21.s6	mg/kg	14	18	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d21.s6	)	19	19	O	)	)	)	)	False
DDI-MedLine.d21.s6	,	20	20	O	,	,	,	,	False
DDI-MedLine.d21.s6	moclobemide	22	32	B-drug	moclobemide	ide	mide	NN	False
DDI-MedLine.d21.s6	(	34	34	O	(	(	(	(	False
DDI-MedLine.d21.s6	30	35	36	O	30	30	30	CD	False
DDI-MedLine.d21.s6	mg/kg	38	42	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d21.s6	)	43	43	O	)	)	)	)	False
DDI-MedLine.d21.s6	,	44	44	O	,	,	,	,	False
DDI-MedLine.d21.s6	clonazepam	46	55	B-drug	clonazepam	pam	epam	NN	False
DDI-MedLine.d21.s6	(	57	57	O	(	(	(	(	False
DDI-MedLine.d21.s6	0.25	58	61	O	0.25	.25	0.25	CD	False
DDI-MedLine.d21.s6	mg/kg	63	67	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d21.s6	)	68	68	O	)	)	)	)	False
DDI-MedLine.d21.s6	,	69	69	O	,	,	,	,	False
DDI-MedLine.d21.s6	fluoxetine	71	80	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d21.s6	(	82	82	O	(	(	(	(	False
DDI-MedLine.d21.s6	20	83	84	O	20	20	20	CD	False
DDI-MedLine.d21.s6	mg/kg	86	90	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d21.s6	)	91	91	O	)	)	)	)	False
DDI-MedLine.d21.s6	sertraline	93	102	B-drug	sertraline	ine	line	NN	drug
DDI-MedLine.d21.s6	(	104	104	O	(	(	(	(	False
DDI-MedLine.d21.s6	30	105	106	O	30	30	30	CD	False
DDI-MedLine.d21.s6	mg/kg	108	112	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d21.s6	)	113	113	O	)	)	)	)	False
DDI-MedLine.d21.s6	or	115	116	O	or	or	or	CC	False
DDI-MedLine.d21.s6	vehicle	118	124	O	vehicle	cle	icle	NN	False
DDI-MedLine.d21.s6	was	126	128	O	was	was	was	VBD	False
DDI-MedLine.d21.s6	administered	130	141	O	administered	red	ered	VBN	False
DDI-MedLine.d21.s6	.	142	142	O	.	.	.	.	False

DDI-MedLine.d21.s7	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d21.s7	30	6	7	O	30	30	30	CD	False
DDI-MedLine.d21.s7	min	9	11	O	min	min	min	NN	False
DDI-MedLine.d21.s7	,	12	12	O	,	,	,	,	False
DDI-MedLine.d21.s7	fasting	14	20	O	fasting	ing	ting	VBG	False
DDI-MedLine.d21.s7	glycemia	22	29	O	glycemia	mia	emia	NN	False
DDI-MedLine.d21.s7	was	31	33	O	was	was	was	VBD	False
DDI-MedLine.d21.s7	measured	35	42	O	measured	red	ured	VBN	False
DDI-MedLine.d21.s7	.	43	43	O	.	.	.	.	False

DDI-MedLine.d21.s8	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d21.s8	oral	3	6	O	oral	ral	oral	JJ	False
DDI-MedLine.d21.s8	glucose	8	14	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s8	overload	16	23	O	overload	oad	load	NN	False
DDI-MedLine.d21.s8	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d21.s8	1	28	28	O	1	1	1	CD	False
DDI-MedLine.d21.s8	ml	30	31	O	ml	ml	ml	NN	False
DDI-MedLine.d21.s8	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d21.s8	a	36	36	O	a	a	a	DT	False
DDI-MedLine.d21.s8	50	38	39	O	50	50	50	CD	False
DDI-MedLine.d21.s8	%	40	40	O	%	%	%	NN	False
DDI-MedLine.d21.s8	glucose	42	48	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s8	solution	50	57	O	solution	ion	tion	NN	False
DDI-MedLine.d21.s8	was	59	61	O	was	was	was	VBD	False
DDI-MedLine.d21.s8	given	63	67	O	given	ven	iven	VBN	False
DDI-MedLine.d21.s8	to	69	70	O	to	to	to	TO	False
DDI-MedLine.d21.s8	rats	72	75	O	rats	ats	rats	NNS	False
DDI-MedLine.d21.s8	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d21.s8	blood	81	85	O	blood	ood	lood	NN	False
DDI-MedLine.d21.s8	glucose	87	93	O	glucose	ose	cose	NN	False
DDI-MedLine.d21.s8	was	95	97	O	was	was	was	VBD	False
DDI-MedLine.d21.s8	determined	99	108	O	determined	ned	ined	VBN	False
DDI-MedLine.d21.s8	after	110	114	O	after	ter	fter	IN	False
DDI-MedLine.d21.s8	30	116	117	O	30	30	30	CD	False
DDI-MedLine.d21.s8	,	118	118	O	,	,	,	,	False
DDI-MedLine.d21.s8	60	120	121	O	60	60	60	CD	False
DDI-MedLine.d21.s8	and	123	125	O	and	and	and	CC	False
DDI-MedLine.d21.s8	90	127	128	O	90	90	90	CD	False
DDI-MedLine.d21.s8	min	130	132	O	min	min	min	NN	False
DDI-MedLine.d21.s8	.	133	133	O	.	.	.	.	False

DDI-MedLine.d21.s9	Imipramine	0	9	B-drug	Imipramine	ine	mine	NN	drug
DDI-MedLine.d21.s9	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d21.s9	clonazepam	15	24	B-drug	clonazepam	pam	epam	NN	False
DDI-MedLine.d21.s9	did	26	28	O	did	did	did	VBD	False
DDI-MedLine.d21.s9	not	30	32	O	not	not	not	RB	False
DDI-MedLine.d21.s9	change	34	39	O	change	nge	ange	NN	False
DDI-MedLine.d21.s9	fasting	41	47	O	fasting	ing	ting	VBG	False
DDI-MedLine.d21.s9	or	49	50	O	or	or	or	CC	False
DDI-MedLine.d21.s9	overload	52	59	O	overload	oad	load	NN	False
DDI-MedLine.d21.s9	glycemia	61	68	O	glycemia	mia	emia	NN	False
DDI-MedLine.d21.s9	.	69	69	O	.	.	.	.	False

DDI-MedLine.d21.s10	Fluoxetine	0	9	B-drug	Fluoxetine	ine	tine	NN	drug
DDI-MedLine.d21.s10	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d21.s10	moclobemide	15	25	B-drug	moclobemide	ide	mide	NN	False
DDI-MedLine.d21.s10	increased	27	35	O	increased	sed	ased	VBN	False
DDI-MedLine.d21.s10	blood	37	41	O	blood	ood	lood	NN	False
DDI-MedLine.d21.s10	glucose	43	49	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s10	at	51	52	O	at	at	at	IN	False
DDI-MedLine.d21.s10	different	54	62	O	different	ent	rent	JJ	False
DDI-MedLine.d21.s10	times	64	68	O	times	mes	imes	NNS	False
DDI-MedLine.d21.s10	after	70	74	O	after	ter	fter	IN	False
DDI-MedLine.d21.s10	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d21.s10	glucose	80	86	O	glucose	ose	cose	NN	False
DDI-MedLine.d21.s10	overload	88	95	O	overload	oad	load	NN	False
DDI-MedLine.d21.s10	.	96	96	O	.	.	.	.	False

DDI-MedLine.d21.s11	Sertraline	0	9	B-drug	Sertraline	ine	line	NN	drug
DDI-MedLine.d21.s11	neutralized	11	21	O	neutralized	zed	ized	VBN	False
DDI-MedLine.d21.s11	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d21.s11	increase	27	34	O	increase	ase	ease	NN	False
DDI-MedLine.d21.s11	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d21.s11	glycemia	39	46	O	glycemia	mia	emia	NN	False
DDI-MedLine.d21.s11	induced	48	54	O	induced	ced	uced	JJ	False
DDI-MedLine.d21.s11	by	56	57	O	by	by	by	IN	False
DDI-MedLine.d21.s11	oral	59	62	O	oral	ral	oral	JJ	False
DDI-MedLine.d21.s11	glucose	64	70	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s11	overload	72	79	O	overload	oad	load	NN	False
DDI-MedLine.d21.s11	.	80	80	O	.	.	.	.	False

DDI-MedLine.d21.s12	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d21.s12	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d21.s12	second	7	12	O	second	ond	cond	JJ	False
DDI-MedLine.d21.s12	experiment	14	23	O	experiment	ent	ment	NN	False
DDI-MedLine.d21.s12	,	24	24	O	,	,	,	,	False
DDI-MedLine.d21.s12	non-diabetic	26	37	O	non-diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s12	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d21.s12	streptozotocin-induced	43	64	O	streptozotocin-induced	ced	uced	JJ	False
DDI-MedLine.d21.s12	diabetic	66	73	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s12	rats	75	78	O	rats	ats	rats	NNS	False
DDI-MedLine.d21.s12	were	80	83	O	were	ere	were	VBD	False
DDI-MedLine.d21.s12	fasted	85	90	O	fasted	ted	sted	VBN	False
DDI-MedLine.d21.s12	,	91	91	O	,	,	,	,	False
DDI-MedLine.d21.s12	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d21.s12	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d21.s12	same	101	104	O	same	ame	same	JJ	False
DDI-MedLine.d21.s12	procedures	106	115	O	procedures	res	ures	NNS	False
DDI-MedLine.d21.s12	were	117	120	O	were	ere	were	VBD	False
DDI-MedLine.d21.s12	followed	122	129	O	followed	wed	owed	VBD	False
DDI-MedLine.d21.s12	for	131	133	O	for	for	for	IN	False
DDI-MedLine.d21.s12	estimation	135	144	O	estimation	ion	tion	NN	False
DDI-MedLine.d21.s12	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d21.s12	glucose	149	155	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s12	tolerance	157	165	O	tolerance	nce	ance	NN	False
DDI-MedLine.d21.s12	30	167	168	O	30	30	30	CD	False
DDI-MedLine.d21.s12	min	170	172	O	min	min	min	NN	False
DDI-MedLine.d21.s12	after	174	178	O	after	ter	fter	IN	False
DDI-MedLine.d21.s12	glucose	180	186	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s12	overload	188	195	O	overload	oad	load	NN	False
DDI-MedLine.d21.s12	.	196	196	O	.	.	.	.	False

DDI-MedLine.d21.s13	Again	0	4	O	Again	ain	gain	NN	False
DDI-MedLine.d21.s13	,	5	5	O	,	,	,	,	False
DDI-MedLine.d21.s13	sertraline	7	16	B-drug	sertraline	ine	line	NN	drug
DDI-MedLine.d21.s13	neutralized	18	28	O	neutralized	zed	ized	VBN	False
DDI-MedLine.d21.s13	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d21.s13	increase	34	41	O	increase	ase	ease	NN	False
DDI-MedLine.d21.s13	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d21.s13	glycemia	46	53	O	glycemia	mia	emia	NN	False
DDI-MedLine.d21.s13	after	55	59	O	after	ter	fter	IN	False
DDI-MedLine.d21.s13	glucose	61	67	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d21.s13	overload	69	76	O	overload	oad	load	NN	False
DDI-MedLine.d21.s13	both	78	81	O	both	oth	both	DT	False
DDI-MedLine.d21.s13	in	83	84	O	in	in	in	IN	False
DDI-MedLine.d21.s13	diabetic	86	93	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s13	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d21.s13	non-diabetic	99	110	O	non-diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s13	rats	112	115	O	rats	ats	rats	NNS	False
DDI-MedLine.d21.s13	.	116	116	O	.	.	.	.	False

DDI-MedLine.d21.s14	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d21.s14	data	6	9	O	data	ata	data	NNS	False
DDI-MedLine.d21.s14	raise	11	15	O	raise	ise	aise	NN	False
DDI-MedLine.d21.s14	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d21.s14	question	21	28	O	question	ion	tion	NN	False
DDI-MedLine.d21.s14	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d21.s14	whether	33	39	O	whether	her	ther	IN	False
DDI-MedLine.d21.s14	sertraline	41	50	B-drug	sertraline	ine	line	NN	drug
DDI-MedLine.d21.s14	is	52	53	O	is	is	is	VBZ	False
DDI-MedLine.d21.s14	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d21.s14	best	59	62	O	best	est	best	JJS	False
DDI-MedLine.d21.s14	choice	64	69	O	choice	ice	oice	NN	False
DDI-MedLine.d21.s14	for	71	73	O	for	for	for	IN	False
DDI-MedLine.d21.s14	prolonged	75	83	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d21.s14	use	85	87	O	use	use	use	NN	False
DDI-MedLine.d21.s14	for	89	91	O	for	for	for	IN	False
DDI-MedLine.d21.s14	diabetic	93	100	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d21.s14	individuals	102	112	O	individuals	als	uals	NNS	False
DDI-MedLine.d21.s14	,	113	113	O	,	,	,	,	False
DDI-MedLine.d21.s14	because	115	121	O	because	use	ause	IN	False
DDI-MedLine.d21.s14	of	123	124	O	of	of	of	IN	False
DDI-MedLine.d21.s14	its	126	128	O	its	its	its	PRP$	False
DDI-MedLine.d21.s14	antihyperglycemic	130	146	O	antihyperglycemic	mic	emic	JJ	False
DDI-MedLine.d21.s14	effects	148	154	O	effects	cts	ects	NNS	False
DDI-MedLine.d21.s14	.	155	155	O	.	.	.	.	False

DDI-MedLine.d21.s15	Clonazepam	0	9	B-drug	Clonazepam	pam	epam	NN	False
DDI-MedLine.d21.s15	would	11	15	O	would	uld	ould	MD	False
DDI-MedLine.d21.s15	be	17	18	O	be	be	be	VB	False
DDI-MedLine.d21.s15	useful	20	25	O	useful	ful	eful	JJ	False
DDI-MedLine.d21.s15	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d21.s15	cases	30	34	O	cases	ses	ases	NNS	False
DDI-MedLine.d21.s15	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d21.s15	potential	41	49	O	potential	ial	tial	JJ	False
DDI-MedLine.d21.s15	risk	51	54	O	risk	isk	risk	NN	False
DDI-MedLine.d21.s15	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d21.s15	hypoglycemia	59	70	O	hypoglycemia	mia	emia	NN	False
DDI-MedLine.d21.s15	.	71	71	O	.	.	.	.	False

DDI-MedLine.d41.s0	Interferon	0	9	O	Interferon	ron	eron	NNP	False
DDI-MedLine.d41.s0	induction	11	19	O	induction	ion	tion	NN	False
DDI-MedLine.d41.s0	:	20	20	O	:	:	:	:	False
DDI-MedLine.d41.s0	tool	22	25	O	tool	ool	tool	NN	False
DDI-MedLine.d41.s0	for	27	29	O	for	for	for	IN	False
DDI-MedLine.d41.s0	establishing	31	42	O	establishing	ing	hing	VBG	False
DDI-MedLine.d41.s0	interactions	44	55	O	interactions	ons	ions	NNS	False
DDI-MedLine.d41.s0	among	57	61	O	among	ong	mong	IN	False
DDI-MedLine.d41.s0	homopolyribonucleotides	63	85	O	homopolyribonucleotides	des	ides	NNS	group
DDI-MedLine.d41.s0	.	86	86	O	.	.	.	.	False

DDI-MedLine.d41.s1	Hitherto	0	7	O	Hitherto	rto	erto	NN	False
DDI-MedLine.d41.s1	unrecognized	9	20	O	unrecognized	zed	ized	JJ	False
DDI-MedLine.d41.s1	interactions	22	33	O	interactions	ons	ions	NNS	False
DDI-MedLine.d41.s1	between	35	41	O	between	een	ween	IN	False
DDI-MedLine.d41.s1	homopolyribonucleotides	43	65	O	homopolyribonucleotides	des	ides	NNS	group
DDI-MedLine.d41.s1	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d41.s1	complexes	71	79	O	complexes	xes	exes	NNS	False
DDI-MedLine.d41.s1	thereof	81	87	O	thereof	eof	reof	NN	False
DDI-MedLine.d41.s1	are	89	91	O	are	are	are	VBP	False
DDI-MedLine.d41.s1	suggested	93	101	O	suggested	ted	sted	VBN	False
DDI-MedLine.d41.s1	by	103	104	O	by	by	by	IN	False
DDI-MedLine.d41.s1	interferon	106	115	O	interferon	ron	eron	NN	False
DDI-MedLine.d41.s1	induction	117	125	O	induction	ion	tion	NN	False
DDI-MedLine.d41.s1	data	127	130	O	data	ata	data	NNS	False
DDI-MedLine.d41.s1	obtained	132	139	O	obtained	ned	ined	VBN	False
DDI-MedLine.d41.s1	in	141	142	O	in	in	in	IN	False
DDI-MedLine.d41.s1	a	144	144	O	a	a	a	DT	False
DDI-MedLine.d41.s1	highly	146	151	O	highly	hly	ghly	RB	False
DDI-MedLine.d41.s1	sensitive	153	161	O	sensitive	ive	tive	JJ	False
DDI-MedLine.d41.s1	assay	163	167	O	assay	say	ssay	NN	False
DDI-MedLine.d41.s1	system	169	174	O	system	tem	stem	NN	False
DDI-MedLine.d41.s1	of	176	177	O	of	of	of	IN	False
DDI-MedLine.d41.s1	primary	179	185	O	primary	ary	mary	NN	False
DDI-MedLine.d41.s1	rabbit	187	192	O	rabbit	bit	bbit	NN	False
DDI-MedLine.d41.s1	kidney	194	199	O	kidney	ney	dney	NN	False
DDI-MedLine.d41.s1	cell	201	204	O	cell	ell	cell	NN	False
DDI-MedLine.d41.s1	cultures	206	213	O	cultures	res	ures	NNS	False
DDI-MedLine.d41.s1	superinduced	215	226	O	superinduced	ced	uced	VBN	False
DDI-MedLine.d41.s1	by	228	229	O	by	by	by	IN	False
DDI-MedLine.d41.s1	metabolic	231	239	O	metabolic	lic	olic	NN	False
DDI-MedLine.d41.s1	inhibitors	241	250	O	inhibitors	ors	tors	NNS	False
DDI-MedLine.d41.s1	.	251	251	O	.	.	.	.	False

DDI-MedLine.d119.s0	Development	0	10	O	Development	ent	ment	NNP	False
DDI-MedLine.d119.s0	and	12	14	O	and	and	and	CC	False
DDI-MedLine.d119.s0	pharmacology	16	27	O	pharmacology	ogy	logy	NN	False
DDI-MedLine.d119.s0	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d119.s0	fluvastatin	32	42	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s0	.	43	43	O	.	.	.	.	False

DDI-MedLine.d119.s1	Fluvastatin	0	10	B-drug	Fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s1	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d119.s1	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d119.s1	first	19	23	O	first	rst	irst	RB	False
DDI-MedLine.d119.s1	synthetic	25	33	B-group	synthetic	tic	etic	JJ	False
DDI-MedLine.d119.s1	3-hydroxy-3-methylglutaryl	35	60	I-group	3-hydroxy-3-methylglutaryl	ryl	aryl	JJ	False
DDI-MedLine.d119.s1	coenzyme	62	69	I-group	coenzyme	yme	zyme	NN	False
DDI-MedLine.d119.s1	A	71	71	I-group	A	A	A	DT	brand
DDI-MedLine.d119.s1	(	73	73	I-group	(	(	(	(	False
DDI-MedLine.d119.s1	HMGCoA	74	79	I-group	HMGCoA	CoA	GCoA	NN	False
DDI-MedLine.d119.s1	)	80	80	I-group	)	)	)	)	False
DDI-MedLine.d119.s1	reductase	82	90	I-group	reductase	ase	tase	NN	False
DDI-MedLine.d119.s1	inhibitor	92	100	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d119.s1	to	102	103	O	to	to	to	TO	False
DDI-MedLine.d119.s1	be	105	106	O	be	be	be	VB	False
DDI-MedLine.d119.s1	approved	108	115	O	approved	ved	oved	VBN	False
DDI-MedLine.d119.s1	for	117	119	O	for	for	for	IN	False
DDI-MedLine.d119.s1	clinical	121	128	O	clinical	cal	ical	JJ	False
DDI-MedLine.d119.s1	use	130	132	O	use	use	use	NN	False
DDI-MedLine.d119.s1	,	133	133	O	,	,	,	,	False
DDI-MedLine.d119.s1	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d119.s1	has	139	141	O	has	has	has	VBZ	False
DDI-MedLine.d119.s1	been	143	146	O	been	een	been	VBN	False
DDI-MedLine.d119.s1	studied	148	154	O	studied	ied	died	VBN	False
DDI-MedLine.d119.s1	extensively	156	166	O	extensively	ely	vely	RB	False
DDI-MedLine.d119.s1	in	168	169	O	in	in	in	IN	False
DDI-MedLine.d119.s1	humans	171	176	O	humans	ans	mans	NNS	False
DDI-MedLine.d119.s1	since	178	182	O	since	nce	ince	IN	False
DDI-MedLine.d119.s1	1986	184	187	O	1986	986	1986	CD	False
DDI-MedLine.d119.s1	.	188	188	O	.	.	.	.	False

DDI-MedLine.d119.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d119.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d119.s2	structurally	6	17	O	structurally	lly	ally	RB	False
DDI-MedLine.d119.s2	distinct	19	26	O	distinct	nct	inct	NN	False
DDI-MedLine.d119.s2	from	28	31	O	from	rom	from	IN	False
DDI-MedLine.d119.s2	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d119.s2	other	37	41	O	other	her	ther	JJ	False
DDI-MedLine.d119.s2	currently	43	51	O	currently	tly	ntly	RB	False
DDI-MedLine.d119.s2	available	53	61	O	available	ble	able	JJ	False
DDI-MedLine.d119.s2	HMGCoA	63	68	B-group	HMGCoA	CoA	GCoA	NN	False
DDI-MedLine.d119.s2	reductase	70	78	I-group	reductase	ase	tase	NN	False
DDI-MedLine.d119.s2	inhibitors	80	89	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d119.s2	(	91	91	O	(	(	(	(	False
DDI-MedLine.d119.s2	lovastatin	92	101	B-drug	lovastatin	tin	atin	NN	False
DDI-MedLine.d119.s2	,	102	102	O	,	,	,	,	False
DDI-MedLine.d119.s2	simvastatin	104	114	B-drug	simvastatin	tin	atin	NN	False
DDI-MedLine.d119.s2	,	115	115	O	,	,	,	,	False
DDI-MedLine.d119.s2	and	117	119	O	and	and	and	CC	False
DDI-MedLine.d119.s2	pravastatin	121	131	B-drug	pravastatin	tin	atin	NN	False
DDI-MedLine.d119.s2	)	132	132	O	)	)	)	)	False
DDI-MedLine.d119.s2	,	133	133	O	,	,	,	,	False
DDI-MedLine.d119.s2	leading	135	141	O	leading	ing	ding	VBG	False
DDI-MedLine.d119.s2	to	143	144	O	to	to	to	TO	False
DDI-MedLine.d119.s2	unique	146	151	O	unique	que	ique	NN	False
DDI-MedLine.d119.s2	biopharmaceutical	153	169	O	biopharmaceutical	cal	ical	JJ	False
DDI-MedLine.d119.s2	properties	171	180	O	properties	ies	ties	NNS	False
DDI-MedLine.d119.s2	relative	182	189	O	relative	ive	tive	NN	False
DDI-MedLine.d119.s2	to	191	192	O	to	to	to	TO	False
DDI-MedLine.d119.s2	the	194	196	O	the	the	the	DT	False
DDI-MedLine.d119.s2	other	198	202	O	other	her	ther	JJ	False
DDI-MedLine.d119.s2	agents	204	209	O	agents	nts	ents	NNS	False
DDI-MedLine.d119.s2	of	211	212	O	of	of	of	IN	False
DDI-MedLine.d119.s2	this	214	217	O	this	his	this	DT	False
DDI-MedLine.d119.s2	class	219	223	O	class	ass	lass	NN	False
DDI-MedLine.d119.s2	.	224	224	O	.	.	.	.	False

DDI-MedLine.d119.s3	Absorption	0	9	O	Absorption	ion	tion	NN	False
DDI-MedLine.d119.s3	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d119.s3	fluvastatin	14	24	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s3	is	26	27	O	is	is	is	VBZ	False
DDI-MedLine.d119.s3	virtually	29	37	O	virtually	lly	ally	RB	False
DDI-MedLine.d119.s3	complete	39	46	O	complete	ete	lete	JJ	False
DDI-MedLine.d119.s3	across	48	53	O	across	oss	ross	IN	False
DDI-MedLine.d119.s3	all	55	57	O	all	all	all	DT	False
DDI-MedLine.d119.s3	species	59	65	O	species	ies	cies	NNS	False
DDI-MedLine.d119.s3	,	66	66	O	,	,	,	,	False
DDI-MedLine.d119.s3	including	68	76	O	including	ing	ding	VBG	False
DDI-MedLine.d119.s3	man	78	80	O	man	man	man	NN	False
DDI-MedLine.d119.s3	,	81	81	O	,	,	,	,	False
DDI-MedLine.d119.s3	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d119.s3	is	87	88	O	is	is	is	VBZ	False
DDI-MedLine.d119.s3	not	90	92	O	not	not	not	RB	False
DDI-MedLine.d119.s3	affected	94	101	O	affected	ted	cted	JJ	False
DDI-MedLine.d119.s3	by	103	104	O	by	by	by	IN	False
DDI-MedLine.d119.s3	the	106	108	O	the	the	the	DT	False
DDI-MedLine.d119.s3	presence	110	117	O	presence	nce	ence	NN	False
DDI-MedLine.d119.s3	of	119	120	O	of	of	of	IN	False
DDI-MedLine.d119.s3	food	122	125	O	food	ood	food	NN	False
DDI-MedLine.d119.s3	.	126	126	O	.	.	.	.	False

DDI-MedLine.d119.s4	Systemic	0	7	O	Systemic	mic	emic	JJ	False
DDI-MedLine.d119.s4	exposure	9	16	O	exposure	ure	sure	NN	False
DDI-MedLine.d119.s4	is	18	19	O	is	is	is	VBZ	False
DDI-MedLine.d119.s4	limited	21	27	O	limited	ted	ited	JJ	False
DDI-MedLine.d119.s4	,	28	28	O	,	,	,	,	False
DDI-MedLine.d119.s4	as	30	31	O	as	as	as	IN	False
DDI-MedLine.d119.s4	fluvastatin	33	43	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s4	is	45	46	O	is	is	is	VBZ	False
DDI-MedLine.d119.s4	subject	48	54	O	subject	ect	ject	NN	False
DDI-MedLine.d119.s4	to	56	57	O	to	to	to	TO	False
DDI-MedLine.d119.s4	first-pass	59	68	O	first-pass	ass	pass	NN	False
DDI-MedLine.d119.s4	metabolism	70	79	O	metabolism	ism	lism	NN	False
DDI-MedLine.d119.s4	,	80	80	O	,	,	,	,	False
DDI-MedLine.d119.s4	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d119.s4	the	86	88	O	the	the	the	DT	False
DDI-MedLine.d119.s4	plasma	90	95	O	plasma	sma	asma	NN	False
DDI-MedLine.d119.s4	half-life	97	105	O	half-life	ife	life	NN	False
DDI-MedLine.d119.s4	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d119.s4	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d119.s4	drug	114	117	O	drug	rug	drug	NN	False
DDI-MedLine.d119.s4	is	119	120	O	is	is	is	VBZ	False
DDI-MedLine.d119.s4	approximately	122	134	O	approximately	ely	tely	RB	False
DDI-MedLine.d119.s4	30	136	137	O	30	30	30	CD	False
DDI-MedLine.d119.s4	minutes	139	145	O	minutes	tes	utes	NNS	False
DDI-MedLine.d119.s4	.	146	146	O	.	.	.	.	False

DDI-MedLine.d119.s5	Some	0	3	O	Some	ome	Some	DT	False
DDI-MedLine.d119.s5	95	5	6	O	95	95	95	CD	False
DDI-MedLine.d119.s5	%	7	7	O	%	%	%	NN	False
DDI-MedLine.d119.s5	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d119.s5	a	12	12	O	a	a	a	DT	False
DDI-MedLine.d119.s5	single	14	19	O	single	gle	ngle	JJ	False
DDI-MedLine.d119.s5	dosage	21	26	O	dosage	age	sage	NN	False
DDI-MedLine.d119.s5	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d119.s5	fluvastatin	31	41	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s5	is	43	44	O	is	is	is	VBZ	False
DDI-MedLine.d119.s5	excreted	46	53	O	excreted	ted	eted	VBN	False
DDI-MedLine.d119.s5	via	55	57	O	via	via	via	IN	False
DDI-MedLine.d119.s5	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d119.s5	biliary	63	69	O	biliary	ary	iary	NN	False
DDI-MedLine.d119.s5	route	71	75	O	route	ute	oute	NN	False
DDI-MedLine.d119.s5	,	76	76	O	,	,	,	,	False
DDI-MedLine.d119.s5	with	78	81	O	with	ith	with	IN	False
DDI-MedLine.d119.s5	less	83	86	O	less	ess	less	RBR	False
DDI-MedLine.d119.s5	than	88	91	O	than	han	than	IN	False
DDI-MedLine.d119.s5	2	93	93	O	2	2	2	CD	False
DDI-MedLine.d119.s5	%	94	94	O	%	%	%	NN	False
DDI-MedLine.d119.s5	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d119.s5	this	99	102	O	this	his	this	DT	False
DDI-MedLine.d119.s5	being	104	108	O	being	ing	eing	VBG	False
DDI-MedLine.d119.s5	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d119.s5	parent	114	119	O	parent	ent	rent	NN	False
DDI-MedLine.d119.s5	compound	121	128	O	compound	und	ound	NN	False
DDI-MedLine.d119.s5	.	129	129	O	.	.	.	.	False

DDI-MedLine.d119.s6	Additionally	0	11	O	Additionally	lly	ally	RB	False
DDI-MedLine.d119.s6	,	12	12	O	,	,	,	,	False
DDI-MedLine.d119.s6	there	14	18	O	there	ere	here	RB	False
DDI-MedLine.d119.s6	is	20	21	O	is	is	is	VBZ	False
DDI-MedLine.d119.s6	no	23	24	O	no	no	no	DT	False
DDI-MedLine.d119.s6	evidence	26	33	O	evidence	nce	ence	NN	False
DDI-MedLine.d119.s6	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d119.s6	circulating	38	48	O	circulating	ing	ting	VBG	False
DDI-MedLine.d119.s6	active	50	55	O	active	ive	tive	JJ	False
DDI-MedLine.d119.s6	metabolites	57	67	O	metabolites	tes	ites	NNS	False
DDI-MedLine.d119.s6	or	69	70	O	or	or	or	CC	False
DDI-MedLine.d119.s6	accumulation	72	83	O	accumulation	ion	tion	NN	False
DDI-MedLine.d119.s6	during	85	90	O	during	ing	ring	IN	False
DDI-MedLine.d119.s6	chronic	92	98	O	chronic	nic	onic	NN	False
DDI-MedLine.d119.s6	dosing	100	105	O	dosing	ing	sing	VBG	False
DDI-MedLine.d119.s6	.	106	106	O	.	.	.	.	False

DDI-MedLine.d119.s7	Studies	0	6	O	Studies	ies	dies	NNS	False
DDI-MedLine.d119.s7	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d119.s7	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d119.s7	effect	15	20	O	effect	ect	fect	NN	False
DDI-MedLine.d119.s7	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d119.s7	food	25	28	O	food	ood	food	NN	False
DDI-MedLine.d119.s7	on	30	31	O	on	on	on	IN	False
DDI-MedLine.d119.s7	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d119.s7	pharmacokinetics	37	52	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d119.s7	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d119.s7	fluvastatin	57	67	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s7	have	69	72	O	have	ave	have	VB	False
DDI-MedLine.d119.s7	demonstrated	74	85	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d119.s7	marked	87	92	O	marked	ked	rked	NNS	False
DDI-MedLine.d119.s7	reductions	94	103	O	reductions	ons	ions	NNS	False
DDI-MedLine.d119.s7	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d119.s7	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d119.s7	rate	112	115	O	rate	ate	rate	NN	False
DDI-MedLine.d119.s7	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d119.s7	bioavailability	120	134	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d119.s7	--	135	136	O	--	--	--	:	False
DDI-MedLine.d119.s7	from	137	140	O	from	rom	from	IN	False
DDI-MedLine.d119.s7	40	142	143	O	40	40	40	CD	False
DDI-MedLine.d119.s7	%	144	144	O	%	%	%	NN	False
DDI-MedLine.d119.s7	to	146	147	O	to	to	to	TO	False
DDI-MedLine.d119.s7	60	149	150	O	60	60	60	CD	False
DDI-MedLine.d119.s7	%	151	151	O	%	%	%	NN	False
DDI-MedLine.d119.s7	;	152	152	O	;	;	;	:	False

DDI-MedLine.d119.s8	however	0	6	O	however	ver	ever	RB	False
DDI-MedLine.d119.s8	,	7	7	O	,	,	,	,	False
DDI-MedLine.d119.s8	a	9	9	O	a	a	a	DT	False
DDI-MedLine.d119.s8	comparison	11	20	O	comparison	son	ison	NN	False
DDI-MedLine.d119.s8	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d119.s8	fluvastatin	25	35	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s8	administration	37	50	O	administration	ion	tion	NN	False
DDI-MedLine.d119.s8	with	52	55	O	with	ith	with	IN	False
DDI-MedLine.d119.s8	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d119.s8	evening	61	67	O	evening	ing	ning	VBG	False
DDI-MedLine.d119.s8	meal	69	72	O	meal	eal	meal	NN	False
DDI-MedLine.d119.s8	or	74	75	O	or	or	or	CC	False
DDI-MedLine.d119.s8	at	77	78	O	at	at	at	IN	False
DDI-MedLine.d119.s8	bedtime	80	86	O	bedtime	ime	time	NN	False
DDI-MedLine.d119.s8	has	88	90	O	has	has	has	VBZ	False
DDI-MedLine.d119.s8	revealed	92	99	O	revealed	led	aled	VBD	False
DDI-MedLine.d119.s8	no	101	102	O	no	no	no	DT	False
DDI-MedLine.d119.s8	significant	104	114	O	significant	ant	cant	JJ	False
DDI-MedLine.d119.s8	differences	116	126	O	differences	ces	nces	NNS	False
DDI-MedLine.d119.s8	in	128	129	O	in	in	in	IN	False
DDI-MedLine.d119.s8	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d119.s8	extent	135	140	O	extent	ent	tent	NN	False
DDI-MedLine.d119.s8	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d119.s8	bioavailability	145	159	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d119.s8	(	161	161	O	(	(	(	(	False
DDI-MedLine.d119.s8	area	162	165	O	area	rea	area	NN	False
DDI-MedLine.d119.s8	under	167	171	O	under	der	nder	IN	False
DDI-MedLine.d119.s8	the	173	175	O	the	the	the	DT	False
DDI-MedLine.d119.s8	curve	177	181	O	curve	rve	urve	NN	False
DDI-MedLine.d119.s8	)	182	182	O	)	)	)	)	False
DDI-MedLine.d119.s8	of	184	185	O	of	of	of	IN	False
DDI-MedLine.d119.s8	these	187	191	O	these	ese	hese	DT	False
DDI-MedLine.d119.s8	two	193	195	O	two	two	two	CD	False
DDI-MedLine.d119.s8	regimens	197	204	O	regimens	ens	mens	NNS	False
DDI-MedLine.d119.s8	.	205	205	O	.	.	.	.	False

DDI-MedLine.d119.s9	Furthermore	0	10	O	Furthermore	ore	more	RB	False
DDI-MedLine.d119.s9	,	11	11	O	,	,	,	,	False
DDI-MedLine.d119.s9	no	13	14	O	no	no	no	DT	False
DDI-MedLine.d119.s9	significant	16	26	O	significant	ant	cant	JJ	False
DDI-MedLine.d119.s9	difference	28	37	O	difference	nce	ence	NN	False
DDI-MedLine.d119.s9	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d119.s9	pharmacodynamic	42	56	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d119.s9	effect	58	63	O	effect	ect	fect	NN	False
DDI-MedLine.d119.s9	(	65	65	O	(	(	(	(	False
DDI-MedLine.d119.s9	reduction	66	74	O	reduction	ion	tion	NN	False
DDI-MedLine.d119.s9	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d119.s9	low-density	79	89	O	low-density	ity	sity	NN	False
DDI-MedLine.d119.s9	lipoprotein	91	101	O	lipoprotein	ein	tein	NN	False
DDI-MedLine.d119.s9	cholesterol	103	113	O	cholesterol	rol	erol	NN	False
DDI-MedLine.d119.s9	levels	115	120	O	levels	els	vels	NNS	False
DDI-MedLine.d119.s9	)	121	121	O	)	)	)	)	False
DDI-MedLine.d119.s9	could	123	127	O	could	uld	ould	MD	False
DDI-MedLine.d119.s9	be	129	130	O	be	be	be	VB	False
DDI-MedLine.d119.s9	ascertained	132	142	O	ascertained	ned	ined	VBN	False
DDI-MedLine.d119.s9	between	144	150	O	between	een	ween	IN	False
DDI-MedLine.d119.s9	mealtime	152	159	O	mealtime	ime	time	NN	False
DDI-MedLine.d119.s9	dosing	161	166	O	dosing	ing	sing	VBG	False
DDI-MedLine.d119.s9	and	168	170	O	and	and	and	CC	False
DDI-MedLine.d119.s9	bedtime	172	178	O	bedtime	ime	time	NN	False
DDI-MedLine.d119.s9	dosing	180	185	O	dosing	ing	sing	VBG	False
DDI-MedLine.d119.s9	.	186	186	O	.	.	.	.	False

DDI-MedLine.d119.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d119.s10	pharmacokinetics	4	19	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d119.s10	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d119.s10	fluvastatin	24	34	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s10	have	36	39	O	have	ave	have	VB	False
DDI-MedLine.d119.s10	also	41	44	O	also	lso	also	RB	False
DDI-MedLine.d119.s10	been	46	49	O	been	een	been	VBN	False
DDI-MedLine.d119.s10	assessed	51	58	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d119.s10	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d119.s10	various	63	69	O	various	ous	ious	JJ	False
DDI-MedLine.d119.s10	demographic	71	81	O	demographic	hic	phic	JJ	False
DDI-MedLine.d119.s10	groups	83	88	O	groups	ups	oups	NNS	False
DDI-MedLine.d119.s10	.	89	89	O	.	.	.	.	False

DDI-MedLine.d119.s11	Relative	0	7	O	Relative	ive	tive	JJ	False
DDI-MedLine.d119.s11	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d119.s11	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d119.s11	general	16	22	O	general	ral	eral	JJ	False
DDI-MedLine.d119.s11	population	24	33	O	population	ion	tion	NN	False
DDI-MedLine.d119.s11	,	34	34	O	,	,	,	,	False
DDI-MedLine.d119.s11	plasma	36	41	O	plasma	sma	asma	NN	False
DDI-MedLine.d119.s11	concentrations	43	56	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d119.s11	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d119.s11	fluvastatin	61	71	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s11	do	73	74	O	do	do	do	VB	False
DDI-MedLine.d119.s11	not	76	78	O	not	not	not	RB	False
DDI-MedLine.d119.s11	vary	80	83	O	vary	ary	vary	NN	False
DDI-MedLine.d119.s11	as	85	86	O	as	as	as	IN	False
DDI-MedLine.d119.s11	a	88	88	O	a	a	a	DT	False
DDI-MedLine.d119.s11	function	90	97	O	function	ion	tion	NN	False
DDI-MedLine.d119.s11	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d119.s11	either	102	107	O	either	her	ther	DT	False
DDI-MedLine.d119.s11	age	109	111	O	age	age	age	NN	False
DDI-MedLine.d119.s11	or	113	114	O	or	or	or	CC	False
DDI-MedLine.d119.s11	gender	116	121	O	gender	der	nder	NN	False
DDI-MedLine.d119.s11	.	122	122	O	.	.	.	.	False

DDI-MedLine.d119.s12	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d119.s12	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d119.s12	,	11	11	O	,	,	,	,	False
DDI-MedLine.d119.s12	administration	13	26	O	administration	ion	tion	NN	False
DDI-MedLine.d119.s12	to	28	29	O	to	to	to	TO	False
DDI-MedLine.d119.s12	a	31	31	O	a	a	a	DT	False
DDI-MedLine.d119.s12	patient	33	39	O	patient	ent	ient	NN	False
DDI-MedLine.d119.s12	population	41	50	O	population	ion	tion	NN	False
DDI-MedLine.d119.s12	with	52	55	O	with	ith	with	IN	False
DDI-MedLine.d119.s12	hepatic	57	63	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d119.s12	insufficiency	65	77	O	insufficiency	ncy	ency	NN	False
DDI-MedLine.d119.s12	resulted	79	86	O	resulted	ted	lted	VBD	False
DDI-MedLine.d119.s12	in	88	89	O	in	in	in	IN	False
DDI-MedLine.d119.s12	a	91	91	O	a	a	a	DT	False
DDI-MedLine.d119.s12	2.5-fold	93	100	O	2.5-fold	old	fold	JJ	False
DDI-MedLine.d119.s12	increase	102	109	O	increase	ase	ease	NN	False
DDI-MedLine.d119.s12	in	111	112	O	in	in	in	IN	False
DDI-MedLine.d119.s12	both	114	117	O	both	oth	both	DT	False
DDI-MedLine.d119.s12	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d119.s12	rate	123	126	O	rate	ate	rate	NN	False
DDI-MedLine.d119.s12	and	128	130	O	and	and	and	CC	False
DDI-MedLine.d119.s12	extent	132	137	O	extent	ent	tent	NN	False
DDI-MedLine.d119.s12	of	139	140	O	of	of	of	IN	False
DDI-MedLine.d119.s12	bioavailability	142	156	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d119.s12	relative	158	165	O	relative	ive	tive	NN	False
DDI-MedLine.d119.s12	to	167	168	O	to	to	to	TO	False
DDI-MedLine.d119.s12	controls	170	177	O	controls	ols	rols	NNS	False
DDI-MedLine.d119.s12	.	178	178	O	.	.	.	.	False

DDI-MedLine.d119.s13	Also	0	3	O	Also	lso	Also	RB	False
DDI-MedLine.d119.s13	,	4	4	O	,	,	,	,	False
DDI-MedLine.d119.s13	although	6	13	O	although	ugh	ough	IN	False
DDI-MedLine.d119.s13	minimal	15	21	O	minimal	mal	imal	NN	False
DDI-MedLine.d119.s13	alterations	23	33	O	alterations	ons	ions	NNS	False
DDI-MedLine.d119.s13	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d119.s13	fluvastatin	38	48	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s13	clearance	50	58	O	clearance	nce	ance	NN	False
DDI-MedLine.d119.s13	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d119.s13	patients	63	70	O	patients	nts	ents	NNS	False
DDI-MedLine.d119.s13	with	72	75	O	with	ith	with	IN	False
DDI-MedLine.d119.s13	renal	77	81	O	renal	nal	enal	NN	False
DDI-MedLine.d119.s13	insufficiency	83	95	O	insufficiency	ncy	ency	NN	False
DDI-MedLine.d119.s13	are	97	99	O	are	are	are	VBP	False
DDI-MedLine.d119.s13	anticipated	101	111	O	anticipated	ted	ated	VBN	False
DDI-MedLine.d119.s13	due	113	115	O	due	due	due	JJ	False
DDI-MedLine.d119.s13	to	117	118	O	to	to	to	TO	False
DDI-MedLine.d119.s13	limited	120	126	O	limited	ted	ited	JJ	False
DDI-MedLine.d119.s13	renal	128	132	O	renal	nal	enal	NN	False
DDI-MedLine.d119.s13	excretion	134	142	O	excretion	ion	tion	NN	False
DDI-MedLine.d119.s13	(	144	144	O	(	(	(	(	False
DDI-MedLine.d119.s13	5	145	145	O	5	5	5	CD	False
DDI-MedLine.d119.s13	%	146	146	O	%	%	%	NN	False
DDI-MedLine.d119.s13	)	147	147	O	)	)	)	)	False
DDI-MedLine.d119.s13	,	148	148	O	,	,	,	,	False
DDI-MedLine.d119.s13	a	150	150	O	a	a	a	DT	False
DDI-MedLine.d119.s13	study	152	156	O	study	udy	tudy	NN	False
DDI-MedLine.d119.s13	in	158	159	O	in	in	in	IN	False
DDI-MedLine.d119.s13	this	161	164	O	this	his	this	DT	False
DDI-MedLine.d119.s13	patient	166	172	O	patient	ent	ient	NN	False
DDI-MedLine.d119.s13	group	174	178	O	group	oup	roup	NN	False
DDI-MedLine.d119.s13	is	180	181	O	is	is	is	VBZ	False
DDI-MedLine.d119.s13	currently	183	191	O	currently	tly	ntly	RB	False
DDI-MedLine.d119.s13	underway	193	200	O	underway	way	rway	RB	False
DDI-MedLine.d119.s13	to	202	203	O	to	to	to	TO	False
DDI-MedLine.d119.s13	examine	205	211	O	examine	ine	mine	NN	drug
DDI-MedLine.d119.s13	this	213	216	O	this	his	this	DT	False
DDI-MedLine.d119.s13	further	218	224	O	further	her	ther	RB	False
DDI-MedLine.d119.s13	.	225	225	O	.	.	.	.	False

DDI-MedLine.d119.s14	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d119.s14	studies	12	18	O	studies	ies	dies	NNS	False
DDI-MedLine.d119.s14	have	20	23	O	have	ave	have	VB	False
DDI-MedLine.d119.s14	been	25	28	O	been	een	been	VBN	False
DDI-MedLine.d119.s14	performed	30	38	O	performed	med	rmed	VBN	False
DDI-MedLine.d119.s14	with	40	43	O	with	ith	with	IN	False
DDI-MedLine.d119.s14	fluvastatin	45	55	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s14	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d119.s14	several	61	67	O	several	ral	eral	JJ	False
DDI-MedLine.d119.s14	drugs	69	73	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d119.s14	with	75	78	O	with	ith	with	IN	False
DDI-MedLine.d119.s14	which	80	84	O	which	ich	hich	WDT	False
DDI-MedLine.d119.s14	it	86	87	O	it	it	it	PRP	False
DDI-MedLine.d119.s14	might	89	93	O	might	ght	ight	MD	False
DDI-MedLine.d119.s14	be	95	96	O	be	be	be	VB	False
DDI-MedLine.d119.s14	coadministered	98	111	O	coadministered	red	ered	VBN	False
DDI-MedLine.d119.s14	.	112	112	O	.	.	.	.	False

DDI-MedLine.d119.s15	Cholestyramine	0	13	B-drug	Cholestyramine	ine	mine	NN	drug
DDI-MedLine.d119.s15	,	14	14	O	,	,	,	,	False
DDI-MedLine.d119.s15	an	16	17	O	an	an	an	DT	False
DDI-MedLine.d119.s15	anionic-binding	19	33	O	anionic-binding	ing	ding	NN	False
DDI-MedLine.d119.s15	resin	35	39	O	resin	sin	esin	NN	False
DDI-MedLine.d119.s15	,	40	40	O	,	,	,	,	False
DDI-MedLine.d119.s15	has	42	44	O	has	has	has	VBZ	False
DDI-MedLine.d119.s15	a	46	46	O	a	a	a	DT	False
DDI-MedLine.d119.s15	considerable	48	59	O	considerable	ble	able	JJ	False
DDI-MedLine.d119.s15	effect	61	66	O	effect	ect	fect	NN	False
DDI-MedLine.d119.s15	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d119.s15	lowering	71	78	O	lowering	ing	ring	VBG	False
DDI-MedLine.d119.s15	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d119.s15	rate	84	87	O	rate	ate	rate	NN	False
DDI-MedLine.d119.s15	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d119.s15	extent	93	98	O	extent	ent	tent	NN	False
DDI-MedLine.d119.s15	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d119.s15	fluvastatin	103	113	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s15	bioavailability	115	129	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d119.s15	.	130	130	O	.	.	.	.	False

DDI-MedLine.d119.s16	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d119.s16	this	9	12	O	this	his	this	DT	False
DDI-MedLine.d119.s16	effect	14	19	O	effect	ect	fect	NN	False
DDI-MedLine.d119.s16	was	21	23	O	was	was	was	VBD	False
DDI-MedLine.d119.s16	noted	25	29	O	noted	ted	oted	VBN	False
DDI-MedLine.d119.s16	even	31	34	O	even	ven	even	RB	False
DDI-MedLine.d119.s16	when	36	39	O	when	hen	when	WRB	False
DDI-MedLine.d119.s16	cholestyramine	41	54	B-drug	cholestyramine	ine	mine	NN	drug
DDI-MedLine.d119.s16	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d119.s16	given	60	64	O	given	ven	iven	VBN	False
DDI-MedLine.d119.s16	4	66	66	O	4	4	4	CD	False
DDI-MedLine.d119.s16	hours	68	72	O	hours	urs	ours	NNS	False
DDI-MedLine.d119.s16	prior	74	78	O	prior	ior	rior	RB	False
DDI-MedLine.d119.s16	to	80	81	O	to	to	to	TO	False
DDI-MedLine.d119.s16	fluvastatin	83	93	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s16	,	94	94	O	,	,	,	,	False
DDI-MedLine.d119.s16	this	96	99	O	this	his	this	DT	False
DDI-MedLine.d119.s16	regimen	101	107	O	regimen	men	imen	NNS	False
DDI-MedLine.d119.s16	did	109	111	O	did	did	did	VBD	False
DDI-MedLine.d119.s16	not	113	115	O	not	not	not	RB	False
DDI-MedLine.d119.s16	result	117	122	O	result	ult	sult	NN	False
DDI-MedLine.d119.s16	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d119.s16	diminished	127	136	O	diminished	hed	shed	VBN	False
DDI-MedLine.d119.s16	efficacy	138	145	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d119.s16	.	146	146	O	.	.	.	.	False

DDI-MedLine.d119.s17	Further	0	6	O	Further	her	ther	RB	False
DDI-MedLine.d119.s17	,	7	7	O	,	,	,	,	False
DDI-MedLine.d119.s17	no	9	10	O	no	no	no	DT	False
DDI-MedLine.d119.s17	effects	12	18	O	effects	cts	ects	NNS	False
DDI-MedLine.d119.s17	on	20	21	O	on	on	on	IN	False
DDI-MedLine.d119.s17	either	23	28	O	either	her	ther	DT	False
DDI-MedLine.d119.s17	warfarin	30	37	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d119.s17	levels	39	44	O	levels	els	vels	NNS	False
DDI-MedLine.d119.s17	or	46	47	O	or	or	or	CC	False
DDI-MedLine.d119.s17	prothrombin	49	59	O	prothrombin	bin	mbin	NN	False
DDI-MedLine.d119.s17	times	61	65	O	times	mes	imes	NNS	False
DDI-MedLine.d119.s17	were	67	70	O	were	ere	were	VBD	False
DDI-MedLine.d119.s17	observed	72	79	O	observed	ved	rved	VBN	False
DDI-MedLine.d119.s17	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d119.s17	a	84	84	O	a	a	a	DT	False
DDI-MedLine.d119.s17	study	86	90	O	study	udy	tudy	NN	False
DDI-MedLine.d119.s17	involving	92	100	O	involving	ing	ving	VBG	False
DDI-MedLine.d119.s17	concomitant	102	112	O	concomitant	ant	tant	NN	False
DDI-MedLine.d119.s17	administration	114	127	O	administration	ion	tion	NN	False
DDI-MedLine.d119.s17	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d119.s17	warfarin	132	139	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d119.s17	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d119.s17	fluvastatin	145	155	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s17	.	156	156	O	.	.	.	.	False

DDI-MedLine.d119.s18	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d119.s18	,	8	8	O	,	,	,	,	False
DDI-MedLine.d119.s18	additional	10	19	O	additional	nal	onal	JJ	False
DDI-MedLine.d119.s18	interaction	21	31	O	interaction	ion	tion	NN	False
DDI-MedLine.d119.s18	studies	33	39	O	studies	ies	dies	NNS	False
DDI-MedLine.d119.s18	with	41	44	O	with	ith	with	IN	False
DDI-MedLine.d119.s18	niacin	46	51	B-drug	niacin	cin	acin	NN	drug
DDI-MedLine.d119.s18	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d119.s18	propranolol	57	67	B-drug	propranolol	lol	olol	NN	False
DDI-MedLine.d119.s18	have	69	72	O	have	ave	have	VB	False
DDI-MedLine.d119.s18	not	74	76	O	not	not	not	RB	False
DDI-MedLine.d119.s18	demonstrated	78	89	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d119.s18	any	91	93	O	any	any	any	DT	False
DDI-MedLine.d119.s18	effect	95	100	O	effect	ect	fect	NN	False
DDI-MedLine.d119.s18	on	102	103	O	on	on	on	IN	False
DDI-MedLine.d119.s18	fluvastatin	105	115	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s18	plasma	117	122	O	plasma	sma	asma	NN	False
DDI-MedLine.d119.s18	levels	124	129	O	levels	els	vels	NNS	False
DDI-MedLine.d119.s18	,	130	130	O	,	,	,	,	False
DDI-MedLine.d119.s18	and	132	134	O	and	and	and	CC	False
DDI-MedLine.d119.s18	administration	136	149	O	administration	ion	tion	NN	False
DDI-MedLine.d119.s18	to	151	152	O	to	to	to	TO	False
DDI-MedLine.d119.s18	a	154	154	O	a	a	a	DT	False
DDI-MedLine.d119.s18	patient	156	162	O	patient	ent	ient	NN	False
DDI-MedLine.d119.s18	population	164	173	O	population	ion	tion	NN	False
DDI-MedLine.d119.s18	chronically	175	185	O	chronically	lly	ally	RB	False
DDI-MedLine.d119.s18	receiving	187	195	O	receiving	ing	ving	VBG	False
DDI-MedLine.d119.s18	digoxin	197	203	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d119.s18	resulted	205	212	O	resulted	ted	lted	VBD	False
DDI-MedLine.d119.s18	in	214	215	O	in	in	in	IN	False
DDI-MedLine.d119.s18	no	217	218	O	no	no	no	DT	False
DDI-MedLine.d119.s18	difference	220	229	O	difference	nce	ence	NN	False
DDI-MedLine.d119.s18	in	231	232	O	in	in	in	IN	False
DDI-MedLine.d119.s18	the	234	236	O	the	the	the	DT	False
DDI-MedLine.d119.s18	extent	238	243	O	extent	ent	tent	NN	False
DDI-MedLine.d119.s18	of	245	246	O	of	of	of	IN	False
DDI-MedLine.d119.s18	bioavailability	248	262	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d119.s18	of	264	265	O	of	of	of	IN	False
DDI-MedLine.d119.s18	digoxin	267	273	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d119.s18	relative	275	282	O	relative	ive	tive	NN	False
DDI-MedLine.d119.s18	to	284	285	O	to	to	to	TO	False
DDI-MedLine.d119.s18	control	287	293	O	control	rol	trol	NN	False
DDI-MedLine.d119.s18	data	295	298	O	data	ata	data	NNS	False
DDI-MedLine.d119.s18	.	299	299	O	.	.	.	.	False

DDI-MedLine.d119.s19	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d119.s19	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d119.s19	generated	12	20	O	generated	ted	ated	VBN	False
DDI-MedLine.d119.s19	to	22	23	O	to	to	to	TO	False
DDI-MedLine.d119.s19	date	25	28	O	date	ate	date	NN	False
DDI-MedLine.d119.s19	in	30	31	O	in	in	in	IN	False
DDI-MedLine.d119.s19	clinical	33	40	O	clinical	cal	ical	JJ	False
DDI-MedLine.d119.s19	pharmacokinetic	42	56	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d119.s19	studies	58	64	O	studies	ies	dies	NNS	False
DDI-MedLine.d119.s19	with	66	69	O	with	ith	with	IN	False
DDI-MedLine.d119.s19	fluvastatin	71	81	B-drug	fluvastatin	tin	atin	NN	False
DDI-MedLine.d119.s19	thus	83	86	O	thus	hus	thus	RB	False
DDI-MedLine.d119.s19	support	88	94	O	support	ort	port	NN	False
DDI-MedLine.d119.s19	its	96	98	O	its	its	its	PRP$	False
DDI-MedLine.d119.s19	use	100	102	O	use	use	use	NN	False
DDI-MedLine.d119.s19	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d119.s19	a	107	107	O	a	a	a	DT	False
DDI-MedLine.d119.s19	broad	109	113	O	broad	oad	road	JJ	False
DDI-MedLine.d119.s19	population	115	124	O	population	ion	tion	NN	False
DDI-MedLine.d119.s19	of	126	127	O	of	of	of	IN	False
DDI-MedLine.d119.s19	hypercholesterolaemic	129	149	O	hypercholesterolaemic	mic	emic	NN	False
DDI-MedLine.d119.s19	patients	151	158	O	patients	nts	ents	NNS	False
DDI-MedLine.d119.s19	.	159	159	O	.	.	.	.	False

DDI-MedLine.d108.s0	Administration	0	13	O	Administration	ion	tion	NN	False
DDI-MedLine.d108.s0	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d108.s0	lithium	18	24	B-drug	lithium	ium	hium	NN	drug
DDI-MedLine.d108.s0	prophylaxis	26	36	O	prophylaxis	xis	axis	NN	False
DDI-MedLine.d108.s0	.	37	37	O	.	.	.	.	False

DDI-MedLine.d108.s1	Successful	0	9	O	Successful	ful	sful	JJ	False
DDI-MedLine.d108.s1	prophylaxis	11	21	O	prophylaxis	xis	axis	NN	False
DDI-MedLine.d108.s1	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d108.s1	manic-depressive	26	41	O	manic-depressive	ive	sive	JJ	False
DDI-MedLine.d108.s1	disorder	43	50	O	disorder	der	rder	NN	False
DDI-MedLine.d108.s1	requires	52	59	O	requires	res	ires	VBZ	False
DDI-MedLine.d108.s1	more	61	64	O	more	ore	more	RBR	False
DDI-MedLine.d108.s1	than	66	69	O	than	han	than	IN	False
DDI-MedLine.d108.s1	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d108.s1	prescription	75	86	O	prescription	ion	tion	NN	False
DDI-MedLine.d108.s1	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d108.s1	lithium	91	97	B-drug	lithium	ium	hium	NN	drug
DDI-MedLine.d108.s1	carbonate	99	107	I-drug	carbonate	ate	nate	NN	False
DDI-MedLine.d108.s1	.	108	108	O	.	.	.	.	False

DDI-MedLine.d108.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d108.s2	administrative	4	17	O	administrative	ive	tive	JJ	False
DDI-MedLine.d108.s2	arrangements	19	30	O	arrangements	nts	ents	NNS	False
DDI-MedLine.d108.s2	in	32	33	O	in	in	in	IN	False
DDI-MedLine.d108.s2	an	35	36	O	an	an	an	DT	False
DDI-MedLine.d108.s2	area	38	41	O	area	rea	area	NN	False
DDI-MedLine.d108.s2	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d108.s2	Scotland	46	53	O	Scotland	and	land	NN	False
DDI-MedLine.d108.s2	were	55	58	O	were	ere	were	VBD	False
DDI-MedLine.d108.s2	accompanied	60	70	O	accompanied	ied	nied	VBN	False
DDI-MedLine.d108.s2	by	72	73	O	by	by	by	IN	False
DDI-MedLine.d108.s2	a	75	75	O	a	a	a	DT	False
DDI-MedLine.d108.s2	300	77	79	O	300	300	300	CD	False
DDI-MedLine.d108.s2	%	80	80	O	%	%	%	NN	False
DDI-MedLine.d108.s2	increase	82	89	O	increase	ase	ease	NN	False
DDI-MedLine.d108.s2	in	91	92	O	in	in	in	IN	False
DDI-MedLine.d108.s2	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d108.s2	frequency	98	106	O	frequency	ncy	ency	NN	False
DDI-MedLine.d108.s2	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d108.s2	admissions	111	120	O	admissions	ons	ions	NNS	False
DDI-MedLine.d108.s2	for	122	124	O	for	for	for	IN	False
DDI-MedLine.d108.s2	mania	126	130	O	mania	nia	ania	NN	False
DDI-MedLine.d108.s2	,	131	131	O	,	,	,	,	False
DDI-MedLine.d108.s2	whereas	133	139	O	whereas	eas	reas	NNS	False
DDI-MedLine.d108.s2	in	141	142	O	in	in	in	IN	False
DDI-MedLine.d108.s2	an	144	145	O	an	an	an	DT	False
DDI-MedLine.d108.s2	area	147	150	O	area	rea	area	NN	False
DDI-MedLine.d108.s2	of	152	153	O	of	of	of	IN	False
DDI-MedLine.d108.s2	the	155	157	O	the	the	the	DT	False
DDI-MedLine.d108.s2	West	159	162	O	West	est	West	NNP	False
DDI-MedLine.d108.s2	Midlands	164	171	O	Midlands	nds	ands	NNS	False
DDI-MedLine.d108.s2	,	172	172	O	,	,	,	,	False
DDI-MedLine.d108.s2	a	174	174	O	a	a	a	DT	False
DDI-MedLine.d108.s2	large	176	180	O	large	rge	arge	JJ	False
DDI-MedLine.d108.s2	decrease	182	189	O	decrease	ase	ease	NN	False
DDI-MedLine.d108.s2	was	191	193	O	was	was	was	VBD	False
DDI-MedLine.d108.s2	achieved	195	202	O	achieved	ved	eved	VBN	False
DDI-MedLine.d108.s2	.	203	203	O	.	.	.	.	False

DDI-MedLine.d40.s0	Studies	0	6	O	Studies	ies	dies	NNS	False
DDI-MedLine.d40.s0	on	8	9	O	on	on	on	IN	False
DDI-MedLine.d40.s0	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d40.s0	mechanism	15	23	O	mechanism	ism	nism	NN	False
DDI-MedLine.d40.s0	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d40.s0	action	28	33	O	action	ion	tion	NN	False
DDI-MedLine.d40.s0	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d40.s0	miconazole	38	47	B-drug	miconazole	ole	zole	NN	drug
DDI-MedLine.d40.s0	:	48	48	O	:	:	:	:	False
DDI-MedLine.d40.s0	effect	50	55	O	effect	ect	fect	NN	False
DDI-MedLine.d40.s0	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d40.s0	miconazole	60	69	B-drug	miconazole	ole	zole	NN	drug
DDI-MedLine.d40.s0	on	71	72	O	on	on	on	IN	False
DDI-MedLine.d40.s0	respiration	74	84	O	respiration	ion	tion	NN	False
DDI-MedLine.d40.s0	and	86	88	O	and	and	and	CC	False
DDI-MedLine.d40.s0	cell	90	93	O	cell	ell	cell	NN	False
DDI-MedLine.d40.s0	permeability	95	106	O	permeability	ity	lity	NN	False
DDI-MedLine.d40.s0	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d40.s0	Candida	111	117	O	Candida	ida	dida	NN	False
DDI-MedLine.d40.s0	albicans	119	126	O	albicans	ans	cans	NNS	False
DDI-MedLine.d40.s0	.	127	127	O	.	.	.	.	False

DDI-MedLine.d40.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d40.s1	antifungal	4	13	B-group	antifungal	gal	ngal	NN	False
DDI-MedLine.d40.s1	drug	15	18	I-group	drug	rug	drug	NN	False
DDI-MedLine.d40.s1	,	19	19	O	,	,	,	,	False
DDI-MedLine.d40.s1	miconazole	21	30	B-drug	miconazole	ole	zole	NN	drug
DDI-MedLine.d40.s1	nitrate	32	38	I-drug	nitrate	ate	rate	NN	False
DDI-MedLine.d40.s1	,	39	39	O	,	,	,	,	False
DDI-MedLine.d40.s1	inhibits	41	48	O	inhibits	its	bits	NNS	False
DDI-MedLine.d40.s1	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d40.s1	growth	54	59	O	growth	wth	owth	NN	False
DDI-MedLine.d40.s1	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d40.s1	several	64	70	O	several	ral	eral	JJ	False
DDI-MedLine.d40.s1	species	72	78	O	species	ies	cies	NNS	False
DDI-MedLine.d40.s1	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d40.s1	Candida	83	89	O	Candida	ida	dida	NN	False
DDI-MedLine.d40.s1	.	90	90	O	.	.	.	.	False

DDI-MedLine.d40.s2	Candida	0	6	O	Candida	ida	dida	NN	False
DDI-MedLine.d40.s2	albicans	8	15	O	albicans	ans	cans	NNS	False
DDI-MedLine.d40.s2	,	16	16	O	,	,	,	,	False
DDI-MedLine.d40.s2	one	18	20	O	one	one	one	CD	False
DDI-MedLine.d40.s2	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d40.s2	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d40.s2	pathogenic	29	38	O	pathogenic	nic	enic	NN	False
DDI-MedLine.d40.s2	species	40	46	O	species	ies	cies	NNS	False
DDI-MedLine.d40.s2	,	47	47	O	,	,	,	,	False
DDI-MedLine.d40.s2	was	49	51	O	was	was	was	VBD	False
DDI-MedLine.d40.s2	totally	53	59	O	totally	lly	ally	RB	False
DDI-MedLine.d40.s2	inhibited	61	69	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d40.s2	at	71	72	O	at	at	at	IN	False
DDI-MedLine.d40.s2	a	74	74	O	a	a	a	DT	False
DDI-MedLine.d40.s2	concentration	76	88	O	concentration	ion	tion	NN	False
DDI-MedLine.d40.s2	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d40.s2	approximately	93	105	O	approximately	ely	tely	RB	False
DDI-MedLine.d40.s2	10	107	108	O	10	10	10	CD	False
DDI-MedLine.d40.s2	mug/ml	110	115	O	mug/ml	/ml	g/ml	NN	False
DDI-MedLine.d40.s2	.	116	116	O	.	.	.	.	False

DDI-MedLine.d40.s3	Endogenous	0	9	O	Endogenous	ous	nous	JJ	False
DDI-MedLine.d40.s3	respiration	11	21	O	respiration	ion	tion	NN	False
DDI-MedLine.d40.s3	was	23	25	O	was	was	was	VBD	False
DDI-MedLine.d40.s3	unaffected	27	36	O	unaffected	ted	cted	JJ	False
DDI-MedLine.d40.s3	by	38	39	O	by	by	by	IN	False
DDI-MedLine.d40.s3	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d40.s3	drug	45	48	O	drug	rug	drug	NN	False
DDI-MedLine.d40.s3	at	50	51	O	at	at	at	IN	False
DDI-MedLine.d40.s3	a	53	53	O	a	a	a	DT	False
DDI-MedLine.d40.s3	concentration	55	67	O	concentration	ion	tion	NN	False
DDI-MedLine.d40.s3	as	69	70	O	as	as	as	IN	False
DDI-MedLine.d40.s3	high	72	75	O	high	igh	high	JJ	False
DDI-MedLine.d40.s3	as	77	78	O	as	as	as	IN	False
DDI-MedLine.d40.s3	100	80	82	O	100	100	100	CD	False
DDI-MedLine.d40.s3	mug/ml	84	89	O	mug/ml	/ml	g/ml	NN	False
DDI-MedLine.d40.s3	,	90	90	O	,	,	,	,	False
DDI-MedLine.d40.s3	whereas	92	98	O	whereas	eas	reas	NNS	False
DDI-MedLine.d40.s3	exogenous	100	108	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d40.s3	respiration	110	120	O	respiration	ion	tion	NN	False
DDI-MedLine.d40.s3	was	122	124	O	was	was	was	VBD	False
DDI-MedLine.d40.s3	markedly	126	133	O	markedly	dly	edly	RB	False
DDI-MedLine.d40.s3	sensitive	135	143	O	sensitive	ive	tive	JJ	False
DDI-MedLine.d40.s3	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d40.s3	inhibited	149	157	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d40.s3	to	159	160	O	to	to	to	TO	False
DDI-MedLine.d40.s3	an	162	163	O	an	an	an	DT	False
DDI-MedLine.d40.s3	extent	165	170	O	extent	ent	tent	NN	False
DDI-MedLine.d40.s3	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d40.s3	85	175	176	O	85	85	85	CD	False
DDI-MedLine.d40.s3	%	177	177	O	%	%	%	NN	False
DDI-MedLine.d40.s3	.	178	178	O	.	.	.	.	False

DDI-MedLine.d40.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d40.s4	permeability	4	15	O	permeability	ity	lity	NN	False
DDI-MedLine.d40.s4	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d40.s4	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d40.s4	cell	24	27	O	cell	ell	cell	NN	False
DDI-MedLine.d40.s4	membrane	29	36	O	membrane	ane	rane	NN	False
DDI-MedLine.d40.s4	was	38	40	O	was	was	was	VBD	False
DDI-MedLine.d40.s4	changed	42	48	O	changed	ged	nged	VBN	False
DDI-MedLine.d40.s4	as	50	51	O	as	as	as	IN	False
DDI-MedLine.d40.s4	evidenced	53	61	O	evidenced	ced	nced	VBN	False
DDI-MedLine.d40.s4	by	63	64	O	by	by	by	IN	False
DDI-MedLine.d40.s4	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d40.s4	leakage	70	76	O	leakage	age	kage	NN	False
DDI-MedLine.d40.s4	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d40.s4	260-nm	81	86	O	260-nm	-nm	0-nm	JJ	False
DDI-MedLine.d40.s4	absorbing	88	96	O	absorbing	ing	bing	VBG	False
DDI-MedLine.d40.s4	materials	98	106	O	materials	als	ials	NNS	False
DDI-MedLine.d40.s4	,	107	107	O	,	,	,	,	False
DDI-MedLine.d40.s4	amino	109	113	O	amino	ino	mino	NN	False
DDI-MedLine.d40.s4	acids	115	119	O	acids	ids	cids	NNS	False
DDI-MedLine.d40.s4	,	120	120	O	,	,	,	,	False
DDI-MedLine.d40.s4	proteins	122	129	O	proteins	ins	eins	NNS	False
DDI-MedLine.d40.s4	,	130	130	O	,	,	,	,	False
DDI-MedLine.d40.s4	and	132	134	O	and	and	and	CC	False
DDI-MedLine.d40.s4	inorganic	136	144	O	inorganic	nic	anic	NN	False
DDI-MedLine.d40.s4	cations	146	152	O	cations	ons	ions	NNS	False
DDI-MedLine.d40.s4	.	153	153	O	.	.	.	.	False

DDI-MedLine.d40.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d40.s5	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d40.s5	we	12	13	O	we	we	we	PRP	False
DDI-MedLine.d40.s5	present	15	21	O	present	ent	sent	NN	False
DDI-MedLine.d40.s5	clearly	23	29	O	clearly	rly	arly	RB	False
DDI-MedLine.d40.s5	show	31	34	O	show	how	show	NN	False
DDI-MedLine.d40.s5	that	36	39	O	that	hat	that	IN	False
DDI-MedLine.d40.s5	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d40.s5	drug	45	48	O	drug	rug	drug	NN	False
DDI-MedLine.d40.s5	alters	50	55	O	alters	ers	ters	NNS	False
DDI-MedLine.d40.s5	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d40.s5	cellular	61	68	O	cellular	lar	ular	JJ	False
DDI-MedLine.d40.s5	permeability	70	81	O	permeability	ity	lity	NN	False
DDI-MedLine.d40.s5	,	82	82	O	,	,	,	,	False
DDI-MedLine.d40.s5	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d40.s5	thus	88	91	O	thus	hus	thus	RB	False
DDI-MedLine.d40.s5	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d40.s5	exogenous	97	105	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d40.s5	respiration	107	117	O	respiration	ion	tion	NN	False
DDI-MedLine.d40.s5	becomes	119	125	O	becomes	mes	omes	NNS	False
DDI-MedLine.d40.s5	sensitive	127	135	O	sensitive	ive	tive	JJ	False
DDI-MedLine.d40.s5	to	137	138	O	to	to	to	TO	False
DDI-MedLine.d40.s5	the	140	142	O	the	the	the	DT	False
DDI-MedLine.d40.s5	drug	144	147	O	drug	rug	drug	NN	False
DDI-MedLine.d40.s5	.	148	148	O	.	.	.	.	False

DDI-MedLine.d74.s0	Responses	0	8	O	Responses	ses	nses	NNS	False
DDI-MedLine.d74.s0	to	10	11	O	to	to	to	TO	False
DDI-MedLine.d74.s0	arginine	13	20	B-drug	arginine	ine	nine	NN	drug
DDI-MedLine.d74.s0	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d74.s0	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d74.s0	perfused	29	36	O	perfused	sed	used	VBN	False
DDI-MedLine.d74.s0	pancreas	38	45	O	pancreas	eas	reas	NNS	False
DDI-MedLine.d74.s0	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d74.s0	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d74.s0	genetically	54	64	O	genetically	lly	ally	RB	False
DDI-MedLine.d74.s0	diabetic	66	73	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d74.s0	Chinese	75	81	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d74.s0	hamster	83	89	O	hamster	ter	ster	NN	False
DDI-MedLine.d74.s0	.	90	90	O	.	.	.	.	False

DDI-MedLine.d74.s1	Nonketotic	0	9	O	Nonketotic	tic	otic	JJ	False
DDI-MedLine.d74.s1	,	10	10	O	,	,	,	,	False
DDI-MedLine.d74.s1	genetically	12	22	O	genetically	lly	ally	RB	False
DDI-MedLine.d74.s1	diabetic	24	31	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d74.s1	Cinese	33	38	O	Cinese	ese	nese	JJ	False
DDI-MedLine.d74.s1	hamsters	40	47	O	hamsters	ers	ters	NNS	False
DDI-MedLine.d74.s1	show	49	52	O	show	how	show	NN	False
DDI-MedLine.d74.s1	subnormal	54	62	O	subnormal	mal	rmal	NN	False
DDI-MedLine.d74.s1	pancreatic	64	73	O	pancreatic	tic	atic	JJ	False
DDI-MedLine.d74.s1	insulin	75	81	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s1	release	83	89	O	release	ase	ease	NN	False
DDI-MedLine.d74.s1	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d74.s1	impaired	95	102	O	impaired	red	ired	JJ	False
DDI-MedLine.d74.s1	suppression	104	114	O	suppression	ion	sion	NN	False
DDI-MedLine.d74.s1	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d74.s1	glucagon	119	126	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s1	in	128	129	O	in	in	in	IN	False
DDI-MedLine.d74.s1	response	131	138	O	response	nse	onse	NN	False
DDI-MedLine.d74.s1	to	140	141	O	to	to	to	TO	False
DDI-MedLine.d74.s1	glucose	143	149	O	glucose	ose	cose	NN	False
DDI-MedLine.d74.s1	.	150	150	O	.	.	.	.	False

DDI-MedLine.d74.s2	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d74.s2	study	3	7	O	study	udy	tudy	NN	False
DDI-MedLine.d74.s2	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d74.s2	pancreatic	13	22	O	pancreatic	tic	atic	JJ	False
DDI-MedLine.d74.s2	effects	24	30	O	effects	cts	ects	NNS	False
DDI-MedLine.d74.s2	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d74.s2	other	35	39	O	other	her	ther	JJ	False
DDI-MedLine.d74.s2	agents	41	46	O	agents	nts	ents	NNS	False
DDI-MedLine.d74.s2	,	47	47	O	,	,	,	,	False
DDI-MedLine.d74.s2	dynamic	49	55	O	dynamic	mic	amic	JJ	False
DDI-MedLine.d74.s2	insulin	57	63	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s2	and	65	67	O	and	and	and	CC	False
DDI-MedLine.d74.s2	glucagon	69	76	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s2	release	78	84	O	release	ase	ease	NN	False
DDI-MedLine.d74.s2	was	86	88	O	was	was	was	VBD	False
DDI-MedLine.d74.s2	measured	90	97	O	measured	red	ured	VBN	False
DDI-MedLine.d74.s2	from	99	102	O	from	rom	from	IN	False
DDI-MedLine.d74.s2	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d74.s2	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d74.s2	vitro	111	115	O	vitro	tro	itro	NN	False
DDI-MedLine.d74.s2	perfused	117	124	O	perfused	sed	used	VBN	False
DDI-MedLine.d74.s2	pancreases	126	135	O	pancreases	ses	ases	NNS	False
DDI-MedLine.d74.s2	of	137	138	O	of	of	of	IN	False
DDI-MedLine.d74.s2	normal	140	145	O	normal	mal	rmal	JJ	False
DDI-MedLine.d74.s2	and	147	149	O	and	and	and	CC	False
DDI-MedLine.d74.s2	diabetic	151	158	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d74.s2	Chinese	160	166	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d74.s2	hamsters	168	175	O	hamsters	ers	ters	NNS	False
DDI-MedLine.d74.s2	in	177	178	O	in	in	in	IN	False
DDI-MedLine.d74.s2	response	180	187	O	response	nse	onse	NN	False
DDI-MedLine.d74.s2	to	189	190	O	to	to	to	TO	False
DDI-MedLine.d74.s2	various	192	198	O	various	ous	ious	JJ	False
DDI-MedLine.d74.s2	combinations	200	211	O	combinations	ons	ions	NNS	False
DDI-MedLine.d74.s2	of	213	214	O	of	of	of	IN	False
DDI-MedLine.d74.s2	arginine	216	223	B-drug	arginine	ine	nine	NN	drug
DDI-MedLine.d74.s2	(	225	225	O	(	(	(	(	False
DDI-MedLine.d74.s2	20mM	226	229	O	20mM	0mM	20mM	CD	False
DDI-MedLine.d74.s2	)	230	230	O	)	)	)	)	False
DDI-MedLine.d74.s2	,	231	231	O	,	,	,	,	False
DDI-MedLine.d74.s2	glucose	233	239	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d74.s2	(	241	241	O	(	(	(	(	False
DDI-MedLine.d74.s2	100	242	244	O	100	100	100	CD	False
DDI-MedLine.d74.s2	or	246	247	O	or	or	or	CC	False
DDI-MedLine.d74.s2	150	249	251	O	150	150	150	CD	False
DDI-MedLine.d74.s2	mg.	253	255	O	mg.	mg.	mg.	NN	False
DDI-MedLine.d74.s2	per	257	259	O	per	per	per	IN	False
DDI-MedLine.d74.s2	100	261	263	O	100	100	100	CD	False
DDI-MedLine.d74.s2	ml	265	266	O	ml	ml	ml	NN	False
DDI-MedLine.d74.s2	.	267	267	O	.	.	.	.	False
DDI-MedLine.d74.s2	)	268	268	O	)	)	)	)	False
DDI-MedLine.d74.s2	,	269	269	O	,	,	,	,	False
DDI-MedLine.d74.s2	and	271	273	O	and	and	and	CC	False
DDI-MedLine.d74.s2	theophylline	275	286	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d74.s2	(	288	288	O	(	(	(	(	False
DDI-MedLine.d74.s2	10	289	290	O	10	10	10	CD	False
DDI-MedLine.d74.s2	mM	292	293	O	mM	mM	mM	NN	False
DDI-MedLine.d74.s2	)	294	294	O	)	)	)	)	False
DDI-MedLine.d74.s2	.	295	295	O	.	.	.	.	False

DDI-MedLine.d74.s3	Theophylline	0	11	B-drug	Theophylline	ine	line	NN	drug
DDI-MedLine.d74.s3	alone	13	17	O	alone	one	lone	RB	False
DDI-MedLine.d74.s3	caused	19	24	O	caused	sed	used	VBN	False
DDI-MedLine.d74.s3	identical	26	34	O	identical	cal	ical	JJ	False
DDI-MedLine.d74.s3	insulin	36	42	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s3	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d74.s3	glucagon	48	55	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s3	release	57	63	O	release	ase	ease	NN	False
DDI-MedLine.d74.s3	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d74.s3	diabetics	68	76	O	diabetics	ics	tics	NNS	False
DDI-MedLine.d74.s3	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d74.s3	normals	82	88	O	normals	als	mals	NNS	False
DDI-MedLine.d74.s3	.	89	89	O	.	.	.	.	False

DDI-MedLine.d74.s4	Glucose	0	6	B-drug	Glucose	ose	cose	VB	False
DDI-MedLine.d74.s4	,	7	7	O	,	,	,	,	False
DDI-MedLine.d74.s4	alone	9	13	O	alone	one	lone	RB	False
DDI-MedLine.d74.s4	and	15	17	O	and	and	and	CC	False
DDI-MedLine.d74.s4	in	19	20	O	in	in	in	IN	False
DDI-MedLine.d74.s4	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d74.s4	presence	26	33	O	presence	nce	ence	NN	False
DDI-MedLine.d74.s4	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d74.s4	theophylline	38	49	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d74.s4	,	50	50	O	,	,	,	,	False
DDI-MedLine.d74.s4	caused	52	57	O	caused	sed	used	VBN	False
DDI-MedLine.d74.s4	subnormal	59	67	O	subnormal	mal	rmal	NN	False
DDI-MedLine.d74.s4	insulin	69	75	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s4	release	77	83	O	release	ase	ease	NN	False
DDI-MedLine.d74.s4	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d74.s4	less	89	92	O	less	ess	less	RBR	False
DDI-MedLine.d74.s4	suppression	94	104	O	suppression	ion	sion	NN	False
DDI-MedLine.d74.s4	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d74.s4	glucagon	109	116	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s4	release	118	124	O	release	ase	ease	NN	False
DDI-MedLine.d74.s4	in	126	127	O	in	in	in	IN	False
DDI-MedLine.d74.s4	the	129	131	O	the	the	the	DT	False
DDI-MedLine.d74.s4	diabectics	133	142	O	diabectics	ics	tics	NNS	False
DDI-MedLine.d74.s4	than	144	147	O	than	han	than	IN	False
DDI-MedLine.d74.s4	in	149	150	O	in	in	in	IN	False
DDI-MedLine.d74.s4	the	152	154	O	the	the	the	DT	False
DDI-MedLine.d74.s4	normals	156	162	O	normals	als	mals	NNS	False
DDI-MedLine.d74.s4	.	163	163	O	.	.	.	.	False

DDI-MedLine.d74.s5	Arginine	0	7	B-drug	Arginine	ine	nine	NN	drug
DDI-MedLine.d74.s5	,	8	8	O	,	,	,	,	False
DDI-MedLine.d74.s5	in	10	11	O	in	in	in	IN	False
DDI-MedLine.d74.s5	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d74.s5	presence	17	24	O	presence	nce	ence	NN	False
DDI-MedLine.d74.s5	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d74.s5	glucose	29	35	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d74.s5	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d74.s5	theophylline	41	52	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d74.s5	,	53	53	O	,	,	,	,	False
DDI-MedLine.d74.s5	caused	55	60	O	caused	sed	used	VBN	False
DDI-MedLine.d74.s5	excessive	62	70	O	excessive	ive	sive	JJ	False
DDI-MedLine.d74.s5	glucagon	72	79	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s5	release	81	87	O	release	ase	ease	NN	False
DDI-MedLine.d74.s5	but	89	91	O	but	but	but	CC	False
DDI-MedLine.d74.s5	nearly	93	98	O	nearly	rly	arly	RB	False
DDI-MedLine.d74.s5	normal	100	105	O	normal	mal	rmal	JJ	False
DDI-MedLine.d74.s5	insulin	107	113	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s5	release	115	121	O	release	ase	ease	NN	False
DDI-MedLine.d74.s5	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d74.s5	the	126	128	O	the	the	the	DT	False
DDI-MedLine.d74.s5	diabetics	130	138	O	diabetics	ics	tics	NNS	False
DDI-MedLine.d74.s5	.	139	139	O	.	.	.	.	False

DDI-MedLine.d74.s6	Arginine	0	7	B-drug	Arginine	ine	nine	NN	drug
DDI-MedLine.d74.s6	,	8	8	O	,	,	,	,	False
DDI-MedLine.d74.s6	in	10	11	O	in	in	in	IN	False
DDI-MedLine.d74.s6	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d74.s6	absence	17	23	O	absence	nce	ence	NN	False
DDI-MedLine.d74.s6	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d74.s6	glucose	28	34	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d74.s6	or	36	37	O	or	or	or	CC	False
DDI-MedLine.d74.s6	theophylline	39	50	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d74.s6	,	51	51	O	,	,	,	,	False
DDI-MedLine.d74.s6	caused	53	58	O	caused	sed	used	VBN	False
DDI-MedLine.d74.s6	excessive	60	68	O	excessive	ive	sive	JJ	False
DDI-MedLine.d74.s6	glucagon	70	77	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s6	release	79	85	O	release	ase	ease	NN	False
DDI-MedLine.d74.s6	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d74.s6	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d74.s6	diabetics	94	102	O	diabetics	ics	tics	NNS	False
DDI-MedLine.d74.s6	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d74.s6	undetectable	108	119	O	undetectable	ble	able	JJ	False
DDI-MedLine.d74.s6	insulin	121	127	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s6	release	129	135	O	release	ase	ease	NN	False
DDI-MedLine.d74.s6	in	137	138	O	in	in	in	IN	False
DDI-MedLine.d74.s6	either	140	145	O	either	her	ther	DT	False
DDI-MedLine.d74.s6	diabetics	147	155	O	diabetics	ics	tics	NNS	False
DDI-MedLine.d74.s6	or	157	158	O	or	or	or	CC	False
DDI-MedLine.d74.s6	normals	160	166	O	normals	als	mals	NNS	False
DDI-MedLine.d74.s6	.	167	167	O	.	.	.	.	False

DDI-MedLine.d74.s7	Pancreatic	0	9	O	Pancreatic	tic	atic	JJ	False
DDI-MedLine.d74.s7	content	11	17	O	content	ent	tent	NN	False
DDI-MedLine.d74.s7	after	19	23	O	after	ter	fter	IN	False
DDI-MedLine.d74.s7	perfusion	25	33	O	perfusion	ion	sion	NN	False
DDI-MedLine.d74.s7	did	35	37	O	did	did	did	VBD	False
DDI-MedLine.d74.s7	not	39	41	O	not	not	not	RB	False
DDI-MedLine.d74.s7	correlate	43	51	O	correlate	ate	late	NN	False
DDI-MedLine.d74.s7	with	53	56	O	with	ith	with	IN	False
DDI-MedLine.d74.s7	release	58	64	O	release	ase	ease	NN	False
DDI-MedLine.d74.s7	during	66	71	O	during	ing	ring	IN	False
DDI-MedLine.d74.s7	perfusion	73	81	O	perfusion	ion	sion	NN	False
DDI-MedLine.d74.s7	.	82	82	O	.	.	.	.	False

DDI-MedLine.d74.s8	Infusion	0	7	O	Infusion	ion	sion	NN	False
DDI-MedLine.d74.s8	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d74.s8	arginine	12	19	B-drug	arginine	ine	nine	NN	drug
DDI-MedLine.d74.s8	alone	21	25	O	alone	one	lone	RB	False
DDI-MedLine.d74.s8	markedly	27	34	O	markedly	dly	edly	RB	False
DDI-MedLine.d74.s8	decreased	36	44	O	decreased	sed	ased	VBN	False
DDI-MedLine.d74.s8	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d74.s8	amount	50	55	O	amount	unt	ount	NN	False
DDI-MedLine.d74.s8	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d74.s8	extractable	60	70	O	extractable	ble	able	JJ	False
DDI-MedLine.d74.s8	pancreatic	72	81	O	pancreatic	tic	atic	JJ	False
DDI-MedLine.d74.s8	insulin	83	89	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s8	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d74.s8	glucagon	95	102	O	glucagon	gon	agon	NN	False
DDI-MedLine.d74.s8	.	103	103	O	.	.	.	.	False

DDI-MedLine.d74.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d74.s9	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d74.s9	indicate	14	21	O	indicate	ate	cate	NN	False
DDI-MedLine.d74.s9	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d74.s9	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d74.s9	pancreatic	32	41	O	pancreatic	tic	atic	JJ	False
DDI-MedLine.d74.s9	alpha	43	47	O	alpha	pha	lpha	NN	False
DDI-MedLine.d74.s9	cell	49	52	O	cell	ell	cell	NN	False
DDI-MedLine.d74.s9	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d74.s9	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d74.s9	diabetic	61	68	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d74.s9	Chinese	70	76	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d74.s9	hamster	78	84	O	hamster	ter	ster	NN	False
DDI-MedLine.d74.s9	responds	86	93	O	responds	nds	onds	NNS	False
DDI-MedLine.d74.s9	excessively	95	105	O	excessively	ely	vely	RB	False
DDI-MedLine.d74.s9	to	107	108	O	to	to	to	TO	False
DDI-MedLine.d74.s9	arginine	110	117	B-drug	arginine	ine	nine	NN	drug
DDI-MedLine.d74.s9	,	118	118	O	,	,	,	,	False
DDI-MedLine.d74.s9	as	120	121	O	as	as	as	IN	False
DDI-MedLine.d74.s9	is	123	124	O	is	is	is	VBZ	False
DDI-MedLine.d74.s9	seen	126	129	O	seen	een	seen	VBN	False
DDI-MedLine.d74.s9	in	131	132	O	in	in	in	IN	False
DDI-MedLine.d74.s9	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d74.s9	human	138	142	O	human	man	uman	NN	False
DDI-MedLine.d74.s9	diabetic	144	151	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d74.s9	.	152	152	O	.	.	.	.	False

DDI-MedLine.d74.s10	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d74.s10	defect	5	10	O	defect	ect	fect	NN	False
DDI-MedLine.d74.s10	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d74.s10	not	15	17	O	not	not	not	RB	False
DDI-MedLine.d74.s10	related	19	25	O	related	ted	ated	JJ	False
DDI-MedLine.d74.s10	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d74.s10	acute	30	34	O	acute	ute	cute	NN	False
DDI-MedLine.d74.s10	insulin	36	42	O	insulin	lin	ulin	NN	False
DDI-MedLine.d74.s10	release	44	50	O	release	ase	ease	NN	False
DDI-MedLine.d74.s10	or	52	53	O	or	or	or	CC	False
DDI-MedLine.d74.s10	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d74.s10	presence	59	66	O	presence	nce	ence	NN	False
DDI-MedLine.d74.s10	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d74.s10	glucose	71	77	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d74.s10	.	78	78	O	.	.	.	.	False

DDI-MedLine.d74.s11	Further	0	6	O	Further	her	ther	RB	False
DDI-MedLine.d74.s11	,	7	7	O	,	,	,	,	False
DDI-MedLine.d74.s11	these	9	13	O	these	ese	hese	DT	False
DDI-MedLine.d74.s11	results	15	21	O	results	lts	ults	NNS	False
DDI-MedLine.d74.s11	confirm	23	29	O	confirm	irm	firm	NN	False
DDI-MedLine.d74.s11	that	31	34	O	that	hat	that	IN	False
DDI-MedLine.d74.s11	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d74.s11	diabetic	40	47	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d74.s11	Chinese	49	55	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d74.s11	hamster	57	63	O	hamster	ter	ster	NN	False
DDI-MedLine.d74.s11	's	64	65	O	's	's	's	POS	False
DDI-MedLine.d74.s11	alpha	67	71	O	alpha	pha	lpha	NN	False
DDI-MedLine.d74.s11	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d74.s11	beta	77	80	O	beta	eta	beta	NN	False
DDI-MedLine.d74.s11	cells	82	86	O	cells	lls	ells	NNS	False
DDI-MedLine.d74.s11	respond	88	94	O	respond	ond	pond	NN	False
DDI-MedLine.d74.s11	normally	96	103	O	normally	lly	ally	RB	False
DDI-MedLine.d74.s11	to	105	106	O	to	to	to	TO	False
DDI-MedLine.d74.s11	theophylline	108	119	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d74.s11	,	120	120	O	,	,	,	,	False
DDI-MedLine.d74.s11	but	122	124	O	but	but	but	CC	False
DDI-MedLine.d74.s11	are	126	128	O	are	are	are	VBP	False
DDI-MedLine.d74.s11	relatively	130	139	O	relatively	ely	vely	RB	False
DDI-MedLine.d74.s11	insensitive	141	151	O	insensitive	ive	tive	JJ	False
DDI-MedLine.d74.s11	to	153	154	O	to	to	to	TO	False
DDI-MedLine.d74.s11	glucose	156	162	B-drug	glucose	ose	cose	NN	False
DDI-MedLine.d74.s11	.	163	163	O	.	.	.	.	False

DDI-MedLine.d51.s0	Effects	0	6	O	Effects	cts	ects	NNS	False
DDI-MedLine.d51.s0	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d51.s0	xanthine	11	18	B-group	xanthine	ine	hine	NN	drug
DDI-MedLine.d51.s0	derivatives	20	30	I-group	derivatives	ves	ives	NNS	False
DDI-MedLine.d51.s0	in	32	33	O	in	in	in	IN	False
DDI-MedLine.d51.s0	a	35	35	O	a	a	a	DT	False
DDI-MedLine.d51.s0	light/dark	37	46	O	light/dark	ark	dark	NN	False
DDI-MedLine.d51.s0	test	48	51	O	test	est	test	NN	False
DDI-MedLine.d51.s0	in	53	54	O	in	in	in	IN	False
DDI-MedLine.d51.s0	mice	56	59	O	mice	ice	mice	NN	False
DDI-MedLine.d51.s0	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d51.s0	the	65	67	O	the	the	the	DT	False
DDI-MedLine.d51.s0	contribution	69	80	O	contribution	ion	tion	NN	False
DDI-MedLine.d51.s0	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d51.s0	adenosine	85	93	O	adenosine	ine	sine	NN	drug
DDI-MedLine.d51.s0	receptors	95	103	O	receptors	ors	tors	NNS	False
DDI-MedLine.d51.s0	.	104	104	O	.	.	.	.	False

DDI-MedLine.d51.s1	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d51.s1	investigated	3	14	O	investigated	ted	ated	VBN	False
DDI-MedLine.d51.s1	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d51.s1	effects	20	26	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s1	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d51.s1	adenosine	31	39	O	adenosine	ine	sine	NN	drug
DDI-MedLine.d51.s1	receptor	41	48	O	receptor	tor	ptor	NN	False
DDI-MedLine.d51.s1	antagonists	50	60	O	antagonists	sts	ists	NNS	False
DDI-MedLine.d51.s1	,	61	61	O	,	,	,	,	False
DDI-MedLine.d51.s1	caffeine	63	70	B-drug	caffeine	ine	eine	NN	drug
DDI-MedLine.d51.s1	,	71	71	O	,	,	,	,	False
DDI-MedLine.d51.s1	theophylline	73	84	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d51.s1	,	85	85	O	,	,	,	,	False
DDI-MedLine.d51.s1	8-phenyltheophylline	87	106	B-drug_n	8-phenyltheophylline	ine	line	JJ	drug
DDI-MedLine.d51.s1	,	107	107	O	,	,	,	,	False
DDI-MedLine.d51.s1	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d51.s1	8-cyclopentyl-1,3-dipropylxanthine	113	146	B-drug_n	8-cyclopentyl-1,3-dipropylxanthine	ine	hine	JJ	drug
DDI-MedLine.d51.s1	(	148	148	O	(	(	(	(	False
DDI-MedLine.d51.s1	DPCPX	149	153	B-drug_n	DPCPX	CPX	PCPX	NN	brand
DDI-MedLine.d51.s1	)	154	154	O	)	)	)	)	False
DDI-MedLine.d51.s1	,	155	155	O	,	,	,	,	False
DDI-MedLine.d51.s1	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d51.s1	a	160	160	O	a	a	a	DT	False
DDI-MedLine.d51.s1	light/dark	162	171	O	light/dark	ark	dark	NN	False
DDI-MedLine.d51.s1	test	173	176	O	test	est	test	NN	False
DDI-MedLine.d51.s1	in	178	179	O	in	in	in	IN	False
DDI-MedLine.d51.s1	mice	181	184	O	mice	ice	mice	NN	False
DDI-MedLine.d51.s1	.	185	185	O	.	.	.	.	False

DDI-MedLine.d51.s2	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d51.s2	antagonists	4	14	O	antagonists	sts	ists	NNS	False
DDI-MedLine.d51.s2	decreased	16	24	O	decreased	sed	ased	VBN	False
DDI-MedLine.d51.s2	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d51.s2	time	30	33	O	time	ime	time	NN	False
DDI-MedLine.d51.s2	spent	35	39	O	spent	ent	pent	NN	False
DDI-MedLine.d51.s2	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d51.s2	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d51.s2	light	48	52	O	light	ght	ight	NN	False
DDI-MedLine.d51.s2	zone	54	57	O	zone	one	zone	NN	False
DDI-MedLine.d51.s2	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d51.s2	this	62	65	O	this	his	this	DT	False
DDI-MedLine.d51.s2	test	67	70	O	test	est	test	NN	False
DDI-MedLine.d51.s2	,	71	71	O	,	,	,	,	False
DDI-MedLine.d51.s2	which	73	77	O	which	ich	hich	WDT	False
DDI-MedLine.d51.s2	suggested	79	87	O	suggested	ted	sted	VBN	False
DDI-MedLine.d51.s2	that	89	92	O	that	hat	that	IN	False
DDI-MedLine.d51.s2	these	94	98	O	these	ese	hese	DT	False
DDI-MedLine.d51.s2	compounds	100	108	O	compounds	nds	unds	NNS	False
DDI-MedLine.d51.s2	have	110	113	O	have	ave	have	VB	False
DDI-MedLine.d51.s2	anxiogenic	115	124	O	anxiogenic	nic	enic	NN	False
DDI-MedLine.d51.s2	effects	126	132	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s2	.	133	133	O	.	.	.	.	False

DDI-MedLine.d51.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d51.s3	anxiogenic	4	13	O	anxiogenic	nic	enic	NN	False
DDI-MedLine.d51.s3	effects	15	21	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s3	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d51.s3	theophylline	26	37	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d51.s3	were	39	42	O	were	ere	were	VBD	False
DDI-MedLine.d51.s3	reduced	44	50	O	reduced	ced	uced	VBN	False
DDI-MedLine.d51.s3	by	52	53	O	by	by	by	IN	False
DDI-MedLine.d51.s3	pretreatment	55	66	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d51.s3	with	68	71	O	with	ith	with	IN	False
DDI-MedLine.d51.s3	CGS	73	75	B-drug_n	CGS	CGS	CGS	NN	brand
DDI-MedLine.d51.s3	21680	77	81	I-drug_n	21680	680	1680	CD	False
DDI-MedLine.d51.s3	,	82	82	O	,	,	,	,	False
DDI-MedLine.d51.s3	an	84	85	O	an	an	an	DT	False
DDI-MedLine.d51.s3	A2-selective	87	98	O	A2-selective	ive	tive	JJ	False
DDI-MedLine.d51.s3	agonist	100	106	O	agonist	ist	nist	NN	False
DDI-MedLine.d51.s3	,	107	107	O	,	,	,	,	False
DDI-MedLine.d51.s3	but	109	111	O	but	but	but	CC	False
DDI-MedLine.d51.s3	not	113	115	O	not	not	not	RB	False
DDI-MedLine.d51.s3	by	117	118	O	by	by	by	IN	False
DDI-MedLine.d51.s3	N6-cyclopentyladenosine	120	142	B-drug_n	N6-cyclopentyladenosine	ine	sine	NN	drug
DDI-MedLine.d51.s3	(	144	144	O	(	(	(	(	False
DDI-MedLine.d51.s3	CPA	145	147	B-drug_n	CPA	CPA	CPA	NN	brand
DDI-MedLine.d51.s3	)	148	148	O	)	)	)	)	False
DDI-MedLine.d51.s3	,	149	149	O	,	,	,	,	False
DDI-MedLine.d51.s3	an	151	152	O	an	an	an	DT	False
DDI-MedLine.d51.s3	A1-selective	154	165	O	A1-selective	ive	tive	JJ	False
DDI-MedLine.d51.s3	agonist	167	173	O	agonist	ist	nist	NN	False
DDI-MedLine.d51.s3	.	174	174	O	.	.	.	.	False

DDI-MedLine.d51.s4	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d51.s4	,	7	7	O	,	,	,	,	False
DDI-MedLine.d51.s4	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d51.s4	antagonism	13	22	O	antagonism	ism	nism	NN	False
DDI-MedLine.d51.s4	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d51.s4	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d51.s4	theophylline-induced	31	50	O	theophylline-induced	ced	uced	JJ	False
DDI-MedLine.d51.s4	anxiogenic	52	61	O	anxiogenic	nic	enic	NN	False
DDI-MedLine.d51.s4	effects	63	69	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s4	by	71	72	O	by	by	by	IN	False
DDI-MedLine.d51.s4	CGS21680	74	81	B-drug_n	CGS21680	680	1680	NN	brand
DDI-MedLine.d51.s4	was	83	85	O	was	was	was	VBD	False
DDI-MedLine.d51.s4	only	87	90	O	only	nly	only	RB	False
DDI-MedLine.d51.s4	observed	92	99	O	observed	ved	rved	VBN	False
DDI-MedLine.d51.s4	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d51.s4	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d51.s4	time	108	111	O	time	ime	time	NN	False
DDI-MedLine.d51.s4	spent	113	117	O	spent	ent	pent	NN	False
DDI-MedLine.d51.s4	in	119	120	O	in	in	in	IN	False
DDI-MedLine.d51.s4	the	122	124	O	the	the	the	DT	False
DDI-MedLine.d51.s4	light	126	130	O	light	ght	ight	NN	False
DDI-MedLine.d51.s4	zone	132	135	O	zone	one	zone	NN	False
DDI-MedLine.d51.s4	,	136	136	O	,	,	,	,	False
DDI-MedLine.d51.s4	and	138	140	O	and	and	and	CC	False
DDI-MedLine.d51.s4	DPCPX-induced	142	154	O	DPCPX-induced	ced	uced	JJ	False
DDI-MedLine.d51.s4	anxiogenic	156	165	O	anxiogenic	nic	enic	NN	False
DDI-MedLine.d51.s4	effects	167	173	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s4	were	175	178	O	were	ere	were	VBD	False
DDI-MedLine.d51.s4	neither	180	186	O	neither	her	ther	DT	False
DDI-MedLine.d51.s4	reversed	188	195	O	reversed	sed	rsed	VBN	False
DDI-MedLine.d51.s4	by	197	198	O	by	by	by	IN	False
DDI-MedLine.d51.s4	CGS	200	202	B-drug	CGS	CGS	CGS	NN	brand
DDI-MedLine.d51.s4	21680	204	208	I-drug	21680	680	1680	CD	False
DDI-MedLine.d51.s4	nor	210	212	O	nor	nor	nor	CC	False
DDI-MedLine.d51.s4	by	214	215	O	by	by	by	IN	False
DDI-MedLine.d51.s4	CPA	217	219	B-drug_n	CPA	CPA	CPA	NN	brand
DDI-MedLine.d51.s4	.	220	220	O	.	.	.	.	False

DDI-MedLine.d51.s5	Finally	0	6	O	Finally	lly	ally	RB	False
DDI-MedLine.d51.s5	,	7	7	O	,	,	,	,	False
DDI-MedLine.d51.s5	it	9	10	O	it	it	it	PRP	False
DDI-MedLine.d51.s5	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d51.s5	notable	15	21	O	notable	ble	able	JJ	False
DDI-MedLine.d51.s5	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d51.s5	xanthine-derived	28	43	O	xanthine-derived	ved	ived	JJ	False
DDI-MedLine.d51.s5	adenosine	45	53	O	adenosine	ine	sine	NN	drug
DDI-MedLine.d51.s5	antagonists	55	65	O	antagonists	sts	ists	NNS	False
DDI-MedLine.d51.s5	tested	67	72	O	tested	ted	sted	VBN	False
DDI-MedLine.d51.s5	here	74	77	O	here	ere	here	RB	False
DDI-MedLine.d51.s5	commonly	79	86	O	commonly	nly	only	RB	False
DDI-MedLine.d51.s5	showed	88	93	O	showed	wed	owed	VBD	False
DDI-MedLine.d51.s5	anxiogenic	95	104	O	anxiogenic	nic	enic	NN	False
DDI-MedLine.d51.s5	effects	106	112	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s5	in	114	115	O	in	in	in	IN	False
DDI-MedLine.d51.s5	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d51.s5	light/dark	121	130	O	light/dark	ark	dark	NN	False
DDI-MedLine.d51.s5	test	132	135	O	test	est	test	NN	False
DDI-MedLine.d51.s5	in	137	138	O	in	in	in	IN	False
DDI-MedLine.d51.s5	mice	140	143	O	mice	ice	mice	NN	False
DDI-MedLine.d51.s5	.	144	144	O	.	.	.	.	False

DDI-MedLine.d51.s6	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d51.s6	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d51.s6	suggested	6	14	O	suggested	ted	sted	VBN	False
DDI-MedLine.d51.s6	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d51.s6	there	21	25	O	there	ere	here	RB	False
DDI-MedLine.d51.s6	is	27	28	O	is	is	is	VBZ	False
DDI-MedLine.d51.s6	a	30	30	O	a	a	a	DT	False
DDI-MedLine.d51.s6	minor	32	36	O	minor	nor	inor	NN	False
DDI-MedLine.d51.s6	contribution	38	49	O	contribution	ion	tion	NN	False
DDI-MedLine.d51.s6	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d51.s6	adenosine	54	62	O	adenosine	ine	sine	NN	drug
DDI-MedLine.d51.s6	receptors	64	72	O	receptors	ors	tors	NNS	False
DDI-MedLine.d51.s6	to	74	75	O	to	to	to	TO	False
DDI-MedLine.d51.s6	these	77	81	O	these	ese	hese	DT	False
DDI-MedLine.d51.s6	effects	83	89	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s6	,	90	90	O	,	,	,	,	False
DDI-MedLine.d51.s6	although	92	99	O	although	ugh	ough	IN	False
DDI-MedLine.d51.s6	theophylline-induced	101	120	O	theophylline-induced	ced	uced	JJ	False
DDI-MedLine.d51.s6	anxiogenic	122	131	O	anxiogenic	nic	enic	NN	False
DDI-MedLine.d51.s6	effects	133	139	O	effects	cts	ects	NNS	False
DDI-MedLine.d51.s6	were	141	144	O	were	ere	were	VBD	False
DDI-MedLine.d51.s6	antagonized	146	156	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d51.s6	by	158	159	O	by	by	by	IN	False
DDI-MedLine.d51.s6	an	161	162	O	an	an	an	DT	False
DDI-MedLine.d51.s6	A2	164	165	O	A2	A2	A2	NN	brand
DDI-MedLine.d51.s6	receptor	167	174	O	receptor	tor	ptor	NN	False
DDI-MedLine.d51.s6	agonist	176	182	O	agonist	ist	nist	NN	False
DDI-MedLine.d51.s6	.	183	183	O	.	.	.	.	False

DDI-MedLine.d68.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d68.s0	The	1	3	O	The	The	The	DT	False
DDI-MedLine.d68.s0	effect	5	10	O	effect	ect	fect	NN	False
DDI-MedLine.d68.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d68.s0	cimetidine	15	24	B-drug	cimetidine	ine	dine	NN	drug
DDI-MedLine.d68.s0	on	26	27	O	on	on	on	IN	False
DDI-MedLine.d68.s0	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d68.s0	renal	33	37	O	renal	nal	enal	NN	False
DDI-MedLine.d68.s0	excretion	39	47	O	excretion	ion	tion	NN	False
DDI-MedLine.d68.s0	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d68.s0	verografin	52	61	B-drug	verografin	fin	afin	NN	False
DDI-MedLine.d68.s0	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d68.s0	iodamide	67	74	B-drug	iodamide	ide	mide	NN	False
DDI-MedLine.d68.s0	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d68.s0	dogs	79	82	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d68.s0	]	83	83	O	]	]	]	NN	False
DDI-MedLine.d68.s0	The	86	88	O	The	The	The	DT	False
DDI-MedLine.d68.s0	intravenous	90	100	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d68.s0	injection	102	110	O	injection	ion	tion	NN	False
DDI-MedLine.d68.s0	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d68.s0	cimetidine	115	124	B-drug	cimetidine	ine	dine	NN	drug
DDI-MedLine.d68.s0	in	126	127	O	in	in	in	IN	False
DDI-MedLine.d68.s0	a	129	129	O	a	a	a	DT	False
DDI-MedLine.d68.s0	dose	131	134	O	dose	ose	dose	NN	False
DDI-MedLine.d68.s0	of	136	137	O	of	of	of	IN	False
DDI-MedLine.d68.s0	20	139	140	O	20	20	20	CD	False
DDI-MedLine.d68.s0	mg/kg	142	146	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d68.s0	enhanced	148	155	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d68.s0	verografine	157	167	B-drug	verografine	ine	fine	NN	drug
DDI-MedLine.d68.s0	and	169	171	O	and	and	and	CC	False
DDI-MedLine.d68.s0	iodamide	173	180	B-drug	iodamide	ide	mide	NN	False
DDI-MedLine.d68.s0	excretion	182	190	O	excretion	ion	tion	NN	False
DDI-MedLine.d68.s0	in	192	193	O	in	in	in	IN	False
DDI-MedLine.d68.s0	chronic	195	201	O	chronic	nic	onic	NN	False
DDI-MedLine.d68.s0	canine	203	208	O	canine	ine	nine	NN	drug
DDI-MedLine.d68.s0	experiments	210	220	O	experiments	nts	ents	NNS	False
DDI-MedLine.d68.s0	.	221	221	O	.	.	.	.	False

DDI-MedLine.d68.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d68.s1	higher	4	9	O	higher	her	gher	JJR	False
DDI-MedLine.d68.s1	verografine	11	21	B-drug	verografine	ine	fine	NN	drug
DDI-MedLine.d68.s1	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d68.s1	iodamide	27	34	B-drug	iodamide	ide	mide	NN	False
DDI-MedLine.d68.s1	excretion	36	44	O	excretion	ion	tion	NN	False
DDI-MedLine.d68.s1	was	46	48	O	was	was	was	VBD	False
DDI-MedLine.d68.s1	due	50	52	O	due	due	due	JJ	False
DDI-MedLine.d68.s1	to	54	55	O	to	to	to	TO	False
DDI-MedLine.d68.s1	their	57	61	O	their	eir	heir	PRP$	False
DDI-MedLine.d68.s1	increased	63	71	O	increased	sed	ased	VBN	False
DDI-MedLine.d68.s1	renal	73	77	O	renal	nal	enal	NN	False
DDI-MedLine.d68.s1	tubular	79	85	O	tubular	lar	ular	NN	False
DDI-MedLine.d68.s1	secretion	87	95	O	secretion	ion	tion	NN	False
DDI-MedLine.d68.s1	.	96	96	O	.	.	.	.	False

DDI-MedLine.d68.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d68.s2	dogs	3	6	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d68.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d68.s2	cimetidine	9	18	B-drug	cimetidine	ine	dine	NN	drug
DDI-MedLine.d68.s2	unchanged	20	28	O	unchanged	ged	nged	JJ	False
DDI-MedLine.d68.s2	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d68.s2	secretion	34	42	O	secretion	ion	tion	NN	False
DDI-MedLine.d68.s2	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d68.s2	cardiotrast	47	57	B-drug	cardiotrast	ast	rast	NN	False
DDI-MedLine.d68.s2	,	58	58	O	,	,	,	,	False
DDI-MedLine.d68.s2	a	60	60	O	a	a	a	DT	False
DDI-MedLine.d68.s2	test	62	65	O	test	est	test	NN	False
DDI-MedLine.d68.s2	agent	67	71	O	agent	ent	gent	NN	False
DDI-MedLine.d68.s2	for	73	75	O	for	for	for	IN	False
DDI-MedLine.d68.s2	anionic	77	83	O	anionic	nic	onic	NN	False
DDI-MedLine.d68.s2	transport	85	93	O	transport	ort	port	NN	False
DDI-MedLine.d68.s2	.	94	94	O	.	.	.	.	False

DDI-MedLine.d68.s3	Possible	0	7	O	Possible	ble	ible	JJ	False
DDI-MedLine.d68.s3	extrarenal	9	18	O	extrarenal	nal	enal	JJ	False
DDI-MedLine.d68.s3	mechanisms	20	29	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d68.s3	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d68.s3	action	34	39	O	action	ion	tion	NN	False
DDI-MedLine.d68.s3	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d68.s3	cimetidine	44	53	B-drug	cimetidine	ine	dine	NN	drug
DDI-MedLine.d68.s3	on	55	56	O	on	on	on	IN	False
DDI-MedLine.d68.s3	verografine	58	68	B-drug	verografine	ine	fine	NN	drug
DDI-MedLine.d68.s3	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d68.s3	iodamide	74	81	B-drug	iodamide	ide	mide	NN	False
DDI-MedLine.d68.s3	transport	83	91	O	transport	ort	port	NN	False
DDI-MedLine.d68.s3	were	93	96	O	were	ere	were	VBD	False
DDI-MedLine.d68.s3	also	98	101	O	also	lso	also	RB	False
DDI-MedLine.d68.s3	examined	103	110	O	examined	ned	ined	VBN	False
DDI-MedLine.d68.s3	.	111	111	O	.	.	.	.	False

DDI-MedLine.d99.s0	Fluvoxamine	0	10	B-drug	Fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s0	inhibits	12	19	O	inhibits	its	bits	NNS	False
DDI-MedLine.d99.s0	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d99.s0	CYP2C9	25	30	O	CYP2C9	2C9	P2C9	NN	brand
DDI-MedLine.d99.s0	catalyzed	32	40	O	catalyzed	zed	yzed	VBN	False
DDI-MedLine.d99.s0	biotransformation	42	58	O	biotransformation	ion	tion	NN	False
DDI-MedLine.d99.s0	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d99.s0	tolbutamide	63	73	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s0	.	74	74	O	.	.	.	.	False

DDI-MedLine.d99.s1	OBJECTIVE	0	8	O	OBJECTIVE	IVE	TIVE	NN	brand
DDI-MedLine.d99.s1	:	9	9	O	:	:	:	:	False
DDI-MedLine.d99.s1	Our	11	13	O	Our	Our	Our	PRP$	False
DDI-MedLine.d99.s1	objective	15	23	O	objective	ive	tive	NN	False
DDI-MedLine.d99.s1	was	25	27	O	was	was	was	VBD	False
DDI-MedLine.d99.s1	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d99.s1	examine	32	38	O	examine	ine	mine	NN	drug
DDI-MedLine.d99.s1	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d99.s1	interaction	44	54	O	interaction	ion	tion	NN	False
DDI-MedLine.d99.s1	between	56	62	O	between	een	ween	IN	False
DDI-MedLine.d99.s1	fluvoxamine	64	74	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s1	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d99.s1	tolbutamide	80	90	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s1	to	92	93	O	to	to	to	TO	False
DDI-MedLine.d99.s1	confirm	95	101	O	confirm	irm	firm	NN	False
DDI-MedLine.d99.s1	that	103	106	O	that	hat	that	IN	False
DDI-MedLine.d99.s1	fluvoxamine	108	118	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s1	inhibits	120	127	O	inhibits	its	bits	NNS	False
DDI-MedLine.d99.s1	CYP2C9	129	134	O	CYP2C9	2C9	P2C9	NN	brand
DDI-MedLine.d99.s1	.	135	135	O	.	.	.	.	False

DDI-MedLine.d99.s2	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d99.s2	:	7	7	O	:	:	:	:	False
DDI-MedLine.d99.s2	The	9	11	O	The	The	The	DT	False
DDI-MedLine.d99.s2	study	13	17	O	study	udy	tudy	NN	False
DDI-MedLine.d99.s2	was	19	21	O	was	was	was	VBD	False
DDI-MedLine.d99.s2	carried	23	29	O	carried	ied	ried	VBN	False
DDI-MedLine.d99.s2	out	31	33	O	out	out	out	IN	False
DDI-MedLine.d99.s2	as	35	36	O	as	as	as	IN	False
DDI-MedLine.d99.s2	an	38	39	O	an	an	an	DT	False
DDI-MedLine.d99.s2	open	41	44	O	open	pen	open	JJ	False
DDI-MedLine.d99.s2	,	45	45	O	,	,	,	,	False
DDI-MedLine.d99.s2	randomized	47	56	O	randomized	zed	ized	VBN	False
DDI-MedLine.d99.s2	,	57	57	O	,	,	,	,	False
DDI-MedLine.d99.s2	crossover	59	67	O	crossover	ver	over	NN	False
DDI-MedLine.d99.s2	design	69	74	O	design	ign	sign	NN	False
DDI-MedLine.d99.s2	with	76	79	O	with	ith	with	IN	False
DDI-MedLine.d99.s2	14	81	82	O	14	14	14	CD	False
DDI-MedLine.d99.s2	healthy	84	90	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d99.s2	participants	92	103	O	participants	nts	ants	NNS	False
DDI-MedLine.d99.s2	.	104	104	O	.	.	.	.	False

DDI-MedLine.d99.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d99.s3	period	3	8	O	period	iod	riod	NN	False
DDI-MedLine.d99.s3	A	10	10	O	A	A	A	DT	brand
DDI-MedLine.d99.s3	,	11	11	O	,	,	,	,	False
DDI-MedLine.d99.s3	all	13	15	O	all	all	all	DT	False
DDI-MedLine.d99.s3	volunteers	17	26	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d99.s3	took	28	31	O	took	ook	took	VBD	False
DDI-MedLine.d99.s3	500	33	35	O	500	500	500	CD	False
DDI-MedLine.d99.s3	mg	37	38	O	mg	mg	mg	NN	False
DDI-MedLine.d99.s3	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d99.s3	tolbutamide	43	53	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s3	orally	55	60	O	orally	lly	ally	RB	False
DDI-MedLine.d99.s3	.	61	61	O	.	.	.	.	False

DDI-MedLine.d99.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d99.s4	period	3	8	O	period	iod	riod	NN	False
DDI-MedLine.d99.s4	B	10	10	O	B	B	B	NN	brand
DDI-MedLine.d99.s4	,	11	11	O	,	,	,	,	False
DDI-MedLine.d99.s4	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d99.s4	volunteers	17	26	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d99.s4	were	28	31	O	were	ere	were	VBD	False
DDI-MedLine.d99.s4	randomly	33	40	O	randomly	mly	omly	RB	False
DDI-MedLine.d99.s4	assigned	42	49	O	assigned	ned	gned	VBN	False
DDI-MedLine.d99.s4	to	51	52	O	to	to	to	TO	False
DDI-MedLine.d99.s4	one	54	56	O	one	one	one	CD	False
DDI-MedLine.d99.s4	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d99.s4	two	61	63	O	two	two	two	CD	False
DDI-MedLine.d99.s4	groups	65	70	O	groups	ups	oups	NNS	False
DDI-MedLine.d99.s4	.	71	71	O	.	.	.	.	False

DDI-MedLine.d99.s5	Each	0	3	O	Each	ach	Each	DT	False
DDI-MedLine.d99.s5	group	5	9	O	group	oup	roup	NN	False
DDI-MedLine.d99.s5	took	11	14	O	took	ook	took	VBD	False
DDI-MedLine.d99.s5	either	16	21	O	either	her	ther	DT	False
DDI-MedLine.d99.s5	150	23	25	O	150	150	150	CD	False
DDI-MedLine.d99.s5	mg	27	28	O	mg	mg	mg	NN	False
DDI-MedLine.d99.s5	or	30	31	O	or	or	or	CC	False
DDI-MedLine.d99.s5	75	33	34	O	75	75	75	CD	False
DDI-MedLine.d99.s5	mg	36	37	O	mg	mg	mg	NN	False
DDI-MedLine.d99.s5	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d99.s5	fluvoxamine	42	52	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s5	a	54	54	O	a	a	a	DT	False
DDI-MedLine.d99.s5	day	56	58	O	day	day	day	NN	False
DDI-MedLine.d99.s5	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d99.s5	5	64	64	O	5	5	5	CD	False
DDI-MedLine.d99.s5	days	66	69	O	days	ays	days	NNS	False
DDI-MedLine.d99.s5	(	71	71	O	(	(	(	(	False
DDI-MedLine.d99.s5	day	72	74	O	day	day	day	NN	False
DDI-MedLine.d99.s5	-3	76	77	O	-3	-3	-3	NN	False
DDI-MedLine.d99.s5	to	79	80	O	to	to	to	TO	False
DDI-MedLine.d99.s5	day	82	84	O	day	day	day	NN	False
DDI-MedLine.d99.s5	2	86	86	O	2	2	2	CD	False
DDI-MedLine.d99.s5	)	87	87	O	)	)	)	)	False
DDI-MedLine.d99.s5	.	88	88	O	.	.	.	.	False

DDI-MedLine.d99.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d99.s6	groups	4	9	O	groups	ups	oups	NNS	False
DDI-MedLine.d99.s6	then	11	14	O	then	hen	then	RB	False
DDI-MedLine.d99.s6	took	16	19	O	took	ook	took	VBD	False
DDI-MedLine.d99.s6	500	21	23	O	500	500	500	CD	False
DDI-MedLine.d99.s6	mg	25	26	O	mg	mg	mg	NN	False
DDI-MedLine.d99.s6	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d99.s6	tolbutamide	31	41	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s6	as	43	44	O	as	as	as	IN	False
DDI-MedLine.d99.s6	a	46	46	O	a	a	a	DT	False
DDI-MedLine.d99.s6	single	48	53	O	single	gle	ngle	JJ	False
DDI-MedLine.d99.s6	dose	55	58	O	dose	ose	dose	NN	False
DDI-MedLine.d99.s6	(	60	60	O	(	(	(	(	False
DDI-MedLine.d99.s6	day	61	63	O	day	day	day	NN	False
DDI-MedLine.d99.s6	0	65	65	O	0	0	0	CD	False
DDI-MedLine.d99.s6	)	66	66	O	)	)	)	)	False
DDI-MedLine.d99.s6	.	67	67	O	.	.	.	.	False

DDI-MedLine.d99.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d99.s7	both	3	6	O	both	oth	both	DT	False
DDI-MedLine.d99.s7	periods	8	14	O	periods	ods	iods	NNS	False
DDI-MedLine.d99.s7	,	15	15	O	,	,	,	,	False
DDI-MedLine.d99.s7	blood	17	21	O	blood	ood	lood	NN	False
DDI-MedLine.d99.s7	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d99.s7	urine	27	31	O	urine	ine	rine	NN	drug
DDI-MedLine.d99.s7	were	33	36	O	were	ere	were	VBD	False
DDI-MedLine.d99.s7	sampled	38	44	O	sampled	led	pled	VBN	False
DDI-MedLine.d99.s7	at	46	47	O	at	at	at	IN	False
DDI-MedLine.d99.s7	regular	49	55	O	regular	lar	ular	JJ	False
DDI-MedLine.d99.s7	intervals	57	65	O	intervals	als	vals	NNS	False
DDI-MedLine.d99.s7	.	66	66	O	.	.	.	.	False

DDI-MedLine.d99.s8	Plasma	0	5	O	Plasma	sma	asma	NN	False
DDI-MedLine.d99.s8	was	7	9	O	was	was	was	VBD	False
DDI-MedLine.d99.s8	analyzed	11	18	O	analyzed	zed	yzed	VBN	False
DDI-MedLine.d99.s8	for	20	22	O	for	for	for	IN	False
DDI-MedLine.d99.s8	tolbutamide	24	34	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s8	,	35	35	O	,	,	,	,	False
DDI-MedLine.d99.s8	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d99.s8	urine	41	45	O	urine	ine	rine	NN	drug
DDI-MedLine.d99.s8	was	47	49	O	was	was	was	VBD	False
DDI-MedLine.d99.s8	analyzed	51	58	O	analyzed	zed	yzed	VBN	False
DDI-MedLine.d99.s8	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d99.s8	tolbutamide	64	74	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s8	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d99.s8	its	80	82	O	its	its	its	PRP$	False
DDI-MedLine.d99.s8	two	84	86	O	two	two	two	CD	False
DDI-MedLine.d99.s8	metabolites	88	98	O	metabolites	tes	ites	NNS	False
DDI-MedLine.d99.s8	,	99	99	O	,	,	,	,	False
DDI-MedLine.d99.s8	4-hydroxytolbutamide	101	120	B-drug_n	4-hydroxytolbutamide	ide	mide	JJ	False
DDI-MedLine.d99.s8	and	122	124	O	and	and	and	CC	False
DDI-MedLine.d99.s8	carboxytolbutamide	126	143	B-drug_n	carboxytolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s8	by	145	146	O	by	by	by	IN	False
DDI-MedLine.d99.s8	means	148	152	O	means	ans	eans	NNS	False
DDI-MedLine.d99.s8	of	154	155	O	of	of	of	IN	False
DDI-MedLine.d99.s8	HPLC	157	160	O	HPLC	PLC	HPLC	NN	brand
DDI-MedLine.d99.s8	.	161	161	O	.	.	.	.	False

DDI-MedLine.d99.s9	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d99.s9	:	7	7	O	:	:	:	:	False
DDI-MedLine.d99.s9	During	9	14	O	During	ing	ring	IN	False
DDI-MedLine.d99.s9	treatment	16	24	O	treatment	ent	ment	NN	False
DDI-MedLine.d99.s9	with	26	29	O	with	ith	with	IN	False
DDI-MedLine.d99.s9	fluvoxamine	31	41	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s9	,	42	42	O	,	,	,	,	False
DDI-MedLine.d99.s9	there	44	48	O	there	ere	here	RB	False
DDI-MedLine.d99.s9	was	50	52	O	was	was	was	VBD	False
DDI-MedLine.d99.s9	a	54	54	O	a	a	a	DT	False
DDI-MedLine.d99.s9	statistically	56	68	O	statistically	lly	ally	RB	False
DDI-MedLine.d99.s9	significant	70	80	O	significant	ant	cant	JJ	False
DDI-MedLine.d99.s9	decrease	82	89	O	decrease	ase	ease	NN	False
DDI-MedLine.d99.s9	in	91	92	O	in	in	in	IN	False
DDI-MedLine.d99.s9	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d99.s9	median	98	103	O	median	ian	dian	NN	False
DDI-MedLine.d99.s9	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d99.s9	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d99.s9	total	112	116	O	total	tal	otal	JJ	False
DDI-MedLine.d99.s9	clearance	118	126	O	clearance	nce	ance	NN	False
DDI-MedLine.d99.s9	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d99.s9	tolbutamide	131	141	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s9	,	142	142	O	,	,	,	,	False
DDI-MedLine.d99.s9	from	144	147	O	from	rom	from	IN	False
DDI-MedLine.d99.s9	845	149	151	O	845	845	845	CD	False
DDI-MedLine.d99.s9	mL/h	153	156	O	mL/h	L/h	mL/h	NN	False
DDI-MedLine.d99.s9	to	158	159	O	to	to	to	TO	False
DDI-MedLine.d99.s9	688	161	163	O	688	688	688	CD	False
DDI-MedLine.d99.s9	mL/h	165	168	O	mL/h	L/h	mL/h	NN	False
DDI-MedLine.d99.s9	,	169	169	O	,	,	,	,	False
DDI-MedLine.d99.s9	among	171	175	O	among	ong	mong	IN	False
DDI-MedLine.d99.s9	the	177	179	O	the	the	the	DT	False
DDI-MedLine.d99.s9	volunteers	181	190	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d99.s9	who	192	194	O	who	who	who	WP	False
DDI-MedLine.d99.s9	received	196	203	O	received	ved	ived	VBN	False
DDI-MedLine.d99.s9	75	205	206	O	75	75	75	CD	False
DDI-MedLine.d99.s9	mg/d	208	211	O	mg/d	g/d	mg/d	NN	False
DDI-MedLine.d99.s9	.	212	212	O	.	.	.	.	False

DDI-MedLine.d99.s10	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d99.s10	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d99.s10	a	10	10	O	a	a	a	DT	False
DDI-MedLine.d99.s10	reduction	12	20	O	reduction	ion	tion	NN	False
DDI-MedLine.d99.s10	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d99.s10	reached	27	33	O	reached	hed	ched	VBN	False
DDI-MedLine.d99.s10	borderline	35	44	O	borderline	ine	line	NN	drug
DDI-MedLine.d99.s10	statistical	46	56	O	statistical	cal	ical	JJ	False
DDI-MedLine.d99.s10	significance	58	69	O	significance	nce	ance	NN	False
DDI-MedLine.d99.s10	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d99.s10	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d99.s10	group	78	82	O	group	oup	roup	NN	False
DDI-MedLine.d99.s10	that	84	87	O	that	hat	that	IN	False
DDI-MedLine.d99.s10	received	89	96	O	received	ved	ived	VBN	False
DDI-MedLine.d99.s10	150	98	100	O	150	150	150	CD	False
DDI-MedLine.d99.s10	mg/d	102	105	O	mg/d	g/d	mg/d	NN	False
DDI-MedLine.d99.s10	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d99.s10	tolbutamide	110	120	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s10	.	121	121	O	.	.	.	.	False

DDI-MedLine.d99.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d99.s11	clearance	4	12	O	clearance	nce	ance	NN	False
DDI-MedLine.d99.s11	by	14	15	O	by	by	by	IN	False
DDI-MedLine.d99.s11	means	17	21	O	means	ans	eans	NNS	False
DDI-MedLine.d99.s11	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d99.s11	4-hydroxytolbutamide	26	45	B-drug_n	4-hydroxytolbutamide	ide	mide	JJ	False
DDI-MedLine.d99.s11	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d99.s11	carboxytolbutamide	51	68	B-drug_n	carboxytolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s11	was	70	72	O	was	was	was	VBD	False
DDI-MedLine.d99.s11	significantly	74	86	O	significantly	tly	ntly	RB	False
DDI-MedLine.d99.s11	reduced	88	94	O	reduced	ced	uced	VBN	False
DDI-MedLine.d99.s11	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d99.s11	both	99	102	O	both	oth	both	DT	False
DDI-MedLine.d99.s11	groups	104	109	O	groups	ups	oups	NNS	False
DDI-MedLine.d99.s11	(	111	111	O	(	(	(	(	False
DDI-MedLine.d99.s11	ie	112	113	O	ie	ie	ie	NN	False
DDI-MedLine.d99.s11	,	114	114	O	,	,	,	,	False
DDI-MedLine.d99.s11	from	116	119	O	from	rom	from	IN	False
DDI-MedLine.d99.s11	901	121	123	O	901	901	901	CD	False
DDI-MedLine.d99.s11	mL/h	125	128	O	mL/h	L/h	mL/h	NN	False
DDI-MedLine.d99.s11	to	130	131	O	to	to	to	TO	False
DDI-MedLine.d99.s11	318	133	135	O	318	318	318	CD	False
DDI-MedLine.d99.s11	mL/h	137	140	O	mL/h	L/h	mL/h	NN	False
DDI-MedLine.d99.s11	in	142	143	O	in	in	in	IN	False
DDI-MedLine.d99.s11	the	145	147	O	the	the	the	DT	False
DDI-MedLine.d99.s11	group	149	153	O	group	oup	roup	NN	False
DDI-MedLine.d99.s11	that	155	158	O	that	hat	that	IN	False
DDI-MedLine.d99.s11	received	160	167	O	received	ved	ived	VBN	False
DDI-MedLine.d99.s11	150	169	171	O	150	150	150	CD	False
DDI-MedLine.d99.s11	mg	173	174	O	mg	mg	mg	NN	False
DDI-MedLine.d99.s11	of	176	177	O	of	of	of	IN	False
DDI-MedLine.d99.s11	tolbutamide	179	189	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s11	per	191	193	O	per	per	per	IN	False
DDI-MedLine.d99.s11	day	195	197	O	day	day	day	NN	False
DDI-MedLine.d99.s11	and	199	201	O	and	and	and	CC	False
DDI-MedLine.d99.s11	from	203	206	O	from	rom	from	IN	False
DDI-MedLine.d99.s11	723	208	210	O	723	723	723	CD	False
DDI-MedLine.d99.s11	mL/h	212	215	O	mL/h	L/h	mL/h	NN	False
DDI-MedLine.d99.s11	to	217	218	O	to	to	to	TO	False
DDI-MedLine.d99.s11	457	220	222	O	457	457	457	CD	False
DDI-MedLine.d99.s11	mL/h	224	227	O	mL/h	L/h	mL/h	NN	False
DDI-MedLine.d99.s11	in	229	230	O	in	in	in	IN	False
DDI-MedLine.d99.s11	the	232	234	O	the	the	the	DT	False
DDI-MedLine.d99.s11	group	236	240	O	group	oup	roup	NN	False
DDI-MedLine.d99.s11	that	242	245	O	that	hat	that	IN	False
DDI-MedLine.d99.s11	received	247	254	O	received	ved	ived	VBN	False
DDI-MedLine.d99.s11	75	256	257	O	75	75	75	CD	False
DDI-MedLine.d99.s11	mg	259	260	O	mg	mg	mg	NN	False
DDI-MedLine.d99.s11	of	262	263	O	of	of	of	IN	False
DDI-MedLine.d99.s11	tolbutamide	265	275	B-drug	tolbutamide	ide	mide	NN	False
DDI-MedLine.d99.s11	per	277	279	O	per	per	per	IN	False
DDI-MedLine.d99.s11	day	281	283	O	day	day	day	NN	False
DDI-MedLine.d99.s11	)	284	284	O	)	)	)	)	False
DDI-MedLine.d99.s11	.	285	285	O	.	.	.	.	False

DDI-MedLine.d99.s12	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d99.s12	there	5	9	O	there	ere	here	RB	False
DDI-MedLine.d99.s12	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d99.s12	a	15	15	O	a	a	a	DT	False
DDI-MedLine.d99.s12	tendency	17	24	O	tendency	ncy	ency	NN	False
DDI-MedLine.d99.s12	toward	26	31	O	toward	ard	ward	IN	False
DDI-MedLine.d99.s12	a	33	33	O	a	a	a	DT	False
DDI-MedLine.d99.s12	more	35	38	O	more	ore	more	RBR	False
DDI-MedLine.d99.s12	pronounced	40	49	O	pronounced	ced	nced	VBN	False
DDI-MedLine.d99.s12	inhibition	51	60	O	inhibition	ion	tion	NN	False
DDI-MedLine.d99.s12	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d99.s12	the	65	67	O	the	the	the	DT	False
DDI-MedLine.d99.s12	4-hydroxylation	69	83	O	4-hydroxylation	ion	tion	NN	False
DDI-MedLine.d99.s12	during	85	90	O	during	ing	ring	IN	False
DDI-MedLine.d99.s12	treatment	92	100	O	treatment	ent	ment	NN	False
DDI-MedLine.d99.s12	with	102	105	O	with	ith	with	IN	False
DDI-MedLine.d99.s12	150	107	109	O	150	150	150	CD	False
DDI-MedLine.d99.s12	mg/d	111	114	O	mg/d	g/d	mg/d	NN	False
DDI-MedLine.d99.s12	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d99.s12	fluvoxamine	119	129	B-drug	fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s12	compared	131	138	O	compared	red	ared	VBN	False
DDI-MedLine.d99.s12	with	140	143	O	with	ith	with	IN	False
DDI-MedLine.d99.s12	75	145	146	O	75	75	75	CD	False
DDI-MedLine.d99.s12	mg/d	148	151	O	mg/d	g/d	mg/d	NN	False
DDI-MedLine.d99.s12	,	152	152	O	,	,	,	,	False
DDI-MedLine.d99.s12	but	154	156	O	but	but	but	CC	False
DDI-MedLine.d99.s12	the	158	160	O	the	the	the	DT	False
DDI-MedLine.d99.s12	difference	162	171	O	difference	nce	ence	NN	False
DDI-MedLine.d99.s12	was	173	175	O	was	was	was	VBD	False
DDI-MedLine.d99.s12	not	177	179	O	not	not	not	RB	False
DDI-MedLine.d99.s12	statistically	181	193	O	statistically	lly	ally	RB	False
DDI-MedLine.d99.s12	significant	195	205	O	significant	ant	cant	JJ	False
DDI-MedLine.d99.s12	.	206	206	O	.	.	.	.	False

DDI-MedLine.d99.s13	CONCLUSION	0	9	O	CONCLUSION	ION	SION	NN	brand
DDI-MedLine.d99.s13	:	10	10	O	:	:	:	:	False
DDI-MedLine.d99.s13	Fluvoxamine	12	22	B-drug	Fluvoxamine	ine	mine	NN	drug
DDI-MedLine.d99.s13	is	24	25	O	is	is	is	VBZ	False
DDI-MedLine.d99.s13	a	27	27	O	a	a	a	DT	False
DDI-MedLine.d99.s13	moderate	29	36	O	moderate	ate	rate	NN	False
DDI-MedLine.d99.s13	inhibitor	38	46	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d99.s13	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d99.s13	CYP2C9	51	56	O	CYP2C9	2C9	P2C9	NN	brand
DDI-MedLine.d99.s13	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d99.s13	vivo	61	64	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d99.s13	.	65	65	O	.	.	.	.	False

DDI-MedLine.d77.s0	Effects	0	6	O	Effects	cts	ects	NNS	False
DDI-MedLine.d77.s0	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d77.s0	low	11	13	O	low	low	low	JJ	False
DDI-MedLine.d77.s0	temperatures	15	26	O	temperatures	res	ures	NNS	False
DDI-MedLine.d77.s0	on	28	29	O	on	on	on	IN	False
DDI-MedLine.d77.s0	microtubules	31	42	O	microtubules	les	ules	NNS	False
DDI-MedLine.d77.s0	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d77.s0	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d77.s0	non-myelinated	51	64	O	non-myelinated	ted	ated	JJ	False
DDI-MedLine.d77.s0	axons	66	70	O	axons	ons	xons	NNS	False
DDI-MedLine.d77.s0	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d77.s0	post-ganglionic	75	89	O	post-ganglionic	nic	onic	JJ	False
DDI-MedLine.d77.s0	sympathetic	91	101	O	sympathetic	tic	etic	JJ	False
DDI-MedLine.d77.s0	nerves	103	108	O	nerves	ves	rves	NNS	False
DDI-MedLine.d77.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d77.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d77.s1	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d77.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d77.s1	temperature	14	24	O	temperature	ure	ture	NN	False
DDI-MedLine.d77.s1	changes	26	32	O	changes	ges	nges	NNS	False
DDI-MedLine.d77.s1	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d77.s1	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d77.s1	number	41	46	O	number	ber	mber	NN	False
DDI-MedLine.d77.s1	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d77.s1	microtubules	51	62	O	microtubules	les	ules	NNS	False
DDI-MedLine.d77.s1	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d77.s1	non-myelinated	67	80	O	non-myelinated	ted	ated	JJ	False
DDI-MedLine.d77.s1	axons	82	86	O	axons	ons	xons	NNS	False
DDI-MedLine.d77.s1	has	88	90	O	has	has	has	VBZ	False
DDI-MedLine.d77.s1	been	92	95	O	been	een	been	VBN	False
DDI-MedLine.d77.s1	studied	97	103	O	studied	ied	died	VBN	False
DDI-MedLine.d77.s1	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d77.s1	cat	108	110	O	cat	cat	cat	NN	False
DDI-MedLine.d77.s1	inferior	112	119	O	inferior	ior	rior	NN	False
DDI-MedLine.d77.s1	mesenteric	121	130	O	mesenteric	ric	eric	NN	False
DDI-MedLine.d77.s1	ganglion/hypogastric	132	151	O	ganglion/hypogastric	ric	tric	NN	False
DDI-MedLine.d77.s1	nerve	153	157	O	nerve	rve	erve	NN	False
DDI-MedLine.d77.s1	preparations	159	170	O	preparations	ons	ions	NNS	False
DDI-MedLine.d77.s1	incubated	172	180	O	incubated	ted	ated	VBN	False
DDI-MedLine.d77.s1	at	182	183	O	at	at	at	IN	False
DDI-MedLine.d77.s1	various	185	191	O	various	ous	ious	JJ	False
DDI-MedLine.d77.s1	temperatures	193	204	O	temperatures	res	ures	NNS	False
DDI-MedLine.d77.s1	in	206	207	O	in	in	in	IN	False
DDI-MedLine.d77.s1	Eagles	209	214	O	Eagles	les	gles	NNS	False
DDI-MedLine.d77.s1	minimal	216	222	O	minimal	mal	imal	NN	False
DDI-MedLine.d77.s1	essential	224	232	O	essential	ial	tial	JJ	False
DDI-MedLine.d77.s1	tissue	234	239	O	tissue	sue	ssue	NN	False
DDI-MedLine.d77.s1	culture	241	247	O	culture	ure	ture	NN	False
DDI-MedLine.d77.s1	medium	249	254	O	medium	ium	dium	NN	drug
DDI-MedLine.d77.s1	in	256	257	O	in	in	in	IN	False
DDI-MedLine.d77.s1	vitro	259	263	O	vitro	tro	itro	NN	False
DDI-MedLine.d77.s1	.	264	264	O	.	.	.	.	False

DDI-MedLine.d77.s2	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d77.s2	37	3	4	O	37	37	37	CD	False
DDI-MedLine.d77.s2	degrees	6	12	O	degrees	ees	rees	NNS	False
DDI-MedLine.d77.s2	C	14	14	O	C	C	C	SYM	brand
DDI-MedLine.d77.s2	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d77.s2	non-myelinated	20	33	O	non-myelinated	ted	ated	JJ	False
DDI-MedLine.d77.s2	axons	35	39	O	axons	ons	xons	NNS	False
DDI-MedLine.d77.s2	contained	41	49	O	contained	ned	ined	VBN	False
DDI-MedLine.d77.s2	28.4	51	54	O	28.4	8.4	28.4	CD	False
DDI-MedLine.d77.s2	plus	56	59	O	plus	lus	plus	CC	False
DDI-MedLine.d77.s2	or	61	62	O	or	or	or	CC	False
DDI-MedLine.d77.s2	minus	64	68	O	minus	nus	inus	NN	False
DDI-MedLine.d77.s2	0.8	70	72	O	0.8	0.8	0.8	CD	False
DDI-MedLine.d77.s2	S.E.M	74	78	O	S.E.M	E.M	.E.M	NN	brand
DDI-MedLine.d77.s2	.	79	79	O	.	.	.	.	False

DDI-MedLine.d77.s3	(	0	0	O	(	(	(	(	False
DDI-MedLine.d77.s3	54	1	2	O	54	54	54	CD	False
DDI-MedLine.d77.s3	)	3	3	O	)	)	)	)	False
DDI-MedLine.d77.s3	microtubules	5	16	O	microtubules	les	ules	NNS	False
DDI-MedLine.d77.s3	per	18	20	O	per	per	per	IN	False
DDI-MedLine.d77.s3	axon	22	25	O	axon	xon	axon	NN	False
DDI-MedLine.d77.s3	.	26	26	O	.	.	.	.	False

DDI-MedLine.d77.s4	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d77.s4	incubation	6	15	O	incubation	ion	tion	NN	False
DDI-MedLine.d77.s4	at	17	18	O	at	at	at	IN	False
DDI-MedLine.d77.s4	0	20	20	O	0	0	0	CD	False
DDI-MedLine.d77.s4	degrees	22	28	O	degrees	ees	rees	NNS	False
DDI-MedLine.d77.s4	C	30	30	O	C	C	C	SYM	brand
DDI-MedLine.d77.s4	for	32	34	O	for	for	for	IN	False
DDI-MedLine.d77.s4	4	36	36	O	4	4	4	CD	False
DDI-MedLine.d77.s4	h	38	38	O	h	h	h	NN	False
DDI-MedLine.d77.s4	this	40	43	O	this	his	this	DT	False
DDI-MedLine.d77.s4	number	45	50	O	number	ber	mber	NN	False
DDI-MedLine.d77.s4	fell	52	55	O	fell	ell	fell	VBD	False
DDI-MedLine.d77.s4	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d77.s4	2.3	60	62	O	2.3	2.3	2.3	CD	False
DDI-MedLine.d77.s4	plus	64	67	O	plus	lus	plus	CC	False
DDI-MedLine.d77.s4	or	69	70	O	or	or	or	CC	False
DDI-MedLine.d77.s4	minus	72	76	O	minus	nus	inus	NN	False
DDI-MedLine.d77.s4	0.1	78	80	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d77.s4	S.E.M	82	86	O	S.E.M	E.M	.E.M	NN	brand
DDI-MedLine.d77.s4	.	87	87	O	.	.	.	.	False

DDI-MedLine.d77.s5	(	0	0	O	(	(	(	(	False
DDI-MedLine.d77.s5	41	1	2	O	41	41	41	CD	False
DDI-MedLine.d77.s5	)	3	3	O	)	)	)	)	False
DDI-MedLine.d77.s5	but	5	7	O	but	but	but	CC	False
DDI-MedLine.d77.s5	returned	9	16	O	returned	ned	rned	VBN	False
DDI-MedLine.d77.s5	to	18	19	O	to	to	to	TO	False
DDI-MedLine.d77.s5	normal	21	26	O	normal	mal	rmal	JJ	False
DDI-MedLine.d77.s5	levels	28	33	O	levels	els	vels	NNS	False
DDI-MedLine.d77.s5	when	35	38	O	when	hen	when	WRB	False
DDI-MedLine.d77.s5	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d77.s5	nerves	44	49	O	nerves	ves	rves	NNS	False
DDI-MedLine.d77.s5	were	51	54	O	were	ere	were	VBD	False
DDI-MedLine.d77.s5	rewarmed	56	63	O	rewarmed	med	rmed	VBN	False
DDI-MedLine.d77.s5	.	64	64	O	.	.	.	.	False

DDI-MedLine.d77.s6	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d77.s6	loss	5	8	O	loss	oss	loss	NN	False
DDI-MedLine.d77.s6	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d77.s6	microtubules	13	24	O	microtubules	les	ules	NNS	False
DDI-MedLine.d77.s6	on	26	27	O	on	on	on	IN	False
DDI-MedLine.d77.s6	cooling	29	35	O	cooling	ing	ling	VBG	False
DDI-MedLine.d77.s6	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d77.s6	nerves	41	46	O	nerves	ves	rves	NNS	False
DDI-MedLine.d77.s6	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d77.s6	their	52	56	O	their	eir	heir	PRP$	False
DDI-MedLine.d77.s6	reappearance	58	69	O	reappearance	nce	ance	NN	False
DDI-MedLine.d77.s6	on	71	72	O	on	on	on	IN	False
DDI-MedLine.d77.s6	rewarming	74	82	O	rewarming	ing	ming	VBG	False
DDI-MedLine.d77.s6	was	84	86	O	was	was	was	VBD	False
DDI-MedLine.d77.s6	a	88	88	O	a	a	a	DT	False
DDI-MedLine.d77.s6	rapid	90	94	O	rapid	pid	apid	JJ	False
DDI-MedLine.d77.s6	process	96	102	O	process	ess	cess	NN	False
DDI-MedLine.d77.s6	;	103	103	O	;	;	;	:	False

DDI-MedLine.d77.s7	it	0	1	O	it	it	it	PRP	False
DDI-MedLine.d77.s7	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d77.s7	independent	7	17	O	independent	ent	dent	JJ	False
DDI-MedLine.d77.s7	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d77.s7	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d77.s7	influence	26	34	O	influence	nce	ence	NN	False
DDI-MedLine.d77.s7	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d77.s7	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d77.s7	nueronal	43	50	O	nueronal	nal	onal	JJ	False
DDI-MedLine.d77.s7	cell	52	55	O	cell	ell	cell	NN	False
DDI-MedLine.d77.s7	body	57	60	O	body	ody	body	NN	False
DDI-MedLine.d77.s7	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d77.s7	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d77.s7	protein	69	75	O	protein	ein	tein	NN	False
DDI-MedLine.d77.s7	synthesis	77	85	O	synthesis	sis	esis	NN	False
DDI-MedLine.d77.s7	within	87	92	O	within	hin	thin	IN	False
DDI-MedLine.d77.s7	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d77.s7	axon	98	101	O	axon	xon	axon	NN	False
DDI-MedLine.d77.s7	.	102	102	O	.	.	.	.	False

DDI-MedLine.d77.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d77.s8	preservation	4	15	O	preservation	ion	tion	NN	False
DDI-MedLine.d77.s8	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d77.s8	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d77.s8	microtubules	24	35	O	microtubules	les	ules	NNS	False
DDI-MedLine.d77.s8	was	37	39	O	was	was	was	VBD	False
DDI-MedLine.d77.s8	improved	41	48	O	improved	ved	oved	VBN	False
DDI-MedLine.d77.s8	when	50	53	O	when	hen	when	WRB	False
DDI-MedLine.d77.s8	D2O	55	57	O	D2O	D2O	D2O	NN	brand
DDI-MedLine.d77.s8	was	59	61	O	was	was	was	VBD	False
DDI-MedLine.d77.s8	present	63	69	O	present	ent	sent	NN	False
DDI-MedLine.d77.s8	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d77.s8	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d77.s8	incubation	78	87	O	incubation	ion	tion	NN	False
DDI-MedLine.d77.s8	medium	89	94	O	medium	ium	dium	NN	drug
DDI-MedLine.d77.s8	.	95	95	O	.	.	.	.	False

DDI-MedLine.d77.s9	Reformed	0	7	O	Reformed	med	rmed	VBN	False
DDI-MedLine.d77.s9	microtubules	9	20	O	microtubules	les	ules	NNS	False
DDI-MedLine.d77.s9	appeared	22	29	O	appeared	red	ared	VBD	False
DDI-MedLine.d77.s9	to	31	32	O	to	to	to	TO	False
DDI-MedLine.d77.s9	function	34	41	O	function	ion	tion	NN	False
DDI-MedLine.d77.s9	normally	43	50	O	normally	lly	ally	RB	False
DDI-MedLine.d77.s9	with	52	55	O	with	ith	with	IN	False
DDI-MedLine.d77.s9	respect	57	63	O	respect	ect	pect	NN	False
DDI-MedLine.d77.s9	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d77.s9	their	68	72	O	their	eir	heir	PRP$	False
DDI-MedLine.d77.s9	possible	74	81	O	possible	ble	ible	JJ	False
DDI-MedLine.d77.s9	role	83	86	O	role	ole	role	NN	False
DDI-MedLine.d77.s9	in	88	89	O	in	in	in	IN	False
DDI-MedLine.d77.s9	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d77.s9	transport	95	103	O	transport	ort	port	NN	False
DDI-MedLine.d77.s9	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d77.s9	noradrenaline	108	120	O	noradrenaline	ine	line	NN	drug
DDI-MedLine.d77.s9	storage	122	128	O	storage	age	rage	NN	False
DDI-MedLine.d77.s9	vesicles	130	137	O	vesicles	les	cles	NNS	False
DDI-MedLine.d77.s9	along	139	143	O	along	ong	long	IN	False
DDI-MedLine.d77.s9	the	145	147	O	the	the	the	DT	False
DDI-MedLine.d77.s9	axons	149	153	O	axons	ons	xons	NNS	False
DDI-MedLine.d77.s9	.	154	154	O	.	.	.	.	False

DDI-MedLine.d79.s0	If	0	1	O	If	If	If	IN	False
DDI-MedLine.d79.s0	taken	3	7	O	taken	ken	aken	VBN	False
DDI-MedLine.d79.s0	1	9	9	O	1	1	1	CD	False
DDI-MedLine.d79.s0	hour	11	14	O	hour	our	hour	NN	False
DDI-MedLine.d79.s0	before	16	21	O	before	ore	fore	IN	False
DDI-MedLine.d79.s0	indinavir	23	31	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s0	(	33	33	O	(	(	(	(	False
DDI-MedLine.d79.s0	IDV	34	36	B-drug	IDV	IDV	IDV	NN	brand
DDI-MedLine.d79.s0	)	37	37	O	)	)	)	)	False
DDI-MedLine.d79.s0	,	38	38	O	,	,	,	,	False
DDI-MedLine.d79.s0	didanosine	40	49	B-drug	didanosine	ine	sine	NN	drug
DDI-MedLine.d79.s0	does	51	54	O	does	oes	does	VBZ	False
DDI-MedLine.d79.s0	not	56	58	O	not	not	not	RB	False
DDI-MedLine.d79.s0	affect	60	65	O	affect	ect	fect	NN	False
DDI-MedLine.d79.s0	IDV	67	69	B-drug	IDV	IDV	IDV	NN	brand
DDI-MedLine.d79.s0	exposure	71	78	O	exposure	ure	sure	NN	False
DDI-MedLine.d79.s0	,	79	79	O	,	,	,	,	False
DDI-MedLine.d79.s0	despite	81	87	O	despite	ite	pite	IN	False
DDI-MedLine.d79.s0	persistent	89	98	O	persistent	ent	tent	NN	False
DDI-MedLine.d79.s0	buffering	100	108	O	buffering	ing	ring	NN	False
DDI-MedLine.d79.s0	effects	110	116	O	effects	cts	ects	NNS	False
DDI-MedLine.d79.s0	.	117	117	O	.	.	.	.	False

DDI-MedLine.d79.s1	Concurrent	0	9	O	Concurrent	ent	rent	NN	False
DDI-MedLine.d79.s1	administration	11	24	O	administration	ion	tion	NN	False
DDI-MedLine.d79.s1	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d79.s1	indinavir	29	37	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s1	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d79.s1	didanosine	43	52	B-drug	didanosine	ine	sine	NN	drug
DDI-MedLine.d79.s1	significantly	54	66	O	significantly	tly	ntly	RB	False
DDI-MedLine.d79.s1	reduces	68	74	O	reduces	ces	uces	NNS	False
DDI-MedLine.d79.s1	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d79.s1	level	80	84	O	level	vel	evel	NN	False
DDI-MedLine.d79.s1	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d79.s1	exposure	89	96	O	exposure	ure	sure	NN	False
DDI-MedLine.d79.s1	to	98	99	O	to	to	to	TO	False
DDI-MedLine.d79.s1	indinavir	101	109	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s1	,	110	110	O	,	,	,	,	False
DDI-MedLine.d79.s1	but	112	114	O	but	but	but	CC	False
DDI-MedLine.d79.s1	it	116	117	O	it	it	it	PRP	False
DDI-MedLine.d79.s1	is	119	120	O	is	is	is	VBZ	False
DDI-MedLine.d79.s1	unclear	122	128	O	unclear	ear	lear	JJ	False
DDI-MedLine.d79.s1	how	130	132	O	how	how	how	WRB	False
DDI-MedLine.d79.s1	soon	134	137	O	soon	oon	soon	RB	False
DDI-MedLine.d79.s1	after	139	143	O	after	ter	fter	IN	False
DDI-MedLine.d79.s1	didanosine	145	154	B-drug	didanosine	ine	sine	NN	drug
DDI-MedLine.d79.s1	administration	156	169	O	administration	ion	tion	NN	False
DDI-MedLine.d79.s1	indinavir	171	179	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s1	may	181	183	O	may	may	may	MD	False
DDI-MedLine.d79.s1	be	185	186	O	be	be	be	VB	False
DDI-MedLine.d79.s1	given	188	192	O	given	ven	iven	VBN	False
DDI-MedLine.d79.s1	safely	194	199	O	safely	ely	fely	RB	False
DDI-MedLine.d79.s1	.	200	200	O	.	.	.	.	False

DDI-MedLine.d79.s2	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d79.s2	compared	3	10	O	compared	red	ared	VBN	False
DDI-MedLine.d79.s2	indinavir	12	20	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s2	pharmacokinetics	22	37	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d79.s2	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d79.s2	gastric	43	49	O	gastric	ric	tric	NN	False
DDI-MedLine.d79.s2	pH	51	52	O	pH	pH	pH	NN	False
DDI-MedLine.d79.s2	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d79.s2	12	57	58	O	12	12	12	CD	False
DDI-MedLine.d79.s2	human	60	64	O	human	man	uman	NN	False
DDI-MedLine.d79.s2	immunodeficiency	66	81	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d79.s2	virus-positive	83	96	O	virus-positive	ive	tive	JJ	False
DDI-MedLine.d79.s2	patients	98	105	O	patients	nts	ents	NNS	False
DDI-MedLine.d79.s2	by	107	108	O	by	by	by	IN	False
DDI-MedLine.d79.s2	use	110	112	O	use	use	use	NN	False
DDI-MedLine.d79.s2	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d79.s2	800	117	119	O	800	800	800	CD	False
DDI-MedLine.d79.s2	mg	121	122	O	mg	mg	mg	NN	False
DDI-MedLine.d79.s2	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d79.s2	indinavir	127	135	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s2	alone	137	141	O	alone	one	lone	RB	False
DDI-MedLine.d79.s2	versus	143	148	O	versus	sus	rsus	NN	False
DDI-MedLine.d79.s2	800	150	152	O	800	800	800	CD	False
DDI-MedLine.d79.s2	mg	154	155	O	mg	mg	mg	NN	False
DDI-MedLine.d79.s2	of	157	158	O	of	of	of	IN	False
DDI-MedLine.d79.s2	indinavir	160	168	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s2	administered	170	181	O	administered	red	ered	VBN	False
DDI-MedLine.d79.s2	1	183	183	O	1	1	1	CD	False
DDI-MedLine.d79.s2	h	185	185	O	h	h	h	NN	False
DDI-MedLine.d79.s2	after	187	191	O	after	ter	fter	IN	False
DDI-MedLine.d79.s2	didanosine	193	202	B-drug	didanosine	ine	sine	NN	drug
DDI-MedLine.d79.s2	administration	204	217	O	administration	ion	tion	NN	False
DDI-MedLine.d79.s2	.	218	218	O	.	.	.	.	False

DDI-MedLine.d79.s3	Median	0	5	O	Median	ian	dian	JJ	False
DDI-MedLine.d79.s3	gastric	7	13	O	gastric	ric	tric	NN	False
DDI-MedLine.d79.s3	pH	15	16	O	pH	pH	pH	NN	False
DDI-MedLine.d79.s3	was	18	20	O	was	was	was	VBD	False
DDI-MedLine.d79.s3	significantly	22	34	O	significantly	tly	ntly	RB	False
DDI-MedLine.d79.s3	higher	36	41	O	higher	her	gher	JJR	False
DDI-MedLine.d79.s3	when	43	46	O	when	hen	when	WRB	False
DDI-MedLine.d79.s3	indinavir	48	56	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d79.s3	was	58	60	O	was	was	was	VBD	False
DDI-MedLine.d79.s3	taken	62	66	O	taken	ken	aken	VBN	False
DDI-MedLine.d79.s3	after	68	72	O	after	ter	fter	IN	False
DDI-MedLine.d79.s3	didanosine	74	83	B-drug	didanosine	ine	sine	NN	drug
DDI-MedLine.d79.s3	administration	85	98	O	administration	ion	tion	NN	False
DDI-MedLine.d79.s3	;	99	99	O	;	;	;	:	False

DDI-MedLine.d79.s4	however	0	6	O	however	ver	ever	RB	False
DDI-MedLine.d79.s4	,	7	7	O	,	,	,	,	False
DDI-MedLine.d79.s4	no	9	10	O	no	no	no	DT	False
DDI-MedLine.d79.s4	significant	12	22	O	significant	ant	cant	JJ	False
DDI-MedLine.d79.s4	difference	24	33	O	difference	nce	ence	NN	False
DDI-MedLine.d79.s4	in	35	36	O	in	in	in	IN	False
DDI-MedLine.d79.s4	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d79.s4	maximum	42	48	O	maximum	mum	imum	NN	False
DDI-MedLine.d79.s4	concentration	50	62	O	concentration	ion	tion	NN	False
DDI-MedLine.d79.s4	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d79.s4	plasma	67	72	O	plasma	sma	asma	NN	False
DDI-MedLine.d79.s4	or	74	75	O	or	or	or	CC	False
DDI-MedLine.d79.s4	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d79.s4	area	81	84	O	area	rea	area	NN	False
DDI-MedLine.d79.s4	under	86	90	O	under	der	nder	IN	False
DDI-MedLine.d79.s4	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d79.s4	concentration-time	96	113	O	concentration-time	ime	time	NN	False
DDI-MedLine.d79.s4	curve	115	119	O	curve	rve	urve	NN	False
DDI-MedLine.d79.s4	from	121	124	O	from	rom	from	IN	False
DDI-MedLine.d79.s4	time	126	129	O	time	ime	time	NN	False
DDI-MedLine.d79.s4	zero	131	134	O	zero	ero	zero	NN	False
DDI-MedLine.d79.s4	to	136	137	O	to	to	to	TO	False
DDI-MedLine.d79.s4	8	139	139	O	8	8	8	CD	False
DDI-MedLine.d79.s4	h	141	141	O	h	h	h	NN	False
DDI-MedLine.d79.s4	was	143	145	O	was	was	was	VBD	False
DDI-MedLine.d79.s4	observed	147	154	O	observed	ved	rved	VBN	False
DDI-MedLine.d79.s4	.	155	155	O	.	.	.	.	False

DDI-MedLine.d79.s5	Indinavir	0	8	B-drug	Indinavir	vir	avir	NN	False
DDI-MedLine.d79.s5	may	10	12	O	may	may	may	MD	False
DDI-MedLine.d79.s5	be	14	15	O	be	be	be	VB	False
DDI-MedLine.d79.s5	taken	17	21	O	taken	ken	aken	VBN	False
DDI-MedLine.d79.s5	with	23	26	O	with	ith	with	IN	False
DDI-MedLine.d79.s5	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d79.s5	light	30	34	O	light	ght	ight	NN	False
DDI-MedLine.d79.s5	meal	36	39	O	meal	eal	meal	NN	False
DDI-MedLine.d79.s5	1	41	41	O	1	1	1	CD	False
DDI-MedLine.d79.s5	h	43	43	O	h	h	h	NN	False
DDI-MedLine.d79.s5	following	45	53	O	following	ing	wing	VBG	False
DDI-MedLine.d79.s5	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d79.s5	administration	59	72	O	administration	ion	tion	NN	False
DDI-MedLine.d79.s5	of	74	75	O	of	of	of	IN	False
DDI-MedLine.d79.s5	400	77	79	O	400	400	400	CD	False
DDI-MedLine.d79.s5	mg	81	82	O	mg	mg	mg	NN	False
DDI-MedLine.d79.s5	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d79.s5	didanosine	87	96	B-drug	didanosine	ine	sine	NN	drug
DDI-MedLine.d79.s5	.	97	97	O	.	.	.	.	False

DDI-MedLine.d76.s0	Thiolated	0	8	B-drug_n	Thiolated	ted	ated	VBN	False
DDI-MedLine.d76.s0	carboxymethylcellulose	10	31	I-drug_n	carboxymethylcellulose	ose	lose	NN	False
DDI-MedLine.d76.s0	:	32	32	O	:	:	:	:	False
DDI-MedLine.d76.s0	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d76.s0	vitro	37	41	O	vitro	tro	itro	NN	False
DDI-MedLine.d76.s0	evaluation	43	52	O	evaluation	ion	tion	NN	False
DDI-MedLine.d76.s0	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d76.s0	its	57	59	O	its	its	its	PRP$	False
DDI-MedLine.d76.s0	permeation	61	70	O	permeation	ion	tion	NN	False
DDI-MedLine.d76.s0	enhancing	72	80	O	enhancing	ing	cing	VBG	False
DDI-MedLine.d76.s0	effect	82	87	O	effect	ect	fect	NN	False
DDI-MedLine.d76.s0	on	89	90	O	on	on	on	IN	False
DDI-MedLine.d76.s0	peptide	92	98	O	peptide	ide	tide	NN	False
DDI-MedLine.d76.s0	drugs	100	104	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d76.s0	.	105	105	O	.	.	.	.	False

DDI-MedLine.d76.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d76.s1	purpose	4	10	O	purpose	ose	pose	NN	False
DDI-MedLine.d76.s1	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d76.s1	this	15	18	O	this	his	this	DT	False
DDI-MedLine.d76.s1	study	20	24	O	study	udy	tudy	NN	False
DDI-MedLine.d76.s1	was	26	28	O	was	was	was	VBD	False
DDI-MedLine.d76.s1	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d76.s1	evaluate	33	40	O	evaluate	ate	uate	NN	False
DDI-MedLine.d76.s1	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d76.s1	effect	46	51	O	effect	ect	fect	NN	False
DDI-MedLine.d76.s1	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d76.s1	sodium	56	61	B-drug_n	sodium	ium	dium	NN	drug
DDI-MedLine.d76.s1	carboxymethylcellulose	63	84	I-drug_n	carboxymethylcellulose	ose	lose	NN	False
DDI-MedLine.d76.s1	(	86	86	O	(	(	(	(	False
DDI-MedLine.d76.s1	NaCMC	87	91	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s1	)	92	92	O	)	)	)	)	False
DDI-MedLine.d76.s1	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d76.s1	carboxymethylcellulose-cysteine	98	128	B-drug_n	carboxymethylcellulose-cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s1	(	130	130	O	(	(	(	(	False
DDI-MedLine.d76.s1	CMC-Cys	131	137	B-drug_n	CMC-Cys	Cys	-Cys	NN	False
DDI-MedLine.d76.s1	)	138	138	O	)	)	)	)	False
DDI-MedLine.d76.s1	conjugates	140	149	O	conjugates	tes	ates	NNS	False
DDI-MedLine.d76.s1	on	151	152	O	on	on	on	IN	False
DDI-MedLine.d76.s1	the	154	156	O	the	the	the	DT	False
DDI-MedLine.d76.s1	intestinal	158	167	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d76.s1	permeation	169	178	O	permeation	ion	tion	NN	False
DDI-MedLine.d76.s1	of	180	181	O	of	of	of	IN	False
DDI-MedLine.d76.s1	sodium	183	188	B-drug	sodium	ium	dium	NN	drug
DDI-MedLine.d76.s1	fluorescein	190	200	I-drug	fluorescein	ein	cein	NN	False
DDI-MedLine.d76.s1	(	202	202	O	(	(	(	(	False
DDI-MedLine.d76.s1	NaFlu	203	207	B-drug	NaFlu	Flu	aFlu	NN	False
DDI-MedLine.d76.s1	)	208	208	O	)	)	)	)	False
DDI-MedLine.d76.s1	and	210	212	O	and	and	and	CC	False
DDI-MedLine.d76.s1	model	214	218	O	model	del	odel	NN	False
DDI-MedLine.d76.s1	peptide	220	226	O	peptide	ide	tide	NN	False
DDI-MedLine.d76.s1	drugs	228	232	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d76.s1	,	233	233	O	,	,	,	,	False
DDI-MedLine.d76.s1	bacitracin	235	244	B-drug	bacitracin	cin	acin	NN	drug
DDI-MedLine.d76.s1	and	246	248	O	and	and	and	CC	False
DDI-MedLine.d76.s1	insulin	250	256	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d76.s1	.	257	257	O	.	.	.	.	False

DDI-MedLine.d76.s2	Cysteine	0	7	B-drug	Cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s2	was	9	11	O	was	was	was	VBD	False
DDI-MedLine.d76.s2	covalently	13	22	O	covalently	tly	ntly	RB	False
DDI-MedLine.d76.s2	linked	24	29	O	linked	ked	nked	VBN	False
DDI-MedLine.d76.s2	to	31	32	O	to	to	to	TO	False
DDI-MedLine.d76.s2	carbodiimide	34	45	O	carbodiimide	ide	mide	NN	False
DDI-MedLine.d76.s2	activated	47	55	O	activated	ted	ated	VBN	False
DDI-MedLine.d76.s2	NaCMC	57	61	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s2	.	62	62	O	.	.	.	.	False

DDI-MedLine.d76.s3	Iodometric	0	9	O	Iodometric	ric	tric	JJ	False
DDI-MedLine.d76.s3	titration	11	19	O	titration	ion	tion	NN	False
DDI-MedLine.d76.s3	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d76.s3	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d76.s3	polymer	28	34	O	polymer	mer	ymer	NN	False
DDI-MedLine.d76.s3	conjugates	36	45	O	conjugates	tes	ates	NNS	False
DDI-MedLine.d76.s3	was	47	49	O	was	was	was	VBD	False
DDI-MedLine.d76.s3	used	51	54	O	used	sed	used	VBN	False
DDI-MedLine.d76.s3	to	56	57	O	to	to	to	TO	False
DDI-MedLine.d76.s3	determine	59	67	O	determine	ine	mine	NN	drug
DDI-MedLine.d76.s3	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d76.s3	extent	73	78	O	extent	ent	tent	NN	False
DDI-MedLine.d76.s3	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d76.s3	immobilised	83	93	O	immobilised	sed	ised	VBN	False
DDI-MedLine.d76.s3	cysteine	95	102	B-drug	cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s3	.	103	103	O	.	.	.	.	False

DDI-MedLine.d76.s4	Permeation	0	9	O	Permeation	ion	tion	NN	False
DDI-MedLine.d76.s4	studies	11	17	O	studies	ies	dies	NNS	False
DDI-MedLine.d76.s4	were	19	22	O	were	ere	were	VBD	False
DDI-MedLine.d76.s4	performed	24	32	O	performed	med	rmed	VBN	False
DDI-MedLine.d76.s4	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d76.s4	guinea	37	42	O	guinea	nea	inea	NN	False
DDI-MedLine.d76.s4	pig	44	46	O	pig	pig	pig	NN	False
DDI-MedLine.d76.s4	small	48	52	O	small	all	mall	JJ	False
DDI-MedLine.d76.s4	intestinal	54	63	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d76.s4	mucosa	65	70	O	mucosa	osa	cosa	NN	False
DDI-MedLine.d76.s4	mounted	72	78	O	mounted	ted	nted	VBN	False
DDI-MedLine.d76.s4	in	80	81	O	in	in	in	IN	False
DDI-MedLine.d76.s4	Ussing-type	83	93	O	Ussing-type	ype	type	JJ	False
DDI-MedLine.d76.s4	chamber	95	101	O	chamber	ber	mber	NN	False
DDI-MedLine.d76.s4	.	102	102	O	.	.	.	.	False

DDI-MedLine.d76.s5	Unmodified	0	9	O	Unmodified	ied	fied	VBN	False
DDI-MedLine.d76.s5	NaCMC	11	15	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s5	(	17	17	O	(	(	(	(	False
DDI-MedLine.d76.s5	1	18	18	O	1	1	1	CD	False
DDI-MedLine.d76.s5	%	19	19	O	%	%	%	NN	False
DDI-MedLine.d76.s5	m/v	21	23	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s5	)	24	24	O	)	)	)	)	False
DDI-MedLine.d76.s5	significantly	26	38	O	significantly	tly	ntly	RB	False
DDI-MedLine.d76.s5	improved	40	47	O	improved	ved	oved	VBN	False
DDI-MedLine.d76.s5	the	49	51	O	the	the	the	DT	False
DDI-MedLine.d76.s5	transport	53	61	O	transport	ort	port	NN	False
DDI-MedLine.d76.s5	ratio	63	67	O	ratio	tio	atio	NN	False
DDI-MedLine.d76.s5	(	69	69	O	(	(	(	(	False
DDI-MedLine.d76.s5	R=	70	71	O	R=	R=	R=	NN	brand
DDI-MedLine.d76.s5	P	73	73	O	P	P	P	NN	brand
DDI-MedLine.d76.s5	(	74	74	O	(	(	(	(	False
DDI-MedLine.d76.s5	app	75	77	O	app	app	app	NN	False
DDI-MedLine.d76.s5	)	78	78	O	)	)	)	)	False
DDI-MedLine.d76.s5	polymer/	80	87	O	polymer/	er/	mer/	NN	False
DDI-MedLine.d76.s5	P	89	89	O	P	P	P	NN	brand
DDI-MedLine.d76.s5	(	90	90	O	(	(	(	(	False
DDI-MedLine.d76.s5	app	91	93	O	app	app	app	NN	False
DDI-MedLine.d76.s5	)	94	94	O	)	)	)	)	False
DDI-MedLine.d76.s5	control	96	102	O	control	rol	trol	NN	False
DDI-MedLine.d76.s5	)	103	103	O	)	)	)	)	False
DDI-MedLine.d76.s5	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d76.s5	NaFlu	108	112	B-drug	NaFlu	Flu	aFlu	NN	False
DDI-MedLine.d76.s5	to	114	115	O	to	to	to	TO	False
DDI-MedLine.d76.s5	1.3	117	119	O	1.3	1.3	1.3	CD	False
DDI-MedLine.d76.s5	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d76.s5	1	125	125	O	1	1	1	CD	False
DDI-MedLine.d76.s5	%	126	126	O	%	%	%	NN	False
DDI-MedLine.d76.s5	(	128	128	O	(	(	(	(	False
DDI-MedLine.d76.s5	m/v	129	131	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s5	)	132	132	O	)	)	)	)	False
DDI-MedLine.d76.s5	NaCMC	134	138	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s5	conjugated	140	149	O	conjugated	ted	ated	VBN	False
DDI-MedLine.d76.s5	with	151	154	O	with	ith	with	IN	False
DDI-MedLine.d76.s5	cysteine	156	163	B-drug	cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s5	further	165	171	O	further	her	ther	RB	False
DDI-MedLine.d76.s5	enhanced	173	180	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d76.s5	the	182	184	O	the	the	the	DT	False
DDI-MedLine.d76.s5	permeation	186	195	O	permeation	ion	tion	NN	False
DDI-MedLine.d76.s5	.	196	196	O	.	.	.	.	False

DDI-MedLine.d76.s6	Cysteine	0	7	B-drug	Cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s6	conjugation	9	19	O	conjugation	ion	tion	NN	False
DDI-MedLine.d76.s6	at	21	22	O	at	at	at	IN	False
DDI-MedLine.d76.s6	3.6	24	26	O	3.6	3.6	3.6	CD	False
DDI-MedLine.d76.s6	,	27	27	O	,	,	,	,	False
DDI-MedLine.d76.s6	5.3	29	31	O	5.3	5.3	5.3	CD	False
DDI-MedLine.d76.s6	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d76.s6	7.3	37	39	O	7.3	7.3	7.3	CD	False
DDI-MedLine.d76.s6	%	40	40	O	%	%	%	NN	False
DDI-MedLine.d76.s6	(	42	42	O	(	(	(	(	False
DDI-MedLine.d76.s6	m/m	43	45	O	m/m	m/m	m/m	NN	False
DDI-MedLine.d76.s6	)	46	46	O	)	)	)	)	False
DDI-MedLine.d76.s6	resulted	48	55	O	resulted	ted	lted	VBD	False
DDI-MedLine.d76.s6	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d76.s6	R-values	60	67	O	R-values	ues	lues	NNS	False
DDI-MedLine.d76.s6	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d76.s6	1.4	72	74	O	1.4	1.4	1.4	CD	False
DDI-MedLine.d76.s6	,	75	75	O	,	,	,	,	False
DDI-MedLine.d76.s6	1.7	77	79	O	1.7	1.7	1.7	CD	False
DDI-MedLine.d76.s6	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d76.s6	1.8	85	87	O	1.8	1.8	1.8	CD	False
DDI-MedLine.d76.s6	,	88	88	O	,	,	,	,	False
DDI-MedLine.d76.s6	respectively	90	101	O	respectively	ely	vely	RB	False
DDI-MedLine.d76.s6	.	102	102	O	.	.	.	.	False

DDI-MedLine.d76.s7	Decreasing	0	9	O	Decreasing	ing	sing	VBG	False
DDI-MedLine.d76.s7	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d76.s7	concentration	15	27	O	concentration	ion	tion	NN	False
DDI-MedLine.d76.s7	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d76.s7	CMC-Cys	32	38	B-drug_n	CMC-Cys	Cys	-Cys	NN	False
DDI-MedLine.d76.s7	,	39	39	O	,	,	,	,	False
DDI-MedLine.d76.s7	exhibiting	41	50	O	exhibiting	ing	ting	VBG	False
DDI-MedLine.d76.s7	7.3	52	54	O	7.3	7.3	7.3	CD	False
DDI-MedLine.d76.s7	%	55	55	O	%	%	%	NN	False
DDI-MedLine.d76.s7	(	57	57	O	(	(	(	(	False
DDI-MedLine.d76.s7	m/m	58	60	O	m/m	m/m	m/m	NN	False
DDI-MedLine.d76.s7	)	61	61	O	)	)	)	)	False
DDI-MedLine.d76.s7	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d76.s7	immobilised	66	76	O	immobilised	sed	ised	VBN	False
DDI-MedLine.d76.s7	cysteine	78	85	B-drug	cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s7	(	87	87	O	(	(	(	(	False
DDI-MedLine.d76.s7	CMC-Cys7.3	88	97	O	CMC-Cys7.3	7.3	s7.3	NN	False
DDI-MedLine.d76.s7	)	98	98	O	)	)	)	)	False
DDI-MedLine.d76.s7	from	100	103	O	from	rom	from	IN	False
DDI-MedLine.d76.s7	1	105	105	O	1	1	1	CD	False
DDI-MedLine.d76.s7	%	106	106	O	%	%	%	NN	False
DDI-MedLine.d76.s7	(	108	108	O	(	(	(	(	False
DDI-MedLine.d76.s7	m/v	109	111	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s7	)	112	112	O	)	)	)	)	False
DDI-MedLine.d76.s7	to	114	115	O	to	to	to	TO	False
DDI-MedLine.d76.s7	0.5	117	119	O	0.5	0.5	0.5	CD	False
DDI-MedLine.d76.s7	%	120	120	O	%	%	%	NN	False
DDI-MedLine.d76.s7	(	122	122	O	(	(	(	(	False
DDI-MedLine.d76.s7	m/v	123	125	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s7	)	126	126	O	)	)	)	)	False
DDI-MedLine.d76.s7	decreased	128	136	O	decreased	sed	ased	VBN	False
DDI-MedLine.d76.s7	the	138	140	O	the	the	the	DT	False
DDI-MedLine.d76.s7	R-value	142	148	O	R-value	lue	alue	JJ	False
DDI-MedLine.d76.s7	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d76.s7	NaFlu	153	157	B-drug	NaFlu	Flu	aFlu	NN	False
DDI-MedLine.d76.s7	from	159	162	O	from	rom	from	IN	False
DDI-MedLine.d76.s7	1.8	164	166	O	1.8	1.8	1.8	CD	False
DDI-MedLine.d76.s7	to	168	169	O	to	to	to	TO	False
DDI-MedLine.d76.s7	1.2	171	173	O	1.2	1.2	1.2	CD	False
DDI-MedLine.d76.s7	.	174	174	O	.	.	.	.	False

DDI-MedLine.d76.s8	NaCMC	0	4	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s8	at	6	7	O	at	at	at	IN	False
DDI-MedLine.d76.s8	1	9	9	O	1	1	1	CD	False
DDI-MedLine.d76.s8	%	10	10	O	%	%	%	NN	False
DDI-MedLine.d76.s8	(	12	12	O	(	(	(	(	False
DDI-MedLine.d76.s8	m/v	13	15	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s8	)	16	16	O	)	)	)	)	False
DDI-MedLine.d76.s8	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d76.s8	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d76.s8	presence	25	32	O	presence	nce	ence	NN	False
DDI-MedLine.d76.s8	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d76.s8	free	37	40	O	free	ree	free	JJ	False
DDI-MedLine.d76.s8	cysteine	42	49	B-drug	cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s8	had	51	53	O	had	had	had	VBD	False
DDI-MedLine.d76.s8	no	55	56	O	no	no	no	DT	False
DDI-MedLine.d76.s8	significant	58	68	O	significant	ant	cant	JJ	False
DDI-MedLine.d76.s8	effect	70	75	O	effect	ect	fect	NN	False
DDI-MedLine.d76.s8	on	77	78	O	on	on	on	IN	False
DDI-MedLine.d76.s8	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d76.s8	R-value	84	90	O	R-value	lue	alue	JJ	False
DDI-MedLine.d76.s8	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d76.s8	NaFlu	95	99	B-drug	NaFlu	Flu	aFlu	NN	False
DDI-MedLine.d76.s8	compared	101	108	O	compared	red	ared	VBN	False
DDI-MedLine.d76.s8	to	110	111	O	to	to	to	TO	False
DDI-MedLine.d76.s8	NaCMC	113	117	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s8	alone	119	123	O	alone	one	lone	RB	False
DDI-MedLine.d76.s8	.	124	124	O	.	.	.	.	False

DDI-MedLine.d76.s9	Formulation	0	10	O	Formulation	ion	tion	NN	False
DDI-MedLine.d76.s9	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d76.s9	fluorescence	15	26	O	fluorescence	nce	ence	NN	False
DDI-MedLine.d76.s9	labelled	28	35	O	labelled	led	lled	VBN	False
DDI-MedLine.d76.s9	bacitracin	37	46	B-drug	bacitracin	cin	acin	NN	drug
DDI-MedLine.d76.s9	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d76.s9	insulin	52	58	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d76.s9	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d76.s9	unconjugated	63	74	O	unconjugated	ted	ated	JJ	False
DDI-MedLine.d76.s9	NaCMC	76	80	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s9	(	82	82	O	(	(	(	(	False
DDI-MedLine.d76.s9	1	83	83	O	1	1	1	CD	False
DDI-MedLine.d76.s9	%	84	84	O	%	%	%	NN	False
DDI-MedLine.d76.s9	m/v	86	88	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s9	)	89	89	O	)	)	)	)	False
DDI-MedLine.d76.s9	did	91	93	O	did	did	did	VBD	False
DDI-MedLine.d76.s9	not	95	97	O	not	not	not	RB	False
DDI-MedLine.d76.s9	significantly	99	111	O	significantly	tly	ntly	RB	False
DDI-MedLine.d76.s9	improve	113	119	O	improve	ove	rove	VB	False
DDI-MedLine.d76.s9	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d76.s9	permeation	125	134	O	permeation	ion	tion	NN	False
DDI-MedLine.d76.s9	,	135	135	O	,	,	,	,	False
DDI-MedLine.d76.s9	however	137	143	O	however	ver	ever	RB	False
DDI-MedLine.d76.s9	in	145	146	O	in	in	in	IN	False
DDI-MedLine.d76.s9	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d76.s9	presence	152	159	O	presence	nce	ence	NN	False
DDI-MedLine.d76.s9	of	161	162	O	of	of	of	IN	False
DDI-MedLine.d76.s9	1	164	164	O	1	1	1	CD	False
DDI-MedLine.d76.s9	%	165	165	O	%	%	%	NN	False
DDI-MedLine.d76.s9	(	167	167	O	(	(	(	(	False
DDI-MedLine.d76.s9	m/v	168	170	O	m/v	m/v	m/v	NN	False
DDI-MedLine.d76.s9	)	171	171	O	)	)	)	)	False
DDI-MedLine.d76.s9	CMC-Cys7.3	173	182	O	CMC-Cys7.3	7.3	s7.3	NN	False
DDI-MedLine.d76.s9	a	184	184	O	a	a	a	DT	False
DDI-MedLine.d76.s9	significantly	186	198	O	significantly	tly	ntly	RB	False
DDI-MedLine.d76.s9	improved	200	207	O	improved	ved	oved	VBN	False
DDI-MedLine.d76.s9	permeation	209	218	O	permeation	ion	tion	NN	False
DDI-MedLine.d76.s9	was	220	222	O	was	was	was	VBD	False
DDI-MedLine.d76.s9	observed	224	231	O	observed	ved	rved	VBN	False
DDI-MedLine.d76.s9	(	233	233	O	(	(	(	(	False
DDI-MedLine.d76.s9	R=	234	235	O	R=	R=	R=	NN	brand
DDI-MedLine.d76.s9	1.3	237	239	O	1.3	1.3	1.3	CD	False
DDI-MedLine.d76.s9	)	240	240	O	)	)	)	)	False
DDI-MedLine.d76.s9	.	241	241	O	.	.	.	.	False

DDI-MedLine.d76.s10	Conjugation	0	10	O	Conjugation	ion	tion	NN	False
DDI-MedLine.d76.s10	at	12	13	O	at	at	at	IN	False
DDI-MedLine.d76.s10	NaCMC	15	19	B-drug_n	NaCMC	CMC	aCMC	NN	False
DDI-MedLine.d76.s10	with	21	24	O	with	ith	with	IN	False
DDI-MedLine.d76.s10	cysteine	26	33	B-drug	cysteine	ine	eine	NN	drug
DDI-MedLine.d76.s10	moieties	35	42	O	moieties	ies	ties	NNS	False
DDI-MedLine.d76.s10	significantly	44	56	O	significantly	tly	ntly	RB	False
DDI-MedLine.d76.s10	improves	58	65	O	improves	ves	oves	NNS	False
DDI-MedLine.d76.s10	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d76.s10	intestinal	71	80	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d76.s10	permeation	82	91	O	permeation	ion	tion	NN	False
DDI-MedLine.d76.s10	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d76.s10	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d76.s10	hydrophilic	100	110	O	hydrophilic	lic	ilic	NN	False
DDI-MedLine.d76.s10	molecule	112	119	O	molecule	ule	cule	NN	False
DDI-MedLine.d76.s10	NaFlu	121	125	B-drug	NaFlu	Flu	aFlu	NN	False
DDI-MedLine.d76.s10	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d76.s10	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d76.s10	model	135	139	O	model	del	odel	NN	False
DDI-MedLine.d76.s10	peptide	141	147	O	peptide	ide	tide	NN	False
DDI-MedLine.d76.s10	drugs	149	153	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d76.s10	bacitracin	155	164	B-drug	bacitracin	cin	acin	NN	drug
DDI-MedLine.d76.s10	and	166	168	O	and	and	and	CC	False
DDI-MedLine.d76.s10	insulin	170	176	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d76.s10	in	178	179	O	in	in	in	IN	False
DDI-MedLine.d76.s10	vitro	181	185	O	vitro	tro	itro	NN	False
DDI-MedLine.d76.s10	,	186	186	O	,	,	,	,	False
DDI-MedLine.d76.s10	therefore	188	196	O	therefore	ore	fore	RB	False
DDI-MedLine.d76.s10	this	198	201	O	this	his	this	DT	False
DDI-MedLine.d76.s10	conjugated	203	212	O	conjugated	ted	ated	VBN	False
DDI-MedLine.d76.s10	system	214	219	O	system	tem	stem	NN	False
DDI-MedLine.d76.s10	maybe	221	225	O	maybe	ybe	aybe	RB	False
DDI-MedLine.d76.s10	useful	227	232	O	useful	ful	eful	JJ	False
DDI-MedLine.d76.s10	for	234	236	O	for	for	for	IN	False
DDI-MedLine.d76.s10	peroral	238	244	O	peroral	ral	oral	JJ	False
DDI-MedLine.d76.s10	administration	246	259	O	administration	ion	tion	NN	False
DDI-MedLine.d76.s10	of	261	262	O	of	of	of	IN	False
DDI-MedLine.d76.s10	peptide	264	270	O	peptide	ide	tide	NN	False
DDI-MedLine.d76.s10	drugs	272	276	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d76.s10	in	278	279	O	in	in	in	IN	False
DDI-MedLine.d76.s10	the	281	283	O	the	the	the	DT	False
DDI-MedLine.d76.s10	future	285	290	O	future	ure	ture	NN	False
DDI-MedLine.d76.s10	.	291	291	O	.	.	.	.	False

DDI-MedLine.d66.s0	Changes	0	6	O	Changes	ges	nges	NNS	False
DDI-MedLine.d66.s0	in	8	9	O	in	in	in	IN	False
DDI-MedLine.d66.s0	urinary	11	17	O	urinary	ary	nary	JJ	False
DDI-MedLine.d66.s0	homocysteine	19	30	O	homocysteine	ine	eine	NN	drug
DDI-MedLine.d66.s0	following	32	40	O	following	ing	wing	VBG	False
DDI-MedLine.d66.s0	synthetic	42	50	B-group	synthetic	tic	etic	JJ	False
DDI-MedLine.d66.s0	steroidal	52	60	I-group	steroidal	dal	idal	NN	False
DDI-MedLine.d66.s0	estrogen	62	69	I-group	estrogen	gen	ogen	NN	brand
DDI-MedLine.d66.s0	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d66.s0	progestogen	75	85	O	progestogen	gen	ogen	NN	brand
DDI-MedLine.d66.s0	administration	87	100	O	administration	ion	tion	NN	False
DDI-MedLine.d66.s0	to	102	103	O	to	to	to	TO	False
DDI-MedLine.d66.s0	rats	105	108	O	rats	ats	rats	NNS	False
DDI-MedLine.d66.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d66.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d66.s1	present	4	10	O	present	ent	sent	NN	False
DDI-MedLine.d66.s1	work	12	15	O	work	ork	work	NN	False
DDI-MedLine.d66.s1	involved	17	24	O	involved	ved	lved	VBN	False
DDI-MedLine.d66.s1	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d66.s1	administration	30	43	O	administration	ion	tion	NN	False
DDI-MedLine.d66.s1	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d66.s1	both	48	51	O	both	oth	both	DT	False
DDI-MedLine.d66.s1	ethynyl	53	59	B-drug	ethynyl	nyl	ynyl	NN	False
DDI-MedLine.d66.s1	estradiol	61	69	I-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d66.s1	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d66.s1	levonorgestrel	75	88	B-drug	levonorgestrel	rel	trel	NN	False
DDI-MedLine.d66.s1	to	90	91	O	to	to	to	TO	False
DDI-MedLine.d66.s1	groups	93	98	O	groups	ups	oups	NNS	False
DDI-MedLine.d66.s1	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d66.s1	rats	103	106	O	rats	ats	rats	NNS	False
DDI-MedLine.d66.s1	,	107	107	O	,	,	,	,	False
DDI-MedLine.d66.s1	followed	109	116	O	followed	wed	owed	VBD	False
DDI-MedLine.d66.s1	by	118	119	O	by	by	by	IN	False
DDI-MedLine.d66.s1	determination	121	133	O	determination	ion	tion	NN	False
DDI-MedLine.d66.s1	of	135	136	O	of	of	of	IN	False
DDI-MedLine.d66.s1	the	138	140	O	the	the	the	DT	False
DDI-MedLine.d66.s1	homocysteine	142	153	O	homocysteine	ine	eine	NN	drug
DDI-MedLine.d66.s1	excretion	155	163	O	excretion	ion	tion	NN	False
DDI-MedLine.d66.s1	rate	165	168	O	rate	ate	rate	NN	False
DDI-MedLine.d66.s1	in	170	171	O	in	in	in	IN	False
DDI-MedLine.d66.s1	urine	173	177	O	urine	ine	rine	NN	drug
DDI-MedLine.d66.s1	.	178	178	O	.	.	.	.	False

DDI-MedLine.d66.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d66.s2	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d66.s2	indicate	12	19	O	indicate	ate	cate	NN	False
DDI-MedLine.d66.s2	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d66.s2	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d66.s2	statistically	28	40	O	statistically	lly	ally	RB	False
DDI-MedLine.d66.s2	significant	42	52	O	significant	ant	cant	JJ	False
DDI-MedLine.d66.s2	difference	54	63	O	difference	nce	ence	NN	False
DDI-MedLine.d66.s2	exists	65	70	O	exists	sts	ists	NNS	False
DDI-MedLine.d66.s2	between	72	78	O	between	een	ween	IN	False
DDI-MedLine.d66.s2	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d66.s2	excreted	84	91	O	excreted	ted	eted	VBN	False
DDI-MedLine.d66.s2	levels	93	98	O	levels	els	vels	NNS	False
DDI-MedLine.d66.s2	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d66.s2	homocysteine	103	114	O	homocysteine	ine	eine	NN	drug
DDI-MedLine.d66.s2	in	116	117	O	in	in	in	IN	False
DDI-MedLine.d66.s2	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d66.s2	urine	123	127	O	urine	ine	rine	NN	drug
DDI-MedLine.d66.s2	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d66.s2	both	132	135	O	both	oth	both	DT	False
DDI-MedLine.d66.s2	control	137	143	O	control	rol	trol	NN	False
DDI-MedLine.d66.s2	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d66.s2	levonorgestrel-treated	149	170	O	levonorgestrel-treated	ted	ated	JJ	False
DDI-MedLine.d66.s2	rats	172	175	O	rats	ats	rats	NNS	False
DDI-MedLine.d66.s2	and	177	179	O	and	and	and	CC	False
DDI-MedLine.d66.s2	the	181	183	O	the	the	the	DT	False
DDI-MedLine.d66.s2	levels	185	190	O	levels	els	vels	NNS	False
DDI-MedLine.d66.s2	shown	192	196	O	shown	own	hown	VBN	False
DDI-MedLine.d66.s2	by	198	199	O	by	by	by	IN	False
DDI-MedLine.d66.s2	rats	201	204	O	rats	ats	rats	NNS	False
DDI-MedLine.d66.s2	treated	206	212	O	treated	ted	ated	VBN	False
DDI-MedLine.d66.s2	with	214	217	O	with	ith	with	IN	False
DDI-MedLine.d66.s2	ethynyl	219	225	B-drug	ethynyl	nyl	ynyl	NN	False
DDI-MedLine.d66.s2	estradiol	227	235	I-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d66.s2	.	236	236	O	.	.	.	.	False

DDI-MedLine.d66.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d66.s3	implications	4	15	O	implications	ons	ions	NNS	False
DDI-MedLine.d66.s3	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d66.s3	these	20	24	O	these	ese	hese	DT	False
DDI-MedLine.d66.s3	results	26	32	O	results	lts	ults	NNS	False
DDI-MedLine.d66.s3	are	34	36	O	are	are	are	VBP	False
DDI-MedLine.d66.s3	discussed	38	46	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d66.s3	,	47	47	O	,	,	,	,	False
DDI-MedLine.d66.s3	especially	49	58	O	especially	lly	ally	RB	False
DDI-MedLine.d66.s3	with	60	63	O	with	ith	with	IN	False
DDI-MedLine.d66.s3	respect	65	71	O	respect	ect	pect	NN	False
DDI-MedLine.d66.s3	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d66.s3	observations	76	87	O	observations	ons	ions	NNS	False
DDI-MedLine.d66.s3	which	89	93	O	which	ich	hich	WDT	False
DDI-MedLine.d66.s3	indicate	95	102	O	indicate	ate	cate	NN	False
DDI-MedLine.d66.s3	that	104	107	O	that	hat	that	IN	False
DDI-MedLine.d66.s3	homocysteine	109	120	O	homocysteine	ine	eine	NN	drug
DDI-MedLine.d66.s3	may	122	124	O	may	may	may	MD	False
DDI-MedLine.d66.s3	be	126	127	O	be	be	be	VB	False
DDI-MedLine.d66.s3	a	129	129	O	a	a	a	DT	False
DDI-MedLine.d66.s3	precipitating	131	143	O	precipitating	ing	ting	VBG	False
DDI-MedLine.d66.s3	factor	145	150	O	factor	tor	ctor	NN	False
DDI-MedLine.d66.s3	in	152	153	O	in	in	in	IN	False
DDI-MedLine.d66.s3	the	155	157	O	the	the	the	DT	False
DDI-MedLine.d66.s3	development	159	169	O	development	ent	ment	NN	False
DDI-MedLine.d66.s3	of	171	172	O	of	of	of	IN	False
DDI-MedLine.d66.s3	thrombosis	174	183	O	thrombosis	sis	osis	NN	False
DDI-MedLine.d66.s3	.	184	184	O	.	.	.	.	False

DDI-MedLine.d66.s4	Also	0	3	O	Also	lso	Also	RB	False
DDI-MedLine.d66.s4	included	5	12	O	included	ded	uded	VBD	False
DDI-MedLine.d66.s4	in	14	15	O	in	in	in	IN	False
DDI-MedLine.d66.s4	this	17	20	O	this	his	this	DT	False
DDI-MedLine.d66.s4	paper	22	26	O	paper	per	aper	NN	False
DDI-MedLine.d66.s4	is	28	29	O	is	is	is	VBZ	False
DDI-MedLine.d66.s4	a	31	31	O	a	a	a	DT	False
DDI-MedLine.d66.s4	study	33	37	O	study	udy	tudy	NN	False
DDI-MedLine.d66.s4	which	39	43	O	which	ich	hich	WDT	False
DDI-MedLine.d66.s4	confirms	45	52	O	confirms	rms	irms	NNS	False
DDI-MedLine.d66.s4	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d66.s4	identity	58	65	O	identity	ity	tity	NN	False
DDI-MedLine.d66.s4	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d66.s4	the	70	72	O	the	the	the	DT	False
DDI-MedLine.d66.s4	HPLC	74	77	O	HPLC	PLC	HPLC	NN	brand
DDI-MedLine.d66.s4	peak	79	82	O	peak	eak	peak	NN	False
DDI-MedLine.d66.s4	as	84	85	O	as	as	as	IN	False
DDI-MedLine.d66.s4	being	87	91	O	being	ing	eing	VBG	False
DDI-MedLine.d66.s4	homocysteine	93	104	O	homocysteine	ine	eine	NN	drug
DDI-MedLine.d66.s4	by	106	107	O	by	by	by	IN	False
DDI-MedLine.d66.s4	forming	109	115	O	forming	ing	ming	VBG	False
DDI-MedLine.d66.s4	a	117	117	O	a	a	a	DT	False
DDI-MedLine.d66.s4	radioactive	119	129	O	radioactive	ive	tive	NN	False
DDI-MedLine.d66.s4	derivative	131	140	O	derivative	ive	tive	JJ	False
DDI-MedLine.d66.s4	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d66.s4	this	145	148	O	this	his	this	DT	False
DDI-MedLine.d66.s4	particular	150	159	O	particular	lar	ular	JJ	False
DDI-MedLine.d66.s4	sulphydryl-containing	161	181	O	sulphydryl-containing	ing	ning	NN	False
DDI-MedLine.d66.s4	amino	183	187	O	amino	ino	mino	NN	False
DDI-MedLine.d66.s4	acid	189	192	O	acid	cid	acid	NN	False
DDI-MedLine.d66.s4	,	193	193	O	,	,	,	,	False
DDI-MedLine.d66.s4	and	195	197	O	and	and	and	CC	False
DDI-MedLine.d66.s4	then	199	202	O	then	hen	then	RB	False
DDI-MedLine.d66.s4	analysing	204	212	O	analysing	ing	sing	VBG	False
DDI-MedLine.d66.s4	the	214	216	O	the	the	the	DT	False
DDI-MedLine.d66.s4	resulting	218	226	O	resulting	ing	ting	VBG	False
DDI-MedLine.d66.s4	mixture	228	234	O	mixture	ure	ture	NN	False
DDI-MedLine.d66.s4	by	236	237	O	by	by	by	IN	False
DDI-MedLine.d66.s4	TLC	239	241	O	TLC	TLC	TLC	NN	brand
DDI-MedLine.d66.s4	.	242	242	O	.	.	.	.	False

DDI-MedLine.d93.s0	Altered	0	6	O	Altered	red	ered	NNP	False
DDI-MedLine.d93.s0	responsiveness	8	21	O	responsiveness	ess	ness	NN	False
DDI-MedLine.d93.s0	to	23	24	O	to	to	to	TO	False
DDI-MedLine.d93.s0	alcohol	26	32	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d93.s0	after	34	38	O	after	ter	fter	IN	False
DDI-MedLine.d93.s0	exposure	40	47	O	exposure	ure	sure	NN	False
DDI-MedLine.d93.s0	to	49	50	O	to	to	to	TO	False
DDI-MedLine.d93.s0	organic	52	58	O	organic	nic	anic	JJ	False
DDI-MedLine.d93.s0	lead	60	63	O	lead	ead	lead	NN	False
DDI-MedLine.d93.s0	.	64	64	O	.	.	.	.	False

DDI-MedLine.d93.s1	Ethyl	0	4	B-drug	Ethyl	hyl	thyl	NN	False
DDI-MedLine.d93.s1	alcohol	6	12	I-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d93.s1	is	14	15	O	is	is	is	VBZ	False
DDI-MedLine.d93.s1	known	17	21	O	known	own	nown	VBN	False
DDI-MedLine.d93.s1	to	23	24	O	to	to	to	TO	False
DDI-MedLine.d93.s1	effect	26	31	O	effect	ect	fect	NN	False
DDI-MedLine.d93.s1	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d93.s1	functional	37	46	O	functional	nal	onal	JJ	False
DDI-MedLine.d93.s1	integrity	48	56	O	integrity	ity	rity	NN	False
DDI-MedLine.d93.s1	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d93.s1	the	61	63	O	the	the	the	DT	False
DDI-MedLine.d93.s1	limbic	65	70	O	limbic	bic	mbic	NN	False
DDI-MedLine.d93.s1	system	72	77	O	system	tem	stem	NN	False
DDI-MedLine.d93.s1	,	78	78	O	,	,	,	,	False
DDI-MedLine.d93.s1	particularly	80	91	O	particularly	rly	arly	RB	False
DDI-MedLine.d93.s1	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d93.s1	hippocampus	97	107	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d93.s1	,	108	108	O	,	,	,	,	False
DDI-MedLine.d93.s1	and	110	112	O	and	and	and	CC	False
DDI-MedLine.d93.s1	to	114	115	O	to	to	to	TO	False
DDI-MedLine.d93.s1	alter	117	121	O	alter	ter	lter	NN	False
DDI-MedLine.d93.s1	behaviors	123	131	O	behaviors	ors	iors	NNS	False
DDI-MedLine.d93.s1	which	133	137	O	which	ich	hich	WDT	False
DDI-MedLine.d93.s1	are	139	141	O	are	are	are	VBP	False
DDI-MedLine.d93.s1	thought	143	149	O	thought	ght	ught	NN	False
DDI-MedLine.d93.s1	to	151	152	O	to	to	to	TO	False
DDI-MedLine.d93.s1	be	154	155	O	be	be	be	VB	False
DDI-MedLine.d93.s1	mediated	157	164	O	mediated	ted	ated	VBN	False
DDI-MedLine.d93.s1	through	166	172	O	through	ugh	ough	IN	False
DDI-MedLine.d93.s1	limbic	174	179	O	limbic	bic	mbic	NN	False
DDI-MedLine.d93.s1	function	181	188	O	function	ion	tion	NN	False
DDI-MedLine.d93.s1	.	189	189	O	.	.	.	.	False

DDI-MedLine.d93.s2	Organometals	0	11	O	Organometals	als	tals	NNS	False
DDI-MedLine.d93.s2	also	13	16	O	also	lso	also	RB	False
DDI-MedLine.d93.s2	compromise	18	27	O	compromise	ise	mise	NN	False
DDI-MedLine.d93.s2	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d93.s2	limbic	33	38	O	limbic	bic	mbic	NN	False
DDI-MedLine.d93.s2	system	40	45	O	system	tem	stem	NN	False
DDI-MedLine.d93.s2	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d93.s2	result	51	56	O	result	ult	sult	NN	False
DDI-MedLine.d93.s2	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d93.s2	deficits	61	68	O	deficits	its	cits	NNS	False
DDI-MedLine.d93.s2	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d93.s2	learning	73	80	O	learning	ing	ning	VBG	False
DDI-MedLine.d93.s2	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d93.s2	memory	86	91	O	memory	ory	mory	NN	False
DDI-MedLine.d93.s2	.	92	92	O	.	.	.	.	False

DDI-MedLine.d93.s3	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d93.s3	both	6	9	O	both	oth	both	DT	False
DDI-MedLine.d93.s3	alcohol	11	17	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d93.s3	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d93.s3	organoleads	23	33	O	organoleads	ads	eads	NNS	False
DDI-MedLine.d93.s3	are	35	37	O	are	are	are	VBP	False
DDI-MedLine.d93.s3	present	39	45	O	present	ent	sent	NN	False
DDI-MedLine.d93.s3	in	47	48	O	in	in	in	IN	False
DDI-MedLine.d93.s3	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d93.s3	environment	54	64	O	environment	ent	ment	NN	False
DDI-MedLine.d93.s3	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d93.s3	seem	70	73	O	seem	eem	seem	NN	False
DDI-MedLine.d93.s3	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d93.s3	influence	78	86	O	influence	nce	ence	NN	False
DDI-MedLine.d93.s3	limbic	88	93	O	limbic	bic	mbic	NN	False
DDI-MedLine.d93.s3	integration	95	105	O	integration	ion	tion	NN	False
DDI-MedLine.d93.s3	,	106	106	O	,	,	,	,	False
DDI-MedLine.d93.s3	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d93.s3	interaction	112	122	O	interaction	ion	tion	NN	False
DDI-MedLine.d93.s3	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d93.s3	these	127	131	O	these	ese	hese	DT	False
DDI-MedLine.d93.s3	two	133	135	O	two	two	two	CD	False
DDI-MedLine.d93.s3	compounds	137	145	O	compounds	nds	unds	NNS	False
DDI-MedLine.d93.s3	was	147	149	O	was	was	was	VBD	False
DDI-MedLine.d93.s3	assessed	151	158	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d93.s3	in	160	161	O	in	in	in	IN	False
DDI-MedLine.d93.s3	the	163	165	O	the	the	the	DT	False
DDI-MedLine.d93.s3	present	167	173	O	present	ent	sent	NN	False
DDI-MedLine.d93.s3	experiment	175	184	O	experiment	ent	ment	NN	False
DDI-MedLine.d93.s3	.	185	185	O	.	.	.	.	False

DDI-MedLine.d93.s4	Thirty	0	5	O	Thirty	rty	irty	NN	False
DDI-MedLine.d93.s4	male	7	10	O	male	ale	male	NN	False
DDI-MedLine.d93.s4	rats	12	15	O	rats	ats	rats	NNS	False
DDI-MedLine.d93.s4	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d93.s4	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d93.s4	Fischer-344	24	34	O	Fischer-344	344	-344	NN	False
DDI-MedLine.d93.s4	strain	36	41	O	strain	ain	rain	NN	False
DDI-MedLine.d93.s4	were	43	46	O	were	ere	were	VBD	False
DDI-MedLine.d93.s4	divided	48	54	O	divided	ded	ided	VBN	False
DDI-MedLine.d93.s4	into	56	59	O	into	nto	into	IN	False
DDI-MedLine.d93.s4	three	61	65	O	three	ree	hree	CD	False
DDI-MedLine.d93.s4	equal	67	71	O	equal	ual	qual	JJ	False
DDI-MedLine.d93.s4	groups	73	78	O	groups	ups	oups	NNS	False
DDI-MedLine.d93.s4	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d93.s4	were	84	87	O	were	ere	were	VBD	False
DDI-MedLine.d93.s4	given	89	93	O	given	ven	iven	VBN	False
DDI-MedLine.d93.s4	injections	95	104	O	injections	ons	ions	NNS	False
DDI-MedLine.d93.s4	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d93.s4	trimethyl	109	117	B-drug_n	trimethyl	hyl	thyl	NN	False
DDI-MedLine.d93.s4	lead	119	122	I-drug_n	lead	ead	lead	NN	False
DDI-MedLine.d93.s4	(	124	124	O	(	(	(	(	False
DDI-MedLine.d93.s4	TML	125	127	B-drug_n	TML	TML	TML	NN	brand
DDI-MedLine.d93.s4	)	128	128	O	)	)	)	)	False
DDI-MedLine.d93.s4	(	130	130	O	(	(	(	(	False
DDI-MedLine.d93.s4	8.0	131	133	O	8.0	8.0	8.0	CD	False
DDI-MedLine.d93.s4	or	135	136	O	or	or	or	CC	False
DDI-MedLine.d93.s4	17.0	138	141	O	17.0	7.0	17.0	CD	False
DDI-MedLine.d93.s4	mg/kg/ml	143	150	O	mg/kg/ml	/ml	g/ml	NN	False
DDI-MedLine.d93.s4	SC	152	153	O	SC	SC	SC	NN	brand
DDI-MedLine.d93.s4	)	154	154	O	)	)	)	)	False
DDI-MedLine.d93.s4	or	156	157	O	or	or	or	CC	False
DDI-MedLine.d93.s4	the	159	161	O	the	the	the	DT	False
DDI-MedLine.d93.s4	saline	163	168	O	saline	ine	line	NN	drug
DDI-MedLine.d93.s4	vehicle	170	176	O	vehicle	cle	icle	NN	False
DDI-MedLine.d93.s4	.	177	177	O	.	.	.	.	False

DDI-MedLine.d93.s5	Fourteen	0	7	O	Fourteen	een	teen	NN	False
DDI-MedLine.d93.s5	days	9	12	O	days	ays	days	NNS	False
DDI-MedLine.d93.s5	later	14	18	O	later	ter	ater	RB	False
DDI-MedLine.d93.s5	,	19	19	O	,	,	,	,	False
DDI-MedLine.d93.s5	all	21	23	O	all	all	all	DT	False
DDI-MedLine.d93.s5	animals	25	31	O	animals	als	mals	NNS	False
DDI-MedLine.d93.s5	were	33	36	O	were	ere	were	VBD	False
DDI-MedLine.d93.s5	challenged	38	47	O	challenged	ged	nged	NN	False
DDI-MedLine.d93.s5	with	49	52	O	with	ith	with	IN	False
DDI-MedLine.d93.s5	a	54	54	O	a	a	a	DT	False
DDI-MedLine.d93.s5	single	56	61	O	single	gle	ngle	JJ	False
DDI-MedLine.d93.s5	hypnotic	63	70	O	hypnotic	tic	otic	JJ	False
DDI-MedLine.d93.s5	dose	72	75	O	dose	ose	dose	NN	False
DDI-MedLine.d93.s5	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d93.s5	ethanol	80	86	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d93.s5	(	88	88	O	(	(	(	(	False
DDI-MedLine.d93.s5	3.5	89	91	O	3.5	3.5	3.5	CD	False
DDI-MedLine.d93.s5	g/kg	93	96	O	g/kg	/kg	g/kg	NN	False
DDI-MedLine.d93.s5	IP	98	99	O	IP	IP	IP	NN	brand
DDI-MedLine.d93.s5	)	100	100	O	)	)	)	)	False
DDI-MedLine.d93.s5	.	101	101	O	.	.	.	.	False

DDI-MedLine.d93.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d93.s6	20	4	5	O	20	20	20	CD	False
DDI-MedLine.d93.s6	%	6	6	O	%	%	%	NN	False
DDI-MedLine.d93.s6	v/v	8	10	O	v/v	v/v	v/v	NN	False
DDI-MedLine.d93.s6	solution	12	19	O	solution	ion	tion	NN	False
DDI-MedLine.d93.s6	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d93.s6	alcohol	24	30	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d93.s6	was	32	34	O	was	was	was	VBD	False
DDI-MedLine.d93.s6	prepared	36	43	O	prepared	red	ared	JJ	False
DDI-MedLine.d93.s6	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d93.s6	water	48	52	O	water	ter	ater	NN	False
DDI-MedLine.d93.s6	from	54	57	O	from	rom	from	IN	False
DDI-MedLine.d93.s6	a	59	59	O	a	a	a	DT	False
DDI-MedLine.d93.s6	stock	61	65	O	stock	ock	tock	NN	False
DDI-MedLine.d93.s6	solution	67	74	O	solution	ion	tion	NN	False
DDI-MedLine.d93.s6	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d93.s6	95	79	80	O	95	95	95	CD	False
DDI-MedLine.d93.s6	%	81	81	O	%	%	%	NN	False
DDI-MedLine.d93.s6	ethanol	83	89	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d93.s6	.	90	90	O	.	.	.	.	False

DDI-MedLine.d93.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d93.s7	latency	4	10	O	latency	ncy	ency	NN	False
DDI-MedLine.d93.s7	to	12	13	O	to	to	to	TO	False
DDI-MedLine.d93.s7	loss	15	18	O	loss	oss	loss	NN	False
DDI-MedLine.d93.s7	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d93.s7	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d93.s7	righting	27	34	O	righting	ing	ting	VBG	False
DDI-MedLine.d93.s7	reflex	36	41	O	reflex	lex	flex	NN	False
DDI-MedLine.d93.s7	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d93.s7	duration	47	54	O	duration	ion	tion	NN	False
DDI-MedLine.d93.s7	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d93.s7	sleep	59	63	O	sleep	eep	leep	NN	False
DDI-MedLine.d93.s7	time	65	68	O	time	ime	time	NN	False
DDI-MedLine.d93.s7	were	70	73	O	were	ere	were	VBD	False
DDI-MedLine.d93.s7	recorded	75	82	O	recorded	ded	rded	VBN	False
DDI-MedLine.d93.s7	while	84	88	O	while	ile	hile	IN	False
DDI-MedLine.d93.s7	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d93.s7	rats	94	97	O	rats	ats	rats	NNS	False
DDI-MedLine.d93.s7	were	99	102	O	were	ere	were	VBD	False
DDI-MedLine.d93.s7	kept	104	107	O	kept	ept	kept	NN	False
DDI-MedLine.d93.s7	in	109	110	O	in	in	in	IN	False
DDI-MedLine.d93.s7	sound-attenuating	112	128	O	sound-attenuating	ing	ting	NN	False
DDI-MedLine.d93.s7	chambers	130	137	O	chambers	ers	bers	NNS	False
DDI-MedLine.d93.s7	.	138	138	O	.	.	.	.	False

DDI-MedLine.d93.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d93.s8	rats	4	7	O	rats	ats	rats	NNS	False
DDI-MedLine.d93.s8	treated	9	15	O	treated	ted	ated	VBN	False
DDI-MedLine.d93.s8	with	17	20	O	with	ith	with	IN	False
DDI-MedLine.d93.s8	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d93.s8	highest	26	32	O	highest	est	hest	JJS	False
DDI-MedLine.d93.s8	dose	34	37	O	dose	ose	dose	NN	False
DDI-MedLine.d93.s8	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d93.s8	TML	42	44	B-drug_n	TML	TML	TML	NN	brand
DDI-MedLine.d93.s8	manifested	46	55	O	manifested	ted	sted	VBN	False
DDI-MedLine.d93.s8	significantly	57	69	O	significantly	tly	ntly	RB	False
DDI-MedLine.d93.s8	longer	71	76	O	longer	ger	nger	NN	False
DDI-MedLine.d93.s8	latencies	78	86	O	latencies	ies	cies	NNS	False
DDI-MedLine.d93.s8	to	88	89	O	to	to	to	TO	False
DDI-MedLine.d93.s8	lose	91	94	O	lose	ose	lose	VB	False
DDI-MedLine.d93.s8	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d93.s8	righting	100	107	O	righting	ing	ting	VBG	False
DDI-MedLine.d93.s8	reflex	109	114	O	reflex	lex	flex	NN	False
DDI-MedLine.d93.s8	and	116	118	O	and	and	and	CC	False
DDI-MedLine.d93.s8	shorter	120	126	O	shorter	ter	rter	NN	False
DDI-MedLine.d93.s8	durations	128	136	O	durations	ons	ions	NNS	False
DDI-MedLine.d93.s8	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d93.s8	sleep	141	145	O	sleep	eep	leep	NN	False
DDI-MedLine.d93.s8	than	147	150	O	than	han	than	IN	False
DDI-MedLine.d93.s8	did	152	154	O	did	did	did	VBD	False
DDI-MedLine.d93.s8	controls	156	163	O	controls	ols	rols	NNS	False
DDI-MedLine.d93.s8	.	164	164	O	.	.	.	.	False

DDI-MedLine.d93.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d93.s9	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d93.s9	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d93.s9	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d93.s9	exposure	27	34	O	exposure	ure	sure	NN	False
DDI-MedLine.d93.s9	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d93.s9	environmental	39	51	O	environmental	tal	ntal	JJ	False
DDI-MedLine.d93.s9	lead	53	56	B-drug_n	lead	ead	lead	NN	False
DDI-MedLine.d93.s9	may	58	60	O	may	may	may	MD	False
DDI-MedLine.d93.s9	alter	62	66	O	alter	ter	lter	NN	False
DDI-MedLine.d93.s9	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d93.s9	biological	72	81	O	biological	cal	ical	JJ	False
DDI-MedLine.d93.s9	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d93.s9	behavioral	87	96	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d93.s9	responsiveness	98	111	O	responsiveness	ess	ness	NN	False
DDI-MedLine.d93.s9	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d93.s9	an	116	117	O	an	an	an	DT	False
DDI-MedLine.d93.s9	animal	119	124	O	animal	mal	imal	NN	False
DDI-MedLine.d93.s9	to	126	127	O	to	to	to	TO	False
DDI-MedLine.d93.s9	alcohol	129	135	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d93.s9	.	136	136	O	.	.	.	.	False

DDI-MedLine.d49.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d49.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d49.s0	clindamycin	15	25	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s0	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d49.s0	gentamicin	31	40	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s0	in	42	43	O	in	in	in	IN	False
DDI-MedLine.d49.s0	vitro	45	49	O	vitro	tro	itro	NN	False
DDI-MedLine.d49.s0	.	50	50	O	.	.	.	.	False

DDI-MedLine.d49.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d49.s1	minimal	4	10	O	minimal	mal	imal	NN	False
DDI-MedLine.d49.s1	inhibitory	12	21	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d49.s1	concentrations	23	36	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d49.s1	of	38	39	O	of	of	of	IN	False
DDI-MedLine.d49.s1	clindamycin	41	51	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s1	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d49.s1	gentamicin	57	66	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s1	alone	68	72	O	alone	one	lone	RB	False
DDI-MedLine.d49.s1	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d49.s1	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d49.s1	combinations	81	92	O	combinations	ons	ions	NNS	False
DDI-MedLine.d49.s1	were	94	97	O	were	ere	were	VBD	False
DDI-MedLine.d49.s1	determined	99	108	O	determined	ned	ined	VBN	False
DDI-MedLine.d49.s1	by	110	111	O	by	by	by	IN	False
DDI-MedLine.d49.s1	a	113	113	O	a	a	a	DT	False
DDI-MedLine.d49.s1	microdilution	115	127	O	microdilution	ion	tion	NN	False
DDI-MedLine.d49.s1	method	129	134	O	method	hod	thod	NN	False
DDI-MedLine.d49.s1	for	136	138	O	for	for	for	IN	False
DDI-MedLine.d49.s1	163	140	142	O	163	163	163	CD	False
DDI-MedLine.d49.s1	aerobic	144	150	O	aerobic	bic	obic	NN	False
DDI-MedLine.d49.s1	,	151	151	O	,	,	,	,	False
DDI-MedLine.d49.s1	facultative	153	163	O	facultative	ive	tive	JJ	False
DDI-MedLine.d49.s1	,	164	164	O	,	,	,	,	False
DDI-MedLine.d49.s1	and	166	168	O	and	and	and	CC	False
DDI-MedLine.d49.s1	anaerobic	170	178	O	anaerobic	bic	obic	NN	False
DDI-MedLine.d49.s1	clinical	180	187	O	clinical	cal	ical	JJ	False
DDI-MedLine.d49.s1	isolates	189	196	O	isolates	tes	ates	NNS	False
DDI-MedLine.d49.s1	.	197	197	O	.	.	.	.	False

DDI-MedLine.d49.s2	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d49.s2	77	4	5	O	77	77	77	CD	False
DDI-MedLine.d49.s2	strains	7	13	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s2	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d49.s2	Staphylococcus	18	31	O	Staphylococcus	cus	ccus	NN	False
DDI-MedLine.d49.s2	aureus	33	38	O	aureus	eus	reus	NN	False
DDI-MedLine.d49.s2	,	39	39	O	,	,	,	,	False
DDI-MedLine.d49.s2	Diplococcus	41	51	O	Diplococcus	cus	ccus	NN	False
DDI-MedLine.d49.s2	pneumoniae	53	62	O	pneumoniae	iae	niae	NN	False
DDI-MedLine.d49.s2	,	63	63	O	,	,	,	,	False
DDI-MedLine.d49.s2	Streptococcus	65	77	O	Streptococcus	cus	ccus	NN	False
DDI-MedLine.d49.s2	pyogenes	79	86	O	pyogenes	nes	enes	NNS	False
DDI-MedLine.d49.s2	,	87	87	O	,	,	,	,	False
DDI-MedLine.d49.s2	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d49.s2	anaerobic	93	101	O	anaerobic	bic	obic	NN	False
DDI-MedLine.d49.s2	bacteria	103	110	O	bacteria	ria	eria	NNS	False
DDI-MedLine.d49.s2	(	112	112	O	(	(	(	(	False
DDI-MedLine.d49.s2	except	113	118	O	except	ept	cept	IN	False
DDI-MedLine.d49.s2	for	120	122	O	for	for	for	IN	False
DDI-MedLine.d49.s2	three	124	128	O	three	ree	hree	CD	False
DDI-MedLine.d49.s2	strains	130	136	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s2	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d49.s2	Clostridium	141	151	O	Clostridium	ium	dium	NN	drug
DDI-MedLine.d49.s2	)	152	152	O	)	)	)	)	False
DDI-MedLine.d49.s2	were	154	157	O	were	ere	were	VBD	False
DDI-MedLine.d49.s2	inhibited	159	167	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d49.s2	by	169	170	O	by	by	by	IN	False
DDI-MedLine.d49.s2	1.6	172	174	O	1.6	1.6	1.6	CD	False
DDI-MedLine.d49.s2	mug	176	178	O	mug	mug	mug	NN	False
DDI-MedLine.d49.s2	or	180	181	O	or	or	or	CC	False
DDI-MedLine.d49.s2	less	183	186	O	less	ess	less	RBR	False
DDI-MedLine.d49.s2	of	188	189	O	of	of	of	IN	False
DDI-MedLine.d49.s2	clindamycin	191	201	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s2	per	203	205	O	per	per	per	IN	False
DDI-MedLine.d49.s2	ml	207	208	O	ml	ml	ml	NN	False
DDI-MedLine.d49.s2	.	209	209	O	.	.	.	.	False

DDI-MedLine.d49.s3	Gentamicin	0	9	B-drug	Gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s3	did	11	13	O	did	did	did	VBD	False
DDI-MedLine.d49.s3	not	15	17	O	not	not	not	RB	False
DDI-MedLine.d49.s3	interfere	19	27	O	interfere	ere	fere	RB	False
DDI-MedLine.d49.s3	with	29	32	O	with	ith	with	IN	False
DDI-MedLine.d49.s3	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d49.s3	activity	38	45	O	activity	ity	vity	NN	False
DDI-MedLine.d49.s3	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d49.s3	clindamycin	50	60	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s3	within	62	67	O	within	hin	thin	IN	False
DDI-MedLine.d49.s3	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d49.s3	range	73	77	O	range	nge	ange	NN	False
DDI-MedLine.d49.s3	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d49.s3	concentrations	82	95	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d49.s3	tested	97	102	O	tested	ted	sted	VBN	False
DDI-MedLine.d49.s3	(	104	104	O	(	(	(	(	False
DDI-MedLine.d49.s3	0.1	105	107	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d49.s3	to	109	110	O	to	to	to	TO	False
DDI-MedLine.d49.s3	100	112	114	O	100	100	100	CD	False
DDI-MedLine.d49.s3	mug/ml	116	121	O	mug/ml	/ml	g/ml	NN	False
DDI-MedLine.d49.s3	)	122	122	O	)	)	)	)	False
DDI-MedLine.d49.s3	;	123	123	O	;	;	;	:	False

DDI-MedLine.d49.s4	for	0	2	O	for	for	for	IN	False
DDI-MedLine.d49.s4	some	4	7	O	some	ome	some	DT	False
DDI-MedLine.d49.s4	strains	9	15	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s4	combinations	17	28	O	combinations	ons	ions	NNS	False
DDI-MedLine.d49.s4	were	30	33	O	were	ere	were	VBD	False
DDI-MedLine.d49.s4	synergistic	35	45	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d49.s4	.	46	46	O	.	.	.	.	False

DDI-MedLine.d49.s5	Sixty-two	0	8	O	Sixty-two	two	-two	NN	False
DDI-MedLine.d49.s5	(	10	10	O	(	(	(	(	False
DDI-MedLine.d49.s5	94	11	12	O	94	94	94	CD	False
DDI-MedLine.d49.s5	%	13	13	O	%	%	%	NN	False
DDI-MedLine.d49.s5	)	14	14	O	)	)	)	)	False
DDI-MedLine.d49.s5	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d49.s5	66	19	20	O	66	66	66	CD	False
DDI-MedLine.d49.s5	strains	22	28	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s5	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d49.s5	Enterobacteriaceae	33	50	O	Enterobacteriaceae	eae	ceae	NN	False
DDI-MedLine.d49.s5	and	52	54	O	and	and	and	CC	False
DDI-MedLine.d49.s5	Pseudomonas	56	66	O	Pseudomonas	nas	onas	NNS	False
DDI-MedLine.d49.s5	aeruginosa	68	77	O	aeruginosa	osa	nosa	NN	False
DDI-MedLine.d49.s5	were	79	82	O	were	ere	were	VBD	False
DDI-MedLine.d49.s5	inhibited	84	92	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d49.s5	by	94	95	O	by	by	by	IN	False
DDI-MedLine.d49.s5	6.2	97	99	O	6.2	6.2	6.2	CD	False
DDI-MedLine.d49.s5	mug	101	103	O	mug	mug	mug	NN	False
DDI-MedLine.d49.s5	or	105	106	O	or	or	or	CC	False
DDI-MedLine.d49.s5	less	108	111	O	less	ess	less	RBR	False
DDI-MedLine.d49.s5	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d49.s5	gentamicin	116	125	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s5	per	127	129	O	per	per	per	IN	False
DDI-MedLine.d49.s5	ml	131	132	O	ml	ml	ml	NN	False
DDI-MedLine.d49.s5	.	133	133	O	.	.	.	.	False

DDI-MedLine.d49.s6	Combinations	0	11	O	Combinations	ons	ions	NNS	False
DDI-MedLine.d49.s6	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d49.s6	clindamycin	16	26	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s6	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d49.s6	gentamicin	32	41	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s6	were	43	46	O	were	ere	were	VBD	False
DDI-MedLine.d49.s6	indifferent	48	58	O	indifferent	ent	rent	NN	False
DDI-MedLine.d49.s6	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d49.s6	29	64	65	O	29	29	29	CD	False
DDI-MedLine.d49.s6	strains	67	73	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s6	and	75	77	O	and	and	and	CC	False
DDI-MedLine.d49.s6	synergistic	79	89	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d49.s6	for	91	93	O	for	for	for	IN	False
DDI-MedLine.d49.s6	33	95	96	O	33	33	33	CD	False
DDI-MedLine.d49.s6	strains	98	104	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s6	.	105	105	O	.	.	.	.	False

DDI-MedLine.d49.s7	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d49.s7	20	4	5	O	20	20	20	CD	False
DDI-MedLine.d49.s7	strains	7	13	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s7	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d49.s7	enterococcus	18	29	O	enterococcus	cus	ccus	NN	False
DDI-MedLine.d49.s7	,	30	30	O	,	,	,	,	False
DDI-MedLine.d49.s7	three	32	36	O	three	ree	hree	CD	False
DDI-MedLine.d49.s7	strains	38	44	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s7	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d49.s7	Clostridium	49	59	O	Clostridium	ium	dium	NN	drug
DDI-MedLine.d49.s7	,	60	60	O	,	,	,	,	False
DDI-MedLine.d49.s7	three	62	66	O	three	ree	hree	CD	False
DDI-MedLine.d49.s7	strains	68	74	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s7	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d49.s7	Escherichia	79	89	O	Escherichia	hia	chia	NN	False
DDI-MedLine.d49.s7	coli	91	94	O	coli	oli	coli	NNS	False
DDI-MedLine.d49.s7	,	95	95	O	,	,	,	,	False
DDI-MedLine.d49.s7	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d49.s7	one	101	103	O	one	one	one	CD	False
DDI-MedLine.d49.s7	strain	105	110	O	strain	ain	rain	NN	False
DDI-MedLine.d49.s7	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d49.s7	Proteus	115	121	O	Proteus	eus	teus	NN	False
DDI-MedLine.d49.s7	rettgeri	123	130	O	rettgeri	eri	geri	NN	False
DDI-MedLine.d49.s7	were	132	135	O	were	ere	were	VBD	False
DDI-MedLine.d49.s7	resistant	137	145	O	resistant	ant	tant	NN	False
DDI-MedLine.d49.s7	to	147	148	O	to	to	to	TO	False
DDI-MedLine.d49.s7	both	150	153	O	both	oth	both	DT	False
DDI-MedLine.d49.s7	clindamycin	155	165	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s7	(	167	167	O	(	(	(	(	False
DDI-MedLine.d49.s7	minimal	168	174	O	minimal	mal	imal	NN	False
DDI-MedLine.d49.s7	inhibitory	176	185	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d49.s7	concentration	187	199	O	concentration	ion	tion	NN	False
DDI-MedLine.d49.s7	greater	201	207	O	greater	ter	ater	JJR	False
DDI-MedLine.d49.s7	than	209	212	O	than	han	than	IN	False
DDI-MedLine.d49.s7	3.1	214	216	O	3.1	3.1	3.1	CD	False
DDI-MedLine.d49.s7	mug/ml	218	223	O	mug/ml	/ml	g/ml	NN	False
DDI-MedLine.d49.s7	)	224	224	O	)	)	)	)	False
DDI-MedLine.d49.s7	and	226	228	O	and	and	and	CC	False
DDI-MedLine.d49.s7	gentamicin	230	239	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s7	(	241	241	O	(	(	(	(	False
DDI-MedLine.d49.s7	minimal	242	248	O	minimal	mal	imal	NN	False
DDI-MedLine.d49.s7	inhibitory	250	259	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d49.s7	concentration	261	273	O	concentration	ion	tion	NN	False
DDI-MedLine.d49.s7	greater	275	281	O	greater	ter	ater	JJR	False
DDI-MedLine.d49.s7	than	283	286	O	than	han	than	IN	False
DDI-MedLine.d49.s7	6.2	288	290	O	6.2	6.2	6.2	CD	False
DDI-MedLine.d49.s7	mug/ml	292	297	O	mug/ml	/ml	g/ml	NN	False
DDI-MedLine.d49.s7	)	298	298	O	)	)	)	)	False
DDI-MedLine.d49.s7	.	299	299	O	.	.	.	.	False

DDI-MedLine.d49.s8	Combinations	0	11	O	Combinations	ons	ions	NNS	False
DDI-MedLine.d49.s8	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d49.s8	clindamycin	16	26	B-drug	clindamycin	cin	ycin	NN	drug
DDI-MedLine.d49.s8	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d49.s8	gentamicin	32	41	B-drug	gentamicin	cin	icin	NN	drug
DDI-MedLine.d49.s8	were	43	46	O	were	ere	were	VBD	False
DDI-MedLine.d49.s8	indifferent	48	58	O	indifferent	ent	rent	NN	False
DDI-MedLine.d49.s8	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d49.s8	16	64	65	O	16	16	16	CD	False
DDI-MedLine.d49.s8	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d49.s8	synergistic	71	81	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d49.s8	for	83	85	O	for	for	for	IN	False
DDI-MedLine.d49.s8	11	87	88	O	11	11	11	CD	False
DDI-MedLine.d49.s8	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d49.s8	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d49.s8	resistant	97	105	O	resistant	ant	tant	NN	False
DDI-MedLine.d49.s8	strains	107	113	O	strains	ins	ains	NNS	False
DDI-MedLine.d49.s8	.	114	114	O	.	.	.	.	False

DDI-MedLine.d49.s9	Except	0	5	O	Except	ept	cept	IN	False
DDI-MedLine.d49.s9	for	7	9	O	for	for	for	IN	False
DDI-MedLine.d49.s9	clindamycin-sensitive	11	31	O	clindamycin-sensitive	ive	tive	JJ	False
DDI-MedLine.d49.s9	isolates	33	40	O	isolates	tes	ates	NNS	False
DDI-MedLine.d49.s9	,	41	41	O	,	,	,	,	False
DDI-MedLine.d49.s9	synergy	43	49	O	synergy	rgy	ergy	NN	False
DDI-MedLine.d49.s9	was	51	53	O	was	was	was	VBD	False
DDI-MedLine.d49.s9	usually	55	61	O	usually	lly	ally	RB	False
DDI-MedLine.d49.s9	observed	63	70	O	observed	ved	rved	VBN	False
DDI-MedLine.d49.s9	only	72	75	O	only	nly	only	RB	False
DDI-MedLine.d49.s9	at	77	78	O	at	at	at	IN	False
DDI-MedLine.d49.s9	concentrations	80	93	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d49.s9	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d49.s9	one	98	100	O	one	one	one	CD	False
DDI-MedLine.d49.s9	or	102	103	O	or	or	or	CC	False
DDI-MedLine.d49.s9	both	105	108	O	both	oth	both	DT	False
DDI-MedLine.d49.s9	drugs	110	114	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d49.s9	which	116	120	O	which	ich	hich	WDT	False
DDI-MedLine.d49.s9	are	122	124	O	are	are	are	VBP	False
DDI-MedLine.d49.s9	not	126	128	O	not	not	not	RB	False
DDI-MedLine.d49.s9	readily	130	136	O	readily	ily	dily	RB	False
DDI-MedLine.d49.s9	obtainable	138	147	O	obtainable	ble	able	JJ	False
DDI-MedLine.d49.s9	in	149	150	O	in	in	in	IN	False
DDI-MedLine.d49.s9	vivo	152	155	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d49.s9	.	156	156	O	.	.	.	.	False

DDI-MedLine.d49.s10	Antagonism	0	9	O	Antagonism	ism	nism	NN	False
DDI-MedLine.d49.s10	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d49.s10	never	15	19	O	never	ver	ever	RB	False
DDI-MedLine.d49.s10	observed	21	28	O	observed	ved	rved	VBN	False
DDI-MedLine.d49.s10	.	29	29	O	.	.	.	.	False

DDI-MedLine.d43.s0	Tumor	0	4	O	Tumor	mor	umor	NN	False
DDI-MedLine.d43.s0	phenotype	6	14	O	phenotype	ype	type	NN	False
DDI-MedLine.d43.s0	and	16	18	O	and	and	and	CC	False
DDI-MedLine.d43.s0	susceptibility	20	33	O	susceptibility	ity	lity	NN	False
DDI-MedLine.d43.s0	to	35	36	O	to	to	to	TO	False
DDI-MedLine.d43.s0	progression	38	48	O	progression	ion	sion	NN	False
DDI-MedLine.d43.s0	as	50	51	O	as	as	as	IN	False
DDI-MedLine.d43.s0	an	53	54	O	an	an	an	DT	False
DDI-MedLine.d43.s0	expression	56	65	O	expression	ion	sion	NN	False
DDI-MedLine.d43.s0	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d43.s0	subpopulations	70	83	O	subpopulations	ons	ions	NNS	False
DDI-MedLine.d43.s0	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d43.s0	initiated	88	96	O	initiated	ted	ated	VBN	False
DDI-MedLine.d43.s0	murine	98	103	O	murine	ine	rine	NN	drug
DDI-MedLine.d43.s0	cells	105	109	O	cells	lls	ells	NNS	False
DDI-MedLine.d43.s0	.	110	110	O	.	.	.	.	False

DDI-MedLine.d43.s1	Currently	0	8	O	Currently	tly	ntly	RB	False
DDI-MedLine.d43.s1	,	9	9	O	,	,	,	,	False
DDI-MedLine.d43.s1	it	11	12	O	it	it	it	PRP	False
DDI-MedLine.d43.s1	is	14	15	O	is	is	is	VBZ	False
DDI-MedLine.d43.s1	conceived	17	25	O	conceived	ved	ived	VBN	False
DDI-MedLine.d43.s1	that	27	30	O	that	hat	that	IN	False
DDI-MedLine.d43.s1	a	32	32	O	a	a	a	DT	False
DDI-MedLine.d43.s1	number	34	39	O	number	ber	mber	NN	False
DDI-MedLine.d43.s1	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d43.s1	events	44	49	O	events	nts	ents	NNS	False
DDI-MedLine.d43.s1	,	50	50	O	,	,	,	,	False
DDI-MedLine.d43.s1	or	52	53	O	or	or	or	CC	False
DDI-MedLine.d43.s1	hits	55	58	O	hits	its	hits	NNS	False
DDI-MedLine.d43.s1	,	59	59	O	,	,	,	,	False
DDI-MedLine.d43.s1	are	61	63	O	are	are	are	VBP	False
DDI-MedLine.d43.s1	required	65	72	O	required	red	ired	VBN	False
DDI-MedLine.d43.s1	for	74	76	O	for	for	for	IN	False
DDI-MedLine.d43.s1	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d43.s1	induction	82	90	O	induction	ion	tion	NN	False
DDI-MedLine.d43.s1	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d43.s1	tumors	95	100	O	tumors	ors	mors	NNS	False
DDI-MedLine.d43.s1	by	102	103	O	by	by	by	IN	False
DDI-MedLine.d43.s1	chemical	105	112	O	chemical	cal	ical	NN	False
DDI-MedLine.d43.s1	agents	114	119	O	agents	nts	ents	NNS	False
DDI-MedLine.d43.s1	.	120	120	O	.	.	.	.	False

DDI-MedLine.d43.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d43.s2	first	4	8	O	first	rst	irst	RB	False
DDI-MedLine.d43.s2	phase	10	14	O	phase	ase	hase	NN	False
DDI-MedLine.d43.s2	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d43.s2	this	19	22	O	this	his	this	DT	False
DDI-MedLine.d43.s2	sequence	24	31	O	sequence	nce	ence	NN	False
DDI-MedLine.d43.s2	,	32	32	O	,	,	,	,	False
DDI-MedLine.d43.s2	initiation	34	43	O	initiation	ion	tion	NN	False
DDI-MedLine.d43.s2	,	44	44	O	,	,	,	,	False
DDI-MedLine.d43.s2	is	46	47	O	is	is	is	VBZ	False
DDI-MedLine.d43.s2	considered	49	58	O	considered	red	ered	VBN	False
DDI-MedLine.d43.s2	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d43.s2	result	63	68	O	result	ult	sult	NN	False
DDI-MedLine.d43.s2	from	70	73	O	from	rom	from	IN	False
DDI-MedLine.d43.s2	at	75	76	O	at	at	at	IN	False
DDI-MedLine.d43.s2	least	78	82	O	least	ast	east	JJS	False
DDI-MedLine.d43.s2	one	84	86	O	one	one	one	CD	False
DDI-MedLine.d43.s2	event	88	92	O	event	ent	vent	NN	False
DDI-MedLine.d43.s2	in	94	95	O	in	in	in	IN	False
DDI-MedLine.d43.s2	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d43.s2	genetic	101	107	O	genetic	tic	etic	JJ	False
DDI-MedLine.d43.s2	apparatus	109	117	O	apparatus	tus	atus	NN	False
DDI-MedLine.d43.s2	.	118	118	O	.	.	.	.	False

DDI-MedLine.d43.s3	Analyses	0	7	O	Analyses	ses	yses	NNS	False
DDI-MedLine.d43.s3	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d43.s3	this	12	15	O	this	his	this	DT	False
DDI-MedLine.d43.s3	sequence	17	24	O	sequence	nce	ence	NN	False
DDI-MedLine.d43.s3	,	25	25	O	,	,	,	,	False
DDI-MedLine.d43.s3	however	27	33	O	however	ver	ever	RB	False
DDI-MedLine.d43.s3	,	34	34	O	,	,	,	,	False
DDI-MedLine.d43.s3	usually	36	42	O	usually	lly	ally	RB	False
DDI-MedLine.d43.s3	give	44	47	O	give	ive	give	VB	False
DDI-MedLine.d43.s3	little	49	54	O	little	tle	ttle	JJ	False
DDI-MedLine.d43.s3	consideration	56	68	O	consideration	ion	tion	NN	False
DDI-MedLine.d43.s3	to	70	71	O	to	to	to	TO	False
DDI-MedLine.d43.s3	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d43.s3	nature	77	82	O	nature	ure	ture	NN	False
DDI-MedLine.d43.s3	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d43.s3	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d43.s3	target	91	96	O	target	get	rget	NN	False
DDI-MedLine.d43.s3	cell	98	101	O	cell	ell	cell	NN	False
DDI-MedLine.d43.s3	or	103	104	O	or	or	or	CC	False
DDI-MedLine.d43.s3	to	106	107	O	to	to	to	TO	False
DDI-MedLine.d43.s3	the	109	111	O	the	the	the	DT	False
DDI-MedLine.d43.s3	characteristics	113	127	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d43.s3	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d43.s3	the	132	134	O	the	the	the	DT	False
DDI-MedLine.d43.s3	resultant	136	144	O	resultant	ant	tant	NN	False
DDI-MedLine.d43.s3	tumors	146	151	O	tumors	ors	mors	NNS	False
DDI-MedLine.d43.s3	.	152	152	O	.	.	.	.	False

DDI-MedLine.d43.s4	Vesselinovitch	0	13	O	Vesselinovitch	tch	itch	NN	False
DDI-MedLine.d43.s4	et	15	16	O	et	et	et	NN	False
DDI-MedLine.d43.s4	al	18	19	O	al	al	al	NN	False
DDI-MedLine.d43.s4	.	20	20	O	.	.	.	.	False

DDI-MedLine.d43.s5	(	0	0	O	(	(	(	(	False
DDI-MedLine.d43.s5	Cancer	1	6	O	Cancer	cer	ncer	NN	False
DDI-MedLine.d43.s5	Res.	8	11	O	Res.	es.	Res.	NN	False
DDI-MedLine.d43.s5	,	12	12	O	,	,	,	,	False
DDI-MedLine.d43.s5	38	14	15	O	38	38	38	CD	False
DDI-MedLine.d43.s5	:	16	16	O	:	:	:	:	False
DDI-MedLine.d43.s5	2003-2010	18	26	O	2003-2010	010	2010	JJ	False
DDI-MedLine.d43.s5	,	27	27	O	,	,	,	,	False
DDI-MedLine.d43.s5	1978	29	32	O	1978	978	1978	CD	False
DDI-MedLine.d43.s5	)	33	33	O	)	)	)	)	False
DDI-MedLine.d43.s5	have	35	38	O	have	ave	have	VB	False
DDI-MedLine.d43.s5	reported	40	47	O	reported	ted	rted	VBD	False
DDI-MedLine.d43.s5	that	49	52	O	that	hat	that	IN	False
DDI-MedLine.d43.s5	a	54	54	O	a	a	a	DT	False
DDI-MedLine.d43.s5	single	56	61	O	single	gle	ngle	JJ	False
DDI-MedLine.d43.s5	,	62	62	O	,	,	,	,	False
DDI-MedLine.d43.s5	small	64	68	O	small	all	mall	JJ	False
DDI-MedLine.d43.s5	pulse	70	74	O	pulse	lse	ulse	NN	False
DDI-MedLine.d43.s5	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d43.s5	carcinogen	79	88	O	carcinogen	gen	ogen	NN	brand
DDI-MedLine.d43.s5	can	90	92	O	can	can	can	MD	False
DDI-MedLine.d43.s5	induce	94	99	O	induce	uce	duce	NN	False
DDI-MedLine.d43.s5	early	101	105	O	early	rly	arly	RB	False
DDI-MedLine.d43.s5	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d43.s5	numerous	111	118	O	numerous	ous	rous	JJ	False
DDI-MedLine.d43.s5	liver	120	124	O	liver	ver	iver	NN	False
DDI-MedLine.d43.s5	tumors	126	131	O	tumors	ors	mors	NNS	False
DDI-MedLine.d43.s5	when	133	136	O	when	hen	when	WRB	False
DDI-MedLine.d43.s5	administered	138	149	O	administered	red	ered	VBN	False
DDI-MedLine.d43.s5	neonatally	151	160	O	neonatally	lly	ally	RB	False
DDI-MedLine.d43.s5	to	162	163	O	to	to	to	TO	False
DDI-MedLine.d43.s5	mice	165	168	O	mice	ice	mice	NN	False
DDI-MedLine.d43.s5	with	170	173	O	with	ith	with	IN	False
DDI-MedLine.d43.s5	a	175	175	O	a	a	a	DT	False
DDI-MedLine.d43.s5	genetic	177	183	O	genetic	tic	etic	JJ	False
DDI-MedLine.d43.s5	predisposition	185	198	O	predisposition	ion	tion	NN	False
DDI-MedLine.d43.s5	to	200	201	O	to	to	to	TO	False
DDI-MedLine.d43.s5	hepatotumorigenesis	203	221	O	hepatotumorigenesis	sis	esis	NN	False
DDI-MedLine.d43.s5	.	222	222	O	.	.	.	.	False

DDI-MedLine.d43.s6	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d43.s6	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d43.s6	current	7	13	O	current	ent	rent	JJ	False
DDI-MedLine.d43.s6	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d43.s6	,	20	20	O	,	,	,	,	False
DDI-MedLine.d43.s6	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d43.s6	nonpredisposed	26	39	O	nonpredisposed	sed	osed	VBN	False
DDI-MedLine.d43.s6	strain	41	46	O	strain	ain	rain	NN	False
DDI-MedLine.d43.s6	C57BL/6N	48	55	O	C57BL/6N	/6N	L/6N	NN	brand
DDI-MedLine.d43.s6	was	57	59	O	was	was	was	VBD	False
DDI-MedLine.d43.s6	also	61	64	O	also	lso	also	RB	False
DDI-MedLine.d43.s6	shown	66	70	O	shown	own	hown	VBN	False
DDI-MedLine.d43.s6	to	72	73	O	to	to	to	TO	False
DDI-MedLine.d43.s6	be	75	76	O	be	be	be	VB	False
DDI-MedLine.d43.s6	highly	78	83	O	highly	hly	ghly	RB	False
DDI-MedLine.d43.s6	susceptible	85	95	O	susceptible	ble	ible	JJ	False
DDI-MedLine.d43.s6	to	97	98	O	to	to	to	TO	False
DDI-MedLine.d43.s6	diethylnitrosamine	100	117	O	diethylnitrosamine	ine	mine	NN	drug
DDI-MedLine.d43.s6	during	119	124	O	during	ing	ring	IN	False
DDI-MedLine.d43.s6	the	126	128	O	the	the	the	DT	False
DDI-MedLine.d43.s6	neonatal	130	137	O	neonatal	tal	atal	JJ	False
DDI-MedLine.d43.s6	period	139	144	O	period	iod	riod	NN	False
DDI-MedLine.d43.s6	.	145	145	O	.	.	.	.	False

DDI-MedLine.d43.s7	C57BL/6N	0	7	O	C57BL/6N	/6N	L/6N	NN	brand
DDI-MedLine.d43.s7	demonstrated	9	20	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d43.s7	large	22	26	O	large	rge	arge	JJ	False
DDI-MedLine.d43.s7	numbers	28	34	O	numbers	ers	bers	NNS	False
DDI-MedLine.d43.s7	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d43.s7	two	39	41	O	two	two	two	CD	False
DDI-MedLine.d43.s7	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d43.s7	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d43.s7	three	50	54	O	three	ree	hree	CD	False
DDI-MedLine.d43.s7	types	56	60	O	types	pes	ypes	NNS	False
DDI-MedLine.d43.s7	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d43.s7	liver	65	69	O	liver	ver	iver	NN	False
DDI-MedLine.d43.s7	tumors	71	76	O	tumors	ors	mors	NNS	False
DDI-MedLine.d43.s7	seen	78	81	O	seen	een	seen	VBN	False
DDI-MedLine.d43.s7	in	83	84	O	in	in	in	IN	False
DDI-MedLine.d43.s7	livers	86	91	O	livers	ers	vers	NNS	False
DDI-MedLine.d43.s7	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d43.s7	genetically	96	106	O	genetically	lly	ally	RB	False
DDI-MedLine.d43.s7	predisposed	108	118	O	predisposed	sed	osed	VBN	False
DDI-MedLine.d43.s7	mice	120	123	O	mice	ice	mice	NN	False
DDI-MedLine.d43.s7	,	124	124	O	,	,	,	,	False
DDI-MedLine.d43.s7	one	126	128	O	one	one	one	CD	False
DDI-MedLine.d43.s7	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d43.s7	which	133	137	O	which	ich	hich	WDT	False
DDI-MedLine.d43.s7	required	139	146	O	required	red	ired	VBN	False
DDI-MedLine.d43.s7	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d43.s7	additional	152	161	O	additional	nal	onal	JJ	False
DDI-MedLine.d43.s7	stimulus	163	170	O	stimulus	lus	ulus	NN	False
DDI-MedLine.d43.s7	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d43.s7	dietary	175	181	O	dietary	ary	tary	JJ	False
DDI-MedLine.d43.s7	phenobarbital	183	195	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d43.s7	for	197	199	O	for	for	for	IN	False
DDI-MedLine.d43.s7	growth	201	206	O	growth	wth	owth	NN	False
DDI-MedLine.d43.s7	.	207	207	O	.	.	.	.	False

DDI-MedLine.d43.s8	Tumors	0	5	O	Tumors	ors	mors	NNS	False
DDI-MedLine.d43.s8	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d43.s8	more	10	13	O	more	ore	more	RBR	False
DDI-MedLine.d43.s8	malignant	15	23	O	malignant	ant	nant	NN	False
DDI-MedLine.d43.s8	phenotype	25	33	O	phenotype	ype	type	NN	False
DDI-MedLine.d43.s8	were	35	38	O	were	ere	were	VBD	False
DDI-MedLine.d43.s8	demonstrated	40	51	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d43.s8	only	53	56	O	only	nly	only	RB	False
DDI-MedLine.d43.s8	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d43.s8	genetically	61	71	O	genetically	lly	ally	RB	False
DDI-MedLine.d43.s8	predisposed	73	83	O	predisposed	sed	osed	VBN	False
DDI-MedLine.d43.s8	mice	85	88	O	mice	ice	mice	NN	False
DDI-MedLine.d43.s8	(	90	90	O	(	(	(	(	False
DDI-MedLine.d43.s8	C57BL/6N	91	98	O	C57BL/6N	/6N	L/6N	NN	brand
DDI-MedLine.d43.s8	X	100	100	O	X	X	X	NN	brand
DDI-MedLine.d43.s8	C3H/HeN	102	108	O	C3H/HeN	HeN	/HeN	NN	False
DDI-MedLine.d43.s8	F1	110	111	O	F1	F1	F1	NN	brand
DDI-MedLine.d43.s8	)	112	112	O	)	)	)	)	False
DDI-MedLine.d43.s8	that	114	117	O	that	hat	that	IN	False
DDI-MedLine.d43.s8	received	119	126	O	received	ved	ived	VBN	False
DDI-MedLine.d43.s8	one	128	130	O	one	one	one	CD	False
DDI-MedLine.d43.s8	dose	132	135	O	dose	ose	dose	NN	False
DDI-MedLine.d43.s8	of	137	138	O	of	of	of	IN	False
DDI-MedLine.d43.s8	carcinogen	140	149	O	carcinogen	gen	ogen	NN	brand
DDI-MedLine.d43.s8	.	150	150	O	.	.	.	.	False

DDI-MedLine.d43.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d43.s9	findings	6	13	O	findings	ngs	ings	NNS	False
DDI-MedLine.d43.s9	suggest	15	21	O	suggest	est	gest	NN	False
DDI-MedLine.d43.s9	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d43.s9	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d43.s9	phenotype	32	40	O	phenotype	ype	type	NN	False
DDI-MedLine.d43.s9	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d43.s9	a	45	45	O	a	a	a	DT	False
DDI-MedLine.d43.s9	tumor	47	51	O	tumor	mor	umor	NN	False
DDI-MedLine.d43.s9	that	53	56	O	that	hat	that	IN	False
DDI-MedLine.d43.s9	results	58	64	O	results	lts	ults	NNS	False
DDI-MedLine.d43.s9	from	66	69	O	from	rom	from	IN	False
DDI-MedLine.d43.s9	a	71	71	O	a	a	a	DT	False
DDI-MedLine.d43.s9	pulse	73	77	O	pulse	lse	ulse	NN	False
DDI-MedLine.d43.s9	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d43.s9	a	82	82	O	a	a	a	DT	False
DDI-MedLine.d43.s9	chemical	84	91	O	chemical	cal	ical	NN	False
DDI-MedLine.d43.s9	carcinogen	93	102	O	carcinogen	gen	ogen	NN	brand
DDI-MedLine.d43.s9	may	104	106	O	may	may	may	MD	False
DDI-MedLine.d43.s9	depend	108	113	O	depend	end	pend	NN	False
DDI-MedLine.d43.s9	upon	115	118	O	upon	pon	upon	IN	False
DDI-MedLine.d43.s9	the	120	122	O	the	the	the	DT	False
DDI-MedLine.d43.s9	target	124	129	O	target	get	rget	NN	False
DDI-MedLine.d43.s9	cell	131	134	O	cell	ell	cell	NN	False
DDI-MedLine.d43.s9	.	135	135	O	.	.	.	.	False

DDI-MedLine.d43.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d43.s10	initiated	4	12	O	initiated	ted	ated	VBN	False
DDI-MedLine.d43.s10	cells	14	18	O	cells	lls	ells	NNS	False
DDI-MedLine.d43.s10	that	20	23	O	that	hat	that	IN	False
DDI-MedLine.d43.s10	result	25	30	O	result	ult	sult	NN	False
DDI-MedLine.d43.s10	from	32	35	O	from	rom	from	IN	False
DDI-MedLine.d43.s10	this	37	40	O	this	his	this	DT	False
DDI-MedLine.d43.s10	hit	42	44	O	hit	hit	hit	NN	False
DDI-MedLine.d43.s10	may	46	48	O	may	may	may	MD	False
DDI-MedLine.d43.s10	vary	50	53	O	vary	ary	vary	NN	False
DDI-MedLine.d43.s10	from	55	58	O	from	rom	from	IN	False
DDI-MedLine.d43.s10	those	60	64	O	those	ose	hose	DT	False
DDI-MedLine.d43.s10	that	66	69	O	that	hat	that	IN	False
DDI-MedLine.d43.s10	demonstrate	71	81	O	demonstrate	ate	rate	NN	False
DDI-MedLine.d43.s10	very	83	86	O	very	ery	very	RB	False
DDI-MedLine.d43.s10	little	88	93	O	little	tle	ttle	JJ	False
DDI-MedLine.d43.s10	progression	95	105	O	progression	ion	sion	NN	False
DDI-MedLine.d43.s10	in	107	108	O	in	in	in	IN	False
DDI-MedLine.d43.s10	cell	110	113	O	cell	ell	cell	NN	False
DDI-MedLine.d43.s10	type	115	118	O	type	ype	type	NN	False
DDI-MedLine.d43.s10	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d43.s10	may	124	126	O	may	may	may	MD	False
DDI-MedLine.d43.s10	or	128	129	O	or	or	or	CC	False
DDI-MedLine.d43.s10	may	131	133	O	may	may	may	MD	False
DDI-MedLine.d43.s10	not	135	137	O	not	not	not	RB	False
DDI-MedLine.d43.s10	require	139	145	O	require	ire	uire	NN	False
DDI-MedLine.d43.s10	exogenous	147	155	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d43.s10	enhancement	157	167	O	enhancement	ent	ment	NN	False
DDI-MedLine.d43.s10	of	169	170	O	of	of	of	IN	False
DDI-MedLine.d43.s10	growth	172	177	O	growth	wth	owth	NN	False
DDI-MedLine.d43.s10	to	179	180	O	to	to	to	TO	False
DDI-MedLine.d43.s10	those	182	186	O	those	ose	hose	DT	False
DDI-MedLine.d43.s10	that	188	191	O	that	hat	that	IN	False
DDI-MedLine.d43.s10	can	193	195	O	can	can	can	MD	False
DDI-MedLine.d43.s10	progress	197	204	O	progress	ess	ress	NN	False
DDI-MedLine.d43.s10	very	206	209	O	very	ery	very	RB	False
DDI-MedLine.d43.s10	rapidly	211	217	O	rapidly	dly	idly	RB	False
DDI-MedLine.d43.s10	to	219	220	O	to	to	to	TO	False
DDI-MedLine.d43.s10	fully	222	226	O	fully	lly	ully	RB	False
DDI-MedLine.d43.s10	malignant	228	236	O	malignant	ant	nant	NN	False
DDI-MedLine.d43.s10	behavior	238	245	O	behavior	ior	vior	NN	False
DDI-MedLine.d43.s10	.	246	246	O	.	.	.	.	False

DDI-MedLine.d43.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d43.s11	latter	4	9	O	latter	ter	tter	NN	False
DDI-MedLine.d43.s11	might	11	15	O	might	ght	ight	MD	False
DDI-MedLine.d43.s11	arise	17	21	O	arise	ise	rise	NN	False
DDI-MedLine.d43.s11	from	23	26	O	from	rom	from	IN	False
DDI-MedLine.d43.s11	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d43.s11	hit	30	32	O	hit	hit	hit	NN	False
DDI-MedLine.d43.s11	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d43.s11	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d43.s11	genetically	39	49	O	genetically	lly	ally	RB	False
DDI-MedLine.d43.s11	initiated	51	59	O	initiated	ted	ated	VBN	False
DDI-MedLine.d43.s11	cell	61	64	O	cell	ell	cell	NN	False
DDI-MedLine.d43.s11	,	65	65	O	,	,	,	,	False
DDI-MedLine.d43.s11	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d43.s11	result	71	76	O	result	ult	sult	NN	False
DDI-MedLine.d43.s11	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d43.s11	which	81	85	O	which	ich	hich	WDT	False
DDI-MedLine.d43.s11	is	87	88	O	is	is	is	VBZ	False
DDI-MedLine.d43.s11	a	90	90	O	a	a	a	DT	False
DDI-MedLine.d43.s11	more	92	95	O	more	ore	more	RBR	False
DDI-MedLine.d43.s11	rapid	97	101	O	rapid	pid	apid	JJ	False
DDI-MedLine.d43.s11	progression	103	113	O	progression	ion	sion	NN	False
DDI-MedLine.d43.s11	in	115	116	O	in	in	in	IN	False
DDI-MedLine.d43.s11	tumor	118	122	O	tumor	mor	umor	NN	False
DDI-MedLine.d43.s11	type	124	127	O	type	ype	type	NN	False
DDI-MedLine.d43.s11	.	128	128	O	.	.	.	.	False

DDI-MedLine.d86.s0	Pharmacokinetic	0	14	O	Pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d86.s0	interaction	16	26	O	interaction	ion	tion	NN	False
DDI-MedLine.d86.s0	between	28	34	O	between	een	ween	IN	False
DDI-MedLine.d86.s0	single	36	41	O	single	gle	ngle	JJ	False
DDI-MedLine.d86.s0	oral	43	46	O	oral	ral	oral	JJ	False
DDI-MedLine.d86.s0	doses	48	52	O	doses	ses	oses	NNS	False
DDI-MedLine.d86.s0	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d86.s0	diltiazem	57	65	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s0	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d86.s0	sirolimus	71	79	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s0	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d86.s0	healthy	84	90	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d86.s0	volunteers	92	101	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d86.s0	.	102	102	O	.	.	.	.	False

DDI-MedLine.d86.s1	AIM	0	2	O	AIM	AIM	AIM	NN	brand
DDI-MedLine.d86.s1	AND	4	6	O	AND	AND	AND	CC	brand
DDI-MedLine.d86.s1	BACKGROUND	8	17	O	BACKGROUND	UND	OUND	NN	brand
DDI-MedLine.d86.s1	:	18	18	O	:	:	:	:	False
DDI-MedLine.d86.s1	The	20	22	O	The	The	The	DT	False
DDI-MedLine.d86.s1	pharmacokinetic	24	38	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d86.s1	interaction	40	50	O	interaction	ion	tion	NN	False
DDI-MedLine.d86.s1	between	52	58	O	between	een	ween	IN	False
DDI-MedLine.d86.s1	sirolimus	60	68	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s1	,	69	69	O	,	,	,	,	False
DDI-MedLine.d86.s1	a	71	71	O	a	a	a	DT	False
DDI-MedLine.d86.s1	macrolide	73	81	B-group	macrolide	ide	lide	NN	False
DDI-MedLine.d86.s1	immunosuppressant	83	99	I-group	immunosuppressant	ant	sant	NN	False
DDI-MedLine.d86.s1	metabolized	101	111	O	metabolized	zed	ized	VBN	False
DDI-MedLine.d86.s1	by	113	114	O	by	by	by	IN	False
DDI-MedLine.d86.s1	CYP3A4	116	121	O	CYP3A4	3A4	P3A4	NN	brand
DDI-MedLine.d86.s1	,	122	122	O	,	,	,	,	False
DDI-MedLine.d86.s1	and	124	126	O	and	and	and	CC	False
DDI-MedLine.d86.s1	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d86.s1	calcium	132	138	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d86.s1	channel	140	146	I-group	channel	nel	nnel	NNS	False
DDI-MedLine.d86.s1	blocker	148	154	I-group	blocker	ker	cker	NN	False
DDI-MedLine.d86.s1	diltiazem	156	164	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s1	was	166	168	O	was	was	was	VBD	False
DDI-MedLine.d86.s1	studied	170	176	O	studied	ied	died	VBN	False
DDI-MedLine.d86.s1	in	178	179	O	in	in	in	IN	False
DDI-MedLine.d86.s1	18	181	182	O	18	18	18	CD	False
DDI-MedLine.d86.s1	healthy	184	190	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d86.s1	subjects	192	199	O	subjects	cts	ects	NNS	False
DDI-MedLine.d86.s1	.	200	200	O	.	.	.	.	False

DDI-MedLine.d86.s2	Several	0	6	O	Several	ral	eral	JJ	False
DDI-MedLine.d86.s2	clinically	8	17	O	clinically	lly	ally	RB	False
DDI-MedLine.d86.s2	important	19	27	O	important	ant	tant	JJ	False
DDI-MedLine.d86.s2	interactions	29	40	O	interactions	ons	ions	NNS	False
DDI-MedLine.d86.s2	have	42	45	O	have	ave	have	VB	False
DDI-MedLine.d86.s2	previously	47	56	O	previously	sly	usly	RB	False
DDI-MedLine.d86.s2	been	58	61	O	been	een	been	VBN	False
DDI-MedLine.d86.s2	reported	63	70	O	reported	ted	rted	VBD	False
DDI-MedLine.d86.s2	for	72	74	O	for	for	for	IN	False
DDI-MedLine.d86.s2	other	76	80	O	other	her	ther	JJ	False
DDI-MedLine.d86.s2	immunosuppressive	82	98	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d86.s2	drugs	100	104	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d86.s2	that	106	109	O	that	hat	that	IN	False
DDI-MedLine.d86.s2	are	111	113	O	are	are	are	VBP	False
DDI-MedLine.d86.s2	metabolized	115	125	O	metabolized	zed	ized	VBN	False
DDI-MedLine.d86.s2	by	127	128	O	by	by	by	IN	False
DDI-MedLine.d86.s2	the	130	132	O	the	the	the	DT	False
DDI-MedLine.d86.s2	same	134	137	O	same	ame	same	JJ	False
DDI-MedLine.d86.s2	enzyme	139	144	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d86.s2	and	146	148	O	and	and	and	CC	False
DDI-MedLine.d86.s2	for	150	152	O	for	for	for	IN	False
DDI-MedLine.d86.s2	calcium	154	160	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d86.s2	antagonists	162	172	I-group	antagonists	sts	ists	NNS	False
DDI-MedLine.d86.s2	.	173	173	O	.	.	.	.	False

DDI-MedLine.d86.s3	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d86.s3	:	7	7	O	:	:	:	:	False
DDI-MedLine.d86.s3	Healthy	9	15	O	Healthy	thy	lthy	JJ	False
DDI-MedLine.d86.s3	subjects	17	24	O	subjects	cts	ects	NNS	False
DDI-MedLine.d86.s3	who	26	28	O	who	who	who	WP	False
DDI-MedLine.d86.s3	were	30	33	O	were	ere	were	VBD	False
DDI-MedLine.d86.s3	20	35	36	O	20	20	20	CD	False
DDI-MedLine.d86.s3	to	38	39	O	to	to	to	TO	False
DDI-MedLine.d86.s3	43	41	42	O	43	43	43	CD	False
DDI-MedLine.d86.s3	years	44	48	O	years	ars	ears	NNS	False
DDI-MedLine.d86.s3	old	50	52	O	old	old	old	JJ	False
DDI-MedLine.d86.s3	participated	54	65	O	participated	ted	ated	VBD	False
DDI-MedLine.d86.s3	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d86.s3	an	70	71	O	an	an	an	DT	False
DDI-MedLine.d86.s3	open	73	76	O	open	pen	open	JJ	False
DDI-MedLine.d86.s3	,	77	77	O	,	,	,	,	False
DDI-MedLine.d86.s3	three-period	79	90	O	three-period	iod	riod	NN	False
DDI-MedLine.d86.s3	,	91	91	O	,	,	,	,	False
DDI-MedLine.d86.s3	randomized	93	102	O	randomized	zed	ized	VBN	False
DDI-MedLine.d86.s3	,	103	103	O	,	,	,	,	False
DDI-MedLine.d86.s3	crossover	105	113	O	crossover	ver	over	NN	False
DDI-MedLine.d86.s3	study	115	119	O	study	udy	tudy	NN	False
DDI-MedLine.d86.s3	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d86.s3	the	124	126	O	the	the	the	DT	False
DDI-MedLine.d86.s3	pharmacokinetics	128	143	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d86.s3	of	145	146	O	of	of	of	IN	False
DDI-MedLine.d86.s3	a	148	148	O	a	a	a	DT	False
DDI-MedLine.d86.s3	single	150	155	O	single	gle	ngle	JJ	False
DDI-MedLine.d86.s3	10-mg	157	161	O	10-mg	-mg	0-mg	JJ	False
DDI-MedLine.d86.s3	oral	163	166	O	oral	ral	oral	JJ	False
DDI-MedLine.d86.s3	dose	168	171	O	dose	ose	dose	NN	False
DDI-MedLine.d86.s3	of	173	174	O	of	of	of	IN	False
DDI-MedLine.d86.s3	sirolimus	176	184	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s3	,	185	185	O	,	,	,	,	False
DDI-MedLine.d86.s3	a	187	187	O	a	a	a	DT	False
DDI-MedLine.d86.s3	single	189	194	O	single	gle	ngle	JJ	False
DDI-MedLine.d86.s3	oral	196	199	O	oral	ral	oral	JJ	False
DDI-MedLine.d86.s3	120-mg	201	206	O	120-mg	-mg	0-mg	JJ	False
DDI-MedLine.d86.s3	dose	208	211	O	dose	ose	dose	NN	False
DDI-MedLine.d86.s3	of	213	214	O	of	of	of	IN	False
DDI-MedLine.d86.s3	diltiazem	216	224	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s3	,	225	225	O	,	,	,	,	False
DDI-MedLine.d86.s3	and	227	229	O	and	and	and	CC	False
DDI-MedLine.d86.s3	the	231	233	O	the	the	the	DT	False
DDI-MedLine.d86.s3	two	235	237	O	two	two	two	CD	False
DDI-MedLine.d86.s3	drugs	239	243	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d86.s3	given	245	249	O	given	ven	iven	VBN	False
DDI-MedLine.d86.s3	together	251	258	O	together	her	ther	RB	False
DDI-MedLine.d86.s3	.	259	259	O	.	.	.	.	False

DDI-MedLine.d86.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d86.s4	three	4	8	O	three	ree	hree	CD	False
DDI-MedLine.d86.s4	study	10	14	O	study	udy	tudy	NN	False
DDI-MedLine.d86.s4	periods	16	22	O	periods	ods	iods	NNS	False
DDI-MedLine.d86.s4	were	24	27	O	were	ere	were	VBD	False
DDI-MedLine.d86.s4	separated	29	37	O	separated	ted	ated	VBN	False
DDI-MedLine.d86.s4	by	39	40	O	by	by	by	IN	False
DDI-MedLine.d86.s4	a	42	42	O	a	a	a	DT	False
DDI-MedLine.d86.s4	21-day	44	49	O	21-day	day	-day	JJ	False
DDI-MedLine.d86.s4	washout	51	57	O	washout	out	hout	NN	False
DDI-MedLine.d86.s4	phase	59	63	O	phase	ase	hase	NN	False
DDI-MedLine.d86.s4	.	64	64	O	.	.	.	.	False

DDI-MedLine.d86.s5	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d86.s5	:	7	7	O	:	:	:	:	False
DDI-MedLine.d86.s5	The	9	11	O	The	The	The	DT	False
DDI-MedLine.d86.s5	geometric	13	21	O	geometric	ric	tric	NN	False
DDI-MedLine.d86.s5	mean	23	26	O	mean	ean	mean	NN	False
DDI-MedLine.d86.s5	(	28	28	O	(	(	(	(	False
DDI-MedLine.d86.s5	90	29	30	O	90	90	90	CD	False
DDI-MedLine.d86.s5	%	31	31	O	%	%	%	NN	False
DDI-MedLine.d86.s5	confidence	33	42	O	confidence	nce	ence	NN	False
DDI-MedLine.d86.s5	interval	44	51	O	interval	val	rval	NN	False
DDI-MedLine.d86.s5	)	52	52	O	)	)	)	)	False
DDI-MedLine.d86.s5	whole	54	58	O	whole	ole	hole	JJ	False
DDI-MedLine.d86.s5	blood	60	64	O	blood	ood	lood	NN	False
DDI-MedLine.d86.s5	sirolimus	66	74	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s5	area	76	79	O	area	rea	area	NN	False
DDI-MedLine.d86.s5	under	81	85	O	under	der	nder	IN	False
DDI-MedLine.d86.s5	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d86.s5	plasma	91	96	O	plasma	sma	asma	NN	False
DDI-MedLine.d86.s5	concentration	98	110	O	concentration	ion	tion	NN	False
DDI-MedLine.d86.s5	time-curve	112	121	O	time-curve	rve	urve	NN	False
DDI-MedLine.d86.s5	increased	123	131	O	increased	sed	ased	VBN	False
DDI-MedLine.d86.s5	60	133	134	O	60	60	60	CD	False
DDI-MedLine.d86.s5	%	135	135	O	%	%	%	NN	False
DDI-MedLine.d86.s5	(	137	137	O	(	(	(	(	False
DDI-MedLine.d86.s5	35	138	139	O	35	35	35	CD	False
DDI-MedLine.d86.s5	%	140	140	O	%	%	%	NN	False
DDI-MedLine.d86.s5	-90	141	143	O	-90	-90	-90	NN	False
DDI-MedLine.d86.s5	%	144	144	O	%	%	%	NN	False
DDI-MedLine.d86.s5	)	145	145	O	)	)	)	)	False
DDI-MedLine.d86.s5	,	146	146	O	,	,	,	,	False
DDI-MedLine.d86.s5	from	148	151	O	from	rom	from	IN	False
DDI-MedLine.d86.s5	736	153	155	O	736	736	736	CD	False
DDI-MedLine.d86.s5	to	157	158	O	to	to	to	TO	False
DDI-MedLine.d86.s5	1178	160	163	O	1178	178	1178	CD	False
DDI-MedLine.d86.s5	ng	165	166	O	ng	ng	ng	NN	False
DDI-MedLine.d86.s5	x	168	168	O	x	x	x	NN	False
DDI-MedLine.d86.s5	h/mL	170	173	O	h/mL	/mL	h/mL	NN	False
DDI-MedLine.d86.s5	,	174	174	O	,	,	,	,	False
DDI-MedLine.d86.s5	and	176	178	O	and	and	and	CC	False
DDI-MedLine.d86.s5	maximum	180	186	O	maximum	mum	imum	NN	False
DDI-MedLine.d86.s5	concentration	188	200	O	concentration	ion	tion	NN	False
DDI-MedLine.d86.s5	increased	202	210	O	increased	sed	ased	VBN	False
DDI-MedLine.d86.s5	43	212	213	O	43	43	43	CD	False
DDI-MedLine.d86.s5	%	214	214	O	%	%	%	NN	False
DDI-MedLine.d86.s5	(	216	216	O	(	(	(	(	False
DDI-MedLine.d86.s5	14	217	218	O	14	14	14	CD	False
DDI-MedLine.d86.s5	%	219	219	O	%	%	%	NN	False
DDI-MedLine.d86.s5	-81	220	222	O	-81	-81	-81	NN	False
DDI-MedLine.d86.s5	%	223	223	O	%	%	%	NN	False
DDI-MedLine.d86.s5	)	224	224	O	)	)	)	)	False
DDI-MedLine.d86.s5	,	225	225	O	,	,	,	,	False
DDI-MedLine.d86.s5	from	227	230	O	from	rom	from	IN	False
DDI-MedLine.d86.s5	67	232	233	O	67	67	67	CD	False
DDI-MedLine.d86.s5	to	235	236	O	to	to	to	TO	False
DDI-MedLine.d86.s5	96	238	239	O	96	96	96	CD	False
DDI-MedLine.d86.s5	ng/mL	241	245	O	ng/mL	/mL	g/mL	NN	False
DDI-MedLine.d86.s5	,	246	246	O	,	,	,	,	False
DDI-MedLine.d86.s5	with	248	251	O	with	ith	with	IN	False
DDI-MedLine.d86.s5	diltiazem	253	261	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s5	coadministration	263	278	O	coadministration	ion	tion	NN	False
DDI-MedLine.d86.s5	,	279	279	O	,	,	,	,	False
DDI-MedLine.d86.s5	whereas	281	287	O	whereas	eas	reas	NNS	False
DDI-MedLine.d86.s5	the	289	291	O	the	the	the	DT	False
DDI-MedLine.d86.s5	mean	293	296	O	mean	ean	mean	NN	False
DDI-MedLine.d86.s5	elimination	298	308	O	elimination	ion	tion	NN	False
DDI-MedLine.d86.s5	half-life	310	318	O	half-life	ife	life	NN	False
DDI-MedLine.d86.s5	of	320	321	O	of	of	of	IN	False
DDI-MedLine.d86.s5	sirolimus	323	331	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s5	decreased	333	341	O	decreased	sed	ased	VBN	False
DDI-MedLine.d86.s5	slightly	343	350	O	slightly	tly	htly	RB	False
DDI-MedLine.d86.s5	,	351	351	O	,	,	,	,	False
DDI-MedLine.d86.s5	from	353	356	O	from	rom	from	IN	False
DDI-MedLine.d86.s5	79	358	359	O	79	79	79	CD	False
DDI-MedLine.d86.s5	to	361	362	O	to	to	to	TO	False
DDI-MedLine.d86.s5	67	364	365	O	67	67	67	CD	False
DDI-MedLine.d86.s5	hours	367	371	O	hours	urs	ours	NNS	False
DDI-MedLine.d86.s5	.	372	372	O	.	.	.	.	False

DDI-MedLine.d86.s6	Apparent	0	7	O	Apparent	ent	rent	NN	False
DDI-MedLine.d86.s6	oral	9	12	O	oral	ral	oral	JJ	False
DDI-MedLine.d86.s6	clearance	14	22	O	clearance	nce	ance	NN	False
DDI-MedLine.d86.s6	and	24	26	O	and	and	and	CC	False
DDI-MedLine.d86.s6	volume	28	33	O	volume	ume	lume	NN	False
DDI-MedLine.d86.s6	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d86.s6	distribution	38	49	O	distribution	ion	tion	NN	False
DDI-MedLine.d86.s6	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d86.s6	sirolimus	54	62	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s6	decreased	64	72	O	decreased	sed	ased	VBN	False
DDI-MedLine.d86.s6	with	74	77	O	with	ith	with	IN	False
DDI-MedLine.d86.s6	38	79	80	O	38	38	38	CD	False
DDI-MedLine.d86.s6	%	81	81	O	%	%	%	NN	False
DDI-MedLine.d86.s6	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d86.s6	45	87	88	O	45	45	45	CD	False
DDI-MedLine.d86.s6	%	89	89	O	%	%	%	NN	False
DDI-MedLine.d86.s6	,	90	90	O	,	,	,	,	False
DDI-MedLine.d86.s6	respectively	92	103	O	respectively	ely	vely	RB	False
DDI-MedLine.d86.s6	,	104	104	O	,	,	,	,	False
DDI-MedLine.d86.s6	when	106	109	O	when	hen	when	WRB	False
DDI-MedLine.d86.s6	sirolimus	111	119	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s6	was	121	123	O	was	was	was	VBD	False
DDI-MedLine.d86.s6	given	125	129	O	given	ven	iven	VBN	False
DDI-MedLine.d86.s6	with	131	134	O	with	ith	with	IN	False
DDI-MedLine.d86.s6	diltiazem	136	144	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s6	.	145	145	O	.	.	.	.	False

DDI-MedLine.d86.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d86.s7	plasma	4	9	O	plasma	sma	asma	NN	False
DDI-MedLine.d86.s7	maximum	11	17	O	maximum	mum	imum	NN	False
DDI-MedLine.d86.s7	concentration	19	31	O	concentration	ion	tion	NN	False
DDI-MedLine.d86.s7	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d86.s7	area	37	40	O	area	rea	area	NN	False
DDI-MedLine.d86.s7	under	42	46	O	under	der	nder	IN	False
DDI-MedLine.d86.s7	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d86.s7	plasma	52	57	O	plasma	sma	asma	NN	False
DDI-MedLine.d86.s7	concentration-time	59	76	O	concentration-time	ime	time	NN	False
DDI-MedLine.d86.s7	curve	78	82	O	curve	rve	urve	NN	False
DDI-MedLine.d86.s7	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d86.s7	diltiazem	87	95	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s7	,	96	96	O	,	,	,	,	False
DDI-MedLine.d86.s7	desacetyldiltiazem	98	115	B-drug_n	desacetyldiltiazem	zem	azem	NN	False
DDI-MedLine.d86.s7	,	116	116	O	,	,	,	,	False
DDI-MedLine.d86.s7	and	118	120	O	and	and	and	CC	False
DDI-MedLine.d86.s7	desmethyldiltiazem	122	139	B-drug_n	desmethyldiltiazem	zem	azem	NN	False
DDI-MedLine.d86.s7	were	141	144	O	were	ere	were	VBD	False
DDI-MedLine.d86.s7	unchanged	146	154	O	unchanged	ged	nged	JJ	False
DDI-MedLine.d86.s7	after	156	160	O	after	ter	fter	IN	False
DDI-MedLine.d86.s7	coadministration	162	177	O	coadministration	ion	tion	NN	False
DDI-MedLine.d86.s7	of	179	180	O	of	of	of	IN	False
DDI-MedLine.d86.s7	sirolimus	182	190	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s7	,	191	191	O	,	,	,	,	False
DDI-MedLine.d86.s7	and	193	195	O	and	and	and	CC	False
DDI-MedLine.d86.s7	no	197	198	O	no	no	no	DT	False
DDI-MedLine.d86.s7	potentiation	200	211	O	potentiation	ion	tion	NN	False
DDI-MedLine.d86.s7	of	213	214	O	of	of	of	IN	False
DDI-MedLine.d86.s7	the	216	218	O	the	the	the	DT	False
DDI-MedLine.d86.s7	effects	220	226	O	effects	cts	ects	NNS	False
DDI-MedLine.d86.s7	of	228	229	O	of	of	of	IN	False
DDI-MedLine.d86.s7	diltiazem	231	239	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s7	on	241	242	O	on	on	on	IN	False
DDI-MedLine.d86.s7	diastolic	244	252	O	diastolic	lic	olic	NN	False
DDI-MedLine.d86.s7	or	254	255	O	or	or	or	CC	False
DDI-MedLine.d86.s7	systolic	257	264	O	systolic	lic	olic	NN	False
DDI-MedLine.d86.s7	blood	266	270	O	blood	ood	lood	NN	False
DDI-MedLine.d86.s7	pressure	272	279	O	pressure	ure	sure	NN	False
DDI-MedLine.d86.s7	or	281	282	O	or	or	or	CC	False
DDI-MedLine.d86.s7	on	284	285	O	on	on	on	IN	False
DDI-MedLine.d86.s7	the	287	289	O	the	the	the	DT	False
DDI-MedLine.d86.s7	electrocardiographic	291	310	O	electrocardiographic	hic	phic	JJ	False
DDI-MedLine.d86.s7	parameters	312	321	O	parameters	ers	ters	NNS	False
DDI-MedLine.d86.s7	was	323	325	O	was	was	was	VBD	False
DDI-MedLine.d86.s7	seen	327	330	O	seen	een	seen	VBN	False
DDI-MedLine.d86.s7	.	331	331	O	.	.	.	.	False

DDI-MedLine.d86.s8	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d86.s8	:	11	11	O	:	:	:	:	False
DDI-MedLine.d86.s8	Single-dose	13	23	O	Single-dose	ose	dose	JJ	False
DDI-MedLine.d86.s8	diltiazem	25	33	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s8	coadministration	35	50	O	coadministration	ion	tion	NN	False
DDI-MedLine.d86.s8	leads	52	56	O	leads	ads	eads	NNS	False
DDI-MedLine.d86.s8	to	58	59	O	to	to	to	TO	False
DDI-MedLine.d86.s8	higher	61	66	O	higher	her	gher	JJR	False
DDI-MedLine.d86.s8	sirolimus	68	76	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s8	exposure	78	85	O	exposure	ure	sure	NN	False
DDI-MedLine.d86.s8	,	86	86	O	,	,	,	,	False
DDI-MedLine.d86.s8	presumably	88	97	O	presumably	bly	ably	RB	False
DDI-MedLine.d86.s8	by	99	100	O	by	by	by	IN	False
DDI-MedLine.d86.s8	inhibition	102	111	O	inhibition	ion	tion	NN	False
DDI-MedLine.d86.s8	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d86.s8	the	116	118	O	the	the	the	DT	False
DDI-MedLine.d86.s8	first-pass	120	129	O	first-pass	ass	pass	NN	False
DDI-MedLine.d86.s8	metabolism	131	140	O	metabolism	ism	lism	NN	False
DDI-MedLine.d86.s8	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d86.s8	sirolimus	145	153	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s8	.	154	154	O	.	.	.	.	False

DDI-MedLine.d86.s9	Because	0	6	O	Because	use	ause	IN	False
DDI-MedLine.d86.s9	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d86.s9	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d86.s9	pronounced	15	24	O	pronounced	ced	nced	VBN	False
DDI-MedLine.d86.s9	intersubject	26	37	O	intersubject	ect	ject	NN	False
DDI-MedLine.d86.s9	variability	39	49	O	variability	ity	lity	NN	False
DDI-MedLine.d86.s9	in	51	52	O	in	in	in	IN	False
DDI-MedLine.d86.s9	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d86.s9	extent	58	63	O	extent	ent	tent	NN	False
DDI-MedLine.d86.s9	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d86.s9	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d86.s9	sirolimus-diltiazem	72	90	O	sirolimus-diltiazem	zem	azem	NN	False
DDI-MedLine.d86.s9	interaction	92	102	O	interaction	ion	tion	NN	False
DDI-MedLine.d86.s9	,	103	103	O	,	,	,	,	False
DDI-MedLine.d86.s9	whole	105	109	O	whole	ole	hole	JJ	False
DDI-MedLine.d86.s9	blood	111	115	O	blood	ood	lood	NN	False
DDI-MedLine.d86.s9	sirolimus	117	125	B-drug	sirolimus	mus	imus	NN	False
DDI-MedLine.d86.s9	concentrations	127	140	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d86.s9	should	142	147	O	should	uld	ould	MD	False
DDI-MedLine.d86.s9	be	149	150	O	be	be	be	VB	False
DDI-MedLine.d86.s9	monitored	152	160	O	monitored	red	ored	VBD	False
DDI-MedLine.d86.s9	closely	162	168	O	closely	ely	sely	RB	False
DDI-MedLine.d86.s9	in	170	171	O	in	in	in	IN	False
DDI-MedLine.d86.s9	patients	173	180	O	patients	nts	ents	NNS	False
DDI-MedLine.d86.s9	treated	182	188	O	treated	ted	ated	VBN	False
DDI-MedLine.d86.s9	with	190	193	O	with	ith	with	IN	False
DDI-MedLine.d86.s9	the	195	197	O	the	the	the	DT	False
DDI-MedLine.d86.s9	two	199	201	O	two	two	two	CD	False
DDI-MedLine.d86.s9	drugs	203	207	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d86.s9	.	208	208	O	.	.	.	.	False

DDI-MedLine.d122.s0	Behavioral	0	9	O	Behavioral	ral	oral	JJ	False
DDI-MedLine.d122.s0	mechanisms	11	20	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d122.s0	underlying	22	31	O	underlying	ing	ying	VBG	False
DDI-MedLine.d122.s0	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d122.s0	link	37	40	O	link	ink	link	NN	False
DDI-MedLine.d122.s0	between	42	48	O	between	een	ween	IN	False
DDI-MedLine.d122.s0	smoking	50	56	O	smoking	ing	king	NN	False
DDI-MedLine.d122.s0	and	58	60	O	and	and	and	CC	False
DDI-MedLine.d122.s0	drinking	62	69	O	drinking	ing	king	NN	False
DDI-MedLine.d122.s0	.	70	70	O	.	.	.	.	False

DDI-MedLine.d122.s1	Many	0	3	O	Many	any	Many	JJ	False
DDI-MedLine.d122.s1	people	5	10	O	people	ple	ople	NNS	False
DDI-MedLine.d122.s1	use	12	14	O	use	use	use	NN	False
DDI-MedLine.d122.s1	both	16	19	O	both	oth	both	DT	False
DDI-MedLine.d122.s1	alcohol	21	27	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d122.s1	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d122.s1	nicotine	33	40	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d122.s1	(	42	42	O	(	(	(	(	False
DDI-MedLine.d122.s1	i.e.	43	46	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d122.s1	,	47	47	O	,	,	,	,	False
DDI-MedLine.d122.s1	cigarettes	49	58	O	cigarettes	tes	ttes	NNS	False
DDI-MedLine.d122.s1	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d122.s1	other	64	68	O	other	her	ther	JJ	False
DDI-MedLine.d122.s1	tobacco	70	76	O	tobacco	cco	acco	NN	False
DDI-MedLine.d122.s1	products	78	85	O	products	cts	ucts	NNS	False
DDI-MedLine.d122.s1	)	86	86	O	)	)	)	)	False
DDI-MedLine.d122.s1	.	87	87	O	.	.	.	.	False

DDI-MedLine.d122.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d122.s2	behavioral	4	13	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d122.s2	effects	15	21	O	effects	cts	ects	NNS	False
DDI-MedLine.d122.s2	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d122.s2	these	26	30	O	these	ese	hese	DT	False
DDI-MedLine.d122.s2	two	32	34	O	two	two	two	CD	False
DDI-MedLine.d122.s2	drugs	36	40	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d122.s2	differ	42	47	O	differ	fer	ffer	NN	False
DDI-MedLine.d122.s2	,	48	48	O	,	,	,	,	False
DDI-MedLine.d122.s2	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d122.s2	they	54	57	O	they	hey	they	PRP	False
DDI-MedLine.d122.s2	do	59	60	O	do	do	do	VB	False
DDI-MedLine.d122.s2	not	62	64	O	not	not	not	RB	False
DDI-MedLine.d122.s2	act	66	68	O	act	act	act	NN	False
DDI-MedLine.d122.s2	on	70	71	O	on	on	on	IN	False
DDI-MedLine.d122.s2	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d122.s2	same	77	80	O	same	ame	same	JJ	False
DDI-MedLine.d122.s2	target	82	87	O	target	get	rget	NN	False
DDI-MedLine.d122.s2	sites	89	93	O	sites	tes	ites	NNS	False
DDI-MedLine.d122.s2	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d122.s2	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d122.s2	brain	102	106	O	brain	ain	rain	NN	False
DDI-MedLine.d122.s2	,	107	107	O	,	,	,	,	False
DDI-MedLine.d122.s2	although	109	116	O	although	ugh	ough	IN	False
DDI-MedLine.d122.s2	they	118	121	O	they	hey	they	PRP	False
DDI-MedLine.d122.s2	may	123	125	O	may	may	may	MD	False
DDI-MedLine.d122.s2	share	127	131	O	share	are	hare	NN	False
DDI-MedLine.d122.s2	,	132	132	O	,	,	,	,	False
DDI-MedLine.d122.s2	or	134	135	O	or	or	or	CC	False
DDI-MedLine.d122.s2	partly	137	142	O	partly	tly	rtly	RB	False
DDI-MedLine.d122.s2	share	144	148	O	share	are	hare	NN	False
DDI-MedLine.d122.s2	,	149	149	O	,	,	,	,	False
DDI-MedLine.d122.s2	certain	151	157	O	certain	ain	tain	JJ	False
DDI-MedLine.d122.s2	properties	159	168	O	properties	ies	ties	NNS	False
DDI-MedLine.d122.s2	.	169	169	O	.	.	.	.	False

DDI-MedLine.d122.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d122.s3	initiation	4	13	O	initiation	ion	tion	NN	False
DDI-MedLine.d122.s3	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d122.s3	alcohol	18	24	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d122.s3	or	26	27	O	or	or	or	CC	False
DDI-MedLine.d122.s3	nicotine	29	36	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d122.s3	use	38	40	O	use	use	use	NN	False
DDI-MedLine.d122.s3	may	42	44	O	may	may	may	MD	False
DDI-MedLine.d122.s3	be	46	47	O	be	be	be	VB	False
DDI-MedLine.d122.s3	precipitated	49	60	O	precipitated	ted	ated	VBN	False
DDI-MedLine.d122.s3	by	62	63	O	by	by	by	IN	False
DDI-MedLine.d122.s3	similar	65	71	O	similar	lar	ilar	JJ	False
DDI-MedLine.d122.s3	personality	73	83	O	personality	ity	lity	NN	False
DDI-MedLine.d122.s3	characteristics	85	99	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d122.s3	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d122.s3	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d122.s3	user	108	111	O	user	ser	user	NN	False
DDI-MedLine.d122.s3	,	112	112	O	,	,	,	,	False
DDI-MedLine.d122.s3	such	114	117	O	such	uch	such	JJ	False
DDI-MedLine.d122.s3	as	119	120	O	as	as	as	IN	False
DDI-MedLine.d122.s3	impulsivity	122	132	O	impulsivity	ity	vity	NN	False
DDI-MedLine.d122.s3	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d122.s3	sensation	138	146	O	sensation	ion	tion	NN	False
DDI-MedLine.d122.s3	seeking	148	154	O	seeking	ing	king	VBG	False
DDI-MedLine.d122.s3	.	155	155	O	.	.	.	.	False

DDI-MedLine.d122.s4	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d122.s4	,	8	8	O	,	,	,	,	False
DDI-MedLine.d122.s4	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d122.s4	mechanisms	14	23	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d122.s4	underlying	25	34	O	underlying	ing	ying	VBG	False
DDI-MedLine.d122.s4	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d122.s4	development	40	50	O	development	ent	ment	NN	False
DDI-MedLine.d122.s4	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d122.s4	dependence	55	64	O	dependence	nce	ence	NN	False
DDI-MedLine.d122.s4	may	66	68	O	may	may	may	MD	False
DDI-MedLine.d122.s4	be	70	71	O	be	be	be	VB	False
DDI-MedLine.d122.s4	similar	73	79	O	similar	lar	ilar	JJ	False
DDI-MedLine.d122.s4	for	81	83	O	for	for	for	IN	False
DDI-MedLine.d122.s4	alcohol	85	91	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d122.s4	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d122.s4	nicotine	97	104	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d122.s4	.	105	105	O	.	.	.	.	False

DDI-MedLine.d122.s5	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d122.s5	,	4	4	O	,	,	,	,	False
DDI-MedLine.d122.s5	certain	6	12	O	certain	ain	tain	JJ	False
DDI-MedLine.d122.s5	factors	14	20	O	factors	ors	tors	NNS	False
DDI-MedLine.d122.s5	,	21	21	O	,	,	,	,	False
DDI-MedLine.d122.s5	such	23	26	O	such	uch	such	JJ	False
DDI-MedLine.d122.s5	as	28	29	O	as	as	as	IN	False
DDI-MedLine.d122.s5	reinforcing	31	41	O	reinforcing	ing	cing	VBG	False
DDI-MedLine.d122.s5	drug	43	46	O	drug	rug	drug	NN	False
DDI-MedLine.d122.s5	effects	48	54	O	effects	cts	ects	NNS	False
DDI-MedLine.d122.s5	,	55	55	O	,	,	,	,	False
DDI-MedLine.d122.s5	conditioning	57	68	O	conditioning	ing	ning	NN	False
DDI-MedLine.d122.s5	processes	70	78	O	processes	ses	sses	NNS	False
DDI-MedLine.d122.s5	,	79	79	O	,	,	,	,	False
DDI-MedLine.d122.s5	automatic	81	89	O	automatic	tic	atic	JJ	False
DDI-MedLine.d122.s5	behavior	91	98	O	behavior	ior	vior	NN	False
DDI-MedLine.d122.s5	,	99	99	O	,	,	,	,	False
DDI-MedLine.d122.s5	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d122.s5	stress	105	110	O	stress	ess	ress	NN	False
DDI-MedLine.d122.s5	,	111	111	O	,	,	,	,	False
DDI-MedLine.d122.s5	may	113	115	O	may	may	may	MD	False
DDI-MedLine.d122.s5	influence	117	125	O	influence	nce	ence	NN	False
DDI-MedLine.d122.s5	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d122.s5	development	131	141	O	development	ent	ment	NN	False
DDI-MedLine.d122.s5	of	143	144	O	of	of	of	IN	False
DDI-MedLine.d122.s5	dependence	146	155	O	dependence	nce	ence	NN	False
DDI-MedLine.d122.s5	on	157	158	O	on	on	on	IN	False
DDI-MedLine.d122.s5	both	160	163	O	both	oth	both	DT	False
DDI-MedLine.d122.s5	drugs	165	169	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d122.s5	.	170	170	O	.	.	.	.	False

DDI-MedLine.d122.s6	Other	0	4	O	Other	her	ther	JJ	False
DDI-MedLine.d122.s6	factors	6	12	O	factors	ors	tors	NNS	False
DDI-MedLine.d122.s6	,	13	13	O	,	,	,	,	False
DDI-MedLine.d122.s6	such	15	18	O	such	uch	such	JJ	False
DDI-MedLine.d122.s6	as	20	21	O	as	as	as	IN	False
DDI-MedLine.d122.s6	tolerance	23	31	O	tolerance	nce	ance	NN	False
DDI-MedLine.d122.s6	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d122.s6	sensitization	37	49	O	sensitization	ion	tion	NN	False
DDI-MedLine.d122.s6	to	51	52	O	to	to	to	TO	False
DDI-MedLine.d122.s6	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d122.s6	drugs	58	62	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d122.s6	'	63	63	O	'	'	'	''	False
DDI-MedLine.d122.s6	actions	65	71	O	actions	ons	ions	NNS	False
DDI-MedLine.d122.s6	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d122.s6	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d122.s6	development	81	91	O	development	ent	ment	NN	False
DDI-MedLine.d122.s6	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d122.s6	withdrawal	96	105	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d122.s6	symptoms	107	114	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d122.s6	,	115	115	O	,	,	,	,	False
DDI-MedLine.d122.s6	may	117	119	O	may	may	may	MD	False
DDI-MedLine.d122.s6	also	121	124	O	also	lso	also	RB	False
DDI-MedLine.d122.s6	contribute	126	135	O	contribute	ute	bute	NN	False
DDI-MedLine.d122.s6	to	137	138	O	to	to	to	TO	False
DDI-MedLine.d122.s6	dependence	140	149	O	dependence	nce	ence	NN	False
DDI-MedLine.d122.s6	.	150	150	O	.	.	.	.	False

DDI-MedLine.d122.s7	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d122.s7	review	5	10	O	review	iew	view	NN	False
DDI-MedLine.d122.s7	discusses	12	20	O	discusses	ses	sses	NNS	False
DDI-MedLine.d122.s7	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d122.s7	actions	26	32	O	actions	ons	ions	NNS	False
DDI-MedLine.d122.s7	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d122.s7	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d122.s7	two	41	43	O	two	two	two	CD	False
DDI-MedLine.d122.s7	drugs	45	49	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d122.s7	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d122.s7	certain	54	60	O	certain	ain	tain	JJ	False
DDI-MedLine.d122.s7	brain	62	66	O	brain	ain	rain	NN	False
DDI-MedLine.d122.s7	chemical	68	75	O	chemical	cal	ical	NN	False
DDI-MedLine.d122.s7	(	77	77	O	(	(	(	(	False
DDI-MedLine.d122.s7	i.e.	78	81	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d122.s7	,	82	82	O	,	,	,	,	False
DDI-MedLine.d122.s7	neurotransmitter	84	99	O	neurotransmitter	ter	tter	NN	False
DDI-MedLine.d122.s7	)	100	100	O	)	)	)	)	False
DDI-MedLine.d122.s7	systems	102	108	O	systems	ems	tems	NNS	False
DDI-MedLine.d122.s7	and	110	112	O	and	and	and	CC	False
DDI-MedLine.d122.s7	the	114	116	O	the	the	the	DT	False
DDI-MedLine.d122.s7	extent	118	123	O	extent	ent	tent	NN	False
DDI-MedLine.d122.s7	to	125	126	O	to	to	to	TO	False
DDI-MedLine.d122.s7	which	128	132	O	which	ich	hich	WDT	False
DDI-MedLine.d122.s7	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d122.s7	effects	138	144	O	effects	cts	ects	NNS	False
DDI-MedLine.d122.s7	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d122.s7	the	149	151	O	the	the	the	DT	False
DDI-MedLine.d122.s7	two	153	155	O	two	two	two	CD	False
DDI-MedLine.d122.s7	drugs	157	161	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d122.s7	may	163	165	O	may	may	may	MD	False
DDI-MedLine.d122.s7	interact	167	174	O	interact	act	ract	NN	False
DDI-MedLine.d122.s7	.	175	175	O	.	.	.	.	False

DDI-MedLine.d95.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d95.s0	mechanism	4	12	O	mechanism	ism	nism	NN	False
DDI-MedLine.d95.s0	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d95.s0	resveratrol-induced	17	35	O	resveratrol-induced	ced	uced	JJ	False
DDI-MedLine.d95.s0	vasorelaxation	37	50	O	vasorelaxation	ion	tion	NN	False
DDI-MedLine.d95.s0	differs	52	58	O	differs	ers	fers	NNS	False
DDI-MedLine.d95.s0	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d95.s0	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d95.s0	mesenteric	67	76	O	mesenteric	ric	eric	NN	False
DDI-MedLine.d95.s0	resistance	78	87	O	resistance	nce	ance	NN	False
DDI-MedLine.d95.s0	arteries	89	96	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s0	of	98	99	O	of	of	of	IN	False
DDI-MedLine.d95.s0	lean	101	104	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s0	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d95.s0	obese	110	114	O	obese	ese	bese	JJ	False
DDI-MedLine.d95.s0	rats	116	119	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s0	.	120	120	O	.	.	.	.	False

DDI-MedLine.d95.s1	Resveratrol	0	10	B-drug_n	Resveratrol	rol	trol	NN	False
DDI-MedLine.d95.s1	has	12	14	O	has	has	has	VBZ	False
DDI-MedLine.d95.s1	been	16	19	O	been	een	been	VBN	False
DDI-MedLine.d95.s1	shown	21	25	O	shown	own	hown	VBN	False
DDI-MedLine.d95.s1	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d95.s1	induce	30	35	O	induce	uce	duce	NN	False
DDI-MedLine.d95.s1	vasorelaxation	37	50	O	vasorelaxation	ion	tion	NN	False
DDI-MedLine.d95.s1	.	51	51	O	.	.	.	.	False

DDI-MedLine.d95.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d95.s2	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d95.s2	study	8	12	O	study	udy	tudy	NN	False
DDI-MedLine.d95.s2	,	13	13	O	,	,	,	,	False
DDI-MedLine.d95.s2	we	15	16	O	we	we	we	PRP	False
DDI-MedLine.d95.s2	investigated	18	29	O	investigated	ted	ated	VBN	False
DDI-MedLine.d95.s2	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d95.s2	mechanism	35	43	O	mechanism	ism	nism	NN	False
DDI-MedLine.d95.s2	(	44	44	O	(	(	(	(	False
DDI-MedLine.d95.s2	s	45	45	O	s	s	s	NN	False
DDI-MedLine.d95.s2	)	46	46	O	)	)	)	)	False
DDI-MedLine.d95.s2	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d95.s2	resveratrol-induced	51	69	O	resveratrol-induced	ced	uced	JJ	False
DDI-MedLine.d95.s2	vasorelaxation	71	84	O	vasorelaxation	ion	tion	NN	False
DDI-MedLine.d95.s2	in	86	87	O	in	in	in	IN	False
DDI-MedLine.d95.s2	resistance	89	98	O	resistance	nce	ance	NN	False
DDI-MedLine.d95.s2	mesenteric	100	109	O	mesenteric	ric	eric	NN	False
DDI-MedLine.d95.s2	arteries	111	118	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s2	from	120	123	O	from	rom	from	IN	False
DDI-MedLine.d95.s2	male	125	128	O	male	ale	male	NN	False
DDI-MedLine.d95.s2	lean	130	133	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s2	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d95.s2	dietary-induced	139	153	O	dietary-induced	ced	uced	JJ	False
DDI-MedLine.d95.s2	obese	155	159	O	obese	ese	bese	JJ	False
DDI-MedLine.d95.s2	rats	161	164	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s2	.	165	165	O	.	.	.	.	False

DDI-MedLine.d95.s3	Compared	0	7	O	Compared	red	ared	VBN	False
DDI-MedLine.d95.s3	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d95.s3	lean	14	17	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s3	rats	19	22	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s3	,	23	23	O	,	,	,	,	False
DDI-MedLine.d95.s3	arteries	25	32	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s3	from	34	37	O	from	rom	from	IN	False
DDI-MedLine.d95.s3	dietary-obese	39	51	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s3	rats	53	56	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s3	showed	58	63	O	showed	wed	owed	VBD	False
DDI-MedLine.d95.s3	significant	65	75	O	significant	ant	cant	JJ	False
DDI-MedLine.d95.s3	(	77	77	O	(	(	(	(	False
DDI-MedLine.d95.s3	P	78	78	O	P	P	P	NN	brand
DDI-MedLine.d95.s3	<	79	79	O	<	<	<	NN	False
DDI-MedLine.d95.s3	0.001	80	84	O	0.001	001	.001	CD	False
DDI-MedLine.d95.s3	)	85	85	O	)	)	)	)	False
DDI-MedLine.d95.s3	endothelial	87	97	O	endothelial	ial	lial	JJ	False
DDI-MedLine.d95.s3	dysfunction	99	109	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d95.s3	,	110	110	O	,	,	,	,	False
DDI-MedLine.d95.s3	as	112	113	O	as	as	as	IN	False
DDI-MedLine.d95.s3	indicated	115	123	O	indicated	ted	ated	VBN	False
DDI-MedLine.d95.s3	by	125	126	O	by	by	by	IN	False
DDI-MedLine.d95.s3	a	128	128	O	a	a	a	DT	False
DDI-MedLine.d95.s3	decrease	130	137	O	decrease	ase	ease	NN	False
DDI-MedLine.d95.s3	(	139	139	O	(	(	(	(	False
DDI-MedLine.d95.s3	>	140	140	O	>	>	>	NN	False
DDI-MedLine.d95.s3	20	141	142	O	20	20	20	CD	False
DDI-MedLine.d95.s3	%	143	143	O	%	%	%	NN	False
DDI-MedLine.d95.s3	)	144	144	O	)	)	)	)	False
DDI-MedLine.d95.s3	in	146	147	O	in	in	in	IN	False
DDI-MedLine.d95.s3	maximal	149	155	O	maximal	mal	imal	NN	False
DDI-MedLine.d95.s3	acetylcholine-induced	157	177	O	acetylcholine-induced	ced	uced	JJ	False
DDI-MedLine.d95.s3	vasorelaxation	179	192	O	vasorelaxation	ion	tion	NN	False
DDI-MedLine.d95.s3	.	193	193	O	.	.	.	.	False

DDI-MedLine.d95.s4	Resveratrol	0	10	B-drug_n	Resveratrol	rol	trol	NN	False
DDI-MedLine.d95.s4	(	12	12	O	(	(	(	(	False
DDI-MedLine.d95.s4	5-35	13	16	O	5-35	-35	5-35	JJ	False
DDI-MedLine.d95.s4	micromol/l	18	27	O	micromol/l	l/l	ol/l	NN	False
DDI-MedLine.d95.s4	)	28	28	O	)	)	)	)	False
DDI-MedLine.d95.s4	induced	30	36	O	induced	ced	uced	JJ	False
DDI-MedLine.d95.s4	concentration-dependent	38	60	O	concentration-dependent	ent	dent	NN	False
DDI-MedLine.d95.s4	relaxation	62	71	O	relaxation	ion	tion	NN	False
DDI-MedLine.d95.s4	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d95.s4	mesenteric	76	85	O	mesenteric	ric	eric	NN	False
DDI-MedLine.d95.s4	arteries	87	94	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s4	preconstricted	96	109	O	preconstricted	ted	cted	VBN	False
DDI-MedLine.d95.s4	with	111	114	O	with	ith	with	IN	False
DDI-MedLine.d95.s4	noradrenaline	116	128	B-drug	noradrenaline	ine	line	NN	drug
DDI-MedLine.d95.s4	(	130	130	O	(	(	(	(	False
DDI-MedLine.d95.s4	8	131	131	O	8	8	8	CD	False
DDI-MedLine.d95.s4	micromol/l	133	142	O	micromol/l	l/l	ol/l	NN	False
DDI-MedLine.d95.s4	)	143	143	O	)	)	)	)	False
DDI-MedLine.d95.s4	or	145	146	O	or	or	or	CC	False
DDI-MedLine.d95.s4	KCl	148	150	B-drug	KCl	KCl	KCl	NNP	False
DDI-MedLine.d95.s4	(	152	152	O	(	(	(	(	False
DDI-MedLine.d95.s4	125	153	155	O	125	125	125	CD	False
DDI-MedLine.d95.s4	mmol/l	157	162	O	mmol/l	l/l	ol/l	NN	False
DDI-MedLine.d95.s4	)	163	163	O	)	)	)	)	False
DDI-MedLine.d95.s4	from	165	168	O	from	rom	from	IN	False
DDI-MedLine.d95.s4	both	170	173	O	both	oth	both	DT	False
DDI-MedLine.d95.s4	lean	175	178	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s4	and	180	182	O	and	and	and	CC	False
DDI-MedLine.d95.s4	dietary-obese	184	196	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s4	rats	198	201	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s4	.	202	202	O	.	.	.	.	False

DDI-MedLine.d95.s5	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d95.s5	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d95.s5	no	11	12	O	no	no	no	DT	False
DDI-MedLine.d95.s5	significant	14	24	O	significant	ant	cant	JJ	False
DDI-MedLine.d95.s5	differences	26	36	O	differences	ces	nces	NNS	False
DDI-MedLine.d95.s5	between	38	44	O	between	een	ween	IN	False
DDI-MedLine.d95.s5	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d95.s5	two	50	52	O	two	two	two	CD	False
DDI-MedLine.d95.s5	groups	54	59	O	groups	ups	oups	NNS	False
DDI-MedLine.d95.s5	,	60	60	O	,	,	,	,	False
DDI-MedLine.d95.s5	achieving	62	70	O	achieving	ing	ving	VBG	False
DDI-MedLine.d95.s5	a	72	72	O	a	a	a	DT	False
DDI-MedLine.d95.s5	maximum	74	80	O	maximum	mum	imum	NN	False
DDI-MedLine.d95.s5	relaxation	82	91	O	relaxation	ion	tion	NN	False
DDI-MedLine.d95.s5	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d95.s5	>	96	96	O	>	>	>	NN	False
DDI-MedLine.d95.s5	95	97	98	O	95	95	95	CD	False
DDI-MedLine.d95.s5	%	99	99	O	%	%	%	NN	False
DDI-MedLine.d95.s5	at	101	102	O	at	at	at	IN	False
DDI-MedLine.d95.s5	a	104	104	O	a	a	a	DT	False
DDI-MedLine.d95.s5	concentration	106	118	O	concentration	ion	tion	NN	False
DDI-MedLine.d95.s5	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d95.s5	35	123	124	O	35	35	35	CD	False
DDI-MedLine.d95.s5	micromol/l	126	135	O	micromol/l	l/l	ol/l	NN	False
DDI-MedLine.d95.s5	.	136	136	O	.	.	.	.	False

DDI-MedLine.d95.s6	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d95.s6	,	7	7	O	,	,	,	,	False
DDI-MedLine.d95.s6	L-NAME	9	14	B-drug_n	L-NAME	AME	NAME	JJ	brand
DDI-MedLine.d95.s6	(	16	16	O	(	(	(	(	False
DDI-MedLine.d95.s6	100	17	19	O	100	100	100	CD	False
DDI-MedLine.d95.s6	and	21	23	O	and	and	and	CC	False
DDI-MedLine.d95.s6	300	25	27	O	300	300	300	CD	False
DDI-MedLine.d95.s6	micromol/l	29	38	O	micromol/l	l/l	ol/l	NN	False
DDI-MedLine.d95.s6	)	39	39	O	)	)	)	)	False
DDI-MedLine.d95.s6	did	41	43	O	did	did	did	VBD	False
DDI-MedLine.d95.s6	not	45	47	O	not	not	not	RB	False
DDI-MedLine.d95.s6	alter	49	53	O	alter	ter	lter	NN	False
DDI-MedLine.d95.s6	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d95.s6	effects	59	65	O	effects	cts	ects	NNS	False
DDI-MedLine.d95.s6	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d95.s6	reseveratrol	70	81	B-drug_n	reseveratrol	rol	trol	NN	False
DDI-MedLine.d95.s6	on	83	84	O	on	on	on	IN	False
DDI-MedLine.d95.s6	arteries	86	93	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s6	from	95	98	O	from	rom	from	IN	False
DDI-MedLine.d95.s6	dietary-obese	100	112	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s6	rats	114	117	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s6	,	118	118	O	,	,	,	,	False
DDI-MedLine.d95.s6	giving	120	125	O	giving	ing	ving	VBG	False
DDI-MedLine.d95.s6	superimposed	127	138	O	superimposed	sed	osed	VBN	False
DDI-MedLine.d95.s6	concentration-responses	140	162	O	concentration-responses	ses	nses	NNS	False
DDI-MedLine.d95.s6	curves	164	169	O	curves	ves	rves	NNS	False
DDI-MedLine.d95.s6	.	170	170	O	.	.	.	.	False

DDI-MedLine.d95.s7	Indomethacin	0	11	B-drug	Indomethacin	cin	acin	NN	drug
DDI-MedLine.d95.s7	was	13	15	O	was	was	was	VBD	False
DDI-MedLine.d95.s7	also	17	20	O	also	lso	also	RB	False
DDI-MedLine.d95.s7	ineffective	22	32	O	ineffective	ive	tive	JJ	False
DDI-MedLine.d95.s7	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d95.s7	altering	37	44	O	altering	ing	ring	VBG	False
DDI-MedLine.d95.s7	resveratrol	46	56	B-drug_n	resveratrol	rol	trol	NN	False
DDI-MedLine.d95.s7	activity	58	65	O	activity	ity	vity	NN	False
DDI-MedLine.d95.s7	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d95.s7	arteries	70	77	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s7	from	79	82	O	from	rom	from	IN	False
DDI-MedLine.d95.s7	both	84	87	O	both	oth	both	DT	False
DDI-MedLine.d95.s7	lean	89	92	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s7	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d95.s7	dietary-obese	98	110	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s7	rats	112	115	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s7	.	116	116	O	.	.	.	.	False

DDI-MedLine.d95.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d95.s8	noradrenaline-precontracted	3	29	O	noradrenaline-precontracted	ted	cted	JJ	False
DDI-MedLine.d95.s8	arteries	31	38	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s8	from	40	43	O	from	rom	from	IN	False
DDI-MedLine.d95.s8	dietary-obese	45	57	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s8	rats	59	62	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s8	,	63	63	O	,	,	,	,	False
DDI-MedLine.d95.s8	responses	65	73	O	responses	ses	nses	NNS	False
DDI-MedLine.d95.s8	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d95.s8	resveratrol	78	88	B-drug_n	resveratrol	rol	trol	NN	False
DDI-MedLine.d95.s8	were	90	93	O	were	ere	were	VBD	False
DDI-MedLine.d95.s8	not	95	97	O	not	not	not	RB	False
DDI-MedLine.d95.s8	attenuated	99	108	O	attenuated	ted	ated	VBN	False
DDI-MedLine.d95.s8	by	110	111	O	by	by	by	IN	False
DDI-MedLine.d95.s8	endothelial	113	123	O	endothelial	ial	lial	JJ	False
DDI-MedLine.d95.s8	denudation	125	134	O	denudation	ion	tion	NN	False
DDI-MedLine.d95.s8	,	135	135	O	,	,	,	,	False
DDI-MedLine.d95.s8	indicating	137	146	O	indicating	ing	ting	VBG	False
DDI-MedLine.d95.s8	an	148	149	O	an	an	an	DT	False
DDI-MedLine.d95.s8	action	151	156	O	action	ion	tion	NN	False
DDI-MedLine.d95.s8	independent	158	168	O	independent	ent	dent	JJ	False
DDI-MedLine.d95.s8	of	170	171	O	of	of	of	IN	False
DDI-MedLine.d95.s8	the	173	175	O	the	the	the	DT	False
DDI-MedLine.d95.s8	endothelium	177	187	O	endothelium	ium	lium	NN	drug
DDI-MedLine.d95.s8	.	188	188	O	.	.	.	.	False

DDI-MedLine.d95.s9	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d95.s9	study	5	9	O	study	udy	tudy	NN	False
DDI-MedLine.d95.s9	indicates	11	19	O	indicates	tes	ates	NNS	False
DDI-MedLine.d95.s9	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d95.s9	:	25	25	O	:	:	:	:	False
DDI-MedLine.d95.s9	(	27	27	O	(	(	(	(	False
DDI-MedLine.d95.s9	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d95.s9	)	29	29	O	)	)	)	)	False
DDI-MedLine.d95.s9	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d95.s9	maximal	35	41	O	maximal	mal	imal	NN	False
DDI-MedLine.d95.s9	effects	43	49	O	effects	cts	ects	NNS	False
DDI-MedLine.d95.s9	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d95.s9	resveratrol	54	64	B-drug_n	resveratrol	rol	trol	NN	False
DDI-MedLine.d95.s9	on	66	67	O	on	on	on	IN	False
DDI-MedLine.d95.s9	resistance	69	78	O	resistance	nce	ance	NN	False
DDI-MedLine.d95.s9	arteries	80	87	O	arteries	ies	ries	NNS	False
DDI-MedLine.d95.s9	from	89	92	O	from	rom	from	IN	False
DDI-MedLine.d95.s9	lean	94	97	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s9	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d95.s9	dietary-obese	103	115	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s9	rats	117	120	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s9	are	122	124	O	are	are	are	VBP	False
DDI-MedLine.d95.s9	not	126	128	O	not	not	not	RB	False
DDI-MedLine.d95.s9	effected	130	137	O	effected	ted	cted	VBN	False
DDI-MedLine.d95.s9	by	139	140	O	by	by	by	IN	False
DDI-MedLine.d95.s9	endothelial	142	152	O	endothelial	ial	lial	JJ	False
DDI-MedLine.d95.s9	dysfunction	154	164	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d95.s9	,	165	165	O	,	,	,	,	False
DDI-MedLine.d95.s9	and	167	169	O	and	and	and	CC	False
DDI-MedLine.d95.s9	(	171	171	O	(	(	(	(	False
DDI-MedLine.d95.s9	b	172	172	O	b	b	b	NN	False
DDI-MedLine.d95.s9	)	173	173	O	)	)	)	)	False
DDI-MedLine.d95.s9	the	175	177	O	the	the	the	DT	False
DDI-MedLine.d95.s9	effects	179	185	O	effects	cts	ects	NNS	False
DDI-MedLine.d95.s9	of	187	188	O	of	of	of	IN	False
DDI-MedLine.d95.s9	resveratrol	190	200	B-drug_n	resveratrol	rol	trol	NN	False
DDI-MedLine.d95.s9	in	202	203	O	in	in	in	IN	False
DDI-MedLine.d95.s9	lean	205	208	O	lean	ean	lean	NN	False
DDI-MedLine.d95.s9	animals	210	216	O	animals	als	mals	NNS	False
DDI-MedLine.d95.s9	(	218	218	O	(	(	(	(	False
DDI-MedLine.d95.s9	where	219	223	O	where	ere	here	WRB	False
DDI-MedLine.d95.s9	endothelial	225	235	O	endothelial	ial	lial	JJ	False
DDI-MedLine.d95.s9	function	237	244	O	function	ion	tion	NN	False
DDI-MedLine.d95.s9	is	246	247	O	is	is	is	VBZ	False
DDI-MedLine.d95.s9	not	249	251	O	not	not	not	RB	False
DDI-MedLine.d95.s9	impaired	253	260	O	impaired	red	ired	JJ	False
DDI-MedLine.d95.s9	)	261	261	O	)	)	)	)	False
DDI-MedLine.d95.s9	,	262	262	O	,	,	,	,	False
DDI-MedLine.d95.s9	but	264	266	O	but	but	but	CC	False
DDI-MedLine.d95.s9	not	268	270	O	not	not	not	RB	False
DDI-MedLine.d95.s9	in	272	273	O	in	in	in	IN	False
DDI-MedLine.d95.s9	dietary-obese	275	287	O	dietary-obese	ese	bese	JJ	False
DDI-MedLine.d95.s9	rats	289	292	O	rats	ats	rats	NNS	False
DDI-MedLine.d95.s9	,	293	293	O	,	,	,	,	False
DDI-MedLine.d95.s9	are	295	297	O	are	are	are	VBP	False
DDI-MedLine.d95.s9	mediated	299	306	O	mediated	ted	ated	VBN	False
DDI-MedLine.d95.s9	via	308	310	O	via	via	via	IN	False
DDI-MedLine.d95.s9	NO	312	313	O	NO	NO	NO	DT	brand
DDI-MedLine.d95.s9	.	314	314	O	.	.	.	.	False

DDI-MedLine.d61.s0	Pharmacokinetic	0	14	O	Pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d61.s0	evaluation	16	25	O	evaluation	ion	tion	NN	False
DDI-MedLine.d61.s0	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d61.s0	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d61.s0	digoxin-amiodarone	34	51	O	digoxin-amiodarone	one	rone	NN	False
DDI-MedLine.d61.s0	interaction	53	63	O	interaction	ion	tion	NN	False
DDI-MedLine.d61.s0	.	64	64	O	.	.	.	.	False

DDI-MedLine.d61.s1	Amiodarone	0	9	B-drug	Amiodarone	one	rone	NN	False
DDI-MedLine.d61.s1	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d61.s1	known	14	18	O	known	own	nown	VBN	False
DDI-MedLine.d61.s1	to	20	21	O	to	to	to	TO	False
DDI-MedLine.d61.s1	raise	23	27	O	raise	ise	aise	NN	False
DDI-MedLine.d61.s1	serum	29	33	O	serum	rum	erum	NN	False
DDI-MedLine.d61.s1	digoxin	35	41	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s1	levels	43	48	O	levels	els	vels	NNS	False
DDI-MedLine.d61.s1	.	49	49	O	.	.	.	.	False

DDI-MedLine.d61.s2	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d61.s2	study	5	9	O	study	udy	tudy	NN	False
DDI-MedLine.d61.s2	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d61.s2	designed	15	22	O	designed	ned	gned	VBN	False
DDI-MedLine.d61.s2	to	24	25	O	to	to	to	TO	False
DDI-MedLine.d61.s2	evaluate	27	34	O	evaluate	ate	uate	NN	False
DDI-MedLine.d61.s2	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d61.s2	pharmacokinetic	40	54	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d61.s2	basis	56	60	O	basis	sis	asis	NN	False
DDI-MedLine.d61.s2	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d61.s2	this	65	68	O	this	his	this	DT	False
DDI-MedLine.d61.s2	interaction	70	80	O	interaction	ion	tion	NN	False
DDI-MedLine.d61.s2	in	82	83	O	in	in	in	IN	False
DDI-MedLine.d61.s2	10	85	86	O	10	10	10	CD	False
DDI-MedLine.d61.s2	normal	88	93	O	normal	mal	rmal	JJ	False
DDI-MedLine.d61.s2	subjects	95	102	O	subjects	cts	ects	NNS	False
DDI-MedLine.d61.s2	.	103	103	O	.	.	.	.	False

DDI-MedLine.d61.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d61.s3	pharmacokinetic	4	18	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d61.s3	variables	20	28	O	variables	les	bles	NNS	False
DDI-MedLine.d61.s3	for	30	32	O	for	for	for	IN	False
DDI-MedLine.d61.s3	digoxin	34	40	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s3	were	42	45	O	were	ere	were	VBD	False
DDI-MedLine.d61.s3	determined	47	56	O	determined	ned	ined	VBN	False
DDI-MedLine.d61.s3	after	58	62	O	after	ter	fter	IN	False
DDI-MedLine.d61.s3	a	64	64	O	a	a	a	DT	False
DDI-MedLine.d61.s3	1.0	66	68	O	1.0	1.0	1.0	CD	False
DDI-MedLine.d61.s3	mg	70	71	O	mg	mg	mg	NN	False
DDI-MedLine.d61.s3	intravenous	73	83	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d61.s3	dose	85	88	O	dose	ose	dose	NN	False
DDI-MedLine.d61.s3	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d61.s3	digoxin	93	99	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s3	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d61.s3	each	104	107	O	each	ach	each	DT	False
DDI-MedLine.d61.s3	subject	109	115	O	subject	ect	ject	NN	False
DDI-MedLine.d61.s3	,	116	116	O	,	,	,	,	False
DDI-MedLine.d61.s3	before	118	123	O	before	ore	fore	IN	False
DDI-MedLine.d61.s3	and	125	127	O	and	and	and	CC	False
DDI-MedLine.d61.s3	after	129	133	O	after	ter	fter	IN	False
DDI-MedLine.d61.s3	oral	135	138	O	oral	ral	oral	JJ	False
DDI-MedLine.d61.s3	amiodarone	140	149	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d61.s3	,	150	150	O	,	,	,	,	False
DDI-MedLine.d61.s3	400	152	154	O	400	400	400	CD	False
DDI-MedLine.d61.s3	mg	156	157	O	mg	mg	mg	NN	False
DDI-MedLine.d61.s3	daily	159	163	O	daily	ily	aily	JJ	False
DDI-MedLine.d61.s3	for	165	167	O	for	for	for	IN	False
DDI-MedLine.d61.s3	3	169	169	O	3	3	3	CD	False
DDI-MedLine.d61.s3	weeks	171	175	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d61.s3	.	176	176	O	.	.	.	.	False

DDI-MedLine.d61.s4	During	0	5	O	During	ing	ring	IN	False
DDI-MedLine.d61.s4	amiodarone	7	16	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d61.s4	administration	18	31	O	administration	ion	tion	NN	False
DDI-MedLine.d61.s4	,	32	32	O	,	,	,	,	False
DDI-MedLine.d61.s4	systemic	34	41	O	systemic	mic	emic	JJ	False
DDI-MedLine.d61.s4	clearance	43	51	O	clearance	nce	ance	NN	False
DDI-MedLine.d61.s4	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d61.s4	digoxin	56	62	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s4	was	64	66	O	was	was	was	VBD	False
DDI-MedLine.d61.s4	reduced	68	74	O	reduced	ced	uced	VBN	False
DDI-MedLine.d61.s4	from	76	79	O	from	rom	from	IN	False
DDI-MedLine.d61.s4	234	81	83	O	234	234	234	CD	False
DDI-MedLine.d61.s4	+/-	85	87	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s4	72	89	90	O	72	72	72	CD	False
DDI-MedLine.d61.s4	ml/min	92	97	O	ml/min	min	/min	NN	False
DDI-MedLine.d61.s4	(	99	99	O	(	(	(	(	False
DDI-MedLine.d61.s4	mean	100	103	O	mean	ean	mean	NN	False
DDI-MedLine.d61.s4	+/-	105	107	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s4	standard	109	116	O	standard	ard	dard	NN	False
DDI-MedLine.d61.s4	deviation	118	126	O	deviation	ion	tion	NN	False
DDI-MedLine.d61.s4	)	127	127	O	)	)	)	)	False
DDI-MedLine.d61.s4	to	129	130	O	to	to	to	TO	False
DDI-MedLine.d61.s4	172	132	134	O	172	172	172	CD	False
DDI-MedLine.d61.s4	+/-	136	138	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s4	33	140	141	O	33	33	33	CD	False
DDI-MedLine.d61.s4	ml/min	143	148	O	ml/min	min	/min	NN	False
DDI-MedLine.d61.s4	(	150	150	O	(	(	(	(	False
DDI-MedLine.d61.s4	p	151	151	O	p	p	p	NN	False
DDI-MedLine.d61.s4	less	153	156	O	less	ess	less	RBR	False
DDI-MedLine.d61.s4	than	158	161	O	than	han	than	IN	False
DDI-MedLine.d61.s4	0.01	163	166	O	0.01	.01	0.01	CD	False
DDI-MedLine.d61.s4	)	167	167	O	)	)	)	)	False
DDI-MedLine.d61.s4	.	168	168	O	.	.	.	.	False

DDI-MedLine.d61.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d61.s5	was	5	7	O	was	was	was	VBD	False
DDI-MedLine.d61.s5	due	9	11	O	due	due	due	JJ	False
DDI-MedLine.d61.s5	to	13	14	O	to	to	to	TO	False
DDI-MedLine.d61.s5	reductions	16	25	O	reductions	ons	ions	NNS	False
DDI-MedLine.d61.s5	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d61.s5	both	30	33	O	both	oth	both	DT	False
DDI-MedLine.d61.s5	renal	35	39	O	renal	nal	enal	NN	False
DDI-MedLine.d61.s5	clearance	41	49	O	clearance	nce	ance	NN	False
DDI-MedLine.d61.s5	(	51	51	O	(	(	(	(	False
DDI-MedLine.d61.s5	from	52	55	O	from	rom	from	IN	False
DDI-MedLine.d61.s5	105	57	59	O	105	105	105	CD	False
DDI-MedLine.d61.s5	+/-	61	63	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s5	39	65	66	O	39	39	39	CD	False
DDI-MedLine.d61.s5	to	68	69	O	to	to	to	TO	False
DDI-MedLine.d61.s5	84	71	72	O	84	84	84	CD	False
DDI-MedLine.d61.s5	+/-	74	76	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s5	15	78	79	O	15	15	15	CD	False
DDI-MedLine.d61.s5	ml/min	81	86	O	ml/min	min	/min	NN	False
DDI-MedLine.d61.s5	)	87	87	O	)	)	)	)	False
DDI-MedLine.d61.s5	(	89	89	O	(	(	(	(	False
DDI-MedLine.d61.s5	p	90	90	O	p	p	p	NN	False
DDI-MedLine.d61.s5	less	92	95	O	less	ess	less	RBR	False
DDI-MedLine.d61.s5	than	97	100	O	than	han	than	IN	False
DDI-MedLine.d61.s5	0.05	102	105	O	0.05	.05	0.05	CD	False
DDI-MedLine.d61.s5	)	106	106	O	)	)	)	)	False
DDI-MedLine.d61.s5	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d61.s5	nonrenal	112	119	O	nonrenal	nal	enal	JJ	False
DDI-MedLine.d61.s5	clearance	121	129	O	clearance	nce	ance	NN	False
DDI-MedLine.d61.s5	(	131	131	O	(	(	(	(	False
DDI-MedLine.d61.s5	from	132	135	O	from	rom	from	IN	False
DDI-MedLine.d61.s5	130	137	139	O	130	130	130	CD	False
DDI-MedLine.d61.s5	+/-	141	143	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s5	38	145	146	O	38	38	38	CD	False
DDI-MedLine.d61.s5	to	148	149	O	to	to	to	TO	False
DDI-MedLine.d61.s5	88	151	152	O	88	88	88	CD	False
DDI-MedLine.d61.s5	+/-	154	156	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s5	20	158	159	O	20	20	20	CD	False
DDI-MedLine.d61.s5	ml/min	161	166	O	ml/min	min	/min	NN	False
DDI-MedLine.d61.s5	)	167	167	O	)	)	)	)	False
DDI-MedLine.d61.s5	(	169	169	O	(	(	(	(	False
DDI-MedLine.d61.s5	p	170	170	O	p	p	p	NN	False
DDI-MedLine.d61.s5	less	172	175	O	less	ess	less	RBR	False
DDI-MedLine.d61.s5	than	177	180	O	than	han	than	IN	False
DDI-MedLine.d61.s5	0.01	182	185	O	0.01	.01	0.01	CD	False
DDI-MedLine.d61.s5	)	186	186	O	)	)	)	)	False
DDI-MedLine.d61.s5	.	187	187	O	.	.	.	.	False

DDI-MedLine.d61.s6	Digoxin	0	6	B-drug	Digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s6	half-life	8	16	O	half-life	ife	life	NN	False
DDI-MedLine.d61.s6	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d61.s6	elimination	21	31	O	elimination	ion	tion	NN	False
DDI-MedLine.d61.s6	was	33	35	O	was	was	was	VBD	False
DDI-MedLine.d61.s6	prolonged	37	45	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d61.s6	from	47	50	O	from	rom	from	IN	False
DDI-MedLine.d61.s6	34	52	53	O	34	34	34	CD	False
DDI-MedLine.d61.s6	+/-	55	57	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s6	13	59	60	O	13	13	13	CD	False
DDI-MedLine.d61.s6	to	62	63	O	to	to	to	TO	False
DDI-MedLine.d61.s6	40	65	66	O	40	40	40	CD	False
DDI-MedLine.d61.s6	+/-	68	70	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d61.s6	16	72	73	O	16	16	16	CD	False
DDI-MedLine.d61.s6	hours	75	79	O	hours	urs	ours	NNS	False
DDI-MedLine.d61.s6	(	81	81	O	(	(	(	(	False
DDI-MedLine.d61.s6	p	82	82	O	p	p	p	NN	False
DDI-MedLine.d61.s6	less	84	87	O	less	ess	less	RBR	False
DDI-MedLine.d61.s6	than	89	92	O	than	han	than	IN	False
DDI-MedLine.d61.s6	0.05	94	97	O	0.05	.05	0.05	CD	False
DDI-MedLine.d61.s6	)	98	98	O	)	)	)	)	False
DDI-MedLine.d61.s6	.	99	99	O	.	.	.	.	False

DDI-MedLine.d61.s7	Digoxin	0	6	B-drug	Digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s7	volume	8	13	O	volume	ume	lume	NN	False
DDI-MedLine.d61.s7	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d61.s7	distribution	18	29	O	distribution	ion	tion	NN	False
DDI-MedLine.d61.s7	was	31	33	O	was	was	was	VBD	False
DDI-MedLine.d61.s7	not	35	37	O	not	not	not	RB	False
DDI-MedLine.d61.s7	significantly	39	51	O	significantly	tly	ntly	RB	False
DDI-MedLine.d61.s7	changed	53	59	O	changed	ged	nged	VBN	False
DDI-MedLine.d61.s7	.	60	60	O	.	.	.	.	False

DDI-MedLine.d61.s8	Amiodarone	0	9	B-drug	Amiodarone	one	rone	NN	False
DDI-MedLine.d61.s8	caused	11	16	O	caused	sed	used	VBN	False
DDI-MedLine.d61.s8	a	18	18	O	a	a	a	DT	False
DDI-MedLine.d61.s8	three-	20	25	O	three-	ee-	ree-	NN	False
DDI-MedLine.d61.s8	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d61.s8	fivefold	30	37	O	fivefold	old	fold	NN	False
DDI-MedLine.d61.s8	increase	39	46	O	increase	ase	ease	NN	False
DDI-MedLine.d61.s8	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d61.s8	serum	51	55	O	serum	rum	erum	NN	False
DDI-MedLine.d61.s8	reverse	57	63	O	reverse	rse	erse	NN	False
DDI-MedLine.d61.s8	triiodothyronine	65	80	O	triiodothyronine	ine	nine	NN	drug
DDI-MedLine.d61.s8	levels	82	87	O	levels	els	vels	NNS	False
DDI-MedLine.d61.s8	,	88	88	O	,	,	,	,	False
DDI-MedLine.d61.s8	but	90	92	O	but	but	but	CC	False
DDI-MedLine.d61.s8	changes	94	100	O	changes	ges	nges	NNS	False
DDI-MedLine.d61.s8	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d61.s8	thyroid	105	111	O	thyroid	oid	roid	NN	False
DDI-MedLine.d61.s8	function	113	120	O	function	ion	tion	NN	False
DDI-MedLine.d61.s8	were	122	125	O	were	ere	were	VBD	False
DDI-MedLine.d61.s8	not	127	129	O	not	not	not	RB	False
DDI-MedLine.d61.s8	quantitatively	131	144	O	quantitatively	ely	vely	RB	False
DDI-MedLine.d61.s8	related	146	152	O	related	ted	ated	JJ	False
DDI-MedLine.d61.s8	to	154	155	O	to	to	to	TO	False
DDI-MedLine.d61.s8	the	157	159	O	the	the	the	DT	False
DDI-MedLine.d61.s8	changes	161	167	O	changes	ges	nges	NNS	False
DDI-MedLine.d61.s8	in	169	170	O	in	in	in	IN	False
DDI-MedLine.d61.s8	digoxin	172	178	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s8	pharmacokinetics	180	195	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d61.s8	.	196	196	O	.	.	.	.	False

DDI-MedLine.d61.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d61.s9	alterations	6	16	O	alterations	ons	ions	NNS	False
DDI-MedLine.d61.s9	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d61.s9	digoxin	21	27	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s9	pharmacokinetics	29	44	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d61.s9	produced	46	53	O	produced	ced	uced	VBN	False
DDI-MedLine.d61.s9	by	55	56	O	by	by	by	IN	False
DDI-MedLine.d61.s9	amiodarone	58	67	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d61.s9	explain	69	75	O	explain	ain	lain	NN	False
DDI-MedLine.d61.s9	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d61.s9	increase	81	88	O	increase	ase	ease	NN	False
DDI-MedLine.d61.s9	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d61.s9	serum	93	97	O	serum	rum	erum	NN	False
DDI-MedLine.d61.s9	digoxin	99	105	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d61.s9	level	107	111	O	level	vel	evel	NN	False
DDI-MedLine.d61.s9	that	113	116	O	that	hat	that	IN	False
DDI-MedLine.d61.s9	has	118	120	O	has	has	has	VBZ	False
DDI-MedLine.d61.s9	been	122	125	O	been	een	been	VBN	False
DDI-MedLine.d61.s9	observed	127	134	O	observed	ved	rved	VBN	False
DDI-MedLine.d61.s9	when	136	139	O	when	hen	when	WRB	False
DDI-MedLine.d61.s9	this	141	144	O	this	his	this	DT	False
DDI-MedLine.d61.s9	drug	146	149	O	drug	rug	drug	NN	False
DDI-MedLine.d61.s9	combination	151	161	O	combination	ion	tion	NN	False
DDI-MedLine.d61.s9	has	163	165	O	has	has	has	VBZ	False
DDI-MedLine.d61.s9	been	167	170	O	been	een	been	VBN	False
DDI-MedLine.d61.s9	used	172	175	O	used	sed	used	VBN	False
DDI-MedLine.d61.s9	clinically	177	186	O	clinically	lly	ally	RB	False
DDI-MedLine.d61.s9	.	187	187	O	.	.	.	.	False

DDI-MedLine.d90.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d90.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d90.s0	gentamycin	15	24	B-drug	gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s0	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d90.s0	atracurium	30	39	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s0	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d90.s0	anaesthetised	44	56	O	anaesthetised	sed	ised	VBN	False
DDI-MedLine.d90.s0	horses	58	63	O	horses	ses	rses	NNS	False
DDI-MedLine.d90.s0	.	64	64	O	.	.	.	.	False

DDI-MedLine.d90.s1	Evoked	0	5	O	Evoked	ked	oked	NNS	False
DDI-MedLine.d90.s1	hind	7	10	O	hind	ind	hind	NN	False
DDI-MedLine.d90.s1	limb	12	15	O	limb	imb	limb	NN	False
DDI-MedLine.d90.s1	digital	17	23	O	digital	tal	ital	NN	False
DDI-MedLine.d90.s1	extensor	25	32	O	extensor	sor	nsor	NN	False
DDI-MedLine.d90.s1	tension	34	40	O	tension	ion	sion	NN	False
DDI-MedLine.d90.s1	(	42	42	O	(	(	(	(	False
DDI-MedLine.d90.s1	hoof	43	46	O	hoof	oof	hoof	NN	False
DDI-MedLine.d90.s1	twitch	48	53	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s1	)	54	54	O	)	)	)	)	False
DDI-MedLine.d90.s1	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d90.s1	maintained	60	69	O	maintained	ned	ined	VBN	False
DDI-MedLine.d90.s1	at	71	72	O	at	at	at	IN	False
DDI-MedLine.d90.s1	40	74	75	O	40	40	40	CD	False
DDI-MedLine.d90.s1	%	76	76	O	%	%	%	NN	False
DDI-MedLine.d90.s1	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d90.s1	baseline	81	88	O	baseline	ine	line	NN	drug
DDI-MedLine.d90.s1	for	90	92	O	for	for	for	IN	False
DDI-MedLine.d90.s1	1	94	94	O	1	1	1	CD	False
DDI-MedLine.d90.s1	h	96	96	O	h	h	h	NN	False
DDI-MedLine.d90.s1	by	98	99	O	by	by	by	IN	False
DDI-MedLine.d90.s1	atracurium	101	110	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s1	infusion	112	119	O	infusion	ion	sion	NN	False
DDI-MedLine.d90.s1	in	121	122	O	in	in	in	IN	False
DDI-MedLine.d90.s1	7	124	124	O	7	7	7	CD	False
DDI-MedLine.d90.s1	horses	126	131	O	horses	ses	rses	NNS	False
DDI-MedLine.d90.s1	anaesthetised	133	145	O	anaesthetised	sed	ised	VBN	False
DDI-MedLine.d90.s1	with	147	150	O	with	ith	with	IN	False
DDI-MedLine.d90.s1	halothane	152	160	B-drug	halothane	ane	hane	NN	False
DDI-MedLine.d90.s1	.	161	161	O	.	.	.	.	False

DDI-MedLine.d90.s2	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d90.s2	1	6	6	O	1	1	1	CD	False
DDI-MedLine.d90.s2	h	8	8	O	h	h	h	NN	False
DDI-MedLine.d90.s2	,	9	9	O	,	,	,	,	False
DDI-MedLine.d90.s2	atracurium	11	20	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s2	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d90.s2	discontinued	26	37	O	discontinued	ued	nued	VBN	False
DDI-MedLine.d90.s2	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d90.s2	hoof	43	46	O	hoof	oof	hoof	NN	False
DDI-MedLine.d90.s2	twitch	48	53	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s2	allowed	55	61	O	allowed	wed	owed	VBN	False
DDI-MedLine.d90.s2	to	63	64	O	to	to	to	TO	False
DDI-MedLine.d90.s2	recover	66	72	O	recover	ver	over	NN	False
DDI-MedLine.d90.s2	to	74	75	O	to	to	to	TO	False
DDI-MedLine.d90.s2	75	77	78	O	75	75	75	CD	False
DDI-MedLine.d90.s2	%	79	79	O	%	%	%	NN	False
DDI-MedLine.d90.s2	.	80	80	O	.	.	.	.	False

DDI-MedLine.d90.s3	Atracurium	0	9	B-drug	Atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s3	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d90.s3	again	15	19	O	again	ain	gain	RB	False
DDI-MedLine.d90.s3	given	21	25	O	given	ven	iven	VBN	False
DDI-MedLine.d90.s3	by	27	28	O	by	by	by	IN	False
DDI-MedLine.d90.s3	infusion	30	37	O	infusion	ion	sion	NN	False
DDI-MedLine.d90.s3	to	39	40	O	to	to	to	TO	False
DDI-MedLine.d90.s3	maintain	42	49	O	maintain	ain	tain	NN	False
DDI-MedLine.d90.s3	40	51	52	O	40	40	40	CD	False
DDI-MedLine.d90.s3	%	53	53	O	%	%	%	NN	False
DDI-MedLine.d90.s3	twitch	55	60	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s3	for	62	64	O	for	for	for	IN	False
DDI-MedLine.d90.s3	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d90.s3	second	68	73	O	second	ond	cond	JJ	False
DDI-MedLine.d90.s3	hour	75	78	O	hour	our	hour	NN	False
DDI-MedLine.d90.s3	,	79	79	O	,	,	,	,	False
DDI-MedLine.d90.s3	then	81	84	O	then	hen	then	RB	False
DDI-MedLine.d90.s3	2	86	86	O	2	2	2	CD	False
DDI-MedLine.d90.s3	mg	88	89	O	mg	mg	mg	NN	False
DDI-MedLine.d90.s3	gentamycin/kg	91	103	O	gentamycin/kg	/kg	n/kg	NN	False
DDI-MedLine.d90.s3	bwt	105	107	O	bwt	bwt	bwt	NN	False
DDI-MedLine.d90.s3	were	109	112	O	were	ere	were	VBD	False
DDI-MedLine.d90.s3	given	114	118	O	given	ven	iven	VBN	False
DDI-MedLine.d90.s3	i.v	120	122	O	i.v	i.v	i.v	NN	False
DDI-MedLine.d90.s3	.	123	123	O	.	.	.	.	False

DDI-MedLine.d90.s4	Atracurium	0	9	B-drug	Atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s4	infusion	11	18	O	infusion	ion	sion	NN	False
DDI-MedLine.d90.s4	was	20	22	O	was	was	was	VBD	False
DDI-MedLine.d90.s4	continued	24	32	O	continued	ued	nued	JJ	False
DDI-MedLine.d90.s4	for	34	36	O	for	for	for	IN	False
DDI-MedLine.d90.s4	a	38	38	O	a	a	a	DT	False
DDI-MedLine.d90.s4	third	40	44	O	third	ird	hird	JJ	False
DDI-MedLine.d90.s4	hour	46	49	O	hour	our	hour	NN	False
DDI-MedLine.d90.s4	,	50	50	O	,	,	,	,	False
DDI-MedLine.d90.s4	and	52	54	O	and	and	and	CC	False
DDI-MedLine.d90.s4	then	56	59	O	then	hen	then	RB	False
DDI-MedLine.d90.s4	hoof	61	64	O	hoof	oof	hoof	NN	False
DDI-MedLine.d90.s4	twitch	66	71	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s4	was	73	75	O	was	was	was	VBD	False
DDI-MedLine.d90.s4	again	77	81	O	again	ain	gain	RB	False
DDI-MedLine.d90.s4	allowed	83	89	O	allowed	wed	owed	VBN	False
DDI-MedLine.d90.s4	to	91	92	O	to	to	to	TO	False
DDI-MedLine.d90.s4	recover	94	100	O	recover	ver	over	NN	False
DDI-MedLine.d90.s4	spontaneously	102	114	O	spontaneously	sly	usly	RB	False
DDI-MedLine.d90.s4	to	116	117	O	to	to	to	TO	False
DDI-MedLine.d90.s4	75	119	120	O	75	75	75	CD	False
DDI-MedLine.d90.s4	%	121	121	O	%	%	%	NN	False
DDI-MedLine.d90.s4	.	122	122	O	.	.	.	.	False

DDI-MedLine.d90.s5	Gentamycin	0	9	B-drug	Gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s5	reduced	11	17	O	reduced	ced	uced	VBN	False
DDI-MedLine.d90.s5	twitch	19	24	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s5	strength	26	33	O	strength	gth	ngth	NN	False
DDI-MedLine.d90.s5	from	35	38	O	from	rom	from	IN	False
DDI-MedLine.d90.s5	40	40	41	O	40	40	40	CD	False
DDI-MedLine.d90.s5	+/-	43	45	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s5	1	47	47	O	1	1	1	CD	False
DDI-MedLine.d90.s5	%	48	48	O	%	%	%	NN	False
DDI-MedLine.d90.s5	(	50	50	O	(	(	(	(	False
DDI-MedLine.d90.s5	mean	51	54	O	mean	ean	mean	NN	False
DDI-MedLine.d90.s5	+/-	56	58	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s5	sem	60	62	O	sem	sem	sem	NN	False
DDI-MedLine.d90.s5	)	63	63	O	)	)	)	)	False
DDI-MedLine.d90.s5	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d90.s5	29	68	69	O	29	29	29	CD	False
DDI-MedLine.d90.s5	+/-	71	73	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s5	4	75	75	O	4	4	4	CD	False
DDI-MedLine.d90.s5	%	76	76	O	%	%	%	NN	False
DDI-MedLine.d90.s5	within	78	83	O	within	hin	thin	IN	False
DDI-MedLine.d90.s5	7.0	85	87	O	7.0	7.0	7.0	CD	False
DDI-MedLine.d90.s5	+/-	89	91	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s5	1.5	93	95	O	1.5	1.5	1.5	CD	False
DDI-MedLine.d90.s5	min	97	99	O	min	min	min	NN	False
DDI-MedLine.d90.s5	(	101	101	O	(	(	(	(	False
DDI-MedLine.d90.s5	P	102	102	O	P	P	P	NN	brand
DDI-MedLine.d90.s5	=	104	104	O	=	=	=	NN	False
DDI-MedLine.d90.s5	0.02	106	109	O	0.02	.02	0.02	CD	False
DDI-MedLine.d90.s5	)	110	110	O	)	)	)	)	False
DDI-MedLine.d90.s5	.	111	111	O	.	.	.	.	False

DDI-MedLine.d90.s6	Twitch	0	5	O	Twitch	tch	itch	NN	False
DDI-MedLine.d90.s6	gradually	7	15	O	gradually	lly	ally	RB	False
DDI-MedLine.d90.s6	returned	17	24	O	returned	ned	rned	VBN	False
DDI-MedLine.d90.s6	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d90.s6	pre-gentamycin	29	42	O	pre-gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s6	strength	44	51	O	strength	gth	ngth	NN	False
DDI-MedLine.d90.s6	over	53	56	O	over	ver	over	IN	False
DDI-MedLine.d90.s6	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d90.s6	course	62	67	O	course	rse	urse	NN	False
DDI-MedLine.d90.s6	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d90.s6	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d90.s6	next	76	79	O	next	ext	next	JJ	False
DDI-MedLine.d90.s6	hour	81	84	O	hour	our	hour	NN	False
DDI-MedLine.d90.s6	.	85	85	O	.	.	.	.	False

DDI-MedLine.d90.s7	Recovery	0	7	O	Recovery	ery	very	NN	False
DDI-MedLine.d90.s7	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d90.s7	hoof	12	15	O	hoof	oof	hoof	NN	False
DDI-MedLine.d90.s7	twitch	17	22	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s7	from	24	27	O	from	rom	from	IN	False
DDI-MedLine.d90.s7	50	29	30	O	50	50	50	CD	False
DDI-MedLine.d90.s7	%	31	31	O	%	%	%	NN	False
DDI-MedLine.d90.s7	to	33	34	O	to	to	to	TO	False
DDI-MedLine.d90.s7	75	36	37	O	75	75	75	CD	False
DDI-MedLine.d90.s7	%	38	38	O	%	%	%	NN	False
DDI-MedLine.d90.s7	took	40	43	O	took	ook	took	VBD	False
DDI-MedLine.d90.s7	7.7	45	47	O	7.7	7.7	7.7	CD	False
DDI-MedLine.d90.s7	+/-	49	51	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s7	0.7	53	55	O	0.7	0.7	0.7	CD	False
DDI-MedLine.d90.s7	min	57	59	O	min	min	min	NN	False
DDI-MedLine.d90.s7	for	61	63	O	for	for	for	IN	False
DDI-MedLine.d90.s7	atracurium	65	74	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s7	alone	76	80	O	alone	one	lone	RB	False
DDI-MedLine.d90.s7	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d90.s7	11.5	86	89	O	11.5	1.5	11.5	CD	False
DDI-MedLine.d90.s7	+/-	91	93	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s7	2.7	95	97	O	2.7	2.7	2.7	CD	False
DDI-MedLine.d90.s7	min	99	101	O	min	min	min	NN	False
DDI-MedLine.d90.s7	for	103	105	O	for	for	for	IN	False
DDI-MedLine.d90.s7	atracurium	107	116	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s7	plus	118	121	O	plus	lus	plus	CC	False
DDI-MedLine.d90.s7	gentamycin	123	132	B-drug	gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s7	(	134	134	O	(	(	(	(	False
DDI-MedLine.d90.s7	P	135	135	O	P	P	P	NN	brand
DDI-MedLine.d90.s7	=	137	137	O	=	=	=	NN	False
DDI-MedLine.d90.s7	0.03	139	142	O	0.03	.03	0.03	CD	False
DDI-MedLine.d90.s7	)	143	143	O	)	)	)	)	False
DDI-MedLine.d90.s7	.	144	144	O	.	.	.	.	False

DDI-MedLine.d90.s8	Recovery	0	7	O	Recovery	ery	very	NN	False
DDI-MedLine.d90.s8	from	9	12	O	from	rom	from	IN	False
DDI-MedLine.d90.s8	50	14	15	O	50	50	50	CD	False
DDI-MedLine.d90.s8	%	16	16	O	%	%	%	NN	False
DDI-MedLine.d90.s8	twitch	18	23	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s8	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d90.s8	75	28	29	O	75	75	75	CD	False
DDI-MedLine.d90.s8	%	30	30	O	%	%	%	NN	False
DDI-MedLine.d90.s8	fade	32	35	O	fade	ade	fade	NN	False
DDI-MedLine.d90.s8	recovery	37	44	O	recovery	ery	very	NN	False
DDI-MedLine.d90.s8	took	46	49	O	took	ook	took	VBD	False
DDI-MedLine.d90.s8	13.8	51	54	O	13.8	3.8	13.8	CD	False
DDI-MedLine.d90.s8	+/-	56	58	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s8	0.8	60	62	O	0.8	0.8	0.8	CD	False
DDI-MedLine.d90.s8	min	64	66	O	min	min	min	NN	False
DDI-MedLine.d90.s8	for	68	70	O	for	for	for	IN	False
DDI-MedLine.d90.s8	atracurium	72	81	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s8	alone	83	87	O	alone	one	lone	RB	False
DDI-MedLine.d90.s8	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d90.s8	13.7	93	96	O	13.7	3.7	13.7	CD	False
DDI-MedLine.d90.s8	+/-	98	100	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s8	1.2	102	104	O	1.2	1.2	1.2	CD	False
DDI-MedLine.d90.s8	min	106	108	O	min	min	min	NN	False
DDI-MedLine.d90.s8	for	110	112	O	for	for	for	IN	False
DDI-MedLine.d90.s8	atracurium	114	123	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s8	plus	125	128	O	plus	lus	plus	CC	False
DDI-MedLine.d90.s8	gentamycin	130	139	B-drug	gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s8	.	140	140	O	.	.	.	.	False

DDI-MedLine.d90.s9	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d90.s9	75	3	4	O	75	75	75	CD	False
DDI-MedLine.d90.s9	%	5	5	O	%	%	%	NN	False
DDI-MedLine.d90.s9	recovery	7	14	O	recovery	ery	very	NN	False
DDI-MedLine.d90.s9	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d90.s9	fade	19	22	O	fade	ade	fade	NN	False
DDI-MedLine.d90.s9	,	23	23	O	,	,	,	,	False
DDI-MedLine.d90.s9	hoof	25	28	O	hoof	oof	hoof	NN	False
DDI-MedLine.d90.s9	twitch	30	35	O	twitch	tch	itch	NN	False
DDI-MedLine.d90.s9	was	37	39	O	was	was	was	VBD	False
DDI-MedLine.d90.s9	87	41	42	O	87	87	87	CD	False
DDI-MedLine.d90.s9	+/-	44	46	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s9	3	48	48	O	3	3	3	CD	False
DDI-MedLine.d90.s9	%	49	49	O	%	%	%	NN	False
DDI-MedLine.d90.s9	for	51	53	O	for	for	for	IN	False
DDI-MedLine.d90.s9	atracurium	55	64	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s9	alone	66	70	O	alone	one	lone	RB	False
DDI-MedLine.d90.s9	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d90.s9	82	76	77	O	82	82	82	CD	False
DDI-MedLine.d90.s9	+/-	79	81	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d90.s9	4	83	83	O	4	4	4	CD	False
DDI-MedLine.d90.s9	%	84	84	O	%	%	%	NN	False
DDI-MedLine.d90.s9	for	86	88	O	for	for	for	IN	False
DDI-MedLine.d90.s9	atracurium	90	99	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s9	plus	101	104	O	plus	lus	plus	CC	False
DDI-MedLine.d90.s9	gentamycin	106	115	B-drug	gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s9	.	116	116	O	.	.	.	.	False

DDI-MedLine.d90.s10	Reversal	0	7	O	Reversal	sal	rsal	NN	False
DDI-MedLine.d90.s10	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d90.s10	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d90.s10	block	16	20	O	block	ock	lock	NN	False
DDI-MedLine.d90.s10	with	22	25	O	with	ith	with	IN	False
DDI-MedLine.d90.s10	edrophonium	27	37	B-drug	edrophonium	ium	nium	NN	drug
DDI-MedLine.d90.s10	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d90.s10	subsequent	43	52	O	subsequent	ent	uent	NN	False
DDI-MedLine.d90.s10	recovery	54	61	O	recovery	ery	very	NN	False
DDI-MedLine.d90.s10	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d90.s10	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d90.s10	horses	70	75	O	horses	ses	rses	NNS	False
DDI-MedLine.d90.s10	from	77	80	O	from	rom	from	IN	False
DDI-MedLine.d90.s10	anaesthesia	82	92	O	anaesthesia	sia	esia	NN	False
DDI-MedLine.d90.s10	were	94	97	O	were	ere	were	VBD	False
DDI-MedLine.d90.s10	uneventful	99	108	O	uneventful	ful	tful	JJ	False
DDI-MedLine.d90.s10	.	109	109	O	.	.	.	.	False

DDI-MedLine.d90.s11	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d90.s11	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d90.s11	concluded	7	15	O	concluded	ded	uded	VBD	False
DDI-MedLine.d90.s11	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d90.s11	,	21	21	O	,	,	,	,	False
DDI-MedLine.d90.s11	although	23	30	O	although	ugh	ough	IN	False
DDI-MedLine.d90.s11	gentamycin	32	41	B-drug	gentamycin	cin	ycin	NN	drug
DDI-MedLine.d90.s11	did	43	45	O	did	did	did	VBD	False
DDI-MedLine.d90.s11	augment	47	53	O	augment	ent	ment	NN	False
DDI-MedLine.d90.s11	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d90.s11	neuromuscular	59	71	O	neuromuscular	lar	ular	JJ	False
DDI-MedLine.d90.s11	blockade	73	80	O	blockade	ade	kade	NN	False
DDI-MedLine.d90.s11	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d90.s11	atracurium	85	94	B-drug	atracurium	ium	rium	NN	drug
DDI-MedLine.d90.s11	,	95	95	O	,	,	,	,	False
DDI-MedLine.d90.s11	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d90.s11	effect	101	106	O	effect	ect	fect	NN	False
DDI-MedLine.d90.s11	was	108	110	O	was	was	was	VBD	False
DDI-MedLine.d90.s11	minimal	112	118	O	minimal	mal	imal	NN	False
DDI-MedLine.d90.s11	.	119	119	O	.	.	.	.	False

DDI-MedLine.d85.s0	Misonidazole	0	11	B-drug_n	Misonidazole	ole	zole	NN	drug
DDI-MedLine.d85.s0	protects	13	20	O	protects	cts	ects	NNS	False
DDI-MedLine.d85.s0	mouse	22	26	O	mouse	use	ouse	NN	False
DDI-MedLine.d85.s0	tumour	28	33	O	tumour	our	mour	NN	False
DDI-MedLine.d85.s0	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d85.s0	normal	39	44	O	normal	mal	rmal	JJ	False
DDI-MedLine.d85.s0	tissues	46	52	O	tissues	ues	sues	NNS	False
DDI-MedLine.d85.s0	from	54	57	O	from	rom	from	IN	False
DDI-MedLine.d85.s0	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d85.s0	toxicity	63	70	O	toxicity	ity	city	NN	False
DDI-MedLine.d85.s0	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d85.s0	oral	75	78	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s0	CCNU	80	83	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s0	.	84	84	O	.	.	.	.	False

DDI-MedLine.d85.s1	Because	0	6	O	Because	use	ause	IN	False
DDI-MedLine.d85.s1	the	8	10	O	the	the	the	DT	False
DDI-MedLine.d85.s1	nitrosourea	12	22	B-group	nitrosourea	rea	urea	NN	False
DDI-MedLine.d85.s1	CCNU	24	27	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s1	is	29	30	O	is	is	is	VBZ	False
DDI-MedLine.d85.s1	given	32	36	O	given	ven	iven	VBN	False
DDI-MedLine.d85.s1	exclusively	38	48	O	exclusively	ely	vely	RB	False
DDI-MedLine.d85.s1	by	50	51	O	by	by	by	IN	False
DDI-MedLine.d85.s1	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d85.s1	oral	57	60	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s1	route	62	66	O	route	ute	oute	NN	False
DDI-MedLine.d85.s1	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d85.s1	man	71	73	O	man	man	man	NN	False
DDI-MedLine.d85.s1	,	74	74	O	,	,	,	,	False
DDI-MedLine.d85.s1	we	76	77	O	we	we	we	PRP	False
DDI-MedLine.d85.s1	have	79	82	O	have	ave	have	VB	False
DDI-MedLine.d85.s1	carried	84	90	O	carried	ied	ried	VBN	False
DDI-MedLine.d85.s1	out	92	94	O	out	out	out	IN	False
DDI-MedLine.d85.s1	studies	96	102	O	studies	ies	dies	NNS	False
DDI-MedLine.d85.s1	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d85.s1	mice	107	110	O	mice	ice	mice	NN	False
DDI-MedLine.d85.s1	on	112	113	O	on	on	on	IN	False
DDI-MedLine.d85.s1	the	115	117	O	the	the	the	DT	False
DDI-MedLine.d85.s1	antitumour	119	128	O	antitumour	our	mour	NN	False
DDI-MedLine.d85.s1	activity	130	137	O	activity	ity	vity	NN	False
DDI-MedLine.d85.s1	,	138	138	O	,	,	,	,	False
DDI-MedLine.d85.s1	acute	140	144	O	acute	ute	cute	NN	False
DDI-MedLine.d85.s1	toxicity	146	153	O	toxicity	ity	city	NN	False
DDI-MedLine.d85.s1	and	155	157	O	and	and	and	CC	False
DDI-MedLine.d85.s1	pharmacokinetics	159	174	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d85.s1	of	176	177	O	of	of	of	IN	False
DDI-MedLine.d85.s1	oral	179	182	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s1	CCNU	184	187	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s1	,	188	188	O	,	,	,	,	False
DDI-MedLine.d85.s1	either	190	195	O	either	her	ther	DT	False
DDI-MedLine.d85.s1	alone	197	201	O	alone	one	lone	RB	False
DDI-MedLine.d85.s1	or	203	204	O	or	or	or	CC	False
DDI-MedLine.d85.s1	in	206	207	O	in	in	in	IN	False
DDI-MedLine.d85.s1	combination	209	219	O	combination	ion	tion	NN	False
DDI-MedLine.d85.s1	with	221	224	O	with	ith	with	IN	False
DDI-MedLine.d85.s1	the	226	228	O	the	the	the	DT	False
DDI-MedLine.d85.s1	chemosensitizer	230	244	O	chemosensitizer	zer	izer	NN	False
DDI-MedLine.d85.s1	misonidazole	246	257	B-drug_n	misonidazole	ole	zole	NN	drug
DDI-MedLine.d85.s1	.	258	258	O	.	.	.	.	False

DDI-MedLine.d85.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d85.s2	both	3	6	O	both	oth	both	DT	False
DDI-MedLine.d85.s2	plasma	8	13	O	plasma	sma	asma	NN	False
DDI-MedLine.d85.s2	and	15	17	O	and	and	and	CC	False
DDI-MedLine.d85.s2	KHT	19	21	O	KHT	KHT	KHT	NNP	brand
DDI-MedLine.d85.s2	tumour	23	28	O	tumour	our	mour	NN	False
DDI-MedLine.d85.s2	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d85.s2	peak	34	37	O	peak	eak	peak	NN	False
DDI-MedLine.d85.s2	concentration	39	51	O	concentration	ion	tion	NN	False
DDI-MedLine.d85.s2	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d85.s2	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d85.s2	early	58	62	O	early	rly	arly	RB	False
DDI-MedLine.d85.s2	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d85.s3	AUC	0	2	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d85.s3	for	4	6	O	for	for	for	IN	False
DDI-MedLine.d85.s3	total	8	12	O	total	tal	otal	JJ	False
DDI-MedLine.d85.s3	nitrosoureas	14	25	B-group	nitrosoureas	eas	reas	NNS	False
DDI-MedLine.d85.s3	were	27	30	O	were	ere	were	VBD	False
DDI-MedLine.d85.s3	about	32	36	O	about	out	bout	IN	False
DDI-MedLine.d85.s3	1.4-1.5	38	44	O	1.4-1.5	1.5	-1.5	JJ	False
DDI-MedLine.d85.s3	fold	46	49	O	fold	old	fold	NN	False
DDI-MedLine.d85.s3	greater	51	57	O	greater	ter	ater	JJR	False
DDI-MedLine.d85.s3	for	59	61	O	for	for	for	IN	False
DDI-MedLine.d85.s3	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d85.s3	oral	67	70	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s3	compared	72	79	O	compared	red	ared	VBN	False
DDI-MedLine.d85.s3	to	81	82	O	to	to	to	TO	False
DDI-MedLine.d85.s3	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d85.s3	i.p	88	90	O	i.p	i.p	i.p	NN	False
DDI-MedLine.d85.s3	.	91	91	O	.	.	.	.	False

DDI-MedLine.d85.s4	route	0	4	O	route	ute	oute	NN	False
DDI-MedLine.d85.s4	.	5	5	O	.	.	.	.	False

DDI-MedLine.d85.s5	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d85.s5	differences	6	16	O	differences	ces	nces	NNS	False
DDI-MedLine.d85.s5	were	18	21	O	were	ere	were	VBD	False
DDI-MedLine.d85.s5	reflected	23	31	O	reflected	ted	cted	VBN	False
DDI-MedLine.d85.s5	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d85.s5	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d85.s5	roughly	40	46	O	roughly	hly	ghly	RB	False
DDI-MedLine.d85.s5	twofold	48	54	O	twofold	old	fold	NN	False
DDI-MedLine.d85.s5	greater	56	62	O	greater	ter	ater	JJR	False
DDI-MedLine.d85.s5	antitumour	64	73	O	antitumour	our	mour	NN	False
DDI-MedLine.d85.s5	activity	75	82	O	activity	ity	vity	NN	False
DDI-MedLine.d85.s5	for	84	86	O	for	for	for	IN	False
DDI-MedLine.d85.s5	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d85.s5	oral	92	95	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s5	route	97	101	O	route	ute	oute	NN	False
DDI-MedLine.d85.s5	.	102	102	O	.	.	.	.	False

DDI-MedLine.d85.s6	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d85.s6	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d85.s6	,	11	11	O	,	,	,	,	False
DDI-MedLine.d85.s6	acute	13	17	O	acute	ute	cute	NN	False
DDI-MedLine.d85.s6	toxicity	19	26	O	toxicity	ity	city	NN	False
DDI-MedLine.d85.s6	tests	28	32	O	tests	sts	ests	NNS	False
DDI-MedLine.d85.s6	showed	34	39	O	showed	wed	owed	VBD	False
DDI-MedLine.d85.s6	that	41	44	O	that	hat	that	IN	False
DDI-MedLine.d85.s6	oral	46	49	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s6	CCNU	51	54	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s6	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d85.s6	1.45	60	63	O	1.45	.45	1.45	CD	False
DDI-MedLine.d85.s6	times	65	69	O	times	mes	imes	NNS	False
DDI-MedLine.d85.s6	less	71	74	O	less	ess	less	RBR	False
DDI-MedLine.d85.s6	toxic	76	80	O	toxic	xic	oxic	NN	False
DDI-MedLine.d85.s6	to	82	83	O	to	to	to	TO	False
DDI-MedLine.d85.s6	normal	85	90	O	normal	mal	rmal	JJ	False
DDI-MedLine.d85.s6	tissue	92	97	O	tissue	sue	ssue	NN	False
DDI-MedLine.d85.s6	,	98	98	O	,	,	,	,	False
DDI-MedLine.d85.s6	although	100	107	O	although	ugh	ough	IN	False
DDI-MedLine.d85.s6	the	109	111	O	the	the	the	DT	False
DDI-MedLine.d85.s6	dose-limiting	113	125	O	dose-limiting	ing	ting	NN	False
DDI-MedLine.d85.s6	organ	127	131	O	organ	gan	rgan	NN	False
DDI-MedLine.d85.s6	may	133	135	O	may	may	may	MD	False
DDI-MedLine.d85.s6	be	137	138	O	be	be	be	VB	False
DDI-MedLine.d85.s6	different	140	148	O	different	ent	rent	JJ	False
DDI-MedLine.d85.s6	for	150	152	O	for	for	for	IN	False
DDI-MedLine.d85.s6	the	154	156	O	the	the	the	DT	False
DDI-MedLine.d85.s6	two	158	160	O	two	two	two	CD	False
DDI-MedLine.d85.s6	routes	162	167	O	routes	tes	utes	NNS	False
DDI-MedLine.d85.s6	.	168	168	O	.	.	.	.	False

DDI-MedLine.d85.s7	Misonidazole	0	11	B-drug_n	Misonidazole	ole	zole	NN	drug
DDI-MedLine.d85.s7	reduced	13	19	O	reduced	ced	uced	VBN	False
DDI-MedLine.d85.s7	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d85.s7	antitumour	25	34	O	antitumour	our	mour	NN	False
DDI-MedLine.d85.s7	activity	36	43	O	activity	ity	vity	NN	False
DDI-MedLine.d85.s7	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d85.s7	oral	48	51	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s7	CCNU	53	56	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s7	by	58	59	O	by	by	by	IN	False
DDI-MedLine.d85.s7	dose	61	64	O	dose	ose	dose	NN	False
DDI-MedLine.d85.s7	modifying	66	74	O	modifying	ing	ying	VBG	False
DDI-MedLine.d85.s7	factors	76	82	O	factors	ors	tors	NNS	False
DDI-MedLine.d85.s7	(	84	84	O	(	(	(	(	False
DDI-MedLine.d85.s7	DMF	85	87	O	DMF	DMF	DMF	NN	brand
DDI-MedLine.d85.s7	)	88	88	O	)	)	)	)	False
DDI-MedLine.d85.s7	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d85.s7	0.58-0.71	93	101	O	0.58-0.71	.71	0.71	NN	False
DDI-MedLine.d85.s7	.	102	102	O	.	.	.	.	False

DDI-MedLine.d85.s8	Similarly	0	8	O	Similarly	rly	arly	RB	False
DDI-MedLine.d85.s8	,	9	9	O	,	,	,	,	False
DDI-MedLine.d85.s8	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d85.s8	acute	15	19	O	acute	ute	cute	NN	False
DDI-MedLine.d85.s8	toxicity	21	28	O	toxicity	ity	city	NN	False
DDI-MedLine.d85.s8	was	30	32	O	was	was	was	VBD	False
DDI-MedLine.d85.s8	also	34	37	O	also	lso	also	RB	False
DDI-MedLine.d85.s8	diminished	39	48	O	diminished	hed	shed	VBN	False
DDI-MedLine.d85.s8	by	50	51	O	by	by	by	IN	False
DDI-MedLine.d85.s8	a	53	53	O	a	a	a	DT	False
DDI-MedLine.d85.s8	DMF	55	57	O	DMF	DMF	DMF	NN	brand
DDI-MedLine.d85.s8	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d85.s8	0.74	62	65	O	0.74	.74	0.74	CD	False
DDI-MedLine.d85.s8	.	66	66	O	.	.	.	.	False

DDI-MedLine.d85.s9	Misonidazole	0	11	B-drug_n	Misonidazole	ole	zole	NN	drug
DDI-MedLine.d85.s9	has	13	15	O	has	has	has	VBZ	False
DDI-MedLine.d85.s9	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d85.s9	complex	19	25	O	complex	lex	plex	JJ	False
DDI-MedLine.d85.s9	effect	27	32	O	effect	ect	fect	NN	False
DDI-MedLine.d85.s9	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d85.s9	oral	37	40	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s9	CCNU	42	45	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s9	pharmacokinetics	47	62	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d85.s9	.	63	63	O	.	.	.	.	False

DDI-MedLine.d85.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d85.s10	plasma	4	9	O	plasma	sma	asma	NN	False
DDI-MedLine.d85.s10	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d85.s10	tumour	15	20	O	tumour	our	mour	NN	False
DDI-MedLine.d85.s10	total	22	26	O	total	tal	otal	JJ	False
DDI-MedLine.d85.s10	nitrosourea	28	38	B-group	nitrosourea	rea	urea	NN	False
DDI-MedLine.d85.s10	peak	40	43	O	peak	eak	peak	NN	False
DDI-MedLine.d85.s10	concentrations	45	58	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d85.s10	were	60	63	O	were	ere	were	VBD	False
DDI-MedLine.d85.s10	reduced	65	71	O	reduced	ced	uced	VBN	False
DDI-MedLine.d85.s10	by	73	74	O	by	by	by	IN	False
DDI-MedLine.d85.s10	1.5	76	78	O	1.5	1.5	1.5	CD	False
DDI-MedLine.d85.s10	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d85.s10	1.7	84	86	O	1.7	1.7	1.7	CD	False
DDI-MedLine.d85.s10	fold	88	91	O	fold	old	fold	NN	False
DDI-MedLine.d85.s10	respectively	93	104	O	respectively	ely	vely	RB	False
DDI-MedLine.d85.s10	.	105	105	O	.	.	.	.	False

DDI-MedLine.d85.s11	Misonidazole	0	11	B-drug_n	Misonidazole	ole	zole	NN	drug
DDI-MedLine.d85.s11	also	13	16	O	also	lso	also	RB	False
DDI-MedLine.d85.s11	reduced	18	24	O	reduced	ced	uced	VBN	False
DDI-MedLine.d85.s11	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d85.s11	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d85.s11	early	31	35	O	early	rly	arly	RB	False
DDI-MedLine.d85.s11	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d85.s12	nitrosourea	0	10	B-group	nitrosourea	rea	urea	NN	False
DDI-MedLine.d85.s12	AUC	12	14	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d85.s12	,	15	15	O	,	,	,	,	False
DDI-MedLine.d85.s12	with	17	20	O	with	ith	with	IN	False
DDI-MedLine.d85.s12	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d85.s12	extent	26	31	O	extent	ent	tent	NN	False
DDI-MedLine.d85.s12	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d85.s12	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d85.s12	reduction	40	48	O	reduction	ion	tion	NN	False
DDI-MedLine.d85.s12	depending	50	58	O	depending	ing	ding	VBG	False
DDI-MedLine.d85.s12	on	60	61	O	on	on	on	IN	False
DDI-MedLine.d85.s12	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d85.s12	minimum	67	73	O	minimum	mum	imum	NN	False
DDI-MedLine.d85.s12	effective	75	83	O	effective	ive	tive	JJ	False
DDI-MedLine.d85.s12	concentration	85	97	O	concentration	ion	tion	NN	False
DDI-MedLine.d85.s12	(	99	99	O	(	(	(	(	False
DDI-MedLine.d85.s12	MEC	100	102	O	MEC	MEC	MEC	NN	brand
DDI-MedLine.d85.s12	)	103	103	O	)	)	)	)	False
DDI-MedLine.d85.s12	chosen	105	110	O	chosen	sen	osen	NN	False
DDI-MedLine.d85.s12	.	111	111	O	.	.	.	.	False

DDI-MedLine.d85.s13	For	0	2	O	For	For	For	IN	False
DDI-MedLine.d85.s13	example	4	10	O	example	ple	mple	NN	False
DDI-MedLine.d85.s13	,	11	11	O	,	,	,	,	False
DDI-MedLine.d85.s13	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d85.s13	plasma	17	22	O	plasma	sma	asma	NN	False
DDI-MedLine.d85.s13	nitrosourea	24	34	B-group	nitrosourea	rea	urea	NN	False
DDI-MedLine.d85.s13	AUC	36	38	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d85.s13	was	40	42	O	was	was	was	VBD	False
DDI-MedLine.d85.s13	reduced	44	50	O	reduced	ced	uced	VBN	False
DDI-MedLine.d85.s13	by	52	53	O	by	by	by	IN	False
DDI-MedLine.d85.s13	factors	55	61	O	factors	ors	tors	NNS	False
DDI-MedLine.d85.s13	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d85.s13	1.05	66	69	O	1.05	.05	1.05	CD	False
DDI-MedLine.d85.s13	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d85.s13	9.6	75	77	O	9.6	9.6	9.6	CD	False
DDI-MedLine.d85.s13	for	79	81	O	for	for	for	IN	False
DDI-MedLine.d85.s13	MEC	83	85	O	MEC	MEC	MEC	NN	brand
DDI-MedLine.d85.s13	values	87	92	O	values	ues	lues	NNS	False
DDI-MedLine.d85.s13	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d85.s13	1	97	97	O	1	1	1	CD	False
DDI-MedLine.d85.s13	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d85.s13	2	103	103	O	2	2	2	CD	False
DDI-MedLine.d85.s13	micrograms	105	114	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d85.s13	ml-1	116	119	O	ml-1	l-1	ml-1	NN	False
DDI-MedLine.d85.s13	respectively	121	132	O	respectively	ely	vely	RB	False
DDI-MedLine.d85.s13	.	133	133	O	.	.	.	.	False

DDI-MedLine.d85.s14	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d85.s14	propose	3	9	O	propose	ose	pose	NN	False
DDI-MedLine.d85.s14	these	11	15	O	these	ese	hese	DT	False
DDI-MedLine.d85.s14	pharmacokinetic	17	31	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d85.s14	changes	33	39	O	changes	ges	nges	NNS	False
DDI-MedLine.d85.s14	to	41	42	O	to	to	to	TO	False
DDI-MedLine.d85.s14	be	44	45	O	be	be	be	VB	False
DDI-MedLine.d85.s14	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d85.s14	underlying	51	60	O	underlying	ing	ying	VBG	False
DDI-MedLine.d85.s14	mechanism	62	70	O	mechanism	ism	nism	NN	False
DDI-MedLine.d85.s14	for	72	74	O	for	for	for	IN	False
DDI-MedLine.d85.s14	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d85.s14	reduction	80	88	O	reduction	ion	tion	NN	False
DDI-MedLine.d85.s14	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d85.s14	oral	93	96	O	oral	ral	oral	JJ	False
DDI-MedLine.d85.s14	CCNU	98	101	B-drug	CCNU	CNU	CCNU	NN	brand
DDI-MedLine.d85.s14	cytotoxicity	103	114	O	cytotoxicity	ity	city	NN	False
DDI-MedLine.d85.s14	by	116	117	O	by	by	by	IN	False
DDI-MedLine.d85.s14	misonidazole	119	130	B-drug_n	misonidazole	ole	zole	NN	drug
DDI-MedLine.d85.s14	.	131	131	O	.	.	.	.	False

DDI-MedLine.d85.s15	Clinical	0	7	O	Clinical	cal	ical	JJ	False
DDI-MedLine.d85.s15	trials	9	14	O	trials	als	ials	NNS	False
DDI-MedLine.d85.s15	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d85.s15	such	19	22	O	such	uch	such	JJ	False
DDI-MedLine.d85.s15	combinations	24	35	O	combinations	ons	ions	NNS	False
DDI-MedLine.d85.s15	should	37	42	O	should	uld	ould	MD	False
DDI-MedLine.d85.s15	be	44	45	O	be	be	be	VB	False
DDI-MedLine.d85.s15	accompanied	47	57	O	accompanied	ied	nied	VBN	False
DDI-MedLine.d85.s15	by	59	60	O	by	by	by	IN	False
DDI-MedLine.d85.s15	detailed	62	69	O	detailed	led	iled	JJ	False
DDI-MedLine.d85.s15	pharmacokinetic	71	85	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d85.s15	evaluation	87	96	O	evaluation	ion	tion	NN	False
DDI-MedLine.d85.s15	.	97	97	O	.	.	.	.	False

DDI-MedLine.d65.s0	Drug	0	3	O	Drug	rug	Drug	NN	False
DDI-MedLine.d65.s0	interactions	5	16	O	interactions	ons	ions	NNS	False
DDI-MedLine.d65.s0	:	17	17	O	:	:	:	:	False
DDI-MedLine.d65.s0	How	19	21	O	How	How	How	WRB	False
DDI-MedLine.d65.s0	to	23	24	O	to	to	to	TO	False
DDI-MedLine.d65.s0	identify	26	33	O	identify	ify	tify	VB	False
DDI-MedLine.d65.s0	them	35	38	O	them	hem	them	PRP	False
DDI-MedLine.d65.s0	.	39	39	O	.	.	.	.	False

DDI-MedLine.d65.s1	Interactions	0	11	O	Interactions	ons	ions	NNS	False
DDI-MedLine.d65.s1	between	13	19	O	between	een	ween	IN	False
DDI-MedLine.d65.s1	theraputic	21	30	O	theraputic	tic	utic	JJ	False
DDI-MedLine.d65.s1	agents	32	37	O	agents	nts	ents	NNS	False
DDI-MedLine.d65.s1	have	39	42	O	have	ave	have	VB	False
DDI-MedLine.d65.s1	been	44	47	O	been	een	been	VBN	False
DDI-MedLine.d65.s1	recognized	49	58	O	recognized	zed	ized	VBN	False
DDI-MedLine.d65.s1	as	60	61	O	as	as	as	IN	False
DDI-MedLine.d65.s1	increasingly	63	74	O	increasingly	gly	ngly	RB	False
DDI-MedLine.d65.s1	important	76	84	O	important	ant	tant	JJ	False
DDI-MedLine.d65.s1	causes	86	91	O	causes	ses	uses	NNS	False
DDI-MedLine.d65.s1	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d65.s1	drug	96	99	O	drug	rug	drug	NN	False
DDI-MedLine.d65.s1	at	101	102	O	at	at	at	IN	False
DDI-MedLine.d65.s1	their	104	108	O	their	eir	heir	PRP$	False
DDI-MedLine.d65.s1	usual	110	114	O	usual	ual	sual	JJ	False
DDI-MedLine.d65.s1	recommended	116	126	O	recommended	ded	nded	VBN	False
DDI-MedLine.d65.s1	dose	128	131	O	dose	ose	dose	NN	False
DDI-MedLine.d65.s1	may	133	135	O	may	may	may	MD	False
DDI-MedLine.d65.s1	,	136	136	O	,	,	,	,	False
DDI-MedLine.d65.s1	under	138	142	O	under	der	nder	IN	False
DDI-MedLine.d65.s1	certain	144	150	O	certain	ain	tain	JJ	False
DDI-MedLine.d65.s1	conditions	152	161	O	conditions	ons	ions	NNS	False
DDI-MedLine.d65.s1	,	162	162	O	,	,	,	,	False
DDI-MedLine.d65.s1	produce	164	170	O	produce	uce	duce	NN	False
DDI-MedLine.d65.s1	toxicity	172	179	O	toxicity	ity	city	NN	False
DDI-MedLine.d65.s1	of	181	182	O	of	of	of	IN	False
DDI-MedLine.d65.s1	life-endangering	184	199	O	life-endangering	ing	ring	NN	False
DDI-MedLine.d65.s1	proportions	201	211	O	proportions	ons	ions	NNS	False
DDI-MedLine.d65.s1	.	212	212	O	.	.	.	.	False

DDI-MedLine.d65.s2	While	0	4	O	While	ile	hile	IN	False
DDI-MedLine.d65.s2	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d65.s2	recognition	10	20	O	recognition	ion	tion	NN	False
DDI-MedLine.d65.s2	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d65.s2	drug	25	28	O	drug	rug	drug	NN	False
DDI-MedLine.d65.s2	toxicity	30	37	O	toxicity	ity	city	NN	False
DDI-MedLine.d65.s2	resulting	39	47	O	resulting	ing	ting	VBG	False
DDI-MedLine.d65.s2	from	49	52	O	from	rom	from	IN	False
DDI-MedLine.d65.s2	interactions	54	65	O	interactions	ons	ions	NNS	False
DDI-MedLine.d65.s2	is	67	68	O	is	is	is	VBZ	False
DDI-MedLine.d65.s2	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d65.s2	importance	73	82	O	importance	nce	ance	NN	False
DDI-MedLine.d65.s2	to	84	85	O	to	to	to	TO	False
DDI-MedLine.d65.s2	all	87	89	O	all	all	all	DT	False
DDI-MedLine.d65.s2	physciains	91	100	O	physciains	ins	ains	NNS	False
DDI-MedLine.d65.s2	,	101	101	O	,	,	,	,	False
DDI-MedLine.d65.s2	it	103	104	O	it	it	it	PRP	False
DDI-MedLine.d65.s2	is	106	107	O	is	is	is	VBZ	False
DDI-MedLine.d65.s2	especially	109	118	O	especially	lly	ally	RB	False
DDI-MedLine.d65.s2	so	120	121	O	so	so	so	RB	False
DDI-MedLine.d65.s2	for	123	125	O	for	for	for	IN	False
DDI-MedLine.d65.s2	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d65.s2	clinician	131	139	O	clinician	ian	cian	NN	False
DDI-MedLine.d65.s2	responsible	141	151	O	responsible	ble	ible	JJ	False
DDI-MedLine.d65.s2	for	153	155	O	for	for	for	IN	False
DDI-MedLine.d65.s2	the	157	159	O	the	the	the	DT	False
DDI-MedLine.d65.s2	welfare	161	167	O	welfare	are	fare	NN	False
DDI-MedLine.d65.s2	of	169	170	O	of	of	of	IN	False
DDI-MedLine.d65.s2	those	172	176	O	those	ose	hose	DT	False
DDI-MedLine.d65.s2	in	178	179	O	in	in	in	IN	False
DDI-MedLine.d65.s2	the	181	183	O	the	the	the	DT	False
DDI-MedLine.d65.s2	aerospace	185	193	O	aerospace	ace	pace	NN	False
DDI-MedLine.d65.s2	environment	195	205	O	environment	ent	ment	NN	False
DDI-MedLine.d65.s2	.	206	206	O	.	.	.	.	False

DDI-MedLine.d65.s3	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d65.s3	paper	5	9	O	paper	per	aper	NN	False
DDI-MedLine.d65.s3	attempts	11	18	O	attempts	pts	mpts	NNS	False
DDI-MedLine.d65.s3	to	20	21	O	to	to	to	TO	False
DDI-MedLine.d65.s3	provide	23	29	O	provide	ide	vide	NN	False
DDI-MedLine.d65.s3	a	31	31	O	a	a	a	DT	False
DDI-MedLine.d65.s3	basis	33	37	O	basis	sis	asis	NN	False
DDI-MedLine.d65.s3	for	39	41	O	for	for	for	IN	False
DDI-MedLine.d65.s3	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d65.s3	understanding	47	59	O	understanding	ing	ding	VBG	False
DDI-MedLine.d65.s3	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d65.s3	identifications	65	79	O	identifications	ons	ions	NNS	False
DDI-MedLine.d65.s3	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d65.s3	important	84	92	O	important	ant	tant	JJ	False
DDI-MedLine.d65.s3	drug	94	97	O	drug	rug	drug	NN	False
DDI-MedLine.d65.s3	interactions	99	110	O	interactions	ons	ions	NNS	False
DDI-MedLine.d65.s3	.	111	111	O	.	.	.	.	False

DDI-MedLine.d65.s4	Guidelines	0	9	O	Guidelines	nes	ines	NNS	group
DDI-MedLine.d65.s4	are	11	13	O	are	are	are	VBP	False
DDI-MedLine.d65.s4	provided	15	22	O	provided	ded	ided	VBN	False
DDI-MedLine.d65.s4	to	24	25	O	to	to	to	TO	False
DDI-MedLine.d65.s4	assist	27	32	O	assist	ist	sist	NN	False
DDI-MedLine.d65.s4	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d65.s4	clinician	38	46	O	clinician	ian	cian	NN	False
DDI-MedLine.d65.s4	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d65.s4	his	51	53	O	his	his	his	PRP$	False
DDI-MedLine.d65.s4	logical	55	61	O	logical	cal	ical	JJ	False
DDI-MedLine.d65.s4	approach	63	70	O	approach	ach	oach	NN	False
DDI-MedLine.d65.s4	to	72	73	O	to	to	to	TO	False
DDI-MedLine.d65.s4	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d65.s4	identification	79	92	O	identification	ion	tion	NN	False
DDI-MedLine.d65.s4	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d65.s4	drug	97	100	O	drug	rug	drug	NN	False
DDI-MedLine.d65.s4	interactions	102	113	O	interactions	ons	ions	NNS	False
DDI-MedLine.d65.s4	when	115	118	O	when	hen	when	WRB	False
DDI-MedLine.d65.s4	serious	120	126	O	serious	ous	ious	JJ	False
DDI-MedLine.d65.s4	drug	128	131	O	drug	rug	drug	NN	False
DDI-MedLine.d65.s4	toxicity	133	140	O	toxicity	ity	city	NN	False
DDI-MedLine.d65.s4	is	142	143	O	is	is	is	VBZ	False
DDI-MedLine.d65.s4	encountered	145	155	O	encountered	red	ered	VBN	False
DDI-MedLine.d65.s4	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d65.s4	a	160	160	O	a	a	a	DT	False
DDI-MedLine.d65.s4	pateint	162	168	O	pateint	int	eint	NN	False
DDI-MedLine.d65.s4	.	169	169	O	.	.	.	.	False

DDI-MedLine.d65.s5	Only	0	3	O	Only	nly	Only	RB	False
DDI-MedLine.d65.s5	with	5	8	O	with	ith	with	IN	False
DDI-MedLine.d65.s5	knowledge	10	18	O	knowledge	dge	edge	NN	False
DDI-MedLine.d65.s5	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d65.s5	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d65.s5	interaction	27	37	O	interaction	ion	tion	NN	False
DDI-MedLine.d65.s5	can	39	41	O	can	can	can	MD	False
DDI-MedLine.d65.s5	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d65.s5	therapeutic	47	57	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d65.s5	regimen	59	65	O	regimen	men	imen	NNS	False
DDI-MedLine.d65.s5	be	67	68	O	be	be	be	VB	False
DDI-MedLine.d65.s5	altered	70	76	O	altered	red	ered	VBN	False
DDI-MedLine.d65.s5	so	78	79	O	so	so	so	RB	False
DDI-MedLine.d65.s5	as	81	82	O	as	as	as	IN	False
DDI-MedLine.d65.s5	to	84	85	O	to	to	to	TO	False
DDI-MedLine.d65.s5	provide	87	93	O	provide	ide	vide	NN	False
DDI-MedLine.d65.s5	therapeutic	95	105	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d65.s5	levels	107	112	O	levels	els	vels	NNS	False
DDI-MedLine.d65.s5	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d65.s5	necessary	117	125	O	necessary	ary	sary	JJ	False
DDI-MedLine.d65.s5	drugs	127	131	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d65.s5	while	133	137	O	while	ile	hile	IN	False
DDI-MedLine.d65.s5	avoiding	139	146	O	avoiding	ing	ding	VBG	False
DDI-MedLine.d65.s5	toxicity	148	155	O	toxicity	ity	city	NN	False
DDI-MedLine.d65.s5	.	156	156	O	.	.	.	.	False

DDI-MedLine.d83.s0	Olanzapine	0	9	B-drug	Olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s0	:	10	10	O	:	:	:	:	False
DDI-MedLine.d83.s0	an	12	13	O	an	an	an	DT	False
DDI-MedLine.d83.s0	updated	15	21	O	updated	ted	ated	VBN	False
DDI-MedLine.d83.s0	review	23	28	O	review	iew	view	NN	False
DDI-MedLine.d83.s0	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d83.s0	its	33	35	O	its	its	its	PRP$	False
DDI-MedLine.d83.s0	use	37	39	O	use	use	use	NN	False
DDI-MedLine.d83.s0	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d83.s0	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d83.s0	management	48	57	O	management	ent	ment	NN	False
DDI-MedLine.d83.s0	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d83.s0	schizophrenia	62	74	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s0	.	75	75	O	.	.	.	.	False

DDI-MedLine.d83.s1	Olanzapine	0	9	B-drug	Olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s1	,	10	10	O	,	,	,	,	False
DDI-MedLine.d83.s1	a	12	12	O	a	a	a	DT	False
DDI-MedLine.d83.s1	thienobenzodiazepine	14	33	B-group	thienobenzodiazepine	ine	pine	NN	drug
DDI-MedLine.d83.s1	derivative	35	44	I-group	derivative	ive	tive	JJ	False
DDI-MedLine.d83.s1	,	45	45	O	,	,	,	,	False
DDI-MedLine.d83.s1	is	47	48	O	is	is	is	VBZ	False
DDI-MedLine.d83.s1	a	50	50	O	a	a	a	DT	False
DDI-MedLine.d83.s1	second	52	57	B-group	second	ond	cond	JJ	False
DDI-MedLine.d83.s1	generation	59	68	I-group	generation	ion	tion	NN	False
DDI-MedLine.d83.s1	(	70	70	I-group	(	(	(	(	False
DDI-MedLine.d83.s1	atypical	71	78	I-group	atypical	cal	ical	JJ	False
DDI-MedLine.d83.s1	)	79	79	I-group	)	)	)	)	False
DDI-MedLine.d83.s1	antipsychotic	81	93	I-group	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d83.s1	agent	95	99	I-group	agent	ent	gent	NN	False
DDI-MedLine.d83.s1	which	101	105	O	which	ich	hich	WDT	False
DDI-MedLine.d83.s1	has	107	109	O	has	has	has	VBZ	False
DDI-MedLine.d83.s1	proven	111	116	O	proven	ven	oven	NN	False
DDI-MedLine.d83.s1	efficacy	118	125	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d83.s1	against	127	133	O	against	nst	inst	IN	False
DDI-MedLine.d83.s1	the	135	137	O	the	the	the	DT	False
DDI-MedLine.d83.s1	positive	139	146	O	positive	ive	tive	JJ	False
DDI-MedLine.d83.s1	and	148	150	O	and	and	and	CC	False
DDI-MedLine.d83.s1	negative	152	159	O	negative	ive	tive	JJ	False
DDI-MedLine.d83.s1	symptoms	161	168	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s1	of	170	171	O	of	of	of	IN	False
DDI-MedLine.d83.s1	schizophrenia	173	185	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s1	.	186	186	O	.	.	.	.	False

DDI-MedLine.d83.s2	Compared	0	7	O	Compared	red	ared	VBN	False
DDI-MedLine.d83.s2	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d83.s2	conventional	14	25	B-group	conventional	nal	onal	JJ	False
DDI-MedLine.d83.s2	antipsychotics	27	40	I-group	antipsychotics	ics	tics	NNS	False
DDI-MedLine.d83.s2	,	41	41	O	,	,	,	,	False
DDI-MedLine.d83.s2	it	43	44	O	it	it	it	PRP	False
DDI-MedLine.d83.s2	has	46	48	O	has	has	has	VBZ	False
DDI-MedLine.d83.s2	greater	50	56	O	greater	ter	ater	JJR	False
DDI-MedLine.d83.s2	affinity	58	65	O	affinity	ity	nity	NN	False
DDI-MedLine.d83.s2	for	67	69	O	for	for	for	IN	False
DDI-MedLine.d83.s2	serotonin	71	79	O	serotonin	nin	onin	NN	False
DDI-MedLine.d83.s2	5-HT2A	81	86	O	5-HT2A	T2A	HT2A	JJ	brand
DDI-MedLine.d83.s2	than	88	91	O	than	han	than	IN	False
DDI-MedLine.d83.s2	for	93	95	O	for	for	for	IN	False
DDI-MedLine.d83.s2	dopamine	97	104	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d83.s2	D2	106	107	O	D2	D2	D2	NN	brand
DDI-MedLine.d83.s2	receptors	109	117	O	receptors	ors	tors	NNS	False
DDI-MedLine.d83.s2	.	118	118	O	.	.	.	.	False

DDI-MedLine.d83.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d83.s3	large	3	7	O	large	rge	arge	JJ	False
DDI-MedLine.d83.s3	,	8	8	O	,	,	,	,	False
DDI-MedLine.d83.s3	well	10	13	O	well	ell	well	RB	False
DDI-MedLine.d83.s3	controlled	15	24	O	controlled	led	lled	VBN	False
DDI-MedLine.d83.s3	trials	26	31	O	trials	als	ials	NNS	False
DDI-MedLine.d83.s3	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d83.s3	patients	36	43	O	patients	nts	ents	NNS	False
DDI-MedLine.d83.s3	with	45	48	O	with	ith	with	IN	False
DDI-MedLine.d83.s3	schizophrenia	50	62	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s3	or	64	65	O	or	or	or	CC	False
DDI-MedLine.d83.s3	related	67	73	O	related	ted	ated	JJ	False
DDI-MedLine.d83.s3	psychoses	75	83	O	psychoses	ses	oses	NNS	False
DDI-MedLine.d83.s3	,	84	84	O	,	,	,	,	False
DDI-MedLine.d83.s3	olanzapine	86	95	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s3	5	97	97	O	5	5	5	CD	False
DDI-MedLine.d83.s3	to	99	100	O	to	to	to	TO	False
DDI-MedLine.d83.s3	20	102	103	O	20	20	20	CD	False
DDI-MedLine.d83.s3	mg/day	105	110	O	mg/day	day	/day	NN	False
DDI-MedLine.d83.s3	was	112	114	O	was	was	was	VBD	False
DDI-MedLine.d83.s3	significantly	116	128	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s3	superior	130	137	O	superior	ior	rior	JJ	False
DDI-MedLine.d83.s3	to	139	140	O	to	to	to	TO	False
DDI-MedLine.d83.s3	haloperidol	142	152	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s3	5	154	154	O	5	5	5	CD	False
DDI-MedLine.d83.s3	to	156	157	O	to	to	to	TO	False
DDI-MedLine.d83.s3	20	159	160	O	20	20	20	CD	False
DDI-MedLine.d83.s3	mg/day	162	167	O	mg/day	day	/day	NN	False
DDI-MedLine.d83.s3	in	169	170	O	in	in	in	IN	False
DDI-MedLine.d83.s3	overall	172	178	O	overall	all	rall	JJ	False
DDI-MedLine.d83.s3	improvements	180	191	O	improvements	nts	ents	NNS	False
DDI-MedLine.d83.s3	in	193	194	O	in	in	in	IN	False
DDI-MedLine.d83.s3	psychopathology	196	210	O	psychopathology	ogy	logy	NN	False
DDI-MedLine.d83.s3	rating	212	217	O	rating	ing	ting	NN	False
DDI-MedLine.d83.s3	scales	219	224	O	scales	les	ales	NNS	False
DDI-MedLine.d83.s3	and	226	228	O	and	and	and	CC	False
DDI-MedLine.d83.s3	in	230	231	O	in	in	in	IN	False
DDI-MedLine.d83.s3	the	233	235	O	the	the	the	DT	False
DDI-MedLine.d83.s3	treatment	237	245	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s3	of	247	248	O	of	of	of	IN	False
DDI-MedLine.d83.s3	depressive	250	259	O	depressive	ive	sive	NN	False
DDI-MedLine.d83.s3	and	261	263	O	and	and	and	CC	False
DDI-MedLine.d83.s3	negative	265	272	O	negative	ive	tive	JJ	False
DDI-MedLine.d83.s3	symptoms	274	281	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s3	,	282	282	O	,	,	,	,	False
DDI-MedLine.d83.s3	and	284	286	O	and	and	and	CC	False
DDI-MedLine.d83.s3	was	288	290	O	was	was	was	VBD	False
DDI-MedLine.d83.s3	comparable	292	301	O	comparable	ble	able	JJ	False
DDI-MedLine.d83.s3	in	303	304	O	in	in	in	IN	False
DDI-MedLine.d83.s3	effects	306	312	O	effects	cts	ects	NNS	False
DDI-MedLine.d83.s3	on	314	315	O	on	on	on	IN	False
DDI-MedLine.d83.s3	positive	317	324	O	positive	ive	tive	JJ	False
DDI-MedLine.d83.s3	psychotic	326	334	O	psychotic	tic	otic	JJ	False
DDI-MedLine.d83.s3	symptoms	336	343	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s3	.	344	344	O	.	.	.	.	False

DDI-MedLine.d83.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d83.s4	1-year	4	9	O	1-year	ear	year	JJ	False
DDI-MedLine.d83.s4	risk	11	14	O	risk	isk	risk	NN	False
DDI-MedLine.d83.s4	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d83.s4	relapse	19	25	O	relapse	pse	apse	NN	False
DDI-MedLine.d83.s4	(	27	27	O	(	(	(	(	False
DDI-MedLine.d83.s4	rehospitalisation	28	44	O	rehospitalisation	ion	tion	NN	False
DDI-MedLine.d83.s4	)	45	45	O	)	)	)	)	False
DDI-MedLine.d83.s4	was	47	49	O	was	was	was	VBD	False
DDI-MedLine.d83.s4	significantly	51	63	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s4	lower	65	69	O	lower	wer	ower	JJR	False
DDI-MedLine.d83.s4	with	71	74	O	with	ith	with	IN	False
DDI-MedLine.d83.s4	olanzapine	76	85	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s4	than	87	90	O	than	han	than	IN	False
DDI-MedLine.d83.s4	with	92	95	O	with	ith	with	IN	False
DDI-MedLine.d83.s4	haloperidol	97	107	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s4	treatment	109	117	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s4	.	118	118	O	.	.	.	.	False

DDI-MedLine.d83.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d83.s5	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d83.s5	first	7	11	O	first	rst	irst	RB	False
DDI-MedLine.d83.s5	double-blind	13	24	O	double-blind	ind	lind	NN	False
DDI-MedLine.d83.s5	comparative	26	36	O	comparative	ive	tive	NN	False
DDI-MedLine.d83.s5	study	38	42	O	study	udy	tudy	NN	False
DDI-MedLine.d83.s5	(	44	44	O	(	(	(	(	False
DDI-MedLine.d83.s5	28-week	45	51	O	28-week	eek	week	JJ	False
DDI-MedLine.d83.s5	)	52	52	O	)	)	)	)	False
DDI-MedLine.d83.s5	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d83.s5	olanzapine	57	66	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s5	and	68	70	O	and	and	and	CC	False
DDI-MedLine.d83.s5	risperidone	72	82	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s5	,	83	83	O	,	,	,	,	False
DDI-MedLine.d83.s5	olanzapine	85	94	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s5	10	96	97	O	10	10	10	CD	False
DDI-MedLine.d83.s5	to	99	100	O	to	to	to	TO	False
DDI-MedLine.d83.s5	20	102	103	O	20	20	20	CD	False
DDI-MedLine.d83.s5	mg/day	105	110	O	mg/day	day	/day	NN	False
DDI-MedLine.d83.s5	proved	112	117	O	proved	ved	oved	VBN	False
DDI-MedLine.d83.s5	to	119	120	O	to	to	to	TO	False
DDI-MedLine.d83.s5	be	122	123	O	be	be	be	VB	False
DDI-MedLine.d83.s5	significantly	125	137	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s5	more	139	142	O	more	ore	more	RBR	False
DDI-MedLine.d83.s5	effective	144	152	O	effective	ive	tive	JJ	False
DDI-MedLine.d83.s5	than	154	157	O	than	han	than	IN	False
DDI-MedLine.d83.s5	risperidone	159	169	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s5	4	171	171	O	4	4	4	CD	False
DDI-MedLine.d83.s5	to	173	174	O	to	to	to	TO	False
DDI-MedLine.d83.s5	12	176	177	O	12	12	12	CD	False
DDI-MedLine.d83.s5	mg/day	179	184	O	mg/day	day	/day	NN	False
DDI-MedLine.d83.s5	in	186	187	O	in	in	in	IN	False
DDI-MedLine.d83.s5	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d83.s5	treatment	193	201	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s5	of	203	204	O	of	of	of	IN	False
DDI-MedLine.d83.s5	negative	206	213	O	negative	ive	tive	JJ	False
DDI-MedLine.d83.s5	and	215	217	O	and	and	and	CC	False
DDI-MedLine.d83.s5	depressive	219	228	O	depressive	ive	sive	NN	False
DDI-MedLine.d83.s5	symptoms	230	237	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s5	but	239	241	O	but	but	but	CC	False
DDI-MedLine.d83.s5	not	243	245	O	not	not	not	RB	False
DDI-MedLine.d83.s5	on	247	248	O	on	on	on	IN	False
DDI-MedLine.d83.s5	overall	250	256	O	overall	all	rall	JJ	False
DDI-MedLine.d83.s5	psychopathology	258	272	O	psychopathology	ogy	logy	NN	False
DDI-MedLine.d83.s5	symptoms	274	281	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s5	.	282	282	O	.	.	.	.	False

DDI-MedLine.d83.s6	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d83.s6	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d83.s6	,	11	11	O	,	,	,	,	False
DDI-MedLine.d83.s6	preliminary	13	23	O	preliminary	ary	nary	JJ	False
DDI-MedLine.d83.s6	results	25	31	O	results	lts	ults	NNS	False
DDI-MedLine.d83.s6	from	33	36	O	from	rom	from	IN	False
DDI-MedLine.d83.s6	an	38	39	O	an	an	an	DT	False
DDI-MedLine.d83.s6	8-week	41	46	O	8-week	eek	week	JJ	False
DDI-MedLine.d83.s6	controlled	48	57	O	controlled	led	lled	VBN	False
DDI-MedLine.d83.s6	study	59	63	O	study	udy	tudy	NN	False
DDI-MedLine.d83.s6	suggested	65	73	O	suggested	ted	sted	VBN	False
DDI-MedLine.d83.s6	risperidone	75	85	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s6	2	87	87	O	2	2	2	CD	False
DDI-MedLine.d83.s6	to	89	90	O	to	to	to	TO	False
DDI-MedLine.d83.s6	6	92	92	O	6	6	6	CD	False
DDI-MedLine.d83.s6	mg/day	94	99	O	mg/day	day	/day	NN	False
DDI-MedLine.d83.s6	was	101	103	O	was	was	was	VBD	False
DDI-MedLine.d83.s6	superior	105	112	O	superior	ior	rior	JJ	False
DDI-MedLine.d83.s6	to	114	115	O	to	to	to	TO	False
DDI-MedLine.d83.s6	olanzapine	117	126	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s6	5	128	128	O	5	5	5	CD	False
DDI-MedLine.d83.s6	to	130	131	O	to	to	to	TO	False
DDI-MedLine.d83.s6	20	133	134	O	20	20	20	CD	False
DDI-MedLine.d83.s6	mg/day	136	141	O	mg/day	day	/day	NN	False
DDI-MedLine.d83.s6	against	143	149	O	against	nst	inst	IN	False
DDI-MedLine.d83.s6	positive	151	158	O	positive	ive	tive	JJ	False
DDI-MedLine.d83.s6	and	160	162	O	and	and	and	CC	False
DDI-MedLine.d83.s6	anxiety/depressive	164	181	O	anxiety/depressive	ive	sive	JJ	False
DDI-MedLine.d83.s6	symptoms	183	190	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s6	(	192	192	O	(	(	(	(	False
DDI-MedLine.d83.s6	p	193	193	O	p	p	p	NN	False
DDI-MedLine.d83.s6	<	195	195	O	<	<	<	NN	False
DDI-MedLine.d83.s6	0.05	197	200	O	0.05	.05	0.05	CD	False
DDI-MedLine.d83.s6	)	201	201	O	)	)	)	)	False
DDI-MedLine.d83.s6	,	202	202	O	,	,	,	,	False
DDI-MedLine.d83.s6	although	204	211	O	although	ugh	ough	IN	False
DDI-MedLine.d83.s6	consistent	213	222	O	consistent	ent	tent	NN	False
DDI-MedLine.d83.s6	with	224	227	O	with	ith	with	IN	False
DDI-MedLine.d83.s6	the	229	231	O	the	the	the	DT	False
DDI-MedLine.d83.s6	first	233	237	O	first	rst	irst	RB	False
DDI-MedLine.d83.s6	study	239	243	O	study	udy	tudy	NN	False
DDI-MedLine.d83.s6	,	244	244	O	,	,	,	,	False
DDI-MedLine.d83.s6	both	246	249	O	both	oth	both	DT	False
DDI-MedLine.d83.s6	agents	251	256	O	agents	nts	ents	NNS	False
DDI-MedLine.d83.s6	demonstrated	258	269	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d83.s6	similar	271	277	O	similar	lar	ilar	JJ	False
DDI-MedLine.d83.s6	efficacy	279	286	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d83.s6	on	288	289	O	on	on	on	IN	False
DDI-MedLine.d83.s6	measures	291	298	O	measures	res	ures	NNS	False
DDI-MedLine.d83.s6	of	300	301	O	of	of	of	IN	False
DDI-MedLine.d83.s6	overall	303	309	O	overall	all	rall	JJ	False
DDI-MedLine.d83.s6	psychopathology	311	325	O	psychopathology	ogy	logy	NN	False
DDI-MedLine.d83.s6	.	326	326	O	.	.	.	.	False

DDI-MedLine.d83.s7	Improvements	0	11	O	Improvements	nts	ents	NNS	False
DDI-MedLine.d83.s7	in	13	14	O	in	in	in	IN	False
DDI-MedLine.d83.s7	general	16	22	O	general	ral	eral	JJ	False
DDI-MedLine.d83.s7	cognitive	24	32	O	cognitive	ive	tive	NN	False
DDI-MedLine.d83.s7	function	34	41	O	function	ion	tion	NN	False
DDI-MedLine.d83.s7	seen	43	46	O	seen	een	seen	VBN	False
DDI-MedLine.d83.s7	with	48	51	O	with	ith	with	IN	False
DDI-MedLine.d83.s7	olanzapine	53	62	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s7	treatment	64	72	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s7	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d83.s7	a	77	77	O	a	a	a	DT	False
DDI-MedLine.d83.s7	1-year	79	84	O	1-year	ear	year	JJ	False
DDI-MedLine.d83.s7	controlled	86	95	O	controlled	led	lled	VBN	False
DDI-MedLine.d83.s7	study	97	101	O	study	udy	tudy	NN	False
DDI-MedLine.d83.s7	of	103	104	O	of	of	of	IN	False
DDI-MedLine.d83.s7	patients	106	113	O	patients	nts	ents	NNS	False
DDI-MedLine.d83.s7	with	115	118	O	with	ith	with	IN	False
DDI-MedLine.d83.s7	early-phase	120	130	O	early-phase	ase	hase	NN	False
DDI-MedLine.d83.s7	schizophrenia	132	144	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s7	,	145	145	O	,	,	,	,	False
DDI-MedLine.d83.s7	were	147	150	O	were	ere	were	VBD	False
DDI-MedLine.d83.s7	significantly	152	164	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s7	greater	166	172	O	greater	ter	ater	JJR	False
DDI-MedLine.d83.s7	than	174	177	O	than	han	than	IN	False
DDI-MedLine.d83.s7	changes	179	185	O	changes	ges	nges	NNS	False
DDI-MedLine.d83.s7	seen	187	190	O	seen	een	seen	VBN	False
DDI-MedLine.d83.s7	with	192	195	O	with	ith	with	IN	False
DDI-MedLine.d83.s7	either	197	202	O	either	her	ther	DT	False
DDI-MedLine.d83.s7	risperidone	204	214	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s7	or	216	217	O	or	or	or	CC	False
DDI-MedLine.d83.s7	haloperidol	219	229	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s7	.	230	230	O	.	.	.	.	False

DDI-MedLine.d83.s8	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d83.s8	,	7	7	O	,	,	,	,	False
DDI-MedLine.d83.s8	preliminary	9	19	O	preliminary	ary	nary	JJ	False
DDI-MedLine.d83.s8	results	21	27	O	results	lts	ults	NNS	False
DDI-MedLine.d83.s8	from	29	32	O	from	rom	from	IN	False
DDI-MedLine.d83.s8	an	34	35	O	an	an	an	DT	False
DDI-MedLine.d83.s8	8-week	37	42	O	8-week	eek	week	JJ	False
DDI-MedLine.d83.s8	trial	44	48	O	trial	ial	rial	NN	False
DDI-MedLine.d83.s8	showed	50	55	O	showed	wed	owed	VBD	False
DDI-MedLine.d83.s8	comparable	57	66	O	comparable	ble	able	JJ	False
DDI-MedLine.d83.s8	cognitive	68	76	O	cognitive	ive	tive	NN	False
DDI-MedLine.d83.s8	enhancing	78	86	O	enhancing	ing	cing	VBG	False
DDI-MedLine.d83.s8	effects	88	94	O	effects	cts	ects	NNS	False
DDI-MedLine.d83.s8	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d83.s8	olanzapine	99	108	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s8	and	110	112	O	and	and	and	CC	False
DDI-MedLine.d83.s8	risperidone	114	124	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s8	treatment	126	134	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s8	in	136	137	O	in	in	in	IN	False
DDI-MedLine.d83.s8	patients	139	146	O	patients	nts	ents	NNS	False
DDI-MedLine.d83.s8	with	148	151	O	with	ith	with	IN	False
DDI-MedLine.d83.s8	schizophrenia	153	165	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s8	or	167	168	O	or	or	or	CC	False
DDI-MedLine.d83.s8	schizoaffective	170	184	O	schizoaffective	ive	tive	NN	False
DDI-MedLine.d83.s8	disorder	186	193	O	disorder	der	rder	NN	False
DDI-MedLine.d83.s8	.	194	194	O	.	.	.	.	False

DDI-MedLine.d83.s9	Several	0	6	O	Several	ral	eral	JJ	False
DDI-MedLine.d83.s9	studies	8	14	O	studies	ies	dies	NNS	False
DDI-MedLine.d83.s9	indicate	16	23	O	indicate	ate	cate	NN	False
DDI-MedLine.d83.s9	that	25	28	O	that	hat	that	IN	False
DDI-MedLine.d83.s9	olanzapine	30	39	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s9	has	41	43	O	has	has	has	VBZ	False
DDI-MedLine.d83.s9	benefits	45	52	O	benefits	its	fits	NNS	False
DDI-MedLine.d83.s9	against	54	60	O	against	nst	inst	IN	False
DDI-MedLine.d83.s9	symptoms	62	69	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s9	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d83.s9	aggression	74	83	O	aggression	ion	sion	NN	False
DDI-MedLine.d83.s9	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d83.s9	agitation	89	97	O	agitation	ion	tion	NN	False
DDI-MedLine.d83.s9	,	98	98	O	,	,	,	,	False
DDI-MedLine.d83.s9	while	100	104	O	while	ile	hile	IN	False
DDI-MedLine.d83.s9	other	106	110	O	other	her	ther	JJ	False
DDI-MedLine.d83.s9	studies	112	118	O	studies	ies	dies	NNS	False
DDI-MedLine.d83.s9	strongly	120	127	O	strongly	gly	ngly	RB	False
DDI-MedLine.d83.s9	support	129	135	O	support	ort	port	NN	False
DDI-MedLine.d83.s9	the	137	139	O	the	the	the	DT	False
DDI-MedLine.d83.s9	effectiveness	141	153	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d83.s9	of	155	156	O	of	of	of	IN	False
DDI-MedLine.d83.s9	olanzapine	158	167	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s9	in	169	170	O	in	in	in	IN	False
DDI-MedLine.d83.s9	the	172	174	O	the	the	the	DT	False
DDI-MedLine.d83.s9	treatment	176	184	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s9	of	186	187	O	of	of	of	IN	False
DDI-MedLine.d83.s9	depressive	189	198	O	depressive	ive	sive	NN	False
DDI-MedLine.d83.s9	symptomatology	200	213	O	symptomatology	ogy	logy	NN	False
DDI-MedLine.d83.s9	.	214	214	O	.	.	.	.	False

DDI-MedLine.d83.s10	Olanzapine	0	9	B-drug	Olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s10	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d83.s10	associated	14	23	O	associated	ted	ated	VBN	False
DDI-MedLine.d83.s10	with	25	28	O	with	ith	with	IN	False
DDI-MedLine.d83.s10	significantly	30	42	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s10	fewer	44	48	O	fewer	wer	ewer	JJR	False
DDI-MedLine.d83.s10	extrapyramidal	50	63	O	extrapyramidal	dal	idal	NN	False
DDI-MedLine.d83.s10	symptoms	65	72	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s10	than	74	77	O	than	han	than	IN	False
DDI-MedLine.d83.s10	haloperidol	79	89	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s10	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d83.s10	risperidone	95	105	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s10	.	106	106	O	.	.	.	.	False

DDI-MedLine.d83.s11	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d83.s11	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d83.s11	,	11	11	O	,	,	,	,	False
DDI-MedLine.d83.s11	olanzapine	13	22	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s11	is	24	25	O	is	is	is	VBZ	False
DDI-MedLine.d83.s11	not	27	29	O	not	not	not	RB	False
DDI-MedLine.d83.s11	associated	31	40	O	associated	ted	ated	VBN	False
DDI-MedLine.d83.s11	with	42	45	O	with	ith	with	IN	False
DDI-MedLine.d83.s11	a	47	47	O	a	a	a	DT	False
DDI-MedLine.d83.s11	risk	49	52	O	risk	isk	risk	NN	False
DDI-MedLine.d83.s11	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d83.s11	agranulocytosis	57	71	O	agranulocytosis	sis	osis	NN	False
DDI-MedLine.d83.s11	as	73	74	O	as	as	as	IN	False
DDI-MedLine.d83.s11	seen	76	79	O	seen	een	seen	VBN	False
DDI-MedLine.d83.s11	with	81	84	O	with	ith	with	IN	False
DDI-MedLine.d83.s11	clozapine	86	94	B-drug	clozapine	ine	pine	NN	drug
DDI-MedLine.d83.s11	or	96	97	O	or	or	or	CC	False
DDI-MedLine.d83.s11	clinically	99	108	O	clinically	lly	ally	RB	False
DDI-MedLine.d83.s11	significant	110	120	O	significant	ant	cant	JJ	False
DDI-MedLine.d83.s11	hyperprolactinaemia	122	140	O	hyperprolactinaemia	mia	emia	NN	False
DDI-MedLine.d83.s11	as	142	143	O	as	as	as	IN	False
DDI-MedLine.d83.s11	seen	145	148	O	seen	een	seen	VBN	False
DDI-MedLine.d83.s11	with	150	153	O	with	ith	with	IN	False
DDI-MedLine.d83.s11	risperidone	155	165	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s11	or	167	168	O	or	or	or	CC	False
DDI-MedLine.d83.s11	prolongation	170	181	O	prolongation	ion	tion	NN	False
DDI-MedLine.d83.s11	of	183	184	O	of	of	of	IN	False
DDI-MedLine.d83.s11	the	186	188	O	the	the	the	DT	False
DDI-MedLine.d83.s11	QT	190	191	O	QT	QT	QT	NN	brand
DDI-MedLine.d83.s11	interval	193	200	O	interval	val	rval	NN	False
DDI-MedLine.d83.s11	.	201	201	O	.	.	.	.	False

DDI-MedLine.d83.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d83.s12	most	4	7	O	most	ost	most	JJS	False
DDI-MedLine.d83.s12	common	9	14	O	common	mon	mmon	JJ	False
DDI-MedLine.d83.s12	adverse	16	22	O	adverse	rse	erse	NN	False
DDI-MedLine.d83.s12	effects	24	30	O	effects	cts	ects	NNS	False
DDI-MedLine.d83.s12	reported	32	39	O	reported	ted	rted	VBD	False
DDI-MedLine.d83.s12	with	41	44	O	with	ith	with	IN	False
DDI-MedLine.d83.s12	olanzapine	46	55	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s12	are	57	59	O	are	are	are	VBP	False
DDI-MedLine.d83.s12	bodyweight	61	70	O	bodyweight	ght	ight	NN	False
DDI-MedLine.d83.s12	gain	72	75	O	gain	ain	gain	NN	False
DDI-MedLine.d83.s12	,	76	76	O	,	,	,	,	False
DDI-MedLine.d83.s12	somnolence	78	87	O	somnolence	nce	ence	NN	False
DDI-MedLine.d83.s12	,	88	88	O	,	,	,	,	False
DDI-MedLine.d83.s12	dizziness	90	98	O	dizziness	ess	ness	NN	False
DDI-MedLine.d83.s12	,	99	99	O	,	,	,	,	False
DDI-MedLine.d83.s12	anticholinergic	101	115	O	anticholinergic	gic	rgic	NN	False
DDI-MedLine.d83.s12	effects	117	123	O	effects	cts	ects	NNS	False
DDI-MedLine.d83.s12	(	125	125	O	(	(	(	(	False
DDI-MedLine.d83.s12	constipation	126	137	O	constipation	ion	tion	NN	False
DDI-MedLine.d83.s12	and	139	141	O	and	and	and	CC	False
DDI-MedLine.d83.s12	dry	143	145	O	dry	dry	dry	NN	False
DDI-MedLine.d83.s12	mouth	147	151	O	mouth	uth	outh	NN	False
DDI-MedLine.d83.s12	)	152	152	O	)	)	)	)	False
DDI-MedLine.d83.s12	and	154	156	O	and	and	and	CC	False
DDI-MedLine.d83.s12	transient	158	166	O	transient	ent	ient	NN	False
DDI-MedLine.d83.s12	asymptomatic	168	179	O	asymptomatic	tic	atic	JJ	False
DDI-MedLine.d83.s12	liver	181	185	O	liver	ver	iver	NN	False
DDI-MedLine.d83.s12	enzyme	187	192	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d83.s12	elevations	194	203	O	elevations	ons	ions	NNS	False
DDI-MedLine.d83.s12	.	204	204	O	.	.	.	.	False

DDI-MedLine.d83.s13	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d83.s13	comparison	3	12	O	comparison	son	ison	NN	False
DDI-MedLine.d83.s13	with	14	17	O	with	ith	with	IN	False
DDI-MedLine.d83.s13	haloperidol	19	29	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s13	,	30	30	O	,	,	,	,	False
DDI-MedLine.d83.s13	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d83.s13	adverse	36	42	O	adverse	rse	erse	NN	False
DDI-MedLine.d83.s13	events	44	49	O	events	nts	ents	NNS	False
DDI-MedLine.d83.s13	reported	51	58	O	reported	ted	rted	VBD	False
DDI-MedLine.d83.s13	significantly	60	72	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s13	more	74	77	O	more	ore	more	RBR	False
DDI-MedLine.d83.s13	frequently	79	88	O	frequently	tly	ntly	RB	False
DDI-MedLine.d83.s13	with	90	93	O	with	ith	with	IN	False
DDI-MedLine.d83.s13	olanzapine	95	104	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s13	in	106	107	O	in	in	in	IN	False
DDI-MedLine.d83.s13	>	109	109	O	>	>	>	NN	False
DDI-MedLine.d83.s13	or	111	112	O	or	or	or	CC	False
DDI-MedLine.d83.s13	=	114	114	O	=	=	=	NN	False
DDI-MedLine.d83.s13	3.5	116	118	O	3.5	3.5	3.5	CD	False
DDI-MedLine.d83.s13	%	119	119	O	%	%	%	NN	False
DDI-MedLine.d83.s13	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d83.s13	patients	124	131	O	patients	nts	ents	NNS	False
DDI-MedLine.d83.s13	were	133	136	O	were	ere	were	VBD	False
DDI-MedLine.d83.s13	dry	138	140	O	dry	dry	dry	NN	False
DDI-MedLine.d83.s13	mouth	142	146	O	mouth	uth	outh	NN	False
DDI-MedLine.d83.s13	,	147	147	O	,	,	,	,	False
DDI-MedLine.d83.s13	bodyweight	149	158	O	bodyweight	ght	ight	NN	False
DDI-MedLine.d83.s13	gain	160	163	O	gain	ain	gain	NN	False
DDI-MedLine.d83.s13	and	165	167	O	and	and	and	CC	False
DDI-MedLine.d83.s13	increased	169	177	O	increased	sed	ased	VBN	False
DDI-MedLine.d83.s13	appetite	179	186	O	appetite	ite	tite	NN	False
DDI-MedLine.d83.s13	and	188	190	O	and	and	and	CC	False
DDI-MedLine.d83.s13	compared	192	199	O	compared	red	ared	VBN	False
DDI-MedLine.d83.s13	with	201	204	O	with	ith	with	IN	False
DDI-MedLine.d83.s13	risperidone	206	216	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s13	,	217	217	O	,	,	,	,	False
DDI-MedLine.d83.s13	only	219	222	O	only	nly	only	RB	False
DDI-MedLine.d83.s13	bodyweight	224	233	O	bodyweight	ght	ight	NN	False
DDI-MedLine.d83.s13	gain	235	238	O	gain	ain	gain	NN	False
DDI-MedLine.d83.s13	occurred	240	247	O	occurred	red	rred	VBD	False
DDI-MedLine.d83.s13	significantly	249	261	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s13	more	263	266	O	more	ore	more	RBR	False
DDI-MedLine.d83.s13	frequently	268	277	O	frequently	tly	ntly	RB	False
DDI-MedLine.d83.s13	with	279	282	O	with	ith	with	IN	False
DDI-MedLine.d83.s13	olanzapine	284	293	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s13	.	294	294	O	.	.	.	.	False

DDI-MedLine.d83.s14	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d83.s14	high	4	7	O	high	igh	high	JJ	False
DDI-MedLine.d83.s14	acquisition	9	19	O	acquisition	ion	tion	NN	False
DDI-MedLine.d83.s14	cost	21	24	O	cost	ost	cost	NN	False
DDI-MedLine.d83.s14	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d83.s14	olanzapine	29	38	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s14	is	40	41	O	is	is	is	VBZ	False
DDI-MedLine.d83.s14	offset	43	48	O	offset	set	fset	NN	False
DDI-MedLine.d83.s14	by	50	51	O	by	by	by	IN	False
DDI-MedLine.d83.s14	reductions	53	62	O	reductions	ons	ions	NNS	False
DDI-MedLine.d83.s14	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d83.s14	other	67	71	O	other	her	ther	JJ	False
DDI-MedLine.d83.s14	treatment	73	81	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s14	costs	83	87	O	costs	sts	osts	NNS	False
DDI-MedLine.d83.s14	(	89	89	O	(	(	(	(	False
DDI-MedLine.d83.s14	inpatient	90	98	O	inpatient	ent	ient	NN	False
DDI-MedLine.d83.s14	and/or	100	105	O	and/or	/or	d/or	NN	False
DDI-MedLine.d83.s14	outpatient	107	116	O	outpatient	ent	ient	NN	False
DDI-MedLine.d83.s14	services	118	125	O	services	ces	ices	NNS	False
DDI-MedLine.d83.s14	)	126	126	O	)	)	)	)	False
DDI-MedLine.d83.s14	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d83.s14	schizophrenia	131	143	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s14	.	144	144	O	.	.	.	.	False

DDI-MedLine.d83.s15	Pharmacoeconomic	0	15	O	Pharmacoeconomic	mic	omic	NNP	False
DDI-MedLine.d83.s15	analyses	17	24	O	analyses	ses	yses	NNS	False
DDI-MedLine.d83.s15	indicate	26	33	O	indicate	ate	cate	NN	False
DDI-MedLine.d83.s15	that	35	38	O	that	hat	that	IN	False
DDI-MedLine.d83.s15	olanzapine	40	49	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s15	does	51	54	O	does	oes	does	VBZ	False
DDI-MedLine.d83.s15	not	56	58	O	not	not	not	RB	False
DDI-MedLine.d83.s15	significantly	60	72	O	significantly	tly	ntly	RB	False
DDI-MedLine.d83.s15	increase	74	81	O	increase	ase	ease	NN	False
DDI-MedLine.d83.s15	,	82	82	O	,	,	,	,	False
DDI-MedLine.d83.s15	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d83.s15	may	88	90	O	may	may	may	MD	False
DDI-MedLine.d83.s15	even	92	95	O	even	ven	even	RB	False
DDI-MedLine.d83.s15	decrease	97	104	O	decrease	ase	ease	NN	False
DDI-MedLine.d83.s15	,	105	105	O	,	,	,	,	False
DDI-MedLine.d83.s15	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d83.s15	overall	111	117	O	overall	all	rall	JJ	False
DDI-MedLine.d83.s15	direct	119	124	O	direct	ect	rect	JJ	False
DDI-MedLine.d83.s15	treatment	126	134	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s15	costs	136	140	O	costs	sts	osts	NNS	False
DDI-MedLine.d83.s15	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d83.s15	schizophrenia	145	157	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s15	,	158	158	O	,	,	,	,	False
DDI-MedLine.d83.s15	compared	160	167	O	compared	red	ared	VBN	False
DDI-MedLine.d83.s15	with	169	172	O	with	ith	with	IN	False
DDI-MedLine.d83.s15	haloperidol	174	184	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s15	.	185	185	O	.	.	.	.	False

DDI-MedLine.d83.s16	Compared	0	7	O	Compared	red	ared	VBN	False
DDI-MedLine.d83.s16	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d83.s16	risperidone	14	24	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s16	,	25	25	O	,	,	,	,	False
DDI-MedLine.d83.s16	olanzapine	27	36	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s16	has	38	40	O	has	has	has	VBZ	False
DDI-MedLine.d83.s16	also	42	45	O	also	lso	also	RB	False
DDI-MedLine.d83.s16	been	47	50	O	been	een	been	VBN	False
DDI-MedLine.d83.s16	reported	52	59	O	reported	ted	rted	VBD	False
DDI-MedLine.d83.s16	to	61	62	O	to	to	to	TO	False
DDI-MedLine.d83.s16	decrease	64	71	O	decrease	ase	ease	NN	False
DDI-MedLine.d83.s16	overall	73	79	O	overall	all	rall	JJ	False
DDI-MedLine.d83.s16	treatment	81	89	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s16	costs	91	95	O	costs	sts	osts	NNS	False
DDI-MedLine.d83.s16	,	96	96	O	,	,	,	,	False
DDI-MedLine.d83.s16	despite	98	104	O	despite	ite	pite	IN	False
DDI-MedLine.d83.s16	the	106	108	O	the	the	the	DT	False
DDI-MedLine.d83.s16	several-fold	110	121	O	several-fold	old	fold	JJ	False
DDI-MedLine.d83.s16	higher	123	128	O	higher	her	gher	JJR	False
DDI-MedLine.d83.s16	daily	130	134	O	daily	ily	aily	JJ	False
DDI-MedLine.d83.s16	acquisition	136	146	O	acquisition	ion	tion	NN	False
DDI-MedLine.d83.s16	cost	148	151	O	cost	ost	cost	NN	False
DDI-MedLine.d83.s16	of	153	154	O	of	of	of	IN	False
DDI-MedLine.d83.s16	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d83.s16	drug	160	163	O	drug	rug	drug	NN	False
DDI-MedLine.d83.s16	.	164	164	O	.	.	.	.	False

DDI-MedLine.d83.s17	Olanzapine	0	9	B-drug	Olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s17	treatment	11	19	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s17	improves	21	28	O	improves	ves	oves	NNS	False
DDI-MedLine.d83.s17	quality	30	36	O	quality	ity	lity	NN	False
DDI-MedLine.d83.s17	of	38	39	O	of	of	of	IN	False
DDI-MedLine.d83.s17	life	41	44	O	life	ife	life	NN	False
DDI-MedLine.d83.s17	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d83.s17	patients	49	56	O	patients	nts	ents	NNS	False
DDI-MedLine.d83.s17	with	58	61	O	with	ith	with	IN	False
DDI-MedLine.d83.s17	schizophrenia	63	75	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s17	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d83.s17	related	81	87	O	related	ted	ated	JJ	False
DDI-MedLine.d83.s17	psychoses	89	97	O	psychoses	ses	oses	NNS	False
DDI-MedLine.d83.s17	to	99	100	O	to	to	to	TO	False
DDI-MedLine.d83.s17	a	102	102	O	a	a	a	DT	False
DDI-MedLine.d83.s17	greater	104	110	O	greater	ter	ater	JJR	False
DDI-MedLine.d83.s17	extent	112	117	O	extent	ent	tent	NN	False
DDI-MedLine.d83.s17	than	119	122	O	than	han	than	IN	False
DDI-MedLine.d83.s17	haloperidol	124	134	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s17	,	135	135	O	,	,	,	,	False
DDI-MedLine.d83.s17	and	137	139	O	and	and	and	CC	False
DDI-MedLine.d83.s17	to	141	142	O	to	to	to	TO	False
DDI-MedLine.d83.s17	broadly	144	150	O	broadly	dly	adly	RB	False
DDI-MedLine.d83.s17	the	152	154	O	the	the	the	DT	False
DDI-MedLine.d83.s17	same	156	159	O	same	ame	same	JJ	False
DDI-MedLine.d83.s17	extent	161	166	O	extent	ent	tent	NN	False
DDI-MedLine.d83.s17	as	168	169	O	as	as	as	IN	False
DDI-MedLine.d83.s17	risperidone	171	181	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s17	.	182	182	O	.	.	.	.	False

DDI-MedLine.d83.s18	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d83.s18	:	11	11	O	:	:	:	:	False
DDI-MedLine.d83.s18	Olanzapine	13	22	B-drug	Olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s18	demonstrated	24	35	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d83.s18	superior	37	44	O	superior	ior	rior	JJ	False
DDI-MedLine.d83.s18	antipsychotic	46	58	O	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d83.s18	efficacy	60	67	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d83.s18	compared	69	76	O	compared	red	ared	VBN	False
DDI-MedLine.d83.s18	with	78	81	O	with	ith	with	IN	False
DDI-MedLine.d83.s18	haloperidol	83	93	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s18	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d83.s18	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d83.s18	treatment	102	110	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s18	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d83.s18	acute	115	119	O	acute	ute	cute	NN	False
DDI-MedLine.d83.s18	phase	121	125	O	phase	ase	hase	NN	False
DDI-MedLine.d83.s18	schizophrenia	127	139	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s18	,	140	140	O	,	,	,	,	False
DDI-MedLine.d83.s18	and	142	144	O	and	and	and	CC	False
DDI-MedLine.d83.s18	in	146	147	O	in	in	in	IN	False
DDI-MedLine.d83.s18	the	149	151	O	the	the	the	DT	False
DDI-MedLine.d83.s18	treatment	153	161	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s18	of	163	164	O	of	of	of	IN	False
DDI-MedLine.d83.s18	some	166	169	O	some	ome	some	DT	False
DDI-MedLine.d83.s18	patients	171	178	O	patients	nts	ents	NNS	False
DDI-MedLine.d83.s18	with	180	183	O	with	ith	with	IN	False
DDI-MedLine.d83.s18	first-episode	185	197	O	first-episode	ode	sode	NN	False
DDI-MedLine.d83.s18	or	199	200	O	or	or	or	CC	False
DDI-MedLine.d83.s18	treatment-resistant	202	220	O	treatment-resistant	ant	tant	JJ	False
DDI-MedLine.d83.s18	schizophrenia	222	234	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s18	.	235	235	O	.	.	.	.	False

DDI-MedLine.d83.s19	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d83.s19	reduced	4	10	O	reduced	ced	uced	VBN	False
DDI-MedLine.d83.s19	risk	12	15	O	risk	isk	risk	NN	False
DDI-MedLine.d83.s19	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d83.s19	adverse	20	26	O	adverse	rse	erse	NN	False
DDI-MedLine.d83.s19	events	28	33	O	events	nts	ents	NNS	False
DDI-MedLine.d83.s19	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d83.s19	therapeutic	39	49	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d83.s19	superiority	51	61	O	superiority	ity	rity	NN	False
DDI-MedLine.d83.s19	compared	63	70	O	compared	red	ared	VBN	False
DDI-MedLine.d83.s19	with	72	75	O	with	ith	with	IN	False
DDI-MedLine.d83.s19	haloperidol	77	87	B-drug	haloperidol	dol	idol	NN	False
DDI-MedLine.d83.s19	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d83.s19	risperidone	93	103	B-drug	risperidone	one	done	NN	False
DDI-MedLine.d83.s19	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d83.s19	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d83.s19	treatment	112	120	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s19	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d83.s19	negative	125	132	O	negative	ive	tive	JJ	False
DDI-MedLine.d83.s19	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d83.s19	depressive	138	147	O	depressive	ive	sive	NN	False
DDI-MedLine.d83.s19	symptoms	149	156	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d83.s19	support	158	164	O	support	ort	port	NN	False
DDI-MedLine.d83.s19	the	166	168	O	the	the	the	DT	False
DDI-MedLine.d83.s19	choice	170	175	O	choice	ice	oice	NN	False
DDI-MedLine.d83.s19	of	177	178	O	of	of	of	IN	False
DDI-MedLine.d83.s19	olanzapine	180	189	B-drug	olanzapine	ine	pine	NN	drug
DDI-MedLine.d83.s19	as	191	192	O	as	as	as	IN	False
DDI-MedLine.d83.s19	a	194	194	O	a	a	a	DT	False
DDI-MedLine.d83.s19	first-line	196	205	O	first-line	ine	line	NN	drug
DDI-MedLine.d83.s19	option	207	212	O	option	ion	tion	NN	False
DDI-MedLine.d83.s19	in	214	215	O	in	in	in	IN	False
DDI-MedLine.d83.s19	the	217	219	O	the	the	the	DT	False
DDI-MedLine.d83.s19	management	221	230	O	management	ent	ment	NN	False
DDI-MedLine.d83.s19	of	232	233	O	of	of	of	IN	False
DDI-MedLine.d83.s19	schizophrenia	235	247	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d83.s19	in	249	250	O	in	in	in	IN	False
DDI-MedLine.d83.s19	the	252	254	O	the	the	the	DT	False
DDI-MedLine.d83.s19	acute	256	260	O	acute	ute	cute	NN	False
DDI-MedLine.d83.s19	phase	262	266	O	phase	ase	hase	NN	False
DDI-MedLine.d83.s19	and	268	270	O	and	and	and	CC	False
DDI-MedLine.d83.s19	for	272	274	O	for	for	for	IN	False
DDI-MedLine.d83.s19	the	276	278	O	the	the	the	DT	False
DDI-MedLine.d83.s19	maintenance	280	290	O	maintenance	nce	ance	NN	False
DDI-MedLine.d83.s19	of	292	293	O	of	of	of	IN	False
DDI-MedLine.d83.s19	treatment	295	303	O	treatment	ent	ment	NN	False
DDI-MedLine.d83.s19	response	305	312	O	response	nse	onse	NN	False
DDI-MedLine.d83.s19	.	313	313	O	.	.	.	.	False

DDI-MedLine.d31.s0	Cancer	0	5	O	Cancer	cer	ncer	NN	False
DDI-MedLine.d31.s0	in	7	8	O	in	in	in	IN	False
DDI-MedLine.d31.s0	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d31.s0	elderly	14	20	O	elderly	rly	erly	RB	False
DDI-MedLine.d31.s0	:	21	21	O	:	:	:	:	False
DDI-MedLine.d31.s0	basic	23	27	O	basic	sic	asic	JJ	False
DDI-MedLine.d31.s0	science	29	35	O	science	nce	ence	NN	False
DDI-MedLine.d31.s0	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d31.s0	clinical	41	48	O	clinical	cal	ical	JJ	False
DDI-MedLine.d31.s0	aspects	50	56	O	aspects	cts	ects	NNS	False
DDI-MedLine.d31.s0	.	57	57	O	.	.	.	.	False

DDI-MedLine.d31.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d31.s1	incidence	4	12	O	incidence	nce	ence	NN	False
DDI-MedLine.d31.s1	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d31.s1	cancer	17	22	O	cancer	cer	ncer	NN	False
DDI-MedLine.d31.s1	increases	24	32	O	increases	ses	ases	NNS	False
DDI-MedLine.d31.s1	progressively	34	46	O	progressively	ely	vely	RB	False
DDI-MedLine.d31.s1	with	48	51	O	with	ith	with	IN	False
DDI-MedLine.d31.s1	age	53	55	O	age	age	age	NN	False
DDI-MedLine.d31.s1	.	56	56	O	.	.	.	.	False

DDI-MedLine.d31.s2	Rearrangements	0	13	O	Rearrangements	nts	ents	NNS	False
DDI-MedLine.d31.s2	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d31.s2	genomes	18	24	O	genomes	mes	omes	NNS	False
DDI-MedLine.d31.s2	have	26	29	O	have	ave	have	VB	False
DDI-MedLine.d31.s2	been	31	34	O	been	een	been	VBN	False
DDI-MedLine.d31.s2	found	36	40	O	found	und	ound	NN	False
DDI-MedLine.d31.s2	to	42	43	O	to	to	to	TO	False
DDI-MedLine.d31.s2	accompany	45	53	O	accompany	any	pany	NN	False
DDI-MedLine.d31.s2	cellular	55	62	O	cellular	lar	ular	JJ	False
DDI-MedLine.d31.s2	aging	64	68	O	aging	ing	ging	VBG	False
DDI-MedLine.d31.s2	.	69	69	O	.	.	.	.	False

DDI-MedLine.d31.s3	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d31.s3	factors	6	12	O	factors	ors	tors	NNS	False
DDI-MedLine.d31.s3	,	13	13	O	,	,	,	,	False
DDI-MedLine.d31.s3	in	15	16	O	in	in	in	IN	False
DDI-MedLine.d31.s3	concert	18	24	O	concert	ert	cert	NN	False
DDI-MedLine.d31.s3	with	26	29	O	with	ith	with	IN	False
DDI-MedLine.d31.s3	age-dependent	31	43	O	age-dependent	ent	dent	NN	False
DDI-MedLine.d31.s3	alterations	45	55	O	alterations	ons	ions	NNS	False
DDI-MedLine.d31.s3	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d31.s3	immune	60	65	O	immune	une	mune	NN	False
DDI-MedLine.d31.s3	function	67	74	O	function	ion	tion	NN	False
DDI-MedLine.d31.s3	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d31.s3	host	80	83	O	host	ost	host	NN	False
DDI-MedLine.d31.s3	defense	85	91	O	defense	nse	ense	NN	False
DDI-MedLine.d31.s3	,	92	92	O	,	,	,	,	False
DDI-MedLine.d31.s3	may	94	96	O	may	may	may	MD	False
DDI-MedLine.d31.s3	help	98	101	O	help	elp	help	NN	False
DDI-MedLine.d31.s3	to	103	104	O	to	to	to	TO	False
DDI-MedLine.d31.s3	explain	106	112	O	explain	ain	lain	NN	False
DDI-MedLine.d31.s3	the	114	116	O	the	the	the	DT	False
DDI-MedLine.d31.s3	increased	118	126	O	increased	sed	ased	VBN	False
DDI-MedLine.d31.s3	risk	128	131	O	risk	isk	risk	NN	False
DDI-MedLine.d31.s3	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d31.s3	malignant	136	144	O	malignant	ant	nant	NN	False
DDI-MedLine.d31.s3	disease	146	152	O	disease	ase	ease	NN	False
DDI-MedLine.d31.s3	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d31.s3	aged	157	160	O	aged	ged	aged	VBN	False
DDI-MedLine.d31.s3	persons	162	168	O	persons	ons	sons	NNS	False
DDI-MedLine.d31.s3	.	169	169	O	.	.	.	.	False

DDI-MedLine.d31.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d31.s4	clinical	4	11	O	clinical	cal	ical	JJ	False
DDI-MedLine.d31.s4	presentation	13	24	O	presentation	ion	tion	NN	False
DDI-MedLine.d31.s4	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d31.s4	natural	30	36	O	natural	ral	ural	JJ	False
DDI-MedLine.d31.s4	history	38	44	O	history	ory	tory	NN	False
DDI-MedLine.d31.s4	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d31.s4	neoplasia	49	57	O	neoplasia	sia	asia	NN	False
DDI-MedLine.d31.s4	are	59	61	O	are	are	are	VBP	False
DDI-MedLine.d31.s4	also	63	66	O	also	lso	also	RB	False
DDI-MedLine.d31.s4	affected	68	75	O	affected	ted	cted	JJ	False
DDI-MedLine.d31.s4	by	77	78	O	by	by	by	IN	False
DDI-MedLine.d31.s4	aging	80	84	O	aging	ing	ging	VBG	False
DDI-MedLine.d31.s4	.	85	85	O	.	.	.	.	False

DDI-MedLine.d31.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d31.s5	conference	5	14	O	conference	nce	ence	NN	False
DDI-MedLine.d31.s5	reviews	16	22	O	reviews	ews	iews	NNS	False
DDI-MedLine.d31.s5	recent	24	29	O	recent	ent	cent	JJ	False
DDI-MedLine.d31.s5	developments	31	42	O	developments	nts	ents	NNS	False
DDI-MedLine.d31.s5	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d31.s5	these	47	51	O	these	ese	hese	DT	False
DDI-MedLine.d31.s5	areas	53	57	O	areas	eas	reas	NNS	False
DDI-MedLine.d31.s5	,	58	58	O	,	,	,	,	False
DDI-MedLine.d31.s5	examines	60	67	O	examines	nes	ines	NNS	group
DDI-MedLine.d31.s5	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d31.s5	effects	73	79	O	effects	cts	ects	NNS	False
DDI-MedLine.d31.s5	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d31.s5	drug	84	87	O	drug	rug	drug	NN	False
DDI-MedLine.d31.s5	use	89	91	O	use	use	use	NN	False
DDI-MedLine.d31.s5	in	93	94	O	in	in	in	IN	False
DDI-MedLine.d31.s5	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d31.s5	elderly	100	106	O	elderly	rly	erly	RB	False
DDI-MedLine.d31.s5	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d31.s5	implications	112	123	O	implications	ons	ions	NNS	False
DDI-MedLine.d31.s5	for	125	127	O	for	for	for	IN	False
DDI-MedLine.d31.s5	management	129	138	O	management	ent	ment	NN	False
DDI-MedLine.d31.s5	,	139	139	O	,	,	,	,	False
DDI-MedLine.d31.s5	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d31.s5	discusses	145	153	O	discusses	ses	sses	NNS	False
DDI-MedLine.d31.s5	current	155	161	O	current	ent	rent	JJ	False
DDI-MedLine.d31.s5	information	163	173	O	information	ion	tion	NN	False
DDI-MedLine.d31.s5	on	175	176	O	on	on	on	IN	False
DDI-MedLine.d31.s5	how	178	180	O	how	how	how	WRB	False
DDI-MedLine.d31.s5	age	182	184	O	age	age	age	NN	False
DDI-MedLine.d31.s5	may	186	188	O	may	may	may	MD	False
DDI-MedLine.d31.s5	influence	190	198	O	influence	nce	ence	NN	False
DDI-MedLine.d31.s5	the	200	202	O	the	the	the	DT	False
DDI-MedLine.d31.s5	response	204	211	O	response	nse	onse	NN	False
DDI-MedLine.d31.s5	of	213	214	O	of	of	of	IN	False
DDI-MedLine.d31.s5	cancer	216	221	O	cancer	cer	ncer	NN	False
DDI-MedLine.d31.s5	to	223	224	O	to	to	to	TO	False
DDI-MedLine.d31.s5	therapy	226	232	O	therapy	apy	rapy	NN	False
DDI-MedLine.d31.s5	.	233	233	O	.	.	.	.	False

DDI-MedLine.d100.s0	Influence	0	8	O	Influence	nce	ence	NN	False
DDI-MedLine.d100.s0	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d100.s0	calcium-channel	13	27	B-group	calcium-channel	nel	nnel	NN	False
DDI-MedLine.d100.s0	blockers	29	36	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d100.s0	on	38	39	O	on	on	on	IN	False
DDI-MedLine.d100.s0	platelet	41	48	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s0	function	50	57	O	function	ion	tion	NN	False
DDI-MedLine.d100.s0	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d100.s0	arachidonic	63	73	O	arachidonic	nic	onic	NN	False
DDI-MedLine.d100.s0	acid	75	78	O	acid	cid	acid	NN	False
DDI-MedLine.d100.s0	metabolism	80	89	O	metabolism	ism	lism	NN	False
DDI-MedLine.d100.s0	.	90	90	O	.	.	.	.	False

DDI-MedLine.d100.s1	Available	0	8	O	Available	ble	able	JJ	False
DDI-MedLine.d100.s1	data	10	13	O	data	ata	data	NNS	False
DDI-MedLine.d100.s1	indicate	15	22	O	indicate	ate	cate	NN	False
DDI-MedLine.d100.s1	that	24	27	O	that	hat	that	IN	False
DDI-MedLine.d100.s1	platelet	29	36	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s1	function	38	45	O	function	ion	tion	NN	False
DDI-MedLine.d100.s1	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d100.s1	arachidonic	51	61	O	arachidonic	nic	onic	NN	False
DDI-MedLine.d100.s1	acid	63	66	O	acid	cid	acid	NN	False
DDI-MedLine.d100.s1	metabolism	68	77	O	metabolism	ism	lism	NN	False
DDI-MedLine.d100.s1	are	79	81	O	are	are	are	VBP	False
DDI-MedLine.d100.s1	important	83	91	O	important	ant	tant	JJ	False
DDI-MedLine.d100.s1	factors	93	99	O	factors	ors	tors	NNS	False
DDI-MedLine.d100.s1	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d100.s1	hemostasis	104	113	O	hemostasis	sis	asis	NN	False
DDI-MedLine.d100.s1	and	115	117	O	and	and	and	CC	False
DDI-MedLine.d100.s1	regulation	119	128	O	regulation	ion	tion	NN	False
DDI-MedLine.d100.s1	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d100.s1	vascular	133	140	O	vascular	lar	ular	NN	False
DDI-MedLine.d100.s1	tone	142	145	O	tone	one	tone	NN	False
DDI-MedLine.d100.s1	.	146	146	O	.	.	.	.	False

DDI-MedLine.d100.s2	Plasma	0	5	O	Plasma	sma	asma	NN	False
DDI-MedLine.d100.s2	membrane	7	14	O	membrane	ane	rane	NN	False
DDI-MedLine.d100.s2	and	16	18	O	and	and	and	CC	False
DDI-MedLine.d100.s2	intracellular	20	32	O	intracellular	lar	ular	NN	False
DDI-MedLine.d100.s2	mobilization	34	45	O	mobilization	ion	tion	NN	False
DDI-MedLine.d100.s2	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d100.s2	calcium	50	56	O	calcium	ium	cium	NN	drug
DDI-MedLine.d100.s2	ions	58	61	O	ions	ons	ions	NNS	False
DDI-MedLine.d100.s2	are	63	65	O	are	are	are	VBP	False
DDI-MedLine.d100.s2	intimately	67	76	O	intimately	ely	tely	RB	False
DDI-MedLine.d100.s2	related	78	84	O	related	ted	ated	JJ	False
DDI-MedLine.d100.s2	to	86	87	O	to	to	to	TO	False
DDI-MedLine.d100.s2	platelet	89	96	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s2	activation	98	107	O	activation	ion	tion	NN	False
DDI-MedLine.d100.s2	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d100.s2	release	113	119	O	release	ase	ease	NN	False
DDI-MedLine.d100.s2	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d100.s2	platelet	124	131	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s2	contents	133	140	O	contents	nts	ents	NNS	False
DDI-MedLine.d100.s2	.	141	141	O	.	.	.	.	False

DDI-MedLine.d100.s3	Release	0	6	O	Release	ase	ease	NN	False
DDI-MedLine.d100.s3	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d100.s3	arachidonic	11	21	O	arachidonic	nic	onic	NN	False
DDI-MedLine.d100.s3	acid	23	26	O	acid	cid	acid	NN	False
DDI-MedLine.d100.s3	from	28	31	O	from	rom	from	IN	False
DDI-MedLine.d100.s3	membrane	33	40	O	membrane	ane	rane	NN	False
DDI-MedLine.d100.s3	phospholipids	42	54	O	phospholipids	ids	pids	NNS	False
DDI-MedLine.d100.s3	as	56	57	O	as	as	as	IN	False
DDI-MedLine.d100.s3	well	59	62	O	well	ell	well	RB	False
DDI-MedLine.d100.s3	as	64	65	O	as	as	as	IN	False
DDI-MedLine.d100.s3	subsequent	67	76	O	subsequent	ent	uent	NN	False
DDI-MedLine.d100.s3	synthesis	78	86	O	synthesis	sis	esis	NN	False
DDI-MedLine.d100.s3	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d100.s3	release	92	98	O	release	ase	ease	NN	False
DDI-MedLine.d100.s3	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d100.s3	vasoconstrictor	103	117	O	vasoconstrictor	tor	ctor	NN	False
DDI-MedLine.d100.s3	thromboxane	119	129	O	thromboxane	ane	xane	NN	False
DDI-MedLine.d100.s3	A2	131	132	O	A2	A2	A2	NN	brand
DDI-MedLine.d100.s3	are	134	136	O	are	are	are	VBP	False
DDI-MedLine.d100.s3	also	138	141	O	also	lso	also	RB	False
DDI-MedLine.d100.s3	regulated	143	151	O	regulated	ted	ated	VBN	False
DDI-MedLine.d100.s3	by	153	154	O	by	by	by	IN	False
DDI-MedLine.d100.s3	movement	156	163	O	movement	ent	ment	NN	False
DDI-MedLine.d100.s3	of	165	166	O	of	of	of	IN	False
DDI-MedLine.d100.s3	calcium	168	174	O	calcium	ium	cium	NN	drug
DDI-MedLine.d100.s3	ions	176	179	O	ions	ons	ions	NNS	False
DDI-MedLine.d100.s3	.	180	180	O	.	.	.	.	False

DDI-MedLine.d100.s4	Adenosine	0	8	O	Adenosine	ine	sine	NN	drug
DDI-MedLine.d100.s4	3':5'-cyclic	10	21	O	3':5'-cyclic	lic	clic	JJ	False
DDI-MedLine.d100.s4	phosphate	23	31	O	phosphate	ate	hate	NN	False
DDI-MedLine.d100.s4	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d100.s4	turn	36	39	O	turn	urn	turn	NN	False
DDI-MedLine.d100.s4	controls	41	48	O	controls	ols	rols	NNS	False
DDI-MedLine.d100.s4	levels	50	55	O	levels	els	vels	NNS	False
DDI-MedLine.d100.s4	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d100.s4	free	60	63	O	free	ree	free	JJ	False
DDI-MedLine.d100.s4	calcium	65	71	O	calcium	ium	cium	NN	drug
DDI-MedLine.d100.s4	ions	73	76	O	ions	ons	ions	NNS	False
DDI-MedLine.d100.s4	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d100.s4	platelets	81	89	O	platelets	ets	lets	NNS	False
DDI-MedLine.d100.s4	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d100.s4	regulates	95	103	O	regulates	tes	ates	NNS	False
DDI-MedLine.d100.s4	calcium-dependent	105	121	O	calcium-dependent	ent	dent	NN	False
DDI-MedLine.d100.s4	reactions	123	131	O	reactions	ons	ions	NNS	False
DDI-MedLine.d100.s4	.	132	132	O	.	.	.	.	False

DDI-MedLine.d100.s5	Slow-channel	0	11	B-group	Slow-channel	nel	nnel	NN	False
DDI-MedLine.d100.s5	calcium	13	19	I-group	calcium	ium	cium	NN	drug
DDI-MedLine.d100.s5	blockers	21	28	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d100.s5	,	29	29	O	,	,	,	,	False
DDI-MedLine.d100.s5	such	31	34	O	such	uch	such	JJ	False
DDI-MedLine.d100.s5	as	36	37	O	as	as	as	IN	False
DDI-MedLine.d100.s5	verapamil	39	47	B-drug	verapamil	mil	amil	NN	False
DDI-MedLine.d100.s5	,	48	48	O	,	,	,	,	False
DDI-MedLine.d100.s5	diltiazem	50	58	B-drug	diltiazem	zem	azem	NN	False
DDI-MedLine.d100.s5	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d100.s5	nifedipine	64	73	B-drug	nifedipine	ine	pine	NN	drug
DDI-MedLine.d100.s5	,	74	74	O	,	,	,	,	False
DDI-MedLine.d100.s5	inhibit	76	82	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d100.s5	platelet	84	91	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s5	activation	93	102	O	activation	ion	tion	NN	False
DDI-MedLine.d100.s5	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d100.s5	vitro	107	111	O	vitro	tro	itro	NN	False
DDI-MedLine.d100.s5	,	112	112	O	,	,	,	,	False
DDI-MedLine.d100.s5	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d100.s5	decrease	118	125	O	decrease	ase	ease	NN	False
DDI-MedLine.d100.s5	platelet	127	134	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s5	adhesion	136	143	O	adhesion	ion	sion	NN	False
DDI-MedLine.d100.s5	intravascularly	145	159	O	intravascularly	rly	arly	RB	False
DDI-MedLine.d100.s5	.	160	160	O	.	.	.	.	False

DDI-MedLine.d100.s6	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d100.s6	agents	6	11	O	agents	nts	ents	NNS	False
DDI-MedLine.d100.s6	have	13	16	O	have	ave	have	VB	False
DDI-MedLine.d100.s6	also	18	21	O	also	lso	also	RB	False
DDI-MedLine.d100.s6	been	23	26	O	been	een	been	VBN	False
DDI-MedLine.d100.s6	shown	28	32	O	shown	own	hown	VBN	False
DDI-MedLine.d100.s6	to	34	35	O	to	to	to	TO	False
DDI-MedLine.d100.s6	decrease	37	44	O	decrease	ase	ease	NN	False
DDI-MedLine.d100.s6	platelet	46	53	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s6	nucleotide	55	64	O	nucleotide	ide	tide	RB	False
DDI-MedLine.d100.s6	release	66	72	O	release	ase	ease	NN	False
DDI-MedLine.d100.s6	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d100.s6	thromboxane	78	88	O	thromboxane	ane	xane	NN	False
DDI-MedLine.d100.s6	A2	90	91	O	A2	A2	A2	NN	brand
DDI-MedLine.d100.s6	generation	93	102	O	generation	ion	tion	NN	False
DDI-MedLine.d100.s6	.	103	103	O	.	.	.	.	False

DDI-MedLine.d100.s7	Some	0	3	O	Some	ome	Some	DT	False
DDI-MedLine.d100.s7	preliminary	5	15	O	preliminary	ary	nary	JJ	False
DDI-MedLine.d100.s7	data	17	20	O	data	ata	data	NNS	False
DDI-MedLine.d100.s7	suggest	22	28	O	suggest	est	gest	NN	False
DDI-MedLine.d100.s7	that	30	33	O	that	hat	that	IN	False
DDI-MedLine.d100.s7	calcium	35	41	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d100.s7	blockers	43	50	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d100.s7	also	52	55	O	also	lso	also	RB	False
DDI-MedLine.d100.s7	increase	57	64	O	increase	ase	ease	NN	False
DDI-MedLine.d100.s7	generation	66	75	O	generation	ion	tion	NN	False
DDI-MedLine.d100.s7	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d100.s7	vasodilator	80	90	O	vasodilator	tor	ator	NN	False
DDI-MedLine.d100.s7	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d100.s7	platelet	96	103	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s7	antiaggregant	105	117	O	antiaggregant	ant	gant	NN	False
DDI-MedLine.d100.s7	prostacyclin	119	130	O	prostacyclin	lin	clin	NN	False
DDI-MedLine.d100.s7	,	131	131	O	,	,	,	,	False
DDI-MedLine.d100.s7	which	133	137	O	which	ich	hich	WDT	False
DDI-MedLine.d100.s7	could	139	143	O	could	uld	ould	MD	False
DDI-MedLine.d100.s7	contribute	145	154	O	contribute	ute	bute	NN	False
DDI-MedLine.d100.s7	to	156	157	O	to	to	to	TO	False
DDI-MedLine.d100.s7	decrease	159	166	O	decrease	ase	ease	NN	False
DDI-MedLine.d100.s7	in	168	169	O	in	in	in	IN	False
DDI-MedLine.d100.s7	platelet	171	178	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s7	function	180	187	O	function	ion	tion	NN	False
DDI-MedLine.d100.s7	.	188	188	O	.	.	.	.	False

DDI-MedLine.d100.s8	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d100.s8	effects	6	12	O	effects	cts	ects	NNS	False
DDI-MedLine.d100.s8	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d100.s8	calcium	17	23	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d100.s8	blockers	25	32	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d100.s8	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d100.s8	platelet	37	44	O	platelet	let	elet	NN	False
DDI-MedLine.d100.s8	function	46	53	O	function	ion	tion	NN	False
DDI-MedLine.d100.s8	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d100.s8	arachidonic	59	69	O	arachidonic	nic	onic	NN	False
DDI-MedLine.d100.s8	acid	71	74	O	acid	cid	acid	NN	False
DDI-MedLine.d100.s8	metabolism	76	85	O	metabolism	ism	lism	NN	False
DDI-MedLine.d100.s8	could	87	91	O	could	uld	ould	MD	False
DDI-MedLine.d100.s8	contribute	93	102	O	contribute	ute	bute	NN	False
DDI-MedLine.d100.s8	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d100.s8	part	107	110	O	part	art	part	NN	False
DDI-MedLine.d100.s8	to	112	113	O	to	to	to	TO	False
DDI-MedLine.d100.s8	their	115	119	O	their	eir	heir	PRP$	False
DDI-MedLine.d100.s8	efficacy	121	128	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d100.s8	in	130	131	O	in	in	in	IN	False
DDI-MedLine.d100.s8	patients	133	140	O	patients	nts	ents	NNS	False
DDI-MedLine.d100.s8	with	142	145	O	with	ith	with	IN	False
DDI-MedLine.d100.s8	ischemic	147	154	O	ischemic	mic	emic	JJ	False
DDI-MedLine.d100.s8	heart	156	160	O	heart	art	eart	NN	False
DDI-MedLine.d100.s8	disease	162	168	O	disease	ase	ease	NN	False
DDI-MedLine.d100.s8	.	169	169	O	.	.	.	.	False

DDI-MedLine.d48.s0	Modification	0	11	O	Modification	ion	tion	NN	False
DDI-MedLine.d48.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d48.s0	surface	16	22	O	surface	ace	face	NN	False
DDI-MedLine.d48.s0	histidine	24	32	O	histidine	ine	dine	NN	drug
DDI-MedLine.d48.s0	residues	34	41	O	residues	ues	dues	NNS	False
DDI-MedLine.d48.s0	abolishes	43	51	O	abolishes	hes	shes	NNS	False
DDI-MedLine.d48.s0	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d48.s0	cytotoxic	57	65	O	cytotoxic	xic	oxic	NN	False
DDI-MedLine.d48.s0	activity	67	74	O	activity	ity	vity	NN	False
DDI-MedLine.d48.s0	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d48.s0	Clostridium	79	89	B-drug_n	Clostridium	ium	dium	NN	drug
DDI-MedLine.d48.s0	difficile	91	99	I-drug_n	difficile	ile	cile	NN	False
DDI-MedLine.d48.s0	toxin	101	105	I-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s0	A	107	107	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s0	.	108	108	O	.	.	.	.	False

DDI-MedLine.d48.s1	Clostridium	0	10	B-drug_n	Clostridium	ium	dium	NN	drug
DDI-MedLine.d48.s1	difficile	12	20	I-drug_n	difficile	ile	cile	NN	False
DDI-MedLine.d48.s1	toxin	22	26	I-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s1	A	28	28	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s1	displays	30	37	O	displays	ays	lays	NNS	False
DDI-MedLine.d48.s1	both	39	42	O	both	oth	both	DT	False
DDI-MedLine.d48.s1	cytotoxic	44	52	O	cytotoxic	xic	oxic	NN	False
DDI-MedLine.d48.s1	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d48.s1	enterotoxic	58	68	O	enterotoxic	xic	oxic	NN	False
DDI-MedLine.d48.s1	activities	70	79	O	activities	ies	ties	NNS	False
DDI-MedLine.d48.s1	.	80	80	O	.	.	.	.	False

DDI-MedLine.d48.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d48.s2	has	3	5	O	has	has	has	VBZ	False
DDI-MedLine.d48.s2	recently	7	14	O	recently	tly	ntly	RB	False
DDI-MedLine.d48.s2	been	16	19	O	been	een	been	VBN	False
DDI-MedLine.d48.s2	demonstrated	21	32	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d48.s2	that	34	37	O	that	hat	that	IN	False
DDI-MedLine.d48.s2	toxin	39	43	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s2	A	45	45	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s2	exerts	47	52	O	exerts	rts	erts	NNS	False
DDI-MedLine.d48.s2	its	54	56	O	its	its	its	PRP$	False
DDI-MedLine.d48.s2	cytotoxic	58	66	O	cytotoxic	xic	oxic	NN	False
DDI-MedLine.d48.s2	effect	68	73	O	effect	ect	fect	NN	False
DDI-MedLine.d48.s2	by	75	76	O	by	by	by	IN	False
DDI-MedLine.d48.s2	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d48.s2	glucosylation	82	94	O	glucosylation	ion	tion	NN	False
DDI-MedLine.d48.s2	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d48.s2	the	99	101	O	the	the	the	DT	False
DDI-MedLine.d48.s2	small	103	107	O	small	all	mall	JJ	False
DDI-MedLine.d48.s2	GTP-binding	109	119	O	GTP-binding	ing	ding	NN	False
DDI-MedLine.d48.s2	proteins	121	128	O	proteins	ins	eins	NNS	False
DDI-MedLine.d48.s2	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d48.s2	the	133	135	O	the	the	the	DT	False
DDI-MedLine.d48.s2	Rho	137	139	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d48.s2	family	141	146	O	family	ily	mily	NN	False
DDI-MedLine.d48.s2	.	147	147	O	.	.	.	.	False

DDI-MedLine.d48.s3	Diethyl	0	6	B-drug_n	Diethyl	hyl	thyl	NN	False
DDI-MedLine.d48.s3	pyrocarbonate	8	20	I-drug_n	pyrocarbonate	ate	nate	NN	False
DDI-MedLine.d48.s3	,	21	21	O	,	,	,	,	False
DDI-MedLine.d48.s3	at	23	24	O	at	at	at	IN	False
DDI-MedLine.d48.s3	pH	26	27	O	pH	pH	pH	NN	False
DDI-MedLine.d48.s3	7.0	29	31	O	7.0	7.0	7.0	CD	False
DDI-MedLine.d48.s3	,	32	32	O	,	,	,	,	False
DDI-MedLine.d48.s3	was	34	36	O	was	was	was	VBD	False
DDI-MedLine.d48.s3	used	38	41	O	used	sed	used	VBN	False
DDI-MedLine.d48.s3	to	43	44	O	to	to	to	TO	False
DDI-MedLine.d48.s3	chemically	46	55	O	chemically	lly	ally	RB	False
DDI-MedLine.d48.s3	modify	57	62	O	modify	ify	dify	NN	False
DDI-MedLine.d48.s3	exposed	64	70	O	exposed	sed	osed	VBN	False
DDI-MedLine.d48.s3	histidine	72	80	O	histidine	ine	dine	NN	drug
DDI-MedLine.d48.s3	residues	82	89	O	residues	ues	dues	NNS	False
DDI-MedLine.d48.s3	on	91	92	O	on	on	on	IN	False
DDI-MedLine.d48.s3	toxin	94	98	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s3	A	100	100	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s3	.	101	101	O	.	.	.	.	False

DDI-MedLine.d48.s4	Modification	0	11	O	Modification	ion	tion	NN	False
DDI-MedLine.d48.s4	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d48.s4	toxin	16	20	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s4	A	22	22	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s4	with	24	27	O	with	ith	with	IN	False
DDI-MedLine.d48.s4	diethyl	29	35	B-drug_n	diethyl	hyl	thyl	NN	False
DDI-MedLine.d48.s4	pyrocarbonate	37	49	I-drug_n	pyrocarbonate	ate	nate	NN	False
DDI-MedLine.d48.s4	abolished	51	59	O	abolished	hed	shed	VBN	False
DDI-MedLine.d48.s4	both	61	64	O	both	oth	both	DT	False
DDI-MedLine.d48.s4	its	66	68	O	its	its	its	PRP$	False
DDI-MedLine.d48.s4	cytotoxic	70	78	O	cytotoxic	xic	oxic	NN	False
DDI-MedLine.d48.s4	activity	80	87	O	activity	ity	vity	NN	False
DDI-MedLine.d48.s4	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d48.s4	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d48.s4	ability	97	103	O	ability	ity	lity	NN	False
DDI-MedLine.d48.s4	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d48.s4	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d48.s4	toxin	112	116	O	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s4	to	118	119	O	to	to	to	TO	False
DDI-MedLine.d48.s4	bind	121	124	O	bind	ind	bind	NN	False
DDI-MedLine.d48.s4	Zn-Sepharose	126	137	O	Zn-Sepharose	ose	rose	JJ	False
DDI-MedLine.d48.s4	gel	139	141	O	gel	gel	gel	NN	False
DDI-MedLine.d48.s4	.	142	142	O	.	.	.	.	False

DDI-MedLine.d48.s5	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d48.s5	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d48.s5	toxin	13	17	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s5	A	19	19	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s5	with	21	24	O	with	ith	with	IN	False
DDI-MedLine.d48.s5	[	26	26	O	[	[	[	NN	False
DDI-MedLine.d48.s5	(	27	27	O	(	(	(	(	False
DDI-MedLine.d48.s5	14	28	29	O	14	14	14	CD	False
DDI-MedLine.d48.s5	)	30	30	O	)	)	)	)	False
DDI-MedLine.d48.s5	C	31	31	O	C	C	C	SYM	brand
DDI-MedLine.d48.s5	]	32	32	O	]	]	]	NN	False
DDI-MedLine.d48.s5	-diethyl	33	40	O	-diethyl	hyl	thyl	NN	False
DDI-MedLine.d48.s5	pyrocarbonate	42	54	I-drug_n	pyrocarbonate	ate	nate	NN	False
DDI-MedLine.d48.s5	revealed	56	63	O	revealed	led	aled	VBD	False
DDI-MedLine.d48.s5	concentration	65	77	O	concentration	ion	tion	NN	False
DDI-MedLine.d48.s5	dependent	79	87	O	dependent	ent	dent	NN	False
DDI-MedLine.d48.s5	labelling	89	97	O	labelling	ing	ling	VBG	False
DDI-MedLine.d48.s5	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d48.s5	histidine	102	110	O	histidine	ine	dine	NN	drug
DDI-MedLine.d48.s5	residues	112	119	O	residues	ues	dues	NNS	False
DDI-MedLine.d48.s5	on	121	122	O	on	on	on	IN	False
DDI-MedLine.d48.s5	the	124	126	O	the	the	the	DT	False
DDI-MedLine.d48.s5	toxin	128	132	O	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s5	molecules	134	142	O	molecules	les	ules	NNS	False
DDI-MedLine.d48.s5	.	143	143	O	.	.	.	.	False

DDI-MedLine.d48.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d48.s6	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d48.s6	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d48.s6	diethyl	15	21	B-drug_n	diethyl	hyl	thyl	NN	False
DDI-MedLine.d48.s6	pyrocarbonate	23	35	I-drug_n	pyrocarbonate	ate	nate	NN	False
DDI-MedLine.d48.s6	could	37	41	O	could	uld	ould	MD	False
DDI-MedLine.d48.s6	be	43	44	O	be	be	be	VB	False
DDI-MedLine.d48.s6	reversed	46	53	O	reversed	sed	rsed	VBN	False
DDI-MedLine.d48.s6	by	55	56	O	by	by	by	IN	False
DDI-MedLine.d48.s6	hydroxylamine	58	70	B-drug_n	hydroxylamine	ine	mine	NN	drug
DDI-MedLine.d48.s6	treatment	72	80	O	treatment	ent	ment	NN	False
DDI-MedLine.d48.s6	.	81	81	O	.	.	.	.	False

DDI-MedLine.d48.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d48.s7	data	6	9	O	data	ata	data	NNS	False
DDI-MedLine.d48.s7	suggest	11	17	O	suggest	est	gest	NN	False
DDI-MedLine.d48.s7	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d48.s7	modified	23	30	O	modified	ied	fied	VBN	False
DDI-MedLine.d48.s7	histidine	32	40	O	histidine	ine	dine	NN	drug
DDI-MedLine.d48.s7	residues	42	49	O	residues	ues	dues	NNS	False
DDI-MedLine.d48.s7	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d48.s7	toxin	54	58	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s7	A	60	60	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s7	are	62	64	O	are	are	are	VBP	False
DDI-MedLine.d48.s7	critical	66	73	O	critical	cal	ical	JJ	False
DDI-MedLine.d48.s7	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d48.s7	its	78	80	O	its	its	its	PRP$	False
DDI-MedLine.d48.s7	cytotoxic	82	90	O	cytotoxic	xic	oxic	NN	False
DDI-MedLine.d48.s7	activity	92	99	O	activity	ity	vity	NN	False
DDI-MedLine.d48.s7	.	100	100	O	.	.	.	.	False

DDI-MedLine.d48.s8	Histidine	0	8	O	Histidine	ine	dine	NN	drug
DDI-MedLine.d48.s8	modification	10	21	O	modification	ion	tion	NN	False
DDI-MedLine.d48.s8	had	23	25	O	had	had	had	VBD	False
DDI-MedLine.d48.s8	no	27	28	O	no	no	no	DT	False
DDI-MedLine.d48.s8	effect	30	35	O	effect	ect	fect	NN	False
DDI-MedLine.d48.s8	on	37	38	O	on	on	on	IN	False
DDI-MedLine.d48.s8	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d48.s8	glucosyl	44	51	O	glucosyl	syl	osyl	NN	False
DDI-MedLine.d48.s8	transferase	53	63	O	transferase	ase	rase	NN	False
DDI-MedLine.d48.s8	enzyme	65	70	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d48.s8	activity	72	79	O	activity	ity	vity	NN	False
DDI-MedLine.d48.s8	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d48.s8	toxin	84	88	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s8	A	90	90	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s8	.	91	91	O	.	.	.	.	False

DDI-MedLine.d48.s9	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d48.s9	,	7	7	O	,	,	,	,	False
DDI-MedLine.d48.s9	modification	9	20	O	modification	ion	tion	NN	False
DDI-MedLine.d48.s9	abolished	22	30	O	abolished	hed	shed	VBN	False
DDI-MedLine.d48.s9	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d48.s9	'cold	36	40	O	'cold	old	cold	NN	False
DDI-MedLine.d48.s9	'	41	41	O	'	'	'	''	False
DDI-MedLine.d48.s9	binding	43	49	O	binding	ing	ding	NN	False
DDI-MedLine.d48.s9	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d48.s9	toxin	54	58	O	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s9	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d48.s9	bovine	63	68	O	bovine	ine	vine	NN	drug
DDI-MedLine.d48.s9	thyroglobulin	70	82	O	thyroglobulin	lin	ulin	NN	False
DDI-MedLine.d48.s9	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d48.s9	an	87	88	O	an	an	an	DT	False
DDI-MedLine.d48.s9	ELISA	90	94	O	ELISA	ISA	LISA	NN	brand
DDI-MedLine.d48.s9	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d48.s9	reduced	100	106	O	reduced	ced	uced	VBN	False
DDI-MedLine.d48.s9	ligand	108	113	O	ligand	and	gand	NN	False
DDI-MedLine.d48.s9	binding	115	121	O	binding	ing	ding	NN	False
DDI-MedLine.d48.s9	activity	123	130	O	activity	ity	vity	NN	False
DDI-MedLine.d48.s9	in	132	133	O	in	in	in	IN	False
DDI-MedLine.d48.s9	a	135	135	O	a	a	a	DT	False
DDI-MedLine.d48.s9	rabbit	137	142	O	rabbit	bit	bbit	NN	False
DDI-MedLine.d48.s9	erythrocyte	144	154	O	erythrocyte	yte	cyte	NN	False
DDI-MedLine.d48.s9	haemagglutination	156	172	O	haemagglutination	ion	tion	NN	False
DDI-MedLine.d48.s9	assay	174	178	O	assay	say	ssay	NN	False
DDI-MedLine.d48.s9	.	179	179	O	.	.	.	.	False

DDI-MedLine.d48.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d48.s10	data	4	7	O	data	ata	data	NNS	False
DDI-MedLine.d48.s10	suggest	9	15	O	suggest	est	gest	NN	False
DDI-MedLine.d48.s10	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d48.s10	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d48.s10	histidine	26	34	O	histidine	ine	dine	NN	drug
DDI-MedLine.d48.s10	residues	36	43	O	residues	ues	dues	NNS	False
DDI-MedLine.d48.s10	may	45	47	O	may	may	may	MD	False
DDI-MedLine.d48.s10	be	49	50	O	be	be	be	VB	False
DDI-MedLine.d48.s10	crucial	52	58	O	crucial	ial	cial	JJ	False
DDI-MedLine.d48.s10	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d48.s10	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d48.s10	receptor-binding	67	82	O	receptor-binding	ing	ding	NN	False
DDI-MedLine.d48.s10	activity	84	91	O	activity	ity	vity	NN	False
DDI-MedLine.d48.s10	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d48.s10	toxin	96	100	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s10	A	102	102	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s10	.	103	103	O	.	.	.	.	False

DDI-MedLine.d48.s11	Exposed	0	6	O	Exposed	sed	osed	VBN	False
DDI-MedLine.d48.s11	histidines	8	17	O	histidines	nes	ines	NNS	group
DDI-MedLine.d48.s11	on	19	20	O	on	on	on	IN	False
DDI-MedLine.d48.s11	toxin	22	26	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s11	A	28	28	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s11	are	30	32	O	are	are	are	VBP	False
DDI-MedLine.d48.s11	available	34	42	O	available	ble	able	JJ	False
DDI-MedLine.d48.s11	for	44	46	O	for	for	for	IN	False
DDI-MedLine.d48.s11	zinc	48	51	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d48.s11	chelation	53	61	O	chelation	ion	tion	NN	False
DDI-MedLine.d48.s11	,	62	62	O	,	,	,	,	False
DDI-MedLine.d48.s11	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d48.s11	these	68	72	O	these	ese	hese	DT	False
DDI-MedLine.d48.s11	have	74	77	O	have	ave	have	VB	False
DDI-MedLine.d48.s11	been	79	82	O	been	een	been	VBN	False
DDI-MedLine.d48.s11	exploited	84	92	O	exploited	ted	ited	VBN	False
DDI-MedLine.d48.s11	in	94	95	O	in	in	in	IN	False
DDI-MedLine.d48.s11	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d48.s11	development	101	111	O	development	ent	ment	NN	False
DDI-MedLine.d48.s11	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d48.s11	a	116	116	O	a	a	a	DT	False
DDI-MedLine.d48.s11	novel	118	122	O	novel	vel	ovel	NN	False
DDI-MedLine.d48.s11	purification	124	135	O	purification	ion	tion	NN	False
DDI-MedLine.d48.s11	protocol	137	144	O	protocol	col	ocol	NN	False
DDI-MedLine.d48.s11	for	146	148	O	for	for	for	IN	False
DDI-MedLine.d48.s11	toxin	150	154	B-drug_n	toxin	xin	oxin	NN	False
DDI-MedLine.d48.s11	A	156	156	I-drug_n	A	A	A	DT	brand
DDI-MedLine.d48.s11	using	158	162	O	using	ing	sing	VBG	False
DDI-MedLine.d48.s11	zinc-chelating	164	177	O	zinc-chelating	ing	ting	NN	False
DDI-MedLine.d48.s11	chromatography	179	192	O	chromatography	phy	aphy	NN	False
DDI-MedLine.d48.s11	.	193	193	O	.	.	.	.	False

DDI-MedLine.d27.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d27.s0	The	1	3	O	The	The	The	DT	False
DDI-MedLine.d27.s0	GABA-ergic	5	14	O	GABA-ergic	gic	rgic	JJ	False
DDI-MedLine.d27.s0	system	16	21	O	system	tem	stem	NN	False
DDI-MedLine.d27.s0	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d27.s0	brain	27	31	O	brain	ain	rain	NN	False
DDI-MedLine.d27.s0	edema	33	37	O	edema	ema	dema	NN	False
DDI-MedLine.d27.s0	]	38	38	O	]	]	]	NN	False
DDI-MedLine.d27.s0	It	41	42	O	It	It	It	PRP	False
DDI-MedLine.d27.s0	has	44	46	O	has	has	has	VBZ	False
DDI-MedLine.d27.s0	been	48	51	O	been	een	been	VBN	False
DDI-MedLine.d27.s0	shown	53	57	O	shown	own	hown	VBN	False
DDI-MedLine.d27.s0	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d27.s0	rats	62	65	O	rats	ats	rats	NNS	False
DDI-MedLine.d27.s0	with	67	70	O	with	ith	with	IN	False
DDI-MedLine.d27.s0	experimental	72	83	O	experimental	tal	ntal	NN	False
DDI-MedLine.d27.s0	toxic	85	89	O	toxic	xic	oxic	NN	False
DDI-MedLine.d27.s0	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d27.s0	traumatic	95	103	O	traumatic	tic	atic	JJ	False
DDI-MedLine.d27.s0	edemas	105	110	O	edemas	mas	emas	NN	False
DDI-MedLine.d27.s0	that	112	115	O	that	hat	that	IN	False
DDI-MedLine.d27.s0	picrotoxin	117	126	B-drug_n	picrotoxin	xin	oxin	NN	False
DDI-MedLine.d27.s0	(	128	128	O	(	(	(	(	False
DDI-MedLine.d27.s0	1	129	129	O	1	1	1	CD	False
DDI-MedLine.d27.s0	mg/kg	131	135	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d27.s0	)	136	136	O	)	)	)	)	False
DDI-MedLine.d27.s0	removes	138	144	O	removes	ves	oves	NNS	False
DDI-MedLine.d27.s0	the	146	148	O	the	the	the	DT	False
DDI-MedLine.d27.s0	antiedematous	150	162	O	antiedematous	ous	tous	JJ	False
DDI-MedLine.d27.s0	action	164	169	O	action	ion	tion	NN	False
DDI-MedLine.d27.s0	of	171	172	O	of	of	of	IN	False
DDI-MedLine.d27.s0	diazepam	174	181	B-drug	diazepam	pam	epam	NN	False
DDI-MedLine.d27.s0	,	182	182	O	,	,	,	,	False
DDI-MedLine.d27.s0	phenazepam	184	193	B-drug_n	phenazepam	pam	epam	NN	False
DDI-MedLine.d27.s0	,	194	194	O	,	,	,	,	False
DDI-MedLine.d27.s0	phenibut	196	203	B-drug_n	phenibut	but	ibut	NN	False
DDI-MedLine.d27.s0	and	205	207	O	and	and	and	CC	False
DDI-MedLine.d27.s0	amizyl	209	214	B-drug_n	amizyl	zyl	izyl	NN	False
DDI-MedLine.d27.s0	and	216	218	O	and	and	and	CC	False
DDI-MedLine.d27.s0	reduces	220	226	O	reduces	ces	uces	NNS	False
DDI-MedLine.d27.s0	the	228	230	O	the	the	the	DT	False
DDI-MedLine.d27.s0	action	232	237	O	action	ion	tion	NN	False
DDI-MedLine.d27.s0	of	239	240	O	of	of	of	IN	False
DDI-MedLine.d27.s0	phentolamine	242	253	B-drug	phentolamine	ine	mine	NN	drug
DDI-MedLine.d27.s0	.	254	254	O	.	.	.	.	False

DDI-MedLine.d27.s1	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d27.s1	the	5	7	O	the	the	the	DT	False
DDI-MedLine.d27.s1	dose	9	12	O	dose	ose	dose	NN	False
DDI-MedLine.d27.s1	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d27.s1	picrotoxin	17	26	B-drug_n	picrotoxin	xin	oxin	NN	False
DDI-MedLine.d27.s1	is	28	29	O	is	is	is	VBZ	False
DDI-MedLine.d27.s1	minimized	31	39	O	minimized	zed	ized	VBN	False
DDI-MedLine.d27.s1	to	41	42	O	to	to	to	TO	False
DDI-MedLine.d27.s1	0.5	44	46	O	0.5	0.5	0.5	CD	False
DDI-MedLine.d27.s1	mg/kg	48	52	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d27.s1	such	54	57	O	such	uch	such	JJ	False
DDI-MedLine.d27.s1	an	59	60	O	an	an	an	DT	False
DDI-MedLine.d27.s1	effect	62	67	O	effect	ect	fect	NN	False
DDI-MedLine.d27.s1	is	69	70	O	is	is	is	VBZ	False
DDI-MedLine.d27.s1	not	72	74	O	not	not	not	RB	False
DDI-MedLine.d27.s1	observed	76	83	O	observed	ved	rved	VBN	False
DDI-MedLine.d27.s1	.	84	84	O	.	.	.	.	False

DDI-MedLine.d27.s2	Prolonged	0	8	O	Prolonged	ged	nged	VBD	False
DDI-MedLine.d27.s2	daily	10	14	O	daily	ily	aily	JJ	False
DDI-MedLine.d27.s2	administration	16	29	O	administration	ion	tion	NN	False
DDI-MedLine.d27.s2	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d27.s2	picrotoxin	34	43	B-drug_n	picrotoxin	xin	oxin	NN	False
DDI-MedLine.d27.s2	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d27.s2	a	48	48	O	a	a	a	DT	False
DDI-MedLine.d27.s2	dose	50	53	O	dose	ose	dose	NN	False
DDI-MedLine.d27.s2	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d27.s2	1	58	58	O	1	1	1	CD	False
DDI-MedLine.d27.s2	mg/kg	60	64	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d27.s2	results	66	72	O	results	lts	ults	NNS	False
DDI-MedLine.d27.s2	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d27.s2	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d27.s2	development	81	91	O	development	ent	ment	NN	False
DDI-MedLine.d27.s2	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d27.s2	brain	96	100	O	brain	ain	rain	NN	False
DDI-MedLine.d27.s2	edema	102	106	O	edema	ema	dema	NN	False
DDI-MedLine.d27.s2	.	107	107	O	.	.	.	.	False

DDI-MedLine.d27.s3	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d27.s3	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d27.s3	recommended	6	16	O	recommended	ded	nded	VBN	False
DDI-MedLine.d27.s3	that	18	21	O	that	hat	that	IN	False
DDI-MedLine.d27.s3	GABA-positive	23	35	O	GABA-positive	ive	tive	JJ	False
DDI-MedLine.d27.s3	drugs	37	41	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d27.s3	be	43	44	O	be	be	be	VB	False
DDI-MedLine.d27.s3	included	46	53	O	included	ded	uded	VBD	False
DDI-MedLine.d27.s3	into	55	58	O	into	nto	into	IN	False
DDI-MedLine.d27.s3	a	60	60	O	a	a	a	DT	False
DDI-MedLine.d27.s3	complex	62	68	O	complex	lex	plex	JJ	False
DDI-MedLine.d27.s3	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d27.s3	treatment	73	81	O	treatment	ent	ment	NN	False
DDI-MedLine.d27.s3	measures	83	90	O	measures	res	ures	NNS	False
DDI-MedLine.d27.s3	for	92	94	O	for	for	for	IN	False
DDI-MedLine.d27.s3	edema	96	100	O	edema	ema	dema	NN	False
DDI-MedLine.d27.s3	.	101	101	O	.	.	.	.	False

DDI-MedLine.d7.s0	Enhanced	0	7	O	Enhanced	ced	nced	NNP	False
DDI-MedLine.d7.s0	theophylline	9	20	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d7.s0	clearance	22	30	O	clearance	nce	ance	NN	False
DDI-MedLine.d7.s0	secondary	32	40	O	secondary	ary	dary	JJ	False
DDI-MedLine.d7.s0	to	42	43	O	to	to	to	TO	False
DDI-MedLine.d7.s0	phenytoin	45	53	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d7.s0	therapy	55	61	O	therapy	apy	rapy	NN	False
DDI-MedLine.d7.s0	.	62	62	O	.	.	.	.	False

DDI-MedLine.d7.s1	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d7.s1	report	5	10	O	report	ort	port	NN	False
DDI-MedLine.d7.s1	describes	12	20	O	describes	bes	ibes	NNS	False
DDI-MedLine.d7.s1	two	22	24	O	two	two	two	CD	False
DDI-MedLine.d7.s1	cases	26	30	O	cases	ses	ases	NNS	False
DDI-MedLine.d7.s1	in	32	33	O	in	in	in	IN	False
DDI-MedLine.d7.s1	which	35	39	O	which	ich	hich	WDT	False
DDI-MedLine.d7.s1	theophylline	41	52	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d7.s1	clearance	54	62	O	clearance	nce	ance	NN	False
DDI-MedLine.d7.s1	accelerated	64	74	O	accelerated	ted	ated	VBN	False
DDI-MedLine.d7.s1	markedly	76	83	O	markedly	dly	edly	RB	False
DDI-MedLine.d7.s1	with	85	88	O	with	ith	with	IN	False
DDI-MedLine.d7.s1	concomitant	90	100	O	concomitant	ant	tant	NN	False
DDI-MedLine.d7.s1	phenytoin	102	110	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d7.s1	administration	112	125	O	administration	ion	tion	NN	False
DDI-MedLine.d7.s1	.	126	126	O	.	.	.	.	False

DDI-MedLine.d7.s2	Maximum	0	6	O	Maximum	mum	imum	NN	False
DDI-MedLine.d7.s2	calculated	8	17	O	calculated	ted	ated	VBN	False
DDI-MedLine.d7.s2	theophylline	19	30	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d7.s2	clearance	32	40	O	clearance	nce	ance	NN	False
DDI-MedLine.d7.s2	ranged	42	47	O	ranged	ged	nged	VBD	False
DDI-MedLine.d7.s2	from	49	52	O	from	rom	from	IN	False
DDI-MedLine.d7.s2	2	54	54	O	2	2	2	CD	False
DDI-MedLine.d7.s2	1/2	56	58	O	1/2	1/2	1/2	CD	False
DDI-MedLine.d7.s2	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d7.s2	3	63	63	O	3	3	3	CD	False
DDI-MedLine.d7.s2	1/2	65	67	O	1/2	1/2	1/2	CD	False
DDI-MedLine.d7.s2	times	69	73	O	times	mes	imes	NNS	False
DDI-MedLine.d7.s2	baseline	75	82	O	baseline	ine	line	NN	drug
DDI-MedLine.d7.s2	.	83	83	O	.	.	.	.	False

DDI-MedLine.d7.s3	Onset	0	4	O	Onset	set	nset	NN	False
DDI-MedLine.d7.s3	of	6	7	O	of	of	of	IN	False
DDI-MedLine.d7.s3	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d7.s3	interaction	13	23	O	interaction	ion	tion	NN	False
DDI-MedLine.d7.s3	began	25	29	O	began	gan	egan	VBD	False
DDI-MedLine.d7.s3	within	31	36	O	within	hin	thin	IN	False
DDI-MedLine.d7.s3	five	38	41	O	five	ive	five	CD	False
DDI-MedLine.d7.s3	days	43	46	O	days	ays	days	NNS	False
DDI-MedLine.d7.s3	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d7.s3	beginning	51	59	O	beginning	ing	ning	VBG	False
DDI-MedLine.d7.s3	concurrent	61	70	O	concurrent	ent	rent	NN	False
DDI-MedLine.d7.s3	therapy	72	78	O	therapy	apy	rapy	NN	False
DDI-MedLine.d7.s3	.	79	79	O	.	.	.	.	False

DDI-MedLine.d7.s4	With	0	3	O	With	ith	With	IN	False
DDI-MedLine.d7.s4	combined	5	12	O	combined	ned	ined	VBN	False
DDI-MedLine.d7.s4	use	14	16	O	use	use	use	NN	False
DDI-MedLine.d7.s4	,	17	17	O	,	,	,	,	False
DDI-MedLine.d7.s4	clinicians	19	28	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d7.s4	should	30	35	O	should	uld	ould	MD	False
DDI-MedLine.d7.s4	be	37	38	O	be	be	be	VB	False
DDI-MedLine.d7.s4	aware	40	44	O	aware	are	ware	JJ	False
DDI-MedLine.d7.s4	,	45	45	O	,	,	,	,	False
DDI-MedLine.d7.s4	when	47	50	O	when	hen	when	WRB	False
DDI-MedLine.d7.s4	phenytoin	52	60	B-drug	phenytoin	oin	toin	NN	False
DDI-MedLine.d7.s4	is	62	63	O	is	is	is	VBZ	False
DDI-MedLine.d7.s4	added	65	69	O	added	ded	dded	VBD	False
DDI-MedLine.d7.s4	,	70	70	O	,	,	,	,	False
DDI-MedLine.d7.s4	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d7.s4	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d7.s4	potential	79	87	O	potential	ial	tial	JJ	False
DDI-MedLine.d7.s4	for	89	91	O	for	for	for	IN	False
DDI-MedLine.d7.s4	reexacerbation	93	106	O	reexacerbation	ion	tion	NN	False
DDI-MedLine.d7.s4	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d7.s4	pulmonary	111	119	O	pulmonary	ary	nary	JJ	False
DDI-MedLine.d7.s4	symptomatology	121	134	O	symptomatology	ogy	logy	NN	False
DDI-MedLine.d7.s4	due	136	138	O	due	due	due	JJ	False
DDI-MedLine.d7.s4	to	140	141	O	to	to	to	TO	False
DDI-MedLine.d7.s4	lowered	143	149	O	lowered	red	ered	VBN	False
DDI-MedLine.d7.s4	serum	151	155	O	serum	rum	erum	NN	False
DDI-MedLine.d7.s4	theophylline	157	168	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d7.s4	concentrations	170	183	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d7.s4	.	184	184	O	.	.	.	.	False

DDI-MedLine.d117.s0	Increased	0	8	O	Increased	sed	ased	VBN	False
DDI-MedLine.d117.s0	stability	10	18	O	stability	ity	lity	NN	False
DDI-MedLine.d117.s0	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d117.s0	nucleophosmin/B23	23	39	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s0	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d117.s0	anti-apoptotic	44	57	O	anti-apoptotic	tic	otic	JJ	False
DDI-MedLine.d117.s0	effect	59	64	O	effect	ect	fect	NN	False
DDI-MedLine.d117.s0	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d117.s0	ras	69	71	O	ras	ras	ras	NNS	False
DDI-MedLine.d117.s0	during	73	78	O	during	ing	ring	IN	False
DDI-MedLine.d117.s0	serum	80	84	O	serum	rum	erum	NN	False
DDI-MedLine.d117.s0	deprivation	86	96	O	deprivation	ion	tion	NN	False
DDI-MedLine.d117.s0	.	97	97	O	.	.	.	.	False

DDI-MedLine.d117.s1	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d117.s1	obtained	3	10	O	obtained	ned	ined	VBN	False
DDI-MedLine.d117.s1	evidence	12	19	O	evidence	nce	ence	NN	False
DDI-MedLine.d117.s1	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d117.s1	increased	26	34	O	increased	sed	ased	VBN	False
DDI-MedLine.d117.s1	stability	36	44	O	stability	ity	lity	NN	False
DDI-MedLine.d117.s1	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d117.s1	nucleophosmin/B23	49	65	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s1	is	67	68	O	is	is	is	VBZ	False
DDI-MedLine.d117.s1	involved	70	77	O	involved	ved	lved	VBN	False
DDI-MedLine.d117.s1	in	79	80	O	in	in	in	IN	False
DDI-MedLine.d117.s1	antiapoptotic	82	94	O	antiapoptotic	tic	otic	JJ	False
DDI-MedLine.d117.s1	effect	96	101	O	effect	ect	fect	NN	False
DDI-MedLine.d117.s1	of	103	104	O	of	of	of	IN	False
DDI-MedLine.d117.s1	ras	106	108	O	ras	ras	ras	NNS	False
DDI-MedLine.d117.s1	during	110	115	O	during	ing	ring	IN	False
DDI-MedLine.d117.s1	serum	117	121	O	serum	rum	erum	NN	False
DDI-MedLine.d117.s1	deprivation	123	133	O	deprivation	ion	tion	NN	False
DDI-MedLine.d117.s1	.	134	134	O	.	.	.	.	False

DDI-MedLine.d117.s2	Nucleophosmin/B23	0	16	O	Nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s2	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d117.s2	serum-deprived	21	34	O	serum-deprived	ved	ived	JJ	False
DDI-MedLine.d117.s2	(	36	36	O	(	(	(	(	False
DDI-MedLine.d117.s2	0	37	37	O	0	0	0	CD	False
DDI-MedLine.d117.s2	%	38	38	O	%	%	%	NN	False
DDI-MedLine.d117.s2	serum	40	44	O	serum	rum	erum	NN	False
DDI-MedLine.d117.s2	)	45	45	O	)	)	)	)	False
DDI-MedLine.d117.s2	NIH-3T3	47	53	O	NIH-3T3	3T3	-3T3	NN	brand
DDI-MedLine.d117.s2	cells	55	59	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s2	was	61	63	O	was	was	was	VBD	False
DDI-MedLine.d117.s2	found	65	69	O	found	und	ound	NN	False
DDI-MedLine.d117.s2	to	71	72	O	to	to	to	TO	False
DDI-MedLine.d117.s2	be	74	75	O	be	be	be	VB	False
DDI-MedLine.d117.s2	highly	77	82	O	highly	hly	ghly	RB	False
DDI-MedLine.d117.s2	unstable	84	91	O	unstable	ble	able	JJ	False
DDI-MedLine.d117.s2	with	93	96	O	with	ith	with	IN	False
DDI-MedLine.d117.s2	a	98	98	O	a	a	a	DT	False
DDI-MedLine.d117.s2	half-life	100	108	O	half-life	ife	life	NN	False
DDI-MedLine.d117.s2	less	110	113	O	less	ess	less	RBR	False
DDI-MedLine.d117.s2	than	115	118	O	than	han	than	IN	False
DDI-MedLine.d117.s2	4	120	120	O	4	4	4	CD	False
DDI-MedLine.d117.s2	h	122	122	O	h	h	h	NN	False
DDI-MedLine.d117.s2	.	123	123	O	.	.	.	.	False

DDI-MedLine.d117.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d117.s3	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d117.s3	,	11	11	O	,	,	,	,	False
DDI-MedLine.d117.s3	nucleophosmin/B23	13	29	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s3	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d117.s3	serum-deprived	34	47	O	serum-deprived	ved	ived	JJ	False
DDI-MedLine.d117.s3	ras-transformed	49	63	O	ras-transformed	med	rmed	JJ	False
DDI-MedLine.d117.s3	(	65	65	O	(	(	(	(	False
DDI-MedLine.d117.s3	RAS-3T3	66	72	O	RAS-3T3	3T3	-3T3	JJ	brand
DDI-MedLine.d117.s3	)	73	73	O	)	)	)	)	False
DDI-MedLine.d117.s3	cells	75	79	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s3	was	81	83	O	was	was	was	VBD	False
DDI-MedLine.d117.s3	as	85	86	O	as	as	as	IN	False
DDI-MedLine.d117.s3	stable	88	93	O	stable	ble	able	JJ	False
DDI-MedLine.d117.s3	as	95	96	O	as	as	as	IN	False
DDI-MedLine.d117.s3	that	98	101	O	that	hat	that	IN	False
DDI-MedLine.d117.s3	in	103	104	O	in	in	in	IN	False
DDI-MedLine.d117.s3	serum-supplemented	106	123	O	serum-supplemented	ted	nted	JJ	False
DDI-MedLine.d117.s3	NIH-3T3	125	131	O	NIH-3T3	3T3	-3T3	NN	brand
DDI-MedLine.d117.s3	or	133	134	O	or	or	or	CC	False
DDI-MedLine.d117.s3	RAS-3T3	136	142	O	RAS-3T3	3T3	-3T3	JJ	brand
DDI-MedLine.d117.s3	cells	144	148	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s3	.	149	149	O	.	.	.	.	False

DDI-MedLine.d117.s4	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d117.s4	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d117.s4	RAS-3T3	13	19	O	RAS-3T3	3T3	-3T3	JJ	brand
DDI-MedLine.d117.s4	cells	21	25	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s4	with	27	30	O	with	ith	with	IN	False
DDI-MedLine.d117.s4	nucleophosmin/B23	32	48	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s4	antisense	50	58	O	antisense	nse	ense	NN	False
DDI-MedLine.d117.s4	oligomer	60	67	O	oligomer	mer	omer	NN	False
DDI-MedLine.d117.s4	significantly	69	81	O	significantly	tly	ntly	RB	False
DDI-MedLine.d117.s4	potentiated	83	93	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d117.s4	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d117.s4	apoptosis	99	107	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d117.s4	induced	109	115	O	induced	ced	uced	JJ	False
DDI-MedLine.d117.s4	by	117	118	O	by	by	by	IN	False
DDI-MedLine.d117.s4	serum	120	124	O	serum	rum	erum	NN	False
DDI-MedLine.d117.s4	deprivation	126	136	O	deprivation	ion	tion	NN	False
DDI-MedLine.d117.s4	.	137	137	O	.	.	.	.	False

DDI-MedLine.d117.s5	Much	0	3	O	Much	uch	Much	JJ	False
DDI-MedLine.d117.s5	less	5	8	O	less	ess	less	RBR	False
DDI-MedLine.d117.s5	caspase-3	10	18	O	caspase-3	e-3	se-3	NN	False
DDI-MedLine.d117.s5	activity	20	27	O	activity	ity	vity	NN	False
DDI-MedLine.d117.s5	was	29	31	O	was	was	was	VBD	False
DDI-MedLine.d117.s5	noted	33	37	O	noted	ted	oted	VBN	False
DDI-MedLine.d117.s5	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d117.s5	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d117.s5	lysate	46	51	O	lysate	ate	sate	NN	False
DDI-MedLine.d117.s5	derived	53	59	O	derived	ved	ived	VBN	False
DDI-MedLine.d117.s5	from	61	64	O	from	rom	from	IN	False
DDI-MedLine.d117.s5	serum-deprived	66	79	O	serum-deprived	ved	ived	JJ	False
DDI-MedLine.d117.s5	RAS-3T3	81	87	O	RAS-3T3	3T3	-3T3	JJ	brand
DDI-MedLine.d117.s5	cells	89	93	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s5	compared	95	102	O	compared	red	ared	VBN	False
DDI-MedLine.d117.s5	with	104	107	O	with	ith	with	IN	False
DDI-MedLine.d117.s5	that	109	112	O	that	hat	that	IN	False
DDI-MedLine.d117.s5	in	114	115	O	in	in	in	IN	False
DDI-MedLine.d117.s5	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d117.s5	lysate	121	126	O	lysate	ate	sate	NN	False
DDI-MedLine.d117.s5	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d117.s5	serum-deprived	131	144	O	serum-deprived	ved	ived	JJ	False
DDI-MedLine.d117.s5	NIH-3T3	146	152	O	NIH-3T3	3T3	-3T3	NN	brand
DDI-MedLine.d117.s5	cells	154	158	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s5	.	159	159	O	.	.	.	.	False

DDI-MedLine.d117.s6	Cell	0	3	O	Cell	ell	Cell	NN	False
DDI-MedLine.d117.s6	permeable	5	13	O	permeable	ble	able	JJ	False
DDI-MedLine.d117.s6	caspase-3	15	23	O	caspase-3	e-3	se-3	NN	False
DDI-MedLine.d117.s6	inhibitor	25	33	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d117.s6	added	35	39	O	added	ded	dded	VBD	False
DDI-MedLine.d117.s6	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d117.s6	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d117.s6	medium	48	53	O	medium	ium	dium	NN	drug
DDI-MedLine.d117.s6	blocked	55	61	O	blocked	ked	cked	VBN	False
DDI-MedLine.d117.s6	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d117.s6	decrease	67	74	O	decrease	ase	ease	NN	False
DDI-MedLine.d117.s6	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d117.s6	nucleophosmin/B23	79	95	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s6	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d117.s6	apoptosis	101	109	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d117.s6	induced	111	117	O	induced	ced	uced	JJ	False
DDI-MedLine.d117.s6	by	119	120	O	by	by	by	IN	False
DDI-MedLine.d117.s6	serum	122	126	O	serum	rum	erum	NN	False
DDI-MedLine.d117.s6	deprivation	128	138	O	deprivation	ion	tion	NN	False
DDI-MedLine.d117.s6	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d117.s6	NIH-3T3	143	149	O	NIH-3T3	3T3	-3T3	NN	brand
DDI-MedLine.d117.s6	cells	151	155	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s6	.	156	156	O	.	.	.	.	False

DDI-MedLine.d117.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d117.s7	inhibitor	4	12	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d117.s7	,	13	13	O	,	,	,	,	False
DDI-MedLine.d117.s7	on	15	16	O	on	on	on	IN	False
DDI-MedLine.d117.s7	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d117.s7	other	22	26	O	other	her	ther	JJ	False
DDI-MedLine.d117.s7	hand	28	31	O	hand	and	hand	NN	False
DDI-MedLine.d117.s7	,	32	32	O	,	,	,	,	False
DDI-MedLine.d117.s7	promoted	34	41	O	promoted	ted	oted	VBN	False
DDI-MedLine.d117.s7	significant	43	53	O	significant	ant	cant	JJ	False
DDI-MedLine.d117.s7	decrease	55	62	O	decrease	ase	ease	NN	False
DDI-MedLine.d117.s7	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d117.s7	nucleolin/C23	67	79	O	nucleolin/C23	C23	/C23	NN	False
DDI-MedLine.d117.s7	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d117.s7	NIH-3T3	84	90	O	NIH-3T3	3T3	-3T3	NN	brand
DDI-MedLine.d117.s7	cells	92	96	O	cells	lls	ells	NNS	False
DDI-MedLine.d117.s7	during	98	103	O	during	ing	ring	IN	False
DDI-MedLine.d117.s7	serum	105	109	O	serum	rum	erum	NN	False
DDI-MedLine.d117.s7	deprivation	111	121	O	deprivation	ion	tion	NN	False
DDI-MedLine.d117.s7	.	122	122	O	.	.	.	.	False

DDI-MedLine.d117.s8	Unlike	0	5	O	Unlike	ike	like	IN	False
DDI-MedLine.d117.s8	nucleolin/C23	7	19	O	nucleolin/C23	C23	/C23	NN	False
DDI-MedLine.d117.s8	,	20	20	O	,	,	,	,	False
DDI-MedLine.d117.s8	down-regulation	22	36	O	down-regulation	ion	tion	NN	False
DDI-MedLine.d117.s8	of	38	39	O	of	of	of	IN	False
DDI-MedLine.d117.s8	nucleophosmin/B23	41	57	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s8	was	59	61	O	was	was	was	VBD	False
DDI-MedLine.d117.s8	thus	63	66	O	thus	hus	thus	RB	False
DDI-MedLine.d117.s8	not	68	70	O	not	not	not	RB	False
DDI-MedLine.d117.s8	proliferation-dependent	72	94	O	proliferation-dependent	ent	dent	NN	False
DDI-MedLine.d117.s8	but	96	98	O	but	but	but	CC	False
DDI-MedLine.d117.s8	caspase-3-	100	109	O	caspase-3-	-3-	e-3-	NN	False
DDI-MedLine.d117.s8	and	111	113	O	and	and	and	CC	False
DDI-MedLine.d117.s8	apoptosis-dependent	115	133	O	apoptosis-dependent	ent	dent	NN	False
DDI-MedLine.d117.s8	.	134	134	O	.	.	.	.	False

DDI-MedLine.d117.s9	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d117.s9	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d117.s9	indicate	12	19	O	indicate	ate	cate	NN	False
DDI-MedLine.d117.s9	important	21	29	O	important	ant	tant	JJ	False
DDI-MedLine.d117.s9	relationships	31	43	O	relationships	ips	hips	NNS	False
DDI-MedLine.d117.s9	among	45	49	O	among	ong	mong	IN	False
DDI-MedLine.d117.s9	ras	51	53	O	ras	ras	ras	NNS	False
DDI-MedLine.d117.s9	,	54	54	O	,	,	,	,	False
DDI-MedLine.d117.s9	nucleophosmin/B23	56	72	O	nucleophosmin/B23	B23	/B23	NN	False
DDI-MedLine.d117.s9	,	73	73	O	,	,	,	,	False
DDI-MedLine.d117.s9	activation	75	84	O	activation	ion	tion	NN	False
DDI-MedLine.d117.s9	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d117.s9	caspase-3	89	97	O	caspase-3	e-3	se-3	NN	False
DDI-MedLine.d117.s9	,	98	98	O	,	,	,	,	False
DDI-MedLine.d117.s9	and	100	102	O	and	and	and	CC	False
DDI-MedLine.d117.s9	induction	104	112	O	induction	ion	tion	NN	False
DDI-MedLine.d117.s9	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d117.s9	apoptosis	117	125	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d117.s9	.	126	126	O	.	.	.	.	False

DDI-MedLine.d111.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d111.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d111.s0	coadministered	10	23	O	coadministered	red	ered	VBN	False
DDI-MedLine.d111.s0	drugs	25	29	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d111.s0	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d111.s0	ethanol	35	41	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d111.s0	on	43	44	O	on	on	on	IN	False
DDI-MedLine.d111.s0	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d111.s0	binding	50	56	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s0	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d111.s0	therapeutic	61	71	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d111.s0	drugs	73	77	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d111.s0	to	79	80	O	to	to	to	TO	False
DDI-MedLine.d111.s0	human	82	86	O	human	man	uman	NN	False
DDI-MedLine.d111.s0	serum	88	92	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s0	in	94	95	O	in	in	in	IN	False
DDI-MedLine.d111.s0	vitro	97	101	O	vitro	tro	itro	NN	False
DDI-MedLine.d111.s0	.	102	102	O	.	.	.	.	False

DDI-MedLine.d111.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d111.s1	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d111.s1	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d111.s1	coadministered	15	28	O	coadministered	red	ered	VBN	False
DDI-MedLine.d111.s1	drugs	30	34	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d111.s1	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d111.s1	ethanol	40	46	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d111.s1	on	48	49	O	on	on	on	IN	False
DDI-MedLine.d111.s1	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d111.s1	binding	55	61	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s1	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d111.s1	therapeutic	66	76	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d111.s1	drugs	78	82	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d111.s1	to	84	85	O	to	to	to	TO	False
DDI-MedLine.d111.s1	human	87	91	O	human	man	uman	NN	False
DDI-MedLine.d111.s1	serum	93	97	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s1	in	99	100	O	in	in	in	IN	False
DDI-MedLine.d111.s1	vitro	102	106	O	vitro	tro	itro	NN	False
DDI-MedLine.d111.s1	was	108	110	O	was	was	was	VBD	False
DDI-MedLine.d111.s1	investigated	112	123	O	investigated	ted	ated	VBN	False
DDI-MedLine.d111.s1	.	124	124	O	.	.	.	.	False

DDI-MedLine.d111.s2	Acetaminophen	0	12	B-drug	Acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s2	,	13	13	O	,	,	,	,	False
DDI-MedLine.d111.s2	lidocaine	15	23	B-drug	lidocaine	ine	aine	NN	drug
DDI-MedLine.d111.s2	,	24	24	O	,	,	,	,	False
DDI-MedLine.d111.s2	phenobarbital	26	38	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s2	,	39	39	O	,	,	,	,	False
DDI-MedLine.d111.s2	quinidine	41	49	B-drug	quinidine	ine	dine	NN	drug
DDI-MedLine.d111.s2	,	50	50	O	,	,	,	,	False
DDI-MedLine.d111.s2	theophylline	52	63	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d111.s2	,	64	64	O	,	,	,	,	False
DDI-MedLine.d111.s2	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d111.s2	valproic	70	77	B-drug	valproic	oic	roic	NN	False
DDI-MedLine.d111.s2	acid	79	82	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d111.s2	were	84	87	O	were	ere	were	VBD	False
DDI-MedLine.d111.s2	added	89	93	O	added	ded	dded	VBD	False
DDI-MedLine.d111.s2	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d111.s2	pooled	98	103	O	pooled	led	oled	VBN	False
DDI-MedLine.d111.s2	human	105	109	O	human	man	uman	NN	False
DDI-MedLine.d111.s2	serum	111	115	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s2	at	117	118	O	at	at	at	IN	False
DDI-MedLine.d111.s2	therapeutic	120	130	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d111.s2	concentrations	132	145	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d111.s2	.	146	146	O	.	.	.	.	False

DDI-MedLine.d111.s3	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d111.s3	each	3	6	O	each	ach	each	DT	False
DDI-MedLine.d111.s3	preparation	8	18	O	preparation	ion	tion	NN	False
DDI-MedLine.d111.s3	was	20	22	O	was	was	was	VBD	False
DDI-MedLine.d111.s3	added	24	28	O	added	ded	dded	VBD	False
DDI-MedLine.d111.s3	one	30	32	O	one	one	one	CD	False
DDI-MedLine.d111.s3	additional	34	43	O	additional	nal	onal	JJ	False
DDI-MedLine.d111.s3	drug	45	48	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s3	at	50	51	O	at	at	at	IN	False
DDI-MedLine.d111.s3	three	53	57	O	three	ree	hree	CD	False
DDI-MedLine.d111.s3	concentrations	59	72	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d111.s3	ranging	74	80	O	ranging	ing	ging	VBG	False
DDI-MedLine.d111.s3	from	82	85	O	from	rom	from	IN	False
DDI-MedLine.d111.s3	therapeutic	87	97	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d111.s3	to	99	100	O	to	to	to	TO	False
DDI-MedLine.d111.s3	toxic	102	106	O	toxic	xic	oxic	NN	False
DDI-MedLine.d111.s3	.	107	107	O	.	.	.	.	False

DDI-MedLine.d111.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d111.s4	following	4	12	O	following	ing	wing	VBG	False
DDI-MedLine.d111.s4	eight	14	18	O	eight	ght	ight	CD	False
DDI-MedLine.d111.s4	target	20	25	O	target	get	rget	NN	False
DDI-MedLine.d111.s4	drug/added	27	36	O	drug/added	ded	dded	VBN	False
DDI-MedLine.d111.s4	drug	38	41	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s4	combinations	43	54	O	combinations	ons	ions	NNS	False
DDI-MedLine.d111.s4	were	56	59	O	were	ere	were	VBD	False
DDI-MedLine.d111.s4	studied	61	67	O	studied	ied	died	VBN	False
DDI-MedLine.d111.s4	:	68	68	O	:	:	:	:	False
DDI-MedLine.d111.s4	acetaminophen/phenobarbital	70	96	O	acetaminophen/phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s4	.	97	97	O	.	.	.	.	False

DDI-MedLine.d111.s5	acetaminophen/theophylline	0	25	O	acetaminophen/theophylline	ine	line	NN	drug
DDI-MedLine.d111.s5	,	26	26	O	,	,	,	,	False
DDI-MedLine.d111.s5	lidocaine/quinidine	28	46	O	lidocaine/quinidine	ine	dine	NN	drug
DDI-MedLine.d111.s5	,	47	47	O	,	,	,	,	False
DDI-MedLine.d111.s5	phenobarbital/acetaminophen	49	75	O	phenobarbital/acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s5	,	76	76	O	,	,	,	,	False
DDI-MedLine.d111.s5	phenobarbital/valproic	78	99	O	phenobarbital/valproic	oic	roic	NN	False
DDI-MedLine.d111.s5	acid	101	104	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d111.s5	,	105	105	O	,	,	,	,	False
DDI-MedLine.d111.s5	quinidine/lidocaine	107	125	O	quinidine/lidocaine	ine	aine	NN	drug
DDI-MedLine.d111.s5	,	126	126	O	,	,	,	,	False
DDI-MedLine.d111.s5	theophylline/acetaminophen	128	153	O	theophylline/acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s5	,	154	154	O	,	,	,	,	False
DDI-MedLine.d111.s5	and	156	158	O	and	and	and	CC	False
DDI-MedLine.d111.s5	valproic	160	167	B-drug	valproic	oic	roic	NN	False
DDI-MedLine.d111.s5	acid/phenobarbital	169	186	O	acid/phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s5	.	187	187	O	.	.	.	.	False

DDI-MedLine.d111.s6	Each	0	3	O	Each	ach	Each	DT	False
DDI-MedLine.d111.s6	serum	5	9	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s6	without	11	17	O	without	out	hout	IN	False
DDI-MedLine.d111.s6	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d111.s6	other	23	27	O	other	her	ther	JJ	False
DDI-MedLine.d111.s6	added	29	33	O	added	ded	dded	VBD	False
DDI-MedLine.d111.s6	drug	35	38	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s6	as	40	41	O	as	as	as	IN	False
DDI-MedLine.d111.s6	well	43	46	O	well	ell	well	RB	False
DDI-MedLine.d111.s6	as	48	49	O	as	as	as	IN	False
DDI-MedLine.d111.s6	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d111.s6	serum	55	59	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s6	supplemented	61	72	O	supplemented	ted	nted	VBN	False
DDI-MedLine.d111.s6	with	74	77	O	with	ith	with	IN	False
DDI-MedLine.d111.s6	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d111.s6	other	83	87	O	other	her	ther	JJ	False
DDI-MedLine.d111.s6	drug	89	92	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s6	at	94	95	O	at	at	at	IN	False
DDI-MedLine.d111.s6	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d111.s6	three	101	105	O	three	ree	hree	CD	False
DDI-MedLine.d111.s6	concentrations	107	120	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d111.s6	was	122	124	O	was	was	was	VBD	False
DDI-MedLine.d111.s6	dialyzed	126	133	O	dialyzed	zed	yzed	VBN	False
DDI-MedLine.d111.s6	against	135	141	O	against	nst	inst	IN	False
DDI-MedLine.d111.s6	phosphate	143	151	O	phosphate	ate	hate	NN	False
DDI-MedLine.d111.s6	buffer	153	158	O	buffer	fer	ffer	NN	False
DDI-MedLine.d111.s6	.	159	159	O	.	.	.	.	False

DDI-MedLine.d111.s7	Similarly	0	8	O	Similarly	rly	arly	RB	False
DDI-MedLine.d111.s7	dialyzed	10	17	O	dialyzed	zed	yzed	VBN	False
DDI-MedLine.d111.s7	were	19	22	O	were	ere	were	VBD	False
DDI-MedLine.d111.s7	phenobarbital	24	36	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s7	,	37	37	O	,	,	,	,	False
DDI-MedLine.d111.s7	quinidine	39	47	B-drug	quinidine	ine	dine	NN	drug
DDI-MedLine.d111.s7	,	48	48	O	,	,	,	,	False
DDI-MedLine.d111.s7	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d111.s7	theophylline	54	65	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d111.s7	,	66	66	O	,	,	,	,	False
DDI-MedLine.d111.s7	both	68	71	O	both	oth	both	DT	False
DDI-MedLine.d111.s7	alone	73	77	O	alone	one	lone	RB	False
DDI-MedLine.d111.s7	at	79	80	O	at	at	at	IN	False
DDI-MedLine.d111.s7	therapeutic	82	92	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d111.s7	concentrations	94	107	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d111.s7	in	109	110	O	in	in	in	IN	False
DDI-MedLine.d111.s7	serum	112	116	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s7	and	118	120	O	and	and	and	CC	False
DDI-MedLine.d111.s7	with	122	125	O	with	ith	with	IN	False
DDI-MedLine.d111.s7	ethanol	127	133	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d111.s7	at	135	136	O	at	at	at	IN	False
DDI-MedLine.d111.s7	three	138	142	O	three	ree	hree	CD	False
DDI-MedLine.d111.s7	different	144	152	O	different	ent	rent	JJ	False
DDI-MedLine.d111.s7	concentrations	154	167	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d111.s7	in	169	170	O	in	in	in	IN	False
DDI-MedLine.d111.s7	serum	172	176	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s7	.	177	177	O	.	.	.	.	False

DDI-MedLine.d111.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d111.s8	percentage	4	13	O	percentage	age	tage	NN	False
DDI-MedLine.d111.s8	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d111.s8	drug	18	21	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s8	binding	23	29	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s8	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d111.s8	each	34	37	O	each	ach	each	DT	False
DDI-MedLine.d111.s8	preparation	39	49	O	preparation	ion	tion	NN	False
DDI-MedLine.d111.s8	was	51	53	O	was	was	was	VBD	False
DDI-MedLine.d111.s8	calculated	55	64	O	calculated	ted	ated	VBN	False
DDI-MedLine.d111.s8	.	65	65	O	.	.	.	.	False

DDI-MedLine.d111.s9	Acetaminophen	0	12	B-drug	Acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s9	diminished	14	23	O	diminished	hed	shed	VBN	False
DDI-MedLine.d111.s9	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d111.s9	binding	29	35	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s9	of	37	38	O	of	of	of	IN	False
DDI-MedLine.d111.s9	theophylline	40	51	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d111.s9	to	53	54	O	to	to	to	TO	False
DDI-MedLine.d111.s9	human	56	60	O	human	man	uman	NN	False
DDI-MedLine.d111.s9	serum	62	66	O	serum	rum	erum	NN	False
DDI-MedLine.d111.s9	by	68	69	O	by	by	by	IN	False
DDI-MedLine.d111.s9	a	71	71	O	a	a	a	DT	False
DDI-MedLine.d111.s9	net	73	75	O	net	net	net	NN	False
DDI-MedLine.d111.s9	change	77	82	O	change	nge	ange	NN	False
DDI-MedLine.d111.s9	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d111.s9	5.7	87	89	O	5.7	5.7	5.7	CD	False
DDI-MedLine.d111.s9	%	90	90	O	%	%	%	NN	False
DDI-MedLine.d111.s9	(	92	92	O	(	(	(	(	False
DDI-MedLine.d111.s9	percentage	93	102	O	percentage	age	tage	NN	False
DDI-MedLine.d111.s9	increase	104	111	O	increase	ase	ease	NN	False
DDI-MedLine.d111.s9	in	113	114	O	in	in	in	IN	False
DDI-MedLine.d111.s9	free	116	119	O	free	ree	free	JJ	False
DDI-MedLine.d111.s9	drug	121	124	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s9	fraction	126	133	O	fraction	ion	tion	NN	False
DDI-MedLine.d111.s9	[	135	135	O	[	[	[	NN	False
DDI-MedLine.d111.s9	FDF	136	138	O	FDF	FDF	FDF	NN	brand
DDI-MedLine.d111.s9	]	139	139	O	]	]	]	NN	False
DDI-MedLine.d111.s9	,	140	140	O	,	,	,	,	False
DDI-MedLine.d111.s9	11.0	142	145	O	11.0	1.0	11.0	CD	False
DDI-MedLine.d111.s9	%	146	146	O	%	%	%	NN	False
DDI-MedLine.d111.s9	)	147	147	O	)	)	)	)	False
DDI-MedLine.d111.s9	at	149	150	O	at	at	at	IN	False
DDI-MedLine.d111.s9	662	152	154	O	662	662	662	CD	False
DDI-MedLine.d111.s9	micromol/L	156	165	O	micromol/L	l/L	ol/L	NN	False
DDI-MedLine.d111.s9	and	167	169	O	and	and	and	CC	False
DDI-MedLine.d111.s9	by	171	172	O	by	by	by	IN	False
DDI-MedLine.d111.s9	a	174	174	O	a	a	a	DT	False
DDI-MedLine.d111.s9	net	176	178	O	net	net	net	NN	False
DDI-MedLine.d111.s9	change	180	185	O	change	nge	ange	NN	False
DDI-MedLine.d111.s9	of	187	188	O	of	of	of	IN	False
DDI-MedLine.d111.s9	7.1	190	192	O	7.1	7.1	7.1	CD	False
DDI-MedLine.d111.s9	%	193	193	O	%	%	%	NN	False
DDI-MedLine.d111.s9	(	195	195	O	(	(	(	(	False
DDI-MedLine.d111.s9	percentage	196	205	O	percentage	age	tage	NN	False
DDI-MedLine.d111.s9	increase	207	214	O	increase	ase	ease	NN	False
DDI-MedLine.d111.s9	in	216	217	O	in	in	in	IN	False
DDI-MedLine.d111.s9	FDF	219	221	O	FDF	FDF	FDF	NN	brand
DDI-MedLine.d111.s9	,	222	222	O	,	,	,	,	False
DDI-MedLine.d111.s9	13.7	224	227	O	13.7	3.7	13.7	CD	False
DDI-MedLine.d111.s9	%	228	228	O	%	%	%	NN	False
DDI-MedLine.d111.s9	)	229	229	O	)	)	)	)	False
DDI-MedLine.d111.s9	at	231	232	O	at	at	at	IN	False
DDI-MedLine.d111.s9	1324	234	237	O	1324	324	1324	CD	False
DDI-MedLine.d111.s9	micromol/L	239	248	O	micromol/L	l/L	ol/L	NN	False
DDI-MedLine.d111.s9	.	249	249	O	.	.	.	.	False

DDI-MedLine.d111.s10	Theophylline	0	11	B-drug	Theophylline	ine	line	NN	drug
DDI-MedLine.d111.s10	decreased	13	21	O	decreased	sed	ased	VBN	False
DDI-MedLine.d111.s10	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d111.s10	binding	27	33	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s10	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d111.s10	acetaminophen	38	50	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s10	by	52	53	O	by	by	by	IN	False
DDI-MedLine.d111.s10	a	55	55	O	a	a	a	DT	False
DDI-MedLine.d111.s10	net	57	59	O	net	net	net	NN	False
DDI-MedLine.d111.s10	change	61	66	O	change	nge	ange	NN	False
DDI-MedLine.d111.s10	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d111.s10	6.8	71	73	O	6.8	6.8	6.8	CD	False
DDI-MedLine.d111.s10	%	74	74	O	%	%	%	NN	False
DDI-MedLine.d111.s10	(	76	76	O	(	(	(	(	False
DDI-MedLine.d111.s10	percentage	77	86	O	percentage	age	tage	NN	False
DDI-MedLine.d111.s10	increase	88	95	O	increase	ase	ease	NN	False
DDI-MedLine.d111.s10	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d111.s10	FDF	100	102	O	FDF	FDF	FDF	NN	brand
DDI-MedLine.d111.s10	,	103	103	O	,	,	,	,	False
DDI-MedLine.d111.s10	8.8	105	107	O	8.8	8.8	8.8	CD	False
DDI-MedLine.d111.s10	%	108	108	O	%	%	%	NN	False
DDI-MedLine.d111.s10	)	109	109	O	)	)	)	)	False
DDI-MedLine.d111.s10	at	111	112	O	at	at	at	IN	False
DDI-MedLine.d111.s10	277.5	114	118	O	277.5	7.5	77.5	CD	False
DDI-MedLine.d111.s10	micromol/L	120	129	O	micromol/L	l/L	ol/L	NN	False
DDI-MedLine.d111.s10	;	130	130	O	;	;	;	:	False

DDI-MedLine.d111.s11	phenobarbital	0	12	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s11	reduced	14	20	O	reduced	ced	uced	VBN	False
DDI-MedLine.d111.s11	it	22	23	O	it	it	it	PRP	False
DDI-MedLine.d111.s11	by	25	26	O	by	by	by	IN	False
DDI-MedLine.d111.s11	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d111.s11	net	30	32	O	net	net	net	NN	False
DDI-MedLine.d111.s11	change	34	39	O	change	nge	ange	NN	False
DDI-MedLine.d111.s11	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d111.s11	6.6	44	46	O	6.6	6.6	6.6	CD	False
DDI-MedLine.d111.s11	%	47	47	O	%	%	%	NN	False
DDI-MedLine.d111.s11	(	49	49	O	(	(	(	(	False
DDI-MedLine.d111.s11	percentage	50	59	O	percentage	age	tage	NN	False
DDI-MedLine.d111.s11	increase	61	68	O	increase	ase	ease	NN	False
DDI-MedLine.d111.s11	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d111.s11	FDF	73	75	O	FDF	FDF	FDF	NN	brand
DDI-MedLine.d111.s11	,	76	76	O	,	,	,	,	False
DDI-MedLine.d111.s11	8.5	78	80	O	8.5	8.5	8.5	CD	False
DDI-MedLine.d111.s11	%	81	81	O	%	%	%	NN	False
DDI-MedLine.d111.s11	)	82	82	O	)	)	)	)	False
DDI-MedLine.d111.s11	at	84	85	O	at	at	at	IN	False
DDI-MedLine.d111.s11	431	87	89	O	431	431	431	CD	False
DDI-MedLine.d111.s11	micromol/L	91	100	O	micromol/L	l/L	ol/L	NN	False
DDI-MedLine.d111.s11	.	101	101	O	.	.	.	.	False

DDI-MedLine.d111.s12	Valproic	0	7	B-drug	Valproic	oic	roic	NN	False
DDI-MedLine.d111.s12	acid	9	12	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d111.s12	diminished	14	23	O	diminished	hed	shed	VBN	False
DDI-MedLine.d111.s12	binding	25	31	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s12	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d111.s12	phenobarbital	36	48	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s12	by	50	51	O	by	by	by	IN	False
DDI-MedLine.d111.s12	a	53	53	O	a	a	a	DT	False
DDI-MedLine.d111.s12	net	55	57	O	net	net	net	NN	False
DDI-MedLine.d111.s12	change	59	64	O	change	nge	ange	NN	False
DDI-MedLine.d111.s12	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d111.s12	9.9	69	71	O	9.9	9.9	9.9	CD	False
DDI-MedLine.d111.s12	%	72	72	O	%	%	%	NN	False
DDI-MedLine.d111.s12	(	74	74	O	(	(	(	(	False
DDI-MedLine.d111.s12	percentage	75	84	O	percentage	age	tage	NN	False
DDI-MedLine.d111.s12	increase	86	93	O	increase	ase	ease	NN	False
DDI-MedLine.d111.s12	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d111.s12	FDF	98	100	O	FDF	FDF	FDF	NN	brand
DDI-MedLine.d111.s12	,	101	101	O	,	,	,	,	False
DDI-MedLine.d111.s12	21.2	103	106	O	21.2	1.2	21.2	CD	False
DDI-MedLine.d111.s12	%	107	107	O	%	%	%	NN	False
DDI-MedLine.d111.s12	)	108	108	O	)	)	)	)	False
DDI-MedLine.d111.s12	at	110	111	O	at	at	at	IN	False
DDI-MedLine.d111.s12	1732	113	116	O	1732	732	1732	CD	False
DDI-MedLine.d111.s12	micromol/L	118	127	O	micromol/L	l/L	ol/L	NN	False
DDI-MedLine.d111.s12	.	128	128	O	.	.	.	.	False

DDI-MedLine.d111.s13	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d111.s13	significant	3	13	O	significant	ant	cant	JJ	False
DDI-MedLine.d111.s13	effects	15	21	O	effects	cts	ects	NNS	False
DDI-MedLine.d111.s13	were	23	26	O	were	ere	were	VBD	False
DDI-MedLine.d111.s13	noted	28	32	O	noted	ted	oted	VBN	False
DDI-MedLine.d111.s13	with	34	37	O	with	ith	with	IN	False
DDI-MedLine.d111.s13	other	39	43	O	other	her	ther	JJ	False
DDI-MedLine.d111.s13	drug	45	48	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s13	combinations	50	61	O	combinations	ons	ions	NNS	False
DDI-MedLine.d111.s13	or	63	64	O	or	or	or	CC	False
DDI-MedLine.d111.s13	with	66	69	O	with	ith	with	IN	False
DDI-MedLine.d111.s13	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d111.s13	addition	75	82	O	addition	ion	tion	NN	False
DDI-MedLine.d111.s13	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d111.s13	ethanol	87	93	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d111.s13	.	94	94	O	.	.	.	.	False

DDI-MedLine.d111.s14	Coingestion	0	10	O	Coingestion	ion	tion	NN	False
DDI-MedLine.d111.s14	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d111.s14	acetaminophen	15	27	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s14	with	29	32	O	with	ith	with	IN	False
DDI-MedLine.d111.s14	theophylline	34	45	B-drug	theophylline	ine	line	NN	drug
DDI-MedLine.d111.s14	,	46	46	O	,	,	,	,	False
DDI-MedLine.d111.s14	phenobarbital	48	60	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s14	with	62	65	O	with	ith	with	IN	False
DDI-MedLine.d111.s14	acetaminophen	67	79	B-drug	acetaminophen	hen	phen	NN	False
DDI-MedLine.d111.s14	,	80	80	O	,	,	,	,	False
DDI-MedLine.d111.s14	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d111.s14	valproic	86	93	B-drug	valproic	oic	roic	NN	False
DDI-MedLine.d111.s14	acid	95	98	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d111.s14	with	100	103	O	with	ith	with	IN	False
DDI-MedLine.d111.s14	phenobarbital	105	117	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d111.s14	at	119	120	O	at	at	at	IN	False
DDI-MedLine.d111.s14	high	122	125	O	high	igh	high	JJ	False
DDI-MedLine.d111.s14	to	127	128	O	to	to	to	TO	False
DDI-MedLine.d111.s14	toxic	130	134	O	toxic	xic	oxic	NN	False
DDI-MedLine.d111.s14	concentrations	136	149	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d111.s14	decreases	151	159	O	decreases	ses	ases	NNS	False
DDI-MedLine.d111.s14	the	161	163	O	the	the	the	DT	False
DDI-MedLine.d111.s14	binding	165	171	O	binding	ing	ding	NN	False
DDI-MedLine.d111.s14	of	173	174	O	of	of	of	IN	False
DDI-MedLine.d111.s14	the	176	178	O	the	the	the	DT	False
DDI-MedLine.d111.s14	target	180	185	O	target	get	rget	NN	False
DDI-MedLine.d111.s14	drug	187	190	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s14	.	191	191	O	.	.	.	.	False

DDI-MedLine.d111.s15	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d111.s15	resulting	4	12	O	resulting	ing	ting	VBG	False
DDI-MedLine.d111.s15	increase	14	21	O	increase	ase	ease	NN	False
DDI-MedLine.d111.s15	in	23	24	O	in	in	in	IN	False
DDI-MedLine.d111.s15	free	26	29	O	free	ree	free	JJ	False
DDI-MedLine.d111.s15	drug	31	34	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s15	concentration	36	48	O	concentration	ion	tion	NN	False
DDI-MedLine.d111.s15	may	50	52	O	may	may	may	MD	False
DDI-MedLine.d111.s15	lead	54	57	O	lead	ead	lead	NN	False
DDI-MedLine.d111.s15	to	59	60	O	to	to	to	TO	False
DDI-MedLine.d111.s15	enhanced	62	69	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d111.s15	drug	71	74	O	drug	rug	drug	NN	False
DDI-MedLine.d111.s15	effect	76	81	O	effect	ect	fect	NN	False
DDI-MedLine.d111.s15	in	83	84	O	in	in	in	IN	False
DDI-MedLine.d111.s15	vivo	86	89	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d111.s15	.	90	90	O	.	.	.	.	False

DDI-MedLine.d72.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d72.s0	Pharmacologic	1	13	O	Pharmacologic	gic	ogic	NN	False
DDI-MedLine.d72.s0	interactions	15	26	O	interactions	ons	ions	NNS	False
DDI-MedLine.d72.s0	in	28	29	O	in	in	in	IN	False
DDI-MedLine.d72.s0	chronic	31	37	O	chronic	nic	onic	NN	False
DDI-MedLine.d72.s0	treatments	39	48	O	treatments	nts	ents	NNS	False
DDI-MedLine.d72.s0	:	49	49	O	:	:	:	:	False
DDI-MedLine.d72.s0	corrective	51	60	O	corrective	ive	tive	NN	False
DDI-MedLine.d72.s0	measures	62	69	O	measures	res	ures	NNS	False
DDI-MedLine.d72.s0	for	71	73	O	for	for	for	IN	False
DDI-MedLine.d72.s0	its	75	77	O	its	its	its	PRP$	False
DDI-MedLine.d72.s0	prevention	79	88	O	prevention	ion	tion	NN	False
DDI-MedLine.d72.s0	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d72.s0	a	93	93	O	a	a	a	DT	False
DDI-MedLine.d72.s0	basic	95	99	O	basic	sic	asic	JJ	False
DDI-MedLine.d72.s0	area	101	104	O	area	rea	area	NN	False
DDI-MedLine.d72.s0	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d72.s0	rural	109	113	O	rural	ral	ural	JJ	False
DDI-MedLine.d72.s0	health	115	120	O	health	lth	alth	NN	False
DDI-MedLine.d72.s0	]	121	121	O	]	]	]	NN	False
DDI-MedLine.d72.s0	OBJECTIVES	124	133	O	OBJECTIVES	VES	IVES	NN	brand
DDI-MedLine.d72.s0	:	134	134	O	:	:	:	:	False
DDI-MedLine.d72.s0	To	136	137	O	To	To	To	TO	False
DDI-MedLine.d72.s0	identify	139	146	O	identify	ify	tify	VB	False
DDI-MedLine.d72.s0	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d72.s0	pharmacological	152	166	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d72.s0	interactions	168	179	O	interactions	ons	ions	NNS	False
DDI-MedLine.d72.s0	of	181	182	O	of	of	of	IN	False
DDI-MedLine.d72.s0	clinical	184	191	O	clinical	cal	ical	JJ	False
DDI-MedLine.d72.s0	relevance	193	201	O	relevance	nce	ance	NN	False
DDI-MedLine.d72.s0	(	203	203	O	(	(	(	(	False
DDI-MedLine.d72.s0	PICR	204	207	O	PICR	ICR	PICR	NN	brand
DDI-MedLine.d72.s0	)	208	208	O	)	)	)	)	False
DDI-MedLine.d72.s0	in	210	211	O	in	in	in	IN	False
DDI-MedLine.d72.s0	the	213	215	O	the	the	the	DT	False
DDI-MedLine.d72.s0	medication	217	226	O	medication	ion	tion	NN	False
DDI-MedLine.d72.s0	authorization	228	240	O	authorization	ion	tion	NN	False
DDI-MedLine.d72.s0	cards	242	246	O	cards	rds	ards	NNS	False
DDI-MedLine.d72.s0	(	248	248	O	(	(	(	(	False
DDI-MedLine.d72.s0	MAC	249	251	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d72.s0	)	252	252	O	)	)	)	)	False
DDI-MedLine.d72.s0	of	254	255	O	of	of	of	IN	False
DDI-MedLine.d72.s0	the	257	259	O	the	the	the	DT	False
DDI-MedLine.d72.s0	chronically	261	271	O	chronically	lly	ally	RB	False
DDI-MedLine.d72.s0	ill	273	275	O	ill	ill	ill	NN	False
DDI-MedLine.d72.s0	and	277	279	O	and	and	and	CC	False
DDI-MedLine.d72.s0	to	281	282	O	to	to	to	TO	False
DDI-MedLine.d72.s0	establish	284	292	O	establish	ish	lish	VB	False
DDI-MedLine.d72.s0	strategies	294	303	O	strategies	ies	gies	NNS	False
DDI-MedLine.d72.s0	to	305	306	O	to	to	to	TO	False
DDI-MedLine.d72.s0	minimise	308	315	O	minimise	ise	mise	NN	False
DDI-MedLine.d72.s0	their	317	321	O	their	eir	heir	PRP$	False
DDI-MedLine.d72.s0	appearance	323	332	O	appearance	nce	ance	NN	False
DDI-MedLine.d72.s0	.	333	333	O	.	.	.	.	False

DDI-MedLine.d72.s1	DESIGN	0	5	O	DESIGN	IGN	SIGN	NN	brand
DDI-MedLine.d72.s1	:	6	6	O	:	:	:	:	False
DDI-MedLine.d72.s1	Cross-sectional	8	22	O	Cross-sectional	nal	onal	JJ	False
DDI-MedLine.d72.s1	descriptive	24	34	O	descriptive	ive	tive	NN	False
DDI-MedLine.d72.s1	study	36	40	O	study	udy	tudy	NN	False
DDI-MedLine.d72.s1	.	41	41	O	.	.	.	.	False

DDI-MedLine.d72.s2	SETTING	0	6	O	SETTING	ING	TING	NN	brand
DDI-MedLine.d72.s2	:	7	7	O	:	:	:	:	False
DDI-MedLine.d72.s2	Rural	9	13	O	Rural	ral	ural	JJ	False
DDI-MedLine.d72.s2	primary	15	21	O	primary	ary	mary	NN	False
DDI-MedLine.d72.s2	care	23	26	O	care	are	care	NN	False
DDI-MedLine.d72.s2	centre	28	33	O	centre	tre	ntre	NN	False
DDI-MedLine.d72.s2	.	34	34	O	.	.	.	.	False

DDI-MedLine.d72.s3	PATIENTS	0	7	O	PATIENTS	NTS	ENTS	NNS	brand
DDI-MedLine.d72.s3	:	8	8	O	:	:	:	:	False
DDI-MedLine.d72.s3	Random	10	15	O	Random	dom	ndom	NN	False
DDI-MedLine.d72.s3	sample	17	22	O	sample	ple	mple	NN	False
DDI-MedLine.d72.s3	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d72.s3	626	27	29	O	626	626	626	CD	False
DDI-MedLine.d72.s3	MAC	31	33	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d72.s3	out	35	37	O	out	out	out	IN	False
DDI-MedLine.d72.s3	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d72.s3	a	42	42	O	a	a	a	DT	False
DDI-MedLine.d72.s3	total	44	48	O	total	tal	otal	JJ	False
DDI-MedLine.d72.s3	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d72.s3	1306	53	56	O	1306	306	1306	CD	False
DDI-MedLine.d72.s3	.	57	57	O	.	.	.	.	False

DDI-MedLine.d72.s4	MEASUREMENTS	0	11	O	MEASUREMENTS	NTS	ENTS	NNS	brand
DDI-MedLine.d72.s4	AND	13	15	O	AND	AND	AND	CC	brand
DDI-MedLine.d72.s4	MAIN	17	20	O	MAIN	AIN	MAIN	NN	brand
DDI-MedLine.d72.s4	RESULTS	22	28	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d72.s4	:	29	29	O	:	:	:	:	False
DDI-MedLine.d72.s4	In	31	32	O	In	In	In	IN	False
DDI-MedLine.d72.s4	December	34	41	O	December	ber	mber	NNP	False
DDI-MedLine.d72.s4	1998	43	46	O	1998	998	1998	CD	False
DDI-MedLine.d72.s4	,	47	47	O	,	,	,	,	False
DDI-MedLine.d72.s4	the	49	51	O	the	the	the	DT	False
DDI-MedLine.d72.s4	following	53	61	O	following	ing	wing	VBG	False
DDI-MedLine.d72.s4	was	63	65	O	was	was	was	VBD	False
DDI-MedLine.d72.s4	gathered	67	74	O	gathered	red	ered	VBN	False
DDI-MedLine.d72.s4	for	76	78	O	for	for	for	IN	False
DDI-MedLine.d72.s4	every	80	84	O	every	ery	very	DT	False
DDI-MedLine.d72.s4	MAC	86	88	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d72.s4	with	90	93	O	with	ith	with	IN	False
DDI-MedLine.d72.s4	more	95	98	O	more	ore	more	RBR	False
DDI-MedLine.d72.s4	than	100	103	O	than	han	than	IN	False
DDI-MedLine.d72.s4	one	105	107	O	one	one	one	CD	False
DDI-MedLine.d72.s4	drug	109	112	O	drug	rug	drug	NN	False
DDI-MedLine.d72.s4	treatment	114	122	O	treatment	ent	ment	NN	False
DDI-MedLine.d72.s4	:	123	123	O	:	:	:	:	False
DDI-MedLine.d72.s4	age	125	127	O	age	age	age	NN	False
DDI-MedLine.d72.s4	,	128	128	O	,	,	,	,	False
DDI-MedLine.d72.s4	sex	130	132	O	sex	sex	sex	NN	False
DDI-MedLine.d72.s4	,	133	133	O	,	,	,	,	False
DDI-MedLine.d72.s4	number	135	140	O	number	ber	mber	NN	False
DDI-MedLine.d72.s4	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d72.s4	drugs	145	149	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d72.s4	,	150	150	O	,	,	,	,	False
DDI-MedLine.d72.s4	intrinsic	152	160	O	intrinsic	sic	nsic	JJ	False
DDI-MedLine.d72.s4	value	162	166	O	value	lue	alue	NN	False
DDI-MedLine.d72.s4	,	167	167	O	,	,	,	,	False
DDI-MedLine.d72.s4	drugs	169	173	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d72.s4	prescribed	175	184	O	prescribed	bed	ibed	NNS	False
DDI-MedLine.d72.s4	,	185	185	O	,	,	,	,	False
DDI-MedLine.d72.s4	daily	187	191	O	daily	ily	aily	JJ	False
DDI-MedLine.d72.s4	dose	193	196	O	dose	ose	dose	NN	False
DDI-MedLine.d72.s4	and	198	200	O	and	and	and	CC	False
DDI-MedLine.d72.s4	pharmacological	202	216	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d72.s4	interactions	218	229	O	interactions	ons	ions	NNS	False
DDI-MedLine.d72.s4	(	231	231	O	(	(	(	(	False
DDI-MedLine.d72.s4	PI	232	233	O	PI	PI	PI	NN	brand
DDI-MedLine.d72.s4	)	234	234	O	)	)	)	)	False
DDI-MedLine.d72.s4	,	235	235	O	,	,	,	,	False
DDI-MedLine.d72.s4	classified	237	246	O	classified	ied	fied	VBN	False
DDI-MedLine.d72.s4	(	248	248	O	(	(	(	(	False
DDI-MedLine.d72.s4	using	249	253	O	using	ing	sing	VBG	False
DDI-MedLine.d72.s4	the	255	257	O	the	the	the	DT	False
DDI-MedLine.d72.s4	scale	259	263	O	scale	ale	cale	NN	False
DDI-MedLine.d72.s4	of	265	266	O	of	of	of	IN	False
DDI-MedLine.d72.s4	Hansten	268	274	O	Hansten	ten	sten	NNP	False
DDI-MedLine.d72.s4	1996	276	279	O	1996	996	1996	CD	False
DDI-MedLine.d72.s4	)	280	280	O	)	)	)	)	False
DDI-MedLine.d72.s4	into	282	285	O	into	nto	into	IN	False
DDI-MedLine.d72.s4	light	287	291	O	light	ght	ight	NN	False
DDI-MedLine.d72.s4	and	293	295	O	and	and	and	CC	False
DDI-MedLine.d72.s4	clinically	297	306	O	clinically	lly	ally	RB	False
DDI-MedLine.d72.s4	relevant	308	315	O	relevant	ant	vant	NN	False
DDI-MedLine.d72.s4	.	316	316	O	.	.	.	.	False

DDI-MedLine.d72.s5	Statistical	0	10	O	Statistical	cal	ical	JJ	False
DDI-MedLine.d72.s5	analysis	12	19	O	analysis	sis	ysis	NN	False
DDI-MedLine.d72.s5	:	20	20	O	:	:	:	:	False
DDI-MedLine.d72.s5	Mantel-Haenszel	22	36	O	Mantel-Haenszel	zel	szel	NN	False
DDI-MedLine.d72.s5	(	38	38	O	(	(	(	(	False
DDI-MedLine.d72.s5	alpha	39	43	O	alpha	pha	lpha	NN	False
DDI-MedLine.d72.s5	=	45	45	O	=	=	=	NN	False
DDI-MedLine.d72.s5	0.05	47	50	O	0.05	.05	0.05	CD	False
DDI-MedLine.d72.s5	)	51	51	O	)	)	)	)	False
DDI-MedLine.d72.s5	.	52	52	O	.	.	.	.	False

DDI-MedLine.d72.s6	Patients	0	7	O	Patients	nts	ents	NNS	False
DDI-MedLine.d72.s6	'	8	8	O	'	'	'	''	False
DDI-MedLine.d72.s6	mean	10	13	O	mean	ean	mean	NN	False
DDI-MedLine.d72.s6	age	15	17	O	age	age	age	NN	False
DDI-MedLine.d72.s6	was	19	21	O	was	was	was	VBD	False
DDI-MedLine.d72.s6	69.1	23	26	O	69.1	9.1	69.1	CD	False
DDI-MedLine.d72.s6	(	28	28	O	(	(	(	(	False
DDI-MedLine.d72.s6	95	29	30	O	95	95	95	CD	False
DDI-MedLine.d72.s6	%	31	31	O	%	%	%	NN	False
DDI-MedLine.d72.s6	CI	33	34	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s6	,	35	35	O	,	,	,	,	False
DDI-MedLine.d72.s6	+/-	37	39	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s6	1.2	41	43	O	1.2	1.2	1.2	CD	False
DDI-MedLine.d72.s6	)	44	44	O	)	)	)	)	False
DDI-MedLine.d72.s6	.	45	45	O	.	.	.	.	False

DDI-MedLine.d72.s7	Mean	0	3	O	Mean	ean	Mean	NN	False
DDI-MedLine.d72.s7	number	5	10	O	number	ber	mber	NN	False
DDI-MedLine.d72.s7	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d72.s7	drugs	15	19	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d72.s7	per	21	23	O	per	per	per	IN	False
DDI-MedLine.d72.s7	MAC	25	27	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d72.s7	was	29	31	O	was	was	was	VBD	False
DDI-MedLine.d72.s7	4	33	33	O	4	4	4	CD	False
DDI-MedLine.d72.s7	(	35	35	O	(	(	(	(	False
DDI-MedLine.d72.s7	95	36	37	O	95	95	95	CD	False
DDI-MedLine.d72.s7	%	38	38	O	%	%	%	NN	False
DDI-MedLine.d72.s7	CI	40	41	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s7	,	42	42	O	,	,	,	,	False
DDI-MedLine.d72.s7	+/-	44	46	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s7	0.2	48	50	O	0.2	0.2	0.2	CD	False
DDI-MedLine.d72.s7	)	51	51	O	)	)	)	)	False
DDI-MedLine.d72.s7	.	52	52	O	.	.	.	.	False

DDI-MedLine.d72.s8	341	0	2	O	341	341	341	CD	False
DDI-MedLine.d72.s8	PI	4	5	O	PI	PI	PI	NN	brand
DDI-MedLine.d72.s8	affecting	7	15	O	affecting	ing	ting	VBG	False
DDI-MedLine.d72.s8	197	17	19	O	197	197	197	CD	False
DDI-MedLine.d72.s8	patients	21	28	O	patients	nts	ents	NNS	False
DDI-MedLine.d72.s8	(	30	30	O	(	(	(	(	False
DDI-MedLine.d72.s8	31.5	31	34	O	31.5	1.5	31.5	CD	False
DDI-MedLine.d72.s8	%	35	35	O	%	%	%	NN	False
DDI-MedLine.d72.s8	,	36	36	O	,	,	,	,	False
DDI-MedLine.d72.s8	95	38	39	O	95	95	95	CD	False
DDI-MedLine.d72.s8	%	40	40	O	%	%	%	NN	False
DDI-MedLine.d72.s8	CI	42	43	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s8	,	44	44	O	,	,	,	,	False
DDI-MedLine.d72.s8	+/-	46	48	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s8	3.6	50	52	O	3.6	3.6	3.6	CD	False
DDI-MedLine.d72.s8	)	53	53	O	)	)	)	)	False
DDI-MedLine.d72.s8	were	55	58	O	were	ere	were	VBD	False
DDI-MedLine.d72.s8	identified	60	69	O	identified	ied	fied	VBN	False
DDI-MedLine.d72.s8	.	70	70	O	.	.	.	.	False

DDI-MedLine.d72.s9	24.9	0	3	O	24.9	4.9	24.9	CD	False
DDI-MedLine.d72.s9	%	4	4	O	%	%	%	NN	False
DDI-MedLine.d72.s9	(	6	6	O	(	(	(	(	False
DDI-MedLine.d72.s9	95	7	8	O	95	95	95	CD	False
DDI-MedLine.d72.s9	%	9	9	O	%	%	%	NN	False
DDI-MedLine.d72.s9	CI	11	12	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s9	,	13	13	O	,	,	,	,	False
DDI-MedLine.d72.s9	+/-	15	17	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s9	4.5	19	21	O	4.5	4.5	4.5	CD	False
DDI-MedLine.d72.s9	)	22	22	O	)	)	)	)	False
DDI-MedLine.d72.s9	were	24	27	O	were	ere	were	VBD	False
DDI-MedLine.d72.s9	PICR	29	32	O	PICR	ICR	PICR	NN	brand
DDI-MedLine.d72.s9	,	33	33	O	,	,	,	,	False
DDI-MedLine.d72.s9	detected	35	42	O	detected	ted	cted	VBN	False
DDI-MedLine.d72.s9	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d72.s9	11.7	47	50	O	11.7	1.7	11.7	CD	False
DDI-MedLine.d72.s9	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d72.s9	(	53	53	O	(	(	(	(	False
DDI-MedLine.d72.s9	95	54	55	O	95	95	95	CD	False
DDI-MedLine.d72.s9	%	56	56	O	%	%	%	NN	False
DDI-MedLine.d72.s9	CI	58	59	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s9	,	60	60	O	,	,	,	,	False
DDI-MedLine.d72.s9	+/-	62	64	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s9	2.5	66	68	O	2.5	2.5	2.5	CD	False
DDI-MedLine.d72.s9	)	69	69	O	)	)	)	)	False
DDI-MedLine.d72.s9	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d72.s9	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d72.s9	MAC	78	80	O	MAC	MAC	MAC	NNP	brand
DDI-MedLine.d72.s9	.	81	81	O	.	.	.	.	False

DDI-MedLine.d72.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d72.s10	existence	4	12	O	existence	nce	ence	NN	False
DDI-MedLine.d72.s10	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d72.s10	PI	17	18	O	PI	PI	PI	NN	brand
DDI-MedLine.d72.s10	was	20	22	O	was	was	was	VBD	False
DDI-MedLine.d72.s10	related	24	30	O	related	ted	ated	JJ	False
DDI-MedLine.d72.s10	to	32	33	O	to	to	to	TO	False
DDI-MedLine.d72.s10	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d72.s10	number	39	44	O	number	ber	mber	NN	False
DDI-MedLine.d72.s10	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d72.s10	drugs	49	53	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d72.s10	prescribed	55	64	O	prescribed	bed	ibed	NNS	False
DDI-MedLine.d72.s10	to	66	67	O	to	to	to	TO	False
DDI-MedLine.d72.s10	each	69	72	O	each	ach	each	DT	False
DDI-MedLine.d72.s10	patient	74	80	O	patient	ent	ient	NN	False
DDI-MedLine.d72.s10	(	82	82	O	(	(	(	(	False
DDI-MedLine.d72.s10	p	83	83	O	p	p	p	NN	False
DDI-MedLine.d72.s10	<	85	85	O	<	<	<	NN	False
DDI-MedLine.d72.s10	0.01	87	90	O	0.01	.01	0.01	CD	False
DDI-MedLine.d72.s10	)	91	91	O	)	)	)	)	False
DDI-MedLine.d72.s10	.	92	92	O	.	.	.	.	False

DDI-MedLine.d72.s11	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d72.s11	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d72.s11	26	11	12	O	26	26	26	CD	False
DDI-MedLine.d72.s11	PI	14	15	O	PI	PI	PI	NN	brand
DDI-MedLine.d72.s11	with	17	20	O	with	ith	with	IN	False
DDI-MedLine.d72.s11	drugs	22	26	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d72.s11	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d72.s11	low	31	33	O	low	low	low	JJ	False
DDI-MedLine.d72.s11	intrinsic	35	43	O	intrinsic	sic	nsic	JJ	False
DDI-MedLine.d72.s11	value	45	49	O	value	lue	alue	NN	False
DDI-MedLine.d72.s11	(	51	51	O	(	(	(	(	False
DDI-MedLine.d72.s11	7.6	52	54	O	7.6	7.6	7.6	CD	False
DDI-MedLine.d72.s11	%	55	55	O	%	%	%	NN	False
DDI-MedLine.d72.s11	;	56	56	O	;	;	;	:	False
DDI-MedLine.d72.s11	95	58	59	O	95	95	95	CD	False
DDI-MedLine.d72.s11	%	60	60	O	%	%	%	NN	False
DDI-MedLine.d72.s11	CI	62	63	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s11	,	64	64	O	,	,	,	,	False
DDI-MedLine.d72.s11	+/-	66	68	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s11	2.8	70	72	O	2.8	2.8	2.8	CD	False
DDI-MedLine.d72.s11	)	73	73	O	)	)	)	)	False
DDI-MedLine.d72.s11	.	74	74	O	.	.	.	.	False

DDI-MedLine.d72.s12	74.1	0	3	O	74.1	4.1	74.1	CD	False
DDI-MedLine.d72.s12	%	4	4	O	%	%	%	NN	False
DDI-MedLine.d72.s12	(	6	6	O	(	(	(	(	False
DDI-MedLine.d72.s12	95	7	8	O	95	95	95	CD	False
DDI-MedLine.d72.s12	%	9	9	O	%	%	%	NN	False
DDI-MedLine.d72.s12	CI	11	12	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s12	,	13	13	O	,	,	,	,	False
DDI-MedLine.d72.s12	+/-	15	17	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s12	9.3	19	21	O	9.3	9.3	9.3	CD	False
DDI-MedLine.d72.s12	)	22	22	O	)	)	)	)	False
DDI-MedLine.d72.s12	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d72.s12	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d72.s12	total	31	35	O	total	tal	otal	JJ	False
DDI-MedLine.d72.s12	PICR	37	40	O	PICR	ICR	PICR	NN	brand
DDI-MedLine.d72.s12	could	42	46	O	could	uld	ould	MD	False
DDI-MedLine.d72.s12	be	48	49	O	be	be	be	VB	False
DDI-MedLine.d72.s12	avoided	51	57	O	avoided	ded	ided	VBD	False
DDI-MedLine.d72.s12	by	59	60	O	by	by	by	IN	False
DDI-MedLine.d72.s12	simple	62	67	O	simple	ple	mple	NN	False
DDI-MedLine.d72.s12	recommendations	69	83	O	recommendations	ons	ions	NNS	False
DDI-MedLine.d72.s12	;	84	84	O	;	;	;	:	False

DDI-MedLine.d72.s13	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d72.s13	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d72.s13	remaining	8	16	O	remaining	ing	ning	VBG	False
DDI-MedLine.d72.s13	25.9	18	21	O	25.9	5.9	25.9	CD	False
DDI-MedLine.d72.s13	%	22	22	O	%	%	%	NN	False
DDI-MedLine.d72.s13	(	24	24	O	(	(	(	(	False
DDI-MedLine.d72.s13	95	25	26	O	95	95	95	CD	False
DDI-MedLine.d72.s13	%	27	27	O	%	%	%	NN	False
DDI-MedLine.d72.s13	CI	29	30	O	CI	CI	CI	NN	brand
DDI-MedLine.d72.s13	,	31	31	O	,	,	,	,	False
DDI-MedLine.d72.s13	+/-	33	35	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d72.s13	9.3	37	39	O	9.3	9.3	9.3	CD	False
DDI-MedLine.d72.s13	)	40	40	O	)	)	)	)	False
DDI-MedLine.d72.s13	by	42	43	O	by	by	by	IN	False
DDI-MedLine.d72.s13	monitoring	45	54	O	monitoring	ing	ring	NN	False
DDI-MedLine.d72.s13	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d72.s13	follow-up	60	68	O	follow-up	-up	w-up	NN	False
DDI-MedLine.d72.s13	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d72.s13	patients	73	80	O	patients	nts	ents	NNS	False
DDI-MedLine.d72.s13	.	81	81	O	.	.	.	.	False

DDI-MedLine.d72.s14	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d72.s14	:	11	11	O	:	:	:	:	False
DDI-MedLine.d72.s14	It	13	14	O	It	It	It	PRP	False
DDI-MedLine.d72.s14	is	16	17	O	is	is	is	VBZ	False
DDI-MedLine.d72.s14	important	19	27	O	important	ant	tant	JJ	False
DDI-MedLine.d72.s14	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d72.s14	identify	32	39	O	identify	ify	tify	VB	False
DDI-MedLine.d72.s14	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d72.s14	medications	45	55	O	medications	ons	ions	NNS	False
DDI-MedLine.d72.s14	most	57	60	O	most	ost	most	JJS	False
DDI-MedLine.d72.s14	commonly	62	69	O	commonly	nly	only	RB	False
DDI-MedLine.d72.s14	involved	71	78	O	involved	ved	lved	VBN	False
DDI-MedLine.d72.s14	in	80	81	O	in	in	in	IN	False
DDI-MedLine.d72.s14	the	83	85	O	the	the	the	DT	False
DDI-MedLine.d72.s14	PICR	87	90	O	PICR	ICR	PICR	NN	brand
DDI-MedLine.d72.s14	so	92	93	O	so	so	so	RB	False
DDI-MedLine.d72.s14	as	95	96	O	as	as	as	IN	False
DDI-MedLine.d72.s14	to	98	99	O	to	to	to	TO	False
DDI-MedLine.d72.s14	establish	101	109	O	establish	ish	lish	VB	False
DDI-MedLine.d72.s14	corrective	111	120	O	corrective	ive	tive	NN	False
DDI-MedLine.d72.s14	measures	122	129	O	measures	res	ures	NNS	False
DDI-MedLine.d72.s14	to	131	132	O	to	to	to	TO	False
DDI-MedLine.d72.s14	minimise	134	141	O	minimise	ise	mise	NN	False
DDI-MedLine.d72.s14	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d72.s14	risks	147	151	O	risks	sks	isks	NNS	False
DDI-MedLine.d72.s14	arising	153	159	O	arising	ing	sing	VBG	False
DDI-MedLine.d72.s14	from	161	164	O	from	rom	from	IN	False
DDI-MedLine.d72.s14	multiple	166	173	O	multiple	ple	iple	NN	False
DDI-MedLine.d72.s14	medication	175	184	O	medication	ion	tion	NN	False
DDI-MedLine.d72.s14	.	185	185	O	.	.	.	.	False

DDI-MedLine.d72.s15	Four	0	3	O	Four	our	Four	CD	False
DDI-MedLine.d72.s15	educational	5	15	O	educational	nal	onal	JJ	False
DDI-MedLine.d72.s15	messages	17	24	O	messages	ges	ages	NNS	False
DDI-MedLine.d72.s15	advise	26	31	O	advise	ise	vise	NN	False
DDI-MedLine.d72.s15	on	33	34	O	on	on	on	IN	False
DDI-MedLine.d72.s15	over	36	39	O	over	ver	over	IN	False
DDI-MedLine.d72.s15	60	41	42	O	60	60	60	CD	False
DDI-MedLine.d72.s15	%	43	43	O	%	%	%	NN	False
DDI-MedLine.d72.s15	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d72.s15	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d72.s15	PICR	52	55	O	PICR	ICR	PICR	NN	brand
DDI-MedLine.d72.s15	detected	57	64	O	detected	ted	cted	VBN	False
DDI-MedLine.d72.s15	.	65	65	O	.	.	.	.	False

DDI-MedLine.d45.s0	Selective	0	8	O	Selective	ive	tive	JJ	False
DDI-MedLine.d45.s0	survival	10	17	O	survival	val	ival	NN	False
DDI-MedLine.d45.s0	in	19	20	O	in	in	in	IN	False
DDI-MedLine.d45.s0	pentazocine	22	32	B-drug	pentazocine	ine	cine	NN	drug
DDI-MedLine.d45.s0	and	34	36	O	and	and	and	CC	False
DDI-MedLine.d45.s0	tripelennamine	38	51	B-drug	tripelennamine	ine	mine	NN	drug
DDI-MedLine.d45.s0	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d45.s0	Pseudomonas	56	66	O	Pseudomonas	nas	onas	NNS	False
DDI-MedLine.d45.s0	aeruginosa	68	77	O	aeruginosa	osa	nosa	NN	False
DDI-MedLine.d45.s0	serotype	79	86	O	serotype	ype	type	NN	False
DDI-MedLine.d45.s0	O11	88	90	O	O11	O11	O11	NN	brand
DDI-MedLine.d45.s0	from	92	95	O	from	rom	from	IN	False
DDI-MedLine.d45.s0	drug	97	100	O	drug	rug	drug	NN	False
DDI-MedLine.d45.s0	addicts	102	108	O	addicts	cts	icts	NNS	False
DDI-MedLine.d45.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d45.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d45.s1	growth	4	9	O	growth	wth	owth	NN	False
DDI-MedLine.d45.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d45.s1	Pseudomonas	14	24	O	Pseudomonas	nas	onas	NNS	False
DDI-MedLine.d45.s1	aeruginosa	26	35	O	aeruginosa	osa	nosa	NN	False
DDI-MedLine.d45.s1	,	36	36	O	,	,	,	,	False
DDI-MedLine.d45.s1	particularly	38	49	O	particularly	rly	arly	RB	False
DDI-MedLine.d45.s1	serotype	51	58	O	serotype	ype	type	NN	False
DDI-MedLine.d45.s1	O11	60	62	O	O11	O11	O11	NN	brand
DDI-MedLine.d45.s1	,	63	63	O	,	,	,	,	False
DDI-MedLine.d45.s1	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d45.s1	pentazocine	68	78	B-drug	pentazocine	ine	cine	NN	drug
DDI-MedLine.d45.s1	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d45.s1	tripelennamine	84	97	B-drug	tripelennamine	ine	mine	NN	drug

DDI-MedLine.d45.s2	was	0	2	O	was	was	was	VBD	False
DDI-MedLine.d45.s2	evaluated	4	12	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d45.s2	as	14	15	O	as	as	as	IN	False
DDI-MedLine.d45.s2	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d45.s2	possible	19	26	O	possible	ble	ible	JJ	False
DDI-MedLine.d45.s2	explanation	28	38	O	explanation	ion	tion	NN	False
DDI-MedLine.d45.s2	for	40	42	O	for	for	for	IN	False
DDI-MedLine.d45.s2	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d45.s2	association	48	58	O	association	ion	tion	NN	False
DDI-MedLine.d45.s2	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d45.s2	deep-seated	63	73	O	deep-seated	ted	ated	JJ	False
DDI-MedLine.d45.s2	infection	75	83	O	infection	ion	tion	NN	False
DDI-MedLine.d45.s2	with	85	88	O	with	ith	with	IN	False
DDI-MedLine.d45.s2	this	90	93	O	this	his	this	DT	False
DDI-MedLine.d45.s2	organism	95	102	O	organism	ism	nism	NN	False
DDI-MedLine.d45.s2	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d45.s2	abuse	108	112	O	abuse	use	buse	NN	False
DDI-MedLine.d45.s2	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d45.s2	these	117	121	O	these	ese	hese	DT	False
DDI-MedLine.d45.s2	drugs	123	127	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d45.s2	.	128	128	O	.	.	.	.	False

DDI-MedLine.d45.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d45.s3	mean	4	7	O	mean	ean	mean	NN	False
DDI-MedLine.d45.s3	reduction	9	17	O	reduction	ion	tion	NN	False
DDI-MedLine.d45.s3	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d45.s3	growth	22	27	O	growth	wth	owth	NN	False
DDI-MedLine.d45.s3	caused	29	34	O	caused	sed	used	VBN	False
DDI-MedLine.d45.s3	by	36	37	O	by	by	by	IN	False
DDI-MedLine.d45.s3	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d45.s3	drugs	43	47	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d45.s3	was	49	51	O	was	was	was	VBD	False
DDI-MedLine.d45.s3	1,000-fold	53	62	O	1,000-fold	old	fold	JJ	False
DDI-MedLine.d45.s3	greater	64	70	O	greater	ter	ater	JJR	False
DDI-MedLine.d45.s3	for	72	74	O	for	for	for	IN	False
DDI-MedLine.d45.s3	49	76	77	O	49	49	49	CD	False
DDI-MedLine.d45.s3	Pseudomonas	79	89	O	Pseudomonas	nas	onas	NNS	False
DDI-MedLine.d45.s3	strains	91	97	O	strains	ins	ains	NNS	False
DDI-MedLine.d45.s3	from	99	102	O	from	rom	from	IN	False
DDI-MedLine.d45.s3	normal	104	109	O	normal	mal	rmal	JJ	False
DDI-MedLine.d45.s3	subjects	111	118	O	subjects	cts	ects	NNS	False
DDI-MedLine.d45.s3	than	120	123	O	than	han	than	IN	False
DDI-MedLine.d45.s3	for	125	127	O	for	for	for	IN	False
DDI-MedLine.d45.s3	32	129	130	O	32	32	32	CD	False
DDI-MedLine.d45.s3	strains	132	138	O	strains	ins	ains	NNS	False
DDI-MedLine.d45.s3	from	140	143	O	from	rom	from	IN	False
DDI-MedLine.d45.s3	drug	145	148	O	drug	rug	drug	NN	False
DDI-MedLine.d45.s3	addicts	150	156	O	addicts	cts	icts	NNS	False
DDI-MedLine.d45.s3	(	158	158	O	(	(	(	(	False
DDI-MedLine.d45.s3	4.2	159	161	O	4.2	4.2	4.2	CD	False
DDI-MedLine.d45.s3	vs.	163	165	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d45.s3	1.3	167	169	O	1.3	1.3	1.3	CD	False
DDI-MedLine.d45.s3	logs	171	174	O	logs	ogs	logs	NNS	False
DDI-MedLine.d45.s3	of	176	177	O	of	of	of	IN	False
DDI-MedLine.d45.s3	reduction	179	187	O	reduction	ion	tion	NN	False
DDI-MedLine.d45.s3	at	189	190	O	at	at	at	IN	False
DDI-MedLine.d45.s3	2	192	192	O	2	2	2	CD	False
DDI-MedLine.d45.s3	hr	194	195	O	hr	hr	hr	NN	False
DDI-MedLine.d45.s3	,	196	196	O	,	,	,	,	False
DDI-MedLine.d45.s3	P	198	198	O	P	P	P	NN	brand
DDI-MedLine.d45.s3	less	200	203	O	less	ess	less	RBR	False
DDI-MedLine.d45.s3	than	205	208	O	than	han	than	IN	False
DDI-MedLine.d45.s3	.0005	210	214	O	.0005	005	0005	NN	False
DDI-MedLine.d45.s3	)	215	215	O	)	)	)	)	False
DDI-MedLine.d45.s3	.	216	216	O	.	.	.	.	False

DDI-MedLine.d45.s4	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d45.s4	common	2	7	O	common	mon	mmon	JJ	False
DDI-MedLine.d45.s4	phenotypic	9	18	O	phenotypic	pic	ypic	NN	False
DDI-MedLine.d45.s4	subset	20	25	O	subset	set	bset	NN	False
DDI-MedLine.d45.s4	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d45.s4	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d45.s4	serotype	34	41	O	serotype	ype	type	NN	False
DDI-MedLine.d45.s4	O11	43	45	O	O11	O11	O11	NN	brand
DDI-MedLine.d45.s4	strains	47	53	O	strains	ins	ains	NNS	False
DDI-MedLine.d45.s4	from	55	58	O	from	rom	from	IN	False
DDI-MedLine.d45.s4	drug	60	63	O	drug	rug	drug	NN	False
DDI-MedLine.d45.s4	addicts	65	71	O	addicts	cts	icts	NNS	False
DDI-MedLine.d45.s4	was	73	75	O	was	was	was	VBD	False
DDI-MedLine.d45.s4	especially	77	86	O	especially	lly	ally	RB	False
DDI-MedLine.d45.s4	resistant	88	96	O	resistant	ant	tant	NN	False
DDI-MedLine.d45.s4	to	98	99	O	to	to	to	TO	False
DDI-MedLine.d45.s4	the	101	103	O	the	the	the	DT	False
DDI-MedLine.d45.s4	inhibitory	105	114	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d45.s4	effects	116	122	O	effects	cts	ects	NNS	False
DDI-MedLine.d45.s4	.	123	123	O	.	.	.	.	False

DDI-MedLine.d45.s5	Twelve	0	5	O	Twelve	lve	elve	NN	False
DDI-MedLine.d45.s5	strains	7	13	O	strains	ins	ains	NNS	False
DDI-MedLine.d45.s5	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d45.s5	Staphylococcus	18	31	O	Staphylococcus	cus	ccus	NN	False
DDI-MedLine.d45.s5	aureus	33	38	O	aureus	eus	reus	NN	False
DDI-MedLine.d45.s5	(	40	40	O	(	(	(	(	False
DDI-MedLine.d45.s5	a	41	41	O	a	a	a	DT	False
DDI-MedLine.d45.s5	frequent	43	50	O	frequent	ent	uent	NN	False
DDI-MedLine.d45.s5	cause	52	56	O	cause	use	ause	NN	False
DDI-MedLine.d45.s5	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d45.s5	infection	61	69	O	infection	ion	tion	NN	False
DDI-MedLine.d45.s5	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d45.s5	heroin	74	79	B-drug_n	heroin	oin	roin	NN	False
DDI-MedLine.d45.s5	,	80	80	O	,	,	,	,	False
DDI-MedLine.d45.s5	but	82	84	O	but	but	but	CC	False
DDI-MedLine.d45.s5	not	86	88	O	not	not	not	RB	False
DDI-MedLine.d45.s5	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d45.s5	pentazocine	93	103	B-drug	pentazocine	ine	cine	NN	drug
DDI-MedLine.d45.s5	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d45.s5	tripelennamine	109	122	B-drug	tripelennamine	ine	mine	NN	drug
DDI-MedLine.d45.s5	,	123	123	O	,	,	,	,	False
DDI-MedLine.d45.s5	addicts	125	131	O	addicts	cts	icts	NNS	False
DDI-MedLine.d45.s5	)	132	132	O	)	)	)	)	False
DDI-MedLine.d45.s5	were	134	137	O	were	ere	were	VBD	False
DDI-MedLine.d45.s5	completely	139	148	O	completely	ely	tely	RB	False
DDI-MedLine.d45.s5	inhibited	150	158	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d45.s5	by	160	161	O	by	by	by	IN	False
DDI-MedLine.d45.s5	the	163	165	O	the	the	the	DT	False
DDI-MedLine.d45.s5	drug	167	170	O	drug	rug	drug	NN	False
DDI-MedLine.d45.s5	combination	172	182	O	combination	ion	tion	NN	False
DDI-MedLine.d45.s5	.	183	183	O	.	.	.	.	False

DDI-MedLine.d45.s6	Dose-response	0	12	O	Dose-response	nse	onse	NN	False
DDI-MedLine.d45.s6	curves	14	19	O	curves	ves	rves	NNS	False
DDI-MedLine.d45.s6	(	21	21	O	(	(	(	(	False
DDI-MedLine.d45.s6	derived	22	28	O	derived	ved	ived	VBN	False
DDI-MedLine.d45.s6	from	30	33	O	from	rom	from	IN	False
DDI-MedLine.d45.s6	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d45.s6	results	39	45	O	results	lts	ults	NNS	False
DDI-MedLine.d45.s6	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d45.s6	using	50	54	O	using	ing	sing	VBG	False
DDI-MedLine.d45.s6	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d45.s6	tablets	60	66	O	tablets	ets	lets	NNS	False
DDI-MedLine.d45.s6	as	68	69	O	as	as	as	IN	False
DDI-MedLine.d45.s6	well	71	74	O	well	ell	well	RB	False
DDI-MedLine.d45.s6	as	76	77	O	as	as	as	IN	False
DDI-MedLine.d45.s6	pure	79	82	O	pure	ure	pure	NN	False
DDI-MedLine.d45.s6	powders	84	90	O	powders	ers	ders	NNS	False
DDI-MedLine.d45.s6	)	91	91	O	)	)	)	)	False
DDI-MedLine.d45.s6	showed	93	98	O	showed	wed	owed	VBD	False
DDI-MedLine.d45.s6	that	100	103	O	that	hat	that	IN	False
DDI-MedLine.d45.s6	tripelennamine	105	118	B-drug	tripelennamine	ine	mine	NN	drug
DDI-MedLine.d45.s6	was	120	122	O	was	was	was	VBD	False
DDI-MedLine.d45.s6	responsible	124	134	O	responsible	ble	ible	JJ	False
DDI-MedLine.d45.s6	for	136	138	O	for	for	for	IN	False
DDI-MedLine.d45.s6	the	140	142	O	the	the	the	DT	False
DDI-MedLine.d45.s6	inhibitory	144	153	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d45.s6	activity	155	162	O	activity	ity	vity	NN	False
DDI-MedLine.d45.s6	,	163	163	O	,	,	,	,	False
DDI-MedLine.d45.s6	which	165	169	O	which	ich	hich	WDT	False
DDI-MedLine.d45.s6	was	171	173	O	was	was	was	VBD	False
DDI-MedLine.d45.s6	partially	175	183	O	partially	lly	ally	RB	False
DDI-MedLine.d45.s6	antagonized	185	195	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d45.s6	by	197	198	O	by	by	by	IN	False
DDI-MedLine.d45.s6	pentazocine	200	210	B-drug	pentazocine	ine	cine	NN	drug
DDI-MedLine.d45.s6	.	211	211	O	.	.	.	.	False

DDI-MedLine.d45.s7	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d45.s7	conclude	3	10	O	conclude	ude	lude	NN	False
DDI-MedLine.d45.s7	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d45.s7	an	17	18	O	an	an	an	DT	False
DDI-MedLine.d45.s7	ability	20	26	O	ability	ity	lity	NN	False
DDI-MedLine.d45.s7	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d45.s7	some	31	34	O	some	ome	some	DT	False
DDI-MedLine.d45.s7	P	36	36	O	P	P	P	NN	brand
DDI-MedLine.d45.s7	.	37	37	O	.	.	.	.	False

DDI-MedLine.d45.s8	aeruginosa	0	9	O	aeruginosa	osa	nosa	NN	False
DDI-MedLine.d45.s8	serotype	11	18	O	serotype	ype	type	NN	False
DDI-MedLine.d45.s8	O11	20	22	O	O11	O11	O11	NN	brand
DDI-MedLine.d45.s8	strains	24	30	O	strains	ins	ains	NNS	False
DDI-MedLine.d45.s8	,	31	31	O	,	,	,	,	False
DDI-MedLine.d45.s8	but	33	35	O	but	but	but	CC	False
DDI-MedLine.d45.s8	not	37	39	O	not	not	not	RB	False
DDI-MedLine.d45.s8	S	41	41	O	S	S	S	NN	brand
DDI-MedLine.d45.s8	.	42	42	O	.	.	.	.	False

DDI-MedLine.d45.s9	aureus	0	5	O	aureus	eus	reus	NN	False
DDI-MedLine.d45.s9	,	6	6	O	,	,	,	,	False
DDI-MedLine.d45.s9	to	8	9	O	to	to	to	TO	False
DDI-MedLine.d45.s9	survive	11	17	O	survive	ive	vive	NN	False
DDI-MedLine.d45.s9	in	19	20	O	in	in	in	IN	False
DDI-MedLine.d45.s9	pentazocine	22	32	B-drug	pentazocine	ine	cine	NN	drug
DDI-MedLine.d45.s9	and	34	36	O	and	and	and	CC	False
DDI-MedLine.d45.s9	tripelennamine	38	51	B-drug	tripelennamine	ine	mine	NN	drug
DDI-MedLine.d45.s9	may	53	55	O	may	may	may	MD	False
DDI-MedLine.d45.s9	explain	57	63	O	explain	ain	lain	NN	False
DDI-MedLine.d45.s9	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d45.s9	part	68	71	O	part	art	part	NN	False
DDI-MedLine.d45.s9	a	73	73	O	a	a	a	DT	False
DDI-MedLine.d45.s9	shift	75	79	O	shift	ift	hift	NN	False
DDI-MedLine.d45.s9	from	81	84	O	from	rom	from	IN	False
DDI-MedLine.d45.s9	S	86	86	O	S	S	S	NN	brand
DDI-MedLine.d45.s9	.	87	87	O	.	.	.	.	False

DDI-MedLine.d45.s10	aureus	0	5	O	aureus	eus	reus	NN	False
DDI-MedLine.d45.s10	to	7	8	O	to	to	to	TO	False
DDI-MedLine.d45.s10	P	10	10	O	P	P	P	NN	brand
DDI-MedLine.d45.s10	.	11	11	O	.	.	.	.	False

DDI-MedLine.d45.s11	aeruginosa	0	9	O	aeruginosa	osa	nosa	NN	False
DDI-MedLine.d45.s11	as	11	12	O	as	as	as	IN	False
DDI-MedLine.d45.s11	common	14	19	O	common	mon	mmon	JJ	False
DDI-MedLine.d45.s11	pathogens	21	29	O	pathogens	ens	gens	NNS	False
DDI-MedLine.d45.s11	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d45.s11	drug	34	37	O	drug	rug	drug	NN	False
DDI-MedLine.d45.s11	addicts	39	45	O	addicts	cts	icts	NNS	False
DDI-MedLine.d45.s11	in	47	48	O	in	in	in	IN	False
DDI-MedLine.d45.s11	areas	50	54	O	areas	eas	reas	NNS	False
DDI-MedLine.d45.s11	where	56	60	O	where	ere	here	WRB	False
DDI-MedLine.d45.s11	abuse	62	66	O	abuse	use	buse	NN	False
DDI-MedLine.d45.s11	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d45.s11	this	71	74	O	this	his	this	DT	False
DDI-MedLine.d45.s11	combination	76	86	O	combination	ion	tion	NN	False
DDI-MedLine.d45.s11	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d45.s11	drugs	91	95	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d45.s11	has	97	99	O	has	has	has	VBZ	False
DDI-MedLine.d45.s11	increased	101	109	O	increased	sed	ased	VBN	False
DDI-MedLine.d45.s11	.	110	110	O	.	.	.	.	False

DDI-MedLine.d53.s0	Induction	0	8	O	Induction	ion	tion	NN	False
DDI-MedLine.d53.s0	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d53.s0	apoptosis	13	21	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d53.s0	in	23	24	O	in	in	in	IN	False
DDI-MedLine.d53.s0	breast	26	31	O	breast	ast	east	NN	False
DDI-MedLine.d53.s0	cancer	33	38	O	cancer	cer	ncer	NN	False
DDI-MedLine.d53.s0	cells	40	44	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s0	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d53.s0	response	49	56	O	response	nse	onse	NN	False
DDI-MedLine.d53.s0	to	58	59	O	to	to	to	TO	False
DDI-MedLine.d53.s0	vitamin	61	67	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d53.s0	D	69	69	I-group	D	D	D	NN	brand
DDI-MedLine.d53.s0	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d53.s0	antiestrogens	75	87	B-group	antiestrogens	ens	gens	NNS	False
DDI-MedLine.d53.s0	.	88	88	O	.	.	.	.	False

DDI-MedLine.d53.s1	1,25-Dihydroxycholecalciferol	0	28	O	1,25-Dihydroxycholecalciferol	rol	erol	JJ	False
DDI-MedLine.d53.s1	D3	30	31	I-drug	D3	D3	D3	NN	brand
DDI-MedLine.d53.s1	(	33	33	O	(	(	(	(	False
DDI-MedLine.d53.s1	1,25	34	37	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s1	(	38	38	I-drug	(	(	(	(	False
DDI-MedLine.d53.s1	OH	39	40	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s1	)	41	41	I-drug	)	)	)	)	False
DDI-MedLine.d53.s1	2D3	42	44	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s1	)	45	45	O	)	)	)	)	False
DDI-MedLine.d53.s1	,	46	46	O	,	,	,	,	False
DDI-MedLine.d53.s1	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d53.s1	active	52	57	O	active	ive	tive	JJ	False
DDI-MedLine.d53.s1	metabolite	59	68	O	metabolite	ite	lite	NN	False
DDI-MedLine.d53.s1	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d53.s1	vitamin	73	79	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d53.s1	D	81	81	I-group	D	D	D	NN	brand
DDI-MedLine.d53.s1	,	82	82	O	,	,	,	,	False
DDI-MedLine.d53.s1	is	84	85	O	is	is	is	VBZ	False
DDI-MedLine.d53.s1	a	87	87	O	a	a	a	DT	False
DDI-MedLine.d53.s1	potent	89	94	O	potent	ent	tent	NN	False
DDI-MedLine.d53.s1	inhibitor	96	104	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d53.s1	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d53.s1	breast	109	114	O	breast	ast	east	NN	False
DDI-MedLine.d53.s1	cancer	116	121	O	cancer	cer	ncer	NN	False
DDI-MedLine.d53.s1	cell	123	126	O	cell	ell	cell	NN	False
DDI-MedLine.d53.s1	growth	128	133	O	growth	wth	owth	NN	False
DDI-MedLine.d53.s1	both	135	138	O	both	oth	both	DT	False
DDI-MedLine.d53.s1	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d53.s1	vivo	143	146	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d53.s1	and	148	150	O	and	and	and	CC	False
DDI-MedLine.d53.s1	in	152	153	O	in	in	in	IN	False
DDI-MedLine.d53.s1	vitro	155	159	O	vitro	tro	itro	NN	False
DDI-MedLine.d53.s1	.	160	160	O	.	.	.	.	False

DDI-MedLine.d53.s2	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d53.s2	have	3	6	O	have	ave	have	VB	False
DDI-MedLine.d53.s2	shown	8	12	O	shown	own	hown	VBN	False
DDI-MedLine.d53.s2	that	14	17	O	that	hat	that	IN	False
DDI-MedLine.d53.s2	MCF-7	19	23	O	MCF-7	F-7	CF-7	NN	brand
DDI-MedLine.d53.s2	cells	25	29	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s2	treated	31	37	O	treated	ted	ated	VBN	False
DDI-MedLine.d53.s2	with	39	42	O	with	ith	with	IN	False
DDI-MedLine.d53.s2	100	44	46	O	100	100	100	CD	False
DDI-MedLine.d53.s2	nM	48	49	O	nM	nM	nM	NN	False
DDI-MedLine.d53.s2	1,25	51	54	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s2	(	55	55	I-drug	(	(	(	(	False
DDI-MedLine.d53.s2	OH	56	57	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s2	)	58	58	I-drug	)	)	)	)	False
DDI-MedLine.d53.s2	2D3	59	61	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s2	exhibit	63	69	O	exhibit	bit	ibit	NN	False
DDI-MedLine.d53.s2	characteristic	71	84	O	characteristic	tic	stic	JJ	False
DDI-MedLine.d53.s2	apoptotic	86	94	O	apoptotic	tic	otic	JJ	False
DDI-MedLine.d53.s2	morphology	96	105	O	morphology	ogy	logy	NN	False
DDI-MedLine.d53.s2	(	107	107	O	(	(	(	(	False
DDI-MedLine.d53.s2	pyknotic	108	115	O	pyknotic	tic	otic	JJ	False
DDI-MedLine.d53.s2	nuclei	117	122	O	nuclei	lei	clei	NN	False
DDI-MedLine.d53.s2	,	123	123	O	,	,	,	,	False
DDI-MedLine.d53.s2	chromatin	125	133	O	chromatin	tin	atin	NN	False
DDI-MedLine.d53.s2	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d53.s2	cytoplasmic	139	149	O	cytoplasmic	mic	smic	NN	False
DDI-MedLine.d53.s2	condensation	151	162	O	condensation	ion	tion	NN	False
DDI-MedLine.d53.s2	,	163	163	O	,	,	,	,	False
DDI-MedLine.d53.s2	nuclear	165	171	O	nuclear	ear	lear	JJ	False
DDI-MedLine.d53.s2	matrix	173	178	O	matrix	rix	trix	NN	False
DDI-MedLine.d53.s2	protein	180	186	O	protein	ein	tein	NN	False
DDI-MedLine.d53.s2	reorganization	188	201	O	reorganization	ion	tion	NN	False
DDI-MedLine.d53.s2	)	202	202	O	)	)	)	)	False
DDI-MedLine.d53.s2	within	204	209	O	within	hin	thin	IN	False
DDI-MedLine.d53.s2	48	211	212	O	48	48	48	CD	False
DDI-MedLine.d53.s2	h	214	214	O	h	h	h	NN	False
DDI-MedLine.d53.s2	.	215	215	O	.	.	.	.	False

DDI-MedLine.d53.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d53.s3	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d53.s3	experiments	7	17	O	experiments	nts	ents	NNS	False
DDI-MedLine.d53.s3	reported	19	26	O	reported	ted	rted	VBD	False
DDI-MedLine.d53.s3	here	28	31	O	here	ere	here	RB	False
DDI-MedLine.d53.s3	,	32	32	O	,	,	,	,	False
DDI-MedLine.d53.s3	we	34	35	O	we	we	we	PRP	False
DDI-MedLine.d53.s3	examined	37	44	O	examined	ned	ined	VBN	False
DDI-MedLine.d53.s3	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d53.s3	interactions	50	61	O	interactions	ons	ions	NNS	False
DDI-MedLine.d53.s3	between	63	69	O	between	een	ween	IN	False
DDI-MedLine.d53.s3	1,25	71	74	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s3	(	75	75	I-drug	(	(	(	(	False
DDI-MedLine.d53.s3	OH	76	77	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s3	)	78	78	I-drug	)	)	)	)	False
DDI-MedLine.d53.s3	2D3	79	81	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s3	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d53.s3	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d53.s3	antiestrogen	91	102	B-group	antiestrogen	gen	ogen	NN	brand
DDI-MedLine.d53.s3	4-hydroxytamoxifen	104	121	B-drug_n	4-hydroxytamoxifen	fen	ifen	JJ	False
DDI-MedLine.d53.s3	(	123	123	O	(	(	(	(	False
DDI-MedLine.d53.s3	TAM	124	126	B-drug_n	TAM	TAM	TAM	NN	brand
DDI-MedLine.d53.s3	)	127	127	O	)	)	)	)	False
DDI-MedLine.d53.s3	,	128	128	O	,	,	,	,	False
DDI-MedLine.d53.s3	which	130	134	O	which	ich	hich	WDT	False
DDI-MedLine.d53.s3	also	136	139	O	also	lso	also	RB	False
DDI-MedLine.d53.s3	induces	141	147	O	induces	ces	uces	NNS	False
DDI-MedLine.d53.s3	apoptosis	149	157	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d53.s3	in	159	160	O	in	in	in	IN	False
DDI-MedLine.d53.s3	MCF-7	162	166	O	MCF-7	F-7	CF-7	NN	brand
DDI-MedLine.d53.s3	cells	168	172	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s3	.	173	173	O	.	.	.	.	False

DDI-MedLine.d53.s4	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d53.s4	data	4	7	O	data	ata	data	NNS	False
DDI-MedLine.d53.s4	suggest	9	15	O	suggest	est	gest	NN	False
DDI-MedLine.d53.s4	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d53.s4	TAM	22	24	B-drug_n	TAM	TAM	TAM	NN	brand
DDI-MedLine.d53.s4	significantly	26	38	O	significantly	tly	ntly	RB	False
DDI-MedLine.d53.s4	potentiates	40	50	O	potentiates	tes	ates	NNS	False
DDI-MedLine.d53.s4	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d53.s4	reduction	56	64	O	reduction	ion	tion	NN	False
DDI-MedLine.d53.s4	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d53.s4	cell	69	72	O	cell	ell	cell	NN	False
DDI-MedLine.d53.s4	number	74	79	O	number	ber	mber	NN	False
DDI-MedLine.d53.s4	induced	81	87	O	induced	ced	uced	JJ	False
DDI-MedLine.d53.s4	by	89	90	O	by	by	by	IN	False
DDI-MedLine.d53.s4	1,25	92	95	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s4	(	96	96	I-drug	(	(	(	(	False
DDI-MedLine.d53.s4	OH	97	98	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s4	)	99	99	I-drug	)	)	)	)	False
DDI-MedLine.d53.s4	2D3	100	102	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s4	alone	104	108	O	alone	one	lone	RB	False
DDI-MedLine.d53.s4	.	109	109	O	.	.	.	.	False

DDI-MedLine.d53.s5	Combined	0	7	O	Combined	ned	ined	VBN	False
DDI-MedLine.d53.s5	treatment	9	17	O	treatment	ent	ment	NN	False
DDI-MedLine.d53.s5	with	19	22	O	with	ith	with	IN	False
DDI-MedLine.d53.s5	1,25	24	27	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s5	(	28	28	I-drug	(	(	(	(	False
DDI-MedLine.d53.s5	OH	29	30	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s5	)	31	31	I-drug	)	)	)	)	False
DDI-MedLine.d53.s5	2D3	32	34	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s5	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d53.s5	TAM	40	42	B-drug_n	TAM	TAM	TAM	NN	brand
DDI-MedLine.d53.s5	enhances	44	51	O	enhances	ces	nces	NNS	False
DDI-MedLine.d53.s5	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d53.s5	degree	57	62	O	degree	ree	gree	NN	False
DDI-MedLine.d53.s5	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d53.s5	apoptosis	67	75	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d53.s5	assessed	77	84	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d53.s5	using	86	90	O	using	ing	sing	VBG	False
DDI-MedLine.d53.s5	morphological	92	104	O	morphological	cal	ical	JJ	False
DDI-MedLine.d53.s5	markers	106	112	O	markers	ers	kers	NNS	False
DDI-MedLine.d53.s5	that	114	117	O	that	hat	that	IN	False
DDI-MedLine.d53.s5	identify	119	126	O	identify	ify	tify	VB	False
DDI-MedLine.d53.s5	chromatin	128	136	O	chromatin	tin	atin	NN	False
DDI-MedLine.d53.s5	and	138	140	O	and	and	and	CC	False
DDI-MedLine.d53.s5	nuclear	142	148	O	nuclear	ear	lear	JJ	False
DDI-MedLine.d53.s5	matrix	150	155	O	matrix	rix	trix	NN	False
DDI-MedLine.d53.s5	protein	157	163	O	protein	ein	tein	NN	False
DDI-MedLine.d53.s5	condensation	165	176	O	condensation	ion	tion	NN	False
DDI-MedLine.d53.s5	.	177	177	O	.	.	.	.	False

DDI-MedLine.d53.s6	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d53.s6	have	3	6	O	have	ave	have	VB	False
DDI-MedLine.d53.s6	selected	8	15	O	selected	ted	cted	VBN	False
DDI-MedLine.d53.s6	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d53.s6	subclone	19	26	O	subclone	one	lone	NN	False
DDI-MedLine.d53.s6	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d53.s6	MCF-7	31	35	O	MCF-7	F-7	CF-7	NN	brand
DDI-MedLine.d53.s6	cells	37	41	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s6	resistant	43	51	O	resistant	ant	tant	NN	False
DDI-MedLine.d53.s6	to	53	54	O	to	to	to	TO	False
DDI-MedLine.d53.s6	1,25	56	59	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s6	(	60	60	I-drug	(	(	(	(	False
DDI-MedLine.d53.s6	OH	61	62	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s6	)	63	63	I-drug	)	)	)	)	False
DDI-MedLine.d53.s6	2D3	64	66	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s6	(	68	68	O	(	(	(	(	False
DDI-MedLine.d53.s6	MCF-7D3Res	69	78	O	MCF-7D3Res	Res	3Res	NN	False
DDI-MedLine.d53.s6	)	79	79	O	)	)	)	)	False
DDI-MedLine.d53.s6	.	80	80	O	.	.	.	.	False

DDI-MedLine.d53.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d53.s7	cells	6	10	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s7	express	12	18	O	express	ess	ress	NN	False
DDI-MedLine.d53.s7	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d53.s7	vitamin	24	30	O	vitamin	min	amin	NN	False
DDI-MedLine.d53.s7	D	32	32	O	D	D	D	NN	brand
DDI-MedLine.d53.s7	receptor	34	41	O	receptor	tor	ptor	NN	False
DDI-MedLine.d53.s7	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d53.s7	exhibit	47	53	O	exhibit	bit	ibit	NN	False
DDI-MedLine.d53.s7	doubling	55	62	O	doubling	ing	ling	VBG	False
DDI-MedLine.d53.s7	times	64	68	O	times	mes	imes	NNS	False
DDI-MedLine.d53.s7	comparable	70	79	O	comparable	ble	able	JJ	False
DDI-MedLine.d53.s7	to	81	82	O	to	to	to	TO	False
DDI-MedLine.d53.s7	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d53.s7	parental	88	95	O	parental	tal	ntal	NN	False
DDI-MedLine.d53.s7	MCF-7	97	101	O	MCF-7	F-7	CF-7	NN	brand
DDI-MedLine.d53.s7	cells	103	107	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s7	,	108	108	O	,	,	,	,	False
DDI-MedLine.d53.s7	even	110	113	O	even	ven	even	RB	False
DDI-MedLine.d53.s7	when	115	118	O	when	hen	when	WRB	False
DDI-MedLine.d53.s7	grown	120	124	O	grown	own	rown	NN	False
DDI-MedLine.d53.s7	in	126	127	O	in	in	in	IN	False
DDI-MedLine.d53.s7	100	129	131	O	100	100	100	CD	False
DDI-MedLine.d53.s7	mM	133	134	O	mM	mM	mM	NN	False
DDI-MedLine.d53.s7	1,25	136	139	B-drug	1,25	,25	1,25	CD	False
DDI-MedLine.d53.s7	(	140	140	I-drug	(	(	(	(	False
DDI-MedLine.d53.s7	OH	141	142	I-drug	OH	OH	OH	UH	brand
DDI-MedLine.d53.s7	)	143	143	I-drug	)	)	)	)	False
DDI-MedLine.d53.s7	2D3	144	146	I-drug	2D3	2D3	2D3	CD	brand
DDI-MedLine.d53.s7	.	147	147	O	.	.	.	.	False

DDI-MedLine.d53.s8	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d53.s8	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d53.s8	both	13	16	O	both	oth	both	DT	False
DDI-MedLine.d53.s8	parental	18	25	O	parental	tal	ntal	NN	False
DDI-MedLine.d53.s8	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d53.s8	resistant	31	39	O	resistant	ant	tant	NN	False
DDI-MedLine.d53.s8	MCF-7	41	45	O	MCF-7	F-7	CF-7	NN	brand
DDI-MedLine.d53.s8	cells	47	51	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s8	with	53	56	O	with	ith	with	IN	False
DDI-MedLine.d53.s8	TAM	58	60	B-drug_n	TAM	TAM	TAM	NN	brand
DDI-MedLine.d53.s8	induces	62	68	O	induces	ces	uces	NNS	False
DDI-MedLine.d53.s8	apoptosis	70	78	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d53.s8	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d53.s8	clusterin	84	92	O	clusterin	rin	erin	NN	False
DDI-MedLine.d53.s8	.	93	93	O	.	.	.	.	False

DDI-MedLine.d53.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d53.s9	data	6	9	O	data	ata	data	NNS	False
DDI-MedLine.d53.s9	emphasize	11	19	O	emphasize	ize	size	VB	False
DDI-MedLine.d53.s9	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d53.s9	apoptosis	26	34	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d53.s9	can	36	38	O	can	can	can	MD	False
DDI-MedLine.d53.s9	be	40	41	O	be	be	be	VB	False
DDI-MedLine.d53.s9	induced	43	49	O	induced	ced	uced	JJ	False
DDI-MedLine.d53.s9	in	51	52	O	in	in	in	IN	False
DDI-MedLine.d53.s9	MCF-7	54	58	O	MCF-7	F-7	CF-7	NN	brand
DDI-MedLine.d53.s9	cells	60	64	O	cells	lls	ells	NNS	False
DDI-MedLine.d53.s9	either	66	71	O	either	her	ther	DT	False
DDI-MedLine.d53.s9	by	73	74	O	by	by	by	IN	False
DDI-MedLine.d53.s9	activation	76	85	O	activation	ion	tion	NN	False
DDI-MedLine.d53.s9	of	87	88	O	of	of	of	IN	False
DDI-MedLine.d53.s9	vitamin-D-mediated	90	107	O	vitamin-D-mediated	ted	ated	JJ	False
DDI-MedLine.d53.s9	signalling	109	118	O	signalling	ing	ling	VBG	False
DDI-MedLine.d53.s9	or	120	121	O	or	or	or	CC	False
DDI-MedLine.d53.s9	disruption	123	132	O	disruption	ion	tion	NN	False
DDI-MedLine.d53.s9	of	134	135	O	of	of	of	IN	False
DDI-MedLine.d53.s9	estrogen-dependent	137	154	O	estrogen-dependent	ent	dent	NN	False
DDI-MedLine.d53.s9	signalling	156	165	O	signalling	ing	ling	VBG	False
DDI-MedLine.d53.s9	.	166	166	O	.	.	.	.	False

DDI-MedLine.d39.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d39.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d39.s0	estradiol	10	18	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d39.s0	on	20	21	O	on	on	on	IN	False
DDI-MedLine.d39.s0	endotoxin-induced	23	39	O	endotoxin-induced	ced	uced	JJ	False
DDI-MedLine.d39.s0	changes	41	47	O	changes	ges	nges	NNS	False
DDI-MedLine.d39.s0	in	49	50	O	in	in	in	IN	False
DDI-MedLine.d39.s0	steroid	52	58	O	steroid	oid	roid	NN	False
DDI-MedLine.d39.s0	hormone	60	66	O	hormone	one	mone	NN	False
DDI-MedLine.d39.s0	levels	68	73	O	levels	els	vels	NNS	False
DDI-MedLine.d39.s0	and	75	77	O	and	and	and	CC	False
DDI-MedLine.d39.s0	lethality	79	87	O	lethality	ity	lity	NN	False
DDI-MedLine.d39.s0	in	89	90	O	in	in	in	IN	False
DDI-MedLine.d39.s0	male	92	95	O	male	ale	male	NN	False
DDI-MedLine.d39.s0	rats	97	100	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s0	.	101	101	O	.	.	.	.	False

DDI-MedLine.d39.s1	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d39.s1	examined	3	10	O	examined	ned	ined	VBN	False
DDI-MedLine.d39.s1	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d39.s1	effect	16	21	O	effect	ect	fect	NN	False
DDI-MedLine.d39.s1	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d39.s1	exogenous	26	34	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d39.s1	estradiol	36	44	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d39.s1	on	46	47	O	on	on	on	IN	False
DDI-MedLine.d39.s1	the	49	51	O	the	the	the	DT	False
DDI-MedLine.d39.s1	changes	53	59	O	changes	ges	nges	NNS	False
DDI-MedLine.d39.s1	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d39.s1	serum	64	68	O	serum	rum	erum	NN	False
DDI-MedLine.d39.s1	steroid	70	76	O	steroid	oid	roid	NN	False
DDI-MedLine.d39.s1	hormone	78	84	O	hormone	one	mone	NN	False
DDI-MedLine.d39.s1	levels	86	91	O	levels	els	vels	NNS	False
DDI-MedLine.d39.s1	induced	93	99	O	induced	ced	uced	JJ	False
DDI-MedLine.d39.s1	by	101	102	O	by	by	by	IN	False
DDI-MedLine.d39.s1	a	104	104	O	a	a	a	DT	False
DDI-MedLine.d39.s1	nonlethal	106	114	O	nonlethal	hal	thal	NN	False
DDI-MedLine.d39.s1	dose	116	119	O	dose	ose	dose	NN	False
DDI-MedLine.d39.s1	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d39.s1	Escherichia	124	134	O	Escherichia	hia	chia	NN	False
DDI-MedLine.d39.s1	coli	136	139	O	coli	oli	coli	NNS	False
DDI-MedLine.d39.s1	endotoxin	141	149	B-drug_n	endotoxin	xin	oxin	NN	False
DDI-MedLine.d39.s1	in	151	152	O	in	in	in	IN	False
DDI-MedLine.d39.s1	male	154	157	O	male	ale	male	NN	False
DDI-MedLine.d39.s1	rats	159	162	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s1	and	164	166	O	and	and	and	CC	False
DDI-MedLine.d39.s1	the	168	170	O	the	the	the	DT	False
DDI-MedLine.d39.s1	deaths	172	177	O	deaths	ths	aths	NNS	False
DDI-MedLine.d39.s1	due	179	181	O	due	due	due	JJ	False
DDI-MedLine.d39.s1	to	183	184	O	to	to	to	TO	False
DDI-MedLine.d39.s1	nonlethal	186	194	O	nonlethal	hal	thal	NN	False
DDI-MedLine.d39.s1	and	196	198	O	and	and	and	CC	False
DDI-MedLine.d39.s1	lethal	200	205	O	lethal	hal	thal	NN	False
DDI-MedLine.d39.s1	doses	207	211	O	doses	ses	oses	NNS	False
DDI-MedLine.d39.s1	of	213	214	O	of	of	of	IN	False
DDI-MedLine.d39.s1	endotoxin	216	224	B-drug_n	endotoxin	xin	oxin	NN	False
DDI-MedLine.d39.s1	.	225	225	O	.	.	.	.	False

DDI-MedLine.d39.s2	Injection	0	8	O	Injection	ion	tion	NN	False
DDI-MedLine.d39.s2	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d39.s2	estradiol	13	21	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d39.s2	5	23	23	O	5	5	5	CD	False
DDI-MedLine.d39.s2	min	25	27	O	min	min	min	NN	False
DDI-MedLine.d39.s2	before	29	34	O	before	ore	fore	IN	False
DDI-MedLine.d39.s2	a	36	36	O	a	a	a	DT	False
DDI-MedLine.d39.s2	nonlethal	38	46	O	nonlethal	hal	thal	NN	False
DDI-MedLine.d39.s2	dose	48	51	O	dose	ose	dose	NN	False
DDI-MedLine.d39.s2	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d39.s2	endotoxin	56	64	B-drug_n	endotoxin	xin	oxin	NN	False
DDI-MedLine.d39.s2	changed	66	72	O	changed	ged	nged	VBN	False
DDI-MedLine.d39.s2	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d39.s2	serum	78	82	O	serum	rum	erum	NN	False
DDI-MedLine.d39.s2	sex	84	86	O	sex	sex	sex	NN	False
DDI-MedLine.d39.s2	steroid	88	94	O	steroid	oid	roid	NN	False
DDI-MedLine.d39.s2	hormone	96	102	O	hormone	one	mone	NN	False
DDI-MedLine.d39.s2	response	104	111	O	response	nse	onse	NN	False
DDI-MedLine.d39.s2	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d39.s2	male	116	119	O	male	ale	male	NN	False
DDI-MedLine.d39.s2	rats	121	124	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s2	to	126	127	O	to	to	to	TO	False
DDI-MedLine.d39.s2	endotoxin	129	137	B-drug_n	endotoxin	xin	oxin	NN	False
DDI-MedLine.d39.s2	.	138	138	O	.	.	.	.	False

DDI-MedLine.d39.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d39.s3	serum	4	8	O	serum	rum	erum	NN	False
DDI-MedLine.d39.s3	estrogen	10	17	O	estrogen	gen	ogen	NN	brand
DDI-MedLine.d39.s3	concentrations	19	32	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d39.s3	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d39.s3	estradiol	37	45	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d39.s3	+	47	47	O	+	+	+	NN	False
DDI-MedLine.d39.s3	endotoxin-treated	49	65	O	endotoxin-treated	ted	ated	JJ	False
DDI-MedLine.d39.s3	rats	67	70	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s3	decreased	72	80	O	decreased	sed	ased	VBN	False
DDI-MedLine.d39.s3	by	82	83	O	by	by	by	IN	False
DDI-MedLine.d39.s3	50	85	86	O	50	50	50	CD	False
DDI-MedLine.d39.s3	%	87	87	O	%	%	%	NN	False
DDI-MedLine.d39.s3	,	88	88	O	,	,	,	,	False
DDI-MedLine.d39.s3	while	90	94	O	while	ile	hile	IN	False
DDI-MedLine.d39.s3	those	96	100	O	those	ose	hose	DT	False
DDI-MedLine.d39.s3	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d39.s3	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d39.s3	endotoxin-treated	109	125	O	endotoxin-treated	ted	ated	JJ	False
DDI-MedLine.d39.s3	rats	127	130	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s3	increased	132	140	O	increased	sed	ased	VBN	False
DDI-MedLine.d39.s3	(	142	142	O	(	(	(	(	False
DDI-MedLine.d39.s3	2-	143	144	O	2-	2-	2-	JJ	False
DDI-MedLine.d39.s3	to	146	147	O	to	to	to	TO	False
DDI-MedLine.d39.s3	5-fold	149	154	O	5-fold	old	fold	JJ	False
DDI-MedLine.d39.s3	)	155	155	O	)	)	)	)	False
DDI-MedLine.d39.s3	.	156	156	O	.	.	.	.	False

DDI-MedLine.d39.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d39.s4	serum	4	8	O	serum	rum	erum	NN	False
DDI-MedLine.d39.s4	androgen	10	17	O	androgen	gen	ogen	NN	brand
DDI-MedLine.d39.s4	concentrations	19	32	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d39.s4	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d39.s4	estradiol	37	45	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d39.s4	+	47	47	O	+	+	+	NN	False
DDI-MedLine.d39.s4	endotoxin-treated	49	65	O	endotoxin-treated	ted	ated	JJ	False
DDI-MedLine.d39.s4	rats	67	70	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s4	did	72	74	O	did	did	did	VBD	False
DDI-MedLine.d39.s4	not	76	78	O	not	not	not	RB	False
DDI-MedLine.d39.s4	change	80	85	O	change	nge	ange	NN	False
DDI-MedLine.d39.s4	significantly	87	99	O	significantly	tly	ntly	RB	False
DDI-MedLine.d39.s4	,	100	100	O	,	,	,	,	False
DDI-MedLine.d39.s4	while	102	106	O	while	ile	hile	IN	False
DDI-MedLine.d39.s4	those	108	112	O	those	ose	hose	DT	False
DDI-MedLine.d39.s4	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d39.s4	endotoxin-treated	117	133	O	endotoxin-treated	ted	ated	JJ	False
DDI-MedLine.d39.s4	rats	135	138	O	rats	ats	rats	NNS	False
DDI-MedLine.d39.s4	dropped	140	146	O	dropped	ped	pped	VBD	False
DDI-MedLine.d39.s4	to	148	149	O	to	to	to	TO	False
DDI-MedLine.d39.s4	30-40	151	155	O	30-40	-40	0-40	JJ	False
DDI-MedLine.d39.s4	%	156	156	O	%	%	%	NN	False

DDI-MedLine.d39.s5	0.001	0	4	O	0.001	001	.001	CD	False
DDI-MedLine.d39.s5	.	5	5	O	.	.	.	.	False

DDI-MedLine.d39.s6	Exogenous	0	8	O	Exogenous	ous	nous	JJ	False
DDI-MedLine.d39.s6	estradiol	10	18	B-drug	estradiol	iol	diol	NN	drug
DDI-MedLine.d39.s6	also	20	23	O	also	lso	also	RB	False
DDI-MedLine.d39.s6	appeared	25	32	O	appeared	red	ared	VBD	False
DDI-MedLine.d39.s6	to	34	35	O	to	to	to	TO	False
DDI-MedLine.d39.s6	influence	37	45	O	influence	nce	ence	NN	False
DDI-MedLine.d39.s6	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d39.s6	percentage	51	60	O	percentage	age	tage	NN	False
DDI-MedLine.d39.s6	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d39.s6	endotoxin-induced	65	81	O	endotoxin-induced	ced	uced	JJ	False
DDI-MedLine.d39.s6	deaths	83	88	O	deaths	ths	aths	NNS	False
DDI-MedLine.d39.s6	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d39.s6	a	93	93	O	a	a	a	DT	False
DDI-MedLine.d39.s6	dose-dependent	95	108	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d39.s6	manner	110	115	O	manner	ner	nner	NN	False
DDI-MedLine.d39.s6	.	116	116	O	.	.	.	.	False

DDI-MedLine.d39.s7	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d39.s7	reduced	3	9	O	reduced	ced	uced	VBN	False
DDI-MedLine.d39.s7	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d39.s7	number	15	20	O	number	ber	mber	NN	False
DDI-MedLine.d39.s7	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d39.s7	deaths	25	30	O	deaths	ths	aths	NNS	False
DDI-MedLine.d39.s7	induced	32	38	O	induced	ced	uced	JJ	False
DDI-MedLine.d39.s7	by	40	41	O	by	by	by	IN	False
DDI-MedLine.d39.s7	nonlethal	43	51	O	nonlethal	hal	thal	NN	False
DDI-MedLine.d39.s7	(	53	53	O	(	(	(	(	False
DDI-MedLine.d39.s7	2	54	54	O	2	2	2	CD	False
DDI-MedLine.d39.s7	mg/kg	56	60	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d39.s7	)	61	61	O	)	)	)	)	False
DDI-MedLine.d39.s7	dose	63	66	O	dose	ose	dose	NN	False
DDI-MedLine.d39.s7	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d39.s7	endotoxin	71	79	B-drug_n	endotoxin	xin	oxin	NN	False
DDI-MedLine.d39.s7	but	81	83	O	but	but	but	CC	False
DDI-MedLine.d39.s7	increased	85	93	O	increased	sed	ased	VBN	False
DDI-MedLine.d39.s7	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d39.s7	number	99	104	O	number	ber	mber	NN	False
DDI-MedLine.d39.s7	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d39.s7	deaths	109	114	O	deaths	ths	aths	NNS	False
DDI-MedLine.d39.s7	induced	116	122	O	induced	ced	uced	JJ	False
DDI-MedLine.d39.s7	by	124	125	O	by	by	by	IN	False
DDI-MedLine.d39.s7	a	127	127	O	a	a	a	DT	False
DDI-MedLine.d39.s7	highly	129	134	O	highly	hly	ghly	RB	False
DDI-MedLine.d39.s7	lethal	136	141	O	lethal	hal	thal	NN	False
DDI-MedLine.d39.s7	dose	143	146	O	dose	ose	dose	NN	False
DDI-MedLine.d39.s7	(	148	148	O	(	(	(	(	False
DDI-MedLine.d39.s7	8	149	149	O	8	8	8	CD	False
DDI-MedLine.d39.s7	mg/kg	151	155	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d39.s7	)	156	156	O	)	)	)	)	False
DDI-MedLine.d39.s7	.	157	157	O	.	.	.	.	False

DDI-MedLine.d39.s8	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d39.s8	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d39.s8	,	13	13	O	,	,	,	,	False
DDI-MedLine.d39.s8	together	15	22	O	together	her	ther	RB	False
DDI-MedLine.d39.s8	with	24	27	O	with	ith	with	IN	False
DDI-MedLine.d39.s8	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d39.s8	known	33	37	O	known	own	nown	VBN	False
DDI-MedLine.d39.s8	relationships	39	51	O	relationships	ips	hips	NNS	False
DDI-MedLine.d39.s8	between	53	59	O	between	een	ween	IN	False
DDI-MedLine.d39.s8	estrogen	61	68	B-group	estrogen	gen	ogen	NN	brand
DDI-MedLine.d39.s8	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d39.s8	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d39.s8	immune	78	83	O	immune	une	mune	NN	False
DDI-MedLine.d39.s8	response	85	92	O	response	nse	onse	NN	False
DDI-MedLine.d39.s8	,	93	93	O	,	,	,	,	False
DDI-MedLine.d39.s8	suggest	95	101	O	suggest	est	gest	NN	False
DDI-MedLine.d39.s8	that	103	106	O	that	hat	that	IN	False
DDI-MedLine.d39.s8	estrogens	108	116	B-group	estrogens	ens	gens	NNS	False
DDI-MedLine.d39.s8	affect	118	123	O	affect	ect	fect	NN	False
DDI-MedLine.d39.s8	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d39.s8	course	129	134	O	course	rse	urse	NN	False
DDI-MedLine.d39.s8	of	136	137	O	of	of	of	IN	False
DDI-MedLine.d39.s8	septic	139	144	O	septic	tic	ptic	JJ	False
DDI-MedLine.d39.s8	shock	146	150	O	shock	ock	hock	NN	False
DDI-MedLine.d39.s8	in	152	153	O	in	in	in	IN	False
DDI-MedLine.d39.s8	a	155	155	O	a	a	a	DT	False
DDI-MedLine.d39.s8	complex	157	163	O	complex	lex	plex	JJ	False
DDI-MedLine.d39.s8	fashion	165	171	O	fashion	ion	hion	NN	False
DDI-MedLine.d39.s8	and	173	175	O	and	and	and	CC	False
DDI-MedLine.d39.s8	may	177	179	O	may	may	may	MD	False
DDI-MedLine.d39.s8	have	181	184	O	have	ave	have	VB	False
DDI-MedLine.d39.s8	either	186	191	O	either	her	ther	DT	False
DDI-MedLine.d39.s8	protective	193	202	O	protective	ive	tive	NN	False
DDI-MedLine.d39.s8	or	204	205	O	or	or	or	CC	False
DDI-MedLine.d39.s8	deleterious	207	217	O	deleterious	ous	ious	JJ	False
DDI-MedLine.d39.s8	effect	219	224	O	effect	ect	fect	NN	False
DDI-MedLine.d39.s8	.	225	225	O	.	.	.	.	False

DDI-MedLine.d97.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d97.s0	2	1	1	O	2	2	2	CD	False
DDI-MedLine.d97.s0	epidemics	3	11	O	epidemics	ics	mics	NNS	False
DDI-MedLine.d97.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d97.s0	arsenical	16	24	O	arsenical	cal	ical	JJ	False
DDI-MedLine.d97.s0	encephalopathy	26	39	O	encephalopathy	thy	athy	NN	False
DDI-MedLine.d97.s0	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d97.s0	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d97.s0	treatment	48	56	O	treatment	ent	ment	NN	False
DDI-MedLine.d97.s0	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d97.s0	trypanosomiasis	61	75	O	trypanosomiasis	sis	asis	NN	False
DDI-MedLine.d97.s0	,	76	76	O	,	,	,	,	False
DDI-MedLine.d97.s0	Uganda	78	83	O	Uganda	nda	anda	NN	False
DDI-MedLine.d97.s0	,	84	84	O	,	,	,	,	False
DDI-MedLine.d97.s0	1992-1993	86	94	O	1992-1993	993	1993	JJ	False
DDI-MedLine.d97.s0	]	95	95	O	]	]	]	NN	False
DDI-MedLine.d97.s0	Since	98	102	O	Since	nce	ince	IN	False
DDI-MedLine.d97.s0	1988	104	107	O	1988	988	1988	CD	False
DDI-MedLine.d97.s0	,	108	108	O	,	,	,	,	False
DDI-MedLine.d97.s0	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d97.s0	french	114	119	O	french	nch	ench	JJ	False
DDI-MedLine.d97.s0	non-governmental	121	136	O	non-governmental	tal	ntal	JJ	False
DDI-MedLine.d97.s0	organisation	138	149	O	organisation	ion	tion	NN	False
DDI-MedLine.d97.s0	M	151	151	O	M	M	M	NN	brand
DDI-MedLine.d97.s0	decins	154	159	O	decins	ins	cins	NNS	group
DDI-MedLine.d97.s0	Sans	161	164	O	Sans	ans	Sans	NNS	False
DDI-MedLine.d97.s0	Fronti	166	171	O	Fronti	nti	onti	NNS	False
DDI-MedLine.d97.s0	res	174	176	O	res	res	res	NNS	False
DDI-MedLine.d97.s0	is	178	179	O	is	is	is	VBZ	False
DDI-MedLine.d97.s0	running	181	187	O	running	ing	ning	VBG	False
DDI-MedLine.d97.s0	a	189	189	O	a	a	a	DT	False
DDI-MedLine.d97.s0	control	191	197	O	control	rol	trol	NN	False
DDI-MedLine.d97.s0	program	199	205	O	program	ram	gram	NN	False
DDI-MedLine.d97.s0	of	207	208	O	of	of	of	IN	False
DDI-MedLine.d97.s0	human	210	214	O	human	man	uman	NN	False
DDI-MedLine.d97.s0	african	216	222	O	african	can	ican	JJ	False
DDI-MedLine.d97.s0	trypanosomiasis	224	238	O	trypanosomiasis	sis	asis	NN	False
DDI-MedLine.d97.s0	in	240	241	O	in	in	in	IN	False
DDI-MedLine.d97.s0	the	243	245	O	the	the	the	DT	False
DDI-MedLine.d97.s0	district	247	254	O	district	ict	rict	NN	False
DDI-MedLine.d97.s0	of	256	257	O	of	of	of	IN	False
DDI-MedLine.d97.s0	Moyo	259	262	O	Moyo	oyo	Moyo	NN	False
DDI-MedLine.d97.s0	,	263	263	O	,	,	,	,	False
DDI-MedLine.d97.s0	North-Uganda	265	276	O	North-Uganda	nda	anda	NN	False
DDI-MedLine.d97.s0	.	277	277	O	.	.	.	.	False

DDI-MedLine.d97.s1	Between	0	6	O	Between	een	ween	NN	False
DDI-MedLine.d97.s1	1988	8	11	O	1988	988	1988	CD	False
DDI-MedLine.d97.s1	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d97.s1	1993	17	20	O	1993	993	1993	CD	False
DDI-MedLine.d97.s1	,	21	21	O	,	,	,	,	False
DDI-MedLine.d97.s1	more	23	26	O	more	ore	more	RBR	False
DDI-MedLine.d97.s1	than	28	31	O	than	han	than	IN	False
DDI-MedLine.d97.s1	7,000	33	37	O	7,000	000	,000	CD	False
DDI-MedLine.d97.s1	patients	39	46	O	patients	nts	ents	NNS	False
DDI-MedLine.d97.s1	were	48	51	O	were	ere	were	VBD	False
DDI-MedLine.d97.s1	diagnosed	53	61	O	diagnosed	sed	osed	VBN	False
DDI-MedLine.d97.s1	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d97.s1	treated	67	73	O	treated	ted	ated	VBN	False
DDI-MedLine.d97.s1	.	74	74	O	.	.	.	.	False

DDI-MedLine.d97.s2	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d97.s2	1988	6	9	O	1988	988	1988	CD	False
DDI-MedLine.d97.s2	,	10	10	O	,	,	,	,	False
DDI-MedLine.d97.s2	it	12	13	O	it	it	it	PRP	False
DDI-MedLine.d97.s2	has	15	17	O	has	has	has	VBZ	False
DDI-MedLine.d97.s2	been	19	22	O	been	een	been	VBN	False
DDI-MedLine.d97.s2	noted	24	28	O	noted	ted	oted	VBN	False
DDI-MedLine.d97.s2	that	30	33	O	that	hat	that	IN	False
DDI-MedLine.d97.s2	incidence	35	43	O	incidence	nce	ence	NN	False
DDI-MedLine.d97.s2	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d97.s2	melarsoprol	48	58	B-drug	melarsoprol	rol	prol	NN	False
DDI-MedLine.d97.s2	reaction	60	67	O	reaction	ion	tion	NN	False
DDI-MedLine.d97.s2	had	69	71	O	had	had	had	VBD	False
DDI-MedLine.d97.s2	increased	73	81	O	increased	sed	ased	VBN	False
DDI-MedLine.d97.s2	systematically	83	96	O	systematically	lly	ally	RB	False
DDI-MedLine.d97.s2	between	98	104	O	between	een	ween	IN	False
DDI-MedLine.d97.s2	June	106	109	O	June	une	June	NNP	False
DDI-MedLine.d97.s2	and	111	113	O	and	and	and	CC	False
DDI-MedLine.d97.s2	October	115	121	O	October	ber	ober	NNP	False
DDI-MedLine.d97.s2	of	123	124	O	of	of	of	IN	False
DDI-MedLine.d97.s2	each	126	129	O	each	ach	each	DT	False
DDI-MedLine.d97.s2	year	131	134	O	year	ear	year	NN	False
DDI-MedLine.d97.s2	,	135	135	O	,	,	,	,	False
DDI-MedLine.d97.s2	indicating	137	146	O	indicating	ing	ting	VBG	False
DDI-MedLine.d97.s2	strong	148	153	O	strong	ong	rong	JJ	False
DDI-MedLine.d97.s2	seasonal	155	162	O	seasonal	nal	onal	JJ	False
DDI-MedLine.d97.s2	variation	164	172	O	variation	ion	tion	NN	False
DDI-MedLine.d97.s2	.	173	173	O	.	.	.	.	False

DDI-MedLine.d97.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d97.s3	1992	3	6	O	1992	992	1992	CD	False
DDI-MedLine.d97.s3	and	8	10	O	and	and	and	CC	False
DDI-MedLine.d97.s3	1993	12	15	O	1993	993	1993	CD	False
DDI-MedLine.d97.s3	,	16	16	O	,	,	,	,	False
DDI-MedLine.d97.s3	two	18	20	O	two	two	two	CD	False
DDI-MedLine.d97.s3	outbreaks	22	30	O	outbreaks	aks	eaks	NNS	False
DDI-MedLine.d97.s3	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d97.s3	arsenical	35	43	O	arsenical	cal	ical	JJ	False
DDI-MedLine.d97.s3	reactive	45	52	O	reactive	ive	tive	NN	False
DDI-MedLine.d97.s3	encephalopathy	54	67	O	encephalopathy	thy	athy	NN	False
DDI-MedLine.d97.s3	(	69	69	O	(	(	(	(	False
DDI-MedLine.d97.s3	ARE	70	72	O	ARE	ARE	ARE	NN	brand
DDI-MedLine.d97.s3	)	73	73	O	)	)	)	)	False
DDI-MedLine.d97.s3	occurred	75	82	O	occurred	red	rred	VBD	False
DDI-MedLine.d97.s3	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d97.s3	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d97.s3	sleeping	91	98	O	sleeping	ing	ping	VBG	False
DDI-MedLine.d97.s3	sickness	100	107	O	sickness	ess	ness	NN	False
DDI-MedLine.d97.s3	center	109	114	O	center	ter	nter	NN	False
DDI-MedLine.d97.s3	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d97.s3	Adjumani	119	126	O	Adjumani	ani	mani	NN	False
DDI-MedLine.d97.s3	.	127	127	O	.	.	.	.	False

DDI-MedLine.d97.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d97.s4	incidence	4	12	O	incidence	nce	ence	NN	False
DDI-MedLine.d97.s4	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d97.s4	ARE	17	19	O	ARE	ARE	ARE	NN	brand
DDI-MedLine.d97.s4	suddenly	21	28	O	suddenly	nly	enly	RB	False
DDI-MedLine.d97.s4	exceeded	30	37	O	exceeded	ded	eded	VBD	False
DDI-MedLine.d97.s4	10	39	40	O	10	10	10	CD	False
DDI-MedLine.d97.s4	%	41	41	O	%	%	%	NN	False
DDI-MedLine.d97.s4	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d97.s4	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d97.s4	patients	50	57	O	patients	nts	ents	NNS	False
DDI-MedLine.d97.s4	treated	59	65	O	treated	ted	ated	VBN	False
DDI-MedLine.d97.s4	by	67	68	O	by	by	by	IN	False
DDI-MedLine.d97.s4	melarsoprol	70	80	B-drug	melarsoprol	rol	prol	NN	False
DDI-MedLine.d97.s4	during	82	87	O	during	ing	ring	IN	False
DDI-MedLine.d97.s4	August	89	94	O	August	ust	gust	NNP	False
DDI-MedLine.d97.s4	1992	96	99	O	1992	992	1992	CD	False
DDI-MedLine.d97.s4	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d97.s4	September	105	113	O	September	ber	mber	NNP	False
DDI-MedLine.d97.s4	1993	115	118	O	1993	993	1993	CD	False
DDI-MedLine.d97.s4	.	119	119	O	.	.	.	.	False

DDI-MedLine.d97.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d97.s5	onset	4	8	O	onset	set	nset	NN	False
DDI-MedLine.d97.s5	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d97.s5	80	13	14	O	80	80	80	CD	False
DDI-MedLine.d97.s5	%	15	15	O	%	%	%	NN	False
DDI-MedLine.d97.s5	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d97.s5	those	20	24	O	those	ose	hose	DT	False
DDI-MedLine.d97.s5	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d97.s5	epidemic	27	34	O	epidemic	mic	emic	JJ	False
DDI-MedLine.d97.s5	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d97.s6	cases	0	4	O	cases	ses	ases	NNS	False
DDI-MedLine.d97.s6	,	5	5	O	,	,	,	,	False
DDI-MedLine.d97.s6	occurred	7	14	O	occurred	red	rred	VBD	False
DDI-MedLine.d97.s6	between	16	22	O	between	een	ween	IN	False
DDI-MedLine.d97.s6	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d97.s6	5th	28	30	O	5th	5th	5th	NNS	False
DDI-MedLine.d97.s6	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d97.s6	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d97.s6	11th	40	43	O	11th	1th	11th	CD	False
DDI-MedLine.d97.s6	day	45	47	O	day	day	day	NN	False
DDI-MedLine.d97.s6	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d97.s6	treatment	52	60	O	treatment	ent	ment	NN	False
DDI-MedLine.d97.s6	.	61	61	O	.	.	.	.	False

DDI-MedLine.d97.s7	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d97.s7	retrospective	4	16	O	retrospective	ive	tive	NN	False
DDI-MedLine.d97.s7	studies	18	24	O	studies	ies	dies	NNS	False
DDI-MedLine.d97.s7	were	26	29	O	were	ere	were	VBD	False
DDI-MedLine.d97.s7	conducted	31	39	O	conducted	ted	cted	VBN	False
DDI-MedLine.d97.s7	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d97.s7	1992	44	47	O	1992	992	1992	CD	False
DDI-MedLine.d97.s7	(	49	49	O	(	(	(	(	False
DDI-MedLine.d97.s7	75	50	51	O	75	75	75	CD	False
DDI-MedLine.d97.s7	cases	53	57	O	cases	ses	ases	NNS	False
DDI-MedLine.d97.s7	)	58	58	O	)	)	)	)	False
DDI-MedLine.d97.s7	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d97.s7	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d97.s7	1993	67	70	O	1993	993	1993	CD	False
DDI-MedLine.d97.s7	(	72	72	O	(	(	(	(	False
DDI-MedLine.d97.s7	51	73	74	O	51	51	51	CD	False
DDI-MedLine.d97.s7	cases	76	80	O	cases	ses	ases	NNS	False
DDI-MedLine.d97.s7	)	81	81	O	)	)	)	)	False
DDI-MedLine.d97.s7	.	82	82	O	.	.	.	.	False

DDI-MedLine.d97.s8	Among	0	4	O	Among	ong	mong	IN	False
DDI-MedLine.d97.s8	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d97.s8	risk	10	13	O	risk	isk	risk	NN	False
DDI-MedLine.d97.s8	factors	15	21	O	factors	ors	tors	NNS	False
DDI-MedLine.d97.s8	studied	23	29	O	studied	ied	died	VBN	False
DDI-MedLine.d97.s8	,	30	30	O	,	,	,	,	False
DDI-MedLine.d97.s8	two	32	34	O	two	two	two	CD	False
DDI-MedLine.d97.s8	appear	36	41	O	appear	ear	pear	VB	False
DDI-MedLine.d97.s8	to	43	44	O	to	to	to	TO	False
DDI-MedLine.d97.s8	increase	46	53	O	increase	ase	ease	NN	False
DDI-MedLine.d97.s8	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d97.s8	risk	59	62	O	risk	isk	risk	NN	False
DDI-MedLine.d97.s8	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d97.s8	ARE	67	69	O	ARE	ARE	ARE	NN	brand
DDI-MedLine.d97.s8	:	70	70	O	:	:	:	:	False
DDI-MedLine.d97.s8	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d97.s8	prescription	76	87	O	prescription	ion	tion	NN	False
DDI-MedLine.d97.s8	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d97.s8	thiabendazole	92	104	B-drug	thiabendazole	ole	zole	NN	drug
DDI-MedLine.d97.s8	to	106	107	O	to	to	to	TO	False
DDI-MedLine.d97.s8	treat	109	113	O	treat	eat	reat	NN	False
DDI-MedLine.d97.s8	strongyloidiasis	115	130	O	strongyloidiasis	sis	asis	NN	False
DDI-MedLine.d97.s8	during	132	137	O	during	ing	ring	IN	False
DDI-MedLine.d97.s8	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d97.s8	melarsoprol	143	153	B-drug	melarsoprol	rol	prol	NN	False
DDI-MedLine.d97.s8	cure	155	158	O	cure	ure	cure	NN	False
DDI-MedLine.d97.s8	and	160	162	O	and	and	and	CC	False
DDI-MedLine.d97.s8	the	164	166	O	the	the	the	DT	False
DDI-MedLine.d97.s8	bad	168	170	O	bad	bad	bad	JJ	False
DDI-MedLine.d97.s8	general	172	178	O	general	ral	eral	JJ	False
DDI-MedLine.d97.s8	clinical	180	187	O	clinical	cal	ical	JJ	False
DDI-MedLine.d97.s8	conditions	189	198	O	conditions	ons	ions	NNS	False
DDI-MedLine.d97.s8	of	200	201	O	of	of	of	IN	False
DDI-MedLine.d97.s8	patients	203	210	O	patients	nts	ents	NNS	False
DDI-MedLine.d97.s8	.	211	211	O	.	.	.	.	False

DDI-MedLine.d97.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d97.s9	observations	6	17	O	observations	ons	ions	NNS	False
DDI-MedLine.d97.s9	suggest	19	25	O	suggest	est	gest	NN	False
DDI-MedLine.d97.s9	that	27	30	O	that	hat	that	IN	False
DDI-MedLine.d97.s9	exogenous	32	40	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d97.s9	co-factors	42	51	O	co-factors	ors	tors	NNS	False
DDI-MedLine.d97.s9	could	53	57	O	could	uld	ould	MD	False
DDI-MedLine.d97.s9	be	59	60	O	be	be	be	VB	False
DDI-MedLine.d97.s9	involved	62	69	O	involved	ved	lved	VBN	False
DDI-MedLine.d97.s9	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d97.s9	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d97.s9	occurrence	78	87	O	occurrence	nce	ence	NN	False
DDI-MedLine.d97.s9	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d97.s9	ARE	92	94	O	ARE	ARE	ARE	NN	brand
DDI-MedLine.d97.s9	.	95	95	O	.	.	.	.	False

DDI-MedLine.d97.s10	Recommendations	0	14	O	Recommendations	ons	ions	NNS	False
DDI-MedLine.d97.s10	were	16	19	O	were	ere	were	VBD	False
DDI-MedLine.d97.s10	to	21	22	O	to	to	to	TO	False
DDI-MedLine.d97.s10	avoid	24	28	O	avoid	oid	void	NN	False
DDI-MedLine.d97.s10	administration	30	43	O	administration	ion	tion	NN	False
DDI-MedLine.d97.s10	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d97.s10	diffusible	48	57	O	diffusible	ble	ible	JJ	False
DDI-MedLine.d97.s10	anti-helminthic	59	73	B-group	anti-helminthic	hic	thic	JJ	False
DDI-MedLine.d97.s10	treatment	75	83	O	treatment	ent	ment	NN	False
DDI-MedLine.d97.s10	during	85	90	O	during	ing	ring	IN	False
DDI-MedLine.d97.s10	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d97.s10	cure	96	99	O	cure	ure	cure	NN	False
DDI-MedLine.d97.s10	,	100	100	O	,	,	,	,	False
DDI-MedLine.d97.s10	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d97.s10	to	106	107	O	to	to	to	TO	False
DDI-MedLine.d97.s10	improve	109	115	O	improve	ove	rove	VB	False
DDI-MedLine.d97.s10	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d97.s10	general	121	127	O	general	ral	eral	JJ	False
DDI-MedLine.d97.s10	conditions	129	138	O	conditions	ons	ions	NNS	False
DDI-MedLine.d97.s10	of	140	141	O	of	of	of	IN	False
DDI-MedLine.d97.s10	patients	143	150	O	patients	nts	ents	NNS	False
DDI-MedLine.d97.s10	before	152	157	O	before	ore	fore	IN	False
DDI-MedLine.d97.s10	the	159	161	O	the	the	the	DT	False
DDI-MedLine.d97.s10	cure	163	166	O	cure	ure	cure	NN	False
DDI-MedLine.d97.s10	of	168	169	O	of	of	of	IN	False
DDI-MedLine.d97.s10	melarsoprol	171	181	B-drug	melarsoprol	rol	prol	NN	False
DDI-MedLine.d97.s10	.	182	182	O	.	.	.	.	False

DDI-MedLine.d110.s0	18-Methoxycoronaridine	0	21	B-drug_n	18-Methoxycoronaridine	ine	dine	JJ	drug
DDI-MedLine.d110.s0	(	23	23	O	(	(	(	(	False
DDI-MedLine.d110.s0	18-MC	24	28	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s0	)	29	29	O	)	)	)	)	False
DDI-MedLine.d110.s0	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d110.s0	ibogaine	35	42	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s0	:	43	43	O	:	:	:	:	False
DDI-MedLine.d110.s0	comparison	45	54	O	comparison	son	ison	NN	False
DDI-MedLine.d110.s0	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d110.s0	antiaddictive	59	71	O	antiaddictive	ive	tive	JJ	False
DDI-MedLine.d110.s0	efficacy	73	80	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d110.s0	,	81	81	O	,	,	,	,	False
DDI-MedLine.d110.s0	toxicity	83	90	O	toxicity	ity	city	NN	False
DDI-MedLine.d110.s0	,	91	91	O	,	,	,	,	False
DDI-MedLine.d110.s0	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d110.s0	mechanisms	97	106	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d110.s0	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d110.s0	action	111	116	O	action	ion	tion	NN	False
DDI-MedLine.d110.s0	.	117	117	O	.	.	.	.	False

DDI-MedLine.d110.s1	18-MC	0	4	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s1	,	5	5	O	,	,	,	,	False
DDI-MedLine.d110.s1	a	7	7	O	a	a	a	DT	False
DDI-MedLine.d110.s1	novel	9	13	O	novel	vel	ovel	NN	False
DDI-MedLine.d110.s1	iboga	15	19	O	iboga	oga	boga	NN	False
DDI-MedLine.d110.s1	alkaloid	21	28	O	alkaloid	oid	loid	NN	False
DDI-MedLine.d110.s1	congener	30	37	O	congener	ner	ener	NN	False
DDI-MedLine.d110.s1	,	38	38	O	,	,	,	,	False
DDI-MedLine.d110.s1	is	40	41	O	is	is	is	VBZ	False
DDI-MedLine.d110.s1	being	43	47	O	being	ing	eing	VBG	False
DDI-MedLine.d110.s1	developed	49	57	O	developed	ped	oped	NN	False
DDI-MedLine.d110.s1	as	59	60	O	as	as	as	IN	False
DDI-MedLine.d110.s1	a	62	62	O	a	a	a	DT	False
DDI-MedLine.d110.s1	potential	64	72	O	potential	ial	tial	JJ	False
DDI-MedLine.d110.s1	treatment	74	82	O	treatment	ent	ment	NN	False
DDI-MedLine.d110.s1	for	84	86	O	for	for	for	IN	False
DDI-MedLine.d110.s1	multiple	88	95	O	multiple	ple	iple	NN	False
DDI-MedLine.d110.s1	forms	97	101	O	forms	rms	orms	NNS	False
DDI-MedLine.d110.s1	of	103	104	O	of	of	of	IN	False
DDI-MedLine.d110.s1	drug	106	109	O	drug	rug	drug	NN	False
DDI-MedLine.d110.s1	abuse	111	115	O	abuse	use	buse	NN	False
DDI-MedLine.d110.s1	.	116	116	O	.	.	.	.	False

DDI-MedLine.d110.s2	Like	0	3	O	Like	ike	Like	IN	False
DDI-MedLine.d110.s2	ibogaine	5	12	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s2	(	14	14	O	(	(	(	(	False
DDI-MedLine.d110.s2	40	15	16	O	40	40	40	CD	False
DDI-MedLine.d110.s2	mg/kg	18	22	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d110.s2	)	23	23	O	)	)	)	)	False
DDI-MedLine.d110.s2	,	24	24	O	,	,	,	,	False
DDI-MedLine.d110.s2	18-MC	26	30	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s2	(	32	32	O	(	(	(	(	False
DDI-MedLine.d110.s2	40	33	34	O	40	40	40	CD	False
DDI-MedLine.d110.s2	mg/kg	36	40	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d110.s2	)	41	41	O	)	)	)	)	False
DDI-MedLine.d110.s2	decreases	43	51	O	decreases	ses	ases	NNS	False
DDI-MedLine.d110.s2	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d110.s2	intravenous	57	67	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d110.s2	self-administration	69	87	O	self-administration	ion	tion	NN	False
DDI-MedLine.d110.s2	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d110.s2	morphine	92	99	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d110.s2	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d110.s2	cocaine	105	111	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d110.s2	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d110.s2	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d110.s2	oral	121	124	O	oral	ral	oral	JJ	False
DDI-MedLine.d110.s2	self-administration	126	144	O	self-administration	ion	tion	NN	False
DDI-MedLine.d110.s2	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d110.s2	ethanol	149	155	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d110.s2	and	157	159	O	and	and	and	CC	False
DDI-MedLine.d110.s2	nicotine	161	168	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d110.s2	in	170	171	O	in	in	in	IN	False
DDI-MedLine.d110.s2	rats	173	176	O	rats	ats	rats	NNS	False
DDI-MedLine.d110.s2	;	177	177	O	;	;	;	:	False

DDI-MedLine.d110.s3	unlike	0	5	O	unlike	ike	like	IN	False
DDI-MedLine.d110.s3	ibogaine	7	14	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s3	,	15	15	O	,	,	,	,	False
DDI-MedLine.d110.s3	18-MC	17	21	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s3	does	23	26	O	does	oes	does	VBZ	False
DDI-MedLine.d110.s3	not	28	30	O	not	not	not	RB	False
DDI-MedLine.d110.s3	affect	32	37	O	affect	ect	fect	NN	False
DDI-MedLine.d110.s3	responding	39	48	O	responding	ing	ding	VBG	False
DDI-MedLine.d110.s3	for	50	52	O	for	for	for	IN	False
DDI-MedLine.d110.s3	a	54	54	O	a	a	a	DT	False
DDI-MedLine.d110.s3	nondrug	56	62	O	nondrug	rug	drug	NN	False
DDI-MedLine.d110.s3	reinforcer	64	73	O	reinforcer	cer	rcer	NN	False
DDI-MedLine.d110.s3	(	75	75	O	(	(	(	(	False
DDI-MedLine.d110.s3	water	76	80	O	water	ter	ater	NN	False
DDI-MedLine.d110.s3	)	81	81	O	)	)	)	)	False
DDI-MedLine.d110.s3	.	82	82	O	.	.	.	.	False

DDI-MedLine.d110.s4	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d110.s4	ibogaine	5	12	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s4	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d110.s4	18-MC	18	22	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s4	ameliorate	24	33	O	ameliorate	ate	rate	NN	False
DDI-MedLine.d110.s4	opioid	35	40	B-group	opioid	oid	ioid	NN	False
DDI-MedLine.d110.s4	withdrawal	42	51	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d110.s4	signs	53	57	O	signs	gns	igns	NNS	False
DDI-MedLine.d110.s4	.	58	58	O	.	.	.	.	False

DDI-MedLine.d110.s5	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d110.s5	ibogaine	5	12	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s5	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d110.s5	18-MC	18	22	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s5	decrease	24	31	O	decrease	ase	ease	NN	False
DDI-MedLine.d110.s5	extracellular	33	45	O	extracellular	lar	ular	NN	False
DDI-MedLine.d110.s5	levels	47	52	O	levels	els	vels	NNS	False
DDI-MedLine.d110.s5	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d110.s5	dopamine	57	64	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d110.s5	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d110.s5	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d110.s5	nucleus	73	79	O	nucleus	eus	leus	NN	False
DDI-MedLine.d110.s5	accumbens	81	89	O	accumbens	ens	bens	NNS	False
DDI-MedLine.d110.s5	,	90	90	O	,	,	,	,	False
DDI-MedLine.d110.s5	but	92	94	O	but	but	but	CC	False
DDI-MedLine.d110.s5	only	96	99	O	only	nly	only	RB	False
DDI-MedLine.d110.s5	ibogaine	101	108	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s5	increases	110	118	O	increases	ses	ases	NNS	False
DDI-MedLine.d110.s5	extracellular	120	132	O	extracellular	lar	ular	NN	False
DDI-MedLine.d110.s5	levels	134	139	O	levels	els	vels	NNS	False
DDI-MedLine.d110.s5	of	141	142	O	of	of	of	IN	False
DDI-MedLine.d110.s5	serotonin	144	152	O	serotonin	nin	onin	NN	False
DDI-MedLine.d110.s5	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d110.s5	the	157	159	O	the	the	the	DT	False
DDI-MedLine.d110.s5	nucleus	161	167	O	nucleus	eus	leus	NN	False
DDI-MedLine.d110.s5	accumbens	169	177	O	accumbens	ens	bens	NNS	False
DDI-MedLine.d110.s5	.	178	178	O	.	.	.	.	False

DDI-MedLine.d110.s6	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d110.s6	ibogaine	5	12	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s6	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d110.s6	18-MC	18	22	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s6	block	24	28	O	block	ock	lock	NN	False
DDI-MedLine.d110.s6	morphine-induced	30	45	O	morphine-induced	ced	uced	JJ	False
DDI-MedLine.d110.s6	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d110.s6	nicotine-induced	51	66	O	nicotine-induced	ced	uced	JJ	False
DDI-MedLine.d110.s6	dopamine	68	75	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d110.s6	release	77	83	O	release	ase	ease	NN	False
DDI-MedLine.d110.s6	in	85	86	O	in	in	in	IN	False
DDI-MedLine.d110.s6	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d110.s6	nucleus	92	98	O	nucleus	eus	leus	NN	False
DDI-MedLine.d110.s6	accumbens	100	108	O	accumbens	ens	bens	NNS	False
DDI-MedLine.d110.s6	;	109	109	O	;	;	;	:	False

DDI-MedLine.d110.s7	only	0	3	O	only	nly	only	RB	False
DDI-MedLine.d110.s7	ibogaine	5	12	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s7	enhances	14	21	O	enhances	ces	nces	NNS	False
DDI-MedLine.d110.s7	cocaine-induced	23	37	O	cocaine-induced	ced	uced	JJ	False
DDI-MedLine.d110.s7	increases	39	47	O	increases	ses	ases	NNS	False
DDI-MedLine.d110.s7	in	49	50	O	in	in	in	IN	False
DDI-MedLine.d110.s7	accumbal	52	59	O	accumbal	bal	mbal	NN	False
DDI-MedLine.d110.s7	dopamine	61	68	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d110.s7	.	69	69	O	.	.	.	.	False

DDI-MedLine.d110.s8	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d110.s8	ibogaine	5	12	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s8	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d110.s8	18-MC	18	22	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s8	enhance	24	30	O	enhance	nce	ance	NN	False
DDI-MedLine.d110.s8	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d110.s8	locomotor	36	44	O	locomotor	tor	otor	NN	False
DDI-MedLine.d110.s8	and/or	46	51	O	and/or	/or	d/or	NN	False
DDI-MedLine.d110.s8	stereotypic	53	63	O	stereotypic	pic	ypic	NN	False
DDI-MedLine.d110.s8	effects	65	71	O	effects	cts	ects	NNS	False
DDI-MedLine.d110.s8	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d110.s8	stimulants	76	85	O	stimulants	nts	ants	NNS	False
DDI-MedLine.d110.s8	.	86	86	O	.	.	.	.	False

DDI-MedLine.d110.s9	Ibogaine	0	7	B-drug_n	Ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s9	attenuates	9	18	O	attenuates	tes	ates	NNS	False
DDI-MedLine.d110.s9	,	19	19	O	,	,	,	,	False
DDI-MedLine.d110.s9	but	21	23	O	but	but	but	CC	False
DDI-MedLine.d110.s9	18-MC	25	29	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s9	potentiates	31	41	O	potentiates	tes	ates	NNS	False
DDI-MedLine.d110.s9	,	42	42	O	,	,	,	,	False
DDI-MedLine.d110.s9	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d110.s9	acute	48	52	O	acute	ute	cute	NN	False
DDI-MedLine.d110.s9	locomotor	54	62	O	locomotor	tor	otor	NN	False
DDI-MedLine.d110.s9	effects	64	70	O	effects	cts	ects	NNS	False
DDI-MedLine.d110.s9	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d110.s9	morphine	75	82	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d110.s9	;	83	83	O	;	;	;	:	False

DDI-MedLine.d110.s10	both	0	3	O	both	oth	both	DT	False
DDI-MedLine.d110.s10	compounds	5	13	O	compounds	nds	unds	NNS	False
DDI-MedLine.d110.s10	attenuate	15	23	O	attenuate	ate	uate	NN	False
DDI-MedLine.d110.s10	morphine-induced	25	40	O	morphine-induced	ced	uced	JJ	False
DDI-MedLine.d110.s10	locomotion	42	51	O	locomotion	ion	tion	NN	False
DDI-MedLine.d110.s10	in	53	54	O	in	in	in	IN	False
DDI-MedLine.d110.s10	morphine-experienced	56	75	O	morphine-experienced	ced	nced	JJ	False
DDI-MedLine.d110.s10	rats	77	80	O	rats	ats	rats	NNS	False
DDI-MedLine.d110.s10	.	81	81	O	.	.	.	.	False

DDI-MedLine.d110.s11	Ibogaine	0	7	B-drug_n	Ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s11	produces	9	16	O	produces	ces	uces	NNS	False
DDI-MedLine.d110.s11	whole	18	22	O	whole	ole	hole	JJ	False
DDI-MedLine.d110.s11	body	24	27	O	body	ody	body	NN	False
DDI-MedLine.d110.s11	tremors	29	35	O	tremors	ors	mors	NNS	False
DDI-MedLine.d110.s11	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d110.s11	,	40	40	O	,	,	,	,	False
DDI-MedLine.d110.s11	at	42	43	O	at	at	at	IN	False
DDI-MedLine.d110.s11	high	45	48	O	high	igh	high	JJ	False
DDI-MedLine.d110.s11	doses	50	54	O	doses	ses	oses	NNS	False
DDI-MedLine.d110.s11	(	56	56	O	(	(	(	(	False
DDI-MedLine.d110.s11	>	57	57	O	>	>	>	NN	False
DDI-MedLine.d110.s11	or	59	60	O	or	or	or	CC	False
DDI-MedLine.d110.s11	=	62	62	O	=	=	=	NN	False
DDI-MedLine.d110.s11	100	64	66	O	100	100	100	CD	False
DDI-MedLine.d110.s11	mg/kg	68	72	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d110.s11	)	73	73	O	)	)	)	)	False
DDI-MedLine.d110.s11	,	74	74	O	,	,	,	,	False
DDI-MedLine.d110.s11	cerebellar	76	85	O	cerebellar	lar	llar	NN	False
DDI-MedLine.d110.s11	damage	87	92	O	damage	age	mage	NN	False
DDI-MedLine.d110.s11	;	93	93	O	;	;	;	:	False

DDI-MedLine.d110.s12	18-MC	0	4	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s12	does	6	9	O	does	oes	does	VBZ	False
DDI-MedLine.d110.s12	not	11	13	O	not	not	not	RB	False
DDI-MedLine.d110.s12	produce	15	21	O	produce	uce	duce	NN	False
DDI-MedLine.d110.s12	these	23	27	O	these	ese	hese	DT	False
DDI-MedLine.d110.s12	effects	29	35	O	effects	cts	ects	NNS	False
DDI-MedLine.d110.s12	.	36	36	O	.	.	.	.	False

DDI-MedLine.d110.s13	Ibogaine	0	7	B-drug_n	Ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s13	,	8	8	O	,	,	,	,	False
DDI-MedLine.d110.s13	but	10	12	O	but	but	but	CC	False
DDI-MedLine.d110.s13	not	14	16	O	not	not	not	RB	False
DDI-MedLine.d110.s13	18-MC	18	22	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s13	,	23	23	O	,	,	,	,	False
DDI-MedLine.d110.s13	decreases	25	33	O	decreases	ses	ases	NNS	False
DDI-MedLine.d110.s13	heart	35	39	O	heart	art	eart	NN	False
DDI-MedLine.d110.s13	rate	41	44	O	rate	ate	rate	NN	False
DDI-MedLine.d110.s13	at	46	47	O	at	at	at	IN	False
DDI-MedLine.d110.s13	high	49	52	O	high	igh	high	JJ	False
DDI-MedLine.d110.s13	doses	54	58	O	doses	ses	oses	NNS	False
DDI-MedLine.d110.s13	.	59	59	O	.	.	.	.	False

DDI-MedLine.d110.s14	While	0	4	O	While	ile	hile	IN	False
DDI-MedLine.d110.s14	18-MC	6	10	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s14	and	12	14	O	and	and	and	CC	False
DDI-MedLine.d110.s14	ibogaine	16	23	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s14	have	25	28	O	have	ave	have	VB	False
DDI-MedLine.d110.s14	similar	30	36	O	similar	lar	ilar	JJ	False
DDI-MedLine.d110.s14	affinities	38	47	O	affinities	ies	ties	NNS	False
DDI-MedLine.d110.s14	for	49	51	O	for	for	for	IN	False
DDI-MedLine.d110.s14	kappa	53	57	O	kappa	ppa	appa	NN	False
DDI-MedLine.d110.s14	opioid	59	64	O	opioid	oid	ioid	NN	False
DDI-MedLine.d110.s14	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d110.s14	possibly	70	77	O	possibly	bly	ibly	RB	False
DDI-MedLine.d110.s14	nicotinic	79	87	O	nicotinic	nic	inic	JJ	False
DDI-MedLine.d110.s14	receptors	89	97	O	receptors	ors	tors	NNS	False
DDI-MedLine.d110.s14	,	98	98	O	,	,	,	,	False
DDI-MedLine.d110.s14	18-MC	100	104	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s14	has	106	108	O	has	has	has	VBZ	False
DDI-MedLine.d110.s14	much	110	113	O	much	uch	much	JJ	False
DDI-MedLine.d110.s14	lower	115	119	O	lower	wer	ower	JJR	False
DDI-MedLine.d110.s14	affinities	121	130	O	affinities	ies	ties	NNS	False
DDI-MedLine.d110.s14	than	132	135	O	than	han	than	IN	False
DDI-MedLine.d110.s14	ibogaine	137	144	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s14	for	146	148	O	for	for	for	IN	False
DDI-MedLine.d110.s14	NMDA	150	153	O	NMDA	MDA	NMDA	NN	brand
DDI-MedLine.d110.s14	and	155	157	O	and	and	and	CC	False
DDI-MedLine.d110.s14	sigma-2	159	165	O	sigma-2	a-2	ma-2	NN	False
DDI-MedLine.d110.s14	receptors	167	175	O	receptors	ors	tors	NNS	False
DDI-MedLine.d110.s14	,	176	176	O	,	,	,	,	False
DDI-MedLine.d110.s14	sodium	178	183	O	sodium	ium	dium	NN	drug
DDI-MedLine.d110.s14	channels	185	192	O	channels	els	nels	NNS	False
DDI-MedLine.d110.s14	,	193	193	O	,	,	,	,	False
DDI-MedLine.d110.s14	and	195	197	O	and	and	and	CC	False
DDI-MedLine.d110.s14	the	199	201	O	the	the	the	DT	False
DDI-MedLine.d110.s14	5-HT	203	206	O	5-HT	-HT	5-HT	JJ	brand
DDI-MedLine.d110.s14	transporter	208	218	O	transporter	ter	rter	NN	False
DDI-MedLine.d110.s14	.	219	219	O	.	.	.	.	False

DDI-MedLine.d110.s15	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d110.s15	18-MC	5	9	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s15	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d110.s15	ibogaine	15	22	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s15	are	24	26	O	are	are	are	VBP	False
DDI-MedLine.d110.s15	sequestered	28	38	O	sequestered	red	ered	VBN	False
DDI-MedLine.d110.s15	in	40	41	O	in	in	in	IN	False
DDI-MedLine.d110.s15	fat	43	45	O	fat	fat	fat	NN	False
DDI-MedLine.d110.s15	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d110.s15	,	50	50	O	,	,	,	,	False
DDI-MedLine.d110.s15	like	52	55	O	like	ike	like	IN	False
DDI-MedLine.d110.s15	ibogaine	57	64	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s15	,	65	65	O	,	,	,	,	False
DDI-MedLine.d110.s15	18-MC	67	71	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s15	probably	73	80	O	probably	bly	ably	RB	False
DDI-MedLine.d110.s15	has	82	84	O	has	has	has	VBZ	False
DDI-MedLine.d110.s15	an	86	87	O	an	an	an	DT	False
DDI-MedLine.d110.s15	active	89	94	O	active	ive	tive	JJ	False
DDI-MedLine.d110.s15	metabolite	96	105	O	metabolite	ite	lite	NN	False
DDI-MedLine.d110.s15	.	106	106	O	.	.	.	.	False

DDI-MedLine.d110.s16	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d110.s16	data	4	7	O	data	ata	data	NNS	False
DDI-MedLine.d110.s16	suggest	9	15	O	suggest	est	gest	NN	False
DDI-MedLine.d110.s16	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d110.s16	18-MC	22	26	B-drug_n	18-MC	-MC	8-MC	JJ	brand
DDI-MedLine.d110.s16	has	28	30	O	has	has	has	VBZ	False
DDI-MedLine.d110.s16	a	32	32	O	a	a	a	DT	False
DDI-MedLine.d110.s16	narrower	34	41	O	narrower	wer	ower	NN	False
DDI-MedLine.d110.s16	spectrum	43	50	O	spectrum	rum	trum	NN	False
DDI-MedLine.d110.s16	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d110.s16	actions	55	61	O	actions	ons	ions	NNS	False
DDI-MedLine.d110.s16	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d110.s16	will	67	70	O	will	ill	will	MD	False
DDI-MedLine.d110.s16	have	72	75	O	have	ave	have	VB	False
DDI-MedLine.d110.s16	a	77	77	O	a	a	a	DT	False
DDI-MedLine.d110.s16	substantially	79	91	O	substantially	lly	ally	RB	False
DDI-MedLine.d110.s16	greater	93	99	O	greater	ter	ater	JJR	False
DDI-MedLine.d110.s16	therapeutic	101	111	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d110.s16	index	113	117	O	index	dex	ndex	NN	False
DDI-MedLine.d110.s16	than	119	122	O	than	han	than	IN	False
DDI-MedLine.d110.s16	ibogaine	124	131	B-drug_n	ibogaine	ine	aine	NN	drug
DDI-MedLine.d110.s16	.	132	132	O	.	.	.	.	False

DDI-MedLine.d59.s0	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d59.s0	proposed	2	9	O	proposed	sed	osed	VBN	False
DDI-MedLine.d59.s0	mechanism	11	19	O	mechanism	ism	nism	NN	False
DDI-MedLine.d59.s0	for	21	23	O	for	for	for	IN	False
DDI-MedLine.d59.s0	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d59.s0	potentiation	29	40	O	potentiation	ion	tion	NN	False
DDI-MedLine.d59.s0	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d59.s0	cAMP-mediated	45	57	O	cAMP-mediated	ted	ated	JJ	False
DDI-MedLine.d59.s0	acid	59	62	O	acid	cid	acid	NN	False
DDI-MedLine.d59.s0	secretion	64	72	O	secretion	ion	tion	NN	False
DDI-MedLine.d59.s0	by	74	75	O	by	by	by	IN	False
DDI-MedLine.d59.s0	carbachol	77	85	B-drug	carbachol	hol	chol	NN	False
DDI-MedLine.d59.s0	.	86	86	O	.	.	.	.	False

DDI-MedLine.d59.s1	Acid	0	3	O	Acid	cid	Acid	NN	False
DDI-MedLine.d59.s1	secretion	5	13	O	secretion	ion	tion	NN	False
DDI-MedLine.d59.s1	in	15	16	O	in	in	in	IN	False
DDI-MedLine.d59.s1	isolated	18	25	O	isolated	ted	ated	JJ	False
DDI-MedLine.d59.s1	rabbit	27	32	O	rabbit	bit	bbit	NN	False
DDI-MedLine.d59.s1	gastric	34	40	O	gastric	ric	tric	NN	False
DDI-MedLine.d59.s1	glands	42	47	O	glands	nds	ands	NNS	False
DDI-MedLine.d59.s1	was	49	51	O	was	was	was	VBD	False
DDI-MedLine.d59.s1	monitored	53	61	O	monitored	red	ored	VBD	False
DDI-MedLine.d59.s1	by	63	64	O	by	by	by	IN	False
DDI-MedLine.d59.s1	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d59.s1	accumulation	70	81	O	accumulation	ion	tion	NN	False
DDI-MedLine.d59.s1	of	83	84	O	of	of	of	IN	False
DDI-MedLine.d59.s1	[	86	86	O	[	[	[	NN	False
DDI-MedLine.d59.s1	(	87	87	O	(	(	(	(	False
DDI-MedLine.d59.s1	14	88	89	O	14	14	14	CD	False
DDI-MedLine.d59.s1	)	90	90	O	)	)	)	)	False
DDI-MedLine.d59.s1	C	91	91	O	C	C	C	SYM	brand
DDI-MedLine.d59.s1	]	92	92	O	]	]	]	NN	False
DDI-MedLine.d59.s1	aminopyrine	93	103	B-drug	aminopyrine	ine	rine	NN	drug
DDI-MedLine.d59.s1	.	104	104	O	.	.	.	.	False

DDI-MedLine.d59.s2	Stimulation	0	10	O	Stimulation	ion	tion	NN	False
DDI-MedLine.d59.s2	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d59.s2	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d59.s2	glands	19	24	O	glands	nds	ands	NNS	False
DDI-MedLine.d59.s2	with	26	29	O	with	ith	with	IN	False
DDI-MedLine.d59.s2	carbachol	31	39	B-drug	carbachol	hol	chol	NN	False
DDI-MedLine.d59.s2	synergistically	41	55	O	synergistically	lly	ally	RB	False
DDI-MedLine.d59.s2	augmented	57	65	O	augmented	ted	nted	VBN	False
DDI-MedLine.d59.s2	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d59.s2	response	71	78	O	response	nse	onse	NN	False
DDI-MedLine.d59.s2	to	80	81	O	to	to	to	TO	False
DDI-MedLine.d59.s2	dibutyryl	83	91	O	dibutyryl	ryl	yryl	NN	False
DDI-MedLine.d59.s2	cAMP	93	96	O	cAMP	AMP	cAMP	NN	False
DDI-MedLine.d59.s2	.	97	97	O	.	.	.	.	False

DDI-MedLine.d59.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d59.s3	augmentation	4	15	O	augmentation	ion	tion	NN	False
DDI-MedLine.d59.s3	persisted	17	25	O	persisted	ted	sted	VBN	False
DDI-MedLine.d59.s3	even	27	30	O	even	ven	even	RB	False
DDI-MedLine.d59.s3	after	32	36	O	after	ter	fter	IN	False
DDI-MedLine.d59.s3	carbachol	38	46	B-drug	carbachol	hol	chol	NN	False
DDI-MedLine.d59.s3	was	48	50	O	was	was	was	VBD	False
DDI-MedLine.d59.s3	washed	52	57	O	washed	hed	shed	VBN	False
DDI-MedLine.d59.s3	out	59	61	O	out	out	out	IN	False
DDI-MedLine.d59.s3	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d59.s3	was	67	69	O	was	was	was	VBD	False
DDI-MedLine.d59.s3	resistant	71	79	O	resistant	ant	tant	NN	False
DDI-MedLine.d59.s3	to	81	82	O	to	to	to	TO	False
DDI-MedLine.d59.s3	chelated	84	91	O	chelated	ted	ated	VBN	False
DDI-MedLine.d59.s3	extracellular	93	105	O	extracellular	lar	ular	NN	False
DDI-MedLine.d59.s3	Ca	107	108	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d59.s3	(	109	109	O	(	(	(	(	False
DDI-MedLine.d59.s3	2+	110	111	O	2+	2+	2+	CD	False
DDI-MedLine.d59.s3	)	112	112	O	)	)	)	)	False
DDI-MedLine.d59.s3	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d59.s3	to	118	119	O	to	to	to	TO	False
DDI-MedLine.d59.s3	inhibitors	121	130	O	inhibitors	ors	tors	NNS	False
DDI-MedLine.d59.s3	of	132	133	O	of	of	of	IN	False
DDI-MedLine.d59.s3	either	135	140	O	either	her	ther	DT	False
DDI-MedLine.d59.s3	protein	142	148	O	protein	ein	tein	NN	False
DDI-MedLine.d59.s3	kinase	150	155	O	kinase	ase	nase	NN	False
DDI-MedLine.d59.s3	C	157	157	O	C	C	C	SYM	brand
DDI-MedLine.d59.s3	or	159	160	O	or	or	or	CC	False
DDI-MedLine.d59.s3	calmodulin	162	171	O	calmodulin	lin	ulin	NN	False
DDI-MedLine.d59.s3	kinase	173	178	O	kinase	ase	nase	NN	False
DDI-MedLine.d59.s3	II	180	181	O	II	II	II	NN	brand
DDI-MedLine.d59.s3	.	182	182	O	.	.	.	.	False

DDI-MedLine.d59.s4	Cytochalasin	0	11	B-drug_n	Cytochalasin	sin	asin	NN	False
DDI-MedLine.d59.s4	D	13	13	I-drug_n	D	D	D	NN	brand
DDI-MedLine.d59.s4	at	15	16	O	at	at	at	IN	False
DDI-MedLine.d59.s4	10	18	19	O	10	10	10	CD	False
DDI-MedLine.d59.s4	microM	21	26	O	microM	roM	croM	NN	False
DDI-MedLine.d59.s4	preferentially	28	41	O	preferentially	lly	ally	RB	False
DDI-MedLine.d59.s4	blocked	43	49	O	blocked	ked	cked	VBN	False
DDI-MedLine.d59.s4	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d59.s4	secretory	55	63	O	secretory	ory	tory	NN	False
DDI-MedLine.d59.s4	effect	65	70	O	effect	ect	fect	NN	False
DDI-MedLine.d59.s4	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d59.s4	carbachol	75	83	B-drug	carbachol	hol	chol	NN	False
DDI-MedLine.d59.s4	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d59.s4	its	89	91	O	its	its	its	PRP$	False
DDI-MedLine.d59.s4	synergism	93	101	O	synergism	ism	gism	NN	False
DDI-MedLine.d59.s4	with	103	106	O	with	ith	with	IN	False
DDI-MedLine.d59.s4	cAMP	108	111	O	cAMP	AMP	cAMP	NN	False
DDI-MedLine.d59.s4	,	112	112	O	,	,	,	,	False
DDI-MedLine.d59.s4	whereas	114	120	O	whereas	eas	reas	NNS	False
DDI-MedLine.d59.s4	it	122	123	O	it	it	it	PRP	False
DDI-MedLine.d59.s4	had	125	127	O	had	had	had	VBD	False
DDI-MedLine.d59.s4	no	129	130	O	no	no	no	DT	False
DDI-MedLine.d59.s4	effect	132	137	O	effect	ect	fect	NN	False
DDI-MedLine.d59.s4	on	139	140	O	on	on	on	IN	False
DDI-MedLine.d59.s4	histamine-	142	151	O	histamine-	ne-	ine-	NN	False
DDI-MedLine.d59.s4	or	153	154	O	or	or	or	CC	False
DDI-MedLine.d59.s4	cAMP-stimulated	156	170	O	cAMP-stimulated	ted	ated	JJ	False
DDI-MedLine.d59.s4	acid	172	175	O	acid	cid	acid	NN	False
DDI-MedLine.d59.s4	secretion	177	185	O	secretion	ion	tion	NN	False
DDI-MedLine.d59.s4	within	187	192	O	within	hin	thin	IN	False
DDI-MedLine.d59.s4	15	194	195	O	15	15	15	CD	False
DDI-MedLine.d59.s4	min	197	199	O	min	min	min	NN	False
DDI-MedLine.d59.s4	.	200	200	O	.	.	.	.	False

DDI-MedLine.d59.s5	Cytochalasin	0	11	B-drug_n	Cytochalasin	sin	asin	NN	False
DDI-MedLine.d59.s5	D	13	13	I-drug_n	D	D	D	NN	brand
DDI-MedLine.d59.s5	inhibited	15	23	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d59.s5	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d59.s5	carbachol-stimulated	29	48	O	carbachol-stimulated	ted	ated	JJ	False
DDI-MedLine.d59.s5	intracellular	50	62	O	intracellular	lar	ular	NN	False
DDI-MedLine.d59.s5	Ca	64	65	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d59.s5	(	66	66	O	(	(	(	(	False
DDI-MedLine.d59.s5	2+	67	68	O	2+	2+	2+	CD	False
DDI-MedLine.d59.s5	)	69	69	O	)	)	)	)	False
DDI-MedLine.d59.s5	concentration	71	83	O	concentration	ion	tion	NN	False
DDI-MedLine.d59.s5	(	85	85	O	(	(	(	(	False
DDI-MedLine.d59.s5	[	86	86	O	[	[	[	NN	False
DDI-MedLine.d59.s5	Ca	87	88	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d59.s5	(	89	89	O	(	(	(	(	False
DDI-MedLine.d59.s5	2+	90	91	O	2+	2+	2+	CD	False
DDI-MedLine.d59.s5	)	92	92	O	)	)	)	)	False
DDI-MedLine.d59.s5	]	93	93	O	]	]	]	NN	False
DDI-MedLine.d59.s5	(	94	94	O	(	(	(	(	False
DDI-MedLine.d59.s5	i	95	95	O	i	i	i	NN	False
DDI-MedLine.d59.s5	)	96	96	O	)	)	)	)	False
DDI-MedLine.d59.s5	)	97	97	O	)	)	)	)	False
DDI-MedLine.d59.s5	increase	99	106	O	increase	ase	ease	NN	False
DDI-MedLine.d59.s5	due	108	110	O	due	due	due	JJ	False
DDI-MedLine.d59.s5	to	112	113	O	to	to	to	TO	False
DDI-MedLine.d59.s5	release	115	121	O	release	ase	ease	NN	False
DDI-MedLine.d59.s5	from	123	126	O	from	rom	from	IN	False
DDI-MedLine.d59.s5	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d59.s5	Ca	132	133	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d59.s5	(	134	134	O	(	(	(	(	False
DDI-MedLine.d59.s5	2+	135	136	O	2+	2+	2+	CD	False
DDI-MedLine.d59.s5	)	137	137	O	)	)	)	)	False
DDI-MedLine.d59.s5	store	139	143	O	store	ore	tore	NN	False
DDI-MedLine.d59.s5	.	144	144	O	.	.	.	.	False

DDI-MedLine.d59.s6	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d59.s6	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d59.s6	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d59.s6	glands	17	22	O	glands	nds	ands	NNS	False
DDI-MedLine.d59.s6	with	24	27	O	with	ith	with	IN	False
DDI-MedLine.d59.s6	cytochalasin	29	40	B-drug_n	cytochalasin	sin	asin	NN	False
DDI-MedLine.d59.s6	D	42	42	I-drug_n	D	D	D	NN	brand
DDI-MedLine.d59.s6	redistributed	44	56	O	redistributed	ted	uted	VBN	False
DDI-MedLine.d59.s6	type	58	61	O	type	ype	type	NN	False
DDI-MedLine.d59.s6	3	63	63	O	3	3	3	CD	False
DDI-MedLine.d59.s6	inositol	65	72	O	inositol	tol	itol	NN	False
DDI-MedLine.d59.s6	1,4,5-trisphosphate	74	92	O	1,4,5-trisphosphate	ate	hate	JJ	False
DDI-MedLine.d59.s6	receptor	94	101	O	receptor	tor	ptor	NN	False
DDI-MedLine.d59.s6	(	103	103	O	(	(	(	(	False
DDI-MedLine.d59.s6	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d59.s6	major	108	112	O	major	jor	ajor	JJ	False
DDI-MedLine.d59.s6	subtype	114	120	O	subtype	ype	type	NN	False
DDI-MedLine.d59.s6	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d59.s6	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d59.s6	parietal	129	136	O	parietal	tal	etal	NN	False
DDI-MedLine.d59.s6	cell	138	141	O	cell	ell	cell	NN	False
DDI-MedLine.d59.s6	)	142	142	O	)	)	)	)	False
DDI-MedLine.d59.s6	from	144	147	O	from	rom	from	IN	False
DDI-MedLine.d59.s6	the	149	151	O	the	the	the	DT	False
DDI-MedLine.d59.s6	fraction	153	160	O	fraction	ion	tion	NN	False
DDI-MedLine.d59.s6	containing	162	171	O	containing	ing	ning	VBG	False
DDI-MedLine.d59.s6	membranes	173	181	O	membranes	nes	anes	NNS	False
DDI-MedLine.d59.s6	of	183	184	O	of	of	of	IN	False
DDI-MedLine.d59.s6	large	186	190	O	large	rge	arge	JJ	False
DDI-MedLine.d59.s6	size	192	195	O	size	ize	size	NN	False
DDI-MedLine.d59.s6	to	197	198	O	to	to	to	TO	False
DDI-MedLine.d59.s6	the	200	202	O	the	the	the	DT	False
DDI-MedLine.d59.s6	microsomal	204	213	O	microsomal	mal	omal	NN	False
DDI-MedLine.d59.s6	fraction	215	222	O	fraction	ion	tion	NN	False
DDI-MedLine.d59.s6	,	223	223	O	,	,	,	,	False
DDI-MedLine.d59.s6	suggesting	225	234	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d59.s6	a	236	236	O	a	a	a	DT	False
DDI-MedLine.d59.s6	dissociation	238	249	O	dissociation	ion	tion	NN	False
DDI-MedLine.d59.s6	of	251	252	O	of	of	of	IN	False
DDI-MedLine.d59.s6	the	254	256	O	the	the	the	DT	False
DDI-MedLine.d59.s6	store	258	262	O	store	ore	tore	NN	False
DDI-MedLine.d59.s6	from	264	267	O	from	rom	from	IN	False
DDI-MedLine.d59.s6	the	269	271	O	the	the	the	DT	False
DDI-MedLine.d59.s6	plasma	273	278	O	plasma	sma	asma	NN	False
DDI-MedLine.d59.s6	membrane	280	287	O	membrane	ane	rane	NN	False
DDI-MedLine.d59.s6	.	288	288	O	.	.	.	.	False

DDI-MedLine.d59.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d59.s7	findings	6	13	O	findings	ngs	ings	NNS	False
DDI-MedLine.d59.s7	suggest	15	21	O	suggest	est	gest	NN	False
DDI-MedLine.d59.s7	that	23	26	O	that	hat	that	IN	False
DDI-MedLine.d59.s7	intracellular	28	40	O	intracellular	lar	ular	NN	False
DDI-MedLine.d59.s7	Ca	42	43	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d59.s7	(	44	44	O	(	(	(	(	False
DDI-MedLine.d59.s7	2+	45	46	O	2+	2+	2+	CD	False
DDI-MedLine.d59.s7	)	47	47	O	)	)	)	)	False
DDI-MedLine.d59.s7	release	49	55	O	release	ase	ease	NN	False
DDI-MedLine.d59.s7	by	57	58	O	by	by	by	IN	False
DDI-MedLine.d59.s7	cholinergic	60	70	O	cholinergic	gic	rgic	NN	False
DDI-MedLine.d59.s7	stimulation	72	82	O	stimulation	ion	tion	NN	False
DDI-MedLine.d59.s7	is	84	85	O	is	is	is	VBZ	False
DDI-MedLine.d59.s7	critical	87	94	O	critical	cal	ical	JJ	False
DDI-MedLine.d59.s7	for	96	98	O	for	for	for	IN	False
DDI-MedLine.d59.s7	determining	100	110	O	determining	ing	ning	VBG	False
DDI-MedLine.d59.s7	synergism	112	120	O	synergism	ism	gism	NN	False
DDI-MedLine.d59.s7	with	122	125	O	with	ith	with	IN	False
DDI-MedLine.d59.s7	cAMP	127	130	O	cAMP	AMP	cAMP	NN	False
DDI-MedLine.d59.s7	in	132	133	O	in	in	in	IN	False
DDI-MedLine.d59.s7	parietal	135	142	O	parietal	tal	etal	NN	False
DDI-MedLine.d59.s7	cell	144	147	O	cell	ell	cell	NN	False
DDI-MedLine.d59.s7	activation	149	158	O	activation	ion	tion	NN	False
DDI-MedLine.d59.s7	and	160	162	O	and	and	and	CC	False
DDI-MedLine.d59.s7	that	164	167	O	that	hat	that	IN	False
DDI-MedLine.d59.s7	functional	169	178	O	functional	nal	onal	JJ	False
DDI-MedLine.d59.s7	coupling	180	187	O	coupling	ing	ling	VBG	False
DDI-MedLine.d59.s7	between	189	195	O	between	een	ween	IN	False
DDI-MedLine.d59.s7	the	197	199	O	the	the	the	DT	False
DDI-MedLine.d59.s7	Ca	201	202	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d59.s7	(	203	203	O	(	(	(	(	False
DDI-MedLine.d59.s7	2+	204	205	O	2+	2+	2+	CD	False
DDI-MedLine.d59.s7	)	206	206	O	)	)	)	)	False
DDI-MedLine.d59.s7	store	208	212	O	store	ore	tore	NN	False
DDI-MedLine.d59.s7	and	214	216	O	and	and	and	CC	False
DDI-MedLine.d59.s7	the	218	220	O	the	the	the	DT	False
DDI-MedLine.d59.s7	receptor	222	229	O	receptor	tor	ptor	NN	False
DDI-MedLine.d59.s7	is	231	232	O	is	is	is	VBZ	False
DDI-MedLine.d59.s7	maintained	234	243	O	maintained	ned	ined	VBN	False
DDI-MedLine.d59.s7	by	245	246	O	by	by	by	IN	False
DDI-MedLine.d59.s7	actin	248	252	O	actin	tin	ctin	NN	False
DDI-MedLine.d59.s7	microfilaments	254	267	O	microfilaments	nts	ents	NNS	False
DDI-MedLine.d59.s7	.	268	268	O	.	.	.	.	False

DDI-MedLine.d58.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d58.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d58.s0	ginsenosides	10	21	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s0	on	23	24	O	on	on	on	IN	False
DDI-MedLine.d58.s0	voltage-dependent	26	42	O	voltage-dependent	ent	dent	NN	False
DDI-MedLine.d58.s0	Ca	44	45	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s0	(	46	46	O	(	(	(	(	False
DDI-MedLine.d58.s0	2+	47	48	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s0	)	49	49	O	)	)	)	)	False
DDI-MedLine.d58.s0	channel	51	57	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s0	subtypes	59	66	O	subtypes	pes	ypes	NNS	False
DDI-MedLine.d58.s0	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d58.s0	bovine	71	76	O	bovine	ine	vine	NN	drug
DDI-MedLine.d58.s0	chromaffin	78	87	O	chromaffin	fin	ffin	NN	False
DDI-MedLine.d58.s0	cells	89	93	O	cells	lls	ells	NNS	False
DDI-MedLine.d58.s0	.	94	94	O	.	.	.	.	False

DDI-MedLine.d58.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d58.s1	previous	3	10	O	previous	ous	ious	JJ	False
DDI-MedLine.d58.s1	reports	12	18	O	reports	rts	orts	NNS	False
DDI-MedLine.d58.s1	we	20	21	O	we	we	we	PRP	False
DDI-MedLine.d58.s1	have	23	26	O	have	ave	have	VB	False
DDI-MedLine.d58.s1	shown	28	32	O	shown	own	hown	VBN	False
DDI-MedLine.d58.s1	that	34	37	O	that	hat	that	IN	False
DDI-MedLine.d58.s1	ginsenosides	39	50	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s1	inhibit	52	58	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d58.s1	high	60	63	O	high	igh	high	JJ	False
DDI-MedLine.d58.s1	threshold	65	73	O	threshold	old	hold	NN	False
DDI-MedLine.d58.s1	voltage-dependent	75	91	O	voltage-dependent	ent	dent	NN	False
DDI-MedLine.d58.s1	Ca	93	94	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s1	(	95	95	O	(	(	(	(	False
DDI-MedLine.d58.s1	2+	96	97	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s1	)	98	98	O	)	)	)	)	False
DDI-MedLine.d58.s1	channels	100	107	O	channels	els	nels	NNS	False
DDI-MedLine.d58.s1	in	109	110	O	in	in	in	IN	False
DDI-MedLine.d58.s1	neuronal	112	119	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d58.s1	cells	121	125	O	cells	lls	ells	NNS	False
DDI-MedLine.d58.s1	.	126	126	O	.	.	.	.	False

DDI-MedLine.d58.s2	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d58.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d58.s2	these	9	13	O	these	ese	hese	DT	False
DDI-MedLine.d58.s2	studies	15	21	O	studies	ies	dies	NNS	False
DDI-MedLine.d58.s2	did	23	25	O	did	did	did	VBD	False
DDI-MedLine.d58.s2	not	27	29	O	not	not	not	RB	False
DDI-MedLine.d58.s2	show	31	34	O	show	how	show	NN	False
DDI-MedLine.d58.s2	whether	36	42	O	whether	her	ther	IN	False
DDI-MedLine.d58.s2	ginsenosides-induced	44	63	O	ginsenosides-induced	ced	uced	JJ	False
DDI-MedLine.d58.s2	inhibition	65	74	O	inhibition	ion	tion	NN	False
DDI-MedLine.d58.s2	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d58.s2	Ca	79	80	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s2	(	81	81	O	(	(	(	(	False
DDI-MedLine.d58.s2	2+	82	83	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s2	)	84	84	O	)	)	)	)	False
DDI-MedLine.d58.s2	currents	86	93	O	currents	nts	ents	NNS	False
DDI-MedLine.d58.s2	discriminates	95	107	O	discriminates	tes	ates	NNS	False
DDI-MedLine.d58.s2	among	109	113	O	among	ong	mong	IN	False
DDI-MedLine.d58.s2	the	115	117	O	the	the	the	DT	False
DDI-MedLine.d58.s2	various	119	125	O	various	ous	ious	JJ	False
DDI-MedLine.d58.s2	Ca	127	128	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s2	(	129	129	O	(	(	(	(	False
DDI-MedLine.d58.s2	2+	130	131	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s2	)	132	132	O	)	)	)	)	False
DDI-MedLine.d58.s2	channel	134	140	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s2	subtypes	142	149	O	subtypes	pes	ypes	NNS	False
DDI-MedLine.d58.s2	,	150	150	O	,	,	,	,	False
DDI-MedLine.d58.s2	although	152	159	O	although	ugh	ough	IN	False
DDI-MedLine.d58.s2	it	161	162	O	it	it	it	PRP	False
DDI-MedLine.d58.s2	is	164	165	O	is	is	is	VBZ	False
DDI-MedLine.d58.s2	known	167	171	O	known	own	nown	VBN	False
DDI-MedLine.d58.s2	that	173	176	O	that	hat	that	IN	False
DDI-MedLine.d58.s2	there	178	182	O	there	ere	here	RB	False
DDI-MedLine.d58.s2	are	184	186	O	are	are	are	VBP	False
DDI-MedLine.d58.s2	at	188	189	O	at	at	at	IN	False
DDI-MedLine.d58.s2	least	191	195	O	least	ast	east	JJS	False
DDI-MedLine.d58.s2	five	197	200	O	five	ive	five	CD	False
DDI-MedLine.d58.s2	different	202	210	O	different	ent	rent	JJ	False
DDI-MedLine.d58.s2	Ca	212	213	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s2	(	214	214	O	(	(	(	(	False
DDI-MedLine.d58.s2	2+	215	216	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s2	)	217	217	O	)	)	)	)	False
DDI-MedLine.d58.s2	channel	219	225	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s2	subtypes	227	234	O	subtypes	pes	ypes	NNS	False
DDI-MedLine.d58.s2	in	236	237	O	in	in	in	IN	False
DDI-MedLine.d58.s2	neuronal	239	246	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d58.s2	cells	248	252	O	cells	lls	ells	NNS	False
DDI-MedLine.d58.s2	.	253	253	O	.	.	.	.	False

DDI-MedLine.d58.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d58.s3	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d58.s3	study	8	12	O	study	udy	tudy	NN	False
DDI-MedLine.d58.s3	we	14	15	O	we	we	we	PRP	False
DDI-MedLine.d58.s3	investigated	17	28	O	investigated	ted	ated	VBN	False
DDI-MedLine.d58.s3	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d58.s3	effect	34	39	O	effect	ect	fect	NN	False
DDI-MedLine.d58.s3	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d58.s3	ginsenosides	44	55	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s3	on	57	58	O	on	on	on	IN	False
DDI-MedLine.d58.s3	high	60	63	O	high	igh	high	JJ	False
DDI-MedLine.d58.s3	threshold	65	73	O	threshold	old	hold	NN	False
DDI-MedLine.d58.s3	voltage-dependent	75	91	O	voltage-dependent	ent	dent	NN	False
DDI-MedLine.d58.s3	Ca	93	94	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s3	(	95	95	O	(	(	(	(	False
DDI-MedLine.d58.s3	2+	96	97	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s3	)	98	98	O	)	)	)	)	False
DDI-MedLine.d58.s3	channel	100	106	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s3	subtypes	108	115	O	subtypes	pes	ypes	NNS	False
DDI-MedLine.d58.s3	using	117	121	O	using	ing	sing	VBG	False
DDI-MedLine.d58.s3	their	123	127	O	their	eir	heir	PRP$	False
DDI-MedLine.d58.s3	selective	129	137	B-group	selective	ive	tive	NN	False
DDI-MedLine.d58.s3	Ca	139	140	I-group	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s3	(	141	141	I-group	(	(	(	(	False
DDI-MedLine.d58.s3	2+	142	143	I-group	2+	2+	2+	CD	False
DDI-MedLine.d58.s3	)	144	144	I-group	)	)	)	)	False
DDI-MedLine.d58.s3	channel	146	152	I-group	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s3	blockers	154	161	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d58.s3	nimodipine	163	172	B-drug	nimodipine	ine	pine	NN	drug
DDI-MedLine.d58.s3	(	174	174	O	(	(	(	(	False
DDI-MedLine.d58.s3	L-type	175	180	O	L-type	ype	type	JJ	False
DDI-MedLine.d58.s3	)	181	181	O	)	)	)	)	False
DDI-MedLine.d58.s3	,	182	182	O	,	,	,	,	False
DDI-MedLine.d58.s3	omega-conotoxin	184	198	B-drug_n	omega-conotoxin	xin	oxin	NN	False
DDI-MedLine.d58.s3	GVIA	200	203	I-drug_n	GVIA	VIA	GVIA	NN	brand
DDI-MedLine.d58.s3	(	205	205	O	(	(	(	(	False
DDI-MedLine.d58.s3	N-type	206	211	O	N-type	ype	type	NN	False
DDI-MedLine.d58.s3	)	212	212	O	)	)	)	)	False
DDI-MedLine.d58.s3	,	213	213	O	,	,	,	,	False
DDI-MedLine.d58.s3	or	215	216	O	or	or	or	CC	False
DDI-MedLine.d58.s3	omega-agatoxin	218	231	B-drug_n	omega-agatoxin	xin	oxin	NN	False
DDI-MedLine.d58.s3	IVA	233	235	I-drug_n	IVA	IVA	IVA	NN	brand
DDI-MedLine.d58.s3	(	237	237	O	(	(	(	(	False
DDI-MedLine.d58.s3	P-type	238	243	O	P-type	ype	type	NN	False
DDI-MedLine.d58.s3	)	244	244	O	)	)	)	)	False
DDI-MedLine.d58.s3	in	246	247	O	in	in	in	IN	False
DDI-MedLine.d58.s3	bovine	249	254	O	bovine	ine	vine	NN	drug
DDI-MedLine.d58.s3	chromaffin	256	265	O	chromaffin	fin	ffin	NN	False
DDI-MedLine.d58.s3	cells	267	271	O	cells	lls	ells	NNS	False
DDI-MedLine.d58.s3	.	272	272	O	.	.	.	.	False

DDI-MedLine.d58.s4	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d58.s4	could	3	7	O	could	uld	ould	MD	False
DDI-MedLine.d58.s4	observe	9	15	O	observe	rve	erve	NN	False
DDI-MedLine.d58.s4	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d58.s4	ginsenosides	22	33	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s4	inhibited	35	43	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d58.s4	high	45	48	O	high	igh	high	JJ	False
DDI-MedLine.d58.s4	threshold	50	58	O	threshold	old	hold	NN	False
DDI-MedLine.d58.s4	voltage-dependent	60	76	O	voltage-dependent	ent	dent	NN	False
DDI-MedLine.d58.s4	Ca	78	79	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s4	(	80	80	O	(	(	(	(	False
DDI-MedLine.d58.s4	2+	81	82	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s4	)	83	83	O	)	)	)	)	False
DDI-MedLine.d58.s4	currents	85	92	O	currents	nts	ents	NNS	False
DDI-MedLine.d58.s4	in	94	95	O	in	in	in	IN	False
DDI-MedLine.d58.s4	a	97	97	O	a	a	a	DT	False
DDI-MedLine.d58.s4	dose-dependent	99	112	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d58.s4	manner	114	119	O	manner	ner	nner	NN	False
DDI-MedLine.d58.s4	.	120	120	O	.	.	.	.	False

DDI-MedLine.d58.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d58.s5	IC	4	5	O	IC	IC	IC	NN	brand
DDI-MedLine.d58.s5	(	6	6	O	(	(	(	(	False
DDI-MedLine.d58.s5	50	7	8	O	50	50	50	CD	False
DDI-MedLine.d58.s5	)	9	9	O	)	)	)	)	False
DDI-MedLine.d58.s5	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d58.s5	about	15	19	O	about	out	bout	IN	False
DDI-MedLine.d58.s5	120	21	23	O	120	120	120	CD	False
DDI-MedLine.d58.s5	microgram/ml	25	36	O	microgram/ml	/ml	m/ml	NN	False
DDI-MedLine.d58.s5	.	37	37	O	.	.	.	.	False

DDI-MedLine.d58.s6	Nimodipine	0	9	B-drug	Nimodipine	ine	pine	NN	drug
DDI-MedLine.d58.s6	had	11	13	O	had	had	had	VBD	False
DDI-MedLine.d58.s6	no	15	16	O	no	no	no	DT	False
DDI-MedLine.d58.s6	effect	18	23	O	effect	ect	fect	NN	False
DDI-MedLine.d58.s6	on	25	26	O	on	on	on	IN	False
DDI-MedLine.d58.s6	ginsenosides	28	39	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s6	response	41	48	O	response	nse	onse	NN	False
DDI-MedLine.d58.s6	.	49	49	O	.	.	.	.	False

DDI-MedLine.d58.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d58.s7	data	6	9	O	data	ata	data	NNS	False
DDI-MedLine.d58.s7	suggest	11	17	O	suggest	est	gest	NN	False
DDI-MedLine.d58.s7	that	19	22	O	that	hat	that	IN	False
DDI-MedLine.d58.s7	ginsenosides	24	35	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s7	are	37	39	O	are	are	are	VBP	False
DDI-MedLine.d58.s7	negatively	41	50	O	negatively	ely	vely	RB	False
DDI-MedLine.d58.s7	coupled	52	58	O	coupled	led	pled	VBN	False
DDI-MedLine.d58.s7	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d58.s7	three	63	67	O	three	ree	hree	CD	False
DDI-MedLine.d58.s7	types	69	73	O	types	pes	ypes	NNS	False
DDI-MedLine.d58.s7	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d58.s7	calcium	78	84	O	calcium	ium	cium	NN	drug
DDI-MedLine.d58.s7	channels	86	93	O	channels	els	nels	NNS	False
DDI-MedLine.d58.s7	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d58.s7	bovine	98	103	O	bovine	ine	vine	NN	drug
DDI-MedLine.d58.s7	chromaffin	105	114	O	chromaffin	fin	ffin	NN	False
DDI-MedLine.d58.s7	cell	116	119	O	cell	ell	cell	NN	False
DDI-MedLine.d58.s7	,	120	120	O	,	,	,	,	False
DDI-MedLine.d58.s7	including	122	130	O	including	ing	ding	VBG	False
DDI-MedLine.d58.s7	an	132	133	O	an	an	an	DT	False
DDI-MedLine.d58.s7	omega-conotoxin	135	149	B-drug_n	omega-conotoxin	xin	oxin	NN	False
DDI-MedLine.d58.s7	GVIA-sensitive	151	164	O	GVIA-sensitive	ive	tive	JJ	False
DDI-MedLine.d58.s7	(	166	166	O	(	(	(	(	False
DDI-MedLine.d58.s7	N-type	167	172	O	N-type	ype	type	NN	False
DDI-MedLine.d58.s7	)	173	173	O	)	)	)	)	False
DDI-MedLine.d58.s7	channel	175	181	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s7	,	182	182	O	,	,	,	,	False
DDI-MedLine.d58.s7	an	184	185	O	an	an	an	DT	False
DDI-MedLine.d58.s7	omega-agatoxin	187	200	B-drug_n	omega-agatoxin	xin	oxin	NN	False
DDI-MedLine.d58.s7	IVA-sensitive	202	214	O	IVA-sensitive	ive	tive	JJ	False
DDI-MedLine.d58.s7	(	216	216	O	(	(	(	(	False
DDI-MedLine.d58.s7	P-type	217	222	O	P-type	ype	type	NN	False
DDI-MedLine.d58.s7	)	223	223	O	)	)	)	)	False
DDI-MedLine.d58.s7	channel	225	231	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s7	and	233	235	O	and	and	and	CC	False
DDI-MedLine.d58.s7	nimodipine/omega-conotoxin	237	262	O	nimodipine/omega-conotoxin	xin	oxin	NN	False
DDI-MedLine.d58.s7	GVIA/omega-agatoxin	264	282	O	GVIA/omega-agatoxin	xin	oxin	NN	False
DDI-MedLine.d58.s7	VIA-resistant	284	296	O	VIA-resistant	ant	tant	JJ	False
DDI-MedLine.d58.s7	(	298	298	O	(	(	(	(	False
DDI-MedLine.d58.s7	presumptive	299	309	O	presumptive	ive	tive	NN	False
DDI-MedLine.d58.s7	Q-type	311	316	O	Q-type	ype	type	NN	False
DDI-MedLine.d58.s7	)	317	317	O	)	)	)	)	False
DDI-MedLine.d58.s7	channel	319	325	O	channel	nel	nnel	NNS	False
DDI-MedLine.d58.s7	.	326	326	O	.	.	.	.	False

DDI-MedLine.d58.s8	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d58.s8	,	4	4	O	,	,	,	,	False
DDI-MedLine.d58.s8	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d58.s8	selective	10	18	O	selective	ive	tive	NN	False
DDI-MedLine.d58.s8	regulation	20	29	O	regulation	ion	tion	NN	False
DDI-MedLine.d58.s8	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d58.s8	voltage-dependent	34	50	O	voltage-dependent	ent	dent	NN	False
DDI-MedLine.d58.s8	Ca	52	53	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d58.s8	(	54	54	O	(	(	(	(	False
DDI-MedLine.d58.s8	2+	55	56	O	2+	2+	2+	CD	False
DDI-MedLine.d58.s8	)	57	57	O	)	)	)	)	False
DDI-MedLine.d58.s8	subtypes	59	66	O	subtypes	pes	ypes	NNS	False
DDI-MedLine.d58.s8	by	68	69	O	by	by	by	IN	False
DDI-MedLine.d58.s8	ginsenosides	71	82	B-drug_n	ginsenosides	des	ides	NNS	group
DDI-MedLine.d58.s8	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d58.s8	bovine	87	92	O	bovine	ine	vine	NN	drug
DDI-MedLine.d58.s8	chromaffin	94	103	O	chromaffin	fin	ffin	NN	False
DDI-MedLine.d58.s8	cell	105	108	O	cell	ell	cell	NN	False
DDI-MedLine.d58.s8	could	110	114	O	could	uld	ould	MD	False
DDI-MedLine.d58.s8	be	116	117	O	be	be	be	VB	False
DDI-MedLine.d58.s8	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d58.s8	cellular	123	130	O	cellular	lar	ular	JJ	False
DDI-MedLine.d58.s8	basis	132	136	O	basis	sis	asis	NN	False
DDI-MedLine.d58.s8	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d58.s8	antistress	141	150	O	antistress	ess	ress	NN	False
DDI-MedLine.d58.s8	effects	152	158	O	effects	cts	ects	NNS	False
DDI-MedLine.d58.s8	induced	160	166	O	induced	ced	uced	JJ	False
DDI-MedLine.d58.s8	by	168	169	O	by	by	by	IN	False
DDI-MedLine.d58.s8	ginseng	171	177	B-drug	ginseng	eng	seng	NN	False
DDI-MedLine.d58.s8	.	178	178	O	.	.	.	.	False

DDI-MedLine.d46.s0	Influence	0	8	O	Influence	nce	ence	NN	False
DDI-MedLine.d46.s0	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d46.s0	coadministration	13	28	O	coadministration	ion	tion	NN	False
DDI-MedLine.d46.s0	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d46.s0	fluoxetine	33	42	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s0	on	44	45	O	on	on	on	IN	False
DDI-MedLine.d46.s0	cisapride	47	55	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s0	pharmacokinetics	57	72	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d46.s0	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d46.s0	QTc	78	80	O	QTc	QTc	QTc	NN	False
DDI-MedLine.d46.s0	intervals	82	90	O	intervals	als	vals	NNS	False
DDI-MedLine.d46.s0	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d46.s0	healthy	95	101	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d46.s0	volunteers	103	112	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d46.s0	.	113	113	O	.	.	.	.	False

DDI-MedLine.d46.s1	STUDY	0	4	O	STUDY	UDY	TUDY	NN	brand
DDI-MedLine.d46.s1	OBJECTIVE	6	14	O	OBJECTIVE	IVE	TIVE	NN	brand
DDI-MedLine.d46.s1	:	15	15	O	:	:	:	:	False
DDI-MedLine.d46.s1	To	17	18	O	To	To	To	TO	False
DDI-MedLine.d46.s1	evaluate	20	27	O	evaluate	ate	uate	NN	False
DDI-MedLine.d46.s1	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d46.s1	effect	33	38	O	effect	ect	fect	NN	False
DDI-MedLine.d46.s1	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d46.s1	fluoxetine	43	52	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s1	on	54	55	O	on	on	on	IN	False
DDI-MedLine.d46.s1	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d46.s1	pharmacokinetics	61	76	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d46.s1	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d46.s1	cardiovascular	82	95	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d46.s1	safety	97	102	O	safety	ety	fety	NN	False
DDI-MedLine.d46.s1	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d46.s1	cisapride	107	115	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s1	at	117	118	O	at	at	at	IN	False
DDI-MedLine.d46.s1	steady	120	125	O	steady	ady	eady	JJ	False
DDI-MedLine.d46.s1	state	127	131	O	state	ate	tate	NN	False
DDI-MedLine.d46.s1	in	133	134	O	in	in	in	IN	False
DDI-MedLine.d46.s1	healthy	136	142	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d46.s1	men	144	146	O	men	men	men	NNS	False
DDI-MedLine.d46.s1	.	147	147	O	.	.	.	.	False

DDI-MedLine.d46.s2	DESIGN	0	5	O	DESIGN	IGN	SIGN	NN	brand
DDI-MedLine.d46.s2	:	6	6	O	:	:	:	:	False
DDI-MedLine.d46.s2	Open-label	8	17	O	Open-label	bel	abel	NN	False
DDI-MedLine.d46.s2	,	18	18	O	,	,	,	,	False
DDI-MedLine.d46.s2	three-phase	20	30	O	three-phase	ase	hase	NN	False
DDI-MedLine.d46.s2	,	31	31	O	,	,	,	,	False
DDI-MedLine.d46.s2	sequential	33	42	O	sequential	ial	tial	JJ	False
DDI-MedLine.d46.s2	study	44	48	O	study	udy	tudy	NN	False
DDI-MedLine.d46.s2	.	49	49	O	.	.	.	.	False

DDI-MedLine.d46.s3	SETTING	0	6	O	SETTING	ING	TING	NN	brand
DDI-MedLine.d46.s3	:	7	7	O	:	:	:	:	False
DDI-MedLine.d46.s3	Clinical	9	16	O	Clinical	cal	ical	JJ	False
DDI-MedLine.d46.s3	research	18	25	O	research	rch	arch	NN	False
DDI-MedLine.d46.s3	center	27	32	O	center	ter	nter	NN	False
DDI-MedLine.d46.s3	.	33	33	O	.	.	.	.	False

DDI-MedLine.d46.s4	SUBJECTS	0	7	O	SUBJECTS	CTS	ECTS	NN	brand
DDI-MedLine.d46.s4	:	8	8	O	:	:	:	:	False
DDI-MedLine.d46.s4	Twelve	9	14	O	Twelve	lve	elve	NN	False
DDI-MedLine.d46.s4	healthy	16	22	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d46.s4	male	24	27	O	male	ale	male	NN	False
DDI-MedLine.d46.s4	volunteers	29	38	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d46.s4	.	39	39	O	.	.	.	.	False

DDI-MedLine.d46.s5	INTERVENTIONS	0	12	O	INTERVENTIONS	ONS	IONS	NN	brand
DDI-MedLine.d46.s5	:	13	13	O	:	:	:	:	False
DDI-MedLine.d46.s5	Each	15	18	O	Each	ach	Each	DT	False
DDI-MedLine.d46.s5	subject	20	26	O	subject	ect	ject	NN	False
DDI-MedLine.d46.s5	was	28	30	O	was	was	was	VBD	False
DDI-MedLine.d46.s5	treated	32	38	O	treated	ted	ated	VBN	False
DDI-MedLine.d46.s5	according	40	48	O	according	ing	ding	VBG	False
DDI-MedLine.d46.s5	to	50	51	O	to	to	to	TO	False
DDI-MedLine.d46.s5	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d46.s5	following	57	65	O	following	ing	wing	VBG	False
DDI-MedLine.d46.s5	sequence	67	74	O	sequence	nce	ence	NN	False
DDI-MedLine.d46.s5	:	75	75	O	:	:	:	:	False
DDI-MedLine.d46.s5	baseline	77	84	O	baseline	ine	line	NN	drug
DDI-MedLine.d46.s5	;	85	85	O	;	;	;	:	False

DDI-MedLine.d46.s6	phase	0	4	O	phase	ase	hase	NN	False
DDI-MedLine.d46.s6	1	6	6	O	1	1	1	CD	False
DDI-MedLine.d46.s6	(	8	8	O	(	(	(	(	False
DDI-MedLine.d46.s6	days	9	12	O	days	ays	days	NNS	False
DDI-MedLine.d46.s6	1-6	14	16	O	1-6	1-6	1-6	JJ	False
DDI-MedLine.d46.s6	)	17	17	O	)	)	)	)	False
DDI-MedLine.d46.s6	:	18	18	O	:	:	:	:	False
DDI-MedLine.d46.s6	cisapride	20	28	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s6	10	30	31	O	10	10	10	CD	False
DDI-MedLine.d46.s6	mg	33	34	O	mg	mg	mg	NN	False
DDI-MedLine.d46.s6	4	36	36	O	4	4	4	CD	False
DDI-MedLine.d46.s6	times/day	38	46	O	times/day	day	/day	NN	False
DDI-MedLine.d46.s6	;	47	47	O	;	;	;	:	False

DDI-MedLine.d46.s7	washout	0	6	O	washout	out	hout	NN	False
DDI-MedLine.d46.s7	(	8	8	O	(	(	(	(	False
DDI-MedLine.d46.s7	days	9	12	O	days	ays	days	NNS	False
DDI-MedLine.d46.s7	7-13	14	17	O	7-13	-13	7-13	JJ	False
DDI-MedLine.d46.s7	)	18	18	O	)	)	)	)	False
DDI-MedLine.d46.s7	;	19	19	O	;	;	;	:	False

DDI-MedLine.d46.s8	phase	0	4	O	phase	ase	hase	NN	False
DDI-MedLine.d46.s8	2	6	6	O	2	2	2	CD	False
DDI-MedLine.d46.s8	(	8	8	O	(	(	(	(	False
DDI-MedLine.d46.s8	days	9	12	O	days	ays	days	NNS	False
DDI-MedLine.d46.s8	14-44	14	18	O	14-44	-44	4-44	JJ	False
DDI-MedLine.d46.s8	)	19	19	O	)	)	)	)	False
DDI-MedLine.d46.s8	:	20	20	O	:	:	:	:	False
DDI-MedLine.d46.s8	fluoxetine	22	31	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s8	20	33	34	O	20	20	20	CD	False
DDI-MedLine.d46.s8	mg/day	36	41	O	mg/day	day	/day	NN	False
DDI-MedLine.d46.s8	;	42	42	O	;	;	;	:	False

DDI-MedLine.d46.s9	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d46.s9	phase	4	8	O	phase	ase	hase	NN	False
DDI-MedLine.d46.s9	3	10	10	O	3	3	3	CD	False
DDI-MedLine.d46.s9	(	12	12	O	(	(	(	(	False
DDI-MedLine.d46.s9	days	13	16	O	days	ays	days	NNS	False
DDI-MedLine.d46.s9	45-52	18	22	O	45-52	-52	5-52	JJ	False
DDI-MedLine.d46.s9	)	23	23	O	)	)	)	)	False
DDI-MedLine.d46.s9	:	24	24	O	:	:	:	:	False
DDI-MedLine.d46.s9	cisapride	26	34	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s9	10	36	37	O	10	10	10	CD	False
DDI-MedLine.d46.s9	mg	39	40	O	mg	mg	mg	NN	False
DDI-MedLine.d46.s9	4	42	42	O	4	4	4	CD	False
DDI-MedLine.d46.s9	times/day	44	52	O	times/day	day	/day	NN	False
DDI-MedLine.d46.s9	(	54	54	O	(	(	(	(	False
DDI-MedLine.d46.s9	days	55	58	O	days	ays	days	NNS	False
DDI-MedLine.d46.s9	45-51	60	64	O	45-51	-51	5-51	JJ	False
DDI-MedLine.d46.s9	)	65	65	O	)	)	)	)	False
DDI-MedLine.d46.s9	plus	67	70	O	plus	lus	plus	CC	False
DDI-MedLine.d46.s9	fluoxetine	72	81	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s9	20	83	84	O	20	20	20	CD	False
DDI-MedLine.d46.s9	mg/day	86	91	O	mg/day	day	/day	NN	False
DDI-MedLine.d46.s9	(	93	93	O	(	(	(	(	False
DDI-MedLine.d46.s9	days	94	97	O	days	ays	days	NNS	False
DDI-MedLine.d46.s9	45-52	99	103	O	45-52	-52	5-52	JJ	False
DDI-MedLine.d46.s9	)	104	104	O	)	)	)	)	False
DDI-MedLine.d46.s9	.	105	105	O	.	.	.	.	False

DDI-MedLine.d46.s10	MEASUREMENTS	0	11	O	MEASUREMENTS	NTS	ENTS	NNS	brand
DDI-MedLine.d46.s10	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d46.s10	MAIN	17	20	O	MAIN	AIN	MAIN	NN	brand
DDI-MedLine.d46.s10	RESULTS	22	28	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d46.s10	:	29	29	O	:	:	:	:	False
DDI-MedLine.d46.s10	Blood	31	35	O	Blood	ood	lood	NN	False
DDI-MedLine.d46.s10	samples	37	43	O	samples	les	ples	NNS	False
DDI-MedLine.d46.s10	were	45	48	O	were	ere	were	VBD	False
DDI-MedLine.d46.s10	drawn	50	54	O	drawn	awn	rawn	NN	False
DDI-MedLine.d46.s10	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d46.s10	12-lead	60	66	O	12-lead	ead	lead	JJ	False
DDI-MedLine.d46.s10	electrocardiograms	68	85	O	electrocardiograms	ams	rams	NNS	False
DDI-MedLine.d46.s10	performed	87	95	O	performed	med	rmed	VBN	False
DDI-MedLine.d46.s10	at	97	98	O	at	at	at	IN	False
DDI-MedLine.d46.s10	specified	100	108	O	specified	ied	fied	VBN	False
DDI-MedLine.d46.s10	time	110	113	O	time	ime	time	NN	False
DDI-MedLine.d46.s10	points	115	120	O	points	nts	ints	NNS	False
DDI-MedLine.d46.s10	after	122	126	O	after	ter	fter	IN	False
DDI-MedLine.d46.s10	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d46.s10	last	132	135	O	last	ast	last	JJ	False
DDI-MedLine.d46.s10	morning	137	143	O	morning	ing	ning	NN	False
DDI-MedLine.d46.s10	dose	145	148	O	dose	ose	dose	NN	False
DDI-MedLine.d46.s10	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d46.s10	cisapride	153	161	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s10	in	163	164	O	in	in	in	IN	False
DDI-MedLine.d46.s10	phases	166	171	O	phases	ses	ases	NNS	False
DDI-MedLine.d46.s10	1	173	173	O	1	1	1	CD	False
DDI-MedLine.d46.s10	and	175	177	O	and	and	and	CC	False
DDI-MedLine.d46.s10	3	179	179	O	3	3	3	CD	False
DDI-MedLine.d46.s10	.	180	180	O	.	.	.	.	False

DDI-MedLine.d46.s11	Blood	0	4	O	Blood	ood	lood	NN	False
DDI-MedLine.d46.s11	samples	6	12	O	samples	les	ples	NNS	False
DDI-MedLine.d46.s11	also	14	17	O	also	lso	also	RB	False
DDI-MedLine.d46.s11	were	19	22	O	were	ere	were	VBD	False
DDI-MedLine.d46.s11	taken	24	28	O	taken	ken	aken	VBN	False
DDI-MedLine.d46.s11	before	30	35	O	before	ore	fore	IN	False
DDI-MedLine.d46.s11	morning	37	43	O	morning	ing	ning	NN	False
DDI-MedLine.d46.s11	doses	45	49	O	doses	ses	oses	NNS	False
DDI-MedLine.d46.s11	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d46.s11	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d46.s11	3rd	58	60	O	3rd	3rd	3rd	CD	False
DDI-MedLine.d46.s11	,	61	61	O	,	,	,	,	False
DDI-MedLine.d46.s11	4th	63	65	O	4th	4th	4th	CD	False
DDI-MedLine.d46.s11	,	66	66	O	,	,	,	,	False
DDI-MedLine.d46.s11	and	68	70	O	and	and	and	CC	False
DDI-MedLine.d46.s11	5th	72	74	O	5th	5th	5th	NNS	False
DDI-MedLine.d46.s11	days	76	79	O	days	ays	days	NNS	False
DDI-MedLine.d46.s11	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d46.s11	phases	84	89	O	phases	ses	ases	NNS	False
DDI-MedLine.d46.s11	1	91	91	O	1	1	1	CD	False
DDI-MedLine.d46.s11	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d46.s11	3	97	97	O	3	3	3	CD	False
DDI-MedLine.d46.s11	.	98	98	O	.	.	.	.	False

DDI-MedLine.d46.s12	Electrocardiograms	0	17	O	Electrocardiograms	ams	rams	NNS	False
DDI-MedLine.d46.s12	were	19	22	O	were	ere	were	VBD	False
DDI-MedLine.d46.s12	done	24	27	O	done	one	done	VBN	False
DDI-MedLine.d46.s12	at	29	30	O	at	at	at	IN	False
DDI-MedLine.d46.s12	baseline	32	39	O	baseline	ine	line	NN	drug
DDI-MedLine.d46.s12	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d46.s12	on	45	46	O	on	on	on	IN	False
DDI-MedLine.d46.s12	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d46.s12	last	52	55	O	last	ast	last	JJ	False
DDI-MedLine.d46.s12	day	57	59	O	day	day	day	NN	False
DDI-MedLine.d46.s12	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d46.s12	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d46.s12	washout	68	74	O	washout	out	hout	NN	False
DDI-MedLine.d46.s12	period	76	81	O	period	iod	riod	NN	False
DDI-MedLine.d46.s12	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d46.s12	phase	87	91	O	phase	ase	hase	NN	False
DDI-MedLine.d46.s12	2	93	93	O	2	2	2	CD	False
DDI-MedLine.d46.s12	.	94	94	O	.	.	.	.	False

DDI-MedLine.d46.s13	Coadministration	0	15	O	Coadministration	ion	tion	NN	False
DDI-MedLine.d46.s13	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d46.s13	fluoxetine	20	29	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s13	significantly	31	43	O	significantly	tly	ntly	RB	False
DDI-MedLine.d46.s13	decreased	45	53	O	decreased	sed	ased	VBN	False
DDI-MedLine.d46.s13	cisapride	55	63	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s13	plasma	65	70	O	plasma	sma	asma	NN	False
DDI-MedLine.d46.s13	concentrations	72	85	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d46.s13	.	86	86	O	.	.	.	.	False

DDI-MedLine.d46.s14	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d46.s14	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d46.s14	no	11	12	O	no	no	no	DT	False
DDI-MedLine.d46.s14	clinically	14	23	O	clinically	lly	ally	RB	False
DDI-MedLine.d46.s14	significant	25	35	O	significant	ant	cant	JJ	False
DDI-MedLine.d46.s14	changes	37	43	O	changes	ges	nges	NNS	False
DDI-MedLine.d46.s14	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d46.s14	corrected	48	56	O	corrected	ted	cted	VBN	False
DDI-MedLine.d46.s14	QT	58	59	O	QT	QT	QT	NN	brand
DDI-MedLine.d46.s14	intervals	61	69	O	intervals	als	vals	NNS	False
DDI-MedLine.d46.s14	during	71	76	O	during	ing	ring	IN	False
DDI-MedLine.d46.s14	administration	78	91	O	administration	ion	tion	NN	False
DDI-MedLine.d46.s14	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d46.s14	cisapride	96	104	B-drug	cisapride	ide	ride	NN	False
DDI-MedLine.d46.s14	alone	106	110	O	alone	one	lone	RB	False
DDI-MedLine.d46.s14	or	112	113	O	or	or	or	CC	False
DDI-MedLine.d46.s14	with	115	118	O	with	ith	with	IN	False
DDI-MedLine.d46.s14	fluoxetine	120	129	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s14	.	130	130	O	.	.	.	.	False

DDI-MedLine.d46.s15	Cisapride	0	8	B-drug	Cisapride	ide	ride	NN	False
DDI-MedLine.d46.s15	was	10	12	O	was	was	was	VBD	False
DDI-MedLine.d46.s15	well	14	17	O	well	ell	well	RB	False
DDI-MedLine.d46.s15	tolerated	19	27	O	tolerated	ted	ated	VBN	False
DDI-MedLine.d46.s15	when	29	32	O	when	hen	when	WRB	False
DDI-MedLine.d46.s15	administered	34	45	O	administered	red	ered	VBN	False
DDI-MedLine.d46.s15	alone	47	51	O	alone	one	lone	RB	False
DDI-MedLine.d46.s15	or	53	54	O	or	or	or	CC	False
DDI-MedLine.d46.s15	with	56	59	O	with	ith	with	IN	False
DDI-MedLine.d46.s15	fluoxetine	61	70	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s15	.	71	71	O	.	.	.	.	False

DDI-MedLine.d46.s16	CONCLUSION	0	9	O	CONCLUSION	ION	SION	NN	brand
DDI-MedLine.d46.s16	:	10	10	O	:	:	:	:	False
DDI-MedLine.d46.s16	Cisapride	12	20	B-drug	Cisapride	ide	ride	NN	False
DDI-MedLine.d46.s16	can	22	24	O	can	can	can	MD	False
DDI-MedLine.d46.s16	be	26	27	O	be	be	be	VB	False
DDI-MedLine.d46.s16	administered	29	40	O	administered	red	ered	VBN	False
DDI-MedLine.d46.s16	safely	42	47	O	safely	ely	fely	RB	False
DDI-MedLine.d46.s16	to	49	50	O	to	to	to	TO	False
DDI-MedLine.d46.s16	patients	52	59	O	patients	nts	ents	NNS	False
DDI-MedLine.d46.s16	receiving	61	69	O	receiving	ing	ving	VBG	False
DDI-MedLine.d46.s16	low	71	73	O	low	low	low	JJ	False
DDI-MedLine.d46.s16	therapeutic	75	85	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d46.s16	dosages	87	93	O	dosages	ges	ages	NNS	False
DDI-MedLine.d46.s16	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d46.s16	fluoxetine	98	107	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d46.s16	.	108	108	O	.	.	.	.	False

DDI-MedLine.d114.s0	Inhibitory	0	9	O	Inhibitory	ory	tory	NN	False
DDI-MedLine.d114.s0	effects	11	17	O	effects	cts	ects	NNS	False
DDI-MedLine.d114.s0	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d114.s0	ruthenium	22	30	B-drug_n	ruthenium	ium	nium	NN	drug
DDI-MedLine.d114.s0	red	32	34	I-drug_n	red	red	red	JJ	False
DDI-MedLine.d114.s0	on	36	37	O	on	on	on	IN	False
DDI-MedLine.d114.s0	inositol	39	46	O	inositol	tol	itol	NN	False
DDI-MedLine.d114.s0	1,4	48	50	O	1,4	1,4	1,4	CD	False
DDI-MedLine.d114.s0	,	51	51	O	,	,	,	,	False
DDI-MedLine.d114.s0	5-trisphosphate-induced	53	75	O	5-trisphosphate-induced	ced	uced	JJ	False
DDI-MedLine.d114.s0	responses	77	85	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s0	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d114.s0	rat	90	92	O	rat	rat	rat	NN	False
DDI-MedLine.d114.s0	megakaryocytes	94	107	O	megakaryocytes	tes	ytes	NNS	False
DDI-MedLine.d114.s0	.	108	108	O	.	.	.	.	False

DDI-MedLine.d114.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d114.s1	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d114.s1	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d114.s1	ruthenium	15	23	B-drug_n	ruthenium	ium	nium	NN	drug
DDI-MedLine.d114.s1	red	25	27	I-drug_n	red	red	red	JJ	False
DDI-MedLine.d114.s1	(	29	29	O	(	(	(	(	False
DDI-MedLine.d114.s1	RR	30	31	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s1	)	32	32	O	)	)	)	)	False
DDI-MedLine.d114.s1	on	34	35	O	on	on	on	IN	False
DDI-MedLine.d114.s1	inositol	37	44	B-drug_n	inositol	tol	itol	NN	False
DDI-MedLine.d114.s1	1,4,5-trisphosphate	46	64	I-drug_n	1,4,5-trisphosphate	ate	hate	JJ	False
DDI-MedLine.d114.s1	(	66	66	O	(	(	(	(	False
DDI-MedLine.d114.s1	InsP	67	70	B-drug_n	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s1	(	71	71	I-drug_n	(	(	(	(	False
DDI-MedLine.d114.s1	3	72	72	I-drug_n	3	3	3	CD	False
DDI-MedLine.d114.s1	)	73	73	I-drug_n	)	)	)	)	False
DDI-MedLine.d114.s1	)	74	74	O	)	)	)	)	False
DDI-MedLine.d114.s1	-induced	75	82	O	-induced	ced	uced	VBN	False
DDI-MedLine.d114.s1	responses	84	92	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s1	were	94	97	O	were	ere	were	VBD	False
DDI-MedLine.d114.s1	studied	99	105	O	studied	ied	died	VBN	False
DDI-MedLine.d114.s1	in	107	108	O	in	in	in	IN	False
DDI-MedLine.d114.s1	rat	110	112	O	rat	rat	rat	NN	False
DDI-MedLine.d114.s1	bone	114	117	O	bone	one	bone	NN	False
DDI-MedLine.d114.s1	marrow	119	124	O	marrow	row	rrow	NN	False
DDI-MedLine.d114.s1	megakaryocytes	126	139	O	megakaryocytes	tes	ytes	NNS	False
DDI-MedLine.d114.s1	with	141	144	O	with	ith	with	IN	False
DDI-MedLine.d114.s1	the	146	148	O	the	the	the	DT	False
DDI-MedLine.d114.s1	patch-clamp	150	160	O	patch-clamp	amp	lamp	NN	False
DDI-MedLine.d114.s1	whole-cell	162	171	O	whole-cell	ell	cell	NN	False
DDI-MedLine.d114.s1	recording	173	181	O	recording	ing	ding	VBG	False
DDI-MedLine.d114.s1	technique	183	191	O	technique	que	ique	NN	False
DDI-MedLine.d114.s1	in	193	194	O	in	in	in	IN	False
DDI-MedLine.d114.s1	combination	196	206	O	combination	ion	tion	NN	False
DDI-MedLine.d114.s1	with	208	211	O	with	ith	with	IN	False
DDI-MedLine.d114.s1	fura-2	213	218	O	fura-2	a-2	ra-2	NN	False
DDI-MedLine.d114.s1	microfluorometry	220	235	O	microfluorometry	try	etry	NN	False
DDI-MedLine.d114.s1	.	236	236	O	.	.	.	.	False

DDI-MedLine.d114.s2	Internal	0	7	O	Internal	nal	rnal	NNP	False
DDI-MedLine.d114.s2	application	9	19	O	application	ion	tion	NN	False
DDI-MedLine.d114.s2	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d114.s2	InsP	24	27	B-drug_n	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s2	(	28	28	I-drug_n	(	(	(	(	False
DDI-MedLine.d114.s2	3	29	29	I-drug_n	3	3	3	CD	False
DDI-MedLine.d114.s2	)	30	30	I-drug_n	)	)	)	)	False
DDI-MedLine.d114.s2	(	32	32	O	(	(	(	(	False
DDI-MedLine.d114.s2	100	33	35	O	100	100	100	CD	False
DDI-MedLine.d114.s2	microM	37	42	O	microM	roM	croM	NN	False
DDI-MedLine.d114.s2	)	43	43	O	)	)	)	)	False
DDI-MedLine.d114.s2	increased	45	53	O	increased	sed	ased	VBN	False
DDI-MedLine.d114.s2	intracellular	55	67	O	intracellular	lar	ular	NN	False
DDI-MedLine.d114.s2	Ca	69	70	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d114.s2	(	71	71	O	(	(	(	(	False
DDI-MedLine.d114.s2	2+	72	73	O	2+	2+	2+	CD	False
DDI-MedLine.d114.s2	)	74	74	O	)	)	)	)	False
DDI-MedLine.d114.s2	concentration	76	88	O	concentration	ion	tion	NN	False
DDI-MedLine.d114.s2	(	90	90	O	(	(	(	(	False
DDI-MedLine.d114.s2	[	91	91	O	[	[	[	NN	False
DDI-MedLine.d114.s2	Ca	92	93	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d114.s2	(	94	94	O	(	(	(	(	False
DDI-MedLine.d114.s2	2+	95	96	O	2+	2+	2+	CD	False
DDI-MedLine.d114.s2	)	97	97	O	)	)	)	)	False
DDI-MedLine.d114.s2	]	98	98	O	]	]	]	NN	False
DDI-MedLine.d114.s2	(	99	99	O	(	(	(	(	False
DDI-MedLine.d114.s2	i	100	100	O	i	i	i	NN	False
DDI-MedLine.d114.s2	)	101	101	O	)	)	)	)	False
DDI-MedLine.d114.s2	)	102	102	O	)	)	)	)	False
DDI-MedLine.d114.s2	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d114.s2	activated	108	116	O	activated	ted	ated	VBN	False
DDI-MedLine.d114.s2	the	118	120	O	the	the	the	DT	False
DDI-MedLine.d114.s2	Ca	122	123	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d114.s2	(	124	124	O	(	(	(	(	False
DDI-MedLine.d114.s2	2+	125	126	O	2+	2+	2+	CD	False
DDI-MedLine.d114.s2	)	127	127	O	)	)	)	)	False
DDI-MedLine.d114.s2	-dependent	128	137	O	-dependent	ent	dent	NN	False
DDI-MedLine.d114.s2	K	139	139	O	K	K	K	NNP	brand
DDI-MedLine.d114.s2	(	140	140	O	(	(	(	(	False
DDI-MedLine.d114.s2	+	141	141	O	+	+	+	NN	False
DDI-MedLine.d114.s2	)	142	142	O	)	)	)	)	False
DDI-MedLine.d114.s2	current	144	150	O	current	ent	rent	JJ	False
DDI-MedLine.d114.s2	.	151	151	O	.	.	.	.	False

DDI-MedLine.d114.s3	Administering	0	12	O	Administering	ing	ring	VBG	False
DDI-MedLine.d114.s3	InsP	14	17	B-drug_n	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s3	(	18	18	I-drug_n	(	(	(	(	False
DDI-MedLine.d114.s3	3	19	19	I-drug_n	3	3	3	CD	False
DDI-MedLine.d114.s3	)	20	20	I-drug_n	)	)	)	)	False
DDI-MedLine.d114.s3	together	22	29	O	together	her	ther	RB	False
DDI-MedLine.d114.s3	with	31	34	O	with	ith	with	IN	False
DDI-MedLine.d114.s3	RR	36	37	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s3	(	39	39	O	(	(	(	(	False
DDI-MedLine.d114.s3	100-500	40	46	O	100-500	500	-500	JJ	False
DDI-MedLine.d114.s3	microM	48	53	O	microM	roM	croM	NN	False
DDI-MedLine.d114.s3	)	54	54	O	)	)	)	)	False
DDI-MedLine.d114.s3	inhibited	56	64	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d114.s3	InsP	66	69	O	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s3	(	70	70	O	(	(	(	(	False
DDI-MedLine.d114.s3	3	71	71	O	3	3	3	CD	False
DDI-MedLine.d114.s3	)	72	72	O	)	)	)	)	False
DDI-MedLine.d114.s3	-induced	73	80	O	-induced	ced	uced	VBN	False
DDI-MedLine.d114.s3	responses	82	90	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s3	(	92	92	O	(	(	(	(	False
DDI-MedLine.d114.s3	both	93	96	O	both	oth	both	DT	False
DDI-MedLine.d114.s3	Ca	98	99	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d114.s3	(	100	100	O	(	(	(	(	False
DDI-MedLine.d114.s3	2+	101	102	O	2+	2+	2+	CD	False
DDI-MedLine.d114.s3	)	103	103	O	)	)	)	)	False
DDI-MedLine.d114.s3	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d114.s3	current	109	115	O	current	ent	rent	JJ	False
DDI-MedLine.d114.s3	responses	117	125	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s3	)	126	126	O	)	)	)	)	False
DDI-MedLine.d114.s3	in	128	129	O	in	in	in	IN	False
DDI-MedLine.d114.s3	a	131	131	O	a	a	a	DT	False
DDI-MedLine.d114.s3	dose-dependent	133	146	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d114.s3	fashion	148	154	O	fashion	ion	hion	NN	False
DDI-MedLine.d114.s3	.	155	155	O	.	.	.	.	False

DDI-MedLine.d114.s4	Pretreatment	0	11	O	Pretreatment	ent	ment	NN	False
DDI-MedLine.d114.s4	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d114.s4	megakaryocytes	16	29	O	megakaryocytes	tes	ytes	NNS	False
DDI-MedLine.d114.s4	with	31	34	O	with	ith	with	IN	False
DDI-MedLine.d114.s4	extracellular	36	48	O	extracellular	lar	ular	NN	False
DDI-MedLine.d114.s4	RR	50	51	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s4	(	53	53	O	(	(	(	(	False
DDI-MedLine.d114.s4	50	54	55	O	50	50	50	CD	False
DDI-MedLine.d114.s4	microM	57	62	O	microM	roM	croM	NN	False
DDI-MedLine.d114.s4	)	63	63	O	)	)	)	)	False
DDI-MedLine.d114.s4	also	65	68	O	also	lso	also	RB	False
DDI-MedLine.d114.s4	inhibited	70	78	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d114.s4	InsP	80	83	B-drug_n	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s4	(	84	84	I-drug_n	(	(	(	(	False
DDI-MedLine.d114.s4	3	85	85	I-drug_n	3	3	3	CD	False
DDI-MedLine.d114.s4	)	86	86	I-drug_n	)	)	)	)	False
DDI-MedLine.d114.s4	-induced	87	94	O	-induced	ced	uced	VBN	False
DDI-MedLine.d114.s4	responses	96	104	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s4	.	105	105	O	.	.	.	.	False

DDI-MedLine.d114.s5	Intracellular	0	12	O	Intracellular	lar	ular	JJ	False
DDI-MedLine.d114.s5	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d114.s5	extracellular	18	30	O	extracellular	lar	ular	NN	False
DDI-MedLine.d114.s5	application	32	42	O	application	ion	tion	NN	False
DDI-MedLine.d114.s5	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d114.s5	RR	47	48	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s5	reduced	50	56	O	reduced	ced	uced	VBN	False
DDI-MedLine.d114.s5	ADP-induced	58	68	O	ADP-induced	ced	uced	JJ	False
DDI-MedLine.d114.s5	increases	70	78	O	increases	ses	ases	NNS	False
DDI-MedLine.d114.s5	in	80	81	O	in	in	in	IN	False
DDI-MedLine.d114.s5	[	83	83	O	[	[	[	NN	False
DDI-MedLine.d114.s5	Ca	84	85	O	Ca	Ca	Ca	NN	False
DDI-MedLine.d114.s5	(	86	86	O	(	(	(	(	False
DDI-MedLine.d114.s5	2+	87	88	O	2+	2+	2+	CD	False
DDI-MedLine.d114.s5	)	89	89	O	)	)	)	)	False
DDI-MedLine.d114.s5	]	90	90	O	]	]	]	NN	False
DDI-MedLine.d114.s5	(	91	91	O	(	(	(	(	False
DDI-MedLine.d114.s5	i	92	92	O	i	i	i	NN	False
DDI-MedLine.d114.s5	)	93	93	O	)	)	)	)	False
DDI-MedLine.d114.s5	.	94	94	O	.	.	.	.	False

DDI-MedLine.d114.s6	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d114.s6	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d114.s6	,	11	11	O	,	,	,	,	False
DDI-MedLine.d114.s6	in	13	14	O	in	in	in	IN	False
DDI-MedLine.d114.s6	isolated	16	23	O	isolated	ted	ated	JJ	False
DDI-MedLine.d114.s6	single	25	30	O	single	gle	ngle	JJ	False
DDI-MedLine.d114.s6	pancreatic	32	41	O	pancreatic	tic	atic	JJ	False
DDI-MedLine.d114.s6	acinar	43	48	O	acinar	nar	inar	NN	False
DDI-MedLine.d114.s6	cells	50	54	O	cells	lls	ells	NNS	False
DDI-MedLine.d114.s6	,	55	55	O	,	,	,	,	False
DDI-MedLine.d114.s6	RR	57	58	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s6	had	60	62	O	had	had	had	VBD	False
DDI-MedLine.d114.s6	no	64	65	O	no	no	no	DT	False
DDI-MedLine.d114.s6	effect	67	72	O	effect	ect	fect	NN	False
DDI-MedLine.d114.s6	on	74	75	O	on	on	on	IN	False
DDI-MedLine.d114.s6	InsP	77	80	B-drug_n	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s6	(	81	81	I-drug_n	(	(	(	(	False
DDI-MedLine.d114.s6	3	82	82	I-drug_n	3	3	3	CD	False
DDI-MedLine.d114.s6	)	83	83	I-drug_n	)	)	)	)	False
DDI-MedLine.d114.s6	-induced	84	91	O	-induced	ced	uced	VBN	False
DDI-MedLine.d114.s6	responses	93	101	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s6	.	102	102	O	.	.	.	.	False

DDI-MedLine.d114.s7	Taken	0	4	O	Taken	ken	aken	VBN	False
DDI-MedLine.d114.s7	together	6	13	O	together	her	ther	RB	False
DDI-MedLine.d114.s7	,	14	14	O	,	,	,	,	False
DDI-MedLine.d114.s7	these	16	20	O	these	ese	hese	DT	False
DDI-MedLine.d114.s7	results	22	28	O	results	lts	ults	NNS	False
DDI-MedLine.d114.s7	suggest	30	36	O	suggest	est	gest	NN	False
DDI-MedLine.d114.s7	that	38	41	O	that	hat	that	IN	False
DDI-MedLine.d114.s7	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d114.s7	site	47	50	O	site	ite	site	NN	False
DDI-MedLine.d114.s7	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d114.s7	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d114.s7	inhibitory	59	68	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d114.s7	action	70	75	O	action	ion	tion	NN	False
DDI-MedLine.d114.s7	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d114.s7	RR	80	81	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s7	is	83	84	O	is	is	is	VBZ	False
DDI-MedLine.d114.s7	at	86	87	O	at	at	at	IN	False
DDI-MedLine.d114.s7	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d114.s7	InsP	93	96	O	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s7	(	97	97	O	(	(	(	(	False
DDI-MedLine.d114.s7	3	98	98	O	3	3	3	CD	False
DDI-MedLine.d114.s7	)	99	99	O	)	)	)	)	False
DDI-MedLine.d114.s7	receptor	101	108	O	receptor	tor	ptor	NN	False
DDI-MedLine.d114.s7	,	109	109	O	,	,	,	,	False
DDI-MedLine.d114.s7	or	111	112	O	or	or	or	CC	False
DDI-MedLine.d114.s7	its	114	116	O	its	its	its	PRP$	False
DDI-MedLine.d114.s7	closely	118	124	O	closely	ely	sely	RB	False
DDI-MedLine.d114.s7	associated	126	135	O	associated	ted	ated	VBN	False
DDI-MedLine.d114.s7	proteins	137	144	O	proteins	ins	eins	NNS	False
DDI-MedLine.d114.s7	.	145	145	O	.	.	.	.	False

DDI-MedLine.d114.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d114.s8	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d114.s8	,	11	11	O	,	,	,	,	False
DDI-MedLine.d114.s8	we	13	14	O	we	we	we	PRP	False
DDI-MedLine.d114.s8	have	16	19	O	have	ave	have	VB	False
DDI-MedLine.d114.s8	shown	21	25	O	shown	own	hown	VBN	False
DDI-MedLine.d114.s8	that	27	30	O	that	hat	that	IN	False
DDI-MedLine.d114.s8	RR	32	33	B-drug_n	RR	RR	RR	NN	brand
DDI-MedLine.d114.s8	is	35	36	O	is	is	is	VBZ	False
DDI-MedLine.d114.s8	a	38	38	O	a	a	a	DT	False
DDI-MedLine.d114.s8	useful	40	45	O	useful	ful	eful	JJ	False
DDI-MedLine.d114.s8	pharmacological	47	61	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d114.s8	tool	63	66	O	tool	ool	tool	NN	False
DDI-MedLine.d114.s8	with	68	71	O	with	ith	with	IN	False
DDI-MedLine.d114.s8	which	73	77	O	which	ich	hich	WDT	False
DDI-MedLine.d114.s8	to	79	80	O	to	to	to	TO	False
DDI-MedLine.d114.s8	examine	82	88	O	examine	ine	mine	NN	drug
DDI-MedLine.d114.s8	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d114.s8	InsP	94	97	B-drug_n	InsP	nsP	InsP	NN	False
DDI-MedLine.d114.s8	(	98	98	I-drug_n	(	(	(	(	False
DDI-MedLine.d114.s8	3	99	99	I-drug_n	3	3	3	CD	False
DDI-MedLine.d114.s8	)	100	100	I-drug_n	)	)	)	)	False
DDI-MedLine.d114.s8	-mediated	101	109	O	-mediated	ted	ated	VBN	False
DDI-MedLine.d114.s8	responses	111	119	O	responses	ses	nses	NNS	False
DDI-MedLine.d114.s8	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d114.s8	megakaryocytes	124	137	O	megakaryocytes	tes	ytes	NNS	False
DDI-MedLine.d114.s8	.	138	138	O	.	.	.	.	False

DDI-MedLine.d24.s0	Excretion	0	8	O	Excretion	ion	tion	NN	False
DDI-MedLine.d24.s0	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d24.s0	thioethers	13	22	O	thioethers	ers	hers	NNS	False
DDI-MedLine.d24.s0	in	24	25	O	in	in	in	IN	False
DDI-MedLine.d24.s0	urine	27	31	O	urine	ine	rine	NN	drug
DDI-MedLine.d24.s0	after	33	37	O	after	ter	fter	IN	False
DDI-MedLine.d24.s0	exposure	39	46	O	exposure	ure	sure	NN	False
DDI-MedLine.d24.s0	to	48	49	O	to	to	to	TO	False
DDI-MedLine.d24.s0	electrophilic	51	63	O	electrophilic	lic	ilic	NN	False
DDI-MedLine.d24.s0	chemicals	65	73	O	chemicals	als	cals	NNS	False
DDI-MedLine.d24.s0	.	74	74	O	.	.	.	.	False

DDI-MedLine.d24.s1	Electrophilic	0	12	O	Electrophilic	lic	ilic	JJ	False
DDI-MedLine.d24.s1	agents	14	19	O	agents	nts	ents	NNS	False
DDI-MedLine.d24.s1	--	20	21	O	--	--	--	:	False
DDI-MedLine.d24.s1	a	22	22	O	a	a	a	DT	False
DDI-MedLine.d24.s1	class	24	28	O	class	ass	lass	NN	False
DDI-MedLine.d24.s1	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d24.s1	chemicals	33	41	O	chemicals	als	cals	NNS	False
DDI-MedLine.d24.s1	that	43	46	O	that	hat	that	IN	False
DDI-MedLine.d24.s1	includes	48	55	O	includes	des	udes	VBZ	False
DDI-MedLine.d24.s1	most	57	60	O	most	ost	most	JJS	False
DDI-MedLine.d24.s1	genotoxic	62	70	O	genotoxic	xic	oxic	NN	False
DDI-MedLine.d24.s1	compounds	72	80	O	compounds	nds	unds	NNS	False
DDI-MedLine.d24.s1	--	81	82	O	--	--	--	:	False
DDI-MedLine.d24.s1	can	83	85	O	can	can	can	MD	False
DDI-MedLine.d24.s1	be	87	88	O	be	be	be	VB	False
DDI-MedLine.d24.s1	inactivated	90	100	O	inactivated	ted	ated	VBN	False
DDI-MedLine.d24.s1	by	102	103	O	by	by	by	IN	False
DDI-MedLine.d24.s1	reaction	105	112	O	reaction	ion	tion	NN	False
DDI-MedLine.d24.s1	with	114	117	O	with	ith	with	IN	False
DDI-MedLine.d24.s1	glutathione	119	129	O	glutathione	one	ione	NN	False
DDI-MedLine.d24.s1	or	131	132	O	or	or	or	CC	False
DDI-MedLine.d24.s1	other	134	138	O	other	her	ther	JJ	False
DDI-MedLine.d24.s1	SH-bearing	140	149	O	SH-bearing	ing	ring	NN	False
DDI-MedLine.d24.s1	molecules	151	159	O	molecules	les	ules	NNS	False
DDI-MedLine.d24.s1	.	160	160	O	.	.	.	.	False

DDI-MedLine.d24.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d24.s2	conjugates	4	13	O	conjugates	tes	ates	NNS	False
DDI-MedLine.d24.s2	so	15	16	O	so	so	so	RB	False
DDI-MedLine.d24.s2	formed	18	23	O	formed	med	rmed	VBN	False
DDI-MedLine.d24.s2	often	25	29	O	often	ten	ften	RB	False
DDI-MedLine.d24.s2	appear	31	36	O	appear	ear	pear	VB	False
DDI-MedLine.d24.s2	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d24.s2	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d24.s2	urine	45	49	O	urine	ine	rine	NN	drug
DDI-MedLine.d24.s2	as	51	52	O	as	as	as	IN	False
DDI-MedLine.d24.s2	mercapturic	54	64	O	mercapturic	ric	uric	NN	False
DDI-MedLine.d24.s2	acids	66	70	O	acids	ids	cids	NNS	False
DDI-MedLine.d24.s2	or	72	73	O	or	or	or	CC	False
DDI-MedLine.d24.s2	other	75	79	O	other	her	ther	JJ	False
DDI-MedLine.d24.s2	thioether	81	89	O	thioether	her	ther	NN	False
DDI-MedLine.d24.s2	products	91	98	O	products	cts	ucts	NNS	False
DDI-MedLine.d24.s2	.	99	99	O	.	.	.	.	False

DDI-MedLine.d24.s3	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d24.s3	paper	5	9	O	paper	per	aper	NN	False
DDI-MedLine.d24.s3	critically	11	20	O	critically	lly	ally	RB	False
DDI-MedLine.d24.s3	reviews	22	28	O	reviews	ews	iews	NNS	False
DDI-MedLine.d24.s3	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d24.s3	suitability	34	44	O	suitability	ity	lity	NN	False
DDI-MedLine.d24.s3	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d24.s3	the	49	51	O	the	the	the	DT	False
DDI-MedLine.d24.s3	urinary	53	59	O	urinary	ary	nary	JJ	False
DDI-MedLine.d24.s3	thioether	61	69	O	thioether	her	ther	NN	False
DDI-MedLine.d24.s3	assay	71	75	O	assay	say	ssay	NN	False
DDI-MedLine.d24.s3	as	77	78	O	as	as	as	IN	False
DDI-MedLine.d24.s3	a	80	80	O	a	a	a	DT	False
DDI-MedLine.d24.s3	method	82	87	O	method	hod	thod	NN	False
DDI-MedLine.d24.s3	for	89	91	O	for	for	for	IN	False
DDI-MedLine.d24.s3	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d24.s3	detection	97	105	O	detection	ion	tion	NN	False
DDI-MedLine.d24.s3	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d24.s3	exposure	110	117	O	exposure	ure	sure	NN	False
DDI-MedLine.d24.s3	to	119	120	O	to	to	to	TO	False
DDI-MedLine.d24.s3	electrophilic	122	134	O	electrophilic	lic	ilic	NN	False
DDI-MedLine.d24.s3	agents	136	141	O	agents	nts	ents	NNS	False
DDI-MedLine.d24.s3	or	143	144	O	or	or	or	CC	False
DDI-MedLine.d24.s3	their	146	150	O	their	eir	heir	PRP$	False
DDI-MedLine.d24.s3	precursors	152	161	O	precursors	ors	sors	NNS	False
DDI-MedLine.d24.s3	.	162	162	O	.	.	.	.	False

DDI-MedLine.d24.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d24.s4	practice	3	10	O	practice	ice	tice	NN	False
DDI-MedLine.d24.s4	,	11	11	O	,	,	,	,	False
DDI-MedLine.d24.s4	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d24.s4	greatest	17	24	O	greatest	est	test	JJS	False
DDI-MedLine.d24.s4	value	26	30	O	value	lue	alue	NN	False
DDI-MedLine.d24.s4	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d24.s4	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d24.s4	thioether	39	47	O	thioether	her	ther	NN	False
DDI-MedLine.d24.s4	assay	49	53	O	assay	say	ssay	NN	False
DDI-MedLine.d24.s4	appears	55	61	O	appears	ars	ears	VBZ	False
DDI-MedLine.d24.s4	to	63	64	O	to	to	to	TO	False
DDI-MedLine.d24.s4	lie	66	68	O	lie	lie	lie	NN	False
DDI-MedLine.d24.s4	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d24.s4	its	73	75	O	its	its	its	PRP$	False
DDI-MedLine.d24.s4	signal	77	82	O	signal	nal	gnal	NN	False
DDI-MedLine.d24.s4	function	84	91	O	function	ion	tion	NN	False
DDI-MedLine.d24.s4	.	92	92	O	.	.	.	.	False

DDI-MedLine.d24.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d24.s5	is	5	6	O	is	is	is	VBZ	False
DDI-MedLine.d24.s5	demonstrated	8	19	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d24.s5	for	21	23	O	for	for	for	IN	False
DDI-MedLine.d24.s5	cigarette	25	33	O	cigarette	tte	ette	NN	False
DDI-MedLine.d24.s5	smokers	35	41	O	smokers	ers	kers	NNS	False
DDI-MedLine.d24.s5	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d24.s5	industrial	47	56	O	industrial	ial	rial	JJ	False
DDI-MedLine.d24.s5	workers	58	64	O	workers	ers	kers	NNS	False
DDI-MedLine.d24.s5	involved	66	73	O	involved	ved	lved	VBN	False
DDI-MedLine.d24.s5	in	75	76	O	in	in	in	IN	False
DDI-MedLine.d24.s5	chemical	78	85	O	chemical	cal	ical	NN	False
DDI-MedLine.d24.s5	waste	87	91	O	waste	ste	aste	NN	False
DDI-MedLine.d24.s5	incineration	93	104	O	incineration	ion	tion	NN	False
DDI-MedLine.d24.s5	.	105	105	O	.	.	.	.	False

DDI-MedLine.d24.s6	Whenever	0	7	O	Whenever	ver	ever	WRB	False
DDI-MedLine.d24.s6	increased	9	17	O	increased	sed	ased	VBN	False
DDI-MedLine.d24.s6	thioether	19	27	O	thioether	her	ther	NN	False
DDI-MedLine.d24.s6	excretion	29	37	O	excretion	ion	tion	NN	False
DDI-MedLine.d24.s6	is	39	40	O	is	is	is	VBZ	False
DDI-MedLine.d24.s6	observed	42	49	O	observed	ved	rved	VBN	False
DDI-MedLine.d24.s6	,	50	50	O	,	,	,	,	False
DDI-MedLine.d24.s6	it	52	53	O	it	it	it	PRP	False
DDI-MedLine.d24.s6	is	55	56	O	is	is	is	VBZ	False
DDI-MedLine.d24.s6	likely	58	63	O	likely	ely	kely	JJ	False
DDI-MedLine.d24.s6	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d24.s6	be	68	69	O	be	be	be	VB	False
DDI-MedLine.d24.s6	due	71	73	O	due	due	due	JJ	False
DDI-MedLine.d24.s6	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d24.s6	exposure	78	85	O	exposure	ure	sure	NN	False
DDI-MedLine.d24.s6	to	87	88	O	to	to	to	TO	False
DDI-MedLine.d24.s6	one	90	92	O	one	one	one	CD	False
DDI-MedLine.d24.s6	or	94	95	O	or	or	or	CC	False
DDI-MedLine.d24.s6	more	97	100	O	more	ore	more	RBR	False
DDI-MedLine.d24.s6	suspect	102	108	O	suspect	ect	pect	NN	False
DDI-MedLine.d24.s6	compounds	110	118	O	compounds	nds	unds	NNS	False
DDI-MedLine.d24.s6	.	119	119	O	.	.	.	.	False

DDI-MedLine.d24.s7	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d24.s7	,	7	7	O	,	,	,	,	False
DDI-MedLine.d24.s7	when	9	12	O	when	hen	when	WRB	False
DDI-MedLine.d24.s7	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d24.s7	thioether	18	26	O	thioether	her	ther	NN	False
DDI-MedLine.d24.s7	concentration	28	40	O	concentration	ion	tion	NN	False
DDI-MedLine.d24.s7	ranges	42	47	O	ranges	ges	nges	NNS	False
DDI-MedLine.d24.s7	within	49	54	O	within	hin	thin	IN	False
DDI-MedLine.d24.s7	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d24.s7	limits	60	65	O	limits	its	mits	NNS	False
DDI-MedLine.d24.s7	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d24.s7	the	70	72	O	the	the	the	DT	False
DDI-MedLine.d24.s7	normal	74	79	O	normal	mal	rmal	JJ	False
DDI-MedLine.d24.s7	value	81	85	O	value	lue	alue	NN	False
DDI-MedLine.d24.s7	,	86	86	O	,	,	,	,	False
DDI-MedLine.d24.s7	one	88	90	O	one	one	one	CD	False
DDI-MedLine.d24.s7	must	92	95	O	must	ust	must	MD	False
DDI-MedLine.d24.s7	not	97	99	O	not	not	not	RB	False
DDI-MedLine.d24.s7	conclude	101	108	O	conclude	ude	lude	NN	False
DDI-MedLine.d24.s7	that	110	113	O	that	hat	that	IN	False
DDI-MedLine.d24.s7	there	115	119	O	there	ere	here	RB	False
DDI-MedLine.d24.s7	is	121	122	O	is	is	is	VBZ	False
DDI-MedLine.d24.s7	no	124	125	O	no	no	no	DT	False
DDI-MedLine.d24.s7	,	126	126	O	,	,	,	,	False
DDI-MedLine.d24.s7	or	128	129	O	or	or	or	CC	False
DDI-MedLine.d24.s7	negligible	131	140	O	negligible	ble	ible	JJ	False
DDI-MedLine.d24.s7	,	141	141	O	,	,	,	,	False
DDI-MedLine.d24.s7	exposure	143	150	O	exposure	ure	sure	NN	False
DDI-MedLine.d24.s7	.	151	151	O	.	.	.	.	False

DDI-MedLine.d24.s8	More	0	3	O	More	ore	More	RBR	False
DDI-MedLine.d24.s8	specific	5	12	O	specific	fic	ific	JJ	False
DDI-MedLine.d24.s8	applications	14	25	O	applications	ons	ions	NNS	False
DDI-MedLine.d24.s8	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d24.s8	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d24.s8	assay	34	38	O	assay	say	ssay	NN	False
DDI-MedLine.d24.s8	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d24.s8	thio	43	46	O	thio	hio	thio	NN	False
DDI-MedLine.d24.s8	compounds	48	56	O	compounds	nds	unds	NNS	False
DDI-MedLine.d24.s8	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d24.s8	urine	61	65	O	urine	ine	rine	NN	drug
DDI-MedLine.d24.s8	allow	67	71	O	allow	low	llow	VB	False
DDI-MedLine.d24.s8	development	73	83	O	development	ent	ment	NN	False
DDI-MedLine.d24.s8	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d24.s8	selective	88	96	O	selective	ive	tive	NN	False
DDI-MedLine.d24.s8	methods	98	104	O	methods	ods	hods	NNS	False
DDI-MedLine.d24.s8	that	106	109	O	that	hat	that	IN	False
DDI-MedLine.d24.s8	may	111	113	O	may	may	may	MD	False
DDI-MedLine.d24.s8	be	115	116	O	be	be	be	VB	False
DDI-MedLine.d24.s8	useful	118	123	O	useful	ful	eful	JJ	False
DDI-MedLine.d24.s8	for	125	127	O	for	for	for	IN	False
DDI-MedLine.d24.s8	biological	129	138	O	biological	cal	ical	JJ	False
DDI-MedLine.d24.s8	monitoring	140	149	O	monitoring	ing	ring	NN	False
DDI-MedLine.d24.s8	.	150	150	O	.	.	.	.	False

DDI-MedLine.d22.s0	Spermine	0	7	B-drug	Spermine	ine	mine	NN	drug
DDI-MedLine.d22.s0	promotes	9	16	O	promotes	tes	otes	NNS	False
DDI-MedLine.d22.s0	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d22.s0	translocation	22	34	O	translocation	ion	tion	NN	False
DDI-MedLine.d22.s0	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d22.s0	phosphatidate	39	51	O	phosphatidate	ate	date	NN	False
DDI-MedLine.d22.s0	phosphohydrolase	53	68	O	phosphohydrolase	ase	lase	NN	False
DDI-MedLine.d22.s0	from	70	73	O	from	rom	from	IN	False
DDI-MedLine.d22.s0	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d22.s0	cytosol	79	85	O	cytosol	sol	osol	NN	False
DDI-MedLine.d22.s0	to	87	88	O	to	to	to	TO	False
DDI-MedLine.d22.s0	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d22.s0	microsomal	94	103	O	microsomal	mal	omal	NN	False
DDI-MedLine.d22.s0	fraction	105	112	O	fraction	ion	tion	NN	False
DDI-MedLine.d22.s0	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d22.s0	rat	117	119	O	rat	rat	rat	NN	False
DDI-MedLine.d22.s0	liver	121	125	O	liver	ver	iver	NN	False
DDI-MedLine.d22.s0	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d22.s0	it	131	132	O	it	it	it	PRP	False
DDI-MedLine.d22.s0	enhances	134	141	O	enhances	ces	nces	NNS	False
DDI-MedLine.d22.s0	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d22.s0	effects	147	153	O	effects	cts	ects	NNS	False
DDI-MedLine.d22.s0	of	155	156	O	of	of	of	IN	False
DDI-MedLine.d22.s0	oleate	158	163	O	oleate	ate	eate	NN	False
DDI-MedLine.d22.s0	in	165	166	O	in	in	in	IN	False
DDI-MedLine.d22.s0	this	168	171	O	this	his	this	DT	False
DDI-MedLine.d22.s0	respect	173	179	O	respect	ect	pect	NN	False
DDI-MedLine.d22.s0	.	180	180	O	.	.	.	.	False

DDI-MedLine.d22.s1	Spermine	0	7	B-drug	Spermine	ine	mine	NN	drug
DDI-MedLine.d22.s1	(	9	9	O	(	(	(	(	False
DDI-MedLine.d22.s1	0.5-2	10	14	O	0.5-2	5-2	.5-2	NN	False
DDI-MedLine.d22.s1	mM	16	17	O	mM	mM	mM	NN	False
DDI-MedLine.d22.s1	)	18	18	O	)	)	)	)	False
DDI-MedLine.d22.s1	promoted	20	27	O	promoted	ted	oted	VBN	False
DDI-MedLine.d22.s1	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d22.s1	translocation	33	45	O	translocation	ion	tion	NN	False
DDI-MedLine.d22.s1	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d22.s1	phosphatidate	50	62	O	phosphatidate	ate	date	NN	False
DDI-MedLine.d22.s1	phosphohydrolase	64	79	O	phosphohydrolase	ase	lase	NN	False
DDI-MedLine.d22.s1	from	81	84	O	from	rom	from	IN	False
DDI-MedLine.d22.s1	the	86	88	O	the	the	the	DT	False
DDI-MedLine.d22.s1	soluble	90	96	O	soluble	ble	uble	JJ	False
DDI-MedLine.d22.s1	to	98	99	O	to	to	to	TO	False
DDI-MedLine.d22.s1	the	101	103	O	the	the	the	DT	False
DDI-MedLine.d22.s1	microsomal	105	114	O	microsomal	mal	omal	NN	False
DDI-MedLine.d22.s1	fraction	116	123	O	fraction	ion	tion	NN	False
DDI-MedLine.d22.s1	in	125	126	O	in	in	in	IN	False
DDI-MedLine.d22.s1	a	128	128	O	a	a	a	DT	False
DDI-MedLine.d22.s1	cell-free	130	138	O	cell-free	ree	free	JJ	False
DDI-MedLine.d22.s1	system	140	145	O	system	tem	stem	NN	False
DDI-MedLine.d22.s1	derived	147	153	O	derived	ved	ived	VBN	False
DDI-MedLine.d22.s1	from	155	158	O	from	rom	from	IN	False
DDI-MedLine.d22.s1	rat	160	162	O	rat	rat	rat	NN	False
DDI-MedLine.d22.s1	liver	164	168	O	liver	ver	iver	NN	False
DDI-MedLine.d22.s1	.	169	169	O	.	.	.	.	False

DDI-MedLine.d22.s2	By	0	1	O	By	By	By	IN	False
DDI-MedLine.d22.s2	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d22.s2	,	11	11	O	,	,	,	,	False
DDI-MedLine.d22.s2	spermidine	13	22	B-drug_n	spermidine	ine	dine	NN	drug
DDI-MedLine.d22.s2	(	24	24	O	(	(	(	(	False
DDI-MedLine.d22.s2	1	25	25	O	1	1	1	CD	False
DDI-MedLine.d22.s2	mM	27	28	O	mM	mM	mM	NN	False
DDI-MedLine.d22.s2	)	29	29	O	)	)	)	)	False
DDI-MedLine.d22.s2	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d22.s2	putrescine	35	44	B-drug_n	putrescine	ine	cine	NN	drug
DDI-MedLine.d22.s2	(	46	46	O	(	(	(	(	False
DDI-MedLine.d22.s2	1	47	47	O	1	1	1	CD	False
DDI-MedLine.d22.s2	mM	49	50	O	mM	mM	mM	NN	False
DDI-MedLine.d22.s2	)	51	51	O	)	)	)	)	False
DDI-MedLine.d22.s2	had	53	55	O	had	had	had	VBD	False
DDI-MedLine.d22.s2	no	57	58	O	no	no	no	DT	False
DDI-MedLine.d22.s2	significant	60	70	O	significant	ant	cant	JJ	False
DDI-MedLine.d22.s2	effect	72	77	O	effect	ect	fect	NN	False
DDI-MedLine.d22.s2	on	79	80	O	on	on	on	IN	False
DDI-MedLine.d22.s2	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d22.s2	translocation	86	98	O	translocation	ion	tion	NN	False
DDI-MedLine.d22.s2	when	100	103	O	when	hen	when	WRB	False
DDI-MedLine.d22.s2	added	105	109	O	added	ded	dded	VBD	False
DDI-MedLine.d22.s2	alone	111	115	O	alone	one	lone	RB	False
DDI-MedLine.d22.s2	.	116	116	O	.	.	.	.	False

DDI-MedLine.d22.s3	Spermine	0	7	B-drug	Spermine	ine	mine	NN	drug
DDI-MedLine.d22.s3	,	8	8	O	,	,	,	,	False
DDI-MedLine.d22.s3	and	10	12	O	and	and	and	CC	False
DDI-MedLine.d22.s3	to	14	15	O	to	to	to	TO	False
DDI-MedLine.d22.s3	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d22.s3	lesser	19	24	O	lesser	ser	sser	NN	False
DDI-MedLine.d22.s3	extent	26	31	O	extent	ent	tent	NN	False
DDI-MedLine.d22.s3	,	32	32	O	,	,	,	,	False
DDI-MedLine.d22.s3	spermidine	34	43	B-drug_n	spermidine	ine	dine	NN	drug
DDI-MedLine.d22.s3	,	44	44	O	,	,	,	,	False
DDI-MedLine.d22.s3	enhanced	46	53	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d22.s3	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d22.s3	translocating	59	71	O	translocating	ing	ting	VBG	False
DDI-MedLine.d22.s3	action	73	78	O	action	ion	tion	NN	False
DDI-MedLine.d22.s3	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d22.s3	oleate	83	88	O	oleate	ate	eate	NN	False
DDI-MedLine.d22.s3	and	90	92	O	and	and	and	CC	False
DDI-MedLine.d22.s3	increased	94	102	O	increased	sed	ased	VBN	False
DDI-MedLine.d22.s3	its	104	106	O	its	its	its	PRP$	False
DDI-MedLine.d22.s3	effectiveness	108	120	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d22.s3	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d22.s3	transferring	125	136	O	transferring	ing	ring	VBG	False
DDI-MedLine.d22.s3	the	138	140	O	the	the	the	DT	False
DDI-MedLine.d22.s3	phosphohydrolase	142	157	O	phosphohydrolase	ase	lase	NN	False
DDI-MedLine.d22.s3	from	159	162	O	from	rom	from	IN	False
DDI-MedLine.d22.s3	the	164	166	O	the	the	the	DT	False
DDI-MedLine.d22.s3	soluble	168	174	O	soluble	ble	uble	JJ	False
DDI-MedLine.d22.s3	to	176	177	O	to	to	to	TO	False
DDI-MedLine.d22.s3	the	179	181	O	the	the	the	DT	False
DDI-MedLine.d22.s3	microsomal	183	192	O	microsomal	mal	omal	NN	False
DDI-MedLine.d22.s3	fraction	194	201	O	fraction	ion	tion	NN	False
DDI-MedLine.d22.s3	.	202	202	O	.	.	.	.	False

DDI-MedLine.d22.s4	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d22.s4	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d22.s4	proposed	6	13	O	proposed	sed	osed	VBN	False
DDI-MedLine.d22.s4	that	15	18	O	that	hat	that	IN	False
DDI-MedLine.d22.s4	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d22.s4	phosphohydrolase	24	39	O	phosphohydrolase	ase	lase	NN	False
DDI-MedLine.d22.s4	becomes	41	47	O	becomes	mes	omes	NNS	False
DDI-MedLine.d22.s4	metabolically	49	61	O	metabolically	lly	ally	RB	False
DDI-MedLine.d22.s4	active	63	68	O	active	ive	tive	JJ	False
DDI-MedLine.d22.s4	when	70	73	O	when	hen	when	WRB	False
DDI-MedLine.d22.s4	it	75	76	O	it	it	it	PRP	False
DDI-MedLine.d22.s4	combines	78	85	O	combines	nes	ines	NNS	group
DDI-MedLine.d22.s4	with	87	90	O	with	ith	with	IN	False
DDI-MedLine.d22.s4	membranes	92	100	O	membranes	nes	anes	NNS	False
DDI-MedLine.d22.s4	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d22.s4	that	106	109	O	that	hat	that	IN	False
DDI-MedLine.d22.s4	polyamines	111	120	O	polyamines	nes	ines	NNS	group
DDI-MedLine.d22.s4	might	122	126	O	might	ght	ight	MD	False
DDI-MedLine.d22.s4	help	128	131	O	help	elp	help	NN	False
DDI-MedLine.d22.s4	to	133	134	O	to	to	to	TO	False
DDI-MedLine.d22.s4	regulate	136	143	O	regulate	ate	late	NN	False
DDI-MedLine.d22.s4	this	145	148	O	this	his	this	DT	False
DDI-MedLine.d22.s4	interaction	150	160	O	interaction	ion	tion	NN	False
DDI-MedLine.d22.s4	.	161	161	O	.	.	.	.	False

DDI-MedLine.d22.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d22.s5	could	5	9	O	could	uld	ould	MD	False
DDI-MedLine.d22.s5	facilitate	11	20	O	facilitate	ate	tate	NN	False
DDI-MedLine.d22.s5	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d22.s5	action	26	31	O	action	ion	tion	NN	False
DDI-MedLine.d22.s5	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d22.s5	fatty	36	40	O	fatty	tty	atty	NN	False
DDI-MedLine.d22.s5	acids	42	46	O	acids	ids	cids	NNS	False
DDI-MedLine.d22.s5	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d22.s5	enable	52	57	O	enable	ble	able	JJ	False
DDI-MedLine.d22.s5	cells	59	63	O	cells	lls	ells	NNS	False
DDI-MedLine.d22.s5	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d22.s5	increase	68	75	O	increase	ase	ease	NN	False
DDI-MedLine.d22.s5	their	77	81	O	their	eir	heir	PRP$	False
DDI-MedLine.d22.s5	capacity	83	90	O	capacity	ity	city	NN	False
DDI-MedLine.d22.s5	for	92	94	O	for	for	for	IN	False
DDI-MedLine.d22.s5	triacylglycerol	96	110	O	triacylglycerol	rol	erol	NN	False
DDI-MedLine.d22.s5	synthesis	112	120	O	synthesis	sis	esis	NN	False
DDI-MedLine.d22.s5	to	122	123	O	to	to	to	TO	False
DDI-MedLine.d22.s5	match	125	129	O	match	tch	atch	NN	False
DDI-MedLine.d22.s5	an	131	132	O	an	an	an	DT	False
DDI-MedLine.d22.s5	increased	134	142	O	increased	sed	ased	VBN	False
DDI-MedLine.d22.s5	availability	144	155	O	availability	ity	lity	NN	False
DDI-MedLine.d22.s5	of	157	158	O	of	of	of	IN	False
DDI-MedLine.d22.s5	fatty	160	164	O	fatty	tty	atty	NN	False
DDI-MedLine.d22.s5	acids	166	170	O	acids	ids	cids	NNS	False
DDI-MedLine.d22.s5	.	171	171	O	.	.	.	.	False

DDI-MedLine.d109.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d109.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d109.s0	rofecoxib	10	18	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s0	on	20	21	O	on	on	on	IN	False
DDI-MedLine.d109.s0	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d109.s0	pharmacokinetics	27	42	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d109.s0	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d109.s0	digoxin	47	53	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s0	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d109.s0	healthy	58	64	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d109.s0	volunteers	66	75	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d109.s0	.	76	76	O	.	.	.	.	False

DDI-MedLine.d109.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d109.s1	authors	4	10	O	authors	ors	hors	NNS	False
DDI-MedLine.d109.s1	examined	12	19	O	examined	ned	ined	VBN	False
DDI-MedLine.d109.s1	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d109.s1	effect	25	30	O	effect	ect	fect	NN	False
DDI-MedLine.d109.s1	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d109.s1	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d109.s1	cyclooxygenase-2	39	54	O	cyclooxygenase-2	e-2	se-2	NN	False
DDI-MedLine.d109.s1	(	56	56	O	(	(	(	(	False
DDI-MedLine.d109.s1	COX-2	57	61	O	COX-2	X-2	OX-2	NN	brand
DDI-MedLine.d109.s1	)	62	62	O	)	)	)	)	False
DDI-MedLine.d109.s1	inhibitor	64	72	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d109.s1	,	73	73	O	,	,	,	,	False
DDI-MedLine.d109.s1	rofecoxib	75	83	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s1	,	84	84	O	,	,	,	,	False
DDI-MedLine.d109.s1	at	86	87	O	at	at	at	IN	False
DDI-MedLine.d109.s1	steady	89	94	O	steady	ady	eady	JJ	False
DDI-MedLine.d109.s1	state	96	100	O	state	ate	tate	NN	False
DDI-MedLine.d109.s1	on	102	103	O	on	on	on	IN	False
DDI-MedLine.d109.s1	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d109.s1	pharmacokinetics	109	124	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d109.s1	of	126	127	O	of	of	of	IN	False
DDI-MedLine.d109.s1	digoxin	129	135	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s1	following	137	145	O	following	ing	wing	VBG	False
DDI-MedLine.d109.s1	a	147	147	O	a	a	a	DT	False
DDI-MedLine.d109.s1	single	149	154	O	single	gle	ngle	JJ	False
DDI-MedLine.d109.s1	dose	156	159	O	dose	ose	dose	NN	False
DDI-MedLine.d109.s1	in	161	162	O	in	in	in	IN	False
DDI-MedLine.d109.s1	healthy	164	170	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d109.s1	subjects	172	179	O	subjects	cts	ects	NNS	False
DDI-MedLine.d109.s1	.	180	180	O	.	.	.	.	False

DDI-MedLine.d109.s2	Each	0	3	O	Each	ach	Each	DT	False
DDI-MedLine.d109.s2	healthy	5	11	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d109.s2	subject	13	19	O	subject	ect	ject	NN	False
DDI-MedLine.d109.s2	(	21	21	O	(	(	(	(	False
DDI-MedLine.d109.s2	N	22	22	O	N	N	N	NN	brand
DDI-MedLine.d109.s2	=	24	24	O	=	=	=	NN	False
DDI-MedLine.d109.s2	10	26	27	O	10	10	10	CD	False
DDI-MedLine.d109.s2	)	28	28	O	)	)	)	)	False
DDI-MedLine.d109.s2	received	30	37	O	received	ved	ived	VBN	False
DDI-MedLine.d109.s2	rofecoxib	39	47	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s2	(	49	49	O	(	(	(	(	False
DDI-MedLine.d109.s2	75	50	51	O	75	75	75	CD	False
DDI-MedLine.d109.s2	mg	53	54	O	mg	mg	mg	NN	False
DDI-MedLine.d109.s2	once	56	59	O	once	nce	once	RB	False
DDI-MedLine.d109.s2	daily	61	65	O	daily	ily	aily	JJ	False
DDI-MedLine.d109.s2	)	66	66	O	)	)	)	)	False
DDI-MedLine.d109.s2	or	68	69	O	or	or	or	CC	False
DDI-MedLine.d109.s2	placebo	71	77	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d109.s2	for	79	81	O	for	for	for	IN	False
DDI-MedLine.d109.s2	11	83	84	O	11	11	11	CD	False
DDI-MedLine.d109.s2	days	86	89	O	days	ays	days	NNS	False
DDI-MedLine.d109.s2	in	91	92	O	in	in	in	IN	False
DDI-MedLine.d109.s2	a	94	94	O	a	a	a	DT	False
DDI-MedLine.d109.s2	double-blind	96	107	O	double-blind	ind	lind	NN	False
DDI-MedLine.d109.s2	,	108	108	O	,	,	,	,	False
DDI-MedLine.d109.s2	randomized	110	119	O	randomized	zed	ized	VBN	False
DDI-MedLine.d109.s2	,	120	120	O	,	,	,	,	False
DDI-MedLine.d109.s2	balanced	122	129	O	balanced	ced	nced	VBN	False
DDI-MedLine.d109.s2	,	130	130	O	,	,	,	,	False
DDI-MedLine.d109.s2	two-period	132	141	O	two-period	iod	riod	NN	False
DDI-MedLine.d109.s2	crossover	143	151	O	crossover	ver	over	NN	False
DDI-MedLine.d109.s2	study	153	157	O	study	udy	tudy	NN	False
DDI-MedLine.d109.s2	.	158	158	O	.	.	.	.	False

DDI-MedLine.d109.s3	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d109.s3	single	2	7	O	single	gle	ngle	JJ	False
DDI-MedLine.d109.s3	0.5	9	11	O	0.5	0.5	0.5	CD	False
DDI-MedLine.d109.s3	mg	13	14	O	mg	mg	mg	NN	False
DDI-MedLine.d109.s3	oral	16	19	O	oral	ral	oral	JJ	False
DDI-MedLine.d109.s3	dose	21	24	O	dose	ose	dose	NN	False
DDI-MedLine.d109.s3	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d109.s3	digoxin	29	35	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s3	elixir	37	42	O	elixir	xir	ixir	NN	False
DDI-MedLine.d109.s3	was	44	46	O	was	was	was	VBD	False
DDI-MedLine.d109.s3	administered	48	59	O	administered	red	ered	VBN	False
DDI-MedLine.d109.s3	on	61	62	O	on	on	on	IN	False
DDI-MedLine.d109.s3	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d109.s3	7th	68	70	O	7th	7th	7th	NNS	False
DDI-MedLine.d109.s3	day	72	74	O	day	day	day	NN	False
DDI-MedLine.d109.s3	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d109.s3	each	79	82	O	each	ach	each	DT	False
DDI-MedLine.d109.s3	11-day	84	89	O	11-day	day	-day	JJ	False
DDI-MedLine.d109.s3	period	91	96	O	period	iod	riod	NN	False
DDI-MedLine.d109.s3	.	97	97	O	.	.	.	.	False

DDI-MedLine.d109.s4	Each	0	3	O	Each	ach	Each	DT	False
DDI-MedLine.d109.s4	treatment	5	13	O	treatment	ent	ment	NN	False
DDI-MedLine.d109.s4	period	15	20	O	period	iod	riod	NN	False
DDI-MedLine.d109.s4	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d109.s4	separated	26	34	O	separated	ted	ated	VBN	False
DDI-MedLine.d109.s4	by	36	37	O	by	by	by	IN	False
DDI-MedLine.d109.s4	14	39	40	O	14	14	14	CD	False
DDI-MedLine.d109.s4	to	42	43	O	to	to	to	TO	False
DDI-MedLine.d109.s4	21	45	46	O	21	21	21	CD	False
DDI-MedLine.d109.s4	days	48	51	O	days	ays	days	NNS	False
DDI-MedLine.d109.s4	.	52	52	O	.	.	.	.	False

DDI-MedLine.d109.s5	Samples	0	6	O	Samples	les	ples	NNS	False
DDI-MedLine.d109.s5	for	8	10	O	for	for	for	IN	False
DDI-MedLine.d109.s5	plasma	12	17	O	plasma	sma	asma	NN	False
DDI-MedLine.d109.s5	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d109.s5	urine	23	27	O	urine	ine	rine	NN	drug
DDI-MedLine.d109.s5	immunoreactive	29	42	O	immunoreactive	ive	tive	JJ	False
DDI-MedLine.d109.s5	digoxin	44	50	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s5	concentrations	52	65	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d109.s5	were	67	70	O	were	ere	were	VBD	False
DDI-MedLine.d109.s5	collected	72	80	O	collected	ted	cted	VBN	False
DDI-MedLine.d109.s5	through	82	88	O	through	ugh	ough	IN	False
DDI-MedLine.d109.s5	120	90	92	O	120	120	120	CD	False
DDI-MedLine.d109.s5	hours	94	98	O	hours	urs	ours	NNS	False
DDI-MedLine.d109.s5	following	100	108	O	following	ing	wing	VBG	False
DDI-MedLine.d109.s5	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d109.s5	digoxin	114	120	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s5	dose	122	125	O	dose	ose	dose	NN	False
DDI-MedLine.d109.s5	.	126	126	O	.	.	.	.	False

DDI-MedLine.d109.s6	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d109.s6	statistically	3	15	O	statistically	lly	ally	RB	False
DDI-MedLine.d109.s6	significant	17	27	O	significant	ant	cant	JJ	False
DDI-MedLine.d109.s6	differences	29	39	O	differences	ces	nces	NNS	False
DDI-MedLine.d109.s6	between	41	47	O	between	een	ween	IN	False
DDI-MedLine.d109.s6	treatment	49	57	O	treatment	ent	ment	NN	False
DDI-MedLine.d109.s6	groups	59	64	O	groups	ups	oups	NNS	False
DDI-MedLine.d109.s6	were	66	69	O	were	ere	were	VBD	False
DDI-MedLine.d109.s6	observed	71	78	O	observed	ved	rved	VBN	False
DDI-MedLine.d109.s6	for	80	82	O	for	for	for	IN	False
DDI-MedLine.d109.s6	any	84	86	O	any	any	any	DT	False
DDI-MedLine.d109.s6	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d109.s6	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d109.s6	calculated	95	104	O	calculated	ted	ated	VBN	False
DDI-MedLine.d109.s6	digoxin	106	112	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s6	pharmacokinetic	114	128	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d109.s6	parameters	130	139	O	parameters	ers	ters	NNS	False
DDI-MedLine.d109.s6	.	140	140	O	.	.	.	.	False

DDI-MedLine.d109.s7	For	0	2	O	For	For	For	IN	False
DDI-MedLine.d109.s7	digoxin	4	10	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s7	AUC	12	14	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d109.s7	(	15	15	O	(	(	(	(	False
DDI-MedLine.d109.s7	0-infinity	16	25	O	0-infinity	ity	nity	NN	False
DDI-MedLine.d109.s7	)	26	26	O	)	)	)	)	False
DDI-MedLine.d109.s7	,	27	27	O	,	,	,	,	False
DDI-MedLine.d109.s7	AUC	29	31	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d109.s7	(	32	32	O	(	(	(	(	False
DDI-MedLine.d109.s7	0-24	33	36	O	0-24	-24	0-24	NN	False
DDI-MedLine.d109.s7	)	37	37	O	)	)	)	)	False
DDI-MedLine.d109.s7	,	38	38	O	,	,	,	,	False
DDI-MedLine.d109.s7	and	40	42	O	and	and	and	CC	False
DDI-MedLine.d109.s7	Cmax	44	47	O	Cmax	max	Cmax	NN	False
DDI-MedLine.d109.s7	,	48	48	O	,	,	,	,	False
DDI-MedLine.d109.s7	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d109.s7	geometric	54	62	O	geometric	ric	tric	NN	False
DDI-MedLine.d109.s7	mean	64	67	O	mean	ean	mean	NN	False
DDI-MedLine.d109.s7	ratios	69	74	O	ratios	ios	tios	NNS	False
DDI-MedLine.d109.s7	(	76	76	O	(	(	(	(	False
DDI-MedLine.d109.s7	90	77	78	O	90	90	90	CD	False
DDI-MedLine.d109.s7	%	79	79	O	%	%	%	NN	False
DDI-MedLine.d109.s7	confidence	81	90	O	confidence	nce	ence	NN	False
DDI-MedLine.d109.s7	interval	92	99	O	interval	val	rval	NN	False
DDI-MedLine.d109.s7	)	100	100	O	)	)	)	)	False
DDI-MedLine.d109.s7	for	102	104	O	for	for	for	IN	False
DDI-MedLine.d109.s7	(	106	106	O	(	(	(	(	False
DDI-MedLine.d109.s7	rofecoxib	107	115	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s7	+	117	117	O	+	+	+	NN	False
DDI-MedLine.d109.s7	digoxin/placebo	119	133	O	digoxin/placebo	ebo	cebo	NN	False
DDI-MedLine.d109.s7	+	135	135	O	+	+	+	NN	False
DDI-MedLine.d109.s7	digoxin	137	143	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s7	)	144	144	O	)	)	)	)	False
DDI-MedLine.d109.s7	were	146	149	O	were	ere	were	VBD	False
DDI-MedLine.d109.s7	1.04	151	154	O	1.04	.04	1.04	CD	False
DDI-MedLine.d109.s7	(	156	156	O	(	(	(	(	False
DDI-MedLine.d109.s7	0.94	157	160	O	0.94	.94	0.94	CD	False
DDI-MedLine.d109.s7	,	161	161	O	,	,	,	,	False
DDI-MedLine.d109.s7	1.14	163	166	O	1.14	.14	1.14	CD	False
DDI-MedLine.d109.s7	)	167	167	O	)	)	)	)	False
DDI-MedLine.d109.s7	,	168	168	O	,	,	,	,	False
DDI-MedLine.d109.s7	1.02	170	173	O	1.02	.02	1.02	CD	False
DDI-MedLine.d109.s7	(	175	175	O	(	(	(	(	False
DDI-MedLine.d109.s7	0.94	176	179	O	0.94	.94	0.94	CD	False
DDI-MedLine.d109.s7	,	180	180	O	,	,	,	,	False
DDI-MedLine.d109.s7	1.09	182	185	O	1.09	.09	1.09	CD	False
DDI-MedLine.d109.s7	)	186	186	O	)	)	)	)	False
DDI-MedLine.d109.s7	,	187	187	O	,	,	,	,	False
DDI-MedLine.d109.s7	and	189	191	O	and	and	and	CC	False
DDI-MedLine.d109.s7	1.00	193	196	O	1.00	.00	1.00	CD	False
DDI-MedLine.d109.s7	(	198	198	O	(	(	(	(	False
DDI-MedLine.d109.s7	0.91	199	202	O	0.91	.91	0.91	CD	False
DDI-MedLine.d109.s7	,	203	203	O	,	,	,	,	False
DDI-MedLine.d109.s7	1.10	205	208	O	1.10	.10	1.10	CD	False
DDI-MedLine.d109.s7	)	209	209	O	)	)	)	)	False
DDI-MedLine.d109.s7	,	210	210	O	,	,	,	,	False
DDI-MedLine.d109.s7	respectively	212	223	O	respectively	ely	vely	RB	False
DDI-MedLine.d109.s7	.	224	224	O	.	.	.	.	False

DDI-MedLine.d109.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d109.s8	digoxin	4	10	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s8	median	12	17	O	median	ian	dian	NN	False
DDI-MedLine.d109.s8	tmax	19	22	O	tmax	max	tmax	NN	False
DDI-MedLine.d109.s8	was	24	26	O	was	was	was	VBD	False
DDI-MedLine.d109.s8	0.5	28	30	O	0.5	0.5	0.5	CD	False
DDI-MedLine.d109.s8	hours	32	36	O	hours	urs	ours	NNS	False
DDI-MedLine.d109.s8	for	38	40	O	for	for	for	IN	False
DDI-MedLine.d109.s8	both	42	45	O	both	oth	both	DT	False
DDI-MedLine.d109.s8	treatments	47	56	O	treatments	nts	ents	NNS	False
DDI-MedLine.d109.s8	.	57	57	O	.	.	.	.	False

DDI-MedLine.d109.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d109.s9	harmonic	4	11	O	harmonic	nic	onic	NN	False
DDI-MedLine.d109.s9	mean	13	16	O	mean	ean	mean	NN	False
DDI-MedLine.d109.s9	elimination	18	28	O	elimination	ion	tion	NN	False
DDI-MedLine.d109.s9	half-life	30	38	O	half-life	ife	life	NN	False
DDI-MedLine.d109.s9	was	40	42	O	was	was	was	VBD	False
DDI-MedLine.d109.s9	45.7	44	47	O	45.7	5.7	45.7	CD	False
DDI-MedLine.d109.s9	and	49	51	O	and	and	and	CC	False
DDI-MedLine.d109.s9	43.4	53	56	O	43.4	3.4	43.4	CD	False
DDI-MedLine.d109.s9	hours	58	62	O	hours	urs	ours	NNS	False
DDI-MedLine.d109.s9	for	64	66	O	for	for	for	IN	False
DDI-MedLine.d109.s9	rofecoxib	68	76	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s9	+	78	78	O	+	+	+	NN	False
DDI-MedLine.d109.s9	digoxin	80	86	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s9	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d109.s9	placebo	92	98	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d109.s9	+	100	100	O	+	+	+	NN	False
DDI-MedLine.d109.s9	digoxin	102	108	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s9	treatments	110	119	O	treatments	nts	ents	NNS	False
DDI-MedLine.d109.s9	,	120	120	O	,	,	,	,	False
DDI-MedLine.d109.s9	respectively	122	133	O	respectively	ely	vely	RB	False
DDI-MedLine.d109.s9	.	134	134	O	.	.	.	.	False

DDI-MedLine.d109.s10	Digoxin	0	6	B-drug	Digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s10	is	8	9	O	is	is	is	VBZ	False
DDI-MedLine.d109.s10	eliminated	11	20	O	eliminated	ted	ated	VBN	False
DDI-MedLine.d109.s10	renally	22	28	O	renally	lly	ally	RB	False
DDI-MedLine.d109.s10	.	29	29	O	.	.	.	.	False

DDI-MedLine.d109.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d109.s11	mean	4	7	O	mean	ean	mean	NN	False
DDI-MedLine.d109.s11	(	9	9	O	(	(	(	(	False
DDI-MedLine.d109.s11	SD	10	11	O	SD	SD	SD	NN	brand
DDI-MedLine.d109.s11	)	12	12	O	)	)	)	)	False
DDI-MedLine.d109.s11	cumulative	14	23	O	cumulative	ive	tive	JJ	False
DDI-MedLine.d109.s11	urinary	25	31	O	urinary	ary	nary	JJ	False
DDI-MedLine.d109.s11	excretion	33	41	O	excretion	ion	tion	NN	False
DDI-MedLine.d109.s11	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d109.s11	immunoreactive	46	59	O	immunoreactive	ive	tive	JJ	False
DDI-MedLine.d109.s11	digoxin	61	67	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s11	after	69	73	O	after	ter	fter	IN	False
DDI-MedLine.d109.s11	concurrent	75	84	O	concurrent	ent	rent	NN	False
DDI-MedLine.d109.s11	treatment	86	94	O	treatment	ent	ment	NN	False
DDI-MedLine.d109.s11	with	96	99	O	with	ith	with	IN	False
DDI-MedLine.d109.s11	rofecoxib	101	109	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s11	or	111	112	O	or	or	or	CC	False
DDI-MedLine.d109.s11	placebo	114	120	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d109.s11	was	122	124	O	was	was	was	VBD	False
DDI-MedLine.d109.s11	228.2	126	130	O	228.2	8.2	28.2	CD	False
DDI-MedLine.d109.s11	(	132	132	O	(	(	(	(	False
DDI-MedLine.d109.s11	+/-	133	135	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d109.s11	30.8	137	140	O	30.8	0.8	30.8	CD	False
DDI-MedLine.d109.s11	)	141	141	O	)	)	)	)	False
DDI-MedLine.d109.s11	and	143	145	O	and	and	and	CC	False
DDI-MedLine.d109.s11	235.1	147	151	O	235.1	5.1	35.1	CD	False
DDI-MedLine.d109.s11	(	153	153	O	(	(	(	(	False
DDI-MedLine.d109.s11	+/-	154	156	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d109.s11	39.1	158	161	O	39.1	9.1	39.1	CD	False
DDI-MedLine.d109.s11	)	162	162	O	)	)	)	)	False
DDI-MedLine.d109.s11	micrograms/120	164	177	O	micrograms/120	120	/120	NN	False
DDI-MedLine.d109.s11	hours	179	183	O	hours	urs	ours	NNS	False
DDI-MedLine.d109.s11	,	184	184	O	,	,	,	,	False
DDI-MedLine.d109.s11	respectively	186	197	O	respectively	ely	vely	RB	False
DDI-MedLine.d109.s11	.	198	198	O	.	.	.	.	False

DDI-MedLine.d109.s12	Transient	0	8	O	Transient	ent	ient	NN	False
DDI-MedLine.d109.s12	and	10	12	O	and	and	and	CC	False
DDI-MedLine.d109.s12	minor	14	18	O	minor	nor	inor	NN	False
DDI-MedLine.d109.s12	adverse	20	26	O	adverse	rse	erse	NN	False
DDI-MedLine.d109.s12	events	28	33	O	events	nts	ents	NNS	False
DDI-MedLine.d109.s12	occurred	35	42	O	occurred	red	rred	VBD	False
DDI-MedLine.d109.s12	with	44	47	O	with	ith	with	IN	False
DDI-MedLine.d109.s12	similar	49	55	O	similar	lar	ilar	JJ	False
DDI-MedLine.d109.s12	frequency	57	65	O	frequency	ncy	ency	NN	False
DDI-MedLine.d109.s12	on	67	68	O	on	on	on	IN	False
DDI-MedLine.d109.s12	placebo	70	76	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d109.s12	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d109.s12	rofecoxib	82	90	B-drug	rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s12	treatments	92	101	O	treatments	nts	ents	NNS	False
DDI-MedLine.d109.s12	,	102	102	O	,	,	,	,	False
DDI-MedLine.d109.s12	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d109.s12	no	108	109	O	no	no	no	DT	False
DDI-MedLine.d109.s12	treatment-related	111	127	O	treatment-related	ted	ated	JJ	False
DDI-MedLine.d109.s12	pattern	129	135	O	pattern	ern	tern	NN	False
DDI-MedLine.d109.s12	was	137	139	O	was	was	was	VBD	False
DDI-MedLine.d109.s12	apparent	141	148	O	apparent	ent	rent	NN	False
DDI-MedLine.d109.s12	.	149	149	O	.	.	.	.	False

DDI-MedLine.d109.s13	Rofecoxib	0	8	B-drug	Rofecoxib	xib	oxib	NN	False
DDI-MedLine.d109.s13	did	10	12	O	did	did	did	VBD	False
DDI-MedLine.d109.s13	not	14	16	O	not	not	not	RB	False
DDI-MedLine.d109.s13	influence	18	26	O	influence	nce	ence	NN	False
DDI-MedLine.d109.s13	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d109.s13	plasma	32	37	O	plasma	sma	asma	NN	False
DDI-MedLine.d109.s13	pharmacokinetics	39	54	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d109.s13	or	56	57	O	or	or	or	CC	False
DDI-MedLine.d109.s13	renal	59	63	O	renal	nal	enal	NN	False
DDI-MedLine.d109.s13	elimination	65	75	O	elimination	ion	tion	NN	False
DDI-MedLine.d109.s13	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d109.s13	a	80	80	O	a	a	a	DT	False
DDI-MedLine.d109.s13	single	82	87	O	single	gle	ngle	JJ	False
DDI-MedLine.d109.s13	oral	89	92	O	oral	ral	oral	JJ	False
DDI-MedLine.d109.s13	dose	94	97	O	dose	ose	dose	NN	False
DDI-MedLine.d109.s13	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d109.s13	digoxin	102	108	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d109.s13	.	109	109	O	.	.	.	.	False

DDI-MedLine.d106.s0	Clinical	0	7	O	Clinical	cal	ical	JJ	False
DDI-MedLine.d106.s0	implications	9	20	O	implications	ons	ions	NNS	False
DDI-MedLine.d106.s0	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d106.s0	warfarin	25	32	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d106.s0	interactions	34	45	O	interactions	ons	ions	NNS	False
DDI-MedLine.d106.s0	with	47	50	O	with	ith	with	IN	False
DDI-MedLine.d106.s0	five	52	55	O	five	ive	five	CD	False
DDI-MedLine.d106.s0	sedatives	57	65	B-group	sedatives	ves	ives	NNS	False
DDI-MedLine.d106.s0	.	66	66	O	.	.	.	.	False

DDI-MedLine.d106.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d106.s1	intensity	4	12	O	intensity	ity	sity	NN	False
DDI-MedLine.d106.s1	,	13	13	O	,	,	,	,	False
DDI-MedLine.d106.s1	uniformity	15	24	O	uniformity	ity	mity	NN	False
DDI-MedLine.d106.s1	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d106.s1	time	30	33	O	time	ime	time	NN	False
DDI-MedLine.d106.s1	course	35	40	O	course	rse	urse	NN	False
DDI-MedLine.d106.s1	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d106.s1	anticoagulant	45	57	B-group	anticoagulant	ant	lant	NN	False
DDI-MedLine.d106.s1	interference	59	70	O	interference	nce	ence	NN	False
DDI-MedLine.d106.s1	by	72	73	O	by	by	by	IN	False
DDI-MedLine.d106.s1	phenobarbital	75	87	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d106.s1	,	88	88	O	,	,	,	,	False
DDI-MedLine.d106.s1	secobarbital	90	101	B-drug	secobarbital	tal	ital	NN	False
DDI-MedLine.d106.s1	,	102	102	O	,	,	,	,	False
DDI-MedLine.d106.s1	glutethimide	104	115	B-drug	glutethimide	ide	mide	NN	False
DDI-MedLine.d106.s1	,	116	116	O	,	,	,	,	False
DDI-MedLine.d106.s1	chloral	118	124	B-drug	chloral	ral	oral	JJ	False
DDI-MedLine.d106.s1	hydrate	126	132	I-drug	hydrate	ate	rate	NN	False
DDI-MedLine.d106.s1	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d106.s1	methaqualone	138	149	B-drug	methaqualone	one	lone	NN	False
DDI-MedLine.d106.s1	were	151	154	O	were	ere	were	VBD	False
DDI-MedLine.d106.s1	systematically	156	169	O	systematically	lly	ally	RB	False
DDI-MedLine.d106.s1	investigated	171	182	O	investigated	ted	ated	VBN	False
DDI-MedLine.d106.s1	in	184	185	O	in	in	in	IN	False
DDI-MedLine.d106.s1	16	187	188	O	16	16	16	CD	False
DDI-MedLine.d106.s1	patients	190	197	O	patients	nts	ents	NNS	False
DDI-MedLine.d106.s1	receiving	199	207	O	receiving	ing	ving	VBG	False
DDI-MedLine.d106.s1	coumarin	209	216	B-group	coumarin	rin	arin	NN	False
DDI-MedLine.d106.s1	therapy	218	224	O	therapy	apy	rapy	NN	False
DDI-MedLine.d106.s1	.	225	225	O	.	.	.	.	False

DDI-MedLine.d106.s2	Each	0	3	O	Each	ach	Each	DT	False
DDI-MedLine.d106.s2	subject	5	11	O	subject	ect	ject	NN	False
DDI-MedLine.d106.s2	received	13	20	O	received	ved	ived	VBN	False
DDI-MedLine.d106.s2	an	22	23	O	an	an	an	DT	False
DDI-MedLine.d106.s2	individualized	25	38	O	individualized	zed	ized	VBN	False
DDI-MedLine.d106.s2	fixed	40	44	O	fixed	xed	ixed	VBN	False
DDI-MedLine.d106.s2	daily	46	50	O	daily	ily	aily	JJ	False
DDI-MedLine.d106.s2	dose	52	55	O	dose	ose	dose	NN	False
DDI-MedLine.d106.s2	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d106.s2	warfarin	60	67	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d106.s2	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d106.s2	served	73	78	O	served	ved	rved	VBD	False
DDI-MedLine.d106.s2	as	80	81	O	as	as	as	IN	False
DDI-MedLine.d106.s2	his	83	85	O	his	his	his	PRP$	False
DDI-MedLine.d106.s2	own	87	89	O	own	own	own	JJ	False
DDI-MedLine.d106.s2	pre-	91	94	O	pre-	re-	pre-	NN	False
DDI-MedLine.d106.s2	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d106.s2	postsedative	100	111	O	postsedative	ive	tive	NN	False
DDI-MedLine.d106.s2	treatment	113	121	O	treatment	ent	ment	NN	False
DDI-MedLine.d106.s2	control	123	129	O	control	rol	trol	NN	False
DDI-MedLine.d106.s2	.	130	130	O	.	.	.	.	False

DDI-MedLine.d106.s3	Prothrombin	0	10	O	Prothrombin	bin	mbin	NN	False
DDI-MedLine.d106.s3	times	12	16	O	times	mes	imes	NNS	False
DDI-MedLine.d106.s3	were	18	21	O	were	ere	were	VBD	False
DDI-MedLine.d106.s3	measured	23	30	O	measured	red	ured	VBN	False
DDI-MedLine.d106.s3	four	32	35	O	four	our	four	CD	False
DDI-MedLine.d106.s3	times	37	41	O	times	mes	imes	NNS	False
DDI-MedLine.d106.s3	weekly	43	48	O	weekly	kly	ekly	JJ	False
DDI-MedLine.d106.s3	during	50	55	O	during	ing	ring	IN	False
DDI-MedLine.d106.s3	five	57	60	O	five	ive	five	CD	False
DDI-MedLine.d106.s3	long-term	62	70	O	long-term	erm	term	JJ	False
DDI-MedLine.d106.s3	experiments	72	82	O	experiments	nts	ents	NNS	False
DDI-MedLine.d106.s3	.	83	83	O	.	.	.	.	False

DDI-MedLine.d106.s4	Anticoagulant	0	12	O	Anticoagulant	ant	lant	NN	False
DDI-MedLine.d106.s4	inhibition	14	23	O	inhibition	ion	tion	NN	False
DDI-MedLine.d106.s4	was	25	27	O	was	was	was	VBD	False
DDI-MedLine.d106.s4	observed	29	36	O	observed	ved	rved	VBN	False
DDI-MedLine.d106.s4	during	38	43	O	during	ing	ring	IN	False
DDI-MedLine.d106.s4	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d106.s4	administration	49	62	O	administration	ion	tion	NN	False
DDI-MedLine.d106.s4	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d106.s4	phenobarbital	67	79	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d106.s4	,	80	80	O	,	,	,	,	False
DDI-MedLine.d106.s4	secobarbital	82	93	B-drug	secobarbital	tal	ital	NN	False
DDI-MedLine.d106.s4	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d106.s4	glutethimide	99	110	B-drug	glutethimide	ide	mide	NN	False
DDI-MedLine.d106.s4	;	111	111	O	;	;	;	:	False

DDI-MedLine.d106.s5	there	0	4	O	there	ere	here	RB	False
DDI-MedLine.d106.s5	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d106.s5	no	10	11	O	no	no	no	DT	False
DDI-MedLine.d106.s5	significant	13	23	O	significant	ant	cant	JJ	False
DDI-MedLine.d106.s5	change	25	30	O	change	nge	ange	NN	False
DDI-MedLine.d106.s5	in	32	33	O	in	in	in	IN	False
DDI-MedLine.d106.s5	prothrombin	35	45	O	prothrombin	bin	mbin	NN	False
DDI-MedLine.d106.s5	test	47	50	O	test	est	test	NN	False
DDI-MedLine.d106.s5	results	52	58	O	results	lts	ults	NNS	False
DDI-MedLine.d106.s5	during	60	65	O	during	ing	ring	IN	False
DDI-MedLine.d106.s5	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d106.s5	trials	71	76	O	trials	als	ials	NNS	False
DDI-MedLine.d106.s5	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d106.s5	chloral	81	87	B-drug	chloral	ral	oral	JJ	False
DDI-MedLine.d106.s5	hydrate	89	95	I-drug	hydrate	ate	rate	NN	False
DDI-MedLine.d106.s5	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d106.s5	methaqualone	101	112	B-drug	methaqualone	one	lone	NN	False
DDI-MedLine.d106.s5	.	113	113	O	.	.	.	.	False

DDI-MedLine.d106.s6	Barbiturates	0	11	B-group	Barbiturates	tes	ates	NNS	False
DDI-MedLine.d106.s6	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d106.s6	glutethimide	17	28	B-drug	glutethimide	ide	mide	NN	False
DDI-MedLine.d106.s6	should	30	35	O	should	uld	ould	MD	False
DDI-MedLine.d106.s6	not	37	39	O	not	not	not	RB	False
DDI-MedLine.d106.s6	be	41	42	O	be	be	be	VB	False
DDI-MedLine.d106.s6	administered	44	55	O	administered	red	ered	VBN	False
DDI-MedLine.d106.s6	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d106.s6	patients	60	67	O	patients	nts	ents	NNS	False
DDI-MedLine.d106.s6	receiving	69	77	O	receiving	ing	ving	VBG	False
DDI-MedLine.d106.s6	coumarin	79	86	B-group	coumarin	rin	arin	NN	False
DDI-MedLine.d106.s6	drugs	88	92	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d106.s6	.	93	93	O	.	.	.	.	False

DDI-MedLine.d106.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d106.s7	concurrent	4	13	O	concurrent	ent	rent	NN	False
DDI-MedLine.d106.s7	use	15	17	O	use	use	use	NN	False
DDI-MedLine.d106.s7	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d106.s7	drugs	22	26	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d106.s7	from	28	31	O	from	rom	from	IN	False
DDI-MedLine.d106.s7	these	33	37	O	these	ese	hese	DT	False
DDI-MedLine.d106.s7	groups	39	44	O	groups	ups	oups	NNS	False
DDI-MedLine.d106.s7	is	46	47	O	is	is	is	VBZ	False
DDI-MedLine.d106.s7	decreasing	49	58	O	decreasing	ing	sing	VBG	False
DDI-MedLine.d106.s7	according	60	68	O	according	ing	ding	VBG	False
DDI-MedLine.d106.s7	to	70	71	O	to	to	to	TO	False
DDI-MedLine.d106.s7	a	73	73	O	a	a	a	DT	False
DDI-MedLine.d106.s7	survey	75	80	O	survey	vey	rvey	NN	False
DDI-MedLine.d106.s7	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d106.s7	200	85	87	O	200	200	200	CD	False
DDI-MedLine.d106.s7	hospital	89	96	O	hospital	tal	ital	NN	False
DDI-MedLine.d106.s7	medical	98	104	O	medical	cal	ical	JJ	False
DDI-MedLine.d106.s7	records	106	112	O	records	rds	ords	NNS	False
DDI-MedLine.d106.s7	.	113	113	O	.	.	.	.	False

DDI-MedLine.d106.s8	Chloral	0	6	B-drug	Chloral	ral	oral	JJ	False
DDI-MedLine.d106.s8	hydrate	8	14	I-drug	hydrate	ate	rate	NN	False
DDI-MedLine.d106.s8	and	16	18	O	and	and	and	CC	False
DDI-MedLine.d106.s8	methaqualone	20	31	B-drug	methaqualone	one	lone	NN	False
DDI-MedLine.d106.s8	interact	33	40	O	interact	act	ract	NN	False
DDI-MedLine.d106.s8	pharmacologically	42	58	O	pharmacologically	lly	ally	RB	False
DDI-MedLine.d106.s8	with	60	63	O	with	ith	with	IN	False
DDI-MedLine.d106.s8	orally	65	70	O	orally	lly	ally	RB	False
DDI-MedLine.d106.s8	administered	72	83	O	administered	red	ered	VBN	False
DDI-MedLine.d106.s8	anticoagulant	85	97	B-group	anticoagulant	ant	lant	NN	False
DDI-MedLine.d106.s8	agents	99	104	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d106.s8	,	105	105	O	,	,	,	,	False
DDI-MedLine.d106.s8	but	107	109	O	but	but	but	CC	False
DDI-MedLine.d106.s8	the	111	113	O	the	the	the	DT	False
DDI-MedLine.d106.s8	effect	115	120	O	effect	ect	fect	NN	False
DDI-MedLine.d106.s8	is	122	123	O	is	is	is	VBZ	False
DDI-MedLine.d106.s8	not	125	127	O	not	not	not	RB	False
DDI-MedLine.d106.s8	clinically	129	138	O	clinically	lly	ally	RB	False
DDI-MedLine.d106.s8	significant	140	150	O	significant	ant	cant	JJ	False
DDI-MedLine.d106.s8	.	151	151	O	.	.	.	.	False

DDI-MedLine.d106.s9	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d106.s9	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d106.s9	concluded	6	14	O	concluded	ded	uded	VBD	False
DDI-MedLine.d106.s9	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d106.s9	chloral	21	27	B-drug	chloral	ral	oral	JJ	False
DDI-MedLine.d106.s9	hydrate	29	35	I-drug	hydrate	ate	rate	NN	False
DDI-MedLine.d106.s9	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d106.s9	methaqualone	41	52	B-drug	methaqualone	one	lone	NN	False
DDI-MedLine.d106.s9	may	54	56	O	may	may	may	MD	False
DDI-MedLine.d106.s9	be	58	59	O	be	be	be	VB	False
DDI-MedLine.d106.s9	administered	61	72	O	administered	red	ered	VBN	False
DDI-MedLine.d106.s9	safely	74	79	O	safely	ely	fely	RB	False
DDI-MedLine.d106.s9	without	81	87	O	without	out	hout	IN	False
DDI-MedLine.d106.s9	additional	89	98	O	additional	nal	onal	JJ	False
DDI-MedLine.d106.s9	caution	100	106	O	caution	ion	tion	NN	False
DDI-MedLine.d106.s9	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d106.s9	prothrombin	111	121	O	prothrombin	bin	mbin	NN	False
DDI-MedLine.d106.s9	test	123	126	O	test	est	test	NN	False
DDI-MedLine.d106.s9	monitoring	128	137	O	monitoring	ing	ring	NN	False
DDI-MedLine.d106.s9	during	139	144	O	during	ing	ring	IN	False
DDI-MedLine.d106.s9	oral	146	149	O	oral	ral	oral	JJ	False
DDI-MedLine.d106.s9	anticoagulant	151	163	B-group	anticoagulant	ant	lant	NN	False
DDI-MedLine.d106.s9	therapy	165	171	O	therapy	apy	rapy	NN	False
DDI-MedLine.d106.s9	.	172	172	O	.	.	.	.	False

DDI-MedLine.d17.s0	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d17.s0	vitro	3	7	O	vitro	tro	itro	NN	False
DDI-MedLine.d17.s0	interaction	9	19	O	interaction	ion	tion	NN	False
DDI-MedLine.d17.s0	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d17.s0	prostaglandin	24	36	B-drug	prostaglandin	din	ndin	NN	False
DDI-MedLine.d17.s0	F2alpha	38	44	I-drug	F2alpha	pha	lpha	NN	False
DDI-MedLine.d17.s0	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d17.s0	oxytocin	50	57	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d17.s0	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d17.s0	placental	62	70	O	placental	tal	ntal	NN	False
DDI-MedLine.d17.s0	vessels	72	78	O	vessels	els	sels	NNS	False
DDI-MedLine.d17.s0	.	79	79	O	.	.	.	.	False

DDI-MedLine.d17.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d17.s1	interaction	4	14	O	interaction	ion	tion	NN	False
DDI-MedLine.d17.s1	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d17.s1	prostaglandin	19	31	B-drug	prostaglandin	din	ndin	NN	False
DDI-MedLine.d17.s1	F2alpha	33	39	I-drug	F2alpha	pha	lpha	NN	False
DDI-MedLine.d17.s1	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d17.s1	synthetic	45	53	O	synthetic	tic	etic	JJ	False
DDI-MedLine.d17.s1	oxytocin	55	62	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d17.s1	on	64	65	O	on	on	on	IN	False
DDI-MedLine.d17.s1	placental	67	75	O	placental	tal	ntal	NN	False
DDI-MedLine.d17.s1	vessels	77	83	O	vessels	els	sels	NNS	False
DDI-MedLine.d17.s1	was	85	87	O	was	was	was	VBD	False
DDI-MedLine.d17.s1	studied	89	95	O	studied	ied	died	VBN	False
DDI-MedLine.d17.s1	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d17.s1	vitro	100	104	O	vitro	tro	itro	NN	False
DDI-MedLine.d17.s1	.	105	105	O	.	.	.	.	False

DDI-MedLine.d17.s2	Resistance	0	9	O	Resistance	nce	ance	NN	False
DDI-MedLine.d17.s2	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d17.s2	measured	15	22	O	measured	red	ured	VBN	False
DDI-MedLine.d17.s2	near	24	27	O	near	ear	near	IN	False
DDI-MedLine.d17.s2	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d17.s2	placental	33	41	O	placental	tal	ntal	NN	False
DDI-MedLine.d17.s2	margin	43	48	O	margin	gin	rgin	NN	False
DDI-MedLine.d17.s2	after	50	54	O	after	ter	fter	IN	False
DDI-MedLine.d17.s2	spontaneous	56	66	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d17.s2	term	68	71	O	term	erm	term	NN	False
DDI-MedLine.d17.s2	delivery	73	80	O	delivery	ery	very	NN	False
DDI-MedLine.d17.s2	.	81	81	O	.	.	.	.	False

DDI-MedLine.d17.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d17.s3	seven	3	7	O	seven	ven	even	CD	False
DDI-MedLine.d17.s3	experiments	9	19	O	experiments	nts	ents	NNS	False
DDI-MedLine.d17.s3	reactions	21	29	O	reactions	ons	ions	NNS	False
DDI-MedLine.d17.s3	to	31	32	O	to	to	to	TO	False
DDI-MedLine.d17.s3	norepinephrine	34	47	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d17.s3	and	49	51	O	and	and	and	CC	False
DDI-MedLine.d17.s3	oxytocin	53	60	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d17.s3	were	62	65	O	were	ere	were	VBD	False
DDI-MedLine.d17.s3	PGF2alpha	67	75	B-drug	PGF2alpha	pha	lpha	NN	False
DDI-MedLine.d17.s3	.	76	76	O	.	.	.	.	False

DDI-MedLine.d17.s4	PGF2alpha	0	8	B-drug	PGF2alpha	pha	lpha	NN	False
DDI-MedLine.d17.s4	produced	10	17	O	produced	ced	uced	VBN	False
DDI-MedLine.d17.s4	significantly	19	31	O	significantly	tly	ntly	RB	False
DDI-MedLine.d17.s4	increased	33	41	O	increased	sed	ased	VBN	False
DDI-MedLine.d17.s4	vasoconstriction	43	58	O	vasoconstriction	ion	tion	NN	False
DDI-MedLine.d17.s4	after	60	64	O	after	ter	fter	IN	False
DDI-MedLine.d17.s4	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d17.s4	single	68	73	O	single	gle	ngle	JJ	False
DDI-MedLine.d17.s4	administration	75	88	O	administration	ion	tion	NN	False
DDI-MedLine.d17.s4	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d17.s4	oxytocin	93	100	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d17.s4	.	101	101	O	.	.	.	.	False

DDI-MedLine.d17.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d17.s5	eight	3	7	O	eight	ght	ight	CD	False
DDI-MedLine.d17.s5	experiments	9	19	O	experiments	nts	ents	NNS	False
DDI-MedLine.d17.s5	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d17.s5	perfusion	25	33	O	perfusion	ion	sion	NN	False
DDI-MedLine.d17.s5	medium	35	40	O	medium	ium	dium	NN	drug
DDI-MedLine.d17.s5	contained	42	50	O	contained	ned	ined	VBN	False
DDI-MedLine.d17.s5	oxytocin	52	59	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d17.s5	.	60	60	O	.	.	.	.	False

DDI-MedLine.d17.s6	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d17.s6	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d17.s6	no	10	11	O	no	no	no	DT	False
DDI-MedLine.d17.s6	change	13	18	O	change	nge	ange	NN	False
DDI-MedLine.d17.s6	after	20	24	O	after	ter	fter	IN	False
DDI-MedLine.d17.s6	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d17.s6	single	28	33	O	single	gle	ngle	JJ	False
DDI-MedLine.d17.s6	dose	35	38	O	dose	ose	dose	NN	False
DDI-MedLine.d17.s6	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d17.s6	PGF2alpha	43	51	B-drug	PGF2alpha	pha	lpha	NN	False
DDI-MedLine.d17.s6	.	52	52	O	.	.	.	.	False

DDI-MedLine.d17.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d17.s7	reaction	4	11	O	reaction	ion	tion	NN	False
DDI-MedLine.d17.s7	after	13	17	O	after	ter	fter	IN	False
DDI-MedLine.d17.s7	norepinephrine	19	32	B-drug	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d17.s7	remained	34	41	O	remained	ned	ined	VBD	False
DDI-MedLine.d17.s7	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d17.s7	same	47	50	O	same	ame	same	JJ	False
DDI-MedLine.d17.s7	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d17.s7	both	55	58	O	both	oth	both	DT	False
DDI-MedLine.d17.s7	groups	60	65	O	groups	ups	oups	NNS	False
DDI-MedLine.d17.s7	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d17.s7	experiments	70	80	O	experiments	nts	ents	NNS	False
DDI-MedLine.d17.s7	.	81	81	O	.	.	.	.	False

DDI-MedLine.d17.s8	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d17.s8	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d17.s8	thus	9	12	O	thus	hus	thus	RB	False
DDI-MedLine.d17.s8	an	14	15	O	an	an	an	DT	False
DDI-MedLine.d17.s8	enhancement	17	27	O	enhancement	ent	ment	NN	False
DDI-MedLine.d17.s8	effect	29	34	O	effect	ect	fect	NN	False

DDI-MedLine.d17.s9	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d17.s9	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d17.s9	thus	9	12	O	thus	hus	thus	RB	False
DDI-MedLine.d17.s9	an	14	15	O	an	an	an	DT	False
DDI-MedLine.d17.s9	enhancement	17	27	O	enhancement	ent	ment	NN	False
DDI-MedLine.d17.s9	effect	29	34	O	effect	ect	fect	NN	False
DDI-MedLine.d17.s9	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d17.s9	PGF2alpha	39	47	B-drug	PGF2alpha	pha	lpha	NN	False
DDI-MedLine.d17.s9	upon	49	52	O	upon	pon	upon	IN	False
DDI-MedLine.d17.s9	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d17.s9	reaction	58	65	O	reaction	ion	tion	NN	False
DDI-MedLine.d17.s9	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d17.s9	placental	70	78	O	placental	tal	ntal	NN	False
DDI-MedLine.d17.s9	vessels	80	86	O	vessels	els	sels	NNS	False
DDI-MedLine.d17.s9	to	88	89	O	to	to	to	TO	False
DDI-MedLine.d17.s9	oxytocin	91	98	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d17.s9	in	100	101	O	in	in	in	IN	False
DDI-MedLine.d17.s9	vitro	103	107	O	vitro	tro	itro	NN	False
DDI-MedLine.d17.s9	.	108	108	O	.	.	.	.	False

DDI-MedLine.d115.s0	Concomitant	0	10	O	Concomitant	ant	tant	NN	False
DDI-MedLine.d115.s0	cyclophosphamide	12	27	B-drug	cyclophosphamide	ide	mide	NN	False
DDI-MedLine.d115.s0	,	28	28	O	,	,	,	,	False
DDI-MedLine.d115.s0	doxorubicin	30	40	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d115.s0	,	41	41	O	,	,	,	,	False
DDI-MedLine.d115.s0	vincristine	43	53	B-drug	vincristine	ine	tine	NN	drug
DDI-MedLine.d115.s0	,	54	54	O	,	,	,	,	False
DDI-MedLine.d115.s0	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d115.s0	prednisone	60	69	B-drug	prednisone	one	sone	NN	False
DDI-MedLine.d115.s0	chemotherapy	71	82	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s0	plus	84	87	O	plus	lus	plus	CC	False
DDI-MedLine.d115.s0	highly	89	94	B-group	highly	hly	ghly	RB	False
DDI-MedLine.d115.s0	active	96	101	I-group	active	ive	tive	JJ	False
DDI-MedLine.d115.s0	antiretroviral	103	116	I-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d115.s0	therapy	118	124	O	therapy	apy	rapy	NN	False
DDI-MedLine.d115.s0	in	126	127	O	in	in	in	IN	False
DDI-MedLine.d115.s0	patients	129	136	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s0	with	138	141	O	with	ith	with	IN	False
DDI-MedLine.d115.s0	human	143	147	O	human	man	uman	NN	False
DDI-MedLine.d115.s0	immunodeficiency	149	164	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d115.s0	virus-related	166	178	O	virus-related	ted	ated	JJ	False
DDI-MedLine.d115.s0	,	179	179	O	,	,	,	,	False
DDI-MedLine.d115.s0	non-Hodgkin	181	191	O	non-Hodgkin	kin	gkin	JJ	False
DDI-MedLine.d115.s0	lymphoma	193	200	O	lymphoma	oma	homa	NN	False
DDI-MedLine.d115.s0	.	201	201	O	.	.	.	.	False

DDI-MedLine.d115.s1	BACKGROUND	0	9	O	BACKGROUND	UND	OUND	NN	brand
DDI-MedLine.d115.s1	:	10	10	O	:	:	:	:	False
DDI-MedLine.d115.s1	The	12	14	O	The	The	The	DT	False
DDI-MedLine.d115.s1	feasibility	16	26	O	feasibility	ity	lity	NN	False
DDI-MedLine.d115.s1	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d115.s1	efficacy	32	39	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d115.s1	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d115.s1	concomitant	44	54	O	concomitant	ant	tant	NN	False
DDI-MedLine.d115.s1	chemotherapy	56	67	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s1	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d115.s1	highly	73	78	B-group	highly	hly	ghly	RB	False
DDI-MedLine.d115.s1	active	80	85	I-group	active	ive	tive	JJ	False
DDI-MedLine.d115.s1	antiretroviral	87	100	I-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d115.s1	therapy	102	108	O	therapy	apy	rapy	NN	False
DDI-MedLine.d115.s1	(	110	110	O	(	(	(	(	False
DDI-MedLine.d115.s1	HAART	111	115	O	HAART	ART	AART	NN	brand
DDI-MedLine.d115.s1	)	116	116	O	)	)	)	)	False
DDI-MedLine.d115.s1	is	118	119	O	is	is	is	VBZ	False
DDI-MedLine.d115.s1	still	121	125	O	still	ill	till	RB	False
DDI-MedLine.d115.s1	unknown	127	133	O	unknown	own	nown	JJ	False
DDI-MedLine.d115.s1	in	135	136	O	in	in	in	IN	False
DDI-MedLine.d115.s1	patients	138	145	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s1	with	147	150	O	with	ith	with	IN	False
DDI-MedLine.d115.s1	human	152	156	O	human	man	uman	NN	False
DDI-MedLine.d115.s1	immunodeficiency	158	173	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d115.s1	virus	175	179	O	virus	rus	irus	NN	False
DDI-MedLine.d115.s1	(	181	181	O	(	(	(	(	False
DDI-MedLine.d115.s1	HIV	182	184	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d115.s1	)	185	185	O	)	)	)	)	False
DDI-MedLine.d115.s1	-related	186	193	O	-related	ted	ated	VBN	False
DDI-MedLine.d115.s1	malignancies	195	206	O	malignancies	ies	cies	NNS	False
DDI-MedLine.d115.s1	.	207	207	O	.	.	.	.	False

DDI-MedLine.d115.s2	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d115.s2	evaluate	3	10	O	evaluate	ate	uate	NN	False
DDI-MedLine.d115.s2	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d115.s2	impact	16	21	O	impact	act	pact	NN	False
DDI-MedLine.d115.s2	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d115.s2	chemotherapy	26	37	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s2	plus	39	42	O	plus	lus	plus	CC	False
DDI-MedLine.d115.s2	HAART	44	48	O	HAART	ART	AART	NN	brand
DDI-MedLine.d115.s2	on	50	51	O	on	on	on	IN	False
DDI-MedLine.d115.s2	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d115.s2	clinical	57	64	O	clinical	cal	ical	JJ	False
DDI-MedLine.d115.s2	course	66	71	O	course	rse	urse	NN	False
DDI-MedLine.d115.s2	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d115.s2	patients	76	83	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s2	with	85	88	O	with	ith	with	IN	False
DDI-MedLine.d115.s2	HIV-related	90	100	O	HIV-related	ted	ated	JJ	False
DDI-MedLine.d115.s2	,	101	101	O	,	,	,	,	False
DDI-MedLine.d115.s2	systemic	103	110	O	systemic	mic	emic	JJ	False
DDI-MedLine.d115.s2	,	111	111	O	,	,	,	,	False
DDI-MedLine.d115.s2	non-Hodgkin	113	123	O	non-Hodgkin	kin	gkin	JJ	False
DDI-MedLine.d115.s2	lymphoma	125	132	O	lymphoma	oma	homa	NN	False
DDI-MedLine.d115.s2	(	134	134	O	(	(	(	(	False
DDI-MedLine.d115.s2	HIV-NHL	135	141	O	HIV-NHL	NHL	-NHL	NN	brand
DDI-MedLine.d115.s2	)	142	142	O	)	)	)	)	False
DDI-MedLine.d115.s2	,	143	143	O	,	,	,	,	False
DDI-MedLine.d115.s2	the	145	147	O	the	the	the	DT	False
DDI-MedLine.d115.s2	authors	149	155	O	authors	ors	hors	NNS	False
DDI-MedLine.d115.s2	compared	157	164	O	compared	red	ared	VBN	False
DDI-MedLine.d115.s2	retrospectively	166	180	O	retrospectively	ely	vely	RB	False
DDI-MedLine.d115.s2	a	182	182	O	a	a	a	DT	False
DDI-MedLine.d115.s2	group	184	188	O	group	oup	roup	NN	False
DDI-MedLine.d115.s2	of	190	191	O	of	of	of	IN	False
DDI-MedLine.d115.s2	24	193	194	O	24	24	24	CD	False
DDI-MedLine.d115.s2	patients	196	203	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s2	with	205	208	O	with	ith	with	IN	False
DDI-MedLine.d115.s2	HIV-NHL	210	216	O	HIV-NHL	NHL	-NHL	NN	brand
DDI-MedLine.d115.s2	who	218	220	O	who	who	who	WP	False
DDI-MedLine.d115.s2	were	222	225	O	were	ere	were	VBD	False
DDI-MedLine.d115.s2	treated	227	233	O	treated	ted	ated	VBN	False
DDI-MedLine.d115.s2	with	235	238	O	with	ith	with	IN	False
DDI-MedLine.d115.s2	the	240	242	O	the	the	the	DT	False
DDI-MedLine.d115.s2	cyclophosphamide	244	259	B-drug	cyclophosphamide	ide	mide	NN	False
DDI-MedLine.d115.s2	,	260	260	O	,	,	,	,	False
DDI-MedLine.d115.s2	doxorubicin	262	272	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d115.s2	,	273	273	O	,	,	,	,	False
DDI-MedLine.d115.s2	vincristine	275	285	B-drug	vincristine	ine	tine	NN	drug
DDI-MedLine.d115.s2	,	286	286	O	,	,	,	,	False
DDI-MedLine.d115.s2	and	288	290	O	and	and	and	CC	False
DDI-MedLine.d115.s2	prednisone	292	301	B-drug	prednisone	one	sone	NN	False
DDI-MedLine.d115.s2	(	303	303	O	(	(	(	(	False
DDI-MedLine.d115.s2	CHOP	304	307	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s2	)	308	308	O	)	)	)	)	False
DDI-MedLine.d115.s2	chemotherapy	310	321	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s2	regimen	323	329	O	regimen	men	imen	NNS	False
DDI-MedLine.d115.s2	plus	331	334	O	plus	lus	plus	CC	False
DDI-MedLine.d115.s2	HAART	336	340	O	HAART	ART	AART	NN	brand
DDI-MedLine.d115.s2	with	342	345	O	with	ith	with	IN	False
DDI-MedLine.d115.s2	a	347	347	O	a	a	a	DT	False
DDI-MedLine.d115.s2	group	349	353	O	group	oup	roup	NN	False
DDI-MedLine.d115.s2	of	355	356	O	of	of	of	IN	False
DDI-MedLine.d115.s2	80	358	359	O	80	80	80	CD	False
DDI-MedLine.d115.s2	patients	361	368	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s2	who	370	372	O	who	who	who	WP	False
DDI-MedLine.d115.s2	were	374	377	O	were	ere	were	VBD	False
DDI-MedLine.d115.s2	treated	379	385	O	treated	ted	ated	VBN	False
DDI-MedLine.d115.s2	with	387	390	O	with	ith	with	IN	False
DDI-MedLine.d115.s2	CHOP	392	395	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s2	chemotherapy	397	408	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s2	or	410	411	O	or	or	or	CC	False
DDI-MedLine.d115.s2	a	413	413	O	a	a	a	DT	False
DDI-MedLine.d115.s2	CHOP-like	415	423	O	CHOP-like	ike	like	NN	False
DDI-MedLine.d115.s2	regimen	425	431	O	regimen	men	imen	NNS	False
DDI-MedLine.d115.s2	(	433	433	O	(	(	(	(	False
DDI-MedLine.d115.s2	i.e.	434	437	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d115.s2	,	438	438	O	,	,	,	,	False
DDI-MedLine.d115.s2	cyclophosphamide	440	455	B-drug	cyclophosphamide	ide	mide	NN	False
DDI-MedLine.d115.s2	,	456	456	O	,	,	,	,	False
DDI-MedLine.d115.s2	doxorubicin	458	468	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d115.s2	,	469	469	O	,	,	,	,	False
DDI-MedLine.d115.s2	teniposide	471	480	B-drug	teniposide	ide	side	NN	False
DDI-MedLine.d115.s2	,	481	481	O	,	,	,	,	False
DDI-MedLine.d115.s2	and	483	485	O	and	and	and	CC	False
DDI-MedLine.d115.s2	prednisone	487	496	B-drug	prednisone	one	sone	NN	False
DDI-MedLine.d115.s2	with	498	501	O	with	ith	with	IN	False
DDI-MedLine.d115.s2	vincristine	503	513	B-drug	vincristine	ine	tine	NN	drug
DDI-MedLine.d115.s2	plus	515	518	O	plus	lus	plus	CC	False
DDI-MedLine.d115.s2	bleomycin	520	528	B-drug	bleomycin	cin	ycin	NN	drug
DDI-MedLine.d115.s2	)	529	529	O	)	)	)	)	False
DDI-MedLine.d115.s2	without	531	537	O	without	out	hout	IN	False
DDI-MedLine.d115.s2	receiving	539	547	O	receiving	ing	ving	VBG	False
DDI-MedLine.d115.s2	antiretroviral	549	562	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d115.s2	therapy	564	570	O	therapy	apy	rapy	NN	False
DDI-MedLine.d115.s2	.	571	571	O	.	.	.	.	False

DDI-MedLine.d115.s3	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d115.s3	:	7	7	O	:	:	:	:	False
DDI-MedLine.d115.s3	All	9	11	O	All	All	All	DT	False
DDI-MedLine.d115.s3	patients	13	20	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s3	were	22	25	O	were	ere	were	VBD	False
DDI-MedLine.d115.s3	enrolled	27	34	O	enrolled	led	lled	VBN	False
DDI-MedLine.d115.s3	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d115.s3	two	39	41	O	two	two	two	CD	False
DDI-MedLine.d115.s3	sequential	43	52	O	sequential	ial	tial	JJ	False
DDI-MedLine.d115.s3	trials	54	59	O	trials	als	ials	NNS	False
DDI-MedLine.d115.s3	performed	61	69	O	performed	med	rmed	VBN	False
DDI-MedLine.d115.s3	at	71	72	O	at	at	at	IN	False
DDI-MedLine.d115.s3	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d115.s3	Aviano	78	83	O	Aviano	ano	iano	NN	False
DDI-MedLine.d115.s3	Cancer	85	90	O	Cancer	cer	ncer	NN	False
DDI-MedLine.d115.s3	Center	92	97	O	Center	ter	nter	NNP	False
DDI-MedLine.d115.s3	,	98	98	O	,	,	,	,	False
DDI-MedLine.d115.s3	Italy	100	104	O	Italy	aly	taly	NNP	False
DDI-MedLine.d115.s3	,	105	105	O	,	,	,	,	False
DDI-MedLine.d115.s3	from	107	110	O	from	rom	from	IN	False
DDI-MedLine.d115.s3	April	112	116	O	April	ril	pril	NNP	False
DDI-MedLine.d115.s3	1988	118	121	O	1988	988	1988	CD	False
DDI-MedLine.d115.s3	to	123	124	O	to	to	to	TO	False
DDI-MedLine.d115.s3	December	126	133	O	December	ber	mber	NNP	False
DDI-MedLine.d115.s3	1998	135	138	O	1998	998	1998	CD	False
DDI-MedLine.d115.s3	.	139	139	O	.	.	.	.	False

DDI-MedLine.d115.s4	HAART	0	4	O	HAART	ART	AART	NN	brand
DDI-MedLine.d115.s4	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d115.s4	included	10	17	O	included	ded	uded	VBD	False
DDI-MedLine.d115.s4	with	19	22	O	with	ith	with	IN	False
DDI-MedLine.d115.s4	combination	24	34	O	combination	ion	tion	NN	False
DDI-MedLine.d115.s4	therapy	36	42	O	therapy	apy	rapy	NN	False
DDI-MedLine.d115.s4	from	44	47	O	from	rom	from	IN	False
DDI-MedLine.d115.s4	January	49	55	O	January	ary	uary	NNP	False
DDI-MedLine.d115.s4	1997	57	60	O	1997	997	1997	CD	False
DDI-MedLine.d115.s4	.	61	61	O	.	.	.	.	False

DDI-MedLine.d115.s5	Antiretroviral	0	13	B-group	Antiretroviral	ral	iral	JJ	False
DDI-MedLine.d115.s5	regimens	15	22	O	regimens	ens	mens	NNS	False
DDI-MedLine.d115.s5	consisted	24	32	O	consisted	ted	sted	VBN	False
DDI-MedLine.d115.s5	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d115.s5	two	37	39	O	two	two	two	CD	False
DDI-MedLine.d115.s5	reverse	41	47	B-group	reverse	rse	erse	NN	False
DDI-MedLine.d115.s5	transcriptase	49	61	I-group	transcriptase	ase	tase	NN	False
DDI-MedLine.d115.s5	inhibitors	63	72	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d115.s5	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d115.s5	one	78	80	O	one	one	one	CD	False
DDI-MedLine.d115.s5	protease	82	89	B-group	protease	ase	ease	NN	False
DDI-MedLine.d115.s5	inhibitor	91	99	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d115.s5	.	100	100	O	.	.	.	.	False

DDI-MedLine.d115.s6	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d115.s6	:	7	7	O	:	:	:	:	False
DDI-MedLine.d115.s6	The	9	11	O	The	The	The	DT	False
DDI-MedLine.d115.s6	two	13	15	O	two	two	two	CD	False
DDI-MedLine.d115.s6	treatment	17	25	O	treatment	ent	ment	NN	False
DDI-MedLine.d115.s6	groups	27	32	O	groups	ups	oups	NNS	False
DDI-MedLine.d115.s6	were	34	37	O	were	ere	were	VBD	False
DDI-MedLine.d115.s6	well	39	42	O	well	ell	well	RB	False
DDI-MedLine.d115.s6	matched	44	50	O	matched	hed	ched	VBN	False
DDI-MedLine.d115.s6	with	52	55	O	with	ith	with	IN	False
DDI-MedLine.d115.s6	regard	57	62	O	regard	ard	gard	NN	False
DDI-MedLine.d115.s6	to	64	65	O	to	to	to	TO	False
DDI-MedLine.d115.s6	patient	67	73	O	patient	ent	ient	NN	False
DDI-MedLine.d115.s6	demographics	75	86	O	demographics	ics	hics	NNS	False
DDI-MedLine.d115.s6	,	87	87	O	,	,	,	,	False
DDI-MedLine.d115.s6	NHL	89	91	O	NHL	NHL	NHL	NN	brand
DDI-MedLine.d115.s6	characteristics	93	107	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d115.s6	,	108	108	O	,	,	,	,	False
DDI-MedLine.d115.s6	HIV	110	112	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d115.s6	status	114	119	O	status	tus	atus	NN	False
DDI-MedLine.d115.s6	,	120	120	O	,	,	,	,	False
DDI-MedLine.d115.s6	and	122	124	O	and	and	and	CC	False
DDI-MedLine.d115.s6	treatment	126	134	O	treatment	ent	ment	NN	False
DDI-MedLine.d115.s6	,	135	135	O	,	,	,	,	False
DDI-MedLine.d115.s6	i.e.	137	140	O	i.e.	.e.	i.e.	NN	False
DDI-MedLine.d115.s6	,	141	141	O	,	,	,	,	False
DDI-MedLine.d115.s6	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d115.s6	number	147	152	O	number	ber	mber	NN	False
DDI-MedLine.d115.s6	of	154	155	O	of	of	of	IN	False
DDI-MedLine.d115.s6	cycles	157	162	O	cycles	les	cles	NNS	False
DDI-MedLine.d115.s6	and	164	166	O	and	and	and	CC	False
DDI-MedLine.d115.s6	chemotherapy	168	179	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s6	dose	181	184	O	dose	ose	dose	NN	False
DDI-MedLine.d115.s6	.	185	185	O	.	.	.	.	False

DDI-MedLine.d115.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d115.s7	response	4	11	O	response	nse	onse	NN	False
DDI-MedLine.d115.s7	rates	13	17	O	rates	tes	ates	NNS	False
DDI-MedLine.d115.s7	were	19	22	O	were	ere	were	VBD	False
DDI-MedLine.d115.s7	similar	24	30	O	similar	lar	ilar	JJ	False
DDI-MedLine.d115.s7	between	32	38	O	between	een	ween	IN	False
DDI-MedLine.d115.s7	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d115.s7	two	44	46	O	two	two	two	CD	False
DDI-MedLine.d115.s7	groups	48	53	O	groups	ups	oups	NNS	False
DDI-MedLine.d115.s7	.	54	54	O	.	.	.	.	False

DDI-MedLine.d115.s8	Severe	0	5	O	Severe	ere	vere	JJ	False
DDI-MedLine.d115.s8	anemia	7	12	O	anemia	mia	emia	NN	False
DDI-MedLine.d115.s8	(	14	14	O	(	(	(	(	False
DDI-MedLine.d115.s8	Grade	15	19	O	Grade	ade	rade	NN	False
DDI-MedLine.d115.s8	3-4	21	23	O	3-4	3-4	3-4	JJ	False
DDI-MedLine.d115.s8	according	25	33	O	according	ing	ding	VBG	False
DDI-MedLine.d115.s8	to	35	36	O	to	to	to	TO	False
DDI-MedLine.d115.s8	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d115.s8	World	42	46	O	World	rld	orld	NN	False
DDI-MedLine.d115.s8	Health	48	53	O	Health	lth	alth	NNP	False
DDI-MedLine.d115.s8	Organization	55	66	O	Organization	ion	tion	NN	False
DDI-MedLine.d115.s8	criteria	68	75	O	criteria	ria	eria	NNS	False
DDI-MedLine.d115.s8	)	76	76	O	)	)	)	)	False
DDI-MedLine.d115.s8	was	78	80	O	was	was	was	VBD	False
DDI-MedLine.d115.s8	significantly	82	94	O	significantly	tly	ntly	RB	False
DDI-MedLine.d115.s8	greater	96	102	O	greater	ter	ater	JJR	False
DDI-MedLine.d115.s8	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d115.s8	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d115.s8	patients	111	118	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s8	who	120	122	O	who	who	who	WP	False
DDI-MedLine.d115.s8	received	124	131	O	received	ved	ived	VBN	False
DDI-MedLine.d115.s8	CHOP-HAART	133	142	O	CHOP-HAART	ART	AART	NN	brand
DDI-MedLine.d115.s8	compared	144	151	O	compared	red	ared	VBN	False
DDI-MedLine.d115.s8	with	153	156	O	with	ith	with	IN	False
DDI-MedLine.d115.s8	the	158	160	O	the	the	the	DT	False
DDI-MedLine.d115.s8	patients	162	169	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s8	who	171	173	O	who	who	who	WP	False
DDI-MedLine.d115.s8	received	175	182	O	received	ved	ived	VBN	False
DDI-MedLine.d115.s8	CHOP	184	187	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s8	alone	189	193	O	alone	one	lone	RB	False
DDI-MedLine.d115.s8	(	195	195	O	(	(	(	(	False
DDI-MedLine.d115.s8	33	196	197	O	33	33	33	CD	False
DDI-MedLine.d115.s8	%	198	198	O	%	%	%	NN	False
DDI-MedLine.d115.s8	vs.	200	202	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d115.s8	7	204	204	O	7	7	7	CD	False
DDI-MedLine.d115.s8	%	205	205	O	%	%	%	NN	False
DDI-MedLine.d115.s8	,	206	206	O	,	,	,	,	False
DDI-MedLine.d115.s8	respectively	208	219	O	respectively	ely	vely	RB	False
DDI-MedLine.d115.s8	;	220	220	O	;	;	;	:	False
DDI-MedLine.d115.s8	P	222	222	O	P	P	P	NN	brand
DDI-MedLine.d115.s8	=	224	224	O	=	=	=	NN	False
DDI-MedLine.d115.s8	0.001	226	230	O	0.001	001	.001	CD	False
DDI-MedLine.d115.s8	)	231	231	O	)	)	)	)	False
DDI-MedLine.d115.s8	.	232	232	O	.	.	.	.	False

DDI-MedLine.d115.s9	Leukopenia	0	9	O	Leukopenia	nia	enia	NNP	False
DDI-MedLine.d115.s9	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d115.s9	similar	15	21	O	similar	lar	ilar	JJ	False
DDI-MedLine.d115.s9	between	23	29	O	between	een	ween	IN	False
DDI-MedLine.d115.s9	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d115.s9	two	35	37	O	two	two	two	CD	False
DDI-MedLine.d115.s9	groups	39	44	O	groups	ups	oups	NNS	False
DDI-MedLine.d115.s9	,	45	45	O	,	,	,	,	False
DDI-MedLine.d115.s9	but	47	49	O	but	but	but	CC	False
DDI-MedLine.d115.s9	colony	51	56	O	colony	ony	lony	NN	False
DDI-MedLine.d115.s9	stimulating	58	68	O	stimulating	ing	ting	VBG	False
DDI-MedLine.d115.s9	factor	70	75	O	factor	tor	ctor	NN	False
DDI-MedLine.d115.s9	support	77	83	O	support	ort	port	NN	False
DDI-MedLine.d115.s9	was	85	87	O	was	was	was	VBD	False
DDI-MedLine.d115.s9	significantly	89	101	O	significantly	tly	ntly	RB	False
DDI-MedLine.d115.s9	greater	103	109	O	greater	ter	ater	JJR	False
DDI-MedLine.d115.s9	in	111	112	O	in	in	in	IN	False
DDI-MedLine.d115.s9	the	114	116	O	the	the	the	DT	False
DDI-MedLine.d115.s9	CHOP-HAART	118	127	O	CHOP-HAART	ART	AART	NN	brand
DDI-MedLine.d115.s9	group	129	133	O	group	oup	roup	NN	False
DDI-MedLine.d115.s9	than	135	138	O	than	han	than	IN	False
DDI-MedLine.d115.s9	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d115.s9	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d115.s9	control	147	153	O	control	rol	trol	NN	False
DDI-MedLine.d115.s9	group	155	159	O	group	oup	roup	NN	False
DDI-MedLine.d115.s9	(	161	161	O	(	(	(	(	False
DDI-MedLine.d115.s9	92	162	163	O	92	92	92	CD	False
DDI-MedLine.d115.s9	%	164	164	O	%	%	%	NN	False
DDI-MedLine.d115.s9	vs.	166	168	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d115.s9	66	170	171	O	66	66	66	CD	False
DDI-MedLine.d115.s9	%	172	172	O	%	%	%	NN	False
DDI-MedLine.d115.s9	,	173	173	O	,	,	,	,	False
DDI-MedLine.d115.s9	respectively	175	186	O	respectively	ely	vely	RB	False
DDI-MedLine.d115.s9	;	187	187	O	;	;	;	:	False
DDI-MedLine.d115.s9	P	189	189	O	P	P	P	NN	brand
DDI-MedLine.d115.s9	=	191	191	O	=	=	=	NN	False
DDI-MedLine.d115.s9	0.03	193	196	O	0.03	.03	0.03	CD	False
DDI-MedLine.d115.s9	)	197	197	O	)	)	)	)	False
DDI-MedLine.d115.s9	.	198	198	O	.	.	.	.	False

DDI-MedLine.d115.s10	Seventeen	0	8	O	Seventeen	een	teen	NN	False
DDI-MedLine.d115.s10	percent	10	16	O	percent	ent	cent	NN	False
DDI-MedLine.d115.s10	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d115.s10	CHOP-HAART	21	30	O	CHOP-HAART	ART	AART	NN	brand
DDI-MedLine.d115.s10	patients	32	39	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s10	developed	41	49	O	developed	ped	oped	NN	False
DDI-MedLine.d115.s10	severe	51	56	O	severe	ere	vere	JJ	False
DDI-MedLine.d115.s10	autonomic	58	66	O	autonomic	mic	omic	JJ	False
DDI-MedLine.d115.s10	neurotoxicity	68	80	O	neurotoxicity	ity	city	NN	False
DDI-MedLine.d115.s10	,	81	81	O	,	,	,	,	False
DDI-MedLine.d115.s10	whereas	83	89	O	whereas	eas	reas	NNS	False
DDI-MedLine.d115.s10	none	91	94	O	none	one	none	NN	False
DDI-MedLine.d115.s10	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d115.s10	the	99	101	O	the	the	the	DT	False
DDI-MedLine.d115.s10	CHOP	103	106	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s10	patients	108	115	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s10	developed	117	125	O	developed	ped	oped	NN	False
DDI-MedLine.d115.s10	neurotoxicity	127	139	O	neurotoxicity	ity	city	NN	False
DDI-MedLine.d115.s10	(	141	141	O	(	(	(	(	False
DDI-MedLine.d115.s10	P	142	142	O	P	P	P	NN	brand
DDI-MedLine.d115.s10	=	144	144	O	=	=	=	NN	False
DDI-MedLine.d115.s10	0.002	146	150	O	0.002	002	.002	CD	False
DDI-MedLine.d115.s10	)	151	151	O	)	)	)	)	False
DDI-MedLine.d115.s10	.	152	152	O	.	.	.	.	False

DDI-MedLine.d115.s11	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d115.s11	similar	3	9	O	similar	lar	ilar	JJ	False
DDI-MedLine.d115.s11	median	11	16	O	median	ian	dian	NN	False
DDI-MedLine.d115.s11	follow-up	18	26	O	follow-up	-up	w-up	NN	False
DDI-MedLine.d115.s11	,	27	27	O	,	,	,	,	False
DDI-MedLine.d115.s11	opportunistic	29	41	O	opportunistic	tic	stic	JJ	False
DDI-MedLine.d115.s11	infection	43	51	O	infection	ion	tion	NN	False
DDI-MedLine.d115.s11	(	53	53	O	(	(	(	(	False
DDI-MedLine.d115.s11	OI	54	55	O	OI	OI	OI	NN	brand
DDI-MedLine.d115.s11	)	56	56	O	)	)	)	)	False
DDI-MedLine.d115.s11	rates	58	62	O	rates	tes	ates	NNS	False
DDI-MedLine.d115.s11	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d115.s11	mortality	68	76	O	mortality	ity	lity	NN	False
DDI-MedLine.d115.s11	were	78	81	O	were	ere	were	VBD	False
DDI-MedLine.d115.s11	significantly	83	95	O	significantly	tly	ntly	RB	False
DDI-MedLine.d115.s11	lower	97	101	O	lower	wer	ower	JJR	False
DDI-MedLine.d115.s11	in	103	104	O	in	in	in	IN	False
DDI-MedLine.d115.s11	the	106	108	O	the	the	the	DT	False
DDI-MedLine.d115.s11	CHOP-HAART	110	119	O	CHOP-HAART	ART	AART	NN	brand
DDI-MedLine.d115.s11	patients	121	128	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s11	than	130	133	O	than	han	than	IN	False
DDI-MedLine.d115.s11	in	135	136	O	in	in	in	IN	False
DDI-MedLine.d115.s11	the	138	140	O	the	the	the	DT	False
DDI-MedLine.d115.s11	CHOP	142	145	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s11	patients	147	154	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s11	(	156	156	O	(	(	(	(	False
DDI-MedLine.d115.s11	18	157	158	O	18	18	18	CD	False
DDI-MedLine.d115.s11	%	159	159	O	%	%	%	NN	False
DDI-MedLine.d115.s11	vs.	161	163	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d115.s11	52	165	166	O	52	52	52	CD	False
DDI-MedLine.d115.s11	%	167	167	O	%	%	%	NN	False
DDI-MedLine.d115.s11	,	168	168	O	,	,	,	,	False
DDI-MedLine.d115.s11	respectively	170	181	O	respectively	ely	vely	RB	False
DDI-MedLine.d115.s11	;	182	182	O	;	;	;	:	False
DDI-MedLine.d115.s11	P	184	184	O	P	P	P	NN	brand
DDI-MedLine.d115.s11	=	186	186	O	=	=	=	NN	False
DDI-MedLine.d115.s11	0.05	188	191	O	0.05	.05	0.05	CD	False
DDI-MedLine.d115.s11	;	192	192	O	;	;	;	:	False
DDI-MedLine.d115.s11	and	194	196	O	and	and	and	CC	False
DDI-MedLine.d115.s11	38	198	199	O	38	38	38	CD	False
DDI-MedLine.d115.s11	%	200	200	O	%	%	%	NN	False
DDI-MedLine.d115.s11	vs.	202	204	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d115.s11	85	206	207	O	85	85	85	CD	False
DDI-MedLine.d115.s11	%	208	208	O	%	%	%	NN	False
DDI-MedLine.d115.s11	,	209	209	O	,	,	,	,	False
DDI-MedLine.d115.s11	respectively	211	222	O	respectively	ely	vely	RB	False
DDI-MedLine.d115.s11	;	223	223	O	;	;	;	:	False
DDI-MedLine.d115.s11	P	225	225	O	P	P	P	NN	brand
DDI-MedLine.d115.s11	=	227	227	O	=	=	=	NN	False
DDI-MedLine.d115.s11	0.001	229	233	O	0.001	001	.001	CD	False
DDI-MedLine.d115.s11	)	234	234	O	)	)	)	)	False
DDI-MedLine.d115.s11	.	235	235	O	.	.	.	.	False

DDI-MedLine.d115.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d115.s12	median	4	9	O	median	ian	dian	NN	False
DDI-MedLine.d115.s12	survival	11	18	O	survival	val	ival	NN	False
DDI-MedLine.d115.s12	for	20	22	O	for	for	for	IN	False
DDI-MedLine.d115.s12	CHOP-HAART	24	33	O	CHOP-HAART	ART	AART	NN	brand
DDI-MedLine.d115.s12	patients	35	42	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s12	was	44	46	O	was	was	was	VBD	False
DDI-MedLine.d115.s12	not	48	50	O	not	not	not	RB	False
DDI-MedLine.d115.s12	reached	52	58	O	reached	hed	ched	VBN	False
DDI-MedLine.d115.s12	,	59	59	O	,	,	,	,	False
DDI-MedLine.d115.s12	whereas	61	67	O	whereas	eas	reas	NNS	False
DDI-MedLine.d115.s12	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d115.s12	medial	73	78	O	medial	ial	dial	NN	False
DDI-MedLine.d115.s12	survival	80	87	O	survival	val	ival	NN	False
DDI-MedLine.d115.s12	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d115.s12	CHOP	92	95	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s12	patients	97	104	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s12	was	106	108	O	was	was	was	VBD	False
DDI-MedLine.d115.s12	7	110	110	O	7	7	7	CD	False
DDI-MedLine.d115.s12	months	112	117	O	months	ths	nths	NNS	False
DDI-MedLine.d115.s12	(	119	119	O	(	(	(	(	False
DDI-MedLine.d115.s12	P	120	120	O	P	P	P	NN	brand
DDI-MedLine.d115.s12	=	122	122	O	=	=	=	NN	False
DDI-MedLine.d115.s12	0.03	124	127	O	0.03	.03	0.03	CD	False
DDI-MedLine.d115.s12	)	128	128	O	)	)	)	)	False
DDI-MedLine.d115.s12	.	129	129	O	.	.	.	.	False

DDI-MedLine.d115.s13	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d115.s13	:	11	11	O	:	:	:	:	False
DDI-MedLine.d115.s13	The	13	15	O	The	The	The	DT	False
DDI-MedLine.d115.s13	combination	17	27	O	combination	ion	tion	NN	False
DDI-MedLine.d115.s13	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d115.s13	CHOP	32	35	O	CHOP	HOP	CHOP	NN	brand
DDI-MedLine.d115.s13	plus	37	40	O	plus	lus	plus	CC	False
DDI-MedLine.d115.s13	HAART	42	46	O	HAART	ART	AART	NN	brand
DDI-MedLine.d115.s13	is	48	49	O	is	is	is	VBZ	False
DDI-MedLine.d115.s13	feasible	51	58	O	feasible	ble	ible	JJ	False
DDI-MedLine.d115.s13	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d115.s13	may	64	66	O	may	may	may	MD	False
DDI-MedLine.d115.s13	reduce	68	73	O	reduce	uce	duce	VB	False
DDI-MedLine.d115.s13	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d115.s13	morbidity	79	87	O	morbidity	ity	dity	NN	False
DDI-MedLine.d115.s13	from	89	92	O	from	rom	from	IN	False
DDI-MedLine.d115.s13	OIs	94	96	O	OIs	OIs	OIs	NN	False
DDI-MedLine.d115.s13	in	98	99	O	in	in	in	IN	False
DDI-MedLine.d115.s13	HIV-NHL	101	107	O	HIV-NHL	NHL	-NHL	NN	brand
DDI-MedLine.d115.s13	patients	109	116	O	patients	nts	ents	NNS	False
DDI-MedLine.d115.s13	.	117	117	O	.	.	.	.	False

DDI-MedLine.d115.s14	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d115.s14	,	7	7	O	,	,	,	,	False
DDI-MedLine.d115.s14	careful	9	15	O	careful	ful	eful	NN	False
DDI-MedLine.d115.s14	attention	17	25	O	attention	ion	tion	NN	False
DDI-MedLine.d115.s14	must	27	30	O	must	ust	must	MD	False
DDI-MedLine.d115.s14	be	32	33	O	be	be	be	VB	False
DDI-MedLine.d115.s14	directed	35	42	O	directed	ted	cted	VBN	False
DDI-MedLine.d115.s14	to	44	45	O	to	to	to	TO	False
DDI-MedLine.d115.s14	cross	47	51	O	cross	oss	ross	NN	False
DDI-MedLine.d115.s14	toxicity	53	60	O	toxicity	ity	city	NN	False
DDI-MedLine.d115.s14	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d115.s14	possible	66	73	O	possible	ble	ible	JJ	False
DDI-MedLine.d115.s14	pharmacokinetic	75	89	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d115.s14	interactions	91	102	O	interactions	ons	ions	NNS	False
DDI-MedLine.d115.s14	between	104	110	O	between	een	ween	IN	False
DDI-MedLine.d115.s14	antiretroviral	112	125	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d115.s14	and	127	129	O	and	and	and	CC	False
DDI-MedLine.d115.s14	antineoplastic	131	144	B-group	antineoplastic	tic	stic	JJ	False
DDI-MedLine.d115.s14	drugs	146	150	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d115.s14	.	151	151	O	.	.	.	.	False

DDI-MedLine.d115.s15	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d115.s15	impact	4	9	O	impact	act	pact	NN	False
DDI-MedLine.d115.s15	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d115.s15	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d115.s15	combined	18	25	O	combined	ned	ined	VBN	False
DDI-MedLine.d115.s15	chemotherapy	27	38	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d115.s15	plus	40	43	O	plus	lus	plus	CC	False
DDI-MedLine.d115.s15	HAART	45	49	O	HAART	ART	AART	NN	brand
DDI-MedLine.d115.s15	treatment	51	59	O	treatment	ent	ment	NN	False
DDI-MedLine.d115.s15	on	61	62	O	on	on	on	IN	False
DDI-MedLine.d115.s15	patient	64	70	O	patient	ent	ient	NN	False
DDI-MedLine.d115.s15	survival	72	79	O	survival	val	ival	NN	False
DDI-MedLine.d115.s15	needs	81	85	O	needs	eds	eeds	NNS	False
DDI-MedLine.d115.s15	urgently	87	94	O	urgently	tly	ntly	RB	False
DDI-MedLine.d115.s15	to	96	97	O	to	to	to	TO	False
DDI-MedLine.d115.s15	be	99	100	O	be	be	be	VB	False
DDI-MedLine.d115.s15	evaluated	102	110	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d115.s15	in	112	113	O	in	in	in	IN	False
DDI-MedLine.d115.s15	prospective	115	125	O	prospective	ive	tive	JJ	False
DDI-MedLine.d115.s15	studies	127	133	O	studies	ies	dies	NNS	False
DDI-MedLine.d115.s15	.	134	134	O	.	.	.	.	False

DDI-MedLine.d124.s0	Lack	0	3	O	Lack	ack	Lack	NN	False
DDI-MedLine.d124.s0	of	5	6	O	of	of	of	IN	False
DDI-MedLine.d124.s0	interaction	8	18	O	interaction	ion	tion	NN	False
DDI-MedLine.d124.s0	between	20	26	O	between	een	ween	IN	False
DDI-MedLine.d124.s0	levofloxacin	28	39	B-drug	levofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s0	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d124.s0	oxycodone	45	53	B-drug	oxycodone	one	done	NN	False
DDI-MedLine.d124.s0	:	54	54	O	:	:	:	:	False
DDI-MedLine.d124.s0	pharmacokinetics	56	71	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d124.s0	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d124.s0	drug	77	80	O	drug	rug	drug	NN	False
DDI-MedLine.d124.s0	disposition	82	92	O	disposition	ion	tion	NN	False
DDI-MedLine.d124.s0	.	93	93	O	.	.	.	.	False

DDI-MedLine.d124.s1	Previous	0	7	O	Previous	ous	ious	JJ	False
DDI-MedLine.d124.s1	studies	9	15	O	studies	ies	dies	NNS	False
DDI-MedLine.d124.s1	have	17	20	O	have	ave	have	VB	False
DDI-MedLine.d124.s1	demonstrated	22	33	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d124.s1	a	35	35	O	a	a	a	DT	False
DDI-MedLine.d124.s1	significant	37	47	O	significant	ant	cant	JJ	False
DDI-MedLine.d124.s1	reduction	49	57	O	reduction	ion	tion	NN	False
DDI-MedLine.d124.s1	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d124.s1	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d124.s1	oral	66	69	O	oral	ral	oral	JJ	False
DDI-MedLine.d124.s1	bioavailability	71	85	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d124.s1	of	87	88	O	of	of	of	IN	False
DDI-MedLine.d124.s1	trovafloxacin	90	102	B-drug	trovafloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s1	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d124.s1	ciprofloxacin	108	120	B-drug	ciprofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s1	when	122	125	O	when	hen	when	WRB	False
DDI-MedLine.d124.s1	administered	127	138	O	administered	red	ered	VBN	False
DDI-MedLine.d124.s1	concomitantly	140	152	O	concomitantly	tly	ntly	RB	False
DDI-MedLine.d124.s1	with	154	157	O	with	ith	with	IN	False
DDI-MedLine.d124.s1	an	159	160	O	an	an	an	DT	False
DDI-MedLine.d124.s1	intravenous	162	172	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d124.s1	opiate	174	179	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d124.s1	such	181	184	O	such	uch	such	JJ	False
DDI-MedLine.d124.s1	as	186	187	O	as	as	as	IN	False
DDI-MedLine.d124.s1	morphine	189	196	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d124.s1	.	197	197	O	.	.	.	.	False

DDI-MedLine.d124.s2	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d124.s2	decrease	5	12	O	decrease	ase	ease	NN	False
DDI-MedLine.d124.s2	in	14	15	O	in	in	in	IN	False
DDI-MedLine.d124.s2	absorption	17	26	O	absorption	ion	tion	NN	False
DDI-MedLine.d124.s2	results	28	34	O	results	lts	ults	NNS	False
DDI-MedLine.d124.s2	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d124.s2	a	39	39	O	a	a	a	DT	False
DDI-MedLine.d124.s2	36	41	42	O	36	36	36	CD	False
DDI-MedLine.d124.s2	%	43	43	O	%	%	%	NN	False
DDI-MedLine.d124.s2	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d124.s2	50	49	50	O	50	50	50	CD	False
DDI-MedLine.d124.s2	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d124.s2	lower	53	57	O	lower	wer	ower	JJR	False
DDI-MedLine.d124.s2	AUC	59	61	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d124.s2	for	63	65	O	for	for	for	IN	False
DDI-MedLine.d124.s2	trovafloxacin	67	79	B-drug	trovafloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s2	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d124.s2	ciprofloxacin	85	97	B-drug	ciprofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s2	,	98	98	O	,	,	,	,	False
DDI-MedLine.d124.s2	respectively	100	111	O	respectively	ely	vely	RB	False
DDI-MedLine.d124.s2	,	112	112	O	,	,	,	,	False
DDI-MedLine.d124.s2	which	114	118	O	which	ich	hich	WDT	False
DDI-MedLine.d124.s2	could	120	124	O	could	uld	ould	MD	False
DDI-MedLine.d124.s2	cause	126	130	O	cause	use	ause	NN	False
DDI-MedLine.d124.s2	clinical	132	139	O	clinical	cal	ical	JJ	False
DDI-MedLine.d124.s2	failures	141	148	O	failures	res	ures	NNS	False
DDI-MedLine.d124.s2	.	149	149	O	.	.	.	.	False

DDI-MedLine.d124.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d124.s3	authors	4	10	O	authors	ors	hors	NNS	False
DDI-MedLine.d124.s3	investigated	12	23	O	investigated	ted	ated	VBN	False
DDI-MedLine.d124.s3	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d124.s3	possibility	29	39	O	possibility	ity	lity	NN	False
DDI-MedLine.d124.s3	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d124.s3	a	44	44	O	a	a	a	DT	False
DDI-MedLine.d124.s3	similar	46	52	O	similar	lar	ilar	JJ	False
DDI-MedLine.d124.s3	interaction	54	64	O	interaction	ion	tion	NN	False
DDI-MedLine.d124.s3	between	66	72	O	between	een	ween	IN	False
DDI-MedLine.d124.s3	oxycodone	74	82	B-drug	oxycodone	one	done	NN	False
DDI-MedLine.d124.s3	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d124.s3	levofloxacin	88	99	B-drug	levofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s3	.	100	100	O	.	.	.	.	False

DDI-MedLine.d124.s4	Eight	0	4	O	Eight	ght	ight	CD	False
DDI-MedLine.d124.s4	healthy	6	12	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d124.s4	volunteers	14	23	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d124.s4	were	25	28	O	were	ere	were	VBD	False
DDI-MedLine.d124.s4	randomized	30	39	O	randomized	zed	ized	VBN	False
DDI-MedLine.d124.s4	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d124.s4	an	44	45	O	an	an	an	DT	False
DDI-MedLine.d124.s4	open-label	47	56	O	open-label	bel	abel	NN	False
DDI-MedLine.d124.s4	,	57	57	O	,	,	,	,	False
DDI-MedLine.d124.s4	two-way	59	65	O	two-way	way	-way	NN	False
DDI-MedLine.d124.s4	crossover	67	75	O	crossover	ver	over	NN	False
DDI-MedLine.d124.s4	study	77	81	O	study	udy	tudy	NN	False
DDI-MedLine.d124.s4	to	83	84	O	to	to	to	TO	False
DDI-MedLine.d124.s4	receive	86	92	O	receive	ive	eive	NN	False
DDI-MedLine.d124.s4	oxycodone	94	102	B-drug	oxycodone	one	done	NN	False
DDI-MedLine.d124.s4	,	103	103	O	,	,	,	,	False
DDI-MedLine.d124.s4	5	105	105	O	5	5	5	CD	False
DDI-MedLine.d124.s4	mg	107	108	O	mg	mg	mg	NN	False
DDI-MedLine.d124.s4	p.o	110	112	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d124.s4	.	113	113	O	.	.	.	.	False

DDI-MedLine.d124.s5	Q4H	0	2	O	Q4H	Q4H	Q4H	NN	brand
DDI-MedLine.d124.s5	,	3	3	O	,	,	,	,	False
DDI-MedLine.d124.s5	and	5	7	O	and	and	and	CC	False
DDI-MedLine.d124.s5	levofloxacin	9	20	B-drug	levofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s5	,	21	21	O	,	,	,	,	False
DDI-MedLine.d124.s5	500	23	25	O	500	500	500	CD	False
DDI-MedLine.d124.s5	mg	27	28	O	mg	mg	mg	NN	False
DDI-MedLine.d124.s5	p.o	30	32	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d124.s5	.	33	33	O	.	.	.	.	False

DDI-MedLine.d124.s6	1	0	0	O	1	1	1	CD	False
DDI-MedLine.d124.s6	hour	2	5	O	hour	our	hour	NN	False
DDI-MedLine.d124.s6	after	7	11	O	after	ter	fter	IN	False
DDI-MedLine.d124.s6	starting	13	20	O	starting	ing	ting	VBG	False
DDI-MedLine.d124.s6	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d124.s6	oxycodone	26	34	B-drug	oxycodone	one	done	NN	False
DDI-MedLine.d124.s6	or	36	37	O	or	or	or	CC	False
DDI-MedLine.d124.s6	levofloxacin	39	50	B-drug	levofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s6	500	52	54	O	500	500	500	CD	False
DDI-MedLine.d124.s6	mg	56	57	O	mg	mg	mg	NN	False
DDI-MedLine.d124.s6	p.o	59	61	O	p.o	p.o	p.o	NN	False
DDI-MedLine.d124.s6	.	62	62	O	.	.	.	.	False

DDI-MedLine.d124.s7	alone	0	4	O	alone	one	lone	RB	False
DDI-MedLine.d124.s7	.	5	5	O	.	.	.	.	False

DDI-MedLine.d124.s8	Blood	0	4	O	Blood	ood	lood	NN	False
DDI-MedLine.d124.s8	samples	6	12	O	samples	les	ples	NNS	False
DDI-MedLine.d124.s8	were	14	17	O	were	ere	were	VBD	False
DDI-MedLine.d124.s8	drawn	19	23	O	drawn	awn	rawn	NN	False
DDI-MedLine.d124.s8	at	25	26	O	at	at	at	IN	False
DDI-MedLine.d124.s8	0	28	28	O	0	0	0	CD	False
DDI-MedLine.d124.s8	,	29	29	O	,	,	,	,	False
DDI-MedLine.d124.s8	0.5	31	33	O	0.5	0.5	0.5	CD	False
DDI-MedLine.d124.s8	,	34	34	O	,	,	,	,	False
DDI-MedLine.d124.s8	1	36	36	O	1	1	1	CD	False
DDI-MedLine.d124.s8	,	37	37	O	,	,	,	,	False
DDI-MedLine.d124.s8	1.5	39	41	O	1.5	1.5	1.5	CD	False
DDI-MedLine.d124.s8	,	42	42	O	,	,	,	,	False
DDI-MedLine.d124.s8	2	44	44	O	2	2	2	CD	False
DDI-MedLine.d124.s8	,	45	45	O	,	,	,	,	False
DDI-MedLine.d124.s8	3	47	47	O	3	3	3	CD	False
DDI-MedLine.d124.s8	,	48	48	O	,	,	,	,	False
DDI-MedLine.d124.s8	4	50	50	O	4	4	4	CD	False
DDI-MedLine.d124.s8	,	51	51	O	,	,	,	,	False
DDI-MedLine.d124.s8	6	53	53	O	6	6	6	CD	False
DDI-MedLine.d124.s8	,	54	54	O	,	,	,	,	False
DDI-MedLine.d124.s8	8	56	56	O	8	8	8	CD	False
DDI-MedLine.d124.s8	,	57	57	O	,	,	,	,	False
DDI-MedLine.d124.s8	12	59	60	O	12	12	12	CD	False
DDI-MedLine.d124.s8	,	61	61	O	,	,	,	,	False
DDI-MedLine.d124.s8	18	63	64	O	18	18	18	CD	False
DDI-MedLine.d124.s8	,	65	65	O	,	,	,	,	False
DDI-MedLine.d124.s8	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d124.s8	24	71	72	O	24	24	24	CD	False
DDI-MedLine.d124.s8	hours	74	78	O	hours	urs	ours	NNS	False
DDI-MedLine.d124.s8	for	80	82	O	for	for	for	IN	False
DDI-MedLine.d124.s8	Cmax	84	87	O	Cmax	max	Cmax	NN	False
DDI-MedLine.d124.s8	,	88	88	O	,	,	,	,	False
DDI-MedLine.d124.s8	tmax	90	93	O	tmax	max	tmax	NN	False
DDI-MedLine.d124.s8	,	94	94	O	,	,	,	,	False
DDI-MedLine.d124.s8	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d124.s8	AUC	100	102	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d124.s8	determinations	104	117	O	determinations	ons	ions	NNS	False
DDI-MedLine.d124.s8	.	118	118	O	.	.	.	.	False

DDI-MedLine.d124.s9	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d124.s9	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d124.s9	not	10	12	O	not	not	not	RB	False
DDI-MedLine.d124.s9	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d124.s9	significant	16	26	O	significant	ant	cant	JJ	False
DDI-MedLine.d124.s9	difference	28	37	O	difference	nce	ence	NN	False
DDI-MedLine.d124.s9	(	39	39	O	(	(	(	(	False
DDI-MedLine.d124.s9	p	40	40	O	p	p	p	NN	False
DDI-MedLine.d124.s9	>	42	42	O	>	>	>	NN	False
DDI-MedLine.d124.s9	0.05	44	47	O	0.05	.05	0.05	CD	False
DDI-MedLine.d124.s9	)	48	48	O	)	)	)	)	False
DDI-MedLine.d124.s9	in	50	51	O	in	in	in	IN	False
DDI-MedLine.d124.s9	AUC	53	55	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d124.s9	(	57	57	O	(	(	(	(	False
DDI-MedLine.d124.s9	48.59	58	62	O	48.59	.59	8.59	CD	False
DDI-MedLine.d124.s9	+/-	64	66	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d124.s9	8.52	68	71	O	8.52	.52	8.52	CD	False
DDI-MedLine.d124.s9	vs.	73	75	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d124.s9	49.9	77	80	O	49.9	9.9	49.9	CD	False
DDI-MedLine.d124.s9	+/-	82	84	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d124.s9	9.93	86	89	O	9.93	.93	9.93	CD	False
DDI-MedLine.d124.s9	)	90	90	O	)	)	)	)	False
DDI-MedLine.d124.s9	,	91	91	O	,	,	,	,	False
DDI-MedLine.d124.s9	Cmax	93	96	O	Cmax	max	Cmax	NN	False
DDI-MedLine.d124.s9	(	98	98	O	(	(	(	(	False
DDI-MedLine.d124.s9	7.73	99	102	O	7.73	.73	7.73	CD	False
DDI-MedLine.d124.s9	+/-	104	106	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d124.s9	2.6	108	110	O	2.6	2.6	2.6	CD	False
DDI-MedLine.d124.s9	vs.	112	114	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d124.s9	6.6	116	118	O	6.6	6.6	6.6	CD	False
DDI-MedLine.d124.s9	+/-	120	122	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d124.s9	2.0	124	126	O	2.0	2.0	2.0	CD	False
DDI-MedLine.d124.s9	)	127	127	O	)	)	)	)	False
DDI-MedLine.d124.s9	,	128	128	O	,	,	,	,	False
DDI-MedLine.d124.s9	and	130	132	O	and	and	and	CC	False
DDI-MedLine.d124.s9	tmax	134	137	O	tmax	max	tmax	NN	False
DDI-MedLine.d124.s9	(	139	139	O	(	(	(	(	False
DDI-MedLine.d124.s9	1.1	140	142	O	1.1	1.1	1.1	CD	False
DDI-MedLine.d124.s9	+/-	144	146	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d124.s9	0.6	148	150	O	0.6	0.6	0.6	CD	False
DDI-MedLine.d124.s9	vs.	152	154	O	vs.	vs.	vs.	NN	False
DDI-MedLine.d124.s9	1.6	156	158	O	1.6	1.6	1.6	CD	False
DDI-MedLine.d124.s9	+/-	160	162	O	+/-	+/-	+/-	NN	False
DDI-MedLine.d124.s9	1.1	164	166	O	1.1	1.1	1.1	CD	False
DDI-MedLine.d124.s9	)	167	167	O	)	)	)	)	False
DDI-MedLine.d124.s9	for	169	171	O	for	for	for	IN	False
DDI-MedLine.d124.s9	levofloxacin	173	184	B-drug	levofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s9	versus	186	191	O	versus	sus	rsus	NN	False
DDI-MedLine.d124.s9	levofloxacin/oxycodone	193	214	O	levofloxacin/oxycodone	one	done	NN	False
DDI-MedLine.d124.s9	regimens	216	223	O	regimens	ens	mens	NNS	False
DDI-MedLine.d124.s9	.	224	224	O	.	.	.	.	False

DDI-MedLine.d124.s10	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d124.s10	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d124.s10	concluded	7	15	O	concluded	ded	uded	VBD	False
DDI-MedLine.d124.s10	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d124.s10	oral	22	25	O	oral	ral	oral	JJ	False
DDI-MedLine.d124.s10	oxycodone	27	35	B-drug	oxycodone	one	done	NN	False
DDI-MedLine.d124.s10	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d124.s10	levofloxacin	41	52	B-drug	levofloxacin	cin	acin	NN	drug
DDI-MedLine.d124.s10	can	54	56	O	can	can	can	MD	False
DDI-MedLine.d124.s10	be	58	59	O	be	be	be	VB	False
DDI-MedLine.d124.s10	administered	61	72	O	administered	red	ered	VBN	False
DDI-MedLine.d124.s10	concomitantly	74	86	O	concomitantly	tly	ntly	RB	False
DDI-MedLine.d124.s10	without	88	94	O	without	out	hout	IN	False
DDI-MedLine.d124.s10	a	96	96	O	a	a	a	DT	False
DDI-MedLine.d124.s10	significant	98	108	O	significant	ant	cant	JJ	False
DDI-MedLine.d124.s10	decrease	110	117	O	decrease	ase	ease	NN	False
DDI-MedLine.d124.s10	in	119	120	O	in	in	in	IN	False
DDI-MedLine.d124.s10	AUC	122	124	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d124.s10	,	125	125	O	,	,	,	,	False
DDI-MedLine.d124.s10	Cmax	127	130	O	Cmax	max	Cmax	NN	False
DDI-MedLine.d124.s10	,	131	131	O	,	,	,	,	False
DDI-MedLine.d124.s10	or	133	134	O	or	or	or	CC	False
DDI-MedLine.d124.s10	tmax	136	139	O	tmax	max	tmax	NN	False
DDI-MedLine.d124.s10	.	140	140	O	.	.	.	.	False

DDI-MedLine.d98.s0	Behavioral	0	9	O	Behavioral	ral	oral	JJ	False
DDI-MedLine.d98.s0	responses	11	19	O	responses	ses	nses	NNS	False
DDI-MedLine.d98.s0	to	21	22	O	to	to	to	TO	False
DDI-MedLine.d98.s0	repeated	24	31	O	repeated	ted	ated	VBN	False
DDI-MedLine.d98.s0	cocaine	33	39	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d98.s0	exposure	41	48	O	exposure	ure	sure	NN	False
DDI-MedLine.d98.s0	in	50	51	O	in	in	in	IN	False
DDI-MedLine.d98.s0	mice	53	56	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s0	selectively	58	68	O	selectively	ely	vely	RB	False
DDI-MedLine.d98.s0	bred	70	73	O	bred	red	bred	VBN	False
DDI-MedLine.d98.s0	for	75	77	O	for	for	for	IN	False
DDI-MedLine.d98.s0	differential	79	90	O	differential	ial	tial	NN	False
DDI-MedLine.d98.s0	sensitivity	92	102	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d98.s0	to	104	105	O	to	to	to	TO	False
DDI-MedLine.d98.s0	pentobarbital	107	119	B-drug	pentobarbital	tal	ital	NN	False
DDI-MedLine.d98.s0	.	120	120	O	.	.	.	.	False

DDI-MedLine.d98.s1	Mice	0	3	O	Mice	ice	Mice	NN	False
DDI-MedLine.d98.s1	from	5	8	O	from	rom	from	IN	False
DDI-MedLine.d98.s1	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d98.s1	20th	14	17	O	20th	0th	20th	JJ	False
DDI-MedLine.d98.s1	generation	19	28	O	generation	ion	tion	NN	False
DDI-MedLine.d98.s1	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d98.s1	three	33	37	O	three	ree	hree	CD	False
DDI-MedLine.d98.s1	lines	39	43	O	lines	nes	ines	NNS	group
DDI-MedLine.d98.s1	divergently	45	55	O	divergently	tly	ntly	RB	False
DDI-MedLine.d98.s1	selected	57	64	O	selected	ted	cted	VBN	False
DDI-MedLine.d98.s1	for	66	68	O	for	for	for	IN	False
DDI-MedLine.d98.s1	response	70	77	O	response	nse	onse	NN	False
DDI-MedLine.d98.s1	to	79	80	O	to	to	to	TO	False
DDI-MedLine.d98.s1	pentobarbital-induced	82	102	O	pentobarbital-induced	ced	uced	JJ	False
DDI-MedLine.d98.s1	sedation	104	111	O	sedation	ion	tion	NN	False
DDI-MedLine.d98.s1	times	113	117	O	times	mes	imes	NNS	False
DDI-MedLine.d98.s1	[	119	119	O	[	[	[	NN	False
DDI-MedLine.d98.s1	long-sedation	120	132	O	long-sedation	ion	tion	NN	False
DDI-MedLine.d98.s1	time	134	137	O	time	ime	time	NN	False
DDI-MedLine.d98.s1	(	139	139	O	(	(	(	(	False
DDI-MedLine.d98.s1	LST	140	142	O	LST	LST	LST	NN	brand
DDI-MedLine.d98.s1	)	143	143	O	)	)	)	)	False
DDI-MedLine.d98.s1	,	144	144	O	,	,	,	,	False
DDI-MedLine.d98.s1	short	146	150	O	short	ort	hort	JJ	False
DDI-MedLine.d98.s1	sedation	152	159	O	sedation	ion	tion	NN	False
DDI-MedLine.d98.s1	time	161	164	O	time	ime	time	NN	False
DDI-MedLine.d98.s1	(	166	166	O	(	(	(	(	False
DDI-MedLine.d98.s1	SST	167	169	O	SST	SST	SST	NN	brand
DDI-MedLine.d98.s1	)	170	170	O	)	)	)	)	False
DDI-MedLine.d98.s1	,	171	171	O	,	,	,	,	False
DDI-MedLine.d98.s1	and	173	175	O	and	and	and	CC	False
DDI-MedLine.d98.s1	randomly	177	184	O	randomly	mly	omly	RB	False
DDI-MedLine.d98.s1	bred	186	189	O	bred	red	bred	VBN	False
DDI-MedLine.d98.s1	control	191	197	O	control	rol	trol	NN	False
DDI-MedLine.d98.s1	(	199	199	O	(	(	(	(	False
DDI-MedLine.d98.s1	RBC	200	202	O	RBC	RBC	RBC	NN	brand
DDI-MedLine.d98.s1	)	203	203	O	)	)	)	)	False
DDI-MedLine.d98.s1	]	204	204	O	]	]	]	NN	False
DDI-MedLine.d98.s1	were	206	209	O	were	ere	were	VBD	False
DDI-MedLine.d98.s1	used	211	214	O	used	sed	used	VBN	False
DDI-MedLine.d98.s1	to	216	217	O	to	to	to	TO	False
DDI-MedLine.d98.s1	study	219	223	O	study	udy	tudy	NN	False
DDI-MedLine.d98.s1	cocaine-induced	225	239	O	cocaine-induced	ced	uced	JJ	False
DDI-MedLine.d98.s1	behavioral	241	250	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d98.s1	sensitization	252	264	O	sensitization	ion	tion	NN	False
DDI-MedLine.d98.s1	.	265	265	O	.	.	.	.	False

DDI-MedLine.d98.s2	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d98.s2	lines	6	10	O	lines	nes	ines	NNS	group
DDI-MedLine.d98.s2	showed	12	17	O	showed	wed	owed	VBD	False
DDI-MedLine.d98.s2	variable	19	26	O	variable	ble	able	JJ	False
DDI-MedLine.d98.s2	degrees	28	34	O	degrees	ees	rees	NNS	False
DDI-MedLine.d98.s2	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d98.s2	locomotor	39	47	O	locomotor	tor	otor	NN	False
DDI-MedLine.d98.s2	activities	49	58	O	activities	ies	ties	NNS	False
DDI-MedLine.d98.s2	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d98.s2	response	63	70	O	response	nse	onse	NN	False
DDI-MedLine.d98.s2	to	72	73	O	to	to	to	TO	False
DDI-MedLine.d98.s2	cocaine	75	81	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d98.s2	.	82	82	O	.	.	.	.	False

DDI-MedLine.d98.s3	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d98.s3	a	3	3	O	a	a	a	DT	False
DDI-MedLine.d98.s3	low	5	7	O	low	low	low	JJ	False
DDI-MedLine.d98.s3	cocaine	9	15	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d98.s3	dose	17	20	O	dose	ose	dose	NN	False
DDI-MedLine.d98.s3	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d98.s3	long	26	29	O	long	ong	long	RB	False
DDI-MedLine.d98.s3	withdrawal	31	40	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d98.s3	period	42	47	O	period	iod	riod	NN	False
DDI-MedLine.d98.s3	(	49	49	O	(	(	(	(	False
DDI-MedLine.d98.s3	10	50	51	O	10	10	10	CD	False
DDI-MedLine.d98.s3	mg/kg	53	57	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d98.s3	,	58	58	O	,	,	,	,	False
DDI-MedLine.d98.s3	twice	60	64	O	twice	ice	wice	RB	False
DDI-MedLine.d98.s3	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d98.s3	day	68	70	O	day	day	day	NN	False
DDI-MedLine.d98.s3	for	72	74	O	for	for	for	IN	False
DDI-MedLine.d98.s3	5	76	76	O	5	5	5	CD	False
DDI-MedLine.d98.s3	days	78	81	O	days	ays	days	NNS	False
DDI-MedLine.d98.s3	followed	83	90	O	followed	wed	owed	VBD	False
DDI-MedLine.d98.s3	by	92	93	O	by	by	by	IN	False
DDI-MedLine.d98.s3	a	95	95	O	a	a	a	DT	False
DDI-MedLine.d98.s3	14-day	97	102	O	14-day	day	-day	JJ	False
DDI-MedLine.d98.s3	withdrawal	104	113	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d98.s3	)	114	114	O	)	)	)	)	False
DDI-MedLine.d98.s3	,	115	115	O	,	,	,	,	False
DDI-MedLine.d98.s3	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d98.s3	LST	121	123	O	LST	LST	LST	NN	brand
DDI-MedLine.d98.s3	mice	125	128	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s3	showed	130	135	O	showed	wed	owed	VBD	False
DDI-MedLine.d98.s3	tolerance	137	145	O	tolerance	nce	ance	NN	False
DDI-MedLine.d98.s3	development	147	157	O	development	ent	ment	NN	False
DDI-MedLine.d98.s3	.	158	158	O	.	.	.	.	False

DDI-MedLine.d98.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d98.s4	response	3	10	O	response	nse	onse	NN	False
DDI-MedLine.d98.s4	to	12	13	O	to	to	to	TO	False
DDI-MedLine.d98.s4	cocaine	15	21	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d98.s4	,	22	22	O	,	,	,	,	False
DDI-MedLine.d98.s4	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d98.s4	locomotor	28	36	O	locomotor	tor	otor	NN	False
DDI-MedLine.d98.s4	activities	38	47	O	activities	ies	ties	NNS	False
DDI-MedLine.d98.s4	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d98.s4	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d98.s4	SST	56	58	O	SST	SST	SST	NN	brand
DDI-MedLine.d98.s4	were	60	63	O	were	ere	were	VBD	False
DDI-MedLine.d98.s4	not	65	67	O	not	not	not	RB	False
DDI-MedLine.d98.s4	significantly	69	81	O	significantly	tly	ntly	RB	False
DDI-MedLine.d98.s4	different	83	91	O	different	ent	rent	JJ	False
DDI-MedLine.d98.s4	from	93	96	O	from	rom	from	IN	False
DDI-MedLine.d98.s4	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d98.s4	RBC	102	104	O	RBC	RBC	RBC	NN	brand
DDI-MedLine.d98.s4	group	106	110	O	group	oup	roup	NN	False
DDI-MedLine.d98.s4	.	111	111	O	.	.	.	.	False

DDI-MedLine.d98.s5	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d98.s5	a	3	3	O	a	a	a	DT	False
DDI-MedLine.d98.s5	higher	5	10	O	higher	her	gher	JJR	False
DDI-MedLine.d98.s5	dose	12	15	O	dose	ose	dose	NN	False
DDI-MedLine.d98.s5	and	17	19	O	and	and	and	CC	False
DDI-MedLine.d98.s5	a	21	21	O	a	a	a	DT	False
DDI-MedLine.d98.s5	shorter	23	29	O	shorter	ter	rter	NN	False
DDI-MedLine.d98.s5	withdrawal	31	40	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d98.s5	period	42	47	O	period	iod	riod	NN	False
DDI-MedLine.d98.s5	(	49	49	O	(	(	(	(	False
DDI-MedLine.d98.s5	20	50	51	O	20	20	20	CD	False
DDI-MedLine.d98.s5	mg/kg	53	57	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d98.s5	,	58	58	O	,	,	,	,	False
DDI-MedLine.d98.s5	daily	60	64	O	daily	ily	aily	JJ	False
DDI-MedLine.d98.s5	for	66	68	O	for	for	for	IN	False
DDI-MedLine.d98.s5	7	70	70	O	7	7	7	CD	False
DDI-MedLine.d98.s5	days	72	75	O	days	ays	days	NNS	False
DDI-MedLine.d98.s5	followed	77	84	O	followed	wed	owed	VBD	False
DDI-MedLine.d98.s5	by	86	87	O	by	by	by	IN	False
DDI-MedLine.d98.s5	a	89	89	O	a	a	a	DT	False
DDI-MedLine.d98.s5	3-day	91	95	O	3-day	day	-day	JJ	False
DDI-MedLine.d98.s5	withdrawal	97	106	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d98.s5	)	107	107	O	)	)	)	)	False
DDI-MedLine.d98.s5	,	108	108	O	,	,	,	,	False
DDI-MedLine.d98.s5	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d98.s5	SST	114	116	O	SST	SST	SST	NN	brand
DDI-MedLine.d98.s5	mice	118	121	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s5	showed	123	128	O	showed	wed	owed	VBD	False
DDI-MedLine.d98.s5	behavioral	130	139	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d98.s5	sensitization	141	153	O	sensitization	ion	tion	NN	False
DDI-MedLine.d98.s5	similar	155	161	O	similar	lar	ilar	JJ	False
DDI-MedLine.d98.s5	to	163	164	O	to	to	to	TO	False
DDI-MedLine.d98.s5	the	166	168	O	the	the	the	DT	False
DDI-MedLine.d98.s5	RBC	170	172	O	RBC	RBC	RBC	NN	brand
DDI-MedLine.d98.s5	mice	174	177	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s5	,	178	178	O	,	,	,	,	False
DDI-MedLine.d98.s5	but	180	182	O	but	but	but	CC	False
DDI-MedLine.d98.s5	the	184	186	O	the	the	the	DT	False
DDI-MedLine.d98.s5	LST	188	190	O	LST	LST	LST	NN	brand
DDI-MedLine.d98.s5	mice	192	195	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s5	did	197	199	O	did	did	did	VBD	False
DDI-MedLine.d98.s5	not	201	203	O	not	not	not	RB	False
DDI-MedLine.d98.s5	develop	205	211	O	develop	lop	elop	VB	False
DDI-MedLine.d98.s5	sensitization	213	225	O	sensitization	ion	tion	NN	False
DDI-MedLine.d98.s5	.	226	226	O	.	.	.	.	False

DDI-MedLine.d98.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d98.s6	different	4	12	O	different	ent	rent	JJ	False
DDI-MedLine.d98.s6	responses	14	22	O	responses	ses	nses	NNS	False
DDI-MedLine.d98.s6	in	24	25	O	in	in	in	IN	False
DDI-MedLine.d98.s6	locomotor	27	35	O	locomotor	tor	otor	NN	False
DDI-MedLine.d98.s6	activity	37	44	O	activity	ity	vity	NN	False
DDI-MedLine.d98.s6	induced	46	52	O	induced	ced	uced	JJ	False
DDI-MedLine.d98.s6	by	54	55	O	by	by	by	IN	False
DDI-MedLine.d98.s6	cocaine	57	63	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d98.s6	suggest	65	71	O	suggest	est	gest	NN	False
DDI-MedLine.d98.s6	that	73	76	O	that	hat	that	IN	False
DDI-MedLine.d98.s6	genetic	78	84	O	genetic	tic	etic	JJ	False
DDI-MedLine.d98.s6	factors	86	92	O	factors	ors	tors	NNS	False
DDI-MedLine.d98.s6	may	94	96	O	may	may	may	MD	False
DDI-MedLine.d98.s6	play	98	101	O	play	lay	play	NN	False
DDI-MedLine.d98.s6	a	103	103	O	a	a	a	DT	False
DDI-MedLine.d98.s6	role	105	108	O	role	ole	role	NN	False
DDI-MedLine.d98.s6	in	110	111	O	in	in	in	IN	False
DDI-MedLine.d98.s6	determining	113	123	O	determining	ing	ning	VBG	False
DDI-MedLine.d98.s6	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d98.s6	magnitude	129	137	O	magnitude	ude	tude	NN	False
DDI-MedLine.d98.s6	of	139	140	O	of	of	of	IN	False
DDI-MedLine.d98.s6	response	142	149	O	response	nse	onse	NN	False
DDI-MedLine.d98.s6	to	151	152	O	to	to	to	TO	False
DDI-MedLine.d98.s6	this	154	157	O	this	his	this	DT	False
DDI-MedLine.d98.s6	drug	159	162	O	drug	rug	drug	NN	False
DDI-MedLine.d98.s6	.	163	163	O	.	.	.	.	False

DDI-MedLine.d98.s7	Dopamine	0	7	O	Dopamine	ine	mine	NN	drug
DDI-MedLine.d98.s7	(	9	9	O	(	(	(	(	False
DDI-MedLine.d98.s7	DA	10	11	O	DA	DA	DA	NN	brand
DDI-MedLine.d98.s7	)	12	12	O	)	)	)	)	False
DDI-MedLine.d98.s7	levels	14	19	O	levels	els	vels	NNS	False
DDI-MedLine.d98.s7	did	21	23	O	did	did	did	VBD	False
DDI-MedLine.d98.s7	not	25	27	O	not	not	not	RB	False
DDI-MedLine.d98.s7	differ	29	34	O	differ	fer	ffer	NN	False
DDI-MedLine.d98.s7	significantly	36	48	O	significantly	tly	ntly	RB	False
DDI-MedLine.d98.s7	in	50	51	O	in	in	in	IN	False
DDI-MedLine.d98.s7	either	53	58	O	either	her	ther	DT	False
DDI-MedLine.d98.s7	striatum	60	67	O	striatum	tum	atum	NN	False
DDI-MedLine.d98.s7	(	69	69	O	(	(	(	(	False
DDI-MedLine.d98.s7	STR	70	72	O	STR	STR	STR	NN	brand
DDI-MedLine.d98.s7	)	73	73	O	)	)	)	)	False
DDI-MedLine.d98.s7	or	75	76	O	or	or	or	CC	False
DDI-MedLine.d98.s7	nucleus	78	84	O	nucleus	eus	leus	NN	False
DDI-MedLine.d98.s7	accumbens	86	94	O	accumbens	ens	bens	NNS	False
DDI-MedLine.d98.s7	(	96	96	O	(	(	(	(	False
DDI-MedLine.d98.s7	NAC	97	99	O	NAC	NAC	NAC	NN	brand
DDI-MedLine.d98.s7	)	100	100	O	)	)	)	)	False
DDI-MedLine.d98.s7	for	102	104	O	for	for	for	IN	False
DDI-MedLine.d98.s7	the	106	108	O	the	the	the	DT	False
DDI-MedLine.d98.s7	cocaine-treated	110	124	O	cocaine-treated	ted	ated	JJ	False
DDI-MedLine.d98.s7	animals	126	132	O	animals	als	mals	NNS	False
DDI-MedLine.d98.s7	to	134	135	O	to	to	to	TO	False
DDI-MedLine.d98.s7	their	137	141	O	their	eir	heir	PRP$	False
DDI-MedLine.d98.s7	corresponding	143	155	O	corresponding	ing	ding	VBG	False
DDI-MedLine.d98.s7	saline-treated	157	170	O	saline-treated	ted	ated	JJ	False
DDI-MedLine.d98.s7	controls	172	179	O	controls	ols	rols	NNS	False
DDI-MedLine.d98.s7	.	180	180	O	.	.	.	.	False

DDI-MedLine.d98.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d98.s8	affinity	4	11	O	affinity	ity	nity	NN	False
DDI-MedLine.d98.s8	(	13	13	O	(	(	(	(	False
DDI-MedLine.d98.s8	Kd	14	15	O	Kd	Kd	Kd	NNP	False
DDI-MedLine.d98.s8	)	16	16	O	)	)	)	)	False
DDI-MedLine.d98.s8	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d98.s8	D2	21	22	O	D2	D2	D2	NN	brand
DDI-MedLine.d98.s8	in	24	25	O	in	in	in	IN	False
DDI-MedLine.d98.s8	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d98.s8	NAC	31	33	O	NAC	NAC	NAC	NN	brand
DDI-MedLine.d98.s8	decreased	35	43	O	decreased	sed	ased	VBN	False
DDI-MedLine.d98.s8	significantly	45	57	O	significantly	tly	ntly	RB	False
DDI-MedLine.d98.s8	,	58	58	O	,	,	,	,	False
DDI-MedLine.d98.s8	without	60	66	O	without	out	hout	IN	False
DDI-MedLine.d98.s8	changes	68	74	O	changes	ges	nges	NNS	False
DDI-MedLine.d98.s8	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d98.s8	density	79	85	O	density	ity	sity	NN	False
DDI-MedLine.d98.s8	(	87	87	O	(	(	(	(	False
DDI-MedLine.d98.s8	Bmax	88	91	O	Bmax	max	Bmax	NN	False
DDI-MedLine.d98.s8	)	92	92	O	)	)	)	)	False
DDI-MedLine.d98.s8	,	93	93	O	,	,	,	,	False
DDI-MedLine.d98.s8	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d98.s8	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d98.s8	cocaine-treated	102	116	O	cocaine-treated	ted	ated	JJ	False
DDI-MedLine.d98.s8	SST	118	120	O	SST	SST	SST	NN	brand
DDI-MedLine.d98.s8	and	122	124	O	and	and	and	CC	False
DDI-MedLine.d98.s8	RBC	126	128	O	RBC	RBC	RBC	NN	brand
DDI-MedLine.d98.s8	mice	130	133	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s8	.	134	134	O	.	.	.	.	False

DDI-MedLine.d98.s9	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d98.s9	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d98.s9	other	7	11	O	other	her	ther	JJ	False
DDI-MedLine.d98.s9	hand	13	16	O	hand	and	hand	NN	False
DDI-MedLine.d98.s9	,	17	17	O	,	,	,	,	False
DDI-MedLine.d98.s9	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d98.s9	density	23	29	O	density	ity	sity	NN	False
DDI-MedLine.d98.s9	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d98.s9	D2	34	35	O	D2	D2	D2	NN	brand
DDI-MedLine.d98.s9	binding	37	43	O	binding	ing	ding	NN	False
DDI-MedLine.d98.s9	sites	45	49	O	sites	tes	ites	NNS	False
DDI-MedLine.d98.s9	in	51	52	O	in	in	in	IN	False
DDI-MedLine.d98.s9	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d98.s9	SST	58	60	O	SST	SST	SST	NN	brand
DDI-MedLine.d98.s9	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d98.s9	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d98.s9	RBC	70	72	O	RBC	RBC	RBC	NN	brand
DDI-MedLine.d98.s9	mice	74	77	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s9	in	79	80	O	in	in	in	IN	False
DDI-MedLine.d98.s9	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d98.s9	STR	86	88	O	STR	STR	STR	NN	brand
DDI-MedLine.d98.s9	was	90	92	O	was	was	was	VBD	False
DDI-MedLine.d98.s9	significantly	94	106	O	significantly	tly	ntly	RB	False
DDI-MedLine.d98.s9	increased	108	116	O	increased	sed	ased	VBN	False
DDI-MedLine.d98.s9	in	118	119	O	in	in	in	IN	False
DDI-MedLine.d98.s9	cocaine-treated	121	135	O	cocaine-treated	ted	ated	JJ	False
DDI-MedLine.d98.s9	groups	137	142	O	groups	ups	oups	NNS	False
DDI-MedLine.d98.s9	without	144	150	O	without	out	hout	IN	False
DDI-MedLine.d98.s9	change	152	157	O	change	nge	ange	NN	False
DDI-MedLine.d98.s9	in	159	160	O	in	in	in	IN	False
DDI-MedLine.d98.s9	Kd	162	163	O	Kd	Kd	Kd	NNP	False
DDI-MedLine.d98.s9	.	164	164	O	.	.	.	.	False

DDI-MedLine.d98.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d98.s10	LST	4	6	O	LST	LST	LST	NN	brand
DDI-MedLine.d98.s10	mice	8	11	O	mice	ice	mice	NN	False
DDI-MedLine.d98.s10	did	13	15	O	did	did	did	VBD	False
DDI-MedLine.d98.s10	not	17	19	O	not	not	not	RB	False
DDI-MedLine.d98.s10	show	21	24	O	show	how	show	NN	False
DDI-MedLine.d98.s10	any	26	28	O	any	any	any	DT	False
DDI-MedLine.d98.s10	changes	30	36	O	changes	ges	nges	NNS	False
DDI-MedLine.d98.s10	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d98.s10	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d98.s10	Kd	45	46	O	Kd	Kd	Kd	NNP	False
DDI-MedLine.d98.s10	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d98.s10	Bmax	52	55	O	Bmax	max	Bmax	NN	False
DDI-MedLine.d98.s10	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d98.s10	either	60	65	O	either	her	ther	DT	False
DDI-MedLine.d98.s10	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d98.s10	STR	71	73	O	STR	STR	STR	NN	brand
DDI-MedLine.d98.s10	or	75	76	O	or	or	or	CC	False
DDI-MedLine.d98.s10	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d98.s10	NAC	82	84	O	NAC	NAC	NAC	NN	brand
DDI-MedLine.d98.s10	.	85	85	O	.	.	.	.	False

DDI-MedLine.d98.s11	Taken	0	4	O	Taken	ken	aken	VBN	False
DDI-MedLine.d98.s11	together	6	13	O	together	her	ther	RB	False
DDI-MedLine.d98.s11	,	14	14	O	,	,	,	,	False
DDI-MedLine.d98.s11	these	16	20	O	these	ese	hese	DT	False
DDI-MedLine.d98.s11	findings	22	29	O	findings	ngs	ings	NNS	False
DDI-MedLine.d98.s11	suggest	31	37	O	suggest	est	gest	NN	False
DDI-MedLine.d98.s11	that	39	42	O	that	hat	that	IN	False
DDI-MedLine.d98.s11	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d98.s11	changes	48	54	O	changes	ges	nges	NNS	False
DDI-MedLine.d98.s11	in	56	57	O	in	in	in	IN	False
DDI-MedLine.d98.s11	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d98.s11	Kd	63	64	O	Kd	Kd	Kd	NNP	False
DDI-MedLine.d98.s11	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d98.s11	D2	69	70	O	D2	D2	D2	NN	brand
DDI-MedLine.d98.s11	in	72	73	O	in	in	in	IN	False
DDI-MedLine.d98.s11	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d98.s11	NAC	79	81	O	NAC	NAC	NAC	NN	brand
DDI-MedLine.d98.s11	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d98.s11	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d98.s11	Bmax	91	94	O	Bmax	max	Bmax	NN	False
DDI-MedLine.d98.s11	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d98.s11	D2	99	100	O	D2	D2	D2	NN	brand
DDI-MedLine.d98.s11	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d98.s11	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d98.s11	STR	109	111	O	STR	STR	STR	NN	brand
DDI-MedLine.d98.s11	may	113	115	O	may	may	may	MD	False
DDI-MedLine.d98.s11	contribute	117	126	O	contribute	ute	bute	NN	False
DDI-MedLine.d98.s11	to	128	129	O	to	to	to	TO	False
DDI-MedLine.d98.s11	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d98.s11	differences	135	145	O	differences	ces	nces	NNS	False
DDI-MedLine.d98.s11	in	147	148	O	in	in	in	IN	False
DDI-MedLine.d98.s11	locomotor	150	158	O	locomotor	tor	otor	NN	False
DDI-MedLine.d98.s11	responses	160	168	O	responses	ses	nses	NNS	False
DDI-MedLine.d98.s11	to	170	171	O	to	to	to	TO	False
DDI-MedLine.d98.s11	cocaine	173	179	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d98.s11	exposure	181	188	O	exposure	ure	sure	NN	False
DDI-MedLine.d98.s11	in	190	191	O	in	in	in	IN	False
DDI-MedLine.d98.s11	these	193	197	O	these	ese	hese	DT	False
DDI-MedLine.d98.s11	mouse	199	203	O	mouse	use	ouse	NN	False
DDI-MedLine.d98.s11	lines	205	209	O	lines	nes	ines	NNS	group
DDI-MedLine.d98.s11	.	210	210	O	.	.	.	.	False

DDI-MedLine.d130.s0	High-dose	0	8	O	High-dose	ose	dose	JJ	False
DDI-MedLine.d130.s0	cisplatin	10	18	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s0	with	20	23	O	with	ith	with	IN	False
DDI-MedLine.d130.s0	sodium	25	30	B-drug	sodium	ium	dium	NN	drug
DDI-MedLine.d130.s0	thiosulfate	32	42	I-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s0	protection	44	53	O	protection	ion	tion	NN	False
DDI-MedLine.d130.s0	.	54	54	O	.	.	.	.	False

DDI-MedLine.d130.s1	Nephrotoxicity	0	13	O	Nephrotoxicity	ity	city	NN	False
DDI-MedLine.d130.s1	frequently	15	24	O	frequently	tly	ntly	RB	False
DDI-MedLine.d130.s1	limits	26	31	O	limits	its	mits	NNS	False
DDI-MedLine.d130.s1	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d130.s1	dose	37	40	O	dose	ose	dose	NN	False
DDI-MedLine.d130.s1	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d130.s1	cisplatin	45	53	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s1	to	55	56	O	to	to	to	TO	False
DDI-MedLine.d130.s1	less	58	61	O	less	ess	less	RBR	False
DDI-MedLine.d130.s1	than	63	66	O	than	han	than	IN	False
DDI-MedLine.d130.s1	120	68	70	O	120	120	120	CD	False
DDI-MedLine.d130.s1	mg/m2	72	76	O	mg/m2	/m2	g/m2	NN	False
DDI-MedLine.d130.s1	per	78	80	O	per	per	per	IN	False
DDI-MedLine.d130.s1	injection	82	90	O	injection	ion	tion	NN	False
DDI-MedLine.d130.s1	.	91	91	O	.	.	.	.	False

DDI-MedLine.d130.s2	Sodium	0	5	B-drug	Sodium	ium	dium	NN	drug
DDI-MedLine.d130.s2	thiosulfate	7	17	I-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s2	is	19	20	O	is	is	is	VBZ	False
DDI-MedLine.d130.s2	a	22	22	O	a	a	a	DT	False
DDI-MedLine.d130.s2	neutralizing	24	35	O	neutralizing	ing	zing	VBG	False
DDI-MedLine.d130.s2	agent	37	41	O	agent	ent	gent	NN	False
DDI-MedLine.d130.s2	for	43	45	O	for	for	for	IN	False
DDI-MedLine.d130.s2	cisplatin	47	55	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s2	that	57	60	O	that	hat	that	IN	False
DDI-MedLine.d130.s2	protects	62	69	O	protects	cts	ects	NNS	False
DDI-MedLine.d130.s2	against	71	77	O	against	nst	inst	IN	False
DDI-MedLine.d130.s2	renal	79	83	O	renal	nal	enal	NN	False
DDI-MedLine.d130.s2	damage	85	90	O	damage	age	mage	NN	False
DDI-MedLine.d130.s2	.	91	91	O	.	.	.	.	False

DDI-MedLine.d130.s3	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d130.s3	determine	3	11	O	determine	ine	mine	NN	drug
DDI-MedLine.d130.s3	whether	13	19	O	whether	her	ther	IN	False
DDI-MedLine.d130.s3	injection	21	29	O	injection	ion	tion	NN	False
DDI-MedLine.d130.s3	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d130.s3	thiosulfate	34	44	B-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s3	would	46	50	O	would	uld	ould	MD	False
DDI-MedLine.d130.s3	permit	52	57	O	permit	mit	rmit	NN	False
DDI-MedLine.d130.s3	larger	59	64	O	larger	ger	rger	JJR	False
DDI-MedLine.d130.s3	doses	66	70	O	doses	ses	oses	NNS	False
DDI-MedLine.d130.s3	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d130.s3	cisplatin	75	83	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s3	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d130.s3	be	88	89	O	be	be	be	VB	False
DDI-MedLine.d130.s3	administered	91	102	O	administered	red	ered	VBN	False
DDI-MedLine.d130.s3	,	103	103	O	,	,	,	,	False
DDI-MedLine.d130.s3	a	105	105	O	a	a	a	DT	False
DDI-MedLine.d130.s3	fixed	107	111	O	fixed	xed	ixed	VBN	False
DDI-MedLine.d130.s3	9.9-g/m2	113	120	O	9.9-g/m2	/m2	g/m2	CD	False
DDI-MedLine.d130.s3	dose	122	125	O	dose	ose	dose	NN	False
DDI-MedLine.d130.s3	of	127	128	O	of	of	of	IN	False
DDI-MedLine.d130.s3	thiosulfate	130	140	B-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s3	was	142	144	O	was	was	was	VBD	False
DDI-MedLine.d130.s3	given	146	150	O	given	ven	iven	VBN	False
DDI-MedLine.d130.s3	intravenously	152	164	O	intravenously	sly	usly	RB	False
DDI-MedLine.d130.s3	over	166	169	O	over	ver	over	IN	False
DDI-MedLine.d130.s3	three	171	175	O	three	ree	hree	CD	False
DDI-MedLine.d130.s3	hours	177	181	O	hours	urs	ours	NNS	False
DDI-MedLine.d130.s3	concurrently	183	194	O	concurrently	tly	ntly	RB	False
DDI-MedLine.d130.s3	with	196	199	O	with	ith	with	IN	False
DDI-MedLine.d130.s3	escalating	201	210	O	escalating	ing	ting	VBG	False
DDI-MedLine.d130.s3	doses	212	216	O	doses	ses	oses	NNS	False
DDI-MedLine.d130.s3	of	218	219	O	of	of	of	IN	False
DDI-MedLine.d130.s3	cisplatin	221	229	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s3	.	230	230	O	.	.	.	.	False

DDI-MedLine.d130.s4	Cisplatin	0	8	B-drug	Cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s4	was	10	12	O	was	was	was	VBD	False
DDI-MedLine.d130.s4	administered	14	25	O	administered	red	ered	VBN	False
DDI-MedLine.d130.s4	over	27	30	O	over	ver	over	IN	False
DDI-MedLine.d130.s4	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d130.s4	last	36	39	O	last	ast	last	JJ	False
DDI-MedLine.d130.s4	two	41	43	O	two	two	two	CD	False
DDI-MedLine.d130.s4	hours	45	49	O	hours	urs	ours	NNS	False
DDI-MedLine.d130.s4	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d130.s4	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d130.s4	thiosulfate	58	68	B-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s4	infusion	70	77	O	infusion	ion	sion	NN	False
DDI-MedLine.d130.s4	.	78	78	O	.	.	.	.	False

DDI-MedLine.d130.s5	Using	0	4	O	Using	ing	sing	VBG	False
DDI-MedLine.d130.s5	this	6	9	O	this	his	this	DT	False
DDI-MedLine.d130.s5	technique	11	19	O	technique	que	ique	NN	False
DDI-MedLine.d130.s5	,	20	20	O	,	,	,	,	False
DDI-MedLine.d130.s5	it	22	23	O	it	it	it	PRP	False
DDI-MedLine.d130.s5	was	25	27	O	was	was	was	VBD	False
DDI-MedLine.d130.s5	possible	29	36	O	possible	ble	ible	JJ	False
DDI-MedLine.d130.s5	to	38	39	O	to	to	to	TO	False
DDI-MedLine.d130.s5	escalate	41	48	O	escalate	ate	late	NN	False
DDI-MedLine.d130.s5	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d130.s5	cisplatin	54	62	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s5	dose	64	67	O	dose	ose	dose	NN	False
DDI-MedLine.d130.s5	to	69	70	O	to	to	to	TO	False
DDI-MedLine.d130.s5	225	72	74	O	225	225	225	CD	False
DDI-MedLine.d130.s5	mg/m2	76	80	O	mg/m2	/m2	g/m2	NN	False
DDI-MedLine.d130.s5	before	82	87	O	before	ore	fore	IN	False
DDI-MedLine.d130.s5	dose-limiting	89	101	O	dose-limiting	ing	ting	NN	False
DDI-MedLine.d130.s5	toxicities	103	112	O	toxicities	ies	ties	NNS	False
DDI-MedLine.d130.s5	were	114	117	O	were	ere	were	VBD	False
DDI-MedLine.d130.s5	encountered	119	129	O	encountered	red	ered	VBN	False
DDI-MedLine.d130.s5	.	130	130	O	.	.	.	.	False

DDI-MedLine.d130.s6	Comparison	0	9	O	Comparison	son	ison	NN	False
DDI-MedLine.d130.s6	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d130.s6	cisplatin	14	22	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s6	pharmacokinetics	24	39	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d130.s6	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d130.s6	patients	44	51	O	patients	nts	ents	NNS	False
DDI-MedLine.d130.s6	treated	53	59	O	treated	ted	ated	VBN	False
DDI-MedLine.d130.s6	with	61	64	O	with	ith	with	IN	False
DDI-MedLine.d130.s6	202.5	66	70	O	202.5	2.5	02.5	CD	False
DDI-MedLine.d130.s6	mg/m2	72	76	O	mg/m2	/m2	g/m2	NN	False
DDI-MedLine.d130.s6	plus	78	81	O	plus	lus	plus	CC	False
DDI-MedLine.d130.s6	thiosulfate	83	93	B-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s6	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d130.s6	those	98	102	O	those	ose	hose	DT	False
DDI-MedLine.d130.s6	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d130.s6	patients	107	114	O	patients	nts	ents	NNS	False
DDI-MedLine.d130.s6	treated	116	122	O	treated	ted	ated	VBN	False
DDI-MedLine.d130.s6	with	124	127	O	with	ith	with	IN	False
DDI-MedLine.d130.s6	100	129	131	O	100	100	100	CD	False
DDI-MedLine.d130.s6	mg/m2	133	137	O	mg/m2	/m2	g/m2	NN	False
DDI-MedLine.d130.s6	without	139	145	O	without	out	hout	IN	False
DDI-MedLine.d130.s6	thiosulfate	147	157	B-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s6	indicated	159	167	O	indicated	ted	ated	VBN	False
DDI-MedLine.d130.s6	that	169	172	O	that	hat	that	IN	False
DDI-MedLine.d130.s6	there	174	178	O	there	ere	here	RB	False
DDI-MedLine.d130.s6	were	180	183	O	were	ere	were	VBD	False
DDI-MedLine.d130.s6	no	185	186	O	no	no	no	DT	False
DDI-MedLine.d130.s6	changes	188	194	O	changes	ges	nges	NNS	False
DDI-MedLine.d130.s6	in	196	197	O	in	in	in	IN	False
DDI-MedLine.d130.s6	the	199	201	O	the	the	the	DT	False
DDI-MedLine.d130.s6	elimination	203	213	O	elimination	ion	tion	NN	False
DDI-MedLine.d130.s6	rate	215	218	O	rate	ate	rate	NN	False
DDI-MedLine.d130.s6	constant	220	227	O	constant	ant	tant	JJ	False
DDI-MedLine.d130.s6	,	228	228	O	,	,	,	,	False
DDI-MedLine.d130.s6	volume	230	235	O	volume	ume	lume	NN	False
DDI-MedLine.d130.s6	of	237	238	O	of	of	of	IN	False
DDI-MedLine.d130.s6	distribution	240	251	O	distribution	ion	tion	NN	False
DDI-MedLine.d130.s6	,	252	252	O	,	,	,	,	False
DDI-MedLine.d130.s6	or	254	255	O	or	or	or	CC	False
DDI-MedLine.d130.s6	total	257	261	O	total	tal	otal	JJ	False
DDI-MedLine.d130.s6	body	263	266	O	body	ody	body	NN	False
DDI-MedLine.d130.s6	clearance	268	276	O	clearance	nce	ance	NN	False
DDI-MedLine.d130.s6	of	278	279	O	of	of	of	IN	False
DDI-MedLine.d130.s6	cisplatin	281	289	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s6	.	290	290	O	.	.	.	.	False

DDI-MedLine.d130.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d130.s7	total	4	8	O	total	tal	otal	JJ	False
DDI-MedLine.d130.s7	drug	10	13	O	drug	rug	drug	NN	False
DDI-MedLine.d130.s7	exposure	15	22	O	exposure	ure	sure	NN	False
DDI-MedLine.d130.s7	for	24	26	O	for	for	for	IN	False
DDI-MedLine.d130.s7	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d130.s7	plasma	32	37	O	plasma	sma	asma	NN	False
DDI-MedLine.d130.s7	was	39	41	O	was	was	was	VBD	False
DDI-MedLine.d130.s7	approximately	43	55	O	approximately	ely	tely	RB	False
DDI-MedLine.d130.s7	twofold	57	63	O	twofold	old	fold	NN	False
DDI-MedLine.d130.s7	at	65	66	O	at	at	at	IN	False
DDI-MedLine.d130.s7	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d130.s7	higher	72	77	O	higher	her	gher	JJR	False
DDI-MedLine.d130.s7	cisplatin	79	87	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s7	dose	89	92	O	dose	ose	dose	NN	False
DDI-MedLine.d130.s7	.	93	93	O	.	.	.	.	False

DDI-MedLine.d130.s8	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d130.s8	study	5	9	O	study	udy	tudy	NN	False
DDI-MedLine.d130.s8	demonstrates	11	22	O	demonstrates	tes	ates	NNS	False
DDI-MedLine.d130.s8	that	24	27	O	that	hat	that	IN	False
DDI-MedLine.d130.s8	concurrent	29	38	O	concurrent	ent	rent	NN	False
DDI-MedLine.d130.s8	administration	40	53	O	administration	ion	tion	NN	False
DDI-MedLine.d130.s8	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d130.s8	thiosulfate	58	68	B-drug	thiosulfate	ate	fate	NN	False
DDI-MedLine.d130.s8	permits	70	76	O	permits	its	mits	NNS	False
DDI-MedLine.d130.s8	at	78	79	O	at	at	at	IN	False
DDI-MedLine.d130.s8	least	81	85	O	least	ast	east	JJS	False
DDI-MedLine.d130.s8	a	87	87	O	a	a	a	DT	False
DDI-MedLine.d130.s8	twofold	89	95	O	twofold	old	fold	NN	False
DDI-MedLine.d130.s8	increase	97	104	O	increase	ase	ease	NN	False
DDI-MedLine.d130.s8	in	106	107	O	in	in	in	IN	False
DDI-MedLine.d130.s8	dose	109	112	O	dose	ose	dose	NN	False
DDI-MedLine.d130.s8	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d130.s8	total	118	122	O	total	tal	otal	JJ	False
DDI-MedLine.d130.s8	exposure	124	131	O	exposure	ure	sure	NN	False
DDI-MedLine.d130.s8	to	133	134	O	to	to	to	TO	False
DDI-MedLine.d130.s8	cisplatin	136	144	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d130.s8	.	145	145	O	.	.	.	.	False

DDI-MedLine.d50.s0	Ascorbic	0	7	B-drug	Ascorbic	bic	rbic	NNP	False
DDI-MedLine.d50.s0	acid	9	12	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d50.s0	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d50.s0	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d50.s0	common	22	27	O	common	mon	mmon	JJ	False
DDI-MedLine.d50.s0	cold	29	32	O	cold	old	cold	NN	False
DDI-MedLine.d50.s0	.	33	33	O	.	.	.	.	False

DDI-MedLine.d50.s1	Evaluation	0	9	O	Evaluation	ion	tion	NN	False
DDI-MedLine.d50.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d50.s1	its	14	16	O	its	its	its	PRP$	False
DDI-MedLine.d50.s1	efficacy	18	25	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d50.s1	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d50.s1	toxicity	31	38	O	toxicity	ity	city	NN	False
DDI-MedLine.d50.s1	.	39	39	O	.	.	.	.	False

DDI-MedLine.d50.s2	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d50.s2	reviewed	3	10	O	reviewed	wed	ewed	VBN	False
DDI-MedLine.d50.s2	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d50.s2	clinical	16	23	O	clinical	cal	ical	JJ	False
DDI-MedLine.d50.s2	data	25	28	O	data	ata	data	NNS	False
DDI-MedLine.d50.s2	relating	30	37	O	relating	ing	ting	VBG	False
DDI-MedLine.d50.s2	to	39	40	O	to	to	to	TO	False
DDI-MedLine.d50.s2	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d50.s2	efficacy	46	53	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d50.s2	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d50.s2	safety	59	64	O	safety	ety	fety	NN	False
DDI-MedLine.d50.s2	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d50.s2	pharmacologic	69	81	O	pharmacologic	gic	ogic	NN	False
DDI-MedLine.d50.s2	doses	83	87	O	doses	ses	oses	NNS	False
DDI-MedLine.d50.s2	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d50.s2	ascorbic	92	99	B-drug	ascorbic	bic	rbic	NN	False
DDI-MedLine.d50.s2	acid	101	104	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d50.s2	in	106	107	O	in	in	in	IN	False
DDI-MedLine.d50.s2	the	109	111	O	the	the	the	DT	False
DDI-MedLine.d50.s2	prevention	113	122	O	prevention	ion	tion	NN	False
DDI-MedLine.d50.s2	and	124	126	O	and	and	and	CC	False
DDI-MedLine.d50.s2	treatment	128	136	O	treatment	ent	ment	NN	False
DDI-MedLine.d50.s2	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d50.s2	the	141	143	O	the	the	the	DT	False
DDI-MedLine.d50.s2	common	145	150	O	common	mon	mmon	JJ	False
DDI-MedLine.d50.s2	cold	152	155	O	cold	old	cold	NN	False
DDI-MedLine.d50.s2	.	156	156	O	.	.	.	.	False

DDI-MedLine.d50.s3	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d50.s3	one	9	11	O	one	one	one	CD	False
DDI-MedLine.d50.s3	study	13	17	O	study	udy	tudy	NN	False
DDI-MedLine.d50.s3	tentatively	19	29	O	tentatively	ely	vely	RB	False
DDI-MedLine.d50.s3	supports	31	38	O	supports	rts	orts	NNS	False
DDI-MedLine.d50.s3	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d50.s3	hypothesis	44	53	O	hypothesis	sis	esis	NN	False
DDI-MedLine.d50.s3	that	55	58	O	that	hat	that	IN	False
DDI-MedLine.d50.s3	such	60	63	O	such	uch	such	JJ	False
DDI-MedLine.d50.s3	doses	65	69	O	doses	ses	oses	NNS	False
DDI-MedLine.d50.s3	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d50.s3	ascorbic	74	81	B-drug	ascorbic	bic	rbic	NN	False
DDI-MedLine.d50.s3	acid	83	86	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d50.s3	may	88	90	O	may	may	may	MD	False
DDI-MedLine.d50.s3	be	92	93	O	be	be	be	VB	False
DDI-MedLine.d50.s3	efficacious	95	105	O	efficacious	ous	ious	JJ	False
DDI-MedLine.d50.s3	,	106	106	O	,	,	,	,	False
DDI-MedLine.d50.s3	a	108	108	O	a	a	a	DT	False
DDI-MedLine.d50.s3	second	110	115	O	second	ond	cond	JJ	False
DDI-MedLine.d50.s3	study	117	121	O	study	udy	tudy	NN	False
DDI-MedLine.d50.s3	by	123	124	O	by	by	by	IN	False
DDI-MedLine.d50.s3	the	126	128	O	the	the	the	DT	False
DDI-MedLine.d50.s3	same	130	133	O	same	ame	same	JJ	False
DDI-MedLine.d50.s3	group	135	139	O	group	oup	roup	NN	False
DDI-MedLine.d50.s3	did	141	143	O	did	did	did	VBD	False
DDI-MedLine.d50.s3	not	145	147	O	not	not	not	RB	False
DDI-MedLine.d50.s3	confirm	149	155	O	confirm	irm	firm	NN	False
DDI-MedLine.d50.s3	the	157	159	O	the	the	the	DT	False
DDI-MedLine.d50.s3	significant	161	171	O	significant	ant	cant	JJ	False
DDI-MedLine.d50.s3	findings	173	180	O	findings	ngs	ings	NNS	False
DDI-MedLine.d50.s3	,	181	181	O	,	,	,	,	False
DDI-MedLine.d50.s3	and	183	185	O	and	and	and	CC	False
DDI-MedLine.d50.s3	no	187	188	O	no	no	no	DT	False
DDI-MedLine.d50.s3	clear	190	194	O	clear	ear	lear	JJ	False
DDI-MedLine.d50.s3	,	195	195	O	,	,	,	,	False
DDI-MedLine.d50.s3	reproducible	197	208	O	reproducible	ble	ible	JJ	False
DDI-MedLine.d50.s3	pattern	210	216	O	pattern	ern	tern	NN	False
DDI-MedLine.d50.s3	of	218	219	O	of	of	of	IN	False
DDI-MedLine.d50.s3	efficacy	221	228	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d50.s3	has	230	232	O	has	has	has	VBZ	False
DDI-MedLine.d50.s3	emerged	234	240	O	emerged	ged	rged	VBD	False
DDI-MedLine.d50.s3	from	242	245	O	from	rom	from	IN	False
DDI-MedLine.d50.s3	the	247	249	O	the	the	the	DT	False
DDI-MedLine.d50.s3	review	251	256	O	review	iew	view	NN	False
DDI-MedLine.d50.s3	of	258	259	O	of	of	of	IN	False
DDI-MedLine.d50.s3	all	261	263	O	all	all	all	DT	False
DDI-MedLine.d50.s3	the	265	267	O	the	the	the	DT	False
DDI-MedLine.d50.s3	evidence	269	276	O	evidence	nce	ence	NN	False
DDI-MedLine.d50.s3	.	277	277	O	.	.	.	.	False

DDI-MedLine.d50.s4	Similarly	0	8	O	Similarly	rly	arly	RB	False
DDI-MedLine.d50.s4	,	9	9	O	,	,	,	,	False
DDI-MedLine.d50.s4	there	11	15	O	there	ere	here	RB	False
DDI-MedLine.d50.s4	is	17	18	O	is	is	is	VBZ	False
DDI-MedLine.d50.s4	currently	20	28	O	currently	tly	ntly	RB	False
DDI-MedLine.d50.s4	little	30	35	O	little	tle	ttle	JJ	False
DDI-MedLine.d50.s4	adequate	37	44	O	adequate	ate	uate	NN	False
DDI-MedLine.d50.s4	evidence	46	53	O	evidence	nce	ence	NN	False
DDI-MedLine.d50.s4	on	55	56	O	on	on	on	IN	False
DDI-MedLine.d50.s4	either	58	63	O	either	her	ther	DT	False
DDI-MedLine.d50.s4	the	65	67	O	the	the	the	DT	False
DDI-MedLine.d50.s4	presence	69	76	O	presence	nce	ence	NN	False
DDI-MedLine.d50.s4	or	78	79	O	or	or	or	CC	False
DDI-MedLine.d50.s4	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d50.s4	absence	85	91	O	absence	nce	ence	NN	False
DDI-MedLine.d50.s4	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d50.s4	serious	96	102	O	serious	ous	ious	JJ	False
DDI-MedLine.d50.s4	adverse	104	110	O	adverse	rse	erse	NN	False
DDI-MedLine.d50.s4	reactions	112	120	O	reactions	ons	ions	NNS	False
DDI-MedLine.d50.s4	to	122	123	O	to	to	to	TO	False
DDI-MedLine.d50.s4	such	125	128	O	such	uch	such	JJ	False
DDI-MedLine.d50.s4	doses	130	134	O	doses	ses	oses	NNS	False
DDI-MedLine.d50.s4	of	136	137	O	of	of	of	IN	False
DDI-MedLine.d50.s4	ascorbic	139	146	B-drug	ascorbic	bic	rbic	NN	False
DDI-MedLine.d50.s4	acid	148	151	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d50.s4	,	152	152	O	,	,	,	,	False
DDI-MedLine.d50.s4	although	154	161	O	although	ugh	ough	IN	False
DDI-MedLine.d50.s4	many	163	166	O	many	any	many	JJ	False
DDI-MedLine.d50.s4	such	168	171	O	such	uch	such	JJ	False
DDI-MedLine.d50.s4	reactions	173	181	O	reactions	ons	ions	NNS	False
DDI-MedLine.d50.s4	have	183	186	O	have	ave	have	VB	False
DDI-MedLine.d50.s4	been	188	191	O	been	een	been	VBN	False
DDI-MedLine.d50.s4	hypothesized	193	204	O	hypothesized	zed	ized	VBN	False
DDI-MedLine.d50.s4	.	205	205	O	.	.	.	.	False

DDI-MedLine.d50.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d50.s5	unrestricted	4	15	O	unrestricted	ted	cted	JJ	False
DDI-MedLine.d50.s5	use	17	19	O	use	use	use	NN	False
DDI-MedLine.d50.s5	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d50.s5	ascorbic	24	31	B-drug	ascorbic	bic	rbic	NN	False
DDI-MedLine.d50.s5	acid	33	36	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d50.s5	for	38	40	O	for	for	for	IN	False
DDI-MedLine.d50.s5	these	42	46	O	these	ese	hese	DT	False
DDI-MedLine.d50.s5	purposes	48	55	O	purposes	ses	oses	NNS	False
DDI-MedLine.d50.s5	can	57	59	O	can	can	can	MD	False
DDI-MedLine.d50.s5	not	60	62	O	not	not	not	RB	False
DDI-MedLine.d50.s5	be	64	65	O	be	be	be	VB	False
DDI-MedLine.d50.s5	advocated	67	75	O	advocated	ted	ated	VBN	False
DDI-MedLine.d50.s5	on	77	78	O	on	on	on	IN	False
DDI-MedLine.d50.s5	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d50.s5	basis	84	88	O	basis	sis	asis	NN	False
DDI-MedLine.d50.s5	of	90	91	O	of	of	of	IN	False
DDI-MedLine.d50.s5	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d50.s5	evidence	97	104	O	evidence	nce	ence	NN	False
DDI-MedLine.d50.s5	currently	106	114	O	currently	tly	ntly	RB	False
DDI-MedLine.d50.s5	available	116	124	O	available	ble	able	JJ	False
DDI-MedLine.d50.s5	.	125	125	O	.	.	.	.	False

DDI-MedLine.d18.s0	Note	0	3	O	Note	ote	Note	NN	False
DDI-MedLine.d18.s0	:	4	4	O	:	:	:	:	False
DDI-MedLine.d18.s0	dissolution	6	16	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s0	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d18.s0	aerosol	21	27	O	aerosol	sol	osol	NN	False
DDI-MedLine.d18.s0	particles	29	37	O	particles	les	cles	NNS	False
DDI-MedLine.d18.s0	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d18.s0	budesonide	42	51	B-drug	budesonide	ide	nide	NN	False
DDI-MedLine.d18.s0	in	53	54	O	in	in	in	IN	False
DDI-MedLine.d18.s0	Survanta	56	63	B-brand	Survanta	nta	anta	NN	False
DDI-MedLine.d18.s0	,	64	64	O	,	,	,	,	False
DDI-MedLine.d18.s0	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d18.s0	model	68	72	O	model	del	odel	NN	False
DDI-MedLine.d18.s0	lung	74	77	B-group	lung	ung	lung	NN	False
DDI-MedLine.d18.s0	surfactant	79	88	I-group	surfactant	ant	tant	NN	False
DDI-MedLine.d18.s0	.	89	89	O	.	.	.	.	False

DDI-MedLine.d18.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d18.s1	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d18.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d18.s1	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d18.s1	pulmonary	16	24	B-group	pulmonary	ary	nary	JJ	False
DDI-MedLine.d18.s1	surfactant	26	35	I-group	surfactant	ant	tant	NN	False
DDI-MedLine.d18.s1	extract	37	43	O	extract	act	ract	NN	False
DDI-MedLine.d18.s1	from	45	48	O	from	rom	from	IN	False
DDI-MedLine.d18.s1	bovine	50	55	O	bovine	ine	vine	NN	drug
DDI-MedLine.d18.s1	lung	57	60	O	lung	ung	lung	NN	False
DDI-MedLine.d18.s1	,	61	61	O	,	,	,	,	False
DDI-MedLine.d18.s1	Survanta	63	70	B-brand	Survanta	nta	anta	NN	False
DDI-MedLine.d18.s1	,	71	71	O	,	,	,	,	False
DDI-MedLine.d18.s1	on	73	74	O	on	on	on	IN	False
DDI-MedLine.d18.s1	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d18.s1	dissolution	80	90	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s1	rate	92	95	O	rate	ate	rate	NN	False
DDI-MedLine.d18.s1	of	97	98	O	of	of	of	IN	False
DDI-MedLine.d18.s1	aerosol	100	106	O	aerosol	sol	osol	NN	False
DDI-MedLine.d18.s1	particles	108	116	O	particles	les	cles	NNS	False
DDI-MedLine.d18.s1	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d18.s1	budesonide	121	130	B-drug	budesonide	ide	nide	NN	False
DDI-MedLine.d18.s1	was	132	134	O	was	was	was	VBD	False
DDI-MedLine.d18.s1	determined	136	145	O	determined	ned	ined	VBN	False
DDI-MedLine.d18.s1	.	146	146	O	.	.	.	.	False

DDI-MedLine.d18.s2	Aerosol	0	6	O	Aerosol	sol	osol	NN	False
DDI-MedLine.d18.s2	particles	8	16	O	particles	les	cles	NNS	False
DDI-MedLine.d18.s2	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d18.s2	budesonide	21	30	B-drug	budesonide	ide	nide	NN	False
DDI-MedLine.d18.s2	were	32	35	O	were	ere	were	VBD	False
DDI-MedLine.d18.s2	generated	37	45	O	generated	ted	ated	VBN	False
DDI-MedLine.d18.s2	from	47	50	O	from	rom	from	IN	False
DDI-MedLine.d18.s2	an	52	53	O	an	an	an	DT	False
DDI-MedLine.d18.s2	ethanol	55	61	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d18.s2	solution	63	70	O	solution	ion	tion	NN	False
DDI-MedLine.d18.s2	,	71	71	O	,	,	,	,	False
DDI-MedLine.d18.s2	dried	73	77	O	dried	ied	ried	VBN	False
DDI-MedLine.d18.s2	,	78	78	O	,	,	,	,	False
DDI-MedLine.d18.s2	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d18.s2	collected	84	92	O	collected	ted	cted	VBN	False
DDI-MedLine.d18.s2	by	94	95	O	by	by	by	IN	False
DDI-MedLine.d18.s2	a	97	97	O	a	a	a	DT	False
DDI-MedLine.d18.s2	cascade	99	105	O	cascade	ade	cade	NN	False
DDI-MedLine.d18.s2	impactor	107	114	O	impactor	tor	ctor	NN	False
DDI-MedLine.d18.s2	for	116	118	O	for	for	for	IN	False
DDI-MedLine.d18.s2	characterization	120	135	O	characterization	ion	tion	NN	False
DDI-MedLine.d18.s2	or	137	138	O	or	or	or	CC	False
DDI-MedLine.d18.s2	by	140	141	O	by	by	by	IN	False
DDI-MedLine.d18.s2	a	143	143	O	a	a	a	DT	False
DDI-MedLine.d18.s2	liquid	145	150	O	liquid	uid	quid	NN	False
DDI-MedLine.d18.s2	impinger	152	159	O	impinger	ger	nger	NN	False
DDI-MedLine.d18.s2	for	161	163	O	for	for	for	IN	False
DDI-MedLine.d18.s2	dissolution	165	175	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s2	experiments	177	187	O	experiments	nts	ents	NNS	False
DDI-MedLine.d18.s2	.	188	188	O	.	.	.	.	False

DDI-MedLine.d18.s3	Powder	0	5	O	Powder	der	wder	NN	False
DDI-MedLine.d18.s3	x-ray	7	11	O	x-ray	ray	-ray	NN	False
DDI-MedLine.d18.s3	diffraction	13	23	O	diffraction	ion	tion	NN	False
DDI-MedLine.d18.s3	,	24	24	O	,	,	,	,	False
DDI-MedLine.d18.s3	differential	26	37	O	differential	ial	tial	NN	False
DDI-MedLine.d18.s3	scanning	39	46	O	scanning	ing	ning	VBG	False
DDI-MedLine.d18.s3	calorimetry	48	58	O	calorimetry	try	etry	NN	False
DDI-MedLine.d18.s3	,	59	59	O	,	,	,	,	False
DDI-MedLine.d18.s3	differential	61	72	O	differential	ial	tial	NN	False
DDI-MedLine.d18.s3	thermal	74	80	O	thermal	mal	rmal	NN	False
DDI-MedLine.d18.s3	analysis	82	89	O	analysis	sis	ysis	NN	False
DDI-MedLine.d18.s3	,	90	90	O	,	,	,	,	False
DDI-MedLine.d18.s3	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d18.s3	scanning	96	103	O	scanning	ing	ning	VBG	False
DDI-MedLine.d18.s3	electron	105	112	O	electron	ron	tron	NN	False
DDI-MedLine.d18.s3	microscopy	114	123	O	microscopy	opy	copy	NN	False
DDI-MedLine.d18.s3	were	125	128	O	were	ere	were	VBD	False
DDI-MedLine.d18.s3	used	130	133	O	used	sed	used	VBN	False
DDI-MedLine.d18.s3	to	135	136	O	to	to	to	TO	False
DDI-MedLine.d18.s3	characterize	138	149	O	characterize	ize	rize	NN	False
DDI-MedLine.d18.s3	the	151	153	O	the	the	the	DT	False
DDI-MedLine.d18.s3	aerosol	155	161	O	aerosol	sol	osol	NN	False
DDI-MedLine.d18.s3	particles	163	171	O	particles	les	cles	NNS	False
DDI-MedLine.d18.s3	and	173	175	O	and	and	and	CC	False
DDI-MedLine.d18.s3	starting	177	184	O	starting	ing	ting	VBG	False
DDI-MedLine.d18.s3	material	186	193	O	material	ial	rial	NN	False
DDI-MedLine.d18.s3	.	194	194	O	.	.	.	.	False

DDI-MedLine.d18.s4	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d18.s4	change	3	8	O	change	nge	ange	NN	False
DDI-MedLine.d18.s4	in	10	11	O	in	in	in	IN	False
DDI-MedLine.d18.s4	phase	13	17	O	phase	ase	hase	NN	False
DDI-MedLine.d18.s4	was	19	21	O	was	was	was	VBD	False
DDI-MedLine.d18.s4	detected	23	30	O	detected	ted	cted	VBN	False
DDI-MedLine.d18.s4	,	31	31	O	,	,	,	,	False
DDI-MedLine.d18.s4	although	33	40	O	although	ugh	ough	IN	False
DDI-MedLine.d18.s4	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d18.s4	aerosol	46	52	O	aerosol	sol	osol	NN	False
DDI-MedLine.d18.s4	particles	54	62	O	particles	les	cles	NNS	False
DDI-MedLine.d18.s4	appeared	64	71	O	appeared	red	ared	VBD	False
DDI-MedLine.d18.s4	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d18.s4	contain	76	82	O	contain	ain	tain	NN	False
DDI-MedLine.d18.s4	residual	84	91	O	residual	ual	dual	JJ	False
DDI-MedLine.d18.s4	solvent	93	99	B-group	solvent	ent	vent	NN	False
DDI-MedLine.d18.s4	.	100	100	O	.	.	.	.	False

DDI-MedLine.d18.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d18.s5	dissolution	4	14	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s5	rate	16	19	O	rate	ate	rate	NN	False
DDI-MedLine.d18.s5	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d18.s5	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d18.s5	aerosol	28	34	O	aerosol	sol	osol	NN	False
DDI-MedLine.d18.s5	particles	36	44	O	particles	les	cles	NNS	False
DDI-MedLine.d18.s5	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d18.s5	saline	49	54	O	saline	ine	line	NN	drug
DDI-MedLine.d18.s5	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d18.s5	low	60	62	O	low	low	low	JJ	False
DDI-MedLine.d18.s5	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d18.s5	variable	68	75	O	variable	ble	able	JJ	False
DDI-MedLine.d18.s5	.	76	76	O	.	.	.	.	False

DDI-MedLine.d18.s6	Survanta	0	7	B-brand	Survanta	nta	anta	NN	False
DDI-MedLine.d18.s6	increased	9	17	O	increased	sed	ased	VBN	False
DDI-MedLine.d18.s6	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d18.s6	extent	23	28	O	extent	ent	tent	NN	False
DDI-MedLine.d18.s6	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d18.s6	dissolution	33	43	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s6	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d18.s6	budesonide	48	57	B-drug	budesonide	ide	nide	NN	False
DDI-MedLine.d18.s6	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d18.s6	proportion	62	71	O	proportion	ion	tion	NN	False
DDI-MedLine.d18.s6	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d18.s6	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d18.s6	added	80	84	O	added	ded	dded	VBD	False
DDI-MedLine.d18.s6	concentration	86	98	O	concentration	ion	tion	NN	False
DDI-MedLine.d18.s6	,	99	99	O	,	,	,	,	False
DDI-MedLine.d18.s6	which	101	105	O	which	ich	hich	WDT	False
DDI-MedLine.d18.s6	was	107	109	O	was	was	was	VBD	False
DDI-MedLine.d18.s6	also	111	114	O	also	lso	also	RB	False
DDI-MedLine.d18.s6	verified	116	123	O	verified	ied	fied	VBN	False
DDI-MedLine.d18.s6	by	125	126	O	by	by	by	IN	False
DDI-MedLine.d18.s6	equilibrium	128	138	O	equilibrium	ium	rium	NN	drug
DDI-MedLine.d18.s6	solubilization	140	153	O	solubilization	ion	tion	NN	False
DDI-MedLine.d18.s6	studies	155	161	O	studies	ies	dies	NNS	False
DDI-MedLine.d18.s6	.	162	162	O	.	.	.	.	False

DDI-MedLine.d18.s7	Survanta	0	7	B-brand	Survanta	nta	anta	NN	False
DDI-MedLine.d18.s7	also	9	12	O	also	lso	also	RB	False
DDI-MedLine.d18.s7	increased	14	22	O	increased	sed	ased	VBN	False
DDI-MedLine.d18.s7	rate	24	27	O	rate	ate	rate	NN	False
DDI-MedLine.d18.s7	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d18.s7	dissolution	32	42	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s7	,	43	43	O	,	,	,	,	False
DDI-MedLine.d18.s7	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d18.s7	a	48	48	O	a	a	a	DT	False
DDI-MedLine.d18.s7	manner	50	55	O	manner	ner	nner	NN	False
DDI-MedLine.d18.s7	similar	57	63	O	similar	lar	ilar	JJ	False
DDI-MedLine.d18.s7	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d18.s7	sodium	68	73	B-drug_n	sodium	ium	dium	NN	drug
DDI-MedLine.d18.s7	dodecyl	75	81	I-drug_n	dodecyl	cyl	ecyl	NN	False
DDI-MedLine.d18.s7	sulfate	83	89	I-drug_n	sulfate	ate	fate	NN	False
DDI-MedLine.d18.s7	.	90	90	O	.	.	.	.	False

DDI-MedLine.d18.s8	Analysis	0	7	O	Analysis	sis	ysis	NN	False
DDI-MedLine.d18.s8	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d18.s8	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d18.s8	concentration	16	28	O	concentration	ion	tion	NN	False
DDI-MedLine.d18.s8	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d18.s8	budesonide	33	42	B-drug	budesonide	ide	nide	NN	False
DDI-MedLine.d18.s8	following	44	52	O	following	ing	wing	VBG	False
DDI-MedLine.d18.s8	ultracentrifugation	54	72	O	ultracentrifugation	ion	tion	NN	False
DDI-MedLine.d18.s8	indicated	74	82	O	indicated	ted	ated	VBN	False
DDI-MedLine.d18.s8	that	84	87	O	that	hat	that	IN	False
DDI-MedLine.d18.s8	there	89	93	O	there	ere	here	RB	False
DDI-MedLine.d18.s8	is	95	96	O	is	is	is	VBZ	False
DDI-MedLine.d18.s8	rapid	98	102	O	rapid	pid	apid	JJ	False
DDI-MedLine.d18.s8	equilibration	104	116	O	equilibration	ion	tion	NN	False
DDI-MedLine.d18.s8	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d18.s8	budesonide	121	130	B-drug	budesonide	ide	nide	NN	False
DDI-MedLine.d18.s8	between	132	138	O	between	een	ween	IN	False
DDI-MedLine.d18.s8	the	140	142	O	the	the	the	DT	False
DDI-MedLine.d18.s8	Survanta	144	151	B-brand	Survanta	nta	anta	NN	False
DDI-MedLine.d18.s8	and	153	155	O	and	and	and	CC	False
DDI-MedLine.d18.s8	aqueous	157	163	O	aqueous	ous	eous	JJ	False
DDI-MedLine.d18.s8	phase	165	169	O	phase	ase	hase	NN	False
DDI-MedLine.d18.s8	.	170	170	O	.	.	.	.	False

DDI-MedLine.d18.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d18.s9	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d18.s9	show	14	17	O	show	how	show	NN	False
DDI-MedLine.d18.s9	that	19	22	O	that	hat	that	IN	False
DDI-MedLine.d18.s9	lung	24	27	B-group	lung	ung	lung	NN	False
DDI-MedLine.d18.s9	surfactant	29	38	I-group	surfactant	ant	tant	NN	False
DDI-MedLine.d18.s9	has	40	42	O	has	has	has	VBZ	False
DDI-MedLine.d18.s9	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d18.s9	potential	48	56	O	potential	ial	tial	JJ	False
DDI-MedLine.d18.s9	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d18.s9	enhancing	61	69	O	enhancing	ing	cing	VBG	False
DDI-MedLine.d18.s9	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d18.s9	rate	75	78	O	rate	ate	rate	NN	False
DDI-MedLine.d18.s9	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d18.s9	extent	84	89	O	extent	ent	tent	NN	False
DDI-MedLine.d18.s9	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d18.s9	dissolution	94	104	O	dissolution	ion	tion	NN	False
DDI-MedLine.d18.s9	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d18.s9	drugs	109	113	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d18.s9	administered	115	126	O	administered	red	ered	VBN	False
DDI-MedLine.d18.s9	to	128	129	O	to	to	to	TO	False
DDI-MedLine.d18.s9	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d18.s9	lung	135	138	O	lung	ung	lung	NN	False
DDI-MedLine.d18.s9	.	139	139	O	.	.	.	.	False

DDI-MedLine.d116.s0	Rifampin	0	7	B-drug	Rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s0	and	9	11	O	and	and	and	CC	False
DDI-MedLine.d116.s0	warfarin	13	20	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s0	:	21	21	O	:	:	:	:	False
DDI-MedLine.d116.s0	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d116.s0	drug	25	28	O	drug	rug	drug	NN	False
DDI-MedLine.d116.s0	interaction	30	40	O	interaction	ion	tion	NN	False
DDI-MedLine.d116.s0	.	41	41	O	.	.	.	.	False

DDI-MedLine.d116.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d116.s1	drug	4	7	O	drug	rug	drug	NN	False
DDI-MedLine.d116.s1	interaction	9	19	O	interaction	ion	tion	NN	False
DDI-MedLine.d116.s1	between	21	27	O	between	een	ween	IN	False
DDI-MedLine.d116.s1	warfarin	29	36	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s1	and	38	40	O	and	and	and	CC	False
DDI-MedLine.d116.s1	rifampin	42	49	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s1	is	51	52	O	is	is	is	VBZ	False
DDI-MedLine.d116.s1	not	54	56	O	not	not	not	RB	False
DDI-MedLine.d116.s1	well	58	61	O	well	ell	well	RB	False
DDI-MedLine.d116.s1	known	63	67	O	known	own	nown	VBN	False
DDI-MedLine.d116.s1	.	68	68	O	.	.	.	.	False

DDI-MedLine.d116.s2	Rifampin	0	7	B-drug	Rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s2	has	9	11	O	has	has	has	VBZ	False
DDI-MedLine.d116.s2	been	13	16	O	been	een	been	VBN	False
DDI-MedLine.d116.s2	reported	18	25	O	reported	ted	rted	VBD	False
DDI-MedLine.d116.s2	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d116.s2	increase	30	37	O	increase	ase	ease	NN	False
DDI-MedLine.d116.s2	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d116.s2	warfarin	43	50	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s2	requirements	52	63	O	requirements	nts	ents	NNS	False
DDI-MedLine.d116.s2	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d116.s2	human	68	72	O	human	man	uman	NN	False
DDI-MedLine.d116.s2	subjects	74	81	O	subjects	cts	ects	NNS	False
DDI-MedLine.d116.s2	ingesting	83	91	O	ingesting	ing	ting	VBG	False
DDI-MedLine.d116.s2	these	93	97	O	these	ese	hese	DT	False
DDI-MedLine.d116.s2	agents	99	104	O	agents	nts	ents	NNS	False
DDI-MedLine.d116.s2	simultaneously	106	119	O	simultaneously	sly	usly	RB	False
DDI-MedLine.d116.s2	.	120	120	O	.	.	.	.	False

DDI-MedLine.d116.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d116.s3	concomitant	4	14	O	concomitant	ant	tant	NN	False
DDI-MedLine.d116.s3	administration	16	29	O	administration	ion	tion	NN	False
DDI-MedLine.d116.s3	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d116.s3	rifampin	34	41	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s3	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d116.s3	warfarin	47	54	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s3	resulted	56	63	O	resulted	ted	lted	VBD	False
DDI-MedLine.d116.s3	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d116.s3	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d116.s3	need	72	75	O	need	eed	need	NN	False
DDI-MedLine.d116.s3	for	77	79	O	for	for	for	IN	False
DDI-MedLine.d116.s3	an	81	82	O	an	an	an	DT	False
DDI-MedLine.d116.s3	unusually	84	92	O	unusually	lly	ally	RB	False
DDI-MedLine.d116.s3	high	94	97	O	high	igh	high	JJ	False
DDI-MedLine.d116.s3	maintenance	99	109	O	maintenance	nce	ance	NN	False
DDI-MedLine.d116.s3	dose	111	114	O	dose	ose	dose	NN	False
DDI-MedLine.d116.s3	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d116.s3	warfarin	119	126	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s3	(	128	128	O	(	(	(	(	False
DDI-MedLine.d116.s3	20	129	130	O	20	20	20	CD	False
DDI-MedLine.d116.s3	mg	132	133	O	mg	mg	mg	NN	False
DDI-MedLine.d116.s3	per	135	137	O	per	per	per	IN	False
DDI-MedLine.d116.s3	day	139	141	O	day	day	day	NN	False
DDI-MedLine.d116.s3	)	142	142	O	)	)	)	)	False
DDI-MedLine.d116.s3	in	144	145	O	in	in	in	IN	False
DDI-MedLine.d116.s3	order	147	151	O	order	der	rder	NN	False
DDI-MedLine.d116.s3	to	153	154	O	to	to	to	TO	False
DDI-MedLine.d116.s3	produce	156	162	O	produce	uce	duce	NN	False
DDI-MedLine.d116.s3	a	164	164	O	a	a	a	DT	False
DDI-MedLine.d116.s3	therapeutic	166	176	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d116.s3	effect	178	183	O	effect	ect	fect	NN	False
DDI-MedLine.d116.s3	.	184	184	O	.	.	.	.	False

DDI-MedLine.d116.s4	Withdrawal	0	9	O	Withdrawal	wal	awal	NN	False
DDI-MedLine.d116.s4	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d116.s4	rifampin	14	21	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s4	decreased	23	31	O	decreased	sed	ased	VBN	False
DDI-MedLine.d116.s4	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d116.s4	warfarin	37	44	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s4	requirement	46	56	O	requirement	ent	ment	NN	False
DDI-MedLine.d116.s4	by	58	59	O	by	by	by	IN	False
DDI-MedLine.d116.s4	50	61	62	O	50	50	50	CD	False
DDI-MedLine.d116.s4	%	63	63	O	%	%	%	NN	False
DDI-MedLine.d116.s4	.	64	64	O	.	.	.	.	False

DDI-MedLine.d116.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d116.s5	effect	5	10	O	effect	ect	fect	NN	False
DDI-MedLine.d116.s5	may	12	14	O	may	may	may	MD	False
DDI-MedLine.d116.s5	be	16	17	O	be	be	be	VB	False
DDI-MedLine.d116.s5	mediated	19	26	O	mediated	ted	ated	VBN	False
DDI-MedLine.d116.s5	by	28	29	O	by	by	by	IN	False
DDI-MedLine.d116.s5	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d116.s5	ability	35	41	O	ability	ity	lity	NN	False
DDI-MedLine.d116.s5	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d116.s5	rifampin	46	53	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s5	to	55	56	O	to	to	to	TO	False
DDI-MedLine.d116.s5	induce	58	63	O	induce	uce	duce	NN	False
DDI-MedLine.d116.s5	microsomal	65	74	O	microsomal	mal	omal	NN	False
DDI-MedLine.d116.s5	enzymes	76	82	O	enzymes	mes	ymes	NNS	False
DDI-MedLine.d116.s5	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d116.s5	,	87	87	O	,	,	,	,	False
DDI-MedLine.d116.s5	thus	89	92	O	thus	hus	thus	RB	False
DDI-MedLine.d116.s5	,	93	93	O	,	,	,	,	False
DDI-MedLine.d116.s5	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d116.s5	catabolism	99	108	O	catabolism	ism	lism	NN	False
DDI-MedLine.d116.s5	of	110	111	O	of	of	of	IN	False
DDI-MedLine.d116.s5	warfarin	113	120	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s5	.	121	121	O	.	.	.	.	False

DDI-MedLine.d116.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d116.s6	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d116.s6	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d116.s6	rifampin	14	21	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s6	on	23	24	O	on	on	on	IN	False
DDI-MedLine.d116.s6	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d116.s6	warfarin	30	37	B-drug	warfarin	rin	arin	NN	False
DDI-MedLine.d116.s6	requirement	39	49	O	requirement	ent	ment	NN	False
DDI-MedLine.d116.s6	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d116.s6	our	54	56	O	our	our	our	PRP$	False
DDI-MedLine.d116.s6	patient	58	64	O	patient	ent	ient	NN	False
DDI-MedLine.d116.s6	appeared	66	73	O	appeared	red	ared	VBD	False
DDI-MedLine.d116.s6	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d116.s6	be	78	79	O	be	be	be	VB	False
DDI-MedLine.d116.s6	maximal	81	87	O	maximal	mal	imal	NN	False
DDI-MedLine.d116.s6	5	89	89	O	5	5	5	CD	False
DDI-MedLine.d116.s6	to	91	92	O	to	to	to	TO	False
DDI-MedLine.d116.s6	7	94	94	O	7	7	7	CD	False
DDI-MedLine.d116.s6	days	96	99	O	days	ays	days	NNS	False
DDI-MedLine.d116.s6	after	101	105	O	after	ter	fter	IN	False
DDI-MedLine.d116.s6	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d116.s6	initiation	111	120	O	initiation	ion	tion	NN	False
DDI-MedLine.d116.s6	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d116.s6	rifampin	125	132	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s6	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d116.s6	extended	138	145	O	extended	ded	nded	VBN	False
DDI-MedLine.d116.s6	a	147	147	O	a	a	a	DT	False
DDI-MedLine.d116.s6	similar	149	155	O	similar	lar	ilar	JJ	False
DDI-MedLine.d116.s6	length	157	162	O	length	gth	ngth	NN	False
DDI-MedLine.d116.s6	of	164	165	O	of	of	of	IN	False
DDI-MedLine.d116.s6	time	167	170	O	time	ime	time	NN	False
DDI-MedLine.d116.s6	after	172	176	O	after	ter	fter	IN	False
DDI-MedLine.d116.s6	rifampin	178	185	B-drug	rifampin	pin	mpin	NN	False
DDI-MedLine.d116.s6	withdrawal	187	196	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d116.s6	.	197	197	O	.	.	.	.	False

DDI-MedLine.d116.s7	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d116.s7	interaction	5	15	O	interaction	ion	tion	NN	False
DDI-MedLine.d116.s7	appears	17	23	O	appears	ars	ears	VBZ	False
DDI-MedLine.d116.s7	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d116.s7	be	28	29	O	be	be	be	VB	False
DDI-MedLine.d116.s7	clinically	31	40	O	clinically	lly	ally	RB	False
DDI-MedLine.d116.s7	significant	42	52	O	significant	ant	cant	JJ	False
DDI-MedLine.d116.s7	.	53	53	O	.	.	.	.	False

DDI-MedLine.d62.s0	Activation	0	9	O	Activation	ion	tion	NN	False
DDI-MedLine.d62.s0	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d62.s0	an	14	15	O	an	an	an	DT	False
DDI-MedLine.d62.s0	effector	17	24	O	effector	tor	ctor	NN	False
DDI-MedLine.d62.s0	immediate-early	26	40	O	immediate-early	rly	arly	JJ	False
DDI-MedLine.d62.s0	gene	42	45	O	gene	ene	gene	NN	False
DDI-MedLine.d62.s0	arc	47	49	O	arc	arc	arc	NN	False
DDI-MedLine.d62.s0	by	51	52	O	by	by	by	IN	False
DDI-MedLine.d62.s0	methamphetamine	54	68	B-drug	methamphetamine	ine	mine	NN	drug
DDI-MedLine.d62.s0	.	69	69	O	.	.	.	.	False

DDI-MedLine.d62.s1	As	0	1	O	As	As	As	IN	False
DDI-MedLine.d62.s1	immediate-early	3	17	O	immediate-early	rly	arly	JJ	False
DDI-MedLine.d62.s1	genes	19	23	O	genes	nes	enes	NNS	False
DDI-MedLine.d62.s1	(	25	25	O	(	(	(	(	False
DDI-MedLine.d62.s1	IEGs	26	29	O	IEGs	EGs	IEGs	NN	False
DDI-MedLine.d62.s1	)	30	30	O	)	)	)	)	False
DDI-MedLine.d62.s1	are	32	34	O	are	are	are	VBP	False
DDI-MedLine.d62.s1	thought	36	42	O	thought	ght	ught	NN	False
DDI-MedLine.d62.s1	to	44	45	O	to	to	to	TO	False
DDI-MedLine.d62.s1	play	47	50	O	play	lay	play	NN	False
DDI-MedLine.d62.s1	a	52	52	O	a	a	a	DT	False
DDI-MedLine.d62.s1	critical	54	61	O	critical	cal	ical	JJ	False
DDI-MedLine.d62.s1	role	63	66	O	role	ole	role	NN	False
DDI-MedLine.d62.s1	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d62.s1	mediating	71	79	O	mediating	ing	ting	VBG	False
DDI-MedLine.d62.s1	stimulus-induced	81	96	O	stimulus-induced	ced	uced	JJ	False
DDI-MedLine.d62.s1	neural	98	103	O	neural	ral	ural	JJ	False
DDI-MedLine.d62.s1	plasticity	105	114	O	plasticity	ity	city	NN	False
DDI-MedLine.d62.s1	,	115	115	O	,	,	,	,	False
DDI-MedLine.d62.s1	IEG	117	119	O	IEG	IEG	IEG	NN	brand
DDI-MedLine.d62.s1	response	121	128	O	response	nse	onse	NN	False
DDI-MedLine.d62.s1	induced	130	136	O	induced	ced	uced	JJ	False
DDI-MedLine.d62.s1	by	138	139	O	by	by	by	IN	False
DDI-MedLine.d62.s1	methamphetamine	141	155	B-drug	methamphetamine	ine	mine	NN	drug
DDI-MedLine.d62.s1	(	157	157	O	(	(	(	(	False
DDI-MedLine.d62.s1	METH	158	161	B-drug	METH	ETH	METH	NN	brand
DDI-MedLine.d62.s1	)	162	162	O	)	)	)	)	False
DDI-MedLine.d62.s1	has	164	166	O	has	has	has	VBZ	False
DDI-MedLine.d62.s1	been	168	171	O	been	een	been	VBN	False
DDI-MedLine.d62.s1	characterized	173	185	O	characterized	zed	ized	VBN	False
DDI-MedLine.d62.s1	to	187	188	O	to	to	to	TO	False
DDI-MedLine.d62.s1	define	190	195	O	define	ine	fine	NN	drug
DDI-MedLine.d62.s1	the	197	199	O	the	the	the	DT	False
DDI-MedLine.d62.s1	changes	201	207	O	changes	ges	nges	NNS	False
DDI-MedLine.d62.s1	in	209	210	O	in	in	in	IN	False
DDI-MedLine.d62.s1	gene	212	215	O	gene	ene	gene	NN	False
DDI-MedLine.d62.s1	expression	217	226	O	expression	ion	sion	NN	False
DDI-MedLine.d62.s1	that	228	231	O	that	hat	that	IN	False
DDI-MedLine.d62.s1	may	233	235	O	may	may	may	MD	False
DDI-MedLine.d62.s1	underlie	237	244	O	underlie	lie	rlie	NN	False
DDI-MedLine.d62.s1	its	246	248	O	its	its	its	PRP$	False
DDI-MedLine.d62.s1	long-lasting	250	261	O	long-lasting	ing	ting	NN	False
DDI-MedLine.d62.s1	behavioral	263	272	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d62.s1	effects	274	280	O	effects	cts	ects	NNS	False
DDI-MedLine.d62.s1	.	281	281	O	.	.	.	.	False

DDI-MedLine.d62.s2	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d62.s2	activation	9	18	O	activation	ion	tion	NN	False
DDI-MedLine.d62.s2	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d62.s2	several	23	29	O	several	ral	eral	JJ	False
DDI-MedLine.d62.s2	transcription	31	43	O	transcription	ion	tion	NN	False
DDI-MedLine.d62.s2	factor	45	50	O	factor	tor	ctor	NN	False
DDI-MedLine.d62.s2	IEGs	52	55	O	IEGs	EGs	IEGs	NN	False
DDI-MedLine.d62.s2	has	57	59	O	has	has	has	VBZ	False
DDI-MedLine.d62.s2	been	61	64	O	been	een	been	VBN	False
DDI-MedLine.d62.s2	described	66	74	O	described	bed	ibed	NN	False
DDI-MedLine.d62.s2	,	75	75	O	,	,	,	,	False
DDI-MedLine.d62.s2	little	77	82	O	little	tle	ttle	JJ	False
DDI-MedLine.d62.s2	is	84	85	O	is	is	is	VBZ	False
DDI-MedLine.d62.s2	known	87	91	O	known	own	nown	VBN	False
DDI-MedLine.d62.s2	about	93	97	O	about	out	bout	IN	False
DDI-MedLine.d62.s2	effector	99	106	O	effector	tor	ctor	NN	False
DDI-MedLine.d62.s2	IEGs	108	111	O	IEGs	EGs	IEGs	NN	False
DDI-MedLine.d62.s2	.	112	112	O	.	.	.	.	False

DDI-MedLine.d62.s3	Here	0	3	O	Here	ere	Here	RB	False
DDI-MedLine.d62.s3	,	4	4	O	,	,	,	,	False
DDI-MedLine.d62.s3	we	6	7	O	we	we	we	PRP	False
DDI-MedLine.d62.s3	have	9	12	O	have	ave	have	VB	False
DDI-MedLine.d62.s3	examined	14	21	O	examined	ned	ined	VBN	False
DDI-MedLine.d62.s3	whether	23	29	O	whether	her	ther	IN	False
DDI-MedLine.d62.s3	METH	31	34	B-drug	METH	ETH	METH	NN	brand
DDI-MedLine.d62.s3	administration	36	49	O	administration	ion	tion	NN	False
DDI-MedLine.d62.s3	affects	51	57	O	affects	cts	ects	NNS	False
DDI-MedLine.d62.s3	expression	59	68	O	expression	ion	sion	NN	False
DDI-MedLine.d62.s3	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d62.s3	an	73	74	O	an	an	an	DT	False
DDI-MedLine.d62.s3	effector	76	83	O	effector	tor	ctor	NN	False
DDI-MedLine.d62.s3	IEG	85	87	O	IEG	IEG	IEG	NN	brand
DDI-MedLine.d62.s3	arc	89	91	O	arc	arc	arc	NN	False
DDI-MedLine.d62.s3	(	93	93	O	(	(	(	(	False
DDI-MedLine.d62.s3	activity-regulated	94	111	O	activity-regulated	ted	ated	JJ	False
DDI-MedLine.d62.s3	,	112	112	O	,	,	,	,	False
DDI-MedLine.d62.s3	cytoskeleton-associated	114	136	O	cytoskeleton-associated	ted	ated	JJ	False
DDI-MedLine.d62.s3	)	137	137	O	)	)	)	)	False
DDI-MedLine.d62.s3	that	139	142	O	that	hat	that	IN	False
DDI-MedLine.d62.s3	encodes	144	150	O	encodes	des	odes	NNS	False
DDI-MedLine.d62.s3	a	152	152	O	a	a	a	DT	False
DDI-MedLine.d62.s3	protein	154	160	O	protein	ein	tein	NN	False
DDI-MedLine.d62.s3	with	162	165	O	with	ith	with	IN	False
DDI-MedLine.d62.s3	homology	167	174	O	homology	ogy	logy	NN	False
DDI-MedLine.d62.s3	to	176	177	O	to	to	to	TO	False
DDI-MedLine.d62.s3	spectrin	179	186	O	spectrin	rin	trin	NN	False
DDI-MedLine.d62.s3	.	187	187	O	.	.	.	.	False

DDI-MedLine.d62.s4	Using	0	4	O	Using	ing	sing	VBG	False
DDI-MedLine.d62.s4	in	6	7	O	in	in	in	IN	False
DDI-MedLine.d62.s4	situ	9	12	O	situ	itu	situ	NN	False
DDI-MedLine.d62.s4	hybridization	14	26	O	hybridization	ion	tion	NN	False
DDI-MedLine.d62.s4	,	27	27	O	,	,	,	,	False
DDI-MedLine.d62.s4	we	29	30	O	we	we	we	PRP	False
DDI-MedLine.d62.s4	observed	32	39	O	observed	ved	rved	VBN	False
DDI-MedLine.d62.s4	that	41	44	O	that	hat	that	IN	False
DDI-MedLine.d62.s4	METH	46	49	B-drug	METH	ETH	METH	NN	brand
DDI-MedLine.d62.s4	caused	51	56	O	caused	sed	used	VBN	False
DDI-MedLine.d62.s4	a	58	58	O	a	a	a	DT	False
DDI-MedLine.d62.s4	rapid	60	64	O	rapid	pid	apid	JJ	False
DDI-MedLine.d62.s4	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d62.s4	transient	70	78	O	transient	ent	ient	NN	False
DDI-MedLine.d62.s4	dose-dependent	80	93	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d62.s4	increase	95	102	O	increase	ase	ease	NN	False
DDI-MedLine.d62.s4	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d62.s4	arc	107	109	O	arc	arc	arc	NN	False
DDI-MedLine.d62.s4	mRNA	111	114	O	mRNA	RNA	mRNA	NN	False
DDI-MedLine.d62.s4	level	116	120	O	level	vel	evel	NN	False
DDI-MedLine.d62.s4	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d62.s4	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d62.s4	striatum	129	136	O	striatum	tum	atum	NN	False
DDI-MedLine.d62.s4	and	138	140	O	and	and	and	CC	False
DDI-MedLine.d62.s4	cortex	142	147	O	cortex	tex	rtex	NN	False
DDI-MedLine.d62.s4	that	149	152	O	that	hat	that	IN	False
DDI-MedLine.d62.s4	was	154	156	O	was	was	was	VBD	False
DDI-MedLine.d62.s4	abolished	158	166	O	abolished	hed	shed	VBN	False
DDI-MedLine.d62.s4	by	168	169	O	by	by	by	IN	False
DDI-MedLine.d62.s4	pretreatment	171	182	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d62.s4	with	184	187	O	with	ith	with	IN	False
DDI-MedLine.d62.s4	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d62.s4	specific	193	200	O	specific	fic	ific	JJ	False
DDI-MedLine.d62.s4	dopamine	202	209	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d62.s4	D1	211	212	O	D1	D1	D1	NN	brand
DDI-MedLine.d62.s4	receptor	214	221	O	receptor	tor	ptor	NN	False
DDI-MedLine.d62.s4	antagonist	223	232	O	antagonist	ist	nist	NN	False
DDI-MedLine.d62.s4	SCH-23390	234	242	B-drug_n	SCH-23390	390	3390	NN	brand
DDI-MedLine.d62.s4	but	244	246	O	but	but	but	CC	False
DDI-MedLine.d62.s4	not	248	250	O	not	not	not	RB	False
DDI-MedLine.d62.s4	by	252	253	O	by	by	by	IN	False
DDI-MedLine.d62.s4	an	255	256	O	an	an	an	DT	False
DDI-MedLine.d62.s4	atypical	258	265	B-group	atypical	cal	ical	JJ	False
DDI-MedLine.d62.s4	neuroleptic	267	277	I-group	neuroleptic	tic	ptic	JJ	False
DDI-MedLine.d62.s4	clozapine	279	287	B-drug	clozapine	ine	pine	NN	drug
DDI-MedLine.d62.s4	.	288	288	O	.	.	.	.	False

DDI-MedLine.d62.s5	METH	0	3	B-drug	METH	ETH	METH	NN	brand
DDI-MedLine.d62.s5	induced	5	11	O	induced	ced	uced	JJ	False
DDI-MedLine.d62.s5	arc	13	15	O	arc	arc	arc	NN	False
DDI-MedLine.d62.s5	mRNA	17	20	O	mRNA	RNA	mRNA	NN	False
DDI-MedLine.d62.s5	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d62.s5	layers	25	30	O	layers	ers	yers	NNS	False
DDI-MedLine.d62.s5	IV	32	33	O	IV	IV	IV	NN	brand
DDI-MedLine.d62.s5	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d62.s5	VI	39	40	O	VI	VI	VI	NN	brand
DDI-MedLine.d62.s5	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d62.s5	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d62.s5	cortex	49	54	O	cortex	tex	rtex	NN	False
DDI-MedLine.d62.s5	which	56	60	O	which	ich	hich	WDT	False
DDI-MedLine.d62.s5	dopamine	62	69	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d62.s5	receptor	71	78	O	receptor	tor	ptor	NN	False
DDI-MedLine.d62.s5	are	80	82	O	are	are	are	VBP	False
DDI-MedLine.d62.s5	localized	84	92	O	localized	zed	ized	VBN	False
DDI-MedLine.d62.s5	to	94	95	O	to	to	to	TO	False
DDI-MedLine.d62.s5	.	96	96	O	.	.	.	.	False

DDI-MedLine.d62.s6	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d62.s6	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d62.s6	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d62.s6	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d62.s6	D1	27	28	O	D1	D1	D1	NN	brand
DDI-MedLine.d62.s6	receptors	30	38	O	receptors	ors	tors	NNS	False
DDI-MedLine.d62.s6	are	40	42	O	are	are	are	VBP	False
DDI-MedLine.d62.s6	coupled	44	50	O	coupled	led	pled	VBN	False
DDI-MedLine.d62.s6	to	52	53	O	to	to	to	TO	False
DDI-MedLine.d62.s6	activation	55	64	O	activation	ion	tion	NN	False
DDI-MedLine.d62.s6	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d62.s6	arc	69	71	O	arc	arc	arc	NN	False
DDI-MedLine.d62.s6	gene	73	76	O	gene	ene	gene	NN	False
DDI-MedLine.d62.s6	,	77	77	O	,	,	,	,	False
DDI-MedLine.d62.s6	which	79	83	O	which	ich	hich	WDT	False
DDI-MedLine.d62.s6	may	85	87	O	may	may	may	MD	False
DDI-MedLine.d62.s6	be	89	90	O	be	be	be	VB	False
DDI-MedLine.d62.s6	involved	92	99	O	involved	ved	lved	VBN	False
DDI-MedLine.d62.s6	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d62.s6	functional	104	113	O	functional	nal	onal	JJ	False
DDI-MedLine.d62.s6	or	115	116	O	or	or	or	CC	False
DDI-MedLine.d62.s6	structural	118	127	O	structural	ral	ural	JJ	False
DDI-MedLine.d62.s6	alterations	129	139	O	alterations	ons	ions	NNS	False
DDI-MedLine.d62.s6	underlying	141	150	O	underlying	ing	ying	VBG	False
DDI-MedLine.d62.s6	neural	152	157	O	neural	ral	ural	JJ	False
DDI-MedLine.d62.s6	plasticity	159	168	O	plasticity	ity	city	NN	False
DDI-MedLine.d62.s6	triggered	170	178	O	triggered	red	ered	VBN	False
DDI-MedLine.d62.s6	by	180	181	O	by	by	by	IN	False
DDI-MedLine.d62.s6	METH	183	186	B-drug	METH	ETH	METH	NN	brand
DDI-MedLine.d62.s6	.	187	187	O	.	.	.	.	False

DDI-MedLine.d54.s0	Cholinergic	0	10	O	Cholinergic	gic	rgic	NN	False
DDI-MedLine.d54.s0	role	12	15	O	role	ole	role	NN	False
DDI-MedLine.d54.s0	in	17	18	O	in	in	in	IN	False
DDI-MedLine.d54.s0	alcohol	20	26	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d54.s0	's	27	28	O	's	's	's	POS	False
DDI-MedLine.d54.s0	effects	30	36	O	effects	cts	ects	NNS	False
DDI-MedLine.d54.s0	on	38	39	O	on	on	on	IN	False
DDI-MedLine.d54.s0	evoked	41	46	O	evoked	ked	oked	VBN	False
DDI-MedLine.d54.s0	potentials	48	57	O	potentials	als	ials	NNS	False
DDI-MedLine.d54.s0	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d54.s0	visual	62	67	O	visual	ual	sual	JJ	False
DDI-MedLine.d54.s0	cortex	69	74	O	cortex	tex	rtex	NN	False
DDI-MedLine.d54.s0	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d54.s0	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d54.s0	albino	83	88	O	albino	ino	bino	NN	False
DDI-MedLine.d54.s0	rat	90	92	O	rat	rat	rat	NN	False
DDI-MedLine.d54.s0	.	93	93	O	.	.	.	.	False

DDI-MedLine.d54.s1	Photic	0	5	O	Photic	tic	otic	JJ	False
DDI-MedLine.d54.s1	evoked	7	12	O	evoked	ked	oked	VBN	False
DDI-MedLine.d54.s1	potentials	14	23	O	potentials	als	ials	NNS	False
DDI-MedLine.d54.s1	were	25	28	O	were	ere	were	VBD	False
DDI-MedLine.d54.s1	recorded	30	37	O	recorded	ded	rded	VBN	False
DDI-MedLine.d54.s1	from	39	42	O	from	rom	from	IN	False
DDI-MedLine.d54.s1	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d54.s1	visual	48	53	O	visual	ual	sual	JJ	False
DDI-MedLine.d54.s1	cortex	55	60	O	cortex	tex	rtex	NN	False
DDI-MedLine.d54.s1	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d54.s1	chronically	65	75	O	chronically	lly	ally	RB	False
DDI-MedLine.d54.s1	implanted	77	85	O	implanted	ted	nted	VBN	False
DDI-MedLine.d54.s1	albino	87	92	O	albino	ino	bino	NN	False
DDI-MedLine.d54.s1	rats	94	97	O	rats	ats	rats	NNS	False
DDI-MedLine.d54.s1	.	98	98	O	.	.	.	.	False

DDI-MedLine.d54.s2	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d54.s2	photic	6	11	O	photic	tic	otic	JJ	False
DDI-MedLine.d54.s2	evoked	13	18	O	evoked	ked	oked	VBN	False
DDI-MedLine.d54.s2	potential	20	28	O	potential	ial	tial	JJ	False
DDI-MedLine.d54.s2	components	30	39	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s2	are	41	43	O	are	are	are	VBP	False
DDI-MedLine.d54.s2	representations	45	59	O	representations	ons	ions	NNS	False
DDI-MedLine.d54.s2	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d54.s2	neural	64	69	O	neural	ral	ural	JJ	False
DDI-MedLine.d54.s2	pathways	71	78	O	pathways	ays	ways	NNS	False
DDI-MedLine.d54.s2	which	80	84	O	which	ich	hich	WDT	False
DDI-MedLine.d54.s2	are	86	88	O	are	are	are	VBP	False
DDI-MedLine.d54.s2	activated	90	98	O	activated	ted	ated	VBN	False
DDI-MedLine.d54.s2	during	100	105	O	during	ing	ring	IN	False
DDI-MedLine.d54.s2	photic	107	112	O	photic	tic	otic	JJ	False
DDI-MedLine.d54.s2	stimulation	114	124	O	stimulation	ion	tion	NN	False
DDI-MedLine.d54.s2	,	125	125	O	,	,	,	,	False
DDI-MedLine.d54.s2	study	127	131	O	study	udy	tudy	NN	False
DDI-MedLine.d54.s2	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d54.s2	the	136	138	O	the	the	the	DT	False
DDI-MedLine.d54.s2	effects	140	146	O	effects	cts	ects	NNS	False
DDI-MedLine.d54.s2	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d54.s2	alcohol	151	157	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d54.s2	on	159	160	O	on	on	on	IN	False
DDI-MedLine.d54.s2	these	162	166	O	these	ese	hese	DT	False
DDI-MedLine.d54.s2	components	168	177	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s2	may	179	181	O	may	may	may	MD	False
DDI-MedLine.d54.s2	help	183	186	O	help	elp	help	NN	False
DDI-MedLine.d54.s2	to	188	189	O	to	to	to	TO	False
DDI-MedLine.d54.s2	trace	191	195	O	trace	ace	race	NN	False
DDI-MedLine.d54.s2	pathways	197	204	O	pathways	ays	ways	NNS	False
DDI-MedLine.d54.s2	which	206	210	O	which	ich	hich	WDT	False
DDI-MedLine.d54.s2	are	212	214	O	are	are	are	VBP	False
DDI-MedLine.d54.s2	affected	216	223	O	affected	ted	cted	JJ	False
DDI-MedLine.d54.s2	by	225	226	O	by	by	by	IN	False
DDI-MedLine.d54.s2	alcohol	228	234	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d54.s2	.	235	235	O	.	.	.	.	False

DDI-MedLine.d54.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d54.s3	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d54.s3	present	7	13	O	present	ent	sent	NN	False
DDI-MedLine.d54.s3	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d54.s3	,	20	20	O	,	,	,	,	False
DDI-MedLine.d54.s3	evoked	22	27	O	evoked	ked	oked	VBN	False
DDI-MedLine.d54.s3	potentials	29	38	O	potentials	als	ials	NNS	False
DDI-MedLine.d54.s3	were	40	43	O	were	ere	were	VBD	False
DDI-MedLine.d54.s3	recorded	45	52	O	recorded	ded	rded	VBN	False
DDI-MedLine.d54.s3	at	54	55	O	at	at	at	IN	False
DDI-MedLine.d54.s3	5	57	57	O	5	5	5	CD	False
DDI-MedLine.d54.s3	,	58	58	O	,	,	,	,	False
DDI-MedLine.d54.s3	20	60	61	O	20	20	20	CD	False
DDI-MedLine.d54.s3	,	62	62	O	,	,	,	,	False
DDI-MedLine.d54.s3	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d54.s3	40	68	69	O	40	40	40	CD	False
DDI-MedLine.d54.s3	min	71	73	O	min	min	min	NN	False
DDI-MedLine.d54.s3	following	75	83	O	following	ing	wing	VBG	False
DDI-MedLine.d54.s3	IP	85	86	O	IP	IP	IP	NN	brand
DDI-MedLine.d54.s3	injections	88	97	O	injections	ons	ions	NNS	False
DDI-MedLine.d54.s3	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d54.s3	saline	102	107	O	saline	ine	line	NN	drug
DDI-MedLine.d54.s3	,	108	108	O	,	,	,	,	False
DDI-MedLine.d54.s3	ethanol	110	116	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d54.s3	(	118	118	O	(	(	(	(	False
DDI-MedLine.d54.s3	2.0	119	121	O	2.0	2.0	2.0	CD	False
DDI-MedLine.d54.s3	g/kg	123	126	O	g/kg	/kg	g/kg	NN	False
DDI-MedLine.d54.s3	)	127	127	O	)	)	)	)	False
DDI-MedLine.d54.s3	,	128	128	O	,	,	,	,	False
DDI-MedLine.d54.s3	physostigmine	130	142	B-drug	physostigmine	ine	mine	NN	drug
DDI-MedLine.d54.s3	(	144	144	O	(	(	(	(	False
DDI-MedLine.d54.s3	0.6	145	147	O	0.6	0.6	0.6	CD	False
DDI-MedLine.d54.s3	mg/kg	149	153	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d54.s3	)	154	154	O	)	)	)	)	False
DDI-MedLine.d54.s3	or	156	157	O	or	or	or	CC	False
DDI-MedLine.d54.s3	atropine	159	166	B-drug	atropine	ine	pine	NN	drug
DDI-MedLine.d54.s3	(	168	168	O	(	(	(	(	False
DDI-MedLine.d54.s3	15.0	169	172	O	15.0	5.0	15.0	CD	False
DDI-MedLine.d54.s3	mg/kg	174	178	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d54.s3	)	179	179	O	)	)	)	)	False
DDI-MedLine.d54.s3	on	181	182	O	on	on	on	IN	False
DDI-MedLine.d54.s3	separate	184	191	O	separate	ate	rate	JJ	False
DDI-MedLine.d54.s3	days	193	196	O	days	ays	days	NNS	False
DDI-MedLine.d54.s3	.	197	197	O	.	.	.	.	False

DDI-MedLine.d54.s4	Ethanol	0	6	B-drug	Ethanol	nol	anol	NN	False
DDI-MedLine.d54.s4	depressed	8	16	O	depressed	sed	ssed	JJ	False
DDI-MedLine.d54.s4	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d54.s4	amplitudes	22	31	O	amplitudes	des	udes	NNS	False
DDI-MedLine.d54.s4	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d54.s4	most	36	39	O	most	ost	most	JJS	False
DDI-MedLine.d54.s4	evoked	41	46	O	evoked	ked	oked	VBN	False
DDI-MedLine.d54.s4	potential	48	56	O	potential	ial	tial	JJ	False
DDI-MedLine.d54.s4	components	58	67	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s4	in	69	70	O	in	in	in	IN	False
DDI-MedLine.d54.s4	comparison	72	81	O	comparison	son	ison	NN	False
DDI-MedLine.d54.s4	to	83	84	O	to	to	to	TO	False
DDI-MedLine.d54.s4	saline	86	91	O	saline	ine	line	NN	drug
DDI-MedLine.d54.s4	administration	93	106	O	administration	ion	tion	NN	False
DDI-MedLine.d54.s4	.	107	107	O	.	.	.	.	False

DDI-MedLine.d54.s5	Component	0	8	O	Component	ent	nent	NN	False
DDI-MedLine.d54.s5	P2	10	11	O	P2	P2	P2	NN	brand
DDI-MedLine.d54.s5	,	12	12	O	,	,	,	,	False
DDI-MedLine.d54.s5	however	14	20	O	however	ver	ever	RB	False
DDI-MedLine.d54.s5	,	21	21	O	,	,	,	,	False
DDI-MedLine.d54.s5	was	23	25	O	was	was	was	VBD	False
DDI-MedLine.d54.s5	increased	27	35	O	increased	sed	ased	VBN	False
DDI-MedLine.d54.s5	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d54.s5	amplitude	40	48	O	amplitude	ude	tude	NN	False
DDI-MedLine.d54.s5	.	49	49	O	.	.	.	.	False

DDI-MedLine.d54.s6	Physostigmine	0	12	B-drug	Physostigmine	ine	mine	NN	drug
DDI-MedLine.d54.s6	briefly	14	20	O	briefly	fly	efly	NN	False
DDI-MedLine.d54.s6	reduced	22	28	O	reduced	ced	uced	VBN	False
DDI-MedLine.d54.s6	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d54.s6	amplitude	34	42	O	amplitude	ude	tude	NN	False
DDI-MedLine.d54.s6	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d54.s6	most	47	50	O	most	ost	most	JJS	False
DDI-MedLine.d54.s6	components	52	61	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s6	,	62	62	O	,	,	,	,	False
DDI-MedLine.d54.s6	including	64	72	O	including	ing	ding	VBG	False
DDI-MedLine.d54.s6	P2	74	75	O	P2	P2	P2	NN	brand
DDI-MedLine.d54.s6	.	76	76	O	.	.	.	.	False

DDI-MedLine.d54.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d54.s7	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d54.s7	,	11	11	O	,	,	,	,	False
DDI-MedLine.d54.s7	atropine	13	20	B-drug	atropine	ine	pine	NN	drug
DDI-MedLine.d54.s7	increased	22	30	O	increased	sed	ased	VBN	False
DDI-MedLine.d54.s7	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d54.s7	amplitudes	36	45	O	amplitudes	des	udes	NNS	False
DDI-MedLine.d54.s7	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d54.s7	components	50	59	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s7	P1	61	62	O	P1	P1	P1	NN	brand
DDI-MedLine.d54.s7	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d54.s7	P2	68	69	O	P2	P2	P2	NN	brand
DDI-MedLine.d54.s7	,	70	70	O	,	,	,	,	False
DDI-MedLine.d54.s7	while	72	76	O	while	ile	hile	IN	False
DDI-MedLine.d54.s7	decreasing	78	87	O	decreasing	ing	sing	VBG	False
DDI-MedLine.d54.s7	components	89	98	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s7	N1	100	101	O	N1	N1	N1	NN	brand
DDI-MedLine.d54.s7	,	102	102	O	,	,	,	,	False
DDI-MedLine.d54.s7	N2	104	105	O	N2	N2	N2	NN	brand
DDI-MedLine.d54.s7	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d54.s7	N3	111	112	O	N3	N3	N3	NN	brand
DDI-MedLine.d54.s7	for	114	116	O	for	for	for	IN	False
DDI-MedLine.d54.s7	varying	118	124	O	varying	ing	ying	VBG	False
DDI-MedLine.d54.s7	durations	126	134	O	durations	ons	ions	NNS	False
DDI-MedLine.d54.s7	of	136	137	O	of	of	of	IN	False
DDI-MedLine.d54.s7	time	139	142	O	time	ime	time	NN	False
DDI-MedLine.d54.s7	.	143	143	O	.	.	.	.	False

DDI-MedLine.d54.s8	Physostigmine	0	12	B-drug	Physostigmine	ine	mine	NN	drug
DDI-MedLine.d54.s8	pretreatment	14	25	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d54.s8	augmented	27	35	O	augmented	ted	nted	VBN	False
DDI-MedLine.d54.s8	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d54.s8	depressant	41	50	O	depressant	ant	sant	NN	False
DDI-MedLine.d54.s8	effect	52	57	O	effect	ect	fect	NN	False
DDI-MedLine.d54.s8	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d54.s8	alcohol	62	68	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d54.s8	on	70	71	O	on	on	on	IN	False
DDI-MedLine.d54.s8	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d54.s8	early	77	81	O	early	rly	arly	RB	False
DDI-MedLine.d54.s8	components	83	92	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s8	P1	94	95	O	P1	P1	P1	NN	brand
DDI-MedLine.d54.s8	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d54.s8	N1	101	102	O	N1	N1	N1	NN	brand
DDI-MedLine.d54.s8	,	103	103	O	,	,	,	,	False
DDI-MedLine.d54.s8	while	105	109	O	while	ile	hile	IN	False
DDI-MedLine.d54.s8	attenuating	111	121	O	attenuating	ing	ting	VBG	False
DDI-MedLine.d54.s8	alcohol	123	129	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d54.s8	's	130	131	O	's	's	's	POS	False
DDI-MedLine.d54.s8	influence	133	141	O	influence	nce	ence	NN	False
DDI-MedLine.d54.s8	on	143	144	O	on	on	on	IN	False
DDI-MedLine.d54.s8	components	146	155	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s8	P2	157	158	O	P2	P2	P2	NN	brand
DDI-MedLine.d54.s8	and	160	162	O	and	and	and	CC	False
DDI-MedLine.d54.s8	P3	164	165	O	P3	P3	P3	NN	brand
DDI-MedLine.d54.s8	.	166	166	O	.	.	.	.	False

DDI-MedLine.d54.s9	Pretreatment	0	11	O	Pretreatment	ent	ment	NN	False
DDI-MedLine.d54.s9	with	13	16	O	with	ith	with	IN	False
DDI-MedLine.d54.s9	atropine	18	25	B-drug	atropine	ine	pine	NN	drug
DDI-MedLine.d54.s9	likewise	27	34	O	likewise	ise	wise	RB	False
DDI-MedLine.d54.s9	further	36	42	O	further	her	ther	RB	False
DDI-MedLine.d54.s9	reduced	44	50	O	reduced	ced	uced	VBN	False
DDI-MedLine.d54.s9	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d54.s9	amplitudes	56	65	O	amplitudes	des	udes	NNS	False
DDI-MedLine.d54.s9	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d54.s9	components	70	79	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s9	P1	81	82	O	P1	P1	P1	NN	brand
DDI-MedLine.d54.s9	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d54.s9	N1	88	89	O	N1	N1	N1	NN	brand
DDI-MedLine.d54.s9	,	90	90	O	,	,	,	,	False
DDI-MedLine.d54.s9	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d54.s9	produced	96	103	O	produced	ced	uced	VBN	False
DDI-MedLine.d54.s9	a	105	105	O	a	a	a	DT	False
DDI-MedLine.d54.s9	similar	107	113	O	similar	lar	ilar	JJ	False
DDI-MedLine.d54.s9	effect	115	120	O	effect	ect	fect	NN	False
DDI-MedLine.d54.s9	on	122	123	O	on	on	on	IN	False
DDI-MedLine.d54.s9	component	125	133	O	component	ent	nent	NN	False
DDI-MedLine.d54.s9	N3	135	136	O	N3	N3	N3	NN	brand
DDI-MedLine.d54.s9	.	137	137	O	.	.	.	.	False

DDI-MedLine.d54.s10	Atropine	0	7	B-drug	Atropine	ine	pine	NN	drug
DDI-MedLine.d54.s10	,	8	8	O	,	,	,	,	False
DDI-MedLine.d54.s10	either	10	15	O	either	her	ther	DT	False
DDI-MedLine.d54.s10	alone	17	21	O	alone	one	lone	RB	False
DDI-MedLine.d54.s10	or	23	24	O	or	or	or	CC	False
DDI-MedLine.d54.s10	in	26	27	O	in	in	in	IN	False
DDI-MedLine.d54.s10	combination	29	39	O	combination	ion	tion	NN	False
DDI-MedLine.d54.s10	with	41	44	O	with	ith	with	IN	False
DDI-MedLine.d54.s10	alcohol	46	52	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d54.s10	,	53	53	O	,	,	,	,	False
DDI-MedLine.d54.s10	produced	55	62	O	produced	ced	uced	VBN	False
DDI-MedLine.d54.s10	approximately	64	76	O	approximately	ely	tely	RB	False
DDI-MedLine.d54.s10	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d54.s10	same	82	85	O	same	ame	same	JJ	False
DDI-MedLine.d54.s10	degree	87	92	O	degree	ree	gree	NN	False
DDI-MedLine.d54.s10	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d54.s10	enhancement	97	107	O	enhancement	ent	ment	NN	False
DDI-MedLine.d54.s10	of	109	110	O	of	of	of	IN	False
DDI-MedLine.d54.s10	component	112	120	O	component	ent	nent	NN	False
DDI-MedLine.d54.s10	P2	122	123	O	P2	P2	P2	NN	brand
DDI-MedLine.d54.s10	.	124	124	O	.	.	.	.	False

DDI-MedLine.d54.s11	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d54.s11	comparison	3	12	O	comparison	son	ison	NN	False
DDI-MedLine.d54.s11	to	14	15	O	to	to	to	TO	False
DDI-MedLine.d54.s11	saline	17	22	O	saline	ine	line	NN	drug
DDI-MedLine.d54.s11	values	24	29	O	values	ues	lues	NNS	False
DDI-MedLine.d54.s11	,	30	30	O	,	,	,	,	False
DDI-MedLine.d54.s11	all	32	34	O	all	all	all	DT	False
DDI-MedLine.d54.s11	three	36	40	O	three	ree	hree	CD	False
DDI-MedLine.d54.s11	agents	42	47	O	agents	nts	ents	NNS	False
DDI-MedLine.d54.s11	produced	49	56	O	produced	ced	uced	VBN	False
DDI-MedLine.d54.s11	reliable	58	65	O	reliable	ble	able	JJ	False
DDI-MedLine.d54.s11	increases	67	75	O	increases	ses	ases	NNS	False
DDI-MedLine.d54.s11	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d54.s11	peak	80	83	O	peak	eak	peak	NN	False
DDI-MedLine.d54.s11	latency	85	91	O	latency	ncy	ency	NN	False
DDI-MedLine.d54.s11	for	93	95	O	for	for	for	IN	False
DDI-MedLine.d54.s11	most	97	100	O	most	ost	most	JJS	False
DDI-MedLine.d54.s11	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d54.s11	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d54.s11	components	109	118	O	components	nts	ents	NNS	False
DDI-MedLine.d54.s11	,	119	119	O	,	,	,	,	False
DDI-MedLine.d54.s11	with	121	124	O	with	ith	with	IN	False
DDI-MedLine.d54.s11	only	126	129	O	only	nly	only	RB	False
DDI-MedLine.d54.s11	N3	131	132	O	N3	N3	N3	NN	brand
DDI-MedLine.d54.s11	showing	134	140	O	showing	ing	wing	VBG	False
DDI-MedLine.d54.s11	no	142	143	O	no	no	no	DT	False
DDI-MedLine.d54.s11	effects	145	151	O	effects	cts	ects	NNS	False
DDI-MedLine.d54.s11	.	152	152	O	.	.	.	.	False

DDI-MedLine.d54.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d54.s12	amplitude	4	12	O	amplitude	ude	tude	NN	False
DDI-MedLine.d54.s12	data	14	17	O	data	ata	data	NNS	False
DDI-MedLine.d54.s12	from	19	22	O	from	rom	from	IN	False
DDI-MedLine.d54.s12	this	24	27	O	this	his	this	DT	False
DDI-MedLine.d54.s12	study	29	33	O	study	udy	tudy	NN	False
DDI-MedLine.d54.s12	suggest	35	41	O	suggest	est	gest	NN	False
DDI-MedLine.d54.s12	that	43	46	O	that	hat	that	IN	False
DDI-MedLine.d54.s12	ethanol	48	54	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d54.s12	's	55	56	O	's	's	's	POS	False
DDI-MedLine.d54.s12	augmentation	58	69	O	augmentation	ion	tion	NN	False
DDI-MedLine.d54.s12	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d54.s12	component	74	82	O	component	ent	nent	NN	False
DDI-MedLine.d54.s12	P2	84	85	O	P2	P2	P2	NN	brand
DDI-MedLine.d54.s12	may	87	89	O	may	may	may	MD	False
DDI-MedLine.d54.s12	result	91	96	O	result	ult	sult	NN	False
DDI-MedLine.d54.s12	,	97	97	O	,	,	,	,	False
DDI-MedLine.d54.s12	at	99	100	O	at	at	at	IN	False
DDI-MedLine.d54.s12	least	102	106	O	least	ast	east	JJS	False
DDI-MedLine.d54.s12	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d54.s12	part	111	114	O	part	art	part	NN	False
DDI-MedLine.d54.s12	,	115	115	O	,	,	,	,	False
DDI-MedLine.d54.s12	from	117	120	O	from	rom	from	IN	False
DDI-MedLine.d54.s12	alterations	122	132	O	alterations	ons	ions	NNS	False
DDI-MedLine.d54.s12	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d54.s12	cholinergic	137	147	O	cholinergic	gic	rgic	NN	False
DDI-MedLine.d54.s12	functions	149	157	O	functions	ons	ions	NNS	False
DDI-MedLine.d54.s12	.	158	158	O	.	.	.	.	False

DDI-MedLine.d140.s0	Longitudinal	0	11	O	Longitudinal	nal	inal	JJ	False
DDI-MedLine.d140.s0	assessment	13	22	O	assessment	ent	ment	NN	False
DDI-MedLine.d140.s0	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d140.s0	everolimus	27	36	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s0	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d140.s0	de	41	42	O	de	de	de	NNS	False
DDI-MedLine.d140.s0	novo	44	47	O	novo	ovo	novo	NN	False
DDI-MedLine.d140.s0	renal	49	53	O	renal	nal	enal	NN	False
DDI-MedLine.d140.s0	transplant	55	64	O	transplant	ant	lant	NN	False
DDI-MedLine.d140.s0	recipients	66	75	O	recipients	nts	ents	NNS	False
DDI-MedLine.d140.s0	over	77	80	O	over	ver	over	IN	False
DDI-MedLine.d140.s0	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d140.s0	first	86	90	O	first	rst	irst	RB	False
DDI-MedLine.d140.s0	post-transplant	92	106	O	post-transplant	ant	lant	JJ	False
DDI-MedLine.d140.s0	year	108	111	O	year	ear	year	NN	False
DDI-MedLine.d140.s0	:	112	112	O	:	:	:	:	False
DDI-MedLine.d140.s0	pharmacokinetics	114	129	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d140.s0	,	130	130	O	,	,	,	,	False
DDI-MedLine.d140.s0	exposure-response	132	148	O	exposure-response	nse	onse	NN	False
DDI-MedLine.d140.s0	relationships	150	162	O	relationships	ips	hips	NNS	False
DDI-MedLine.d140.s0	,	163	163	O	,	,	,	,	False
DDI-MedLine.d140.s0	and	165	167	O	and	and	and	CC	False
DDI-MedLine.d140.s0	influence	169	177	O	influence	nce	ence	NN	False
DDI-MedLine.d140.s0	on	179	180	O	on	on	on	IN	False
DDI-MedLine.d140.s0	cyclosporine	182	193	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s0	.	194	194	O	.	.	.	.	False

DDI-MedLine.d140.s1	OBJECTIVE	0	8	O	OBJECTIVE	IVE	TIVE	NN	brand
DDI-MedLine.d140.s1	:	9	9	O	:	:	:	:	False
DDI-MedLine.d140.s1	Our	11	13	O	Our	Our	Our	PRP$	False
DDI-MedLine.d140.s1	objective	15	23	O	objective	ive	tive	NN	False
DDI-MedLine.d140.s1	was	25	27	O	was	was	was	VBD	False
DDI-MedLine.d140.s1	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d140.s1	characterize	32	43	O	characterize	ize	rize	NN	False
DDI-MedLine.d140.s1	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d140.s1	steady-state	49	60	O	steady-state	ate	tate	NN	False
DDI-MedLine.d140.s1	pharmacokinetics	62	77	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d140.s1	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d140.s1	everolimus	82	91	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s1	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d140.s1	cyclosporine	97	108	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s1	(	110	110	O	(	(	(	(	False
DDI-MedLine.d140.s1	INN	111	113	O	INN	INN	INN	NN	brand
DDI-MedLine.d140.s1	,	114	114	O	,	,	,	,	False
DDI-MedLine.d140.s1	ciclosporin	116	126	B-drug	ciclosporin	rin	orin	NN	False
DDI-MedLine.d140.s1	)	127	127	O	)	)	)	)	False
DDI-MedLine.d140.s1	when	129	132	O	when	hen	when	WRB	False
DDI-MedLine.d140.s1	coadministered	134	147	O	coadministered	red	ered	VBN	False
DDI-MedLine.d140.s1	in	149	150	O	in	in	in	IN	False
DDI-MedLine.d140.s1	de	152	153	O	de	de	de	NNS	False
DDI-MedLine.d140.s1	novo	155	158	O	novo	ovo	novo	NN	False
DDI-MedLine.d140.s1	kidney	160	165	O	kidney	ney	dney	NN	False
DDI-MedLine.d140.s1	allograft	167	175	O	allograft	aft	raft	NN	False
DDI-MedLine.d140.s1	recipients	177	186	O	recipients	nts	ents	NNS	False
DDI-MedLine.d140.s1	during	188	193	O	during	ing	ring	IN	False
DDI-MedLine.d140.s1	the	195	197	O	the	the	the	DT	False
DDI-MedLine.d140.s1	first	199	203	O	first	rst	irst	RB	False
DDI-MedLine.d140.s1	year	205	208	O	year	ear	year	NN	False
DDI-MedLine.d140.s1	after	210	214	O	after	ter	fter	IN	False
DDI-MedLine.d140.s1	transplantation	216	230	O	transplantation	ion	tion	NN	False
DDI-MedLine.d140.s1	.	231	231	O	.	.	.	.	False

DDI-MedLine.d140.s2	METHOD	0	5	O	METHOD	HOD	THOD	NN	brand
DDI-MedLine.d140.s2	:	6	6	O	:	:	:	:	False
DDI-MedLine.d140.s2	This	8	11	O	This	his	This	DT	False
DDI-MedLine.d140.s2	study	13	17	O	study	udy	tudy	NN	False
DDI-MedLine.d140.s2	was	19	21	O	was	was	was	VBD	False
DDI-MedLine.d140.s2	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d140.s2	multicenter	25	35	O	multicenter	ter	nter	NN	False
DDI-MedLine.d140.s2	randomized	37	46	O	randomized	zed	ized	VBN	False
DDI-MedLine.d140.s2	double-blind	48	59	O	double-blind	ind	lind	NN	False
DDI-MedLine.d140.s2	study	61	65	O	study	udy	tudy	NN	False
DDI-MedLine.d140.s2	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d140.s2	101	70	72	O	101	101	101	CD	False
DDI-MedLine.d140.s2	patients	74	81	O	patients	nts	ents	NNS	False
DDI-MedLine.d140.s2	who	83	85	O	who	who	who	WP	False
DDI-MedLine.d140.s2	were	87	90	O	were	ere	were	VBD	False
DDI-MedLine.d140.s2	randomly	92	99	O	randomly	mly	omly	RB	False
DDI-MedLine.d140.s2	assigned	101	108	O	assigned	ned	gned	VBN	False
DDI-MedLine.d140.s2	1:1:1	110	114	O	1:1:1	1:1	:1:1	CD	False
DDI-MedLine.d140.s2	to	116	117	O	to	to	to	TO	False
DDI-MedLine.d140.s2	receive	119	125	O	receive	ive	eive	NN	False
DDI-MedLine.d140.s2	everolimus	127	136	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s2	tablets	138	144	O	tablets	ets	lets	NNS	False
DDI-MedLine.d140.s2	at	146	147	O	at	at	at	IN	False
DDI-MedLine.d140.s2	doses	149	153	O	doses	ses	oses	NNS	False
DDI-MedLine.d140.s2	of	155	156	O	of	of	of	IN	False
DDI-MedLine.d140.s2	0.5	158	160	O	0.5	0.5	0.5	CD	False
DDI-MedLine.d140.s2	mg	162	163	O	mg	mg	mg	NN	False
DDI-MedLine.d140.s2	,	164	164	O	,	,	,	,	False
DDI-MedLine.d140.s2	1	166	166	O	1	1	1	CD	False
DDI-MedLine.d140.s2	mg	168	169	O	mg	mg	mg	NN	False
DDI-MedLine.d140.s2	,	170	170	O	,	,	,	,	False
DDI-MedLine.d140.s2	or	172	173	O	or	or	or	CC	False
DDI-MedLine.d140.s2	2	175	175	O	2	2	2	CD	False
DDI-MedLine.d140.s2	mg	177	178	O	mg	mg	mg	NN	False
DDI-MedLine.d140.s2	twice	180	184	O	twice	ice	wice	RB	False
DDI-MedLine.d140.s2	daily	186	190	O	daily	ily	aily	JJ	False
DDI-MedLine.d140.s2	with	192	195	O	with	ith	with	IN	False
DDI-MedLine.d140.s2	cyclosporine	197	208	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s2	and	210	212	O	and	and	and	CC	False
DDI-MedLine.d140.s2	prednisone	214	223	B-drug	prednisone	one	sone	NN	False
DDI-MedLine.d140.s2	.	224	224	O	.	.	.	.	False

DDI-MedLine.d140.s3	Blood	0	4	O	Blood	ood	lood	NN	False
DDI-MedLine.d140.s3	sampling	6	13	O	sampling	ing	ling	VBG	False
DDI-MedLine.d140.s3	for	15	17	O	for	for	for	IN	False
DDI-MedLine.d140.s3	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d140.s3	pharmacokinetics	23	38	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d140.s3	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d140.s3	everolimus	43	52	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s3	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d140.s3	cyclosporine	58	69	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s3	was	71	73	O	was	was	was	VBD	False
DDI-MedLine.d140.s3	performed	75	83	O	performed	med	rmed	VBN	False
DDI-MedLine.d140.s3	on	85	86	O	on	on	on	IN	False
DDI-MedLine.d140.s3	day	88	90	O	day	day	day	NN	False
DDI-MedLine.d140.s3	1	92	92	O	1	1	1	CD	False
DDI-MedLine.d140.s3	,	93	93	O	,	,	,	,	False
DDI-MedLine.d140.s3	on	95	96	O	on	on	on	IN	False
DDI-MedLine.d140.s3	weeks	98	102	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d140.s3	1	104	104	O	1	1	1	CD	False
DDI-MedLine.d140.s3	,	105	105	O	,	,	,	,	False
DDI-MedLine.d140.s3	2	107	107	O	2	2	2	CD	False
DDI-MedLine.d140.s3	,	108	108	O	,	,	,	,	False
DDI-MedLine.d140.s3	3	110	110	O	3	3	3	CD	False
DDI-MedLine.d140.s3	,	111	111	O	,	,	,	,	False
DDI-MedLine.d140.s3	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d140.s3	4	117	117	O	4	4	4	CD	False
DDI-MedLine.d140.s3	,	118	118	O	,	,	,	,	False
DDI-MedLine.d140.s3	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d140.s3	on	124	125	O	on	on	on	IN	False
DDI-MedLine.d140.s3	months	127	132	O	months	ths	nths	NNS	False
DDI-MedLine.d140.s3	2	134	134	O	2	2	2	CD	False
DDI-MedLine.d140.s3	,	135	135	O	,	,	,	,	False
DDI-MedLine.d140.s3	3	137	137	O	3	3	3	CD	False
DDI-MedLine.d140.s3	,	138	138	O	,	,	,	,	False
DDI-MedLine.d140.s3	6	140	140	O	6	6	6	CD	False
DDI-MedLine.d140.s3	,	141	141	O	,	,	,	,	False
DDI-MedLine.d140.s3	9	143	143	O	9	9	9	CD	False
DDI-MedLine.d140.s3	,	144	144	O	,	,	,	,	False
DDI-MedLine.d140.s3	and	146	148	O	and	and	and	CC	False
DDI-MedLine.d140.s3	12	150	151	O	12	12	12	CD	False
DDI-MedLine.d140.s3	.	152	152	O	.	.	.	.	False

DDI-MedLine.d140.s4	Everolimus	0	9	B-drug	Everolimus	mus	imus	NN	False
DDI-MedLine.d140.s4	dose-proportionality	11	30	O	dose-proportionality	ity	lity	NN	False
DDI-MedLine.d140.s4	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d140.s4	stability	36	44	O	stability	ity	lity	NN	False
DDI-MedLine.d140.s4	over	46	49	O	over	ver	over	IN	False
DDI-MedLine.d140.s4	time	51	54	O	time	ime	time	NN	False
DDI-MedLine.d140.s4	were	56	59	O	were	ere	were	VBD	False
DDI-MedLine.d140.s4	assessed	61	68	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d140.s4	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d140.s4	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d140.s4	context	77	83	O	context	ext	text	NN	False
DDI-MedLine.d140.s4	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d140.s4	linear	88	93	O	linear	ear	near	NN	False
DDI-MedLine.d140.s4	regression	95	104	O	regression	ion	sion	NN	False
DDI-MedLine.d140.s4	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d140.s4	ANOVA	110	114	O	ANOVA	OVA	NOVA	NN	brand
DDI-MedLine.d140.s4	models	116	121	O	models	els	dels	NNS	False
DDI-MedLine.d140.s4	.	122	122	O	.	.	.	.	False

DDI-MedLine.d140.s5	Everolimus	0	9	B-drug	Everolimus	mus	imus	NN	False
DDI-MedLine.d140.s5	exposure-response	11	27	O	exposure-response	nse	onse	NN	False
DDI-MedLine.d140.s5	relationships	29	41	O	relationships	ips	hips	NNS	False
DDI-MedLine.d140.s5	between	43	49	O	between	een	ween	IN	False
DDI-MedLine.d140.s5	area	51	54	O	area	rea	area	NN	False
DDI-MedLine.d140.s5	under	56	60	O	under	der	nder	IN	False
DDI-MedLine.d140.s5	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d140.s5	blood	66	70	O	blood	ood	lood	NN	False
DDI-MedLine.d140.s5	concentration-time	72	89	O	concentration-time	ime	time	NN	False
DDI-MedLine.d140.s5	curve	91	95	O	curve	rve	urve	NN	False
DDI-MedLine.d140.s5	(	97	97	O	(	(	(	(	False
DDI-MedLine.d140.s5	AUC	98	100	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d140.s5	)	101	101	O	)	)	)	)	False
DDI-MedLine.d140.s5	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d140.s5	changes	107	113	O	changes	ges	nges	NNS	False
DDI-MedLine.d140.s5	in	115	116	O	in	in	in	IN	False
DDI-MedLine.d140.s5	platelets	118	126	O	platelets	ets	lets	NNS	False
DDI-MedLine.d140.s5	,	127	127	O	,	,	,	,	False
DDI-MedLine.d140.s5	leukocytes	129	138	O	leukocytes	tes	ytes	NNS	False
DDI-MedLine.d140.s5	,	139	139	O	,	,	,	,	False
DDI-MedLine.d140.s5	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d140.s5	lipids	145	150	O	lipids	ids	pids	NNS	False
DDI-MedLine.d140.s5	were	152	155	O	were	ere	were	VBD	False
DDI-MedLine.d140.s5	explored	157	164	O	explored	red	ored	VBN	False
DDI-MedLine.d140.s5	with	166	169	O	with	ith	with	IN	False
DDI-MedLine.d140.s5	the	171	173	O	the	the	the	DT	False
DDI-MedLine.d140.s5	median-effect	175	187	O	median-effect	ect	fect	NN	False
DDI-MedLine.d140.s5	model	189	193	O	model	del	odel	NN	False
DDI-MedLine.d140.s5	.	194	194	O	.	.	.	.	False

DDI-MedLine.d140.s6	Potential	0	8	O	Potential	ial	tial	JJ	False
DDI-MedLine.d140.s6	differences	10	20	O	differences	ces	nces	NNS	False
DDI-MedLine.d140.s6	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d140.s6	cyclosporine	25	36	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s6	dosing	38	43	O	dosing	ing	sing	VBG	False
DDI-MedLine.d140.s6	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d140.s6	pharmacokinetics	49	64	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d140.s6	at	66	67	O	at	at	at	IN	False
DDI-MedLine.d140.s6	different	69	77	O	different	ent	rent	JJ	False
DDI-MedLine.d140.s6	levels	79	84	O	levels	els	vels	NNS	False
DDI-MedLine.d140.s6	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d140.s6	everolimus	89	98	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s6	exposure	100	107	O	exposure	ure	sure	NN	False
DDI-MedLine.d140.s6	were	109	112	O	were	ere	were	VBD	False
DDI-MedLine.d140.s6	assessed	114	121	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d140.s6	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d140.s6	the	126	128	O	the	the	the	DT	False
DDI-MedLine.d140.s6	context	130	136	O	context	ext	text	NN	False
DDI-MedLine.d140.s6	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d140.s6	ANOVA	141	145	O	ANOVA	OVA	NOVA	NN	brand
DDI-MedLine.d140.s6	.	146	146	O	.	.	.	.	False

DDI-MedLine.d140.s7	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d140.s7	:	7	7	O	:	:	:	:	False
DDI-MedLine.d140.s7	Everolimus	9	18	B-drug	Everolimus	mus	imus	NN	False
DDI-MedLine.d140.s7	steady	20	25	O	steady	ady	eady	JJ	False
DDI-MedLine.d140.s7	state	27	31	O	state	ate	tate	NN	False
DDI-MedLine.d140.s7	was	33	35	O	was	was	was	VBD	False
DDI-MedLine.d140.s7	reached	37	43	O	reached	hed	ched	VBN	False
DDI-MedLine.d140.s7	on	45	46	O	on	on	on	IN	False
DDI-MedLine.d140.s7	or	48	49	O	or	or	or	CC	False
DDI-MedLine.d140.s7	before	51	56	O	before	ore	fore	IN	False
DDI-MedLine.d140.s7	day	58	60	O	day	day	day	NN	False
DDI-MedLine.d140.s7	7	62	62	O	7	7	7	CD	False
DDI-MedLine.d140.s7	,	63	63	O	,	,	,	,	False
DDI-MedLine.d140.s7	with	65	68	O	with	ith	with	IN	False
DDI-MedLine.d140.s7	a	70	70	O	a	a	a	DT	False
DDI-MedLine.d140.s7	median	72	77	O	median	ian	dian	NN	False
DDI-MedLine.d140.s7	3-fold	79	84	O	3-fold	old	fold	JJ	False
DDI-MedLine.d140.s7	accumulation	86	97	O	accumulation	ion	tion	NN	False
DDI-MedLine.d140.s7	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d140.s7	drug	102	105	O	drug	rug	drug	NN	False
DDI-MedLine.d140.s7	exposure	107	114	O	exposure	ure	sure	NN	False
DDI-MedLine.d140.s7	compared	116	123	O	compared	red	ared	VBN	False
DDI-MedLine.d140.s7	with	125	128	O	with	ith	with	IN	False
DDI-MedLine.d140.s7	that	130	133	O	that	hat	that	IN	False
DDI-MedLine.d140.s7	after	135	139	O	after	ter	fter	IN	False
DDI-MedLine.d140.s7	the	141	143	O	the	the	the	DT	False
DDI-MedLine.d140.s7	first	145	149	O	first	rst	irst	RB	False
DDI-MedLine.d140.s7	postoperative	151	163	O	postoperative	ive	tive	NN	False
DDI-MedLine.d140.s7	dose	165	168	O	dose	ose	dose	NN	False
DDI-MedLine.d140.s7	.	169	169	O	.	.	.	.	False

DDI-MedLine.d140.s8	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d140.s8	steady-state	5	16	O	steady-state	ate	tate	NN	False
DDI-MedLine.d140.s8	maximum	18	24	O	maximum	mum	imum	NN	False
DDI-MedLine.d140.s8	concentration	26	38	O	concentration	ion	tion	NN	False
DDI-MedLine.d140.s8	and	40	42	O	and	and	and	CC	False
DDI-MedLine.d140.s8	AUC	44	46	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d140.s8	were	48	51	O	were	ere	were	VBD	False
DDI-MedLine.d140.s8	dose	53	56	O	dose	ose	dose	NN	False
DDI-MedLine.d140.s8	proportional	58	69	O	proportional	nal	onal	NN	False
DDI-MedLine.d140.s8	over	71	74	O	over	ver	over	IN	False
DDI-MedLine.d140.s8	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d140.s8	full	80	83	O	full	ull	full	JJ	False
DDI-MedLine.d140.s8	dose	85	88	O	dose	ose	dose	NN	False
DDI-MedLine.d140.s8	range	90	94	O	range	nge	ange	NN	False
DDI-MedLine.d140.s8	when	96	99	O	when	hen	when	WRB	False
DDI-MedLine.d140.s8	assessed	101	108	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d140.s8	on	110	111	O	on	on	on	IN	False
DDI-MedLine.d140.s8	day	113	115	O	day	day	day	NN	False
DDI-MedLine.d140.s8	1	117	117	O	1	1	1	CD	False
DDI-MedLine.d140.s8	,	118	118	O	,	,	,	,	False
DDI-MedLine.d140.s8	as	120	121	O	as	as	as	IN	False
DDI-MedLine.d140.s8	well	123	126	O	well	ell	well	RB	False
DDI-MedLine.d140.s8	as	128	129	O	as	as	as	IN	False
DDI-MedLine.d140.s8	for	131	133	O	for	for	for	IN	False
DDI-MedLine.d140.s8	the	135	137	O	the	the	the	DT	False
DDI-MedLine.d140.s8	full	139	142	O	full	ull	full	JJ	False
DDI-MedLine.d140.s8	duration	144	151	O	duration	ion	tion	NN	False
DDI-MedLine.d140.s8	of	153	154	O	of	of	of	IN	False
DDI-MedLine.d140.s8	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d140.s8	study	160	164	O	study	udy	tudy	NN	False
DDI-MedLine.d140.s8	at	166	167	O	at	at	at	IN	False
DDI-MedLine.d140.s8	steady	169	174	O	steady	ady	eady	JJ	False
DDI-MedLine.d140.s8	state	176	180	O	state	ate	tate	NN	False
DDI-MedLine.d140.s8	.	181	181	O	.	.	.	.	False

DDI-MedLine.d140.s9	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d140.s9	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d140.s9	evidence	10	17	O	evidence	nce	ence	NN	False
DDI-MedLine.d140.s9	for	19	21	O	for	for	for	IN	False
DDI-MedLine.d140.s9	longitudinal	23	34	O	longitudinal	nal	inal	JJ	False
DDI-MedLine.d140.s9	stability	36	44	O	stability	ity	lity	NN	False
DDI-MedLine.d140.s9	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d140.s9	AUC	49	51	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d140.s9	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d140.s9	everolimus	56	65	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s9	during	67	72	O	during	ing	ring	IN	False
DDI-MedLine.d140.s9	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d140.s9	course	78	83	O	course	rse	urse	NN	False
DDI-MedLine.d140.s9	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d140.s9	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d140.s9	study	92	96	O	study	udy	tudy	NN	False
DDI-MedLine.d140.s9	.	97	97	O	.	.	.	.	False

DDI-MedLine.d140.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d140.s10	interindividual	4	18	O	interindividual	ual	dual	JJ	False
DDI-MedLine.d140.s10	pharmacokinetic	20	34	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d140.s10	variability	36	46	O	variability	ity	lity	NN	False
DDI-MedLine.d140.s10	for	48	50	O	for	for	for	IN	False
DDI-MedLine.d140.s10	AUC	52	54	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d140.s10	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d140.s10	85.4	60	63	O	85.4	5.4	85.4	CD	False
DDI-MedLine.d140.s10	%	64	64	O	%	%	%	NN	False
DDI-MedLine.d140.s10	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d140.s10	intraindividual	70	84	O	intraindividual	ual	dual	JJ	False
DDI-MedLine.d140.s10	,	85	85	O	,	,	,	,	False
DDI-MedLine.d140.s10	interoccasion	87	99	O	interoccasion	ion	sion	NN	False
DDI-MedLine.d140.s10	variability	101	111	O	variability	ity	lity	NN	False
DDI-MedLine.d140.s10	was	113	115	O	was	was	was	VBD	False
DDI-MedLine.d140.s10	40.8	117	120	O	40.8	0.8	40.8	CD	False
DDI-MedLine.d140.s10	%	121	121	O	%	%	%	NN	False
DDI-MedLine.d140.s10	.	122	122	O	.	.	.	.	False

DDI-MedLine.d140.s11	Age	0	2	O	Age	Age	Age	NN	False
DDI-MedLine.d140.s11	(	4	4	O	(	(	(	(	False
DDI-MedLine.d140.s11	range	5	9	O	range	nge	ange	NN	False
DDI-MedLine.d140.s11	,	10	10	O	,	,	,	,	False
DDI-MedLine.d140.s11	17-69	12	16	O	17-69	-69	7-69	JJ	False
DDI-MedLine.d140.s11	years	18	22	O	years	ars	ears	NNS	False
DDI-MedLine.d140.s11	)	23	23	O	)	)	)	)	False
DDI-MedLine.d140.s11	,	24	24	O	,	,	,	,	False
DDI-MedLine.d140.s11	weight	26	31	O	weight	ght	ight	NN	False
DDI-MedLine.d140.s11	(	33	33	O	(	(	(	(	False
DDI-MedLine.d140.s11	range	34	38	O	range	nge	ange	NN	False
DDI-MedLine.d140.s11	,	39	39	O	,	,	,	,	False
DDI-MedLine.d140.s11	49-106	41	46	O	49-106	106	-106	JJ	False
DDI-MedLine.d140.s11	kg	48	49	O	kg	kg	kg	NN	False
DDI-MedLine.d140.s11	)	50	50	O	)	)	)	)	False
DDI-MedLine.d140.s11	,	51	51	O	,	,	,	,	False
DDI-MedLine.d140.s11	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d140.s11	sex	57	59	O	sex	sex	sex	NN	False
DDI-MedLine.d140.s11	(	61	61	O	(	(	(	(	False
DDI-MedLine.d140.s11	65	62	63	O	65	65	65	CD	False
DDI-MedLine.d140.s11	men	65	67	O	men	men	men	NNS	False
DDI-MedLine.d140.s11	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d140.s11	36	73	74	O	36	36	36	CD	False
DDI-MedLine.d140.s11	women	76	80	O	women	men	omen	NNS	False
DDI-MedLine.d140.s11	)	81	81	O	)	)	)	)	False
DDI-MedLine.d140.s11	were	83	86	O	were	ere	were	VBD	False
DDI-MedLine.d140.s11	not	88	90	O	not	not	not	RB	False
DDI-MedLine.d140.s11	significant	92	102	O	significant	ant	cant	JJ	False
DDI-MedLine.d140.s11	contributors	104	115	O	contributors	ors	tors	NNS	False
DDI-MedLine.d140.s11	to	117	118	O	to	to	to	TO	False
DDI-MedLine.d140.s11	variability	120	130	O	variability	ity	lity	NN	False
DDI-MedLine.d140.s11	.	131	131	O	.	.	.	.	False

DDI-MedLine.d140.s12	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d140.s12	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d140.s12	an	10	11	O	an	an	an	DT	False
DDI-MedLine.d140.s12	increasing	13	22	O	increasing	ing	sing	VBG	False
DDI-MedLine.d140.s12	incidence	24	32	O	incidence	nce	ence	NN	False
DDI-MedLine.d140.s12	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d140.s12	transient	37	45	O	transient	ent	ient	NN	False
DDI-MedLine.d140.s12	thrombocytopenia	47	62	O	thrombocytopenia	nia	enia	NN	False
DDI-MedLine.d140.s12	(	64	64	O	(	(	(	(	False
DDI-MedLine.d140.s12	or	65	66	O	or	or	or	CC	False
DDI-MedLine.d140.s12	=100	68	71	O	=100	100	=100	NN	False
DDI-MedLine.d140.s12	x	73	73	O	x	x	x	NN	False
DDI-MedLine.d140.s12	10	75	76	O	10	10	10	CD	False
DDI-MedLine.d140.s12	(	77	77	O	(	(	(	(	False
DDI-MedLine.d140.s12	9	78	78	O	9	9	9	CD	False
DDI-MedLine.d140.s12	)	79	79	O	)	)	)	)	False
DDI-MedLine.d140.s12	/L	80	81	O	/L	/L	/L	NN	brand
DDI-MedLine.d140.s12	)	82	82	O	)	)	)	)	False
DDI-MedLine.d140.s12	with	84	87	O	with	ith	with	IN	False
DDI-MedLine.d140.s12	increasing	89	98	O	increasing	ing	sing	VBG	False
DDI-MedLine.d140.s12	everolimus	100	109	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s12	AUC	111	113	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d140.s12	(	115	115	O	(	(	(	(	False
DDI-MedLine.d140.s12	P	116	116	O	P	P	P	NN	brand
DDI-MedLine.d140.s12	=	118	118	O	=	=	=	NN	False
DDI-MedLine.d140.s12	.03	120	122	O	.03	.03	.03	NN	False
DDI-MedLine.d140.s12	)	123	123	O	)	)	)	)	False
DDI-MedLine.d140.s12	.	124	124	O	.	.	.	.	False

DDI-MedLine.d140.s13	Cyclosporine	0	11	B-drug	Cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s13	doses	13	17	O	doses	ses	oses	NNS	False
DDI-MedLine.d140.s13	,	18	18	O	,	,	,	,	False
DDI-MedLine.d140.s13	trough	20	25	O	trough	ugh	ough	NN	False
DDI-MedLine.d140.s13	concentrations	27	40	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d140.s13	,	41	41	O	,	,	,	,	False
DDI-MedLine.d140.s13	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d140.s13	AUC	47	49	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d140.s13	exhibited	51	59	O	exhibited	ted	ited	VBN	False
DDI-MedLine.d140.s13	similar	61	67	O	similar	lar	ilar	JJ	False
DDI-MedLine.d140.s13	temporal	69	76	O	temporal	ral	oral	JJ	False
DDI-MedLine.d140.s13	patterns	78	85	O	patterns	rns	erns	NNS	False
DDI-MedLine.d140.s13	during	87	92	O	during	ing	ring	IN	False
DDI-MedLine.d140.s13	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d140.s13	course	98	103	O	course	rse	urse	NN	False
DDI-MedLine.d140.s13	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d140.s13	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d140.s13	study	112	116	O	study	udy	tudy	NN	False
DDI-MedLine.d140.s13	regardless	118	127	O	regardless	ess	less	RB	False
DDI-MedLine.d140.s13	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d140.s13	the	132	134	O	the	the	the	DT	False
DDI-MedLine.d140.s13	co-administered	136	150	O	co-administered	red	ered	JJ	False
DDI-MedLine.d140.s13	everolimus	152	161	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s13	dose	163	166	O	dose	ose	dose	NN	False
DDI-MedLine.d140.s13	level	168	172	O	level	vel	evel	NN	False
DDI-MedLine.d140.s13	(	174	174	O	(	(	(	(	False
DDI-MedLine.d140.s13	P	175	175	O	P	P	P	NN	brand
DDI-MedLine.d140.s13	=	177	177	O	=	=	=	NN	False
DDI-MedLine.d140.s13	.13	179	181	O	.13	.13	.13	NN	False
DDI-MedLine.d140.s13	,	182	182	O	,	,	,	,	False
DDI-MedLine.d140.s13	.82	184	186	O	.82	.82	.82	NN	False
DDI-MedLine.d140.s13	,	187	187	O	,	,	,	,	False
DDI-MedLine.d140.s13	and	189	191	O	and	and	and	CC	False
DDI-MedLine.d140.s13	.76	193	195	O	.76	.76	.76	NN	False
DDI-MedLine.d140.s13	,	196	196	O	,	,	,	,	False
DDI-MedLine.d140.s13	respectively	198	209	O	respectively	ely	vely	RB	False
DDI-MedLine.d140.s13	)	210	210	O	)	)	)	)	False
DDI-MedLine.d140.s13	.	211	211	O	.	.	.	.	False

DDI-MedLine.d140.s14	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d140.s14	:	11	11	O	:	:	:	:	False
DDI-MedLine.d140.s14	Everolimus	13	22	B-drug	Everolimus	mus	imus	NN	False
DDI-MedLine.d140.s14	exhibited	24	32	O	exhibited	ted	ited	VBN	False
DDI-MedLine.d140.s14	dose-proportional	34	50	O	dose-proportional	nal	onal	JJ	False
DDI-MedLine.d140.s14	,	51	51	O	,	,	,	,	False
DDI-MedLine.d140.s14	stable	53	58	O	stable	ble	able	JJ	False
DDI-MedLine.d140.s14	exposure	60	67	O	exposure	ure	sure	NN	False
DDI-MedLine.d140.s14	during	69	74	O	during	ing	ring	IN	False
DDI-MedLine.d140.s14	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d140.s14	first	80	84	O	first	rst	irst	RB	False
DDI-MedLine.d140.s14	post-transplant	86	100	O	post-transplant	ant	lant	JJ	False
DDI-MedLine.d140.s14	year	102	105	O	year	ear	year	NN	False
DDI-MedLine.d140.s14	.	106	106	O	.	.	.	.	False

DDI-MedLine.d140.s15	For	0	2	O	For	For	For	IN	False
DDI-MedLine.d140.s15	a	4	4	O	a	a	a	DT	False
DDI-MedLine.d140.s15	4-fold	6	11	O	4-fold	old	fold	JJ	False
DDI-MedLine.d140.s15	range	13	17	O	range	nge	ange	NN	False
DDI-MedLine.d140.s15	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d140.s15	everolimus	22	31	B-drug	everolimus	mus	imus	NN	False
DDI-MedLine.d140.s15	doses	33	37	O	doses	ses	oses	NNS	False
DDI-MedLine.d140.s15	there	39	43	O	there	ere	here	RB	False
DDI-MedLine.d140.s15	were	45	48	O	were	ere	were	VBD	False
DDI-MedLine.d140.s15	no	50	51	O	no	no	no	DT	False
DDI-MedLine.d140.s15	differential	53	64	O	differential	ial	tial	NN	False
DDI-MedLine.d140.s15	effects	66	72	O	effects	cts	ects	NNS	False
DDI-MedLine.d140.s15	on	74	75	O	on	on	on	IN	False
DDI-MedLine.d140.s15	cyclosporine	77	88	B-drug	cyclosporine	ine	rine	NN	drug
DDI-MedLine.d140.s15	dosing	90	95	O	dosing	ing	sing	VBG	False
DDI-MedLine.d140.s15	or	97	98	O	or	or	or	CC	False
DDI-MedLine.d140.s15	pharmacokinetics	100	115	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d140.s15	.	116	116	O	.	.	.	.	False

DDI-MedLine.d34.s0	Interactions	0	11	O	Interactions	ons	ions	NNS	False
DDI-MedLine.d34.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d34.s0	cobalt	16	21	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s0	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d34.s0	iron	27	30	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s0	in	32	33	O	in	in	in	IN	False
DDI-MedLine.d34.s0	absorption	35	44	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s0	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d34.s0	retention	50	58	O	retention	ion	tion	NN	False
DDI-MedLine.d34.s0	.	59	59	O	.	.	.	.	False

DDI-MedLine.d34.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d34.s1	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d34.s1	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d34.s1	supplementary	15	27	O	supplementary	ary	tary	JJ	False
DDI-MedLine.d34.s1	oral	29	32	O	oral	ral	oral	JJ	False
DDI-MedLine.d34.s1	cobalt	34	39	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s1	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d34.s1	iron	45	48	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s1	,	49	49	O	,	,	,	,	False
DDI-MedLine.d34.s1	as	51	52	O	as	as	as	IN	False
DDI-MedLine.d34.s1	well	54	57	O	well	ell	well	RB	False
DDI-MedLine.d34.s1	as	59	60	O	as	as	as	IN	False
DDI-MedLine.d34.s1	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d34.s1	interaction	66	76	O	interaction	ion	tion	NN	False
DDI-MedLine.d34.s1	between	78	84	O	between	een	ween	IN	False
DDI-MedLine.d34.s1	both	86	89	O	both	oth	both	DT	False
DDI-MedLine.d34.s1	at	91	92	O	at	at	at	IN	False
DDI-MedLine.d34.s1	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d34.s1	absorption	98	107	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s1	site	109	112	O	site	ite	site	NN	False
DDI-MedLine.d34.s1	,	113	113	O	,	,	,	,	False
DDI-MedLine.d34.s1	fecal	115	119	O	fecal	cal	ecal	JJ	False
DDI-MedLine.d34.s1	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d34.s1	urinary	125	131	O	urinary	ary	nary	JJ	False
DDI-MedLine.d34.s1	excretion	133	141	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s1	as	143	144	O	as	as	as	IN	False
DDI-MedLine.d34.s1	well	146	149	O	well	ell	well	RB	False
DDI-MedLine.d34.s1	as	151	152	O	as	as	as	IN	False
DDI-MedLine.d34.s1	the	154	156	O	the	the	the	DT	False
DDI-MedLine.d34.s1	retention	158	166	O	retention	ion	tion	NN	False
DDI-MedLine.d34.s1	of	168	169	O	of	of	of	IN	False
DDI-MedLine.d34.s1	these	171	175	O	these	ese	hese	DT	False
DDI-MedLine.d34.s1	trace	177	181	O	trace	ace	race	NN	False
DDI-MedLine.d34.s1	elements	183	190	O	elements	nts	ents	NNS	False
DDI-MedLine.d34.s1	were	192	195	O	were	ere	were	VBD	False
DDI-MedLine.d34.s1	determined	197	206	O	determined	ned	ined	VBN	False
DDI-MedLine.d34.s1	by	208	209	O	by	by	by	IN	False
DDI-MedLine.d34.s1	using	211	215	O	using	ing	sing	VBG	False
DDI-MedLine.d34.s1	four	217	220	O	four	our	four	CD	False
DDI-MedLine.d34.s1	diets	222	226	O	diets	ets	iets	NNS	False
DDI-MedLine.d34.s1	containing	228	237	O	containing	ing	ning	VBG	False
DDI-MedLine.d34.s1	either	239	244	O	either	her	ther	DT	False
DDI-MedLine.d34.s1	9	246	246	O	9	9	9	CD	False
DDI-MedLine.d34.s1	or	248	249	O	or	or	or	CC	False
DDI-MedLine.d34.s1	63	251	252	O	63	63	63	CD	False
DDI-MedLine.d34.s1	micrograms/kg	254	266	O	micrograms/kg	/kg	s/kg	NN	False
DDI-MedLine.d34.s1	of	268	269	O	of	of	of	IN	False
DDI-MedLine.d34.s1	Co	271	272	B-drug	Co	Co	Co	NNP	False
DDI-MedLine.d34.s1	and	274	276	O	and	and	and	CC	False
DDI-MedLine.d34.s1	48	278	279	O	48	48	48	CD	False
DDI-MedLine.d34.s1	or	281	282	O	or	or	or	CC	False
DDI-MedLine.d34.s1	446	284	286	O	446	446	446	CD	False
DDI-MedLine.d34.s1	mg/kg	288	292	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d34.s1	of	294	295	O	of	of	of	IN	False
DDI-MedLine.d34.s1	Fe	297	298	B-drug	Fe	Fe	Fe	NNP	False
DDI-MedLine.d34.s1	over	300	303	O	over	ver	over	IN	False
DDI-MedLine.d34.s1	a	305	305	O	a	a	a	DT	False
DDI-MedLine.d34.s1	period	307	312	O	period	iod	riod	NN	False
DDI-MedLine.d34.s1	of	314	315	O	of	of	of	IN	False
DDI-MedLine.d34.s1	19	317	318	O	19	19	19	CD	False
DDI-MedLine.d34.s1	days	320	323	O	days	ays	days	NNS	False
DDI-MedLine.d34.s1	in	325	326	O	in	in	in	IN	False
DDI-MedLine.d34.s1	a	328	328	O	a	a	a	DT	False
DDI-MedLine.d34.s1	total	330	334	O	total	tal	otal	JJ	False
DDI-MedLine.d34.s1	of	336	337	O	of	of	of	IN	False
DDI-MedLine.d34.s1	24	339	340	O	24	24	24	CD	False
DDI-MedLine.d34.s1	rats	342	345	O	rats	ats	rats	NNS	False
DDI-MedLine.d34.s1	.	346	346	O	.	.	.	.	False

DDI-MedLine.d34.s2	Retention	0	8	O	Retention	ion	tion	NN	False
DDI-MedLine.d34.s2	was	10	12	O	was	was	was	VBD	False
DDI-MedLine.d34.s2	calculated	14	23	O	calculated	ted	ated	VBN	False
DDI-MedLine.d34.s2	by	25	26	O	by	by	by	IN	False
DDI-MedLine.d34.s2	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d34.s2	balance	32	38	O	balance	nce	ance	NN	False
DDI-MedLine.d34.s2	technique	40	48	O	technique	que	ique	NN	False
DDI-MedLine.d34.s2	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d34.s2	by	54	55	O	by	by	by	IN	False
DDI-MedLine.d34.s2	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d34.s2	comparative	61	71	O	comparative	ive	tive	NN	False
DDI-MedLine.d34.s2	slaughter	73	81	O	slaughter	ter	hter	NN	False
DDI-MedLine.d34.s2	technique	83	91	O	technique	que	ique	NN	False
DDI-MedLine.d34.s2	.	92	92	O	.	.	.	.	False

DDI-MedLine.d34.s3	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d34.s3	one	6	8	O	one	one	one	CD	False
DDI-MedLine.d34.s3	day	10	12	O	day	day	day	NN	False
DDI-MedLine.d34.s3	,	13	13	O	,	,	,	,	False
DDI-MedLine.d34.s3	fecal	15	19	O	fecal	cal	ecal	JJ	False
DDI-MedLine.d34.s3	as	21	22	O	as	as	as	IN	False
DDI-MedLine.d34.s3	well	24	27	O	well	ell	well	RB	False
DDI-MedLine.d34.s3	as	29	30	O	as	as	as	IN	False
DDI-MedLine.d34.s3	urinary	32	38	O	urinary	ary	nary	JJ	False
DDI-MedLine.d34.s3	excretion	40	48	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s3	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d34.s3	both	53	56	O	both	oth	both	DT	False
DDI-MedLine.d34.s3	elements	58	65	O	elements	nts	ents	NNS	False
DDI-MedLine.d34.s3	had	67	69	O	had	had	had	VBD	False
DDI-MedLine.d34.s3	already	71	77	O	already	ady	eady	RB	False
DDI-MedLine.d34.s3	responded	79	87	O	responded	ded	nded	VBD	False
DDI-MedLine.d34.s3	to	89	90	O	to	to	to	TO	False
DDI-MedLine.d34.s3	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d34.s3	dietary	96	102	O	dietary	ary	tary	JJ	False
DDI-MedLine.d34.s3	treatments	104	113	O	treatments	nts	ents	NNS	False
DDI-MedLine.d34.s3	,	114	114	O	,	,	,	,	False
DDI-MedLine.d34.s3	with	116	119	O	with	ith	with	IN	False
DDI-MedLine.d34.s3	constant	121	128	O	constant	ant	tant	JJ	False
DDI-MedLine.d34.s3	values	130	135	O	values	ues	lues	NNS	False
DDI-MedLine.d34.s3	being	137	141	O	being	ing	eing	VBG	False
DDI-MedLine.d34.s3	reached	143	149	O	reached	hed	ched	VBN	False
DDI-MedLine.d34.s3	after	151	155	O	after	ter	fter	IN	False
DDI-MedLine.d34.s3	approximately	157	169	O	approximately	ely	tely	RB	False
DDI-MedLine.d34.s3	three	171	175	O	three	ree	hree	CD	False
DDI-MedLine.d34.s3	days	177	180	O	days	ays	days	NNS	False
DDI-MedLine.d34.s3	.	181	181	O	.	.	.	.	False

DDI-MedLine.d34.s4	Cobalt	0	5	B-drug	Cobalt	alt	balt	NN	False
DDI-MedLine.d34.s4	excretion	7	15	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s4	was	17	19	O	was	was	was	VBD	False
DDI-MedLine.d34.s4	enhanced	21	28	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d34.s4	by	30	31	O	by	by	by	IN	False
DDI-MedLine.d34.s4	supplementary	33	45	O	supplementary	ary	tary	JJ	False
DDI-MedLine.d34.s4	cobalt	47	52	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s4	;	53	53	O	;	;	;	:	False

DDI-MedLine.d34.s5	fecal	0	4	O	fecal	cal	ecal	JJ	False
DDI-MedLine.d34.s5	excretion	6	14	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s5	,	15	15	O	,	,	,	,	False
DDI-MedLine.d34.s5	too	17	19	O	too	too	too	RB	False
DDI-MedLine.d34.s5	,	20	20	O	,	,	,	,	False
DDI-MedLine.d34.s5	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d34.s5	increased	26	34	O	increased	sed	ased	VBN	False
DDI-MedLine.d34.s5	by	36	37	O	by	by	by	IN	False
DDI-MedLine.d34.s5	supplementary	39	51	O	supplementary	ary	tary	JJ	False
DDI-MedLine.d34.s5	iron	53	56	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s5	;	57	57	O	;	;	;	:	False

DDI-MedLine.d34.s6	whereas	0	6	O	whereas	eas	reas	NNS	False
DDI-MedLine.d34.s6	urinary	8	14	O	urinary	ary	nary	JJ	False
DDI-MedLine.d34.s6	excretion	16	24	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s6	was	26	28	O	was	was	was	VBD	False
DDI-MedLine.d34.s6	decreased	30	38	O	decreased	sed	ased	VBN	False
DDI-MedLine.d34.s6	in	40	41	O	in	in	in	IN	False
DDI-MedLine.d34.s6	both	43	46	O	both	oth	both	DT	False
DDI-MedLine.d34.s6	cases	48	52	O	cases	ses	ases	NNS	False
DDI-MedLine.d34.s6	.	53	53	O	.	.	.	.	False

DDI-MedLine.d34.s7	Additional	0	9	O	Additional	nal	onal	JJ	False
DDI-MedLine.d34.s7	iron	11	14	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s7	significantly	16	28	O	significantly	tly	ntly	RB	False
DDI-MedLine.d34.s7	inhibited	30	38	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d34.s7	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d34.s7	absorption	44	53	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s7	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d34.s7	cobalt	58	63	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s7	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d34.s7	both	68	71	O	both	oth	both	DT	False
DDI-MedLine.d34.s7	dietary	73	79	O	dietary	ary	tary	JJ	False
DDI-MedLine.d34.s7	cobalt	81	86	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s7	treatments	88	97	O	treatments	nts	ents	NNS	False
DDI-MedLine.d34.s7	.	98	98	O	.	.	.	.	False

DDI-MedLine.d34.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d34.s8	lower	4	8	O	lower	wer	ower	JJR	False
DDI-MedLine.d34.s8	rate	10	13	O	rate	ate	rate	NN	False
DDI-MedLine.d34.s8	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d34.s8	absorption	18	27	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s8	in	29	30	O	in	in	in	IN	False
DDI-MedLine.d34.s8	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d34.s8	groups	36	41	O	groups	ups	oups	NNS	False
DDI-MedLine.d34.s8	receiving	43	51	O	receiving	ing	ving	VBG	False
DDI-MedLine.d34.s8	446	53	55	O	446	446	446	CD	False
DDI-MedLine.d34.s8	mg	57	58	O	mg	mg	mg	NN	False
DDI-MedLine.d34.s8	Fe	60	61	B-drug	Fe	Fe	Fe	NNP	False
DDI-MedLine.d34.s8	instead	63	69	O	instead	ead	tead	RB	False
DDI-MedLine.d34.s8	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d34.s8	48	74	75	O	48	48	48	CD	False
DDI-MedLine.d34.s8	mg	77	78	O	mg	mg	mg	NN	False
DDI-MedLine.d34.s8	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d34.s8	Fe	83	84	B-drug	Fe	Fe	Fe	NNP	False
DDI-MedLine.d34.s8	per	86	88	O	per	per	per	IN	False
DDI-MedLine.d34.s8	kg	90	91	O	kg	kg	kg	NN	False
DDI-MedLine.d34.s8	diet	93	96	O	diet	iet	diet	NN	False
DDI-MedLine.d34.s8	resulted	98	105	O	resulted	ted	lted	VBD	False
DDI-MedLine.d34.s8	in	107	108	O	in	in	in	IN	False
DDI-MedLine.d34.s8	a	110	110	O	a	a	a	DT	False
DDI-MedLine.d34.s8	decreased	112	120	O	decreased	sed	ased	VBN	False
DDI-MedLine.d34.s8	renal	122	126	O	renal	nal	enal	NN	False
DDI-MedLine.d34.s8	excretion	128	136	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s8	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d34.s8	cobalt	141	146	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s8	.	147	147	O	.	.	.	.	False

DDI-MedLine.d34.s9	Consequently	0	11	O	Consequently	tly	ntly	RB	False
DDI-MedLine.d34.s9	,	12	12	O	,	,	,	,	False
DDI-MedLine.d34.s9	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d34.s9	effect	18	23	O	effect	ect	fect	NN	False
DDI-MedLine.d34.s9	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d34.s9	iron	28	31	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s9	on	33	34	O	on	on	on	IN	False
DDI-MedLine.d34.s9	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d34.s9	retention	40	48	O	retention	ion	tion	NN	False
DDI-MedLine.d34.s9	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d34.s9	cobalt	53	58	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s9	was	60	62	O	was	was	was	VBD	False
DDI-MedLine.d34.s9	lower	64	68	O	lower	wer	ower	JJR	False
DDI-MedLine.d34.s9	than	70	73	O	than	han	than	IN	False
DDI-MedLine.d34.s9	on	75	76	O	on	on	on	IN	False
DDI-MedLine.d34.s9	absorption	78	87	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s9	.	88	88	O	.	.	.	.	False

DDI-MedLine.d34.s10	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d34.s10	suggests	5	12	O	suggests	sts	ests	NNS	False
DDI-MedLine.d34.s10	that	14	17	O	that	hat	that	IN	False
DDI-MedLine.d34.s10	interactions	19	30	O	interactions	ons	ions	NNS	False
DDI-MedLine.d34.s10	between	32	38	O	between	een	ween	IN	False
DDI-MedLine.d34.s10	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d34.s10	two	44	46	O	two	two	two	CD	False
DDI-MedLine.d34.s10	elements	48	55	O	elements	nts	ents	NNS	False
DDI-MedLine.d34.s10	only	57	60	O	only	nly	only	RB	False
DDI-MedLine.d34.s10	take	62	65	O	take	ake	take	VB	False
DDI-MedLine.d34.s10	place	67	71	O	place	ace	lace	NN	False
DDI-MedLine.d34.s10	at	73	74	O	at	at	at	IN	False
DDI-MedLine.d34.s10	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d34.s10	site	80	83	O	site	ite	site	NN	False
DDI-MedLine.d34.s10	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d34.s10	absorption	88	97	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s10	.	98	98	O	.	.	.	.	False

DDI-MedLine.d34.s11	Because	0	6	O	Because	use	ause	IN	False
DDI-MedLine.d34.s11	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d34.s11	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d34.s11	low	15	17	O	low	low	low	JJ	False
DDI-MedLine.d34.s11	dietary	19	25	O	dietary	ary	tary	JJ	False
DDI-MedLine.d34.s11	cobalt	27	32	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s11	concentration	34	46	O	concentration	ion	tion	NN	False
DDI-MedLine.d34.s11	as	48	49	O	as	as	as	IN	False
DDI-MedLine.d34.s11	compared	51	58	O	compared	red	ared	VBN	False
DDI-MedLine.d34.s11	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d34.s11	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d34.s11	iron	67	70	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s11	contents	72	79	O	contents	nts	ents	NNS	False
DDI-MedLine.d34.s11	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d34.s11	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d34.s11	diets	88	92	O	diets	ets	iets	NNS	False
DDI-MedLine.d34.s11	,	93	93	O	,	,	,	,	False
DDI-MedLine.d34.s11	no	95	96	O	no	no	no	DT	False
DDI-MedLine.d34.s11	effect	98	103	O	effect	ect	fect	NN	False
DDI-MedLine.d34.s11	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d34.s11	cobalt	108	113	B-drug	cobalt	alt	balt	NN	False
DDI-MedLine.d34.s11	on	115	116	O	on	on	on	IN	False
DDI-MedLine.d34.s11	iron	118	121	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s11	absorption	123	132	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s11	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d34.s11	excretion	138	146	O	excretion	ion	tion	NN	False
DDI-MedLine.d34.s11	occurred	148	155	O	occurred	red	rred	VBD	False
DDI-MedLine.d34.s11	.	156	156	O	.	.	.	.	False

DDI-MedLine.d34.s12	Differences	0	10	O	Differences	ces	nces	NNS	False
DDI-MedLine.d34.s12	in	12	13	O	in	in	in	IN	False
DDI-MedLine.d34.s12	iron	15	18	B-drug	iron	ron	iron	NN	False
DDI-MedLine.d34.s12	balance	20	26	O	balance	nce	ance	NN	False
DDI-MedLine.d34.s12	were	28	31	O	were	ere	were	VBD	False
DDI-MedLine.d34.s12	only	33	36	O	only	nly	only	RB	False
DDI-MedLine.d34.s12	observed	38	45	O	observed	ved	rved	VBN	False
DDI-MedLine.d34.s12	between	47	53	O	between	een	ween	IN	False
DDI-MedLine.d34.s12	both	55	58	O	both	oth	both	DT	False
DDI-MedLine.d34.s12	dietary	60	66	O	dietary	ary	tary	JJ	False
DDI-MedLine.d34.s12	concentrations	68	81	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d34.s12	,	82	82	O	,	,	,	,	False
DDI-MedLine.d34.s12	showing	84	90	O	showing	ing	wing	VBG	False
DDI-MedLine.d34.s12	a	92	92	O	a	a	a	DT	False
DDI-MedLine.d34.s12	higher	94	99	O	higher	her	gher	JJR	False
DDI-MedLine.d34.s12	absolute	101	108	O	absolute	ute	lute	NN	False
DDI-MedLine.d34.s12	but	110	112	O	but	but	but	CC	False
DDI-MedLine.d34.s12	a	114	114	O	a	a	a	DT	False
DDI-MedLine.d34.s12	lower	116	120	O	lower	wer	ower	JJR	False
DDI-MedLine.d34.s12	relative	122	129	O	relative	ive	tive	NN	False
DDI-MedLine.d34.s12	absorption	131	140	O	absorption	ion	tion	NN	False
DDI-MedLine.d34.s12	as	142	143	O	as	as	as	IN	False
DDI-MedLine.d34.s12	well	145	148	O	well	ell	well	RB	False
DDI-MedLine.d34.s12	as	150	151	O	as	as	as	IN	False
DDI-MedLine.d34.s12	retention	153	161	O	retention	ion	tion	NN	False
DDI-MedLine.d34.s12	in	163	164	O	in	in	in	IN	False
DDI-MedLine.d34.s12	the	166	168	O	the	the	the	DT	False
DDI-MedLine.d34.s12	groups	170	175	O	groups	ups	oups	NNS	False
DDI-MedLine.d34.s12	fed	177	179	O	fed	fed	fed	NN	False
DDI-MedLine.d34.s12	further	181	187	O	further	her	ther	RB	False
DDI-MedLine.d34.s12	Fe	189	190	B-drug	Fe	Fe	Fe	NNP	False
DDI-MedLine.d34.s12	.	191	191	O	.	.	.	.	False
DDI-MedLine.d34.s12	(	192	192	O	(	(	(	(	False
DDI-MedLine.d34.s12	ABSTRACT	193	200	O	ABSTRACT	ACT	RACT	NN	brand
DDI-MedLine.d34.s12	TRUNCATED	202	210	O	TRUNCATED	TED	ATED	NN	brand
DDI-MedLine.d34.s12	AT	212	213	O	AT	AT	AT	NN	brand
DDI-MedLine.d34.s12	250	215	217	O	250	250	250	CD	False
DDI-MedLine.d34.s12	WORDS	219	223	O	WORDS	RDS	ORDS	NN	brand
DDI-MedLine.d34.s12	)	224	224	O	)	)	)	)	False

DDI-MedLine.d13.s0	Death	0	4	O	Death	ath	eath	NN	False
DDI-MedLine.d13.s0	in	6	7	O	in	in	in	IN	False
DDI-MedLine.d13.s0	amphetamine	9	19	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d13.s0	users	21	25	O	users	ers	sers	NNS	False
DDI-MedLine.d13.s0	:	26	26	O	:	:	:	:	False
DDI-MedLine.d13.s0	causes	28	33	O	causes	ses	uses	NNS	False
DDI-MedLine.d13.s0	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d13.s0	rates	39	43	O	rates	tes	ates	NNS	False
DDI-MedLine.d13.s0	.	44	44	O	.	.	.	.	False

DDI-MedLine.d13.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d13.s1	world	4	8	O	world	rld	orld	NN	False
DDI-MedLine.d13.s1	medical	10	16	O	medical	cal	ical	JJ	False
DDI-MedLine.d13.s1	literature	18	27	O	literature	ure	ture	NN	False
DDI-MedLine.d13.s1	contains	29	36	O	contains	ins	ains	NNS	False
DDI-MedLine.d13.s1	43	38	39	O	43	43	43	CD	False
DDI-MedLine.d13.s1	reports	41	47	O	reports	rts	orts	NNS	False
DDI-MedLine.d13.s1	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d13.s1	deaths	52	57	O	deaths	ths	aths	NNS	False
DDI-MedLine.d13.s1	associated	59	68	O	associated	ted	ated	VBN	False
DDI-MedLine.d13.s1	with	70	73	O	with	ith	with	IN	False
DDI-MedLine.d13.s1	amphetamines	75	86	B-drug	amphetamines	nes	ines	NNS	group
DDI-MedLine.d13.s1	in	88	89	O	in	in	in	IN	False
DDI-MedLine.d13.s1	a	91	91	O	a	a	a	DT	False
DDI-MedLine.d13.s1	35-year	93	99	O	35-year	ear	year	JJ	False
DDI-MedLine.d13.s1	period	101	106	O	period	iod	riod	NN	False
DDI-MedLine.d13.s1	.	107	107	O	.	.	.	.	False

DDI-MedLine.d13.s2	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d13.s2	included	6	13	O	included	ded	uded	VBD	False
DDI-MedLine.d13.s2	seven	15	19	O	seven	ven	even	CD	False
DDI-MedLine.d13.s2	cerebrovascular	21	35	O	cerebrovascular	lar	ular	NN	False
DDI-MedLine.d13.s2	accidents	37	45	O	accidents	nts	ents	NNS	False
DDI-MedLine.d13.s2	,	46	46	O	,	,	,	,	False
DDI-MedLine.d13.s2	six	48	50	O	six	six	six	CD	False
DDI-MedLine.d13.s2	sudden	52	57	O	sudden	den	dden	JJ	False
DDI-MedLine.d13.s2	cardiac	59	65	O	cardiac	iac	diac	NN	False
DDI-MedLine.d13.s2	deaths	67	72	O	deaths	ths	aths	NNS	False
DDI-MedLine.d13.s2	,	73	73	O	,	,	,	,	False
DDI-MedLine.d13.s2	three	75	79	O	three	ree	hree	CD	False
DDI-MedLine.d13.s2	cases	81	85	O	cases	ses	ases	NNS	False
DDI-MedLine.d13.s2	of	87	88	O	of	of	of	IN	False
DDI-MedLine.d13.s2	hyperpyrexia	90	101	O	hyperpyrexia	xia	exia	NN	False
DDI-MedLine.d13.s2	,	102	102	O	,	,	,	,	False
DDI-MedLine.d13.s2	eight	104	108	O	eight	ght	ight	CD	False
DDI-MedLine.d13.s2	poisonings	110	119	O	poisonings	ngs	ings	NNS	False
DDI-MedLine.d13.s2	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d13.s2	uncertain	124	132	O	uncertain	ain	tain	JJ	False
DDI-MedLine.d13.s2	mechanism	134	142	O	mechanism	ism	nism	NN	False
DDI-MedLine.d13.s2	and	144	146	O	and	and	and	CC	False
DDI-MedLine.d13.s2	seven	148	152	O	seven	ven	even	CD	False
DDI-MedLine.d13.s2	cases	154	158	O	cases	ses	ases	NNS	False
DDI-MedLine.d13.s2	of	160	161	O	of	of	of	IN	False
DDI-MedLine.d13.s2	medical	163	169	O	medical	cal	ical	JJ	False
DDI-MedLine.d13.s2	complications	171	183	O	complications	ons	ions	NNS	False
DDI-MedLine.d13.s2	of	185	186	O	of	of	of	IN	False
DDI-MedLine.d13.s2	intravenous	188	198	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d13.s2	injection	200	208	O	injection	ion	tion	NN	False
DDI-MedLine.d13.s2	;	209	209	O	;	;	;	:	False

DDI-MedLine.d13.s3	the	0	2	O	the	the	the	DT	False
DDI-MedLine.d13.s3	remainder	4	12	O	remainder	der	nder	NN	False
DDI-MedLine.d13.s3	were	14	17	O	were	ere	were	VBD	False
DDI-MedLine.d13.s3	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d13.s3	uncertain	22	30	O	uncertain	ain	tain	JJ	False
DDI-MedLine.d13.s3	cause	32	36	O	cause	use	ause	NN	False
DDI-MedLine.d13.s3	.	37	37	O	.	.	.	.	False

DDI-MedLine.d13.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d13.s4	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d13.s4	,	11	11	O	,	,	,	,	False
DDI-MedLine.d13.s4	in	13	14	O	in	in	in	IN	False
DDI-MedLine.d13.s4	Ontario	16	22	O	Ontario	rio	ario	NN	False
DDI-MedLine.d13.s4	alone	24	28	O	alone	one	lone	RB	False
DDI-MedLine.d13.s4	,	29	29	O	,	,	,	,	False
DDI-MedLine.d13.s4	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d13.s4	1972	34	37	O	1972	972	1972	CD	False
DDI-MedLine.d13.s4	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d13.s4	1973	43	46	O	1973	973	1973	CD	False
DDI-MedLine.d13.s4	there	48	52	O	there	ere	here	RB	False
DDI-MedLine.d13.s4	were	54	57	O	were	ere	were	VBD	False
DDI-MedLine.d13.s4	26	59	60	O	26	26	26	CD	False
DDI-MedLine.d13.s4	deaths	62	67	O	deaths	ths	aths	NNS	False
DDI-MedLine.d13.s4	in	69	70	O	in	in	in	IN	False
DDI-MedLine.d13.s4	amphetamine	72	82	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d13.s4	users	84	88	O	users	ers	sers	NNS	False
DDI-MedLine.d13.s4	,	89	89	O	,	,	,	,	False
DDI-MedLine.d13.s4	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d13.s4	which	94	98	O	which	ich	hich	WDT	False
DDI-MedLine.d13.s4	16	100	101	O	16	16	16	CD	False
DDI-MedLine.d13.s4	were	103	106	O	were	ere	were	VBD	False
DDI-MedLine.d13.s4	due	108	110	O	due	due	due	JJ	False
DDI-MedLine.d13.s4	to	112	113	O	to	to	to	TO	False
DDI-MedLine.d13.s4	accident	115	122	O	accident	ent	dent	NN	False
DDI-MedLine.d13.s4	suicide	124	130	O	suicide	ide	cide	NN	False
DDI-MedLine.d13.s4	or	132	133	O	or	or	or	CC	False
DDI-MedLine.d13.s4	homicide	135	142	O	homicide	ide	cide	NN	False
DDI-MedLine.d13.s4	.	143	143	O	.	.	.	.	False

DDI-MedLine.d13.s5	Of	0	1	O	Of	Of	Of	IN	False
DDI-MedLine.d13.s5	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d13.s5	remaining	7	15	O	remaining	ing	ning	VBG	False
DDI-MedLine.d13.s5	cases	17	21	O	cases	ses	ases	NNS	False
DDI-MedLine.d13.s5	,	22	22	O	,	,	,	,	False
DDI-MedLine.d13.s5	two	24	26	O	two	two	two	CD	False
DDI-MedLine.d13.s5	were	28	31	O	were	ere	were	VBD	False
DDI-MedLine.d13.s5	cardiac	33	39	O	cardiac	iac	diac	NN	False
DDI-MedLine.d13.s5	,	40	40	O	,	,	,	,	False
DDI-MedLine.d13.s5	two	42	44	O	two	two	two	CD	False
DDI-MedLine.d13.s5	hepatic	46	52	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d13.s5	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d13.s5	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d13.s5	rest	62	65	O	rest	est	rest	NN	False
DDI-MedLine.d13.s5	were	67	70	O	were	ere	were	VBD	False
DDI-MedLine.d13.s5	mixed	72	76	O	mixed	xed	ixed	JJ	False
DDI-MedLine.d13.s5	drug	78	81	O	drug	rug	drug	NN	False
DDI-MedLine.d13.s5	overdose	83	90	O	overdose	ose	dose	NN	False
DDI-MedLine.d13.s5	.	91	91	O	.	.	.	.	False

DDI-MedLine.d13.s6	Pulmonary	0	8	O	Pulmonary	ary	nary	JJ	False
DDI-MedLine.d13.s6	granulomata	10	20	O	granulomata	ata	mata	NNS	False
DDI-MedLine.d13.s6	,	21	21	O	,	,	,	,	False
DDI-MedLine.d13.s6	subacute	23	30	O	subacute	ute	cute	NN	False
DDI-MedLine.d13.s6	hepatitis	32	40	O	hepatitis	tis	itis	NN	False
DDI-MedLine.d13.s6	and	42	44	O	and	and	and	CC	False
DDI-MedLine.d13.s6	other	46	50	O	other	her	ther	JJ	False
DDI-MedLine.d13.s6	lesions	52	58	O	lesions	ons	ions	NNS	False
DDI-MedLine.d13.s6	resulting	60	68	O	resulting	ing	ting	VBG	False
DDI-MedLine.d13.s6	from	70	73	O	from	rom	from	IN	False
DDI-MedLine.d13.s6	intravenous	75	85	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d13.s6	drug	87	90	O	drug	rug	drug	NN	False
DDI-MedLine.d13.s6	use	92	94	O	use	use	use	NN	False
DDI-MedLine.d13.s6	were	96	99	O	were	ere	were	VBD	False
DDI-MedLine.d13.s6	common	101	106	O	common	mon	mmon	JJ	False
DDI-MedLine.d13.s6	findings	108	115	O	findings	ngs	ings	NNS	False
DDI-MedLine.d13.s6	at	117	118	O	at	at	at	IN	False
DDI-MedLine.d13.s6	autopsy	120	126	O	autopsy	psy	opsy	NN	False
DDI-MedLine.d13.s6	.	127	127	O	.	.	.	.	False

DDI-MedLine.d13.s7	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d13.s7	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d13.s7	basis	7	11	O	basis	sis	asis	NN	False
DDI-MedLine.d13.s7	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d13.s7	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d13.s7	estimated	20	28	O	estimated	ted	ated	VBN	False
DDI-MedLine.d13.s7	number	30	35	O	number	ber	mber	NN	False
DDI-MedLine.d13.s7	of	37	38	O	of	of	of	IN	False
DDI-MedLine.d13.s7	regular	40	46	O	regular	lar	ular	JJ	False
DDI-MedLine.d13.s7	users	48	52	O	users	ers	sers	NNS	False
DDI-MedLine.d13.s7	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d13.s7	intravenous	57	67	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d13.s7	amphetamine	69	79	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d13.s7	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d13.s7	Ontario	84	90	O	Ontario	rio	ario	NN	False
DDI-MedLine.d13.s7	,	91	91	O	,	,	,	,	False
DDI-MedLine.d13.s7	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d13.s7	mortality	97	105	O	mortality	ity	lity	NN	False
DDI-MedLine.d13.s7	rate	107	110	O	rate	ate	rate	NN	False
DDI-MedLine.d13.s7	in	112	113	O	in	in	in	IN	False
DDI-MedLine.d13.s7	such	115	118	O	such	uch	such	JJ	False
DDI-MedLine.d13.s7	users	120	124	O	users	ers	sers	NNS	False
DDI-MedLine.d13.s7	is	126	127	O	is	is	is	VBZ	False
DDI-MedLine.d13.s7	at	129	130	O	at	at	at	IN	False
DDI-MedLine.d13.s7	least	132	136	O	least	ast	east	JJS	False
DDI-MedLine.d13.s7	four	138	141	O	four	our	four	CD	False
DDI-MedLine.d13.s7	times	143	147	O	times	mes	imes	NNS	False
DDI-MedLine.d13.s7	as	149	150	O	as	as	as	IN	False
DDI-MedLine.d13.s7	high	152	155	O	high	igh	high	JJ	False
DDI-MedLine.d13.s7	as	157	158	O	as	as	as	IN	False
DDI-MedLine.d13.s7	in	160	161	O	in	in	in	IN	False
DDI-MedLine.d13.s7	the	163	165	O	the	the	the	DT	False
DDI-MedLine.d13.s7	general	167	173	O	general	ral	eral	JJ	False
DDI-MedLine.d13.s7	population	175	184	O	population	ion	tion	NN	False
DDI-MedLine.d13.s7	of	186	187	O	of	of	of	IN	False
DDI-MedLine.d13.s7	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d13.s7	same	193	196	O	same	ame	same	JJ	False
DDI-MedLine.d13.s7	age	198	200	O	age	age	age	NN	False
DDI-MedLine.d13.s7	,	201	201	O	,	,	,	,	False
DDI-MedLine.d13.s7	and	203	205	O	and	and	and	CC	False
DDI-MedLine.d13.s7	is	207	208	O	is	is	is	VBZ	False
DDI-MedLine.d13.s7	comparable	210	219	O	comparable	ble	able	JJ	False
DDI-MedLine.d13.s7	to	221	222	O	to	to	to	TO	False
DDI-MedLine.d13.s7	that	224	227	O	that	hat	that	IN	False
DDI-MedLine.d13.s7	in	229	230	O	in	in	in	IN	False
DDI-MedLine.d13.s7	alcoholics	232	241	O	alcoholics	ics	lics	NNS	False
DDI-MedLine.d13.s7	and	243	245	O	and	and	and	CC	False
DDI-MedLine.d13.s7	heroin	247	252	B-drug_n	heroin	oin	roin	NN	False
DDI-MedLine.d13.s7	addicts	254	260	O	addicts	cts	icts	NNS	False
DDI-MedLine.d13.s7	.	261	261	O	.	.	.	.	False

DDI-MedLine.d13.s8	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d13.s8	,	7	7	O	,	,	,	,	False
DDI-MedLine.d13.s8	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d13.s8	absolute	13	20	O	absolute	ute	lute	NN	False
DDI-MedLine.d13.s8	number	22	27	O	number	ber	mber	NN	False
DDI-MedLine.d13.s8	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d13.s8	alcohol-related	32	46	O	alcohol-related	ted	ated	JJ	False
DDI-MedLine.d13.s8	deaths	48	53	O	deaths	ths	aths	NNS	False
DDI-MedLine.d13.s8	is	55	56	O	is	is	is	VBZ	False
DDI-MedLine.d13.s8	far	58	60	O	far	far	far	RB	False
DDI-MedLine.d13.s8	greater	62	68	O	greater	ter	ater	JJR	False
DDI-MedLine.d13.s8	than	70	73	O	than	han	than	IN	False
DDI-MedLine.d13.s8	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d13.s8	number	79	84	O	number	ber	mber	NN	False
DDI-MedLine.d13.s8	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d13.s8	deaths	89	94	O	deaths	ths	aths	NNS	False
DDI-MedLine.d13.s8	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d13.s8	amphetamine	99	109	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d13.s8	or	111	112	O	or	or	or	CC	False
DDI-MedLine.d13.s8	heroin	114	119	B-drug_n	heroin	oin	roin	NN	False
DDI-MedLine.d13.s8	users	121	125	O	users	ers	sers	NNS	False
DDI-MedLine.d13.s8	.	126	126	O	.	.	.	.	False

DDI-MedLine.d113.s0	Acid-catalyzed	0	13	O	Acid-catalyzed	zed	yzed	JJ	False
DDI-MedLine.d113.s0	ethanolysis	15	25	O	ethanolysis	sis	ysis	NN	False
DDI-MedLine.d113.s0	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d113.s0	temazepam	30	38	B-drug	temazepam	pam	epam	NN	False
DDI-MedLine.d113.s0	in	40	41	O	in	in	in	IN	False
DDI-MedLine.d113.s0	anhydrous	43	51	O	anhydrous	ous	rous	JJ	False
DDI-MedLine.d113.s0	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d113.s0	aqueous	57	63	O	aqueous	ous	eous	JJ	False
DDI-MedLine.d113.s0	ethanol	65	71	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d113.s0	solutions	73	81	O	solutions	ons	ions	NNS	False
DDI-MedLine.d113.s0	.	82	82	O	.	.	.	.	False

DDI-MedLine.d113.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d113.s1	benzodiazepines	4	18	B-group	benzodiazepines	nes	ines	NNS	group
DDI-MedLine.d113.s1	are	20	22	O	are	are	are	VBP	False
DDI-MedLine.d113.s1	a	24	24	O	a	a	a	DT	False
DDI-MedLine.d113.s1	family	26	31	O	family	ily	mily	NN	False
DDI-MedLine.d113.s1	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d113.s1	anxiolytic	36	45	B-group	anxiolytic	tic	ytic	JJ	False
DDI-MedLine.d113.s1	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d113.s1	hypnotic	51	58	B-group	hypnotic	tic	otic	JJ	False
DDI-MedLine.d113.s1	drugs	60	64	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d113.s1	.	65	65	O	.	.	.	.	False

DDI-MedLine.d113.s2	When	0	3	O	When	hen	When	WRB	False
DDI-MedLine.d113.s2	taken	5	9	O	taken	ken	aken	VBN	False
DDI-MedLine.d113.s2	concurrently	11	22	O	concurrently	tly	ntly	RB	False
DDI-MedLine.d113.s2	with	24	27	O	with	ith	with	IN	False
DDI-MedLine.d113.s2	ethanol	29	35	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d113.s2	,	36	36	O	,	,	,	,	False
DDI-MedLine.d113.s2	a	38	38	O	a	a	a	DT	False
DDI-MedLine.d113.s2	pharmacological	40	54	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d113.s2	interaction	56	66	O	interaction	ion	tion	NN	False
DDI-MedLine.d113.s2	may	68	70	O	may	may	may	MD	False
DDI-MedLine.d113.s2	occur	72	76	O	occur	cur	ccur	NN	False
DDI-MedLine.d113.s2	,	77	77	O	,	,	,	,	False
DDI-MedLine.d113.s2	potentiating	79	90	O	potentiating	ing	ting	VBG	False
DDI-MedLine.d113.s2	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d113.s2	central	96	102	O	central	ral	tral	JJ	False
DDI-MedLine.d113.s2	nervous	104	110	O	nervous	ous	vous	JJ	False
DDI-MedLine.d113.s2	system	112	117	O	system	tem	stem	NN	False
DDI-MedLine.d113.s2	depression	119	128	O	depression	ion	sion	NN	False
DDI-MedLine.d113.s2	produced	130	137	O	produced	ced	uced	VBN	False
DDI-MedLine.d113.s2	by	139	140	O	by	by	by	IN	False
DDI-MedLine.d113.s2	either	142	147	O	either	her	ther	DT	False
DDI-MedLine.d113.s2	drug	149	152	O	drug	rug	drug	NN	False
DDI-MedLine.d113.s2	.	153	153	O	.	.	.	.	False

DDI-MedLine.d113.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d113.s3	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d113.s3	to	12	13	O	to	to	to	TO	False
DDI-MedLine.d113.s3	this	15	18	O	this	his	this	DT	False
DDI-MedLine.d113.s3	pharmacological	20	34	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d113.s3	interaction	36	46	O	interaction	ion	tion	NN	False
DDI-MedLine.d113.s3	,	47	47	O	,	,	,	,	False
DDI-MedLine.d113.s3	this	49	52	O	this	his	this	DT	False
DDI-MedLine.d113.s3	report	54	59	O	report	ort	port	NN	False
DDI-MedLine.d113.s3	describes	61	69	O	describes	bes	ibes	NNS	False
DDI-MedLine.d113.s3	a	71	71	O	a	a	a	DT	False
DDI-MedLine.d113.s3	novel	73	77	O	novel	vel	ovel	NN	False
DDI-MedLine.d113.s3	chemical	79	86	O	chemical	cal	ical	NN	False
DDI-MedLine.d113.s3	reaction	88	95	O	reaction	ion	tion	NN	False
DDI-MedLine.d113.s3	between	97	103	O	between	een	ween	IN	False
DDI-MedLine.d113.s3	temazepam	105	113	B-drug	temazepam	pam	epam	NN	False
DDI-MedLine.d113.s3	(	115	115	O	(	(	(	(	False
DDI-MedLine.d113.s3	a	116	116	O	a	a	a	DT	False
DDI-MedLine.d113.s3	benzodiazepine	118	131	B-group	benzodiazepine	ine	pine	NN	drug
DDI-MedLine.d113.s3	)	132	132	O	)	)	)	)	False
DDI-MedLine.d113.s3	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d113.s3	ethanol	138	144	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d113.s3	under	146	150	O	under	der	nder	IN	False
DDI-MedLine.d113.s3	acidic	152	157	O	acidic	dic	idic	NN	False
DDI-MedLine.d113.s3	conditions	159	168	O	conditions	ons	ions	NNS	False
DDI-MedLine.d113.s3	similar	170	176	O	similar	lar	ilar	JJ	False
DDI-MedLine.d113.s3	to	178	179	O	to	to	to	TO	False
DDI-MedLine.d113.s3	those	181	185	O	those	ose	hose	DT	False
DDI-MedLine.d113.s3	found	187	191	O	found	und	ound	NN	False
DDI-MedLine.d113.s3	in	193	194	O	in	in	in	IN	False
DDI-MedLine.d113.s3	vivo	196	199	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d113.s3	,	200	200	O	,	,	,	,	False
DDI-MedLine.d113.s3	resulting	202	210	O	resulting	ing	ting	VBG	False
DDI-MedLine.d113.s3	in	212	213	O	in	in	in	IN	False
DDI-MedLine.d113.s3	a	215	215	O	a	a	a	DT	False
DDI-MedLine.d113.s3	3-ethoxylated	217	229	O	3-ethoxylated	ted	ated	JJ	False
DDI-MedLine.d113.s3	product	231	237	O	product	uct	duct	NN	False
DDI-MedLine.d113.s3	.	238	238	O	.	.	.	.	False

DDI-MedLine.d113.s4	Optimal	0	6	O	Optimal	mal	imal	NN	False
DDI-MedLine.d113.s4	conditions	8	17	O	conditions	ons	ions	NNS	False
DDI-MedLine.d113.s4	,	18	18	O	,	,	,	,	False
DDI-MedLine.d113.s4	kinetics	20	27	O	kinetics	ics	tics	NNS	False
DDI-MedLine.d113.s4	,	28	28	O	,	,	,	,	False
DDI-MedLine.d113.s4	equilibrium	30	40	O	equilibrium	ium	rium	NN	drug
DDI-MedLine.d113.s4	,	41	41	O	,	,	,	,	False
DDI-MedLine.d113.s4	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d113.s4	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d113.s4	mechanism	51	59	O	mechanism	ism	nism	NN	False
DDI-MedLine.d113.s4	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d113.s4	this	64	67	O	this	his	this	DT	False
DDI-MedLine.d113.s4	acid-catalyzed	69	82	O	acid-catalyzed	zed	yzed	JJ	False
DDI-MedLine.d113.s4	ethanolysis	84	94	O	ethanolysis	sis	ysis	NN	False
DDI-MedLine.d113.s4	are	96	98	O	are	are	are	VBP	False
DDI-MedLine.d113.s4	reported	100	107	O	reported	ted	rted	VBD	False
DDI-MedLine.d113.s4	.	108	108	O	.	.	.	.	False

DDI-MedLine.d113.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d113.s5	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d113.s5	raise	12	16	O	raise	ise	aise	NN	False
DDI-MedLine.d113.s5	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d113.s5	possibility	22	32	O	possibility	ity	lity	NN	False
DDI-MedLine.d113.s5	that	34	37	O	that	hat	that	IN	False
DDI-MedLine.d113.s5	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d113.s5	ethanolysis	43	53	O	ethanolysis	sis	ysis	NN	False
DDI-MedLine.d113.s5	reaction	55	62	O	reaction	ion	tion	NN	False
DDI-MedLine.d113.s5	may	64	66	O	may	may	may	MD	False
DDI-MedLine.d113.s5	occur	68	72	O	occur	cur	ccur	NN	False
DDI-MedLine.d113.s5	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d113.s5	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d113.s5	stomach	81	87	O	stomach	ach	mach	NN	False
DDI-MedLine.d113.s5	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d113.s5	people	92	97	O	people	ple	ople	NNS	False
DDI-MedLine.d113.s5	who	99	101	O	who	who	who	WP	False
DDI-MedLine.d113.s5	consume	103	109	O	consume	ume	sume	NN	False
DDI-MedLine.d113.s5	alcohol	111	117	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d113.s5	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d113.s5	3-hydroxy-1,4-benzodiazepine	123	150	B-group	3-hydroxy-1,4-benzodiazepine	ine	pine	JJ	drug
DDI-MedLine.d113.s5	on	152	153	O	on	on	on	IN	False
DDI-MedLine.d113.s5	a	155	155	O	a	a	a	DT	False
DDI-MedLine.d113.s5	regular	157	163	O	regular	lar	ular	JJ	False
DDI-MedLine.d113.s5	basis	165	169	O	basis	sis	asis	NN	False
DDI-MedLine.d113.s5	.	170	170	O	.	.	.	.	False

DDI-MedLine.d113.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d113.s6	acid-catalyzed	4	17	O	acid-catalyzed	zed	yzed	JJ	False
DDI-MedLine.d113.s6	ethanol-drug	19	30	O	ethanol-drug	rug	drug	JJ	False
DDI-MedLine.d113.s6	reaction	32	39	O	reaction	ion	tion	NN	False
DDI-MedLine.d113.s6	is	41	42	O	is	is	is	VBZ	False
DDI-MedLine.d113.s6	a	44	44	O	a	a	a	DT	False
DDI-MedLine.d113.s6	relatively	46	55	O	relatively	ely	vely	RB	False
DDI-MedLine.d113.s6	unexplored	57	66	O	unexplored	red	ored	JJ	False
DDI-MedLine.d113.s6	area	68	71	O	area	rea	area	NN	False
DDI-MedLine.d113.s6	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d113.s6	may	77	79	O	may	may	may	MD	False
DDI-MedLine.d113.s6	alter	81	85	O	alter	ter	lter	NN	False
DDI-MedLine.d113.s6	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d113.s6	pharmacological	91	105	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d113.s6	action	107	112	O	action	ion	tion	NN	False
DDI-MedLine.d113.s6	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d113.s6	some	117	120	O	some	ome	some	DT	False
DDI-MedLine.d113.s6	drugs	122	126	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d113.s6	.	127	127	O	.	.	.	.	False

DDI-MedLine.d35.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d35.s0	Importance	1	10	O	Importance	nce	ance	NN	False
DDI-MedLine.d35.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d35.s0	pharmacogenetics	15	30	O	pharmacogenetics	ics	tics	NNS	False
DDI-MedLine.d35.s0	]	31	31	O	]	]	]	NN	False
DDI-MedLine.d35.s0	Pharmacogenetics	34	49	O	Pharmacogenetics	ics	tics	NNS	False
DDI-MedLine.d35.s0	deals	51	55	O	deals	als	eals	NNS	False
DDI-MedLine.d35.s0	with	57	60	O	with	ith	with	IN	False
DDI-MedLine.d35.s0	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d35.s0	differences	66	76	O	differences	ces	nces	NNS	False
DDI-MedLine.d35.s0	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d35.s0	effect	81	86	O	effect	ect	fect	NN	False
DDI-MedLine.d35.s0	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d35.s0	drugs	91	95	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d35.s0	caused	97	102	O	caused	sed	used	VBN	False
DDI-MedLine.d35.s0	by	104	105	O	by	by	by	IN	False
DDI-MedLine.d35.s0	genetic	107	113	O	genetic	tic	etic	JJ	False
DDI-MedLine.d35.s0	variation	115	123	O	variation	ion	tion	NN	False
DDI-MedLine.d35.s0	.	124	124	O	.	.	.	.	False

DDI-MedLine.d35.s1	Differences	0	10	O	Differences	ces	nces	NNS	False
DDI-MedLine.d35.s1	can	12	14	O	can	can	can	MD	False
DDI-MedLine.d35.s1	occur	16	20	O	occur	cur	ccur	NN	False
DDI-MedLine.d35.s1	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d35.s1	therapeutic	25	35	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d35.s1	effect	37	42	O	effect	ect	fect	NN	False
DDI-MedLine.d35.s1	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d35.s1	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d35.s1	adverse	51	57	O	adverse	rse	erse	NN	False
DDI-MedLine.d35.s1	events	59	64	O	events	nts	ents	NNS	False
DDI-MedLine.d35.s1	.	65	65	O	.	.	.	.	False

DDI-MedLine.d35.s2	Genetic	0	6	O	Genetic	tic	etic	JJ	False
DDI-MedLine.d35.s2	variation	8	16	O	variation	ion	tion	NN	False
DDI-MedLine.d35.s2	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d35.s2	metabolism	21	30	O	metabolism	ism	lism	NN	False
DDI-MedLine.d35.s2	may	32	34	O	may	may	may	MD	False
DDI-MedLine.d35.s2	result	36	41	O	result	ult	sult	NN	False
DDI-MedLine.d35.s2	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d35.s2	high	46	49	O	high	igh	high	JJ	False
DDI-MedLine.d35.s2	concentrations	51	64	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d35.s2	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d35.s2	drugs	69	73	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d35.s2	and	75	77	O	and	and	and	CC	False
DDI-MedLine.d35.s2	an	79	80	O	an	an	an	DT	False
DDI-MedLine.d35.s2	increased	82	90	O	increased	sed	ased	VBN	False
DDI-MedLine.d35.s2	risk	92	95	O	risk	isk	risk	NN	False
DDI-MedLine.d35.s2	of	97	98	O	of	of	of	IN	False
DDI-MedLine.d35.s2	adverse	100	106	O	adverse	rse	erse	NN	False
DDI-MedLine.d35.s2	effects	108	114	O	effects	cts	ects	NNS	False
DDI-MedLine.d35.s2	in	116	117	O	in	in	in	IN	False
DDI-MedLine.d35.s2	slow	119	122	O	slow	low	slow	VB	False
DDI-MedLine.d35.s2	metabolizers	124	135	O	metabolizers	ers	zers	NNS	False
DDI-MedLine.d35.s2	,	136	136	O	,	,	,	,	False
DDI-MedLine.d35.s2	which	138	142	O	which	ich	hich	WDT	False
DDI-MedLine.d35.s2	is	144	145	O	is	is	is	VBZ	False
DDI-MedLine.d35.s2	important	147	155	O	important	ant	tant	JJ	False
DDI-MedLine.d35.s2	when	157	160	O	when	hen	when	WRB	False
DDI-MedLine.d35.s2	using	162	166	O	using	ing	sing	VBG	False
DDI-MedLine.d35.s2	for	168	170	O	for	for	for	IN	False
DDI-MedLine.d35.s2	example	172	178	O	example	ple	mple	NN	False
DDI-MedLine.d35.s2	antidepressants	180	194	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d35.s2	or	196	197	O	or	or	or	CC	False
DDI-MedLine.d35.s2	chemotherapy	199	210	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d35.s2	.	211	211	O	.	.	.	.	False

DDI-MedLine.d35.s3	Genetic	0	6	O	Genetic	tic	etic	JJ	False
DDI-MedLine.d35.s3	variation	8	16	O	variation	ion	tion	NN	False
DDI-MedLine.d35.s3	also	18	21	O	also	lso	also	RB	False
DDI-MedLine.d35.s3	occurs	23	28	O	occurs	urs	curs	NNS	False
DDI-MedLine.d35.s3	in	30	31	O	in	in	in	IN	False
DDI-MedLine.d35.s3	proteins	33	40	O	proteins	ins	eins	NNS	False
DDI-MedLine.d35.s3	interacting	42	52	O	interacting	ing	ting	VBG	False
DDI-MedLine.d35.s3	with	54	57	O	with	ith	with	IN	False
DDI-MedLine.d35.s3	drugs	59	63	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d35.s3	,	64	64	O	,	,	,	,	False
DDI-MedLine.d35.s3	which	66	70	O	which	ich	hich	WDT	False
DDI-MedLine.d35.s3	may	72	74	O	may	may	may	MD	False
DDI-MedLine.d35.s3	change	76	81	O	change	nge	ange	NN	False
DDI-MedLine.d35.s3	the	83	85	O	the	the	the	DT	False
DDI-MedLine.d35.s3	effect	87	92	O	effect	ect	fect	NN	False
DDI-MedLine.d35.s3	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d35.s3	e.g	97	99	O	e.g	e.g	e.g	NN	False
DDI-MedLine.d35.s3	.	100	100	O	.	.	.	.	False

DDI-MedLine.d35.s4	asthma	0	5	O	asthma	hma	thma	NN	False
DDI-MedLine.d35.s4	drugs	7	11	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d35.s4	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d35.s4	antipsychotics	17	30	B-group	antipsychotics	ics	tics	NNS	False
DDI-MedLine.d35.s4	.	31	31	O	.	.	.	.	False

DDI-MedLine.d35.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d35.s5	selection	4	12	O	selection	ion	tion	NN	False
DDI-MedLine.d35.s5	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d35.s5	drugs	17	21	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d35.s5	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d35.s5	their	27	31	O	their	eir	heir	PRP$	False
DDI-MedLine.d35.s5	dosages	33	39	O	dosages	ges	ages	NNS	False
DDI-MedLine.d35.s5	may	41	43	O	may	may	may	MD	False
DDI-MedLine.d35.s5	be	45	46	O	be	be	be	VB	False
DDI-MedLine.d35.s5	improved	48	55	O	improved	ved	oved	VBN	False
DDI-MedLine.d35.s5	,	56	56	O	,	,	,	,	False
DDI-MedLine.d35.s5	and	58	60	O	and	and	and	CC	False
DDI-MedLine.d35.s5	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d35.s5	number	66	71	O	number	ber	mber	NN	False
DDI-MedLine.d35.s5	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d35.s5	adverse	76	82	O	adverse	rse	erse	NN	False
DDI-MedLine.d35.s5	effects	84	90	O	effects	cts	ects	NNS	False
DDI-MedLine.d35.s5	reduced	92	98	O	reduced	ced	uced	VBN	False
DDI-MedLine.d35.s5	by	100	101	O	by	by	by	IN	False
DDI-MedLine.d35.s5	pharmacogenetic	103	117	O	pharmacogenetic	tic	etic	JJ	False
DDI-MedLine.d35.s5	investigations	119	132	O	investigations	ons	ions	NNS	False
DDI-MedLine.d35.s5	.	133	133	O	.	.	.	.	False

DDI-MedLine.d35.s6	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d35.s6	,	7	7	O	,	,	,	,	False
DDI-MedLine.d35.s6	it	9	10	O	it	it	it	PRP	False
DDI-MedLine.d35.s6	may	12	14	O	may	may	may	MD	False
DDI-MedLine.d35.s6	be	16	17	O	be	be	be	VB	False
DDI-MedLine.d35.s6	important	19	27	O	important	ant	tant	JJ	False
DDI-MedLine.d35.s6	also	29	32	O	also	lso	also	RB	False
DDI-MedLine.d35.s6	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d35.s6	case	37	40	O	case	ase	case	NN	False
DDI-MedLine.d35.s6	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d35.s6	medical	45	51	O	medical	cal	ical	JJ	False
DDI-MedLine.d35.s6	examinations	53	64	O	examinations	ons	ions	NNS	False
DDI-MedLine.d35.s6	for	66	68	O	for	for	for	IN	False
DDI-MedLine.d35.s6	insurances	70	79	O	insurances	ces	nces	NNS	False
DDI-MedLine.d35.s6	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d35.s6	job	85	87	O	job	job	job	NN	False
DDI-MedLine.d35.s6	appointments	89	100	O	appointments	nts	ents	NNS	False
DDI-MedLine.d35.s6	,	101	101	O	,	,	,	,	False
DDI-MedLine.d35.s6	since	103	107	O	since	nce	ince	IN	False
DDI-MedLine.d35.s6	some	109	112	O	some	ome	some	DT	False
DDI-MedLine.d35.s6	patients	114	121	O	patients	nts	ents	NNS	False
DDI-MedLine.d35.s6	may	123	125	O	may	may	may	MD	False
DDI-MedLine.d35.s6	turn	127	130	O	turn	urn	turn	NN	False
DDI-MedLine.d35.s6	out	132	134	O	out	out	out	IN	False
DDI-MedLine.d35.s6	to	136	137	O	to	to	to	TO	False
DDI-MedLine.d35.s6	need	139	142	O	need	eed	need	NN	False
DDI-MedLine.d35.s6	expensive	144	152	O	expensive	ive	sive	JJ	False
DDI-MedLine.d35.s6	drugs	154	158	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d35.s6	or	160	161	O	or	or	or	CC	False
DDI-MedLine.d35.s6	to	163	164	O	to	to	to	TO	False
DDI-MedLine.d35.s6	be	166	167	O	be	be	be	VB	False
DDI-MedLine.d35.s6	susceptible	169	179	O	susceptible	ble	ible	JJ	False
DDI-MedLine.d35.s6	to	181	182	O	to	to	to	TO	False
DDI-MedLine.d35.s6	a	184	184	O	a	a	a	DT	False
DDI-MedLine.d35.s6	certain	186	192	O	certain	ain	tain	JJ	False
DDI-MedLine.d35.s6	disease	194	200	O	disease	ase	ease	NN	False
DDI-MedLine.d35.s6	.	201	201	O	.	.	.	.	False

DDI-MedLine.d35.s7	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d35.s7	,	9	9	O	,	,	,	,	False
DDI-MedLine.d35.s7	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d35.s7	use	15	17	O	use	use	use	NN	False
DDI-MedLine.d35.s7	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d35.s7	genetic	22	28	O	genetic	tic	etic	JJ	False
DDI-MedLine.d35.s7	data	30	33	O	data	ata	data	NNS	False
DDI-MedLine.d35.s7	in	35	36	O	in	in	in	IN	False
DDI-MedLine.d35.s7	these	38	42	O	these	ese	hese	DT	False
DDI-MedLine.d35.s7	instances	44	52	O	instances	ces	nces	NNS	False
DDI-MedLine.d35.s7	has	54	56	O	has	has	has	VBZ	False
DDI-MedLine.d35.s7	to	58	59	O	to	to	to	TO	False
DDI-MedLine.d35.s7	be	61	62	O	be	be	be	VB	False
DDI-MedLine.d35.s7	regulated	64	72	O	regulated	ted	ated	VBN	False
DDI-MedLine.d35.s7	.	73	73	O	.	.	.	.	False

DDI-MedLine.d132.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d132.s0	emerging	4	11	O	emerging	ing	ging	VBG	False
DDI-MedLine.d132.s0	roles	13	17	O	roles	les	oles	NNS	group
DDI-MedLine.d132.s0	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d132.s0	non-nucleoside	22	35	B-group	non-nucleoside	ide	side	JJ	False
DDI-MedLine.d132.s0	reverse	37	43	I-group	reverse	rse	erse	NN	False
DDI-MedLine.d132.s0	transcriptase	45	57	I-group	transcriptase	ase	tase	NN	False
DDI-MedLine.d132.s0	inhibitors	59	68	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d132.s0	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d132.s0	antiretroviral	73	86	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d132.s0	therapy	88	94	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s0	.	95	95	O	.	.	.	.	False

DDI-MedLine.d132.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d132.s1	availability	4	15	O	availability	ity	lity	NN	False
DDI-MedLine.d132.s1	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d132.s1	potent	20	25	O	potent	ent	tent	NN	False
DDI-MedLine.d132.s1	non-nucleoside	27	40	B-group	non-nucleoside	ide	side	JJ	False
DDI-MedLine.d132.s1	reverse	42	48	I-group	reverse	rse	erse	NN	False
DDI-MedLine.d132.s1	transcriptase	50	62	I-group	transcriptase	ase	tase	NN	False
DDI-MedLine.d132.s1	inhibitor	64	72	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d132.s1	(	74	74	O	(	(	(	(	False
DDI-MedLine.d132.s1	NNRTI	75	79	B-group	NNRTI	RTI	NRTI	NN	brand
DDI-MedLine.d132.s1	)	80	80	O	)	)	)	)	False
DDI-MedLine.d132.s1	-based	81	86	O	-based	sed	ased	VBN	False
DDI-MedLine.d132.s1	regimens	88	95	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s1	for	97	99	O	for	for	for	IN	False
DDI-MedLine.d132.s1	antiretroviral	101	114	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d132.s1	therapy	116	122	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s1	and	124	126	O	and	and	and	CC	False
DDI-MedLine.d132.s1	concerns	128	135	O	concerns	rns	erns	NNS	False
DDI-MedLine.d132.s1	regarding	137	145	O	regarding	ing	ding	VBG	False
DDI-MedLine.d132.s1	protease	147	154	B-group	protease	ase	ease	NN	False
DDI-MedLine.d132.s1	inhibitor	156	164	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d132.s1	(	166	166	O	(	(	(	(	False
DDI-MedLine.d132.s1	PI	167	168	B-group	PI	PI	PI	NN	brand
DDI-MedLine.d132.s1	)	169	169	O	)	)	)	)	False
DDI-MedLine.d132.s1	-related	170	177	O	-related	ted	ated	VBN	False
DDI-MedLine.d132.s1	metabolic	179	187	O	metabolic	lic	olic	NN	False
DDI-MedLine.d132.s1	disturbances	189	200	O	disturbances	ces	nces	NNS	False
DDI-MedLine.d132.s1	have	202	205	O	have	ave	have	VB	False
DDI-MedLine.d132.s1	led	207	209	O	led	led	led	VBN	False
DDI-MedLine.d132.s1	to	211	212	O	to	to	to	TO	False
DDI-MedLine.d132.s1	significant	214	224	O	significant	ant	cant	JJ	False
DDI-MedLine.d132.s1	shifts	226	231	O	shifts	fts	ifts	NNS	False
DDI-MedLine.d132.s1	in	233	234	O	in	in	in	IN	False
DDI-MedLine.d132.s1	treatment	236	244	O	treatment	ent	ment	NN	False
DDI-MedLine.d132.s1	practices	246	254	O	practices	ces	ices	NNS	False
DDI-MedLine.d132.s1	in	256	257	O	in	in	in	IN	False
DDI-MedLine.d132.s1	HIV	259	261	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d132.s1	infection	263	271	O	infection	ion	tion	NN	False
DDI-MedLine.d132.s1	.	272	272	O	.	.	.	.	False

DDI-MedLine.d132.s2	NNRTI-based	0	10	O	NNRTI-based	sed	ased	JJ	False
DDI-MedLine.d132.s2	regimens	12	19	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s2	may	21	23	O	may	may	may	MD	False
DDI-MedLine.d132.s2	have	25	28	O	have	ave	have	VB	False
DDI-MedLine.d132.s2	several	30	36	O	several	ral	eral	JJ	False
DDI-MedLine.d132.s2	advantages	38	47	O	advantages	ges	ages	NNS	False
DDI-MedLine.d132.s2	over	49	52	O	over	ver	over	IN	False
DDI-MedLine.d132.s2	PI-based	54	61	O	PI-based	sed	ased	JJ	False
DDI-MedLine.d132.s2	therapy	63	69	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s2	for	71	73	O	for	for	for	IN	False
DDI-MedLine.d132.s2	initial	75	81	O	initial	ial	tial	JJ	False
DDI-MedLine.d132.s2	or	83	84	O	or	or	or	CC	False
DDI-MedLine.d132.s2	prolonged	86	94	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d132.s2	therapy	96	102	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s2	,	103	103	O	,	,	,	,	False
DDI-MedLine.d132.s2	including	105	113	O	including	ing	ding	VBG	False
DDI-MedLine.d132.s2	more	115	118	O	more	ore	more	RBR	False
DDI-MedLine.d132.s2	convenient	120	129	O	convenient	ent	ient	NN	False
DDI-MedLine.d132.s2	administration	131	144	O	administration	ion	tion	NN	False
DDI-MedLine.d132.s2	regimens	146	153	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s2	,	154	154	O	,	,	,	,	False
DDI-MedLine.d132.s2	lower	156	160	O	lower	wer	ower	JJR	False
DDI-MedLine.d132.s2	tablet	162	167	O	tablet	let	blet	NN	False
DDI-MedLine.d132.s2	volume	169	174	O	volume	ume	lume	NN	False
DDI-MedLine.d132.s2	,	175	175	O	,	,	,	,	False
DDI-MedLine.d132.s2	fewer	177	181	O	fewer	wer	ewer	JJR	False
DDI-MedLine.d132.s2	drug	183	186	O	drug	rug	drug	NN	False
DDI-MedLine.d132.s2	interactions	188	199	O	interactions	ons	ions	NNS	False
DDI-MedLine.d132.s2	,	200	200	O	,	,	,	,	False
DDI-MedLine.d132.s2	and	202	204	O	and	and	and	CC	False
DDI-MedLine.d132.s2	central	206	212	O	central	ral	tral	JJ	False
DDI-MedLine.d132.s2	nervous	214	220	O	nervous	ous	vous	JJ	False
DDI-MedLine.d132.s2	system	222	227	O	system	tem	stem	NN	False
DDI-MedLine.d132.s2	penetration	229	239	O	penetration	ion	tion	NN	False
DDI-MedLine.d132.s2	.	240	240	O	.	.	.	.	False

DDI-MedLine.d132.s3	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d132.s3	data	3	6	O	data	ata	data	NNS	False
DDI-MedLine.d132.s3	from	8	11	O	from	rom	from	IN	False
DDI-MedLine.d132.s3	prospective	13	23	O	prospective	ive	tive	JJ	False
DDI-MedLine.d132.s3	clinical	25	32	O	clinical	cal	ical	JJ	False
DDI-MedLine.d132.s3	trials	34	39	O	trials	als	ials	NNS	False
DDI-MedLine.d132.s3	currently	41	49	O	currently	tly	ntly	RB	False
DDI-MedLine.d132.s3	exist	51	55	O	exist	ist	xist	NN	False
DDI-MedLine.d132.s3	comparing	57	65	O	comparing	ing	ring	VBG	False
DDI-MedLine.d132.s3	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d132.s3	3	71	71	O	3	3	3	CD	False
DDI-MedLine.d132.s3	approved	73	80	O	approved	ved	oved	VBN	False
DDI-MedLine.d132.s3	agents	82	87	O	agents	nts	ents	NNS	False
DDI-MedLine.d132.s3	(	89	89	O	(	(	(	(	False
DDI-MedLine.d132.s3	efavirenz	90	98	B-drug	efavirenz	enz	renz	NN	False
DDI-MedLine.d132.s3	,	99	99	O	,	,	,	,	False
DDI-MedLine.d132.s3	nevirapine	101	110	B-drug	nevirapine	ine	pine	NN	drug
DDI-MedLine.d132.s3	or	112	113	O	or	or	or	CC	False
DDI-MedLine.d132.s3	delavirdine	115	125	B-drug	delavirdine	ine	dine	NN	drug
DDI-MedLine.d132.s3	)	126	126	O	)	)	)	)	False
DDI-MedLine.d132.s3	.	127	127	O	.	.	.	.	False

DDI-MedLine.d132.s4	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d132.s4	efavirenz	5	13	B-drug	efavirenz	enz	renz	NN	False
DDI-MedLine.d132.s4	and	15	17	O	and	and	and	CC	False
DDI-MedLine.d132.s4	nevirapine	19	28	B-drug	nevirapine	ine	pine	NN	drug
DDI-MedLine.d132.s4	have	30	33	O	have	ave	have	VB	False
DDI-MedLine.d132.s4	been	35	38	O	been	een	been	VBN	False
DDI-MedLine.d132.s4	compared	40	47	O	compared	red	ared	VBN	False
DDI-MedLine.d132.s4	to	49	50	O	to	to	to	TO	False
DDI-MedLine.d132.s4	triple	52	57	O	triple	ple	iple	NN	False
DDI-MedLine.d132.s4	therapy	59	65	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s4	with	67	70	O	with	ith	with	IN	False
DDI-MedLine.d132.s4	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d132.s4	PI	76	77	B-group	PI	PI	PI	NN	brand
DDI-MedLine.d132.s4	indinavir	79	87	B-drug	indinavir	vir	avir	NN	False
DDI-MedLine.d132.s4	over	89	92	O	over	ver	over	IN	False
DDI-MedLine.d132.s4	48	94	95	O	48	48	48	CD	False
DDI-MedLine.d132.s4	weeks	97	101	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d132.s4	as	103	104	O	as	as	as	IN	False
DDI-MedLine.d132.s4	initial	106	112	O	initial	ial	tial	JJ	False
DDI-MedLine.d132.s4	therapy	114	120	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s4	,	121	121	O	,	,	,	,	False
DDI-MedLine.d132.s4	with	123	126	O	with	ith	with	IN	False
DDI-MedLine.d132.s4	similar	128	134	O	similar	lar	ilar	JJ	False
DDI-MedLine.d132.s4	responses	136	144	O	responses	ses	nses	NNS	False
DDI-MedLine.d132.s4	being	146	150	O	being	ing	eing	VBG	False
DDI-MedLine.d132.s4	observed	152	159	O	observed	ved	rved	VBN	False
DDI-MedLine.d132.s4	with	161	164	O	with	ith	with	IN	False
DDI-MedLine.d132.s4	nevirapine	166	175	B-drug	nevirapine	ine	pine	NN	drug
DDI-MedLine.d132.s4	regimens	177	184	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s4	and	186	188	O	and	and	and	CC	False
DDI-MedLine.d132.s4	superiority	190	200	O	superiority	ity	rity	NN	False
DDI-MedLine.d132.s4	observed	202	209	O	observed	ved	rved	VBN	False
DDI-MedLine.d132.s4	with	211	214	O	with	ith	with	IN	False
DDI-MedLine.d132.s4	efavirenz	216	224	B-drug	efavirenz	enz	renz	NN	False
DDI-MedLine.d132.s4	.	225	225	O	.	.	.	.	False

DDI-MedLine.d132.s5	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d132.s5	smaller	2	8	O	smaller	ler	ller	JJR	False
DDI-MedLine.d132.s5	24-week	10	16	O	24-week	eek	week	JJ	False
DDI-MedLine.d132.s5	study	18	22	O	study	udy	tudy	NN	False
DDI-MedLine.d132.s5	has	24	26	O	has	has	has	VBZ	False
DDI-MedLine.d132.s5	suggested	28	36	O	suggested	ted	sted	VBN	False
DDI-MedLine.d132.s5	nevirapine	38	47	B-drug	nevirapine	ine	pine	NN	drug
DDI-MedLine.d132.s5	may	49	51	O	may	may	may	MD	False
DDI-MedLine.d132.s5	be	53	54	O	be	be	be	VB	False
DDI-MedLine.d132.s5	superior	56	63	O	superior	ior	rior	JJ	False
DDI-MedLine.d132.s5	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d132.s5	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d132.s5	PI	72	73	B-group	PI	PI	PI	NN	brand
DDI-MedLine.d132.s5	nelfinavir	75	84	B-drug	nelfinavir	vir	avir	NN	False
DDI-MedLine.d132.s5	.	85	85	O	.	.	.	.	False

DDI-MedLine.d132.s6	Limited	0	6	O	Limited	ted	ited	JJ	False
DDI-MedLine.d132.s6	comparative	8	18	O	comparative	ive	tive	NN	False
DDI-MedLine.d132.s6	data	20	23	O	data	ata	data	NNS	False
DDI-MedLine.d132.s6	in	25	26	O	in	in	in	IN	False
DDI-MedLine.d132.s6	patients	28	35	O	patients	nts	ents	NNS	False
DDI-MedLine.d132.s6	with	37	40	O	with	ith	with	IN	False
DDI-MedLine.d132.s6	high	42	45	O	high	igh	high	JJ	False
DDI-MedLine.d132.s6	viral	47	51	O	viral	ral	iral	JJ	False
DDI-MedLine.d132.s6	loads	53	57	O	loads	ads	oads	NNS	False
DDI-MedLine.d132.s6	treated	59	65	O	treated	ted	ated	VBN	False
DDI-MedLine.d132.s6	with	67	70	O	with	ith	with	IN	False
DDI-MedLine.d132.s6	nevirapine-	72	82	O	nevirapine-	ne-	ine-	JJ	False
DDI-MedLine.d132.s6	or	84	85	O	or	or	or	CC	False
DDI-MedLine.d132.s6	delavirdine-based	87	103	O	delavirdine-based	sed	ased	JJ	False
DDI-MedLine.d132.s6	regimens	105	112	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s6	currently	114	122	O	currently	tly	ntly	RB	False
DDI-MedLine.d132.s6	exist	124	128	O	exist	ist	xist	NN	False
DDI-MedLine.d132.s6	.	129	129	O	.	.	.	.	False

DDI-MedLine.d132.s7	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d132.s7	,	7	7	O	,	,	,	,	False
DDI-MedLine.d132.s7	cohort	9	14	O	cohort	ort	hort	NN	False
DDI-MedLine.d132.s7	data	16	19	O	data	ata	data	NNS	False
DDI-MedLine.d132.s7	and	21	23	O	and	and	and	CC	False
DDI-MedLine.d132.s7	selected	25	32	O	selected	ted	cted	VBN	False
DDI-MedLine.d132.s7	patient	34	40	O	patient	ent	ient	NN	False
DDI-MedLine.d132.s7	data	42	45	O	data	ata	data	NNS	False
DDI-MedLine.d132.s7	from	47	50	O	from	rom	from	IN	False
DDI-MedLine.d132.s7	clinical	52	59	O	clinical	cal	ical	JJ	False
DDI-MedLine.d132.s7	trials	61	66	O	trials	als	ials	NNS	False
DDI-MedLine.d132.s7	suggest	68	74	O	suggest	est	gest	NN	False
DDI-MedLine.d132.s7	comparable	76	85	O	comparable	ble	able	JJ	False
DDI-MedLine.d132.s7	activity	87	94	O	activity	ity	vity	NN	False
DDI-MedLine.d132.s7	to	96	97	O	to	to	to	TO	False
DDI-MedLine.d132.s7	PI-based	99	106	O	PI-based	sed	ased	JJ	False
DDI-MedLine.d132.s7	regimens	108	115	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s7	in	117	118	O	in	in	in	IN	False
DDI-MedLine.d132.s7	these	120	124	O	these	ese	hese	DT	False
DDI-MedLine.d132.s7	patients	126	133	O	patients	nts	ents	NNS	False
DDI-MedLine.d132.s7	.	134	134	O	.	.	.	.	False

DDI-MedLine.d132.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d132.s8	superiority	4	14	O	superiority	ity	rity	NN	False
DDI-MedLine.d132.s8	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d132.s8	efavirenz	19	27	B-drug	efavirenz	enz	renz	NN	False
DDI-MedLine.d132.s8	over	29	32	O	over	ver	over	IN	False
DDI-MedLine.d132.s8	indinavir-based	34	48	O	indinavir-based	sed	ased	JJ	False
DDI-MedLine.d132.s8	regimens	50	57	O	regimens	ens	mens	NNS	False
DDI-MedLine.d132.s8	has	59	61	O	has	has	has	VBZ	False
DDI-MedLine.d132.s8	been	63	66	O	been	een	been	VBN	False
DDI-MedLine.d132.s8	observed	68	75	O	observed	ved	rved	VBN	False
DDI-MedLine.d132.s8	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d132.s8	comparative	80	90	O	comparative	ive	tive	NN	False
DDI-MedLine.d132.s8	data	92	95	O	data	ata	data	NNS	False
DDI-MedLine.d132.s8	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d132.s8	a	100	100	O	a	a	a	DT	False
DDI-MedLine.d132.s8	subset	102	107	O	subset	set	bset	NN	False
DDI-MedLine.d132.s8	of	109	110	O	of	of	of	IN	False
DDI-MedLine.d132.s8	patients	112	119	O	patients	nts	ents	NNS	False
DDI-MedLine.d132.s8	with	121	124	O	with	ith	with	IN	False
DDI-MedLine.d132.s8	high	126	129	O	high	igh	high	JJ	False
DDI-MedLine.d132.s8	viral	131	135	O	viral	ral	iral	JJ	False
DDI-MedLine.d132.s8	loads	137	141	O	loads	ads	oads	NNS	False
DDI-MedLine.d132.s8	.	142	142	O	.	.	.	.	False

DDI-MedLine.d132.s9	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d132.s9	treatment-experienced	3	23	O	treatment-experienced	ced	nced	JJ	False
DDI-MedLine.d132.s9	patients	25	32	O	patients	nts	ents	NNS	False
DDI-MedLine.d132.s9	,	33	33	O	,	,	,	,	False
DDI-MedLine.d132.s9	available	35	43	O	available	ble	able	JJ	False
DDI-MedLine.d132.s9	uncontrolled	45	56	O	uncontrolled	led	lled	JJ	False
DDI-MedLine.d132.s9	data	58	61	O	data	ata	data	NNS	False
DDI-MedLine.d132.s9	suggest	63	69	O	suggest	est	gest	NN	False
DDI-MedLine.d132.s9	these	71	75	O	these	ese	hese	DT	False
DDI-MedLine.d132.s9	agents	77	82	O	agents	nts	ents	NNS	False
DDI-MedLine.d132.s9	contribute	84	93	O	contribute	ute	bute	NN	False
DDI-MedLine.d132.s9	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d132.s9	regimen	98	104	O	regimen	men	imen	NNS	False
DDI-MedLine.d132.s9	efficacy	106	113	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d132.s9	in	115	116	O	in	in	in	IN	False
DDI-MedLine.d132.s9	NNRTI-na	118	125	O	NNRTI-na	-na	I-na	NN	False
DDI-MedLine.d132.s9	ve	128	129	O	ve	ve	ve	NN	False
DDI-MedLine.d132.s9	,	130	130	O	,	,	,	,	False
DDI-MedLine.d132.s9	treatment-experienced	132	152	O	treatment-experienced	ced	nced	JJ	False
DDI-MedLine.d132.s9	patients	154	161	O	patients	nts	ents	NNS	False
DDI-MedLine.d132.s9	.	162	162	O	.	.	.	.	False

DDI-MedLine.d132.s10	Efavirenz	0	8	B-drug	Efavirenz	enz	renz	NNP	False
DDI-MedLine.d132.s10	has	10	12	O	has	has	has	VBZ	False
DDI-MedLine.d132.s10	demonstrated	14	25	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d132.s10	superiority	27	37	O	superiority	ity	rity	NN	False
DDI-MedLine.d132.s10	over	39	42	O	over	ver	over	IN	False
DDI-MedLine.d132.s10	nelfinavir	44	53	B-drug	nelfinavir	vir	avir	NN	False
DDI-MedLine.d132.s10	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d132.s10	nucleoside-experienced	58	79	O	nucleoside-experienced	ced	nced	JJ	False
DDI-MedLine.d132.s10	patients	81	88	O	patients	nts	ents	NNS	False
DDI-MedLine.d132.s10	,	89	89	O	,	,	,	,	False
DDI-MedLine.d132.s10	although	91	98	O	although	ugh	ough	IN	False
DDI-MedLine.d132.s10	combining	100	108	O	combining	ing	ning	VBG	False
DDI-MedLine.d132.s10	these	110	114	O	these	ese	hese	DT	False
DDI-MedLine.d132.s10	2	116	116	O	2	2	2	CD	False
DDI-MedLine.d132.s10	agents	118	123	O	agents	nts	ents	NNS	False
DDI-MedLine.d132.s10	may	125	127	O	may	may	may	MD	False
DDI-MedLine.d132.s10	represent	129	137	O	represent	ent	sent	NN	False
DDI-MedLine.d132.s10	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d132.s10	best	143	146	O	best	est	best	JJS	False
DDI-MedLine.d132.s10	approach	148	155	O	approach	ach	oach	NN	False
DDI-MedLine.d132.s10	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d132.s10	these	160	164	O	these	ese	hese	DT	False
DDI-MedLine.d132.s10	circumstances	166	178	O	circumstances	ces	nces	NNS	False
DDI-MedLine.d132.s10	.	179	179	O	.	.	.	.	False

DDI-MedLine.d132.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d132.s11	tolerability	4	15	O	tolerability	ity	lity	NN	False
DDI-MedLine.d132.s11	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d132.s11	NNRTIs	20	25	B-group	NNRTIs	TIs	RTIs	NN	False
DDI-MedLine.d132.s11	appears	27	33	O	appears	ars	ears	VBZ	False
DDI-MedLine.d132.s11	generally	35	43	O	generally	lly	ally	RB	False
DDI-MedLine.d132.s11	good	45	48	O	good	ood	good	JJ	False
DDI-MedLine.d132.s11	with	50	53	O	with	ith	with	IN	False
DDI-MedLine.d132.s11	few	55	57	O	few	few	few	JJ	False
DDI-MedLine.d132.s11	individuals	59	69	O	individuals	als	uals	NNS	False
DDI-MedLine.d132.s11	discontinuing	71	83	O	discontinuing	ing	uing	VBG	False
DDI-MedLine.d132.s11	in	85	86	O	in	in	in	IN	False
DDI-MedLine.d132.s11	clinical	88	95	O	clinical	cal	ical	JJ	False
DDI-MedLine.d132.s11	studies	97	103	O	studies	ies	dies	NNS	False
DDI-MedLine.d132.s11	as	105	106	O	as	as	as	IN	False
DDI-MedLine.d132.s11	a	108	108	O	a	a	a	DT	False
DDI-MedLine.d132.s11	result	110	115	O	result	ult	sult	NN	False
DDI-MedLine.d132.s11	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d132.s11	adverse	120	126	O	adverse	rse	erse	NN	False
DDI-MedLine.d132.s11	drug	128	131	O	drug	rug	drug	NN	False
DDI-MedLine.d132.s11	events	133	138	O	events	nts	ents	NNS	False
DDI-MedLine.d132.s11	.	139	139	O	.	.	.	.	False

DDI-MedLine.d132.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d132.s12	majority	4	11	O	majority	ity	rity	NN	False
DDI-MedLine.d132.s12	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d132.s12	adverse	16	22	O	adverse	rse	erse	NN	False
DDI-MedLine.d132.s12	events	24	29	O	events	nts	ents	NNS	False
DDI-MedLine.d132.s12	with	31	34	O	with	ith	with	IN	False
DDI-MedLine.d132.s12	NNRTIs	36	41	B-group	NNRTIs	TIs	RTIs	NN	False
DDI-MedLine.d132.s12	occur	43	47	O	occur	cur	ccur	NN	False
DDI-MedLine.d132.s12	within	49	54	O	within	hin	thin	IN	False
DDI-MedLine.d132.s12	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d132.s12	first	60	64	O	first	rst	irst	RB	False
DDI-MedLine.d132.s12	month	66	70	O	month	nth	onth	NN	False
DDI-MedLine.d132.s12	,	71	71	O	,	,	,	,	False
DDI-MedLine.d132.s12	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d132.s12	are	77	79	O	are	are	are	VBP	False
DDI-MedLine.d132.s12	predictable	81	91	O	predictable	ble	able	JJ	False
DDI-MedLine.d132.s12	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d132.s12	manageable	97	106	O	manageable	ble	able	JJ	False
DDI-MedLine.d132.s12	without	108	114	O	without	out	hout	IN	False
DDI-MedLine.d132.s12	therapy	116	122	O	therapy	apy	rapy	NN	False
DDI-MedLine.d132.s12	interruption	124	135	O	interruption	ion	tion	NN	False
DDI-MedLine.d132.s12	.	136	136	O	.	.	.	.	False

DDI-MedLine.d78.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d78.s0	fluoroquinolones	4	19	B-group	fluoroquinolones	nes	ones	NNS	False
DDI-MedLine.d78.s0	for	21	23	O	for	for	for	IN	False
DDI-MedLine.d78.s0	urinary	25	31	O	urinary	ary	nary	JJ	False
DDI-MedLine.d78.s0	tract	33	37	O	tract	act	ract	NN	False
DDI-MedLine.d78.s0	infections	39	48	O	infections	ons	ions	NNS	False
DDI-MedLine.d78.s0	:	49	49	O	:	:	:	:	False
DDI-MedLine.d78.s0	a	51	51	O	a	a	a	DT	False
DDI-MedLine.d78.s0	review	53	58	O	review	iew	view	NN	False
DDI-MedLine.d78.s0	.	59	59	O	.	.	.	.	False

DDI-MedLine.d78.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d78.s1	fluoroquinolones	4	19	B-group	fluoroquinolones	nes	ones	NNS	False
DDI-MedLine.d78.s1	are	21	23	O	are	are	are	VBP	False
DDI-MedLine.d78.s1	a	25	25	O	a	a	a	DT	False
DDI-MedLine.d78.s1	rapidly	27	33	O	rapidly	dly	idly	RB	False
DDI-MedLine.d78.s1	growing	35	41	O	growing	ing	wing	VBG	False
DDI-MedLine.d78.s1	class	43	47	O	class	ass	lass	NN	False
DDI-MedLine.d78.s1	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d78.s1	antibiotics	52	62	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d78.s1	with	64	67	O	with	ith	with	IN	False
DDI-MedLine.d78.s1	a	69	69	O	a	a	a	DT	False
DDI-MedLine.d78.s1	broad	71	75	O	broad	oad	road	JJ	False
DDI-MedLine.d78.s1	spectrum	77	84	O	spectrum	rum	trum	NN	False
DDI-MedLine.d78.s1	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d78.s1	activity	89	96	O	activity	ity	vity	NN	False
DDI-MedLine.d78.s1	against	98	104	O	against	nst	inst	IN	False
DDI-MedLine.d78.s1	gram-negative	106	118	O	gram-negative	ive	tive	JJ	False
DDI-MedLine.d78.s1	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d78.s1	some	124	127	O	some	ome	some	DT	False
DDI-MedLine.d78.s1	gram-positive	129	141	O	gram-positive	ive	tive	JJ	False
DDI-MedLine.d78.s1	aerobic	143	149	O	aerobic	bic	obic	NN	False
DDI-MedLine.d78.s1	bacteria	151	158	O	bacteria	ria	eria	NNS	False
DDI-MedLine.d78.s1	.	159	159	O	.	.	.	.	False

DDI-MedLine.d78.s2	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d78.s2	agents	6	11	O	agents	nts	ents	NNS	False
DDI-MedLine.d78.s2	,	12	12	O	,	,	,	,	False
DDI-MedLine.d78.s2	including	14	22	O	including	ing	ding	VBG	False
DDI-MedLine.d78.s2	norfloxacin	24	34	B-drug	norfloxacin	cin	acin	NN	drug
DDI-MedLine.d78.s2	,	35	35	O	,	,	,	,	False
DDI-MedLine.d78.s2	ciprofloxacin	37	49	B-drug	ciprofloxacin	cin	acin	NN	drug
DDI-MedLine.d78.s2	,	50	50	O	,	,	,	,	False
DDI-MedLine.d78.s2	ofloxacin	52	60	B-drug	ofloxacin	cin	acin	NN	drug
DDI-MedLine.d78.s2	,	61	61	O	,	,	,	,	False
DDI-MedLine.d78.s2	enoxacin	63	70	B-drug	enoxacin	cin	acin	NN	drug
DDI-MedLine.d78.s2	,	71	71	O	,	,	,	,	False
DDI-MedLine.d78.s2	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d78.s2	lomefloxacin	77	88	B-drug	lomefloxacin	cin	acin	NN	drug
DDI-MedLine.d78.s2	,	89	89	O	,	,	,	,	False
DDI-MedLine.d78.s2	have	91	94	O	have	ave	have	VB	False
DDI-MedLine.d78.s2	been	96	99	O	been	een	been	VBN	False
DDI-MedLine.d78.s2	extensively	101	111	O	extensively	ely	vely	RB	False
DDI-MedLine.d78.s2	studied	113	119	O	studied	ied	died	VBN	False
DDI-MedLine.d78.s2	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d78.s2	have	125	128	O	have	ave	have	VB	False
DDI-MedLine.d78.s2	demonstrated	130	141	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d78.s2	efficacy	143	150	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d78.s2	and	152	154	O	and	and	and	CC	False
DDI-MedLine.d78.s2	safety	156	161	O	safety	ety	fety	NN	False
DDI-MedLine.d78.s2	profiles	163	170	O	profiles	les	iles	NNS	False
DDI-MedLine.d78.s2	comparable	172	181	O	comparable	ble	able	JJ	False
DDI-MedLine.d78.s2	to	183	184	O	to	to	to	TO	False
DDI-MedLine.d78.s2	those	186	190	O	those	ose	hose	DT	False
DDI-MedLine.d78.s2	of	192	193	O	of	of	of	IN	False
DDI-MedLine.d78.s2	other	195	199	O	other	her	ther	JJ	False
DDI-MedLine.d78.s2	traditional	201	211	O	traditional	nal	onal	JJ	False
DDI-MedLine.d78.s2	agents	213	218	O	agents	nts	ents	NNS	False
DDI-MedLine.d78.s2	for	220	222	O	for	for	for	IN	False
DDI-MedLine.d78.s2	the	224	226	O	the	the	the	DT	False
DDI-MedLine.d78.s2	treatment	228	236	O	treatment	ent	ment	NN	False
DDI-MedLine.d78.s2	of	238	239	O	of	of	of	IN	False
DDI-MedLine.d78.s2	complicated	241	251	O	complicated	ted	ated	VBN	False
DDI-MedLine.d78.s2	or	253	254	O	or	or	or	CC	False
DDI-MedLine.d78.s2	uncomplicated	256	268	O	uncomplicated	ted	ated	JJ	False
DDI-MedLine.d78.s2	urinary	270	276	O	urinary	ary	nary	JJ	False
DDI-MedLine.d78.s2	tract	278	282	O	tract	act	ract	NN	False
DDI-MedLine.d78.s2	infections	284	293	O	infections	ons	ions	NNS	False
DDI-MedLine.d78.s2	and	295	297	O	and	and	and	CC	False
DDI-MedLine.d78.s2	prostatitis	299	309	O	prostatitis	tis	itis	NN	False
DDI-MedLine.d78.s2	.	310	310	O	.	.	.	.	False

DDI-MedLine.d78.s3	Advantages	0	9	O	Advantages	ges	ages	NNS	False
DDI-MedLine.d78.s3	offered	11	17	O	offered	red	ered	VBN	False
DDI-MedLine.d78.s3	by	19	20	O	by	by	by	IN	False
DDI-MedLine.d78.s3	this	22	25	O	this	his	this	DT	False
DDI-MedLine.d78.s3	class	27	31	O	class	ass	lass	NN	False
DDI-MedLine.d78.s3	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d78.s3	antibiotics	36	46	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d78.s3	include	48	54	O	include	ude	lude	NN	False
DDI-MedLine.d78.s3	optimal	56	62	O	optimal	mal	imal	JJ	False
DDI-MedLine.d78.s3	pharmacokinetics	64	79	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d78.s3	,	80	80	O	,	,	,	,	False
DDI-MedLine.d78.s3	effectiveness	82	94	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d78.s3	against	96	102	O	against	nst	inst	IN	False
DDI-MedLine.d78.s3	multidrug-resistant	104	122	O	multidrug-resistant	ant	tant	JJ	False
DDI-MedLine.d78.s3	organisms	124	132	O	organisms	sms	isms	NNS	False
DDI-MedLine.d78.s3	,	133	133	O	,	,	,	,	False
DDI-MedLine.d78.s3	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d78.s3	oral	139	142	O	oral	ral	oral	JJ	False
DDI-MedLine.d78.s3	administration	144	157	O	administration	ion	tion	NN	False
DDI-MedLine.d78.s3	even	159	162	O	even	ven	even	RB	False
DDI-MedLine.d78.s3	when	164	167	O	when	hen	when	WRB	False
DDI-MedLine.d78.s3	parenteral	169	178	O	parenteral	ral	eral	JJ	False
DDI-MedLine.d78.s3	antibiotics	180	190	B-drug	antibiotics	ics	tics	NNS	False
DDI-MedLine.d78.s3	are	192	194	O	are	are	are	VBP	False
DDI-MedLine.d78.s3	generally	196	204	O	generally	lly	ally	RB	False
DDI-MedLine.d78.s3	used	206	209	O	used	sed	used	VBN	False
DDI-MedLine.d78.s3	.	210	210	O	.	.	.	.	False

DDI-MedLine.d78.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d78.s4	fluoroquinolones	4	19	B-group	fluoroquinolones	nes	ones	NNS	False
DDI-MedLine.d78.s4	are	21	23	O	are	are	are	VBP	False
DDI-MedLine.d78.s4	also	25	28	O	also	lso	also	RB	False
DDI-MedLine.d78.s4	extensively	30	40	O	extensively	ely	vely	RB	False
DDI-MedLine.d78.s4	used	42	45	O	used	sed	used	VBN	False
DDI-MedLine.d78.s4	in	47	48	O	in	in	in	IN	False
DDI-MedLine.d78.s4	urologic	50	57	O	urologic	gic	ogic	JJ	False
DDI-MedLine.d78.s4	surgery	59	65	O	surgery	ery	gery	NN	False
DDI-MedLine.d78.s4	.	66	66	O	.	.	.	.	False

DDI-MedLine.d135.s0	Combinations	0	11	O	Combinations	ons	ions	NNS	False
DDI-MedLine.d135.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d135.s0	clozapine	16	24	B-drug	clozapine	ine	pine	NN	drug
DDI-MedLine.d135.s0	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d135.s0	phencyclidine	30	42	B-drug_n	phencyclidine	ine	dine	NN	drug
DDI-MedLine.d135.s0	:	43	43	O	:	:	:	:	False
DDI-MedLine.d135.s0	effects	45	51	O	effects	cts	ects	NNS	False
DDI-MedLine.d135.s0	on	53	54	O	on	on	on	IN	False
DDI-MedLine.d135.s0	drug	56	59	O	drug	rug	drug	NN	False
DDI-MedLine.d135.s0	discrimination	61	74	O	discrimination	ion	tion	NN	False
DDI-MedLine.d135.s0	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d135.s0	behavioral	80	89	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d135.s0	inhibition	91	100	O	inhibition	ion	tion	NN	False
DDI-MedLine.d135.s0	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d135.s0	rats	105	108	O	rats	ats	rats	NNS	False
DDI-MedLine.d135.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d135.s1	Phencyclidine	0	12	B-drug_n	Phencyclidine	ine	dine	NN	drug
DDI-MedLine.d135.s1	(	14	14	O	(	(	(	(	False
DDI-MedLine.d135.s1	PCP	15	17	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s1	)	18	18	O	)	)	)	)	False
DDI-MedLine.d135.s1	produces	20	27	O	produces	ces	uces	NNS	False
DDI-MedLine.d135.s1	psychotomimetic	29	43	O	psychotomimetic	tic	etic	JJ	False
DDI-MedLine.d135.s1	effects	45	51	O	effects	cts	ects	NNS	False
DDI-MedLine.d135.s1	in	53	54	O	in	in	in	IN	False
DDI-MedLine.d135.s1	humans	56	61	O	humans	ans	mans	NNS	False
DDI-MedLine.d135.s1	that	63	66	O	that	hat	that	IN	False
DDI-MedLine.d135.s1	resemble	68	75	O	resemble	ble	mble	JJ	False
DDI-MedLine.d135.s1	schizophrenia	77	89	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d135.s1	symptoms	91	98	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d135.s1	.	99	99	O	.	.	.	.	False

DDI-MedLine.d135.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d135.s2	an	3	4	O	an	an	an	DT	False
DDI-MedLine.d135.s2	effort	6	11	O	effort	ort	fort	NN	False
DDI-MedLine.d135.s2	to	13	14	O	to	to	to	TO	False
DDI-MedLine.d135.s2	screen	16	21	O	screen	een	reen	NN	False
DDI-MedLine.d135.s2	compounds	23	31	O	compounds	nds	unds	NNS	False
DDI-MedLine.d135.s2	for	33	35	O	for	for	for	IN	False
DDI-MedLine.d135.s2	antipsychotic	37	49	O	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d135.s2	activity	51	58	O	activity	ity	vity	NN	False
DDI-MedLine.d135.s2	,	59	59	O	,	,	,	,	False
DDI-MedLine.d135.s2	preclinical	61	71	O	preclinical	cal	ical	JJ	False
DDI-MedLine.d135.s2	researchers	73	83	O	researchers	ers	hers	NNS	False
DDI-MedLine.d135.s2	have	85	88	O	have	ave	have	VB	False
DDI-MedLine.d135.s2	investigated	90	101	O	investigated	ted	ated	VBN	False
DDI-MedLine.d135.s2	whether	103	109	O	whether	her	ther	IN	False
DDI-MedLine.d135.s2	these	111	115	O	these	ese	hese	DT	False
DDI-MedLine.d135.s2	compounds	117	125	O	compounds	nds	unds	NNS	False
DDI-MedLine.d135.s2	block	127	131	O	block	ock	lock	NN	False
DDI-MedLine.d135.s2	PCP-induced	133	143	O	PCP-induced	ced	uced	JJ	False
DDI-MedLine.d135.s2	behaviors	145	153	O	behaviors	ors	iors	NNS	False
DDI-MedLine.d135.s2	in	155	156	O	in	in	in	IN	False
DDI-MedLine.d135.s2	animals	158	164	O	animals	als	mals	NNS	False
DDI-MedLine.d135.s2	.	165	165	O	.	.	.	.	False

DDI-MedLine.d135.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d135.s3	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d135.s3	present	7	13	O	present	ent	sent	NN	False
DDI-MedLine.d135.s3	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d135.s3	,	20	20	O	,	,	,	,	False
DDI-MedLine.d135.s3	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d135.s3	atypical	26	33	B-group	atypical	cal	ical	JJ	False
DDI-MedLine.d135.s3	antipsychotic	35	47	I-group	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d135.s3	clozapine	49	57	B-drug	clozapine	ine	pine	NN	drug
DDI-MedLine.d135.s3	was	59	61	O	was	was	was	VBD	False
DDI-MedLine.d135.s3	tested	63	68	O	tested	ted	sted	VBN	False
DDI-MedLine.d135.s3	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d135.s3	combination	73	83	O	combination	ion	tion	NN	False
DDI-MedLine.d135.s3	with	85	88	O	with	ith	with	IN	False
DDI-MedLine.d135.s3	an	90	91	O	an	an	an	DT	False
DDI-MedLine.d135.s3	active	93	98	O	active	ive	tive	JJ	False
DDI-MedLine.d135.s3	dose	100	103	O	dose	ose	dose	NN	False
DDI-MedLine.d135.s3	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d135.s3	PCP	108	110	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s3	in	112	113	O	in	in	in	IN	False
DDI-MedLine.d135.s3	two-lever	115	123	O	two-lever	ver	ever	NN	False
DDI-MedLine.d135.s3	drug	125	128	O	drug	rug	drug	NN	False
DDI-MedLine.d135.s3	discrimination	130	143	O	discrimination	ion	tion	NN	False
DDI-MedLine.d135.s3	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d135.s3	mixed	149	153	O	mixed	xed	ixed	JJ	False
DDI-MedLine.d135.s3	signalled-unsignalled	155	175	O	signalled-unsignalled	led	lled	JJ	False
DDI-MedLine.d135.s3	differential-reinforcement-of-low-rates	177	215	O	differential-reinforcement-of-low-rates	tes	ates	NNS	False
DDI-MedLine.d135.s3	(	217	217	O	(	(	(	(	False
DDI-MedLine.d135.s3	DRL	218	220	O	DRL	DRL	DRL	NN	brand
DDI-MedLine.d135.s3	)	221	221	O	)	)	)	)	False
DDI-MedLine.d135.s3	procedures	223	232	O	procedures	res	ures	NNS	False
DDI-MedLine.d135.s3	.	233	233	O	.	.	.	.	False

DDI-MedLine.d135.s4	PCP	0	2	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s4	produced	4	11	O	produced	ced	uced	VBN	False
DDI-MedLine.d135.s4	distinctive	13	23	O	distinctive	ive	tive	NN	False
DDI-MedLine.d135.s4	effects	25	31	O	effects	cts	ects	NNS	False
DDI-MedLine.d135.s4	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d135.s4	each	36	39	O	each	ach	each	DT	False
DDI-MedLine.d135.s4	task	41	44	O	task	ask	task	NN	False
DDI-MedLine.d135.s4	:	45	45	O	:	:	:	:	False
DDI-MedLine.d135.s4	it	47	48	O	it	it	it	PRP	False
DDI-MedLine.d135.s4	substituted	50	60	O	substituted	ted	uted	VBN	False
DDI-MedLine.d135.s4	for	62	64	O	for	for	for	IN	False
DDI-MedLine.d135.s4	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d135.s4	training	70	77	O	training	ing	ning	NN	False
DDI-MedLine.d135.s4	dose	79	82	O	dose	ose	dose	NN	False
DDI-MedLine.d135.s4	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d135.s4	PCP	87	89	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s4	discrimination	91	104	O	discrimination	ion	tion	NN	False
DDI-MedLine.d135.s4	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d135.s4	it	110	111	O	it	it	it	PRP	False
DDI-MedLine.d135.s4	increased	113	121	O	increased	sed	ased	VBN	False
DDI-MedLine.d135.s4	the	123	125	O	the	the	the	DT	False
DDI-MedLine.d135.s4	number	127	132	O	number	ber	mber	NN	False
DDI-MedLine.d135.s4	of	134	135	O	of	of	of	IN	False
DDI-MedLine.d135.s4	responses	137	145	O	responses	ses	nses	NNS	False
DDI-MedLine.d135.s4	with	147	150	O	with	ith	with	IN	False
DDI-MedLine.d135.s4	short	152	156	O	short	ort	hort	JJ	False
DDI-MedLine.d135.s4	(	158	158	O	(	(	(	(	False
DDI-MedLine.d135.s4	<	159	159	O	<	<	<	NN	False
DDI-MedLine.d135.s4	3	160	160	O	3	3	3	CD	False
DDI-MedLine.d135.s4	s	162	162	O	s	s	s	NN	False
DDI-MedLine.d135.s4	)	163	163	O	)	)	)	)	False
DDI-MedLine.d135.s4	interresponse	165	177	O	interresponse	nse	onse	NN	False
DDI-MedLine.d135.s4	times	179	183	O	times	mes	imes	NNS	False
DDI-MedLine.d135.s4	as	185	186	O	as	as	as	IN	False
DDI-MedLine.d135.s4	well	188	191	O	well	ell	well	RB	False
DDI-MedLine.d135.s4	as	193	194	O	as	as	as	IN	False
DDI-MedLine.d135.s4	increasing	196	205	O	increasing	ing	sing	VBG	False
DDI-MedLine.d135.s4	overall	207	213	O	overall	all	rall	JJ	False
DDI-MedLine.d135.s4	response	215	222	O	response	nse	onse	NN	False
DDI-MedLine.d135.s4	rates	224	228	O	rates	tes	ates	NNS	False
DDI-MedLine.d135.s4	in	230	231	O	in	in	in	IN	False
DDI-MedLine.d135.s4	the	233	235	O	the	the	the	DT	False
DDI-MedLine.d135.s4	DRL	237	239	O	DRL	DRL	DRL	NN	brand
DDI-MedLine.d135.s4	schedule	241	248	O	schedule	ule	dule	NN	False
DDI-MedLine.d135.s4	.	249	249	O	.	.	.	.	False

DDI-MedLine.d135.s5	Acute	0	4	O	Acute	ute	cute	NN	False
DDI-MedLine.d135.s5	dosing	6	11	O	dosing	ing	sing	VBG	False
DDI-MedLine.d135.s5	with	13	16	O	with	ith	with	IN	False
DDI-MedLine.d135.s5	clozapine	18	26	B-drug	clozapine	ine	pine	NN	drug
DDI-MedLine.d135.s5	failed	28	33	O	failed	led	iled	VBD	False
DDI-MedLine.d135.s5	to	35	36	O	to	to	to	TO	False
DDI-MedLine.d135.s5	alter	38	42	O	alter	ter	lter	NN	False
DDI-MedLine.d135.s5	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d135.s5	behavioral	48	57	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d135.s5	effects	59	65	O	effects	cts	ects	NNS	False
DDI-MedLine.d135.s5	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d135.s5	PCP	70	72	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s5	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d135.s5	either	77	82	O	either	her	ther	DT	False
DDI-MedLine.d135.s5	procedure	84	92	O	procedure	ure	dure	NN	False
DDI-MedLine.d135.s5	even	94	97	O	even	ven	even	RB	False
DDI-MedLine.d135.s5	when	99	102	O	when	hen	when	WRB	False
DDI-MedLine.d135.s5	tested	104	109	O	tested	ted	sted	VBN	False
DDI-MedLine.d135.s5	up	111	112	O	up	up	up	RB	False
DDI-MedLine.d135.s5	to	114	115	O	to	to	to	TO	False
DDI-MedLine.d135.s5	doses	117	121	O	doses	ses	oses	NNS	False
DDI-MedLine.d135.s5	that	123	126	O	that	hat	that	IN	False
DDI-MedLine.d135.s5	produced	128	135	O	produced	ced	uced	VBN	False
DDI-MedLine.d135.s5	pharmacological	137	151	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d135.s5	effects	153	159	O	effects	cts	ects	NNS	False
DDI-MedLine.d135.s5	alone	161	165	O	alone	one	lone	RB	False
DDI-MedLine.d135.s5	.	166	166	O	.	.	.	.	False

DDI-MedLine.d135.s6	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d135.s6	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d135.s6	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d135.s6	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d135.s6	acute	27	31	O	acute	ute	cute	NN	False
DDI-MedLine.d135.s6	dosing	33	38	O	dosing	ing	sing	VBG	False
DDI-MedLine.d135.s6	with	40	43	O	with	ith	with	IN	False
DDI-MedLine.d135.s6	clozapine	45	53	B-drug	clozapine	ine	pine	NN	drug
DDI-MedLine.d135.s6	would	55	59	O	would	uld	ould	MD	False
DDI-MedLine.d135.s6	not	61	63	O	not	not	not	RB	False
DDI-MedLine.d135.s6	affect	65	70	O	affect	ect	fect	NN	False
DDI-MedLine.d135.s6	behaviors	72	80	O	behaviors	ors	iors	NNS	False
DDI-MedLine.d135.s6	most	82	85	O	most	ost	most	JJS	False
DDI-MedLine.d135.s6	closely	87	93	O	closely	ely	sely	RB	False
DDI-MedLine.d135.s6	associated	95	104	O	associated	ted	ated	VBN	False
DDI-MedLine.d135.s6	with	106	109	O	with	ith	with	IN	False
DDI-MedLine.d135.s6	PCP	111	113	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s6	intoxication	115	126	O	intoxication	ion	tion	NN	False
DDI-MedLine.d135.s6	.	127	127	O	.	.	.	.	False

DDI-MedLine.d135.s7	Further	0	6	O	Further	her	ther	RB	False
DDI-MedLine.d135.s7	,	7	7	O	,	,	,	,	False
DDI-MedLine.d135.s7	they	9	12	O	they	hey	they	PRP	False
DDI-MedLine.d135.s7	bring	14	18	O	bring	ing	ring	NN	False
DDI-MedLine.d135.s7	into	20	23	O	into	nto	into	IN	False
DDI-MedLine.d135.s7	question	25	32	O	question	ion	tion	NN	False
DDI-MedLine.d135.s7	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d135.s7	utility	38	44	O	utility	ity	lity	NN	False
DDI-MedLine.d135.s7	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d135.s7	using	49	53	O	using	ing	sing	VBG	False
DDI-MedLine.d135.s7	PCP	55	57	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s7	combination	59	69	O	combination	ion	tion	NN	False
DDI-MedLine.d135.s7	procedures	71	80	O	procedures	res	ures	NNS	False
DDI-MedLine.d135.s7	in	82	83	O	in	in	in	IN	False
DDI-MedLine.d135.s7	animals	85	91	O	animals	als	mals	NNS	False
DDI-MedLine.d135.s7	to	93	94	O	to	to	to	TO	False
DDI-MedLine.d135.s7	screen	96	101	O	screen	een	reen	NN	False
DDI-MedLine.d135.s7	for	103	105	O	for	for	for	IN	False
DDI-MedLine.d135.s7	antipsychotic	107	119	O	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d135.s7	potential	121	129	O	potential	ial	tial	JJ	False
DDI-MedLine.d135.s7	.	130	130	O	.	.	.	.	False

DDI-MedLine.d135.s8	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d135.s8	chronic	6	12	O	chronic	nic	onic	NN	False
DDI-MedLine.d135.s8	dosing	14	19	O	dosing	ing	sing	VBG	False
DDI-MedLine.d135.s8	is	21	22	O	is	is	is	VBZ	False
DDI-MedLine.d135.s8	required	24	31	O	required	red	ired	VBN	False
DDI-MedLine.d135.s8	for	33	35	O	for	for	for	IN	False
DDI-MedLine.d135.s8	therapeutic	37	47	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d135.s8	efficacy	49	56	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d135.s8	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d135.s8	antipsychotics	61	74	B-group	antipsychotics	ics	tics	NNS	False
DDI-MedLine.d135.s8	,	75	75	O	,	,	,	,	False
DDI-MedLine.d135.s8	future	77	82	O	future	ure	ture	NN	False
DDI-MedLine.d135.s8	studies	84	90	O	studies	ies	dies	NNS	False
DDI-MedLine.d135.s8	should	92	97	O	should	uld	ould	MD	False
DDI-MedLine.d135.s8	focus	99	103	O	focus	cus	ocus	NN	False
DDI-MedLine.d135.s8	on	105	106	O	on	on	on	IN	False
DDI-MedLine.d135.s8	investigation	108	120	O	investigation	ion	tion	NN	False
DDI-MedLine.d135.s8	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d135.s8	chronic	125	131	O	chronic	nic	onic	NN	False
DDI-MedLine.d135.s8	dosing	133	138	O	dosing	ing	sing	VBG	False
DDI-MedLine.d135.s8	effects	140	146	O	effects	cts	ects	NNS	False
DDI-MedLine.d135.s8	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d135.s8	these	151	155	O	these	ese	hese	DT	False
DDI-MedLine.d135.s8	drugs	157	161	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d135.s8	in	163	164	O	in	in	in	IN	False
DDI-MedLine.d135.s8	combination	166	176	O	combination	ion	tion	NN	False
DDI-MedLine.d135.s8	with	178	181	O	with	ith	with	IN	False
DDI-MedLine.d135.s8	PCP	183	185	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d135.s8	.	186	186	O	.	.	.	.	False

DDI-MedLine.d11.s0	Immunosuppressive	0	16	B-group	Immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d11.s0	drugs	18	22	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d11.s0	and	24	26	O	and	and	and	CC	False
DDI-MedLine.d11.s0	their	28	32	O	their	eir	heir	PRP$	False
DDI-MedLine.d11.s0	complications	34	46	O	complications	ons	ions	NNS	False
DDI-MedLine.d11.s0	.	47	47	O	.	.	.	.	False

DDI-MedLine.d11.s1	Drugs	0	4	O	Drugs	ugs	rugs	NNS	False
DDI-MedLine.d11.s1	that	6	9	O	that	hat	that	IN	False
DDI-MedLine.d11.s1	suppress	11	18	O	suppress	ess	ress	NN	False
DDI-MedLine.d11.s1	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d11.s1	immune	24	29	O	immune	une	mune	NN	False
DDI-MedLine.d11.s1	system	31	36	O	system	tem	stem	NN	False
DDI-MedLine.d11.s1	are	38	40	O	are	are	are	VBP	False
DDI-MedLine.d11.s1	widely	42	47	O	widely	ely	dely	RB	False
DDI-MedLine.d11.s1	used	49	52	O	used	sed	used	VBN	False
DDI-MedLine.d11.s1	.	53	53	O	.	.	.	.	False

DDI-MedLine.d11.s2	They	0	3	O	They	hey	They	PRP	False
DDI-MedLine.d11.s2	are	5	7	O	are	are	are	VBP	False
DDI-MedLine.d11.s2	part	9	12	O	part	art	part	NN	False
DDI-MedLine.d11.s2	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d11.s2	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d11.s2	treatment	21	29	O	treatment	ent	ment	NN	False
DDI-MedLine.d11.s2	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d11.s2	patients	34	41	O	patients	nts	ents	NNS	False
DDI-MedLine.d11.s2	with	43	46	O	with	ith	with	IN	False
DDI-MedLine.d11.s2	organ	48	52	O	organ	gan	rgan	NN	False
DDI-MedLine.d11.s2	transplants	54	64	O	transplants	nts	ants	NNS	False
DDI-MedLine.d11.s2	,	65	65	O	,	,	,	,	False
DDI-MedLine.d11.s2	malignancy	67	76	O	malignancy	ncy	ancy	NN	False
DDI-MedLine.d11.s2	,	77	77	O	,	,	,	,	False
DDI-MedLine.d11.s2	and	79	81	O	and	and	and	CC	False
DDI-MedLine.d11.s2	increasingly	83	94	O	increasingly	gly	ngly	RB	False
DDI-MedLine.d11.s2	those	96	100	O	those	ose	hose	DT	False
DDI-MedLine.d11.s2	with	102	105	O	with	ith	with	IN	False
DDI-MedLine.d11.s2	conditions	107	116	O	conditions	ons	ions	NNS	False
DDI-MedLine.d11.s2	such	118	121	O	such	uch	such	JJ	False
DDI-MedLine.d11.s2	as	123	124	O	as	as	as	IN	False
DDI-MedLine.d11.s2	psoriasis	126	134	O	psoriasis	sis	asis	NN	False
DDI-MedLine.d11.s2	,	135	135	O	,	,	,	,	False
DDI-MedLine.d11.s2	rheumatoid	137	146	O	rheumatoid	oid	toid	NN	False
DDI-MedLine.d11.s2	arthritis	148	156	O	arthritis	tis	itis	NN	False
DDI-MedLine.d11.s2	,	157	157	O	,	,	,	,	False
DDI-MedLine.d11.s2	and	159	161	O	and	and	and	CC	False
DDI-MedLine.d11.s2	liver	163	167	O	liver	ver	iver	NN	False
DDI-MedLine.d11.s2	and	169	171	O	and	and	and	CC	False
DDI-MedLine.d11.s2	bowel	173	177	O	bowel	wel	owel	NN	False
DDI-MedLine.d11.s2	disease	179	185	O	disease	ase	ease	NN	False
DDI-MedLine.d11.s2	in	187	188	O	in	in	in	IN	False
DDI-MedLine.d11.s2	which	190	194	O	which	ich	hich	WDT	False
DDI-MedLine.d11.s2	inflammation	196	207	O	inflammation	ion	tion	NN	False
DDI-MedLine.d11.s2	is	209	210	O	is	is	is	VBZ	False
DDI-MedLine.d11.s2	an	212	213	O	an	an	an	DT	False
DDI-MedLine.d11.s2	aetiological	215	226	O	aetiological	cal	ical	JJ	False
DDI-MedLine.d11.s2	factor	228	233	O	factor	tor	ctor	NN	False
DDI-MedLine.d11.s2	.	234	234	O	.	.	.	.	False

DDI-MedLine.d11.s3	Because	0	6	O	Because	use	ause	IN	False
DDI-MedLine.d11.s3	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d11.s3	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d11.s3	broadening	15	24	O	broadening	ing	ning	NN	False
DDI-MedLine.d11.s3	indications	26	36	O	indications	ons	ions	NNS	False
DDI-MedLine.d11.s3	for	38	40	O	for	for	for	IN	False
DDI-MedLine.d11.s3	immunosuppressive	42	58	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d11.s3	drugs	60	64	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d11.s3	,	65	65	O	,	,	,	,	False
DDI-MedLine.d11.s3	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d11.s3	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d11.s3	prolonged	75	83	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d11.s3	survival	85	92	O	survival	val	ival	NN	False
DDI-MedLine.d11.s3	in	94	95	O	in	in	in	IN	False
DDI-MedLine.d11.s3	conditions	97	106	O	conditions	ons	ions	NNS	False
DDI-MedLine.d11.s3	for	108	110	O	for	for	for	IN	False
DDI-MedLine.d11.s3	which	112	116	O	which	ich	hich	WDT	False
DDI-MedLine.d11.s3	they	118	121	O	they	hey	they	PRP	False
DDI-MedLine.d11.s3	are	123	125	O	are	are	are	VBP	False
DDI-MedLine.d11.s3	being	127	131	O	being	ing	eing	VBG	False
DDI-MedLine.d11.s3	used	133	136	O	used	sed	used	VBN	False
DDI-MedLine.d11.s3	,	137	137	O	,	,	,	,	False
DDI-MedLine.d11.s3	many	139	142	O	many	any	many	JJ	False
DDI-MedLine.d11.s3	patients	144	151	O	patients	nts	ents	NNS	False
DDI-MedLine.d11.s3	on	153	154	O	on	on	on	IN	False
DDI-MedLine.d11.s3	immunosuppression	156	172	O	immunosuppression	ion	sion	NN	False
DDI-MedLine.d11.s3	are	174	176	O	are	are	are	VBP	False
DDI-MedLine.d11.s3	now	178	180	O	now	now	now	RB	False
DDI-MedLine.d11.s3	cared	182	186	O	cared	red	ared	VBN	False
DDI-MedLine.d11.s3	for	188	190	O	for	for	for	IN	False
DDI-MedLine.d11.s3	in	192	193	O	in	in	in	IN	False
DDI-MedLine.d11.s3	the	195	197	O	the	the	the	DT	False
DDI-MedLine.d11.s3	community	199	207	O	community	ity	nity	NN	False
DDI-MedLine.d11.s3	or	209	210	O	or	or	or	CC	False
DDI-MedLine.d11.s3	seen	212	215	O	seen	een	seen	VBN	False
DDI-MedLine.d11.s3	in	217	218	O	in	in	in	IN	False
DDI-MedLine.d11.s3	non-specialist	220	233	O	non-specialist	ist	list	JJ	False
DDI-MedLine.d11.s3	hospitals	235	243	O	hospitals	als	tals	NNS	False
DDI-MedLine.d11.s3	,	244	244	O	,	,	,	,	False
DDI-MedLine.d11.s3	usually	246	252	O	usually	lly	ally	RB	False
DDI-MedLine.d11.s3	in	254	255	O	in	in	in	IN	False
DDI-MedLine.d11.s3	close	257	261	O	close	ose	lose	RB	False
DDI-MedLine.d11.s3	collaboration	263	275	O	collaboration	ion	tion	NN	False
DDI-MedLine.d11.s3	with	277	280	O	with	ith	with	IN	False
DDI-MedLine.d11.s3	a	282	282	O	a	a	a	DT	False
DDI-MedLine.d11.s3	specialist	284	293	O	specialist	ist	list	NN	False
DDI-MedLine.d11.s3	.	294	294	O	.	.	.	.	False

DDI-MedLine.d11.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d11.s4	article	5	11	O	article	cle	icle	NN	False
DDI-MedLine.d11.s4	looks	13	17	O	looks	oks	ooks	NNS	False
DDI-MedLine.d11.s4	at	19	20	O	at	at	at	IN	False
DDI-MedLine.d11.s4	five	22	25	O	five	ive	five	CD	False
DDI-MedLine.d11.s4	commonly	27	34	O	commonly	nly	only	RB	False
DDI-MedLine.d11.s4	used	36	39	O	used	sed	used	VBN	False
DDI-MedLine.d11.s4	immunosuppressive	41	57	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d11.s4	drugs	59	63	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d11.s4	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d11.s4	turn	68	71	O	turn	urn	turn	NN	False
DDI-MedLine.d11.s4	(	73	73	O	(	(	(	(	False
DDI-MedLine.d11.s4	corticosteroids	74	88	B-group	corticosteroids	ids	oids	NNS	False
DDI-MedLine.d11.s4	,	89	89	O	,	,	,	,	False
DDI-MedLine.d11.s4	cyclosporin	91	101	B-drug	cyclosporin	rin	orin	NN	False
DDI-MedLine.d11.s4	,	102	102	O	,	,	,	,	False
DDI-MedLine.d11.s4	azathioprine	104	115	B-drug	azathioprine	ine	rine	NN	drug
DDI-MedLine.d11.s4	,	116	116	O	,	,	,	,	False
DDI-MedLine.d11.s4	methotrexate	118	129	B-drug	methotrexate	ate	xate	NN	False
DDI-MedLine.d11.s4	,	130	130	O	,	,	,	,	False
DDI-MedLine.d11.s4	cyclophosphamide	132	147	B-drug	cyclophosphamide	ide	mide	NN	False
DDI-MedLine.d11.s4	)	148	148	O	)	)	)	)	False
DDI-MedLine.d11.s4	,	149	149	O	,	,	,	,	False
DDI-MedLine.d11.s4	discussing	151	160	O	discussing	ing	sing	VBG	False
DDI-MedLine.d11.s4	the	162	164	O	the	the	the	DT	False
DDI-MedLine.d11.s4	main	166	169	O	main	ain	main	JJ	False
DDI-MedLine.d11.s4	,	170	170	O	,	,	,	,	False
DDI-MedLine.d11.s4	non-infection	172	184	O	non-infection	ion	tion	NN	False
DDI-MedLine.d11.s4	,	185	185	O	,	,	,	,	False
DDI-MedLine.d11.s4	unwanted	187	194	O	unwanted	ted	nted	JJ	False
DDI-MedLine.d11.s4	effects	196	202	O	effects	cts	ects	NNS	False
DDI-MedLine.d11.s4	,	203	203	O	,	,	,	,	False
DDI-MedLine.d11.s4	ways	205	208	O	ways	ays	ways	NNS	False
DDI-MedLine.d11.s4	to	210	211	O	to	to	to	TO	False
DDI-MedLine.d11.s4	avoid	213	217	O	avoid	oid	void	NN	False
DDI-MedLine.d11.s4	them	219	222	O	them	hem	them	PRP	False
DDI-MedLine.d11.s4	and	224	226	O	and	and	and	CC	False
DDI-MedLine.d11.s4	what	228	231	O	what	hat	what	WP	False
DDI-MedLine.d11.s4	to	233	234	O	to	to	to	TO	False
DDI-MedLine.d11.s4	do	236	237	O	do	do	do	VB	False
DDI-MedLine.d11.s4	if	239	240	O	if	if	if	IN	False
DDI-MedLine.d11.s4	problems	242	249	O	problems	ems	lems	NNS	False
DDI-MedLine.d11.s4	arise	251	255	O	arise	ise	rise	NN	False
DDI-MedLine.d11.s4	.	256	256	O	.	.	.	.	False

DDI-MedLine.d11.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d11.s5	management	4	13	O	management	ent	ment	NN	False
DDI-MedLine.d11.s5	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d11.s5	infection	18	26	O	infection	ion	tion	NN	False
DDI-MedLine.d11.s5	is	28	29	O	is	is	is	VBZ	False
DDI-MedLine.d11.s5	dealt	31	35	O	dealt	alt	ealt	NN	False
DDI-MedLine.d11.s5	with	37	40	O	with	ith	with	IN	False
DDI-MedLine.d11.s5	as	42	43	O	as	as	as	IN	False
DDI-MedLine.d11.s5	a	45	45	O	a	a	a	DT	False
DDI-MedLine.d11.s5	separate	47	54	O	separate	ate	rate	JJ	False
DDI-MedLine.d11.s5	section	56	62	O	section	ion	tion	NN	False
DDI-MedLine.d11.s5	.	63	63	O	.	.	.	.	False

DDI-MedLine.d112.s0	Effect	0	5	O	Effect	ect	fect	NN	False
DDI-MedLine.d112.s0	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d112.s0	dofetillide	10	20	B-drug	dofetillide	ide	lide	NN	False
DDI-MedLine.d112.s0	on	22	23	O	on	on	on	IN	False
DDI-MedLine.d112.s0	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d112.s0	pharmacokinetics	29	44	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d112.s0	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d112.s0	digoxin	49	55	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d112.s0	.	56	56	O	.	.	.	.	False

DDI-MedLine.d112.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d112.s1	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d112.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d112.s1	dofetilide	14	23	B-drug	dofetilide	ide	lide	NN	False
DDI-MedLine.d112.s1	on	25	26	O	on	on	on	IN	False
DDI-MedLine.d112.s1	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d112.s1	steady-state	32	43	O	steady-state	ate	tate	NN	False
DDI-MedLine.d112.s1	pharmacokinetics	45	60	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d112.s1	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d112.s1	digoxin	65	71	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d112.s1	was	73	75	O	was	was	was	VBD	False
DDI-MedLine.d112.s1	evaluated	77	85	O	evaluated	ted	ated	VBN	False
DDI-MedLine.d112.s1	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d112.s1	a	90	90	O	a	a	a	DT	False
DDI-MedLine.d112.s1	randomized	92	101	O	randomized	zed	ized	VBN	False
DDI-MedLine.d112.s1	,	102	102	O	,	,	,	,	False
DDI-MedLine.d112.s1	double-blind	104	115	O	double-blind	ind	lind	NN	False
DDI-MedLine.d112.s1	study	117	121	O	study	udy	tudy	NN	False
DDI-MedLine.d112.s1	.	122	122	O	.	.	.	.	False

DDI-MedLine.d112.s2	Five	0	3	O	Five	ive	Five	CD	False
DDI-MedLine.d112.s2	days	5	8	O	days	ays	days	NNS	False
DDI-MedLine.d112.s2	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d112.s2	dofetilide	13	22	B-drug	dofetilide	ide	lide	NN	False
DDI-MedLine.d112.s2	treatment	24	32	O	treatment	ent	ment	NN	False
DDI-MedLine.d112.s2	did	34	36	O	did	did	did	VBD	False
DDI-MedLine.d112.s2	not	38	40	O	not	not	not	RB	False
DDI-MedLine.d112.s2	significantly	42	54	O	significantly	tly	ntly	RB	False
DDI-MedLine.d112.s2	affect	56	61	O	affect	ect	fect	NN	False
DDI-MedLine.d112.s2	steady-state	63	74	O	steady-state	ate	tate	NN	False
DDI-MedLine.d112.s2	pharmacokinetic	76	90	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d112.s2	variables	92	100	O	variables	les	bles	NNS	False
DDI-MedLine.d112.s2	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d112.s2	digoxin	105	111	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d112.s2	compared	113	120	O	compared	red	ared	VBN	False
DDI-MedLine.d112.s2	with	122	125	O	with	ith	with	IN	False
DDI-MedLine.d112.s2	placebo	127	133	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d112.s2	;	134	134	O	;	;	;	:	False

DDI-MedLine.d112.s3	therefore	0	8	O	therefore	ore	fore	RB	False
DDI-MedLine.d112.s3	,	9	9	O	,	,	,	,	False
DDI-MedLine.d112.s3	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d112.s3	use	15	17	O	use	use	use	NN	False
DDI-MedLine.d112.s3	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d112.s3	dofetilide	22	31	B-drug	dofetilide	ide	lide	NN	False
DDI-MedLine.d112.s3	does	33	36	O	does	oes	does	VBZ	False
DDI-MedLine.d112.s3	not	38	40	O	not	not	not	RB	False
DDI-MedLine.d112.s3	necessitate	42	52	O	necessitate	ate	tate	NN	False
DDI-MedLine.d112.s3	an	54	55	O	an	an	an	DT	False
DDI-MedLine.d112.s3	adjustment	57	66	O	adjustment	ent	ment	NN	False
DDI-MedLine.d112.s3	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d112.s3	digoxin	71	77	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d112.s3	dose	79	82	O	dose	ose	dose	NN	False
DDI-MedLine.d112.s3	to	84	85	O	to	to	to	TO	False
DDI-MedLine.d112.s3	maintain	87	94	O	maintain	ain	tain	NN	False
DDI-MedLine.d112.s3	therapeutic	96	106	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d112.s3	digoxin	108	114	O	digoxin	xin	oxin	NN	False
DDI-MedLine.d112.s3	levels	116	121	O	levels	els	vels	NNS	False
DDI-MedLine.d112.s3	.	122	122	O	.	.	.	.	False

DDI-MedLine.d37.s0	Anticoagulants	0	13	B-group	Anticoagulants	nts	ants	NNS	False
DDI-MedLine.d37.s0	.	14	14	O	.	.	.	.	False

DDI-MedLine.d37.s1	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d37.s1	plans	10	14	O	plans	ans	lans	NNS	False
DDI-MedLine.d37.s1	for	16	18	O	for	for	for	IN	False
DDI-MedLine.d37.s1	patients	20	27	O	patients	nts	ents	NNS	False
DDI-MedLine.d37.s1	taking	29	34	O	taking	ing	king	VBG	False
DDI-MedLine.d37.s1	anticoagulants	36	49	B-group	anticoagulants	nts	ants	NNS	False
DDI-MedLine.d37.s1	can	51	53	O	can	can	can	MD	False
DDI-MedLine.d37.s1	become	55	60	O	become	ome	come	NN	False
DDI-MedLine.d37.s1	complicated	62	72	O	complicated	ted	ated	VBN	False
DDI-MedLine.d37.s1	.	73	73	O	.	.	.	.	False

DDI-MedLine.d37.s2	Anticoagulants	0	13	B-group	Anticoagulants	nts	ants	NNS	False
DDI-MedLine.d37.s2	predispose	15	24	O	predispose	ose	pose	NN	False
DDI-MedLine.d37.s2	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d37.s2	patient	28	34	O	patient	ent	ient	NN	False
DDI-MedLine.d37.s2	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d37.s2	bleeding	39	46	O	bleeding	ing	ding	NN	False
DDI-MedLine.d37.s2	problems	48	55	O	problems	ems	lems	NNS	False
DDI-MedLine.d37.s2	.	56	56	O	.	.	.	.	False

DDI-MedLine.d37.s3	Many	0	3	O	Many	any	Many	JJ	False
DDI-MedLine.d37.s3	drugs	5	9	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d37.s3	used	11	14	O	used	sed	used	VBN	False
DDI-MedLine.d37.s3	in	16	17	O	in	in	in	IN	False
DDI-MedLine.d37.s3	dentistry	19	27	O	dentistry	try	stry	NN	False
DDI-MedLine.d37.s3	can	29	31	O	can	can	can	MD	False
DDI-MedLine.d37.s3	not	32	34	O	not	not	not	RB	False
DDI-MedLine.d37.s3	be	36	37	O	be	be	be	VB	False
DDI-MedLine.d37.s3	taken	39	43	O	taken	ken	aken	VBN	False
DDI-MedLine.d37.s3	concomitantly	45	57	O	concomitantly	tly	ntly	RB	False
DDI-MedLine.d37.s3	with	59	62	O	with	ith	with	IN	False
DDI-MedLine.d37.s3	these	64	68	O	these	ese	hese	DT	False
DDI-MedLine.d37.s3	medications	70	80	O	medications	ons	ions	NNS	False
DDI-MedLine.d37.s3	.	81	81	O	.	.	.	.	False

DDI-MedLine.d6.s0	Pharmacokinetic	0	14	O	Pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d6.s0	profile	16	22	O	profile	ile	file	NN	False
DDI-MedLine.d6.s0	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d6.s0	etodolac	27	34	B-drug	etodolac	lac	olac	NN	False
DDI-MedLine.d6.s0	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d6.s0	special	39	45	O	special	ial	cial	JJ	False
DDI-MedLine.d6.s0	populations	47	57	O	populations	ons	ions	NNS	False
DDI-MedLine.d6.s0	.	58	58	O	.	.	.	.	False

DDI-MedLine.d6.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d6.s1	pharmacokinetics	4	19	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d6.s1	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d6.s1	etodolac	24	31	B-drug	etodolac	lac	olac	NN	False
DDI-MedLine.d6.s1	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d6.s1	healthy	36	42	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d6.s1	normal	44	49	O	normal	mal	rmal	JJ	False
DDI-MedLine.d6.s1	volunteers	51	60	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d6.s1	has	62	64	O	has	has	has	VBZ	False
DDI-MedLine.d6.s1	been	66	69	O	been	een	been	VBN	False
DDI-MedLine.d6.s1	extensively	71	81	O	extensively	ely	vely	RB	False
DDI-MedLine.d6.s1	studied	83	89	O	studied	ied	died	VBN	False
DDI-MedLine.d6.s1	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d6.s1	is	95	96	O	is	is	is	VBZ	False
DDI-MedLine.d6.s1	well	98	101	O	well	ell	well	RB	False
DDI-MedLine.d6.s1	described	103	111	O	described	bed	ibed	NN	False
DDI-MedLine.d6.s1	.	112	112	O	.	.	.	.	False

DDI-MedLine.d6.s2	Etodolac	0	7	B-drug	Etodolac	lac	olac	NN	False
DDI-MedLine.d6.s2	is	9	10	O	is	is	is	VBZ	False
DDI-MedLine.d6.s2	characterised	12	24	O	characterised	sed	ised	VBN	False
DDI-MedLine.d6.s2	by	26	27	O	by	by	by	IN	False
DDI-MedLine.d6.s2	a	29	29	O	a	a	a	DT	False
DDI-MedLine.d6.s2	high	31	34	O	high	igh	high	JJ	False
DDI-MedLine.d6.s2	oral	36	39	O	oral	ral	oral	JJ	False
DDI-MedLine.d6.s2	bioavailability	41	55	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d6.s2	,	56	56	O	,	,	,	,	False
DDI-MedLine.d6.s2	low	58	60	O	low	low	low	JJ	False
DDI-MedLine.d6.s2	clearance	62	70	O	clearance	nce	ance	NN	False
DDI-MedLine.d6.s2	,	71	71	O	,	,	,	,	False
DDI-MedLine.d6.s2	a	73	73	O	a	a	a	DT	False
DDI-MedLine.d6.s2	small	75	79	O	small	all	mall	JJ	False
DDI-MedLine.d6.s2	volume	81	86	O	volume	ume	lume	NN	False
DDI-MedLine.d6.s2	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d6.s2	distribution	91	102	O	distribution	ion	tion	NN	False
DDI-MedLine.d6.s2	,	103	103	O	,	,	,	,	False
DDI-MedLine.d6.s2	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d6.s2	a	109	109	O	a	a	a	DT	False
DDI-MedLine.d6.s2	7-hour	111	116	O	7-hour	our	hour	JJ	False
DDI-MedLine.d6.s2	half-life	118	126	O	half-life	ife	life	NN	False
DDI-MedLine.d6.s2	.	127	127	O	.	.	.	.	False

DDI-MedLine.d6.s3	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d6.s3	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d6.s3	essentially	6	16	O	essentially	lly	ally	RB	False
DDI-MedLine.d6.s3	completely	18	27	O	completely	ely	tely	RB	False
DDI-MedLine.d6.s3	metabolised	29	39	O	metabolised	sed	ised	VBN	False
DDI-MedLine.d6.s3	,	40	40	O	,	,	,	,	False
DDI-MedLine.d6.s3	therefore	42	50	O	therefore	ore	fore	RB	False
DDI-MedLine.d6.s3	little	52	57	O	little	tle	ttle	JJ	False
DDI-MedLine.d6.s3	is	59	60	O	is	is	is	VBZ	False
DDI-MedLine.d6.s3	excreted	62	69	O	excreted	ted	eted	VBN	False
DDI-MedLine.d6.s3	unchanged	71	79	O	unchanged	ged	nged	JJ	False
DDI-MedLine.d6.s3	.	80	80	O	.	.	.	.	False

DDI-MedLine.d6.s4	Etodolac	0	7	B-drug	Etodolac	lac	olac	NN	False
DDI-MedLine.d6.s4	is	9	10	O	is	is	is	VBZ	False
DDI-MedLine.d6.s4	highly	12	17	O	highly	hly	ghly	RB	False
DDI-MedLine.d6.s4	protein	19	25	O	protein	ein	tein	NN	False
DDI-MedLine.d6.s4	bound	27	31	O	bound	und	ound	NN	False
DDI-MedLine.d6.s4	.	32	32	O	.	.	.	.	False

DDI-MedLine.d6.s5	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d6.s5	investigate	3	13	O	investigate	ate	gate	NN	False
DDI-MedLine.d6.s5	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d6.s5	effect	19	24	O	effect	ect	fect	NN	False
DDI-MedLine.d6.s5	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d6.s5	disease	29	35	O	disease	ase	ease	NN	False
DDI-MedLine.d6.s5	states	37	42	O	states	tes	ates	NNS	False
DDI-MedLine.d6.s5	or	44	45	O	or	or	or	CC	False
DDI-MedLine.d6.s5	concomitant	47	57	O	concomitant	ant	tant	NN	False
DDI-MedLine.d6.s5	drug	59	62	O	drug	rug	drug	NN	False
DDI-MedLine.d6.s5	administration	64	77	O	administration	ion	tion	NN	False
DDI-MedLine.d6.s5	on	79	80	O	on	on	on	IN	False
DDI-MedLine.d6.s5	a	82	82	O	a	a	a	DT	False
DDI-MedLine.d6.s5	patient	84	90	O	patient	ent	ient	NN	False
DDI-MedLine.d6.s5	's	91	92	O	's	's	's	POS	False
DDI-MedLine.d6.s5	response	94	101	O	response	nse	onse	NN	False
DDI-MedLine.d6.s5	to	103	104	O	to	to	to	TO	False
DDI-MedLine.d6.s5	etodolac	106	113	B-drug	etodolac	lac	olac	NN	False
DDI-MedLine.d6.s5	,	114	114	O	,	,	,	,	False
DDI-MedLine.d6.s5	additional	116	125	O	additional	nal	onal	JJ	False
DDI-MedLine.d6.s5	pharmacokinetic	127	141	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d6.s5	studies	143	149	O	studies	ies	dies	NNS	False
DDI-MedLine.d6.s5	were	151	154	O	were	ere	were	VBD	False
DDI-MedLine.d6.s5	carried	156	162	O	carried	ied	ried	VBN	False
DDI-MedLine.d6.s5	out	164	166	O	out	out	out	IN	False
DDI-MedLine.d6.s5	in	168	169	O	in	in	in	IN	False
DDI-MedLine.d6.s5	special	171	177	O	special	ial	cial	JJ	False
DDI-MedLine.d6.s5	populations	179	189	O	populations	ons	ions	NNS	False
DDI-MedLine.d6.s5	.	190	190	O	.	.	.	.	False

DDI-MedLine.d6.s6	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d6.s6	etodolac	6	13	B-drug	etodolac	lac	olac	NN	False
DDI-MedLine.d6.s6	has	15	17	O	has	has	has	VBZ	False
DDI-MedLine.d6.s6	a	19	19	O	a	a	a	DT	False
DDI-MedLine.d6.s6	well-defined	21	32	O	well-defined	ned	ined	JJ	False
DDI-MedLine.d6.s6	pharmacokinetic-pharmacodynamic	34	64	O	pharmacokinetic-pharmacodynamic	mic	amic	JJ	False
DDI-MedLine.d6.s6	relationship	66	77	O	relationship	hip	ship	NN	False
DDI-MedLine.d6.s6	,	78	78	O	,	,	,	,	False
DDI-MedLine.d6.s6	measurement	80	90	O	measurement	ent	ment	NN	False
DDI-MedLine.d6.s6	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d6.s6	pharmacokinetic	95	109	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d6.s6	parameters	111	120	O	parameters	ers	ters	NNS	False
DDI-MedLine.d6.s6	is	122	123	O	is	is	is	VBZ	False
DDI-MedLine.d6.s6	clinically	125	134	O	clinically	lly	ally	RB	False
DDI-MedLine.d6.s6	relevant	136	143	O	relevant	ant	vant	NN	False
DDI-MedLine.d6.s6	.	144	144	O	.	.	.	.	False

DDI-MedLine.d6.s7	Data	0	3	O	Data	ata	Data	NNS	False
DDI-MedLine.d6.s7	from	5	8	O	from	rom	from	IN	False
DDI-MedLine.d6.s7	studies	10	16	O	studies	ies	dies	NNS	False
DDI-MedLine.d6.s7	to	18	19	O	to	to	to	TO	False
DDI-MedLine.d6.s7	date	21	24	O	date	ate	date	NN	False
DDI-MedLine.d6.s7	show	26	29	O	show	how	show	NN	False
DDI-MedLine.d6.s7	that	31	34	O	that	hat	that	IN	False
DDI-MedLine.d6.s7	disease	36	42	O	disease	ase	ease	NN	False
DDI-MedLine.d6.s7	states	44	49	O	states	tes	ates	NNS	False
DDI-MedLine.d6.s7	,	50	50	O	,	,	,	,	False
DDI-MedLine.d6.s7	underlying	52	61	O	underlying	ing	ying	VBG	False
DDI-MedLine.d6.s7	conditions	63	72	O	conditions	ons	ions	NNS	False
DDI-MedLine.d6.s7	,	73	73	O	,	,	,	,	False
DDI-MedLine.d6.s7	and	75	77	O	and	and	and	CC	False
DDI-MedLine.d6.s7	concomitantly	79	91	O	concomitantly	tly	ntly	RB	False
DDI-MedLine.d6.s7	administered	93	104	O	administered	red	ered	VBN	False
DDI-MedLine.d6.s7	highly	106	111	O	highly	hly	ghly	RB	False
DDI-MedLine.d6.s7	protein-bound	113	125	O	protein-bound	und	ound	NN	False
DDI-MedLine.d6.s7	drugs	127	131	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d6.s7	have	133	136	O	have	ave	have	VB	False
DDI-MedLine.d6.s7	essentially	138	148	O	essentially	lly	ally	RB	False
DDI-MedLine.d6.s7	no	150	151	O	no	no	no	DT	False
DDI-MedLine.d6.s7	effect	153	158	O	effect	ect	fect	NN	False
DDI-MedLine.d6.s7	on	160	161	O	on	on	on	IN	False
DDI-MedLine.d6.s7	etodolac	163	170	B-drug	etodolac	lac	olac	NN	False
DDI-MedLine.d6.s7	pharmacokinetics	172	187	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d6.s7	.	188	188	O	.	.	.	.	False

DDI-MedLine.d6.s8	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d6.s8	,	9	9	O	,	,	,	,	False
DDI-MedLine.d6.s8	etodolac	11	18	B-drug	etodolac	lac	olac	NN	False
DDI-MedLine.d6.s8	can	20	22	O	can	can	can	MD	False
DDI-MedLine.d6.s8	generally	24	32	O	generally	lly	ally	RB	False
DDI-MedLine.d6.s8	be	34	35	O	be	be	be	VB	False
DDI-MedLine.d6.s8	given	37	41	O	given	ven	iven	VBN	False
DDI-MedLine.d6.s8	without	43	49	O	without	out	hout	IN	False
DDI-MedLine.d6.s8	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d6.s8	need	55	58	O	need	eed	need	NN	False
DDI-MedLine.d6.s8	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d6.s8	dosage	64	69	O	dosage	age	sage	NN	False
DDI-MedLine.d6.s8	modifications	71	83	O	modifications	ons	ions	NNS	False
DDI-MedLine.d6.s8	in	85	86	O	in	in	in	IN	False
DDI-MedLine.d6.s8	special	88	94	O	special	ial	cial	JJ	False
DDI-MedLine.d6.s8	populations	96	106	O	populations	ons	ions	NNS	False
DDI-MedLine.d6.s8	such	108	111	O	such	uch	such	JJ	False
DDI-MedLine.d6.s8	as	113	114	O	as	as	as	IN	False
DDI-MedLine.d6.s8	uncompromised	116	128	O	uncompromised	sed	ised	JJ	False
DDI-MedLine.d6.s8	elderly	130	136	O	elderly	rly	erly	RB	False
DDI-MedLine.d6.s8	patients	138	145	O	patients	nts	ents	NNS	False
DDI-MedLine.d6.s8	,	146	146	O	,	,	,	,	False
DDI-MedLine.d6.s8	those	148	152	O	those	ose	hose	DT	False
DDI-MedLine.d6.s8	with	154	157	O	with	ith	with	IN	False
DDI-MedLine.d6.s8	moderate	159	166	O	moderate	ate	rate	NN	False
DDI-MedLine.d6.s8	renal	168	172	O	renal	nal	enal	NN	False
DDI-MedLine.d6.s8	impairment	174	183	O	impairment	ent	ment	NN	False
DDI-MedLine.d6.s8	,	184	184	O	,	,	,	,	False
DDI-MedLine.d6.s8	and	186	188	O	and	and	and	CC	False
DDI-MedLine.d6.s8	patients	190	197	O	patients	nts	ents	NNS	False
DDI-MedLine.d6.s8	with	199	202	O	with	ith	with	IN	False
DDI-MedLine.d6.s8	stable	204	209	O	stable	ble	able	JJ	False
DDI-MedLine.d6.s8	hepatic	211	217	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d6.s8	disease	219	225	O	disease	ase	ease	NN	False
DDI-MedLine.d6.s8	.	226	226	O	.	.	.	.	False

DDI-MedLine.d33.s0	Determinants	0	11	O	Determinants	nts	ants	NNS	False
DDI-MedLine.d33.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d33.s0	cellular	16	23	O	cellular	lar	ular	JJ	False
DDI-MedLine.d33.s0	sensitivity	25	35	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d33.s0	to	37	38	O	to	to	to	TO	False
DDI-MedLine.d33.s0	topoisomerase-targeting	40	62	B-group	topoisomerase-targeting	ing	ting	NN	False
DDI-MedLine.d33.s0	antitumor	64	72	I-group	antitumor	mor	umor	NN	False
DDI-MedLine.d33.s0	drugs	74	78	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d33.s0	.	79	79	O	.	.	.	.	False

DDI-MedLine.d33.s1	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d33.s1	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d33.s1	now	6	8	O	now	now	now	RB	False
DDI-MedLine.d33.s1	clear	10	14	O	clear	ear	lear	JJ	False
DDI-MedLine.d33.s1	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d33.s1	topoisomerase	21	33	O	topoisomerase	ase	rase	NN	False
DDI-MedLine.d33.s1	activity	35	42	O	activity	ity	vity	NN	False
DDI-MedLine.d33.s1	level	44	48	O	level	vel	evel	NN	False
DDI-MedLine.d33.s1	is	50	51	O	is	is	is	VBZ	False
DDI-MedLine.d33.s1	an	53	54	O	an	an	an	DT	False
DDI-MedLine.d33.s1	important	56	64	O	important	ant	tant	JJ	False
DDI-MedLine.d33.s1	determinant	66	76	O	determinant	ant	nant	NN	False
DDI-MedLine.d33.s1	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d33.s1	sensitivity	81	91	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d33.s1	to	93	94	O	to	to	to	TO	False
DDI-MedLine.d33.s1	topo	96	99	O	topo	opo	topo	NN	False
DDI-MedLine.d33.s1	drugs	101	105	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d33.s1	.	106	106	O	.	.	.	.	False

DDI-MedLine.d33.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d33.s2	regulation	4	13	O	regulation	ion	tion	NN	False
DDI-MedLine.d33.s2	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d33.s2	topoisomerases	18	31	O	topoisomerases	ses	ases	NNS	False
DDI-MedLine.d33.s2	is	33	34	O	is	is	is	VBZ	False
DDI-MedLine.d33.s2	no	36	37	O	no	no	no	DT	False
DDI-MedLine.d33.s2	doubt	39	43	O	doubt	ubt	oubt	NN	False
DDI-MedLine.d33.s2	complex	45	51	O	complex	lex	plex	JJ	False
DDI-MedLine.d33.s2	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d33.s2	multifaceted	57	68	O	multifaceted	ted	eted	VBN	False
DDI-MedLine.d33.s2	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d33.s2	is	74	75	O	is	is	is	VBZ	False
DDI-MedLine.d33.s2	probably	77	84	O	probably	bly	ably	RB	False
DDI-MedLine.d33.s2	accomplished	86	97	O	accomplished	hed	shed	VBN	False
DDI-MedLine.d33.s2	through	99	105	O	through	ugh	ough	IN	False
DDI-MedLine.d33.s2	redundancy	107	116	O	redundancy	ncy	ancy	NN	False
DDI-MedLine.d33.s2	at	118	119	O	at	at	at	IN	False
DDI-MedLine.d33.s2	many	121	124	O	many	any	many	JJ	False
DDI-MedLine.d33.s2	control	126	132	O	control	rol	trol	NN	False
DDI-MedLine.d33.s2	levels	134	139	O	levels	els	vels	NNS	False
DDI-MedLine.d33.s2	.	140	140	O	.	.	.	.	False

DDI-MedLine.d33.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d33.s3	mechanism	4	12	O	mechanism	ism	nism	NN	False
DDI-MedLine.d33.s3	(	13	13	O	(	(	(	(	False
DDI-MedLine.d33.s3	s	14	14	O	s	s	s	NN	False
DDI-MedLine.d33.s3	)	15	15	O	)	)	)	)	False
DDI-MedLine.d33.s3	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d33.s3	altered	20	26	O	altered	red	ered	VBN	False
DDI-MedLine.d33.s3	topo	28	31	O	topo	opo	topo	NN	False
DDI-MedLine.d33.s3	I	33	33	O	I	I	I	PRP	brand
DDI-MedLine.d33.s3	expression	35	44	O	expression	ion	sion	NN	False
DDI-MedLine.d33.s3	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d33.s3	certain	49	55	O	certain	ain	tain	JJ	False
DDI-MedLine.d33.s3	tumor	57	61	O	tumor	mor	umor	NN	False
DDI-MedLine.d33.s3	types	63	67	O	types	pes	ypes	NNS	False
DDI-MedLine.d33.s3	is	69	70	O	is	is	is	VBZ	False
DDI-MedLine.d33.s3	unknown	72	78	O	unknown	own	nown	JJ	False
DDI-MedLine.d33.s3	,	79	79	O	,	,	,	,	False
DDI-MedLine.d33.s3	but	81	83	O	but	but	but	CC	False
DDI-MedLine.d33.s3	may	85	87	O	may	may	may	MD	False
DDI-MedLine.d33.s3	be	89	90	O	be	be	be	VB	False
DDI-MedLine.d33.s3	related	92	98	O	related	ted	ated	JJ	False
DDI-MedLine.d33.s3	to	100	101	O	to	to	to	TO	False
DDI-MedLine.d33.s3	the	103	105	O	the	the	the	DT	False
DDI-MedLine.d33.s3	central	107	113	O	central	ral	tral	JJ	False
DDI-MedLine.d33.s3	importance	115	124	O	importance	nce	ance	NN	False
DDI-MedLine.d33.s3	of	126	127	O	of	of	of	IN	False
DDI-MedLine.d33.s3	topoisomerases	129	142	O	topoisomerases	ses	ases	NNS	False
DDI-MedLine.d33.s3	in	144	145	O	in	in	in	IN	False
DDI-MedLine.d33.s3	proliferating	147	159	O	proliferating	ing	ting	VBG	False
DDI-MedLine.d33.s3	cell	161	164	O	cell	ell	cell	NN	False
DDI-MedLine.d33.s3	functions	166	174	O	functions	ons	ions	NNS	False
DDI-MedLine.d33.s3	(	176	176	O	(	(	(	(	False
DDI-MedLine.d33.s3	transcription	177	189	O	transcription	ion	tion	NN	False
DDI-MedLine.d33.s3	,	190	190	O	,	,	,	,	False
DDI-MedLine.d33.s3	replication	192	202	O	replication	ion	tion	NN	False
DDI-MedLine.d33.s3	,	203	203	O	,	,	,	,	False
DDI-MedLine.d33.s3	etc	205	207	O	etc	etc	etc	NN	False
DDI-MedLine.d33.s3	.	208	208	O	.	.	.	.	False
DDI-MedLine.d33.s3	)	209	209	O	)	)	)	)	False
DDI-MedLine.d33.s3	,	210	210	O	,	,	,	,	False
DDI-MedLine.d33.s3	and	212	214	O	and	and	and	CC	False
DDI-MedLine.d33.s3	the	216	218	O	the	the	the	DT	False
DDI-MedLine.d33.s3	aberrant	220	227	O	aberrant	ant	rant	NN	False
DDI-MedLine.d33.s3	and	229	231	O	and	and	and	CC	False
DDI-MedLine.d33.s3	chronic	233	239	O	chronic	nic	onic	NN	False
DDI-MedLine.d33.s3	activation	241	250	O	activation	ion	tion	NN	False
DDI-MedLine.d33.s3	of	252	253	O	of	of	of	IN	False
DDI-MedLine.d33.s3	these	255	259	O	these	ese	hese	DT	False
DDI-MedLine.d33.s3	functions	261	269	O	functions	ons	ions	NNS	False
DDI-MedLine.d33.s3	as	271	272	O	as	as	as	IN	False
DDI-MedLine.d33.s3	a	274	274	O	a	a	a	DT	False
DDI-MedLine.d33.s3	result	276	281	O	result	ult	sult	NN	False
DDI-MedLine.d33.s3	of	283	284	O	of	of	of	IN	False
DDI-MedLine.d33.s3	specific	286	293	O	specific	fic	ific	JJ	False
DDI-MedLine.d33.s3	tumorigenic	295	305	O	tumorigenic	nic	enic	NN	False
DDI-MedLine.d33.s3	alterations	307	317	O	alterations	ons	ions	NNS	False
DDI-MedLine.d33.s3	.	318	318	O	.	.	.	.	False

DDI-MedLine.d33.s4	Small	0	4	O	Small	all	mall	NN	False
DDI-MedLine.d33.s4	differences	6	16	O	differences	ces	nces	NNS	False
DDI-MedLine.d33.s4	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d33.s4	sensitivity	21	31	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d33.s4	to	33	34	O	to	to	to	TO	False
DDI-MedLine.d33.s4	chemotherapy	36	47	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d33.s4	can	49	51	O	can	can	can	MD	False
DDI-MedLine.d33.s4	have	53	56	O	have	ave	have	VB	False
DDI-MedLine.d33.s4	a	58	58	O	a	a	a	DT	False
DDI-MedLine.d33.s4	dramatic	60	67	O	dramatic	tic	atic	JJ	False
DDI-MedLine.d33.s4	effect	69	74	O	effect	ect	fect	NN	False
DDI-MedLine.d33.s4	on	76	77	O	on	on	on	IN	False
DDI-MedLine.d33.s4	cure	79	82	O	cure	ure	cure	NN	False
DDI-MedLine.d33.s4	rates	84	88	O	rates	tes	ates	NNS	False
DDI-MedLine.d33.s4	,	89	89	O	,	,	,	,	False
DDI-MedLine.d33.s4	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d33.s4	therefore	95	103	O	therefore	ore	fore	RB	False
DDI-MedLine.d33.s4	subtle	105	110	O	subtle	tle	btle	NN	False
DDI-MedLine.d33.s4	cell	112	115	O	cell	ell	cell	NN	False
DDI-MedLine.d33.s4	type-specific	117	129	O	type-specific	fic	ific	NN	False
DDI-MedLine.d33.s4	differences	131	141	O	differences	ces	nces	NNS	False
DDI-MedLine.d33.s4	may	143	145	O	may	may	may	MD	False
DDI-MedLine.d33.s4	be	147	148	O	be	be	be	VB	False
DDI-MedLine.d33.s4	important	150	158	O	important	ant	tant	JJ	False
DDI-MedLine.d33.s4	determinants	160	171	O	determinants	nts	ants	NNS	False
DDI-MedLine.d33.s4	of	173	174	O	of	of	of	IN	False
DDI-MedLine.d33.s4	drug	176	179	O	drug	rug	drug	NN	False
DDI-MedLine.d33.s4	sensitivity	181	191	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d33.s4	.	192	192	O	.	.	.	.	False

DDI-MedLine.d33.s5	Whether	0	6	O	Whether	her	ther	IN	False
DDI-MedLine.d33.s5	abnormal	8	15	O	abnormal	mal	rmal	JJ	False
DDI-MedLine.d33.s5	topoisomerase	17	29	O	topoisomerase	ase	rase	NN	False
DDI-MedLine.d33.s5	quantity	31	38	O	quantity	ity	tity	NN	False
DDI-MedLine.d33.s5	and	40	42	O	and	and	and	CC	False
DDI-MedLine.d33.s5	specific	44	51	O	specific	fic	ific	JJ	False
DDI-MedLine.d33.s5	activity	53	60	O	activity	ity	vity	NN	False
DDI-MedLine.d33.s5	are	62	64	O	are	are	are	VBP	False
DDI-MedLine.d33.s5	associated	66	75	O	associated	ted	ated	VBN	False
DDI-MedLine.d33.s5	with	77	80	O	with	ith	with	IN	False
DDI-MedLine.d33.s5	resistance	82	91	O	resistance	nce	ance	NN	False
DDI-MedLine.d33.s5	or	93	94	O	or	or	or	CC	False
DDI-MedLine.d33.s5	sensitivity	96	106	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d33.s5	to	108	109	O	to	to	to	TO	False
DDI-MedLine.d33.s5	topoisomerase-targeted	111	132	O	topoisomerase-targeted	ted	eted	JJ	False
DDI-MedLine.d33.s5	chemotherapy	134	145	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d33.s5	in	147	148	O	in	in	in	IN	False
DDI-MedLine.d33.s5	the	150	152	O	the	the	the	DT	False
DDI-MedLine.d33.s5	clinic	154	159	O	clinic	nic	inic	NN	False
DDI-MedLine.d33.s5	is	161	162	O	is	is	is	VBZ	False
DDI-MedLine.d33.s5	now	164	166	O	now	now	now	RB	False
DDI-MedLine.d33.s5	being	168	172	O	being	ing	eing	VBG	False
DDI-MedLine.d33.s5	studied	174	180	O	studied	ied	died	VBN	False
DDI-MedLine.d33.s5	.	181	181	O	.	.	.	.	False

DDI-MedLine.d33.s6	Determinants	0	11	O	Determinants	nts	ants	NNS	False
DDI-MedLine.d33.s6	downstream	13	22	O	downstream	eam	ream	NN	False
DDI-MedLine.d33.s6	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d33.s6	cleavable	27	35	O	cleavable	ble	able	JJ	False
DDI-MedLine.d33.s6	complex	37	43	O	complex	lex	plex	JJ	False
DDI-MedLine.d33.s6	formation	45	53	O	formation	ion	tion	NN	False
DDI-MedLine.d33.s6	that	55	58	O	that	hat	that	IN	False
DDI-MedLine.d33.s6	affect	60	65	O	affect	ect	fect	NN	False
DDI-MedLine.d33.s6	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d33.s6	sensitivity	71	81	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d33.s6	of	83	84	O	of	of	of	IN	False
DDI-MedLine.d33.s6	tumor	86	90	O	tumor	mor	umor	NN	False
DDI-MedLine.d33.s6	versus	92	97	O	versus	sus	rsus	NN	False
DDI-MedLine.d33.s6	normal	99	104	O	normal	mal	rmal	JJ	False
DDI-MedLine.d33.s6	cells	106	110	O	cells	lls	ells	NNS	False
DDI-MedLine.d33.s6	to	112	113	O	to	to	to	TO	False
DDI-MedLine.d33.s6	topo	115	118	O	topo	opo	topo	NN	False
DDI-MedLine.d33.s6	drugs	120	124	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d33.s6	in	126	127	O	in	in	in	IN	False
DDI-MedLine.d33.s6	particular	129	138	O	particular	lar	ular	JJ	False
DDI-MedLine.d33.s6	and	140	142	O	and	and	and	CC	False
DDI-MedLine.d33.s6	DNA-damaging	144	155	O	DNA-damaging	ing	ging	NN	False
DDI-MedLine.d33.s6	agents	157	162	O	agents	nts	ents	NNS	False
DDI-MedLine.d33.s6	in	164	165	O	in	in	in	IN	False
DDI-MedLine.d33.s6	general	167	173	O	general	ral	eral	JJ	False
DDI-MedLine.d33.s6	are	175	177	O	are	are	are	VBP	False
DDI-MedLine.d33.s6	little	179	184	O	little	tle	ttle	JJ	False
DDI-MedLine.d33.s6	known	186	190	O	known	own	nown	VBN	False
DDI-MedLine.d33.s6	.	191	191	O	.	.	.	.	False

DDI-MedLine.d33.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d33.s7	goal	4	7	O	goal	oal	goal	NN	False
DDI-MedLine.d33.s7	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d33.s7	enhancing	12	20	O	enhancing	ing	cing	VBG	False
DDI-MedLine.d33.s7	selective	22	30	O	selective	ive	tive	NN	False
DDI-MedLine.d33.s7	tumor	32	36	O	tumor	mor	umor	NN	False
DDI-MedLine.d33.s7	cell	38	41	O	cell	ell	cell	NN	False
DDI-MedLine.d33.s7	killing	43	49	O	killing	ing	ling	VBG	False
DDI-MedLine.d33.s7	relative	51	58	O	relative	ive	tive	NN	False
DDI-MedLine.d33.s7	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d33.s7	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d33.s7	normal	67	72	O	normal	mal	rmal	JJ	False
DDI-MedLine.d33.s7	cells	74	78	O	cells	lls	ells	NNS	False
DDI-MedLine.d33.s7	that	80	83	O	that	hat	that	IN	False
DDI-MedLine.d33.s7	are	85	87	O	are	are	are	VBP	False
DDI-MedLine.d33.s7	dose	89	92	O	dose	ose	dose	NN	False
DDI-MedLine.d33.s7	limiting	94	101	O	limiting	ing	ting	VBG	False
DDI-MedLine.d33.s7	may	103	105	O	may	may	may	MD	False
DDI-MedLine.d33.s7	be	107	108	O	be	be	be	VB	False
DDI-MedLine.d33.s7	achieved	110	117	O	achieved	ved	eved	VBN	False
DDI-MedLine.d33.s7	either	119	124	O	either	her	ther	DT	False
DDI-MedLine.d33.s7	by	126	127	O	by	by	by	IN	False
DDI-MedLine.d33.s7	overcoming	129	138	O	overcoming	ing	ming	VBG	False
DDI-MedLine.d33.s7	tumor	140	144	O	tumor	mor	umor	NN	False
DDI-MedLine.d33.s7	cell	146	149	O	cell	ell	cell	NN	False
DDI-MedLine.d33.s7	resistance	151	160	O	resistance	nce	ance	NN	False
DDI-MedLine.d33.s7	or	162	163	O	or	or	or	CC	False
DDI-MedLine.d33.s7	by	165	166	O	by	by	by	IN	False
DDI-MedLine.d33.s7	protecting	168	177	O	protecting	ing	ting	VBG	False
DDI-MedLine.d33.s7	normal	179	184	O	normal	mal	rmal	JJ	False
DDI-MedLine.d33.s7	cells	186	190	O	cells	lls	ells	NNS	False
DDI-MedLine.d33.s7	.	191	191	O	.	.	.	.	False

DDI-MedLine.d33.s8	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d33.s8	of	5	6	O	of	of	of	IN	False
DDI-MedLine.d33.s8	these	8	12	O	these	ese	hese	DT	False
DDI-MedLine.d33.s8	strategies	14	23	O	strategies	ies	gies	NNS	False
DDI-MedLine.d33.s8	will	25	28	O	will	ill	will	MD	False
DDI-MedLine.d33.s8	become	30	35	O	become	ome	come	NN	False
DDI-MedLine.d33.s8	more	37	40	O	more	ore	more	RBR	False
DDI-MedLine.d33.s8	feasible	42	49	O	feasible	ble	ible	JJ	False
DDI-MedLine.d33.s8	as	51	52	O	as	as	as	IN	False
DDI-MedLine.d33.s8	specific	54	61	O	specific	fic	ific	JJ	False
DDI-MedLine.d33.s8	molecular	63	71	O	molecular	lar	ular	NN	False
DDI-MedLine.d33.s8	differences	73	83	O	differences	ces	nces	NNS	False
DDI-MedLine.d33.s8	between	85	91	O	between	een	ween	IN	False
DDI-MedLine.d33.s8	tumor	93	97	O	tumor	mor	umor	NN	False
DDI-MedLine.d33.s8	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d33.s8	normal	103	108	O	normal	mal	rmal	JJ	False
DDI-MedLine.d33.s8	cells	110	114	O	cells	lls	ells	NNS	False
DDI-MedLine.d33.s8	are	116	118	O	are	are	are	VBP	False
DDI-MedLine.d33.s8	being	120	124	O	being	ing	eing	VBG	False
DDI-MedLine.d33.s8	rapidly	126	132	O	rapidly	dly	idly	RB	False
DDI-MedLine.d33.s8	identified	134	143	O	identified	ied	fied	VBN	False
DDI-MedLine.d33.s8	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d33.s8	new	149	151	O	new	new	new	JJ	False
DDI-MedLine.d33.s8	combination	153	163	O	combination	ion	tion	NN	False
DDI-MedLine.d33.s8	therapies	165	173	O	therapies	ies	pies	NNS	False
DDI-MedLine.d33.s8	that	175	178	O	that	hat	that	IN	False
DDI-MedLine.d33.s8	take	180	183	O	take	ake	take	VB	False
DDI-MedLine.d33.s8	advantage	185	193	O	advantage	age	tage	NN	False
DDI-MedLine.d33.s8	of	195	196	O	of	of	of	IN	False
DDI-MedLine.d33.s8	these	198	202	O	these	ese	hese	DT	False
DDI-MedLine.d33.s8	differences	204	214	O	differences	ces	nces	NNS	False
DDI-MedLine.d33.s8	are	216	218	O	are	are	are	VBP	False
DDI-MedLine.d33.s8	being	220	224	O	being	ing	eing	VBG	False
DDI-MedLine.d33.s8	designed	226	233	O	designed	ned	gned	VBN	False
DDI-MedLine.d33.s8	and	235	237	O	and	and	and	CC	False
DDI-MedLine.d33.s8	tested	239	244	O	tested	ted	sted	VBN	False
DDI-MedLine.d33.s8	.	245	245	O	.	.	.	.	False

DDI-MedLine.d38.s0	Acute	0	4	O	Acute	ute	cute	NN	False
DDI-MedLine.d38.s0	hydrocortisone	6	19	B-drug	hydrocortisone	one	sone	NN	False
DDI-MedLine.d38.s0	administration	21	34	O	administration	ion	tion	NN	False
DDI-MedLine.d38.s0	does	36	39	O	does	oes	does	VBZ	False
DDI-MedLine.d38.s0	not	41	43	O	not	not	not	RB	False
DDI-MedLine.d38.s0	affect	45	50	O	affect	ect	fect	NN	False
DDI-MedLine.d38.s0	subjective	52	61	O	subjective	ive	tive	NN	False
DDI-MedLine.d38.s0	responses	63	71	O	responses	ses	nses	NNS	False
DDI-MedLine.d38.s0	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d38.s0	d-amphetamine	76	88	B-drug	d-amphetamine	ine	mine	NN	drug
DDI-MedLine.d38.s0	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d38.s0	humans	93	98	O	humans	ans	mans	NNS	False
DDI-MedLine.d38.s0	.	99	99	O	.	.	.	.	False

DDI-MedLine.d38.s1	RATIONALE	0	8	O	RATIONALE	ALE	NALE	NN	brand
DDI-MedLine.d38.s1	:	9	9	O	:	:	:	:	False
DDI-MedLine.d38.s1	Stress	11	16	O	Stress	ess	ress	NN	False
DDI-MedLine.d38.s1	and	18	20	O	and	and	and	CC	False
DDI-MedLine.d38.s1	glucocorticoids	22	36	B-group	glucocorticoids	ids	oids	NNS	False
DDI-MedLine.d38.s1	facilitate	38	47	O	facilitate	ate	tate	NN	False
DDI-MedLine.d38.s1	and	49	51	O	and	and	and	CC	False
DDI-MedLine.d38.s1	reinstate	53	61	O	reinstate	ate	tate	NN	False
DDI-MedLine.d38.s1	psychostimulant	63	77	O	psychostimulant	ant	lant	NN	False
DDI-MedLine.d38.s1	self-administration	79	97	O	self-administration	ion	tion	NN	False
DDI-MedLine.d38.s1	in	99	100	O	in	in	in	IN	False
DDI-MedLine.d38.s1	rodents	102	108	O	rodents	nts	ents	NNS	False
DDI-MedLine.d38.s1	.	109	109	O	.	.	.	.	False

DDI-MedLine.d38.s2	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d38.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d38.s2	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d38.s2	effects	13	19	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s2	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d38.s2	stress	24	29	O	stress	ess	ress	NN	False
DDI-MedLine.d38.s2	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d38.s2	glucocorticoids	35	49	B-group	glucocorticoids	ids	oids	NNS	False
DDI-MedLine.d38.s2	on	51	52	O	on	on	on	IN	False
DDI-MedLine.d38.s2	the	54	56	O	the	the	the	DT	False
DDI-MedLine.d38.s2	subjective	58	67	O	subjective	ive	tive	NN	False
DDI-MedLine.d38.s2	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d38.s2	behavioral	73	82	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d38.s2	effects	84	90	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s2	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d38.s2	psychostimulants	95	110	B-group	psychostimulants	nts	ants	NNS	False
DDI-MedLine.d38.s2	have	112	115	O	have	ave	have	VB	False
DDI-MedLine.d38.s2	not	117	119	O	not	not	not	RB	False
DDI-MedLine.d38.s2	been	121	124	O	been	een	been	VBN	False
DDI-MedLine.d38.s2	well	126	129	O	well	ell	well	RB	False
DDI-MedLine.d38.s2	studied	131	137	O	studied	ied	died	VBN	False
DDI-MedLine.d38.s2	in	139	140	O	in	in	in	IN	False
DDI-MedLine.d38.s2	humans	142	147	O	humans	ans	mans	NNS	False
DDI-MedLine.d38.s2	.	148	148	O	.	.	.	.	False

DDI-MedLine.d38.s3	OBJECTIVES	0	9	O	OBJECTIVES	VES	IVES	NN	brand
DDI-MedLine.d38.s3	:	10	10	O	:	:	:	:	False
DDI-MedLine.d38.s3	To	12	13	O	To	To	To	TO	False
DDI-MedLine.d38.s3	examine	15	21	O	examine	ine	mine	NN	drug
DDI-MedLine.d38.s3	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d38.s3	effects	27	33	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s3	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d38.s3	acute	38	42	O	acute	ute	cute	NN	False
DDI-MedLine.d38.s3	hydrocortisone	44	57	B-drug	hydrocortisone	one	sone	NN	False
DDI-MedLine.d38.s3	pretreatment	59	70	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d38.s3	on	72	73	O	on	on	on	IN	False
DDI-MedLine.d38.s3	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d38.s3	subjective	79	88	O	subjective	ive	tive	NN	False
DDI-MedLine.d38.s3	and	90	92	O	and	and	and	CC	False
DDI-MedLine.d38.s3	behavioral	94	103	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d38.s3	effects	105	111	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s3	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d38.s3	d-amphetamine	116	128	B-drug	d-amphetamine	ine	mine	NN	drug
DDI-MedLine.d38.s3	.	129	129	O	.	.	.	.	False

DDI-MedLine.d38.s4	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d38.s4	:	7	7	O	:	:	:	:	False
DDI-MedLine.d38.s4	Hydrocortisone	9	22	B-drug	Hydrocortisone	one	sone	NN	False
DDI-MedLine.d38.s4	(	24	24	O	(	(	(	(	False
DDI-MedLine.d38.s4	100	25	27	O	100	100	100	CD	False
DDI-MedLine.d38.s4	mg	29	30	O	mg	mg	mg	NN	False
DDI-MedLine.d38.s4	)	31	31	O	)	)	)	)	False
DDI-MedLine.d38.s4	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d38.s4	d-amphetamine	37	49	B-drug	d-amphetamine	ine	mine	NN	drug
DDI-MedLine.d38.s4	(	51	51	O	(	(	(	(	False
DDI-MedLine.d38.s4	20	52	53	O	20	20	20	CD	False
DDI-MedLine.d38.s4	mg	55	56	O	mg	mg	mg	NN	False
DDI-MedLine.d38.s4	)	57	57	O	)	)	)	)	False
DDI-MedLine.d38.s4	were	59	62	O	were	ere	were	VBD	False
DDI-MedLine.d38.s4	administered	64	75	O	administered	red	ered	VBN	False
DDI-MedLine.d38.s4	orally	77	82	O	orally	lly	ally	RB	False
DDI-MedLine.d38.s4	to	84	85	O	to	to	to	TO	False
DDI-MedLine.d38.s4	16	87	88	O	16	16	16	CD	False
DDI-MedLine.d38.s4	healthy	90	96	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d38.s4	male	98	101	O	male	ale	male	NN	False
DDI-MedLine.d38.s4	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d38.s4	female	107	112	O	female	ale	male	NN	False
DDI-MedLine.d38.s4	volunteers	114	123	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d38.s4	in	125	126	O	in	in	in	IN	False
DDI-MedLine.d38.s4	a	128	128	O	a	a	a	DT	False
DDI-MedLine.d38.s4	four-session	130	141	O	four-session	ion	sion	NN	False
DDI-MedLine.d38.s4	,	142	142	O	,	,	,	,	False
DDI-MedLine.d38.s4	placebo-controlled	144	161	O	placebo-controlled	led	lled	JJ	False
DDI-MedLine.d38.s4	,	162	162	O	,	,	,	,	False
DDI-MedLine.d38.s4	within-subject	164	177	O	within-subject	ect	ject	NN	False
DDI-MedLine.d38.s4	,	178	178	O	,	,	,	,	False
DDI-MedLine.d38.s4	crossover	180	188	O	crossover	ver	over	NN	False
DDI-MedLine.d38.s4	design	190	195	O	design	ign	sign	NN	False
DDI-MedLine.d38.s4	.	196	196	O	.	.	.	.	False

DDI-MedLine.d38.s5	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d38.s5	prevent	3	9	O	prevent	ent	vent	NN	False
DDI-MedLine.d38.s5	stomach	11	17	O	stomach	ach	mach	NN	False
DDI-MedLine.d38.s5	irritation	19	28	O	irritation	ion	tion	NN	False
DDI-MedLine.d38.s5	,	29	29	O	,	,	,	,	False
DDI-MedLine.d38.s5	subjects	31	38	O	subjects	cts	ects	NNS	False
DDI-MedLine.d38.s5	received	40	47	O	received	ved	ived	VBN	False
DDI-MedLine.d38.s5	rantidine	49	57	B-drug	rantidine	ine	dine	NN	drug
DDI-MedLine.d38.s5	hydrochloride	59	71	I-drug	hydrochloride	ide	ride	NN	False
DDI-MedLine.d38.s5	before	73	78	O	before	ore	fore	IN	False
DDI-MedLine.d38.s5	each	80	83	O	each	ach	each	DT	False
DDI-MedLine.d38.s5	experimental	85	96	O	experimental	tal	ntal	NN	False
DDI-MedLine.d38.s5	session	98	104	O	session	ion	sion	NN	False
DDI-MedLine.d38.s5	.	105	105	O	.	.	.	.	False

DDI-MedLine.d38.s6	Dependent	0	8	O	Dependent	ent	dent	NN	False
DDI-MedLine.d38.s6	measures	10	17	O	measures	res	ures	NNS	False
DDI-MedLine.d38.s6	included	19	26	O	included	ded	uded	VBD	False
DDI-MedLine.d38.s6	self-reported	28	40	O	self-reported	ted	rted	JJ	False
DDI-MedLine.d38.s6	mood	42	45	O	mood	ood	mood	NN	False
DDI-MedLine.d38.s6	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d38.s6	subjective	51	60	O	subjective	ive	tive	NN	False
DDI-MedLine.d38.s6	effects	62	68	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s6	(	70	70	O	(	(	(	(	False
DDI-MedLine.d38.s6	Addiction	71	79	O	Addiction	ion	tion	NN	False
DDI-MedLine.d38.s6	Research	81	88	O	Research	rch	arch	NN	False
DDI-MedLine.d38.s6	Center	90	95	O	Center	ter	nter	NNP	False
DDI-MedLine.d38.s6	inventory	97	105	O	inventory	ory	tory	NN	False
DDI-MedLine.d38.s6	,	106	106	O	,	,	,	,	False
DDI-MedLine.d38.s6	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d38.s6	profile	112	118	O	profile	ile	file	NN	False
DDI-MedLine.d38.s6	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d38.s6	mood	123	126	O	mood	ood	mood	NN	False
DDI-MedLine.d38.s6	states	128	133	O	states	tes	ates	NNS	False
DDI-MedLine.d38.s6	,	134	134	O	,	,	,	,	False
DDI-MedLine.d38.s6	and	136	138	O	and	and	and	CC	False
DDI-MedLine.d38.s6	a	140	140	O	a	a	a	DT	False
DDI-MedLine.d38.s6	series	142	147	O	series	ies	ries	NN	False
DDI-MedLine.d38.s6	of	149	150	O	of	of	of	IN	False
DDI-MedLine.d38.s6	visual	152	157	O	visual	ual	sual	JJ	False
DDI-MedLine.d38.s6	analogue	159	166	O	analogue	gue	ogue	NN	False
DDI-MedLine.d38.s6	scales	168	173	O	scales	les	ales	NNS	False
DDI-MedLine.d38.s6	)	174	174	O	)	)	)	)	False
DDI-MedLine.d38.s6	,	175	175	O	,	,	,	,	False
DDI-MedLine.d38.s6	vital	177	181	O	vital	tal	ital	NN	False
DDI-MedLine.d38.s6	signs	183	187	O	signs	gns	igns	NNS	False
DDI-MedLine.d38.s6	,	188	188	O	,	,	,	,	False
DDI-MedLine.d38.s6	salivary	190	197	O	salivary	ary	vary	JJ	False
DDI-MedLine.d38.s6	cortisol	199	206	O	cortisol	sol	isol	NN	False
DDI-MedLine.d38.s6	,	207	207	O	,	,	,	,	False
DDI-MedLine.d38.s6	and	209	211	O	and	and	and	CC	False
DDI-MedLine.d38.s6	psychomotor	213	223	O	psychomotor	tor	otor	NN	False
DDI-MedLine.d38.s6	performance	225	235	O	performance	nce	ance	NN	False
DDI-MedLine.d38.s6	.	236	236	O	.	.	.	.	False

DDI-MedLine.d38.s7	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d38.s7	:	7	7	O	:	:	:	:	False
DDI-MedLine.d38.s7	Hydrocortisone	9	22	B-drug	Hydrocortisone	one	sone	NN	False
DDI-MedLine.d38.s7	elevated	24	31	O	elevated	ted	ated	VBN	False
DDI-MedLine.d38.s7	salivary	33	40	O	salivary	ary	vary	JJ	False
DDI-MedLine.d38.s7	cortisol	42	49	O	cortisol	sol	isol	NN	False
DDI-MedLine.d38.s7	levels	51	56	O	levels	els	vels	NNS	False
DDI-MedLine.d38.s7	,	57	57	O	,	,	,	,	False
DDI-MedLine.d38.s7	produced	59	66	O	produced	ced	uced	VBN	False
DDI-MedLine.d38.s7	modest	68	73	O	modest	est	dest	JJ	False
DDI-MedLine.d38.s7	dysphoria	75	83	O	dysphoria	ria	oria	NNS	False
DDI-MedLine.d38.s7	,	84	84	O	,	,	,	,	False
DDI-MedLine.d38.s7	and	86	88	O	and	and	and	CC	False
DDI-MedLine.d38.s7	reduced	90	96	O	reduced	ced	uced	VBN	False
DDI-MedLine.d38.s7	subjects	98	105	O	subjects	cts	ects	NNS	False
DDI-MedLine.d38.s7	'	106	106	O	'	'	'	''	False
DDI-MedLine.d38.s7	reports	108	114	O	reports	rts	orts	NNS	False
DDI-MedLine.d38.s7	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d38.s7	wanting	119	125	O	wanting	ing	ting	VBG	False
DDI-MedLine.d38.s7	more	127	130	O	more	ore	more	RBR	False
DDI-MedLine.d38.s7	drug	132	135	O	drug	rug	drug	NN	False
DDI-MedLine.d38.s7	.	136	136	O	.	.	.	.	False

DDI-MedLine.d38.s8	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d38.s8	,	7	7	O	,	,	,	,	False
DDI-MedLine.d38.s8	hydrocortisone	9	22	B-drug	hydrocortisone	one	sone	NN	False
DDI-MedLine.d38.s8	pretreatment	24	35	O	pretreatment	ent	ment	NN	False
DDI-MedLine.d38.s8	did	37	39	O	did	did	did	VBD	False
DDI-MedLine.d38.s8	not	41	43	O	not	not	not	RB	False
DDI-MedLine.d38.s8	affect	45	50	O	affect	ect	fect	NN	False
DDI-MedLine.d38.s8	any	52	54	O	any	any	any	DT	False
DDI-MedLine.d38.s8	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d38.s8	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d38.s8	physiological	63	75	O	physiological	cal	ical	JJ	False
DDI-MedLine.d38.s8	,	76	76	O	,	,	,	,	False
DDI-MedLine.d38.s8	behavioral	78	87	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d38.s8	,	88	88	O	,	,	,	,	False
DDI-MedLine.d38.s8	or	90	91	O	or	or	or	CC	False
DDI-MedLine.d38.s8	subjective	93	102	O	subjective	ive	tive	NN	False
DDI-MedLine.d38.s8	effects	104	110	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s8	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d38.s8	d-amphetamine	115	127	B-drug	d-amphetamine	ine	mine	NN	drug
DDI-MedLine.d38.s8	.	128	128	O	.	.	.	.	False

DDI-MedLine.d38.s9	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d38.s9	:	11	11	O	:	:	:	:	False
DDI-MedLine.d38.s9	In	13	14	O	In	In	In	IN	False
DDI-MedLine.d38.s9	contrast	16	23	O	contrast	ast	rast	NN	False
DDI-MedLine.d38.s9	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d38.s9	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d38.s9	effects	32	38	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s9	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d38.s9	glucocorticoids	43	57	B-group	glucocorticoids	ids	oids	NNS	False
DDI-MedLine.d38.s9	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d38.s9	rodent	62	67	O	rodent	ent	dent	NN	False
DDI-MedLine.d38.s9	studies	69	75	O	studies	ies	dies	NNS	False
DDI-MedLine.d38.s9	,	76	76	O	,	,	,	,	False
DDI-MedLine.d38.s9	these	78	82	O	these	ese	hese	DT	False
DDI-MedLine.d38.s9	results	84	90	O	results	lts	ults	NNS	False
DDI-MedLine.d38.s9	indicate	92	99	O	indicate	ate	cate	NN	False
DDI-MedLine.d38.s9	that	101	104	O	that	hat	that	IN	False
DDI-MedLine.d38.s9	an	106	107	O	an	an	an	DT	False
DDI-MedLine.d38.s9	acute	109	113	O	acute	ute	cute	NN	False
DDI-MedLine.d38.s9	increase	115	122	O	increase	ase	ease	NN	False
DDI-MedLine.d38.s9	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d38.s9	cortisol	127	134	O	cortisol	sol	isol	NN	False
DDI-MedLine.d38.s9	does	136	139	O	does	oes	does	VBZ	False
DDI-MedLine.d38.s9	not	141	143	O	not	not	not	RB	False
DDI-MedLine.d38.s9	enhance	145	151	O	enhance	nce	ance	NN	False
DDI-MedLine.d38.s9	the	153	155	O	the	the	the	DT	False
DDI-MedLine.d38.s9	psychostimulant	157	171	O	psychostimulant	ant	lant	NN	False
DDI-MedLine.d38.s9	effects	173	179	O	effects	cts	ects	NNS	False
DDI-MedLine.d38.s9	of	181	182	O	of	of	of	IN	False
DDI-MedLine.d38.s9	d-amphetamine	184	196	B-drug	d-amphetamine	ine	mine	NN	drug
DDI-MedLine.d38.s9	in	198	199	O	in	in	in	IN	False
DDI-MedLine.d38.s9	humans	201	206	O	humans	ans	mans	NNS	False
DDI-MedLine.d38.s9	.	207	207	O	.	.	.	.	False

DDI-MedLine.d107.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d107.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d107.s0	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d107.s0	constituents	19	30	O	constituents	nts	ents	NNS	False
DDI-MedLine.d107.s0	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d107.s0	alcoholic	35	43	O	alcoholic	lic	olic	JJ	False
DDI-MedLine.d107.s0	beverages	45	53	O	beverages	ges	ages	NNS	False
DDI-MedLine.d107.s0	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d107.s0	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d107.s0	promotion	62	70	O	promotion	ion	tion	NN	False
DDI-MedLine.d107.s0	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d107.s0	liver	75	79	O	liver	ver	iver	NN	False
DDI-MedLine.d107.s0	damage	81	86	O	damage	age	mage	NN	False
DDI-MedLine.d107.s0	.	87	87	O	.	.	.	.	False

DDI-MedLine.d107.s1	Little	0	5	O	Little	tle	ttle	JJ	False
DDI-MedLine.d107.s1	has	7	9	O	has	has	has	VBZ	False
DDI-MedLine.d107.s1	been	11	14	O	been	een	been	VBN	False
DDI-MedLine.d107.s1	studied	16	22	O	studied	ied	died	VBN	False
DDI-MedLine.d107.s1	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d107.s1	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d107.s1	adverse	31	37	O	adverse	rse	erse	NN	False
DDI-MedLine.d107.s1	effects	39	45	O	effects	cts	ects	NNS	False
DDI-MedLine.d107.s1	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d107.s1	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d107.s1	exposure	54	61	O	exposure	ure	sure	NN	False
DDI-MedLine.d107.s1	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d107.s1	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d107.s1	liver	70	74	O	liver	ver	iver	NN	False
DDI-MedLine.d107.s1	to	76	77	O	to	to	to	TO	False
DDI-MedLine.d107.s1	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d107.s1	interaction	83	93	O	interaction	ion	tion	NN	False
DDI-MedLine.d107.s1	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d107.s1	ethanol	98	104	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d107.s1	with	106	109	O	with	ith	with	IN	False
DDI-MedLine.d107.s1	its	111	113	O	its	its	its	PRP$	False
DDI-MedLine.d107.s1	congeners	115	123	O	congeners	ers	ners	NNS	False
DDI-MedLine.d107.s1	and	125	127	O	and	and	and	CC	False
DDI-MedLine.d107.s1	acetaldehyde	129	140	B-drug_n	acetaldehyde	yde	hyde	NN	False
DDI-MedLine.d107.s1	,	141	141	O	,	,	,	,	False
DDI-MedLine.d107.s1	coexisting	143	152	O	coexisting	ing	ting	VBG	False
DDI-MedLine.d107.s1	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d107.s1	the	157	159	O	the	the	the	DT	False
DDI-MedLine.d107.s1	contents	161	168	O	contents	nts	ents	NNS	False
DDI-MedLine.d107.s1	of	170	171	O	of	of	of	IN	False
DDI-MedLine.d107.s1	alcoholic	173	181	O	alcoholic	lic	olic	JJ	False
DDI-MedLine.d107.s1	beverages	183	191	O	beverages	ges	ages	NNS	False
DDI-MedLine.d107.s1	.	192	192	O	.	.	.	.	False

DDI-MedLine.d107.s2	Twenty	0	5	O	Twenty	nty	enty	NN	False
DDI-MedLine.d107.s2	four	7	10	O	four	our	four	CD	False
DDI-MedLine.d107.s2	male	12	15	O	male	ale	male	NN	False
DDI-MedLine.d107.s2	Wistar	17	22	O	Wistar	tar	star	NN	False
DDI-MedLine.d107.s2	rats	24	27	O	rats	ats	rats	NNS	False
DDI-MedLine.d107.s2	were	29	32	O	were	ere	were	VBD	False
DDI-MedLine.d107.s2	divided	34	40	O	divided	ded	ided	VBN	False
DDI-MedLine.d107.s2	into	42	45	O	into	nto	into	IN	False
DDI-MedLine.d107.s2	four	47	50	O	four	our	four	CD	False
DDI-MedLine.d107.s2	groups	52	57	O	groups	ups	oups	NNS	False
DDI-MedLine.d107.s2	.	58	58	O	.	.	.	.	False

DDI-MedLine.d107.s3	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d107.s3	groups	4	9	O	groups	ups	oups	NNS	False
DDI-MedLine.d107.s3	(	11	11	O	(	(	(	(	False
DDI-MedLine.d107.s3	SH/DA	12	16	O	SH/DA	/DA	H/DA	NN	brand
DDI-MedLine.d107.s3	;	17	17	O	;	;	;	:	False
DDI-MedLine.d107.s3	SH/FA	19	23	O	SH/FA	/FA	H/FA	NN	brand
DDI-MedLine.d107.s3	)	24	24	O	)	)	)	)	False
DDI-MedLine.d107.s3	were	26	29	O	were	ere	were	VBD	False
DDI-MedLine.d107.s3	submitted	31	39	O	submitted	ted	tted	VBN	False
DDI-MedLine.d107.s3	to	41	42	O	to	to	to	TO	False
DDI-MedLine.d107.s3	daily	44	48	O	daily	ily	aily	JJ	False
DDI-MedLine.d107.s3	treatment	50	58	O	treatment	ent	ment	NN	False
DDI-MedLine.d107.s3	with	60	63	O	with	ith	with	IN	False
DDI-MedLine.d107.s3	synthetic	65	73	O	synthetic	tic	etic	JJ	False
DDI-MedLine.d107.s3	hydroalcoholic	75	88	O	hydroalcoholic	lic	olic	NN	False
DDI-MedLine.d107.s3	solutions	90	98	O	solutions	ons	ions	NNS	False
DDI-MedLine.d107.s3	containing	100	109	O	containing	ing	ning	VBG	False
DDI-MedLine.d107.s3	ethanol	111	117	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d107.s3	,	118	118	O	,	,	,	,	False
DDI-MedLine.d107.s3	methanol	120	127	B-drug_n	methanol	nol	anol	NN	False
DDI-MedLine.d107.s3	,	128	128	O	,	,	,	,	False
DDI-MedLine.d107.s3	higher	130	135	O	higher	her	gher	JJR	False
DDI-MedLine.d107.s3	alcohols	137	144	B-drug_n	alcohols	ols	hols	NNS	False
DDI-MedLine.d107.s3	and	146	148	O	and	and	and	CC	False
DDI-MedLine.d107.s3	acetaldehyde	150	161	B-drug_n	acetaldehyde	yde	hyde	NN	False
DDI-MedLine.d107.s3	in	163	164	O	in	in	in	IN	False
DDI-MedLine.d107.s3	the	166	168	O	the	the	the	DT	False
DDI-MedLine.d107.s3	same	170	173	O	same	ame	same	JJ	False
DDI-MedLine.d107.s3	proportions	175	185	O	proportions	ons	ions	NNS	False
DDI-MedLine.d107.s3	as	187	188	O	as	as	as	IN	False
DDI-MedLine.d107.s3	those	190	194	O	those	ose	hose	DT	False
DDI-MedLine.d107.s3	found	196	200	O	found	und	ound	NN	False
DDI-MedLine.d107.s3	in	202	203	O	in	in	in	IN	False
DDI-MedLine.d107.s3	most	205	208	O	most	ost	most	JJS	False
DDI-MedLine.d107.s3	common	210	215	O	common	mon	mmon	JJ	False
DDI-MedLine.d107.s3	distilled	217	225	O	distilled	led	lled	VBN	False
DDI-MedLine.d107.s3	and	227	229	O	and	and	and	CC	False
DDI-MedLine.d107.s3	fermented	231	239	O	fermented	ted	nted	VBN	False
DDI-MedLine.d107.s3	alcoholic	241	249	O	alcoholic	lic	olic	JJ	False
DDI-MedLine.d107.s3	beverages	251	259	O	beverages	ges	ages	NNS	False
DDI-MedLine.d107.s3	;	260	260	O	;	;	;	:	False

DDI-MedLine.d107.s4	the	0	2	O	the	the	the	DT	False
DDI-MedLine.d107.s4	third	4	8	O	third	ird	hird	JJ	False
DDI-MedLine.d107.s4	group	10	14	O	group	oup	roup	NN	False
DDI-MedLine.d107.s4	(	16	16	O	(	(	(	(	False
DDI-MedLine.d107.s4	SH/EA	17	21	O	SH/EA	/EA	H/EA	NN	brand
DDI-MedLine.d107.s4	)	22	22	O	)	)	)	)	False
DDI-MedLine.d107.s4	was	24	26	O	was	was	was	VBD	False
DDI-MedLine.d107.s4	treated	28	34	O	treated	ted	ated	VBN	False
DDI-MedLine.d107.s4	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d107.s4	a	41	41	O	a	a	a	DT	False
DDI-MedLine.d107.s4	hydroalcoholic	43	56	O	hydroalcoholic	lic	olic	NN	False
DDI-MedLine.d107.s4	solution	58	65	O	solution	ion	tion	NN	False
DDI-MedLine.d107.s4	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d107.s4	ethanol	70	76	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d107.s4	;	77	77	O	;	;	;	:	False

DDI-MedLine.d107.s5	the	0	2	O	the	the	the	DT	False
DDI-MedLine.d107.s5	fourth	4	9	O	fourth	rth	urth	JJ	False
DDI-MedLine.d107.s5	group	11	15	O	group	oup	roup	NN	False
DDI-MedLine.d107.s5	served	17	22	O	served	ved	rved	VBD	False
DDI-MedLine.d107.s5	as	24	25	O	as	as	as	IN	False
DDI-MedLine.d107.s5	control	27	33	O	control	rol	trol	NN	False
DDI-MedLine.d107.s5	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d107.s5	received	39	46	O	received	ved	ived	VBN	False
DDI-MedLine.d107.s5	an	48	49	O	an	an	an	DT	False
DDI-MedLine.d107.s5	equivalent	51	60	O	equivalent	ent	lent	NN	False
DDI-MedLine.d107.s5	volume	62	67	O	volume	ume	lume	NN	False
DDI-MedLine.d107.s5	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d107.s5	an	72	73	O	an	an	an	DT	False
DDI-MedLine.d107.s5	isocaloric	75	84	O	isocaloric	ric	oric	NN	False
DDI-MedLine.d107.s5	solution	86	93	O	solution	ion	tion	NN	False
DDI-MedLine.d107.s5	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d107.s5	dextrose	98	105	B-drug	dextrose	ose	rose	NN	False
DDI-MedLine.d107.s5	.	106	106	O	.	.	.	.	False

DDI-MedLine.d107.s6	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d107.s6	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d107.s6	animals	8	14	O	animals	als	mals	NNS	False
DDI-MedLine.d107.s6	were	16	19	O	were	ere	were	VBD	False
DDI-MedLine.d107.s6	killed	21	26	O	killed	led	lled	VBN	False
DDI-MedLine.d107.s6	at	28	29	O	at	at	at	IN	False
DDI-MedLine.d107.s6	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d107.s6	end	35	37	O	end	end	end	NN	False
DDI-MedLine.d107.s6	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d107.s6	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d107.s6	9th	46	48	O	9th	9th	9th	CD	False
DDI-MedLine.d107.s6	week	50	53	O	week	eek	week	NN	False
DDI-MedLine.d107.s6	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d107.s6	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d107.s6	experiment	62	71	O	experiment	ent	ment	NN	False
DDI-MedLine.d107.s6	.	72	72	O	.	.	.	.	False

DDI-MedLine.d107.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d107.s7	ratio	4	8	O	ratio	tio	atio	NN	False
DDI-MedLine.d107.s7	between	10	16	O	between	een	ween	IN	False
DDI-MedLine.d107.s7	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d107.s7	liver	22	26	O	liver	ver	iver	NN	False
DDI-MedLine.d107.s7	weight	28	33	O	weight	ght	ight	NN	False
DDI-MedLine.d107.s7	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d107.s7	body	39	42	O	body	ody	body	NN	False
DDI-MedLine.d107.s7	weight	44	49	O	weight	ght	ight	NN	False
DDI-MedLine.d107.s7	was	51	53	O	was	was	was	VBD	False
DDI-MedLine.d107.s7	found	55	59	O	found	und	ound	NN	False
DDI-MedLine.d107.s7	to	61	62	O	to	to	to	TO	False
DDI-MedLine.d107.s7	be	64	65	O	be	be	be	VB	False
DDI-MedLine.d107.s7	lower	67	71	O	lower	wer	ower	JJR	False
DDI-MedLine.d107.s7	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d107.s7	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d107.s7	treated	80	86	O	treated	ted	ated	VBN	False
DDI-MedLine.d107.s7	animals	88	94	O	animals	als	mals	NNS	False
DDI-MedLine.d107.s7	than	96	99	O	than	han	than	IN	False
DDI-MedLine.d107.s7	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d107.s7	the	104	106	O	the	the	the	DT	False
DDI-MedLine.d107.s7	control	108	114	O	control	rol	trol	NN	False
DDI-MedLine.d107.s7	group	116	120	O	group	oup	roup	NN	False
DDI-MedLine.d107.s7	.	121	121	O	.	.	.	.	False

DDI-MedLine.d107.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d107.s8	histology	4	12	O	histology	ogy	logy	NN	False
DDI-MedLine.d107.s8	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d107.s8	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d107.s8	liver	21	25	O	liver	ver	iver	NN	False
DDI-MedLine.d107.s8	was	27	29	O	was	was	was	VBD	False
DDI-MedLine.d107.s8	altered	31	37	O	altered	red	ered	VBN	False
DDI-MedLine.d107.s8	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d107.s8	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d107.s8	three	46	50	O	three	ree	hree	CD	False
DDI-MedLine.d107.s8	groups	52	57	O	groups	ups	oups	NNS	False
DDI-MedLine.d107.s8	which	59	63	O	which	ich	hich	WDT	False
DDI-MedLine.d107.s8	were	65	68	O	were	ere	were	VBD	False
DDI-MedLine.d107.s8	submitted	70	78	O	submitted	ted	tted	VBN	False
DDI-MedLine.d107.s8	to	80	81	O	to	to	to	TO	False
DDI-MedLine.d107.s8	treatment	83	91	O	treatment	ent	ment	NN	False
DDI-MedLine.d107.s8	with	93	96	O	with	ith	with	IN	False
DDI-MedLine.d107.s8	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d107.s8	hydroalcoholic	102	115	O	hydroalcoholic	lic	olic	NN	False
DDI-MedLine.d107.s8	solutions	117	125	O	solutions	ons	ions	NNS	False
DDI-MedLine.d107.s8	,	126	126	O	,	,	,	,	False
DDI-MedLine.d107.s8	with	128	131	O	with	ith	with	IN	False
DDI-MedLine.d107.s8	quantitative	133	144	O	quantitative	ive	tive	NN	False
DDI-MedLine.d107.s8	and	146	148	O	and	and	and	CC	False
DDI-MedLine.d107.s8	qualitative	150	160	O	qualitative	ive	tive	NN	False
DDI-MedLine.d107.s8	differences	162	172	O	differences	ces	nces	NNS	False
DDI-MedLine.d107.s8	between	174	180	O	between	een	ween	IN	False
DDI-MedLine.d107.s8	the	182	184	O	the	the	the	DT	False
DDI-MedLine.d107.s8	groups	186	191	O	groups	ups	oups	NNS	False
DDI-MedLine.d107.s8	.	192	192	O	.	.	.	.	False

DDI-MedLine.d107.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d107.s9	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d107.s9	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d107.s9	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d107.s9	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d107.s9	hepatoxicity	31	42	O	hepatoxicity	ity	city	NN	False
DDI-MedLine.d107.s9	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d107.s9	ethanol	47	53	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d107.s9	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d107.s9	alcoholic	58	66	O	alcoholic	lic	olic	JJ	False
DDI-MedLine.d107.s9	beverages	68	76	O	beverages	ges	ages	NNS	False
DDI-MedLine.d107.s9	is	78	79	O	is	is	is	VBZ	False
DDI-MedLine.d107.s9	enhanced	81	88	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d107.s9	by	90	91	O	by	by	by	IN	False
DDI-MedLine.d107.s9	interaction	93	103	O	interaction	ion	tion	NN	False
DDI-MedLine.d107.s9	with	105	108	O	with	ith	with	IN	False
DDI-MedLine.d107.s9	its	110	112	O	its	its	its	PRP$	False
DDI-MedLine.d107.s9	congeners	114	122	O	congeners	ers	ners	NNS	False
DDI-MedLine.d107.s9	and	124	126	O	and	and	and	CC	False
DDI-MedLine.d107.s9	acetaldehyde	128	139	B-drug_n	acetaldehyde	yde	hyde	NN	False
DDI-MedLine.d107.s9	;	140	140	O	;	;	;	:	False

DDI-MedLine.d107.s10	they	0	3	O	they	hey	they	PRP	False
DDI-MedLine.d107.s10	also	5	8	O	also	lso	also	RB	False
DDI-MedLine.d107.s10	suggest	10	16	O	suggest	est	gest	NN	False
DDI-MedLine.d107.s10	that	18	21	O	that	hat	that	IN	False
DDI-MedLine.d107.s10	alcoholic	23	31	O	alcoholic	lic	olic	JJ	False
DDI-MedLine.d107.s10	beverages	33	41	O	beverages	ges	ages	NNS	False
DDI-MedLine.d107.s10	are	43	45	O	are	are	are	VBP	False
DDI-MedLine.d107.s10	not	47	49	O	not	not	not	RB	False
DDI-MedLine.d107.s10	equivalent	51	60	O	equivalent	ent	lent	NN	False
DDI-MedLine.d107.s10	in	62	63	O	in	in	in	IN	False
DDI-MedLine.d107.s10	their	65	69	O	their	eir	heir	PRP$	False
DDI-MedLine.d107.s10	potential	71	79	O	potential	ial	tial	JJ	False
DDI-MedLine.d107.s10	to	81	82	O	to	to	to	TO	False
DDI-MedLine.d107.s10	cause	84	88	O	cause	use	ause	NN	False
DDI-MedLine.d107.s10	liver	90	94	O	liver	ver	iver	NN	False
DDI-MedLine.d107.s10	damage	96	101	O	damage	age	mage	NN	False
DDI-MedLine.d107.s10	.	102	102	O	.	.	.	.	False

DDI-MedLine.d127.s0	Serum	0	4	O	Serum	rum	erum	NN	False
DDI-MedLine.d127.s0	digoxin	6	12	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d127.s0	levels	14	19	O	levels	els	vels	NNS	False
DDI-MedLine.d127.s0	using	21	25	O	using	ing	sing	VBG	False
DDI-MedLine.d127.s0	an	27	28	O	an	an	an	DT	False
DDI-MedLine.d127.s0	125I-labelled	30	42	O	125I-labelled	led	lled	JJ	False
DDI-MedLine.d127.s0	antigen	44	50	O	antigen	gen	igen	NN	brand
DDI-MedLine.d127.s0	:	51	51	O	:	:	:	:	False
DDI-MedLine.d127.s0	Validation	53	62	O	Validation	ion	tion	NN	False
DDI-MedLine.d127.s0	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d127.s0	method	67	72	O	method	hod	thod	NN	False
DDI-MedLine.d127.s0	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d127.s0	observations	78	89	O	observations	ons	ions	NNS	False
DDI-MedLine.d127.s0	on	91	92	O	on	on	on	IN	False
DDI-MedLine.d127.s0	cardiac	94	100	O	cardiac	iac	diac	NN	False
DDI-MedLine.d127.s0	patients	102	109	O	patients	nts	ents	NNS	False
DDI-MedLine.d127.s0	.	110	110	O	.	.	.	.	False

DDI-MedLine.d127.s1	1	0	0	O	1	1	1	CD	False
DDI-MedLine.d127.s1	.	1	1	O	.	.	.	.	False

DDI-MedLine.d127.s2	Determinations	0	13	O	Determinations	ons	ions	NNS	False
DDI-MedLine.d127.s2	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d127.s2	serum	18	22	O	serum	rum	erum	NN	False
DDI-MedLine.d127.s2	digoxin	24	30	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d127.s2	levels	32	37	O	levels	els	vels	NNS	False
DDI-MedLine.d127.s2	utilizing	39	47	O	utilizing	ing	zing	VBG	False
DDI-MedLine.d127.s2	commercially	49	60	O	commercially	lly	ally	RB	False
DDI-MedLine.d127.s2	available	62	70	O	available	ble	able	JJ	False
DDI-MedLine.d127.s2	kits	72	75	O	kits	its	kits	NNS	False
DDI-MedLine.d127.s2	with	77	80	O	with	ith	with	IN	False
DDI-MedLine.d127.s2	an	82	83	O	an	an	an	DT	False
DDI-MedLine.d127.s2	125I-labelled	85	97	O	125I-labelled	led	lled	JJ	False
DDI-MedLine.d127.s2	antigen	99	105	O	antigen	gen	igen	NN	brand
DDI-MedLine.d127.s2	were	107	110	O	were	ere	were	VBD	False
DDI-MedLine.d127.s2	precise	112	118	O	precise	ise	cise	NN	False
DDI-MedLine.d127.s2	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d127.s2	not	124	126	O	not	not	not	RB	False
DDI-MedLine.d127.s2	materially	128	137	O	materially	lly	ally	RB	False
DDI-MedLine.d127.s2	different	139	147	O	different	ent	rent	JJ	False
DDI-MedLine.d127.s2	from	149	152	O	from	rom	from	IN	False
DDI-MedLine.d127.s2	results	154	160	O	results	lts	ults	NNS	False
DDI-MedLine.d127.s2	obtained	162	169	O	obtained	ned	ined	VBN	False
DDI-MedLine.d127.s2	with	171	174	O	with	ith	with	IN	False
DDI-MedLine.d127.s2	a	176	176	O	a	a	a	DT	False
DDI-MedLine.d127.s2	3H-labelled	178	188	O	3H-labelled	led	lled	JJ	False
DDI-MedLine.d127.s2	antigen	190	196	O	antigen	gen	igen	NN	brand
DDI-MedLine.d127.s2	.	197	197	O	.	.	.	.	False

DDI-MedLine.d127.s3	2	0	0	O	2	2	2	CD	False
DDI-MedLine.d127.s3	.	1	1	O	.	.	.	.	False

DDI-MedLine.d127.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d127.s4	order	3	7	O	order	der	rder	NN	False
DDI-MedLine.d127.s4	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d127.s4	approximate	12	22	O	approximate	ate	mate	NN	False
DDI-MedLine.d127.s4	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d127.s4	steady	28	33	O	steady	ady	eady	JJ	False
DDI-MedLine.d127.s4	state	35	39	O	state	ate	tate	NN	False
DDI-MedLine.d127.s4	level	41	45	O	level	vel	evel	NN	False
DDI-MedLine.d127.s4	,	46	46	O	,	,	,	,	False
DDI-MedLine.d127.s4	serum	48	52	O	serum	rum	erum	NN	False
DDI-MedLine.d127.s4	digoxin	54	60	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d127.s4	levels	62	67	O	levels	els	vels	NNS	False
DDI-MedLine.d127.s4	should	69	74	O	should	uld	ould	MD	False
DDI-MedLine.d127.s4	be	76	77	O	be	be	be	VB	False
DDI-MedLine.d127.s4	drawn	79	83	O	drawn	awn	rawn	NN	False
DDI-MedLine.d127.s4	either	85	90	O	either	her	ther	DT	False
DDI-MedLine.d127.s4	before	92	97	O	before	ore	fore	IN	False
DDI-MedLine.d127.s4	or	99	100	O	or	or	or	CC	False
DDI-MedLine.d127.s4	at	102	103	O	at	at	at	IN	False
DDI-MedLine.d127.s4	least	105	109	O	least	ast	east	JJS	False
DDI-MedLine.d127.s4	six	111	113	O	six	six	six	CD	False
DDI-MedLine.d127.s4	hours	115	119	O	hours	urs	ours	NNS	False
DDI-MedLine.d127.s4	following	121	129	O	following	ing	wing	VBG	False
DDI-MedLine.d127.s4	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d127.s4	administration	135	148	O	administration	ion	tion	NN	False
DDI-MedLine.d127.s4	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d127.s4	an	153	154	O	an	an	an	DT	False
DDI-MedLine.d127.s4	oral	156	159	O	oral	ral	oral	JJ	False
DDI-MedLine.d127.s4	tablet	161	166	O	tablet	let	blet	NN	False
DDI-MedLine.d127.s4	.	167	167	O	.	.	.	.	False

DDI-MedLine.d127.s5	3	0	0	O	3	3	3	CD	False
DDI-MedLine.d127.s5	.	1	1	O	.	.	.	.	False

DDI-MedLine.d127.s6	Concomitantly	0	12	O	Concomitantly	tly	ntly	RB	False
DDI-MedLine.d127.s6	given	14	18	O	given	ven	iven	VBN	False
DDI-MedLine.d127.s6	thiazide	20	27	B-group	thiazide	ide	zide	NN	False
DDI-MedLine.d127.s6	diuretics	29	37	I-group	diuretics	ics	tics	NNS	False
DDI-MedLine.d127.s6	did	39	41	O	did	did	did	VBD	False
DDI-MedLine.d127.s6	not	43	45	O	not	not	not	RB	False
DDI-MedLine.d127.s6	interfere	47	55	O	interfere	ere	fere	RB	False
DDI-MedLine.d127.s6	with	57	60	O	with	ith	with	IN	False
DDI-MedLine.d127.s6	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d127.s6	absorption	66	75	O	absorption	ion	tion	NN	False
DDI-MedLine.d127.s6	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d127.s6	a	80	80	O	a	a	a	DT	False
DDI-MedLine.d127.s6	tablet	82	87	O	tablet	let	blet	NN	False
DDI-MedLine.d127.s6	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d127.s6	digoxin	92	98	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d127.s6	.	99	99	O	.	.	.	.	False

DDI-MedLine.d127.s7	4	0	0	O	4	4	4	CD	False
DDI-MedLine.d127.s7	.	1	1	O	.	.	.	.	False

DDI-MedLine.d127.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d127.s8	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d127.s8	digitalized	7	17	O	digitalized	zed	ized	VBN	False
DDI-MedLine.d127.s8	patient	19	25	O	patient	ent	ient	NN	False
DDI-MedLine.d127.s8	,	26	26	O	,	,	,	,	False
DDI-MedLine.d127.s8	slow	28	31	O	slow	low	slow	VB	False
DDI-MedLine.d127.s8	alterations	33	43	O	alterations	ons	ions	NNS	False
DDI-MedLine.d127.s8	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d127.s8	serum	48	52	O	serum	rum	erum	NN	False
DDI-MedLine.d127.s8	levels	54	59	O	levels	els	vels	NNS	False
DDI-MedLine.d127.s8	after	61	65	O	after	ter	fter	IN	False
DDI-MedLine.d127.s8	oral	67	70	O	oral	ral	oral	JJ	False
DDI-MedLine.d127.s8	administration	72	85	O	administration	ion	tion	NN	False
DDI-MedLine.d127.s8	appeared	87	94	O	appeared	red	ared	VBD	False
DDI-MedLine.d127.s8	well	96	99	O	well	ell	well	RB	False
DDI-MedLine.d127.s8	correlated	101	110	O	correlated	ted	ated	VBN	False
DDI-MedLine.d127.s8	with	112	115	O	with	ith	with	IN	False
DDI-MedLine.d127.s8	,	116	116	O	,	,	,	,	False
DDI-MedLine.d127.s8	at	118	119	O	at	at	at	IN	False
DDI-MedLine.d127.s8	least	121	125	O	least	ast	east	JJS	False
DDI-MedLine.d127.s8	,	126	126	O	,	,	,	,	False
DDI-MedLine.d127.s8	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d127.s8	negative	132	139	O	negative	ive	tive	JJ	False
DDI-MedLine.d127.s8	chronotropic	141	152	O	chronotropic	pic	opic	NN	False
DDI-MedLine.d127.s8	effects	154	160	O	effects	cts	ects	NNS	False
DDI-MedLine.d127.s8	of	162	163	O	of	of	of	IN	False
DDI-MedLine.d127.s8	the	165	167	O	the	the	the	DT	False
DDI-MedLine.d127.s8	drug	169	172	O	drug	rug	drug	NN	False
DDI-MedLine.d127.s8	.	173	173	O	.	.	.	.	False

DDI-MedLine.d127.s9	5	0	0	O	5	5	5	CD	False
DDI-MedLine.d127.s9	.	1	1	O	.	.	.	.	False

DDI-MedLine.d127.s10	Maximal	0	6	O	Maximal	mal	imal	JJ	False
DDI-MedLine.d127.s10	exercise	8	15	O	exercise	ise	cise	NN	False
DDI-MedLine.d127.s10	testing	17	23	O	testing	ing	ting	VBG	False
DDI-MedLine.d127.s10	,	24	24	O	,	,	,	,	False
DDI-MedLine.d127.s10	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d127.s10	maneuver	28	35	O	maneuver	ver	uver	NN	False
DDI-MedLine.d127.s10	often	37	41	O	often	ten	ften	RB	False
DDI-MedLine.d127.s10	applied	43	49	O	applied	ied	lied	VBN	False
DDI-MedLine.d127.s10	to	51	52	O	to	to	to	TO	False
DDI-MedLine.d127.s10	cardiac	54	60	O	cardiac	iac	diac	NN	False
DDI-MedLine.d127.s10	patients	62	69	O	patients	nts	ents	NNS	False
DDI-MedLine.d127.s10	,	70	70	O	,	,	,	,	False
DDI-MedLine.d127.s10	does	72	75	O	does	oes	does	VBZ	False
DDI-MedLine.d127.s10	not	77	79	O	not	not	not	RB	False
DDI-MedLine.d127.s10	significantly	81	93	O	significantly	tly	ntly	RB	False
DDI-MedLine.d127.s10	alter	95	99	O	alter	ter	lter	NN	False
DDI-MedLine.d127.s10	the	101	103	O	the	the	the	DT	False
DDI-MedLine.d127.s10	serum	105	109	O	serum	rum	erum	NN	False
DDI-MedLine.d127.s10	digoxin	111	117	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d127.s10	level	119	123	O	level	vel	evel	NN	False
DDI-MedLine.d127.s10	.	124	124	O	.	.	.	.	False

DDI-MedLine.d82.s0	Intestinal	0	9	O	Intestinal	nal	inal	JJ	False
DDI-MedLine.d82.s0	absorption	11	20	O	absorption	ion	tion	NN	False
DDI-MedLine.d82.s0	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d82.s0	arsenate	25	32	B-drug_n	arsenate	ate	nate	NN	False
DDI-MedLine.d82.s0	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d82.s0	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d82.s0	chick	41	45	O	chick	ick	hick	NN	False
DDI-MedLine.d82.s0	.	46	46	O	.	.	.	.	False

DDI-MedLine.d82.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d82.s1	intestinal	4	13	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d82.s1	absorption	15	24	O	absorption	ion	tion	NN	False
DDI-MedLine.d82.s1	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d82.s1	arsenate	29	36	B-drug_n	arsenate	ate	nate	NN	False
DDI-MedLine.d82.s1	(	37	37	O	(	(	(	(	False
DDI-MedLine.d82.s1	As	38	39	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s1	(	40	40	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s1	V	41	41	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s1	)	42	42	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s1	)	43	43	O	)	)	)	)	False
DDI-MedLine.d82.s1	has	45	47	O	has	has	has	VBZ	False
DDI-MedLine.d82.s1	been	49	52	O	been	een	been	VBN	False
DDI-MedLine.d82.s1	investigated	54	65	O	investigated	ted	ated	VBN	False
DDI-MedLine.d82.s1	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d82.s1	the	70	72	O	the	the	the	DT	False
DDI-MedLine.d82.s1	chick	74	78	O	chick	ick	hick	NN	False
DDI-MedLine.d82.s1	by	80	81	O	by	by	by	IN	False
DDI-MedLine.d82.s1	means	83	87	O	means	ans	eans	NNS	False
DDI-MedLine.d82.s1	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d82.s1	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d82.s1	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d82.s1	situ	99	102	O	situ	itu	situ	NN	False
DDI-MedLine.d82.s1	ligated	104	110	O	ligated	ted	ated	VBN	False
DDI-MedLine.d82.s1	duodenal	112	119	O	duodenal	nal	enal	JJ	False
DDI-MedLine.d82.s1	loop	121	124	O	loop	oop	loop	NN	False
DDI-MedLine.d82.s1	technique	126	134	O	technique	que	ique	NN	False
DDI-MedLine.d82.s1	.	135	135	O	.	.	.	.	False

DDI-MedLine.d82.s2	By	0	1	O	By	By	By	IN	False
DDI-MedLine.d82.s2	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d82.s2	procedure	8	16	O	procedure	ure	dure	NN	False
DDI-MedLine.d82.s2	,	17	17	O	,	,	,	,	False
DDI-MedLine.d82.s2	it	19	20	O	it	it	it	PRP	False
DDI-MedLine.d82.s2	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d82.s2	observed	26	33	O	observed	ved	rved	VBN	False
DDI-MedLine.d82.s2	that	35	38	O	that	hat	that	IN	False
DDI-MedLine.d82.s2	arsenate	40	47	B-drug_n	arsenate	ate	nate	NN	False
DDI-MedLine.d82.s2	is	49	50	O	is	is	is	VBZ	False
DDI-MedLine.d82.s2	rapidly	52	58	O	rapidly	dly	idly	RB	False
DDI-MedLine.d82.s2	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d82.s2	essentially	64	74	O	essentially	lly	ally	RB	False
DDI-MedLine.d82.s2	completely	76	85	O	completely	ely	tely	RB	False
DDI-MedLine.d82.s2	absorbed	87	94	O	absorbed	bed	rbed	NNS	False
DDI-MedLine.d82.s2	(	96	96	O	(	(	(	(	False
DDI-MedLine.d82.s2	80-95	97	101	O	80-95	-95	0-95	JJ	False
DDI-MedLine.d82.s2	%	102	102	O	%	%	%	NN	False
DDI-MedLine.d82.s2	)	103	103	O	)	)	)	)	False
DDI-MedLine.d82.s2	from	105	108	O	from	rom	from	IN	False
DDI-MedLine.d82.s2	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d82.s2	lumen	114	118	O	lumen	men	umen	NNS	False
DDI-MedLine.d82.s2	at	120	121	O	at	at	at	IN	False
DDI-MedLine.d82.s2	As	123	124	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s2	(	125	125	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s2	V	126	126	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s2	)	127	127	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s2	concentrations	129	142	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d82.s2	up	144	145	O	up	up	up	RB	False
DDI-MedLine.d82.s2	to	147	148	O	to	to	to	TO	False
DDI-MedLine.d82.s2	5	150	150	O	5	5	5	CD	False
DDI-MedLine.d82.s2	mM	152	153	O	mM	mM	mM	NN	False
DDI-MedLine.d82.s2	,	154	154	O	,	,	,	,	False
DDI-MedLine.d82.s2	declining	156	164	O	declining	ing	ning	VBG	False
DDI-MedLine.d82.s2	to	166	167	O	to	to	to	TO	False
DDI-MedLine.d82.s2	about	169	173	O	about	out	bout	IN	False
DDI-MedLine.d82.s2	50	175	176	O	50	50	50	CD	False
DDI-MedLine.d82.s2	%	177	177	O	%	%	%	NN	False
DDI-MedLine.d82.s2	absorption	179	188	O	absorption	ion	tion	NN	False
DDI-MedLine.d82.s2	at	190	191	O	at	at	at	IN	False
DDI-MedLine.d82.s2	50	193	194	O	50	50	50	CD	False
DDI-MedLine.d82.s2	mM	196	197	O	mM	mM	mM	NN	False
DDI-MedLine.d82.s2	.	198	198	O	.	.	.	.	False

DDI-MedLine.d82.s3	Transfer	0	7	O	Transfer	fer	sfer	NN	False
DDI-MedLine.d82.s3	from	9	12	O	from	rom	from	IN	False
DDI-MedLine.d82.s3	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d82.s3	intestinal	18	27	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d82.s3	lumen	29	33	O	lumen	men	umen	NNS	False
DDI-MedLine.d82.s3	to	35	36	O	to	to	to	TO	False
DDI-MedLine.d82.s3	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d82.s3	mucosal	42	48	O	mucosal	sal	osal	NN	False
DDI-MedLine.d82.s3	cells	50	54	O	cells	lls	ells	NNS	False
DDI-MedLine.d82.s3	at	56	57	O	at	at	at	IN	False
DDI-MedLine.d82.s3	low	59	61	O	low	low	low	JJ	False
DDI-MedLine.d82.s3	As	63	64	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s3	(	65	65	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s3	V	66	66	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s3	)	67	67	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s3	concentration	69	81	O	concentration	ion	tion	NN	False
DDI-MedLine.d82.s3	(	83	83	O	(	(	(	(	False
DDI-MedLine.d82.s3	0.1	84	86	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d82.s3	mM	88	89	O	mM	mM	mM	NN	False
DDI-MedLine.d82.s3	)	90	90	O	)	)	)	)	False
DDI-MedLine.d82.s3	is	92	93	O	is	is	is	VBZ	False
DDI-MedLine.d82.s3	rapid	95	99	O	rapid	pid	apid	JJ	False
DDI-MedLine.d82.s3	,	100	100	O	,	,	,	,	False
DDI-MedLine.d82.s3	while	102	106	O	while	ile	hile	IN	False
DDI-MedLine.d82.s3	transfer	108	115	O	transfer	fer	sfer	NN	False
DDI-MedLine.d82.s3	from	117	120	O	from	rom	from	IN	False
DDI-MedLine.d82.s3	the	122	124	O	the	the	the	DT	False
DDI-MedLine.d82.s3	mucosal	126	132	O	mucosal	sal	osal	NN	False
DDI-MedLine.d82.s3	cells	134	138	O	cells	lls	ells	NNS	False
DDI-MedLine.d82.s3	to	140	141	O	to	to	to	TO	False
DDI-MedLine.d82.s3	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d82.s3	body	147	150	O	body	ody	body	NN	False
DDI-MedLine.d82.s3	occurs	152	157	O	occurs	urs	curs	NNS	False
DDI-MedLine.d82.s3	more	159	162	O	more	ore	more	RBR	False
DDI-MedLine.d82.s3	slowly	164	169	O	slowly	wly	owly	RB	False
DDI-MedLine.d82.s3	.	170	170	O	.	.	.	.	False

DDI-MedLine.d82.s4	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d82.s4	stable	3	8	O	stable	ble	able	JJ	False
DDI-MedLine.d82.s4	As	10	11	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s4	(	12	12	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s4	V	13	13	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s4	)	14	14	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s4	concentrations	16	29	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d82.s4	greater	31	37	O	greater	ter	ater	JJR	False
DDI-MedLine.d82.s4	than	39	42	O	than	han	than	IN	False
DDI-MedLine.d82.s4	1	44	44	O	1	1	1	CD	False
DDI-MedLine.d82.s4	mM	46	47	O	mM	mM	mM	NN	False
DDI-MedLine.d82.s4	,	48	48	O	,	,	,	,	False
DDI-MedLine.d82.s4	fractional	50	59	O	fractional	nal	onal	JJ	False
DDI-MedLine.d82.s4	mucosal	61	67	O	mucosal	sal	osal	NN	False
DDI-MedLine.d82.s4	cell	69	72	O	cell	ell	cell	NN	False
DDI-MedLine.d82.s4	accumulation	74	85	O	accumulation	ion	tion	NN	False
DDI-MedLine.d82.s4	of	87	88	O	of	of	of	IN	False
DDI-MedLine.d82.s4	As	90	91	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s4	(	92	92	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s4	V	93	93	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s4	)	94	94	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s4	remains	96	102	O	remains	ins	ains	NNS	False
DDI-MedLine.d82.s4	constant	104	111	O	constant	ant	tant	JJ	False
DDI-MedLine.d82.s4	,	112	112	O	,	,	,	,	False
DDI-MedLine.d82.s4	while	114	118	O	while	ile	hile	IN	False
DDI-MedLine.d82.s4	fractional	120	129	O	fractional	nal	onal	JJ	False
DDI-MedLine.d82.s4	transfer	131	138	O	transfer	fer	sfer	NN	False
DDI-MedLine.d82.s4	to	140	141	O	to	to	to	TO	False
DDI-MedLine.d82.s4	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d82.s4	body	147	150	O	body	ody	body	NN	False
DDI-MedLine.d82.s4	declines	152	159	O	declines	nes	ines	NNS	group
DDI-MedLine.d82.s4	.	160	160	O	.	.	.	.	False

DDI-MedLine.d82.s5	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d82.s5	,	7	7	O	,	,	,	,	False
DDI-MedLine.d82.s5	total	9	13	O	total	tal	otal	JJ	False
DDI-MedLine.d82.s5	mucosal	15	21	O	mucosal	sal	osal	NN	False
DDI-MedLine.d82.s5	accumulation	23	34	O	accumulation	ion	tion	NN	False
DDI-MedLine.d82.s5	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d82.s5	As	39	40	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s5	(	41	41	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s5	V	42	42	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s5	)	43	43	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s5	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d82.s5	that	49	52	O	that	hat	that	IN	False
DDI-MedLine.d82.s5	transferred	54	64	O	transferred	red	rred	VBN	False
DDI-MedLine.d82.s5	to	66	67	O	to	to	to	TO	False
DDI-MedLine.d82.s5	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d82.s5	body	73	76	O	body	ody	body	NN	False
DDI-MedLine.d82.s5	increase	78	85	O	increase	ase	ease	NN	False
DDI-MedLine.d82.s5	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d82.s5	a	90	90	O	a	a	a	DT	False
DDI-MedLine.d82.s5	linear	92	97	O	linear	ear	near	NN	False
DDI-MedLine.d82.s5	logarithmic	99	109	O	logarithmic	mic	hmic	JJ	False
DDI-MedLine.d82.s5	fashion	111	117	O	fashion	ion	hion	NN	False
DDI-MedLine.d82.s5	from	119	122	O	from	rom	from	IN	False
DDI-MedLine.d82.s5	0.05	124	127	O	0.05	.05	0.05	CD	False
DDI-MedLine.d82.s5	to	129	130	O	to	to	to	TO	False
DDI-MedLine.d82.s5	5	132	132	O	5	5	5	CD	False
DDI-MedLine.d82.s5	mm	134	135	O	mm	mm	mm	NN	False
DDI-MedLine.d82.s5	As	137	138	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s5	(	139	139	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s5	V	140	140	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s5	)	141	141	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s5	.	142	142	O	.	.	.	.	False

DDI-MedLine.d82.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d82.s6	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d82.s6	indicate	12	19	O	indicate	ate	cate	NN	False
DDI-MedLine.d82.s6	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d82.s6	As	26	27	B-drug_n	As	As	As	IN	False
DDI-MedLine.d82.s6	(	28	28	I-drug_n	(	(	(	(	False
DDI-MedLine.d82.s6	V	29	29	I-drug_n	V	V	V	NN	brand
DDI-MedLine.d82.s6	)	30	30	I-drug_n	)	)	)	)	False
DDI-MedLine.d82.s6	readily	32	38	O	readily	ily	dily	RB	False
DDI-MedLine.d82.s6	penetrates	40	49	O	penetrates	tes	ates	NNS	False
DDI-MedLine.d82.s6	both	51	54	O	both	oth	both	DT	False
DDI-MedLine.d82.s6	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d82.s6	mucosal	60	66	O	mucosal	sal	osal	NN	False
DDI-MedLine.d82.s6	and	68	70	O	and	and	and	CC	False
DDI-MedLine.d82.s6	serosal	72	78	O	serosal	sal	osal	NN	False
DDI-MedLine.d82.s6	surfaces	80	87	O	surfaces	ces	aces	NNS	False
DDI-MedLine.d82.s6	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d82.s6	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d82.s6	epithelial	96	105	O	epithelial	ial	lial	JJ	False
DDI-MedLine.d82.s6	membrane	107	114	O	membrane	ane	rane	NN	False
DDI-MedLine.d82.s6	.	115	115	O	.	.	.	.	False

DDI-MedLine.d82.s7	Furthermore	0	10	O	Furthermore	ore	more	RB	False
DDI-MedLine.d82.s7	,	11	11	O	,	,	,	,	False
DDI-MedLine.d82.s7	arsenate	13	20	B-drug_n	arsenate	ate	nate	NN	False
DDI-MedLine.d82.s7	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d82.s7	phosphate	26	34	B-drug	phosphate	ate	hate	NN	False
DDI-MedLine.d82.s7	do	36	37	O	do	do	do	VB	False
DDI-MedLine.d82.s7	not	39	41	O	not	not	not	RB	False
DDI-MedLine.d82.s7	appear	43	48	O	appear	ear	pear	VB	False
DDI-MedLine.d82.s7	to	50	51	O	to	to	to	TO	False
DDI-MedLine.d82.s7	share	53	57	O	share	are	hare	NN	False
DDI-MedLine.d82.s7	a	59	59	O	a	a	a	DT	False
DDI-MedLine.d82.s7	common	61	66	O	common	mon	mmon	JJ	False
DDI-MedLine.d82.s7	transport	68	76	O	transport	ort	port	NN	False
DDI-MedLine.d82.s7	pathway	78	84	O	pathway	way	hway	NN	False
DDI-MedLine.d82.s7	in	86	87	O	in	in	in	IN	False
DDI-MedLine.d82.s7	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d82.s7	duodenum	93	100	O	duodenum	num	enum	NN	False
DDI-MedLine.d82.s7	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d82.s7	no	106	107	O	no	no	no	DT	False
DDI-MedLine.d82.s7	evidence	109	116	O	evidence	nce	ence	NN	False
DDI-MedLine.d82.s7	was	118	120	O	was	was	was	VBD	False
DDI-MedLine.d82.s7	obtained	122	129	O	obtained	ned	ined	VBN	False
DDI-MedLine.d82.s7	for	131	133	O	for	for	for	IN	False
DDI-MedLine.d82.s7	any	135	137	O	any	any	any	DT	False
DDI-MedLine.d82.s7	interaction	139	149	O	interaction	ion	tion	NN	False
DDI-MedLine.d82.s7	between	151	157	O	between	een	ween	IN	False
DDI-MedLine.d82.s7	the	159	161	O	the	the	the	DT	False
DDI-MedLine.d82.s7	two	163	165	O	two	two	two	CD	False
DDI-MedLine.d82.s7	at	167	168	O	at	at	at	IN	False
DDI-MedLine.d82.s7	this	170	173	O	this	his	this	DT	False
DDI-MedLine.d82.s7	level	175	179	O	level	vel	evel	NN	False
DDI-MedLine.d82.s7	.	180	180	O	.	.	.	.	False

DDI-MedLine.d82.s8	Vitamin	0	6	B-drug	Vitamin	min	amin	NN	False
DDI-MedLine.d82.s8	D3	8	9	I-drug	D3	D3	D3	NN	brand
DDI-MedLine.d82.s8	administration	11	24	O	administration	ion	tion	NN	False
DDI-MedLine.d82.s8	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d82.s8	rachitic	29	36	O	rachitic	tic	itic	JJ	False
DDI-MedLine.d82.s8	chicks	38	43	O	chicks	cks	icks	NNS	False
DDI-MedLine.d82.s8	was	45	47	O	was	was	was	VBD	False
DDI-MedLine.d82.s8	effective	49	57	O	effective	ive	tive	JJ	False
DDI-MedLine.d82.s8	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d82.s8	significantly	62	74	O	significantly	tly	ntly	RB	False
DDI-MedLine.d82.s8	elevating	76	84	O	elevating	ing	ting	VBG	False
DDI-MedLine.d82.s8	duodenal	86	93	O	duodenal	nal	enal	JJ	False
DDI-MedLine.d82.s8	arsenate	95	102	B-drug_n	arsenate	ate	nate	NN	False
DDI-MedLine.d82.s8	absorption	104	113	O	absorption	ion	tion	NN	False
DDI-MedLine.d82.s8	,	114	114	O	,	,	,	,	False
DDI-MedLine.d82.s8	acting	116	121	O	acting	ing	ting	VBG	False
DDI-MedLine.d82.s8	primarily	123	131	O	primarily	ily	rily	RB	False
DDI-MedLine.d82.s8	to	133	134	O	to	to	to	TO	False
DDI-MedLine.d82.s8	enhance	136	142	O	enhance	nce	ance	NN	False
DDI-MedLine.d82.s8	serosal	144	150	O	serosal	sal	osal	NN	False
DDI-MedLine.d82.s8	transport	152	160	O	transport	ort	port	NN	False
DDI-MedLine.d82.s8	.	161	161	O	.	.	.	.	False

DDI-MedLine.d81.s0	Hypothermia	0	10	O	Hypothermia	mia	rmia	NN	False
DDI-MedLine.d81.s0	as	12	13	O	as	as	as	IN	False
DDI-MedLine.d81.s0	an	15	16	O	an	an	an	DT	False
DDI-MedLine.d81.s0	index	18	22	O	index	dex	ndex	NN	False
DDI-MedLine.d81.s0	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d81.s0	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d81.s0	disulfiram-ethanol	31	48	O	disulfiram-ethanol	nol	anol	NN	False
DDI-MedLine.d81.s0	reaction	50	57	O	reaction	ion	tion	NN	False
DDI-MedLine.d81.s0	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d81.s0	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d81.s0	rat	66	68	O	rat	rat	rat	NN	False
DDI-MedLine.d81.s0	.	69	69	O	.	.	.	.	False

DDI-MedLine.d81.s1	Decreased	0	8	O	Decreased	sed	ased	VBN	False
DDI-MedLine.d81.s1	core	10	13	O	core	ore	core	NN	False
DDI-MedLine.d81.s1	temperature	15	25	O	temperature	ure	ture	NN	False
DDI-MedLine.d81.s1	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d81.s1	female	30	35	O	female	ale	male	NN	False
DDI-MedLine.d81.s1	rats	37	40	O	rats	ats	rats	NNS	False
DDI-MedLine.d81.s1	was	42	44	O	was	was	was	VBD	False
DDI-MedLine.d81.s1	investigated	46	57	O	investigated	ted	ated	VBN	False
DDI-MedLine.d81.s1	as	59	60	O	as	as	as	IN	False
DDI-MedLine.d81.s1	one	62	64	O	one	one	one	CD	False
DDI-MedLine.d81.s1	possible	66	73	O	possible	ble	ible	JJ	False
DDI-MedLine.d81.s1	index	75	79	O	index	dex	ndex	NN	False
DDI-MedLine.d81.s1	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d81.s1	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d81.s1	disulfiram-ethanol	88	105	O	disulfiram-ethanol	nol	anol	NN	False
DDI-MedLine.d81.s1	reaction	107	114	O	reaction	ion	tion	NN	False
DDI-MedLine.d81.s1	(	116	116	O	(	(	(	(	False
DDI-MedLine.d81.s1	DER	117	119	O	DER	DER	DER	NN	brand
DDI-MedLine.d81.s1	)	120	120	O	)	)	)	)	False
DDI-MedLine.d81.s1	.	121	121	O	.	.	.	.	False

DDI-MedLine.d81.s2	Core	0	3	O	Core	ore	Core	NN	False
DDI-MedLine.d81.s2	temperature	5	15	O	temperature	ure	ture	NN	False
DDI-MedLine.d81.s2	was	17	19	O	was	was	was	VBD	False
DDI-MedLine.d81.s2	decreased	21	29	O	decreased	sed	ased	VBN	False
DDI-MedLine.d81.s2	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d81.s2	rats	34	37	O	rats	ats	rats	NNS	False
DDI-MedLine.d81.s2	in	39	40	O	in	in	in	IN	False
DDI-MedLine.d81.s2	a	42	42	O	a	a	a	DT	False
DDI-MedLine.d81.s2	dose-dependent	44	57	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d81.s2	manner	59	64	O	manner	ner	nner	NN	False
DDI-MedLine.d81.s2	when	66	69	O	when	hen	when	WRB	False
DDI-MedLine.d81.s2	ethanol	71	77	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s2	was	79	81	O	was	was	was	VBD	False
DDI-MedLine.d81.s2	administered	83	94	O	administered	red	ered	VBN	False
DDI-MedLine.d81.s2	to	96	97	O	to	to	to	TO	False
DDI-MedLine.d81.s2	rats	99	102	O	rats	ats	rats	NNS	False
DDI-MedLine.d81.s2	treated	104	110	O	treated	ted	ated	VBN	False
DDI-MedLine.d81.s2	with	112	115	O	with	ith	with	IN	False
DDI-MedLine.d81.s2	disulfiram	117	126	B-drug	disulfiram	ram	iram	NN	False
DDI-MedLine.d81.s2	8	128	128	O	8	8	8	CD	False
DDI-MedLine.d81.s2	hours	130	134	O	hours	urs	ours	NNS	False
DDI-MedLine.d81.s2	before	136	141	O	before	ore	fore	IN	False
DDI-MedLine.d81.s2	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d81.s2	ethanol	147	153	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s2	challenge	155	163	O	challenge	nge	enge	NN	False
DDI-MedLine.d81.s2	.	164	164	O	.	.	.	.	False

DDI-MedLine.d81.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d81.s3	decrease	4	11	O	decrease	ase	ease	NN	False
DDI-MedLine.d81.s3	in	13	14	O	in	in	in	IN	False
DDI-MedLine.d81.s3	temperature	16	26	O	temperature	ure	ture	NN	False
DDI-MedLine.d81.s3	began	28	32	O	began	gan	egan	VBD	False
DDI-MedLine.d81.s3	within	34	39	O	within	hin	thin	IN	False
DDI-MedLine.d81.s3	20	41	42	O	20	20	20	CD	False
DDI-MedLine.d81.s3	minutes	44	50	O	minutes	tes	utes	NNS	False
DDI-MedLine.d81.s3	after	52	56	O	after	ter	fter	IN	False
DDI-MedLine.d81.s3	ethanol	58	64	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s3	administration	66	79	O	administration	ion	tion	NN	False
DDI-MedLine.d81.s3	,	80	80	O	,	,	,	,	False
DDI-MedLine.d81.s3	reaching	82	89	O	reaching	ing	hing	VBG	False
DDI-MedLine.d81.s3	a	91	91	O	a	a	a	DT	False
DDI-MedLine.d81.s3	maximal	93	99	O	maximal	mal	imal	NN	False
DDI-MedLine.d81.s3	decrease	101	108	O	decrease	ase	ease	NN	False
DDI-MedLine.d81.s3	between	110	116	O	between	een	ween	IN	False
DDI-MedLine.d81.s3	60	118	119	O	60	60	60	CD	False
DDI-MedLine.d81.s3	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d81.s3	120	125	127	O	120	120	120	CD	False
DDI-MedLine.d81.s3	minutes	129	135	O	minutes	tes	utes	NNS	False
DDI-MedLine.d81.s3	post	137	140	O	post	ost	post	NN	False
DDI-MedLine.d81.s3	ethanol	142	148	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s3	.	149	149	O	.	.	.	.	False

DDI-MedLine.d81.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d81.s4	core	4	7	O	core	ore	core	NN	False
DDI-MedLine.d81.s4	temperature	9	19	O	temperature	ure	ture	NN	False
DDI-MedLine.d81.s4	returned	21	28	O	returned	ned	rned	VBN	False
DDI-MedLine.d81.s4	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d81.s4	normal	33	38	O	normal	mal	rmal	JJ	False
DDI-MedLine.d81.s4	300	40	42	O	300	300	300	CD	False
DDI-MedLine.d81.s4	minutes	44	50	O	minutes	tes	utes	NNS	False
DDI-MedLine.d81.s4	after	52	56	O	after	ter	fter	IN	False
DDI-MedLine.d81.s4	ethanol	58	64	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s4	.	65	65	O	.	.	.	.	False

DDI-MedLine.d81.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d81.s5	blood	4	8	O	blood	ood	lood	NN	False
DDI-MedLine.d81.s5	pressure	10	17	O	pressure	ure	sure	NN	False
DDI-MedLine.d81.s5	(	19	19	O	(	(	(	(	False
DDI-MedLine.d81.s5	carotid	20	26	O	carotid	tid	otid	NN	False
DDI-MedLine.d81.s5	cannulation	28	38	O	cannulation	ion	tion	NN	False
DDI-MedLine.d81.s5	)	39	39	O	)	)	)	)	False
DDI-MedLine.d81.s5	decreased	41	49	O	decreased	sed	ased	VBN	False
DDI-MedLine.d81.s5	along	51	55	O	along	ong	long	IN	False
DDI-MedLine.d81.s5	with	57	60	O	with	ith	with	IN	False
DDI-MedLine.d81.s5	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d81.s5	core	66	69	O	core	ore	core	NN	False
DDI-MedLine.d81.s5	temperature	71	81	O	temperature	ure	ture	NN	False
DDI-MedLine.d81.s5	.	82	82	O	.	.	.	.	False

DDI-MedLine.d81.s6	Maximal	0	6	O	Maximal	mal	imal	JJ	False
DDI-MedLine.d81.s6	hypotension	8	18	O	hypotension	ion	sion	NN	False
DDI-MedLine.d81.s6	was	20	22	O	was	was	was	VBD	False
DDI-MedLine.d81.s6	found	24	28	O	found	und	ound	NN	False
DDI-MedLine.d81.s6	120	30	32	O	120	120	120	CD	False
DDI-MedLine.d81.s6	minutes	34	40	O	minutes	tes	utes	NNS	False
DDI-MedLine.d81.s6	post	42	45	O	post	ost	post	NN	False
DDI-MedLine.d81.s6	ethanol	47	53	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s6	,	54	54	O	,	,	,	,	False
DDI-MedLine.d81.s6	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d81.s6	returned	60	67	O	returned	ned	rned	VBN	False
DDI-MedLine.d81.s6	to	69	70	O	to	to	to	TO	False
DDI-MedLine.d81.s6	normal	72	77	O	normal	mal	rmal	JJ	False
DDI-MedLine.d81.s6	300	79	81	O	300	300	300	CD	False
DDI-MedLine.d81.s6	minutes	83	89	O	minutes	tes	utes	NNS	False
DDI-MedLine.d81.s6	after	91	95	O	after	ter	fter	IN	False
DDI-MedLine.d81.s6	ethanol	97	103	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s6	.	104	104	O	.	.	.	.	False

DDI-MedLine.d81.s7	Heart	0	4	O	Heart	art	eart	NN	False
DDI-MedLine.d81.s7	rate	6	9	O	rate	ate	rate	NN	False
DDI-MedLine.d81.s7	increased	11	19	O	increased	sed	ased	VBN	False
DDI-MedLine.d81.s7	initially	21	29	O	initially	lly	ally	RB	False
DDI-MedLine.d81.s7	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d81.s7	returned	35	42	O	returned	ned	rned	VBN	False
DDI-MedLine.d81.s7	to	44	45	O	to	to	to	TO	False
DDI-MedLine.d81.s7	normal	47	52	O	normal	mal	rmal	JJ	False
DDI-MedLine.d81.s7	40	54	55	O	40	40	40	CD	False
DDI-MedLine.d81.s7	minutes	57	63	O	minutes	tes	utes	NNS	False
DDI-MedLine.d81.s7	after	65	69	O	after	ter	fter	IN	False
DDI-MedLine.d81.s7	ethanol	71	77	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d81.s7	challenge	79	87	O	challenge	nge	enge	NN	False
DDI-MedLine.d81.s7	.	88	88	O	.	.	.	.	False

DDI-MedLine.d42.s0	Sildenafil	0	9	B-drug	Sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s0	citrate	11	17	I-drug	citrate	ate	rate	NN	False
DDI-MedLine.d42.s0	:	18	18	O	:	:	:	:	False
DDI-MedLine.d42.s0	a	20	20	O	a	a	a	DT	False
DDI-MedLine.d42.s0	therapeutic	22	32	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d42.s0	update	34	39	O	update	ate	date	NN	False
DDI-MedLine.d42.s0	.	40	40	O	.	.	.	.	False

DDI-MedLine.d42.s1	BACKGROUND	0	9	O	BACKGROUND	UND	OUND	NN	brand
DDI-MedLine.d42.s1	:	10	10	O	:	:	:	:	False
DDI-MedLine.d42.s1	Since	12	16	O	Since	nce	ince	IN	False
DDI-MedLine.d42.s1	its	18	20	O	its	its	its	PRP$	False
DDI-MedLine.d42.s1	approval	22	29	O	approval	val	oval	NN	False
DDI-MedLine.d42.s1	by	31	32	O	by	by	by	IN	False
DDI-MedLine.d42.s1	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d42.s1	US	38	39	O	US	US	US	NN	brand
DDI-MedLine.d42.s1	Food	41	44	O	Food	ood	Food	NN	False
DDI-MedLine.d42.s1	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d42.s1	Drug	50	53	O	Drug	rug	Drug	NN	False
DDI-MedLine.d42.s1	Administration	55	68	O	Administration	ion	tion	NN	False
DDI-MedLine.d42.s1	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d42.s1	March	73	77	O	March	rch	arch	NNP	False
DDI-MedLine.d42.s1	1998	79	82	O	1998	998	1998	CD	False
DDI-MedLine.d42.s1	,	83	83	O	,	,	,	,	False
DDI-MedLine.d42.s1	sildenafil	85	94	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s1	citrate	96	102	I-drug	citrate	ate	rate	NN	False
DDI-MedLine.d42.s1	has	104	106	O	has	has	has	VBZ	False
DDI-MedLine.d42.s1	been	108	111	O	been	een	been	VBN	False
DDI-MedLine.d42.s1	used	113	116	O	used	sed	used	VBN	False
DDI-MedLine.d42.s1	by	118	119	O	by	by	by	IN	False
DDI-MedLine.d42.s1	millions	121	128	O	millions	ons	ions	NNS	False
DDI-MedLine.d42.s1	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d42.s1	men	133	135	O	men	men	men	NNS	False
DDI-MedLine.d42.s1	for	137	139	O	for	for	for	IN	False
DDI-MedLine.d42.s1	the	141	143	O	the	the	the	DT	False
DDI-MedLine.d42.s1	treatment	145	153	O	treatment	ent	ment	NN	False
DDI-MedLine.d42.s1	of	155	156	O	of	of	of	IN	False
DDI-MedLine.d42.s1	erectile	158	165	O	erectile	ile	tile	NN	False
DDI-MedLine.d42.s1	dysfunction	167	177	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s1	.	178	178	O	.	.	.	.	False

DDI-MedLine.d42.s2	Recent	0	5	O	Recent	ent	cent	NN	False
DDI-MedLine.d42.s2	studies	7	13	O	studies	ies	dies	NNS	False
DDI-MedLine.d42.s2	and	15	17	O	and	and	and	CC	False
DDI-MedLine.d42.s2	consensus	19	27	O	consensus	sus	nsus	NN	False
DDI-MedLine.d42.s2	reports	29	35	O	reports	rts	orts	NNS	False
DDI-MedLine.d42.s2	have	37	40	O	have	ave	have	VB	False
DDI-MedLine.d42.s2	expanded	42	49	O	expanded	ded	nded	VBN	False
DDI-MedLine.d42.s2	our	51	53	O	our	our	our	PRP$	False
DDI-MedLine.d42.s2	understanding	55	67	O	understanding	ing	ding	VBG	False
DDI-MedLine.d42.s2	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d42.s2	its	72	74	O	its	its	its	PRP$	False
DDI-MedLine.d42.s2	efficacy	76	83	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d42.s2	,	84	84	O	,	,	,	,	False
DDI-MedLine.d42.s2	safety	86	91	O	safety	ety	fety	NN	False
DDI-MedLine.d42.s2	,	92	92	O	,	,	,	,	False
DDI-MedLine.d42.s2	contraindications	94	110	O	contraindications	ons	ions	NNS	False
DDI-MedLine.d42.s2	,	111	111	O	,	,	,	,	False
DDI-MedLine.d42.s2	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d42.s2	drug	117	120	O	drug	rug	drug	NN	False
DDI-MedLine.d42.s2	interactions	122	133	O	interactions	ons	ions	NNS	False
DDI-MedLine.d42.s2	.	134	134	O	.	.	.	.	False

DDI-MedLine.d42.s3	OBJECTIVE	0	8	O	OBJECTIVE	IVE	TIVE	NN	brand
DDI-MedLine.d42.s3	:	9	9	O	:	:	:	:	False
DDI-MedLine.d42.s3	This	11	14	O	This	his	This	DT	False
DDI-MedLine.d42.s3	paper	16	20	O	paper	per	aper	NN	False
DDI-MedLine.d42.s3	reviews	22	28	O	reviews	ews	iews	NNS	False
DDI-MedLine.d42.s3	recent	30	35	O	recent	ent	cent	JJ	False
DDI-MedLine.d42.s3	studies	37	43	O	studies	ies	dies	NNS	False
DDI-MedLine.d42.s3	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d42.s3	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d42.s3	efficacy	52	59	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d42.s3	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d42.s3	sildenafil	64	73	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s3	,	74	74	O	,	,	,	,	False
DDI-MedLine.d42.s3	its	76	78	O	its	its	its	PRP$	False
DDI-MedLine.d42.s3	adverse	80	86	O	adverse	rse	erse	NN	False
DDI-MedLine.d42.s3	effects	88	94	O	effects	cts	ects	NNS	False
DDI-MedLine.d42.s3	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d42.s3	drug	100	103	O	drug	rug	drug	NN	False
DDI-MedLine.d42.s3	interactions	105	116	O	interactions	ons	ions	NNS	False
DDI-MedLine.d42.s3	,	117	117	O	,	,	,	,	False
DDI-MedLine.d42.s3	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d42.s3	socioeconomic	123	135	O	socioeconomic	mic	omic	JJ	False
DDI-MedLine.d42.s3	factors	137	143	O	factors	ors	tors	NNS	False
DDI-MedLine.d42.s3	involved	145	152	O	involved	ved	lved	VBN	False
DDI-MedLine.d42.s3	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d42.s3	its	157	159	O	its	its	its	PRP$	False
DDI-MedLine.d42.s3	use	161	163	O	use	use	use	NN	False
DDI-MedLine.d42.s3	,	164	164	O	,	,	,	,	False
DDI-MedLine.d42.s3	with	166	169	O	with	ith	with	IN	False
DDI-MedLine.d42.s3	a	171	171	O	a	a	a	DT	False
DDI-MedLine.d42.s3	focus	173	177	O	focus	cus	ocus	NN	False
DDI-MedLine.d42.s3	on	179	180	O	on	on	on	IN	False
DDI-MedLine.d42.s3	specific	182	189	O	specific	fic	ific	JJ	False
DDI-MedLine.d42.s3	patient	191	197	O	patient	ent	ient	NN	False
DDI-MedLine.d42.s3	populations	199	209	O	populations	ons	ions	NNS	False
DDI-MedLine.d42.s3	(	211	211	O	(	(	(	(	False
DDI-MedLine.d42.s3	prostate	212	219	O	prostate	ate	tate	NN	False
DDI-MedLine.d42.s3	cancer	221	226	O	cancer	cer	ncer	NN	False
DDI-MedLine.d42.s3	,	227	227	O	,	,	,	,	False
DDI-MedLine.d42.s3	diabetes	229	236	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d42.s3	mellitus	238	245	O	mellitus	tus	itus	NN	False
DDI-MedLine.d42.s3	,	246	246	O	,	,	,	,	False
DDI-MedLine.d42.s3	ischemic	248	255	O	ischemic	mic	emic	JJ	False
DDI-MedLine.d42.s3	heart	257	261	O	heart	art	eart	NN	False
DDI-MedLine.d42.s3	disease	263	269	O	disease	ase	ease	NN	False
DDI-MedLine.d42.s3	,	270	270	O	,	,	,	,	False
DDI-MedLine.d42.s3	spinal	272	277	O	spinal	nal	inal	NN	False
DDI-MedLine.d42.s3	cord	279	282	O	cord	ord	cord	NN	False
DDI-MedLine.d42.s3	injuries	284	291	O	injuries	ies	ries	NNS	False
DDI-MedLine.d42.s3	,	292	292	O	,	,	,	,	False
DDI-MedLine.d42.s3	neurologic	294	303	O	neurologic	gic	ogic	NN	False
DDI-MedLine.d42.s3	disorders	305	313	O	disorders	ers	ders	NNS	False
DDI-MedLine.d42.s3	)	314	314	O	)	)	)	)	False
DDI-MedLine.d42.s3	.	315	315	O	.	.	.	.	False

DDI-MedLine.d42.s4	METHODS	0	6	O	METHODS	ODS	HODS	NN	brand
DDI-MedLine.d42.s4	:	7	7	O	:	:	:	:	False
DDI-MedLine.d42.s4	Clinical	9	16	O	Clinical	cal	ical	JJ	False
DDI-MedLine.d42.s4	studies	18	24	O	studies	ies	dies	NNS	False
DDI-MedLine.d42.s4	,	25	25	O	,	,	,	,	False
DDI-MedLine.d42.s4	case	27	30	O	case	ase	case	NN	False
DDI-MedLine.d42.s4	reports	32	38	O	reports	rts	orts	NNS	False
DDI-MedLine.d42.s4	,	39	39	O	,	,	,	,	False
DDI-MedLine.d42.s4	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d42.s4	commentaries	45	56	O	commentaries	ies	ries	NNS	False
DDI-MedLine.d42.s4	and	58	60	O	and	and	and	CC	False
DDI-MedLine.d42.s4	editorials	62	71	O	editorials	als	ials	NNS	False
DDI-MedLine.d42.s4	concerning	73	82	O	concerning	ing	ning	VBG	False
DDI-MedLine.d42.s4	sildenafil	84	93	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s4	published	95	103	O	published	hed	shed	VBN	False
DDI-MedLine.d42.s4	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d42.s4	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d42.s4	international	112	124	O	international	nal	onal	JJ	False
DDI-MedLine.d42.s4	literature	126	135	O	literature	ure	ture	NN	False
DDI-MedLine.d42.s4	between	137	143	O	between	een	ween	IN	False
DDI-MedLine.d42.s4	January	145	151	O	January	ary	uary	NNP	False
DDI-MedLine.d42.s4	1999	153	156	O	1999	999	1999	CD	False
DDI-MedLine.d42.s4	and	158	160	O	and	and	and	CC	False
DDI-MedLine.d42.s4	August	162	167	O	August	ust	gust	NNP	False
DDI-MedLine.d42.s4	2000	169	172	O	2000	000	2000	CD	False
DDI-MedLine.d42.s4	were	174	177	O	were	ere	were	VBD	False
DDI-MedLine.d42.s4	identified	179	188	O	identified	ied	fied	VBN	False
DDI-MedLine.d42.s4	through	190	196	O	through	ugh	ough	IN	False
DDI-MedLine.d42.s4	searches	198	205	O	searches	hes	ches	NNS	False
DDI-MedLine.d42.s4	of	207	208	O	of	of	of	IN	False
DDI-MedLine.d42.s4	MEDLINE	210	216	O	MEDLINE	INE	LINE	NN	brand
DDI-MedLine.d42.s4	,	217	217	O	,	,	,	,	False
DDI-MedLine.d42.s4	PREMEDLINE	219	228	O	PREMEDLINE	INE	LINE	NN	brand
DDI-MedLine.d42.s4	,	229	229	O	,	,	,	,	False
DDI-MedLine.d42.s4	and	231	233	O	and	and	and	CC	False
DDI-MedLine.d42.s4	International	235	247	O	International	nal	onal	NNP	False
DDI-MedLine.d42.s4	Pharmaceutical	249	262	O	Pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d42.s4	Abstracts	264	272	O	Abstracts	cts	acts	NNS	False
DDI-MedLine.d42.s4	,	273	273	O	,	,	,	,	False
DDI-MedLine.d42.s4	using	275	279	O	using	ing	sing	VBG	False
DDI-MedLine.d42.s4	the	281	283	O	the	the	the	DT	False
DDI-MedLine.d42.s4	terms	285	289	O	terms	rms	erms	NNS	False
DDI-MedLine.d42.s4	sildenafil	291	300	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s4	,	301	301	O	,	,	,	,	False
DDI-MedLine.d42.s4	Viagra	303	308	B-brand	Viagra	gra	agra	NN	False
DDI-MedLine.d42.s4	,	309	309	O	,	,	,	,	False
DDI-MedLine.d42.s4	and	311	313	O	and	and	and	CC	False
DDI-MedLine.d42.s4	erectile	315	322	O	erectile	ile	tile	NN	False
DDI-MedLine.d42.s4	dysfunction	324	334	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s4	.	335	335	O	.	.	.	.	False

DDI-MedLine.d42.s5	RESULTS	0	6	O	RESULTS	LTS	ULTS	NN	brand
DDI-MedLine.d42.s5	:	7	7	O	:	:	:	:	False
DDI-MedLine.d42.s5	Sildenafil	9	18	B-drug	Sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s5	has	20	22	O	has	has	has	VBZ	False
DDI-MedLine.d42.s5	demonstrated	24	35	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d42.s5	effectiveness	37	49	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d42.s5	in	51	52	O	in	in	in	IN	False
DDI-MedLine.d42.s5	men	54	56	O	men	men	men	NNS	False
DDI-MedLine.d42.s5	with	58	61	O	with	ith	with	IN	False
DDI-MedLine.d42.s5	erectile	63	70	O	erectile	ile	tile	NN	False
DDI-MedLine.d42.s5	dysfunction	72	82	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s5	associated	84	93	O	associated	ted	ated	VBN	False
DDI-MedLine.d42.s5	with	95	98	O	with	ith	with	IN	False
DDI-MedLine.d42.s5	prostatectomy	100	112	O	prostatectomy	omy	tomy	NN	False
DDI-MedLine.d42.s5	,	113	113	O	,	,	,	,	False
DDI-MedLine.d42.s5	radiation	115	123	O	radiation	ion	tion	NN	False
DDI-MedLine.d42.s5	therapy	125	131	O	therapy	apy	rapy	NN	False
DDI-MedLine.d42.s5	,	132	132	O	,	,	,	,	False
DDI-MedLine.d42.s5	diabetes	134	141	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d42.s5	mellitus	143	150	O	mellitus	tus	itus	NN	False
DDI-MedLine.d42.s5	,	151	151	O	,	,	,	,	False
DDI-MedLine.d42.s5	certain	153	159	O	certain	ain	tain	JJ	False
DDI-MedLine.d42.s5	neurologic	161	170	O	neurologic	gic	ogic	NN	False
DDI-MedLine.d42.s5	disorders	172	180	O	disorders	ers	ders	NNS	False
DDI-MedLine.d42.s5	,	181	181	O	,	,	,	,	False
DDI-MedLine.d42.s5	and	183	185	O	and	and	and	CC	False
DDI-MedLine.d42.s5	drug	187	190	O	drug	rug	drug	NN	False
DDI-MedLine.d42.s5	therapy	192	198	O	therapy	apy	rapy	NN	False
DDI-MedLine.d42.s5	(	200	200	O	(	(	(	(	False
DDI-MedLine.d42.s5	eg	201	202	O	eg	eg	eg	NN	False
DDI-MedLine.d42.s5	,	203	203	O	,	,	,	,	False
DDI-MedLine.d42.s5	selective	205	213	B-group	selective	ive	tive	NN	False
DDI-MedLine.d42.s5	serotonin	215	223	I-group	serotonin	nin	onin	NN	False
DDI-MedLine.d42.s5	reuptake	225	232	I-group	reuptake	ake	take	NN	False
DDI-MedLine.d42.s5	inhibitors	234	243	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d42.s5	[	245	245	O	[	[	[	NN	False
DDI-MedLine.d42.s5	SSRIs	246	250	B-group	SSRIs	RIs	SRIs	NN	False
DDI-MedLine.d42.s5	]	251	251	O	]	]	]	NN	False
DDI-MedLine.d42.s5	)	252	252	O	)	)	)	)	False
DDI-MedLine.d42.s5	.	253	253	O	.	.	.	.	False

DDI-MedLine.d42.s6	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d42.s6	has	3	5	O	has	has	has	VBZ	False
DDI-MedLine.d42.s6	not	7	9	O	not	not	not	RB	False
DDI-MedLine.d42.s6	been	11	14	O	been	een	been	VBN	False
DDI-MedLine.d42.s6	as	16	17	O	as	as	as	IN	False
DDI-MedLine.d42.s6	effective	19	27	O	effective	ive	tive	JJ	False
DDI-MedLine.d42.s6	in	29	30	O	in	in	in	IN	False
DDI-MedLine.d42.s6	women	32	36	O	women	men	omen	NNS	False
DDI-MedLine.d42.s6	with	38	41	O	with	ith	with	IN	False
DDI-MedLine.d42.s6	sexual	43	48	O	sexual	ual	xual	JJ	False
DDI-MedLine.d42.s6	dysfunction	50	60	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s6	,	61	61	O	,	,	,	,	False
DDI-MedLine.d42.s6	with	63	66	O	with	ith	with	IN	False
DDI-MedLine.d42.s6	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d42.s6	exception	72	80	O	exception	ion	tion	NN	False
DDI-MedLine.d42.s6	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d42.s6	SSRI-associated	85	99	O	SSRI-associated	ted	ated	JJ	False
DDI-MedLine.d42.s6	sexual	101	106	O	sexual	ual	xual	JJ	False
DDI-MedLine.d42.s6	dysfunction	108	118	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s6	.	119	119	O	.	.	.	.	False

DDI-MedLine.d42.s7	Some	0	3	O	Some	ome	Some	DT	False
DDI-MedLine.d42.s7	disorders	5	13	O	disorders	ers	ders	NNS	False
DDI-MedLine.d42.s7	unrelated	15	23	O	unrelated	ted	ated	JJ	False
DDI-MedLine.d42.s7	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d42.s7	sexual	28	33	O	sexual	ual	xual	JJ	False
DDI-MedLine.d42.s7	dysfunction	35	45	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s7	(	47	47	O	(	(	(	(	False
DDI-MedLine.d42.s7	eg	48	49	O	eg	eg	eg	NN	False
DDI-MedLine.d42.s7	,	50	50	O	,	,	,	,	False
DDI-MedLine.d42.s7	esophageal	52	61	O	esophageal	eal	geal	NN	False
DDI-MedLine.d42.s7	motility	63	70	O	motility	ity	lity	NN	False
DDI-MedLine.d42.s7	dysfunction	72	82	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s7	)	83	83	O	)	)	)	)	False
DDI-MedLine.d42.s7	may	85	87	O	may	may	may	MD	False
DDI-MedLine.d42.s7	also	89	92	O	also	lso	also	RB	False
DDI-MedLine.d42.s7	respond	94	100	O	respond	ond	pond	NN	False
DDI-MedLine.d42.s7	to	102	103	O	to	to	to	TO	False
DDI-MedLine.d42.s7	sildenafil	105	114	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s7	.	115	115	O	.	.	.	.	False

DDI-MedLine.d42.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d42.s8	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d42.s8	general	7	13	O	general	ral	eral	JJ	False
DDI-MedLine.d42.s8	population	15	24	O	population	ion	tion	NN	False
DDI-MedLine.d42.s8	,	25	25	O	,	,	,	,	False
DDI-MedLine.d42.s8	sildenafil	27	36	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s8	is	38	39	O	is	is	is	VBZ	False
DDI-MedLine.d42.s8	considered	41	50	O	considered	red	ered	VBN	False
DDI-MedLine.d42.s8	to	52	53	O	to	to	to	TO	False
DDI-MedLine.d42.s8	have	55	58	O	have	ave	have	VB	False
DDI-MedLine.d42.s8	an	60	61	O	an	an	an	DT	False
DDI-MedLine.d42.s8	acceptable	63	72	O	acceptable	ble	able	JJ	False
DDI-MedLine.d42.s8	tolerability	74	85	O	tolerability	ity	lity	NN	False
DDI-MedLine.d42.s8	profile	87	93	O	profile	ile	file	NN	False
DDI-MedLine.d42.s8	;	94	94	O	;	;	;	:	False

DDI-MedLine.d42.s9	however	0	6	O	however	ver	ever	RB	False
DDI-MedLine.d42.s9	,	7	7	O	,	,	,	,	False
DDI-MedLine.d42.s9	patients	9	16	O	patients	nts	ents	NNS	False
DDI-MedLine.d42.s9	with	18	21	O	with	ith	with	IN	False
DDI-MedLine.d42.s9	moderate	23	30	O	moderate	ate	rate	NN	False
DDI-MedLine.d42.s9	to	32	33	O	to	to	to	TO	False
DDI-MedLine.d42.s9	severe	35	40	O	severe	ere	vere	JJ	False
DDI-MedLine.d42.s9	cardiovascular	42	55	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d42.s9	disease	57	63	O	disease	ase	ease	NN	False
DDI-MedLine.d42.s9	or	65	66	O	or	or	or	CC	False
DDI-MedLine.d42.s9	those	68	72	O	those	ose	hose	DT	False
DDI-MedLine.d42.s9	taking	74	79	O	taking	ing	king	VBG	False
DDI-MedLine.d42.s9	nitrate	81	87	B-group	nitrate	ate	rate	NN	False
DDI-MedLine.d42.s9	therapy	89	95	O	therapy	apy	rapy	NN	False
DDI-MedLine.d42.s9	are	97	99	O	are	are	are	VBP	False
DDI-MedLine.d42.s9	at	101	102	O	at	at	at	IN	False
DDI-MedLine.d42.s9	increased	104	112	O	increased	sed	ased	VBN	False
DDI-MedLine.d42.s9	risk	114	117	O	risk	isk	risk	NN	False
DDI-MedLine.d42.s9	for	119	121	O	for	for	for	IN	False
DDI-MedLine.d42.s9	potentially	123	133	O	potentially	lly	ally	RB	False
DDI-MedLine.d42.s9	serious	135	141	O	serious	ous	ious	JJ	False
DDI-MedLine.d42.s9	cardiovascular	143	156	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d42.s9	adverse	158	164	O	adverse	rse	erse	NN	False
DDI-MedLine.d42.s9	effects	166	172	O	effects	cts	ects	NNS	False
DDI-MedLine.d42.s9	with	174	177	O	with	ith	with	IN	False
DDI-MedLine.d42.s9	sildenafil	179	188	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s9	therapy	190	196	O	therapy	apy	rapy	NN	False
DDI-MedLine.d42.s9	.	197	197	O	.	.	.	.	False

DDI-MedLine.d42.s10	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d42.s10	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d42.s10	,	11	11	O	,	,	,	,	False
DDI-MedLine.d42.s10	patients	13	20	O	patients	nts	ents	NNS	False
DDI-MedLine.d42.s10	taking	22	27	O	taking	ing	king	VBG	False
DDI-MedLine.d42.s10	drugs	29	33	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d42.s10	that	35	38	O	that	hat	that	IN	False
DDI-MedLine.d42.s10	inhibit	40	46	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d42.s10	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d42.s10	cytochrome	52	61	O	cytochrome	ome	rome	NN	False
DDI-MedLine.d42.s10	P450	63	66	O	P450	450	P450	NN	brand
DDI-MedLine.d42.s10	3A4	68	70	O	3A4	3A4	3A4	CD	brand
DDI-MedLine.d42.s10	isozyme	72	78	O	isozyme	yme	zyme	NN	False
DDI-MedLine.d42.s10	,	79	79	O	,	,	,	,	False
DDI-MedLine.d42.s10	which	81	85	O	which	ich	hich	WDT	False
DDI-MedLine.d42.s10	metabolizes	87	97	O	metabolizes	zes	izes	NNS	False
DDI-MedLine.d42.s10	sildenafil	99	108	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s10	,	109	109	O	,	,	,	,	False
DDI-MedLine.d42.s10	may	111	113	O	may	may	may	MD	False
DDI-MedLine.d42.s10	experience	115	124	O	experience	nce	ence	NN	False
DDI-MedLine.d42.s10	increased	126	134	O	increased	sed	ased	VBN	False
DDI-MedLine.d42.s10	drug	136	139	O	drug	rug	drug	NN	False
DDI-MedLine.d42.s10	concentrations	141	154	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d42.s10	and	156	158	O	and	and	and	CC	False
DDI-MedLine.d42.s10	possible	160	167	O	possible	ble	ible	JJ	False
DDI-MedLine.d42.s10	toxicity	169	176	O	toxicity	ity	city	NN	False
DDI-MedLine.d42.s10	from	178	181	O	from	rom	from	IN	False
DDI-MedLine.d42.s10	normal	183	188	O	normal	mal	rmal	JJ	False
DDI-MedLine.d42.s10	doses	190	194	O	doses	ses	oses	NNS	False
DDI-MedLine.d42.s10	of	196	197	O	of	of	of	IN	False
DDI-MedLine.d42.s10	sildenafil	199	208	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s10	.	209	209	O	.	.	.	.	False

DDI-MedLine.d42.s11	CONCLUSIONS	0	10	O	CONCLUSIONS	ONS	IONS	NN	brand
DDI-MedLine.d42.s11	:	11	11	O	:	:	:	:	False
DDI-MedLine.d42.s11	Sildenafil	13	22	B-drug	Sildenafil	fil	afil	NN	False
DDI-MedLine.d42.s11	is	24	25	O	is	is	is	VBZ	False
DDI-MedLine.d42.s11	an	27	28	O	an	an	an	DT	False
DDI-MedLine.d42.s11	effective	30	38	O	effective	ive	tive	JJ	False
DDI-MedLine.d42.s11	first-line	40	49	O	first-line	ine	line	NN	drug
DDI-MedLine.d42.s11	therapy	51	57	O	therapy	apy	rapy	NN	False
DDI-MedLine.d42.s11	for	59	61	O	for	for	for	IN	False
DDI-MedLine.d42.s11	erectile	63	70	O	erectile	ile	tile	NN	False
DDI-MedLine.d42.s11	dysfunction	72	82	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d42.s11	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d42.s11	men	87	89	O	men	men	men	NNS	False
DDI-MedLine.d42.s11	.	90	90	O	.	.	.	.	False

DDI-MedLine.d42.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d42.s12	decision	4	11	O	decision	ion	sion	NN	False
DDI-MedLine.d42.s12	to	13	14	O	to	to	to	TO	False
DDI-MedLine.d42.s12	prescribe	16	24	O	prescribe	ibe	ribe	NN	False
DDI-MedLine.d42.s12	this	26	29	O	this	his	this	DT	False
DDI-MedLine.d42.s12	agent	31	35	O	agent	ent	gent	NN	False
DDI-MedLine.d42.s12	should	37	42	O	should	uld	ould	MD	False
DDI-MedLine.d42.s12	include	44	50	O	include	ude	lude	NN	False
DDI-MedLine.d42.s12	such	52	55	O	such	uch	such	JJ	False
DDI-MedLine.d42.s12	considerations	57	70	O	considerations	ons	ions	NNS	False
DDI-MedLine.d42.s12	as	72	73	O	as	as	as	IN	False
DDI-MedLine.d42.s12	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d42.s12	cost-risk-benefit	79	95	O	cost-risk-benefit	fit	efit	NN	False
DDI-MedLine.d42.s12	balance	97	103	O	balance	nce	ance	NN	False
DDI-MedLine.d42.s12	,	104	104	O	,	,	,	,	False
DDI-MedLine.d42.s12	patient	106	112	O	patient	ent	ient	NN	False
DDI-MedLine.d42.s12	access	114	119	O	access	ess	cess	NN	False
DDI-MedLine.d42.s12	,	120	120	O	,	,	,	,	False
DDI-MedLine.d42.s12	drug	122	125	O	drug	rug	drug	NN	False
DDI-MedLine.d42.s12	distribution	127	138	O	distribution	ion	tion	NN	False
DDI-MedLine.d42.s12	pathways	140	147	O	pathways	ays	ways	NNS	False
DDI-MedLine.d42.s12	,	148	148	O	,	,	,	,	False
DDI-MedLine.d42.s12	and	150	152	O	and	and	and	CC	False
DDI-MedLine.d42.s12	prescription	154	165	O	prescription	ion	tion	NN	False
DDI-MedLine.d42.s12	drug	167	170	O	drug	rug	drug	NN	False
DDI-MedLine.d42.s12	coverage	172	179	O	coverage	age	rage	NN	False
DDI-MedLine.d42.s12	.	180	180	O	.	.	.	.	False

DDI-MedLine.d28.s0	New	0	2	O	New	New	New	NNP	False
DDI-MedLine.d28.s0	oral	4	7	O	oral	ral	oral	JJ	False
DDI-MedLine.d28.s0	therapies	9	17	O	therapies	ies	pies	NNS	False
DDI-MedLine.d28.s0	for	19	21	O	for	for	for	IN	False
DDI-MedLine.d28.s0	type	23	26	O	type	ype	type	NN	False
DDI-MedLine.d28.s0	2	28	28	O	2	2	2	CD	False
DDI-MedLine.d28.s0	diabetes	30	37	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d28.s0	mellitus	39	46	O	mellitus	tus	itus	NN	False
DDI-MedLine.d28.s0	:	47	47	O	:	:	:	:	False
DDI-MedLine.d28.s0	The	49	51	O	The	The	The	DT	False
DDI-MedLine.d28.s0	glitazones	53	62	B-group	glitazones	nes	ones	NNS	False
DDI-MedLine.d28.s0	or	64	65	O	or	or	or	CC	False
DDI-MedLine.d28.s0	insulin	67	73	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s0	sensitizers	75	85	O	sensitizers	ers	zers	NNS	False
DDI-MedLine.d28.s0	.	86	86	O	.	.	.	.	False

DDI-MedLine.d28.s1	Type	0	3	O	Type	ype	Type	NN	False
DDI-MedLine.d28.s1	2	5	5	O	2	2	2	CD	False
DDI-MedLine.d28.s1	diabetes	7	14	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d28.s1	mellitus	16	23	O	mellitus	tus	itus	NN	False
DDI-MedLine.d28.s1	is	25	26	O	is	is	is	VBZ	False
DDI-MedLine.d28.s1	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d28.s1	growing	30	36	O	growing	ing	wing	VBG	False
DDI-MedLine.d28.s1	problem	38	44	O	problem	lem	blem	NN	False
DDI-MedLine.d28.s1	not	46	48	O	not	not	not	RB	False
DDI-MedLine.d28.s1	only	50	53	O	only	nly	only	RB	False
DDI-MedLine.d28.s1	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d28.s1	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d28.s1	United	62	67	O	United	ted	ited	NNP	False
DDI-MedLine.d28.s1	States	69	74	O	States	tes	ates	NNS	False
DDI-MedLine.d28.s1	but	76	78	O	but	but	but	CC	False
DDI-MedLine.d28.s1	also	80	83	O	also	lso	also	RB	False
DDI-MedLine.d28.s1	across	85	90	O	across	oss	ross	IN	False
DDI-MedLine.d28.s1	the	92	94	O	the	the	the	DT	False
DDI-MedLine.d28.s1	world	96	100	O	world	rld	orld	NN	False
DDI-MedLine.d28.s1	.	101	101	O	.	.	.	.	False

DDI-MedLine.d28.s2	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d28.s2	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d28.s2	now	9	11	O	now	now	now	RB	False
DDI-MedLine.d28.s2	strong	13	18	O	strong	ong	rong	JJ	False
DDI-MedLine.d28.s2	evidence	20	27	O	evidence	nce	ence	NN	False
DDI-MedLine.d28.s2	that	29	32	O	that	hat	that	IN	False
DDI-MedLine.d28.s2	intensive	34	42	O	intensive	ive	sive	JJ	False
DDI-MedLine.d28.s2	control	44	50	O	control	rol	trol	NN	False
DDI-MedLine.d28.s2	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d28.s2	blood	55	59	O	blood	ood	lood	NN	False
DDI-MedLine.d28.s2	glucose	61	67	O	glucose	ose	cose	NN	False
DDI-MedLine.d28.s2	can	69	71	O	can	can	can	MD	False
DDI-MedLine.d28.s2	significantly	73	85	O	significantly	tly	ntly	RB	False
DDI-MedLine.d28.s2	reduce	87	92	O	reduce	uce	duce	VB	False
DDI-MedLine.d28.s2	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d28.s2	retard	98	103	O	retard	ard	tard	NN	False
DDI-MedLine.d28.s2	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d28.s2	microvascular	109	121	O	microvascular	lar	ular	NN	False
DDI-MedLine.d28.s2	complications	123	135	O	complications	ons	ions	NNS	False
DDI-MedLine.d28.s2	of	137	138	O	of	of	of	IN	False
DDI-MedLine.d28.s2	retinopathy	140	150	O	retinopathy	thy	athy	NN	False
DDI-MedLine.d28.s2	,	151	151	O	,	,	,	,	False
DDI-MedLine.d28.s2	nephropathy	153	163	O	nephropathy	thy	athy	JJ	False
DDI-MedLine.d28.s2	,	164	164	O	,	,	,	,	False
DDI-MedLine.d28.s2	and	166	168	O	and	and	and	CC	False
DDI-MedLine.d28.s2	neuropathy	170	179	O	neuropathy	thy	athy	JJ	False
DDI-MedLine.d28.s2	.	180	180	O	.	.	.	.	False

DDI-MedLine.d28.s3	Ultimately	0	9	O	Ultimately	ely	tely	RB	False
DDI-MedLine.d28.s3	however	11	17	O	however	ver	ever	RB	False
DDI-MedLine.d28.s3	,	18	18	O	,	,	,	,	False
DDI-MedLine.d28.s3	up	20	21	O	up	up	up	RB	False
DDI-MedLine.d28.s3	to	23	24	O	to	to	to	TO	False
DDI-MedLine.d28.s3	80	26	27	O	80	80	80	CD	False
DDI-MedLine.d28.s3	%	28	28	O	%	%	%	NN	False
DDI-MedLine.d28.s3	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d28.s3	type	33	36	O	type	ype	type	NN	False
DDI-MedLine.d28.s3	2	38	38	O	2	2	2	CD	False
DDI-MedLine.d28.s3	diabetics	40	48	O	diabetics	ics	tics	NNS	False
DDI-MedLine.d28.s3	die	50	52	O	die	die	die	NN	False
DDI-MedLine.d28.s3	from	54	57	O	from	rom	from	IN	False
DDI-MedLine.d28.s3	macrovascular	59	71	O	macrovascular	lar	ular	NN	False
DDI-MedLine.d28.s3	cardiovascular	73	86	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d28.s3	disease	88	94	O	disease	ase	ease	NN	False
DDI-MedLine.d28.s3	.	95	95	O	.	.	.	.	False

DDI-MedLine.d28.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d28.s4	increased	5	13	O	increased	sed	ased	VBN	False
DDI-MedLine.d28.s4	incidence	15	23	O	incidence	nce	ence	NN	False
DDI-MedLine.d28.s4	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d28.s4	atherosclerotic	28	42	O	atherosclerotic	tic	otic	JJ	False
DDI-MedLine.d28.s4	disease	44	50	O	disease	ase	ease	NN	False
DDI-MedLine.d28.s4	is	52	53	O	is	is	is	VBZ	False
DDI-MedLine.d28.s4	intricately	55	65	O	intricately	ely	tely	RB	False
DDI-MedLine.d28.s4	associated	67	76	O	associated	ted	ated	VBN	False
DDI-MedLine.d28.s4	with	78	81	O	with	ith	with	IN	False
DDI-MedLine.d28.s4	insulin	83	89	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s4	resistance	91	100	O	resistance	nce	ance	NN	False
DDI-MedLine.d28.s4	,	101	101	O	,	,	,	,	False
DDI-MedLine.d28.s4	which	103	107	O	which	ich	hich	WDT	False
DDI-MedLine.d28.s4	is	109	110	O	is	is	is	VBZ	False
DDI-MedLine.d28.s4	a	112	112	O	a	a	a	DT	False
DDI-MedLine.d28.s4	major	114	118	O	major	jor	ajor	JJ	False
DDI-MedLine.d28.s4	pathophysiologic	120	135	O	pathophysiologic	gic	ogic	NN	False
DDI-MedLine.d28.s4	abnormality	137	147	O	abnormality	ity	lity	NN	False
DDI-MedLine.d28.s4	in	149	150	O	in	in	in	IN	False
DDI-MedLine.d28.s4	type	152	155	O	type	ype	type	NN	False
DDI-MedLine.d28.s4	2	157	157	O	2	2	2	CD	False
DDI-MedLine.d28.s4	diabetes	159	166	O	diabetes	tes	etes	NNS	False
DDI-MedLine.d28.s4	.	167	167	O	.	.	.	.	False

DDI-MedLine.d28.s5	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d28.s5	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d28.s5	strong	9	14	O	strong	ong	rong	JJ	False
DDI-MedLine.d28.s5	evidence	16	23	O	evidence	nce	ence	NN	False
DDI-MedLine.d28.s5	that	25	28	O	that	hat	that	IN	False
DDI-MedLine.d28.s5	insulin	30	36	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s5	resistance	38	47	O	resistance	nce	ance	NN	False
DDI-MedLine.d28.s5	is	49	50	O	is	is	is	VBZ	False
DDI-MedLine.d28.s5	involved	52	59	O	involved	ved	lved	VBN	False
DDI-MedLine.d28.s5	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d28.s5	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d28.s5	development	68	78	O	development	ent	ment	NN	False
DDI-MedLine.d28.s5	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d28.s5	not	83	85	O	not	not	not	RB	False
DDI-MedLine.d28.s5	only	87	90	O	only	nly	only	RB	False
DDI-MedLine.d28.s5	hyperglycemia	92	104	O	hyperglycemia	mia	emia	NN	False
DDI-MedLine.d28.s5	,	105	105	O	,	,	,	,	False
DDI-MedLine.d28.s5	but	107	109	O	but	but	but	CC	False
DDI-MedLine.d28.s5	also	111	114	O	also	lso	also	RB	False
DDI-MedLine.d28.s5	dyslipidemia	116	127	O	dyslipidemia	mia	emia	NN	False
DDI-MedLine.d28.s5	,	128	128	O	,	,	,	,	False
DDI-MedLine.d28.s5	hypertension	130	141	O	hypertension	ion	sion	NN	False
DDI-MedLine.d28.s5	,	142	142	O	,	,	,	,	False
DDI-MedLine.d28.s5	hypercoagulation	144	159	O	hypercoagulation	ion	tion	NN	False
DDI-MedLine.d28.s5	,	160	160	O	,	,	,	,	False
DDI-MedLine.d28.s5	vasculopathy	162	173	O	vasculopathy	thy	athy	NN	False
DDI-MedLine.d28.s5	,	174	174	O	,	,	,	,	False
DDI-MedLine.d28.s5	and	176	178	O	and	and	and	CC	False
DDI-MedLine.d28.s5	ultimately	180	189	O	ultimately	ely	tely	RB	False
DDI-MedLine.d28.s5	atherosclerotic	191	205	O	atherosclerotic	tic	otic	JJ	False
DDI-MedLine.d28.s5	cardiovascular	207	220	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d28.s5	disease	222	228	O	disease	ase	ease	NN	False
DDI-MedLine.d28.s5	.	229	229	O	.	.	.	.	False

DDI-MedLine.d28.s6	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d28.s6	cluster	5	11	O	cluster	ter	ster	NN	False
DDI-MedLine.d28.s6	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d28.s6	metabolic	16	24	O	metabolic	lic	olic	NN	False
DDI-MedLine.d28.s6	abnormalities	26	38	O	abnormalities	ies	ties	NNS	False
DDI-MedLine.d28.s6	has	40	42	O	has	has	has	VBZ	False
DDI-MedLine.d28.s6	been	44	47	O	been	een	been	VBN	False
DDI-MedLine.d28.s6	termed	49	54	O	termed	med	rmed	VBN	False
DDI-MedLine.d28.s6	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d28.s6	insulin	60	66	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s6	resistance	68	77	O	resistance	nce	ance	NN	False
DDI-MedLine.d28.s6	or	79	80	O	or	or	or	CC	False
DDI-MedLine.d28.s6	cardiovascular	82	95	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d28.s6	dysmetabolic	97	108	O	dysmetabolic	lic	olic	NN	False
DDI-MedLine.d28.s6	syndrome	110	117	O	syndrome	ome	rome	NN	False
DDI-MedLine.d28.s6	.	118	118	O	.	.	.	.	False

DDI-MedLine.d28.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d28.s7	thiazolidinediones	4	21	B-group	thiazolidinediones	nes	ones	NNS	False
DDI-MedLine.d28.s7	(	23	23	O	(	(	(	(	False
DDI-MedLine.d28.s7	rosiglitazone	24	36	B-drug	rosiglitazone	one	zone	NN	False
DDI-MedLine.d28.s7	and	38	40	O	and	and	and	CC	False
DDI-MedLine.d28.s7	pioglitazone	42	53	B-drug	pioglitazone	one	zone	NN	False
DDI-MedLine.d28.s7	)	54	54	O	)	)	)	)	False
DDI-MedLine.d28.s7	,	55	55	O	,	,	,	,	False
DDI-MedLine.d28.s7	a	57	57	O	a	a	a	DT	False
DDI-MedLine.d28.s7	new	59	61	O	new	new	new	JJ	False
DDI-MedLine.d28.s7	class	63	67	O	class	ass	lass	NN	False
DDI-MedLine.d28.s7	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d28.s7	oral	72	75	O	oral	ral	oral	JJ	False
DDI-MedLine.d28.s7	antidiabetic	77	88	B-group	antidiabetic	tic	etic	JJ	False
DDI-MedLine.d28.s7	agents	90	95	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d28.s7	,	96	96	O	,	,	,	,	False
DDI-MedLine.d28.s7	are	98	100	O	are	are	are	VBP	False
DDI-MedLine.d28.s7	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d28.s7	insulin	103	109	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s7	sensitizers	111	121	O	sensitizers	ers	zers	NNS	False
DDI-MedLine.d28.s7	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d28.s8	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d28.s8	exert	4	8	O	exert	ert	xert	NN	False
DDI-MedLine.d28.s8	direct	10	15	O	direct	ect	rect	JJ	False
DDI-MedLine.d28.s8	effects	17	23	O	effects	cts	ects	NNS	False
DDI-MedLine.d28.s8	on	25	26	O	on	on	on	IN	False
DDI-MedLine.d28.s8	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d28.s8	mechanisms	32	41	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d28.s8	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d28.s8	insulin	46	52	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s8	resistance	54	63	O	resistance	nce	ance	NN	False
DDI-MedLine.d28.s8	.	64	64	O	.	.	.	.	False

DDI-MedLine.d28.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d28.s9	effects	6	12	O	effects	cts	ects	NNS	False
DDI-MedLine.d28.s9	not	14	16	O	not	not	not	RB	False
DDI-MedLine.d28.s9	only	18	21	O	only	nly	only	RB	False
DDI-MedLine.d28.s9	improve	23	29	O	improve	ove	rove	VB	False
DDI-MedLine.d28.s9	insulin	31	37	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s9	sensitivity	39	49	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d28.s9	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d28.s9	glycemic	55	62	O	glycemic	mic	emic	NN	False
DDI-MedLine.d28.s9	control	64	70	O	control	rol	trol	NN	False
DDI-MedLine.d28.s9	with	72	75	O	with	ith	with	IN	False
DDI-MedLine.d28.s9	reduced	77	83	O	reduced	ced	uced	VBN	False
DDI-MedLine.d28.s9	insulin	85	91	O	insulin	lin	ulin	NN	False
DDI-MedLine.d28.s9	requirements	93	104	O	requirements	nts	ents	NNS	False
DDI-MedLine.d28.s9	,	105	105	O	,	,	,	,	False
DDI-MedLine.d28.s9	but	107	109	O	but	but	but	CC	False
DDI-MedLine.d28.s9	also	111	114	O	also	lso	also	RB	False
DDI-MedLine.d28.s9	have	116	119	O	have	ave	have	VB	False
DDI-MedLine.d28.s9	potentially	121	131	O	potentially	lly	ally	RB	False
DDI-MedLine.d28.s9	favorable	133	141	O	favorable	ble	able	JJ	False
DDI-MedLine.d28.s9	effects	143	149	O	effects	cts	ects	NNS	False
DDI-MedLine.d28.s9	on	151	152	O	on	on	on	IN	False
DDI-MedLine.d28.s9	other	154	158	O	other	her	ther	JJ	False
DDI-MedLine.d28.s9	components	160	169	O	components	nts	ents	NNS	False
DDI-MedLine.d28.s9	of	171	172	O	of	of	of	IN	False
DDI-MedLine.d28.s9	the	174	176	O	the	the	the	DT	False
DDI-MedLine.d28.s9	cardiovascular	178	191	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d28.s9	dysmetabolic	193	204	O	dysmetabolic	lic	olic	NN	False
DDI-MedLine.d28.s9	syndrome	206	213	O	syndrome	ome	rome	NN	False
DDI-MedLine.d28.s9	.	214	214	O	.	.	.	.	False

DDI-MedLine.d28.s10	Long-term	0	8	O	Long-term	erm	term	JJ	False
DDI-MedLine.d28.s10	studies	10	16	O	studies	ies	dies	NNS	False
DDI-MedLine.d28.s10	are	18	20	O	are	are	are	VBP	False
DDI-MedLine.d28.s10	needed	22	27	O	needed	ded	eded	VBN	False
DDI-MedLine.d28.s10	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d28.s10	determine	32	40	O	determine	ine	mine	NN	drug
DDI-MedLine.d28.s10	whether	42	48	O	whether	her	ther	IN	False
DDI-MedLine.d28.s10	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d28.s10	insulin-sensitizing	54	72	O	insulin-sensitizing	ing	zing	NN	False
DDI-MedLine.d28.s10	effects	74	80	O	effects	cts	ects	NNS	False
DDI-MedLine.d28.s10	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d28.s10	the	85	87	O	the	the	the	DT	False
DDI-MedLine.d28.s10	glitazones	89	98	B-group	glitazones	nes	ones	NNS	False
DDI-MedLine.d28.s10	can	100	102	O	can	can	can	MD	False
DDI-MedLine.d28.s10	prevent	104	110	O	prevent	ent	vent	NN	False
DDI-MedLine.d28.s10	or	112	113	O	or	or	or	CC	False
DDI-MedLine.d28.s10	delay	115	119	O	delay	lay	elay	NN	False
DDI-MedLine.d28.s10	premature	121	129	O	premature	ure	ture	NN	False
DDI-MedLine.d28.s10	atherosclerotic	131	145	O	atherosclerotic	tic	otic	JJ	False
DDI-MedLine.d28.s10	cardiovascular	147	160	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d28.s10	disease	162	168	O	disease	ase	ease	NN	False
DDI-MedLine.d28.s10	,	169	169	O	,	,	,	,	False
DDI-MedLine.d28.s10	morbidity	171	179	O	morbidity	ity	dity	NN	False
DDI-MedLine.d28.s10	,	180	180	O	,	,	,	,	False
DDI-MedLine.d28.s10	and	182	184	O	and	and	and	CC	False
DDI-MedLine.d28.s10	death	186	190	O	death	ath	eath	NN	False
DDI-MedLine.d28.s10	.	191	191	O	.	.	.	.	False

DDI-MedLine.d10.s0	Herbal	0	5	O	Herbal	bal	rbal	NNP	False
DDI-MedLine.d10.s0	remedies	7	14	O	remedies	ies	dies	NNS	False
DDI-MedLine.d10.s0	,	15	15	O	,	,	,	,	False
DDI-MedLine.d10.s0	nephropathies	17	29	O	nephropathies	ies	hies	NNS	False
DDI-MedLine.d10.s0	,	30	30	O	,	,	,	,	False
DDI-MedLine.d10.s0	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d10.s0	renal	36	40	O	renal	nal	enal	NN	False
DDI-MedLine.d10.s0	disease	42	48	O	disease	ase	ease	NN	False
DDI-MedLine.d10.s0	.	49	49	O	.	.	.	.	False

DDI-MedLine.d10.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d10.s1	use	4	6	O	use	use	use	NN	False
DDI-MedLine.d10.s1	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d10.s1	herbal	11	16	O	herbal	bal	rbal	NN	False
DDI-MedLine.d10.s1	remedies	18	25	O	remedies	ies	dies	NNS	False
DDI-MedLine.d10.s1	is	27	28	O	is	is	is	VBZ	False
DDI-MedLine.d10.s1	becoming	30	37	O	becoming	ing	ming	VBG	False
DDI-MedLine.d10.s1	increasingly	39	50	O	increasingly	gly	ngly	RB	False
DDI-MedLine.d10.s1	popular	52	58	O	popular	lar	ular	JJ	False
DDI-MedLine.d10.s1	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d10.s1	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d10.s1	United	67	72	O	United	ted	ited	NNP	False
DDI-MedLine.d10.s1	States	74	79	O	States	tes	ates	NNS	False
DDI-MedLine.d10.s1	.	80	80	O	.	.	.	.	False

DDI-MedLine.d10.s2	Research	0	7	O	Research	rch	arch	NN	False
DDI-MedLine.d10.s2	has	9	11	O	has	has	has	VBZ	False
DDI-MedLine.d10.s2	shown	13	17	O	shown	own	hown	VBN	False
DDI-MedLine.d10.s2	that	19	22	O	that	hat	that	IN	False
DDI-MedLine.d10.s2	herbal	24	29	O	herbal	bal	rbal	NN	False
DDI-MedLine.d10.s2	remedy	31	36	O	remedy	edy	medy	NN	False
DDI-MedLine.d10.s2	use	38	40	O	use	use	use	NN	False
DDI-MedLine.d10.s2	may	42	44	O	may	may	may	MD	False
DDI-MedLine.d10.s2	be	46	47	O	be	be	be	VB	False
DDI-MedLine.d10.s2	associated	49	58	O	associated	ted	ated	VBN	False
DDI-MedLine.d10.s2	with	60	63	O	with	ith	with	IN	False
DDI-MedLine.d10.s2	acute	65	69	O	acute	ute	cute	NN	False
DDI-MedLine.d10.s2	renal	71	75	O	renal	nal	enal	NN	False
DDI-MedLine.d10.s2	failure	77	83	O	failure	ure	lure	NN	False
DDI-MedLine.d10.s2	.	84	84	O	.	.	.	.	False

DDI-MedLine.d10.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d10.s3	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d10.s3	,	11	11	O	,	,	,	,	False
DDI-MedLine.d10.s3	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d10.s3	use	17	19	O	use	use	use	NN	False
DDI-MedLine.d10.s3	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d10.s3	herbal	24	29	O	herbal	bal	rbal	NN	False
DDI-MedLine.d10.s3	remedies	31	38	O	remedies	ies	dies	NNS	False
DDI-MedLine.d10.s3	may	40	42	O	may	may	may	MD	False
DDI-MedLine.d10.s3	be	44	45	O	be	be	be	VB	False
DDI-MedLine.d10.s3	detrimental	47	57	O	detrimental	tal	ntal	NN	False
DDI-MedLine.d10.s3	for	59	61	O	for	for	for	IN	False
DDI-MedLine.d10.s3	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d10.s3	patient	67	73	O	patient	ent	ient	NN	False
DDI-MedLine.d10.s3	with	75	78	O	with	ith	with	IN	False
DDI-MedLine.d10.s3	compromised	80	90	O	compromised	sed	ised	VBN	False
DDI-MedLine.d10.s3	renal	92	96	O	renal	nal	enal	NN	False
DDI-MedLine.d10.s3	function	98	105	O	function	ion	tion	NN	False
DDI-MedLine.d10.s3	.	106	106	O	.	.	.	.	False

DDI-MedLine.d10.s4	Patients	0	7	O	Patients	nts	ents	NNS	False
DDI-MedLine.d10.s4	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d10.s4	renal	14	18	O	renal	nal	enal	NN	False
DDI-MedLine.d10.s4	insufficiency	20	32	O	insufficiency	ncy	ency	NN	False
DDI-MedLine.d10.s4	or	34	35	O	or	or	or	CC	False
DDI-MedLine.d10.s4	renal	37	41	O	renal	nal	enal	NN	False
DDI-MedLine.d10.s4	failure	43	49	O	failure	ure	lure	NN	False
DDI-MedLine.d10.s4	may	51	53	O	may	may	may	MD	False
DDI-MedLine.d10.s4	be	55	56	O	be	be	be	VB	False
DDI-MedLine.d10.s4	at	58	59	O	at	at	at	IN	False
DDI-MedLine.d10.s4	risk	61	64	O	risk	isk	risk	NN	False
DDI-MedLine.d10.s4	for	66	68	O	for	for	for	IN	False
DDI-MedLine.d10.s4	further	70	76	O	further	her	ther	RB	False
DDI-MedLine.d10.s4	kidney	78	83	O	kidney	ney	dney	NN	False
DDI-MedLine.d10.s4	damage	85	90	O	damage	age	mage	NN	False
DDI-MedLine.d10.s4	as	92	93	O	as	as	as	IN	False
DDI-MedLine.d10.s4	well	95	98	O	well	ell	well	RB	False
DDI-MedLine.d10.s4	as	100	101	O	as	as	as	IN	False
DDI-MedLine.d10.s4	complications	103	115	O	complications	ons	ions	NNS	False
DDI-MedLine.d10.s4	related	117	123	O	related	ted	ated	JJ	False
DDI-MedLine.d10.s4	to	125	126	O	to	to	to	TO	False
DDI-MedLine.d10.s4	interactions	128	139	O	interactions	ons	ions	NNS	False
DDI-MedLine.d10.s4	of	141	142	O	of	of	of	IN	False
DDI-MedLine.d10.s4	herbal	144	149	O	herbal	bal	rbal	NN	False
DDI-MedLine.d10.s4	remedies	151	158	O	remedies	ies	dies	NNS	False
DDI-MedLine.d10.s4	with	160	163	O	with	ith	with	IN	False
DDI-MedLine.d10.s4	complex	165	171	O	complex	lex	plex	JJ	False
DDI-MedLine.d10.s4	renal	173	177	O	renal	nal	enal	NN	False
DDI-MedLine.d10.s4	therapy	179	185	O	therapy	apy	rapy	NN	False
DDI-MedLine.d10.s4	regimens	187	194	O	regimens	ens	mens	NNS	False
DDI-MedLine.d10.s4	.	195	195	O	.	.	.	.	False

DDI-MedLine.d10.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d10.s5	article	5	11	O	article	cle	icle	NN	False
DDI-MedLine.d10.s5	will	13	16	O	will	ill	will	MD	False
DDI-MedLine.d10.s5	describe	18	25	O	describe	ibe	ribe	NN	False
DDI-MedLine.d10.s5	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d10.s5	escalating	31	40	O	escalating	ing	ting	VBG	False
DDI-MedLine.d10.s5	use	42	44	O	use	use	use	NN	False
DDI-MedLine.d10.s5	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d10.s5	herbal	49	54	O	herbal	bal	rbal	NN	False
DDI-MedLine.d10.s5	therapy	56	62	O	therapy	apy	rapy	NN	False
DDI-MedLine.d10.s5	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d10.s5	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d10.s5	hazards	72	78	O	hazards	rds	ards	NNS	False
DDI-MedLine.d10.s5	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d10.s5	herbal	83	88	O	herbal	bal	rbal	NN	False
DDI-MedLine.d10.s5	remedy	90	95	O	remedy	edy	medy	NN	False
DDI-MedLine.d10.s5	use	97	99	O	use	use	use	NN	False
DDI-MedLine.d10.s5	among	101	105	O	among	ong	mong	IN	False
DDI-MedLine.d10.s5	patients	107	114	O	patients	nts	ents	NNS	False
DDI-MedLine.d10.s5	.	115	115	O	.	.	.	.	False

DDI-MedLine.d104.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d104.s0	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d104.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d104.s0	DCG-IV	15	20	B-drug_n	DCG-IV	-IV	G-IV	NN	brand
DDI-MedLine.d104.s0	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d104.s0	L-CCG-1	26	32	B-drug_n	L-CCG-1	G-1	CG-1	JJ	brand
DDI-MedLine.d104.s0	upon	34	37	O	upon	pon	upon	IN	False
DDI-MedLine.d104.s0	phencyclidine	39	51	B-drug_n	phencyclidine	ine	dine	NN	drug
DDI-MedLine.d104.s0	(	53	53	O	(	(	(	(	False
DDI-MedLine.d104.s0	PCP	54	56	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d104.s0	)	57	57	O	)	)	)	)	False
DDI-MedLine.d104.s0	-induced	58	65	O	-induced	ced	uced	VBN	False
DDI-MedLine.d104.s0	locomotion	67	76	O	locomotion	ion	tion	NN	False
DDI-MedLine.d104.s0	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d104.s0	behavioral	82	91	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d104.s0	changes	93	99	O	changes	ges	nges	NNS	False
DDI-MedLine.d104.s0	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d104.s0	mice	104	107	O	mice	ice	mice	NN	False
DDI-MedLine.d104.s0	.	108	108	O	.	.	.	.	False

DDI-MedLine.d104.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d104.s1	behavioral	4	13	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d104.s1	changes	15	21	O	changes	ges	nges	NNS	False
DDI-MedLine.d104.s1	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d104.s1	mice	26	29	O	mice	ice	mice	NN	False
DDI-MedLine.d104.s1	induced	31	37	O	induced	ced	uced	JJ	False
DDI-MedLine.d104.s1	by	39	40	O	by	by	by	IN	False
DDI-MedLine.d104.s1	acute	42	46	O	acute	ute	cute	NN	False
DDI-MedLine.d104.s1	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d104.s1	repeated	52	59	O	repeated	ted	ated	VBN	False
DDI-MedLine.d104.s1	i.p	61	63	O	i.p	i.p	i.p	NN	False
DDI-MedLine.d104.s1	.	64	64	O	.	.	.	.	False

DDI-MedLine.d104.s2	injection	0	8	O	injection	ion	tion	NN	False
DDI-MedLine.d104.s2	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d104.s2	phencyclidine	13	25	B-drug_n	phencyclidine	ine	dine	NN	drug
DDI-MedLine.d104.s2	(	27	27	O	(	(	(	(	False
DDI-MedLine.d104.s2	PCP	28	30	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d104.s2	)	31	31	O	)	)	)	)	False
DDI-MedLine.d104.s2	were	33	36	O	were	ere	were	VBD	False
DDI-MedLine.d104.s2	observed	38	45	O	observed	ved	rved	VBN	False
DDI-MedLine.d104.s2	by	47	48	O	by	by	by	IN	False
DDI-MedLine.d104.s2	measuring	50	58	O	measuring	ing	ring	VBG	False
DDI-MedLine.d104.s2	locomotor	60	68	O	locomotor	tor	otor	NN	False
DDI-MedLine.d104.s2	activity	70	77	O	activity	ity	vity	NN	False
DDI-MedLine.d104.s2	and	79	81	O	and	and	and	CC	False
DDI-MedLine.d104.s2	stereotyped	83	93	O	stereotyped	ped	yped	VBD	False
DDI-MedLine.d104.s2	behavior	95	102	O	behavior	ior	vior	NN	False
DDI-MedLine.d104.s2	.	103	103	O	.	.	.	.	False

DDI-MedLine.d104.s3	Then	0	3	O	Then	hen	Then	RB	False
DDI-MedLine.d104.s3	,	4	4	O	,	,	,	,	False
DDI-MedLine.d104.s3	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d104.s3	effects	10	16	O	effects	cts	ects	NNS	False
DDI-MedLine.d104.s3	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d104.s3	metabotropic	21	32	O	metabotropic	pic	opic	NN	False
DDI-MedLine.d104.s3	glutamate	34	42	O	glutamate	ate	mate	NN	False
DDI-MedLine.d104.s3	receptor	44	51	O	receptor	tor	ptor	NN	False
DDI-MedLine.d104.s3	(	53	53	O	(	(	(	(	False
DDI-MedLine.d104.s3	mGluR	54	58	O	mGluR	luR	GluR	NN	False
DDI-MedLine.d104.s3	)	59	59	O	)	)	)	)	False
DDI-MedLine.d104.s3	agonists	61	68	O	agonists	sts	ists	NNS	False
DDI-MedLine.d104.s3	,	69	69	O	,	,	,	,	False
DDI-MedLine.d104.s3	DCG-IV	71	76	B-drug_n	DCG-IV	-IV	G-IV	NN	brand
DDI-MedLine.d104.s3	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d104.s3	L-CCG-1	82	88	B-drug_n	L-CCG-1	G-1	CG-1	JJ	brand
DDI-MedLine.d104.s3	,	89	89	O	,	,	,	,	False
DDI-MedLine.d104.s3	on	91	92	O	on	on	on	IN	False
DDI-MedLine.d104.s3	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d104.s3	above	98	102	O	above	ove	bove	IN	False
DDI-MedLine.d104.s3	behavioral	104	113	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d104.s3	changes	115	121	O	changes	ges	nges	NNS	False
DDI-MedLine.d104.s3	induced	123	129	O	induced	ced	uced	JJ	False
DDI-MedLine.d104.s3	by	131	132	O	by	by	by	IN	False
DDI-MedLine.d104.s3	PCP	134	136	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d104.s3	were	138	141	O	were	ere	were	VBD	False
DDI-MedLine.d104.s3	found	143	147	O	found	und	ound	NN	False
DDI-MedLine.d104.s3	.	148	148	O	.	.	.	.	False

DDI-MedLine.d104.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d104.s4	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d104.s4	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d104.s4	DCG-IV	15	20	B-drug_n	DCG-IV	-IV	G-IV	NN	brand
DDI-MedLine.d104.s4	were	22	25	O	were	ere	were	VBD	False
DDI-MedLine.d104.s4	very	27	30	O	very	ery	very	RB	False
DDI-MedLine.d104.s4	strong	32	37	O	strong	ong	rong	JJ	False
DDI-MedLine.d104.s4	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d104.s4	completely	43	52	O	completely	ely	tely	RB	False
DDI-MedLine.d104.s4	depressed	54	62	O	depressed	sed	ssed	JJ	False
DDI-MedLine.d104.s4	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d104.s4	PCP-induced	68	78	O	PCP-induced	ced	uced	JJ	False
DDI-MedLine.d104.s4	hyperlocomotion	80	94	O	hyperlocomotion	ion	tion	NN	False
DDI-MedLine.d104.s4	.	95	95	O	.	.	.	.	False

DDI-MedLine.d104.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d104.s5	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d104.s5	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d104.s5	L-CCG-1	15	21	B-drug_n	L-CCG-1	G-1	CG-1	JJ	brand
DDI-MedLine.d104.s5	were	23	26	O	were	ere	were	VBD	False
DDI-MedLine.d104.s5	not	28	30	O	not	not	not	RB	False
DDI-MedLine.d104.s5	so	32	33	O	so	so	so	RB	False
DDI-MedLine.d104.s5	strong	35	40	O	strong	ong	rong	JJ	False
DDI-MedLine.d104.s5	.	41	41	O	.	.	.	.	False

DDI-MedLine.d104.s6	Repeated	0	7	O	Repeated	ted	ated	VBN	False
DDI-MedLine.d104.s6	injection	9	17	O	injection	ion	tion	NN	False
DDI-MedLine.d104.s6	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d104.s6	PCP	22	24	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d104.s6	for	26	28	O	for	for	for	IN	False
DDI-MedLine.d104.s6	20	30	31	O	20	20	20	CD	False
DDI-MedLine.d104.s6	days	33	36	O	days	ays	days	NNS	False
DDI-MedLine.d104.s6	into	38	41	O	into	nto	into	IN	False
DDI-MedLine.d104.s6	mice	43	46	O	mice	ice	mice	NN	False
DDI-MedLine.d104.s6	induced	48	54	O	induced	ced	uced	JJ	False
DDI-MedLine.d104.s6	lower	56	60	O	lower	wer	ower	JJR	False
DDI-MedLine.d104.s6	locomotor	62	70	O	locomotor	tor	otor	NN	False
DDI-MedLine.d104.s6	activity	72	79	O	activity	ity	vity	NN	False
DDI-MedLine.d104.s6	than	81	84	O	than	han	than	IN	False
DDI-MedLine.d104.s6	that	86	89	O	that	hat	that	IN	False
DDI-MedLine.d104.s6	in	91	92	O	in	in	in	IN	False
DDI-MedLine.d104.s6	acutely	94	100	O	acutely	ely	tely	RB	False
DDI-MedLine.d104.s6	injected	102	109	O	injected	ted	cted	VBN	False
DDI-MedLine.d104.s6	mice	111	114	O	mice	ice	mice	NN	False
DDI-MedLine.d104.s6	.	115	115	O	.	.	.	.	False

DDI-MedLine.d104.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d104.s7	behavioral	6	15	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d104.s7	changes	17	23	O	changes	ges	nges	NNS	False
DDI-MedLine.d104.s7	may	25	27	O	may	may	may	MD	False
DDI-MedLine.d104.s7	be	29	30	O	be	be	be	VB	False
DDI-MedLine.d104.s7	related	32	38	O	related	ted	ated	JJ	False
DDI-MedLine.d104.s7	with	40	43	O	with	ith	with	IN	False
DDI-MedLine.d104.s7	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d104.s7	negative	49	56	O	negative	ive	tive	JJ	False
DDI-MedLine.d104.s7	symptoms	58	65	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d104.s7	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d104.s7	schizophrenia	70	82	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d104.s7	.	83	83	O	.	.	.	.	False

DDI-MedLine.d104.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d104.s8	order	3	7	O	order	der	rder	NN	False
DDI-MedLine.d104.s8	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d104.s8	examine	12	18	O	examine	ine	mine	NN	drug
DDI-MedLine.d104.s8	some	20	23	O	some	ome	some	DT	False
DDI-MedLine.d104.s8	molecular	25	33	O	molecular	lar	ular	NN	False
DDI-MedLine.d104.s8	mechanisms	35	44	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d104.s8	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d104.s8	PCP-induced	49	59	O	PCP-induced	ced	uced	JJ	False
DDI-MedLine.d104.s8	behavioral	61	70	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d104.s8	changes	72	78	O	changes	ges	nges	NNS	False
DDI-MedLine.d104.s8	,	79	79	O	,	,	,	,	False
DDI-MedLine.d104.s8	Northern	81	88	O	Northern	ern	hern	NNP	False
DDI-MedLine.d104.s8	blot	90	93	O	blot	lot	blot	NN	False
DDI-MedLine.d104.s8	analysis	95	102	O	analysis	sis	ysis	NN	False
DDI-MedLine.d104.s8	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d104.s8	total	107	111	O	total	tal	otal	JJ	False
DDI-MedLine.d104.s8	RNA	113	115	O	RNA	RNA	RNA	NN	brand
DDI-MedLine.d104.s8	from	117	120	O	from	rom	from	IN	False
DDI-MedLine.d104.s8	prefrontal	122	131	O	prefrontal	tal	ntal	NN	False
DDI-MedLine.d104.s8	cortical	133	140	O	cortical	cal	ical	JJ	False
DDI-MedLine.d104.s8	tissues	142	148	O	tissues	ues	sues	NNS	False
DDI-MedLine.d104.s8	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d104.s8	mice	153	156	O	mice	ice	mice	NN	False
DDI-MedLine.d104.s8	treated	158	164	O	treated	ted	ated	VBN	False
DDI-MedLine.d104.s8	with	166	169	O	with	ith	with	IN	False
DDI-MedLine.d104.s8	PCP	171	173	B-drug_n	PCP	PCP	PCP	NN	brand
DDI-MedLine.d104.s8	,	174	174	O	,	,	,	,	False
DDI-MedLine.d104.s8	DCG-IV	176	181	B-drug_n	DCG-IV	-IV	G-IV	NN	brand
DDI-MedLine.d104.s8	,	182	182	O	,	,	,	,	False
DDI-MedLine.d104.s8	and	184	186	O	and	and	and	CC	False
DDI-MedLine.d104.s8	L-CCG-1	188	194	B-drug_n	L-CCG-1	G-1	CG-1	JJ	brand
DDI-MedLine.d104.s8	was	196	198	O	was	was	was	VBD	False
DDI-MedLine.d104.s8	carried	200	206	O	carried	ied	ried	VBN	False
DDI-MedLine.d104.s8	out	208	210	O	out	out	out	IN	False
DDI-MedLine.d104.s8	.	211	211	O	.	.	.	.	False

DDI-MedLine.d70.s0	Toxicity	0	7	O	Toxicity	ity	city	NN	False
DDI-MedLine.d70.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d70.s0	cadmium	12	18	O	cadmium	ium	mium	NN	drug
DDI-MedLine.d70.s0	and	20	22	O	and	and	and	CC	False
DDI-MedLine.d70.s0	zinc	24	27	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d70.s0	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d70.s0	miracidia	32	40	O	miracidia	dia	idia	NN	False
DDI-MedLine.d70.s0	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d70.s0	Schistosoma	45	55	O	Schistosoma	oma	soma	NN	False
DDI-MedLine.d70.s0	mansoni	57	63	O	mansoni	oni	soni	NN	False
DDI-MedLine.d70.s0	.	64	64	O	.	.	.	.	False

DDI-MedLine.d70.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d70.s1	specific	4	11	O	specific	fic	ific	JJ	False
DDI-MedLine.d70.s1	objectives	13	22	O	objectives	ves	ives	NNS	False
DDI-MedLine.d70.s1	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d70.s1	this	27	30	O	this	his	this	DT	False
DDI-MedLine.d70.s1	study	32	36	O	study	udy	tudy	NN	False
DDI-MedLine.d70.s1	were	38	41	O	were	ere	were	VBD	False
DDI-MedLine.d70.s1	to	43	44	O	to	to	to	TO	False
DDI-MedLine.d70.s1	elucidate	46	54	O	elucidate	ate	date	NN	False
DDI-MedLine.d70.s1	metal	56	60	O	metal	tal	etal	NN	False
DDI-MedLine.d70.s1	toxicity	62	69	O	toxicity	ity	city	NN	False
DDI-MedLine.d70.s1	to	71	72	O	to	to	to	TO	False
DDI-MedLine.d70.s1	hatching	74	81	O	hatching	ing	hing	VBG	False
DDI-MedLine.d70.s1	,	82	82	O	,	,	,	,	False
DDI-MedLine.d70.s1	survival	84	91	O	survival	val	ival	NN	False
DDI-MedLine.d70.s1	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d70.s1	avoidance	97	105	O	avoidance	nce	ance	NN	False
DDI-MedLine.d70.s1	behaviour	107	115	O	behaviour	our	iour	NN	False
DDI-MedLine.d70.s1	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d70.s1	Schistosoma	120	130	O	Schistosoma	oma	soma	NN	False
DDI-MedLine.d70.s1	mansoni	132	138	O	mansoni	oni	soni	NN	False
DDI-MedLine.d70.s1	miracidia	140	148	O	miracidia	dia	idia	NN	False
DDI-MedLine.d70.s1	.	149	149	O	.	.	.	.	False

DDI-MedLine.d70.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d70.s2	toxicity	4	11	O	toxicity	ity	city	NN	False
DDI-MedLine.d70.s2	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d70.s2	cadmium	16	22	O	cadmium	ium	mium	NN	drug
DDI-MedLine.d70.s2	,	23	23	O	,	,	,	,	False
DDI-MedLine.d70.s2	zinc	25	28	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d70.s2	,	29	29	O	,	,	,	,	False
DDI-MedLine.d70.s2	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d70.s2	cadmium/zinc	35	46	O	cadmium/zinc	inc	zinc	NN	False
DDI-MedLine.d70.s2	mixtures	48	55	O	mixtures	res	ures	NNS	False
DDI-MedLine.d70.s2	at	57	58	O	at	at	at	IN	False
DDI-MedLine.d70.s2	concentrations	60	73	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d70.s2	ranging	75	81	O	ranging	ing	ging	VBG	False
DDI-MedLine.d70.s2	from	83	86	O	from	rom	from	IN	False
DDI-MedLine.d70.s2	10000	88	92	O	10000	000	0000	CD	False
DDI-MedLine.d70.s2	to	94	95	O	to	to	to	TO	False
DDI-MedLine.d70.s2	10	97	98	O	10	10	10	CD	False
DDI-MedLine.d70.s2	microg/l	100	107	O	microg/l	g/l	og/l	NN	False
DDI-MedLine.d70.s2	was	109	111	O	was	was	was	VBD	False
DDI-MedLine.d70.s2	investigated	113	124	O	investigated	ted	ated	VBN	False
DDI-MedLine.d70.s2	.	125	125	O	.	.	.	.	False

DDI-MedLine.d70.s3	Metal	0	4	O	Metal	tal	etal	NN	False
DDI-MedLine.d70.s3	mixture	6	12	O	mixture	ure	ture	NN	False
DDI-MedLine.d70.s3	toxicity	14	21	O	toxicity	ity	city	NN	False
DDI-MedLine.d70.s3	investigation	23	35	O	investigation	ion	tion	NN	False
DDI-MedLine.d70.s3	was	37	39	O	was	was	was	VBD	False
DDI-MedLine.d70.s3	undertaken	41	50	O	undertaken	ken	aken	JJ	False
DDI-MedLine.d70.s3	with	52	55	O	with	ith	with	IN	False
DDI-MedLine.d70.s3	equal	57	61	O	equal	ual	qual	JJ	False
DDI-MedLine.d70.s3	concentrations	63	76	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d70.s3	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d70.s3	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d70.s3	metals	85	90	O	metals	als	tals	NNS	False
DDI-MedLine.d70.s3	.	91	91	O	.	.	.	.	False

DDI-MedLine.d70.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d70.s4	hatching	4	11	O	hatching	ing	hing	VBG	False
DDI-MedLine.d70.s4	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d70.s4	miracidia	16	24	O	miracidia	dia	idia	NN	False
DDI-MedLine.d70.s4	from	26	29	O	from	rom	from	IN	False
DDI-MedLine.d70.s4	eggs	31	34	O	eggs	ggs	eggs	NNS	False
DDI-MedLine.d70.s4	was	36	38	O	was	was	was	VBD	False
DDI-MedLine.d70.s4	inhibited	40	48	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d70.s4	by	50	51	O	by	by	by	IN	False
DDI-MedLine.d70.s4	concentrations	53	66	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d70.s4	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d70.s4	1000-10000	71	80	O	1000-10000	000	0000	CD	False
DDI-MedLine.d70.s4	microg/l	82	89	O	microg/l	g/l	og/l	NN	False
DDI-MedLine.d70.s4	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d70.s4	single	94	99	O	single	gle	ngle	JJ	False
DDI-MedLine.d70.s4	metals	101	106	O	metals	als	tals	NNS	False
DDI-MedLine.d70.s4	.	107	107	O	.	.	.	.	False

DDI-MedLine.d70.s5	Metal	0	4	O	Metal	tal	etal	NN	False
DDI-MedLine.d70.s5	mixtures	6	13	O	mixtures	res	ures	NNS	False
DDI-MedLine.d70.s5	had	15	17	O	had	had	had	VBD	False
DDI-MedLine.d70.s5	no	19	20	O	no	no	no	DT	False
DDI-MedLine.d70.s5	effect	22	27	O	effect	ect	fect	NN	False
DDI-MedLine.d70.s5	on	29	30	O	on	on	on	IN	False
DDI-MedLine.d70.s5	egg	32	34	B-drug	egg	egg	egg	NN	False
DDI-MedLine.d70.s5	hatching	36	43	O	hatching	ing	hing	VBG	False
DDI-MedLine.d70.s5	.	44	44	O	.	.	.	.	False

DDI-MedLine.d70.s6	Survival	0	7	O	Survival	val	ival	NN	False
DDI-MedLine.d70.s6	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d70.s6	miracidia	12	20	O	miracidia	dia	idia	NN	False
DDI-MedLine.d70.s6	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d70.s6	reduced	26	32	O	reduced	ced	uced	VBN	False
DDI-MedLine.d70.s6	by	34	35	O	by	by	by	IN	False
DDI-MedLine.d70.s6	increasing	37	46	O	increasing	ing	sing	VBG	False
DDI-MedLine.d70.s6	metal	48	52	O	metal	tal	etal	NN	False
DDI-MedLine.d70.s6	concentration	54	66	O	concentration	ion	tion	NN	False
DDI-MedLine.d70.s6	except	68	73	O	except	ept	cept	IN	False
DDI-MedLine.d70.s6	at	75	76	O	at	at	at	IN	False
DDI-MedLine.d70.s6	concentrations	78	91	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d70.s6	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d70.s6	10	96	97	O	10	10	10	CD	False
DDI-MedLine.d70.s6	microg/l	99	106	O	microg/l	g/l	og/l	NN	False
DDI-MedLine.d70.s6	for	108	110	O	for	for	for	IN	False
DDI-MedLine.d70.s6	single	112	117	O	single	gle	ngle	JJ	False
DDI-MedLine.d70.s6	metal	119	123	O	metal	tal	etal	NN	False
DDI-MedLine.d70.s6	toxicity	125	132	O	toxicity	ity	city	NN	False
DDI-MedLine.d70.s6	where	134	138	O	where	ere	here	WRB	False
DDI-MedLine.d70.s6	survival	140	147	O	survival	val	ival	NN	False
DDI-MedLine.d70.s6	was	149	151	O	was	was	was	VBD	False
DDI-MedLine.d70.s6	increased	153	161	O	increased	sed	ased	VBN	False
DDI-MedLine.d70.s6	above	163	167	O	above	ove	bove	IN	False
DDI-MedLine.d70.s6	the	169	171	O	the	the	the	DT	False
DDI-MedLine.d70.s6	control	173	179	O	control	rol	trol	NN	False
DDI-MedLine.d70.s6	.	180	180	O	.	.	.	.	False

DDI-MedLine.d70.s7	Miracidia	0	8	O	Miracidia	dia	idia	NNP	False
DDI-MedLine.d70.s7	demonstrated	10	21	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d70.s7	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d70.s7	rapid	25	29	O	rapid	pid	apid	JJ	False
DDI-MedLine.d70.s7	avoidance	31	39	O	avoidance	nce	ance	NN	False
DDI-MedLine.d70.s7	behaviour	41	49	O	behaviour	our	iour	NN	False
DDI-MedLine.d70.s7	when	51	54	O	when	hen	when	WRB	False
DDI-MedLine.d70.s7	briefly	56	62	O	briefly	fly	efly	NN	False
DDI-MedLine.d70.s7	exposed	64	70	O	exposed	sed	osed	VBN	False
DDI-MedLine.d70.s7	to	72	73	O	to	to	to	TO	False
DDI-MedLine.d70.s7	heavy	75	79	O	heavy	avy	eavy	JJ	False
DDI-MedLine.d70.s7	metals	81	86	O	metals	als	tals	NNS	False
DDI-MedLine.d70.s7	.	87	87	O	.	.	.	.	False

DDI-MedLine.d70.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d70.s8	mechanisms	4	13	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d70.s8	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d70.s8	metal	18	22	O	metal	tal	etal	NN	False
DDI-MedLine.d70.s8	toxicity	24	31	O	toxicity	ity	city	NN	False
DDI-MedLine.d70.s8	to	33	34	O	to	to	to	TO	False
DDI-MedLine.d70.s8	miracidia	36	44	O	miracidia	dia	idia	NN	False
DDI-MedLine.d70.s8	are	46	48	O	are	are	are	VBP	False
DDI-MedLine.d70.s8	briefly	50	56	O	briefly	fly	efly	NN	False
DDI-MedLine.d70.s8	discussed	58	66	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d70.s8	.	67	67	O	.	.	.	.	False

DDI-MedLine.d134.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d134.s0	Dose-time	1	9	O	Dose-time	ime	time	NN	False
DDI-MedLine.d134.s0	effects	11	17	O	effects	cts	ects	NNS	False
DDI-MedLine.d134.s0	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d134.s0	competitive	22	32	O	competitive	ive	tive	JJ	False
DDI-MedLine.d134.s0	displacement	34	45	O	displacement	ent	ment	NN	False
DDI-MedLine.d134.s0	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d134.s0	radiopertechnetate	50	67	B-drug	radiopertechnetate	ate	tate	NN	False
DDI-MedLine.d134.s0	by	69	70	O	by	by	by	IN	False
DDI-MedLine.d134.s0	sodium	72	77	B-drug_n	sodium	ium	dium	NN	drug
DDI-MedLine.d134.s0	perchlorate	79	89	I-drug_n	perchlorate	ate	rate	NN	False
DDI-MedLine.d134.s0	following	91	99	O	following	ing	wing	VBG	False
DDI-MedLine.d134.s0	oral	101	104	O	oral	ral	oral	JJ	False
DDI-MedLine.d134.s0	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d134.s0	intravenous	110	120	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d134.s0	administration	122	135	O	administration	ion	tion	NN	False
DDI-MedLine.d134.s0	]	136	136	O	]	]	]	NN	False
DDI-MedLine.d134.s0	The	139	141	O	The	The	The	DT	False
DDI-MedLine.d134.s0	effect	143	148	O	effect	ect	fect	NN	False
DDI-MedLine.d134.s0	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d134.s0	various	153	159	O	various	ous	ious	JJ	False
DDI-MedLine.d134.s0	doses	161	165	O	doses	ses	oses	NNS	False
DDI-MedLine.d134.s0	of	167	168	O	of	of	of	IN	False
DDI-MedLine.d134.s0	sodium	170	175	B-drug_n	sodium	ium	dium	NN	drug
DDI-MedLine.d134.s0	perchlorate	177	187	I-drug_n	perchlorate	ate	rate	NN	False
DDI-MedLine.d134.s0	in	189	190	O	in	in	in	IN	False
DDI-MedLine.d134.s0	several	192	198	O	several	ral	eral	JJ	False
DDI-MedLine.d134.s0	dose	200	203	O	dose	ose	dose	NN	False
DDI-MedLine.d134.s0	fractions	205	213	O	fractions	ons	ions	NNS	False
DDI-MedLine.d134.s0	on	215	216	O	on	on	on	IN	False
DDI-MedLine.d134.s0	the	218	220	O	the	the	the	DT	False
DDI-MedLine.d134.s0	extent	222	227	O	extent	ent	tent	NN	False
DDI-MedLine.d134.s0	and	229	231	O	and	and	and	CC	False
DDI-MedLine.d134.s0	the	233	235	O	the	the	the	DT	False
DDI-MedLine.d134.s0	time	237	240	O	time	ime	time	NN	False
DDI-MedLine.d134.s0	scale	242	246	O	scale	ale	cale	NN	False
DDI-MedLine.d134.s0	of	248	249	O	of	of	of	IN	False
DDI-MedLine.d134.s0	displacement	251	262	O	displacement	ent	ment	NN	False
DDI-MedLine.d134.s0	of	264	265	O	of	of	of	IN	False
DDI-MedLine.d134.s0	radiopertechnetate	267	284	B-drug	radiopertechnetate	ate	tate	NN	False
DDI-MedLine.d134.s0	,	285	285	O	,	,	,	,	False
DDI-MedLine.d134.s0	in	287	288	O	in	in	in	IN	False
DDI-MedLine.d134.s0	dependence	290	299	O	dependence	nce	ence	NN	False
DDI-MedLine.d134.s0	on	301	302	O	on	on	on	IN	False
DDI-MedLine.d134.s0	application	304	314	O	application	ion	tion	NN	False
DDI-MedLine.d134.s0	mode	316	319	O	mode	ode	mode	NN	False
DDI-MedLine.d134.s0	,	320	320	O	,	,	,	,	False
DDI-MedLine.d134.s0	was	322	324	O	was	was	was	VBD	False
DDI-MedLine.d134.s0	studied	326	332	O	studied	ied	died	VBN	False
DDI-MedLine.d134.s0	.	333	333	O	.	.	.	.	False

DDI-MedLine.d134.s1	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d134.s1	intravenous	3	13	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d134.s1	dose	15	18	O	dose	ose	dose	NN	False
DDI-MedLine.d134.s1	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d134.s1	50	23	24	O	50	50	50	CD	False
DDI-MedLine.d134.s1	mg	26	27	O	mg	mg	mg	NN	False
DDI-MedLine.d134.s1	perchlorate	29	39	B-drug_n	perchlorate	ate	rate	NN	False
DDI-MedLine.d134.s1	was	41	43	O	was	was	was	VBD	False
DDI-MedLine.d134.s1	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d134.s1	respect	48	54	O	respect	ect	pect	NN	False
DDI-MedLine.d134.s1	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d134.s1	competitive	59	69	O	competitive	ive	tive	JJ	False
DDI-MedLine.d134.s1	suppression	71	81	O	suppression	ion	sion	NN	False
DDI-MedLine.d134.s1	of	83	84	O	of	of	of	IN	False
DDI-MedLine.d134.s1	organs	86	91	O	organs	ans	gans	NNS	False
DDI-MedLine.d134.s1	actively	93	100	O	actively	ely	vely	RB	False
DDI-MedLine.d134.s1	concentrating	102	114	O	concentrating	ing	ting	VBG	False
DDI-MedLine.d134.s1	pertechnetate	116	128	B-drug	pertechnetate	ate	tate	NN	False
DDI-MedLine.d134.s1	as	130	131	O	as	as	as	IN	False
DDI-MedLine.d134.s1	effective	133	141	O	effective	ive	tive	JJ	False
DDI-MedLine.d134.s1	as	143	144	O	as	as	as	IN	False
DDI-MedLine.d134.s1	intravenous	146	156	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d134.s1	1000	158	161	O	1000	000	1000	CD	False
DDI-MedLine.d134.s1	mg	163	164	O	mg	mg	mg	NN	False
DDI-MedLine.d134.s1	ClO-4-	166	171	O	ClO-4-	-4-	O-4-	NN	False
DDI-MedLine.d134.s1	simultaneously	173	186	O	simultaneously	sly	usly	RB	False
DDI-MedLine.d134.s1	or	188	189	O	or	or	or	CC	False
DDI-MedLine.d134.s1	1000	191	194	O	1000	000	1000	CD	False
DDI-MedLine.d134.s1	mg	196	197	O	mg	mg	mg	NN	False
DDI-MedLine.d134.s1	orally	199	204	O	orally	lly	ally	RB	False
DDI-MedLine.d134.s1	30	206	207	O	30	30	30	CD	False
DDI-MedLine.d134.s1	min	209	211	O	min	min	min	NN	False
DDI-MedLine.d134.s1	before	213	218	O	before	ore	fore	IN	False
DDI-MedLine.d134.s1	the	220	222	O	the	the	the	DT	False
DDI-MedLine.d134.s1	injection	224	232	O	injection	ion	tion	NN	False
DDI-MedLine.d134.s1	of	234	235	O	of	of	of	IN	False
DDI-MedLine.d134.s1	radiopertechnetate	237	254	B-drug	radiopertechnetate	ate	tate	NN	False
DDI-MedLine.d134.s1	.	255	255	O	.	.	.	.	False

DDI-MedLine.d134.s2	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d134.s2	intravenous	3	13	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d134.s2	injection	15	23	O	injection	ion	tion	NN	False
DDI-MedLine.d134.s2	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d134.s2	perchlorate	28	38	B-drug_n	perchlorate	ate	rate	NN	False
DDI-MedLine.d134.s2	given	40	44	O	given	ven	iven	VBN	False
DDI-MedLine.d134.s2	later	46	50	O	later	ter	ater	RB	False
DDI-MedLine.d134.s2	also	52	55	O	also	lso	also	RB	False
DDI-MedLine.d134.s2	produces	57	64	O	produces	ces	uces	NNS	False
DDI-MedLine.d134.s2	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d134.s2	complete	68	75	O	complete	ete	lete	JJ	False
DDI-MedLine.d134.s2	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d134.s2	immediately	81	91	O	immediately	ely	tely	RB	False
DDI-MedLine.d134.s2	beginning	93	101	O	beginning	ing	ning	VBG	False
DDI-MedLine.d134.s2	depletion	103	111	O	depletion	ion	tion	NN	False
DDI-MedLine.d134.s2	of	113	114	O	of	of	of	IN	False
DDI-MedLine.d134.s2	pertechnetate	116	128	B-drug	pertechnetate	ate	tate	NN	False
DDI-MedLine.d134.s2	already	130	136	O	already	ady	eady	RB	False
DDI-MedLine.d134.s2	accumulated	138	148	O	accumulated	ted	ated	VBN	False
DDI-MedLine.d134.s2	in	150	151	O	in	in	in	IN	False
DDI-MedLine.d134.s2	the	153	155	O	the	the	the	DT	False
DDI-MedLine.d134.s2	thyroid	157	163	O	thyroid	oid	roid	NN	False
DDI-MedLine.d134.s2	,	164	164	O	,	,	,	,	False
DDI-MedLine.d134.s2	within	166	171	O	within	hin	thin	IN	False
DDI-MedLine.d134.s2	a	173	173	O	a	a	a	DT	False
DDI-MedLine.d134.s2	period	175	180	O	period	iod	riod	NN	False
DDI-MedLine.d134.s2	of	182	183	O	of	of	of	IN	False
DDI-MedLine.d134.s2	195	185	187	O	195	195	195	CD	False
DDI-MedLine.d134.s2	min	189	191	O	min	min	min	NN	False
DDI-MedLine.d134.s2	after	193	197	O	after	ter	fter	IN	False
DDI-MedLine.d134.s2	99m-TcO-4-injection	199	217	O	99m-TcO-4-injection	ion	tion	NN	False
DDI-MedLine.d134.s2	with	219	222	O	with	ith	with	IN	False
DDI-MedLine.d134.s2	a	224	224	O	a	a	a	DT	False
DDI-MedLine.d134.s2	corresponding	226	238	O	corresponding	ing	ding	VBG	False
DDI-MedLine.d134.s2	increase	240	247	O	increase	ase	ease	NN	False
DDI-MedLine.d134.s2	in	249	250	O	in	in	in	IN	False
DDI-MedLine.d134.s2	blood	252	256	O	blood	ood	lood	NN	False
DDI-MedLine.d134.s2	levels	258	263	O	levels	els	vels	NNS	False
DDI-MedLine.d134.s2	.	264	264	O	.	.	.	.	False

DDI-MedLine.d134.s3	20	0	1	O	20	20	20	CD	False
DDI-MedLine.d134.s3	mg	3	4	O	mg	mg	mg	NN	False
DDI-MedLine.d134.s3	result	6	11	O	result	ult	sult	NN	False
DDI-MedLine.d134.s3	in	13	14	O	in	in	in	IN	False
DDI-MedLine.d134.s3	incomplete	16	25	O	incomplete	ete	lete	NN	False
DDI-MedLine.d134.s3	depletion	27	35	O	depletion	ion	tion	NN	False
DDI-MedLine.d134.s3	which	37	41	O	which	ich	hich	WDT	False
DDI-MedLine.d134.s3	becomes	43	49	O	becomes	mes	omes	NNS	False
DDI-MedLine.d134.s3	complete	51	58	O	complete	ete	lete	JJ	False
DDI-MedLine.d134.s3	after	60	64	O	after	ter	fter	IN	False
DDI-MedLine.d134.s3	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d134.s3	second	68	73	O	second	ond	cond	JJ	False
DDI-MedLine.d134.s3	additional	75	84	O	additional	nal	onal	JJ	False
DDI-MedLine.d134.s3	dose	86	89	O	dose	ose	dose	NN	False
DDI-MedLine.d134.s3	.	90	90	O	.	.	.	.	False

DDI-MedLine.d134.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d134.s4	intravenous	4	14	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d134.s4	application	16	26	O	application	ion	tion	NN	False
DDI-MedLine.d134.s4	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d134.s4	perchlorate	31	41	B-drug_n	perchlorate	ate	rate	NN	False
DDI-MedLine.d134.s4	offers	43	48	O	offers	ers	fers	NNS	False
DDI-MedLine.d134.s4	advantages	50	59	O	advantages	ges	ages	NNS	False
DDI-MedLine.d134.s4	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d134.s4	clinical	64	71	O	clinical	cal	ical	JJ	False
DDI-MedLine.d134.s4	use	73	75	O	use	use	use	NN	False
DDI-MedLine.d134.s4	.	76	76	O	.	.	.	.	False

DDI-MedLine.d36.s0	Carbamazepine	0	12	B-drug	Carbamazepine	ine	pine	NN	drug
DDI-MedLine.d36.s0	overdose	14	21	O	overdose	ose	dose	NN	False
DDI-MedLine.d36.s0	recognized	23	32	O	recognized	zed	ized	VBN	False
DDI-MedLine.d36.s0	by	34	35	O	by	by	by	IN	False
DDI-MedLine.d36.s0	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d36.s0	tricyclic	39	47	B-group	tricyclic	lic	clic	NN	False
DDI-MedLine.d36.s0	antidepressant	49	62	I-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d36.s0	assay	64	68	O	assay	say	ssay	NN	False
DDI-MedLine.d36.s0	.	69	69	O	.	.	.	.	False

DDI-MedLine.d36.s1	Altered	0	6	O	Altered	red	ered	NNP	False
DDI-MedLine.d36.s1	mental	8	13	O	mental	tal	ntal	NN	False
DDI-MedLine.d36.s1	status	15	20	O	status	tus	atus	NN	False
DDI-MedLine.d36.s1	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d36.s1	an	25	26	O	an	an	an	DT	False
DDI-MedLine.d36.s1	adolescent	28	37	O	adolescent	ent	cent	NN	False
DDI-MedLine.d36.s1	presents	39	46	O	presents	nts	ents	NNS	False
DDI-MedLine.d36.s1	a	48	48	O	a	a	a	DT	False
DDI-MedLine.d36.s1	diagnostic	50	59	O	diagnostic	tic	stic	JJ	False
DDI-MedLine.d36.s1	challenge	61	69	O	challenge	nge	enge	NN	False
DDI-MedLine.d36.s1	,	70	70	O	,	,	,	,	False
DDI-MedLine.d36.s1	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d36.s1	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d36.s1	clinician	80	88	O	clinician	ian	cian	NN	False
DDI-MedLine.d36.s1	depends	90	96	O	depends	nds	ends	NNS	False
DDI-MedLine.d36.s1	on	98	99	O	on	on	on	IN	False
DDI-MedLine.d36.s1	clinical	101	108	O	clinical	cal	ical	JJ	False
DDI-MedLine.d36.s1	evaluation	110	119	O	evaluation	ion	tion	NN	False
DDI-MedLine.d36.s1	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d36.s1	laboratory	125	134	O	laboratory	ory	tory	NN	False
DDI-MedLine.d36.s1	studies	136	142	O	studies	ies	dies	NNS	False
DDI-MedLine.d36.s1	to	144	145	O	to	to	to	TO	False
DDI-MedLine.d36.s1	determine	147	155	O	determine	ine	mine	NN	drug
DDI-MedLine.d36.s1	therapy	157	163	O	therapy	apy	rapy	NN	False
DDI-MedLine.d36.s1	and	165	167	O	and	and	and	CC	False
DDI-MedLine.d36.s1	prognosis	169	177	O	prognosis	sis	osis	NN	False
DDI-MedLine.d36.s1	.	178	178	O	.	.	.	.	False

DDI-MedLine.d36.s2	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d36.s2	report	3	8	O	report	ort	port	NN	False
DDI-MedLine.d36.s2	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d36.s2	case	14	17	O	case	ase	case	NN	False
DDI-MedLine.d36.s2	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d36.s2	an	22	23	O	an	an	an	DT	False
DDI-MedLine.d36.s2	adolescent	25	34	O	adolescent	ent	cent	NN	False
DDI-MedLine.d36.s2	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d36.s2	altered	41	47	O	altered	red	ered	VBN	False
DDI-MedLine.d36.s2	consciousness	49	61	O	consciousness	ess	ness	NN	False
DDI-MedLine.d36.s2	caused	63	68	O	caused	sed	used	VBN	False
DDI-MedLine.d36.s2	by	70	71	O	by	by	by	IN	False
DDI-MedLine.d36.s2	carbamazepine	73	85	B-drug	carbamazepine	ine	pine	NN	drug
DDI-MedLine.d36.s2	overdose	87	94	O	overdose	ose	dose	NN	False
DDI-MedLine.d36.s2	with	96	99	O	with	ith	with	IN	False
DDI-MedLine.d36.s2	a	101	101	O	a	a	a	DT	False
DDI-MedLine.d36.s2	positive	103	110	O	positive	ive	tive	JJ	False
DDI-MedLine.d36.s2	tricyclic	112	120	B-group	tricyclic	lic	clic	NN	False
DDI-MedLine.d36.s2	antidepressant	122	135	I-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d36.s2	level	137	141	O	level	vel	evel	NN	False
DDI-MedLine.d36.s2	to	143	144	O	to	to	to	TO	False
DDI-MedLine.d36.s2	alert	146	150	O	alert	ert	lert	NN	False
DDI-MedLine.d36.s2	clinicians	152	161	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d36.s2	to	163	164	O	to	to	to	TO	False
DDI-MedLine.d36.s2	the	166	168	O	the	the	the	DT	False
DDI-MedLine.d36.s2	cross-reactivity	170	185	O	cross-reactivity	ity	vity	NN	False
DDI-MedLine.d36.s2	of	187	188	O	of	of	of	IN	False
DDI-MedLine.d36.s2	carbamazepine	190	202	B-drug	carbamazepine	ine	pine	NN	drug
DDI-MedLine.d36.s2	with	204	207	O	with	ith	with	IN	False
DDI-MedLine.d36.s2	a	209	209	O	a	a	a	DT	False
DDI-MedLine.d36.s2	toxicology	211	220	O	toxicology	ogy	logy	NN	False
DDI-MedLine.d36.s2	screen	222	227	O	screen	een	reen	NN	False
DDI-MedLine.d36.s2	for	229	231	O	for	for	for	IN	False
DDI-MedLine.d36.s2	tricyclic	233	241	B-group	tricyclic	lic	clic	NN	False
DDI-MedLine.d36.s2	antidepressants	243	257	I-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d36.s2	.	258	258	O	.	.	.	.	False

DDI-MedLine.d139.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d139.s0	Quantitative	1	12	O	Quantitative	ive	tive	JJ	False
DDI-MedLine.d139.s0	approach	14	21	O	approach	ach	oach	NN	False
DDI-MedLine.d139.s0	to	23	24	O	to	to	to	TO	False
DDI-MedLine.d139.s0	treatment	26	34	O	treatment	ent	ment	NN	False
DDI-MedLine.d139.s0	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d139.s0	incisive	41	48	O	incisive	ive	sive	JJ	False
DDI-MedLine.d139.s0	neuroleptics	50	61	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d139.s0	by	63	64	O	by	by	by	IN	False
DDI-MedLine.d139.s0	therapeutic	66	76	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d139.s0	monitoring	78	87	O	monitoring	ing	ring	NN	False
DDI-MedLine.d139.s0	]	88	88	O	]	]	]	NN	False
DDI-MedLine.d139.s0	;	89	89	O	;	;	;	:	False
DDI-MedLine.d139.s0	The	91	93	O	The	The	The	DT	False
DDI-MedLine.d139.s0	problems	95	102	O	problems	ems	lems	NNS	False
DDI-MedLine.d139.s0	encountered	104	114	O	encountered	red	ered	VBN	False
DDI-MedLine.d139.s0	during	116	121	O	during	ing	ring	IN	False
DDI-MedLine.d139.s0	the	123	125	O	the	the	the	DT	False
DDI-MedLine.d139.s0	longterm	127	134	O	longterm	erm	term	NN	False
DDI-MedLine.d139.s0	treatment	136	144	O	treatment	ent	ment	NN	False
DDI-MedLine.d139.s0	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d139.s0	psychotic	149	157	O	psychotic	tic	otic	JJ	False
DDI-MedLine.d139.s0	patients	159	166	O	patients	nts	ents	NNS	False
DDI-MedLine.d139.s0	with	168	171	O	with	ith	with	IN	False
DDI-MedLine.d139.s0	neuroleptics	173	184	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d139.s0	are	186	188	O	are	are	are	VBP	False
DDI-MedLine.d139.s0	illustrated	190	200	O	illustrated	ted	ated	VBN	False
DDI-MedLine.d139.s0	by	202	203	O	by	by	by	IN	False
DDI-MedLine.d139.s0	six	205	207	O	six	six	six	CD	False
DDI-MedLine.d139.s0	typical	209	215	O	typical	cal	ical	JJ	False
DDI-MedLine.d139.s0	case	217	220	O	case	ase	case	NN	False
DDI-MedLine.d139.s0	reports	222	228	O	reports	rts	orts	NNS	False
DDI-MedLine.d139.s0	.	229	229	O	.	.	.	.	False

DDI-MedLine.d139.s1	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d139.s1	group	2	6	O	group	oup	roup	NN	False
DDI-MedLine.d139.s1	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d139.s1	patients	11	18	O	patients	nts	ents	NNS	False
DDI-MedLine.d139.s1	who	20	22	O	who	who	who	WP	False
DDI-MedLine.d139.s1	had	24	26	O	had	had	had	VBD	False
DDI-MedLine.d139.s1	had	28	30	O	had	had	had	VBD	False
DDI-MedLine.d139.s1	a	32	32	O	a	a	a	DT	False
DDI-MedLine.d139.s1	new	34	36	O	new	new	new	JJ	False
DDI-MedLine.d139.s1	acute	38	42	O	acute	ute	cute	NN	False
DDI-MedLine.d139.s1	episode	44	50	O	episode	ode	sode	NN	False
DDI-MedLine.d139.s1	despite	52	58	O	despite	ite	pite	IN	False
DDI-MedLine.d139.s1	seemingly	60	68	O	seemingly	gly	ngly	RB	False
DDI-MedLine.d139.s1	adequate	70	77	O	adequate	ate	uate	NN	False
DDI-MedLine.d139.s1	treatment	79	87	O	treatment	ent	ment	NN	False
DDI-MedLine.d139.s1	were	89	92	O	were	ere	were	VBD	False
DDI-MedLine.d139.s1	selected	94	101	O	selected	ted	cted	VBN	False
DDI-MedLine.d139.s1	.	102	102	O	.	.	.	.	False

DDI-MedLine.d139.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d139.s2	these	3	7	O	these	ese	hese	DT	False
DDI-MedLine.d139.s2	six	9	11	O	six	six	six	CD	False
DDI-MedLine.d139.s2	cases	13	17	O	cases	ses	ases	NNS	False
DDI-MedLine.d139.s2	it	19	20	O	it	it	it	PRP	False
DDI-MedLine.d139.s2	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d139.s2	demonstrated	26	37	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d139.s2	that	39	42	O	that	hat	that	IN	False
DDI-MedLine.d139.s2	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d139.s2	neuroleptics	48	59	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d139.s2	dosage	61	66	O	dosage	age	sage	NN	False
DDI-MedLine.d139.s2	was	68	70	O	was	was	was	VBD	False
DDI-MedLine.d139.s2	inappropriate	72	84	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d139.s2	,	85	85	O	,	,	,	,	False
DDI-MedLine.d139.s2	being	87	91	O	being	ing	eing	VBG	False
DDI-MedLine.d139.s2	either	93	98	O	either	her	ther	DT	False
DDI-MedLine.d139.s2	too	100	102	O	too	too	too	RB	False
DDI-MedLine.d139.s2	high	104	107	O	high	igh	high	JJ	False
DDI-MedLine.d139.s2	or	109	110	O	or	or	or	CC	False
DDI-MedLine.d139.s2	too	112	114	O	too	too	too	RB	False
DDI-MedLine.d139.s2	low	116	118	O	low	low	low	JJ	False
DDI-MedLine.d139.s2	as	120	121	O	as	as	as	IN	False
DDI-MedLine.d139.s2	judged	123	128	O	judged	ged	dged	NN	False
DDI-MedLine.d139.s2	from	130	133	O	from	rom	from	IN	False
DDI-MedLine.d139.s2	the	135	137	O	the	the	the	DT	False
DDI-MedLine.d139.s2	plasma	139	144	O	plasma	sma	asma	NN	False
DDI-MedLine.d139.s2	concentrations	146	159	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d139.s2	.	160	160	O	.	.	.	.	False

DDI-MedLine.d139.s3	Ways	0	3	O	Ways	ays	Ways	NNS	False
DDI-MedLine.d139.s3	of	5	6	O	of	of	of	IN	False
DDI-MedLine.d139.s3	improving	8	16	O	improving	ing	ving	VBG	False
DDI-MedLine.d139.s3	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d139.s3	adequacy	22	29	O	adequacy	acy	uacy	NN	False
DDI-MedLine.d139.s3	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d139.s3	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d139.s3	treatment	38	46	O	treatment	ent	ment	NN	False
DDI-MedLine.d139.s3	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d139.s3	psychotic	51	59	O	psychotic	tic	otic	JJ	False
DDI-MedLine.d139.s3	patients	61	68	O	patients	nts	ents	NNS	False
DDI-MedLine.d139.s3	with	70	73	O	with	ith	with	IN	False
DDI-MedLine.d139.s3	neuroleptics	75	86	B-group	neuroleptics	ics	tics	NNS	False
DDI-MedLine.d139.s3	are	88	90	O	are	are	are	VBP	False
DDI-MedLine.d139.s3	discussed	92	100	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d139.s3	.	101	101	O	.	.	.	.	False

DDI-MedLine.d69.s0	Differential	0	11	O	Differential	ial	tial	NN	False
DDI-MedLine.d69.s0	regulation	13	22	O	regulation	ion	tion	NN	False
DDI-MedLine.d69.s0	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d69.s0	tyrosine	27	34	O	tyrosine	ine	sine	NN	drug
DDI-MedLine.d69.s0	phosphorylation	36	50	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s0	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d69.s0	tumor	55	59	O	tumor	mor	umor	NN	False
DDI-MedLine.d69.s0	cells	61	65	O	cells	lls	ells	NNS	False
DDI-MedLine.d69.s0	by	67	68	O	by	by	by	IN	False
DDI-MedLine.d69.s0	contortrostatin	70	84	B-drug_n	contortrostatin	tin	atin	NN	False
DDI-MedLine.d69.s0	,	85	85	O	,	,	,	,	False
DDI-MedLine.d69.s0	a	87	87	O	a	a	a	DT	False
DDI-MedLine.d69.s0	homodimeric	89	99	O	homodimeric	ric	eric	NN	False
DDI-MedLine.d69.s0	disintegrin	101	111	O	disintegrin	rin	grin	NN	False
DDI-MedLine.d69.s0	,	112	112	O	,	,	,	,	False
DDI-MedLine.d69.s0	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d69.s0	monomeric	118	126	O	monomeric	ric	eric	NN	False
DDI-MedLine.d69.s0	disintegrins	128	139	O	disintegrins	ins	rins	NNS	False
DDI-MedLine.d69.s0	echistatin	141	150	B-drug_n	echistatin	tin	atin	NN	False
DDI-MedLine.d69.s0	and	152	154	O	and	and	and	CC	False
DDI-MedLine.d69.s0	flavoridin	156	165	B-drug_n	flavoridin	din	idin	NN	False
DDI-MedLine.d69.s0	.	166	166	O	.	.	.	.	False

DDI-MedLine.d69.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d69.s1	homodimeric	4	14	O	homodimeric	ric	eric	NN	False
DDI-MedLine.d69.s1	disintegrin	16	26	O	disintegrin	rin	grin	NN	False
DDI-MedLine.d69.s1	contortrostatin	28	42	B-drug_n	contortrostatin	tin	atin	NN	False
DDI-MedLine.d69.s1	was	44	46	O	was	was	was	VBD	False
DDI-MedLine.d69.s1	compared	48	55	O	compared	red	ared	VBN	False
DDI-MedLine.d69.s1	directly	57	64	O	directly	tly	ctly	RB	False
DDI-MedLine.d69.s1	to	66	67	O	to	to	to	TO	False
DDI-MedLine.d69.s1	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d69.s1	monomeric	73	81	O	monomeric	ric	eric	NN	False
DDI-MedLine.d69.s1	disintegrins	83	94	O	disintegrins	ins	rins	NNS	False
DDI-MedLine.d69.s1	echistatin	96	105	B-drug_n	echistatin	tin	atin	NN	False
DDI-MedLine.d69.s1	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d69.s1	flavoridin	111	120	B-drug_n	flavoridin	din	idin	NN	False
DDI-MedLine.d69.s1	for	122	124	O	for	for	for	IN	False
DDI-MedLine.d69.s1	the	126	128	O	the	the	the	DT	False
DDI-MedLine.d69.s1	ability	130	136	O	ability	ity	lity	NN	False
DDI-MedLine.d69.s1	to	138	139	O	to	to	to	TO	False
DDI-MedLine.d69.s1	affect	141	146	O	affect	ect	fect	NN	False
DDI-MedLine.d69.s1	protein	148	154	O	protein	ein	tein	NN	False
DDI-MedLine.d69.s1	tyrosine	156	163	O	tyrosine	ine	sine	NN	drug
DDI-MedLine.d69.s1	phosphorylation	165	179	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s1	in	181	182	O	in	in	in	IN	False
DDI-MedLine.d69.s1	tumor	184	188	O	tumor	mor	umor	NN	False
DDI-MedLine.d69.s1	cells	190	194	O	cells	lls	ells	NNS	False
DDI-MedLine.d69.s1	.	195	195	O	.	.	.	.	False

DDI-MedLine.d69.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d69.s2	was	3	5	O	was	was	was	VBD	False
DDI-MedLine.d69.s2	observed	7	14	O	observed	ved	rved	VBN	False
DDI-MedLine.d69.s2	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d69.s2	contortrostatin	21	35	B-drug_n	contortrostatin	tin	atin	NN	False
DDI-MedLine.d69.s2	had	37	39	O	had	had	had	VBD	False
DDI-MedLine.d69.s2	a	41	41	O	a	a	a	DT	False
DDI-MedLine.d69.s2	dramatic	43	50	O	dramatic	tic	atic	JJ	False
DDI-MedLine.d69.s2	effect	52	57	O	effect	ect	fect	NN	False
DDI-MedLine.d69.s2	on	59	60	O	on	on	on	IN	False
DDI-MedLine.d69.s2	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d69.s2	tyrosine	66	73	O	tyrosine	ine	sine	NN	drug
DDI-MedLine.d69.s2	phosphorylation	75	89	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s2	status	91	96	O	status	tus	atus	NN	False
DDI-MedLine.d69.s2	of	98	99	O	of	of	of	IN	False
DDI-MedLine.d69.s2	several	101	107	O	several	ral	eral	JJ	False
DDI-MedLine.d69.s2	proteins	109	116	O	proteins	ins	eins	NNS	False
DDI-MedLine.d69.s2	in	118	119	O	in	in	in	IN	False
DDI-MedLine.d69.s2	T24	121	123	O	T24	T24	T24	NN	brand
DDI-MedLine.d69.s2	human	125	129	O	human	man	uman	NN	False
DDI-MedLine.d69.s2	bladder	131	137	O	bladder	der	dder	NN	False
DDI-MedLine.d69.s2	cancer	139	144	O	cancer	cer	ncer	NN	False
DDI-MedLine.d69.s2	cells	146	150	O	cells	lls	ells	NNS	False
DDI-MedLine.d69.s2	,	151	151	O	,	,	,	,	False
DDI-MedLine.d69.s2	including	153	161	O	including	ing	ding	VBG	False
DDI-MedLine.d69.s2	robust	163	168	O	robust	ust	bust	NN	False
DDI-MedLine.d69.s2	induction	170	178	O	induction	ion	tion	NN	False
DDI-MedLine.d69.s2	of	180	181	O	of	of	of	IN	False
DDI-MedLine.d69.s2	phosphorylation	183	197	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s2	of	199	200	O	of	of	of	IN	False
DDI-MedLine.d69.s2	proteins	202	209	O	proteins	ins	eins	NNS	False
DDI-MedLine.d69.s2	in	211	212	O	in	in	in	IN	False
DDI-MedLine.d69.s2	the	214	216	O	the	the	the	DT	False
DDI-MedLine.d69.s2	range	218	222	O	range	nge	ange	NN	False
DDI-MedLine.d69.s2	of	224	225	O	of	of	of	IN	False
DDI-MedLine.d69.s2	120-140	227	233	O	120-140	140	-140	JJ	False
DDI-MedLine.d69.s2	kDa	235	237	O	kDa	kDa	kDa	NN	False
DDI-MedLine.d69.s2	.	238	238	O	.	.	.	.	False

DDI-MedLine.d69.s3	Echistatin	0	9	B-drug_n	Echistatin	tin	atin	NN	False
DDI-MedLine.d69.s3	alone	11	15	O	alone	one	lone	RB	False
DDI-MedLine.d69.s3	had	17	19	O	had	had	had	VBD	False
DDI-MedLine.d69.s3	no	21	22	O	no	no	no	DT	False
DDI-MedLine.d69.s3	effect	24	29	O	effect	ect	fect	NN	False
DDI-MedLine.d69.s3	on	31	32	O	on	on	on	IN	False
DDI-MedLine.d69.s3	tyrosine	34	41	O	tyrosine	ine	sine	NN	drug
DDI-MedLine.d69.s3	phosphorylation	43	57	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s3	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d69.s3	T24	62	64	O	T24	T24	T24	NN	brand
DDI-MedLine.d69.s3	cells	66	70	O	cells	lls	ells	NNS	False
DDI-MedLine.d69.s3	,	71	71	O	,	,	,	,	False
DDI-MedLine.d69.s3	but	73	75	O	but	but	but	CC	False
DDI-MedLine.d69.s3	dose-dependently	77	92	O	dose-dependently	tly	ntly	RB	False
DDI-MedLine.d69.s3	inhibits	94	101	O	inhibits	its	bits	NNS	False
DDI-MedLine.d69.s3	the	103	105	O	the	the	the	DT	False
DDI-MedLine.d69.s3	effects	107	113	O	effects	cts	ects	NNS	False
DDI-MedLine.d69.s3	of	115	116	O	of	of	of	IN	False
DDI-MedLine.d69.s3	contortrostatin	118	132	B-drug_n	contortrostatin	tin	atin	NN	False
DDI-MedLine.d69.s3	when	134	137	O	when	hen	when	WRB	False
DDI-MedLine.d69.s3	both	139	142	O	both	oth	both	DT	False
DDI-MedLine.d69.s3	are	144	146	O	are	are	are	VBP	False
DDI-MedLine.d69.s3	added	148	152	O	added	ded	dded	VBD	False
DDI-MedLine.d69.s3	simultaneously	154	167	O	simultaneously	sly	usly	RB	False
DDI-MedLine.d69.s3	.	168	168	O	.	.	.	.	False

DDI-MedLine.d69.s4	Among	0	4	O	Among	ong	mong	IN	False
DDI-MedLine.d69.s4	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d69.s4	proteins	10	17	O	proteins	ins	eins	NNS	False
DDI-MedLine.d69.s4	that	19	22	O	that	hat	that	IN	False
DDI-MedLine.d69.s4	undergo	24	30	O	undergo	rgo	ergo	NN	False
DDI-MedLine.d69.s4	tyrosine	32	39	O	tyrosine	ine	sine	NN	drug
DDI-MedLine.d69.s4	phosphorylation	41	55	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s4	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d69.s4	response	60	67	O	response	nse	onse	NN	False
DDI-MedLine.d69.s4	to	69	70	O	to	to	to	TO	False
DDI-MedLine.d69.s4	contortrostatin	72	86	B-drug_n	contortrostatin	tin	atin	NN	False
DDI-MedLine.d69.s4	treatment	88	96	O	treatment	ent	ment	NN	False
DDI-MedLine.d69.s4	is	98	99	O	is	is	is	VBZ	False
DDI-MedLine.d69.s4	CAS	101	103	O	CAS	CAS	CAS	NN	brand
DDI-MedLine.d69.s4	,	104	104	O	,	,	,	,	False
DDI-MedLine.d69.s4	a	106	106	O	a	a	a	DT	False
DDI-MedLine.d69.s4	130	108	110	O	130	130	130	CD	False
DDI-MedLine.d69.s4	kDa	112	114	O	kDa	kDa	kDa	NN	False
DDI-MedLine.d69.s4	adapter	116	122	O	adapter	ter	pter	NN	False
DDI-MedLine.d69.s4	protein	124	130	O	protein	ein	tein	NN	False
DDI-MedLine.d69.s4	involved	132	139	O	involved	ved	lved	VBN	False
DDI-MedLine.d69.s4	in	141	142	O	in	in	in	IN	False
DDI-MedLine.d69.s4	integrin	144	151	O	integrin	rin	grin	NN	False
DDI-MedLine.d69.s4	signaling	153	161	O	signaling	ing	ling	VBG	False
DDI-MedLine.d69.s4	.	162	162	O	.	.	.	.	False

DDI-MedLine.d69.s5	Flavoridin	0	9	B-drug_n	Flavoridin	din	idin	NN	False
DDI-MedLine.d69.s5	alone	11	15	O	alone	one	lone	RB	False
DDI-MedLine.d69.s5	was	17	19	O	was	was	was	VBD	False
DDI-MedLine.d69.s5	found	21	25	O	found	und	ound	NN	False
DDI-MedLine.d69.s5	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d69.s5	have	30	33	O	have	ave	have	VB	False
DDI-MedLine.d69.s5	no	35	36	O	no	no	no	DT	False
DDI-MedLine.d69.s5	effect	38	43	O	effect	ect	fect	NN	False
DDI-MedLine.d69.s5	on	45	46	O	on	on	on	IN	False
DDI-MedLine.d69.s5	CAS	48	50	O	CAS	CAS	CAS	NN	brand
DDI-MedLine.d69.s5	,	51	51	O	,	,	,	,	False
DDI-MedLine.d69.s5	but	53	55	O	but	but	but	CC	False
DDI-MedLine.d69.s5	can	57	59	O	can	can	can	MD	False
DDI-MedLine.d69.s5	completely	61	70	O	completely	ely	tely	RB	False
DDI-MedLine.d69.s5	block	72	76	O	block	ock	lock	NN	False
DDI-MedLine.d69.s5	contortrostatin-induced	78	100	O	contortrostatin-induced	ced	uced	JJ	False
DDI-MedLine.d69.s5	phosphorylation	102	116	O	phosphorylation	ion	tion	NN	False
DDI-MedLine.d69.s5	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d69.s5	this	121	124	O	this	his	this	DT	False
DDI-MedLine.d69.s5	protein	126	132	O	protein	ein	tein	NN	False
DDI-MedLine.d69.s5	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d69.s5	MDA-MB-435	137	146	O	MDA-MB-435	435	-435	NN	brand
DDI-MedLine.d69.s5	cells	148	152	O	cells	lls	ells	NNS	False
DDI-MedLine.d69.s5	.	153	153	O	.	.	.	.	False

DDI-MedLine.d69.s6	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d69.s6	observations	6	17	O	observations	ons	ions	NNS	False
DDI-MedLine.d69.s6	strongly	19	26	O	strongly	gly	ngly	RB	False
DDI-MedLine.d69.s6	suggest	28	34	O	suggest	est	gest	NN	False
DDI-MedLine.d69.s6	that	36	39	O	that	hat	that	IN	False
DDI-MedLine.d69.s6	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d69.s6	homodimeric	45	55	O	homodimeric	ric	eric	NN	False
DDI-MedLine.d69.s6	structure	57	65	O	structure	ure	ture	NN	False
DDI-MedLine.d69.s6	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d69.s6	contortrostatin	70	84	B-drug_n	contortrostatin	tin	atin	NN	False
DDI-MedLine.d69.s6	functionally	86	97	O	functionally	lly	ally	RB	False
DDI-MedLine.d69.s6	distinguishes	99	111	O	distinguishes	hes	shes	NNS	False
DDI-MedLine.d69.s6	it	113	114	O	it	it	it	PRP	False
DDI-MedLine.d69.s6	from	116	119	O	from	rom	from	IN	False
DDI-MedLine.d69.s6	other	121	125	O	other	her	ther	JJ	False
DDI-MedLine.d69.s6	monomeric	127	135	O	monomeric	ric	eric	NN	False
DDI-MedLine.d69.s6	members	137	143	O	members	ers	bers	NNS	False
DDI-MedLine.d69.s6	of	145	146	O	of	of	of	IN	False
DDI-MedLine.d69.s6	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d69.s6	disintegrin	152	162	O	disintegrin	rin	grin	NN	False
DDI-MedLine.d69.s6	family	164	169	O	family	ily	mily	NN	False
DDI-MedLine.d69.s6	.	170	170	O	.	.	.	.	False

DDI-MedLine.d1.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d1.s0	Drug	1	4	O	Drug	rug	Drug	NN	False
DDI-MedLine.d1.s0	treatment	6	14	O	treatment	ent	ment	NN	False
DDI-MedLine.d1.s0	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d1.s0	erection	19	26	O	erection	ion	tion	NN	False
DDI-MedLine.d1.s0	disorders	28	36	O	disorders	ers	ders	NNS	False
DDI-MedLine.d1.s0	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d1.s0	patients	41	48	O	patients	nts	ents	NNS	False
DDI-MedLine.d1.s0	with	50	53	O	with	ith	with	IN	False
DDI-MedLine.d1.s0	cardiovascular	55	68	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d1.s0	disease	70	76	O	disease	ase	ease	NN	False
DDI-MedLine.d1.s0	]	77	77	O	]	]	]	NN	False
DDI-MedLine.d1.s0	Erectile	79	86	O	Erectile	ile	tile	NN	False
DDI-MedLine.d1.s0	dysfunction	88	98	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d1.s0	is	100	101	O	is	is	is	VBZ	False
DDI-MedLine.d1.s0	a	103	103	O	a	a	a	DT	False
DDI-MedLine.d1.s0	frequent	105	112	O	frequent	ent	uent	NN	False
DDI-MedLine.d1.s0	condition	114	122	O	condition	ion	tion	NN	False
DDI-MedLine.d1.s0	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d1.s0	cardiovascular	127	140	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d1.s0	patients	142	149	O	patients	nts	ents	NNS	False
DDI-MedLine.d1.s0	.	150	150	O	.	.	.	.	False

DDI-MedLine.d1.s1	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d1.s1	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d1.s1	arrival	10	16	O	arrival	val	ival	NN	False
DDI-MedLine.d1.s1	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d1.s1	oral	21	24	O	oral	ral	oral	JJ	False
DDI-MedLine.d1.s1	erection-supporting	26	44	B-group	erection-supporting	ing	ting	NN	False
DDI-MedLine.d1.s1	medication	46	55	I-group	medication	ion	tion	NN	False
DDI-MedLine.d1.s1	,	56	56	O	,	,	,	,	False
DDI-MedLine.d1.s1	patients	58	65	O	patients	nts	ents	NNS	False
DDI-MedLine.d1.s1	want	67	70	O	want	ant	want	NN	False
DDI-MedLine.d1.s1	to	72	73	O	to	to	to	TO	False
DDI-MedLine.d1.s1	know	75	78	O	know	now	know	VB	False
DDI-MedLine.d1.s1	how	80	82	O	how	how	how	WRB	False
DDI-MedLine.d1.s1	safe	84	87	O	safe	afe	safe	JJ	False
DDI-MedLine.d1.s1	sexual	89	94	O	sexual	ual	xual	JJ	False
DDI-MedLine.d1.s1	activity	96	103	O	activity	ity	vity	NN	False
DDI-MedLine.d1.s1	is	105	106	O	is	is	is	VBZ	False
DDI-MedLine.d1.s1	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d1.s1	cardiovascular	111	124	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d1.s1	disease	126	132	O	disease	ase	ease	NN	False
DDI-MedLine.d1.s1	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d1.s1	general	137	143	O	general	ral	eral	JJ	False
DDI-MedLine.d1.s1	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d1.s1	during	149	154	O	during	ing	ring	IN	False
DDI-MedLine.d1.s1	use	156	158	O	use	use	use	NN	False
DDI-MedLine.d1.s1	of	160	161	O	of	of	of	IN	False
DDI-MedLine.d1.s1	erection-supporting	163	181	B-group	erection-supporting	ing	ting	NN	False
DDI-MedLine.d1.s1	medication	183	192	I-group	medication	ion	tion	NN	False
DDI-MedLine.d1.s1	in	194	195	O	in	in	in	IN	False
DDI-MedLine.d1.s1	particular	197	206	O	particular	lar	ular	JJ	False
DDI-MedLine.d1.s1	.	207	207	O	.	.	.	.	False

DDI-MedLine.d1.s2	Sexual	0	5	O	Sexual	ual	xual	JJ	False
DDI-MedLine.d1.s2	intercourse	7	17	O	intercourse	rse	urse	NN	False
DDI-MedLine.d1.s2	with	19	22	O	with	ith	with	IN	False
DDI-MedLine.d1.s2	a	24	24	O	a	a	a	DT	False
DDI-MedLine.d1.s2	steady	26	31	O	steady	ady	eady	JJ	False
DDI-MedLine.d1.s2	partner	33	39	O	partner	ner	tner	NN	False
DDI-MedLine.d1.s2	causes	41	46	O	causes	ses	uses	NNS	False
DDI-MedLine.d1.s2	no	48	49	O	no	no	no	DT	False
DDI-MedLine.d1.s2	more	51	54	O	more	ore	more	RBR	False
DDI-MedLine.d1.s2	cardiovascular	56	69	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d1.s2	risk	71	74	O	risk	isk	risk	NN	False
DDI-MedLine.d1.s2	than	76	79	O	than	han	than	IN	False
DDI-MedLine.d1.s2	normal	81	86	O	normal	mal	rmal	JJ	False
DDI-MedLine.d1.s2	daily	88	92	O	daily	ily	aily	JJ	False
DDI-MedLine.d1.s2	activities	94	103	O	activities	ies	ties	NNS	False
DDI-MedLine.d1.s2	such	105	108	O	such	uch	such	JJ	False
DDI-MedLine.d1.s2	as	110	111	O	as	as	as	IN	False
DDI-MedLine.d1.s2	ironing	113	119	O	ironing	ing	ning	VBG	False
DDI-MedLine.d1.s2	,	120	120	O	,	,	,	,	False
DDI-MedLine.d1.s2	2	122	122	O	2	2	2	CD	False
DDI-MedLine.d1.s2	kilometers	124	133	O	kilometers	ers	ters	NNS	False
DDI-MedLine.d1.s2	of	135	136	O	of	of	of	IN	False
DDI-MedLine.d1.s2	walking	138	144	O	walking	ing	king	VBG	False
DDI-MedLine.d1.s2	without	146	152	O	without	out	hout	IN	False
DDI-MedLine.d1.s2	climbing	154	161	O	climbing	ing	bing	VBG	False
DDI-MedLine.d1.s2	,	162	162	O	,	,	,	,	False
DDI-MedLine.d1.s2	paperhanging	164	175	O	paperhanging	ing	ging	VBG	False
DDI-MedLine.d1.s2	,	176	176	O	,	,	,	,	False
DDI-MedLine.d1.s2	playing	178	184	O	playing	ing	ying	VBG	False
DDI-MedLine.d1.s2	golf	186	189	O	golf	olf	golf	NN	False
DDI-MedLine.d1.s2	or	191	192	O	or	or	or	CC	False
DDI-MedLine.d1.s2	gardening	194	202	O	gardening	ing	ning	NN	False
DDI-MedLine.d1.s2	.	203	203	O	.	.	.	.	False

DDI-MedLine.d1.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d1.s3	relative	4	11	O	relative	ive	tive	NN	False
DDI-MedLine.d1.s3	risk	13	16	O	risk	isk	risk	NN	False
DDI-MedLine.d1.s3	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d1.s3	myocardial	21	30	O	myocardial	ial	dial	NN	False
DDI-MedLine.d1.s3	infarction	32	41	O	infarction	ion	tion	NN	False
DDI-MedLine.d1.s3	during	43	48	O	during	ing	ring	IN	False
DDI-MedLine.d1.s3	sexual	50	55	O	sexual	ual	xual	JJ	False
DDI-MedLine.d1.s3	activity	57	64	O	activity	ity	vity	NN	False
DDI-MedLine.d1.s3	is	66	67	O	is	is	is	VBZ	False
DDI-MedLine.d1.s3	not	69	71	O	not	not	not	RB	False
DDI-MedLine.d1.s3	significantly	73	85	O	significantly	tly	ntly	RB	False
DDI-MedLine.d1.s3	higher	87	92	O	higher	her	gher	JJR	False
DDI-MedLine.d1.s3	than	94	97	O	than	han	than	IN	False
DDI-MedLine.d1.s3	for	99	101	O	for	for	for	IN	False
DDI-MedLine.d1.s3	healthy	103	109	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d1.s3	persons	111	117	O	persons	ons	sons	NNS	False
DDI-MedLine.d1.s3	.	118	118	O	.	.	.	.	False

DDI-MedLine.d1.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d1.s4	incidence	4	12	O	incidence	nce	ence	NN	False
DDI-MedLine.d1.s4	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d1.s4	cardiovascular	17	30	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d1.s4	morbidity	32	40	O	morbidity	ity	dity	NN	False
DDI-MedLine.d1.s4	and	42	44	O	and	and	and	CC	False
DDI-MedLine.d1.s4	mortality	46	54	O	mortality	ity	lity	NN	False
DDI-MedLine.d1.s4	is	56	57	O	is	is	is	VBZ	False
DDI-MedLine.d1.s4	not	59	61	O	not	not	not	RB	False
DDI-MedLine.d1.s4	higher	63	68	O	higher	her	gher	JJR	False
DDI-MedLine.d1.s4	among	70	74	O	among	ong	mong	IN	False
DDI-MedLine.d1.s4	users	76	80	O	users	ers	sers	NNS	False
DDI-MedLine.d1.s4	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d1.s4	sildenafil	85	94	B-drug	sildenafil	fil	afil	NN	False
DDI-MedLine.d1.s4	.	95	95	O	.	.	.	.	False

DDI-MedLine.d1.s5	Sildenafil	0	9	B-drug	Sildenafil	fil	afil	NN	False
DDI-MedLine.d1.s5	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d1.s5	contraindicated	14	28	O	contraindicated	ted	ated	VBN	False
DDI-MedLine.d1.s5	in	30	31	O	in	in	in	IN	False
DDI-MedLine.d1.s5	patients	33	40	O	patients	nts	ents	NNS	False
DDI-MedLine.d1.s5	using	42	46	O	using	ing	sing	VBG	False
DDI-MedLine.d1.s5	long-acting	48	58	B-group	long-acting	ing	ting	NN	False
DDI-MedLine.d1.s5	nitrates	60	67	I-group	nitrates	tes	ates	NNS	False
DDI-MedLine.d1.s5	or	69	70	O	or	or	or	CC	False
DDI-MedLine.d1.s5	who	72	74	O	who	who	who	WP	False
DDI-MedLine.d1.s5	may	76	78	O	may	may	may	MD	False
DDI-MedLine.d1.s5	need	80	83	O	need	eed	need	NN	False
DDI-MedLine.d1.s5	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d1.s5	use	88	90	O	use	use	use	NN	False
DDI-MedLine.d1.s5	short-acting	92	103	B-group	short-acting	ing	ting	NN	False
DDI-MedLine.d1.s5	nitrates	105	112	I-group	nitrates	tes	ates	NNS	False
DDI-MedLine.d1.s5	,	113	113	O	,	,	,	,	False
DDI-MedLine.d1.s5	because	115	121	O	because	use	ause	IN	False
DDI-MedLine.d1.s5	the	123	125	O	the	the	the	DT	False
DDI-MedLine.d1.s5	combination	127	137	O	combination	ion	tion	NN	False
DDI-MedLine.d1.s5	may	139	141	O	may	may	may	MD	False
DDI-MedLine.d1.s5	cause	143	147	O	cause	use	ause	NN	False
DDI-MedLine.d1.s5	a	149	149	O	a	a	a	DT	False
DDI-MedLine.d1.s5	sharp	151	155	O	sharp	arp	harp	JJ	False
DDI-MedLine.d1.s5	fall	157	160	O	fall	all	fall	NN	False
DDI-MedLine.d1.s5	of	162	163	O	of	of	of	IN	False
DDI-MedLine.d1.s5	the	165	167	O	the	the	the	DT	False
DDI-MedLine.d1.s5	blood	169	173	O	blood	ood	lood	NN	False
DDI-MedLine.d1.s5	pressure	175	182	O	pressure	ure	sure	NN	False
DDI-MedLine.d1.s5	.	183	183	O	.	.	.	.	False

DDI-MedLine.d1.s6	No	0	1	O	No	No	No	DT	False
DDI-MedLine.d1.s6	interactions	3	14	O	interactions	ons	ions	NNS	False
DDI-MedLine.d1.s6	have	16	19	O	have	ave	have	VB	False
DDI-MedLine.d1.s6	been	21	24	O	been	een	been	VBN	False
DDI-MedLine.d1.s6	observed	26	33	O	observed	ved	rved	VBN	False
DDI-MedLine.d1.s6	with	35	38	O	with	ith	with	IN	False
DDI-MedLine.d1.s6	beta-receptor	40	52	B-group	beta-receptor	tor	ptor	NN	False
DDI-MedLine.d1.s6	blockers	54	61	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d1.s6	,	62	62	O	,	,	,	,	False
DDI-MedLine.d1.s6	calcium	64	70	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d1.s6	antagonists	72	82	I-group	antagonists	sts	ists	NNS	False
DDI-MedLine.d1.s6	,	83	83	O	,	,	,	,	False
DDI-MedLine.d1.s6	thiazide	85	92	B-group	thiazide	ide	zide	NN	False
DDI-MedLine.d1.s6	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d1.s6	loop	98	101	B-group	loop	oop	loop	NN	False
DDI-MedLine.d1.s6	diuretics	103	111	I-group	diuretics	ics	tics	NNS	False
DDI-MedLine.d1.s6	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d1.s6	ACE	117	119	B-group	ACE	ACE	ACE	NN	brand
DDI-MedLine.d1.s6	inhibitors	121	130	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d1.s6	.	131	131	O	.	.	.	.	False

DDI-MedLine.d1.s7	Before	0	5	O	Before	ore	fore	IN	False
DDI-MedLine.d1.s7	prescribing	7	17	O	prescribing	ing	bing	VBG	False
DDI-MedLine.d1.s7	a	19	19	O	a	a	a	DT	False
DDI-MedLine.d1.s7	symptomatic	21	31	O	symptomatic	tic	atic	JJ	False
DDI-MedLine.d1.s7	(	33	33	O	(	(	(	(	False
DDI-MedLine.d1.s7	pharmaceutical	34	47	O	pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d1.s7	)	48	48	O	)	)	)	)	False
DDI-MedLine.d1.s7	treatment	50	58	O	treatment	ent	ment	NN	False
DDI-MedLine.d1.s7	for	60	62	O	for	for	for	IN	False
DDI-MedLine.d1.s7	patients	64	71	O	patients	nts	ents	NNS	False
DDI-MedLine.d1.s7	with	73	76	O	with	ith	with	IN	False
DDI-MedLine.d1.s7	an	78	79	O	an	an	an	DT	False
DDI-MedLine.d1.s7	erection	81	88	O	erection	ion	tion	NN	False
DDI-MedLine.d1.s7	disorder	90	97	O	disorder	der	rder	NN	False
DDI-MedLine.d1.s7	,	98	98	O	,	,	,	,	False
DDI-MedLine.d1.s7	attention	100	108	O	attention	ion	tion	NN	False
DDI-MedLine.d1.s7	should	110	115	O	should	uld	ould	MD	False
DDI-MedLine.d1.s7	be	117	118	O	be	be	be	VB	False
DDI-MedLine.d1.s7	given	120	124	O	given	ven	iven	VBN	False
DDI-MedLine.d1.s7	tot	126	128	O	tot	tot	tot	NN	False
DDI-MedLine.d1.s7	the	130	132	O	the	the	the	DT	False
DDI-MedLine.d1.s7	sexological	134	144	O	sexological	cal	ical	JJ	False
DDI-MedLine.d1.s7	,	145	145	O	,	,	,	,	False
DDI-MedLine.d1.s7	psychological	147	159	O	psychological	cal	ical	JJ	False
DDI-MedLine.d1.s7	and	161	163	O	and	and	and	CC	False
DDI-MedLine.d1.s7	medical	165	171	O	medical	cal	ical	JJ	False
DDI-MedLine.d1.s7	backgrounds	173	183	O	backgrounds	nds	unds	NNS	False
DDI-MedLine.d1.s7	of	185	186	O	of	of	of	IN	False
DDI-MedLine.d1.s7	the	188	190	O	the	the	the	DT	False
DDI-MedLine.d1.s7	disorder	192	199	O	disorder	der	rder	NN	False
DDI-MedLine.d1.s7	.	200	200	O	.	.	.	.	False

DDI-MedLine.d1.s8	Secondary	0	8	O	Secondary	ary	dary	JJ	False
DDI-MedLine.d1.s8	prevention	10	19	O	prevention	ion	tion	NN	False
DDI-MedLine.d1.s8	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d1.s8	atherosclerotic	24	38	O	atherosclerotic	tic	otic	JJ	False
DDI-MedLine.d1.s8	risk	40	43	O	risk	isk	risk	NN	False
DDI-MedLine.d1.s8	factors	45	51	O	factors	ors	tors	NNS	False
DDI-MedLine.d1.s8	is	53	54	O	is	is	is	VBZ	False
DDI-MedLine.d1.s8	also	56	59	O	also	lso	also	RB	False
DDI-MedLine.d1.s8	important	61	69	O	important	ant	tant	JJ	False
DDI-MedLine.d1.s8	:	70	70	O	:	:	:	:	False
DDI-MedLine.d1.s8	regulation	72	81	O	regulation	ion	tion	NN	False
DDI-MedLine.d1.s8	of	83	84	O	of	of	of	IN	False
DDI-MedLine.d1.s8	blood	86	90	O	blood	ood	lood	NN	False
DDI-MedLine.d1.s8	pressure	92	99	O	pressure	ure	sure	NN	False
DDI-MedLine.d1.s8	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d1.s8	blood	105	109	O	blood	ood	lood	NN	False
DDI-MedLine.d1.s8	sugar	111	115	O	sugar	gar	ugar	NN	False
DDI-MedLine.d1.s8	level	117	121	O	level	vel	evel	NN	False
DDI-MedLine.d1.s8	,	122	122	O	,	,	,	,	False
DDI-MedLine.d1.s8	hyperlipidaemia	124	138	O	hyperlipidaemia	mia	emia	NN	False
DDI-MedLine.d1.s8	and	140	142	O	and	and	and	CC	False
DDI-MedLine.d1.s8	obesity	144	150	O	obesity	ity	sity	NN	False
DDI-MedLine.d1.s8	,	151	151	O	,	,	,	,	False
DDI-MedLine.d1.s8	as	153	154	O	as	as	as	IN	False
DDI-MedLine.d1.s8	well	156	159	O	well	ell	well	RB	False
DDI-MedLine.d1.s8	as	161	162	O	as	as	as	IN	False
DDI-MedLine.d1.s8	a	164	164	O	a	a	a	DT	False
DDI-MedLine.d1.s8	change	166	171	O	change	nge	ange	NN	False
DDI-MedLine.d1.s8	of	173	174	O	of	of	of	IN	False
DDI-MedLine.d1.s8	lifestyle	176	184	O	lifestyle	yle	tyle	NN	False
DDI-MedLine.d1.s8	(	186	186	O	(	(	(	(	False
DDI-MedLine.d1.s8	giving	187	192	O	giving	ing	ving	VBG	False
DDI-MedLine.d1.s8	up	194	195	O	up	up	up	RB	False
DDI-MedLine.d1.s8	smoking	197	203	O	smoking	ing	king	NN	False
DDI-MedLine.d1.s8	,	204	204	O	,	,	,	,	False
DDI-MedLine.d1.s8	adapting	206	213	O	adapting	ing	ting	VBG	False
DDI-MedLine.d1.s8	of	215	216	O	of	of	of	IN	False
DDI-MedLine.d1.s8	diet	218	221	O	diet	iet	diet	NN	False
DDI-MedLine.d1.s8	and	223	225	O	and	and	and	CC	False
DDI-MedLine.d1.s8	more	227	230	O	more	ore	more	RBR	False
DDI-MedLine.d1.s8	physical	232	239	O	physical	cal	ical	JJ	False
DDI-MedLine.d1.s8	exertion	241	248	O	exertion	ion	tion	NN	False
DDI-MedLine.d1.s8	)	249	249	O	)	)	)	)	False
DDI-MedLine.d1.s8	.	250	250	O	.	.	.	.	False

DDI-MedLine.d1.s9	Patients	0	7	O	Patients	nts	ents	NNS	False
DDI-MedLine.d1.s9	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d1.s9	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d1.s9	very	16	19	O	very	ery	very	RB	False
DDI-MedLine.d1.s9	low	21	23	O	low	low	low	JJ	False
DDI-MedLine.d1.s9	cardiac	25	31	O	cardiac	iac	diac	NN	False
DDI-MedLine.d1.s9	capacity	33	40	O	capacity	ity	city	NN	False
DDI-MedLine.d1.s9	should	42	47	O	should	uld	ould	MD	False
DDI-MedLine.d1.s9	be	49	50	O	be	be	be	VB	False
DDI-MedLine.d1.s9	advised	52	58	O	advised	sed	ised	VBN	False
DDI-MedLine.d1.s9	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d1.s9	refrain	63	69	O	refrain	ain	rain	NN	False
DDI-MedLine.d1.s9	from	71	74	O	from	rom	from	IN	False
DDI-MedLine.d1.s9	treatment	76	84	O	treatment	ent	ment	NN	False
DDI-MedLine.d1.s9	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d1.s9	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d1.s9	erection	93	100	O	erection	ion	tion	NN	False
DDI-MedLine.d1.s9	disorder	102	109	O	disorder	der	rder	NN	False
DDI-MedLine.d1.s9	.	110	110	O	.	.	.	.	False

DDI-MedLine.d136.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d136.s0	Multiple	1	8	O	Multiple	ple	iple	NN	False
DDI-MedLine.d136.s0	occupational	10	21	O	occupational	nal	onal	JJ	False
DDI-MedLine.d136.s0	exposure	23	30	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s0	to	32	33	O	to	to	to	TO	False
DDI-MedLine.d136.s0	solvents	35	42	O	solvents	nts	ents	NNS	False
DDI-MedLine.d136.s0	]	43	43	O	]	]	]	NN	False
DDI-MedLine.d136.s0	This	46	49	O	This	his	This	DT	False
DDI-MedLine.d136.s0	article	51	57	O	article	cle	icle	NN	False
DDI-MedLine.d136.s0	review	59	64	O	review	iew	view	NN	False
DDI-MedLine.d136.s0	papers	66	71	O	papers	ers	pers	NNS	False
DDI-MedLine.d136.s0	published	73	81	O	published	hed	shed	VBN	False
DDI-MedLine.d136.s0	over	83	86	O	over	ver	over	IN	False
DDI-MedLine.d136.s0	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d136.s0	last	92	95	O	last	ast	last	JJ	False
DDI-MedLine.d136.s0	20	97	98	O	20	20	20	CD	False
DDI-MedLine.d136.s0	years	100	104	O	years	ars	ears	NNS	False
DDI-MedLine.d136.s0	on	106	107	O	on	on	on	IN	False
DDI-MedLine.d136.s0	multiple	109	116	O	multiple	ple	iple	NN	False
DDI-MedLine.d136.s0	occupational	118	129	O	occupational	nal	onal	JJ	False
DDI-MedLine.d136.s0	exposure	131	138	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s0	to	140	141	O	to	to	to	TO	False
DDI-MedLine.d136.s0	solvents	143	150	O	solvents	nts	ents	NNS	False
DDI-MedLine.d136.s0	.	151	151	O	.	.	.	.	False

DDI-MedLine.d136.s1	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d136.s1	low-levels	3	12	O	low-levels	els	vels	NNS	False
DDI-MedLine.d136.s1	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d136.s1	exposure	17	24	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s1	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d136.s1	toxicokinetic	30	42	O	toxicokinetic	tic	etic	JJ	False
DDI-MedLine.d136.s1	interferences	44	56	O	interferences	ces	nces	NNS	False
DDI-MedLine.d136.s1	between	58	64	O	between	een	ween	IN	False
DDI-MedLine.d136.s1	solvents	66	73	O	solvents	nts	ents	NNS	False
DDI-MedLine.d136.s1	have	75	78	O	have	ave	have	VB	False
DDI-MedLine.d136.s1	generally	80	88	O	generally	lly	ally	RB	False
DDI-MedLine.d136.s1	not	90	92	O	not	not	not	RB	False
DDI-MedLine.d136.s1	been	94	97	O	been	een	been	VBN	False
DDI-MedLine.d136.s1	observed	99	106	O	observed	ved	rved	VBN	False
DDI-MedLine.d136.s1	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d136.s1	man	111	113	O	man	man	man	NN	False
DDI-MedLine.d136.s1	and	115	117	O	and	and	and	CC	False
DDI-MedLine.d136.s1	presumably	119	128	O	presumably	bly	ably	RB	False
DDI-MedLine.d136.s1	a	130	130	O	a	a	a	DT	False
DDI-MedLine.d136.s1	threshold	132	140	O	threshold	old	hold	NN	False
DDI-MedLine.d136.s1	limit	142	146	O	limit	mit	imit	NN	False
DDI-MedLine.d136.s1	exists	148	153	O	exists	sts	ists	NNS	False
DDI-MedLine.d136.s1	.	154	154	O	.	.	.	.	False

DDI-MedLine.d136.s2	Conversely	0	9	O	Conversely	ely	sely	RB	False
DDI-MedLine.d136.s2	,	10	10	O	,	,	,	,	False
DDI-MedLine.d136.s2	at	12	13	O	at	at	at	IN	False
DDI-MedLine.d136.s2	exposure	15	22	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s2	levels	24	29	O	levels	els	vels	NNS	False
DDI-MedLine.d136.s2	close	31	35	O	close	ose	lose	RB	False
DDI-MedLine.d136.s2	to	37	38	O	to	to	to	TO	False
DDI-MedLine.d136.s2	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d136.s2	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d136.s2	limit	45	49	O	limit	mit	imit	NN	False
DDI-MedLine.d136.s2	values	51	56	O	values	ues	lues	NNS	False
DDI-MedLine.d136.s2	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d136.s3	metabolic	0	8	O	metabolic	lic	olic	NN	False
DDI-MedLine.d136.s3	interference	10	21	O	interference	nce	ence	NN	False
DDI-MedLine.d136.s3	has	23	25	O	has	has	has	VBZ	False
DDI-MedLine.d136.s3	sometimes	27	35	O	sometimes	mes	imes	RB	False
DDI-MedLine.d136.s3	been	37	40	O	been	een	been	VBN	False
DDI-MedLine.d136.s3	observed	42	49	O	observed	ved	rved	VBN	False
DDI-MedLine.d136.s3	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d136.s3	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d136.s3	behaviour	59	67	O	behaviour	our	iour	NN	False
DDI-MedLine.d136.s3	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d136.s3	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d136.s3	biological	76	85	O	biological	cal	ical	JJ	False
DDI-MedLine.d136.s3	indicators	87	96	O	indicators	ors	tors	NNS	False
DDI-MedLine.d136.s3	differs	98	104	O	differs	ers	fers	NNS	False
DDI-MedLine.d136.s3	from	106	109	O	from	rom	from	IN	False
DDI-MedLine.d136.s3	what	111	114	O	what	hat	what	WP	False
DDI-MedLine.d136.s3	would	116	120	O	would	uld	ould	MD	False
DDI-MedLine.d136.s3	be	122	123	O	be	be	be	VB	False
DDI-MedLine.d136.s3	expected	125	132	O	expected	ted	cted	VBN	False
DDI-MedLine.d136.s3	.	133	133	O	.	.	.	.	False

DDI-MedLine.d136.s4	Toxicodynamic	0	12	O	Toxicodynamic	mic	amic	NNP	False
DDI-MedLine.d136.s4	interference	14	25	O	interference	nce	ence	NN	False
DDI-MedLine.d136.s4	between	27	33	O	between	een	ween	IN	False
DDI-MedLine.d136.s4	solvents	35	42	O	solvents	nts	ents	NNS	False
DDI-MedLine.d136.s4	can	44	46	O	can	can	can	MD	False
DDI-MedLine.d136.s4	give	48	51	O	give	ive	give	VB	False
DDI-MedLine.d136.s4	rise	53	56	O	rise	ise	rise	NN	False
DDI-MedLine.d136.s4	to	58	59	O	to	to	to	TO	False
DDI-MedLine.d136.s4	additive	61	68	O	additive	ive	tive	JJ	False
DDI-MedLine.d136.s4	,	69	69	O	,	,	,	,	False
DDI-MedLine.d136.s4	potentiation	71	82	O	potentiation	ion	tion	NN	False
DDI-MedLine.d136.s4	,	83	83	O	,	,	,	,	False
DDI-MedLine.d136.s4	synergistic	85	95	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d136.s4	,	96	96	O	,	,	,	,	False
DDI-MedLine.d136.s4	antagonistic	98	109	O	antagonistic	tic	stic	JJ	False
DDI-MedLine.d136.s4	effects	111	117	O	effects	cts	ects	NNS	False
DDI-MedLine.d136.s4	.	118	118	O	.	.	.	.	False

DDI-MedLine.d136.s5	For	0	2	O	For	For	For	IN	False
DDI-MedLine.d136.s5	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d136.s5	identification	8	21	O	identification	ion	tion	NN	False
DDI-MedLine.d136.s5	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d136.s5	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d136.s5	limit	27	31	O	limit	mit	imit	NN	False
DDI-MedLine.d136.s5	values	33	38	O	values	ues	lues	NNS	False
DDI-MedLine.d136.s5	''	-1	0	O	''	''	''	''	False
DDI-MedLine.d136.s5	,	40	40	O	,	,	,	,	False
DDI-MedLine.d136.s5	it	42	43	O	it	it	it	PRP	False
DDI-MedLine.d136.s5	has	45	47	O	has	has	has	VBZ	False
DDI-MedLine.d136.s5	generally	49	57	O	generally	lly	ally	RB	False
DDI-MedLine.d136.s5	been	59	62	O	been	een	been	VBN	False
DDI-MedLine.d136.s5	suggested	64	72	O	suggested	ted	sted	VBN	False
DDI-MedLine.d136.s5	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d136.s5	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d136.s5	literature	81	90	O	literature	ure	ture	NN	False
DDI-MedLine.d136.s5	that	92	95	O	that	hat	that	IN	False
DDI-MedLine.d136.s5	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d136.s5	possible	101	108	O	possible	ble	ible	JJ	False
DDI-MedLine.d136.s5	effects	110	116	O	effects	cts	ects	NNS	False
DDI-MedLine.d136.s5	deriving	118	125	O	deriving	ing	ving	VBG	False
DDI-MedLine.d136.s5	from	127	130	O	from	rom	from	IN	False
DDI-MedLine.d136.s5	multiple	132	139	O	multiple	ple	iple	NN	False
DDI-MedLine.d136.s5	exposure	141	148	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s5	be	150	151	O	be	be	be	VB	False
DDI-MedLine.d136.s5	considered	153	162	O	considered	red	ered	VBN	False
DDI-MedLine.d136.s5	as	164	165	O	as	as	as	IN	False
DDI-MedLine.d136.s5	additive	167	174	O	additive	ive	tive	JJ	False
DDI-MedLine.d136.s5	.	175	175	O	.	.	.	.	False

DDI-MedLine.d136.s6	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d136.s6	,	7	7	O	,	,	,	,	False
DDI-MedLine.d136.s6	numerous	9	16	O	numerous	ous	rous	JJ	False
DDI-MedLine.d136.s6	potentiation	18	29	O	potentiation	ion	tion	NN	False
DDI-MedLine.d136.s6	effects	31	37	O	effects	cts	ects	NNS	False
DDI-MedLine.d136.s6	have	39	42	O	have	ave	have	VB	False
DDI-MedLine.d136.s6	frequently	44	53	O	frequently	tly	ntly	RB	False
DDI-MedLine.d136.s6	been	55	58	O	been	een	been	VBN	False
DDI-MedLine.d136.s6	reported	60	67	O	reported	ted	rted	VBD	False
DDI-MedLine.d136.s6	for	69	71	O	for	for	for	IN	False
DDI-MedLine.d136.s6	combined	73	80	O	combined	ned	ined	VBN	False
DDI-MedLine.d136.s6	exposure	82	89	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s6	to	91	92	O	to	to	to	TO	False
DDI-MedLine.d136.s6	substances	94	103	O	substances	ces	nces	NNS	False
DDI-MedLine.d136.s6	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d136.s6	widespread	108	117	O	widespread	ead	read	JJ	False
DDI-MedLine.d136.s6	use	119	121	O	use	use	use	NN	False
DDI-MedLine.d136.s6	.	122	122	O	.	.	.	.	False

DDI-MedLine.d136.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d136.s7	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d136.s7	paper	8	12	O	paper	per	aper	NN	False
DDI-MedLine.d136.s7	lists	14	18	O	lists	sts	ists	NNS	False
DDI-MedLine.d136.s7	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d136.s7	multiple	23	30	O	multiple	ple	iple	NN	False
DDI-MedLine.d136.s7	exposure	32	39	O	exposure	ure	sure	NN	False
DDI-MedLine.d136.s7	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d136.s7	which	44	48	O	which	ich	hich	WDT	False
DDI-MedLine.d136.s7	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d136.s7	doses	54	58	O	doses	ses	oses	NNS	False
DDI-MedLine.d136.s7	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d136.s7	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d136.s7	substances	67	76	O	substances	ces	nces	NNS	False
DDI-MedLine.d136.s7	,	77	77	O	,	,	,	,	False
DDI-MedLine.d136.s7	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d136.s7	types	83	87	O	types	pes	ypes	NNS	False
DDI-MedLine.d136.s7	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d136.s7	interferences	92	104	O	interferences	ces	nces	NNS	False
DDI-MedLine.d136.s7	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d136.s7	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d136.s7	behaviour	114	122	O	behaviour	our	iour	NN	False
DDI-MedLine.d136.s7	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d136.s7	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d136.s7	biological	131	140	O	biological	cal	ical	JJ	False
DDI-MedLine.d136.s7	levels	142	147	O	levels	els	vels	NNS	False
DDI-MedLine.d136.s7	have	149	152	O	have	ave	have	VB	False
DDI-MedLine.d136.s7	been	154	157	O	been	een	been	VBN	False
DDI-MedLine.d136.s7	drawn	159	163	O	drawn	awn	rawn	NN	False
DDI-MedLine.d136.s7	up	165	166	O	up	up	up	RB	False
DDI-MedLine.d136.s7	and	168	170	O	and	and	and	CC	False
DDI-MedLine.d136.s7	proposed	172	179	O	proposed	sed	osed	VBN	False
DDI-MedLine.d136.s7	as	181	182	O	as	as	as	IN	False
DDI-MedLine.d136.s7	a	184	184	O	a	a	a	DT	False
DDI-MedLine.d136.s7	tool	186	189	O	tool	ool	tool	NN	False
DDI-MedLine.d136.s7	for	191	193	O	for	for	for	IN	False
DDI-MedLine.d136.s7	easy	195	198	O	easy	asy	easy	JJ	False
DDI-MedLine.d136.s7	consultation	200	211	O	consultation	ion	tion	NN	False
DDI-MedLine.d136.s7	.	212	212	O	.	.	.	.	False

DDI-MedLine.d71.s0	Drug-lab	0	7	O	Drug-lab	lab	-lab	NN	False
DDI-MedLine.d71.s0	interactions	9	20	O	interactions	ons	ions	NNS	False
DDI-MedLine.d71.s0	:	21	21	O	:	:	:	:	False
DDI-MedLine.d71.s0	implications	23	34	O	implications	ons	ions	NNS	False
DDI-MedLine.d71.s0	for	36	38	O	for	for	for	IN	False
DDI-MedLine.d71.s0	nutrition	40	48	O	nutrition	ion	tion	NN	False
DDI-MedLine.d71.s0	support	50	56	O	support	ort	port	NN	False
DDI-MedLine.d71.s0	.	57	57	O	.	.	.	.	False

DDI-MedLine.d71.s1	Acetylcysteine	0	13	B-drug	Acetylcysteine	ine	eine	NN	drug
DDI-MedLine.d71.s1	interference	15	26	O	interference	nce	ence	NN	False
DDI-MedLine.d71.s1	with	28	31	O	with	ith	with	IN	False
DDI-MedLine.d71.s1	urine	33	37	O	urine	ine	rine	NN	drug
DDI-MedLine.d71.s1	ketone	39	44	O	ketone	one	tone	NN	False
DDI-MedLine.d71.s1	test	46	49	O	test	est	test	NN	False
DDI-MedLine.d71.s1	.	50	50	O	.	.	.	.	False

DDI-MedLine.d71.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d71.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d71.s2	important	6	14	O	important	ant	tant	JJ	False
DDI-MedLine.d71.s2	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d71.s2	health	21	26	O	health	lth	alth	NN	False
DDI-MedLine.d71.s2	care	28	31	O	care	are	care	NN	False
DDI-MedLine.d71.s2	professionals	33	45	O	professionals	als	nals	NNS	False
DDI-MedLine.d71.s2	be	47	48	O	be	be	be	VB	False
DDI-MedLine.d71.s2	aware	50	54	O	aware	are	ware	JJ	False
DDI-MedLine.d71.s2	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d71.s2	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d71.s2	potential	63	71	O	potential	ial	tial	JJ	False
DDI-MedLine.d71.s2	for	73	75	O	for	for	for	IN	False
DDI-MedLine.d71.s2	medications	77	87	O	medications	ons	ions	NNS	False
DDI-MedLine.d71.s2	to	89	90	O	to	to	to	TO	False
DDI-MedLine.d71.s2	interfere	92	100	O	interfere	ere	fere	RB	False
DDI-MedLine.d71.s2	with	102	105	O	with	ith	with	IN	False
DDI-MedLine.d71.s2	clinical	107	114	O	clinical	cal	ical	JJ	False
DDI-MedLine.d71.s2	laboratory	116	125	O	laboratory	ory	tory	NN	False
DDI-MedLine.d71.s2	tests	127	131	O	tests	sts	ests	NNS	False
DDI-MedLine.d71.s2	.	132	132	O	.	.	.	.	False

DDI-MedLine.d71.s3	Medications	0	10	O	Medications	ons	ions	NNS	False
DDI-MedLine.d71.s3	can	12	14	O	can	can	can	MD	False
DDI-MedLine.d71.s3	cause	16	20	O	cause	use	ause	NN	False
DDI-MedLine.d71.s3	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d71.s3	vivo	25	28	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d71.s3	effects	30	36	O	effects	cts	ects	NNS	False
DDI-MedLine.d71.s3	when	38	41	O	when	hen	when	WRB	False
DDI-MedLine.d71.s3	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d71.s3	concentration	47	59	O	concentration	ion	tion	NN	False
DDI-MedLine.d71.s3	or	61	62	O	or	or	or	CC	False
DDI-MedLine.d71.s3	activity	64	71	O	activity	ity	vity	NN	False
DDI-MedLine.d71.s3	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d71.s3	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d71.s3	analyte	80	86	O	analyte	yte	lyte	NN	False
DDI-MedLine.d71.s3	is	88	89	O	is	is	is	VBZ	False
DDI-MedLine.d71.s3	altered	91	97	O	altered	red	ered	VBN	False
DDI-MedLine.d71.s3	before	99	104	O	before	ore	fore	IN	False
DDI-MedLine.d71.s3	the	106	108	O	the	the	the	DT	False
DDI-MedLine.d71.s3	analysis	110	117	O	analysis	sis	ysis	NN	False
DDI-MedLine.d71.s3	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d71.s3	therefore	123	131	O	therefore	ore	fore	RB	False
DDI-MedLine.d71.s3	the	133	135	O	the	the	the	DT	False
DDI-MedLine.d71.s3	assay	137	141	O	assay	say	ssay	NN	False
DDI-MedLine.d71.s3	result	143	148	O	result	ult	sult	NN	False
DDI-MedLine.d71.s3	is	150	151	O	is	is	is	VBZ	False
DDI-MedLine.d71.s3	true	153	156	O	true	rue	true	JJ	False
DDI-MedLine.d71.s3	and	158	160	O	and	and	and	CC	False
DDI-MedLine.d71.s3	accurate	162	169	O	accurate	ate	rate	NN	False
DDI-MedLine.d71.s3	.	170	170	O	.	.	.	.	False

DDI-MedLine.d71.s4	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d71.s4	in	3	4	O	in	in	in	IN	False
DDI-MedLine.d71.s4	vitro	6	10	O	vitro	tro	itro	NN	False
DDI-MedLine.d71.s4	effect	12	17	O	effect	ect	fect	NN	False
DDI-MedLine.d71.s4	occurs	19	24	O	occurs	urs	curs	NNS	False
DDI-MedLine.d71.s4	when	26	29	O	when	hen	when	WRB	False
DDI-MedLine.d71.s4	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d71.s4	medication	35	44	O	medication	ion	tion	NN	False
DDI-MedLine.d71.s4	interferes	46	55	O	interferes	res	eres	NNS	False
DDI-MedLine.d71.s4	with	57	60	O	with	ith	with	IN	False
DDI-MedLine.d71.s4	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d71.s4	assay	66	70	O	assay	say	ssay	NN	False
DDI-MedLine.d71.s4	,	71	71	O	,	,	,	,	False
DDI-MedLine.d71.s4	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d71.s4	the	77	79	O	the	the	the	DT	False
DDI-MedLine.d71.s4	result	81	86	O	result	ult	sult	NN	False
DDI-MedLine.d71.s4	is	88	89	O	is	is	is	VBZ	False
DDI-MedLine.d71.s4	erroneous	91	99	O	erroneous	ous	eous	JJ	False
DDI-MedLine.d71.s4	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d71.s4	can	105	107	O	can	can	can	MD	False
DDI-MedLine.d71.s4	not	108	110	O	not	not	not	RB	False
DDI-MedLine.d71.s4	be	112	113	O	be	be	be	VB	False
DDI-MedLine.d71.s4	interpreted	115	125	O	interpreted	ted	eted	VBN	False
DDI-MedLine.d71.s4	.	126	126	O	.	.	.	.	False

DDI-MedLine.d71.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d71.s5	report	5	10	O	report	ort	port	NN	False
DDI-MedLine.d71.s5	describes	12	20	O	describes	bes	ibes	NNS	False
DDI-MedLine.d71.s5	a	22	22	O	a	a	a	DT	False
DDI-MedLine.d71.s5	recently	24	31	O	recently	tly	ntly	RB	False
DDI-MedLine.d71.s5	identified	33	42	O	identified	ied	fied	VBN	False
DDI-MedLine.d71.s5	case	44	47	O	case	ase	case	NN	False
DDI-MedLine.d71.s5	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d71.s5	interference	52	63	O	interference	nce	ence	NN	False
DDI-MedLine.d71.s5	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d71.s5	acetylcysteine	68	81	B-drug	acetylcysteine	ine	eine	NN	drug
DDI-MedLine.d71.s5	with	83	86	O	with	ith	with	IN	False
DDI-MedLine.d71.s5	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d71.s5	urine	92	96	O	urine	ine	rine	NN	drug
DDI-MedLine.d71.s5	test	98	101	O	test	est	test	NN	False
DDI-MedLine.d71.s5	for	103	105	O	for	for	for	IN	False
DDI-MedLine.d71.s5	ketones	107	113	O	ketones	nes	ones	NNS	False
DDI-MedLine.d71.s5	and	115	117	O	and	and	and	CC	False
DDI-MedLine.d71.s5	demonstrates	119	130	O	demonstrates	tes	ates	NNS	False
DDI-MedLine.d71.s5	the	132	134	O	the	the	the	DT	False
DDI-MedLine.d71.s5	importance	136	145	O	importance	nce	ance	NN	False
DDI-MedLine.d71.s5	of	147	148	O	of	of	of	IN	False
DDI-MedLine.d71.s5	a	150	150	O	a	a	a	DT	False
DDI-MedLine.d71.s5	thorough	152	159	O	thorough	ugh	ough	NN	False
DDI-MedLine.d71.s5	medication	161	170	O	medication	ion	tion	NN	False
DDI-MedLine.d71.s5	review	172	177	O	review	iew	view	NN	False
DDI-MedLine.d71.s5	in	179	180	O	in	in	in	IN	False
DDI-MedLine.d71.s5	evaluating	182	191	O	evaluating	ing	ting	VBG	False
DDI-MedLine.d71.s5	abnormal	193	200	O	abnormal	mal	rmal	JJ	False
DDI-MedLine.d71.s5	laboratory	202	211	O	laboratory	ory	tory	NN	False
DDI-MedLine.d71.s5	tests	213	217	O	tests	sts	ests	NNS	False
DDI-MedLine.d71.s5	.	218	218	O	.	.	.	.	False

DDI-MedLine.d12.s0	Dexamethasone	0	12	B-drug	Dexamethasone	one	sone	NN	False
DDI-MedLine.d12.s0	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d12.s0	retinyl	18	24	B-drug	retinyl	nyl	inyl	NN	False
DDI-MedLine.d12.s0	acetate	26	32	I-drug	acetate	ate	tate	NN	False
DDI-MedLine.d12.s0	similarly	34	42	O	similarly	rly	arly	RB	False
DDI-MedLine.d12.s0	inhibit	44	50	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d12.s0	and	52	54	O	and	and	and	CC	False
DDI-MedLine.d12.s0	stimulate	56	64	O	stimulate	ate	late	NN	False
DDI-MedLine.d12.s0	EGF-	66	69	O	EGF-	GF-	EGF-	NN	brand
DDI-MedLine.d12.s0	or	71	72	O	or	or	or	CC	False
DDI-MedLine.d12.s0	insulin-induced	74	88	O	insulin-induced	ced	uced	JJ	False
DDI-MedLine.d12.s0	proliferation	90	102	O	proliferation	ion	tion	NN	False
DDI-MedLine.d12.s0	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d12.s0	prostatic	107	115	O	prostatic	tic	atic	JJ	False
DDI-MedLine.d12.s0	epithelium	117	126	O	epithelium	ium	lium	NN	drug
DDI-MedLine.d12.s0	.	127	127	O	.	.	.	.	False

DDI-MedLine.d12.s1	Prostatic	0	8	O	Prostatic	tic	atic	JJ	False
DDI-MedLine.d12.s1	epithelium	10	19	O	epithelium	ium	lium	NN	drug
DDI-MedLine.d12.s1	proliferates	21	32	O	proliferates	tes	ates	NNS	False
DDI-MedLine.d12.s1	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d12.s1	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d12.s1	defined	39	45	O	defined	ned	ined	VBN	False
DDI-MedLine.d12.s1	medium	47	52	O	medium	ium	dium	NN	drug
DDI-MedLine.d12.s1	consisting	54	63	O	consisting	ing	ting	VBG	False
DDI-MedLine.d12.s1	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d12.s1	basal	68	72	O	basal	sal	asal	NN	False
DDI-MedLine.d12.s1	medium	74	79	O	medium	ium	dium	NN	drug
DDI-MedLine.d12.s1	RPMI1640	81	88	O	RPMI1640	640	1640	NN	brand
DDI-MedLine.d12.s1	containing	90	99	O	containing	ing	ning	VBG	False
DDI-MedLine.d12.s1	transferrin	101	111	B-drug_n	transferrin	rin	rrin	NN	False
DDI-MedLine.d12.s1	(	113	113	O	(	(	(	(	False
DDI-MedLine.d12.s1	1	114	114	O	1	1	1	CD	False
DDI-MedLine.d12.s1	microgram/ml	116	127	O	microgram/ml	/ml	m/ml	NN	False
DDI-MedLine.d12.s1	)	128	128	O	)	)	)	)	False
DDI-MedLine.d12.s1	,	129	129	O	,	,	,	,	False
DDI-MedLine.d12.s1	EGF	131	133	B-drug_n	EGF	EGF	EGF	NN	brand
DDI-MedLine.d12.s1	(	135	135	O	(	(	(	(	False
DDI-MedLine.d12.s1	10	136	137	O	10	10	10	CD	False
DDI-MedLine.d12.s1	ng/ml	139	143	O	ng/ml	/ml	g/ml	NN	False
DDI-MedLine.d12.s1	)	144	144	O	)	)	)	)	False
DDI-MedLine.d12.s1	,	145	145	O	,	,	,	,	False
DDI-MedLine.d12.s1	and	147	149	O	and	and	and	CC	False
DDI-MedLine.d12.s1	insulin	151	157	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d12.s1	(	159	159	O	(	(	(	(	False
DDI-MedLine.d12.s1	3.7	160	162	O	3.7	3.7	3.7	CD	False
DDI-MedLine.d12.s1	micrograms/ml	164	176	O	micrograms/ml	/ml	s/ml	NN	False
DDI-MedLine.d12.s1	or	178	179	O	or	or	or	CC	False
DDI-MedLine.d12.s1	0.1	181	183	O	0.1	0.1	0.1	CD	False
DDI-MedLine.d12.s1	IU/ml	185	189	O	IU/ml	/ml	U/ml	NN	False
DDI-MedLine.d12.s1	)	190	190	O	)	)	)	)	False
DDI-MedLine.d12.s1	.	191	191	O	.	.	.	.	False

DDI-MedLine.d12.s2	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d12.s2	neither	9	15	O	neither	her	ther	DT	False
DDI-MedLine.d12.s2	dexamethasone	17	29	B-drug	dexamethasone	one	sone	NN	False
DDI-MedLine.d12.s2	nor	31	33	O	nor	nor	nor	CC	False
DDI-MedLine.d12.s2	retinyl	35	41	B-drug	retinyl	nyl	inyl	NN	False
DDI-MedLine.d12.s2	acetate	43	49	I-drug	acetate	ate	tate	NN	False
DDI-MedLine.d12.s2	affected	51	58	O	affected	ted	cted	JJ	False
DDI-MedLine.d12.s2	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d12.s2	proliferation	64	76	O	proliferation	ion	tion	NN	False
DDI-MedLine.d12.s2	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d12.s2	prostatic	81	89	O	prostatic	tic	atic	JJ	False
DDI-MedLine.d12.s2	epithelium	91	100	O	epithelium	ium	lium	NN	drug
DDI-MedLine.d12.s2	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d12.s2	RPMI1640	105	112	O	RPMI1640	640	1640	NN	brand
DDI-MedLine.d12.s2	containing	114	123	O	containing	ing	ning	VBG	False
DDI-MedLine.d12.s2	transferrin	125	135	B-drug_n	transferrin	rin	rrin	NN	False
DDI-MedLine.d12.s2	alone	137	141	O	alone	one	lone	RB	False
DDI-MedLine.d12.s2	,	142	142	O	,	,	,	,	False
DDI-MedLine.d12.s2	they	144	147	O	they	hey	they	PRP	False
DDI-MedLine.d12.s2	modify	149	154	O	modify	ify	dify	NN	False
DDI-MedLine.d12.s2	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d12.s2	mitogenic	160	168	O	mitogenic	nic	enic	NN	False
DDI-MedLine.d12.s2	effect	170	175	O	effect	ect	fect	NN	False
DDI-MedLine.d12.s2	of	177	178	O	of	of	of	IN	False
DDI-MedLine.d12.s2	EGF	180	182	B-drug_n	EGF	EGF	EGF	NN	brand
DDI-MedLine.d12.s2	and	184	186	O	and	and	and	CC	False
DDI-MedLine.d12.s2	insulin	188	194	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d12.s2	.	195	195	O	.	.	.	.	False

DDI-MedLine.d12.s3	Dexamethasone	0	12	B-drug	Dexamethasone	one	sone	NN	False
DDI-MedLine.d12.s3	at	14	15	O	at	at	at	IN	False
DDI-MedLine.d12.s3	10	17	18	O	10	10	10	CD	False
DDI-MedLine.d12.s3	(	19	19	O	(	(	(	(	False
DDI-MedLine.d12.s3	-10	20	22	O	-10	-10	-10	NN	False
DDI-MedLine.d12.s3	)	23	23	O	)	)	)	)	False
DDI-MedLine.d12.s3	M	25	25	O	M	M	M	NN	brand
DDI-MedLine.d12.s3	or	27	28	O	or	or	or	CC	False
DDI-MedLine.d12.s3	retinyl	30	36	B-drug	retinyl	nyl	inyl	NN	False
DDI-MedLine.d12.s3	acetate	38	44	I-drug	acetate	ate	tate	NN	False
DDI-MedLine.d12.s3	at	46	47	O	at	at	at	IN	False
DDI-MedLine.d12.s3	about	49	53	O	about	out	bout	IN	False
DDI-MedLine.d12.s3	3	55	55	O	3	3	3	CD	False
DDI-MedLine.d12.s3	X	57	57	O	X	X	X	NN	brand
DDI-MedLine.d12.s3	10	59	60	O	10	10	10	CD	False
DDI-MedLine.d12.s3	(	61	61	O	(	(	(	(	False
DDI-MedLine.d12.s3	-9	62	63	O	-9	-9	-9	NN	False
DDI-MedLine.d12.s3	)	64	64	O	)	)	)	)	False
DDI-MedLine.d12.s3	M	66	66	O	M	M	M	NN	brand
DDI-MedLine.d12.s3	inhibits	68	75	O	inhibits	its	bits	NNS	False
DDI-MedLine.d12.s3	proliferation	77	89	O	proliferation	ion	tion	NN	False
DDI-MedLine.d12.s3	stimulated	91	100	O	stimulated	ted	ated	VBN	False
DDI-MedLine.d12.s3	by	102	103	O	by	by	by	IN	False
DDI-MedLine.d12.s3	EGF	105	107	B-drug_n	EGF	EGF	EGF	NN	brand
DDI-MedLine.d12.s3	.	108	108	O	.	.	.	.	False

DDI-MedLine.d12.s4	Higher	0	5	O	Higher	her	gher	JJR	False
DDI-MedLine.d12.s4	concentrations	7	20	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d12.s4	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d12.s4	dexamethasone	25	37	B-drug	dexamethasone	one	sone	NN	False
DDI-MedLine.d12.s4	(	39	39	O	(	(	(	(	False
DDI-MedLine.d12.s4	10	40	41	O	10	10	10	CD	False
DDI-MedLine.d12.s4	(	42	42	O	(	(	(	(	False
DDI-MedLine.d12.s4	-8	43	44	O	-8	-8	-8	NN	False
DDI-MedLine.d12.s4	)	45	45	O	)	)	)	)	False
DDI-MedLine.d12.s4	-	47	47	O	-	-	-	:	False
DDI-MedLine.d12.s4	10	49	50	O	10	10	10	CD	False
DDI-MedLine.d12.s4	(	51	51	O	(	(	(	(	False
DDI-MedLine.d12.s4	-6	52	53	O	-6	-6	-6	NN	False
DDI-MedLine.d12.s4	)	54	54	O	)	)	)	)	False
DDI-MedLine.d12.s4	M	56	56	O	M	M	M	NN	brand
DDI-MedLine.d12.s4	)	57	57	O	)	)	)	)	False
DDI-MedLine.d12.s4	or	59	60	O	or	or	or	CC	False
DDI-MedLine.d12.s4	retinyl	62	68	B-drug	retinyl	nyl	inyl	NN	False
DDI-MedLine.d12.s4	acetate	70	76	I-drug	acetate	ate	tate	NN	False
DDI-MedLine.d12.s4	(	78	78	O	(	(	(	(	False
DDI-MedLine.d12.s4	3	79	79	O	3	3	3	CD	False
DDI-MedLine.d12.s4	X	81	81	O	X	X	X	NN	brand
DDI-MedLine.d12.s4	10	83	84	O	10	10	10	CD	False
DDI-MedLine.d12.s4	(	85	85	O	(	(	(	(	False
DDI-MedLine.d12.s4	-8	86	87	O	-8	-8	-8	NN	False
DDI-MedLine.d12.s4	)	88	88	O	)	)	)	)	False
DDI-MedLine.d12.s4	-	90	90	O	-	-	-	:	False
DDI-MedLine.d12.s4	10	92	93	O	10	10	10	CD	False
DDI-MedLine.d12.s4	(	94	94	O	(	(	(	(	False
DDI-MedLine.d12.s4	-7	95	96	O	-7	-7	-7	NN	False
DDI-MedLine.d12.s4	)	97	97	O	)	)	)	)	False
DDI-MedLine.d12.s4	M	99	99	O	M	M	M	NN	brand
DDI-MedLine.d12.s4	)	100	100	O	)	)	)	)	False
DDI-MedLine.d12.s4	enhance	102	108	O	enhance	nce	ance	NN	False
DDI-MedLine.d12.s4	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d12.s4	mitogenic	114	122	O	mitogenic	nic	enic	NN	False
DDI-MedLine.d12.s4	activity	124	131	O	activity	ity	vity	NN	False
DDI-MedLine.d12.s4	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d12.s4	EGF	136	138	B-drug_n	EGF	EGF	EGF	NN	brand
DDI-MedLine.d12.s4	.	139	139	O	.	.	.	.	False

DDI-MedLine.d12.s5	Dexamethasone	0	12	B-drug	Dexamethasone	one	sone	NN	False
DDI-MedLine.d12.s5	had	14	16	O	had	had	had	VBD	False
DDI-MedLine.d12.s5	a	18	18	O	a	a	a	DT	False
DDI-MedLine.d12.s5	similar	20	26	O	similar	lar	ilar	JJ	False
DDI-MedLine.d12.s5	effect	28	33	O	effect	ect	fect	NN	False
DDI-MedLine.d12.s5	in	35	36	O	in	in	in	IN	False
DDI-MedLine.d12.s5	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d12.s5	presence	42	49	O	presence	nce	ence	NN	False
DDI-MedLine.d12.s5	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d12.s5	insulin	54	60	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d12.s5	.	61	61	O	.	.	.	.	False

DDI-MedLine.d12.s6	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d12.s6	,	7	7	O	,	,	,	,	False
DDI-MedLine.d12.s6	retinyl	9	15	B-drug	retinyl	nyl	inyl	NN	False
DDI-MedLine.d12.s6	acetate	17	23	I-drug	acetate	ate	tate	NN	False
DDI-MedLine.d12.s6	stimulated	25	34	O	stimulated	ted	ated	VBN	False
DDI-MedLine.d12.s6	,	35	35	O	,	,	,	,	False
DDI-MedLine.d12.s6	but	37	39	O	but	but	but	CC	False
DDI-MedLine.d12.s6	did	41	43	O	did	did	did	VBD	False
DDI-MedLine.d12.s6	not	45	47	O	not	not	not	RB	False
DDI-MedLine.d12.s6	significantly	49	61	O	significantly	tly	ntly	RB	False
DDI-MedLine.d12.s6	inhibit	63	69	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d12.s6	,	70	70	O	,	,	,	,	False
DDI-MedLine.d12.s6	proliferation	72	84	O	proliferation	ion	tion	NN	False
DDI-MedLine.d12.s6	in	86	87	O	in	in	in	IN	False
DDI-MedLine.d12.s6	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d12.s6	presence	93	100	O	presence	nce	ence	NN	False
DDI-MedLine.d12.s6	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d12.s6	insulin	105	111	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d12.s6	.	112	112	O	.	.	.	.	False

DDI-MedLine.d12.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d12.s7	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d12.s7	suggest	14	20	O	suggest	est	gest	NN	False
DDI-MedLine.d12.s7	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d12.s7	both	27	30	O	both	oth	both	DT	False
DDI-MedLine.d12.s7	dexamethasone	32	44	B-drug	dexamethasone	one	sone	NN	False
DDI-MedLine.d12.s7	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d12.s7	retinyl	50	56	B-drug	retinyl	nyl	inyl	NN	False
DDI-MedLine.d12.s7	acetate	58	64	I-drug	acetate	ate	tate	NN	False
DDI-MedLine.d12.s7	,	65	65	O	,	,	,	,	False
DDI-MedLine.d12.s7	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d12.s7	possibly	71	78	O	possibly	bly	ibly	RB	False
DDI-MedLine.d12.s7	other	80	84	O	other	her	ther	JJ	False
DDI-MedLine.d12.s7	glucocorticoids	86	100	B-group	glucocorticoids	ids	oids	NNS	False
DDI-MedLine.d12.s7	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d12.s7	retinoids	106	114	B-group	retinoids	ids	oids	NNS	False
DDI-MedLine.d12.s7	,	115	115	O	,	,	,	,	False
DDI-MedLine.d12.s7	may	117	119	O	may	may	may	MD	False
DDI-MedLine.d12.s7	regulate	121	128	O	regulate	ate	late	NN	False
DDI-MedLine.d12.s7	the	130	132	O	the	the	the	DT	False
DDI-MedLine.d12.s7	proliferation	134	146	O	proliferation	ion	tion	NN	False
DDI-MedLine.d12.s7	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d12.s7	prostate	151	158	O	prostate	ate	tate	NN	False
DDI-MedLine.d12.s7	epithelium	160	169	O	epithelium	ium	lium	NN	drug
DDI-MedLine.d12.s7	by	171	172	O	by	by	by	IN	False
DDI-MedLine.d12.s7	a	174	174	O	a	a	a	DT	False
DDI-MedLine.d12.s7	dose-dependent	176	189	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d12.s7	modification	191	202	O	modification	ion	tion	NN	False
DDI-MedLine.d12.s7	of	204	205	O	of	of	of	IN	False
DDI-MedLine.d12.s7	the	207	209	O	the	the	the	DT	False
DDI-MedLine.d12.s7	activity	211	218	O	activity	ity	vity	NN	False
DDI-MedLine.d12.s7	of	220	221	O	of	of	of	IN	False
DDI-MedLine.d12.s7	insulin	223	229	B-drug	insulin	lin	ulin	NN	False
DDI-MedLine.d12.s7	and	231	233	O	and	and	and	CC	False
DDI-MedLine.d12.s7	EGF	235	237	B-drug_n	EGF	EGF	EGF	NN	brand
DDI-MedLine.d12.s7	.	238	238	O	.	.	.	.	False

DDI-MedLine.d138.s0	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d138.s0	between	12	18	O	between	een	ween	IN	False
DDI-MedLine.d138.s0	oxytocin	20	27	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d138.s0	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d138.s0	antidiuretic	33	44	O	antidiuretic	tic	etic	JJ	False
DDI-MedLine.d138.s0	hormone	46	52	O	hormone	one	mone	NN	False
DDI-MedLine.d138.s0	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d138.s0	its	58	60	O	its	its	its	PRP$	False
DDI-MedLine.d138.s0	effect	62	67	O	effect	ect	fect	NN	False
DDI-MedLine.d138.s0	on	69	70	O	on	on	on	IN	False
DDI-MedLine.d138.s0	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d138.s0	milk	76	79	O	milk	ilk	milk	NN	False
DDI-MedLine.d138.s0	secretion	81	89	O	secretion	ion	tion	NN	False
DDI-MedLine.d138.s0	by	91	92	O	by	by	by	IN	False
DDI-MedLine.d138.s0	alveoli	94	100	O	alveoli	oli	eoli	NN	False
DDI-MedLine.d138.s0	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d138.s0	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d138.s0	mammary	109	115	O	mammary	ary	mary	NN	False
DDI-MedLine.d138.s0	gland	117	121	O	gland	and	land	NN	False
DDI-MedLine.d138.s0	of	123	124	O	of	of	of	IN	False
DDI-MedLine.d138.s0	lactating	126	134	O	lactating	ing	ting	VBG	False
DDI-MedLine.d138.s0	rats	136	139	O	rats	ats	rats	NNS	False
DDI-MedLine.d138.s0	.	140	140	O	.	.	.	.	False

DDI-MedLine.d138.s1	Interaction	0	10	O	Interaction	ion	tion	NN	False
DDI-MedLine.d138.s1	between	12	18	O	between	een	ween	IN	False
DDI-MedLine.d138.s1	exogenous	20	28	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d138.s1	and	30	32	O	and	and	and	CC	False
DDI-MedLine.d138.s1	endogenous	34	43	O	endogenous	ous	nous	JJ	False
DDI-MedLine.d138.s1	oxytocin	45	52	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d138.s1	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d138.s1	vasopressin	58	68	O	vasopressin	sin	ssin	NN	False
DDI-MedLine.d138.s1	was	70	72	O	was	was	was	VBD	False
DDI-MedLine.d138.s1	found	74	78	O	found	und	ound	NN	False
DDI-MedLine.d138.s1	to	80	81	O	to	to	to	TO	False
DDI-MedLine.d138.s1	affect	83	88	O	affect	ect	fect	NN	False
DDI-MedLine.d138.s1	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d138.s1	mechanism	94	102	O	mechanism	ism	nism	NN	False
DDI-MedLine.d138.s1	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d138.s1	milk	107	110	O	milk	ilk	milk	NN	False
DDI-MedLine.d138.s1	ejection	112	119	O	ejection	ion	tion	NN	False
DDI-MedLine.d138.s1	by	121	122	O	by	by	by	IN	False
DDI-MedLine.d138.s1	the	124	126	O	the	the	the	DT	False
DDI-MedLine.d138.s1	alveoli	128	134	O	alveoli	oli	eoli	NN	False
DDI-MedLine.d138.s1	of	136	137	O	of	of	of	IN	False
DDI-MedLine.d138.s1	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d138.s1	mammary	143	149	O	mammary	ary	mary	NN	False
DDI-MedLine.d138.s1	gland	151	155	O	gland	and	land	NN	False
DDI-MedLine.d138.s1	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d138.s1	lactating	160	168	O	lactating	ing	ting	VBG	False
DDI-MedLine.d138.s1	rats	170	173	O	rats	ats	rats	NNS	False
DDI-MedLine.d138.s1	.	174	174	O	.	.	.	.	False

DDI-MedLine.d138.s2	Inhibition	0	9	O	Inhibition	ion	tion	NN	False
DDI-MedLine.d138.s2	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d138.s2	stimulation	15	25	O	stimulation	ion	tion	NN	False
DDI-MedLine.d138.s2	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d138.s2	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d138.s2	effect	34	39	O	effect	ect	fect	NN	False
DDI-MedLine.d138.s2	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d138.s2	oxytocin	44	51	B-drug	oxytocin	cin	ocin	NN	drug
DDI-MedLine.d138.s2	on	53	54	O	on	on	on	IN	False
DDI-MedLine.d138.s2	milk	56	59	O	milk	ilk	milk	NN	False
DDI-MedLine.d138.s2	ejection	61	68	O	ejection	ion	tion	NN	False
DDI-MedLine.d138.s2	by	70	71	O	by	by	by	IN	False
DDI-MedLine.d138.s2	vasopressin	73	83	O	vasopressin	sin	ssin	NN	False
DDI-MedLine.d138.s2	was	85	87	O	was	was	was	VBD	False
DDI-MedLine.d138.s2	demonstrated	89	100	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d138.s2	.	101	101	O	.	.	.	.	False

DDI-MedLine.d138.s3	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d138.s3	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d138.s3	basis	7	11	O	basis	sis	asis	NN	False
DDI-MedLine.d138.s3	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d138.s3	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d138.s3	principles	20	29	O	principles	les	ples	NNS	False
DDI-MedLine.d138.s3	observed	31	38	O	observed	ved	rved	VBN	False
DDI-MedLine.d138.s3	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d138.s3	concentrations	44	57	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d138.s3	fo	59	60	O	fo	fo	fo	NN	False
DDI-MedLine.d138.s3	these	62	66	O	these	ese	hese	DT	False
DDI-MedLine.d138.s3	hormones	68	75	O	hormones	nes	ones	NNS	False
DDI-MedLine.d138.s3	were	77	80	O	were	ere	were	VBD	False
DDI-MedLine.d138.s3	investigated	82	93	O	investigated	ted	ated	VBN	False
DDI-MedLine.d138.s3	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d138.s3	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d138.s3	plasma	102	107	O	plasma	sma	asma	NN	False
DDI-MedLine.d138.s3	of	109	110	O	of	of	of	IN	False
DDI-MedLine.d138.s3	dogs	112	115	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d138.s3	deprived	117	124	O	deprived	ved	ived	VBN	False
DDI-MedLine.d138.s3	of	126	127	O	of	of	of	IN	False
DDI-MedLine.d138.s3	water	129	133	O	water	ter	ater	NN	False
DDI-MedLine.d138.s3	for	135	137	O	for	for	for	IN	False
DDI-MedLine.d138.s3	3	139	139	O	3	3	3	CD	False
DDI-MedLine.d138.s3	days	141	144	O	days	ays	days	NNS	False
DDI-MedLine.d138.s3	and	146	148	O	and	and	and	CC	False
DDI-MedLine.d138.s3	then	150	153	O	then	hen	then	RB	False
DDI-MedLine.d138.s3	allowed	155	161	O	allowed	wed	owed	VBN	False
DDI-MedLine.d138.s3	to	163	164	O	to	to	to	TO	False
DDI-MedLine.d138.s3	drink	166	170	O	drink	ink	rink	NN	False
DDI-MedLine.d138.s3	.	171	171	O	.	.	.	.	False

DDI-MedLine.d87.s0	ADL	0	2	B-drug	ADL	ADL	ADL	NN	brand
DDI-MedLine.d87.s0	8-2698	4	9	I-drug	8-2698	698	2698	JJ	False
DDI-MedLine.d87.s0	,	10	10	O	,	,	,	,	False
DDI-MedLine.d87.s0	a	12	12	O	a	a	a	DT	False
DDI-MedLine.d87.s0	trans-3,4-dimethyl-4-	14	34	O	trans-3,4-dimethyl-4-	-4-	l-4-	NN	False
DDI-MedLine.d87.s0	(	35	35	O	(	(	(	(	False
DDI-MedLine.d87.s0	3-hydroxyphenyl	36	50	O	3-hydroxyphenyl	nyl	enyl	JJ	False
DDI-MedLine.d87.s0	)	51	51	O	)	)	)	)	False
DDI-MedLine.d87.s0	piperidine	53	62	O	piperidine	ine	dine	NN	drug
DDI-MedLine.d87.s0	,	63	63	O	,	,	,	,	False
DDI-MedLine.d87.s0	prevents	65	72	O	prevents	nts	ents	NNS	False
DDI-MedLine.d87.s0	gastrointestinal	74	89	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d87.s0	effects	91	97	O	effects	cts	ects	NNS	False
DDI-MedLine.d87.s0	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d87.s0	intravenous	102	112	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d87.s0	morphine	114	121	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d87.s0	without	123	129	O	without	out	hout	IN	False
DDI-MedLine.d87.s0	affecting	131	139	O	affecting	ing	ting	VBG	False
DDI-MedLine.d87.s0	analgesia	141	149	O	analgesia	sia	esia	NN	False
DDI-MedLine.d87.s0	.	150	150	O	.	.	.	.	False

DDI-MedLine.d87.s1	ADL-8-2698	0	9	B-drug	ADL-8-2698	698	2698	JJ	brand
DDI-MedLine.d87.s1	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d87.s1	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d87.s1	novel	16	20	O	novel	vel	ovel	NN	False
DDI-MedLine.d87.s1	peripherally	22	33	B-group	peripherally	lly	ally	RB	False
DDI-MedLine.d87.s1	restricted	35	44	I-group	restricted	ted	cted	VBN	False
DDI-MedLine.d87.s1	opioid	46	51	I-group	opioid	oid	ioid	NN	False
DDI-MedLine.d87.s1	antagonist	53	62	I-group	antagonist	ist	nist	NN	False
DDI-MedLine.d87.s1	that	64	67	O	that	hat	that	IN	False
DDI-MedLine.d87.s1	may	69	71	O	may	may	may	MD	False
DDI-MedLine.d87.s1	selectively	73	83	O	selectively	ely	vely	RB	False
DDI-MedLine.d87.s1	prevent	85	91	O	prevent	ent	vent	NN	False
DDI-MedLine.d87.s1	opioid-induced	93	106	O	opioid-induced	ced	uced	JJ	False
DDI-MedLine.d87.s1	gastrointestinal	108	123	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d87.s1	effects	125	131	O	effects	cts	ects	NNS	False
DDI-MedLine.d87.s1	without	133	139	O	without	out	hout	IN	False
DDI-MedLine.d87.s1	reversing	141	149	O	reversing	ing	sing	VBG	False
DDI-MedLine.d87.s1	analgesia	151	159	O	analgesia	sia	esia	NN	False
DDI-MedLine.d87.s1	.	160	160	O	.	.	.	.	False

DDI-MedLine.d87.s2	Gastrointestinal	0	15	O	Gastrointestinal	nal	inal	JJ	False
DDI-MedLine.d87.s2	transit	17	23	O	transit	sit	nsit	NN	False
DDI-MedLine.d87.s2	time	25	28	O	time	ime	time	NN	False
DDI-MedLine.d87.s2	(	30	30	O	(	(	(	(	False
DDI-MedLine.d87.s2	lactulose	31	39	O	lactulose	ose	lose	NN	False
DDI-MedLine.d87.s2	hydrogen	41	48	O	hydrogen	gen	ogen	NN	brand
DDI-MedLine.d87.s2	breath	50	55	O	breath	ath	eath	NN	False
DDI-MedLine.d87.s2	test	57	60	O	test	est	test	NN	False
DDI-MedLine.d87.s2	)	61	61	O	)	)	)	)	False
DDI-MedLine.d87.s2	was	63	65	O	was	was	was	VBD	False
DDI-MedLine.d87.s2	measured	67	74	O	measured	red	ured	VBN	False
DDI-MedLine.d87.s2	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d87.s2	14	79	80	O	14	14	14	CD	False
DDI-MedLine.d87.s2	volunteers	82	91	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d87.s2	with	93	96	O	with	ith	with	IN	False
DDI-MedLine.d87.s2	oral	98	101	O	oral	ral	oral	JJ	False
DDI-MedLine.d87.s2	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d87.s2	intravenous	107	117	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d87.s2	placebo	119	125	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d87.s2	,	126	126	O	,	,	,	,	False
DDI-MedLine.d87.s2	oral	128	131	O	oral	ral	oral	JJ	False
DDI-MedLine.d87.s2	placebo	133	139	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d87.s2	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d87.s2	intravenous	145	155	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d87.s2	morphine	157	164	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d87.s2	(	166	166	O	(	(	(	(	False
DDI-MedLine.d87.s2	0.05	167	170	O	0.05	.05	0.05	CD	False
DDI-MedLine.d87.s2	mg	172	173	O	mg	mg	mg	NN	False
DDI-MedLine.d87.s2	x	175	175	O	x	x	x	NN	False
DDI-MedLine.d87.s2	kg	177	178	O	kg	kg	kg	NN	False
DDI-MedLine.d87.s2	(	179	179	O	(	(	(	(	False
DDI-MedLine.d87.s2	-1	180	181	O	-1	-1	-1	NN	False
DDI-MedLine.d87.s2	)	182	182	O	)	)	)	)	False
DDI-MedLine.d87.s2	)	183	183	O	)	)	)	)	False
DDI-MedLine.d87.s2	,	184	184	O	,	,	,	,	False
DDI-MedLine.d87.s2	and	186	188	O	and	and	and	CC	False
DDI-MedLine.d87.s2	oral	190	193	O	oral	ral	oral	JJ	False
DDI-MedLine.d87.s2	ADL	195	197	B-drug	ADL	ADL	ADL	NN	brand
DDI-MedLine.d87.s2	8-2698	199	204	I-drug	8-2698	698	2698	JJ	False
DDI-MedLine.d87.s2	(	206	206	O	(	(	(	(	False
DDI-MedLine.d87.s2	4	207	207	O	4	4	4	CD	False
DDI-MedLine.d87.s2	mg	209	210	O	mg	mg	mg	NN	False
DDI-MedLine.d87.s2	)	211	211	O	)	)	)	)	False
DDI-MedLine.d87.s2	and	213	215	O	and	and	and	CC	False
DDI-MedLine.d87.s2	intravenous	217	227	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d87.s2	morphine	229	236	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d87.s2	(	238	238	O	(	(	(	(	False
DDI-MedLine.d87.s2	0.05	239	242	O	0.05	.05	0.05	CD	False
DDI-MedLine.d87.s2	mg	244	245	O	mg	mg	mg	NN	False
DDI-MedLine.d87.s2	x	247	247	O	x	x	x	NN	False
DDI-MedLine.d87.s2	kg	249	250	O	kg	kg	kg	NN	False
DDI-MedLine.d87.s2	(	251	251	O	(	(	(	(	False
DDI-MedLine.d87.s2	-1	252	253	O	-1	-1	-1	NN	False
DDI-MedLine.d87.s2	)	254	254	O	)	)	)	)	False
DDI-MedLine.d87.s2	)	255	255	O	)	)	)	)	False
DDI-MedLine.d87.s2	in	257	258	O	in	in	in	IN	False
DDI-MedLine.d87.s2	a	260	260	O	a	a	a	DT	False
DDI-MedLine.d87.s2	double	262	267	O	double	ble	uble	RB	False
DDI-MedLine.d87.s2	blind	269	273	O	blind	ind	lind	NN	False
DDI-MedLine.d87.s2	,	274	274	O	,	,	,	,	False
DDI-MedLine.d87.s2	cross-over	276	285	O	cross-over	ver	over	NN	False
DDI-MedLine.d87.s2	study	287	291	O	study	udy	tudy	NN	False
DDI-MedLine.d87.s2	.	292	292	O	.	.	.	.	False

DDI-MedLine.d87.s3	Morphine	0	7	B-drug	Morphine	ine	hine	NN	drug
DDI-MedLine.d87.s3	prolonged	9	17	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d87.s3	gastrointestinal	19	34	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d87.s3	transit	36	42	O	transit	sit	nsit	NN	False
DDI-MedLine.d87.s3	time	44	47	O	time	ime	time	NN	False
DDI-MedLine.d87.s3	from	49	52	O	from	rom	from	IN	False
DDI-MedLine.d87.s3	69	54	55	O	69	69	69	CD	False
DDI-MedLine.d87.s3	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d87.s3	103	60	62	O	103	103	103	CD	False
DDI-MedLine.d87.s3	minutes	64	70	O	minutes	tes	utes	NNS	False
DDI-MedLine.d87.s3	(	72	72	O	(	(	(	(	False
DDI-MedLine.d87.s3	P	73	73	O	P	P	P	NN	brand
DDI-MedLine.d87.s3	=	75	75	O	=	=	=	NN	False
DDI-MedLine.d87.s3	.005	77	80	O	.005	005	.005	NN	False
DDI-MedLine.d87.s3	)	81	81	O	)	)	)	)	False
DDI-MedLine.d87.s3	;	82	82	O	;	;	;	:	False

DDI-MedLine.d87.s4	Morphine	0	7	B-drug	Morphine	ine	hine	NN	drug
DDI-MedLine.d87.s4	prolonged	9	17	O	prolonged	ged	nged	VBN	False
DDI-MedLine.d87.s4	gastrointestinal	19	34	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d87.s4	transit	36	42	O	transit	sit	nsit	NN	False
DDI-MedLine.d87.s4	time	44	47	O	time	ime	time	NN	False
DDI-MedLine.d87.s4	from	49	52	O	from	rom	from	IN	False
DDI-MedLine.d87.s4	69	54	55	O	69	69	69	CD	False
DDI-MedLine.d87.s4	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d87.s4	103	60	62	O	103	103	103	CD	False
DDI-MedLine.d87.s4	minutes	64	70	O	minutes	tes	utes	NNS	False
DDI-MedLine.d87.s4	(	72	72	O	(	(	(	(	False
DDI-MedLine.d87.s4	P	73	73	O	P	P	P	NN	brand
DDI-MedLine.d87.s4	=	75	75	O	=	=	=	NN	False
DDI-MedLine.d87.s4	.005	77	80	O	.005	005	.005	NN	False
DDI-MedLine.d87.s4	)	81	81	O	)	)	)	)	False
DDI-MedLine.d87.s4	;	82	82	O	;	;	;	:	False
DDI-MedLine.d87.s4	this	84	87	O	this	his	this	DT	False
DDI-MedLine.d87.s4	was	89	91	O	was	was	was	VBD	False
DDI-MedLine.d87.s4	prevented	93	101	O	prevented	ted	nted	VBN	False
DDI-MedLine.d87.s4	by	103	104	O	by	by	by	IN	False
DDI-MedLine.d87.s4	ADL	106	108	B-drug	ADL	ADL	ADL	NN	brand
DDI-MedLine.d87.s4	8-2698	110	115	I-drug	8-2698	698	2698	JJ	False
DDI-MedLine.d87.s4	(	117	117	O	(	(	(	(	False
DDI-MedLine.d87.s4	P	118	118	O	P	P	P	NN	brand
DDI-MedLine.d87.s4	=	120	120	O	=	=	=	NN	False
DDI-MedLine.d87.s4	.004	122	125	O	.004	004	.004	NN	False
DDI-MedLine.d87.s4	)	126	126	O	)	)	)	)	False
DDI-MedLine.d87.s4	.	127	127	O	.	.	.	.	False

DDI-MedLine.d87.s5	Postoperatively	0	14	O	Postoperatively	ely	vely	RB	False
DDI-MedLine.d87.s5	,	15	15	O	,	,	,	,	False
DDI-MedLine.d87.s5	45	17	18	O	45	45	45	CD	False
DDI-MedLine.d87.s5	patients	20	27	O	patients	nts	ents	NNS	False
DDI-MedLine.d87.s5	were	29	32	O	were	ere	were	VBD	False
DDI-MedLine.d87.s5	randomly	34	41	O	randomly	mly	omly	RB	False
DDI-MedLine.d87.s5	assigned	43	50	O	assigned	ned	gned	VBN	False
DDI-MedLine.d87.s5	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d87.s5	a	55	55	O	a	a	a	DT	False
DDI-MedLine.d87.s5	double-blind	57	68	O	double-blind	ind	lind	NN	False
DDI-MedLine.d87.s5	fashion	70	76	O	fashion	ion	hion	NN	False
DDI-MedLine.d87.s5	to	78	79	O	to	to	to	TO	False
DDI-MedLine.d87.s5	receive	81	87	O	receive	ive	eive	NN	False
DDI-MedLine.d87.s5	ADL	89	91	B-drug	ADL	ADL	ADL	NN	brand
DDI-MedLine.d87.s5	8-2698	93	98	I-drug	8-2698	698	2698	JJ	False
DDI-MedLine.d87.s5	(	100	100	O	(	(	(	(	False
DDI-MedLine.d87.s5	4	101	101	O	4	4	4	CD	False
DDI-MedLine.d87.s5	mg	103	104	O	mg	mg	mg	NN	False
DDI-MedLine.d87.s5	)	105	105	O	)	)	)	)	False
DDI-MedLine.d87.s5	or	107	108	O	or	or	or	CC	False
DDI-MedLine.d87.s5	placebo	110	116	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d87.s5	and	118	120	O	and	and	and	CC	False
DDI-MedLine.d87.s5	intravenous	122	132	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d87.s5	morphine	134	141	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d87.s5	(	143	143	O	(	(	(	(	False
DDI-MedLine.d87.s5	0.15	144	147	O	0.15	.15	0.15	CD	False
DDI-MedLine.d87.s5	mg/kg	149	153	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d87.s5	)	154	154	O	)	)	)	)	False
DDI-MedLine.d87.s5	or	156	157	O	or	or	or	CC	False
DDI-MedLine.d87.s5	to	159	160	O	to	to	to	TO	False
DDI-MedLine.d87.s5	receive	162	168	O	receive	ive	eive	NN	False
DDI-MedLine.d87.s5	oral	170	173	O	oral	ral	oral	JJ	False
DDI-MedLine.d87.s5	and	175	177	O	and	and	and	CC	False
DDI-MedLine.d87.s5	intravenous	179	189	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d87.s5	placebo	191	197	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d87.s5	.	198	198	O	.	.	.	.	False

DDI-MedLine.d87.s6	Analgesia	0	8	O	Analgesia	sia	esia	NN	False
DDI-MedLine.d87.s6	and	10	12	O	and	and	and	CC	False
DDI-MedLine.d87.s6	pupil	14	18	O	pupil	pil	upil	NN	False
DDI-MedLine.d87.s6	constriction	20	31	O	constriction	ion	tion	NN	False
DDI-MedLine.d87.s6	were	33	36	O	were	ere	were	VBD	False
DDI-MedLine.d87.s6	measured	38	45	O	measured	red	ured	VBN	False
DDI-MedLine.d87.s6	.	46	46	O	.	.	.	.	False

DDI-MedLine.d87.s7	Morphine	0	7	B-drug	Morphine	ine	hine	NN	drug
DDI-MedLine.d87.s7	analgesia	9	17	O	analgesia	sia	esia	NN	False
DDI-MedLine.d87.s7	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d87.s7	pupil	23	27	O	pupil	pil	upil	NN	False
DDI-MedLine.d87.s7	constriction	29	40	O	constriction	ion	tion	NN	False
DDI-MedLine.d87.s7	were	42	45	O	were	ere	were	VBD	False
DDI-MedLine.d87.s7	unaffected	47	56	O	unaffected	ted	cted	JJ	False
DDI-MedLine.d87.s7	by	58	59	O	by	by	by	IN	False
DDI-MedLine.d87.s7	ADL	61	63	B-drug	ADL	ADL	ADL	NN	brand
DDI-MedLine.d87.s7	8-2698	65	70	I-drug	8-2698	698	2698	JJ	False
DDI-MedLine.d87.s7	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d87.s7	differed	76	83	O	differed	red	ered	VBN	False
DDI-MedLine.d87.s7	from	85	88	O	from	rom	from	IN	False
DDI-MedLine.d87.s7	placebo	90	96	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d87.s7	(	98	98	O	(	(	(	(	False
DDI-MedLine.d87.s7	P	99	99	O	P	P	P	NN	brand
DDI-MedLine.d87.s7	<	101	101	O	<	<	<	NN	False
DDI-MedLine.d87.s7	.002	103	106	O	.002	002	.002	NN	False
DDI-MedLine.d87.s7	)	107	107	O	)	)	)	)	False
DDI-MedLine.d87.s7	.	108	108	O	.	.	.	.	False

DDI-MedLine.d87.s8	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d87.s8	conclude	3	10	O	conclude	ude	lude	NN	False
DDI-MedLine.d87.s8	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d87.s8	ADL	17	19	B-drug	ADL	ADL	ADL	NN	brand
DDI-MedLine.d87.s8	8-2698	21	26	I-drug	8-2698	698	2698	JJ	False
DDI-MedLine.d87.s8	prevents	28	35	O	prevents	nts	ents	NNS	False
DDI-MedLine.d87.s8	morphine-induced	37	52	O	morphine-induced	ced	uced	JJ	False
DDI-MedLine.d87.s8	increases	54	62	O	increases	ses	ases	NNS	False
DDI-MedLine.d87.s8	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d87.s8	gastrointestinal	67	82	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d87.s8	transit	84	90	O	transit	sit	nsit	NN	False
DDI-MedLine.d87.s8	time	92	95	O	time	ime	time	NN	False
DDI-MedLine.d87.s8	by	97	98	O	by	by	by	IN	False
DDI-MedLine.d87.s8	means	100	104	O	means	ans	eans	NNS	False
DDI-MedLine.d87.s8	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d87.s8	selective	109	117	O	selective	ive	tive	NN	False
DDI-MedLine.d87.s8	peripheral	119	128	O	peripheral	ral	eral	JJ	False
DDI-MedLine.d87.s8	opioid	130	135	O	opioid	oid	ioid	NN	False
DDI-MedLine.d87.s8	anitagonism	137	147	O	anitagonism	ism	nism	NN	False
DDI-MedLine.d87.s8	without	149	155	O	without	out	hout	IN	False
DDI-MedLine.d87.s8	affecting	157	165	O	affecting	ing	ting	VBG	False
DDI-MedLine.d87.s8	central	167	173	O	central	ral	tral	JJ	False
DDI-MedLine.d87.s8	opioid	175	180	O	opioid	oid	ioid	NN	False
DDI-MedLine.d87.s8	analgesia	182	190	O	analgesia	sia	esia	NN	False
DDI-MedLine.d87.s8	.	191	191	O	.	.	.	.	False

DDI-MedLine.d47.s0	Activity	0	7	O	Activity	ity	vity	NN	False
DDI-MedLine.d47.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d47.s0	buforin	12	18	B-drug_n	buforin	rin	orin	NN	False
DDI-MedLine.d47.s0	II	20	21	I-drug_n	II	II	II	NN	brand
DDI-MedLine.d47.s0	alone	23	27	O	alone	one	lone	RB	False
DDI-MedLine.d47.s0	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d47.s0	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d47.s0	combination	36	46	O	combination	ion	tion	NN	False
DDI-MedLine.d47.s0	with	48	51	O	with	ith	with	IN	False
DDI-MedLine.d47.s0	azithromycin	53	64	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d47.s0	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d47.s0	minocycline	70	80	B-drug	minocycline	ine	line	NN	drug
DDI-MedLine.d47.s0	against	82	88	O	against	nst	inst	IN	False
DDI-MedLine.d47.s0	Cryptosporidium	90	104	O	Cryptosporidium	ium	dium	NN	drug
DDI-MedLine.d47.s0	parvum	106	111	O	parvum	vum	rvum	NN	False
DDI-MedLine.d47.s0	in	113	114	O	in	in	in	IN	False
DDI-MedLine.d47.s0	cell	116	119	O	cell	ell	cell	NN	False
DDI-MedLine.d47.s0	culture	121	127	O	culture	ure	ture	NN	False
DDI-MedLine.d47.s0	.	128	128	O	.	.	.	.	False

DDI-MedLine.d47.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d47.s1	in	4	5	O	in	in	in	IN	False
DDI-MedLine.d47.s1	vitro	7	11	O	vitro	tro	itro	NN	False
DDI-MedLine.d47.s1	anti-cryptosporidial	13	32	O	anti-cryptosporidial	ial	dial	JJ	False
DDI-MedLine.d47.s1	activity	34	41	O	activity	ity	vity	NN	False
DDI-MedLine.d47.s1	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d47.s1	buforin	46	52	B-drug_n	buforin	rin	orin	NN	False
DDI-MedLine.d47.s1	II	54	55	I-drug_n	II	II	II	NN	brand
DDI-MedLine.d47.s1	alone	57	61	O	alone	one	lone	RB	False
DDI-MedLine.d47.s1	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d47.s1	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d47.s1	combination	70	80	O	combination	ion	tion	NN	False
DDI-MedLine.d47.s1	with	82	85	O	with	ith	with	IN	False
DDI-MedLine.d47.s1	azithromycin	87	98	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d47.s1	and	100	102	O	and	and	and	CC	False
DDI-MedLine.d47.s1	minocycline	104	114	B-drug	minocycline	ine	line	NN	drug
DDI-MedLine.d47.s1	was	116	118	O	was	was	was	VBD	False
DDI-MedLine.d47.s1	investigated	120	131	O	investigated	ted	ated	VBN	False
DDI-MedLine.d47.s1	.	132	132	O	.	.	.	.	False

DDI-MedLine.d47.s2	Buforin	0	6	B-drug_n	Buforin	rin	orin	NN	False
DDI-MedLine.d47.s2	II	8	9	I-drug_n	II	II	II	NN	brand
DDI-MedLine.d47.s2	showed	11	16	O	showed	wed	owed	VBD	False
DDI-MedLine.d47.s2	moderate	18	25	O	moderate	ate	rate	NN	False
DDI-MedLine.d47.s2	activity	27	34	O	activity	ity	vity	NN	False
DDI-MedLine.d47.s2	,	35	35	O	,	,	,	,	False
DDI-MedLine.d47.s2	which	37	41	O	which	ich	hich	WDT	False
DDI-MedLine.d47.s2	increased	43	51	O	increased	sed	ased	VBN	False
DDI-MedLine.d47.s2	with	53	56	O	with	ith	with	IN	False
DDI-MedLine.d47.s2	increasing	58	67	O	increasing	ing	sing	VBG	False
DDI-MedLine.d47.s2	concentration	69	81	O	concentration	ion	tion	NN	False
DDI-MedLine.d47.s2	to	83	84	O	to	to	to	TO	False
DDI-MedLine.d47.s2	55.7	86	89	O	55.7	5.7	55.7	CD	False
DDI-MedLine.d47.s2	%	90	90	O	%	%	%	NN	False
DDI-MedLine.d47.s2	suppression	92	102	O	suppression	ion	sion	NN	False
DDI-MedLine.d47.s2	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d47.s2	growth	107	112	O	growth	wth	owth	NN	False
DDI-MedLine.d47.s2	at	114	115	O	at	at	at	IN	False
DDI-MedLine.d47.s2	20	117	118	O	20	20	20	CD	False
DDI-MedLine.d47.s2	microM	120	125	O	microM	roM	croM	NN	False
DDI-MedLine.d47.s2	.	126	126	O	.	.	.	.	False

DDI-MedLine.d47.s3	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d47.s3	,	8	8	O	,	,	,	,	False
DDI-MedLine.d47.s3	its	10	12	O	its	its	its	PRP$	False
DDI-MedLine.d47.s3	activity	14	21	O	activity	ity	vity	NN	False
DDI-MedLine.d47.s3	was	23	25	O	was	was	was	VBD	False
DDI-MedLine.d47.s3	enhanced	27	34	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d47.s3	when	36	39	O	when	hen	when	WRB	False
DDI-MedLine.d47.s3	it	41	42	O	it	it	it	PRP	False
DDI-MedLine.d47.s3	was	44	46	O	was	was	was	VBD	False
DDI-MedLine.d47.s3	combined	48	55	O	combined	ned	ined	VBN	False
DDI-MedLine.d47.s3	with	57	60	O	with	ith	with	IN	False
DDI-MedLine.d47.s3	either	62	67	O	either	her	ther	DT	False
DDI-MedLine.d47.s3	azithromycin	69	80	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d47.s3	or	82	83	O	or	or	or	CC	False
DDI-MedLine.d47.s3	minocycline	85	95	B-drug	minocycline	ine	line	NN	drug
DDI-MedLine.d47.s3	with	97	100	O	with	ith	with	IN	False
DDI-MedLine.d47.s3	90	102	103	O	90	90	90	CD	False
DDI-MedLine.d47.s3	%	104	104	O	%	%	%	NN	False
DDI-MedLine.d47.s3	parasite	106	113	O	parasite	ite	site	NN	False
DDI-MedLine.d47.s3	reduction	115	123	O	reduction	ion	tion	NN	False
DDI-MedLine.d47.s3	at	125	126	O	at	at	at	IN	False
DDI-MedLine.d47.s3	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d47.s3	highest	132	138	O	highest	est	hest	JJS	False
DDI-MedLine.d47.s3	concentration	140	152	O	concentration	ion	tion	NN	False
DDI-MedLine.d47.s3	tested	154	159	O	tested	ted	sted	VBN	False
DDI-MedLine.d47.s3	.	160	160	O	.	.	.	.	False

DDI-MedLine.d47.s4	Buforin	0	6	B-drug_n	Buforin	rin	orin	NN	False
DDI-MedLine.d47.s4	II	8	9	I-drug_n	II	II	II	NN	brand
DDI-MedLine.d47.s4	may	11	13	O	may	may	may	MD	False
DDI-MedLine.d47.s4	be	15	16	O	be	be	be	VB	False
DDI-MedLine.d47.s4	active	18	23	O	active	ive	tive	JJ	False
DDI-MedLine.d47.s4	in	25	26	O	in	in	in	IN	False
DDI-MedLine.d47.s4	inhibiting	28	37	O	inhibiting	ing	ting	VBG	False
DDI-MedLine.d47.s4	Cryptosporidium	39	53	O	Cryptosporidium	ium	dium	NN	drug
DDI-MedLine.d47.s4	parvum	55	60	O	parvum	vum	rvum	NN	False
DDI-MedLine.d47.s4	growth	62	67	O	growth	wth	owth	NN	False
DDI-MedLine.d47.s4	in	69	70	O	in	in	in	IN	False
DDI-MedLine.d47.s4	vitro	72	76	O	vitro	tro	itro	NN	False
DDI-MedLine.d47.s4	upon	78	81	O	upon	pon	upon	IN	False
DDI-MedLine.d47.s4	combination	83	93	O	combination	ion	tion	NN	False
DDI-MedLine.d47.s4	with	95	98	O	with	ith	with	IN	False
DDI-MedLine.d47.s4	either	100	105	O	either	her	ther	DT	False
DDI-MedLine.d47.s4	azithromycin	107	118	B-drug	azithromycin	cin	ycin	NN	drug
DDI-MedLine.d47.s4	or	120	121	O	or	or	or	CC	False
DDI-MedLine.d47.s4	minocycline	123	133	B-drug	minocycline	ine	line	NN	drug
DDI-MedLine.d47.s4	.	134	134	O	.	.	.	.	False

DDI-MedLine.d88.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d88.s0	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d88.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d88.s0	chlordiazepoxide	15	30	B-drug	chlordiazepoxide	ide	xide	NN	False
DDI-MedLine.d88.s0	,	31	31	O	,	,	,	,	False
DDI-MedLine.d88.s0	amphetamine	33	43	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d88.s0	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d88.s0	cocaine	49	55	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d88.s0	on	57	58	O	on	on	on	IN	False
DDI-MedLine.d88.s0	bar-press	60	68	O	bar-press	ess	ress	NN	False
DDI-MedLine.d88.s0	behavior	70	77	O	behavior	ior	vior	NN	False
DDI-MedLine.d88.s0	in	79	80	O	in	in	in	IN	False
DDI-MedLine.d88.s0	normal	82	87	O	normal	mal	rmal	JJ	False
DDI-MedLine.d88.s0	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d88.s0	genetically	93	103	O	genetically	lly	ally	RB	False
DDI-MedLine.d88.s0	nervous	105	111	O	nervous	ous	vous	JJ	False
DDI-MedLine.d88.s0	dogs	113	116	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d88.s0	.	117	117	O	.	.	.	.	False

DDI-MedLine.d88.s1	Studies	0	6	O	Studies	ies	dies	NNS	False
DDI-MedLine.d88.s1	on	8	9	O	on	on	on	IN	False
DDI-MedLine.d88.s1	two	11	13	O	two	two	two	CD	False
DDI-MedLine.d88.s1	strains	15	21	O	strains	ins	ains	NNS	False
DDI-MedLine.d88.s1	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d88.s1	pointer	26	32	O	pointer	ter	nter	NN	False
DDI-MedLine.d88.s1	dogs	34	37	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d88.s1	have	39	42	O	have	ave	have	VB	False
DDI-MedLine.d88.s1	demonstrated	44	55	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d88.s1	that	57	60	O	that	hat	that	IN	False
DDI-MedLine.d88.s1	administration	62	75	O	administration	ion	tion	NN	False
DDI-MedLine.d88.s1	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d88.s1	a	80	80	O	a	a	a	DT	False
DDI-MedLine.d88.s1	benzodiazepine	82	95	B-group	benzodiazepine	ine	pine	NN	drug
DDI-MedLine.d88.s1	(	97	97	O	(	(	(	(	False
DDI-MedLine.d88.s1	chlordiazepoxide	98	113	B-drug	chlordiazepoxide	ide	xide	NN	False
DDI-MedLine.d88.s1	)	114	114	O	)	)	)	)	False
DDI-MedLine.d88.s1	facilitates	116	126	O	facilitates	tes	ates	NNS	False
DDI-MedLine.d88.s1	acquisition	128	138	O	acquisition	ion	tion	NN	False
DDI-MedLine.d88.s1	of	140	141	O	of	of	of	IN	False
DDI-MedLine.d88.s1	goal-directed	143	155	O	goal-directed	ted	cted	JJ	False
DDI-MedLine.d88.s1	behavior	157	164	O	behavior	ior	vior	NN	False
DDI-MedLine.d88.s1	in	166	167	O	in	in	in	IN	False
DDI-MedLine.d88.s1	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d88.s1	genetically	170	180	O	genetically	lly	ally	RB	False
DDI-MedLine.d88.s1	nervous	182	188	O	nervous	ous	vous	JJ	False
DDI-MedLine.d88.s1	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d88.s2	subjects	0	7	O	subjects	cts	ects	NNS	False
DDI-MedLine.d88.s2	.	8	8	O	.	.	.	.	False

DDI-MedLine.d88.s3	Continued	0	8	O	Continued	ued	nued	JJ	False
DDI-MedLine.d88.s3	admistration	10	21	O	admistration	ion	tion	NN	False
DDI-MedLine.d88.s3	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d88.s3	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d88.s3	drug	30	33	O	drug	rug	drug	NN	False
DDI-MedLine.d88.s3	is	35	36	O	is	is	is	VBZ	False
DDI-MedLine.d88.s3	required	38	45	O	required	red	ired	VBN	False
DDI-MedLine.d88.s3	to	47	48	O	to	to	to	TO	False
DDI-MedLine.d88.s3	maintain	50	57	O	maintain	ain	tain	NN	False
DDI-MedLine.d88.s3	barpress	59	66	O	barpress	ess	ress	NN	False
DDI-MedLine.d88.s3	response	68	75	O	response	nse	onse	NN	False
DDI-MedLine.d88.s3	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d88.s3	this	80	83	O	this	his	this	DT	False
DDI-MedLine.d88.s3	strain	85	90	O	strain	ain	rain	NN	False
DDI-MedLine.d88.s3	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d88.s3	dogs	95	98	O	dogs	ogs	dogs	NNS	False
DDI-MedLine.d88.s3	.	99	99	O	.	.	.	.	False

DDI-MedLine.d88.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d88.s4	concomitant	4	14	O	concomitant	ant	tant	NN	False
DDI-MedLine.d88.s4	administration	16	29	O	administration	ion	tion	NN	False
DDI-MedLine.d88.s4	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d88.s4	either	34	39	O	either	her	ther	DT	False
DDI-MedLine.d88.s4	cocaine	41	47	B-drug	cocaine	ine	aine	NN	drug
DDI-MedLine.d88.s4	or	49	50	O	or	or	or	CC	False
DDI-MedLine.d88.s4	amphetamine	52	62	B-drug	amphetamine	ine	mine	NN	drug
DDI-MedLine.d88.s4	,	63	63	O	,	,	,	,	False
DDI-MedLine.d88.s4	compounds	65	73	O	compounds	nds	unds	NNS	False
DDI-MedLine.d88.s4	which	75	79	O	which	ich	hich	WDT	False
DDI-MedLine.d88.s4	inhibit	81	87	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d88.s4	neuronal	89	96	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d88.s4	reuptake	98	105	O	reuptake	ake	take	NN	False
DDI-MedLine.d88.s4	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d88.s4	norepinephrine	110	123	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d88.s4	,	124	124	O	,	,	,	,	False
DDI-MedLine.d88.s4	disrupts	126	133	O	disrupts	pts	upts	NNS	False
DDI-MedLine.d88.s4	the	135	137	O	the	the	the	DT	False
DDI-MedLine.d88.s4	behavioral	139	148	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d88.s4	response	150	157	O	response	nse	onse	NN	False
DDI-MedLine.d88.s4	of	159	160	O	of	of	of	IN	False
DDI-MedLine.d88.s4	the	162	164	O	the	the	the	DT	False
DDI-MedLine.d88.s4	genetically	166	176	O	genetically	lly	ally	RB	False
DDI-MedLine.d88.s4	nervous	178	184	O	nervous	ous	vous	JJ	False
DDI-MedLine.d88.s4	E-strain	186	193	O	E-strain	ain	rain	NN	False
DDI-MedLine.d88.s4	subjects	195	202	O	subjects	cts	ects	NNS	False
DDI-MedLine.d88.s4	to	204	205	O	to	to	to	TO	False
DDI-MedLine.d88.s4	a	207	207	O	a	a	a	DT	False
DDI-MedLine.d88.s4	far	209	211	O	far	far	far	RB	False
DDI-MedLine.d88.s4	greater	213	219	O	greater	ter	ater	JJR	False
DDI-MedLine.d88.s4	extent	221	226	O	extent	ent	tent	NN	False
DDI-MedLine.d88.s4	than	228	231	O	than	han	than	IN	False
DDI-MedLine.d88.s4	the	233	235	O	the	the	the	DT	False
DDI-MedLine.d88.s4	stable	237	242	O	stable	ble	able	JJ	False
DDI-MedLine.d88.s4	A-strain	244	251	O	A-strain	ain	rain	NN	False
DDI-MedLine.d88.s4	subjects	253	260	O	subjects	cts	ects	NNS	False
DDI-MedLine.d88.s4	.	261	261	O	.	.	.	.	False

DDI-MedLine.d88.s5	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d88.s5	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d88.s5	also	6	9	O	also	lso	also	RB	False
DDI-MedLine.d88.s5	shown	11	15	O	shown	own	hown	VBN	False
DDI-MedLine.d88.s5	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d88.s5	after	22	26	O	after	ter	fter	IN	False
DDI-MedLine.d88.s5	14	28	29	O	14	14	14	CD	False
DDI-MedLine.d88.s5	days	31	34	O	days	ays	days	NNS	False
DDI-MedLine.d88.s5	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d88.s5	daily	39	43	O	daily	ily	aily	JJ	False
DDI-MedLine.d88.s5	administration	45	58	O	administration	ion	tion	NN	False
DDI-MedLine.d88.s5	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d88.s5	chlordiazepoxide	63	78	B-drug	chlordiazepoxide	ide	xide	NN	False
DDI-MedLine.d88.s5	,	79	79	O	,	,	,	,	False
DDI-MedLine.d88.s5	withdrawal	81	90	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d88.s5	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d88.s5	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d88.s5	drug	99	102	O	drug	rug	drug	NN	False
DDI-MedLine.d88.s5	not	104	106	O	not	not	not	RB	False
DDI-MedLine.d88.s5	only	108	111	O	only	nly	only	RB	False
DDI-MedLine.d88.s5	re-results	113	122	O	re-results	lts	ults	NNS	False
DDI-MedLine.d88.s5	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d88.s5	almost	127	132	O	almost	ost	most	RB	False
DDI-MedLine.d88.s5	complete	134	141	O	complete	ete	lete	JJ	False
DDI-MedLine.d88.s5	loss	143	146	O	loss	oss	loss	NN	False
DDI-MedLine.d88.s5	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d88.s5	bar-press	151	159	O	bar-press	ess	ress	NN	False
DDI-MedLine.d88.s5	response	161	168	O	response	nse	onse	NN	False
DDI-MedLine.d88.s5	in	170	171	O	in	in	in	IN	False
DDI-MedLine.d88.s5	the	173	175	O	the	the	the	DT	False
DDI-MedLine.d88.s5	E-strain	177	184	O	E-strain	ain	rain	NN	False
DDI-MedLine.d88.s5	subjects	186	193	O	subjects	cts	ects	NNS	False
DDI-MedLine.d88.s5	but	195	197	O	but	but	but	CC	False
DDI-MedLine.d88.s5	also	199	202	O	also	lso	also	RB	False
DDI-MedLine.d88.s5	results	204	210	O	results	lts	ults	NNS	False
DDI-MedLine.d88.s5	in	212	213	O	in	in	in	IN	False
DDI-MedLine.d88.s5	a	215	215	O	a	a	a	DT	False
DDI-MedLine.d88.s5	temporary	217	225	O	temporary	ary	rary	JJ	False
DDI-MedLine.d88.s5	decrease	227	234	O	decrease	ase	ease	NN	False
DDI-MedLine.d88.s5	in	236	237	O	in	in	in	IN	False
DDI-MedLine.d88.s5	the	239	241	O	the	the	the	DT	False
DDI-MedLine.d88.s5	acquired	243	250	O	acquired	red	ired	VBN	False
DDI-MedLine.d88.s5	behavioral	252	261	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d88.s5	response	263	270	O	response	nse	onse	NN	False
DDI-MedLine.d88.s5	of	272	273	O	of	of	of	IN	False
DDI-MedLine.d88.s5	the	275	277	O	the	the	the	DT	False
DDI-MedLine.d88.s5	stable	279	284	O	stable	ble	able	JJ	False
DDI-MedLine.d88.s5	A-strain	286	293	O	A-strain	ain	rain	NN	False
DDI-MedLine.d88.s5	subjects	295	302	O	subjects	cts	ects	NNS	False
DDI-MedLine.d88.s5	.	303	303	O	.	.	.	.	False

DDI-MedLine.d123.s0	Vancomycin	0	9	O	Vancomycin	cin	ycin	NN	drug
DDI-MedLine.d123.s0	resistance	11	20	O	resistance	nce	ance	NN	False
DDI-MedLine.d123.s0	reversal	22	29	O	reversal	sal	rsal	NN	False
DDI-MedLine.d123.s0	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d123.s0	enterococci	34	44	O	enterococci	cci	occi	NN	False
DDI-MedLine.d123.s0	by	46	47	O	by	by	by	IN	False
DDI-MedLine.d123.s0	flavonoids	49	58	O	flavonoids	ids	oids	NNS	False
DDI-MedLine.d123.s0	.	59	59	O	.	.	.	.	False

DDI-MedLine.d123.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d123.s1	development	4	14	O	development	ent	ment	NN	False
DDI-MedLine.d123.s1	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d123.s1	clinical	19	26	O	clinical	cal	ical	JJ	False
DDI-MedLine.d123.s1	vancomycin-resistant	28	47	O	vancomycin-resistant	ant	tant	JJ	False
DDI-MedLine.d123.s1	strains	49	55	O	strains	ins	ains	NNS	False
DDI-MedLine.d123.s1	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d123.s1	enterococci	60	70	O	enterococci	cci	occi	NN	False
DDI-MedLine.d123.s1	(	72	72	O	(	(	(	(	False
DDI-MedLine.d123.s1	VRE	73	75	O	VRE	VRE	VRE	NN	brand
DDI-MedLine.d123.s1	)	76	76	O	)	)	)	)	False
DDI-MedLine.d123.s1	is	78	79	O	is	is	is	VBZ	False
DDI-MedLine.d123.s1	a	81	81	O	a	a	a	DT	False
DDI-MedLine.d123.s1	major	83	87	O	major	jor	ajor	JJ	False
DDI-MedLine.d123.s1	cause	89	93	O	cause	use	ause	NN	False
DDI-MedLine.d123.s1	for	95	97	O	for	for	for	IN	False
DDI-MedLine.d123.s1	concern	99	105	O	concern	ern	cern	NN	False
DDI-MedLine.d123.s1	.	106	106	O	.	.	.	.	False

DDI-MedLine.d123.s2	Here	0	3	O	Here	ere	Here	RB	False
DDI-MedLine.d123.s2	we	5	6	O	we	we	we	PRP	False
DDI-MedLine.d123.s2	show	8	11	O	show	how	show	NN	False
DDI-MedLine.d123.s2	that	13	16	O	that	hat	that	IN	False
DDI-MedLine.d123.s2	a	18	18	O	a	a	a	DT	False
DDI-MedLine.d123.s2	combination	20	30	O	combination	ion	tion	NN	False
DDI-MedLine.d123.s2	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d123.s2	galangin	35	42	B-drug	galangin	gin	ngin	NN	False
DDI-MedLine.d123.s2	or	44	45	O	or	or	or	CC	False
DDI-MedLine.d123.s2	3,7-dihydroxyflavone	47	66	O	3,7-dihydroxyflavone	one	vone	CD	False
DDI-MedLine.d123.s2	with	68	71	O	with	ith	with	IN	False
DDI-MedLine.d123.s2	vancomycin	73	82	B-drug	vancomycin	cin	ycin	NN	drug
DDI-MedLine.d123.s2	may	84	86	O	may	may	may	MD	False
DDI-MedLine.d123.s2	be	88	89	O	be	be	be	VB	False
DDI-MedLine.d123.s2	used	91	94	O	used	sed	used	VBN	False
DDI-MedLine.d123.s2	to	96	97	O	to	to	to	TO	False
DDI-MedLine.d123.s2	sensitize	99	107	O	sensitize	ize	tize	VB	False
DDI-MedLine.d123.s2	resistant	109	117	O	resistant	ant	tant	NN	False
DDI-MedLine.d123.s2	strains	119	125	O	strains	ins	ains	NNS	False
DDI-MedLine.d123.s2	of	127	128	O	of	of	of	IN	False
DDI-MedLine.d123.s2	Enterococcus	130	141	O	Enterococcus	cus	ccus	NN	False
DDI-MedLine.d123.s2	faecalis	143	150	O	faecalis	lis	alis	NN	False
DDI-MedLine.d123.s2	and	152	154	O	and	and	and	CC	False
DDI-MedLine.d123.s2	Enterococcus	156	167	O	Enterococcus	cus	ccus	NN	False
DDI-MedLine.d123.s2	faecium	169	175	O	faecium	ium	cium	NN	drug
DDI-MedLine.d123.s2	to	177	178	O	to	to	to	TO	False
DDI-MedLine.d123.s2	the	180	182	O	the	the	the	DT	False
DDI-MedLine.d123.s2	level	184	188	O	level	vel	evel	NN	False
DDI-MedLine.d123.s2	of	190	191	O	of	of	of	IN	False
DDI-MedLine.d123.s2	vancomycin-sensitive	193	212	O	vancomycin-sensitive	ive	tive	JJ	False
DDI-MedLine.d123.s2	strains	214	220	O	strains	ins	ains	NNS	False
DDI-MedLine.d123.s2	.	221	221	O	.	.	.	.	False

DDI-MedLine.d123.s3	Minimum	0	6	O	Minimum	mum	imum	NN	False
DDI-MedLine.d123.s3	inhibitory	8	17	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d123.s3	concentrations	19	32	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d123.s3	(	34	34	O	(	(	(	(	False
DDI-MedLine.d123.s3	MICs	35	38	O	MICs	ICs	MICs	NNS	False
DDI-MedLine.d123.s3	)	39	39	O	)	)	)	)	False
DDI-MedLine.d123.s3	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d123.s3	viable	45	50	O	viable	ble	able	JJ	False
DDI-MedLine.d123.s3	counts	52	57	O	counts	nts	unts	NNS	False
DDI-MedLine.d123.s3	were	59	62	O	were	ere	were	VBD	False
DDI-MedLine.d123.s3	determined	64	73	O	determined	ned	ined	VBN	False
DDI-MedLine.d123.s3	in	75	76	O	in	in	in	IN	False
DDI-MedLine.d123.s3	Iso-sensitest	78	90	O	Iso-sensitest	est	test	NN	False
DDI-MedLine.d123.s3	broth	92	96	O	broth	oth	roth	NN	False
DDI-MedLine.d123.s3	using	98	102	O	using	ing	sing	VBG	False
DDI-MedLine.d123.s3	a	104	104	O	a	a	a	DT	False
DDI-MedLine.d123.s3	microtitre	106	115	O	microtitre	tre	itre	NN	False
DDI-MedLine.d123.s3	method	117	122	O	method	hod	thod	NN	False
DDI-MedLine.d123.s3	.	123	123	O	.	.	.	.	False

DDI-MedLine.d123.s4	MICs	0	3	O	MICs	ICs	MICs	NNS	False
DDI-MedLine.d123.s4	of	5	6	O	of	of	of	IN	False
DDI-MedLine.d123.s4	vancomycin	8	17	B-drug	vancomycin	cin	ycin	NN	drug
DDI-MedLine.d123.s4	against	19	25	O	against	nst	inst	IN	False
DDI-MedLine.d123.s4	67	27	28	O	67	67	67	CD	False
DDI-MedLine.d123.s4	%	29	29	O	%	%	%	NN	False
DDI-MedLine.d123.s4	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d123.s4	resistant	34	42	O	resistant	ant	tant	NN	False
DDI-MedLine.d123.s4	clinical	44	51	O	clinical	cal	ical	JJ	False
DDI-MedLine.d123.s4	isolates	53	60	O	isolates	tes	ates	NNS	False
DDI-MedLine.d123.s4	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d123.s4	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d123.s4	type	68	71	O	type	ype	type	NN	False
DDI-MedLine.d123.s4	strain	73	78	O	strain	ain	rain	NN	False
DDI-MedLine.d123.s4	of	80	81	O	of	of	of	IN	False
DDI-MedLine.d123.s4	enterococci	83	93	O	enterococci	cci	occi	NN	False
DDI-MedLine.d123.s4	were	95	98	O	were	ere	were	VBD	False
DDI-MedLine.d123.s4	lowered	100	106	O	lowered	red	ered	VBN	False
DDI-MedLine.d123.s4	from	108	111	O	from	rom	from	IN	False
DDI-MedLine.d123.s4	>	113	113	O	>	>	>	NN	False
DDI-MedLine.d123.s4	250	115	117	O	250	250	250	CD	False
DDI-MedLine.d123.s4	microg	119	124	O	microg	rog	crog	NN	False
DDI-MedLine.d123.s4	mL	126	127	O	mL	mL	mL	NN	False
DDI-MedLine.d123.s4	(	128	128	O	(	(	(	(	False
DDI-MedLine.d123.s4	-1	129	130	O	-1	-1	-1	NN	False
DDI-MedLine.d123.s4	)	131	131	O	)	)	)	)	False
DDI-MedLine.d123.s4	to	133	134	O	to	to	to	TO	False
DDI-MedLine.d123.s4	1	136	136	O	1	1	1	CD	False

DDI-MedLine.d123.s5	4	0	0	O	4	4	4	CD	False
DDI-MedLine.d123.s5	microg	2	7	O	microg	rog	crog	NN	False
DDI-MedLine.d123.s5	mL	9	10	O	mL	mL	mL	NN	False
DDI-MedLine.d123.s5	(	11	11	O	(	(	(	(	False
DDI-MedLine.d123.s5	-1	12	13	O	-1	-1	-1	NN	False
DDI-MedLine.d123.s5	)	14	14	O	)	)	)	)	False
DDI-MedLine.d123.s5	in	16	17	O	in	in	in	IN	False
DDI-MedLine.d123.s5	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d123.s5	presence	23	30	O	presence	nce	ence	NN	False
DDI-MedLine.d123.s5	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d123.s5	galangin	35	42	B-drug	galangin	gin	ngin	NN	False
DDI-MedLine.d123.s5	(	44	44	O	(	(	(	(	False
DDI-MedLine.d123.s5	12.5	45	48	O	12.5	2.5	12.5	CD	False
DDI-MedLine.d123.s5	microg	50	55	O	microg	rog	crog	NN	False
DDI-MedLine.d123.s5	mL	57	58	O	mL	mL	mL	NN	False
DDI-MedLine.d123.s5	(	59	59	O	(	(	(	(	False
DDI-MedLine.d123.s5	-1	60	61	O	-1	-1	-1	NN	False
DDI-MedLine.d123.s5	)	62	62	O	)	)	)	)	False
DDI-MedLine.d123.s5	)	63	63	O	)	)	)	)	False
DDI-MedLine.d123.s5	or	65	66	O	or	or	or	CC	False
DDI-MedLine.d123.s5	3,7-dihydroxyflavone	68	87	O	3,7-dihydroxyflavone	one	vone	CD	False
DDI-MedLine.d123.s5	(	89	89	O	(	(	(	(	False
DDI-MedLine.d123.s5	6.25	90	93	O	6.25	.25	6.25	CD	False
DDI-MedLine.d123.s5	microg	95	100	O	microg	rog	crog	NN	False
DDI-MedLine.d123.s5	mL	102	103	O	mL	mL	mL	NN	False
DDI-MedLine.d123.s5	(	104	104	O	(	(	(	(	False
DDI-MedLine.d123.s5	-1	105	106	O	-1	-1	-1	NN	False
DDI-MedLine.d123.s5	)	107	107	O	)	)	)	)	False
DDI-MedLine.d123.s5	)	108	108	O	)	)	)	)	False
DDI-MedLine.d123.s5	.	109	109	O	.	.	.	.	False

DDI-MedLine.d123.s6	Viable	0	5	O	Viable	ble	able	JJ	False
DDI-MedLine.d123.s6	counts	7	12	O	counts	nts	unts	NNS	False
DDI-MedLine.d123.s6	for	14	16	O	for	for	for	IN	False
DDI-MedLine.d123.s6	type	18	21	O	type	ype	type	NN	False
DDI-MedLine.d123.s6	culture	23	29	O	culture	ure	ture	NN	False
DDI-MedLine.d123.s6	E	31	31	O	E	E	E	NN	brand
DDI-MedLine.d123.s6	.	32	32	O	.	.	.	.	False

DDI-MedLine.d123.s7	faecalis	0	7	O	faecalis	lis	alis	NN	False
DDI-MedLine.d123.s7	ATCC	9	12	O	ATCC	TCC	ATCC	NN	brand
DDI-MedLine.d123.s7	51299	14	18	O	51299	299	1299	CD	False
DDI-MedLine.d123.s7	showed	20	25	O	showed	wed	owed	VBD	False
DDI-MedLine.d123.s7	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d123.s7	flavonoids	31	40	O	flavonoids	ids	oids	NNS	False
DDI-MedLine.d123.s7	alone	42	46	O	alone	one	lone	RB	False
DDI-MedLine.d123.s7	significantly	48	60	O	significantly	tly	ntly	RB	False
DDI-MedLine.d123.s7	lowered	62	68	O	lowered	red	ered	VBN	False
DDI-MedLine.d123.s7	numbers	70	76	O	numbers	ers	bers	NNS	False
DDI-MedLine.d123.s7	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d123.s7	colony	81	86	O	colony	ony	lony	NN	False
DDI-MedLine.d123.s7	forming	88	94	O	forming	ing	ming	VBG	False
DDI-MedLine.d123.s7	units	96	100	O	units	its	nits	NNS	False
DDI-MedLine.d123.s7	(	102	102	O	(	(	(	(	False
DDI-MedLine.d123.s7	CFUs	103	106	O	CFUs	FUs	CFUs	NN	False
DDI-MedLine.d123.s7	)	107	107	O	)	)	)	)	False
DDI-MedLine.d123.s7	.	108	108	O	.	.	.	.	False

DDI-MedLine.d123.s8	CFUs	0	3	O	CFUs	FUs	CFUs	NN	False
DDI-MedLine.d123.s8	were	5	8	O	were	ere	were	VBD	False
DDI-MedLine.d123.s8	maintained	10	19	O	maintained	ned	ined	VBN	False
DDI-MedLine.d123.s8	at	21	22	O	at	at	at	IN	False
DDI-MedLine.d123.s8	low	24	26	O	low	low	low	JJ	False
DDI-MedLine.d123.s8	levels	28	33	O	levels	els	vels	NNS	False
DDI-MedLine.d123.s8	(	35	35	O	(	(	(	(	False
DDI-MedLine.d123.s8	10	36	37	O	10	10	10	CD	False
DDI-MedLine.d123.s8	(	38	38	O	(	(	(	(	False
DDI-MedLine.d123.s8	3	39	39	O	3	3	3	CD	False
DDI-MedLine.d123.s8	)	40	40	O	)	)	)	)	False
DDI-MedLine.d123.s8	CFU	42	44	O	CFU	CFU	CFU	NN	brand
DDI-MedLine.d123.s8	mL	46	47	O	mL	mL	mL	NN	False
DDI-MedLine.d123.s8	(	48	48	O	(	(	(	(	False
DDI-MedLine.d123.s8	-1	49	50	O	-1	-1	-1	NN	False
DDI-MedLine.d123.s8	)	51	51	O	)	)	)	)	False
DDI-MedLine.d123.s8	)	52	52	O	)	)	)	)	False
DDI-MedLine.d123.s8	for	54	56	O	for	for	for	IN	False
DDI-MedLine.d123.s8	24	58	59	O	24	24	24	CD	False
DDI-MedLine.d123.s8	h	61	61	O	h	h	h	NN	False
DDI-MedLine.d123.s8	by	63	64	O	by	by	by	IN	False
DDI-MedLine.d123.s8	vancomycin/flavone	66	83	O	vancomycin/flavone	one	vone	NN	False
DDI-MedLine.d123.s8	combinations	85	96	O	combinations	ons	ions	NNS	False
DDI-MedLine.d123.s8	.	97	97	O	.	.	.	.	False

DDI-MedLine.d123.s9	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d123.s9	combinational	5	17	O	combinational	nal	onal	NN	False
DDI-MedLine.d123.s9	action	19	24	O	action	ion	tion	NN	False
DDI-MedLine.d123.s9	in	26	27	O	in	in	in	IN	False
DDI-MedLine.d123.s9	reversing	29	37	O	reversing	ing	sing	VBG	False
DDI-MedLine.d123.s9	vancomycin	39	48	O	vancomycin	cin	ycin	NN	drug
DDI-MedLine.d123.s9	resistance	50	59	O	resistance	nce	ance	NN	False
DDI-MedLine.d123.s9	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d123.s9	enterococci	64	74	O	enterococci	cci	occi	NN	False
DDI-MedLine.d123.s9	highlights	76	85	O	highlights	hts	ghts	NNS	False
DDI-MedLine.d123.s9	novel	87	91	O	novel	vel	ovel	NN	False
DDI-MedLine.d123.s9	drug	93	96	O	drug	rug	drug	NN	False
DDI-MedLine.d123.s9	targets	98	104	O	targets	ets	gets	NNS	False
DDI-MedLine.d123.s9	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d123.s9	has	110	112	O	has	has	has	VBZ	False
DDI-MedLine.d123.s9	importance	114	123	O	importance	nce	ance	NN	False
DDI-MedLine.d123.s9	in	125	126	O	in	in	in	IN	False
DDI-MedLine.d123.s9	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d123.s9	design	132	137	O	design	ign	sign	NN	False
DDI-MedLine.d123.s9	of	139	140	O	of	of	of	IN	False
DDI-MedLine.d123.s9	new	142	144	O	new	new	new	JJ	False
DDI-MedLine.d123.s9	therapeutic	146	156	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d123.s9	regimes	158	164	O	regimes	mes	imes	NNS	False
DDI-MedLine.d123.s9	against	166	172	O	against	nst	inst	IN	False
DDI-MedLine.d123.s9	resistant	174	182	O	resistant	ant	tant	NN	False
DDI-MedLine.d123.s9	pathogens	184	192	O	pathogens	ens	gens	NNS	False
DDI-MedLine.d123.s9	.	193	193	O	.	.	.	.	False

DDI-MedLine.d63.s0	Differential	0	11	O	Differential	ial	tial	NN	False
DDI-MedLine.d63.s0	actions	13	19	O	actions	ons	ions	NNS	False
DDI-MedLine.d63.s0	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d63.s0	intrathecal	24	34	O	intrathecal	cal	ecal	JJ	False
DDI-MedLine.d63.s0	naloxone	36	43	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d63.s0	on	45	46	O	on	on	on	IN	False
DDI-MedLine.d63.s0	blocking	48	55	O	blocking	ing	king	VBG	False
DDI-MedLine.d63.s0	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d63.s0	tail-flick	61	70	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s0	inhibition	72	81	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s0	induced	83	89	O	induced	ced	uced	JJ	False
DDI-MedLine.d63.s0	by	91	92	O	by	by	by	IN	False
DDI-MedLine.d63.s0	intraventricular	94	109	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s0	beta-endorphin	111	124	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s0	and	126	128	O	and	and	and	CC	False
DDI-MedLine.d63.s0	morphine	130	137	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s0	in	139	140	O	in	in	in	IN	False
DDI-MedLine.d63.s0	rats	142	145	O	rats	ats	rats	NNS	False
DDI-MedLine.d63.s0	.	146	146	O	.	.	.	.	False

DDI-MedLine.d63.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d63.s1	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d63.s1	present	7	13	O	present	ent	sent	NN	False
DDI-MedLine.d63.s1	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d63.s1	,	20	20	O	,	,	,	,	False
DDI-MedLine.d63.s1	it	22	23	O	it	it	it	PRP	False
DDI-MedLine.d63.s1	is	25	26	O	is	is	is	VBZ	False
DDI-MedLine.d63.s1	proposed	28	35	O	proposed	sed	osed	VBN	False
DDI-MedLine.d63.s1	that	37	40	O	that	hat	that	IN	False
DDI-MedLine.d63.s1	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d63.s1	opioids	46	52	B-group	opioids	ids	oids	NNS	False
DDI-MedLine.d63.s1	applied	54	60	O	applied	ied	lied	VBN	False
DDI-MedLine.d63.s1	to	62	63	O	to	to	to	TO	False
DDI-MedLine.d63.s1	supraspinal	65	75	O	supraspinal	nal	inal	JJ	False
DDI-MedLine.d63.s1	brain	77	81	O	brain	ain	rain	NN	False
DDI-MedLine.d63.s1	sites	83	87	O	sites	tes	ites	NNS	False
DDI-MedLine.d63.s1	produced	89	96	O	produced	ced	uced	VBN	False
DDI-MedLine.d63.s1	their	98	102	O	their	eir	heir	PRP$	False
DDI-MedLine.d63.s1	analgesic	104	112	O	analgesic	sic	esic	JJ	False
DDI-MedLine.d63.s1	effects	114	120	O	effects	cts	ects	NNS	False
DDI-MedLine.d63.s1	by	122	123	O	by	by	by	IN	False
DDI-MedLine.d63.s1	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d63.s1	activation	129	138	O	activation	ion	tion	NN	False
DDI-MedLine.d63.s1	of	140	141	O	of	of	of	IN	False
DDI-MedLine.d63.s1	different	143	151	O	different	ent	rent	JJ	False
DDI-MedLine.d63.s1	descending	153	162	O	descending	ing	ding	VBG	False
DDI-MedLine.d63.s1	pain	164	167	O	pain	ain	pain	NN	False
DDI-MedLine.d63.s1	inhibitory	169	178	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d63.s1	systems	180	186	O	systems	ems	tems	NNS	False
DDI-MedLine.d63.s1	.	187	187	O	.	.	.	.	False

DDI-MedLine.d63.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d63.s2	blockade	4	11	O	blockade	ade	kade	NN	False
DDI-MedLine.d63.s2	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d63.s2	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d63.s2	spinal	20	25	O	spinal	nal	inal	NN	False
DDI-MedLine.d63.s2	endorphinergic	27	40	O	endorphinergic	gic	rgic	NN	False
DDI-MedLine.d63.s2	system	42	47	O	system	tem	stem	NN	False
DDI-MedLine.d63.s2	by	49	50	O	by	by	by	IN	False
DDI-MedLine.d63.s2	intrathecal	52	62	O	intrathecal	cal	ecal	JJ	False
DDI-MedLine.d63.s2	naloxone	64	71	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d63.s2	on	73	74	O	on	on	on	IN	False
DDI-MedLine.d63.s2	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d63.s2	production	80	89	O	production	ion	tion	NN	False
DDI-MedLine.d63.s2	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d63.s2	tail-flick	94	103	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s2	inhibition	105	114	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s2	induced	116	122	O	induced	ced	uced	JJ	False
DDI-MedLine.d63.s2	by	124	125	O	by	by	by	IN	False
DDI-MedLine.d63.s2	intraventricular	127	142	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s2	beta-endorphin	144	157	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s2	and	159	161	O	and	and	and	CC	False
DDI-MedLine.d63.s2	morphine	163	170	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s2	was	172	174	O	was	was	was	VBD	False
DDI-MedLine.d63.s2	then	176	179	O	then	hen	then	RB	False
DDI-MedLine.d63.s2	studied	181	187	O	studied	ied	died	VBN	False
DDI-MedLine.d63.s2	.	188	188	O	.	.	.	.	False

DDI-MedLine.d63.s3	Intraventricular	0	15	O	Intraventricular	lar	ular	JJ	False
DDI-MedLine.d63.s3	injection	17	25	O	injection	ion	tion	NN	False
DDI-MedLine.d63.s3	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d63.s3	beta-endorphin	30	43	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s3	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d63.s3	morphine	49	56	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s3	produced	58	65	O	produced	ced	uced	VBN	False
DDI-MedLine.d63.s3	an	67	68	O	an	an	an	DT	False
DDI-MedLine.d63.s3	inhibition	70	79	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s3	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d63.s3	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d63.s3	tail-flick	88	97	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s3	response	99	106	O	response	nse	onse	NN	False
DDI-MedLine.d63.s3	to	108	109	O	to	to	to	TO	False
DDI-MedLine.d63.s3	the	111	113	O	the	the	the	DT	False
DDI-MedLine.d63.s3	heat	115	118	O	heat	eat	heat	NN	False
DDI-MedLine.d63.s3	stimulus	120	127	O	stimulus	lus	ulus	NN	False
DDI-MedLine.d63.s3	in	129	130	O	in	in	in	IN	False
DDI-MedLine.d63.s3	rats	132	135	O	rats	ats	rats	NNS	False
DDI-MedLine.d63.s3	.	136	136	O	.	.	.	.	False

DDI-MedLine.d63.s4	Intrathecal	0	10	O	Intrathecal	cal	ecal	JJ	False
DDI-MedLine.d63.s4	injection	12	20	O	injection	ion	tion	NN	False
DDI-MedLine.d63.s4	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d63.s4	naloxone	25	32	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d63.s4	at	34	35	O	at	at	at	IN	False
DDI-MedLine.d63.s4	doses	37	41	O	doses	ses	oses	NNS	False
DDI-MedLine.d63.s4	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d63.s4	0.4	46	48	O	0.4	0.4	0.4	CD	False
DDI-MedLine.d63.s4	to	50	51	O	to	to	to	TO	False
DDI-MedLine.d63.s4	40	53	54	O	40	40	40	CD	False
DDI-MedLine.d63.s4	micrograms	56	65	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d63.s4	caused	67	72	O	caused	sed	used	VBN	False
DDI-MedLine.d63.s4	a	74	74	O	a	a	a	DT	False
DDI-MedLine.d63.s4	dose-related	76	87	O	dose-related	ted	ated	JJ	False
DDI-MedLine.d63.s4	blockade	89	96	O	blockade	ade	kade	NN	False
DDI-MedLine.d63.s4	of	98	99	O	of	of	of	IN	False
DDI-MedLine.d63.s4	the	101	103	O	the	the	the	DT	False
DDI-MedLine.d63.s4	inhibition	105	114	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s4	of	116	117	O	of	of	of	IN	False
DDI-MedLine.d63.s4	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d63.s4	tail-flick	123	132	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s4	response	134	141	O	response	nse	onse	NN	False
DDI-MedLine.d63.s4	induced	143	149	O	induced	ced	uced	JJ	False
DDI-MedLine.d63.s4	by	151	152	O	by	by	by	IN	False
DDI-MedLine.d63.s4	intraventricular	154	169	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s4	injection	171	179	O	injection	ion	tion	NN	False
DDI-MedLine.d63.s4	of	181	182	O	of	of	of	IN	False
DDI-MedLine.d63.s4	beta-endorphin	184	197	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s4	,	198	198	O	,	,	,	,	False
DDI-MedLine.d63.s4	and	200	202	O	and	and	and	CC	False
DDI-MedLine.d63.s4	a	204	204	O	a	a	a	DT	False
DDI-MedLine.d63.s4	high	206	209	O	high	igh	high	JJ	False
DDI-MedLine.d63.s4	dose	211	214	O	dose	ose	dose	NN	False
DDI-MedLine.d63.s4	of	216	217	O	of	of	of	IN	False
DDI-MedLine.d63.s4	naloxone	219	226	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d63.s4	(	228	228	O	(	(	(	(	False
DDI-MedLine.d63.s4	40	229	230	O	40	40	40	CD	False
DDI-MedLine.d63.s4	micrograms	232	241	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d63.s4	)	242	242	O	)	)	)	)	False
DDI-MedLine.d63.s4	completely	244	253	O	completely	ely	tely	RB	False
DDI-MedLine.d63.s4	blocked	255	261	O	blocked	ked	cked	VBN	False
DDI-MedLine.d63.s4	the	263	265	O	the	the	the	DT	False
DDI-MedLine.d63.s4	tail-flick	267	276	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s4	inhibition	278	287	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s4	induced	289	295	O	induced	ced	uced	JJ	False
DDI-MedLine.d63.s4	by	297	298	O	by	by	by	IN	False
DDI-MedLine.d63.s4	intraventricular	300	315	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s4	beta-endorphin	317	330	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s4	(	332	332	O	(	(	(	(	False
DDI-MedLine.d63.s4	16	333	334	O	16	16	16	CD	False
DDI-MedLine.d63.s4	micrograms	336	345	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d63.s4	)	346	346	O	)	)	)	)	False
DDI-MedLine.d63.s4	.	347	347	O	.	.	.	.	False

DDI-MedLine.d63.s5	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d63.s5	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d63.s5	other	7	11	O	other	her	ther	JJ	False
DDI-MedLine.d63.s5	hand	13	16	O	hand	and	hand	NN	False
DDI-MedLine.d63.s5	,	17	17	O	,	,	,	,	False
DDI-MedLine.d63.s5	intrathecal	19	29	O	intrathecal	cal	ecal	JJ	False
DDI-MedLine.d63.s5	naloxone	31	38	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d63.s5	(	40	40	O	(	(	(	(	False
DDI-MedLine.d63.s5	12-120	41	46	O	12-120	120	-120	JJ	False
DDI-MedLine.d63.s5	micrograms	48	57	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d63.s5	)	58	58	O	)	)	)	)	False
DDI-MedLine.d63.s5	had	60	62	O	had	had	had	VBD	False
DDI-MedLine.d63.s5	only	64	67	O	only	nly	only	RB	False
DDI-MedLine.d63.s5	a	69	69	O	a	a	a	DT	False
DDI-MedLine.d63.s5	very	71	74	O	very	ery	very	RB	False
DDI-MedLine.d63.s5	weak	76	79	O	weak	eak	weak	JJ	False
DDI-MedLine.d63.s5	effect	81	86	O	effect	ect	fect	NN	False
DDI-MedLine.d63.s5	on	88	89	O	on	on	on	IN	False
DDI-MedLine.d63.s5	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d63.s5	tail-flick	95	104	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s5	inhibition	106	115	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s5	induced	117	123	O	induced	ced	uced	JJ	False
DDI-MedLine.d63.s5	by	125	126	O	by	by	by	IN	False
DDI-MedLine.d63.s5	intraventricular	128	143	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s5	morphine	145	152	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s5	(	154	154	O	(	(	(	(	False
DDI-MedLine.d63.s5	40	155	156	O	40	40	40	CD	False
DDI-MedLine.d63.s5	micrograms	158	167	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d63.s5	)	168	168	O	)	)	)	)	False
DDI-MedLine.d63.s5	.	169	169	O	.	.	.	.	False

DDI-MedLine.d63.s6	Intraventricular	0	15	O	Intraventricular	lar	ular	JJ	False
DDI-MedLine.d63.s6	injection	17	25	O	injection	ion	tion	NN	False
DDI-MedLine.d63.s6	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d63.s6	naloxone	30	37	B-drug	naloxone	one	xone	NN	False
DDI-MedLine.d63.s6	at	39	40	O	at	at	at	IN	False
DDI-MedLine.d63.s6	doses	42	46	O	doses	ses	oses	NNS	False
DDI-MedLine.d63.s6	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d63.s6	1.2	51	53	O	1.2	1.2	1.2	CD	False
DDI-MedLine.d63.s6	to	55	56	O	to	to	to	TO	False
DDI-MedLine.d63.s6	12	58	59	O	12	12	12	CD	False
DDI-MedLine.d63.s6	micrograms	61	70	O	micrograms	ams	rams	NNS	False
DDI-MedLine.d63.s6	equally	72	78	O	equally	lly	ally	RB	False
DDI-MedLine.d63.s6	antagonized	80	90	O	antagonized	zed	ized	VBN	False
DDI-MedLine.d63.s6	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d63.s6	a	95	95	O	a	a	a	DT	False
DDI-MedLine.d63.s6	dose-dependent	97	110	O	dose-dependent	ent	dent	NN	False
DDI-MedLine.d63.s6	manner	112	117	O	manner	ner	nner	NN	False
DDI-MedLine.d63.s6	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d63.s6	tail-flick	123	132	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s6	inhibition	134	143	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s6	induced	145	151	O	induced	ced	uced	JJ	False
DDI-MedLine.d63.s6	by	153	154	O	by	by	by	IN	False
DDI-MedLine.d63.s6	intraventricular	156	171	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s6	beta-endorphin	173	186	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s6	and	188	190	O	and	and	and	CC	False
DDI-MedLine.d63.s6	morphine	192	199	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s6	.	200	200	O	.	.	.	.	False

DDI-MedLine.d63.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d63.s7	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d63.s7	indicate	12	19	O	indicate	ate	cate	NN	False
DDI-MedLine.d63.s7	that	21	24	O	that	hat	that	IN	False
DDI-MedLine.d63.s7	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d63.s7	spinal	28	33	O	spinal	nal	inal	NN	False
DDI-MedLine.d63.s7	naloxone-sensitive	35	52	O	naloxone-sensitive	ive	tive	JJ	False
DDI-MedLine.d63.s7	endorphinergic	54	67	O	endorphinergic	gic	rgic	NN	False
DDI-MedLine.d63.s7	system	69	74	O	system	tem	stem	NN	False
DDI-MedLine.d63.s7	is	76	77	O	is	is	is	VBZ	False
DDI-MedLine.d63.s7	involved	79	86	O	involved	ved	lved	VBN	False
DDI-MedLine.d63.s7	in	88	89	O	in	in	in	IN	False
DDI-MedLine.d63.s7	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d63.s7	production	95	104	O	production	ion	tion	NN	False
DDI-MedLine.d63.s7	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d63.s7	beta-endorphin	109	122	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s7	but	124	126	O	but	but	but	CC	False
DDI-MedLine.d63.s7	not	128	130	O	not	not	not	RB	False
DDI-MedLine.d63.s7	morphine-induced	132	147	O	morphine-induced	ced	uced	JJ	False
DDI-MedLine.d63.s7	tail-flick	149	158	O	tail-flick	ick	lick	NN	False
DDI-MedLine.d63.s7	inhibition	160	169	O	inhibition	ion	tion	NN	False
DDI-MedLine.d63.s7	,	170	170	O	,	,	,	,	False
DDI-MedLine.d63.s7	and	172	174	O	and	and	and	CC	False
DDI-MedLine.d63.s7	suggest	176	182	O	suggest	est	gest	NN	False
DDI-MedLine.d63.s7	that	184	187	O	that	hat	that	IN	False
DDI-MedLine.d63.s7	intraventricular	189	204	O	intraventricular	lar	ular	NN	False
DDI-MedLine.d63.s7	beta-endorphin	206	219	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s7	and	221	223	O	and	and	and	CC	False
DDI-MedLine.d63.s7	morphine	225	232	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s7	elicit	234	239	O	elicit	cit	icit	NN	False
DDI-MedLine.d63.s7	their	241	245	O	their	eir	heir	PRP$	False
DDI-MedLine.d63.s7	pharmacological	247	261	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d63.s7	actions	263	269	O	actions	ons	ions	NNS	False
DDI-MedLine.d63.s7	via	271	273	O	via	via	via	IN	False
DDI-MedLine.d63.s7	the	275	277	O	the	the	the	DT	False
DDI-MedLine.d63.s7	activation	279	288	O	activation	ion	tion	NN	False
DDI-MedLine.d63.s7	of	290	291	O	of	of	of	IN	False
DDI-MedLine.d63.s7	different	293	301	O	different	ent	rent	JJ	False
DDI-MedLine.d63.s7	descending	303	312	O	descending	ing	ding	VBG	False
DDI-MedLine.d63.s7	pain	314	317	O	pain	ain	pain	NN	False
DDI-MedLine.d63.s7	inhibitory	319	328	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d63.s7	systems	330	336	O	systems	ems	tems	NNS	False
DDI-MedLine.d63.s7	;	337	337	O	;	;	;	:	False

DDI-MedLine.d63.s8	descending	0	9	O	descending	ing	ding	VBG	False
DDI-MedLine.d63.s8	epsilon	11	17	O	epsilon	lon	ilon	NN	False
DDI-MedLine.d63.s8	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d63.s8	mu	23	24	O	mu	mu	mu	NN	False
DDI-MedLine.d63.s8	systems	26	32	O	systems	ems	tems	NNS	False
DDI-MedLine.d63.s8	for	34	36	O	for	for	for	IN	False
DDI-MedLine.d63.s8	beta-endorphin	38	51	B-drug_n	beta-endorphin	hin	phin	NN	False
DDI-MedLine.d63.s8	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d63.s8	morphine	57	64	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d63.s8	,	65	65	O	,	,	,	,	False
DDI-MedLine.d63.s8	respectively	67	78	O	respectively	ely	vely	RB	False
DDI-MedLine.d63.s8	,	79	79	O	,	,	,	,	False
DDI-MedLine.d63.s8	are	81	83	O	are	are	are	VBP	False
DDI-MedLine.d63.s8	proposed	85	92	O	proposed	sed	osed	VBN	False
DDI-MedLine.d63.s8	.	93	93	O	.	.	.	.	False

